Effects	NNS	O
of	IN	O
prelinguistic	JJ	O
milieu	NN	O
teaching	NN	O
and	CC	O
parent	NN	O
responsivity	NN	O
education	NN	O
on	IN	O
dyads	NNS	O
involving	VBG	O
children	NNS	O
with	IN	O
intellectual	JJ	O
disabilities	NNS	O
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
method	NN	O
of	IN	O
facilitating	VBG	O
prelinguistic	JJ	O
communication	NN	O
on	IN	O
parents	NNS	O
'	POS	O
responsivity	NN	O
and	CC	O
children	NNS	O
's	POS	O
communication	NN	O
and	CC	O
productive	JJ	O
language	NN	O
development	NN	O
.	.	O

The	DT	O
method	NN	O
involved	VBN	O
Responsivity	NNP	O
education	NN	O
for	IN	O
the	DT	O
parents	NNS	O
and	CC	O
Prelinguistic	NNP	O
Milieu	NNP	O
Teaching	NNP	O
for	IN	O
the	DT	O
children	NNS	O
(	(	O
RPMT	NNP	O
)	)	O
.	.	O

Thirty-nine	JJ	O
prelinguistic	JJ	O
toddlers	NNS	O
with	IN	O
intellectual	JJ	O
disabilities	NNS	O
and	CC	O
their	PRP$	O
primary	JJ	O
caregivers	NNS	O
participated	VBD	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Parent-child	JJ	O
pairs	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
the	DT	O
RPMT	NNP	O
group	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Communication	NNP	O
and	CC	O
language	NN	O
were	VBD	O
assessed	VBN	O
at	IN	O
study	NN	O
entry	NN	O
and	CC	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
later	RB	O
.	.	O

RPMT	NNP	O
facilitated	VBD	O
parental	JJ	O
responsivity	NN	O
in	IN	O
the	DT	O
posttreatment	JJ	O
period	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
RPMT	NNP	O
on	IN	O
growth	NN	O
rate	NN	O
of	IN	O
child-initiated	JJ	O
comments	NNS	O
(	(	O
i.e.	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
type	NN	O
of	IN	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
)	)	O
varied	VBN	O
by	IN	O
pretreatment	JJ	O
measures	NNS	O
of	IN	O
that	DT	O
variable	JJ	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
RPMT	NNP	O
on	IN	O
growth	NN	O
rate	NN	O
of	IN	O
child-initiated	JJ	O
requests	NNS	O
(	(	O
i.e.	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
type	NN	O
of	IN	O
initiating	VBG	O
behavior	JJ	O
regulation	NN	O
)	)	O
varied	VBN	O
by	IN	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
Down	NNP	O
syndrome	NN	O
.	.	O

Finally	RB	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
RPMT	NNP	O
on	IN	O
growth	NN	O
of	IN	O
productive	JJ	O
language	NN	O
varied	VBN	O
by	IN	O
pretreatment	JJ	O
frequency	NN	O
of	IN	O
canonical	JJ	O
vocal	JJ	O
communication	NN	O
.	.	O

Recommended	VBN	O
alterations	NNS	O
in	IN	O
PMT	NNP	O
and	CC	O
implications	NNS	O
for	IN	O
defining	VBG	O
which	WDT	O
nonspeaking	VBG	O
children	NNS	O
are	VBP	O
appropriate	JJ	O
for	IN	O
prelinguistic	JJ	O
goals	NNS	O
and	CC	O
treatment	NN	O
were	VBD	O
discussed	VBN	O
.	.	O

Vitamin	NNP	O
C	NNP	O
and	CC	O
acute	JJ	O
illness	NN	O
in	IN	O
Navajo	NNP	Condition
school	NN	Condition
children	NNS	Condition
.	.	Condition

To	TO	O
evaluate	VB	O
earlier	JJR	O
observations	NNS	O
,	,	O
including	VBG	O
our	PRP$	O
own	JJ	O
,	,	O
showing	VBG	O
usefulness	NN	O
of	IN	O
vitamin	NN	O
C	NNP	O
for	IN	O
managing	VBG	O
the	DT	O
common	JJ	O
cold	NN	O
,	,	O
we	PRP	O
performed	VBD	O
a	DT	O
double-blind	JJ	O
trial	NN	O
of	IN	O
vitamin	NN	O
C	NNP	O
versus	NN	O
placebo	NN	O
in	IN	O
868	CD	O
children	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
number	NN	O
becoming	VBG	O
ill	JJ	O
(	(	O
133	CD	O
versus	IN	O
129	CD	O
)	)	O
,	,	O
number	NN	O
of	IN	O
episodes	NNS	O
(	(	O
166	CD	O
versus	IN	O
159	CD	O
)	)	O
or	CC	O
mean	JJ	O
illness	JJ	O
duration	NN	O
(	(	O
5.5	CD	O
versus	NN	O
5.8	CD	O
days	NNS	O
)	)	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Children	NNP	O
receiving	VBG	O
vitamin	NN	O
C	NNP	O
had	VBD	O
fewer	JJR	O
throat	NN	O
cultures	NNS	O
yielding	VBG	O
beta-hemolytic	JJ	O
streptococcus	NN	O
(	(	O
six	CD	O
versus	NN	O
13	CD	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.10	CD	O
)	)	O
,	,	O
but	CC	O
no	DT	O
difference	NN	O
in	IN	O
overall	JJ	O
complicated	JJ	O
illness	NN	O
rate	NN	O
(	(	O
24	CD	O
versus	IN	O
25	CD	O
)	)	O
.	.	O

Plasma	NNP	O
ascorbic	JJ	O
acid	NN	O
levels	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
vitamin	NN	O
group	NN	O
24	CD	O
to	TO	O
26	CD	O
hours	NNS	O
after	IN	O
supplementation	NN	O
(	(	O
1.28	CD	O
versus	NN	O
1.04	CD	O
mg	NN	O
per	IN	O
100	CD	O
ml	NN	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Children	NNP	O
with	IN	O
high	JJ	O
plasma	NN	O
ascorbic	JJ	O
acid	JJ	O
concentrations	NNS	O
had	VBD	O
longer	RBR	O
mean	JJ	O
illness	NN	O
(	(	O
6.8	CD	O
versus	NN	O
4.0	CD	O
days	NNS	O
,	,	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
than	IN	O
those	DT	O
with	IN	O
low	JJ	O
levels	NNS	O
.	.	O

Vitamin	NNP	O
C	NNP	O
does	VBZ	O
not	RB	O
seem	VB	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
prophylactic	NN	O
or	CC	O
therapeutic	JJ	O
agent	NN	O
for	IN	O
upper	JJ	O
respiratory	NN	O
illness	NN	O
.	.	O

Clinical	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
contact	NN	O
sensitization	NN	O
potential	NN	O
of	IN	O
a	DT	O
transdermal	JJ	O
nicotine	NN	O
system	NN	O
(	(	O
Nicoderm	NNP	O
)	)	O
BACKGROUND	NNP	O
Transdermal	NNP	O
nicotine	NN	O
therapy	NN	O
has	VBZ	O
shown	VBN	O
promise	NN	O
as	IN	O
a	DT	O
smoking	NN	O
cessation	NN	O
aid	NN	O
,	,	O
but	CC	O
questions	NNS	O
about	IN	O
its	PRP$	O
contact	NN	O
sensitization	NN	O
potential	NN	O
and	CC	O
long-term	JJ	O
topical	JJ	O
safety	NN	O
have	VBP	O
been	VBN	O
raised	VBN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
contact	NN	O
sensitization	NN	O
potential	NN	O
of	IN	O
one	CD	O
nicotine	NN	O
transdermal	NN	O
system	NN	O
(	(	O
Nicoderm	NNP	O
,	,	O
Marion	NNP	O
Merrell	NNP	O
Dow	NNP	O
Inc	NNP	O
,	,	O
Kansas	NNP	O
City	NNP	O
,	,	O
Mo	NNP	O
,	,	O
and	CC	O
ALZA	NNP	O
Corporation	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif	NNP	O
)	)	O
in	IN	O
a	DT	O
population	NN	O
who	WP	O
were	VBD	O
allowed	VBN	O
to	TO	O
continue	VB	O
smoking	VBG	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
comprised	VBD	O
two	CD	O
phases	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
2-week	JJ	O
rest	NN	O
interval	NN	O
.	.	O

During	IN	O
phase	NN	O
1	CD	O
,	,	O
a	DT	O
42-day	JJ	O
open-label	JJ	O
induction	NN	O
period	NN	O
,	,	O
subjects	VBZ	O
wore	IN	O
only	RB	O
active	JJ	O
transdermal	JJ	O
nicotine	JJ	O
systems	NNS	O
.	.	O

During	IN	O
phase	NN	O
2	CD	O
,	,	O
a	DT	O
4-day	JJ	O
double-blind	JJ	O
challenge	NN	O
period	NN	O
,	,	O
subjects	NNS	O
wore	VBD	O
active	JJ	O
and	CC	O
placebo	JJ	O
systems	NNS	O
concurrently	RB	O
.	.	O

Upon	IN	O
removal	NN	O
of	IN	O
each	DT	O
patch	NN	O
,	,	O
skin	NN	O
sites	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
signs	NNS	O
of	IN	O
irritation	NN	O
,	,	O
and	CC	O
subjective	JJ	O
complaints	NNS	O
such	JJ	O
as	IN	O
itching	NN	O
or	CC	O
burning	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
186	CD	O
subjects	NNS	O
completing	VBG	O
the	DT	O
study	NN	O
,	,	O
3	CD	O
(	(	O
1.6	CD	O
%	NN	O
)	)	O
exhibited	VBD	O
evidence	NN	O
of	IN	O
delayed	JJ	O
contact	NN	O
sensitization	NN	O
manifested	VBD	O
as	IN	O
erythema	NN	O
with	IN	O
or	CC	O
without	IN	O
infiltration	NN	O
and	CC	O
confined	VBD	O
solely	RB	O
to	TO	O
sites	NNS	O
of	IN	O
active	JJ	O
transdermal	JJ	O
nicotine	NN	O
system	NN	O
application	NN	O
.	.	O

Nonallergic	NNP	O
skin	JJ	O
irritation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
less	JJR	O
than	IN	O
3	CD	O
%	NN	O
of	IN	O
all	DT	O
applications	NNS	O
.	.	O

All	DT	O
reactions	NNS	O
resolved	VBN	O
without	IN	O
incident	NN	O
.	.	O

No	DT	O
subjects	NNS	O
developed	VBD	O
systemic	JJ	O
reactions	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
transdermal	JJ	O
nicotine	NN	O
system	NN	O
used	VBN	O
in	IN	O
this	DT	O
trial	NN	O
had	VBD	O
a	DT	O
low	JJ	O
contact	NN	O
sensitization	NN	O
incidence	NN	O
and	CC	O
was	VBD	O
well	RB	O
tolerated	VBN	O
topically	RB	O
with	IN	O
minimal	JJ	O
irritation	NN	O
.	.	O

Randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
the	DT	O
focus	NN	O
parent	NN	O
training	NN	O
for	IN	O
toddlers	NNS	Age
with	IN	O
autism	NN	Condition
:	:	O
1-year	JJ	O
outcome	NN	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
compared	VBN	O
results	NNS	O
obtained	VBD	O
after	IN	O
12	CD	O
months	NNS	O
of	IN	O
nonintensive	JJ	O
parent	NN	O
training	VBG	O
plus	CC	O
care-as-usual	JJ	O
and	CC	O
care-as-usual	JJ	O
alone	NN	O
.	.	O

The	DT	O
training	NN	O
focused	VBD	O
on	IN	O
stimulating	VBG	O
joint	JJ	O
attention	NN	O
and	CC	O
language	NN	O
skills	NNS	O
and	CC	O
was	VBD	O
based	VBN	O
on	IN	O
the	DT	O
intervention	NN	O
described	VBN	O
by	IN	O
Drew	NNP	O
et	CC	O
al	NN	O
.	.	O

(	(	O
Eur	NNP	O
Child	NNP	O
Adolesc	NNP	O
Psychiatr	NNP	O
11:266-272	CD	O
,	,	O
2002	CD	O
)	)	O
.	.	O

Seventy-five	JJ	O
toddlers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
65	CD	O
autism	NN	O
,	,	O
10	CD	O
PDD-NOS	NN	O
,	,	O
mean	JJ	O
age	NN	O
=	VBD	O
34.4	CD	O
months	NNS	O
,	,	O
SD	NNP	O
=	NNP	O
6.2	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
.	.	O

Analyses	NNS	O
were	VBD	O
conducted	VBN	O
on	IN	O
a	DT	O
final	JJ	O
sample	NN	O
of	IN	O
67	CD	O
children	NNS	O
(	(	O
lost	VBN	O
to	TO	O
follow-up	JJ	O
=	NNP	O
8	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
intervention	NN	O
effects	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
primary	JJ	O
(	(	O
language	NN	O
)	)	O
,	,	O
secondary	JJ	O
(	(	O
global	JJ	O
clinical	JJ	O
improvement	NN	O
)	)	O
,	,	O
or	CC	O
mediating	NN	O
(	(	O
child	JJ	O
engagement	NN	O
,	,	O
early	JJ	O
precursors	NNS	O
of	IN	O
social	JJ	O
communication	NN	O
,	,	O
or	CC	O
parental	JJ	O
skills	NNS	O
)	)	O
outcome	VBP	O
variables	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
the	DT	O
'Focus	NNP	O
parent	NN	O
training	VBG	O
'	''	O
was	VBD	O
not	RB	O
of	IN	O
additional	JJ	O
value	NN	O
to	TO	O
the	DT	O
more	JJR	O
general	JJ	O
care-as-usual	JJ	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
ophthalmic	JJ	O
insert	NN	O
Mydriasert	NNP	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
retinal	JJ	Condition
angiography	NN	Condition
.	.	O

PURPOSE	NNP	O
To	TO	O
verify	VB	O
the	DT	O
efficacy	NN	O
to	TO	O
obtain	VB	O
mydriasis	NN	O
and	CC	O
cardiovascular	JJ	O
safety	NN	O
of	IN	O
Mydriasert	NNP	O
(	(	O
ophthalmic	JJ	O
insert	NN	O
containing	VBG	O
tropicamide	NN	O
and	CC	O
phenylephrine	NN	O
)	)	O
in	IN	O
diabetic	JJ	Condition
and	CC	O
nondiabetic	JJ	Condition
patients	NNS	O
undergoing	VBG	O
retinal	JJ	O
angiography	NN	O
by	IN	O
comparing	VBG	O
it	PRP	O
with	IN	O
usually	RB	O
administered	VBN	O
eyedrops	NNS	O
(	(	O
tropicamide	VB	O
1	CD	O
%	NN	O
and	CC	O
phenylephrine	VB	O
10	CD	O
%	NN	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
154	CD	O
eyes	NNS	O
of	IN	O
77	CD	SampleSize
patients	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
:	:	O
group	NN	O
1	CD	O
consisted	VBD	O
of	IN	O
78	CD	O
eyes	NNS	O
,	,	O
group	NN	O
2	CD	O
consisted	VBD	O
of	IN	O
76	CD	O
eyes	NNS	O
,	,	O
and	CC	O
the	DT	O
patients	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
pupillary	JJ	O
dilation	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
and	CC	O
possible	JJ	O
adverse	JJ	O
effects	NNS	O
at	IN	O
0	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
60	CD	O
,	,	O
and	CC	O
90	CD	O
minutes	NNS	O
.	.	O

RESULTS	NNP	O
No	NNP	O
severe	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
entire	JJ	O
sample	NN	O
studied	VBD	O
,	,	O
the	DT	O
mean	JJ	O
pupillary	JJ	O
diameter	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
eyedrops	NNS	O
group	NN	O
after	IN	O
20	CD	O
and	CC	O
40	CD	O
minutes	NNS	O
,	,	O
while	IN	O
mydriasis	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
after	IN	O
60	CD	O
minutes	NNS	O
.	.	O

The	DT	O
diabetic	JJ	Condition
patients	NNS	Condition
treated	VBN	O
with	IN	O
Mydriasert	NNP	O
had	VBD	O
less	JJR	O
mydriasis	NN	O
than	IN	O
those	DT	O
treated	VBN	O
with	IN	O
eyedrops	NNS	O
after	IN	O
20	CD	O
and	CC	O
40	CD	O
minutes	NNS	O
,	,	O
and	CC	O
diabetic	JJ	O
patients	NNS	O
showed	VBD	O
less	JJR	O
mydriasis	NN	O
than	IN	O
the	DT	O
nondiabetic	JJ	O
patients	NNS	O
after	IN	O
60	CD	O
and	CC	O
90	CD	O
minutes	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
between-group	JJ	O
difference	NN	O
in	IN	O
mean	JJ	O
heart	NN	O
rate	NN	O
or	CC	O
systolic	NN	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
at	IN	O
any	DT	O
of	IN	O
the	DT	O
time	NN	O
points	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Mydriasert	NNP	O
assures	VBZ	O
an	DT	O
adequate	JJ	O
degree	NN	O
of	IN	O
mydriasis	NN	O
for	IN	O
retinal	JJ	O
angiography	NN	O
in	IN	O
both	DT	O
diabetic	JJ	O
and	CC	O
nondiabetic	JJ	O
patients	NNS	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
differences	NNS	O
in	IN	O
efficacy	NN	O
or	CC	O
safety	NN	O
between	IN	O
the	DT	O
insert	NN	O
and	CC	O
the	DT	O
usually	RB	O
administered	VBN	O
eyedrops	NNS	O
,	,	O
but	CC	O
the	DT	O
low	JJ	O
total	JJ	O
drug	NN	O
dose	NN	O
administered	VBN	O
with	IN	O
the	DT	O
insert	NN	O
reduces	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
side	NN	O
effects	NNS	O
.	.	O

A	DT	O
randomized	VBN	O
study	NN	O
comparing	VBG	O
glucagon	NN	O
and	CC	O
hyoscine	VB	O
N-butyl	NNP	O
bromide	NN	O
before	IN	O
endoscopic	NN	O
retrograde	NN	O
cholangiopancreatography	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
tried	VBD	O
to	TO	O
resolve	VB	O
whether	IN	O
glucagon	NN	O
is	VBZ	O
a	DT	O
better	JJR	O
premedication	NN	O
for	IN	O
endoscopic	NN	O
retrograde	NN	O
cholangiopancreatography	NN	O
(	(	O
ERCP	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
first	RB	O
measured	VBD	O
the	DT	O
basal	NN	O
blood	NN	O
sugar	NN	O
and	CC	O
amylase	NN	O
levels	NNS	O
.	.	O

Then	RB	O
an	DT	O
endoscope	NN	O
was	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
duodenum	NN	O
without	IN	O
premedication	NN	O
,	,	O
and	CC	O
basal	NN	O
pulse	NN	O
and	CC	O
duodenal	JJ	O
peristaltic	JJ	O
rates	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

ERCP	NNP	O
began	VBD	O
after	IN	O
studied	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
premedicated	VBN	O
with	IN	O
either	DT	O
1	CD	O
mg	NN	O
glucagon	NN	O
(	(	O
n	JJ	O
=	NNP	O
38	CD	O
)	)	O
or	CC	O
40	CD	O
mg	JJ	O
hyoscine	NN	O
N-butyl	NNP	O
bromide	NN	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
intravenously	RB	O
.	.	O

Ten	CD	O
minutes	NNS	O
later	RB	O
the	DT	O
variables	NNS	O
were	VBD	O
measured	VBN	O
again	RB	O
.	.	O

RESULTS	NNP	O
Glucagon	NNP	O
elicited	VBD	O
hyperglycemia	NN	O
whereas	NNS	O
hyoscine	VBP	O
N-butyl	NNP	O
bromide	NN	O
manifested	VBD	O
an	DT	O
anticholinergic	JJ	O
effect	NN	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
these	DT	O
two	CD	O
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
necessary	JJ	O
interval	NN	O
for	IN	O
ERCP	NNP	O
(	(	O
20.6	CD	O
+/-	JJ	O
14.1	CD	O
min	NN	O
versus	NN	O
21.4	CD	O
+/-	JJ	O
14.7	CD	O
min	NN	O
;	:	O
NS	NNP	O
)	)	O
or	CC	O
the	DT	O
success	NN	O
rate	NN	O
for	IN	O
cholangiopancreatography	NN	O
(	(	O
92.1	CD	O
%	NN	O
versus	IN	O
91.7	CD	O
%	NN	O
;	:	O
NS	NNP	O
)	)	O
.	.	O

Neither	CC	O
hyperamylasemia	JJ	O
nor	CC	O
pancreatitis	NN	O
was	VBD	O
preventable	JJ	O
when	WRB	O
glucagon	NN	O
was	VBD	O
used	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
two	CD	O
premedications	NNS	O
appear	VBP	O
equally	RB	O
effective	JJ	O
in	IN	O
the	DT	O
performance	NN	O
of	IN	O
ERCP	NNP	O
.	.	O

Effect	NN	O
of	IN	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
on	IN	O
postexercise	NN	Condition
hypotension	NN	Condition
in	IN	O
humans	NNS	O
.	.	O

An	DT	O
acute	JJ	O
bout	NN	O
of	IN	O
aerobic	JJ	O
exercise	NN	O
results	NNS	O
in	IN	O
a	DT	O
reduced	JJ	O
blood	NN	O
pressure	NN	O
that	WDT	O
lasts	VBZ	O
several	JJ	O
hours	NNS	O
.	.	O

Animal	NNP	O
studies	NNS	O
suggest	VBP	O
this	DT	O
response	NN	O
is	VBZ	O
mediated	VBN	O
by	IN	O
increased	JJ	O
production	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
[	NNP	O
N	NNP	O
(	(	O
G	NNP	O
)	)	O
-monomethyl-L-arginine	NN	O
(	(	O
L-NMMA	NNP	O
)	)	O
]	NN	O
can	MD	O
reverse	VB	O
the	DT	O
drop	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
that	WDT	O
occurs	VBZ	O
after	IN	O
exercise	NN	O
in	IN	O
humans	NNS	O
.	.	O

Eight	NNP	SampleSize
healthy	JJ	O
subjects	NNS	O
underwent	JJ	O
parallel	JJ	O
experiments	NNS	O
on	IN	O
2	CD	O
separate	JJ	O
days	NNS	O
.	.	O

The	DT	O
order	NN	O
of	IN	O
the	DT	O
experiments	NNS	O
was	VBD	O
randomized	VBN	O
between	IN	O
sham	NN	O
(	(	O
60	CD	O
min	NN	O
of	IN	O
seated	JJ	O
upright	JJ	O
rest	NN	O
)	)	O
and	CC	O
exercise	NN	O
(	(	O
60	CD	O
min	NN	O
of	IN	O
upright	JJ	O
cycling	NN	O
at	IN	O
60	CD	O
%	NN	O
peak	NN	O
aerobic	JJ	O
capacity	NN	O
)	)	O
.	.	O

After	IN	O
both	DT	O
sham	NN	O
and	CC	O
exercise	NN	O
,	,	O
subjects	VBZ	O
received	VBN	O
,	,	O
in	IN	O
sequence	NN	O
,	,	O
systemic	JJ	O
alpha-adrenergic	JJ	O
blockade	NN	O
(	(	O
phentolamine	NN	O
)	)	O
and	CC	O
L-NMMA	NNP	O
.	.	O

Phentolamine	NNP	O
was	VBD	O
given	VBN	O
first	RB	O
to	TO	O
isolate	VB	O
the	DT	O
contribution	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
to	TO	O
postexercise	VB	O
hypotension	NN	O
by	IN	O
preventing	VBG	O
reflex	JJ	O
changes	NNS	O
in	IN	O
sympathetic	JJ	O
tone	NN	O
that	WDT	O
result	NN	O
from	IN	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
and	CC	O
to	TO	O
control	VB	O
for	IN	O
alterations	NNS	O
in	IN	O
resting	VBG	O
sympathetic	JJ	O
activity	NN	O
after	IN	O
exercise	NN	O
.	.	O

During	IN	O
each	DT	O
condition	NN	O
,	,	O
systemic	JJ	O
and	CC	O
regional	JJ	O
hemodynamics	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Throughout	IN	O
the	DT	O
study	NN	O
,	,	O
arterial	JJ	O
pressure	NN	O
and	CC	O
vascular	JJ	O
resistances	NNS	O
remained	VBD	O
lower	JJR	O
postexercise	NN	O
vs.	FW	O
postsham	NN	O
despite	IN	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
inhibition	NN	O
(	(	O
e.g.	JJ	O
,	,	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
after	IN	O
L-NMMA	NNP	O
was	VBD	O
108.0+/-2.4	JJ	O
mmHg	NN	O
postsham	NN	O
vs.	FW	O
102.1+/-3.3	JJ	O
mmHg	NN	O
postexercise	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Thus	VB	O
it	PRP	O
does	VBZ	O
not	RB	O
appear	VB	O
that	IN	O
postexercise	NN	O
hypotension	NN	O
is	VBZ	O
dependent	JJ	O
on	IN	O
increased	JJ	O
production	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
in	IN	O
humans	NNS	O
.	.	O

Safety	NN	O
of	IN	O
intravitreous	JJ	O
fomivirsen	NN	O
for	IN	O
treatment	NN	O
of	IN	O
cytomegalovirus	NN	Condition
retinitis	NN	Condition
in	IN	Condition
patients	NNS	Condition
with	IN	Condition
AIDS	NNP	Condition
.	.	Condition

PURPOSE	NNP	O
To	TO	O
report	VB	O
data	NNS	O
regarding	VBG	O
the	DT	O
safety	NN	O
of	IN	O
intravitreous	JJ	O
fomivirsen	NN	O
for	IN	O
treatment	NN	O
of	IN	O
cytomegalovirus	NN	O
(	(	O
CMV	NNP	O
)	)	O
retinitis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
(	(	O
AIDS	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Critical	NNP	O
review	NN	O
of	IN	O
safety	NN	O
data	NNS	O
from	IN	O
three	CD	O
randomized	NNS	O
controlled	VBD	O
clinical	JJ	O
trials	NNS	O
with	IN	O
supplemental	JJ	O
information	NN	O
from	IN	O
an	DT	O
expanded	VBN	O
drug	NN	O
access	NN	O
program	NN	O
.	.	O

METHODS	NNP	O
Adverse	NNP	O
ocular	JJ	O
events	NNS	O
reported	VBN	O
by	IN	O
clinician	JJ	O
investigators	NNS	O
were	VBD	O
listed	VBN	O
using	VBG	O
terms	NNS	O
modified	VBN	O
from	IN	O
the	DT	O
COSTART	NNP	O
dictionary	NN	O
.	.	O

Data	NNP	O
for	IN	O
two	CD	O
doses	NNS	O
(	(	O
165-microg/injection	JJ	O
[	NN	O
35	CD	O
eyes	NNS	O
,	,	O
30	CD	SampleSize
patients	NNS	O
]	JJ	O
and	CC	O
330-microg/injection	JJ	O
[	NN	O
153	CD	O
eyes	NNS	O
,	,	O
120	CD	SampleSize
patients	NNS	O
]	JJ	O
)	)	O
and	CC	O
two	CD	O
330-microg/injection	JJ	O
dose	JJ	O
schedules	NNS	O
of	IN	O
different	JJ	O
intensity	NN	O
were	VBD	O
pooled	VBN	O
to	TO	O
calculate	VB	O
incidence	NN	O
rates	NNS	O
for	IN	O
each	DT	O
event	NN	O
.	.	O

Rates	NNS	O
were	VBD	O
calculated	VBN	O
as	IN	O
events/patient-year	JJ	O
(	(	O
based	VBN	O
on	IN	O
total	JJ	O
cumulative	JJ	O
reported	VBD	O
events	NNS	O
and	CC	O
duration	NN	O
of	IN	O
treatment	NN	O
)	)	O
for	IN	O
events	NNS	O
that	WDT	O
could	MD	O
recur	VB	O
during	IN	O
treatment	NN	O
.	.	O

Rates	NNS	O
were	VBD	O
calculated	VBN	O
as	IN	O
patients	NNS	O
with	IN	O
events/person-year	JJ	O
for	IN	O
the	DT	O
following	JJ	O
events	NNS	O
:	:	O
retinal	JJ	O
detachment	NN	O
,	,	O
cataract	NN	O
,	,	O
visual	JJ	O
field	NN	O
disturbance	NN	O
,	,	O
and	CC	O
retinal	JJ	O
pigment	NN	O
epitheliopathy	NN	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
ability	NN	O
to	TO	O
manage	VB	O
events	NNS	O
,	,	O
we	PRP	O
reviewed	VBD	O
treatments	NNS	O
given	VBN	O
for	IN	O
two	CD	O
events	NNS	O
(	(	O
anterior	JJ	O
chamber	NN	O
inflammation	NN	O
,	,	O
increased	VBD	O
intraocular	JJ	O
pressure	NN	O
)	)	O
in	IN	O
one	CD	O
trial	NN	O
.	.	O

We	PRP	O
also	RB	O
report	VBP	O
an	DT	O
analysis	NN	O
comparing	VBG	O
the	DT	O
proportion	NN	O
of	IN	O
eyes	NNS	O
that	WDT	O
developed	VBD	O
one	CD	O
or	CC	O
more	JJR	O
key	JJ	O
events	NNS	O
to	TO	O
the	DT	O
cumulative	JJ	O
number	NN	O
of	IN	O
injections	NNS	O
.	.	O

RESULTS	JJ	O
Incidence	NN	O
rates	NNS	O
were	VBD	O
dose	JJ	O
and	CC	O
schedule	JJ	O
dependent	NN	O
(	(	O
165	CD	O
microg/injection	NN	O
,	,	O
4.06	CD	O
events/patient-year	JJ	O
;	:	O
330	CD	O
microg/injection	NN	O
,	,	O
6.58	CD	O
events/patient-year	JJ	O
[	NNP	O
less	JJR	O
intense	JJ	O
regimen	NNS	O
]	VBP	O
and	CC	O
8.35	CD	O
events/patient-year	JJ	O
[	NNP	O
more	JJR	O
intense	JJ	O
regimen	NNS	O
]	VBP	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBN	O
events	NNS	O
were	VBD	O
anterior	JJ	O
chamber	NN	O
inflammation	NN	O
and	CC	O
increased	VBD	O
intraocular	JJ	O
pressure	NN	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
events	NNS	O
increased	VBN	O
as	IN	O
the	DT	O
number	NN	O
of	IN	O
injections	NNS	O
increased	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Intravitreous	NNP	O
fomivirsen	NN	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
with	IN	O
an	DT	O
acceptable	JJ	O
safety	NN	O
profile	NN	O
.	.	O

Adverse	JJ	O
ocular	JJ	O
events	NNS	O
associated	VBN	O
with	IN	O
doses	NNS	O
and	CC	O
schedules	NNS	O
used	VBN	O
clinically	RB	O
can	MD	O
be	VB	O
managed	VBN	O
successfully	RB	O
with	IN	O
medical	JJ	O
therapy	NN	O
.	.	O

Early-stage	JJ	O
squamous	JJ	Condition
cell	NN	Condition
carcinoma	NN	Condition
of	IN	O
the	DT	O
oropharynx	NN	O
:	:	O
radiotherapy	NN	O
vs.	IN	O
trans-oral	JJ	O
robotic	JJ	O
surgery	NN	O
(	(	O
ORATOR	NNP	O
)	)	O
--	:	O
study	NN	O
protocol	NN	O
for	IN	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
incidence	NN	O
of	IN	O
oropharyngeal	JJ	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
(	(	O
OPSCC	NNP	Condition
)	)	O
has	VBZ	O
markedly	RB	O
increased	VBN	O
over	IN	O
the	DT	O
last	JJ	O
three	CD	O
decades	NNS	O
due	JJ	O
to	TO	O
newly	RB	O
found	VBN	O
associations	NNS	O
with	IN	O
human	JJ	O
papillomavirus	NN	O
(	(	O
HPV	NNP	O
)	)	O
infection	NN	O
.	.	O

Primary	JJ	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
is	VBZ	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
OPSCC	NNP	O
at	IN	O
most	JJS	O
centers	NNS	O
,	,	O
and	CC	O
over	IN	O
the	DT	O
last	JJ	O
decade	NN	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
concurrent	NN	O
chemotherapy	NN	O
has	VBZ	O
led	VBN	O
to	TO	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
survival	NN	O
,	,	O
but	CC	O
at	IN	O
the	DT	O
cost	NN	O
of	IN	O
increased	VBN	O
acute	NN	O
and	CC	O
late	JJ	O
toxicity	NN	O
.	.	O

Transoral	NNP	O
robotic	JJ	O
surgery	NN	O
(	(	O
TORS	NNP	O
)	)	O
has	VBZ	O
emerged	VBN	O
as	IN	O
a	DT	O
promising	JJ	O
alternative	JJ	O
treatment	NN	O
,	,	O
with	IN	O
preliminary	JJ	O
case	NN	O
series	NN	O
demonstrating	VBG	O
encouraging	JJ	O
oncologic	NN	O
,	,	O
functional	JJ	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
outcomes	VBZ	O
.	.	O

However	RB	O
,	,	O
comparisons	NNS	O
of	IN	O
TORS	NNP	O
and	CC	O
RT	NNP	O
in	IN	O
a	DT	O
non-randomized	JJ	O
fashion	NN	O
are	VBP	O
susceptible	JJ	O
to	TO	O
bias	VB	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
is	VBZ	O
to	TO	O
compare	VB	O
QOL	NNP	O
,	,	O
functional	JJ	O
outcomes	NNS	O
,	,	O
toxicity	NN	O
profiles	NNS	O
,	,	O
and	CC	O
survival	NN	O
following	VBG	O
primary	JJ	O
RT	NNP	O
(	(	O
?	.	O
chemotherapy	NN	O
)	)	O
vs.	FW	O
TORS	NNP	O
(	(	O
?	.	O
adjuvant	NN	O
[	NN	O
chemo	NN	O
]	NNP	O
RT	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
OPSCC	NNP	O
.	.	O

METHODS/DESIGN	NNP	O
The	DT	O
target	NN	O
patient	JJ	O
population	NN	O
comprises	NNS	O
OPSCC	NNP	O
patients	NNS	O
who	WP	O
would	MD	O
be	VB	O
unlikely	JJ	O
to	TO	O
require	VB	O
chemotherapy	JJ	O
post-resection	NN	O
:	:	O
Tumor	NN	O
stage	NN	O
T1-T2	NN	O
with	IN	O
likely	JJ	O
negative	JJ	O
margins	NNS	O
at	IN	O
surgery	NN	O
;	:	O
Nodal	NNP	O
stage	NN	O
N0-2	NNP	O
,	,	O
?3	NNP	O
cm	NN	O
in	IN	O
size	NN	O
,	,	O
with	IN	O
no	DT	O
evidence	NN	O
of	IN	O
extranodal	JJ	O
extension	NN	O
on	IN	O
imaging	VBG	O
.	.	O

Participants	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
in	IN	O
a	DT	O
1:1	CD	O
ratio	NN	O
between	IN	O
Arm	NNP	O
1	CD	O
(	(	O
RT	NNP	O
?	.	O
chemotherapy	NN	O
)	)	O
and	CC	O
Arm	$	O
2	CD	O
(	(	O
TORS	NNP	O
?	.	O
adjuvant	JJ	O
[	NN	O
chemo	NN	O
]	NNP	O
RT	NNP	O
)	)	O
.	.	O

In	IN	O
Arm	NNP	O
1	CD	O
,	,	O
patients	NNS	O
with	IN	O
N0	NNP	O
disease	NN	O
will	MD	O
receive	VB	O
RT	NNP	O
alone	RB	O
,	,	O
whereas	JJ	O
N1-2	JJ	O
patients	NNS	O
will	MD	O
receive	VB	O
concurrent	JJ	O
chemoradiation	NN	O
.	.	O

In	IN	O
Arm	NNP	O
2	CD	O
,	,	O
patients	NNS	O
will	MD	O
undergo	VB	O
TORS	NNP	O
along	IN	O
with	IN	O
selective	JJ	O
neck	NN	O
dissections	NNS	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
staged	VBN	O
.	.	O

Pathologic	NNP	O
high-risk	JJ	O
features	NNS	O
will	MD	O
be	VB	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
requirement	NN	O
for	IN	O
adjuvant	JJ	O
radiotherapy	NN	O
+/-	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
is	VBZ	O
QOL	NNP	O
score	NN	O
using	VBG	O
the	DT	O
M.D	NNP	O
.	.	O

Anderson	NNP	O
Dysphagia	NNP	O
Inventory	NNP	O
(	(	O
MDADI	NNP	O
)	)	O
,	,	O
with	IN	O
secondary	JJ	O
endpoints	NNS	O
including	VBG	O
survival	NN	O
,	,	O
toxicity	NN	O
,	,	O
other	JJ	O
QOL	NNP	O
outcomes	NNS	O
,	,	O
and	CC	O
swallowing	VBG	O
function	NN	O
.	.	O

A	DT	O
sample	NN	O
of	IN	O
68	CD	O
patients	NNS	O
is	VBZ	O
required	VBN	O
.	.	O

DISCUSSION	VB	O
This	DT	O
study	NN	O
,	,	O
if	IN	O
successful	JJ	O
,	,	O
will	MD	O
provide	VB	O
a	DT	O
much-needed	JJ	O
randomized	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
conventional	JJ	O
strategy	NN	O
of	IN	O
primary	JJ	O
RT	NNP	O
vs.	IN	O
the	DT	O
novel	JJ	O
strategy	NN	O
of	IN	O
primary	JJ	O
TORS	NNP	O
.	.	O

The	DT	O
trial	NN	O
is	VBZ	O
designed	VBN	O
to	TO	O
provide	VB	O
a	DT	O
definitive	JJ	O
QOL	NNP	O
comparison	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
,	,	O
and	CC	O
to	TO	O
inform	VB	O
the	DT	O
design	NN	O
of	IN	O
an	DT	O
eventual	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
for	IN	O
survival	JJ	O
outcomes	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
NCT01590355	NNP	O
.	.	O

Is	VBZ	O
hands-on	JJ	O
experience	NN	O
more	RBR	O
effective	JJ	O
than	IN	O
didactic	JJ	O
workshops	NNS	O
in	IN	O
postgraduate	NN	O
cancer	NN	Condition
pain	NN	O
education	NN	O
?	.	O
BACKGROUND	NNP	O
This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
nurse	JJ	O
outcomes	NNS	O
of	IN	O
a	DT	O
cancer	NN	Condition
pain	NN	O
education	NN	O
program	NN	O
for	IN	O
nurses	NNS	O
of	IN	O
patients	NNS	O
from	IN	O
11	CD	O
different	JJ	O
ethnic	JJ	O
groups	NNS	O
.	.	O

METHODS	NNP	O
Four	CD	SampleSize
hundred	VBD	SampleSize
ninety	NN	SampleSize
six	CD	SampleSize
home	NN	O
,	,	O
hospital	NN	O
,	,	O
and	CC	O
hospice	NN	O
nurses	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
one-day	JJ	O
workshop	NN	O
or	CC	O
two	CD	O
half-day	JJ	O
workshops	NNS	O
on	IN	O
cancer	NN	Condition
pain	NN	O
assessment	NN	O
and	CC	O
management	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
116	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
participate	VB	O
in	IN	O
a	DT	O
bedside-precepted	JJ	O
visit	NN	O
with	IN	O
an	DT	O
oncology	NN	O
nurse	JJ	O
specialist	NN	O
with	IN	O
pain	NN	O
specialization	NN	O
and	CC	O
a	DT	O
focus	NN	O
group	NN	O
to	TO	O
discuss	VB	O
attitudinal	JJ	O
issues	NNS	O
.	.	O

Eighty-six	JJ	SampleSize
nurses	NNS	O
served	VBD	O
as	IN	O
controls	NNS	O
.	.	O

Pre-	NNP	O
,	,	O
post-	JJ	O
and	CC	O
one-year	JJ	O
follow-up	JJ	O
tests	NNS	O
were	VBD	O
administered	VBN	O
.	.	O

RESULTS	NNP	O
Attitudes	NNP	O
,	,	O
knowledge	NN	O
,	,	O
and	CC	O
application	NN	O
skills	NNS	O
significantly	RB	O
improved	VBN	O
for	IN	O
workshop-only	JJ	O
and	CC	O
enriched-model	JJ	O
nurses	NNS	O
relative	VBP	O
to	TO	O
controls	NNS	O
.	.	O

CONCLUSION	NNP	O
For	IN	O
postgraduate	NN	O
nurses	NNS	O
,	,	O
daylong	JJ	O
cancer	NN	O
pain	NN	O
education	NN	O
workshops	NNS	O
were	VBD	O
,	,	O
in	IN	O
the	DT	O
group	NN	O
studied	VBD	O
,	,	O
as	RB	O
effective	JJ	O
as	IN	O
hands-on	JJ	O
experience	NN	O
in	IN	O
improving	VBG	O
cancer	NN	O
pain	NN	O
knowledge	NN	O
and	CC	O
changing	VBG	O
attitudes	NNS	O
.	.	O

Both	DT	O
the	DT	O
workshop-only	JJ	O
and	CC	O
the	DT	O
enriched-model	JJ	O
nurses	NNS	O
relative	VBP	O
to	TO	O
controls	NNS	O
had	VBD	O
significantly	RB	O
improved	VBN	O
knowledge	NN	O
and	CC	O
changed	VBD	O
attitudes	NNS	O
towards	IN	O
optimal	JJ	O
pain	NN	O
management	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
investigating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
porcine	NN	O
secretin	NN	O
in	IN	O
children	NNS	Age
with	IN	O
autism	NN	Condition
.	.	O

OBJECTIVES	CC	O
A	DT	O
recent	JJ	O
patient	NN	O
series	NN	O
reported	VBD	O
the	DT	O
incidental	JJ	O
findings	NNS	O
of	IN	O
improved	VBN	O
social	JJ	O
and	CC	O
language	NN	O
skills	NNS	O
in	IN	O
3	CD	O
children	NNS	Age
with	IN	O
autistic	JJ	Condition
spectrum	NN	Condition
disorders	NNS	Condition
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
secretin	NN	O
,	,	O
a	DT	O
peptide	NN	O
hormone	NN	O
.	.	O

However	RB	O
,	,	O
a	DT	O
subsequent	JJ	O
study	NN	O
did	VBD	O
not	RB	O
find	VB	O
evidence	NN	O
for	IN	O
a	DT	O
drug	NN	O
effect	NN	O
.	.	O

Parents	NNS	O
are	VBP	O
seeking	VBG	O
treatment	NN	O
with	IN	O
secretin	JJ	O
despite	IN	O
the	DT	O
absence	NN	O
of	IN	O
empirical	JJ	O
investigations	NNS	O
demonstrating	VBG	O
amelioration	NN	O
in	IN	O
autism	NN	O
symptomology	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
more	RBR	O
precisely	RB	O
measure	VB	O
the	DT	O
effects	NNS	O
of	IN	O
secretin	NN	O
,	,	O
this	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
porcine	NN	O
secretin	NN	O
on	IN	O
12	CD	SampleSize
autistic	JJ	O
children	NNS	Age
through	IN	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Children	NNP	O
were	VBD	O
assessed	VBN	O
on	IN	O
objective	JJ	O
language	NN	O
and	CC	O
on	IN	O
social	JJ	O
,	,	O
neuropsychological	JJ	O
,	,	O
and	CC	O
gastrointestinal	JJ	O
measures	NNS	O
to	TO	O
evaluate	VB	O
drug	NN	O
effects	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
over	IN	O
a	DT	O
16-week	JJ	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
significant	JJ	O
differences	NNS	O
were	VBD	O
not	RB	O
observed	VBN	O
on	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
dependent	JJ	O
variables	NNS	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
on	IN	O
measures	NNS	O
of	IN	O
positive	JJ	O
affect	NN	O
and	CC	O
activity	NN	O
level	NN	O
following	VBG	O
secretin	JJ	O
infusion	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
autistic	JJ	O
children	NNS	Age
did	VBD	O
not	RB	O
demonstrate	VB	O
the	DT	O
improvements	NNS	O
described	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
retrospective	JJ	O
report	NN	O
.	.	O

Effect	NN	O
of	IN	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
n-3	JJ	O
fatty	JJ	O
acids	NNS	O
on	IN	O
coronary	JJ	Condition
artery	NN	Condition
bypass	NN	Condition
graft	NN	Condition
patency	NN	O
.	.	O

Epidemiologic	NNP	O
and	CC	O
experimental	JJ	O
data	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
high	JJ	O
dietary	JJ	O
intake	NN	O
of	IN	O
long-chain	JJ	O
polyunsaturated	JJ	O
n-3	JJ	O
fatty	JJ	O
acids	NNS	O
may	MD	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
atherothrombotic	JJ	O
disease	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBD	O
study	NN	O
,	,	O
610	CD	SampleSize
patients	NNS	O
undergoing	JJ	O
coronary	JJ	Condition
artery	NN	Condition
bypass	NN	Condition
grafting	VBG	Condition
were	VBD	O
assigned	VBN	O
either	RB	O
to	TO	O
a	DT	O
fish	JJ	O
oil	NN	O
group	NN	O
,	,	O
receiving	VBG	O
4	CD	O
g/day	NN	O
of	IN	O
fish	JJ	O
oil	NN	O
concentrate	NN	O
,	,	O
or	CC	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
antithrombotic	JJ	Condition
treatment	NN	Condition
,	,	O
either	CC	O
aspirin	NN	O
or	CC	O
warfarin	NN	O
.	.	O

Their	PRP$	O
diet	JJ	O
and	CC	O
serum	JJ	O
phospholipid	JJ	O
fatty	JJ	O
acid	NN	O
profiles	NNS	O
were	VBD	O
monitored	VBN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
1-year	JJ	O
graft	NN	O
patency	NN	O
,	,	O
which	WDT	O
was	VBD	O
assessed	VBN	O
by	IN	O
angiography	NN	O
in	IN	O
95	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Vein	NNP	O
graft	JJ	O
occlusion	NN	O
rates	NNS	O
per	IN	O
distal	JJ	O
anastomoses	NNS	O
were	VBD	O
27	CD	O
%	NN	O
in	IN	O
the	DT	O
fish	JJ	O
oil	NN	O
group	NN	O
and	CC	O
33	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
0.77	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.60	CD	O
to	TO	O
0.99	CD	O
,	,	O
p	NN	O
=	NNP	O
0.034	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
fish	JJ	O
oil	NN	O
group	NN	O
,	,	O
43	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
>	VBN	O
or	CC	O
=	$	O
1	CD	O
occluded	VBN	O
vein	NN	O
graft	NN	O
(	(	O
s	PRP	O
)	)	O
compared	VBN	O
with	IN	O
51	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
0.72	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.51	CD	O
to	TO	O
1.01	CD	O
,	,	O
p	NN	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
in	IN	O
the	DT	O
entire	JJ	O
patient	NN	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
trend	NN	O
to	TO	O
fewer	JJR	O
patients	NNS	O
with	IN	O
vein	JJ	O
graft	NN	O
occlusions	NNS	O
with	IN	O
increasing	VBG	O
relative	JJ	O
change	NN	O
in	IN	O
serum	JJ	O
phospholipid	JJ	O
n-3	JJ	O
fatty	JJ	O
acids	NNS	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
(	(	O
p	NN	O
for	IN	O
linear	JJ	O
trend	NN	O
=	VBZ	O
0.0037	CD	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	Condition
artery	NN	Condition
bypass	NN	Condition
grafting	NN	Condition
,	,	O
dietary	JJ	O
supplementation	NN	O
with	IN	O
n-3	JJ	O
fatty	JJ	O
acids	NNS	O
reduced	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
vein	NN	O
graft	NN	O
occlusion	NN	O
,	,	O
and	CC	O
an	DT	O
inverse	JJ	O
relation	NN	O
between	IN	O
relative	JJ	O
change	NN	O
in	IN	O
serum	JJ	O
phospholipid	JJ	O
n-3	JJ	O
fatty	JJ	O
acids	NNS	O
and	CC	O
vein	NN	O
graft	NN	O
occlusions	NNS	O
was	VBD	O
observed	VBN	O
.	.	O

Medication	NN	O
and	CC	O
parent	NN	O
training	NN	O
in	IN	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
and	CC	O
serious	JJ	O
behavior	NN	O
problems	NNS	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	NNP	O
Many	JJ	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
(	(	O
PDDs	NNP	O
)	)	O
have	VBP	O
serious	JJ	O
,	,	O
functionally	RB	O
impairing	VBG	O
behavioral	JJ	O
problems	NNS	O
.	.	O

We	PRP	O
tested	VBD	O
whether	IN	O
combined	VBN	O
treatment	NN	O
(	(	O
COMB	NNP	O
)	)	O
with	IN	O
risperidone	NN	O
and	CC	O
parent	NN	O
training	NN	O
(	(	O
PT	NNP	O
)	)	O
in	IN	O
behavior	JJ	O
management	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
medication	VB	O
alone	RB	O
(	(	O
MED	NNP	O
)	)	O
in	IN	O
improving	VBG	O
severe	JJ	O
behavioral	JJ	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
PDDs	NNP	O
.	.	O

METHOD	NNP	O
This	DT	O
24-week	JJ	O
,	,	O
three-site	JJ	O
,	,	O
randomized	VBN	O
,	,	O
parallel-groups	JJ	O
clinical	JJ	O
trial	NN	O
enrolled	VBD	O
124	CD	O
children	NNS	O
,	,	O
aged	VBD	O
4	CD	O
through	IN	O
13	CD	O
years	NNS	O
,	,	O
with	IN	O
PDDs	NNP	O
,	,	O
accompanied	VBN	O
by	IN	O
frequent	JJ	O
tantrums	NNS	O
,	,	O
self-injury	NN	O
,	,	O
and	CC	O
aggression	NN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
randomized	VBN	O
3:2	CD	O
to	TO	O
COMB	NNP	O
(	(	O
n	JJ	O
=	NNP	O
75	CD	O
)	)	O
or	CC	O
MED	NNP	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
.	.	O

The	DT	O
participants	NNS	O
received	VBD	O
risperidone	JJ	O
monotherapy	NN	O
from	IN	O
0.5	CD	O
to	TO	O
3.5	CD	O
mg/day	NN	O
(	(	O
with	IN	O
switch	NN	O
to	TO	O
aripiprazole	VB	O
if	IN	O
risperidone	NN	O
was	VBD	O
ineffective	JJ	O
)	)	O
.	.	O

Parents	NNS	O
in	IN	O
the	DT	O
COMB	NNP	O
group	NN	O
(	(	O
n	JJ	O
=	VBZ	O
75	CD	O
;	:	O
60.5	CD	O
%	NN	O
)	)	O
received	VBD	O
a	DT	O
mean	NN	O
of	IN	O
10.9	CD	O
PT	NNP	O
sessions	NNS	O
.	.	O

The	DT	O
primary	JJ	O
measure	NN	O
of	IN	O
compliance	NN	O
was	VBD	O
the	DT	O
Home	NNP	O
Situations	NNP	O
Questionnaire	NNP	O
(	(	O
HSQ	NNP	O
)	)	O
score	NN	O
.	.	O

RESULTS	NNP	O
Primary	JJ	O
:	:	O
intent-to-treat	JJ	O
random	NN	O
effects	NNS	O
regression	NN	O
showed	VBD	O
that	IN	O
COMB	NNP	O
was	VBD	O
superior	JJ	O
to	TO	O
MED	NNP	O
on	IN	O
HSQ	NNP	O
(	(	O
p	JJ	O
=	NNP	O
.006	NNP	O
)	)	O
[	VBP	O
effect	NN	O
size	NN	O
at	IN	O
week	NN	O
24	CD	O
(	(	O
d	NN	O
)	)	O
=	VBZ	O
0.34	CD	O
]	NN	O
.	.	O

The	DT	O
HSQ	NNP	O
score	NN	O
declined	VBD	O
from	IN	O
4.31	CD	O
(	(	O
?	.	O
1.67	CD	O
)	)	O
to	TO	O
1.23	CD	O
(	(	O
?	.	O
1.36	CD	O
)	)	O
for	IN	O
COMB	NNP	O
compared	VBN	O
with	IN	O
4.16	CD	O
(	(	O
?	.	O
1.47	CD	O
)	)	O
to	TO	O
1.68	CD	O
(	(	O
?	.	O
1.36	CD	O
)	)	O
for	IN	O
MED	NNP	O
.	.	O

Secondary	JJ	O
:	:	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
on	IN	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NN	O
scores	NNS	O
at	IN	O
endpoint	NN	O
;	:	O
compared	VBN	O
with	IN	O
MED	NNP	O
,	,	O
COMB	NNP	O
showed	VBD	O
significant	JJ	O
reductions	NNS	O
on	IN	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
Irritability	NNP	O
(	(	O
d	JJ	O
=	VBZ	O
0.48	CD	O
;	:	O
p	NN	O
=	NNP	O
.01	NNP	O
)	)	O
,	,	O
Stereotypic	NNP	O
Behavior	NNP	O
(	(	O
d	JJ	O
=	VBZ	O
0.23	CD	O
;	:	O
p	NN	O
=	NNP	O
.04	NNP	O
)	)	O
,	,	O
and	CC	O
Hyperactivity/Noncompliance	NNP	O
subscales	NNS	O
(	(	O
d	VB	O
=	RB	O
0.55	CD	O
;	:	O
p	NN	O
=	NNP	O
.04	NNP	O
)	)	O
.	.	O

Final	NNP	O
risperidone	NN	O
mean	NN	O
dose	NN	O
for	IN	O
MED	NNP	O
was	VBD	O
2.26	CD	O
mg/day	NN	O
(	(	O
0.071	CD	O
mg/kg	NN	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
1.98	CD	O
mg/day	NN	O
for	IN	O
COMB	NNP	O
(	(	O
0.066	CD	O
mg/kg	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
.04	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Medication	NNP	O
plus	CC	O
PT	NNP	O
resulted	VBD	O
in	IN	O
greater	JJR	O
reduction	NN	O
of	IN	O
serious	JJ	O
maladaptive	JJ	O
behavior	NN	O
than	IN	O
MED	NNP	O
in	IN	O
children	NNS	O
with	IN	O
PDDs	NNP	O
,	,	O
with	IN	O
a	DT	O
lower	JJR	O
risperidone	NN	O
dose	NN	O
.	.	O

Treatment	NN	O
of	IN	O
adult	NN	O
asthma	NN	O
:	:	O
controlled	VBN	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
oxitropium	NN	O
bromide	NN	O
.	.	O

Sixteen	NNP	O
young	JJ	O
adult	NN	O
sufferers	NNS	O
from	IN	O
extrinsic	JJ	O
paroxysmal	JJ	O
asthma	NN	O
with	IN	O
pollen	JJ	O
hypersensitivity	NN	O
took	VBD	O
part	NN	O
in	IN	O
a	DT	O
therapeutic	JJ	O
trial	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
anticholinergic	NN	O
agent	NN	O
oxitropium	NN	O
bromide	NN	O
administered	VBN	O
by	IN	O
a	DT	O
metered	VBN	O
dose	NN	O
inhaler	NN	O
.	.	O

The	DT	O
study	NN	O
comprised	VBD	O
three	CD	O
3-week	JJ	O
periods	NNS	O
.	.	O

The	DT	O
first	JJ	O
,	,	O
run-in	JJ	O
period	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
confirm	VB	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
patients	NNS	O
to	TO	O
maintain	VB	O
a	DT	O
daily	JJ	O
record	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

During	IN	O
the	DT	O
second	JJ	O
and	CC	O
third	JJ	O
periods	NNS	O
,	,	O
the	DT	O
patient	NN	O
received	VBD	O
3	CD	O
X	NNP	O
2	CD	O
inhalations	NNS	O
of	IN	O
drug	NN	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
cross-over	JJ	O
design	NN	O
.	.	O

The	DT	O
medical	JJ	O
staff	NN	O
was	VBD	O
blind	NN	O
to	TO	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
aerosol	NN	O
(	(	O
drug	NN	O
or	CC	O
placebo	NN	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
given	VBN	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

The	DT	O
run-in	JJ	O
clinical	JJ	O
score	NN	O
was	VBD	O
high	JJ	O
.	.	O

Asymptomatic	JJ	O
days	NNS	O
were	VBD	O
relatively	RB	O
infrequent	JJ	O
and	CC	O
daily	JJ	O
drug	NN	O
consumption	NN	O
was	VBD	O
high	JJ	O
.	.	O

Functional	JJ	O
studies	NNS	O
between	IN	O
the	DT	O
cross-over	NN	O
periods	NNS	O
showed	VBD	O
flow-rate	JJ	O
values	NNS	O
close	RB	O
to	TO	O
normal	JJ	O
,	,	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
residual	JJ	O
volume	NN	O
and	CC	O
functional	JJ	O
residual	JJ	O
capacity	NN	O
.	.	O

During	IN	O
treatment	NN	O
either	CC	O
with	IN	O
placebo	NN	O
or	CC	O
oxitropium	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
decrease	NN	O
in	IN	O
clinical	JJ	O
scores	NNS	O
.	.	O

Results	NNS	O
for	IN	O
oxitropium	JJ	O
bromide	NN	O
treatment	NN	O
were	VBD	O
significantly	RB	O
better	JJR	O
than	IN	O
the	DT	O
run-in	JJ	O
values	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
and	CC	O
the	DT	O
placebo	NN	O
period	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
in	IN	O
non-trial	JJ	O
drug	NN	O
consumption	NN	O
.	.	O

Functional	NNP	O
values	NNS	O
showed	VBD	O
no	DT	O
difference	NN	O
in	IN	O
terms	NNS	O
of	IN	O
flow	NN	O
rate	NN	O
,	,	O
although	IN	O
oxitropium	NN	O
did	VBD	O
cause	VB	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
RV/TLC	NNP	O
ratio	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
reported	VBN	O
.	.	O

Rifampicin	NNP	O
plus	CC	O
isoniazid	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
tuberculosis	NN	O
in	IN	O
an	DT	O
immigrant	JJ	O
population	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
tolerance	NN	O
,	,	O
adherence	NN	O
and	CC	O
effectiveness	NN	O
of	IN	O
two	CD	O
approaches	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
latent	JJ	O
tuberculosis	NN	O
infection	NN	O
(	(	O
LTBI	NNP	O
)	)	O
:	:	O
6	CD	O
months	NNS	O
of	IN	O
isoniazid	NN	O
(	(	O
6H	CD	O
)	)	O
vs.	FW	O
3	CD	O
months	NNS	O
of	IN	O
isoniazid	JJ	O
plus	CC	O
rifampicin	JJ	O
(	(	O
3RH	CD	O
)	)	O
.	.	O

POPULATION	JJ	O
Immigrants	NNS	Condition
with	IN	O
LTBI	NNP	Condition
.	.	O

METHODS	NNP	O
Participants	NNPS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
controlled	VBN	O
,	,	O
randomised	VBD	O
clinical	JJ	O
trial	NN	O
in	IN	O
Barcelona	NNP	O
,	,	O
Spain	NNP	O
,	,	O
from	IN	O
April	NNP	O
2001	CD	O
to	TO	O
April	NNP	O
2005	CD	O
.	.	O

Monthly	JJ	O
follow-up	NN	O
was	VBD	O
done	VBN	O
to	TO	O
assess	VB	O
tolerance	NN	O
,	,	O
side	NN	O
effects	NNS	O
and	CC	O
adherence	NN	O
.	.	O

Effectiveness	NNP	O
was	VBD	O
evaluated	VBN	O
at	IN	O
5	CD	O
years	NNS	O
.	.	O

RESULTS	NN	O
In	IN	O
the	DT	O
590	CD	SampleSize
subjects	NNS	O
enrolled	VBN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
adherence	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
3RH	CD	O
than	IN	O
in	IN	O
the	DT	O
6H	CD	O
arm	NN	O
(	(	O
72	CD	O
%	NN	O
vs.	FW	O
52.4	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	UH	O
differences	NNS	O
between	IN	O
study	NN	O
arms	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
respect	NN	O
to	TO	O
hepatotoxicity	NN	O
or	CC	O
side	NN	O
effects	NNS	O
.	.	O

Variables	NNS	O
associated	VBN	O
with	IN	O
non-adherence	NN	O
were	VBD	O
diagnosis	VBN	O
by	IN	O
screening	VBG	O
(	(	O
OR	CC	O
1.88	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.26-2.82	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
illegal	JJ	O
immigration	NN	O
status	NN	O
(	(	O
OR	CC	O
1.48	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.01-2.15	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
unemployment	NN	O
(	(	O
OR	CC	O
1.91	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.28-2.85	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0008	CD	O
)	)	O
,	,	O
illiteracy	NN	O
(	(	O
OR	CC	O
1.73	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.04-2.88	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
lack	NN	O
of	IN	O
family	NN	O
support	NN	O
(	(	O
OR	NNP	O
3.7	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
2.54-5.4	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
and	CC	O
the	DT	O
6-month	JJ	O
treatment	NN	O
regimen	NNS	O
(	(	O
OR	NNP	O
2.45	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.68-3.57	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
patients	NNS	O
who	WP	O
completed	VBD	O
either	CC	O
treatment	NN	O
developed	VBD	O
tuberculosis	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
3RH	CD	O
regimen	NNS	O
facilitates	VBZ	O
adherence	NN	O
to	TO	O
LTBI	NNP	O
treatment	NN	O
and	CC	O
offers	VBZ	O
a	DT	O
safe	JJ	O
,	,	O
well-tolerated	JJ	O
and	CC	O
effective	JJ	O
alternative	NN	O
.	.	O

A	DT	O
limited	JJ	O
sampling	NN	O
method	NN	O
for	IN	O
the	DT	O
estimation	NN	O
of	IN	O
flunarizine	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
and	CC	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
.	.	O

A	DT	O
limited	JJ	O
sampling	NN	O
model	NN	O
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
flunarizine	NN	O
following	VBG	O
a	DT	O
30	CD	O
mg	JJ	O
oral	JJ	O
dose	NN	O
in	IN	O
epileptic	JJ	Condition
patients	NNS	Condition
who	WP	O
were	VBD	O
receiving	VBG	Condition
phenytoin	NN	Condition
or	CC	Condition
carbamazepine	NN	Condition
or	CC	Condition
both	DT	Condition
,	,	O
to	TO	O
estimate	VB	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
and	CC	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
.	.	O

The	DT	O
model	NN	O
was	VBD	O
developed	VBN	O
using	VBG	O
training	VBG	O
data	NNS	O
sets	NNS	O
from	IN	O
30	CD	O
,	,	O
20	CD	O
,	,	O
15	CD	O
,	,	O
or	CC	O
10	CD	O
patients	NNS	O
at	IN	O
one	CD	O
or	CC	O
two	CD	O
time	NN	O
points	NNS	O
.	.	O

The	DT	O
equations	NNS	O
describing	VBG	O
the	DT	O
models	NNS	O
for	IN	O
AUC	NNP	O
using	VBG	O
two	CD	O
time	NN	O
points	NNS	O
(	(	O
3	CD	O
and	CC	O
24h	CD	O
)	)	O
and	CC	O
Cmax	NNP	O
for	IN	O
the	DT	O
training	NN	O
data	NNS	O
set	NN	O
of	IN	O
30	CD	O
subjects	NNS	O
were	VBD	O
AUCpredicted	NNP	O
=	NNP	O
11.1	CD	O
C3h	NNP	O
+	VBD	O
121.4	CD	O
C24h	NNP	O
-	:	O
157	CD	O
(	(	O
r	NN	O
=	RB	O
0.80	CD	O
)	)	O
Cmax	NNP	O
(	(	O
predicted	VBN	O
)	)	O
=	$	O
0.036	CD	O
AUC	NNP	O
+	$	O
42.9	CD	O
(	(	O
r	NN	O
=	RB	O
0.74	CD	O
)	)	O
The	DT	O
model	NN	O
was	VBD	O
validated	VBN	O
on	IN	O
64	CD	SampleSize
patients	NNS	O
who	WP	O
received	VBD	O
flunarizine	JJ	O
orally	RB	O
.	.	O

The	DT	O
model	NN	O
provided	VBD	O
reasonably	RB	O
good	JJ	O
estimates	NNS	O
for	IN	O
both	DT	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
.	.	O

The	DT	O
mean	NN	O
predicted	VBD	O
AUC	NNP	O
of	IN	O
flunarizine	NN	O
was	VBD	O
1230	CD	O
+/-	JJ	O
717	CD	O
ng	JJ	O
h	NN	O
mL-1	NN	O
,	,	O
whereas	IN	O
the	DT	O
observed	JJ	O
AUC	NNP	O
was	VBD	O
1203	CD	O
+/-	JJ	O
900	CD	O
ng	JJ	O
h	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	O
of	IN	O
the	DT	O
prediction	NN	O
was	VBD	O
2	CD	O
%	NN	O
and	CC	O
precision	NN	O
was	VBD	O
28	CD	O
%	NN	O
.	.	O

The	DT	O
mean	NN	O
predicted	VBD	O
Cmax	NNP	O
of	IN	O
flunarizine	NN	O
was	VBD	O
86	CD	O
+/-	JJ	O
32	CD	O
ng	JJ	O
mL-1	NN	O
as	IN	O
compared	VBN	O
to	TO	O
an	DT	O
observed	JJ	O
mean	NN	O
Cmax	NNP	O
of	IN	O
90	CD	O
+/-	JJ	O
42	CD	O
ng	JJ	O
mL-1	NN	O
.	.	O

The	DT	O
bias	NN	O
and	CC	O
precision	NN	O
of	IN	O
the	DT	O
prediction	NN	O
were	VBD	O
4	CD	O
%	NN	O
and	CC	O
24	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
method	NN	O
described	VBD	O
here	RB	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
estimate	VB	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
for	IN	O
flunarizine	NN	O
without	IN	O
detailed	JJ	O
pharmacokinetic	JJ	O
studies	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
brain	NN	O
metastases	NNS	O
of	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
:	:	O
comparing	NN	O
teniposide	NN	O
and	CC	O
teniposide	NN	O
with	IN	O
whole-brain	JJ	O
radiotherapy	NN	O
--	:	O
a	DT	O
phase	NN	O
III	NNP	O
study	NN	O
of	IN	O
the	DT	O
European	JJ	O
Organization	NNP	O
for	IN	O
the	DT	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
Lung	NNP	O
Cancer	NNP	O
Cooperative	NNP	O
Group	NNP	O
.	.	O

PURPOSE	NNP	O
Approximately	RB	O
60	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
SCLC	NNP	O
)	)	O
develop	VB	O
brain	NN	O
metastases	NNS	O
.	.	O

Whole-brain	JJ	O
radiotherapy	NN	O
(	(	O
WBRT	NNP	O
)	)	O
gives	VBZ	O
symptomatic	JJ	O
improvement	NN	O
in	IN	O
more	JJR	O
than	IN	O
50	CD	O
%	NN	O
of	IN	O
these	DT	O
patients	NNS	O
.	.	O

Because	IN	O
brain	NN	O
metastases	NNS	O
are	VBP	O
a	DT	O
sign	NN	O
of	IN	O
systemic	JJ	O
progression	NN	O
,	,	O
and	CC	O
chemotherapy	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
as	IN	O
well	RB	O
,	,	O
it	PRP	O
becomes	VBZ	O
questionable	JJ	O
whether	IN	O
WBRT	NNP	O
is	VBZ	O
the	DT	O
only	JJ	O
appropriate	JJ	O
therapy	NN	O
in	IN	O
this	DT	O
situation	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
phase	NN	O
III	NNP	O
study	NN	O
,	,	O
SCLC	NNP	O
patients	NNS	O
with	IN	O
brain	NN	O
metastases	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
teniposide	NN	O
with	IN	O
or	CC	O
without	IN	O
WBRT	NNP	O
.	.	O

Teniposide	NNP	O
120	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
was	VBD	O
given	VBN	O
intravenously	RB	O
three	CD	O
times	NNS	O
a	DT	O
week	NN	O
,	,	O
every	DT	O
3	CD	O
weeks	NNS	O
.	.	O

WBRT	NNP	O
(	(	O
10	CD	O
fractions	NNS	O
of	IN	O
3	CD	O
Gy	NNP	O
)	)	O
had	VBD	O
to	TO	O
start	VB	O
within	IN	O
3	CD	O
weeks	NNS	O
from	IN	O
the	DT	O
start	NN	O
of	IN	O
chemotherapy	NN	O
.	.	O

Response	NNP	O
was	VBD	O
measured	VBN	O
clinically	RB	O
and	CC	O
by	IN	O
computed	JJ	O
tomography	NN	O
of	IN	O
the	DT	O
brain	NN	O
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
twenty	NN	O
eligible	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

A	DT	O
57	CD	O
%	NN	O
response	NN	O
rate	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
combined-modality	NN	O
arm	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
43	CD	O
%	NN	O
to	TO	O
69	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
a	DT	O
22	CD	O
%	NN	O
response	NN	O
rate	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
teniposide-alone	JJ	O
arm	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
12	CD	O
%	NN	O
to	TO	O
34	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Time	NN	O
to	TO	O
progression	NN	O
in	IN	O
the	DT	O
brain	NN	O
was	VBD	O
longer	RBR	O
in	IN	O
the	DT	O
combined-modality	NN	O
group	NN	O
(	(	O
P=.005	NNP	O
)	)	O
.	.	O

Clinical	JJ	O
response	NN	O
and	CC	O
response	NN	O
outside	IN	O
the	DT	O
brain	NN	O
were	VBD	O
not	RB	O
different	JJ	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
time	NN	O
was	VBD	O
3.5	CD	O
months	NNS	O
in	IN	O
the	DT	O
combined-modality	NN	O
arm	NN	O
and	CC	O
3.2	CD	O
months	NNS	O
in	IN	O
the	DT	O
teniposide-alone	JJ	O
arm	NN	O
.	.	O

Overall	JJ	O
survival	NN	O
in	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
not	RB	O
different	JJ	O
(	(	O
P=.087	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Adding	NNP	O
WBRT	NNP	O
to	TO	O
teniposide	VB	O
results	NNS	O
in	IN	O
a	DT	O
much	RB	O
higher	JJR	O
response	NN	O
rate	NN	O
of	IN	O
brain	NN	O
metastases	NNS	O
and	CC	O
in	IN	O
a	DT	O
longer	JJR	O
time	NN	O
to	TO	O
progression	NN	O
of	IN	O
brain	NN	O
metastases	NNS	O
than	IN	O
teniposide	RB	O
alone	JJ	O
.	.	O

Survival	NNP	O
was	VBD	O
poor	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
and	CC	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

Motion	NNP	O
style	NN	O
acupuncture	NN	O
treatment	NN	O
(	(	O
MSAT	NNP	O
)	)	O
for	IN	O
acute	NN	Condition
low	JJ	Condition
back	RB	Condition
pain	NN	Condition
with	IN	O
severe	JJ	O
disability	NN	O
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
protocol	NN	O
.	.	O

BACKGROUND	NNP	O
Acupuncture	NNP	O
is	VBZ	O
widely-used	JJ	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
low	JJ	Condition
back	RB	Condition
pain	NN	Condition
,	,	O
despite	IN	O
insufficient	JJ	O
evidence	NN	O
of	IN	O
the	DT	O
technique	NN	O
's	POS	O
efficacy	NN	O
for	IN	O
acute	NN	O
back	RB	O
pain	NN	O
.	.	O

Motion	NNP	O
style	NN	O
acupuncture	NN	O
treatment	NN	O
(	(	O
MSAT	NNP	O
)	)	O
is	VBZ	O
a	DT	O
non-traditional	JJ	O
acupuncture	NN	O
treatment	NN	O
requiring	VBG	O
a	DT	O
patient	NN	O
to	TO	O
exercise	VB	O
while	IN	O
receiving	VBG	O
acupuncture	NN	O
.	.	O

In	IN	O
Korea	NNP	O
,	,	O
MSAT	NNP	O
is	VBZ	O
used	VBN	O
to	TO	O
reduce	VB	O
musculoskeletal	JJ	O
pain	NN	O
and	CC	O
improve	VB	O
functional	JJ	O
status	NN	O
.	.	O

The	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
MSAT	NNP	O
on	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
with	IN	O
severe	JJ	O
disability	NN	O
.	.	O

METHODS/DESIGN	NNP	O
This	DT	O
study	NN	O
is	VBZ	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
active-controlled	JJ	O
trial	NN	O
with	IN	O
two	CD	O
parallel	JJ	O
arms	NNS	O
.	.	O

Participants	NNS	O
with	IN	O
acute	NN	O
low	JJ	Condition
back	RB	Condition
pain	NN	Condition
and	CC	O
severe	JJ	O
functional	JJ	O
disability	NN	O
,	,	O
defined	VBD	O
as	IN	O
an	DT	O
Oswestry	NNP	O
Disability	NNP	O
Index	NNP	O
(	(	O
ODI	NNP	O
)	)	O
value	NN	O
>	$	O
60	CD	O
%	NN	O
,	,	O
will	MD	O
be	VB	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
acupuncture	NN	O
group	NN	O
and	CC	O
the	DT	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drug	NN	O
(	(	O
NSAID	NNP	O
)	)	O
injection	NN	O
group	NN	O
.	.	O

The	DT	O
acupuncture	NN	O
group	NN	O
will	MD	O
receive	VB	O
MSAT	NNP	O
and	CC	O
the	DT	O
NSAID	NNP	O
injection	NN	O
group	NN	O
will	MD	O
receive	VB	O
an	DT	O
intramuscular	JJ	O
injection	NN	O
of	IN	O
diclofenac	NN	O
.	.	O

All	DT	O
procedures	NNS	O
will	MD	O
be	VB	O
limited	VBN	O
to	TO	O
one	CD	O
session	NN	O
and	CC	O
the	DT	O
symptoms	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
will	MD	O
be	VB	O
measured	VBN	O
by	IN	O
assessors	NNS	O
blinded	VBD	O
to	TO	O
treatment	NN	O
allocation	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
will	MD	O
be	VB	O
measured	VBN	O
at	IN	O
30	CD	O
minutes	NNS	O
after	IN	O
treatment	NN	O
using	VBG	O
the	DT	O
numerical	JJ	O
rating	NN	O
scale	NN	O
(	(	O
NRS	NNP	O
)	)	O
of	IN	O
low	JJ	O
back	RB	O
pain	NN	O
while	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
moving	VBG	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
will	MD	O
be	VB	O
measured	VBN	O
at	IN	O
30	CD	O
minutes	NNS	O
after	IN	O
treatment	NN	O
using	VBG	O
the	DT	O
NRS	NNP	O
of	IN	O
leg	NN	O
pain	NN	O
,	,	O
ODI	NNP	O
,	,	O
patient	NN	O
global	JJ	O
impression	NN	O
of	IN	O
change	NN	O
,	,	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
of	IN	O
the	DT	O
lumbar	NN	O
spine	NN	O
,	,	O
and	CC	O
degrees	NNS	O
of	IN	O
straight	JJ	O
leg	NN	O
raising	VBG	O
(	(	O
SLR	NNP	O
)	)	O
.	.	O

Post-treatment	JJ	O
follow-up	NN	O
will	MD	O
be	VB	O
performed	VBN	O
to	TO	O
measure	VB	O
primary	JJ	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
ROM	NNP	O
and	CC	O
SLR	NNP	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
24	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
.	.	O

DISCUSSION	NNP	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
trial	NN	O
will	MD	O
be	VB	O
discussed	VBN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrial.gov	NNP	O
NCT01315561	NNP	O
.	.	O

Early	RB	O
clinical	JJ	O
outcomes	NNS	O
and	CC	O
toxicity	NN	O
of	IN	O
intensity	NN	O
modulated	VBN	O
versus	IN	O
conventional	JJ	O
pelvic	JJ	O
radiation	NN	O
therapy	NN	O
for	IN	O
locally	RB	O
advanced	JJ	O
cervix	NN	O
carcinoma	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
toxicity	NN	O
and	CC	O
clinical	JJ	O
outcome	NN	O
in	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
cervical	JJ	O
cancer	NN	O
(	(	O
LACC	NNP	O
)	)	O
treated	VBD	O
with	IN	O
whole	JJ	O
pelvic	JJ	O
conventional	JJ	O
radiation	NN	O
therapy	NN	O
(	(	O
WP-CRT	NNP	O
)	)	O
versus	NN	O
intensity	NN	O
modulated	VBN	O
radiation	NN	O
therapy	NN	O
(	(	O
WP-IMRT	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
Between	NNP	O
January	NNP	O
2010	CD	O
and	CC	O
January	NNP	O
2012	CD	O
,	,	O
44	CD	O
patients	NNS	O
with	IN	O
International	NNP	O
Federation	NNP	O
of	IN	O
Gynecology	NNP	O
and	CC	O
Obstetrics	NNP	O
(	(	O
FIGO	NNP	O
2009	CD	O
)	)	O
stage	NN	O
IIB-IIIB	NNP	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
of	IN	O
the	DT	O
cervix	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
50.4	CD	O
Gy	NNP	O
in	IN	O
28	CD	O
fractions	NNS	O
delivered	VBN	O
via	IN	O
either	DT	O
WP-CRT	JJ	O
or	CC	O
WP-IMRT	JJ	O
with	IN	O
concurrent	JJ	O
weekly	JJ	O
cisplatin	NN	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

Acute	NNP	O
toxicity	NN	O
was	VBD	O
graded	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Common	NNP	O
Terminology	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNP	O
,	,	O
version	NN	O
3.0	CD	O
,	,	O
and	CC	O
late	JJ	O
toxicity	NN	O
was	VBD	O
graded	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Radiation	NNP	O
Therapy	NNP	O
Oncology	NNP	O
Group	NNP	O
system	NN	O
.	.	O

The	DT	O
primary	JJ	O
and	CC	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
acute	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
and	CC	O
disease-free	JJ	O
survival	NN	O
,	,	O
respectively	RB	O
.	.	O

RESULTS	NNP	O
Of	IN	O
44	CD	O
patients	NNS	O
,	,	O
22	CD	O
patients	NNS	O
received	VBD	O
WP-CRT	NNP	O
and	CC	O
22	CD	O
received	VBD	O
WP-IMRT	NNP	O
.	.	O

In	IN	O
the	DT	O
WP-CRT	JJ	O
arm	NN	O
,	,	O
13	CD	O
patients	NNS	O
had	VBD	O
stage	NN	O
IIB	NNP	O
disease	NN	O
and	CC	O
9	CD	O
had	VBD	O
stage	NN	O
IIIB	NNP	O
disease	NN	O
;	:	O
in	IN	O
the	DT	O
IMRT	NNP	O
arm	NN	O
,	,	O
12	CD	O
patients	NNS	O
had	VBD	O
stage	NN	O
IIB	NNP	O
disease	NN	O
and	CC	O
10	CD	O
had	VBD	O
stage	NN	O
IIIB	NNP	O
disease	NN	O
.	.	O

The	DT	O
median	JJ	O
follow-up	JJ	O
time	NN	O
in	IN	O
the	DT	O
WP-CRT	JJ	O
arm	NN	O
was	VBD	O
21.7	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
10.7-37.4	JJ	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
WP-IMRT	JJ	O
arm	NN	O
it	PRP	O
was	VBD	O
21.6	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
7.7-34.4	JJ	O
months	NNS	O
)	)	O
.	.	O

At	IN	O
27	CD	O
months	NNS	O
,	,	O
disease-free	JJ	O
survival	NN	O
was	VBD	O
79.4	CD	O
%	NN	O
in	IN	O
the	DT	O
WP-CRT	NNP	O
group	NN	O
versus	VBD	O
60	CD	O
%	NN	O
in	IN	O
the	DT	O
WP-IMRT	NNP	O
group	NN	O
(	(	O
P=.651	NNP	O
)	)	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
was	VBD	O
76	CD	O
%	NN	O
in	IN	O
the	DT	O
WP-CRT	NNP	O
group	NN	O
versus	VBD	O
85.7	CD	O
%	NN	O
in	IN	O
the	DT	O
WP-IMRT	NNP	O
group	NN	O
(	(	O
P=.645	NNP	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
WP-IMRT	JJ	O
arm	NN	O
experienced	VBD	O
significantly	RB	O
fewer	JJR	O
grade	NN	O
?2	NNP	O
acute	VBZ	O
gastrointestinal	JJ	O
toxicities	NNS	O
(	(	O
31.8	CD	O
%	NN	O
vs	JJ	O
63.6	CD	O
%	NN	O
,	,	O
P=.034	NNP	O
)	)	O
and	CC	O
grade	JJ	O
?3	NNP	O
gastrointestinal	JJ	O
toxicities	NNS	O
(	(	O
4.5	CD	O
%	NN	O
vs	JJ	O
27.3	CD	O
%	NN	O
,	,	O
P=.047	NNP	O
)	)	O
than	IN	O
did	VBD	O
patients	NNS	O
receiving	VBG	O
WP-CRT	NNP	O
and	CC	O
had	VBD	O
less	JJR	O
chronic	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
(	(	O
13.6	CD	O
%	NN	O
vs	JJ	O
50	CD	O
%	NN	O
,	,	O
P=.011	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
WP-IMRT	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
significantly	RB	O
less	JJR	O
toxicity	NN	O
compared	VBN	O
with	IN	O
WP-CRT	NNP	O
and	CC	O
has	VBZ	O
a	DT	O
comparable	JJ	O
clinical	JJ	O
outcome	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
with	IN	O
larger	JJR	O
sample	NN	O
sizes	NNS	O
and	CC	O
longer	JJR	O
follow-up	JJ	O
times	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
justify	VB	O
its	PRP$	O
use	NN	O
in	IN	O
routine	JJ	O
clinical	JJ	O
practice	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
nebivolol	JJ	O
treatment	NN	O
on	IN	O
oxidative	JJ	O
stress	NN	O
and	CC	O
antioxidant	JJ	O
status	NN	O
in	IN	O
patients	NNS	O
with	IN	O
cardiac	JJ	Condition
syndrome-X	NN	Condition
.	.	O

BACKGROUND	NNP	O
Free	JJ	O
radical-mediated	JJ	O
oxidative	JJ	O
stress	NN	O
has	VBZ	O
been	VBN	O
implicated	VBN	O
in	IN	O
the	DT	O
etiopathogenesis	NN	O
of	IN	O
several	JJ	O
disorders	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
elucidate	VB	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
nebivolol	NN	O
on	IN	O
the	DT	O
metabolic	JJ	O
state	NN	O
of	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
and	CC	O
antioxidant	JJ	O
status	NN	O
markers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
cardiac	JJ	O
syndrome-X	NN	O
(	(	O
CSX	NNP	Condition
)	)	O
,	,	O
additionally	RB	O
,	,	O
to	TO	O
compare	VB	O
with	IN	O
the	DT	O
effect	NN	O
of	IN	O
metoprolol	NN	O
treatment	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	SampleSize
patients	NNS	O
,	,	O
17	CD	SampleSize
female	NN	Sex
and	CC	O
13	CD	SampleSize
male	NN	Sex
,	,	O
with	IN	O
CSX	NNP	Condition
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Nebivolol	NNP	O
(	(	O
5	CD	O
mg/day	NN	O
)	)	O
or	CC	O
metoprolol	NN	O
(	(	O
50	CD	O
mg/day	NN	O
)	)	O
was	VBD	O
administrated	VBN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Twelve	VB	O
hour	NN	O
fasting	VBG	O
blood	NN	O
samples	NNS	O
,	,	O
taken	VBN	O
at	IN	O
the	DT	O
initiation	NN	O
and	CC	O
on	IN	O
the	DT	O
third	JJ	O
month	NN	O
of	IN	O
therapy	NN	O
,	,	O
were	VBD	O
analyzed	VBN	O
for	IN	O
the	DT	O
levels	NNS	O
of	IN	O
malondialdehyde	NN	O
(	(	O
MDA	NNP	O
)	)	O
,	,	O
nitrite+nitrate	JJ	O
(	(	O
NOx	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
activity	NN	O
of	IN	O
myeloperoxidase	NN	O
(	(	O
MPO	NNP	O
)	)	O
,	,	O
superoxide	JJ	O
dismutase	NN	O
(	(	O
SOD	NNP	O
)	)	O
.	.	O

No	DT	O
patient	NN	O
presented	VBD	O
additional	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
increased	JJ	O
reactive	JJ	O
oxygen	NN	O
species	NNS	O
levels	NNS	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
sixteen	JJ	O
control	NN	O
participants	NNS	O
,	,	O
patients	NNS	O
with	IN	O
CSX	NNP	O
had	VBD	O
significantly	RB	O
higher	JJR	O
activity	NN	O
of	IN	O
MPO	NNP	O
and	CC	O
levels	NNS	O
of	IN	O
MDA	NNP	O
,	,	O
but	CC	O
significantly	RB	O
lower	JJR	O
SOD	NNP	O
activity	NN	O
and	CC	O
levels	NNS	O
of	IN	O
NOx	NNP	O
before	IN	O
treatment	NN	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
MPO	NNP	O
activity	NN	O
and	CC	O
MDA	NNP	O
levels	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
;	:	O
SOD	NNP	O
activity	NN	O
and	CC	O
NOx	NNP	O
levels	NNS	O
were	VBD	O
significantly	RB	O
increased	VBN	O
with	IN	O
nebivolol	NN	O
but	CC	O
remained	VBD	O
unchanged	JJ	O
with	IN	O
metoprolol	NN	O
.	.	O

CONCLUSION	NN	O
We	PRP	O
have	VBP	O
shown	VBN	O
that	IN	O
patients	NNS	O
with	IN	O
CSX	NNP	Condition
who	WP	O
taken	VBN	O
nebivolol	RB	O
have	VBP	O
lower	JJR	O
serum	NN	O
MPO	NNP	O
activity	NN	O
,	,	O
levels	NNS	O
of	IN	O
MDA	NNP	O
and	CC	O
higher	JJR	O
serum	NN	O
SOD	NNP	O
activity	NN	O
,	,	O
NOx	NNP	O
levels	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
metoprolol	JJ	O
treatment	NN	O
.	.	O

Exercise	NNP	O
stress	JJ	O
test	NN	O
parameters	NNS	O
were	VBD	O
also	RB	O
ameliorated	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
taken	VBN	O
nebivolol	RB	O
in	IN	O
contrast	NN	O
to	TO	O
metoprolol	VB	O
.	.	O

Nebivolol	NNP	O
treatment	NN	O
may	MD	O
be	VB	O
a	DT	O
novel	JJ	O
treatment	NN	O
strategy	NN	O
in	IN	O
cases	NNS	O
with	IN	O
CSX	NNP	O
in	IN	O
the	DT	O
future	NN	O
.	.	O

Granulocyte-macrophage	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
GM-CSF	NNP	O
)	)	O
allows	VBZ	O
acceleration	NN	O
and	CC	O
dose	JJ	O
intensity	NN	O
increase	NN	O
of	IN	O
CEF	NNP	O
chemotherapy	NN	O
:	:	O
a	DT	O
randomised	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
.	.	O

A	DT	O
randomised	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
62	CD	SampleSize
patients	NNS	O
with	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
to	TO	O
assess	VB	O
whether	IN	O
granulocyte-macrophage	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
GM-CSF	NNP	O
)	)	O
would	MD	O
yield	VB	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
dose	JJ	O
intensity	NN	O
of	IN	O
a	DT	O
standard-dose	JJ	O
CEF	NNP	O
regimen	NNS	O
through	IN	O
an	DT	O
acceleration	NN	O
of	IN	O
chemotherapy	JJ	O
administration	NN	O
.	.	O

Patients	NNS	O
received	VBD	O
CEF	NNP	O
(	(	O
cyclophosphamide	VB	O
600	CD	O
mg	JJ	O
m-2	NN	O
,	,	O
epidoxorubicin	VBZ	O
60	CD	O
mg	NN	O
m-2	NN	O
and	CC	O
fluorouracil	NN	O
600	CD	O
mg	JJ	O
m-2	NN	O
)	)	O
i.v	NN	O
.	.	O

on	IN	O
day	NN	O
1	CD	O
or	CC	O
the	DT	O
same	JJ	O
chemotherapy	NN	O
,	,	O
plus	CC	O
GM-CSF	NNP	O
10	CD	O
micrograms	NNS	O
kg-1	JJ	O
s.c.	NNS	O
starting	VBG	O
from	IN	O
day	NN	O
4	CD	O
,	,	O
repeated	VBN	O
as	RB	O
soon	RB	O
as	IN	O
haematopoietic	JJ	O
recovery	NN	O
from	IN	O
nadir	NN	O
occurred	VBD	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
CEF	NNP	O
+	NNP	O
GM-CSF	NNP	O
group	NN	O
received	VBD	O
chemotherapy	NN	O
at	IN	O
a	DT	O
median	JJ	O
interval	NN	O
of	IN	O
16	CD	O
days	NNS	O
compared	VBN	O
with	IN	O
20	CD	O
days	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

This	DT	O
led	VBD	O
to	TO	O
a	DT	O
significant	JJ	O
increase	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
in	IN	O
the	DT	O
dose	JJ	O
intensity	NN	O
actually	RB	O
administered	VBN	O
in	IN	O
the	DT	O
third	JJ	O
,	,	O
fourth	JJ	O
and	CC	O
sixth	JJ	O
cycles	NNS	O
:	:	O
+28	CD	O
%	NN	O
,	,	O
+25	CD	O
%	NN	O
,	,	O
+20	CD	O
%	NN	O
respectively	RB	O
.	.	O

Non-haematological	JJ	O
toxicity	NN	O
was	VBD	O
mild	JJ	O
.	.	O

GM-CSF	NNP	O
had	VBD	O
to	TO	O
be	VB	O
reduced	VBN	O
or	CC	O
suspended	VBN	O
in	IN	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
because	IN	O
of	IN	O
toxicity	NN	O
.	.	O

Haematological	JJ	O
toxicity	NN	O
,	,	O
mainly	RB	O
cumulative	JJ	O
anaemia	NN	O
and	CC	O
thrombocytopenia	NN	O
,	,	O
was	VBD	O
manageable	JJ	O
.	.	O

An	DT	O
increase	NN	O
in	IN	O
response	NN	O
rate	NN	O
for	IN	O
patients	NNS	O
with	IN	O
measurable	JJ	O
disease	NN	O
,	,	O
of	IN	O
borderline	JJ	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.088	CD	O
,	,	O
P	NNP	O
for	IN	O
trend	NN	O
=	NNP	O
0.018	CD	O
)	)	O
,	,	O
from	IN	O
42	CD	O
%	NN	O
in	IN	O
the	DT	O
CEF	NNP	O
group	NN	O
to	TO	O
69	CD	O
%	NN	O
in	IN	O
the	DT	O
CEF	NNP	O
+	NNP	O
GM-CSF	NNP	O
group	NN	O
,	,	O
was	VBD	O
observed	VBN	O
.	.	O

This	DT	O
randomised	JJ	O
trial	NN	O
indicates	VBZ	O
that	IN	O
GM-CSF	NNP	O
is	VBZ	O
useful	JJ	O
for	IN	O
chemotherapy	NN	O
acceleration	NN	O
.	.	O

Accelerated	NNP	O
CEF	NNP	O
+	NNP	O
GM-CSF	NNP	O
is	VBZ	O
a	DT	O
moderately	RB	O
dose-intensive	JJ	O
regimen	NNS	O
that	WDT	O
can	MD	O
be	VB	O
administered	VBN	O
in	IN	O
an	DT	O
outpatient	NN	O
clinic	NN	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
high	JJ	O
objective	JJ	O
response	NN	O
.	.	O

Randomized	VBN	O
study	NN	O
of	IN	O
chlorambucil	NN	O
(	(	O
CB	NNP	O
)	)	O
compared	VBN	O
to	TO	O
interferon	VB	O
(	(	O
alfa-2b	JJ	O
)	)	O
combined	VBN	O
with	IN	O
CB	NNP	O
in	IN	O
low-grade	JJ	O
non-Hodgkin	NN	Condition
's	POS	Condition
lymphoma	NN	Condition
:	:	O
an	DT	O
interim	JJ	O
report	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
.	.	O

Non-Hodgkin	NNP	Condition
's	POS	Condition
Lymphoma	NNP	Condition
Cooperative	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

Alpha	NNP	O
interferon	NN	O
has	VBZ	O
shown	VBN	O
initial	JJ	O
promise	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
low-grade	JJ	O
non-Hodgkin	NN	O
's	POS	O
lymphoma	NN	O
(	(	O
NHL	NNP	O
)	)	O
,	,	O
especially	RB	O
with	IN	O
the	DT	O
nodular	JJ	O
form	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
enrolled	VBD	O
70	CD	SampleSize
NHL	NNP	O
patients	NNS	O
who	WP	O
received	VBD	O
either	CC	O
chlorambucil	NN	O
(	(	O
CB	NNP	O
;	:	O
10	CD	O
mg/day	NN	O
)	)	O
or	CC	O
CB	NNP	O
plus	CC	O
interferon	JJ	O
alfa-2b	NN	O
(	(	O
5	CD	O
million	CD	O
units	NNS	O
(	(	O
MU	NNP	O
)	)	O
/m2	VBD	O
subcutaneously	RB	O
three	CD	O
times	NNS	O
a	DT	O
week	NN	O
)	)	O
.	.	O

Among	IN	O
63	CD	SampleSize
evaluable	JJ	O
patients	NNS	O
,	,	O
similar	JJ	O
response	NN	O
rates	NNS	O
(	(	O
62.1	CD	O
%	NN	O
and	CC	O
64.7	CD	O
%	NN	O
respectively	RB	O
)	)	O
were	VBD	O
recorded	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
arms	NNS	O
.	.	O

In	IN	O
patients	NNS	O
receiving	VBG	O
no	DT	Condition
maintenance	NN	Condition
therapy	NN	Condition
,	,	O
those	DT	O
who	WP	O
received	VBD	O
interferon	JJ	O
alfa-2b	JJ	O
during	IN	O
the	DT	O
induction	NN	O
phase	NN	O
showed	VBD	O
a	DT	O
favourable	JJ	O
trend	NN	O
in	IN	O
terms	NNS	O
of	IN	O
incidence	NN	O
of	IN	O
relapse	NN	O
compared	VBN	O
to	TO	O
those	DT	O
who	WP	O
had	VBD	O
received	VBN	O
chlorambucil	NN	O
alone	RB	O
.	.	O

During	IN	O
maintenance	NN	O
therapy	NN	O
with	IN	O
interferon	JJ	O
alfa-2b	NN	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
relapse	NN	O
have	VBP	O
yet	RB	O
been	VBN	O
seen	VBN	O
compared	VBN	O
to	TO	O
patients	NNS	O
on	IN	O
no	DT	Condition
maintenance	NN	Condition
therapy	NN	Condition
.	.	O

A	NNP	O
longer	JJR	O
observation	NN	O
period	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
make	VB	O
a	DT	O
definitive	JJ	O
conclusion	NN	O
about	IN	O
the	DT	O
usefulness	NN	O
of	IN	O
interferon	JJ	O
maintenance	NN	O
therapy	NN	O
and	CC	O
to	TO	O
evaluate	VB	O
further	RBR	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
combined	JJ	O
schedule	NN	O
of	IN	O
chlorambucil	NN	O
and	CC	O
interferon	NN	O
induction	NN	O
on	IN	O
the	DT	O
duration	NN	O
of	IN	O
remission	NN	O
.	.	O

Effects	NNS	O
on	IN	O
parental	JJ	O
mental	JJ	O
health	NN	O
of	IN	O
an	DT	O
education	NN	O
and	CC	O
skills	NNS	O
training	VBG	O
program	NN	O
for	IN	O
parents	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
parent	NN	O
education	NN	O
and	CC	O
behavior	JJ	O
management	NN	O
intervention	NN	O
(	(	O
PEBM	NNP	O
)	)	O
on	IN	O
the	DT	O
mental	JJ	O
health	NN	O
and	CC	O
adjustment	NN	O
of	IN	O
parents	NNS	O
with	IN	O
preschool	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
group-comparison	JJ	O
design	NN	O
involving	VBG	O
a	DT	O
parent	NN	O
education	NN	O
and	CC	O
counseling	VBG	O
intervention	NN	O
to	TO	O
control	VB	O
for	IN	O
nonspecific	JJ	O
therapist	NN	O
effects	NNS	O
and	CC	O
a	DT	O
control	NN	O
sample	NN	O
was	VBD	O
used	VBN	O
.	.	O

Two	CD	O
metropolitan	JJ	O
and	CC	O
two	CD	O
rural	JJ	O
regions	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
intervention	NN	O
groups	NNS	O
(	(	O
n	JJ	O
=	NNP	O
70	CD	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
.	.	O

The	DT	O
parents	NNS	O
of	IN	O
consecutive	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
(	(	O
2	CD	O
(	(	O
1/2	CD	O
)	)	O
-5	CD	O
years	NNS	O
old	JJ	O
)	)	O
from	IN	O
the	DT	O
autism	NN	O
assessment	NN	O
services	NNS	O
for	IN	O
the	DT	O
intervention	NN	O
regions	NNS	O
were	VBD	O
then	RB	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
a	DT	O
20-week	JJ	O
manual-based	JJ	O
parent	NN	O
education	NN	O
and	CC	O
behavior	JJ	O
management	NN	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
or	CC	O
a	DT	O
manual-based	JJ	O
parent	NN	O
education	NN	O
and	CC	O
counseling	VBG	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
.	.	O

The	DT	O
main	JJ	O
outcome	JJ	O
measure	NN	O
of	IN	O
parental	JJ	O
mental	JJ	O
health	NN	O
was	VBD	O
the	DT	O
General	NNP	O
Health	NNP	O
Questionnaire	NNP	O
used	VBD	O
pre-	NN	O
and	CC	O
postintervention	NN	O
and	CC	O
at	IN	O
6-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
treatments	NNS	O
resulted	VBD	O
in	IN	O
significant	JJ	O
and	CC	O
progressive	JJ	O
improvement	NN	O
in	IN	O
overall	JJ	O
mental	JJ	O
health	NN	O
at	IN	O
follow-up	NN	O
(	(	O
F	NNP	O
=	NNP	O
2	CD	O
,	,	O
97	CD	O
,	,	O
p	FW	O
=.007	NN	O
)	)	O
and	CC	O
mental	JJ	O
health	NN	O
significantly	RB	O
improved	VBN	O
over	RP	O
time	NN	O
in	IN	O
the	DT	O
54	CD	O
%	NN	O
of	IN	O
principal	JJ	O
caregivers	NNS	O
who	WP	O
had	VBD	O
the	DT	O
highest	JJS	O
levels	NNS	O
of	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
.	.	O

The	DT	O
parent	NN	O
education	NN	O
and	CC	O
behavior	JJ	O
management	NN	O
intervention	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
alleviating	VBG	O
a	DT	O
greater	JJR	O
percentage	NN	O
of	IN	O
anxiety	NN	O
,	,	O
insomnia	NN	O
,	,	O
and	CC	O
somatic	JJ	O
symptoms	NNS	O
and	CC	O
family	NN	O
dysfunction	NN	O
than	IN	O
parent	NN	O
education	NN	O
and	CC	O
counseling	VBG	O
at	IN	O
6-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
20-week	JJ	O
parent	NN	O
education	NN	O
and	CC	O
skills	NNS	O
training	VBG	O
program	NN	O
for	IN	O
parents	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
newly	RB	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
provides	VBZ	O
significant	JJ	O
improvements	NNS	O
in	IN	O
parental	JJ	O
mental	JJ	O
health	NN	O
and	CC	O
adjustment	NN	O
,	,	O
justifying	VBG	O
its	PRP$	O
addition	NN	O
to	TO	O
early	JJ	O
intervention	NN	O
programs	NNS	O
at	IN	O
least	JJS	O
for	IN	O
parents	NNS	O
with	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
.	.	O

Incidence	NN	O
of	IN	O
puberty	NN	O
in	IN	O
beef	NN	O
heifers	NNS	O
fed	VBP	O
high-	JJ	O
or	CC	O
low-starch	JJ	O
diets	NNS	O
for	IN	O
different	JJ	O
periods	NNS	O
before	IN	O
breeding	VBG	O
.	.	O

Spring-born	JJ	O
Hereford	NNP	O
x	NNP	O
Angus	NNP	O
heifers	NNS	O
(	(	O
n	JJ	O
=	NNP	O
206	CD	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
effects	NNS	O
of	IN	O
energy	NN	O
supplementation	NN	O
programs	NNS	O
and	CC	O
amount	NN	O
of	IN	O
starch	NN	O
in	IN	O
the	DT	O
diet	NN	O
on	IN	O
incidence	NN	O
of	IN	O
puberty	NN	O
.	.	O

In	IN	O
Exp	NNP	O
.	.	O

1	CD	O
,	,	O
heifers	NNS	O
(	(	O
205	CD	O
+/-	JJ	O
5	CD	O
kg	NN	O
;	:	O
n	CC	O
=	VB	O
68	CD	O
)	)	O
grazing	NN	O
dormant	JJ	O
native	JJ	O
pasture	NN	O
were	VBD	O
fed	VBN	O
0.9	CD	O
kg/d	NNS	O
(	(	O
as-fed	JJ	O
basis	NN	O
)	)	O
of	IN	O
a	DT	O
42	CD	O
%	NN	O
CP	NNP	O
supplement	NN	O
from	IN	O
November	NNP	O
until	IN	O
February	NNP	O
14	CD	O
.	.	O

Heifers	NNS	O
were	VBD	O
stratified	VBN	O
by	IN	O
weaning	VBG	O
weight	NN	O
and	CC	O
allotted	VBD	O
randomly	RB	O
to	TO	O
treatment	NN	O
before	IN	O
breeding	VBG	O
(	(	O
May	NNP	O
to	TO	O
July	NNP	O
)	)	O
.	.	O

Treatments	NNS	O
were	VBD	O
1	CD	O
)	)	O
0.9	CD	O
kg	NN	O
(	(	O
as-fed	JJ	O
basis	NN	O
)	)	O
of	IN	O
a	DT	O
42	CD	O
%	NN	O
CP	NNP	O
supplement/d	NN	O
and	CC	O
pasture	NN	O
(	(	O
control	NN	O
)	)	O
;	:	O
2	CD	O
)	)	O
a	DT	O
high-starch	NN	O
(	(	O
HS	NNP	O
)	)	O
diet	NN	O
(	(	O
73	CD	O
%	NN	O
corn	NN	O
;	:	O
53	CD	O
%	NN	O
starch	NN	O
)	)	O
fed	NN	O
in	IN	O
a	DT	O
drylot	NN	O
for	IN	O
60	CD	O
d	NN	O
(	(	O
HS-60	NNP	O
)	)	O
;	:	O
3	CD	O
)	)	O
a	DT	O
HS	NNP	O
diet	JJ	O
fed	NN	O
in	IN	O
drylot	NN	O
for	IN	O
30	CD	O
d	NN	O
(	(	O
HS-30	NNP	O
)	)	O
;	:	O
or	CC	O
4	CD	O
)	)	O
a	DT	O
low-starch	NN	O
(	(	O
LS	NNP	O
)	)	O
diet	NN	O
(	(	O
49	CD	O
%	NN	O
corn	NN	O
;	:	O
37	CD	O
%	NN	O
starch	NN	O
)	)	O
self-fed	NN	O
on	IN	O
pasture	NN	O
for	IN	O
30	CD	O
d	NN	O
(	(	O
LS-30	NNP	O
)	)	O
.	.	O

The	DT	O
HS-60	JJ	O
and	CC	O
HS-30	JJ	O
heifers	NNS	O
were	VBD	O
limited-fed	JJ	O
to	TO	O
gain	VB	O
0.9	CD	O
kg/d	NN	O
,	,	O
and	CC	O
the	DT	O
LS-30	JJ	O
heifers	NNS	O
had	VBD	O
ad	NN	O
libitum	NN	O
access	NN	O
to	TO	O
the	DT	O
diet	JJ	O
.	.	O

High-starch-60	JJ	O
and	CC	O
LS-30	JJ	O
heifers	NNS	O
were	VBD	O
heavier	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
than	IN	O
control	NN	O
and	CC	O
HS-30	JJ	O
heifers	NNS	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
breeding	NN	O
season	NN	O
.	.	O

Thirty-one	CD	O
,	,	O
25	CD	O
,	,	O
and	CC	O
26	CD	O
%	NN	O
more	JJR	O
HS-60	JJ	O
heifers	NNS	O
were	VBD	O
pubertal	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
on	IN	O
May	NNP	O
1	CD	O
compared	VBN	O
with	IN	O
LS-30	NNP	O
,	,	O
HS-30	NNP	O
,	,	O
and	CC	O
control	NN	O
heifers	NNS	O
,	,	O
respectively	RB	O
.	.	O

At	IN	O
puberty	NN	O
,	,	O
HS-60	JJ	O
heifers	NNS	O
were	VBD	O
24	CD	O
and	CC	O
22	CD	O
d	NN	O
younger	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
than	IN	O
LS-30	NNP	O
and	CC	O
control	NN	O
heifers	NNS	O
,	,	O
and	CC	O
31	CD	O
kg	NNS	O
lighter	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
than	IN	O
LS-30	JJ	O
heifers	NNS	O
.	.	O

In	IN	O
Exp	NNP	O
.	.	O

2	CD	O
,	,	O
heifers	NNS	O
grazed	VBD	O
dormant	JJ	O
pasture	NN	O
and	CC	O
were	VBD	O
fed	VBN	O
0.9	CD	O
kg	NNS	O
(	(	O
as-fed	JJ	O
basis	NN	O
)	)	O
of	IN	O
a	DT	O
42	CD	O
%	NN	O
CP	NNP	O
supplement/d	NN	O
from	IN	O
weaning	VBG	O
in	IN	O
October	NNP	O
to	TO	O
late	VB	O
February	NNP	O
;	:	O
then	RB	O
heifers	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
treatments	NNS	O
for	IN	O
60	CD	O
d	NN	O
before	IN	O
the	DT	O
breeding	NN	O
season	NN	O
.	.	O

In	IN	O
two	CD	O
years	NNS	O
,	,	O
control	NN	O
heifers	NNS	O
(	(	O
n	JJ	O
=	NNP	O
46	CD	O
)	)	O
grazed	VBN	O
pasture	NN	O
and	CC	O
received	VBD	O
0.9	CD	O
kg	NN	O
of	IN	O
SBM	NNP	O
supplement/d	NN	O
;	:	O
LS	NNP	O
(	(	O
n	JJ	O
=	NNP	O
46	CD	O
)	)	O
heifers	NNS	O
were	VBD	O
self-fed	JJ	O
a	DT	O
distiller	NN	O
's	POS	O
grain	NN	O
and	CC	O
soybean	JJ	O
hull-based	JJ	O
diet	NN	O
in	IN	O
drylot	NN	O
;	:	O
and	CC	O
HS	NNP	O
heifers	NNS	O
(	(	O
n	JJ	O
=	NNP	O
46	CD	O
)	)	O
were	VBD	O
limited-fed	JJ	O
a	DT	O
corn-based	JJ	O
diet	NN	O
in	IN	O
drylot	NN	O
.	.	O

During	IN	O
treatment	NN	O
,	,	O
HS	NNP	O
and	CC	O
LS	NNP	O
heifers	NNS	O
had	VBD	O
greater	JJR	O
weight	NN	O
gains	NNS	O
than	IN	O
control	NN	O
heifers	NNS	O
.	.	O

Pubertal	JJ	O
BW	NNP	O
(	(	O
313	CD	O
+/-	JJ	O
6	CD	O
kg	NN	O
)	)	O
was	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
treatment	NN	O
,	,	O
but	CC	O
HS	NNP	O
and	CC	O
LS	NNP	O
heifers	NNS	O
were	VBD	O
younger	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.03	CD	O
)	)	O
than	IN	O
control	NN	O
heifers	NNS	O
at	IN	O
puberty	NN	O
.	.	O

During	IN	O
a	DT	O
60-d	JJ	O
breeding	NN	O
period	NN	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
puberty	NN	O
was	VBD	O
greater	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
for	IN	O
HS	NNP	O
and	CC	O
LS	NNP	O
heifers	NNS	O
than	IN	O
for	IN	O
control	NN	O
heifers	NNS	O
and	CC	O
was	VBD	O
greater	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
HS	NNP	O
than	IN	O
in	IN	O
LS	NNP	O
heifers	NNS	O
in	IN	O
Year	JJ	O
1	CD	O
.	.	O

Feeding	VBG	O
a	DT	O
LS	NNP	O
or	CC	O
a	DT	O
HS	NNP	O
diet	NN	O
for	IN	O
30	CD	O
d	NN	O
before	IN	O
breeding	NN	O
may	MD	O
be	VB	O
inadequate	JJ	O
to	TO	O
stimulate	VB	O
puberty	NN	O
in	IN	O
beef	NN	O
heifers	NNS	O
,	,	O
but	CC	O
feeding	VBG	O
a	DT	O
diet	JJ	O
with	IN	O
a	DT	O
greater	JJR	O
amount	NN	O
of	IN	O
starch	NN	O
for	IN	O
60	CD	O
d	NN	O
before	IN	O
breeding	NN	O
may	MD	O
increase	VB	O
the	DT	O
incidence	NN	O
of	IN	O
puberty	NN	O
during	IN	O
breeding	NN	O
of	IN	O
heifers	NNS	O
that	WDT	O
have	VBP	O
inadequate	JJ	O
yearling	NN	O
weight	NN	O
.	.	O

Weight	NNP	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
change	NN	O
with	IN	O
antiretroviral	JJ	Condition
initiation	NN	Condition
and	CC	O
impact	NN	O
on	IN	O
bone	NN	O
mineral	JJ	O
density	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effect	NN	O
that	IN	O
initiating	VBG	O
different	JJ	O
antiretroviral	JJ	O
therapy	NN	O
(	(	O
ART	NNP	O
)	)	O
regimens	VBZ	O
has	VBZ	O
on	IN	O
weight	NN	O
,	,	O
BMI	NNP	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
(	(	O
LBM	NNP	O
)	)	O
and	CC	O
explore	VB	O
how	WRB	O
changes	NNS	O
in	IN	O
body	NN	O
composition	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
A5224s	NNP	O
was	VBD	O
a	DT	O
sub-study	NN	O
of	IN	O
A5202	NNP	O
,	,	O
a	DT	O
prospective	JJ	O
trial	NN	O
of	IN	O
1857	CD	O
ART-naive	JJ	O
participants	NNS	O
randomized	VBN	O
to	TO	O
blinded	VBN	O
abacavir-lamivudine	NN	O
(	(	O
ABC/3TC	NNP	O
)	)	O
or	CC	O
tenofovir	JJ	O
DF-emtricitabine	NNP	O
(	(	O
TDF/FTC	NNP	O
)	)	O
with	IN	O
open-label	JJ	O
efavirenz	NN	O
(	(	O
EFV	NNP	O
)	)	O
or	CC	O
atazanavir-ritonavir	JJ	O
(	(	O
ATV/r	NNP	O
)	)	O
.	.	O

All	DT	O
participants	NNS	O
underwent	JJ	O
dual-energy	JJ	O
absorptiometry	NN	O
(	(	O
DXA	NNP	O
)	)	O
and	CC	O
abdominal	JJ	O
computed	VBN	O
tomography	NN	O
for	IN	O
body	NN	O
composition	NN	O
.	.	O

Analyses	NNS	O
used	VBD	O
two-sample	JJ	O
t-tests	NNS	O
and	CC	O
linear	JJ	O
regression	NN	O
.	.	O

RESULTS	NNP	O
A5224s	NNP	O
included	VBD	O
269	CD	O
participants	NNS	O
:	:	O
85	CD	O
%	NN	O
men	NNS	O
,	,	O
47	CD	O
%	NN	O
white	JJ	O
non-Hispanic	JJ	O
,	,	O
median	JJ	O
age	NN	O
38	CD	O
years	NNS	O
,	,	O
HIV-1	NNP	O
RNA	NNP	O
4.6	CD	O
log10	NN	O
copies/ml	NN	O
,	,	O
and	CC	O
CD4	NNP	O
cell	VBP	O
count	NN	O
233	CD	O
cells/?l	NN	O
.	.	O

Overall	JJ	O
,	,	O
significant	JJ	O
gains	NNS	O
occurred	VBD	O
in	IN	O
weight	NN	O
,	,	O
BMI	NNP	O
,	,	O
and	CC	O
LBM	NNP	O
at	IN	O
96	CD	O
weeks	NNS	O
post-randomization	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Assignment	NN	O
to	TO	O
ATV/r	NNP	O
(	(	O
vs.	FW	O
EFV	NNP	O
)	)	O
resulted	VBD	O
in	IN	O
significantly	RB	O
greater	JJR	O
weight	NN	O
(	(	O
mean	JJ	O
difference	NN	O
3.35	CD	O
kg	NN	O
)	)	O
and	CC	O
BMI	NNP	O
gain	NN	O
(	(	O
0.88	CD	O
kg/m	NN	O
;	:	O
both	DT	O
P=0.02	NNP	O
)	)	O
,	,	O
but	CC	O
not	RB	O
LBM	NNP	O
(	(	O
0.67	CD	O
kg	NN	O
;	:	O
P=0.15	NNP	O
)	)	O
,	,	O
whereas	JJ	O
ABC/3TC	NNP	O
and	CC	O
TDF/FTC	NNP	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
P?0.10	NNP	O
)	)	O
.	.	O

In	IN	O
multivariable	JJ	O
analysis	NN	O
,	,	O
only	RB	O
lower	JJR	O
baseline	NN	O
CD4	NNP	O
cell	NN	O
count	NN	O
and	CC	O
higher	JJR	O
HIV-1	NNP	O
RNA	NNP	O
were	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
increase	NN	O
in	IN	O
weight	NN	O
,	,	O
BMI	NNP	O
,	,	O
or	CC	O
LBM	NNP	O
.	.	O

In	IN	O
multivariable	JJ	O
analyses	NNS	O
,	,	O
increased	VBD	O
LBM	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
hip	NN	O
BMD	NNP	O
.	.	O

CONCLUSION	NNP	O
ABC/3TC	NNP	O
vs.	IN	O
TDF/FTC	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
change	NN	O
in	IN	O
weight	NN	O
,	,	O
BMI	NNP	O
,	,	O
or	CC	O
LBM	NNP	O
;	:	O
ATV/r	NNP	O
vs.	FW	O
EFV	NNP	O
resulted	VBD	O
in	IN	O
greater	JJR	O
weight	NN	O
and	CC	O
BMI	NNP	O
gain	NN	O
but	CC	O
not	RB	O
LBM	NNP	O
.	.	O

A	NNP	O
positive	JJ	O
association	NN	O
between	IN	O
increased	VBN	O
LBM	NNP	O
and	CC	O
increased	VBD	O
hip	NN	O
BMD	NNP	O
should	MD	O
be	VB	O
further	RB	O
investigated	VBN	O
through	IN	O
prospective	JJ	O
interventional	JJ	O
studies	NNS	O
to	TO	O
verify	VB	O
the	DT	O
impact	NN	O
of	IN	O
increased	JJ	O
LBM	NNP	O
on	IN	O
hip	NN	O
BMD	NNP	O
.	.	O

Global	JJ	O
contour	NN	O
saliency	NN	O
and	CC	O
local	JJ	O
colinear	NN	O
interactions	NNS	O
.	.	O

Our	PRP$	O
visual	JJ	O
system	NN	O
can	MD	O
link	VB	O
components	NNS	O
of	IN	O
contours	NNS	O
and	CC	O
segregate	JJ	O
contours	NNS	O
from	IN	O
complex	JJ	O
backgrounds	NNS	O
based	VBN	O
on	IN	O
geometric	JJ	O
grouping	NN	O
rules	NNS	O
.	.	O

This	DT	O
is	VBZ	O
an	DT	O
important	JJ	O
intermediate	JJ	O
step	NN	O
in	IN	O
object	JJ	O
recognition	NN	O
.	.	O

The	DT	O
substrate	NN	O
for	IN	O
contour	JJ	O
integration	NN	O
may	MD	O
be	VB	O
based	VBN	O
on	IN	O
contextual	JJ	O
interactions	NNS	O
and	CC	O
intrinsic	JJ	O
horizontal	NN	O
connections	NNS	O
seen	VBN	O
in	IN	O
primary	JJ	O
visual	JJ	O
cortex	NN	O
(	(	O
V1	NNP	O
)	)	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
perceptual	JJ	O
rules	NNS	O
governing	VBG	O
contour	NN	O
saliency	NN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
spatial	JJ	O
extents	NNS	O
of	IN	O
contextual	JJ	O
interactions	NNS	O
and	CC	O
horizontal	JJ	O
connections	NNS	O
match	VBP	O
those	DT	O
mediating	JJ	O
saliency	NN	O
.	.	O

To	TO	O
quantify	VB	O
these	DT	O
rules	NNS	O
,	,	O
we	PRP	O
used	VBD	O
stimuli	NNS	O
composed	VBN	O
of	IN	O
randomly	RB	O
oriented	VBN	O
nonoverlapping	JJ	O
line	NN	O
segments	NNS	O
.	.	O

Salient	NN	O
contours	NN	O
within	IN	O
this	DT	O
complex	JJ	O
background	NN	O
were	VBD	O
formed	VBN	O
by	IN	O
colinear	JJ	O
alignment	NN	O
of	IN	O
nearby	JJ	O
segments	NNS	O
.	.	O

Contour	NNP	O
detectability	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
2-interval-forced-choice	JJ	O
design	NN	O
.	.	O

Contour	NNP	O
detectability	NN	O
deteriorated	VBN	O
with	IN	O
increasing	VBG	O
spacing	VBG	O
between	IN	O
contour	JJ	O
elements	NNS	O
and	CC	O
improved	VBN	O
as	IN	O
the	DT	O
number	NN	O
of	IN	O
colinear	JJ	O
line	NN	O
elements	NNS	O
was	VBD	O
increased	VBN	O
.	.	O

At	IN	O
short	JJ	O
contour	NN	O
spacing	NN	O
,	,	O
the	DT	O
detectability	NN	O
reached	VBD	O
a	DT	O
plateau	NN	O
with	IN	O
alignment	NN	O
of	IN	O
a	DT	O
few	JJ	O
line	NN	O
segments	NNS	O
that	IN	O
together	RB	O
formed	VBD	O
a	DT	O
contour	NN	O
subtending	VBG	O
several	JJ	O
visual	JJ	O
degrees	NNS	O
.	.	O

At	IN	O
intermediate	JJ	O
spacing	NN	O
,	,	O
saliency	NN	O
built	VBD	O
up	RP	O
progressively	RB	O
with	IN	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
colinear	JJ	O
lines	NNS	O
,	,	O
extending	VBG	O
up	RP	O
to	TO	O
30	CD	O
degrees	NNS	O
.	.	O

When	WRB	O
contour	NN	O
spacing	NN	O
was	VBD	O
beyond	IN	O
a	DT	O
critical	JJ	O
range	NN	O
(	(	O
about	IN	O
2	CD	O
degrees	NNS	O
)	)	O
,	,	O
however	RB	O
,	,	O
the	DT	O
detectability	NN	O
dropped	VBD	O
to	TO	O
chance	NN	O
levels	NNS	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
number	NN	O
of	IN	O
colinear	JJ	O
lines	NNS	O
.	.	O

Contour	NNP	O
detectability	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
a	DT	O
function	NN	O
not	RB	O
only	RB	O
of	IN	O
the	DT	O
relative	JJ	O
spacing	NN	O
of	IN	O
contour	JJ	O
elements	NNS	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
noise	NN	O
elements	NNS	O
but	CC	O
also	RB	O
of	IN	O
the	DT	O
average	JJ	O
density	NN	O
of	IN	O
the	DT	O
overall	JJ	O
pattern	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
training	VBG	O
significantly	RB	O
improved	VBN	O
contour	JJ	O
detection	NN	O
,	,	O
increasing	VBG	O
the	DT	O
critical	JJ	O
spacing	NN	O
of	IN	O
line	NN	O
elements	NNS	O
beyond	IN	O
which	WDT	O
contours	NNS	O
were	VBD	O
no	RB	O
longer	RBR	O
detectable	JJ	O
.	.	O

Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
global	JJ	O
contour	NN	O
integration	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
mechanisms	NNS	O
of	IN	O
limited	JJ	O
spatial	JJ	O
extent	NN	O
,	,	O
comparable	JJ	O
to	TO	O
the	DT	O
interactions	NNS	O
observed	VBD	O
in	IN	O
V1	NNP	O
.	.	O

These	DT	O
interactions	NNS	O
can	MD	O
cascade	VB	O
over	IN	O
larger	JJR	O
distances	NNS	O
provided	VBD	O
the	DT	O
spacing	NN	O
of	IN	O
stimulus	JJ	O
elements	NNS	O
is	VBZ	O
kept	VBN	O
within	IN	O
a	DT	O
limited	JJ	O
range	NN	O
.	.	O

Two	CD	O
different	JJ	O
methods	NNS	O
for	IN	O
donor	JJ	O
hepatic	JJ	O
transection	NN	O
:	:	O
cavitron	NN	O
ultrasonic	JJ	O
surgical	JJ	O
aspirator	NN	O
with	IN	O
bipolar	JJ	O
cautery	NN	O
versus	NN	O
cavitron	NN	O
ultrasonic	JJ	O
surgical	JJ	O
aspirator	NN	O
with	IN	O
radiofrequency	NN	O
coagulator-A	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
Cavitron	NNP	O
ultrasonic	JJ	O
surgical	JJ	O
aspirator	NN	O
(	(	O
CUSA	NNP	O
)	)	O
with	IN	O
bipolar	JJ	O
cautery	NN	O
(	(	O
BP	NNP	O
)	)	O
to	TO	O
CUSA	NNP	O
with	IN	O
a	DT	O
radiofrequency	NN	O
coagulator	NN	O
[	NN	O
TissueLink	NNP	O
(	(	O
TL	NNP	O
)	)	O
]	VBP	O
in	IN	O
terms	NNS	O
of	IN	O
efficacy	NN	O
and	CC	O
safety	NN	O
for	IN	O
hepatic	JJ	O
transection	NN	O
in	IN	O
living	VBG	O
donor	NN	O
liver	JJ	O
transplantation	NN	O
.	.	O

Twenty-four	CD	O
living	NN	O
liver	NN	O
donors	NNS	O
(	(	O
n	JJ	O
=	VBP	O
12	CD	O
for	IN	O
each	DT	O
group	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
undergo	VB	O
hepatic	JJ	O
transection	NN	O
using	VBG	O
CUSA	NNP	O
with	IN	O
BP	NNP	O
or	CC	O
CUSA	NNP	O
with	IN	O
TL	NNP	O
.	.	O

Blood	NNP	O
loss	NN	O
during	IN	O
parenchymal	JJ	O
transection	NN	O
and	CC	O
speed	NN	O
of	IN	O
transection	NN	O
were	VBD	O
the	DT	O
primary	JJ	O
endpoints	NNS	O
,	,	O
whereas	IN	O
the	DT	O
degree	NN	O
of	IN	O
postoperative	JJ	O
liver	JJ	O
injury	NN	O
and	CC	O
morbidity	NN	O
were	VBD	O
secondary	JJ	O
endpoints	NNS	O
.	.	O

Median	JJ	O
blood	NN	O
loss	NN	O
during	IN	O
liver	JJ	O
transection	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
TL	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
BP	NNP	O
group	NN	O
(	(	O
195.2	CD	O
+/-	JJ	O
84.5	CD	O
versus	NN	O
343.3	CD	O
+/-	JJ	O
198.4	CD	O
mL	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.023	CD	O
)	)	O
,	,	O
and	CC	O
liver	JJS	O
transection	NN	O
was	VBD	O
significantly	RB	O
faster	RBR	O
in	IN	O
the	DT	O
TL	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
BP	NNP	O
group	NN	O
(	(	O
0.7	CD	O
+/-	JJ	O
0.2	CD	O
versus	NN	O
0.5	CD	O
+/-	JJ	O
0.2	CD	O
cm	NN	O
(	(	O
2	CD	O
)	)	O
/minute	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.048	CD	O
)	)	O
.	.	O

Significantly	RB	O
fewer	JJR	O
ties	NNS	O
were	VBD	O
required	VBN	O
during	IN	O
liver	JJ	O
transection	NN	O
in	IN	O
the	DT	O
TL	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
BP	NNP	O
group	NN	O
(	(	O
15.8	CD	O
+/-	JJ	O
4.8	CD	O
versus	NN	O
22.8	CD	O
+/-	JJ	O
7.9	CD	O
ties	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.023	CD	O
)	)	O
.	.	O

The	DT	O
morbidity	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
CUSA	NNP	O
with	IN	O
TL	NNP	O
is	VBZ	O
superior	JJ	O
to	TO	O
CUSA	NNP	O
with	IN	O
BP	NNP	O
for	IN	O
donor	JJ	O
hepatectomy	NN	O
in	IN	O
terms	NNS	O
of	IN	O
blood	NN	O
loss	NN	O
and	CC	O
speed	NN	O
of	IN	O
transection	NN	O
with	IN	O
no	DT	O
increase	NN	O
in	IN	O
morbidity	NN	O
.	.	O

Effect	NN	O
of	IN	O
cerivastatin	NN	O
on	IN	O
proteinuria	NNS	O
and	CC	O
urinary	JJ	O
podocytes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
glomerulonephritis	NN	Condition
.	.	O

BACKGROUND	IN	O
We	PRP	O
previously	RB	O
reported	VBD	O
urinary	JJ	O
podocytes	NNS	O
to	TO	O
be	VB	O
a	DT	O
marker	NN	O
of	IN	O
glomerular	JJ	O
injury	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
cerivastatin	NN	O
,	,	O
a	DT	O
newly	RB	O
developed	VBN	O
,	,	O
potent	JJ	O
synthetic	JJ	O
statin	NN	O
,	,	O
affects	VBZ	O
proteinuria	NNS	O
and	CC	O
urinary	JJ	O
podocyte	NN	O
excretion	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
glomerulonephritis	NN	Condition
(	(	O
CGN	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
40	CD	SampleSize
normotensive	JJ	O
hypercholesterolemic	JJ	Condition
patients	NNS	O
with	IN	O
CGN	NNP	Condition
to	TO	O
receive	VB	O
either	DT	O
cerivastatin	NN	O
0.15	CD	O
mg/day	NN	O
(	(	O
n=20	JJ	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=20	JJ	O
)	)	O
.	.	O

Subjects	NNS	O
comprised	VBD	O
24	CD	SampleSize
men	NNS	Sex
and	CC	O
16	CD	SampleSize
women	NNS	Sex
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
40.8+/-14.4	JJ	Age
years	NNS	O
;	:	O
27	CD	SampleSize
had	VBD	O
IgA	NNP	Condition
nephropathy	JJ	Condition
and	CC	O
13	CD	SampleSize
had	VBD	O
non-IgA	JJ	Condition
proliferative	JJ	Condition
glomerulonephritis	NN	Condition
.	.	O

Treatment	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Plasma	NNP	O
total	JJ	O
cholesterol	NN	O
,	,	O
HDL-cholesterol	NNP	O
,	,	O
LDL-cholesterol	NNP	O
and	CC	O
triglycerides	NNS	O
,	,	O
urinary	JJ	O
protein	NN	O
excretion	NN	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
podocytes	NNS	O
were	VBD	O
measured	VBN	O
before	IN	O
treatment	NN	O
and	CC	O
at	IN	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
6	CD	O
months	NNS	O
,	,	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
total	JJ	O
cholesterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
LDL-cholesterol	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
triglycerides	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
HDL-cholesterol	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
cerivastatin	NN	O
.	.	O

Urinary	JJ	O
protein	NN	O
excretion	NN	O
decreased	VBN	O
from	IN	O
1.8+/-0.6	JJ	O
to	TO	O
0.8+/-0.4	JJ	O
g/day	NN	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
in	IN	O
this	DT	O
group	NN	O
,	,	O
and	CC	O
urinary	JJ	O
podocyte	NN	O
excretion	NN	O
decreased	VBN	O
from	IN	O
1.6+/-0.6	JJ	O
to	TO	O
0.9+/-0.4	JJ	O
cells/ml	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
placebo	NN	O
showed	VBD	O
little	JJ	O
effect	NN	O
on	IN	O
these	DT	O
lipid	JJ	O
levels	NNS	O
,	,	O
urinary	JJ	O
protein	NN	O
excretion	NN	O
and	CC	O
urinary	JJ	O
podocyte	NN	O
excretion	NN	O
.	.	O

The	DT	O
differences	NNS	O
between	IN	O
the	DT	O
cerivastatin	NN	O
group	NN	O
and	CC	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
significant	JJ	O
(	(	O
cholesterol	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
LDL-cholesterol	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
triglycerides	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
;	:	O
HDL-cholesterol	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
urinary	JJ	O
protein	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
;	:	O
and	CC	O
urinary	JJ	O
podocytes	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Statins	NNP	O
such	JJ	O
as	IN	O
cerivastatin	NN	O
may	MD	O
be	VB	O
beneficial	JJ	O
for	IN	O
restoration	NN	O
of	IN	O
injured	JJ	O
podocytes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
CGN	NNP	Condition
and	CC	O
hypercholesterolaemia	NN	Condition
.	.	O

BEACOPP	NNP	O
,	,	O
a	DT	O
new	JJ	O
dose-escalated	JJ	O
and	CC	O
accelerated	JJ	O
regimen	NNS	O
,	,	O
is	VBZ	O
at	IN	O
least	JJS	O
as	RB	O
effective	JJ	O
as	IN	O
COPP/ABVD	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
advanced-stage	JJ	O
Hodgkin	NNP	Condition
's	POS	Condition
lymphoma	NN	Condition
:	:	O
interim	JJ	O
report	NN	O
from	IN	O
a	DT	O
trial	NN	O
of	IN	O
the	DT	O
German	JJ	O
Hodgkin	NNP	O
's	POS	O
Lymphoma	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

PURPOSE	NNP	O
The	DT	O
HD9	NNP	O
trial	NN	O
aims	NNS	O
to	TO	O
evaluate	VB	O
whether	IN	O
moderate	JJ	O
dose	JJ	O
escalation	NN	O
and/or	IN	O
acceleration	NN	O
of	IN	O
standard	JJ	O
polychemotherapy	NN	O
is	VBZ	O
beneficial	JJ	O
for	IN	O
advanced-stage	JJ	O
Hodgkin	NNP	O
's	POS	O
disease	NN	O
(	(	O
HD	NNP	Condition
)	)	O
.	.	O

Two	CD	O
variants	NNS	O
of	IN	O
a	DT	O
novel	JJ	O
bleomycin	NN	O
,	,	O
etoposide	RB	O
,	,	O
doxorubicin	NN	O
,	,	O
cyclophosphamide	NN	O
,	,	O
vincristine	NN	O
,	,	O
procarbazine	NN	O
,	,	O
and	CC	O
prednisone	NN	O
(	(	O
BEACOPP	NNP	O
)	)	O
scheme	NN	O
(	(	O
standard	JJ	O
and	CC	O
escalated	VBD	O
dose	NN	O
)	)	O
are	VBP	O
compared	VBN	O
with	IN	O
cyclophosphamide	NN	O
,	,	O
vincristine	NN	O
,	,	O
procarbazine	NN	O
,	,	O
and	CC	O
prednisone	NN	O
(	(	O
COPP	NNP	O
)	)	O
/doxorubicin	NN	O
,	,	O
bleomycin	NN	O
,	,	O
vinblastine	NN	O
,	,	O
and	CC	O
dacarbazine	NN	O
(	(	O
ABVD	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
randomized	VBN	O
,	,	O
three-arm	JJ	O
trial	NN	O
recruited	VBD	O
patients	NNS	O
in	IN	O
stages	NNS	O
IIB	NNP	O
and	CC	O
IIIA	NNP	O
with	IN	O
risk	NN	O
factors	NNS	O
and	CC	O
stages	NNS	O
IIIB	NNP	O
and	CC	O
IV	NNP	O
.	.	O

BEACOPP	NNP	O
in	IN	O
baseline	NN	O
dose	NN	O
contains	VBZ	O
all	DT	O
drug	NN	O
dosages	NNS	O
of	IN	O
COPP/ABVD	NNP	O
(	(	O
except	IN	O
vincristine	NN	O
and	CC	O
procarbazine	NN	O
)	)	O
rearranged	VBD	O
in	IN	O
a	DT	O
shorter	NN	O
,	,	O
3-week	JJ	O
cycle	NN	O
.	.	O

Escalated	VBN	O
BEACOPP	NNP	O
uses	VBZ	O
higher	JJR	O
doses	NNS	O
of	IN	O
cyclophosphamide	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
and	CC	O
etoposide	RB	O
with	IN	O
granulocyte	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
G-CSF	NNP	O
)	)	O
support	NN	O
.	.	O

After	IN	O
eight	CD	O
chemotherapy	NN	O
cycles	NNS	O
,	,	O
initial	JJ	O
bulky	NN	O
and	CC	O
residual	JJ	O
disease	NN	O
is	VBZ	O
irradiated	VBN	O
.	.	O

The	DT	O
trial	NN	O
is	VBZ	O
monitored	VBN	O
and	CC	O
analyzed	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
sequential	JJ	O
strategy	NN	O
.	.	O

RESULTS	NNP	O
An	DT	O
interim	JJ	O
analysis	NN	O
with	IN	O
505	CD	SampleSize
assessable	JJ	O
patients	NNS	O
and	CC	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
23	CD	O
months	NNS	O
showed	VBD	O
a	DT	O
significant	JJ	O
inferiority	NN	O
(	(	O
according	VBG	O
to	TO	O
sequential	JJ	O
monitoring	NN	O
strategy	NN	O
)	)	O
of	IN	O
the	DT	O
COPP/ABVD	NNP	O
regimen	NNS	O
in	IN	O
progression	NN	O
rate	NN	O
and	CC	O
freedom	NN	O
from	IN	O
treatment	NN	O
failure	NN	O
(	(	O
FFTF	NNP	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
pooled	JJ	O
results	NNS	O
of	IN	O
both	DT	O
BEACOPP	NNP	O
variants	NNS	O
.	.	O

The	DT	O
24-month	JJ	O
FFTF	NNP	O
rate	NN	O
was	VBD	O
75	CD	O
%	NN	O
for	IN	O
COPP/ABVD	NNP	O
and	CC	O
84	CD	O
%	NN	O
for	IN	O
BEACOPP	NNP	O
pooled	VBD	O
(	(	O
P	NNP	O
=	NNP	O
.034	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
12	CD	O
%	NN	O
progressive	JJ	O
disease	NN	O
with	IN	O
COPP/ABVD	NNP	O
and	CC	O
6	CD	O
%	NN	O
with	IN	O
BEACOPP	NNP	O
pooled	VBD	O
.	.	O

Differences	NNS	O
in	IN	O
survival	NN	O
were	VBD	O
not	RB	O
significant	JJ	O
in	IN	O
sequential	JJ	O
analysis	NN	O
.	.	O

The	DT	O
acute	JJ	O
toxicity	NN	O
of	IN	O
baseline	NN	O
BEACOPP	NNP	O
resembled	VBD	O
that	IN	O
of	IN	O
COPP/ABVD	NNP	O
;	:	O
escalated	VBD	O
BEACOPP	NNP	O
showed	VBD	O
increased	VBN	O
but	CC	O
manageable	JJ	O
hematologic	JJ	O
toxicity	NN	O
.	.	O

CONCLUSION	NNP	O
Combined	VBD	O
with	IN	O
local	JJ	O
irradiation	NN	O
,	,	O
BEACOPP	NNP	O
in	IN	O
one	CD	O
or	CC	O
both	DT	O
variants	NNS	O
shows	VBZ	O
superior	JJ	O
disease	NN	O
control	NN	O
compared	VBN	O
with	IN	O
COPP/ABVD	NNP	O
,	,	O
with	IN	O
acceptable	JJ	O
acute	JJ	O
toxicity	NN	O
.	.	O

Further	JJ	O
follow-up	NN	O
is	VBZ	O
required	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
dosage	NN	O
and	CC	O
the	DT	O
effect	NN	O
on	IN	O
survival	NN	O
and	CC	O
late	JJ	O
toxicities	NNS	O
.	.	O

Airway	NNP	O
responses	NNS	O
and	CC	O
inflammation	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
asthma	NN	O
after	IN	O
four	CD	O
days	NNS	O
of	IN	O
repeated	JJ	O
high-single-dose	JJ	O
allergen	NN	O
challenge	NN	O
.	.	O

BACKGROUND	NNP	O
Both	NNP	O
standard	JJ	O
and	CC	O
low-dose	JJ	O
allergen	NN	O
provocations	NNS	O
are	VBP	O
an	DT	O
established	JJ	O
tool	NN	O
in	IN	O
asthma	JJ	O
research	NN	O
to	TO	O
improve	VB	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
pathophysiological	JJ	O
mechanism	NN	O
of	IN	O
allergic	JJ	O
asthma	NN	O
.	.	O

However	RB	O
,	,	O
clinical	JJ	O
symptoms	NNS	O
are	VBP	O
less	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
induced	VBN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
designed	VBD	O
a	DT	O
protocol	NN	O
for	IN	O
repetitive	JJ	O
high-dose	JJ	O
bronchial	JJ	O
allergen	NN	O
challenges	NNS	O
to	TO	O
generate	VB	O
clinical	JJ	O
symptoms	NNS	O
and	CC	O
airway	JJ	O
inflammation	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
27	CD	O
patients	NNS	O
aged	VBD	O
18	CD	O
to	TO	O
40	CD	O
years	NNS	O
with	IN	O
positive	JJ	O
skin-prick	JJ	O
tests	NNS	O
and	CC	O
mild	JJ	O
asthma	JJ	O
underwent	JJ	O
repetitive	JJ	O
high-dose	JJ	O
allergen	NN	O
challenges	NNS	O
with	IN	O
household	NN	O
dust	NN	O
mites	NNS	O
for	IN	O
four	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

Pulmonary	JJ	O
function	NN	O
and	CC	O
exhaled	VBD	O
NO	NNP	O
were	VBD	O
measured	VBN	O
at	IN	O
every	DT	O
visit	NN	O
.	.	O

Induced	NNP	O
sputum	NN	O
was	VBD	O
analysed	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
allergen	NN	O
challenges	VBZ	O
for	IN	O
cell	NN	O
counts	NNS	O
,	,	O
ECP	NNP	O
,	,	O
IL-5	NNP	O
,	,	O
INF-?	NNP	O
,	,	O
IL-8	NNP	O
,	,	O
and	CC	O
the	DT	O
transcription	NN	O
factor	NN	O
Foxp3	NNP	O
.	.	O

RESULTS	NNP	O
We	PRP	O
found	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
pulmonary	JJ	O
function	NN	O
,	,	O
an	DT	O
increased	VBN	O
use	NN	O
of	IN	O
salbutamol	NN	O
and	CC	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
late	JJ	O
asthmatic	JJ	O
response	NN	O
and	CC	O
bronchial	JJ	O
hyperresponsiveness	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
significant	JJ	O
induction	NN	O
of	IN	O
eNO	NN	O
,	,	O
eosinophils	NNS	O
,	,	O
and	CC	O
Th-2	NNP	O
cytokines	NNS	O
.	.	O

Repeated	VBN	O
provocation	NN	O
was	VBD	O
feasible	JJ	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
.	.	O

Two	CD	O
subjects	NNS	O
had	VBD	O
severe	JJ	O
adverse	JJ	O
events	NNS	O
requiring	VBG	O
prednisolone	NN	O
to	TO	O
cope	VB	O
with	IN	O
nocturnal	JJ	O
asthma	NN	O
symptoms	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Repeated	VBD	O
high-dose	JJ	O
bronchial	JJ	O
allergen	NN	O
challenges	NNS	O
resulted	VBD	O
in	IN	O
severe	JJ	O
asthma	NN	O
symptoms	NNS	O
and	CC	O
marked	VBD	O
Th-2-mediated	NNP	O
allergic	JJ	O
airway	NN	O
inflammation	NN	O
.	.	O

The	DT	O
high-dose	JJ	O
challenge	NN	O
model	NN	O
is	VBZ	O
suitable	JJ	O
only	RB	O
in	IN	O
an	DT	O
attenuated	JJ	O
form	NN	O
in	IN	O
diseased	JJ	O
volunteers	NNS	O
for	IN	O
proof-of-concept	JJ	O
studies	NNS	O
and	CC	O
in	IN	O
clinical	JJ	O
settings	NNS	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
severe	JJ	O
asthma	JJ	O
exacerbations	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.govNCT00677209	NNP	O
.	.	O

Noninfiltrative	JJ	O
anesthesia	NN	O
for	IN	O
transrectal	JJ	Condition
prostate	NN	Condition
biopsy	NN	Condition
:	:	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
comparing	VBG	O
lidocaine-prilocaine	JJ	O
cream	NN	O
and	CC	O
lidocaine-ketorolac	JJ	O
gel	NN	O
.	.	O

OBJECTIVES	NNP	O
Periprostatic	NNP	O
nerve	NN	O
block	NN	O
(	(	O
PPNB	NNP	O
)	)	O
is	VBZ	O
the	DT	O
standard	JJ	O
anesthesia	NN	O
for	IN	O
ultrasound	NN	O
(	(	O
US	NNP	O
)	)	O
guided	VBD	O
transrectal	JJ	Condition
prostate	NN	Condition
biopsy	NN	Condition
(	(	O
TPB	NNP	Condition
)	)	O
,	,	O
but	CC	O
periprostatic	JJ	O
infiltration	NN	O
itself	PRP	O
constitutes	VBZ	O
a	DT	O
major	JJ	O
,	,	O
though	RB	O
often	RB	O
neglected	VBN	O
,	,	O
source	NN	O
of	IN	O
discomfort	NN	O
even	RB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
perianal-intrarectal	JJ	O
lidocaine-prilocaine	NN	O
(	(	O
PILP	NNP	O
)	)	O
cream	NN	O
before	IN	O
PPNB	NNP	O
.	.	O

Noninfiltrative	NNP	O
anesthesia	NN	O
therefore	NN	O
represents	VBZ	O
an	DT	O
attractive	JJ	O
alternative	NN	O
to	TO	O
periprostatic	JJ	O
infiltration	NN	O
.	.	O

With	IN	O
this	DT	O
in	IN	O
mind	NN	O
,	,	O
we	PRP	O
aimed	VBD	O
to	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
perianal-intrarectal	JJ	O
(	(	O
PI	NNP	O
)	)	O
lidocaine	NN	O
gel	NN	O
,	,	O
lidocaine-ketorolac	JJ	O
gel	NN	O
,	,	O
and	CC	O
lidocaine-prilocaine	JJ	O
cream	NN	O
in	IN	O
relieving	VBG	O
pain	NN	O
during	IN	O
TPB	NNP	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Three	NNP	SampleSize
hundred	VBD	SampleSize
consecutive	JJ	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
US-guided	JJ	O
TPB	NNP	Condition
were	VBD	O
randomized	VBN	O
1:1:1	CD	O
to	TO	O
receive	VB	O
PI	NNP	O
administration	NN	O
of	IN	O
5	CD	O
g	JJ	O
2.5	CD	O
%	NN	O
lidocaine	JJ	O
gel	NN	O
10	CD	O
minutes	NNS	O
before	IN	O
TPB	NNP	O
(	(	O
Group	NNP	O
1	CD	O
)	)	O
,	,	O
or	CC	O
a	DT	O
mixture	NN	O
of	IN	O
5	CD	O
g	JJ	O
2.5	CD	O
%	NN	O
lidocaine	JJ	O
gel	NN	O
and	CC	O
0.3	CD	O
%	NN	O
ketorolac	NN	O
tromethamine	JJ	O
solution	NN	O
1	CD	O
hour	NN	O
before	IN	O
TPB	NNP	O
(	(	O
Group	NNP	O
2	CD	O
)	)	O
,	,	O
or	CC	O
5	CD	O
g	JJ	O
2.5	CD	O
%	NN	O
lidocaine	NN	O
and	CC	O
2.5	CD	O
%	NN	O
prilocaine	NN	O
cream	NN	O
20	CD	O
minutes	NNS	O
before	IN	O
TPB	NNP	O
(	(	O
Group	NNP	O
3	CD	O
)	)	O
.	.	O

The	DT	O
0-to-10	JJ	O
points	NNS	O
visual	JJ	O
analogue	JJ	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
was	VBD	O
used	VBN	O
for	IN	O
assessing	VBG	O
pain	NN	O
at	IN	O
probe	NN	O
insertion	NN	O
and	CC	O
movements	NNS	O
(	(	O
VAS-1	NNP	O
)	)	O
,	,	O
at	IN	O
prostate	NN	O
sampling	NN	O
(	(	O
VAS-2	NNP	O
)	)	O
,	,	O
and	CC	O
maximal	JJ	O
procedural	JJ	O
pain	NN	O
(	(	O
MPP	NNP	O
)	)	O
.	.	O

Complications	NNS	O
occurring	VBG	O
up	RB	O
to	TO	O
20	CD	O
days	NNS	O
after	IN	O
the	DT	O
procedure	NN	O
were	VBD	O
also	RB	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
Four	NNP	O
(	(	O
1.3	CD	O
%	NN	O
)	)	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
because	IN	O
of	IN	O
unbearable	JJ	O
pain	NN	O
during	IN	O
the	DT	O
procedure	NN	O
,	,	O
leaving	VBG	O
Group	NNP	O
1	CD	O
with	IN	O
98	CD	O
patients	NNS	O
,	,	O
Group	NNP	O
2	CD	O
with	IN	O
99	CD	O
,	,	O
and	CC	O
Group	NNP	O
3	CD	O
with	IN	O
99	CD	O
;	:	O
the	DT	O
3	CD	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
patients	NNS	O
'	POS	O
age	NN	O
,	,	O
serum	NN	O
PSA	NNP	O
,	,	O
prostate	NN	O
volume	NN	O
,	,	O
and	CC	O
cancer	NN	O
detection	NN	O
rate	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
either	DT	O
ketorolac	NN	O
or	CC	O
prilocaine	NN	O
to	TO	O
lidocaine	VB	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
reduced	VBD	O
probe-related	JJ	O
,	,	O
sampling-related	JJ	O
,	,	O
and	CC	O
maximal	JJ	O
procedural	JJ	O
pain	NN	O
.	.	O

Compared	VBN	O
with	IN	O
lidocaine-prilocaine	JJ	O
,	,	O
lidocaine-ketorolac	JJ	O
was	VBD	O
less	RBR	O
effective	JJ	O
in	IN	O
relieving	VBG	O
probe-related	JJ	O
pain	NN	O
(	(	O
mean	JJ	O
VAS-1	NNP	O
:	:	O
1.47	CD	O
?	.	O
1.30	CD	O
vs.	IN	O
0.39	CD	O
?	.	O
0.65	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
but	CC	O
more	RBR	O
effective	JJ	O
in	IN	O
relieving	VBG	O
sampling-related	JJ	O
pain	NN	O
(	(	O
mean	JJ	O
VAS-2	NNP	O
:	:	O
0.76	CD	O
?	.	O
0.94	CD	O
vs.	IN	O
1.54	CD	O
?	.	O
1.02	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
;	:	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
MPP	NNP	O
(	(	O
mean	VB	O
1.82	CD	O
?	.	O
1.21	CD	O
vs.	IN	O
1.67	CD	O
?	.	O
0.95	CD	O
)	)	O
,	,	O
probably	RB	O
due	JJ	O
to	TO	O
such	JJ	O
different	JJ	O
efficacy	NN	O
on	IN	O
the	DT	O
two	CD	O
pain	NN	O
sources	NNS	O
.	.	O

Complications	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Lidocaine-prilocaine	JJ	O
cream	NN	O
was	VBD	O
most	RBS	O
effective	JJ	O
on	IN	O
probe-related	JJ	O
pain	NN	O
,	,	O
whereas	IN	O
lidocaine-ketorolac	JJ	O
gel	NN	O
was	VBD	O
most	RBS	O
effective	JJ	O
on	IN	O
sampling-related	JJ	O
pain	NN	O
.	.	O

These	DT	O
noninfiltrative	JJ	O
anesthetics	NNS	O
were	VBD	O
safe	JJ	O
,	,	O
easy	JJ	O
to	TO	O
administer	VB	O
,	,	O
and	CC	O
well	RB	O
accepted	VBN	O
by	IN	O
patients	NNS	O
;	:	O
the	DT	O
possibility	NN	O
to	TO	O
combine	VB	O
them	PRP	O
to	TO	O
further	JJ	O
improve	VB	O
pain	NN	O
control	NN	O
during	IN	O
TPB	NNP	O
deserves	VBZ	O
further	JJ	O
well-designed	JJ	O
studies	NNS	O
.	.	O

Transesophageal	NNP	O
echocardiography	NN	O
in	IN	O
quantification	NN	O
of	IN	O
emboli	NN	O
during	IN	O
femoral	JJ	O
nailing	NN	O
:	:	O
reamed	VBN	O
versus	NN	O
unreamed	JJ	O
techniques	NNS	O
.	.	O

We	PRP	O
quantified	VBD	O
the	DT	O
embolic	JJ	O
load	NN	O
to	TO	O
the	DT	O
lungs	NNS	O
created	VBN	O
with	IN	O
two	CD	O
different	JJ	O
techniques	NNS	O
of	IN	O
femoral	JJ	O
nailing	NN	O
.	.	O

Eleven	JJ	O
patients	NNS	O
with	IN	O
12	CD	O
traumatic	JJ	O
femur	NN	O
fractures	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
reamed	VB	O
(	(	O
7	CD	O
fractures	NNS	O
)	)	O
and	CC	O
unreamed	JJ	O
(	(	O
5	CD	O
fractures	NNS	O
)	)	O
groups	NNS	O
.	.	O

Intramedullary	JJ	O
nailing	NN	O
was	VBD	O
with	IN	O
the	DT	O
AO/ASIF*	NNP	O
universal	NN	O
reamed	VBD	O
or	CC	O
unreamed	JJ	O
nail	NN	O
.	.	O

Transesophageal	NNP	O
echocardiography	NN	O
(	(	O
TEE	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
quantity	NN	O
and	CC	O
quality	NN	O
of	IN	O
emboli	NN	O
generated	VBN	O
by	IN	O
nailing	VBG	O
.	.	O

Data	NNS	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
software	NN	O
that	WDT	O
digitized	VBD	O
the	DT	O
TEE	NNP	O
images	NNS	O
and	CC	O
quantified	VBD	O
the	DT	O
area	NN	O
of	IN	O
embolic	JJ	O
particles	NNS	O
in	IN	O
each	DT	O
frame	NN	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
each	DT	O
level	NN	O
of	IN	O
embolic	JJ	O
phenomena	NNS	O
(	(	O
zero	CD	O
,	,	O
moderate	JJ	O
,	,	O
severe	JJ	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
total	JJ	O
embolic	JJ	O
load	NN	O
with	IN	O
various	JJ	O
steps	NNS	O
(	(	O
fracture	NN	O
manipulation	NN	O
,	,	O
proximal	JJ	O
portal	JJ	O
opening	NN	O
,	,	O
reaming	NN	O
,	,	O
and	CC	O
nail	JJ	O
passage	NN	O
)	)	O
.	.	O

Manual	JJ	O
grading	NN	O
of	IN	O
emboli	NN	O
correlated	VBN	O
highly	RB	O
with	IN	O
software	NN	O
quantification	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
confirm	VBP	O
the	DT	O
presence	NN	O
and	CC	O
similarity	NN	O
of	IN	O
emboli	JJ	O
generation	NN	O
with	IN	O
both	DT	O
methods	NNS	O
of	IN	O
intramedullary	JJ	O
nailing	NN	O
.	.	O

Unreamed	NNP	O
nails	NNS	O
do	VBP	O
not	RB	O
protect	VB	O
the	DT	O
patient	NN	O
from	IN	O
pulmonary	JJ	O
embolization	NN	O
of	IN	O
marrow	NN	O
contents	NNS	O
.	.	O

Sunlight	JJ	O
exposure	NN	O
or	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
for	IN	O
vitamin	JJ	Condition
D-deficient	JJ	Condition
non-western	JJ	O
immigrants	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

UNLABELLED	NNP	O
Vitamin	NNP	O
D	NNP	O
deficiency	NN	O
is	VBZ	O
very	RB	O
common	JJ	O
in	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

In	IN	O
this	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
vitamin	NN	O
D	NNP	O
800	CD	O
IU/day	NNP	O
or	CC	O
100,000	CD	O
IU/3	JJ	O
months	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
advised	JJ	O
sunlight	NN	O
exposure	NN	O
.	.	O

Vitamin	NNP	O
D	NNP	O
supplementation	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
advised	JJ	O
sunlight	JJ	O
exposure	NN	O
in	IN	O
improving	VBG	O
vitamin	NN	O
D	NNP	O
status	NN	O
and	CC	O
lowering	VBG	O
parathyroid	JJ	O
hormone	NN	O
levels	NNS	O
.	.	O

INTRODUCTION	NNP	O
Vitamin	NNP	O
D	NNP	O
deficiency	NN	O
(	(	O
25-hydroxyvitamin	JJ	O
D	NNP	O
[	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
]	NNP	O
<	VBD	O
25	CD	O
nmol/l	NN	O
)	)	O
is	VBZ	O
common	JJ	O
among	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

It	PRP	O
can	MD	O
be	VB	O
treated	VBN	O
with	IN	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
or	CC	O
sunlight	JJ	O
exposure	NN	O
.	.	O

METHODS	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
effect	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
(	(	O
3	CD	O
)	)	O
supplementation	NN	O
(	(	O
daily	JJ	O
800	CD	O
IU	NNP	O
or	CC	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
)	)	O
or	CC	O
sunlight	JJ	O
exposure	NN	O
advice	NN	O
is	VBZ	O
similar	JJ	O
with	IN	O
regard	NN	O
to	TO	O
serum	VB	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
and	CC	O
parathyroid	VB	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
concentrations	NNS	O
.	.	O

Randomized	NNP	O
clinical	JJ	O
trial	NN	O
in	IN	O
11	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
The	DT	O
Netherlands	NNP	O
.	.	O

Non-western	JJ	O
immigrants	NNS	O
,	,	O
aged	VBN	O
18-65	CD	O
years	NNS	O
(	(	O
n	JJ	O
=	NNP	O
232	CD	O
)	)	O
and	CC	O
serum	$	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
<	$	O
25	CD	O
nmol/l	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
supplementation	NN	O
(	(	O
daily	JJ	O
800	CD	O
IU	NNP	O
or	CC	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
)	)	O
or	CC	O
advice	NN	O
for	IN	O
sunlight	JJ	O
exposure	NN	O
for	IN	O
6	CD	O
months	NNS	O
(	(	O
March-September	NNP	O
)	)	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
,	,	O
during	IN	O
treatment	NN	O
(	(	O
3	CD	O
months	NNS	O
,	,	O
6	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
at	IN	O
follow-up	JJ	O
(	(	O
12	CD	O
months	NNS	O
)	)	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
multilevel	JJ	O
regression	NN	O
modelling	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
intention-to-treat	JJ	O
analysis	NN	O
included	VBD	O
211	CD	O
persons	NNS	O
.	.	O

Baseline	NNP	O
serum	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
was	VBD	O
22.5	CD	O
?	.	O
11.1	CD	O
nmol/l	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
mean	VBP	O
serum	JJ	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
increased	VBD	O
to	TO	O
53	CD	O
nmol/l	NNS	O
with	IN	O
800	CD	O
IU/day	NNP	O
,	,	O
to	TO	O
50.5	CD	O
nmol/l	NNS	O
with	IN	O
100,000	CD	O
IU/3	NNP	O
months	NNS	O
,	,	O
and	CC	O
to	TO	O
29.1	CD	O
nmol/l	NNS	O
with	IN	O
advised	JJ	O
sunlight	NN	O
exposure	NN	O
(	(	O
supplementation	NN	O
vs	FW	O
sunshine	NN	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Serum	NNP	O
PTH	NNP	O
decreased	VBD	O
significantly	RB	O
in	IN	O
all	DT	O
groups	NNS	O
after	IN	O
3	CD	O
months	NNS	O
,	,	O
more	RBR	O
in	IN	O
the	DT	O
supplementation	NN	O
groups	NNS	O
than	IN	O
in	IN	O
the	DT	O
advised	JJ	O
sunlight	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
physical	JJ	O
performance	NN	O
and	CC	O
functional	JJ	O
limitations	NNS	O
.	.	O

CONCLUSION	NNP	O
Vitamin	NNP	O
D	NNP	O
supplementation	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
advised	JJ	O
sunlight	JJ	O
exposure	NN	O
for	IN	O
treating	VBG	O
vitamin	NN	O
D	NNP	O
deficiency	NN	O
in	IN	O
non-western	JJ	O
immigrants	NNS	O
.	.	O

Effect	NN	O
of	IN	O
extradural	JJ	O
analgesia	NN	O
on	IN	O
stress	NN	O
responses	NNS	O
to	TO	O
abdominal	JJ	O
surgery	NN	O
in	IN	O
infants	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
40	CD	O
children	NNS	O
younger	JJR	O
than	IN	O
4	CD	O
yr	NNS	O
having	VBG	O
elective	JJ	O
abdominal	JJ	O
surgery	NN	O
under	IN	O
general	JJ	O
anaesthesia	NN	O
supplemented	VBN	O
with	IN	O
either	DT	O
systemic	JJ	O
opioids	NNS	O
or	CC	O
extradural	JJ	O
bupivacaine	NN	O
.	.	O

Venous	JJ	O
blood	NN	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
before	IN	O
tracheal	JJ	O
intubation	NN	O
to	TO	O
measure	VB	O
baseline	JJ	O
concentrations	NNS	O
of	IN	O
adrenaline	NN	O
,	,	O
noradrenaline	NN	O
,	,	O
glucose	NN	O
,	,	O
ACTH	NNP	O
and	CC	O
cortisol	NN	O
.	.	O

Additional	JJ	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
45	CD	O
min	NNS	O
after	IN	O
the	DT	O
start	NN	O
of	IN	O
surgery	NN	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
,	,	O
1	CD	O
h	NN	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
.	.	O

Plasma	NNP	O
concentrations	NNS	O
of	IN	O
bupivacaine	NN	O
were	VBD	O
measured	VBN	O
also	RB	O
in	IN	O
the	DT	O
extradural	JJ	O
group	NN	O
at	IN	O
each	DT	O
sampling	VBG	O
time	NN	O
.	.	O

Both	DT	O
techniques	NNS	O
provided	VBN	O
acceptable	JJ	O
analgesia	NN	O
,	,	O
but	CC	O
the	DT	O
perioperative	JJ	O
increases	NNS	O
in	IN	O
adrenaline	NN	O
,	,	O
glucose	NN	O
and	CC	O
ACTH	NNP	O
were	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
opioid	JJ	O
group	NN	O
.	.	O

Noradrenaline	NNP	O
concentrations	NNS	O
decreased	VBD	O
to	TO	O
less	JJR	O
than	IN	O
baseline	NN	O
values	NNS	O
in	IN	O
the	DT	O
extradural	JJ	O
group	NN	O
and	CC	O
were	VBD	O
significantly	RB	O
less	JJR	O
than	IN	O
in	IN	O
the	DT	O
opioid	JJ	O
group	NN	O
.	.	O

The	DT	O
perioperative	JJ	O
increase	NN	O
in	IN	O
cortisol	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
despite	IN	O
the	DT	O
differences	NNS	O
in	IN	O
ACTH	NNP	O
responses	NNS	O
.	.	O

Most	JJS	O
responses	NNS	O
returned	VBN	O
to	TO	O
the	DT	O
baseline	NN	O
values	NNS	O
within	IN	O
24	CD	O
h.	NN	O
Plasma	NNP	O
bupivacaine	NN	O
concentrations	NNS	O
remained	VBD	O
within	IN	O
safe	JJ	O
limits	NNS	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
but	CC	O
systemic	JJ	O
concentrations	NNS	O
increased	VBD	O
in	IN	O
some	DT	O
of	IN	O
the	DT	O
patients	NNS	O
during	IN	O
postoperative	JJ	O
infusion	NN	O
with	IN	O
0.125	CD	O
%	NN	O
bupivacaine	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
provocative	JJ	O
tests	NNS	O
for	IN	O
unexplained	JJ	O
syncope	NN	O
:	:	O
isoprenaline	NN	O
and	CC	O
glyceryl	NN	O
trinitrate	NN	O
for	IN	O
diagnosing	VBG	O
vasovagal	JJ	O
syncope	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
compare	VB	O
the	DT	O
sensitivity	NN	O
,	,	O
specificity	NN	O
and	CC	O
adverse	JJ	O
event	NN	O
profile	NN	O
of	IN	O
glyceryl	JJ	O
trinitrate	JJ	O
head-up	NN	O
tilt	NN	O
with	IN	O
isoprenaline	JJ	O
head-up	JJ	O
tilt	NN	O
in	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
vasovagal	JJ	O
syncope	NN	O
in	IN	O
patients	NNS	O
with	IN	O
unexplained	JJ	O
syncope	NN	O
and	CC	O
healthy	JJ	O
controls	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Forty-eight	NNP	O
patients	NNS	O
with	IN	O
unexplained	JJ	O
syncope	NN	O
and	CC	O
negative	JJ	O
passive	JJ	O
head-up	NN	O
tilt	NN	O
at	IN	O
70	CD	O
degrees	NNS	O
for	IN	O
40	CD	O
min	NN	O
,	,	O
and	CC	O
14	CD	O
healthy	JJ	O
controls	NNS	O
underwent	JJ	O
glyceryl	JJ	O
trinitrate	NN	O
head-up	NN	O
tilt	NN	O
and	CC	O
isoprenaline	JJ	O
head-up	NN	O
tilt	NN	O
(	(	O
maximum	JJ	O
dose	RB	O
5	CD	O
microg	NNS	O
x	JJ	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
one	CD	O
week	NN	O
apart	RB	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
production	NN	O
of	IN	O
symptoms	NNS	O
(	(	O
syncope	NN	O
,	,	O
pre-syncope	NN	O
)	)	O
with	IN	O
development	NN	O
of	IN	O
hypotension	NN	O
.	.	O

In	IN	O
those	DT	O
with	IN	O
negative	JJ	O
passive	JJ	O
head-up	NN	O
tilt	NN	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
glyceryl	NN	O
trinitrate	NN	O
for	IN	O
diagnosing	VBG	O
vasovagal	JJ	O
syncope	NN	O
was	VBD	O
48	CD	O
%	NN	O
and	CC	O
the	DT	O
specificity	NN	O
was	VBD	O
71	CD	O
%	NN	O
.	.	O

Glyceryl	NNP	O
trinitrate	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Isoprenaline	NNP	O
sensitivity	NN	O
was	VBD	O
21	CD	O
%	NN	O
with	IN	O
specificity	NN	O
64	CD	O
%	NN	O
.	.	O

Side-effects	NNS	O
prevented	JJ	O
completion	NN	O
of	IN	O
the	DT	O
test	NN	O
in	IN	O
68	CD	O
%	NN	O
.	.	O

Commonest	NNP	O
adverse	JJ	O
events	NNS	O
were	VBD	O
the	DT	O
development	NN	O
of	IN	O
hypertension	NN	O
or	CC	O
tachycardia	NN	O
and	CC	O
intolerable	JJ	O
flushing	NN	O
or	CC	O
nausea	NN	O
.	.	O

CONCLUSIONS	NNP	O
Glyceryl	NNP	O
trinitrate	VB	O
head-up	JJ	O
tilt	NN	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
isoprenaline	JJ	O
head-up	JJ	O
tilt	NN	O
as	IN	O
a	DT	O
provocative	JJ	O
agent	NN	O
for	IN	O
vasovagal	JJ	O
syncope	NN	O
and	CC	O
has	VBZ	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

Evaluation	NN	O
of	IN	O
masking	VBG	O
study	NN	O
participants	NNS	O
to	TO	O
intravitreal	VB	O
injections	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
success	NN	O
of	IN	O
masking	VBG	O
study	NN	O
participants	NNS	O
to	TO	O
treatment	NN	O
allocation	NN	O
using	VBG	O
sham	JJ	O
intravitreal	JJ	O
injections	NNS	O
.	.	O

METHODS	NNP	O
Eyes	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
sham	NN	O
injections	NNS	O
plus	CC	O
prompt	JJ	O
laser	NN	O
,	,	O
intravitreal	JJ	O
ranibizumab	NN	O
injections	NNS	O
plus	CC	O
prompt	JJ	O
laser	NN	O
,	,	O
intravitreal	JJ	O
ranibizumab	NN	O
injections	NNS	O
plus	CC	O
deferred	JJ	O
laser	NN	O
,	,	O
or	CC	O
intravitreal	VB	O
triamcinolone	JJ	O
acetonide	JJ	O
injections	NNS	O
plus	CC	O
prompt	NN	O
laser	NN	O
up	RB	O
to	TO	O
every	DT	O
16	CD	O
weeks	NNS	O
with	IN	O
sham	JJ	O
injections	NNS	O
intermittently	RB	O
.	.	O

All	DT	O
eyes	NNS	O
could	MD	O
receive	VB	O
treatment	NN	O
or	CC	O
sham	NN	O
as	RB	O
often	RB	O
as	IN	O
every	DT	O
4	CD	O
weeks	NNS	O
.	.	O

Participants	NNS	O
with	IN	O
2	CD	O
study	NN	O
eyes	NNS	O
had	VBD	O
1	CD	O
eye	NN	O
randomized	VBN	O
to	TO	O
sham	VB	O
plus	JJ	O
prompt	JJ	O
laser	NN	O
and	CC	O
1	CD	O
eye	NN	O
randomized	VBN	O
to	TO	O
a	DT	O
real	JJ	O
injection	NN	O
group	NN	O
.	.	O

Sham	NNP	O
injections	NNS	O
were	VBD	O
performed	VBN	O
by	IN	O
pressing	VBG	O
the	DT	O
syringe	NN	O
hub	NN	O
against	IN	O
the	DT	O
conjunctiva	NN	O
to	TO	O
mimic	VB	O
a	DT	O
real	JJ	O
injection	NN	O
.	.	O

Laser	NNP	O
treatment	NN	O
was	VBD	O
not	RB	O
masked	VBN	O
.	.	O

At	IN	O
the	DT	O
1-year	JJ	O
visit	NN	O
,	,	O
participants	NNS	O
were	VBD	O
asked	VBN	O
if	IN	O
they	PRP	O
believed	VBD	O
that	IN	O
the	DT	O
injections	NNS	O
received	VBD	O
during	IN	O
the	DT	O
study	NN	O
were	VBD	O
real	JJ	O
,	,	O
sham	NN	O
,	,	O
or	CC	O
sometimes	RB	O
real	JJ	O
and	CC	O
sometimes	RB	O
sham	JJ	O
.	.	O

RESULTS	NNP	O
Among	IN	O
423	CD	SampleSize
participants	NNS	O
with	IN	O
1	CD	O
study	NN	O
eye	NN	O
,	,	O
the	DT	O
correct	JJ	O
assignment	NN	O
was	VBD	O
stated	VBN	O
by	IN	O
9.9	CD	O
%	NN	O
of	IN	O
the	DT	O
sham	NN	O
plus	CC	O
prompt	JJ	O
laser	NN	O
group	NN	O
,	,	O
88.0	CD	O
%	NN	O
of	IN	O
the	DT	O
ranibizumab	NN	O
plus	CC	O
prompt	JJ	O
laser	NN	O
group	NN	O
,	,	O
89.6	CD	O
%	NN	O
of	IN	O
the	DT	O
unmasked	JJ	O
ranibizumab	NN	O
plus	CC	O
deferred	JJ	O
laser	NN	O
group	NN	O
,	,	O
and	CC	O
44.0	CD	O
%	NN	O
of	IN	O
the	DT	O
triamcinolone	NN	O
plus	CC	O
prompt	JJ	O
laser	NN	O
group	NN	O
.	.	O

Among	IN	O
112	CD	SampleSize
participants	NNS	O
with	IN	O
2	CD	O
study	NN	O
eyes	NNS	O
,	,	O
the	DT	O
correct	JJ	O
assignment	NN	O
was	VBD	O
stated	VBN	O
for	IN	O
24.1	CD	O
%	NN	O
of	IN	O
the	DT	O
sham	NN	O
plus	CC	O
prompt	JJ	O
laser	NN	O
eyes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Successful	NNP	O
masking	NN	O
of	IN	O
an	DT	O
intravitreal	JJ	O
injection	NN	O
can	MD	O
be	VB	O
accomplished	VBN	O
when	WRB	O
a	DT	O
sham	NN	O
injection	NN	O
procedure	NN	O
carefully	RB	O
mimics	VBZ	O
a	DT	O
real	JJ	O
injection	NN	O
procedure	NN	O
.	.	O

Masking	VBG	O
seems	VBZ	O
less	RBR	O
successful	JJ	O
when	WRB	O
one	CD	O
eye	NN	O
is	VBZ	O
receiving	VBG	O
a	DT	O
real	JJ	O
injection	NN	O
and	CC	O
the	DT	O
other	JJ	O
eye	NN	O
is	VBZ	O
receiving	VBG	O
a	DT	O
sham	JJ	O
injection	NN	O
or	CC	O
when	WRB	O
an	DT	O
individual	JJ	O
eye	NN	O
receives	VBZ	O
both	DT	O
real	JJ	O
and	CC	O
sham	JJ	O
injections	NNS	O
.	.	O

Bites	NNS	O
by	IN	O
the	DT	O
saw-scaled	JJ	O
or	CC	O
carpet	NN	O
viper	NN	O
(	(	O
Echis	NNP	O
carinatus	NN	O
)	)	O
:	:	O
trial	NN	O
of	IN	O
two	CD	O
specific	JJ	O
antivenoms	NNS	O
.	.	O

Echis	NNP	O
carinatus	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
important	JJ	O
cause	NN	O
of	IN	O
morbidity	NN	O
and	CC	O
mortality	NN	O
from	IN	O
snake	JJ	O
bite	NN	O
in	IN	O
Nigeria	NNP	O
and	CC	O
in	IN	O
many	JJ	O
other	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
world	NN	O
.	.	O

Forty-six	JJ	SampleSize
patients	NNS	O
with	IN	O
systemic	JJ	Condition
poisoning	NN	Condition
by	IN	Condition
this	DT	Condition
snake	NN	Condition
were	VBD	O
given	VBN	O
echis	JJ	O
antivenom	NN	O
made	VBD	O
either	CC	O
by	IN	O
the	DT	O
South	JJ	O
African	NNP	O
Institute	NNP	O
for	IN	O
Medical	NNP	O
Research	NNP	O
(	(	O
S.A.I.M.R	NNP	O
.	.	O

)	)	O
or	CC	O
by	IN	O
Behringwerke	NNP	O
(	(	O
North	NNP	O
and	CC	O
West	NNP	O
African	NNP	O
polyvalent	NN	O
antivenom	NN	O
)	)	O
.	.	O

A	DT	O
simple	JJ	O
test	NN	O
of	IN	O
blood	NN	O
coagulability	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
whether	IN	O
an	DT	O
adequate	JJ	O
neutralizing	NN	O
dose	NN	O
of	IN	O
antivenom	NN	O
had	VBD	O
been	VBN	O
given	VBN	O
.	.	O

An	DT	O
average	NN	O
of	IN	O
15.2	CD	O
ml	NN	O
S.A.I.M.R	NNP	O
.	.	O

antivenom	RB	O
restored	VBD	O
normal	JJ	O
coagulability	NN	O
permanently	RB	O
in	IN	O
all	DT	O
23	CD	SampleSize
patients	NNS	O
in	IN	O
one	CD	O
group	NN	O
,	,	O
but	CC	O
in	IN	O
the	DT	O
other	JJ	O
group	NN	O
receiving	VBG	O
an	DT	O
average	JJ	O
dose	NN	O
of	IN	O
37.9	CD	O
ml	NNS	O
Behringwerke	NNP	O
antivenom	VBP	O
normal	JJ	O
clotting	NN	O
resulted	VBD	O
in	IN	O
only	RB	O
18	CD	O
out	IN	O
of	IN	O
23	CD	O
patients	NNS	O
.	.	O

Local	JJ	O
tissue	NN	O
swelling	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
but	CC	O
local	JJ	O
necrosis	NN	O
occurred	VBD	O
in	IN	O
three	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
Behringwerke	NNP	O
antivenom	NN	O
and	CC	O
in	IN	O
none	NN	O
given	VBN	O
S.A.I.M.R	NNP	O
.	.	O

antivenom	NN	O
.	.	O

Temozolomide	NNP	O
and	CC	O
cisplatin	VB	O
versus	NN	O
temozolomide	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	Condition
melanoma	NN	Condition
:	:	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
of	IN	O
the	DT	O
Hellenic	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
.	.	O

PURPOSE	NNP	O
Temozolomide	NNP	O
(	(	O
TMZ	NNP	O
)	)	O
is	VBZ	O
an	DT	O
oral	JJ	O
alkylating	NN	O
agent	NN	O
that	WDT	O
produces	VBZ	O
methyl	JJ	O
adducts	NNS	O
at	IN	O
the	DT	O
0.6	CD	O
position	NN	O
of	IN	O
guanine	NN	O
.	.	O

The	DT	O
methyl	NN	O
adducts	NNS	O
are	VBP	O
removed	VBN	O
by	IN	O
the	DT	O
DNA	NNP	O
repair	NN	O
enzyme	JJ	O
AGAT	NNP	O
.	.	O

As	IN	O
demonstrated	VBN	O
by	IN	O
in	IN	O
vitro	NN	O
studies	NNS	O
,	,	O
cisplatin	NN	O
(	(	O
CDDP	NNP	O
)	)	O
is	VBZ	O
able	JJ	O
to	TO	O
down-regulate	VB	O
the	DT	O
AGAT	NNP	O
activity	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
CDDP	NNP	O
could	MD	O
enhance	VB	O
the	DT	O
antitumor	NN	O
activity	NN	O
of	IN	O
TMZ	NNP	O
.	.	O

We	PRP	O
designed	VBD	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
to	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
the	DT	O
activity	NN	O
and	CC	O
safety	NN	O
profile	NN	O
of	IN	O
the	DT	O
combination	NN	O
versus	IN	O
single-agent	JJ	O
TMZ	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	Condition
melanoma	NN	Condition
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
January	NNP	O
2000	CD	O
to	TO	O
April	NNP	O
2002	CD	O
,	,	O
132	CD	SampleSize
patients	NNS	O
were	VBD	O
enrolled	VBN	O
on	IN	O
the	DT	O
study	NN	O
.	.	O

Patient	NNP	O
and	CC	O
tumor	NN	O
characteristics	NNS	O
were	VBD	O
well	RB	O
balanced	VBN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
cerebral	JJ	Condition
metastases	NNS	Condition
were	VBD	O
included	VBN	O
.	.	O

Patients	NNS	O
received	VBD	O
TMZ	NNP	O
200	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
orally	RB	O
for	IN	O
five	CD	O
consecutive	JJ	O
days	NNS	O
every	DT	O
4	CD	O
weeks	NNS	O
or	CC	O
TMZ	NNP	O
+	NNP	O
CDDP	NNP	O
200	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
daily	RB	O
on	IN	O
days	NNS	O
1-5	CD	O
and	CC	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
of	IN	O
CDDP	NNP	O
on	IN	O
day	NN	O
1	CD	O
.	.	O

RESULTS	NNP	O
Tumor	NNP	O
responses	VBZ	O
(	(	O
complete	JJ	O
and	CC	O
partial	JJ	O
responses	NNS	O
)	)	O
were	VBD	O
seen	VBN	O
in	IN	O
16	CD	O
patients	NNS	O
(	(	O
26	CD	O
%	NN	O
)	)	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
19	CD	O
patients	NNS	O
(	(	O
29	CD	O
%	NN	O
)	)	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
was	VBD	O
3.8	CD	O
months	NNS	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
5.8	CD	O
months	NNS	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

The	DT	O
median	JJ	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
was	VBD	O
11.5	CD	O
months	NNS	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
12	CD	O
months	NNS	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
arms	NNS	O
regarding	VBG	O
objective	JJ	O
response	NN	O
rates	NNS	O
,	,	O
TTP	NNP	O
and	CC	O
OS	NNP	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Toxicity	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
for	IN	O
anemia	NN	O
,	,	O
leukopenia	NN	O
,	,	O
neutropenia	NN	O
,	,	O
thrombocytopenia	NN	O
,	,	O
fatigue	NN	O
,	,	O
constipation	NN	O
and	CC	O
arthralgias/myalgias	NN	O
.	.	O

There	EX	O
was	VBD	O
significantly	RB	O
more	JJR	O
grade	JJ	O
3	CD	O
and	CC	O
4	CD	O
emesis	NN	O
in	IN	O
the	DT	O
combination	NN	O
arm	NN	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	O
clear	JJ	O
benefit	NN	O
in	IN	O
terms	NNS	O
of	IN	O
response	NN	O
rates	NNS	O
,	,	O
median	JJ	O
TTP	NNP	O
or	CC	O
OS	NNP	O
was	VBD	O
shown	VBN	O
with	IN	O
the	DT	O
combination	NN	O
of	IN	O
TMZ	NNP	O
+	NNP	O
CDDP	NNP	O
.	.	O

Additionally	RB	O
,	,	O
the	DT	O
combination	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
incidence	NN	O
of	IN	O
grade	NN	O
3	CD	O
and	CC	O
4	CD	O
emesis	NN	O
.	.	O

Evidence-based	JJ	O
narratives	NNS	O
to	TO	O
improve	VB	O
recall	NN	O
of	IN	O
opioid	JJ	O
prescribing	VBG	O
guidelines	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
experiment	NN	O
.	.	O

OBJECTIVES	NNP	O
Physicians	NNPS	O
adopt	VBP	O
evidence-based	JJ	O
guidelines	NNS	O
with	IN	O
variable	JJ	O
consistency	NN	O
.	.	O

Narratives	NNS	O
,	,	O
or	CC	O
stories	NNS	O
,	,	O
offer	VBP	O
a	DT	O
novel	JJ	O
dissemination	NN	O
strategy	NN	O
for	IN	O
clinical	JJ	O
recommendations	NNS	O
.	.	O

The	DT	O
study	NN	O
objective	NN	O
was	VBD	O
to	TO	O
compare	VB	O
whether	IN	O
evidence-based	JJ	O
narrative	JJ	O
versus	NN	O
traditional	JJ	O
summary	JJ	O
improved	VBN	O
recall	NN	O
of	IN	O
opioid	JJ	O
prescribing	VBG	O
guidelines	NNS	O
from	IN	O
the	DT	O
American	NNP	O
College	NNP	O
of	IN	O
Emergency	NNP	O
Physicians	NNP	O
(	(	O
ACEP	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
controlled	VBD	O
experiment	NN	O
to	TO	O
compare	VB	O
whether	IN	O
narrative	JJ	O
versus	NN	O
summary	JJ	O
promoted	VBD	O
short-term	JJ	O
recall	NN	O
of	IN	O
six	CD	O
themes	NNS	O
contained	VBN	O
in	IN	O
the	DT	O
ACEP	NNP	O
opioid	JJ	O
guideline	NN	O
.	.	O

The	DT	O
experiment	NN	O
was	VBD	O
modeled	VBN	O
after	IN	O
the	DT	O
free-recall	JJ	O
test	NN	O
,	,	O
an	DT	O
established	VBN	O
technique	NN	O
in	IN	O
studies	NNS	O
of	IN	O
memory	NN	O
.	.	O

At	IN	O
a	DT	O
regional	JJ	O
conference	NN	O
,	,	O
emergency	NN	O
physicians	NNS	O
(	(	O
EPs	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
read	VB	O
either	CC	O
a	DT	O
summary	NN	O
of	IN	O
the	DT	O
guideline	NN	O
(	(	O
control	NN	O
)	)	O
or	CC	O
a	DT	O
narrative	JJ	O
(	(	O
intervention	NN	O
)	)	O
.	.	O

The	DT	O
fictional	JJ	O
narrative	NN	O
was	VBD	O
constructed	VBN	O
to	TO	O
match	VB	O
the	DT	O
summary	NN	O
in	IN	O
content	NN	O
and	CC	O
length	NN	O
.	.	O

One	CD	O
hour	NN	O
after	IN	O
reading	VBG	O
the	DT	O
text	NN	O
,	,	O
participants	NNS	O
listed	VBD	O
all	DT	O
content	NN	O
that	IN	O
they	PRP	O
could	MD	O
recall	VB	O
.	.	O

Two	CD	O
reviewers	NNS	O
independently	RB	O
scored	VBD	O
the	DT	O
responses	NNS	O
to	TO	O
assess	VB	O
recall	NN	O
of	IN	O
the	DT	O
six	CD	O
themes	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
total	JJ	O
number	NN	O
of	IN	O
themes	NNS	O
recalled	VBN	O
per	IN	O
participant	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
responses	NNS	O
in	IN	O
each	DT	O
study	NN	O
arm	NN	O
that	WDT	O
recalled	VBD	O
individual	JJ	O
themes	NNS	O
and	CC	O
the	DT	O
proportion	NN	O
of	IN	O
responses	NNS	O
in	IN	O
each	DT	O
arm	NN	O
that	WDT	O
contained	VBD	O
falsely	RB	O
recalled	VBN	O
or	CC	O
extraneous	JJ	O
information	NN	O
.	.	O

RESULTS	NNP	O
Ninety-five	JJ	SampleSize
physicians	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

Eighty-two	JJ	SampleSize
physicians	NNS	O
completed	VBD	O
the	DT	O
experiment	NN	O
,	,	O
for	IN	O
a	DT	O
response	NN	O
rate	NN	O
of	IN	O
86	CD	O
%	NN	O
.	.	O

The	DT	O
mean	NN	O
of	IN	O
the	DT	O
total	JJ	O
number	NN	O
of	IN	O
themes	NNS	O
recalled	VBN	O
per	IN	O
participant	NN	O
was	VBD	O
3.1	CD	O
in	IN	O
the	DT	O
narrative	JJ	O
arm	NN	O
versus	NN	O
2.0	CD	O
in	IN	O
the	DT	O
summary	JJ	O
arm	NN	O
(	(	O
difference	NN	O
=	RB	O
1.1	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
=	VBD	O
0.6	CD	O
to	TO	O
1.7	CD	O
)	)	O
.	.	O

For	IN	O
three	CD	O
themes	NNS	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
responses	NNS	O
that	WDT	O
recalled	VBD	O
the	DT	O
theme	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
narrative	JJ	O
arm	NN	O
compared	VBN	O
to	TO	O
the	DT	O
summary	JJ	O
arm	NN	O
,	,	O
with	IN	O
the	DT	O
differences	NNS	O
ranging	VBG	O
from	IN	O
20	CD	O
%	NN	O
to	TO	O
51	CD	O
%	NN	O
.	.	O

For	IN	O
one	CD	O
theme	NN	O
,	,	O
recall	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
summary	JJ	O
arm	NN	O
.	.	O

For	IN	O
two	CD	O
themes	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
recall	NN	O
between	IN	O
the	DT	O
arms	NNS	O
.	.	O

In	IN	O
the	DT	O
summary	JJ	O
arm	NN	O
,	,	O
54	CD	O
%	NN	O
of	IN	O
responses	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
contain	VB	O
falsely	RB	O
recalled	VBN	O
or	CC	O
extraneous	JJ	O
information	NN	O
versus	IN	O
21	CD	O
%	NN	O
of	IN	O
responses	NNS	O
in	IN	O
the	DT	O
narrative	JJ	O
arm	NN	O
(	(	O
difference	NN	O
=	RB	O
33	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
14	CD	O
%	NN	O
to	TO	O
53	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Physicians	NNPS	O
exposed	VBD	O
to	TO	O
a	DT	O
narrative	JJ	O
about	IN	O
opioid	JJ	O
guidelines	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
recall	VB	O
guideline	JJ	O
content	NN	O
at	IN	O
1	CD	O
hour	NN	O
than	IN	O
those	DT	O
exposed	VBN	O
to	TO	O
a	DT	O
summary	NN	O
of	IN	O
the	DT	O
guidelines	NNS	O
.	.	O

Future	JJ	O
studies	NNS	O
should	MD	O
examine	VB	O
whether	IN	O
the	DT	O
incorporation	NN	O
of	IN	O
narratives	NNS	O
in	IN	O
dissemination	NN	O
campaigns	NNS	O
improves	VBZ	O
guideline	JJ	O
adoption	NN	O
and	CC	O
changes	NNS	O
clinical	JJ	O
practice	NN	O
The	DT	O
influence	NN	O
of	IN	O
pre-	NN	O
and	CC	O
intraoperative	JJ	O
positioning	NN	O
of	IN	O
the	DT	O
condyle	NN	O
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
on	IN	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
disc	NN	O
in	IN	O
orthognathic	JJ	Condition
surgery	NN	O
.	.	O

A	NNP	O
magnetic	JJ	O
resonance	NN	O
study	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
investigated	VBD	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
temporomandibular	JJ	Condition
joint	NN	Condition
(	(	Condition
TMJ	NNP	Condition
)	)	Condition
after	IN	O
bilateral	JJ	Condition
sagittal	JJ	Condition
split	NN	Condition
osteotomy	NN	Condition
of	IN	O
the	DT	O
mandible	JJ	O
for	IN	O
orthognathic	JJ	Condition
surgery	NN	O
and	CC	O
the	DT	O
influence	NN	O
of	IN	O
positioning	NN	O
of	IN	O
the	DT	O
condylar	JJ	O
process	NN	O
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
before	IN	O
and	CC	O
during	IN	O
the	DT	O
operation	NN	O
for	IN	O
preventing	VBG	O
changes	NNS	O
in	IN	O
the	DT	O
TMJ	NNP	O
postoperatively	RB	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
28	CD	SampleSize
patients	NNS	O
with	IN	O
mandibular	JJ	Condition
retrognathism	NN	Condition
had	VBD	O
bilateral	JJ	Condition
sagittal	JJ	Condition
split	NN	Condition
osteotomies	NNS	Condition
for	IN	O
mandibular	JJ	O
advancement	NN	O
.	.	O

In	IN	O
one	CD	O
group	NN	O
of	IN	O
14	CD	SampleSize
patients	NNS	O
(	(	O
28	CD	SampleSize
TMJ	NNP	Condition
)	)	O
,	,	O
the	DT	O
condyles	NNS	O
were	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
before	IN	O
and	CC	O
during	IN	O
the	DT	O
operation	NN	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
other	JJ	O
group	NN	O
they	PRP	O
were	VBD	O
not	RB	O
.	.	O

Differences	NNS	O
on	IN	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
(	(	O
MRI	NNP	O
)	)	O
were	VBD	O
calculated	VBN	O
and	CC	O
the	DT	O
results	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
main	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
at	IN	O
maximal	JJ	O
mouth	NN	O
opening	NN	O
.	.	O

15/28	CD	SampleSize
TMJs	NNP	Condition
(	(	O
54	CD	O
%	NN	O
)	)	O
that	WDT	O
had	VBD	O
not	RB	O
been	VBN	O
positioned	VBN	O
changed	VBD	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
disc	NN	O
from	IN	O
physiological	JJ	O
to	TO	O
anterior	VB	O
disc	JJ	O
derangement	NN	O
with	IN	O
and	CC	O
without	IN	O
reduction	NN	O
postoperatively	RB	O
.	.	O

In	IN	O
the	DT	O
28	CD	SampleSize
that	WDT	O
had	VBD	O
been	VBN	O
positioned	VBN	O
,	,	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
only	RB	O
3	CD	SampleSize
TMJs	NNP	Condition
(	(	O
11	CD	O
%	NN	O
)	)	O
postoperatively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Fixing	VBG	O
the	DT	O
condylar	JJ	O
process	NN	O
in	IN	O
the	DT	O
centre	NN	O
of	IN	O
the	DT	O
articular	JJ	O
fossa	NN	O
intraoperatively	RB	O
before	IN	O
bilateral	JJ	O
sagittal	JJ	O
split	NN	O
osteotomy	NN	O
is	VBZ	O
a	DT	O
factor	NN	O
in	IN	O
preventing	VBG	O
postoperative	JJ	O
structural	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
temporomandibular	JJ	O
joint	NN	O
.	.	O

Is	VBZ	O
a	DT	O
2-week	JJ	O
duration	NN	O
sufficient	NN	O
for	IN	O
stenting	VBG	O
in	IN	O
endopyelotomy	NN	O
?	.	O
PURPOSE	NNP	O
Internal	NNP	O
stenting	NN	O
is	VBZ	O
an	DT	O
integral	JJ	O
part	NN	O
of	IN	O
endopyelotomy	NN	O
.	.	O

Studies	NNS	O
in	IN	O
animals	NNS	O
show	VBP	O
good	JJ	O
healing	NN	O
after	IN	O
1	CD	O
to	TO	O
2	CD	O
weeks	NNS	O
of	IN	O
ureterotomy	JJ	O
.	.	O

Inherent	JJ	O
stent	NN	O
related	VBN	O
problems	NNS	O
warrant	VBP	O
a	DT	O
minimum	JJ	O
possible	JJ	O
duration	NN	O
of	IN	O
stenting	VBG	O
without	IN	O
compromising	VBG	O
the	DT	O
results	NNS	O
of	IN	O
endopyelotomy	JJ	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
optimum	JJ	O
duration	NN	O
of	IN	O
stenting	VBG	O
after	IN	O
endopyelotomy	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
57	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
primary	JJ	O
ureteropelvic	JJ	O
junction	NN	O
obstruction	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
undergo	VB	O
7/14Fr	CD	O
internal	JJ	O
endopyelotomy	NN	O
stent	JJ	O
placement	NN	O
for	IN	O
2	CD	O
(	(	O
group	NN	O
1	CD	O
)	)	O
and	CC	O
4	CD	O
(	(	O
group	NN	O
2	CD	O
)	)	O
weeks	NNS	O
.	.	O

A	DT	O
symptom	NN	O
based	VBN	O
questionnaire	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
all	DT	O
patients	NNS	O
at	IN	O
stent	JJ	O
removal	NN	O
.	.	O

Followup	NNP	O
was	VBD	O
done	VBN	O
with	IN	O
diuretic	JJ	O
scanning	NN	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
and	CC	O
12	CD	O
months	NNS	O
and	CC	O
then	RB	O
yearly	RB	O
,	,	O
and	CC	O
thereafter	RB	O
with	IN	O
diuretic	JJ	O
renography	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
each	DT	O
group	NN	O
26	CD	O
patients	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
evaluation	NN	O
.	.	O

The	DT	O
2	CD	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
symptoms	NNS	O
and	CC	O
ipsilateral	JJ	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
.	.	O

Mean	NNP	O
followup	NN	O
was	VBD	O
22.3	CD	O
(	(	O
range	NN	O
12	CD	O
to	TO	O
36	CD	O
)	)	O
and	CC	O
21.3	CD	O
months	NNS	O
(	(	O
range	VB	O
12	CD	O
to	TO	O
35	CD	O
)	)	O
in	IN	O
groups	NNS	O
1	CD	O
and	CC	O
2	CD	O
,	,	O
respectively	RB	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
1	CD	O
year	NN	O
24	CD	O
group	NN	O
1	CD	O
(	(	O
92.3	CD	O
%	NN	O
)	)	O
and	CC	O
23	CD	O
group	NN	O
2	CD	O
(	(	O
90.3	CD	O
%	NN	O
)	)	O
patients	NNS	O
had	VBD	O
an	DT	O
improved	JJ	O
drainage	NN	O
pattern	NN	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
.	.	O

Stent	NNP	O
related	JJ	O
symptoms	NNS	O
were	VBD	O
present	JJ	O
in	IN	O
a	DT	O
good	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
in	IN	O
groups	NNS	O
1	CD	O
and	CC	O
2	CD	O
but	CC	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
(	(	O
11.5	CD	O
%	NN	O
versus	IN	O
38.1	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
group	NN	O
2	CD	O
patients	NNS	O
64	CD	O
%	NN	O
preferred	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
stenting	VBG	O
.	.	O

CONCLUSIONS	NNP	O
Two	CD	O
weeks	NNS	O
seems	VBZ	O
to	TO	O
be	VB	O
a	DT	O
sufficient	JJ	O
duration	NN	O
to	TO	O
allow	VB	O
functional	JJ	O
restoration	NN	O
across	IN	O
the	DT	O
ureteropelvic	JJ	O
junction	NN	O
after	IN	O
endopyelotomy	NN	O
and	CC	O
decrease	NN	O
stent	NN	O
related	JJ	O
complications	NNS	O
.	.	O

Intravenous	JJ	O
levosimendan	NN	O
treatment	NN	O
is	VBZ	O
cost-effective	JJ	O
compared	VBN	O
with	IN	O
dobutamine	NN	O
in	IN	O
severe	JJ	O
low-output	JJ	O
heart	NN	O
failure	NN	O
:	:	O
an	DT	O
analysis	NN	O
based	VBN	O
on	IN	O
the	DT	O
international	JJ	O
LIDO	NNP	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Levosimendan	NNP	O
,	,	O
a	DT	O
novel	JJ	O
calcium	NN	O
sensitiser	NN	O
,	,	O
improves	VBZ	O
cardiac	JJ	O
performance	NN	O
and	CC	O
symptoms	NNS	O
without	IN	O
increasing	VBG	O
oxygen	NN	O
consumption	NN	O
,	,	O
and	CC	O
decreases	VBZ	O
the	DT	O
mortality	NN	O
of	IN	O
patients	NNS	O
with	IN	O
low-output	JJ	O
heart	NN	O
failure	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
estimate	VB	O
the	DT	O
cost-effectiveness	NN	O
of	IN	O
intravenous	JJ	O
treatment	NN	O
with	IN	O
levosimendan	NNS	O
compared	VBN	O
with	IN	O
dobutamine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
low-output	JJ	O
heart	NN	O
failure	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
economic	JJ	O
evaluation	NN	O
was	VBD	O
based	VBN	O
on	IN	O
a	DT	O
European	JJ	O
clinical	JJ	O
trial	NN	O
(	(	O
LIDO	NNP	O
)	)	O
,	,	O
in	IN	O
which	WDT	O
203	CD	O
patients	NNS	O
with	IN	O
severe	JJ	O
heart	NN	O
failure	NN	O
randomly	RB	O
received	VBD	O
a	DT	O
24	CD	O
h	NN	O
infusion	NN	O
with	IN	O
either	DT	O
levosimendan	NN	O
or	CC	O
dobutamine	NN	O
.	.	O

Survival	NNP	O
and	CC	O
resource	VB	O
utilisation	NN	O
data	NNS	O
were	VBD	O
collected	VBN	O
for	IN	O
6	CD	O
months	NNS	O
;	:	O
survival	NN	O
was	VBD	O
extrapolated	VBN	O
assuming	VBG	O
a	DT	O
mean	JJ	O
additional	JJ	O
lifetime	NN	O
of	IN	O
3	CD	O
years	NNS	O
based	VBN	O
on	IN	O
data	NNS	O
from	IN	O
the	DT	O
Cooperative	NNP	O
North	NNP	O
Scandinavian	JJ	O
Enalapril	NNP	O
Survival	NNP	O
Study	NNP	O
trial	NN	O
.	.	O

Costs	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
study	JJ	O
drug	NN	O
usage	NN	O
and	CC	O
hospitalisation	NN	O
in	IN	O
the	DT	O
6-month	JJ	O
follow-up	NN	O
.	.	O

A	DT	O
sensitivity	NN	O
analysis	NN	O
on	IN	O
dosage	NN	O
of	IN	O
drug	NN	O
and	CC	O
duration	NN	O
of	IN	O
survival	NN	O
was	VBD	O
performed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
survival	NN	O
over	IN	O
6	CD	O
months	NNS	O
was	VBD	O
157+/-52	JJ	O
days	NNS	O
in	IN	O
the	DT	O
levosimendan	NN	O
group	NN	O
and	CC	O
139+/-64	JJ	O
days	NNS	O
in	IN	O
the	DT	O
dobutamine	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

When	WRB	O
extrapolated	VBD	O
up	RB	O
to	TO	O
3	CD	O
years	NNS	O
,	,	O
the	DT	O
gain	NN	O
in	IN	O
life	NN	O
expectancy	NN	O
was	VBD	O
estimated	VBN	O
at	IN	O
0.35	CD	O
years	NNS	O
(	(	O
discounted	VBN	O
at	IN	O
3	CD	O
%	NN	O
)	)	O
.	.	O

Levosimendan	NNP	O
increased	VBD	O
the	DT	O
mean	NN	O
cost	NN	O
per	IN	O
patient	NN	O
by	IN	O
1108	CD	O
,	,	O
which	WDT	O
was	VBD	O
entirely	RB	O
due	JJ	O
to	TO	O
the	DT	O
cost	NN	O
of	IN	O
the	DT	O
study	NN	O
drug	NN	O
.	.	O

The	DT	O
incremental	JJ	O
cost	NN	O
per	IN	O
life-year	JJ	O
saved	NN	O
(	(	O
LYS	NNP	O
)	)	O
was	VBD	O
3205	CD	O
at	IN	O
the	DT	O
European	NNP	O
level	NN	O
;	:	O
in	IN	O
the	DT	O
individual	JJ	O
countries	NNS	O
the	DT	O
cost	NN	O
per	IN	O
LYS	NNP	O
ranged	VBD	O
between	IN	O
3091	CD	O
and	CC	O
3331	CD	O
.	.	O

The	DT	O
result	NN	O
was	VBD	O
robust	JJ	O
in	IN	O
the	DT	O
sensitivity	NN	O
analysis	NN	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
levosimendan	NN	O
group	NN	O
were	VBD	O
alive	JJ	O
for	IN	O
more	JJR	O
days	NNS	O
and	CC	O
thus	RB	O
at	IN	O
risk	NN	O
of	IN	O
hospitalisation	NN	O
for	IN	O
longer	JJR	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
hospitalisation	NN	O
or	CC	O
hospitalisation	NN	O
costs	NNS	O
with	IN	O
levosimendan	JJ	O
treatment	NN	O
.	.	O

The	DT	O
cost	NN	O
per	IN	O
LYS	NNP	O
using	VBG	O
levosimendan	JJ	O
compares	NNS	O
favourably	RB	O
with	IN	O
other	JJ	O
cost-effectiveness	JJ	O
analyses	NNS	O
in	IN	O
cardiology	NN	O
.	.	O

Effect	NN	O
of	IN	O
whole	JJ	O
body	NN	O
vibration	NN	O
on	IN	O
stereotypy	NN	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
case	NN	O
was	VBD	O
report	NN	O
on	IN	O
the	DT	O
effects	NNS	O
of	IN	O
acute	JJ	O
whole	JJ	O
body	NN	O
vibration	NN	O
exposure	NN	O
on	IN	O
stereotyped	JJ	O
behaviour	NN	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Four	CD	O
young	JJ	O
boys	NNS	O
(	(	O
ages	IN	O
4-5	CD	O
years	NNS	O
)	)	O
diagnosed	VBD	O
with	IN	O
autism	NN	O
participated	VBN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
participants	NNS	O
in	IN	O
an	DT	O
early	JJ	O
intensive	JJ	O
behavioural	JJ	O
intervention	NN	O
clinic	NN	O
and	CC	O
during	IN	O
downtimes	NNS	O
stood	VBD	O
on	IN	O
a	DT	O
whole	JJ	O
body	NN	O
vibration	NN	O
platform	NN	O
with	IN	O
the	DT	O
machine	NN	O
turned	VBD	O
off	RP	O
(	(	O
control	VB	O
condition	NN	O
)	)	O
and	CC	O
on	IN	O
(	(	O
treatment	NN	O
condition	NN	O
)	)	O
for	IN	O
three	CD	O
to	TO	O
four	CD	O
,	,	O
30	CD	O
s	NN	O
periods	NNS	O
(	(	O
frequency=28	JJ	O
Hz	NNP	O
;	:	O
amplitude	VBZ	O
0.97	CD	O
mm	NN	O
)	)	O
.	.	O

The	DT	O
outcome	NN	O
measure	NN	O
was	VBD	O
frequency	NN	O
of	IN	O
stereotypic	NN	O
behaviour	NN	O
,	,	O
which	WDT	O
was	VBD	O
evaluated	VBN	O
for	IN	O
5	CD	O
min	NN	O
before	IN	O
and	CC	O
after	IN	O
standing	VBG	O
on	IN	O
the	DT	O
vibration	NN	O
platform	NN	O
.	.	O

The	DT	O
results	NNS	O
revealed	VBD	O
that	IN	O
whole	JJ	O
body	NN	O
vibration	NN	O
was	VBD	O
not	RB	O
able	JJ	O
to	TO	O
uniformly	VB	O
decrease	VB	O
the	DT	O
rates	NNS	O
of	IN	O
all	DT	O
types	NNS	O
of	IN	O
stereotypy	NN	O
;	:	O
that	WDT	O
is	VBZ	O
,	,	O
some	DT	O
stereotypy	NNS	O
decreased	VBN	O
while	IN	O
others	NNS	O
were	VBD	O
unchanged	JJ	O
.	.	O

Subjectively	RB	O
,	,	O
the	DT	O
children	NNS	O
enjoyed	VBD	O
whole	JJ	O
body	NN	O
vibration	NN	O
which	WDT	O
was	VBD	O
easy	JJ	O
to	TO	O
integrate	VB	O
into	IN	O
the	DT	O
behavioural	JJ	O
programme	NN	O
.	.	O

Granulocyte-macrophage	JJ	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
GM-CSF	NNP	O
)	)	O
as	IN	O
adjunct	JJ	O
therapy	NN	O
in	IN	O
relapsed	JJ	O
Hodgkin	NNP	O
disease	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
clinical	JJ	O
and	CC	O
economic	JJ	O
effects	NNS	O
of	IN	O
granulocyte	JJ	O
macrophage	NN	O
colony-stimulating	JJ	O
factor	NN	O
(	(	O
GM-CSF	NNP	O
)	)	O
as	IN	O
adjunct	JJ	O
therapy	NN	O
in	IN	O
relapsed	JJ	O
or	CC	O
refractory	JJ	O
Hodgkin	NNP	O
disease	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
phase	JJ	O
III	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	VB	O
A	DT	O
tertiary	JJ	O
referral	NN	O
center	NN	O
.	.	O

PATIENTS	VB	O
Twenty-four	JJ	O
patients	NNS	O
(	(	O
twelve	NN	O
of	IN	O
whom	WP	O
were	VBD	O
controls	NNS	O
)	)	O
treated	VBN	O
with	IN	O
high-dose	JJ	O
chemotherapy	NN	O
and	CC	O
autologous	JJ	O
bone	NN	O
marrow	NN	O
transplantation	NN	O
.	.	O

MAIN	NNP	O
RESULTS	VBD	O
The	DT	O
12	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
GM-CSF	NNP	O
,	,	O
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	O
recipients	NNS	O
,	,	O
had	VBD	O
shorter	JJR	O
periods	NNS	O
of	IN	O
neutropenia	NN	O
(	(	O
median	JJ	O
duration	NN	O
of	IN	O
an	DT	O
absolute	JJ	O
neutrophil	NN	O
count	NN	O
of	IN	O
less	JJR	O
than	IN	O
1000	CD	O
cells/mm3	NN	O
,	,	O
16	CD	O
days	NNS	O
compared	VBN	O
with	IN	O
27	CD	O
days	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
shorter	JJR	O
periods	NNS	O
of	IN	O
platelet-transfusion	NN	O
dependency	NN	O
(	(	O
median	JJ	O
duration	NN	O
,	,	O
13.5	CD	O
days	NNS	O
compared	VBN	O
with	IN	O
21	CD	O
days	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
and	CC	O
shorter	JJR	O
hospitalizations	NNS	O
(	(	O
median	JJ	O
hospital	NN	O
stay	NN	O
,	,	O
32	CD	O
days	NNS	O
compared	VBN	O
with	IN	O
40.5	CD	O
days	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

Other	JJ	O
clinical	JJ	O
outcomes	NNS	O
,	,	O
such	JJ	O
as	IN	O
frequency	NN	O
and	CC	O
severity	NN	O
of	IN	O
toxicities	NNS	O
,	,	O
development	NN	O
of	IN	O
pneumonia	NN	O
or	CC	O
infection	NN	O
,	,	O
in-hospital	JJ	O
death	NN	O
,	,	O
and	CC	O
response	NN	O
rate	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Actuarial	JJ	O
long-term	JJ	O
disease-free	JJ	O
survival	NN	O
was	VBD	O
64	CD	O
%	NN	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
GM-CSF	NNP	O
and	CC	O
58	CD	O
%	NN	O
for	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
placebo	NN	O
after	IN	O
32	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.15	CD	O
)	)	O
.	.	O

The	DT	O
group	NN	O
treated	VBD	O
with	IN	O
GM-CSF	NNP	O
had	VBD	O
lower	JJR	O
total	NN	O
charges	NNS	O
after	IN	O
infusion	NN	O
of	IN	O
autologous	JJ	O
marrow	NN	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
median	JJ	O
in-hospital	NN	O
charges	NNS	O
,	,	O
$	$	O
39,800	CD	O
compared	VBN	O
with	IN	O
$	$	O
62,500	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
because	IN	O
of	IN	O
lower	JJR	O
post-infusion	NN	O
charges	NNS	O
for	IN	O
room	NN	O
and	CC	O
board	NN	O
,	,	O
antibiotic	JJ	O
therapy	NN	O
,	,	O
transfusions	NNS	O
,	,	O
laboratory	NN	O
tests	NNS	O
,	,	O
and	CC	O
physical	JJ	O
therapy	NN	O
visits	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Administration	NNP	O
of	IN	O
GM-CSF	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
acceleration	NN	O
of	IN	O
myeloid	NN	O
and	CC	O
platelet	NN	O
recovery	NN	O
and	CC	O
was	VBD	O
cost	VBN	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
relapsed	JJ	O
Hodgkin	NNP	O
disease	NN	O
who	WP	O
received	VBD	O
intensive	JJ	O
chemotherapy	NN	O
.	.	O

Intervention	NN	O
in	IN	O
children	NNS	O
with	IN	O
Developmental	NNP	Condition
Coordination	NNP	Condition
Disorder	NNP	Condition
:	:	O
the	DT	O
role	NN	O
of	IN	O
parents	NNS	O
and	CC	O
teachers	NNS	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
Developmental	NNP	Condition
Coordination	NNP	Condition
Disorder	NNP	Condition
(	(	Condition
DCD	NNP	Condition
)	)	Condition
are	VBP	O
a	DT	O
heterogeneous	JJ	O
group	NN	O
who	WP	O
have	VBP	O
a	DT	O
marked	JJ	O
impairment	NN	O
in	IN	O
the	DT	O
performance	NN	O
of	IN	O
functional	JJ	O
skills	NNS	O
.	.	O

Provision	NN	O
for	IN	O
these	DT	O
children	NNS	O
is	VBZ	O
usually	RB	O
made	VBN	O
via	IN	O
a	DT	O
paediatrician	JJ	O
through	IN	O
occupational	JJ	O
or	CC	O
physiotherapy	JJ	O
though	IN	O
,	,	O
with	IN	O
a	DT	O
prevalence	NN	O
rate	NN	O
of	IN	O
5	CD	O
%	NN	O
,	,	O
regular	JJ	O
provision	NN	O
is	VBZ	O
not	RB	O
possible	JJ	O
due	JJ	O
to	TO	O
limited	JJ	O
professional	JJ	O
resources	NNS	O
.	.	O

AIMS	VB	O
The	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
determine	VB	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
parents	NNS	O
and	CC	O
teachers	NNS	O
,	,	O
with	IN	O
guidance	NN	O
,	,	O
can	MD	O
assist	VB	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
children	NNS	O
with	IN	O
DCD	NNP	O
;	:	O
whether	IN	O
children	NNS	O
with	IN	O
DCD	NNP	O
are	VBP	O
helped	VBN	O
in	IN	O
this	DT	O
way	NN	O
and	CC	O
how	WRB	O
this	DT	O
may	MD	O
contribute	VB	O
to	TO	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

SAMPLE	NNP	O
Thirty-one	CD	SampleSize
children	NNS	O
with	IN	O
DCD	NNP	O
aged	VBD	O
7	CD	Age
to	TO	Age
9	CD	Age
years	NNS	Age
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

METHODS	NNP	O
Following	VBG	O
assessment	NN	O
,	,	O
individual	JJ	O
profiles	NNS	O
were	VBD	O
developed	VBN	O
and	CC	O
each	DT	O
week	NN	O
teachers	NNS	O
and	CC	O
parents	NNS	O
were	VBD	O
given	VBN	O
guidelines	NNS	O
for	IN	O
working	VBG	O
with	IN	O
the	DT	O
children	NNS	O
and	CC	O
each	DT	O
child	NN	O
had	VBD	O
three	CD	O
to	TO	O
four	CD	O
sessions	NNS	O
a	DT	O
week	NN	O
lasting	VBG	O
approximately	RB	O
for	IN	O
20	CD	O
minutes	NNS	O
.	.	O

In	IN	O
Phase	NNP	O
1	CD	O
,	,	O
one	CD	O
group	NN	O
of	IN	O
children	NNS	O
worked	VBN	O
with	IN	O
teachers	NNS	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
worked	VBD	O
with	IN	O
parents	NNS	O
.	.	O

In	IN	O
Phase	NNP	O
2	CD	O
,	,	O
the	DT	O
two	CD	O
groups	NNS	O
of	IN	O
children	NNS	O
swapped	VBN	O
over	IN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
assessed	VBN	O
regularly	RB	O
throughout	IN	O
the	DT	O
project	NN	O
using	VBG	O
the	DT	O
Movement	NNP	O
ABC	NNP	O
,	,	O
together	RB	O
with	IN	O
diaries	NNS	O
and	CC	O
comments	NNS	O
from	IN	O
teachers	NNS	O
and	CC	O
parents	NNS	O
.	.	O

RESULTS	NN	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
40-week	JJ	O
study	NN	O
,	,	O
27	CD	SampleSize
children	NNS	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
motor	NN	O
skills	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
teachers	NNS	O
and	CC	O
parents	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
provide	VB	O
effective	JJ	O
intervention	NN	O
for	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
children	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
the	DT	O
children	NNS	O
who	WP	O
did	VBD	O
not	RB	O
improve	VB	O
have	VB	O
difficulties	NNS	O
that	WDT	O
are	VBP	O
of	IN	O
a	DT	O
more	RBR	O
complex	JJ	O
type	NN	O
which	WDT	O
require	VBP	O
more	JJR	O
specialist	JJ	O
therapy	NN	O
to	TO	O
meet	VB	O
their	PRP$	O
need	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
intra-arterial	JJ	O
versus	NN	O
intravenous	JJ	O
heparin	NN	O
on	IN	O
radial	JJ	Condition
artery	NN	Condition
occlusion	NN	Condition
after	IN	Condition
transradial	JJ	Condition
catheterization	NN	Condition
.	.	Condition

Radial	JJ	O
artery	NN	O
occlusion	NN	O
(	(	O
RAO	NNP	O
)	)	O
is	VBZ	O
an	DT	O
infrequent	NN	O
,	,	O
asymptomatic	JJ	O
,	,	O
complication	NN	O
of	IN	O
transradial	JJ	O
catheterization	NN	O
and	CC	O
probably	RB	O
1	CD	O
of	IN	O
the	DT	O
few	JJ	O
.	.	O

Intravenous	JJ	O
heparin	NN	O
and	CC	O
patent	NN	O
hemostasis	NN	O
lower	RBR	O
its	PRP$	O
incidence	NN	O
.	.	O

A	DT	O
possible	JJ	O
local	JJ	O
effect	NN	O
of	IN	O
intra-arterially	RB	O
administered	VBN	O
heparin	NN	O
during	IN	O
transradial	JJ	O
procedures	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	O

We	PRP	O
studied	VBD	O
500	CD	O
consecutive	JJ	O
patients	NNS	O
randomized	VBN	O
to	TO	O
an	DT	O
intravenous	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
250	CD	O
)	)	O
,	,	O
receiving	VBG	O
50	CD	O
U/kg	NNP	O
of	IN	O
unfractionated	JJ	O
heparin	NN	O
(	(	O
maximal	JJ	O
dose	VBP	O
5,000	CD	O
U	NNP	O
)	)	O
intravenously	RB	O
,	,	O
and	CC	O
an	DT	O
intra-arterial	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
250	CD	O
)	)	O
receiving	VBG	O
the	DT	O
same	JJ	O
dose	JJ	O
intra-arterially	RB	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
a	DT	O
vasodilator	NN	O
cocktail	NN	O
intra-arterially	RB	O
and	CC	O
underwent	JJ	O
cardiac	JJ	O
catheterization	NN	O
using	VBG	O
a	DT	O
5F	CD	O
introducer	NN	O
sheath	NN	O
and	CC	O
catheters	NNS	O
.	.	O

The	DT	O
activated	JJ	O
clotting	NN	O
time	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
procedure	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
hemostasis	NN	O
with	IN	O
a	DT	O
radial	JJ	O
compression	NN	O
device	NN	O
(	(	O
TR	NNP	O
Band	NNP	O
)	)	O
,	,	O
applied	VBN	O
after	IN	O
sheath	NN	O
removal	NN	O
,	,	O
for	IN	O
2	CD	O
hours	NNS	O
.	.	O

A	DT	O
plethysmographic	JJ	O
evaluation	NN	O
for	IN	O
RAO	NNP	O
was	VBD	O
performed	VBN	O
at	IN	O
24	CD	O
hours	NNS	O
and	CC	O
30	CD	O
days	NNS	O
after	IN	O
the	DT	O
procedure	NN	O
.	.	O

Early	JJ	O
RAO	NNP	O
occurred	VBD	O
in	IN	O
5.6	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
of	IN	O
the	DT	O
intravenous	JJ	O
group	NN	O
and	CC	O
6	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
of	IN	O
the	DT	O
intra-arterial	JJ	O
group	NN	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
chi-square	JJ	O
=	NN	O
0.037	CD	O
,	,	O
p	NN	O
>	NNP	O
0.8	CD	O
)	)	O
.	.	O

Chronic	NNP	O
RAO	NNP	O
occurred	VBD	O
in	IN	O
3.2	CD	O
%	NN	O
,	,	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
of	IN	O
the	DT	O
intravenous	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
4	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
of	IN	O
the	DT	O
intra-arterial	JJ	O
group	NN	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
chi-square	JJ	O
=	NN	O
0.231	CD	O
,	,	O
p	NN	O
>	NNP	O
0.6	CD	O
)	)	O
.	.	O

The	DT	O
activated	JJ	O
clotting	NN	O
time	NN	O
was	VBD	O
211	CD	O
+/-	JJ	O
16	CD	O
seconds	NNS	O
in	IN	O
the	DT	O
intravenous	JJ	O
group	NN	O
and	CC	O
213	CD	O
+/-	JJ	O
17	CD	O
seconds	NNS	O
in	IN	O
the	DT	O
intra-arterial	JJ	O
group	NN	O
,	,	O
a	DT	O
statistically	RB	O
insignificant	JJ	O
difference	NN	O
(	(	O
t	JJ	O
=	NNP	O
-1.095	NNP	O
,	,	O
p	NN	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
intra-arterial	JJ	O
and	CC	O
intravenous	JJ	O
heparin	NNS	O
administration	NN	O
provide	VBP	O
comparable	JJ	O
efficacy	NN	O
in	IN	O
preventing	VBG	O
RAO	NNP	O
,	,	O
favoring	VBG	O
a	DT	O
probable	JJ	O
systemically	RB	O
mediated	VBD	O
mechanism	NN	O
of	IN	O
action	NN	O
,	,	O
rather	RB	O
than	IN	O
a	DT	O
local	JJ	O
effect	NN	O
.	.	O

Emotional	JJ	O
reactivity	NN	O
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
among	IN	O
persons	NNS	O
with	IN	O
borderline	JJ	Condition
personality	NN	Condition
features	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
emotional	JJ	O
reactivity	NN	O
of	IN	O
persons	NNS	O
with	IN	O
heightened	JJ	Condition
borderline	NN	Condition
personality	NN	Condition
(	(	Condition
BP	NNP	Condition
)	)	Condition
features	VBZ	O
to	TO	O
social	JJ	O
rejection	NN	O
and	CC	O
negative	JJ	O
evaluation	NN	O
in	IN	O
the	DT	O
laboratory	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
high	JJ	Condition
levels	NNS	Condition
of	IN	O
BP	NNP	Condition
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	SampleSize
)	)	O
and	CC	O
controls	NNS	O
with	IN	O
low	JJ	Condition
levels	NNS	Condition
of	IN	O
BP	NNP	Condition
features	NNS	O
(	(	O
n	JJ	O
=	NNP	O
44	CD	SampleSize
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
condition	NN	O
involving	VBG	O
negative	JJ	O
evaluation	NN	O
based	VBN	O
on	IN	O
writing	NN	O
(	(	O
negative	JJ	O
evaluation/academic	NN	O
)	)	O
,	,	O
or	CC	O
a	DT	O
condition	NN	O
involving	VBG	O
negative	JJ	O
evaluation	NN	O
based	VBN	O
on	IN	O
personal	JJ	O
characteristics	NNS	O
as	RB	O
well	RB	O
as	IN	O
social	JJ	O
rejection	NN	O
(	(	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
)	)	O
.	.	O

Hypothesis	$	O
1	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	Condition
individuals	NNS	O
,	,	O
but	CC	O
not	RB	O
low-BP	JJ	Condition
controls	NNS	O
,	,	O
would	MD	O
show	VB	O
greater	JJR	O
emotional	JJ	O
reactivity	NN	O
to	TO	O
the	DT	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
stressor	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	O
evaluation/academic	JJ	O
(	(	O
writing	VBG	O
)	)	O
stressor	NN	O
.	.	O

Hypothesis	$	O
2	CD	O
was	VBD	O
that	IN	O
high-BP	JJ	Condition
individuals	NNS	O
would	MD	O
specifically	RB	O
show	VB	O
greater	JJR	O
reactivity	NN	O
of	IN	O
shame-	JJ	O
and	CC	O
anger-related	JJ	O
emotions	NNS	O
to	TO	O
the	DT	O
negative	JJ	O
evaluation/social	JJ	O
rejection	NN	O
stressor	NN	O
compared	VBN	O
with	IN	O
the	DT	O
negative	JJ	O
evaluation/academic	JJ	O
stressor	NN	O
.	.	O

Findings	NNS	O
indicated	VBD	O
that	IN	O
high-BP	JJ	Condition
individuals	NNS	O
showed	VBD	O
heightened	VBN	O
emotional	JJ	O
reactivity	NN	O
to	TO	O
the	DT	O
social	JJ	O
rejection	NN	O
stressor	NN	O
but	CC	O
not	RB	O
to	TO	O
the	DT	O
negative	JJ	O
evaluation	NN	O
stressor	NN	O
,	,	O
but	CC	O
the	DT	O
opposite	JJ	O
pattern	NN	O
occurred	VBD	O
for	IN	O
controls	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
evidence	NN	O
for	IN	O
heightened	JJ	O
reactivity	NN	O
of	IN	O
irritability	NN	O
,	,	O
distress	NN	O
,	,	O
and	CC	O
shame	NN	O
for	IN	O
the	DT	O
high-BP	JJ	O
group	NN	O
,	,	O
specifically	RB	O
in	IN	O
the	DT	O
social	JJ	O
rejection	NN	O
condition	NN	O
.	.	O

Pazopanib	NNP	O
in	IN	O
locally	RB	O
advanced	JJ	O
or	CC	O
metastatic	JJ	O
renal	NN	Condition
cell	NN	Condition
carcinoma	NN	Condition
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Pazopanib	NNP	O
is	VBZ	O
an	DT	O
oral	JJ	O
angiogenesis	NN	O
inhibitor	NN	O
targeting	VBG	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
platelet-derived	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
and	CC	O
c-Kit	NN	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
evaluated	VBD	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
pazopanib	JJ	O
monotherapy	NN	O
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
(	(	O
RCC	NNP	Condition
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Adult	NNP	O
patients	NNS	O
with	IN	O
measurable	JJ	O
,	,	O
locally	RB	O
advanced	JJ	O
,	,	O
and/or	JJ	O
metastatic	JJ	O
RCC	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
2:1	CD	O
to	TO	O
receive	VB	O
oral	JJ	O
pazopanib	NN	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
overall	JJ	O
survival	NN	O
,	,	O
tumor	NN	O
response	NN	O
rate	NN	O
(	(	O
Response	NNP	O
Evaluation	NNP	O
Criteria	NNP	O
in	IN	O
Solid	NNP	O
Tumors	NNP	O
)	)	O
,	,	O
and	CC	O
safety	NN	O
.	.	O

Radiographic	JJ	O
assessments	NNS	O
of	IN	O
tumors	NNS	O
were	VBD	O
independently	RB	O
reviewed	VBN	O
.	.	O

Results	NNS	O
Of	IN	O
435	CD	SampleSize
patients	NNS	O
enrolled	VBD	O
,	,	O
233	CD	SampleSize
were	VBD	O
treatment	NN	O
naive	JJ	O
(	(	O
54	CD	O
%	NN	O
)	)	O
and	CC	O
202	CD	SampleSize
were	VBD	O
cytokine	NN	O
pretreated	VBN	O
(	(	O
46	CD	O
%	NN	O
)	)	O
.	.	O

PFS	NNP	O
was	VBD	O
significantly	RB	O
prolonged	VBN	O
with	IN	O
pazopanib	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
the	DT	O
overall	JJ	O
study	NN	O
population	NN	O
(	(	O
median	JJ	O
,	,	O
PFS	NNP	O
9.2	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
hazard	PRP$	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
,	,	O
0.46	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.34	CD	O
to	TO	O
0.62	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
the	DT	O
treatment-naive	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
11.1	CD	O
v	NN	O
2.8	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.40	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.27	CD	O
to	TO	O
0.60	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
cytokine-pretreated	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
,	,	O
7.4	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.54	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.35	CD	O
to	TO	O
0.84	CD	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
objective	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
30	CD	O
%	NN	O
with	IN	O
pazopanib	NN	O
compared	VBN	O
with	IN	O
3	CD	O
%	NN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
response	NN	O
was	VBD	O
longer	JJR	O
than	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
diarrhea	RB	O
,	,	O
hypertension	NN	O
,	,	O
hair	NN	O
color	NN	O
changes	NNS	O
,	,	O
nausea	NN	O
,	,	O
anorexia	NN	O
,	,	O
and	CC	O
vomiting	VBG	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
differences	NNS	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
for	IN	O
pazopanib	JJ	O
versus	NN	O
placebo	NN	O
.	.	O

CONCLUSION	NNP	O
Pazopanib	NNP	O
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
PFS	NNP	O
and	CC	O
tumor	NN	O
response	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
and/or	NNS	O
metastatic	JJ	O
RCC	NNP	O
.	.	O

Minimally	RB	O
invasive	JJ	O
treatment	NN	O
combined	VBN	O
with	IN	O
cytokine-induced	JJ	O
killer	NN	O
cells	NNS	O
therapy	VBP	O
lower	JJR	O
the	DT	O
short-term	JJ	O
recurrence	NN	O
rates	NNS	O
of	IN	O
hepatocellular	JJ	Condition
carcinomas	NN	Condition
.	.	O

The	DT	O
recurrence	NN	O
of	IN	O
hepatocellular	JJ	O
carcinoma	NN	O
(	(	O
HCC	NNP	O
)	)	O
after	IN	O
minimally	RB	O
invasive	JJ	O
therapy	NN	O
is	VBZ	O
frequent	JJ	O
.	.	O

Adoptive	JJ	O
immunotherapy	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
method	NN	O
to	TO	O
lower	JJR	O
recurrence	NN	O
and	CC	O
metastasis	NN	O
rates	NNS	O
of	IN	O
malignant	JJ	O
tumors	NNS	O
.	.	O

Therefore	RB	O
,	,	O
85	CD	SampleSize
HCC	NNP	O
patients	NNS	O
after	IN	O
transcatheter	JJ	O
arterial	JJ	O
chemoembolization	NN	O
and	CC	O
radiofrequency	NN	O
ablation	NN	O
therapy	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
immunotherapy	VB	O
group	NN	O
and	CC	O
no	DT	O
adjuvant	JJ	O
therapy	NN	O
group	NN	O
.	.	O

Autologous	JJ	O
cytokine-induced	JJ	O
killer	NN	O
(	(	O
CIK	NNP	O
)	)	O
cells	NNS	O
were	VBD	O
transfused	VBN	O
via	IN	O
hepatic	JJ	O
artery	NN	O
to	TO	O
the	DT	O
patients	NNS	O
.	.	O

The	DT	O
alteration	NN	O
of	IN	O
levels	NNS	O
of	IN	O
lymphocyte	JJ	O
subsets	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
of	IN	O
patients	NNS	O
was	VBD	O
examined	VBN	O
by	IN	O
flow	JJ	O
cytometry	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
screened	VBN	O
by	IN	O
computed	JJ	O
tomography	NN	O
every	DT	O
2	CD	O
months	NNS	O
to	TO	O
observe	VB	O
the	DT	O
tumor	NN	O
recurrent	NN	O
conditions	NNS	O
.	.	O

After	IN	O
CIK	NNP	O
cell	NN	O
infusions	NNS	O
,	,	O
the	DT	O
percentages	NNS	O
of	IN	O
CD3+	NNP	O
,	,	O
CD4+	NNP	O
,	,	O
CD56+	NNP	O
,	,	O
CD3+CD56+	NNP	O
cells	NNS	O
,	,	O
and	CC	O
CD4+/CD8+	NNP	O
ratio	VBP	O
increased	VBN	O
from	IN	O
68.6+/-11.0	CD	O
%	NN	O
,	,	O
31.1+/-9.0	CD	O
%	NN	O
,	,	O
15.6+/-7.9	CD	O
%	NN	O
,	,	O
5.2+/-3.1	CD	O
%	NN	O
,	,	O
and	CC	O
1.1+/-0.5	JJ	O
to	TO	O
70.7+/-10.1	CD	O
%	NN	O
,	,	O
33.5+/-8.0	CD	O
%	NN	O
,	,	O
18.4+/-9.4	CD	O
%	NN	O
,	,	O
5.9+/-2.8	CD	O
%	NN	O
,	,	O
and	CC	O
1.3+/-0.7	JJ	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
;	:	O
whereas	IN	O
the	DT	O
percentage	NN	O
of	IN	O
CD8	NNP	O
cells	NNS	O
decreased	VBN	O
from	IN	O
31.1+/-7.8	CD	O
%	NN	O
to	TO	O
28.6+/-8.3	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
1-year	JJ	O
and	CC	O
18-month	JJ	O
recurrence	NN	O
rates	NNS	O
of	IN	O
the	DT	O
study	NN	O
group	NN	O
were	VBD	O
8.9	CD	O
%	NN	O
and	CC	O
15.6	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
30.0	CD	O
%	NN	O
and	CC	O
40.0	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
both	DT	O
P	NNP	O
value	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
data	NN	O
suggest	NN	O
that	IN	O
CIK	NNP	O
cell	NN	O
transfusion	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
.	.	O

It	PRP	O
can	MD	O
boost	VB	O
the	DT	O
immunologic	JJ	O
function	NN	O
in	IN	O
HCC	NNP	O
patients	NNS	O
and	CC	O
plays	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
reducing	VBG	O
the	DT	O
recurrence	NN	O
rate	NN	O
of	IN	O
HCC	NNP	O
.	.	O

Bevacizumab	NNP	O
plus	CC	O
irinotecan	JJ	O
,	,	O
fluorouracil	NN	O
,	,	O
and	CC	O
leucovorin	NN	O
for	IN	O
metastatic	JJ	Condition
colorectal	JJ	Condition
cancer	NN	Condition
.	.	O

BACKGROUND	NNP	O
Bevacizumab	NNP	O
,	,	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
against	IN	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
,	,	O
has	VBZ	O
shown	VBN	O
promising	JJ	O
preclinical	JJ	O
and	CC	O
clinical	JJ	O
activity	NN	O
against	IN	O
metastatic	JJ	Condition
colorectal	JJ	Condition
cancer	NN	Condition
,	,	O
particularly	RB	O
in	IN	O
combination	NN	O
with	IN	O
chemotherapy	NN	O
.	.	O

METHODS	NNP	O
Of	IN	O
813	CD	SampleSize
patients	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
metastatic	JJ	Condition
colorectal	NN	Condition
cancer	NN	Condition
,	,	O
we	PRP	O
randomly	VBP	O
assigned	VBD	O
402	CD	O
to	TO	O
receive	VB	O
irinotecan	JJ	O
,	,	O
bolus	JJ	O
fluorouracil	NN	O
,	,	O
and	CC	O
leucovorin	NN	O
(	(	O
IFL	NNP	O
)	)	O
plus	CC	O
bevacizumab	NN	O
(	(	O
5	CD	O
mg	NN	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	JJ	O
every	DT	O
two	CD	O
weeks	NNS	O
)	)	O
and	CC	O
411	CD	O
to	TO	O
receive	VB	O
IFL	NNP	O
plus	CC	O
placebo	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
overall	JJ	O
survival	NN	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
progression-free	JJ	O
survival	NN	O
,	,	O
the	DT	O
response	NN	O
rate	NN	O
,	,	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
response	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
survival	NN	O
was	VBD	O
20.3	CD	O
months	NNS	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
IFL	NNP	O
plus	CC	O
bevacizumab	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
15.6	CD	O
months	NNS	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
IFL	NNP	O
plus	CC	O
placebo	NN	O
,	,	O
corresponding	VBG	O
to	TO	O
a	DT	O
hazard	NN	O
ratio	NN	O
for	IN	O
death	NN	O
of	IN	O
0.66	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
progression-free	JJ	O
survival	NN	O
was	VBD	O
10.6	CD	O
months	NNS	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
IFL	NNP	O
plus	CC	O
bevacizumab	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
6.2	CD	O
months	NNS	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
IFL	NNP	O
plus	CC	O
placebo	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
for	IN	O
disease	NN	O
progression	NN	O
,	,	O
0.54	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
;	:	O
the	DT	O
corresponding	JJ	O
rates	NNS	O
of	IN	O
response	NN	O
were	VBD	O
44.8	CD	O
percent	NN	O
and	CC	O
34.8	CD	O
percent	NN	O
(	(	O
P=0.004	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
the	DT	O
response	NN	O
was	VBD	O
10.4	CD	O
months	NNS	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
IFL	NNP	O
plus	CC	O
bevacizumab	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
7.1	CD	O
months	NNS	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
IFL	NNP	O
plus	CC	O
placebo	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
for	IN	O
progression	NN	O
,	,	O
0.62	CD	O
;	:	O
P=0.001	NNP	O
)	)	O
.	.	O

Grade	$	O
3	CD	O
hypertension	NN	O
was	VBD	O
more	RBR	O
common	JJ	O
during	IN	O
treatment	NN	O
with	IN	O
IFL	NNP	O
plus	CC	O
bevacizumab	NN	O
than	IN	O
with	IN	O
IFL	NNP	O
plus	CC	O
placebo	NN	O
(	(	O
11.0	CD	O
percent	NN	O
vs.	FW	O
2.3	CD	O
percent	NN	O
)	)	O
but	CC	O
was	VBD	O
easily	RB	O
managed	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
addition	NN	O
of	IN	O
bevacizumab	NN	O
to	TO	O
fluorouracil-based	JJ	O
combination	NN	O
chemotherapy	NN	O
results	NNS	O
in	IN	O
statistically	RB	O
significant	JJ	O
and	CC	O
clinically	RB	O
meaningful	JJ	O
improvement	NN	O
in	IN	O
survival	NN	O
among	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	Condition
colorectal	JJ	Condition
cancer	NN	Condition
.	.	Condition

Effect	NN	O
of	IN	O
allopurinol	NN	O
on	IN	O
myocardial	JJ	O
oxygen	NN	O
free	JJ	O
radical	JJ	O
production	NN	O
in	IN	O
coronary	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

OBJECTIVES	NNP	O
Allopurinol	NNP	O
protects	VBZ	O
the	DT	O
heart	NN	O
from	IN	O
reperfusion	NN	O
injury	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
myocardial	JJ	O
free	JJ	O
radical	JJ	O
production	NN	O
during	IN	O
reperfusion	NN	O
with	IN	O
and	CC	O
without	IN	O
allopurinol	JJ	O
treatment	NN	O
in	IN	O
coronary	JJ	Condition
artery	NN	Condition
bypass	NN	Condition
grafting	VBG	Condition
patients	NNS	O
randomized	VBN	O
into	IN	O
allopurinol	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	SampleSize
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	SampleSize
)	)	O
groups	NNS	O
.	.	O

DESIGN	NNP	O
Allopurinol	NNP	O
(	(	O
1	CD	O
g	NN	O
)	)	O
was	VBD	O
given	VBN	O
blind	RB	O
prior	JJ	O
to	TO	O
cardiopulmonary	JJ	O
bypass	NN	O
and	CC	O
prior	JJ	O
to	TO	O
opening	VBG	O
the	DT	O
aorta	NN	O
.	.	O

Oxygen	NNP	O
free	JJ	O
radicals	NNS	O
were	VBD	O
measured	VBN	O
before	IN	O
anesthesia	NN	O
in	IN	O
arterial	JJ	O
blood	NN	O
,	,	O
before	IN	O
cross-clamping	JJ	O
and	CC	O
1	CD	O
and	CC	O
10	CD	O
min	NN	O
after	IN	O
reperfusion	NN	O
in	IN	O
arterial	JJ	O
and	CC	O
coronary	JJ	O
sinus	NN	O
blood	NN	O
.	.	O

Levels	NNS	O
were	VBD	O
measured	VBN	O
as	IN	O
relative	JJ	O
concentrations	NNS	O
by	IN	O
the	DT	O
electron	NN	O
spin	NN	O
resonance	NN	O
method	NN	O
.	.	O

RESULTS	NNP	O
One	CD	O
minute	NN	O
after	IN	O
reperfusion	NN	O
the	DT	O
level	NN	O
of	IN	O
spin-trapped	JJ	O
radicals	NNS	O
in	IN	O
arterial	JJ	O
blood	NN	O
was	VBD	O
elevated	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.016	CD	O
)	)	O
in	IN	O
the	DT	O
allopurinol	NN	O
group	NN	O
,	,	O
from	IN	O
7.7	CD	O
(	(	O
SE	NNP	O
:	:	O
0.8	CD	O
)	)	O
to	TO	O
8.6	CD	O
(	(	O
1.4	CD	O
)	)	O
and	CC	O
non-significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.074	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
from	IN	O
7.3	CD	O
(	(	O
0.7	CD	O
)	)	O
to	TO	O
8.3	CD	O
(	(	O
0.8	CD	O
)	)	O
.	.	O

Ten	CD	O
minutes	NNS	O
after	IN	O
reperfusion	NN	O
the	DT	O
arterial	JJ	O
values	NNS	O
were	VBD	O
8.6	CD	O
(	(	O
1.5	CD	O
)	)	O
in	IN	O
the	DT	O
allopurinol	NN	O
and	CC	O
7.6	CD	O
(	(	O
0.7	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
the	DT	O
sinus	NN	O
values	NNS	O
being	VBG	O
7.6	CD	O
(	(	O
1.3	CD	O
)	)	O
and	CC	O
8.3	CD	O
(	(	O
0.8	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Myocardial	NNP	O
free	JJ	O
radical	JJ	O
production	NN	O
was	VBD	O
-0.94	NNP	O
(	(	O
1.21	CD	O
)	)	O
in	IN	O
the	DT	O
allopurinol	NN	O
and	CC	O
+0.79	NNP	O
(	(	O
0.96	CD	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
after	IN	O
10	CD	O
min	JJ	O
reperfusion	NN	O
,	,	O
the	DT	O
difference	NN	O
being	VBG	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
All	DT	O
patients	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
had	VBD	O
an	DT	O
increasing	VBG	O
tendency	NN	O
to	TO	O
free	JJ	O
radical	JJ	O
production	NN	O
during	IN	O
early	JJ	O
reperfusion	NN	O
.	.	O

Patients	NNS	O
treated	VBD	O
with	IN	O
allopurinol	NN	O
showed	VBD	O
less	RBR	O
myocardial	JJ	O
production	NN	O
of	IN	O
free	JJ	O
radicals	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
its	PRP$	O
protective	JJ	O
effect	NN	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
its	PRP$	O
antioxidative	JJ	O
properties	NNS	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	Condition
cancer	NN	Condition
metastatic	NN	O
to	TO	O
bone	NN	O
:	:	O
a	DT	O
multicenter	NN	O
clinical	JJ	O
trial	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
breast	NN	Condition
cancer	NN	Condition
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
bone	NN	Condition
metastases	NNS	Condition
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNS	O
diagnosed	VBD	O
with	IN	O
bone	NN	Condition
metastases	NNS	Condition
<	VBP	O
or	CC	O
=	VBP	O
6	CD	O
weeks	NNS	O
prior	RB	O
to	TO	O
first	JJ	O
visit	NN	O
were	VBD	O
enrolled	VBN	O
.	.	O

Zoledronic	JJ	O
acid	NN	O
(	(	O
4	CD	O
mg	NN	O
)	)	O
was	VBD	O
administered	VBN	O
via	IN	O
a	DT	O
15-minute	JJ	O
infusion	NN	O
every	DT	O
3	CD	O
or	CC	O
4	CD	O
weeks	NNS	O
for	IN	O
12	CD	O
infusions	NNS	O
.	.	O

Skeletal-related	JJ	O
events	NNS	O
(	(	O
SREs	NNP	O
)	)	O
were	VBD	O
defined	VBN	O
as	IN	O
pathologic	JJ	O
bone	NN	O
fractures	NNS	O
,	,	O
spinal	JJ	O
cord	NN	O
compression	NN	O
,	,	O
surgery	NN	O
to	TO	O
bone	VB	O
,	,	O
radiation	NN	O
therapy	NN	O
to	TO	O
bone	VB	O
,	,	O
and	CC	O
hypercalcemia	NN	O
of	IN	O
malignancy	NN	O
.	.	O

Primary	NNP	O
efficacy	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
SRE	NNP	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
first	JJ	O
SRE	NNP	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
pain	NN	O
,	,	O
analgesic	JJ	O
use	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
312	CD	SampleSize
patients	NNS	O
enrolled	VBD	O
,	,	O
30	CD	O
%	NN	O
experienced	VBN	O
at	IN	O
least	JJS	O
one	CD	O
SRE	NNP	O
during	IN	O
the	DT	O
12-month	JJ	O
study	NN	O
,	,	O
and	CC	O
22	CD	O
%	NN	O
experienced	VBD	O
only	RB	O
one	CD	O
SRE	NNP	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
to	TO	O
first	VB	O
SRE	NNP	O
was	VBD	O
not	RB	O
reached	VBN	O
in	IN	O
the	DT	O
intent-to-treat	JJ	O
population	NN	O
.	.	O

Mean	NNP	O
pain	NN	O
and	CC	O
analgesic	JJ	O
scores	NNS	O
declined	VBD	O
from	IN	O
baseline	NN	O
,	,	O
and	CC	O
quality-of-life	JJ	O
scores	NNS	O
remained	VBD	O
stable	JJ	O
to	TO	O
study	VB	O
end	NN	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
adverse	JJ	O
events	NNS	O
,	,	O
regardless	RB	O
of	IN	O
relationship	NN	O
to	TO	O
study	VB	O
drug	NN	O
,	,	O
were	VBD	O
pyrexia	VBN	O
(	(	O
22	CD	O
%	NN	O
)	)	O
and	CC	O
bone	NN	O
pain	NN	O
(	(	O
10	CD	O
%	NN	O
)	)	O
.	.	O

Serum	NNP	O
creatinine	NN	O
levels	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
increase	VB	O
from	IN	O
baseline	NN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
Breast	NNP	Condition
cancer	NN	Condition
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
bone	NN	Condition
metastases	NNS	Condition
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
had	VBD	O
a	DT	O
low	JJ	O
incidence	NN	O
of	IN	O
SREs	NNP	O
compared	VBN	O
with	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
placebo	NN	O
in	IN	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trials	NNS	O
,	,	O
and	CC	O
pain	NN	O
was	VBD	O
decreased	VBN	O
from	IN	O
baseline	NN	O
.	.	O

This	DT	O
study	NN	O
demonstrated	VBD	O
the	DT	O
favorable	JJ	O
risk	NN	O
:	:	O
benefit	NN	O
ratio	NN	O
of	IN	O
zoledronic	JJ	O
acid	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
skeletal	JJ	O
complications	NNS	O
.	.	O

Effect	NN	O
of	IN	O
desonide	NN	O
ointment	NN	O
,	,	O
0.05	CD	O
%	NN	O
,	,	O
on	IN	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
axis	NN	O
of	IN	O
children	NNS	Age
with	IN	O
atopic	NN	Condition
dermatitis	NN	Condition
.	.	O

Desonide	NNP	O
ointment	NN	O
has	VBZ	O
demonstrated	VBN	O
a	DT	O
good	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
profile	NN	O
during	IN	O
the	DT	O
many	JJ	O
years	NNS	O
it	PRP	O
has	VBZ	O
been	VBN	O
used	VBN	O
in	IN	O
treating	VBG	O
dermatoses	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
to	TO	O
evaluate	VB	O
its	PRP$	O
systemic	JJ	O
safety	NN	O
when	WRB	O
used	VBN	O
in	IN	O
treating	VBG	O
children	NNS	Age
.	.	O

Suppression	NN	O
of	IN	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
(	(	O
HPA	NNP	O
)	)	O
axis	NN	O
can	MD	O
occur	VB	O
after	IN	O
repeated	JJ	O
application	NN	O
of	IN	O
topical	JJ	O
corticosteroids	NNS	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
degree	NN	O
of	IN	O
suppression	NN	O
of	IN	O
the	DT	O
HPA	NNP	O
axis	NN	O
function	NN	O
is	VBZ	O
related	VBN	O
to	TO	O
the	DT	O
daily	JJ	O
dosage	NN	O
of	IN	O
steroid	JJ	O
given	VBN	O
,	,	O
the	DT	O
duration	NN	O
of	IN	O
its	PRP$	O
administration	NN	O
,	,	O
the	DT	O
extent	NN	O
of	IN	O
body	NN	O
surface	NN	O
covered	VBN	O
,	,	O
and	CC	O
the	DT	O
potency	NN	O
of	IN	O
the	DT	O
corticosteroid	NN	O
.	.	O

This	DT	O
study	NN	O
sought	VBD	O
to	TO	O
determine	VB	O
the	DT	O
comparative	JJ	O
effects	NNS	O
of	IN	O
0.05	CD	O
percent	NN	O
desonide	NN	O
and	CC	O
2.5	CD	O
percent	NN	O
hydrocortisone	NN	O
ointments	NNS	O
on	IN	O
the	DT	O
HPA	NNP	O
axis	NN	O
of	IN	O
children	NNS	Age
with	IN	O
atopic	NN	Condition
dermatitis	NN	Condition
.	.	O

There	EX	O
was	VBD	O
no	DT	O
suppression	NN	O
of	IN	O
early	JJ	O
morning	NN	O
cortisol	NN	O
in	IN	O
either	DT	O
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
ACTH-stimulated	JJ	O
mean	NN	O
cortisol	NN	O
values	NNS	O
after	IN	O
four	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
the	DT	O
baseline	NN	O
values	VBZ	O
for	IN	O
either	DT	O
treatment	NN	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
neither	CC	O
0.05	CD	O
percent	NN	O
desonide	NN	O
ointment	NN	O
nor	CC	O
2.5	CD	O
percent	NN	O
hydrocortisone	NN	O
ointment	NN	O
compromised	VBD	O
the	DT	O
HPA	NNP	O
axis	NN	O
of	IN	O
children	NNS	Age
with	IN	O
atopic	NN	Condition
dermatitis	NN	Condition
treated	VBD	O
topically	RB	O
for	IN	O
four	CD	O
weeks	NNS	O
.	.	O

Risk	NN	O
factors	NNS	O
for	IN	O
fracture	NN	O
in	IN	O
a	DT	O
UK	JJ	O
population	NN	O
:	:	O
a	DT	O
prospective	JJ	O
cohort	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Common	NNP	O
clinical	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
fracture	NN	O
in	IN	O
older	JJR	O
women	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
.	.	O

To	TO	O
date	NN	O
,	,	O
most	JJS	O
of	IN	O
these	DT	O
risk	NN	O
factors	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
confirmed	VBN	O
in	IN	O
a	DT	O
UK	NNP	O
population	NN	O
.	.	O

AIM	NNP	O
To	TO	O
confirm	VB	O
the	DT	O
important	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
fracture	NN	O
in	IN	O
older	JJR	O
women	NNS	O
.	.	O

DESIGN	NNP	O
Comprehensive	NNP	O
cohort	NN	O
study	NN	O
(	(	O
CCS	NNP	O
)	)	O
with	IN	O
a	DT	O
nested	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
CCS	NNP	O
included	VBD	O
4292	CD	O
women	NNS	O
aged	VBD	O
>	JJ	O
70	CD	O
years	NNS	O
.	.	O

We	PRP	O
assessed	VBD	O
potential	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
fracture	NN	O
,	,	O
and	CC	O
followed-up	JJ	O
participants	NNS	O
for	IN	O
24	CD	O
months	NNS	O
for	IN	O
incidence	NN	O
of	IN	O
non-vertebral	JJ	O
fractures	NNS	O
.	.	O

RESULTS	NNP	O
Odds	NNP	O
ratios	NNS	O
(	(	O
ORs	NNP	O
)	)	O
for	IN	O
predicting	VBG	O
any	DT	O
non-vertebral	JJ	O
fracture	NN	O
were	VBD	O
:	:	O
previous	JJ	O
fracture	NN	O
,	,	O
2.67	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
2.10-3.40	CD	O
)	)	O
;	:	O
a	DT	O
fall	NN	O
in	IN	O
the	DT	O
last	JJ	O
12	CD	O
months	NNS	O
,	,	O
2.06	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.63-2.59	CD	O
)	)	O
;	:	O
and	CC	O
age	NN	O
(	(	O
per	IN	O
year	NN	O
increase	NN	O
)	)	O
,	,	O
1.03	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.01-1.05	CD	O
)	)	O
.	.	O

ORs	NNP	O
for	IN	O
predicting	VBG	O
hip	JJ	O
fracture	NN	O
were	VBD	O
:	:	O
previous	JJ	O
fracture	NN	O
,	,	O
2.31	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.31-4.08	CD	O
)	)	O
;	:	O
low	JJ	O
body	NN	O
weight	NN	O
(	(	O
<	JJ	O
58	CD	O
kg	NN	O
)	)	O
,	,	O
2.20	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.28-3.77	CD	O
)	)	O
;	:	O
maternal	JJ	O
history	NN	O
of	IN	O
hip	NN	O
fracture	NN	O
,	,	O
1.68	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.85-3.31	NN	O
)	)	O
;	:	O
a	DT	O
fall	NN	O
in	IN	O
the	DT	O
last	JJ	O
12	CD	O
months	NNS	O
,	,	O
2.92	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.70-5.01	CD	O
)	)	O
;	:	O
and	CC	O
age	NN	O
(	(	O
per	IN	O
year	NN	O
increase	NN	O
)	)	O
,	,	O
1.09	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.04-1.13	CD	O
)	)	O
.	.	O

ORs	NNP	O
for	IN	O
predicting	VBG	O
wrist	JJ	O
fracture	NN	O
were	VBD	O
:	:	O
previous	JJ	O
fracture	NN	O
,	,	O
2.29	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.56-3.34	CD	O
)	)	O
;	:	O
and	CC	O
a	DT	O
fall	NN	O
in	IN	O
the	DT	O
last	JJ	O
12	CD	O
months	NNS	O
,	,	O
1.60	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.10-2.31	CD	O
)	)	O
.	.	O

Being	VBG	O
a	DT	O
current	JJ	O
smoker	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
risk	NN	O
,	,	O
and	CC	O
was	VBD	O
consistent	JJ	O
across	IN	O
all	DT	O
fracture	NN	O
types	NNS	O
.	.	O

DISCUSSION	NNP	O
Older	NNP	O
women	NNS	O
with	IN	O
the	DT	O
clinical	JJ	O
risk	NN	O
factors	NNS	O
identified	VBN	O
in	IN	O
this	DT	O
study	NN	O
should	MD	O
be	VB	O
investigated	VBN	O
for	IN	O
osteoporosis	NN	O
or	CC	O
offered	VBN	O
preventive	JJ	O
treatment	NN	O
.	.	O

Beneficial	JJ	O
effect	NN	O
of	IN	O
etidronate	NN	O
therapy	NN	O
in	IN	O
chronically	RB	Condition
hospitalized	VBN	Condition
,	,	O
disabled	JJ	Condition
patients	NNS	O
with	IN	O
stroke	NN	Condition
.	.	O

Incidence	NN	O
of	IN	O
hip	NN	O
fractures	NNS	O
is	VBZ	O
high	JJ	O
in	IN	O
chronically	RB	O
hospitalized	VBN	O
,	,	O
disabled	VBD	O
,	,	O
elderly	JJ	Age
patients	NNS	O
after	IN	O
stroke	NN	O
.	.	O

Duration	NN	O
of	IN	O
hospitalization	NN	O
was	VBD	O
more	JJR	O
than	IN	O
1	CD	O
year	NN	O
because	IN	O
of	IN	O
insufficiency	NN	O
of	IN	O
nursing	NN	O
homes	NNS	O
.	.	O

Our	PRP$	O
study	NN	O
showed	VBD	O
that	IN	O
immobilization-induced	JJ	O
hypercalcemia	NN	O
and	CC	O
25-hydroxyvitamin	JJ	O
D	NNP	O
deficiency	NN	O
contribute	NN	O
to	TO	O
reduced	VB	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
address	VB	O
the	DT	O
possibility	NN	O
that	WDT	O
treatment	NN	O
with	IN	O
etidronate	NN	O
may	MD	O
reduce	VB	O
the	DT	O
bone	NN	O
resorption	NN	O
and	CC	O
lower	JJR	O
the	DT	O
incidence	NN	O
of	IN	O
fractures	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
who	WP	O
are	VBP	O
chronically	RB	O
hospitalized	VBN	O
and	CC	O
disabled	VBN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
hemiparesis	NN	Condition
after	IN	O
stroke	NN	O
.	.	O

Patients	NNS	O
with	IN	O
stroke	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
daily	VB	O
treatment	NN	O
with	IN	O
400	CD	O
mg	NNS	O
of	IN	O
etidronate	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
,	,	O
and	CC	O
followed	VBD	O
up	RB	O
for	IN	O
2	CD	O
years	NNS	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
both	DT	O
groups	NNS	O
had	VBD	O
low	JJ	O
BMD	NNP	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
ionized	VBN	O
calcium	NN	O
and	CC	O
urinary	JJ	O
deoxypyridinoline	NN	O
.	.	O

In	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
,	,	O
serum	NN	O
calcium	NN	O
and	CC	O
urinary	JJ	O
deoxypyridinoline	NN	O
levels	NNS	O
decreased	VBN	O
significantly	RB	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
,	,	O
whereas	IN	O
the	DT	O
levels	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
increased	VBN	O
.	.	O

BMD	NNP	O
on	IN	O
the	DT	O
hemiplegic	JJ	O
side	NN	O
increased	VBN	O
by	IN	O
1.4	CD	O
%	NN	O
in	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
and	CC	O
decreased	VBN	O
by	IN	O
2.2	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Two	CD	O
patients	NNS	O
sustained	VBD	O
hip	JJ	O
fractures	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
no	DT	O
hip	NN	O
fracture	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
etidronate	NN	O
group	NN	O
.	.	O

Treatment	NN	O
with	IN	O
etidronate	NN	O
increases	NNS	O
BMD	NNP	O
in	IN	O
chronically	RB	O
hospitalized	VBN	O
patients	NNS	O
poststroke	VBD	O
,	,	O
and	CC	O
may	MD	O
prevent	VB	O
hip	NN	O
fracture	NN	O
.	.	O

Aztreonam	NNP	O
versus	NN	O
gentamicin	NN	O
for	IN	O
short-term	JJ	O
prophylaxis	NN	O
in	IN	O
biliary	JJ	O
and	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

Short-term	NNP	O
antibiotic	JJ	O
prophylaxis	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
80	CD	SampleSize
patients	NNS	O
undergoing	JJ	O
biliary	JJ	O
or	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
g	NN	O
of	IN	O
aztreonam	NN	O
or	CC	O
80	CD	O
mg	NN	O
of	IN	O
gentamicin	NN	O
intravenously	RB	O
30	CD	O
minutes	NNS	O
before	IN	O
surgery	NN	O
and	CC	O
8	CD	O
and	CC	O
16	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
.	.	O

Of	IN	O
samples	NNS	O
taken	VBN	O
from	IN	O
the	DT	O
abdominal	JJ	O
cavity	NN	O
for	IN	O
bacteriologic	NN	O
study	NN	O
,	,	O
53	CD	O
%	NN	O
were	VBD	O
culture	NN	O
positive	JJ	O
.	.	O

Wound	IN	O
infections	NNS	O
developed	VBN	O
in	IN	O
two	CD	O
(	(	O
4.5	CD	O
%	NN	O
)	)	O
of	IN	O
44	CD	O
patients	NNS	O
receiving	VBG	O
aztreonam	NN	O
and	CC	O
in	IN	O
seven	CD	O
(	(	O
19.4	CD	O
%	NN	O
)	)	O
of	IN	O
36	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
gentamicin	NN	O
.	.	O

Staphylococcus	NNP	O
epidermidis	NN	O
and	CC	O
Enterobacter	NNP	O
species	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
sites	NNS	O
of	IN	O
wound	JJ	O
infection	NN	O
in	IN	O
the	DT	O
aztreonam	JJ	O
group	NN	O
;	:	O
Escherichia	NNP	O
coli	NNS	O
(	(	O
two	CD	O
isolates	NNS	O
)	)	O
,	,	O
Pseudomonas	NNP	O
aeruginosa	NN	O
(	(	O
two	CD	O
isolates	NNS	O
)	)	O
,	,	O
Enterobacter	NNP	O
species	NNS	O
,	,	O
Klebsiella	NNP	O
species	NNS	O
,	,	O
Enterococcus	NNP	O
faecalis	NN	O
,	,	O
and	CC	O
Aeromonas	NNP	O
hydrophila	NN	O
were	VBD	O
isolated	VBN	O
from	IN	O
the	DT	O
gentamicin	NN	O
group	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
aztreonam	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
infections	NNS	O
following	VBG	O
biliary	JJ	O
and	CC	O
gastric	JJ	O
surgery	NN	O
.	.	O

Effect	NN	O
of	IN	O
ranitidine	NN	O
on	IN	O
the	DT	O
disposition	NN	O
of	IN	O
orally	RB	O
and	CC	O
intravenously	RB	O
administered	VBN	O
triazolam	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
orally	RB	O
administered	VBN	O
ranitidine	NN	O
on	IN	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
of	IN	O
orally	RB	O
and	CC	O
intravenously	RB	O
administered	VBD	O
triazolam	NN	O
was	VBD	O
determined	VBN	O
.	.	O

Twelve	NNP	Age
healthy	JJ	Age
males	NNS	Age
with	IN	Age
a	DT	Age
mean	JJ	Age
age	NN	Age
of	IN	Age
35	CD	Age
years	NNS	Age
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
four-way	NN	O
,	,	O
randomized	VBN	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Each	DT	O
subject	NN	O
received	VBD	O
a	DT	O
total	NN	O
of	IN	O
four	CD	O
treatments	NNS	O
,	,	O
each	DT	O
separated	VBN	O
by	IN	O
one	CD	O
week	NN	O
.	.	O

The	DT	O
treatments	NNS	O
consisted	VBN	O
of	IN	O
(	(	O
1	CD	O
)	)	O
one	CD	O
orally	RB	O
administered	VBN	O
0.25-mg	JJ	O
triazolam	NN	O
tablet	NN	O
after	IN	O
treatment	NN	O
with	IN	O
ranitidine	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
one	CD	O
orally	RB	O
administered	VBN	O
0.25-mg	JJ	O
triazolam	NN	O
tablet	NN	O
,	,	O
with	IN	O
no	DT	O
ranitidine	JJ	O
pretreatment	NN	O
;	:	O
(	(	O
3	CD	O
)	)	O
a	DT	O
0.25-mg	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
triazolam	NN	O
after	IN	O
treatment	NN	O
with	IN	O
ranitidine	NN	O
;	:	O
and	CC	O
(	(	O
4	CD	O
)	)	O
a	DT	O
0.25-mg	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
triazolam	NN	O
,	,	O
with	IN	O
no	DT	O
ranitidine	NN	O
pretreatment	NN	O
.	.	O

Ranitidine	NNP	O
pretreatment	NN	O
consisted	VBD	O
of	IN	O
five	CD	O
150-mg	JJ	O
oral	JJ	O
doses	NNS	O
(	(	O
as	IN	O
the	DT	O
hydrochloride	NN	O
salt	NN	O
)	)	O
given	VBN	O
every	DT	O
12	CD	O
hours	NNS	O
;	:	O
the	DT	O
last	JJ	O
dose	NN	O
was	VBD	O
given	VBN	O
two	CD	O
hours	NNS	O
before	IN	O
triazolam	NN	O
was	VBD	O
administered	VBN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
taken	VBN	O
at	IN	O
intervals	NNS	O
up	RB	O
to	TO	O
12	CD	O
hours	NNS	O
after	IN	O
triazolam	JJ	O
treatment	NN	O
.	.	O

Serum	NNP	O
triazolam	JJ	O
concentrations	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
modified	JJ	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
,	,	O
and	CC	O
pharmacokinetic	JJ	O
values	NNS	O
were	VBD	O
calculated	VBN	O
.	.	O

Pretreatment	NN	O
with	IN	O
ranitidine	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
disposition	NN	O
of	IN	O
intravenously	RB	O
administered	VBN	O
triazolam	NN	O
but	CC	O
significantly	RB	O
increased	VBD	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
serum	JJ	O
drug	NN	O
concentration-time	JJ	O
curve	NN	O
of	IN	O
oral	JJ	O
triazolam	NN	O
.	.	O

Ranitidine	NNP	O
pretreatment	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
triazolam	NN	O
's	POS	O
terminal	JJ	O
elimination	NN	O
rate	NN	O
constant	JJ	O
or	CC	O
on	IN	O
the	DT	O
time	NN	O
to	TO	O
reach	VB	O
maximum	JJ	O
serum	JJ	O
triazolam	NN	O
concentration	NN	O
.	.	O

Ranitidine	JJ	O
pretreatment	NN	O
increased	VBD	O
the	DT	O
systemic	JJ	O
availability	NN	O
of	IN	O
triazolam	NN	O
by	IN	O
increasing	VBG	O
its	PRP$	O
absorption	NN	O
.	.	O

Testing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
HIV	NNP	O
stigma	NN	O
reduction	NN	O
intervention	NN	O
with	IN	O
medical	JJ	O
students	NNS	O
in	IN	O
Puerto	NNP	O
Rico	NNP	O
:	:	O
the	DT	O
SPACES	NNP	O
project	NN	O
.	.	O

INTRODUCTION	NNP	O
Stigma	NNP	O
associated	VBD	O
with	IN	O
HIV	NNP	O
has	VBZ	O
been	VBN	O
documented	VBN	O
as	IN	O
a	DT	O
barrier	NN	O
for	IN	O
accessing	VBG	O
quality	NN	O
health-related	JJ	O
services	NNS	O
.	.	O

When	WRB	O
the	DT	O
stigma	NN	O
manifests	NNS	O
in	IN	O
the	DT	O
health	NN	O
care	NN	O
setting	VBG	O
,	,	O
people	NNS	O
living	VBG	O
with	IN	O
HIV	NNP	O
receive	VBP	O
substandard	NN	O
services	NNS	O
or	CC	O
even	RB	O
be	VB	O
denied	VBN	O
care	NN	O
altogether	RB	O
.	.	O

Although	IN	O
the	DT	O
consequences	NNS	O
of	IN	O
HIV	NNP	O
stigma	NN	O
have	VBP	O
been	VBN	O
documented	VBN	O
extensively	RB	O
,	,	O
efforts	NNS	O
to	TO	O
reduce	VB	O
these	DT	O
negative	JJ	O
attitudes	NNS	O
have	VBP	O
been	VBN	O
scarce	JJ	O
.	.	O

Interventions	NNS	O
to	TO	O
reduce	VB	O
HIV	NNP	O
stigma	NN	O
should	MD	O
be	VB	O
implemented	VBN	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
formal	JJ	O
training	NN	O
of	IN	O
future	JJ	O
health	NN	O
care	NN	O
professionals	NNS	O
.	.	O

The	DT	O
interventions	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
tested	VBN	O
with	IN	O
health	NN	O
care	NN	O
professionals	NNS	O
and	CC	O
published	VBN	O
have	VBP	O
several	JJ	O
limitations	NNS	O
that	WDT	O
must	MD	O
be	VB	O
surpassed	VBN	O
(	(	O
i.e	NN	O
.	.	O

lack	NN	O
of	IN	O
comparison	NN	O
groups	NNS	O
in	IN	O
research	NN	O
designs	NNS	O
and	CC	O
longitudinal	JJ	O
follow-up	JJ	O
data	NNS	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
Latino	NNP	O
health	NN	O
care	NN	O
professionals	NNS	O
have	VBP	O
been	VBN	O
absent	JJ	O
from	IN	O
these	DT	O
intervention	NN	O
efforts	NNS	O
even	RB	O
though	IN	O
the	DT	O
epidemic	NN	O
has	VBZ	O
affected	VBN	O
this	DT	O
population	NN	O
disproportionately	RB	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
article	NN	O
,	,	O
we	PRP	O
describe	VBP	O
an	DT	O
intervention	NN	O
developed	VBD	O
to	TO	O
reduce	VB	O
HIV	NNP	O
stigma	NN	O
among	IN	O
medical	JJ	O
students	NNS	O
in	IN	O
Puerto	NNP	O
Rico	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
507	CD	SampleSize
medical	JJ	O
students	NNS	O
were	VBD	O
randomly	RB	O
introduced	VBN	O
into	IN	O
our	PRP$	O
intervention	NN	O
and	CC	O
control	NN	O
conditions	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
results	NNS	O
show	VBP	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
;	:	O
intervention	NN	O
group	NN	O
participants	NNS	O
had	VBD	O
lower	JJR	O
HIV	NNP	O
stigma	NN	O
levels	NNS	O
than	IN	O
control	NN	O
participants	NNS	O
after	IN	O
the	DT	O
intervention	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
differences	NNS	O
in	IN	O
HIV	NNP	O
stigma	NN	O
levels	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
sustained	VBN	O
for	IN	O
a	DT	O
12-month	JJ	O
period	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
our	PRP$	O
study	NN	O
demonstrate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
modes	NNS	O
of	IN	O
intervention	NN	O
developed	VBN	O
by	IN	O
us	PRP	O
and	CC	O
serve	VB	O
as	IN	O
a	DT	O
new	JJ	O
training	NN	O
tool	NN	O
for	IN	O
future	JJ	O
health	NN	O
care	NN	O
professionals	NNS	O
with	IN	O
regard	NN	O
to	TO	O
stigma	VB	O
reduction	NN	O
.	.	O

Use	NNP	O
of	IN	O
an	DT	O
Internet	NNP	O
portal	NN	O
to	TO	O
improve	VB	O
community-based	JJ	O
pediatric	JJ	Age
ADHD	NNP	Condition
care	NN	O
:	:	O
a	DT	O
cluster	NN	O
randomized	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
quality	NN	O
improvement	NN	O
program	NN	O
to	TO	O
improve	VB	O
pediatricians	NNS	O
'	POS	O
adherence	NN	O
to	TO	O
existing	VBG	O
,	,	O
evidence-based	JJ	O
,	,	O
attention-deficit/hyperactivity	JJ	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
practice	NN	O
guidelines	NNS	O
.	.	O

METHODS	NNP	O
Forty-nine	JJ	SampleSize
community-based	JJ	O
pediatricians	NNS	O
at	IN	O
8	CD	O
practices	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
cluster-randomized	JJ	O
trial	NN	O
.	.	O

Practices	NNS	O
were	VBD	O
matched	VBN	O
according	VBG	O
to	TO	O
the	DT	O
numbers	NNS	O
of	IN	O
pediatricians	NNS	O
and	CC	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
receiving	VBG	O
Medicaid	NNP	O
.	.	O

The	DT	O
medical	JJ	O
charts	NNS	O
for	IN	O
a	DT	O
random	JJ	O
sample	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ADHD	NNP	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
participating	VBG	O
pediatricians	NNS	O
were	VBD	O
examined	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

All	DT	O
practices	NNS	O
participated	VBN	O
in	IN	O
4	CD	O
sessions	NNS	O
of	IN	O
training	NN	O
,	,	O
including	VBG	O
didactic	JJ	O
lectures	NNS	O
and	CC	O
office	NN	O
flow	NN	O
modification	NN	O
workshops	NNS	O
.	.	O

Practices	NNS	O
were	VBD	O
then	RB	O
given	VBN	O
access	NN	O
to	TO	O
an	DT	O
ADHD	NNP	O
Internet	NNP	O
portal	NN	O
that	WDT	O
allowed	VBD	O
parents	NNS	O
,	,	O
teachers	NNS	O
,	,	O
and	CC	O
pediatricians	NNS	O
to	TO	O
input	VB	O
information	NN	O
(	(	O
eg	NN	O
,	,	O
rating	NN	O
scales	NNS	O
)	)	O
about	IN	O
patients	NNS	O
,	,	O
after	IN	O
which	WDT	O
information	NN	O
was	VBD	O
scored	VBN	O
,	,	O
interpreted	VBN	O
,	,	O
and	CC	O
formatted	VBN	O
in	IN	O
a	DT	O
report	NN	O
style	NN	O
that	WDT	O
was	VBD	O
helpful	JJ	O
for	IN	O
assessment	NN	O
and	CC	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
ADHD	NNP	O
.	.	O

Physicians	NNPS	O
evaluated	VBD	O
their	PRP$	O
practice	NN	O
behaviors	NNS	O
quarterly	RB	O
and	CC	O
addressed	VBD	O
underperforming	JJ	O
areas	NNS	O
.	.	O

RESULTS	NNP	O
Pediatricians	NNPS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
demonstrated	VBD	O
significantly	RB	O
higher	JJR	O
rates	NNS	O
of	IN	O
many	JJ	O
American	JJ	O
Academy	NNP	O
of	IN	O
Pediatrics-recommended	NNP	O
ADHD	NNP	O
care	NN	O
practices	NNS	O
,	,	O
including	VBG	O
collection	NN	O
of	IN	O
parent	NN	O
(	(	O
Cohen	NNP	O
's	POS	O
d	NN	O
=	VBZ	O
0.69	CD	O
)	)	O
and	CC	O
teacher	$	O
(	(	O
d	JJ	O
=	NNP	O
0.68	CD	O
)	)	O
rating	NN	O
scales	NNS	O
for	IN	O
assessment	NN	O
of	IN	O
children	NNS	O
with	IN	O
ADHD	NNP	O
,	,	O
use	NN	O
of	IN	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
,	,	O
criteria	NNS	O
(	(	O
d	VB	O
=	RB	O
0.85	CD	O
)	)	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
teacher	NN	O
rating	NN	O
scales	NNS	O
to	TO	O
monitor	VB	O
treatment	NN	O
responses	NNS	O
(	(	O
d	VB	O
=	RB	O
1.01	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	O
quality	NN	O
improvement	NN	O
intervention	NN	O
that	WDT	O
can	MD	O
be	VB	O
widely	RB	O
disseminated	VBN	O
by	IN	O
using	VBG	O
Internet-based	JJ	O
information	NN	O
technology	NN	O
significantly	RB	O
improved	VBD	O
the	DT	O
quality	NN	O
of	IN	O
ADHD	NNP	O
care	NN	O
in	IN	O
community-based	JJ	O
pediatric	JJ	O
settings	NNS	O
.	.	O

Omitting	VBG	O
radiotherapy	NN	O
in	IN	O
early	JJ	O
positron	NN	O
emission	NN	O
tomography-negative	JJ	O
stage	NN	O
I/II	NNP	O
Hodgkin	NNP	O
lymphoma	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
early	JJ	O
relapse	NN	O
:	:	O
Clinical	JJ	O
results	NNS	O
of	IN	O
the	DT	O
preplanned	JJ	O
interim	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
randomized	JJ	O
EORTC/LYSA/FIL	NNP	O
H10	NNP	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Combined-modality	NNP	O
treatment	NN	O
is	VBZ	O
standard	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
with	IN	O
clinical	JJ	Condition
stage	NN	Condition
I/II	NNP	Condition
Hodgkin	NNP	Condition
lymphoma	NN	Condition
(	(	Condition
HL	NNP	Condition
)	)	Condition
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
an	DT	O
early	JJ	O
positron	NN	O
emission	NN	O
tomography	NN	O
(	(	O
PET	NNP	O
)	)	O
scan	NN	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
adapt	VB	O
treatment	NN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
started	VBD	O
the	DT	O
randomized	VBN	O
EORTC/LYSA/FIL	NNP	O
Intergroup	NNP	O
H10	NNP	O
trial	NN	O
evaluating	VBG	O
whether	IN	O
involved-node	JJ	O
radiotherapy	NN	O
(	(	O
IN-RT	NNP	O
)	)	O
could	MD	O
be	VB	O
omitted	VBN	O
without	IN	O
compromising	VBG	O
progression-free	JJ	O
survival	NN	O
in	IN	O
patients	NNS	O
attaining	VBG	O
a	DT	O
negative	JJ	O
early	JJ	O
PET	NNP	O
scan	NN	O
after	IN	O
two	CD	O
cycles	NNS	O
of	IN	O
ABVD	NNP	O
(	(	O
doxorubicin	NN	O
,	,	O
bleomycin	NN	O
,	,	O
vinblastine	NN	O
,	,	O
and	CC	O
dacarbazine	NN	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
standard	JJ	O
combined-modality	NN	O
treatment	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNP	O
age	NN	Age
15	CD	Age
to	TO	Age
70	CD	Age
years	NNS	Age
with	IN	O
untreated	JJ	Condition
clinical	JJ	Condition
stage	NN	Condition
I/II	NNP	Condition
HL	NNP	Condition
were	VBD	O
eligible	JJ	O
.	.	O

Here	RB	O
we	PRP	O
report	VBP	O
the	DT	O
clinical	JJ	O
outcome	NN	O
of	IN	O
the	DT	O
preplanned	JJ	O
interim	JJ	O
futility	NN	O
analysis	NN	O
scheduled	VBN	O
to	TO	O
occur	VB	O
after	IN	O
documentation	NN	O
of	IN	O
34	CD	O
events	NNS	O
in	IN	O
the	DT	O
early	JJ	O
PET-negative	JJ	O
group	NN	O
.	.	O

Because	IN	O
testing	VBG	O
for	IN	O
futility	NN	O
in	IN	O
this	DT	O
noninferiority	NN	O
trial	NN	O
corresponds	NNS	O
to	TO	O
testing	VBG	O
the	DT	O
hypothesis	NN	O
of	IN	O
no	DT	O
difference	NN	O
,	,	O
a	DT	O
one-sided	JJ	O
superiority	NN	O
test	NN	O
was	VBD	O
conducted	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
analysis	NN	O
included	VBD	O
1,137	CD	SampleSize
patients	NNS	O
.	.	O

In	IN	O
the	DT	O
favorable	JJ	SampleSize
subgroup	NN	SampleSize
,	,	O
85.8	CD	O
%	NN	O
had	VBD	O
a	DT	O
negative	JJ	O
early	JJ	O
PET	JJ	O
scan	JJ	O
(	(	O
standard	JJ	O
arm	NN	O
,	,	O
one	CD	O
event	NN	O
v	NN	O
experimental	JJ	O
arm	NN	O
,	,	O
nine	CD	O
events	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
unfavorable	JJ	SampleSize
subgroup	NN	SampleSize
,	,	O
74.8	CD	O
%	NN	O
had	VBD	O
a	DT	O
negative	JJ	O
early	JJ	O
PET	JJ	O
scan	JJ	O
(	(	O
standard	JJ	O
arm	NN	O
,	,	O
seven	CD	O
events	NNS	O
v	JJ	O
experimental	JJ	O
arm	NN	O
,	,	O
16	CD	O
events	NNS	O
)	)	O
.	.	O

The	DT	O
independent	JJ	O
data	NNS	O
monitoring	NN	O
committee	NN	O
concluded	VBD	O
it	PRP	O
was	VBD	O
unlikely	JJ	O
that	IN	O
we	PRP	O
would	MD	O
show	VB	O
noninferiority	NN	O
in	IN	O
the	DT	O
final	JJ	O
results	NNS	O
for	IN	O
the	DT	O
experimental	JJ	O
arm	NN	O
and	CC	O
advised	VBD	O
stopping	VBG	O
random	JJ	O
assignment	NN	O
for	IN	O
early	JJ	O
PET-negative	JJ	O
patients	NNS	O
.	.	O

CONCLUSION	NNP	O
On	IN	O
the	DT	O
basis	NN	O
of	IN	O
this	DT	O
analysis	NN	O
,	,	O
combined-modality	NN	O
treatment	NN	O
resulted	VBD	O
in	IN	O
fewer	JJR	O
early	JJ	O
progressions	NNS	O
in	IN	O
clinical	JJ	O
stage	NN	O
I/II	NNP	O
HL	NNP	O
,	,	O
although	IN	O
early	JJ	O
outcome	NN	O
was	VBD	O
excellent	JJ	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

The	DT	O
final	JJ	O
analysis	NN	O
will	MD	O
reveal	VB	O
whether	IN	O
this	DT	O
finding	NN	O
is	VBZ	O
maintained	VBN	O
over	IN	O
time	NN	O
.	.	O

[	JJ	O
Rapidity	NNP	O
of	IN	O
pain	NN	O
relief	NN	O
,	,	O
medication	NN	O
requirement	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
reflux	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
physician	NN	O
's	POS	O
office	NN	O
]	NN	O
.	.	O

Treatment	NN	O
of	IN	O
gastroesophageal	NN	Condition
reflux	NN	Condition
disease	NN	Condition
(	(	O
GERD	NNP	Condition
)	)	O
with	IN	O
proton	NN	O
pump	NN	O
inhibitors	NNS	O
was	VBD	O
investigated	VBN	O
in	IN	O
three	CD	O
controlled	VBD	O
prospective	JJ	O
,	,	O
randomized	JJ	O
open	JJ	O
studies	NNS	O
.	.	O

Lansoprazole	NNP	O
,	,	O
omeprazole	JJ	O
MUPS	NNP	O
and	CC	O
esomeprazole	NN	O
were	VBD	O
compared	VBN	O
under	IN	O
doctor	NN	O
's	POS	O
office	NN	O
conditions	NNS	O
.	.	O

The	DT	O
outcomes	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
the	DT	O
rapidity	NN	O
of	IN	O
pain	NN	O
relief	NN	O
achieved	VBN	O
with	IN	O
a	DT	O
single	JJ	O
dose	NN	O
,	,	O
effectiveness	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
on	IN	O
demand	NN	O
therapy	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
study	NN	O
,	,	O
180	CD	SampleSize
patients	NNS	O
with	IN	O
chronic	JJ	Condition
and	CC	Condition
prolonged	JJ	Condition
episodes	NNS	Condition
of	IN	Condition
reflux	NN	Condition
were	VBD	O
investigated	VBN	O
.	.	O

Time	NN	O
to	TO	O
pain	VB	O
relief	NN	O
following	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
was	VBD	O
1.1	CD	O
+/-	JJ	O
0.8	CD	O
hours	NNS	O
with	IN	O
30	CD	O
mg	NNS	O
lansoprazole	JJ	O
,	,	O
3.0	CD	O
+/-	JJ	O
2.5	CD	O
hours	NNS	O
with	IN	O
20	CD	O
mgomeprazole	JJ	O
MUPS	NNP	O
and	CC	O
2.1	CD	O
+/-	JJ	O
1.2	CD	O
hours	NNS	O
with	IN	O
40	CD	O
mg	NNS	O
esomeprazole	JJ	O
.	.	O

Studies	NNS	O
2	CD	O
and	CC	O
3	CD	O
were	VBD	O
designed	VBN	O
as	IN	O
cross-over	NN	O
studies	NNS	O
intended	VBN	O
to	TO	O
investigate	VB	O
drug	NN	O
consumption	NN	O
.	.	O

In	IN	O
study	NN	O
2	CD	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
lansoprazole	NN	O
consumed	VBN	O
was	VBD	O
approximately	RB	O
50	CD	O
%	NN	O
less	JJR	O
than	IN	O
that	DT	O
of	IN	O
omeprazole	NN	O
,	,	O
and	CC	O
this	DT	O
translated	VBN	O
to	TO	O
81	CD	O
%	NN	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
lansoprazole	JJ	O
compared	VBN	O
with	IN	O
only	RB	O
9.5	CD	O
%	NN	O
for	IN	O
omeprazole	NN	O
.	.	O

In	IN	O
study	NN	O
3	CD	O
comparing	VBG	O
lansoprazole	NN	O
and	CC	O
esomeprazole	NN	O
,	,	O
consumption	NN	O
of	IN	O
the	DT	O
former	JJ	O
was	VBD	O
85	CD	O
%	NN	O
that	WDT	O
of	IN	O
the	DT	O
latter	NN	O
.	.	O

58	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
opted	VBD	O
to	TO	O
continuetreatment	VB	O
with	IN	O
lansoprazole	NN	O
,	,	O
compared	VBN	O
with	IN	O
only	RB	O
25	CD	O
%	NN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
esomeprazole	NN	O
.	.	O

The	DT	O
appreciably	RB	O
greater	JJR	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
lansoprazole	NN	O
was	VBD	O
due	JJ	O
tothe	NN	O
faster	RBR	O
pain	NN	O
relief	NN	O
achieved	VBN	O
with	IN	O
this	DT	O
drug	NN	O
.	.	O

Paracetamol	NNP	O
and	CC	O
opioid	JJ	O
pathways	NNS	O
:	:	O
a	DT	O
pilot	NN	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

Previous	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
antinociceptive	JJ	O
action	NN	O
of	IN	O
paracetamol	NN	O
(	(	O
acetaminophen	NN	O
,	,	O
APAP	NNP	O
)	)	O
might	MD	O
involve	VB	O
descending	VBG	O
inhibitory	JJ	O
pain	NN	O
pathways	NNS	O
and	CC	O
the	DT	O
opioidergic	JJ	O
system	NN	O
:	:	O
this	DT	O
study	NN	O
explores	VBZ	O
this	DT	O
issue	NN	O
in	IN	O
humans	NNS	O
with	IN	O
naloxone	NN	O
,	,	O
the	DT	O
opioid	JJ	O
antagonist	NN	O
.	.	O

After	IN	O
ethical	JJ	O
approval	NN	O
,	,	O
12	CD	SampleSize
healthy	JJ	O
male	NN	SampleSize
volunteers	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
double-blind	NN	O
,	,	O
crossover	NN	O
,	,	O
four-arm	JJ	O
study	NN	O
.	.	O

They	PRP	O
were	VBD	O
administered	VBN	O
intravenous	JJ	O
paracetamol	NN	O
(	(	O
APAP	NNP	O
1	CD	O
g	NN	O
)	)	O
or	CC	O
saline	NN	O
(	(	O
placebo	NN	O
,	,	O
pl	NN	O
)	)	O
followed	VBD	O
at	IN	O
100	CD	O
min	NN	O
with	IN	O
IV	NNP	O
naloxone	NN	O
(	(	O
Nal	NNP	O
8	CD	O
mg	NN	O
)	)	O
or	CC	O
saline	NN	O
,	,	O
every	DT	O
week	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

The	DT	O
amplitude	NN	O
of	IN	O
cerebral	JJ	O
potentials	NNS	O
evoked	VBN	O
by	IN	O
thermal/painful	JJ	O
stimuli	NNS	O
applied	VBN	O
on	IN	O
the	DT	O
arm	NN	O
was	VBD	O
recorded	VBN	O
nine	CD	O
times	NNS	O
over	IN	O
150	CD	O
min	NNS	O
,	,	O
witnessing	VBG	O
of	IN	O
pain	NN	O
integration	NN	O
at	IN	O
central	JJ	O
level	NN	O
.	.	O

Amplitude	NNP	O
changes	NNS	O
as	RB	O
well	RB	O
as	IN	O
areas	NNS	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUCs	NNP	O
)	)	O
over	IN	O
150	CD	O
min	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
the	DT	O
four	CD	O
treatments	NNS	O
by	IN	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	O
(	(	O
significance	NN	O
0.05	CD	O
)	)	O
.	.	O

Amplitude	NNP	O
changes	NNS	O
were	VBD	O
significant	JJ	O
for	IN	O
APAP/pl	NNP	O
vs.	FW	O
pl/pl	NN	O
at	IN	O
t150	NN	O
:	:	O
-44	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-58	NNP	O
to	TO	O
-30	VB	O
)	)	O
vs.	FW	O
-27	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-37	NNP	O
to	TO	O
-17	VB	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
but	CC	O
not	RB	O
vs.	IN	O
APAP/Nal	NNP	O
.	.	O

AUC	NNP	O
(	(	O
0-150	JJ	O
)	)	O
of	IN	O
APAP/pl	NNP	O
is	VBZ	O
significantly	RB	O
different	JJ	O
from	IN	O
pl/pl	NN	O
(	(	O
-3452	CD	O
%	NN	O
.min	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-4705	NNP	O
to	TO	O
-2199	VB	O
)	)	O
vs.	FW	O
-933	CD	O
%	NN	O
min	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-2273	NNP	O
to	TO	O
407	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.015	CD	O
)	)	O
but	CC	O
not	RB	O
from	IN	O
APAP/Nal	NNP	O
(	(	O
-1731	CD	O
%	NN	O
min	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-3676	NNP	O
to	TO	O
214	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.08	CD	O
)	)	O
and	CC	O
other	JJ	O
treatments	NNS	O
.	.	O

AUC	NNP	O
(	(	O
90-150	CD	O
)	)	O
is	VBZ	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

This	DT	O
pilot	NN	O
study	NN	O
shows	VBZ	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
in	IN	O
human	JJ	O
volunteers	NNS	O
that	WDT	O
naloxone	RB	O
does	VBZ	O
not	RB	O
inhibit	VB	O
paracetamol	JJ	O
antinociception	NN	O
,	,	O
suggesting	VBG	O
no	DT	O
significant	JJ	O
implication	NN	O
of	IN	O
the	DT	O
opioid	NN	O
system	NN	O
in	IN	O
paracetamol	JJ	O
mechanism	NN	O
of	IN	O
action	NN	O
:	:	O
this	DT	O
needs	VBZ	O
be	VB	O
confirmed	VBN	O
on	IN	O
a	DT	O
larger	JJR	O
number	NN	O
of	IN	O
subjects	NNS	O
.	.	O

Melatonin	NNP	O
versus	NN	O
placebo	NN	O
in	IN	O
children	NNS	Age
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
conditions	NNS	O
and	CC	O
severe	JJ	O
sleep	NN	Condition
problems	NNS	Condition
not	RB	O
amenable	JJ	O
to	TO	O
behaviour	VB	O
management	NN	O
strategies	NNS	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
crossover	NN	O
trial	NN	O
.	.	O

Twenty-two	JJ	SampleSize
children	NNS	O
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorders	NNS	Condition
who	WP	O
had	VBD	O
not	RB	O
responded	VBN	O
to	TO	O
supported	VB	O
behaviour	JJ	O
management	NN	O
strategies	NNS	O
for	IN	O
severe	JJ	O
dysomnias	NN	Condition
entered	VBD	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
randomised	VBN	O
,	,	O
controlled	VBD	O
crossover	RB	O
trial	NN	O
involving	VBG	O
3	CD	O
months	NNS	O
of	IN	O
placebo	NN	O
versus	IN	O
3	CD	O
months	NNS	O
of	IN	O
melatonin	NN	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
10	CD	O
mg.	NNS	O
17	CD	SampleSize
children	NNS	Age
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
sleep	JJ	O
variables	NNS	O
at	IN	O
baseline	NN	O
.	.	O

Melatonin	NNP	O
significantly	RB	O
improved	VBD	O
sleep	JJ	O
latency	NN	O
(	(	O
by	IN	O
an	DT	O
average	NN	O
of	IN	O
47	CD	O
min	NN	O
)	)	O
and	CC	O
total	JJ	O
sleep	NN	O
(	(	O
by	IN	O
an	DT	O
average	NN	O
of	IN	O
52	CD	O
min	NN	O
)	)	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
but	CC	O
not	RB	O
number	NN	O
of	IN	O
night	NN	O
wakenings	NNS	O
.	.	O

The	DT	O
side	NN	O
effect	NN	O
profile	NN	O
was	VBD	O
low	JJ	O
and	CC	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Once-daily	JJ	O
versus	NN	O
twice-daily	RB	O
intravenous	JJ	O
administration	NN	O
of	IN	O
vancomycin	NN	O
for	IN	O
infections	NNS	Condition
in	IN	Condition
hospitalized	JJ	Condition
patients	NNS	Condition
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
toxicity	NN	O
of	IN	O
once-daily	JJ	O
(	(	O
od	MD	O
)	)	O
versus	VB	O
twice-daily	JJ	O
(	(	O
bd	NN	O
)	)	O
dosing	NN	O
of	IN	O
vancomycin	NN	O
was	VBD	O
compared	VBN	O
in	IN	O
121	CD	SampleSize
hospitalized	JJ	Condition
patients	NNS	O
.	.	O

Eighteen	JJ	SampleSize
patients	NNS	O
were	VBD	O
then	RB	O
withdrawn	VBN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

Clinical	NNP	O
and	CC	O
bacteriological	JJ	O
responses	NNS	O
were	VBD	O
evaluated	VBN	O
in	IN	O
all	DT	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
103	CD	SampleSize
)	)	O
.	.	O

Nephrotoxicity	NNP	O
was	VBD	O
assessed	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
nephrotoxic	JJ	O
agents	NNS	O
(	(	O
n	JJ	O
=	NNP	O
76	CD	O
)	)	O
.	.	O

Ototoxicity	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
completed	VBD	O
two	CD	O
audiograms	NNS	O
and	CC	O
were	VBD	O
not	RB	O
receiving	VBG	O
ototoxic	JJ	O
agents	NNS	O
(	(	O
n	JJ	O
=	NNP	O
63	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
for	IN	O
favourable	JJ	O
clinical	JJ	O
response	NN	O
:	:	O
47/51	CD	O
(	(	O
92.1	CD	O
%	NN	O
)	)	O
and	CC	O
49/52	CD	O
(	(	O
94.2	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
od	NN	O
and	CC	O
bd	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
34	CD	O
patients	NNS	O
vancomycin	NN	O
was	VBD	O
the	DT	O
only	JJ	O
effective	JJ	O
antibiotic	JJ	O
.	.	O

Fifteen	NNP	O
of	IN	O
18	CD	O
(	(	O
83.3	CD	O
%	NN	O
)	)	O
evaluated	VBD	O
episodes	NNS	O
in	IN	O
the	DT	O
od	NN	O
and	CC	O
12/16	CD	O
(	(	O
75.0	CD	O
%	NN	O
)	)	O
evaluated	VBD	O
episodes	NNS	O
in	IN	O
the	DT	O
bd	NN	O
group	NN	O
showed	VBD	O
a	DT	O
favourable	JJ	O
bacteriological	JJ	O
response	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
od	NN	O
and	CC	O
bd	NN	O
groups	NNS	O
for	IN	O
all	DT	O
adverse	JJ	O
events	NNS	O
.	.	O

Nephrotoxicity	NNP	O
developed	VBD	O
in	IN	O
4/37	CD	O
(	(	O
10.8	CD	O
%	NN	O
)	)	O
and	CC	O
3/39	CD	O
(	(	O
7.7	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

Hearing	NNP	O
loss	NN	O
developed	VBD	O
in	IN	O
1/31	CD	O
(	(	O
3.2	CD	O
%	NN	O
)	)	O
and	CC	O
5/32	CD	O
(	(	O
15.6	CD	O
%	NN	O
)	)	O
.	.	O

Phlebitis	NN	O
occurred	VBD	O
in	IN	O
7/51	CD	O
(	(	O
13.7	CD	O
%	NN	O
)	)	O
and	CC	O
12/52	CD	O
(	(	O
23.0	CD	O
%	NN	O
)	)	O
.	.	O

Red	JJ	O
man	NN	O
syndrome	NN	O
occurred	VBD	O
in	IN	O
7/51	CD	O
(	(	O
13.7	CD	O
%	NN	O
)	)	O
and	CC	O
5/52	CD	O
(	(	O
9.6	CD	O
%	NN	O
)	)	O
in	IN	O
od	NN	O
and	CC	O
bd	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
profile	NN	O
of	IN	O
od	JJ	O
administration	NN	O
of	IN	O
vancomycin	NN	O
is	VBZ	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
customary	JJ	O
,	,	O
but	CC	O
less	RBR	O
convenient	JJ	O
,	,	O
bd	JJ	O
administration	NN	O
.	.	O

Combined	VBN	O
chemotherapy	NN	O
and	CC	O
radiotherapy	NN	O
compared	VBN	O
with	IN	O
radiotherapy	NN	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
cancer	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
efficacy	NN	O
of	IN	O
conventional	JJ	O
treatment	NN	O
with	IN	O
surgery	NN	O
and	CC	O
radiation	NN	O
for	IN	O
cancer	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
10	CD	O
months	NNS	O
,	,	O
and	CC	O
less	JJR	O
than	IN	O
10	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
survive	VBP	O
for	IN	O
5	CD	O
years	NNS	O
.	.	O

Recent	JJ	O
studies	NNS	O
have	VBP	O
suggested	VBN	O
that	IN	O
combined	JJ	O
chemotherapy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
may	MD	O
result	VB	O
in	IN	O
improved	JJ	O
survival	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
phase	NN	O
III	NNP	O
prospective	NN	O
,	,	O
randomized	VBN	O
,	,	O
and	CC	O
stratified	VBD	O
trial	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
four	CD	O
courses	NNS	O
of	IN	O
combined	JJ	O
fluorouracil	NN	O
(	(	O
1000	CD	O
mg	NN	O
per	IN	O
square	JJ	O
meter	NN	O
of	IN	O
body-surface	JJ	O
area	NN	O
daily	RB	O
for	IN	O
four	CD	O
days	NNS	O
)	)	O
and	CC	O
cisplatin	NN	O
(	(	O
75	CD	O
mg	NN	O
per	IN	O
square	JJ	O
meter	NN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
)	)	O
plus	CC	O
5000	CD	O
cGy	NN	O
of	IN	O
radiation	NN	O
therapy	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
6400	CD	O
cGy	NN	O
of	IN	O
radiation	NN	O
therapy	NN	O
alone	RB	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
squamous-cell	JJ	O
carcinoma	NN	O
or	CC	O
adenocarcinoma	NN	O
of	IN	O
the	DT	O
thoracic	NN	O
esophagus	NN	O
.	.	O

The	DT	O
trial	NN	O
was	VBD	O
stopped	VBN	O
after	IN	O
the	DT	O
accumulated	JJ	O
results	NNS	O
in	IN	O
121	CD	O
patients	NNS	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
advantage	NN	O
for	IN	O
survival	NN	O
in	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
chemotherapy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
8.9	CD	O
months	NNS	O
in	IN	O
the	DT	O
radiation-treated	JJ	O
patients	NNS	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
12.5	CD	O
months	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
.	.	O

In	IN	O
the	DT	O
former	JJ	O
group	NN	O
,	,	O
the	DT	O
survival	NN	O
rates	NNS	O
at	IN	O
12	CD	O
and	CC	O
24	CD	O
months	NNS	O
were	VBD	O
33	CD	O
percent	NN	O
and	CC	O
10	CD	O
percent	NN	O
,	,	O
respectively	RB	O
,	,	O
whereas	IN	O
they	PRP	O
were	VBD	O
50	CD	O
percent	NN	O
and	CC	O
38	CD	O
percent	NN	O
in	IN	O
the	DT	O
patients	NNS	O
receiving	VBG	O
combined	VBN	O
therapy	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Seven	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
radiotherapy	NN	O
group	NN	O
and	CC	O
25	CD	O
in	IN	O
the	DT	O
combined-therapy	JJ	O
group	NN	O
were	VBD	O
alive	JJ	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
analysis	NN	O
.	.	O

The	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
combined	JJ	O
treatment	NN	O
had	VBD	O
fewer	JJR	O
local	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
and	CC	O
fewer	JJR	O
distant	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
recurrences	NNS	O
.	.	O

Severe	NNP	O
and	CC	O
life-threatening	JJ	O
side	NN	O
effects	NNS	O
occurred	VBD	O
in	IN	O
44	CD	O
percent	NN	O
and	CC	O
20	CD	O
percent	NN	O
,	,	O
respectively	RB	O
,	,	O
of	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
combined	JJ	O
therapy	NN	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
25	CD	O
percent	NN	O
and	CC	O
3	CD	O
percent	NN	O
of	IN	O
those	DT	O
treated	VBN	O
with	IN	O
radiation	NN	O
alone	RB	O
.	.	O

CONCLUSIONS	NNP	O
Concurrent	NNP	O
therapy	NN	O
with	IN	O
cisplatin	NN	O
and	CC	O
fluorouracil	NN	O
and	CC	O
radiation	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
radiation	VB	O
therapy	NN	O
alone	RB	O
in	IN	O
patients	NNS	O
with	IN	O
localized	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
control	NN	O
of	IN	O
local	JJ	O
tumors	NNS	O
,	,	O
distant	JJ	O
metastases	NNS	O
,	,	O
and	CC	O
survival	NN	O
,	,	O
but	CC	O
at	IN	O
the	DT	O
cost	NN	O
of	IN	O
increased	JJ	O
side	NN	O
effects	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
telmisartan	NN	O
and	CC	O
enalapril	NN	O
on	IN	O
renoprotection	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
chronic	JJ	Condition
kidney	NN	Condition
disease	NN	Condition
.	.	O

BACKGROUND	NNP	O
Blocking	VBG	O
the	DT	O
renin-angiotensin	NN	O
system	NN	O
(	(	O
RAS	NNP	O
)	)	O
with	IN	O
angiotensin	NN	O
receptor	NN	O
blockers	NNS	O
or	CC	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
protects	VBZ	O
against	IN	O
renal	JJ	O
injury	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
kidney	NN	Condition
disease	NN	Condition
(	(	Condition
CKD	NNP	Condition
)	)	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
chronic	JJ	O
effects	NNS	O
of	IN	O
telmisartan	NN	O
and	CC	O
enalapril	NN	O
on	IN	O
proteinuria	NN	O
,	,	O
urinary	JJ	O
liver-type	JJ	O
fatty	JJ	O
acid-binding	JJ	O
protein	NN	O
(	(	O
L-FABP	NNP	O
)	)	O
and	CC	O
endothelin	$	O
(	(	O
ET	NNP	O
)	)	O
-1	NN	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	Condition
CKD	NNP	Condition
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Thirty	NNP	Condition
CKD	NNP	Condition
patients	NNS	Condition
with	IN	O
mild	JJ	Condition
to	TO	Condition
moderate	VB	Condition
renal	JJ	Condition
insufficiency	NN	Condition
(	(	O
20	CD	Sex
men	NNS	Sex
and	CC	O
10	CD	Sex
women	NNS	Sex
;	:	O
mean	JJ	O
age	NN	O
,	,	O
37	CD	Age
years	NNS	Age
;	:	O
estimated	VBN	O
glomerular	JJ	Condition
filtration	NN	Condition
rate	NN	Condition
(	(	O
eGFR	NN	O
)	)	O
>	VBZ	O
60	CD	O
mL	NN	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
and	CC	O
blood	NN	O
pressure	NN	O
>	VBZ	O
130/85	CD	O
mmHg	NN	O
)	)	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
telmisartan	NN	O
at	IN	O
80	CD	O
mg	NNS	O
day	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
or	CC	O
enalapril	VBN	O
at	IN	O
10	CD	O
mg	NNS	O
day	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
.	.	O

We	PRP	O
measured	VBD	O
blood	NN	O
pressure	NN	O
,	,	O
serum	JJ	O
creatinine	NN	O
,	,	O
eGFR	NN	O
,	,	O
urinary	JJ	O
protein	NN	O
,	,	O
L-FABP	NNP	O
and	CC	O
ET-1	NNP	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
treatment	NN	O
and	CC	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
the	DT	O
start	NN	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
blood	NN	O
pressure	NN	O
reduction	NN	O
rate	NN	O
was	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Urinary	JJ	O
protein	NN	O
,	,	O
L-FABP	NNP	O
and	CC	O
ET-1	NNP	O
levels	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
after	IN	O
treatment	NN	O
,	,	O
but	CC	O
the	DT	O
reduction	NN	O
rates	NNS	O
were	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
telmisartan	NN	O
than	IN	O
in	IN	O
those	DT	O
receiving	VBG	O
enalapril	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
was	VBD	O
increased	VBN	O
similarly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
study	NN	O
results	NNS	O
suggest	VBP	O
that	IN	O
telmisartan	JJ	O
results	NNS	O
in	IN	O
a	DT	O
greater	JJR	O
reduction	NN	O
of	IN	O
urinary	JJ	O
markers	NNS	O
than	IN	O
does	VBZ	O
enalapril	VB	O
and	CC	O
that	IN	O
this	DT	O
effect	NN	O
occurs	VBZ	O
by	IN	O
a	DT	O
mechanism	NN	O
independent	JJ	O
of	IN	O
blood	NN	O
pressure	NN	O
reduction	NN	O
.	.	O

It	PRP	O
would	MD	O
be	VB	O
needed	VBN	O
to	TO	O
investigate	VB	O
whether	IN	O
the	DT	O
differences	NNS	O
may	MD	O
be	VB	O
distinct	JJ	O
or	CC	O
not	RB	O
the	DT	O
same	JJ	O
when	WRB	O
other	JJ	O
dosages	NNS	O
are	VBP	O
used	VBN	O
.	.	O

Sivelestat	NNP	O
sodium	NN	O
hydrate	NN	O
improves	VBZ	O
septic	JJ	O
acute	NN	O
lung	NN	O
injury	NN	O
by	IN	O
reducing	VBG	O
alveolar	JJ	O
dysfunction	NN	O
.	.	O

Sivelestat	NNP	O
sodium	NN	O
hydrate	NN	O
(	(	O
sivelestat	NN	O
)	)	O
is	VBZ	O
a	DT	O
selective	JJ	O
inhibitor	NN	O
of	IN	O
polymorphonuclear	JJ	O
leukocyte	JJ	O
elastase	NN	O
(	(	O
PMN-E	NNP	O
)	)	O
.	.	O

We	PRP	O
administered	VBD	O
sivelestat	NNS	O
to	TO	O
patients	NNS	O
with	IN	O
septic	JJ	Condition
acute	NN	Condition
lung	NN	Condition
injury	NN	Condition
(	(	Condition
ALI	NNP	Condition
)	)	Condition
to	TO	O
examine	VB	O
its	PRP$	O
usefulness	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoints	NNS	O
in	IN	O
the	DT	O
study	NN	O
were	VBD	O
the	DT	O
duration	NN	O
of	IN	O
artificial	JJ	O
ventilation	NN	O
and	CC	O
pulmonary	JJ	O
oxygenation	NN	O
ability	NN	O
,	,	O
and	CC	O
the	DT	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
mortality	NN	O
and	CC	O
the	DT	O
concentrations	NNS	O
of	IN	O
PMN-E	NNP	O
,	,	O
SP-D	NNP	O
,	,	O
TNF-alpha	NNP	O
and	CC	O
IL-8	NNP	O
in	IN	O
blood	NN	O
.	.	O

In	IN	O
the	DT	O
sivelestat	NN	O
group	NN	O
,	,	O
the	DT	O
duration	NN	O
of	IN	O
artificial	JJ	O
ventilation	NN	O
,	,	O
pulmonary	JJ	O
oxygenation	NN	O
ability	NN	O
,	,	O
and	CC	O
the	DT	O
blood	NN	O
PMN-E	NNP	O
,	,	O
SP-D	NNP	O
,	,	O
TNF-alpha	NNP	O
and	CC	O
IL-8	NNP	O
concentrations	NNS	O
decreased	VBD	O
significantly	RB	O
.	.	O

Administration	NNP	O
of	IN	O
sivelestat	NN	O
was	VBD	O
found	VBN	O
to	TO	O
reduce	VB	O
alveolar	JJ	O
dysfunction	NN	O
and	CC	O
improve	VB	O
respiratory	NN	O
function	NN	O
,	,	O
and	CC	O
it	PRP	O
was	VBD	O
suggested	VBN	O
that	IN	O
early	JJ	O
administration	NN	O
might	MD	O
be	VB	O
useful	JJ	O
.	.	O

Hypertension	NN	Condition
and	CC	O
non-insulin-dependent	JJ	Condition
diabetes	NNS	Condition
.	.	O

A	DT	O
comparison	NN	O
between	IN	O
an	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
and	CC	O
a	DT	O
calcium	NN	O
antagonist	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
the	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
lisinopril	NN	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
calcium	NN	O
antagonist	NN	O
nifedipine	NN	O
in	IN	O
162	CD	SampleSize
non-insulin-dependent	JJ	Condition
diabetic	JJ	Condition
hypertensive	NN	Condition
patients	NNS	O
for	IN	O
a	DT	O
24-week	JJ	O
period	NN	O
.	.	O

In	IN	O
83	CD	O
and	CC	O
79	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
lisinopril	JJ	O
and	CC	O
slow-release	JJ	O
nifedipine	NN	O
produced	VBD	O
similar	JJ	O
reductions	NNS	O
in	IN	O
blood	NN	O
pressure	NN	O
(	(	O
systolic/diastolic	JJ	O
:	:	O
-16/-13	NN	O
mmHg	NN	O
supine	NN	O
and	CC	O
-14/-11	NN	O
mmHg	NN	O
standing	NN	O
after	IN	O
lisinopril	NN	O
;	:	O
-15/-12	CC	O
mmHg	VB	O
supine	NN	O
and	CC	O
-14/-11	NN	O
mmHg	NN	O
standing	VBG	O
nifedipine	NN	O
)	)	O
.	.	O

Fasting	VBG	O
and	CC	O
post-prandial	JJ	O
plasma	NN	O
glucose	NN	O
,	,	O
glycosylated	VBN	O
haemoglobin	NN	O
and	CC	O
plasma	JJ	O
lipids	NNS	O
appeared	VBD	O
to	TO	O
be	VB	O
unaffected	VBN	O
by	IN	O
either	DT	O
agent	NN	O
.	.	O

Also	RB	O
,	,	O
28	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
on	IN	O
lisinopril	NN	O
and	CC	O
30	CD	O
%	NN	O
of	IN	O
those	DT	O
on	IN	O
nifedipine	JJ	O
presented	VBN	O
microalbuminuria	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
induced	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
albumin	JJ	O
excretion	NN	O
rate	NN	O
(	(	O
AER	NNP	O
)	)	O
.	.	O

The	DT	O
geometric	JJ	O
mean	NN	O
x	NN	O
:	:	O
tolerance	NN	O
factor	NN	O
of	IN	O
the	DT	O
reduction	NN	O
in	IN	O
AER	NNP	O
among	IN	O
the	DT	O
23	CD	O
microalbuminuric	JJ	O
patients	NNS	O
on	IN	O
lisinopril	NN	O
(	(	O
-10.0	JJ	O
x:1.3	NNP	O
micrograms/min	NN	O
)	)	O
was	VBD	O
greater	JJR	O
,	,	O
though	IN	O
not	RB	O
significantly	RB	O
so	RB	O
,	,	O
than	IN	O
that	DT	O
observed	VBD	O
in	IN	O
the	DT	O
26	CD	O
on	IN	O
nifedipine	NN	O
(	(	O
-0.9	JJ	O
x	$	O
1.2	CD	O
micrograms/min	NN	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
lisinopril	RB	O
appeared	VBD	O
to	TO	O
be	VB	O
better	RB	O
tolerated	VBN	O
than	IN	O
nifedipine	NN	O
in	IN	O
our	PRP$	O
study	NN	O
population	NN	O
.	.	O

Microalbuminuria	NNP	O
is	VBZ	O
an	DT	O
important	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
cardiovascular	JJ	O
mortality	NN	O
in	IN	O
non-insulin-dependent	JJ	Condition
diabetic	JJ	Condition
patients	NNS	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

To	TO	O
what	WP	O
extent	VB	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
AER	NNP	O
could	MD	O
ameliorate	VB	O
diabetic	JJ	O
patients	NNS	O
is	VBZ	O
,	,	O
at	IN	O
present	JJ	O
,	,	O
unknown	JJ	O
.	.	O

Finally	RB	O
,	,	O
both	DT	O
lisinopril	FW	O
and	CC	O
nifedipine	NN	O
showed	VBD	O
a	DT	O
similar	JJ	O
antihypertensive	JJ	O
effect	NN	O
in	IN	O
these	DT	O
patients	NNS	O
which	WDT	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
significant	JJ	O
differences	NNS	O
in	IN	O
plasma	NN	O
glucose	NN	O
,	,	O
insulin	NN	O
or	CC	O
lipid	JJ	O
concentrations	NNS	O
.	.	O

The	DT	O
clinical	JJ	O
consequences	NNS	O
of	IN	O
the	DT	O
insignificant	JJ	O
differences	NNS	O
in	IN	O
AER	NNP	O
remain	VBP	O
unclear	JJ	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
cognitive-behavioural	JJ	O
group	NN	O
therapy	NN	O
for	IN	O
pathological	JJ	O
gamblers	NNS	O
.	.	O

As	IN	O
the	DT	O
number	NN	O
of	IN	O
pathological	JJ	O
gamblers	NNS	O
has	VBZ	O
increased	VBN	O
recently	RB	O
,	,	O
the	DT	O
need	NN	O
for	IN	O
effective	JJ	O
treatment	NN	O
has	VBZ	O
become	VBN	O
more	RBR	O
evident	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
short-term	JJ	O
cognitive-behavioural	JJ	O
group	NN	O
therapy	NN	O
programme	NN	O
for	IN	O
pathological	JJ	O
gamblers	NNS	O
.	.	O

Fourteen	JJ	O
subjects	NNS	O
(	(	O
three	CD	O
females	NNS	O
and	CC	O
11	CD	O
males	NNS	O
)	)	O
,	,	O
who	WP	O
met	VBD	O
the	DT	O
criteria	NNS	O
for	IN	O
pathological	JJ	O
gambling	NN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
IV	NNP	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
Treatment	NNP	O
Group	NNP	O
(	(	O
n=7	RB	O
)	)	O
or	CC	O
a	DT	O
waiting	JJ	O
list	NN	O
Control	NNP	O
Group	NNP	O
(	(	O
n=7	RB	O
)	)	O
.	.	O

An	DT	O
experimental	JJ	O
design	NN	O
with	IN	O
three	CD	O
repeated	VBD	O
measures	NNS	O
was	VBD	O
used	VBN	O
(	(	O
pre-treatment	JJ	O
,	,	O
post-treatment/post-waiting	JJ	O
list	NN	O
and	CC	O
follow-up	NN	O
)	)	O
.	.	O

The	DT	O
dependent	JJ	O
variables	NNS	O
were	VBD	O
DSM-IV	NNP	O
Criteria	NNP	O
for	IN	O
Pathological	NNP	O
Gambling	NNP	O
,	,	O
Money	NNP	O
Spent	NNP	O
on	IN	O
Gambling	VBG	O
During	IN	O
the	DT	O
Last	JJ	O
Week	NNP	O
and	CC	O
Gamblers	NNP	O
Inventory	NNP	O
of	IN	O
Negative	NNP	O
Consequences	NNPS	O
.	.	O

The	DT	O
Treatment	NNP	O
Group	NNP	O
improved	VBD	O
on	IN	O
the	DT	O
DSM-IV	NNP	O
Criteria	NNP	O
for	IN	O
Pathological	NNP	O
Gambling	NNP	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
show	VB	O
a	DT	O
significant	JJ	O
improvement	NN	O
on	IN	O
Money	NNP	O
Spent	NNP	O
on	IN	O
Gambling	VBG	O
During	IN	O
the	DT	O
Last	JJ	O
week	NN	O
from	IN	O
pre-treatment	JJ	O
to	TO	O
post-treatment	JJ	O
.	.	O

Combining	VBG	O
both	DT	O
groups	NNS	O
at	IN	O
3-months	JJ	O
follow-up	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
on	IN	O
all	DT	O
three	CD	O
variables	NNS	O
from	IN	O
pre-treatment	JJ	O
to	TO	O
follow-up	JJ	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
controlled	VBN	O
study	NN	O
indicate	NN	O
that	IN	O
a	DT	O
short-term	JJ	O
cognitive-behavioural	JJ	O
group	NN	O
treatment	NN	O
for	IN	O
pathological	JJ	O
gamblers	NNS	O
had	VBD	O
an	DT	O
effect	NN	O
.	.	O

Dose-response	NNP	O
comparison	NN	O
of	IN	O
RRR-alpha-tocopherol	NNP	O
and	CC	O
all-racemic	JJ	O
alpha-tocopherol	NN	O
on	IN	O
LDL	NNP	O
oxidation	NN	O
.	.	O

Much	JJ	O
data	NNS	O
have	VBP	O
accrued	VBN	O
in	IN	O
support	NN	O
of	IN	O
the	DT	O
concept	NN	O
that	IN	O
oxidation	NN	O
of	IN	O
LDL	NNP	O
is	VBZ	O
a	DT	O
key	JJ	O
early	JJ	O
step	NN	O
in	IN	O
atherogenesis	NN	O
.	.	O

The	DT	O
most	RBS	O
consistent	JJ	O
data	NNS	O
with	IN	O
respect	NN	O
to	TO	O
micronutrient	VB	O
antioxidants	NNS	O
and	CC	O
atherosclerosis	NN	O
appear	VBP	O
to	TO	O
relate	VB	O
to	TO	O
alpha-tocopherol	NN	O
(	(	O
AT	NNP	O
)	)	O
,	,	O
the	DT	O
predominant	JJ	O
lipid-soluble	JJ	O
antioxidant	NN	O
in	IN	O
LDL	NNP	O
.	.	O

There	EX	O
are	VBP	O
scant	JJ	O
data	NNS	O
on	IN	O
the	DT	O
direct	JJ	O
comparison	NN	O
of	IN	O
RRR-AT	NNP	O
and	CC	O
all-racemic	JJ	O
(	(	O
rac	NN	O
)	)	O
-AT	NN	O
on	IN	O
LDL	NNP	O
oxidizability	NN	O
.	.	O

Hence	NNP	O
,	,	O
the	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
relative	JJ	O
effects	NNS	O
of	IN	O
RRR-AT	NNP	O
and	CC	O
all-rac-AT	NN	O
on	IN	O
plasma	NN	O
antioxidant	NN	O
levels	NNS	O
and	CC	O
LDL	NNP	O
oxidation	NN	O
in	IN	O
healthy	JJ	O
persons	NNS	O
in	IN	O
a	DT	O
dose-response	JJ	O
study	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
RRR-AT	NNP	O
and	CC	O
all-rac-AT	NN	O
at	IN	O
doses	NNS	O
of	IN	O
100	CD	O
,	,	O
200	CD	O
,	,	O
400	CD	O
,	,	O
and	CC	O
800	CD	O
IU/d	NNP	O
on	IN	O
plasma	NN	O
and	CC	O
LDL	NNP	O
AT	NNP	O
levels	NNS	O
and	CC	O
LDL	NNP	O
oxidation	NN	O
was	VBD	O
tested	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
79	CD	O
healthy	JJ	O
subjects	NNS	O
.	.	O

Copper-catalyzed	JJ	O
oxidation	NN	O
of	IN	O
LDL	NNP	O
was	VBD	O
monitored	VBN	O
by	IN	O
measuring	VBG	O
the	DT	O
formation	NN	O
of	IN	O
conjugated	JJ	O
dienes	NNS	O
and	CC	O
lipid	JJ	O
peroxides	NNS	O
over	IN	O
an	DT	O
8-hour	JJ	O
time	NN	O
course	NN	O
at	IN	O
baseline	NN	O
and	CC	O
again	RB	O
after	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Plasma	NNP	O
AT	NNP	O
,	,	O
lipid-standardized	JJ	O
AT	NNP	O
,	,	O
and	CC	O
LDL	NNP	O
AT	NNP	O
levels	NNS	O
rose	VBD	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
fashion	NN	O
in	IN	O
both	DT	O
the	DT	O
RRR-AT	NNP	O
and	CC	O
all-rac-AT	JJ	O
groups	NNS	O
compared	VBN	O
with	IN	O
baseline	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
plasma	NN	O
,	,	O
lipid-standardized	JJ	O
,	,	O
and	CC	O
LDL	NNP	O
AT	NNP	O
levels	NNS	O
between	IN	O
RRR-AT	NNP	O
and	CC	O
all-rac-AT	JJ	O
supplementation	NN	O
at	IN	O
any	DT	O
dose	JJ	O
comparison	NN	O
.	.	O

The	DT	O
lag	NN	O
phases	NNS	O
of	IN	O
oxidation	NN	O
were	VBD	O
significantly	RB	O
prolonged	VBN	O
with	IN	O
doses	NNS	O
>	VBP	O
or	CC	O
=	VBP	O
400	CD	O
IU/d	NNP	O
of	IN	O
RRR-AT	NNP	O
and	CC	O
all-rac-AT	JJ	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
conjugated-dienes	NNS	O
assay	NNS	O
and	CC	O
at	IN	O
400	CD	O
IU/d	NNP	O
of	IN	O
RRR-AT	NNP	O
and	CC	O
800	CD	O
IU/d	NNP	O
of	IN	O
both	DT	O
forms	NNS	O
of	IN	O
AT	NNP	O
by	IN	O
lipid	JJ	O
peroxide	NN	O
assay	NN	O
.	.	O

Again	NNP	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
lag	NN	O
phase	NN	O
of	IN	O
oxidation	NN	O
at	IN	O
each	DT	O
dose	NN	O
for	IN	O
RRR-AT	NNP	O
when	WRB	O
compared	VBN	O
with	IN	O
all-rac-AT	NN	O
.	.	O

Also	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
LDL	NNP	O
oxidation	NN	O
after	IN	O
in	IN	O
vitro	JJ	O
enrichment	NN	O
of	IN	O
LDL	NNP	O
with	IN	O
RRR-AT	NNP	O
and	CC	O
all-rac-AT	JJ	O
.	.	O

Thus	RB	O
,	,	O
supplementation	NN	O
with	IN	O
either	DT	O
RRR-AT	JJ	O
or	CC	O
all-rac-AT	JJ	O
resulted	VBN	O
in	IN	O
similar	JJ	O
increases	NNS	O
in	IN	O
plasma	NN	O
and	CC	O
LDL	NNP	O
AT	NNP	O
levels	NNS	O
at	IN	O
equivalent	JJ	O
IU	NNP	O
doses	NNS	O
,	,	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
protection	NN	O
against	IN	O
copper-catalyzed	JJ	O
LDL	NNP	O
oxidation	NN	O
was	VBD	O
only	RB	O
evident	JJ	O
at	IN	O
doses	NNS	O
>	VBP	O
or	CC	O
=	VBP	O
400	CD	O
IU/d	NNP	O
for	IN	O
both	DT	O
forms	NNS	O
.	.	O

Active	JJ	O
treatment	NN	O
programs	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
observer-blinded	JJ	O
study	NN	O
.	.	O

Several	JJ	O
new	JJ	O
studies	NNS	O
have	VBP	O
indicated	VBN	O
that	IN	O
an	DT	O
active	JJ	O
approach	NN	O
to	TO	O
patients	NNS	O
with	IN	O
chronic	JJ	O
disabling	VBG	O
low	JJ	O
back	RB	O
pain	NN	O
(	(	O
LBP	NNP	O
)	)	O
seems	VBZ	O
effective	JJ	O
.	.	O

Some	DT	O
of	IN	O
these	DT	O
studies	NNS	O
emphasize	VBP	O
the	DT	O
importance	NN	O
of	IN	O
dealing	VBG	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
total	JJ	O
situation	NN	O
in	IN	O
comprehensive	JJ	O
multidisciplinary	JJ	O
programs	NNS	O
--	:	O
the	DT	O
bio-psycho-social	JJ	O
model	NN	O
.	.	O

However	RB	O
,	,	O
these	DT	O
programs	NNS	O
are	VBP	O
expensive	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
rehabilitation	NN	O
outcome	NN	O
from	IN	O
three	CD	O
different	JJ	O
active	JJ	O
programs	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
:	:	O
(	(	O
1	CD	O
)	)	O
return-to-work	NN	O
rate	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
days	NNS	O
of	IN	O
sick	JJ	O
leave	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
health-care	NN	O
contacts	NNS	O
,	,	O
(	(	O
4	CD	O
)	)	O
pain	NN	O
and	CC	O
disability	NN	O
scores	NNS	O
,	,	O
and	CC	O
(	(	O
5	CD	O
)	)	O
staying	VBG	O
physically	RB	O
active	JJ	O
.	.	O

The	DT	O
subjects	NNS	O
included	VBD	O
132	CD	O
patients	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
study	NN	O
,	,	O
of	IN	O
whom	WP	O
123	CD	O
started	VBD	O
one	CD	O
of	IN	O
the	DT	O
treatment	NN	O
programs	NNS	O
.	.	O

They	PRP	O
had	VBD	O
all	DT	O
had	VBN	O
at	IN	O
least	JJS	O
6	CD	O
months	NNS	O
of	IN	O
chronic	JJ	O
LBP	NNP	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
one	CD	O
of	IN	O
three	CD	O
programs	NNS	O
:	:	O
group	NN	O
1	CD	O
--	:	O
a	DT	O
full-time	JJ	O
,	,	O
intensive	JJ	O
3-week	JJ	O
multidisciplinary	JJ	O
program	NN	O
,	,	O
including	VBG	O
active	JJ	O
physical	JJ	O
and	CC	O
ergonomic	JJ	O
training	NN	O
and	CC	O
psychological	JJ	O
pain	NN	O
management	NN	O
,	,	O
followed	VBN	O
by	IN	O
1	CD	O
day	NN	O
weekly	VB	O
for	IN	O
the	DT	O
subsequent	JJ	O
3	CD	O
weeks	NNS	O
;	:	O
group	NN	O
2	CD	O
--	:	O
active	JJ	O
physical	JJ	O
training	NN	O
,	,	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
,	,	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
24h	CD	O
;	:	O
group	NN	O
3	CD	O
--	:	O
psychological	JJ	O
pain	NN	O
management	NN	O
combined	VBN	O
with	IN	O
active	JJ	O
physical	JJ	O
training	NN	O
,	,	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
,	,	O
also	RB	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
24h	CD	O
.	.	O

The	DT	O
results	NNS	O
presented	VBN	O
here	RB	O
are	VBP	O
based	VBN	O
on	IN	O
data	NNS	O
collected	VBN	O
4	CD	O
months	NNS	O
following	VBG	O
treatment	NN	O
,	,	O
which	WDT	O
shows	VBZ	O
an	DT	O
86	CD	O
%	NN	O
response	NN	O
rate	NN	O
.	.	O

The	DT	O
initial	JJ	O
examination	NN	O
and	CC	O
the	DT	O
follow-up	JJ	O
evaluation	NN	O
were	VBD	O
performed	VBN	O
by	IN	O
a	DT	O
blinded	VBN	O
observer	NN	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
4	CD	O
months	NNS	O
after	IN	O
treatment	NN	O
,	,	O
the	DT	O
intensive	JJ	O
multidisciplinary	JJ	O
program	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
the	DT	O
less	RBR	O
intensive	JJ	O
programs	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
return-to-work	NN	O
rate	NN	O
,	,	O
health-care	JJ	O
contacts	NNS	O
,	,	O
pain	NN	O
and	CC	O
disability	NN	O
scores	NNS	O
,	,	O
and	CC	O
staying	VBG	O
physically	RB	O
active	JJ	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Effects	NNS	O
of	IN	O
reducing	VBG	O
dietary	JJ	O
[	NN	O
(	(	O
Na+	NNP	O
+	NNP	O
K+	NNP	O
)	)	O
-	:	O
(	(	O
Cl-	JJ	O
+	NNP	O
SO4=	NNP	O
)	)	O
]	NN	O
on	IN	O
the	DT	O
rate	NN	O
of	IN	O
calcium	NN	O
mobilisation	NN	O
by	IN	O
dairy	NN	O
cows	NNS	O
at	IN	O
parturition	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
feeding	VBG	O
diets	NNS	O
with	IN	O
different	JJ	O
milliequivalents	NNS	O
(	(	O
meq	NN	O
)	)	O
of	IN	O
dietary	JJ	O
[	NNP	O
(	(	O
Na+	NNP	O
+	NNP	O
K+	NNP	O
)	)	O
-	:	O
(	(	O
Cl-	JJ	O
+	NNP	O
SO4=	NNP	O
)	)	O
]	VBP	O
to	TO	O
dairy	VB	O
cows	NNS	O
during	IN	O
the	DT	O
last	JJ	O
seven	CD	O
weeks	NNS	O
of	IN	O
pregnancy	NN	O
on	IN	O
their	PRP$	O
acid-base	JJ	O
status	NN	O
and	CC	O
calcium	NN	O
mobilisation	NN	O
rate	NN	O
around	IN	O
parturition	NN	O
were	VBD	O
studied	VBN	O
.	.	O

Ten	CD	O
monozygotic	JJ	O
twin	NN	O
pairs	NNS	O
of	IN	O
pregnant	JJ	O
cows	NNS	O
(	(	O
five	CD	O
pairs	NNS	O
of	IN	O
parity	NN	O
1	CD	O
or	CC	O
2	CD	O
,	,	O
and	CC	O
five	CD	O
pairs	NNS	O
of	IN	O
parity	NN	O
3	CD	O
or	CC	O
more	JJR	O
)	)	O
were	VBD	O
allocated	VBN	O
to	TO	O
two	CD	O
diets	NNS	O
which	WDT	O
were	VBD	O
formulated	VBN	O
to	TO	O
provide	VB	O
either	RB	O
-4	JJ	O
meq	NN	O
(	(	O
anion	NN	O
diet	NN	O
)	)	O
or	CC	O
+572.5	JJ	O
meq	NN	O
(	(	O
cation	NN	O
diet	NN	O
)	)	O
of	IN	O
[	NN	O
(	(	O
Na+	NNP	O
+	NNP	O
K+	NNP	O
)	)	O
-	:	O
(	(	O
Cl-	JJ	O
+	NNP	O
SO4=	NNP	O
)	)	O
]	VBD	O
kg-1	JJ	O
dietary	JJ	O
dry	JJ	O
matter	NN	O
(	(	O
DM	NNP	O
)	)	O
.	.	O

The	DT	O
daily	JJ	O
rations	NNS	O
consisted	VBD	O
of	IN	O
4	CD	O
kg	NNS	O
grass	NN	O
hay	NN	O
and	CC	O
7	CD	O
kg	NN	O
concentrates	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
meq	NN	O
of	IN	O
dietary	JJ	O
[	NNP	O
(	(	O
Na+	NNP	O
+	NNP	O
K+	NNP	O
)	)	O
-	:	O
(	(	O
Cl-	JJ	O
+	NNP	O
SO4=	NNP	O
)	)	O
]	NN	O
were	VBD	O
achieved	VBN	O
by	IN	O
adding	VBG	O
KCl	NNP	O
,	,	O
K2SO4	NNP	O
and	CC	O
(	(	O
NH4	NNP	O
)	)	O
2SO4	CD	O
(	(	O
anion	NN	O
diet	NN	O
)	)	O
or	CC	O
K2CO3	NNP	O
(	(	O
cation	NN	O
diet	NN	O
)	)	O
to	TO	O
basal	VB	O
concentrates	NNS	O
.	.	O

Plasma	NNP	O
calcium	NN	O
concentration	NN	O
and	CC	O
blood	NN	O
acid-base	JJ	O
parameters	NNS	O
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
dietary	JJ	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
urinary	JJ	O
calcium	NN	O
excretion	NN	O
was	VBD	O
markedly	RB	O
higher	JJR	O
and	CC	O
urinary	JJ	O
pH	NN	O
and	CC	O
bicarbonate	NN	O
excretion	NN	O
significantly	RB	O
lower	JJR	O
in	IN	O
cows	NNS	O
fed	VBP	O
the	DT	O
anion	NN	O
diet	NN	O
than	IN	O
in	IN	O
cows	NNS	O
fed	VBP	O
the	DT	O
cation	NN	O
diet	NN	O
.	.	O

The	DT	O
responses	NNS	O
to	TO	O
hypocalcaemia	VB	O
induced	VBN	O
by	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
EDTA	NNP	O
solution	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
cows	NNS	O
fed	VBP	O
either	DT	O
diet	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
tidal	JJ	O
volumes	NNS	O
obtained	VBN	O
by	IN	O
one-handed	JJ	O
and	CC	O
two-handed	JJ	O
ventilation	NN	O
techniques	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
tidal	JJ	O
volumes	NNS	O
delivered	VBN	O
by	IN	O
one-	JJ	O
vs	JJ	O
two-handed	JJ	O
compressions	NNS	O
of	IN	O
a	DT	O
manual	JJ	O
resuscitation	NN	O
bag	NN	O
and	CC	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
subject	JJ	O
characteristics	NNS	O
on	IN	O
those	DT	O
tidal	JJ	O
volumes	NNS	O
.	.	O

DESIGN	NNP	O
Subjects	NNP	O
(	(	O
108	CD	SampleSize
healthcare	NN	O
providers	NNS	O
from	IN	O
a	DT	O
500-bed	JJ	O
teaching	NN	O
hospital	NN	O
)	)	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
procedures	NNS	O
:	:	O
one-	JJ	O
followed	VBN	O
by	IN	O
two-handed	JJ	O
compression	NN	O
or	CC	O
two-	NN	O
followed	VBN	O
by	IN	O
one-handed	JJ	O
compression	NN	O
.	.	O

A	DT	O
1-liter	JJ	O
resuscitation	NN	O
bag	NN	O
,	,	O
lung	NN	O
performance	NN	O
analyzer	NN	O
and	CC	O
Wright	NNP	O
spirometer	NN	O
were	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
tidal	JJ	O
volume	NN	O
.	.	O

Data	NNP	O
collection	NN	O
occurred	VBD	O
in	IN	O
a	DT	O
simulated	JJ	Condition
situation	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
tidal	JJ	O
volume	NN	O
delivered	VBN	O
by	IN	O
one-handed	JJ	O
(	(	O
mean	JJ	O
=	VBP	O
694	CD	O
mL	NN	O
,	,	O
SD	NNP	O
=	NNP	O
111	CD	O
)	)	O
vs	NN	O
two-handed	JJ	O
compressions	NNS	O
(	(	O
mean	JJ	O
=	VBP	O
827	CD	O
mL	NN	O
,	,	O
SD	NNP	O
=	NNP	O
113	CD	O
)	)	O
.	.	O

Hand	NNP	O
size	NN	O
,	,	O
grip	NN	O
strength	NN	O
,	,	O
height	NN	O
and	CC	O
weight	NN	O
were	VBD	O
correlated	VBN	O
with	IN	O
tidal	JJ	O
volumes	NNS	O
generated	VBN	O
by	IN	O
one-handed	JJ	O
and	CC	O
two-handed	JJ	O
procedures	NNS	O
.	.	O

No	DT	O
other	JJ	O
subject	JJ	O
characteristics	NNS	O
were	VBD	O
correlated	VBN	O
with	IN	O
tidal	JJ	O
volumes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Tidal	NNP	O
volumes	NNS	O
delivered	VBN	O
by	IN	O
healthcare	NN	O
providers	NNS	O
using	VBG	O
one-	JJ	O
vs	JJ	O
two-handed	JJ	O
compressions	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significantly	RB	O
different	JJ	O
,	,	O
with	IN	O
those	DT	O
delivered	VBN	O
by	IN	O
two	CD	O
hands	NNS	O
significantly	RB	O
greater	JJR	O
than	IN	O
those	DT	O
delivered	VBN	O
by	IN	O
one	CD	O
hand	NN	O
.	.	O

Strength	NN	O
of	IN	O
hand	NN	O
grip	NN	O
was	VBD	O
the	DT	O
best	JJS	O
predictor	NN	O
of	IN	O
volume	NN	O
delivered	VBN	O
and	CC	O
was	VBD	O
more	RBR	O
strongly	RB	O
correlated	VBN	O
with	IN	O
volumes	NNS	O
delivered	VBN	O
by	IN	O
one	CD	O
rather	RB	O
than	IN	O
two	CD	O
hands	NNS	O
.	.	O

Extracorporeal	NNP	O
shock	NN	O
wave	NN	O
therapy	NN	O
(	(	O
ESWT	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
proximal	JJ	O
plantar	NN	O
fasciitis	NN	O
:	:	O
a	DT	O
2-year	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
extracorporeal	NN	O
shock	NN	O
wave	VBP	O
therapy	NN	O
(	(	O
ESWT	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
chronically	RB	O
painful	JJ	O
proximal	JJ	O
plantar	NN	O
fasciitis	NN	O
with	IN	O
a	DT	O
further	JJ	O
conventional	JJ	O
conservative	JJ	O
treatment	NN	O
.	.	O

Forty-seven	JJ	O
patients	NNS	O
(	(	O
49	CD	O
feet	NNS	O
)	)	O
with	IN	O
a	DT	O
previously	RB	O
unsuccessful	JJ	O
nonsurgical	JJ	O
treatment	NN	O
of	IN	O
at	IN	O
least	JJS	O
6	CD	O
months	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
.	.	O

Heel	NNP	O
cups	NNS	O
had	VBD	O
to	TO	O
be	VB	O
worn	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Group	NNP	O
1	CD	O
(	(	O
25	CD	O
heels	NNS	O
)	)	O
was	VBD	O
treated	VBN	O
immediately	RB	O
with	IN	O
three	CD	O
sessions	NNS	O
of	IN	O
ESWT	NNP	O
(	(	O
3000	CD	O
shock	NN	O
waves/session	NN	O
of	IN	O
0.2	CD	O
mJ/mm2	NN	O
)	)	O
at	IN	O
weekly	JJ	O
intervals	NNS	O
.	.	O

The	DT	O
patients	NNS	O
of	IN	O
group	NN	O
2	CD	O
(	(	O
24	CD	O
heels	NNS	O
)	)	O
continued	VBD	O
nonsurgical	JJ	O
treatment	NN	O
(	(	O
iontophoresis	NN	O
with	IN	O
diclofenac	NN	O
and	CC	O
an	DT	O
oral	JJ	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drug	NN	O
)	)	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

After	IN	O
this	DT	O
period	NN	O
they	PRP	O
were	VBD	O
treated	VBN	O
using	VBG	O
the	DT	O
protocol	NN	O
of	IN	O
group	NN	O
1	CD	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
of	IN	O
pain	NN	O
and	CC	O
walking	NN	O
time	NN	O
after	IN	O
further	JJ	O
nonsurgical	JJ	O
treatment	NN	O
(	(	O
3	CD	O
months	NNS	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

At	IN	O
12	CD	O
weeks	NNS	O
after	IN	O
ESWT	NNP	O
,	,	O
the	DT	O
pain	NN	O
estimation	NN	O
on	IN	O
the	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
for	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
diminished	VBN	O
significantly	RB	O
by	IN	O
62.9	CD	O
%	NN	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
by	IN	O
63.0	CD	O
%	NN	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

The	DT	O
comfortable	JJ	O
walking	NN	O
time	NN	O
had	VBD	O
increased	VBN	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Two	CD	O
years	NNS	O
after	IN	O
ESWT	NNP	O
,	,	O
pain	NN	O
during	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
decreased	VBN	O
by	IN	O
94	CD	O
%	NN	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
by	IN	O
90	CD	O
%	NN	O
in	IN	O
group	NN	O
2	CD	O
on	IN	O
the	DT	O
VAS	NNP	O
and	CC	O
the	DT	O
comfortable	JJ	O
walking	NN	O
time	NN	O
had	VBD	O
increased	VBN	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
esmolol	NN	O
,	,	O
a	DT	O
short-acting	JJ	O
beta	NN	O
blocker	NN	O
,	,	O
with	IN	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
supraventricular	JJ	Condition
tachyarrhythmias	NN	Condition
.	.	O

The	DT	O
Esmolol	NNP	O
vs	NN	O
Placebo	NNP	O
Multicenter	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
esmolol	NN	O
,	,	O
a	DT	O
short-acting	JJ	O
intravenous	JJ	O
beta-adrenergic-blocking	JJ	O
agent	NN	O
,	,	O
and	CC	O
placebo	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
supraventricular	JJ	Condition
tachyarrhythmias	NN	Condition
(	(	O
heart	NN	O
rate	NN	O
greater	JJR	O
than	IN	O
120	CD	O
bpm	NN	O
)	)	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
partial-crossover	JJ	O
study	NN	O
.	.	O

Seventy-one	CD	SampleSize
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
esmolol	NN	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
as	IN	O
initial	JJ	O
treatment	NN	O
.	.	O

Therapeutic	JJ	O
failures	NNS	O
were	VBD	O
crossed	VBN	O
over	IN	O
to	TO	O
the	DT	O
other	JJ	O
study	NN	O
medication	NN	O
.	.	O

Therapeutic	JJ	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
20	CD	O
%	NN	O
reduction	NN	O
in	IN	O
heart	NN	O
rate	NN	O
,	,	O
heart	NN	O
rate	NN	O
less	JJR	O
than	IN	O
100	CD	O
bpm	NN	O
,	,	O
or	CC	O
conversion	NN	O
to	TO	O
normal	JJ	O
sinus	NN	O
rhythm	NN	O
.	.	O

The	DT	O
therapeutic	JJ	O
response	NN	O
to	TO	O
esmolol	VB	O
during	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
period	NN	O
(	(	O
72	CD	O
%	NN	O
)	)	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
obtained	VBN	O
when	WRB	O
esmolol	NN	O
was	VBD	O
given	VBN	O
as	IN	O
a	DT	O
second	JJ	O
agent	NN	O
.	.	O

The	DT	O
average	JJ	O
esmolol	JJ	O
dosage	NN	O
producing	VBG	O
a	DT	O
therapeutic	JJ	O
response	NN	O
was	VBD	O
97.5	CD	O
micrograms/kg/min	NN	O
.	.	O

Four	CD	O
patients	NNS	O
(	(	O
6	CD	O
%	NN	O
)	)	O
converted	VBD	O
to	TO	O
normal	JJ	O
sinus	JJ	O
rhythm	NN	O
during	IN	O
esmolol	JJ	O
infusion	NN	O
.	.	O

In	IN	O
the	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
(	(	O
80	CD	O
%	NN	O
)	)	O
,	,	O
therapeutic	JJ	O
response	NN	O
was	VBD	O
lost	VBN	O
within	IN	O
30	CD	O
minutes	NNS	O
following	VBG	O
discontinuation	NN	O
of	IN	O
esmolol	JJ	O
infusion	NN	O
,	,	O
a	DT	O
finding	JJ	O
indicative	NN	O
of	IN	O
rapid	JJ	O
reversal	NN	O
of	IN	O
beta-adrenoceptor	NN	O
blockade	NN	O
.	.	O

The	DT	O
most	RBS	O
prevalent	JJ	O
adverse	JJ	O
effect	NN	O
during	IN	O
esmolol	JJ	O
infusion	NN	O
was	VBD	O
hypotension	NN	O
which	WDT	O
occurred	VBD	O
in	IN	O
eight	CD	O
patients	NNS	O
(	(	O
12	CD	O
%	NN	O
)	)	O
.	.	O

Hypotension	NN	O
and	CC	O
associated	VBN	O
symptoms	NNS	O
resolved	VBD	O
within	IN	O
30	CD	O
minutes	NNS	O
after	IN	O
discontinuation	NN	O
of	IN	O
esmolol	JJ	O
infusion	NN	O
,	,	O
which	WDT	O
is	VBZ	O
consistent	JJ	O
with	IN	O
the	DT	O
short	JJ	O
duration	NN	O
of	IN	O
action	NN	O
of	IN	O
esmolol	NN	O
(	(	O
elimination	JJ	O
half-life	NN	O
of	IN	O
9.2	CD	O
minutes	NNS	O
)	)	O
.	.	O

Acute	NNP	O
effect	NN	O
of	IN	O
pegvisomant	NN	O
on	IN	O
cardiovascular	JJ	O
risk	NN	O
markers	NNS	O
in	IN	O
healthy	JJ	O
men	NNS	O
:	:	O
implications	NNS	O
for	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
atherosclerosis	NN	O
in	IN	O
GH	NNP	O
deficiency	NN	O
.	.	O

Cardiovascular	JJ	O
risk	NN	O
is	VBZ	O
increased	VBN	O
in	IN	O
GH	NNP	O
deficiency	NN	O
(	(	O
GHD	NNP	O
)	)	O
.	.	O

GHD	NNP	Age
adults	NNS	Age
are	VBP	O
frequently	RB	O
abdominally	RB	O
obese	JJ	O
and	CC	O
display	JJ	O
features	NNS	O
of	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
.	.	O

Otherwise	NNP	O
healthy	JJ	O
abdominally	RB	O
obese	JJ	O
subjects	NNS	O
have	VBP	O
low	JJ	O
GH	NNP	O
levels	NNS	O
and	CC	O
show	NN	O
features	NNS	O
of	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
as	RB	O
well	RB	O
.	.	O

We	PRP	O
investigated	VBD	O
in	IN	O
healthy	JJ	Sex
nonobese	JJ	Sex
males	NNS	Sex
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
GH	NNP	O
receptor	NN	O
antagonist	NN	O
pegvisomant	NN	O
in	IN	O
different	JJ	O
metabolic	JJ	O
conditions	NNS	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
model	NN	O
for	IN	O
acute	JJ	O
GHD	NNP	O
without	IN	O
the	DT	O
alterations	NNS	O
in	IN	O
body	NN	O
composition	NN	O
associated	VBN	O
with	IN	O
GHD	NNP	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
effect	NN	O
of	IN	O
pegvisomant	NN	O
with	IN	O
that	DT	O
of	IN	O
placebo	NN	O
before	IN	O
and	CC	O
after	IN	O
3	CD	O
d	NN	O
of	IN	O
fasting	VBG	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
pegvisomant	JJ	O
under	IN	O
normal	JJ	O
,	,	O
i.e	JJ	O
.	.	O

fed	VBN	O
,	,	O
conditions	NNS	O
.	.	O

Three	CD	O
days	NNS	O
of	IN	O
fasting	NN	O
as	RB	O
well	RB	O
as	IN	O
pegvisomant	JJ	O
alone	NN	O
decreased	VBD	O
serum	JJ	O
free	JJ	O
IGF-I	NN	O
levels	NNS	O
(	(	O
1.0	CD	O
+/-	JJ	O
0.15	CD	O
vs.	FW	O
0.31	CD	O
+/-	JJ	O
0.05	CD	O
ng/ml	NN	O
and	CC	O
0.86	CD	O
+/-	JJ	O
0.23	CD	O
vs.	FW	O
0.46	CD	O
+/-	JJ	O
0.23	CD	O
ng/ml	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Fasting	VBG	O
in	IN	O
combination	NN	O
with	IN	O
pegvisomant	NN	O
also	RB	O
decreased	VBD	O
serum	JJ	O
free	JJ	O
IGF-I	NN	O
levels	NNS	O
(	(	O
1.0	CD	O
+/-	JJ	O
0.15	CD	O
vs.	FW	O
0.31	CD	O
+/-	JJ	O
0.07	CD	O
ng/ml	NN	O
)	)	O
.	.	O

Treatment	NN	O
with	IN	O
pegvisomant	NN	O
had	VBD	O
no	DT	O
additional	JJ	O
influence	NN	O
on	IN	O
the	DT	O
decline	NN	O
of	IN	O
free	JJ	O
IGF-I	NNP	O
induced	VBN	O
by	IN	O
fasting	VBG	O
.	.	O

Pegvisomant	VB	O
alone	RB	O
had	VBD	O
no	DT	O
influence	NN	O
on	IN	O
insulin	NN	O
sensitivity	NN	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
insulin	JJ	O
sensitivity	NN	O
induced	VBN	O
by	IN	O
fasting	VBG	O
was	VBD	O
comparable	JJ	O
to	TO	O
the	DT	O
increase	NN	O
in	IN	O
insulin	JJ	O
sensitivity	NN	O
induced	VBN	O
by	IN	O
fasting	VBG	O
combined	VBN	O
with	IN	O
pegvisomant	JJ	O
.	.	O

Among	IN	O
serum	JJ	O
lipid	JJ	O
concentrations	NNS	O
,	,	O
only	RB	O
serum	JJ	O
triglycerides	NNS	O
increased	VBD	O
significantly	RB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
pegvisomant	NN	O
alone	NN	O
(	(	O
1.0	CD	O
+/-	JJ	O
0.2	CD	O
vs.	FW	O
1.6	CD	O
+/-	JJ	O
0.4	CD	O
mmol/liter	NN	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
lipid	JJ	O
concentrations	NNS	O
induced	VBN	O
by	IN	O
fasting	VBG	O
alone	RB	O
or	CC	O
pegvisomant	VB	O
were	VBD	O
not	RB	O
different	JJ	O
from	IN	O
those	DT	O
induced	VBN	O
by	IN	O
pegvisomant	JJ	O
alone	NN	O
.	.	O

von	JJ	O
Willebrand	NNP	O
factor	NN	O
antigen	NN	O
levels	NNS	O
declined	VBD	O
significantly	RB	O
under	IN	O
the	DT	O
influence	NN	O
of	IN	O
pegvisomant	NN	O
alone	NN	O
(	(	O
1.1	CD	O
+/-	JJ	O
0.07	CD	O
vs.	FW	O
0.8	CD	O
+/-	JJ	O
0.06	CD	O
U/ml	NNP	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
in	IN	O
different	JJ	O
metabolic	JJ	O
conditions	NNS	O
the	DT	O
GH	NNP	O
receptor	NN	O
antagonist	NN	O
pegvisomant	NN	O
induces	VBZ	O
no	DT	O
significant	JJ	O
acute	NN	O
changes	NNS	O
in	IN	O
the	DT	O
major	JJ	O
risk	NN	O
markers	NNS	O
for	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
secondary	JJ	O
metabolic	NN	O
changes	NNS	O
,	,	O
e.g	NN	O
.	.	O

abdominal	JJ	O
obesity	NN	O
or	CC	O
inflammatory	JJ	O
factors	NNS	O
,	,	O
that	WDT	O
develop	VBZ	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
long-standing	JJ	O
GHD	NNP	O
are	VBP	O
of	IN	O
primary	JJ	O
importance	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
atherosclerosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
GHD	NNP	O
.	.	O

Clinical	JJ	O
significance	NN	O
and	CC	O
prognostic	JJ	O
importance	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
hypertrophy	NN	O
in	IN	O
non-Q-wave	JJ	Condition
acute	JJ	Condition
myocardial	JJ	Condition
infarction	NN	Condition
.	.	O

Left	NNP	O
ventricular	NN	O
(	(	O
LV	NNP	O
)	)	O
hypertrophy	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
an	DT	O
independent	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
cardiac	JJ	O
death	NN	O
,	,	O
but	CC	O
its	PRP$	O
significance	NN	O
in	IN	O
non-Q-wave	JJ	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
AMI	NNP	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
assessed	VBN	O
previously	RB	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
diltiazem-placebo-controlled	JJ	O
therapeutic	JJ	O
trial	NN	O
of	IN	O
non-Q-wave	JJ	O
AMI	NNP	O
confirmed	VBN	O
by	IN	O
creatine	NN	O
kinase-MB	NN	O
(	(	O
CK-MB	NNP	O
)	)	O
,	,	O
126	CD	O
of	IN	O
544	CD	SampleSize
patients	NNS	SampleSize
(	(	O
23	CD	O
%	NN	O
)	)	O
exhibited	VBD	O
LV	NNP	O
hypertrophy	NN	O
using	VBG	O
standard	JJ	O
voltage	NN	O
criteria	NNS	O
.	.	O

Compared	VBN	O
to	TO	O
patients	NNS	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
patients	NNS	O
with	IN	O
LV	NNP	O
hypertrophy	NN	O
were	VBD	O
significantly	RB	O
older	JJR	O
(	(	O
65	CD	O
vs	RB	O
60	CD	O
years	NNS	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
and	CC	O
had	VBD	O
smaller	JJR	O
peak	NN	O
adjusted	VBN	O
CK	NNP	O
levels	NNS	O
(	(	O
490	CD	O
+/-	JJ	O
376	CD	O
vs	JJ	O
666	CD	O
+/-	JJ	O
726	CD	O
IU/liter	NNP	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
than	IN	O
patients	NNS	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
.	.	O

Patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
acute	JJ	O
mortality	NN	O
during	IN	O
hospitalization	NN	O
,	,	O
progression	NN	O
to	TO	O
Q	NNP	O
waves	NNS	O
,	,	O
reinfarction	NN	O
by	IN	O
CK-MB	NNP	O
criteria	NNS	O
or	CC	O
angina	NNS	O
associated	VBN	O
with	IN	O
transient	JJ	O
electrocardiographic	JJ	O
changes	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
patients	NNS	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
those	DT	O
patients	NNS	O
with	IN	O
non-Q-wave	JJ	O
AMI	NNP	O
and	CC	O
LV	NNP	O
hypertrophy	NN	O
had	VBD	O
a	DT	O
2-fold	JJ	O
higher	JJR	O
incidence	NN	O
of	IN	O
reinfarction	NN	O
(	(	O
24	CD	O
vs	RB	O
12	CD	O
%	NN	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
and	CC	O
death	NN	O
(	(	O
19	CD	O
vs	RB	O
9	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.044	CD	O
)	)	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

Multivariate	NNP	O
regression	NN	O
analysis	NN	O
revealed	VBD	O
that	IN	O
the	DT	O
relative	JJ	O
risk	NN	O
of	IN	O
death	NN	O
and	CC	O
reinfarction	NN	O
during	IN	O
the	DT	O
initial	JJ	O
year	NN	O
after	IN	O
AMI	NNP	O
was	VBD	O
increased	VBN	O
by	IN	O
a	DT	O
factor	NN	O
of	IN	O
1.7	CD	O
and	CC	O
2.1	CD	O
among	IN	O
patients	NNS	O
with	IN	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
respectively	RB	O
.	.	O

It	PRP	O
was	VBD	O
therefore	RB	O
concluded	VBD	O
that	IN	O
,	,	O
although	IN	O
patients	NNS	O
with	IN	O
LV	NNP	O
hypertrophy	NN	O
and	CC	O
non-Q-wave	JJ	O
AMI	NNP	O
have	VBP	O
smaller	JJR	O
enzymatic	JJ	O
infarcts	NNS	O
and	CC	O
the	DT	O
same	JJ	O
short-term	JJ	O
prognosis	NN	O
as	IN	O
do	JJ	O
patients	NNS	O
without	IN	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
their	PRP$	O
reinfarction	NN	O
and	CC	O
mortality	NN	O
rates	NNS	O
are	VBP	O
significantly	RB	O
increased	VBN	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
[	JJ	O
Efficacy	NNP	O
and	CC	O
immune	JJ	O
memory	NN	O
of	IN	O
plasma-derived	JJ	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
11	CD	O
years	NNS	O
after	IN	O
primary	JJ	O
immunization	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
hepatitis	NN	Condition
B	NNP	Condition
vaccine	NN	O
10	CD	O
years	NNS	O
after	IN	O
primary	JJ	O
immunization	NN	O
to	TO	O
provide	VB	O
scientific	JJ	O
basis	NN	O
for	IN	O
the	DT	O
time	NN	O
of	IN	O
revaccination	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
strictly	RB	O
designed	VBN	O
with	IN	O
randomization	NN	O
,	,	O
double-blinding	NN	O
,	,	O
and	CC	O
placebo-controlled	JJ	O
method	NN	O
to	TO	O
observe	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
immune	JJ	O
memory	NN	O
11	CD	O
years	NNS	O
following	VBG	O
hepatitis	NN	O
B	NNP	O
vaccination	NN	O
.	.	O

RESULTS	NNP	O
Immunogenicity	NNP	O
and	CC	O
protective	JJ	O
rate	NN	O
of	IN	O
vaccine	NN	O
were	VBD	O
still	RB	O
kept	VBN	O
well	RB	O
11	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
with	IN	O
a	DT	O
protective	JJ	O
rate	NN	O
against	IN	O
HBV	NNP	O
infection	NN	O
of	IN	O
73.5	CD	O
%	NN	O
.	.	O

But	CC	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
HBV	NNP	O
infection	NN	O
rates	NNS	O
between	IN	O
vaccine	NN	O
group	NN	O
and	CC	O
placebo-controlled	JJ	O
group	NN	O
(	(	O
7.89	CD	O
%	NN	O
vs.	FW	O
13.25	CD	O
%	NN	O
,	,	O
P	NNP	O
>	NNP	O
0.1	CD	O
)	)	O
nine	CD	O
to	TO	O
11	CD	O
years	NNS	O
following	VBG	O
immunization	NN	O
.	.	O

There	EX	O
still	RB	O
existed	VBD	O
immune	JJ	O
memory	NN	O
11	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
,	,	O
but	CC	O
it	PRP	O
was	VBD	O
significantly	RB	O
weaker	JJR	O
than	IN	O
that	DT	O
within	IN	O
the	DT	O
first	JJ	O
10	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
vaccine	NN	O
had	VBD	O
begun	VBN	O
to	TO	O
drop	VB	O
11	CD	O
years	NNS	O
after	IN	O
immunization	NN	O
,	,	O
which	WDT	O
should	MD	O
be	VB	O
followed	VBN	O
up	RP	O
further	RBR	O
to	TO	O
reach	VB	O
a	DT	O
clear	JJ	O
conclusion	NN	O
.	.	O

Aspirin-associated	JJ	Condition
iron	NN	Condition
loss	NN	Condition
as	IN	O
an	DT	O
anticancer	NN	O
mechanism	NN	O
.	.	O

A	DT	O
consensus	NN	O
view	NN	O
has	VBZ	O
emerged	VBN	O
favoring	VBG	O
an	DT	O
anticancer	JJ	O
effect	NN	O
of	IN	O
long-term	JJ	O
aspirin	NN	O
use	NN	O
.	.	O

Aspirin-induced	JJ	O
loss	NN	O
of	IN	O
stored	VBN	O
iron	NN	O
from	IN	O
chronic	JJ	O
gastrointestinal	JJ	O
bleeding	NN	O
is	VBZ	O
proposed	VBN	O
as	IN	O
a	DT	O
mechanism	NN	O
underlying	VBG	O
this	DT	O
beneficial	JJ	O
effect	NN	O
.	.	O

In	IN	O
iron	NN	O
depletion	NN	O
,	,	O
less	JJR	O
iron	NN	O
may	MD	O
be	VB	O
available	JJ	O
for	IN	O
carcinogenesis	NN	O
through	IN	O
free-radical	JJ	O
mediated	VBN	O
mechanisms	NNS	O
and	CC	O
for	IN	O
promotion	NN	O
of	IN	O
tumor	NN	O
growth	NN	O
.	.	O

Low-dose	JJ	O
aspirin	NN	O
increases	NNS	O
gastrointestinal	JJ	O
losses	NNS	O
of	IN	O
transfused	VBN	O
radiolabeled	VBN	O
autologous	JJ	O
red	JJ	O
cells	NNS	O
.	.	O

Observational	JJ	O
studies	NNS	O
report	VBP	O
lower	JJR	O
serum	NN	O
ferritin	NN	O
values	NNS	O
with	IN	O
regular	JJ	O
aspirin	NN	O
use	NN	O
.	.	O

A	DT	O
protective	JJ	O
effect	NN	O
of	IN	O
induced	JJ	O
iron	NN	O
reduction	NN	O
against	IN	O
cancer	NN	O
mortality	NN	O
has	VBZ	O
been	VBN	O
confirmed	VBN	O
in	IN	O
a	DT	O
recent	JJ	O
trial	NN	O
(	(	O
FeAST	NNP	O
)	)	O
with	IN	O
subjects	NNS	O
randomized	VBN	O
to	TO	O
iron	VB	O
reduction	NN	O
or	CC	O
observation	NN	O
.	.	O

Serum	NNP	O
ferritin	JJ	O
reductions	NNS	O
in	IN	O
the	DT	O
FeAST	NNP	O
trial	NN	O
were	VBD	O
within	IN	O
conventionally	RB	O
normal	JJ	O
reference	NN	O
ranges	NNS	O
and	CC	O
were	VBD	O
quantitatively	RB	O
similar	JJ	O
to	TO	O
ferritin	VB	O
reductions	NNS	O
in	IN	O
observational	JJ	O
studies	NNS	O
in	IN	O
regular	JJ	Condition
aspirin	NN	Condition
users	NNS	Condition
.	.	O

Delayed	NNP	O
anticancer	NN	O
effects	NNS	O
of	IN	O
aspirin	NN	O
are	VBP	O
compatible	JJ	O
with	IN	O
the	DT	O
proposed	VBN	O
mechanism	NN	O
,	,	O
as	IN	O
continual	JJ	O
microbleeding	NN	O
has	VBZ	O
a	DT	O
gradual	JJ	O
cumulative	JJ	O
effect	NN	O
on	IN	O
stored	VBN	O
iron	NN	O
.	.	O

Reduction	NN	O
of	IN	O
oral	JJ	O
mucositis	NN	O
by	IN	O
filgrastim	NN	O
(	(	O
r-metHuG-CSF	JJ	O
)	)	O
in	IN	O
patients	NNS	Condition
receiving	VBG	Condition
chemotherapy	NN	Condition
.	.	O

Mucositis	NNP	O
,	,	O
the	DT	O
inflammation	NN	O
and	CC	O
necrosis	NN	O
of	IN	O
mucosal	NN	O
membranes	NNS	O
,	,	O
is	VBZ	O
a	DT	O
serious	JJ	O
and	CC	O
debilitating	VBG	O
consequence	NN	O
of	IN	O
many	JJ	O
cancer	NN	O
therapies	NNS	O
.	.	O

We	PRP	O
were	VBD	O
interested	JJ	O
in	IN	O
the	DT	O
potential	JJ	O
role	NN	O
of	IN	O
filgrastim	NN	O
(	(	O
recombinant	JJ	O
methionyl	NN	O
human	JJ	O
granulocyte	NN	O
colony-stimulating	NN	O
factor	NN	O
,	,	O
r-metHuG-CSF	NN	O
)	)	O
in	IN	O
the	DT	O
reduction	NN	O
of	IN	O
mucositis	NN	O
.	.	O

Patients	NNS	O
with	IN	O
newly	RB	Condition
diagnosed	VBN	Condition
small-cell	NN	Condition
lung	NN	Condition
cancer	NN	Condition
(	(	Condition
SCLC	NNP	Condition
)	)	Condition
were	VBD	O
treated	VBN	O
with	IN	O
CAE	NNP	O
chemotherapy	NN	O
(	(	O
cyclophosphamide	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
and	CC	O
etoposide	RB	O
)	)	O
and	CC	O
placebo	NN	O
or	CC	O
filgrastim	NN	O
.	.	O

If	IN	O
patients	NNS	O
had	VBD	O
an	DT	O
episode	NN	O
of	IN	O
febrile	JJ	O
neutropenia	NNS	O
,	,	O
they	PRP	O
received	VBD	O
unblinded	JJ	O
filgrastim	NN	O
in	IN	O
subsequent	JJ	O
CAE	NNP	O
cycles	NNS	O
.	.	O

Oral	NNP	O
mucositis	NN	O
was	VBD	O
considered	VBN	O
to	TO	O
have	VB	O
occurred	VBN	O
if	IN	O
a	DT	O
patient	NN	O
reported	VBD	O
any	DT	O
clinical	JJ	O
sign	NN	O
or	CC	O
symptom	NN	O
of	IN	O
oral	JJ	O
mucositis	NN	O
with	IN	O
or	CC	O
without	IN	O
oral	JJ	O
candidiasis	NN	O
.	.	O

Oral	NNP	O
mucositis	NN	O
was	VBD	O
analyzed	VBN	O
using	VBG	O
the	DT	O
unadjusted	JJ	O
chi-square	JJ	O
test	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
first	JJ	O
episode	NN	O
of	IN	O
mucositis	NN	O
was	VBD	O
analyzed	VBN	O
using	VBG	O
the	DT	O
stratified	JJ	O
log-rank	JJ	O
test	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
regression	NN	O
model	NN	O
.	.	O

During	IN	O
cycle	NN	O
1	CD	O
,	,	O
placebo-treated	JJ	O
patients	NNS	O
had	VBD	O
more	RBR	O
episodes	NNS	O
of	IN	O
mucositis	NN	O
(	(	O
47	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
patients	NNS	O
randomized	VBN	O
to	TO	O
filgrastim	VB	O
(	(	O
28	CD	O
%	NN	O
)	)	O
.	.	O

Across	IN	O
all	DT	O
cycles	NNS	O
of	IN	O
treatment	NN	O
,	,	O
70	CD	O
%	NN	O
of	IN	O
placebo-treated	JJ	O
patients	NNS	O
experienced	VBD	O
mucositis	NN	O
,	,	O
compared	VBN	O
with	IN	O
53	CD	O
%	NN	O
of	IN	O
patients	NNS	O
randomized	VBN	O
to	TO	O
filgrastim	VB	O
.	.	O

A	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
chemotherapy-related	JJ	O
oral	JJ	O
mucositis	NN	O
occurred	VBD	O
across	IN	O
multiple	JJ	O
cycles	NNS	O
of	IN	O
treatment	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
filgrastim	NN	O
.	.	O

[	JJ	O
Supplementary	NNP	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
of	IN	O
female	JJ	Condition
patients	NNS	Condition
undergoing	VBG	Condition
curative	JJ	Condition
adjuvant	JJ	Condition
irradiation	NN	Condition
following	VBG	Condition
breast	NN	Condition
cancer	NN	Condition
]	NNP	Condition
.	.	O

1	CD	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
supposed	VBN	O
to	TO	O
investigate	VB	O
a	DT	O
possible	JJ	O
prevention	NN	O
or	CC	O
reduction	NN	O
of	IN	O
the	DT	O
toxicity	NN	O
of	IN	O
radiotherapy	NN	O
by	IN	O
an	DT	O
additional	JJ	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
.	.	O

This	DT	O
question	NN	O
arose	VBD	O
when	WRB	O
performing	VBG	O
an	DT	O
investigation	NN	O
about	IN	O
the	DT	O
effect	NN	O
of	IN	O
Esberitox	NNP	O
in	IN	O
a	DT	O
combined	JJ	O
chemo-radiotherapy	NN	O
.	.	O

Whereas	IN	O
the	DT	O
latter	JJ	O
induces	NNS	O
above	IN	O
all	PDT	O
a	DT	O
systemic	JJ	O
damage	NN	O
to	TO	O
the	DT	O
hemopoietic	JJ	O
system	NN	O
,	,	O
radiotherapy	NN	O
is	VBZ	O
a	DT	O
regional	JJ	O
noxa	NN	O
.	.	O

2	CD	O
.	.	O

The	DT	O
present	JJ	O
prospective	JJ	O
,	,	O
randomized	VBD	O
study	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
50	CD	O
patients	NNS	O
submitted	VBN	O
to	TO	O
curative	VB	O
adjuvant	JJ	O
irradiation	NN	O
following	VBG	O
surgery	NN	O
for	IN	O
mammary	JJ	O
carcinoma	NN	O
.	.	O

The	DT	O
radiotherapy	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
same	JJ	O
way	NN	O
in	IN	O
all	DT	O
patients	NNS	O
with	IN	O
irradiations	NNS	O
of	IN	O
the	DT	O
thoracic	NN	O
wall	NN	O
and	CC	O
the	DT	O
regional	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

Two	CD	O
groups	NNS	O
were	VBD	O
built	VBN	O
by	IN	O
randomization	NN	O
.	.	O

The	DT	O
study	NN	O
group	NN	O
received	VBD	O
an	DT	O
additional	JJ	O
treatment	NN	O
with	IN	O
Esberitox	NNP	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
did	VBD	O
not	RB	O
receive	VB	O
an	DT	O
additional	JJ	O
treatment	NN	O
.	.	O

3	CD	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
no	DT	O
protective	JJ	O
influence	NN	O
of	IN	O
Esberitox	NNP	O
could	MD	O
be	VB	O
demonstrated	VBN	O
.	.	O

The	DT	O
parameters	NNS	O
investigated	VBN	O
were	VBD	O
the	DT	O
peripheral	JJ	O
blood	NN	O
count	NN	O
(	(	O
leucocytes	NNS	O
,	,	O
granulocytes	NNS	O
,	,	O
lymphocytes	NNS	O
,	,	O
monocytes	NNS	O
,	,	O
thrombocytes	NNS	O
,	,	O
hemoglobin	NN	O
,	,	O
hematocrit	NN	O
)	)	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
infections	NNS	O
.	.	O

4	CD	O
.	.	O

This	DT	O
result	NN	O
diverging	VBG	O
from	IN	O
literature	NN	O
is	VBZ	O
discussed	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
probably	RB	O
affected	VBN	O
by	IN	O
volume	NN	O
and	CC	O
extension	NN	O
of	IN	O
the	DT	O
injury	NN	O
induced	VBN	O
by	IN	O
a	DT	O
hematotoxic	NN	O
noxa	NN	O
and	CC	O
furthermore	NN	O
by	IN	O
the	DT	O
ability	NN	O
of	IN	O
regeneration	NN	O
.	.	O

If	IN	O
this	DT	O
ability	NN	O
is	VBZ	O
exhausted	VBN	O
,	,	O
the	DT	O
protective	JJ	O
effect	NN	O
of	IN	O
Esberitox	NNP	O
can	MD	O
act	VB	O
no	DT	O
longer	JJR	O
.	.	O

Therefore	VB	O
the	DT	O
essential	JJ	O
factor	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
duration	NN	O
of	IN	O
exposure	NN	O
to	TO	O
the	DT	O
noxa	NN	O
.	.	O

Esberitox	NNP	O
was	VBD	O
effective	JJ	O
in	IN	O
case	NN	O
of	IN	O
a	DT	O
short	JJ	O
toxicity	NN	O
,	,	O
it	PRP	O
was	VBD	O
ineffective	JJ	O
in	IN	O
case	NN	O
of	IN	O
prolonged	JJ	O
toxicity	NN	O
,	,	O
if	IN	O
the	DT	O
treatment	NN	O
continuity	NN	O
(	(	O
noxa	JJ	O
)	)	O
was	VBD	O
not	RB	O
broken	VBN	O
up	RP	O
by	IN	O
some	DT	O
regeneration	NN	O
intervals	NNS	O
.	.	O

The	DT	O
radiotherapy	NN	O
studied	VBN	O
in	IN	O
this	DT	O
trial	NN	O
had	VBD	O
a	DT	O
duration	NN	O
of	IN	O
50	CD	O
days	NNS	O
,	,	O
and	CC	O
its	PRP$	O
effect	NN	O
was	VBD	O
that	IN	O
of	IN	O
a	DT	O
longterm	JJ	O
injury	NN	O
.	.	O

Risk	NN	O
factors	NNS	O
for	IN	O
malnutrition	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
gastroenterological	JJ	O
and	CC	O
hernia	JJ	O
surgery	NN	O
:	:	O
an	DT	O
analysis	NN	O
of	IN	O
374	CD	O
patients	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
nutritional	JJ	O
status	NN	O
of	IN	O
374	CD	SampleSize
surgical	JJ	Condition
patients	NNS	Condition
with	IN	O
gastrointestinal	JJ	Condition
disease	NN	Condition
and	CC	Condition
hernias	NN	Condition
of	IN	Condition
the	DT	Condition
abdominal	JJ	Condition
wall	NN	Condition
;	:	O
to	TO	O
identify	VB	O
risk	NN	O
factors	NNS	O
associated	VBN	O
with	IN	O
a	DT	O
poorer	JJR	O
nutritional	JJ	O
status	NN	O
in	IN	O
this	DT	O
group	NN	O
of	IN	O
patients	NNS	O
and	CC	O
to	TO	O
assess	VB	O
awareness	NN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
nutritional	JJ	O
status	NN	O
by	IN	O
medical	JJ	O
teams	NNS	O
.	.	O

SUMMARY	NNP	O
BACKGROUND	NNP	O
DATA	NNP	O
Malnutrition	NNP	O
is	VBZ	O
prevalent	JJ	O
among	IN	O
surgical	JJ	O
patients	NNS	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
higher	JJR	O
surgical	JJ	O
complication	NN	O
rates	NNS	O
and	CC	O
mortality	NN	O
.	.	O

The	DT	O
major	JJ	O
causes	NNS	O
of	IN	O
poor	JJ	O
nutritional	JJ	O
status	NN	O
are	VBP	O
related	VBN	O
to	TO	O
the	DT	O
underlying	JJ	O
disease	NN	O
,	,	O
socio-economic	JJ	O
factors	NNS	O
,	,	O
age	NN	O
,	,	O
and	CC	O
length	NN	O
of	IN	O
hospitalization	NN	O
.	.	O

Despite	IN	O
its	PRP$	O
high	JJ	O
prevalence	NN	O
,	,	O
medical	JJ	O
teams	NNS	O
often	RB	O
overlook	VBP	O
malnutrition	NN	O
,	,	O
and	CC	O
screening	NN	O
of	IN	O
these	DT	O
patients	NNS	O
is	VBZ	O
not	RB	O
routine	JJ	O
.	.	O

It	PRP	O
is	VBZ	O
of	IN	O
utmost	JJ	O
importance	NN	O
to	TO	O
identify	VB	O
patients	NNS	O
at	IN	O
risk	NN	O
for	IN	O
malnutrition	NN	O
in	IN	O
order	NN	O
to	TO	O
prevent	VB	O
related	JJ	O
complications	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
374	CD	O
patients	NNS	O
evaluated	VBN	O
in	IN	O
this	DT	O
study	NN	O
were	VBD	O
a	DT	O
subgroup	NN	O
of	IN	O
a	DT	O
larger	JJR	O
multicenter	NN	O
,	,	O
cross-sectional	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
that	WDT	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
1996	CD	O
.	.	O

Nutritional	JJ	O
status	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
using	VBG	O
Subjective	NNP	O
Global	NNP	O
Assessment	NNP	O
.	.	O

RESULTS	NNP	O
Malnutrition	NNP	O
was	VBD	O
present	JJ	O
in	IN	O
55	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
,	,	O
with	IN	O
19	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
severely	RB	O
malnourished	VBN	O
.	.	O

The	DT	O
presence	NN	O
of	IN	O
cancer	NN	O
,	,	O
infection	NN	O
,	,	O
age	NN	O
over	IN	O
60	CD	O
years	NNS	O
,	,	O
upper	JJ	O
gastrointestinal	JJ	O
disease	NN	O
,	,	O
and	CC	O
longer	JJR	O
length	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
all	DT	O
negatively	RB	O
influenced	VBN	O
nutritional	JJ	O
status	NN	O
.	.	O

Despite	IN	O
the	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
malnutrition	NN	O
,	,	O
the	DT	O
medical	JJ	O
teams	NNS	O
only	RB	O
assessed	VBD	O
the	DT	O
nutritional	JJ	O
status	NN	O
of	IN	O
a	DT	O
few	JJ	O
patients	NNS	O
.	.	O

CONCLUSION	NNP	O
Malnutrition	NNP	O
was	VBD	O
highly	RB	O
prevalent	JJ	O
in	IN	O
this	DT	O
setting	NN	O
of	IN	O
patients	NNS	O
.	.	O

Therefore	NNP	O
,	,	O
patients	NNS	O
with	IN	O
the	DT	O
risk	NN	O
factors	NNS	O
above	IN	O
presented	VBN	O
should	MD	O
routinely	RB	O
undergo	VB	O
nutritional	JJ	O
screening	NN	O
and/or	JJ	O
assessment	NN	O
in	IN	O
order	NN	O
to	TO	O
be	VB	O
able	JJ	O
to	TO	O
early	JJ	O
diagnose	NN	O
or	CC	O
prevent	NN	O
malnutrition	NN	O
and	CC	O
its	PRP$	O
correlated	JJ	O
morbidity	NN	O
and	CC	O
mortality	NN	O
.	.	O

Recommendations	NNS	O
for	IN	O
implementing	VBG	O
stereotactic	JJ	O
radiotherapy	NN	O
in	IN	O
peripheral	JJ	O
stage	NN	O
IA	NNP	O
non-small	NN	O
cell	NN	O
lung	NN	O
cancer	NN	O
:	:	O
report	NN	O
from	IN	O
the	DT	O
Quality	NNP	O
Assurance	NNP	O
Working	NNP	O
Party	NNP	O
of	IN	O
the	DT	O
randomised	JJ	O
phase	NN	O
III	NNP	O
ROSEL	NNP	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
A	NNP	O
phase	NN	O
III	NNP	O
multi-centre	NN	O
randomised	VBD	O
trial	NN	O
(	(	O
ROSEL	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
initiated	VBN	O
to	TO	O
establish	VB	O
the	DT	O
role	NN	O
of	IN	O
stereotactic	JJ	O
radiotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
operable	JJ	O
stage	NN	O
IA	NNP	O
lung	NN	O
cancer	NN	O
.	.	O

Due	NNP	O
to	TO	O
rapid	VB	O
changes	NNS	O
in	IN	O
radiotherapy	NN	O
technology	NN	O
and	CC	O
evolving	VBG	O
techniques	NNS	O
for	IN	O
image-guided	JJ	O
delivery	NN	O
,	,	O
guidelines	NNS	O
had	VBD	O
to	TO	O
be	VB	O
developed	VBN	O
in	IN	O
order	NN	O
to	TO	O
ensure	VB	O
uniformity	NN	O
in	IN	O
implementation	NN	O
of	IN	O
stereotactic	JJ	O
radiotherapy	NN	O
in	IN	O
this	DT	O
multi-centre	JJ	O
study	NN	O
.	.	O

METHODS/DESIGN	NNP	O
A	NNP	O
Quality	NNP	O
Assurance	NNP	O
Working	NNP	O
Party	NNP	O
was	VBD	O
formed	VBN	O
by	IN	O
radiation	NN	O
oncologists	NNS	O
and	CC	O
clinical	JJ	O
physicists	NNS	O
from	IN	O
both	DT	O
academic	JJ	O
as	RB	O
well	RB	O
as	IN	O
non-academic	JJ	O
hospitals	NNS	O
that	WDT	O
had	VBD	O
already	RB	O
implemented	VBN	O
stereotactic	JJ	O
radiotherapy	NN	O
for	IN	O
lung	NN	O
cancer	NN	O
.	.	O

A	DT	O
literature	NN	O
survey	NN	O
was	VBD	O
conducted	VBN	O
and	CC	O
consensus	JJ	O
meetings	NNS	O
were	VBD	O
held	VBN	O
in	IN	O
which	WDT	O
both	CC	O
the	DT	O
knowledge	NN	O
from	IN	O
the	DT	O
literature	NN	O
and	CC	O
clinical	JJ	O
experience	NN	O
were	VBD	O
pooled	VBN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
planning	NN	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
26	CD	O
stage	NN	O
I	PRP	O
patients	NNS	O
,	,	O
of	IN	O
which	WDT	O
22	CD	O
were	VBD	O
stage	NN	O
1A	CD	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
develop	VB	O
and	CC	O
evaluate	VB	O
the	DT	O
planning	NN	O
guidelines	NNS	O
.	.	O

Plans	NNS	O
were	VBD	O
optimised	VBN	O
according	VBG	O
to	TO	O
parameters	NNS	O
adopted	VBN	O
from	IN	O
RTOG	NNP	O
trials	NNS	O
using	VBG	O
both	DT	O
an	DT	O
algorithm	NN	O
with	IN	O
a	DT	O
simple	JJ	O
homogeneity	NN	O
correction	NN	O
(	(	O
Type	NNP	O
A	NNP	O
)	)	O
and	CC	O
a	DT	O
more	RBR	O
advanced	JJ	O
algorithm	NN	O
(	(	O
Type	NNP	O
B	NNP	O
)	)	O
.	.	O

Dose	NNP	O
conformity	NN	O
requirements	NNS	O
were	VBD	O
then	RB	O
formulated	VBN	O
based	VBN	O
on	IN	O
these	DT	O
results	NNS	O
.	.	O

CONCLUSION	NNP	O
Based	VBD	O
on	IN	O
current	JJ	O
literature	NN	O
and	CC	O
expert	JJ	O
experience	NN	O
,	,	O
guidelines	NNS	O
were	VBD	O
formulated	VBN	O
for	IN	O
this	DT	O
phase	NN	O
III	NNP	O
study	NN	O
of	IN	O
stereotactic	JJ	O
radiotherapy	NN	O
versus	NN	O
surgery	NN	O
.	.	O

These	DT	O
guidelines	NNS	O
can	MD	O
serve	VB	O
to	TO	O
facilitate	VB	O
the	DT	O
design	NN	O
of	IN	O
future	JJ	O
multi-centre	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
stereotactic	JJ	O
radiotherapy	NN	O
in	IN	O
other	JJ	O
patient	NN	O
groups	NNS	O
and	CC	O
aid	VB	O
a	DT	O
more	RBR	O
uniform	JJ	O
implementation	NN	O
of	IN	O
this	DT	O
technique	NN	O
outside	JJ	O
clinical	JJ	O
trials	NNS	O
.	.	O

Effect	NN	O
of	IN	O
acarbose	NN	O
on	IN	O
additional	JJ	O
insulin	NN	O
therapy	NN	O
in	IN	O
type	NN	Condition
2	CD	Condition
diabetic	JJ	Condition
patients	NNS	O
with	IN	O
late	JJ	Condition
failure	NN	Condition
of	IN	O
sulphonylurea	JJ	Condition
therapy	NN	Condition
.	.	O

AIM	VB	O
The	DT	O
present	JJ	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
acarbose	NN	O
on	IN	O
insulin	NN	O
requirements	NNS	O
and	CC	O
glycaemic	JJ	O
control	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	Condition
2	CD	Condition
diabetes	NNS	Condition
receiving	VBG	O
exogenous	JJ	Condition
insulin	NN	Condition
due	JJ	O
to	TO	O
secondary	JJ	O
failure	NN	Condition
of	IN	O
maximum	NN	O
dose	JJ	O
sulphonylurea	JJ	Condition
therapy	NN	Condition
.	.	O

METHODS	VB	O
A	DT	O
single-centre	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
48	CD	SampleSize
type	NN	Condition
2	CD	Condition
diabetic	JJ	Condition
patients	NNS	O
with	IN	O
late-term	JJ	Condition
failure	NN	Condition
following	VBG	O
at	IN	O
least	JJS	O
3	CD	O
years	NNS	O
of	IN	O
sulphonylurea	JJ	Condition
therapy	NN	Condition
requiring	VBG	O
additional	JJ	O
insulin	NN	Condition
therapy	NN	Condition
to	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
acarbose	NN	O
on	IN	O
glycaemic	JJ	O
control	NN	O
and	CC	O
insulin	NN	O
requirements	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
glycaemic	JJ	O
response	NN	O
rate	NN	O
(	(	O
responders	NNS	O
being	VBG	O
predefined	VBN	O
as	IN	O
patients	NNS	O
who	WP	O
achieve	VBP	O
a	DT	O
decrease	NN	O
in	IN	O
HbA1c	NNP	O
to	TO	O
less	JJR	O
than	IN	O
8	CD	O
%	NN	O
or	CC	O
a	DT	O
reduction	NN	O
by	IN	O
at	IN	O
least	JJS	O
15	CD	O
%	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
baseline	NN	O
values	NNS	O
)	)	O
and	CC	O
the	DT	O
daily	JJ	O
insulin	NN	O
dose	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Secondary	JJ	O
parameters	NNS	O
assessed	VBD	O
included	VBN	O
postprandial	JJ	O
changes	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
,	,	O
serum	JJ	O
insulin	NN	O
and	CC	O
C-peptide	NNP	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
significantly	RB	O
more	JJR	O
responders	NNS	O
in	IN	O
the	DT	O
acarbose-treated	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
20/24	CD	O
patients	NNS	O
vs.	FW	O
10/19	CD	O
patients	NNS	O
;	:	O
p	VB	O
<	$	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
daily	JJ	O
insulin	NN	O
dose	NN	O
after	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
was	VBD	O
16.4	CD	O
+/-	JJ	O
10.1	CD	O
IU	NNP	O
in	IN	O
the	DT	O
acarbose	JJ	O
group	NN	O
and	CC	O
22.4	CD	O
+/-	JJ	O
12.2	CD	O
IU	NNP	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
s.d	NN	O
.	.	O

;	:	O
p	JJ	O
<	NNP	O
0.07	CD	O
)	)	O
.	.	O

Postprandial	JJ	O
increases	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
,	,	O
insulin	NN	O
and	CC	O
C-peptide	NNP	O
were	VBD	O
consistently	RB	O
lower	JJR	O
in	IN	O
the	DT	O
acarbose-treated	JJ	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

For	IN	O
example	NN	O
,	,	O
the	DT	O
mean	JJ	O
increase	NN	O
in	IN	O
2-h	JJ	O
postprandial	JJ	O
serum	NN	O
insulin	NN	O
remained	VBD	O
almost	RB	O
unchanged	JJ	O
in	IN	O
the	DT	O
acarbose	JJ	O
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
compared	VBN	O
to	TO	O
an	DT	O
increase	NN	O
to	TO	O
43	CD	O
+/-	JJ	O
29	CD	O
microU/ml	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
s.d	NN	O
.	.	O

)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
period	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
the	DT	O
addition	NN	O
of	IN	O
acarbose	NN	O
to	TO	O
sulphonylurea/insulin	VB	O
combination	NN	O
therapy	NN	O
can	MD	O
improve	VB	O
glycaemic	JJ	O
control	NN	O
in	IN	O
type	NN	Condition
2	CD	Condition
diabetic	JJ	Condition
patients	NNS	O
.	.	O

Acarbose	NNP	O
may	MD	O
also	RB	O
reduce	VB	O
insulin	NN	O
resistance	NN	O
and	CC	O
hyperinsulinaemia	NN	O
.	.	O

Vitamin	NNP	O
D	NNP	O
supplementation	NN	O
increases	NNS	O
calcium	VBP	O
absorption	NN	O
without	IN	O
a	DT	O
threshold	JJ	O
effect	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
maximal	JJ	O
calcium	NN	O
absorption	NN	O
in	IN	O
response	NN	O
to	TO	O
vitamin	VB	O
D	NNP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
biomarker	NN	O
for	IN	O
vitamin	NN	O
D	NNP	O
sufficiency	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
there	EX	O
is	VBZ	O
a	DT	O
threshold	JJ	O
beyond	IN	O
which	WDT	O
increasing	VBG	O
doses	NNS	O
of	IN	O
vitamin	NN	O
D	NNP	O
,	,	O
or	CC	O
concentrations	NNS	O
of	IN	O
serum	JJ	O
25-hydroxyvitamin	JJ	O
D	NNP	O
[	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
]	NNP	O
,	,	O
no	RB	O
longer	RBR	O
increase	VB	O
calcium	NN	O
absorption	NN	O
.	.	O

DESIGN	NNP	O
This	DT	O
was	VBD	O
a	DT	O
placebo-controlled	JJ	O
,	,	O
dose-response	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
on	IN	O
calcium	NN	O
absorption	NN	O
in	IN	O
healthy	JJ	O
postmenopausal	NN	Condition
women	NNS	Condition
.	.	O

Seventy-six	NNP	SampleSize
healthy	JJ	O
postmenopausal	NN	Condition
women	NNS	Condition
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
placebo	VB	O
or	CC	O
800	CD	O
IU	NNP	O
(	(	O
20	CD	O
?g	NN	O
)	)	O
,	,	O
2000	CD	O
IU	NNP	O
(	(	O
50	CD	O
?g	NN	O
)	)	O
,	,	O
or	CC	O
4000	CD	O
IU	NNP	O
(	(	O
100	CD	O
?g	NN	O
)	)	O
vitamin	NN	O
D?	NNP	O
for	IN	O
8	CD	O
wk	NN	O
.	.	O

The	DT	O
technique	NN	O
of	IN	O
dual	JJ	O
isotopes	NNS	O
of	IN	O
stable	JJ	O
calcium	NN	O
was	VBD	O
used	VBN	O
with	IN	O
a	DT	O
calcium	NN	O
carrier	NN	O
to	TO	O
measure	VB	O
calcium	JJ	O
absorption	NN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
8	CD	O
wk	NN	O
.	.	O

RESULTS	NNP	O
Seventy-one	JJ	O
women	NNS	O
with	IN	O
a	DT	O
mean	NN	O
?	.	O
SD	NNP	O
age	NN	O
of	IN	O
58.8	CD	O
?	.	O
4.9	CD	O
y	NN	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
mean	JJ	O
calcium	NN	O
intake	NN	O
was	VBD	O
1142	CD	O
?	.	O
509	CD	O
mg/d	NN	O
and	CC	O
serum	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
was	VBD	O
63	CD	O
?	.	O
14	CD	O
nmol/L	NN	O
at	IN	O
baseline	NN	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
linear	JJ	O
trend	NN	O
of	IN	O
an	DT	O
increase	NN	O
in	IN	O
calcium	JJ	O
absorption	NN	O
adjusted	VBN	O
for	IN	O
age	NN	O
and	CC	O
body	NN	O
mass	NN	O
index	NN	O
with	IN	O
increasing	VBG	O
vitamin	NN	O
D?	NNP	O
dose	NN	O
or	CC	O
serum	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
concentration	NN	O
was	VBD	O
observed	VBN	O
.	.	O

A	DT	O
6.7	CD	O
%	NN	O
absolute	JJ	O
increase	NN	O
in	IN	O
calcium	JJ	O
absorption	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
highest	JJS	O
vitamin	NN	O
D?	NNP	O
group	NN	O
(	(	O
100	CD	O
?g	NN	O
)	)	O
.	.	O

No	DT	O
evidence	NN	O
of	IN	O
nonlinearity	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
dose-response	JJ	O
curve	NN	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	O
evidence	NN	O
of	IN	O
a	DT	O
threshold	NN	O
of	IN	O
calcium	NN	O
absorption	NN	O
was	VBD	O
found	VBN	O
with	IN	O
a	DT	O
serum	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
range	NN	O
from	IN	O
40	CD	O
to	TO	O
130	CD	O
nmol/L	NNS	O
.	.	O

Calcium	NNP	O
absorption	NN	O
in	IN	O
this	DT	O
range	NN	O
is	VBZ	O
not	RB	O
a	DT	O
useful	JJ	O
biomarker	NN	O
to	TO	O
determine	VB	O
nutritional	JJ	O
recommendations	NNS	O
for	IN	O
vitamin	NN	O
D	NNP	O
.	.	O

Prognostic	JJ	O
value	NN	O
of	IN	O
postoperative	JJ	O
CEA	NNP	O
clearance	NN	O
in	IN	O
rectal	JJ	Condition
cancer	NN	Condition
patients	NNS	Condition
with	IN	Condition
high	JJ	Condition
preoperative	JJ	Condition
CEA	NNP	Condition
levels	NNS	Condition
.	.	O

PURPOSE	NNP	O
We	PRP	O
determined	VBD	O
the	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
carcinoembryonic	JJ	O
antigen	NN	O
(	(	O
CEA	NNP	O
)	)	O
clearance	NN	O
after	IN	O
tumor	NN	O
resection	NN	O
with	IN	O
serial	JJ	O
evaluation	NN	O
of	IN	O
postoperative	JJ	O
CEA	NNP	O
levels	NNS	O
in	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
1994	CD	O
and	CC	O
2004	CD	O
,	,	O
we	PRP	O
retrospectively	RB	O
reviewed	VBD	O
122	CD	SampleSize
patients	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
whose	WP$	O
serum	JJ	O
CEA	NNP	O
levels	NNS	O
were	VBD	O
measured	VBN	O
on	IN	O
the	DT	O
preoperative	JJ	O
day	NN	O
and	CC	O
postoperative	JJ	O
days	NNS	O
7	CD	O
and	CC	O
30	CD	O
.	.	O

Patients	NNS	O
with	IN	O
preoperative	JJ	O
CEA	NNP	O
levels	NNS	O
<	VBP	O
5.0	CD	O
ng/ml	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

An	DT	O
exponential	JJ	O
trend	NN	O
line	NN	O
was	VBD	O
drawn	VBN	O
using	VBG	O
the	DT	O
three	CD	O
CEA	NNP	O
values	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
categorized	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
based	VBN	O
on	IN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
values	NNS	O
calculated	VBN	O
through	IN	O
trend	NN	O
line	NN	O
,	,	O
which	WDT	O
indicates	VBZ	O
the	DT	O
correlation	NN	O
coefficient	NN	O
between	IN	O
exponential	JJ	O
graph	NN	O
and	CC	O
measured	VBD	O
CEA	NNP	O
values	NNS	O
:	:	O
exponential	JJ	O
decrease	NN	O
group	NN	O
(	(	O
group	NN	O
1	CD	O
:	:	O
0.9	CD	O
<	NN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
<	NN	O
or	CC	O
=	VB	O
1.0	CD	O
)	)	O
,	,	O
nearly	RB	O
exponential	JJ	O
decrease	NN	O
group	NN	O
(	(	O
group	NN	O
2	CD	O
:	:	O
0.5	CD	O
<	NN	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
<	NN	O
or	CC	O
=	VB	O
0.9	CD	O
)	)	O
,	,	O
and	CC	O
randomized	JJ	O
clearance	NN	O
group	NN	O
(	(	O
group	NN	O
3	CD	O
:	:	O
0.5	CD	O
<	NN	O
or	CC	O
=	VB	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

We	PRP	O
then	RB	O
analyzed	VBD	O
the	DT	O
CEA	NNP	O
clearance	NN	O
pattern	NN	O
as	IN	O
a	DT	O
prognostic	JJ	O
indicator	NN	O
.	.	O

RESULTS	NNP	O
With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
57	CD	O
months	NNS	O
,	,	O
the	DT	O
5-year	JJ	O
overall	JJ	O
survival	NN	O
was	VBD	O
62.3	CD	O
%	NN	O
vs.	FW	O
48.1	CD	O
%	NN	O
vs.	FW	O
25	CD	O
%	NN	O
and	CC	O
the	DT	O
5-year	JJ	O
disease-free	JJ	O
survival	NN	O
was	VBD	O
58.6	CD	O
%	NN	O
vs.	FW	O
52.7	CD	O
%	NN	O
vs.	FW	O
25	CD	O
%	NN	O
among	IN	O
groups	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.014	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.027	CD	O
,	,	O
respectively	RB	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
stage	NN	Condition
III	NNP	Condition
rectal	JJ	Condition
cancer	NN	Condition
.	.	O

For	IN	O
those	DT	O
with	IN	O
stage	NN	O
II	NNP	O
rectal	NN	O
cancer	NN	O
,	,	O
the	DT	O
5-year	JJ	O
overall	JJ	O
survival	NN	O
rate	NN	O
of	IN	O
group	NN	O
1	CD	O
was	VBD	O
significantly	RB	O
better	JJR	O
than	IN	O
groups	NNS	O
2	CD	O
and	CC	O
3	CD	O
(	(	O
88.8	CD	O
%	NN	O
vs.	FW	O
74.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
postoperative	JJ	O
pattern	NN	O
of	IN	O
CEA	NNP	O
clearance	NN	O
is	VBZ	O
a	DT	O
useful	JJ	O
prognostic	JJ	O
determinant	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
randomized	JJ	O
pattern	NN	O
of	IN	O
CEA	NNP	O
clearance	NN	O
after	IN	O
tumor	NN	O
resection	NN	O
should	MD	O
be	VB	O
regarded	VBN	O
as	IN	O
having	VBG	O
the	DT	O
possibility	NN	O
of	IN	O
a	DT	O
persistent	JJ	O
CEA	NNP	O
source	NN	O
and	CC	O
may	MD	O
require	VB	O
consideration	NN	O
of	IN	O
intensive	JJ	O
follow-up	NN	O
or	CC	O
adjuvant	JJ	O
therapy	NN	O
.	.	O

A	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
trial	NN	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
in	IN	O
adults	NNS	Age
with	IN	O
soft	JJ	Condition
tissue	NN	Condition
sarcomas	NN	Condition
of	IN	Condition
the	DT	Condition
head	NN	Condition
and	CC	Condition
neck	NN	Condition
,	,	Condition
breast	NN	Condition
,	,	Condition
and	CC	Condition
trunk	NN	Condition
.	.	O

Since	IN	O
1977	CD	O
,	,	O
31	CD	O
patients	NNS	O
were	VBD	O
entered	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
prospective	JJ	O
study	NN	O
testing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
after	IN	O
aggressive	JJ	O
local	JJ	O
treatment	NN	O
of	IN	O
high-grade	JJ	O
sarcomas	NN	O
of	IN	O
the	DT	O
head	NN	O
,	,	O
neck	NN	O
,	,	O
breast	NN	O
,	,	O
and	CC	O
trunk	NN	O
(	(	O
excluding	VBG	O
retroperitoneal	VB	O
sarcomas	NN	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
complete	JJ	O
resection	NN	O
of	IN	O
gross	JJ	O
tumor	NN	O
and	CC	O
underwent	JJ	O
postoperative	JJ	O
radiotherapy	NN	O
(	(	O
6000-6300	JJ	O
rads	NNS	O
over	IN	O
7-8	JJ	O
weeks	NNS	O
)	)	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
received	VBD	O
adjuvant	JJ	O
chemotherapy	NN	O
consisting	NN	O
of	IN	O
doxorubicin	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
550	CD	O
mg/m2	NN	O
)	)	O
,	,	O
cyclophosphamide	RB	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
5500	CD	O
mg/m2	NN	O
)	)	O
,	,	O
and	CC	O
methotrexate	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
1000	CD	O
mg/kg	NN	O
)	)	O
.	.	O

Three-year	JJ	O
actuarial	JJ	O
disease-free	JJ	O
survival	NN	O
in	IN	O
the	DT	O
chemotherapy	NN	O
arm	NN	O
was	VBD	O
77	CD	O
%	NN	O
,	,	O
compared	VBN	O
to	TO	O
49	CD	O
%	NN	O
in	IN	O
the	DT	O
no-chemotherapy	JJ	O
arm	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.075	CD	O
)	)	O
.	.	O

Three-year	JJ	O
overall	JJ	O
actuarial	JJ	O
survivals	NNS	O
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
arms	NNS	O
,	,	O
however	RB	O
,	,	O
were	VBD	O
68	CD	O
%	NN	O
and	CC	O
58	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.38	CD	O
)	)	O
.	.	O

Considering	VBG	O
only	JJ	O
patients	NNS	O
with	IN	O
tumors	NNS	O
of	IN	O
the	DT	O
trunk	NN	O
(	(	O
22	CD	O
patients	NNS	O
)	)	O
,	,	O
3-year	JJ	O
actuarial	JJ	O
disease-free	JJ	O
survival	NN	O
in	IN	O
the	DT	O
chemotherapy	NN	O
arm	NN	O
was	VBD	O
92	CD	O
%	NN	O
,	,	O
compared	VBN	O
to	TO	O
47	CD	O
%	NN	O
in	IN	O
the	DT	O
no-chemotherapy	JJ	O
arm	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
.	.	O

Actuarial	JJ	O
3-year	JJ	O
overall	JJ	O
survival	NN	O
in	IN	O
the	DT	O
chemotherapy	NN	O
arm	NN	O
was	VBD	O
82	CD	O
%	NN	O
,	,	O
compared	VBN	O
to	TO	O
61	CD	O
%	NN	O
in	IN	O
the	DT	O
no-chemotherapy	JJ	O
arm	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.18	CD	O
)	)	O
.	.	O

An	DT	O
additional	JJ	O
26	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
in	IN	O
an	DT	O
identical	JJ	O
fashion	NN	O
,	,	O
but	CC	O
were	VBD	O
not	RB	O
part	NN	O
of	IN	O
the	DT	O
randomized	VBN	O
trial	NN	O
because	IN	O
of	IN	O
contraindications	NNS	O
to	TO	O
chemotherapy	VB	O
,	,	O
refusal	NN	O
to	TO	O
enter	VB	O
the	DT	O
randomized	JJ	O
trial	NN	O
,	,	O
or	CC	O
because	IN	O
they	PRP	O
were	VBD	O
treated	VBN	O
before	IN	O
1977	CD	O
in	IN	O
a	DT	O
trial	NN	O
in	IN	O
which	WDT	O
all	DT	O
patients	NNS	O
received	VBD	O
chemotherapy	NN	O
.	.	O

Considering	VBG	O
the	DT	O
entire	JJ	O
group	NN	O
of	IN	O
57	CD	SampleSize
patients	NNS	O
,	,	O
follow-up	JJ	O
ranged	VBD	O
from	IN	O
10	CD	O
to	TO	O
86	CD	O
months	NNS	O
(	(	O
median	JJ	O
,	,	O
35	CD	O
months	NNS	O
)	)	O
.	.	O

Local	JJ	O
control	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
46	CD	O
patients	NNS	O
(	(	O
81	CD	O
%	NN	O
)	)	O
;	:	O
3-year	JJ	O
actuarial	JJ	O
disease-free	NN	O
and	CC	O
overall	JJ	O
survivals	NNS	O
were	VBD	O
67	CD	O
%	NN	O
and	CC	O
77	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

A	DT	O
tendency	NN	O
toward	IN	O
improved	JJ	O
disease-free	JJ	O
survival	NN	O
was	VBD	O
apparent	JJ	O
among	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.018	CD	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
in	IN	O
overall	JJ	O
actuarial	JJ	O
survival	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.46	CD	O
)	)	O
.	.	O

The	DT	O
subgroup	NN	SampleSize
of	IN	SampleSize
patients	NNS	SampleSize
with	IN	SampleSize
sarcomas	NN	SampleSize
of	IN	SampleSize
the	DT	SampleSize
trunk	NN	SampleSize
(	(	SampleSize
39	CD	SampleSize
patients	NNS	SampleSize
)	)	SampleSize
demonstrated	VBD	O
the	DT	O
greatest	JJS	O
benefit	NN	O
from	IN	O
chemotherapy	NN	O
,	,	O
with	IN	O
regard	NN	O
to	TO	O
disease-free	JJ	O
survival	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
significant	JJ	O
toxicity	NN	O
associated	VBN	O
with	IN	O
chemotherapy	NN	O
was	VBD	O
doxorubicin-induced	JJ	O
cardiomyopathy	NN	O
,	,	O
which	WDT	O
resulted	VBD	O
in	IN	O
clinically	RB	O
apparent	JJ	O
congestive	JJ	O
heart	NN	O
failure	NN	O
in	IN	O
five	CD	O
patients	NNS	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
chemotherapy	NN	O
when	WRB	O
combined	VBN	O
with	IN	O
aggressive	JJ	O
local	JJ	O
measures	NNS	O
appears	VBZ	O
to	TO	O
improve	VB	O
disease-free	JJ	O
survival	NN	O
,	,	O
but	CC	O
additional	JJ	O
patients	NNS	O
and	CC	O
longer	JJR	O
follow-up	NN	O
are	VBP	O
necessary	JJ	O
to	TO	O
determine	VB	O
if	IN	O
improved	VBN	O
overall	JJ	O
survival	NN	O
will	MD	O
result	VB	O
.	.	O

Preoperative	JJ	O
beta-blocker	NN	O
usage	NN	O
:	:	O
is	VBZ	O
it	PRP	O
really	RB	O
worthy	JJ	O
of	IN	O
being	VBG	O
a	DT	O
quality	NN	O
indicator	NN	O
?	.	O
BACKGROUND	NNP	O
Since	IN	O
2007	CD	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
preoperative	JJ	O
?-blockers	NNS	O
has	VBZ	O
been	VBN	O
used	VBN	O
as	IN	O
a	DT	O
quality	NN	O
standard	NN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
have	VBP	O
called	VBN	O
into	IN	O
question	NN	O
of	IN	O
the	DT	O
benefit	NN	O
of	IN	O
empiric	JJ	O
preoperative	JJ	O
?-blocker	NN	O
use	NN	O
.	.	O

METHODS	NNP	O
Data	NNP	O
were	VBD	O
extracted	VBN	O
from	IN	O
our	PRP$	O
Society	NN	O
of	IN	O
Thoracic	NNP	O
Surgeons	NNP	O
certified	VBD	O
database	NN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
isolated	JJ	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
from	IN	O
2000	CD	O
to	TO	O
2008	CD	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
outcomes	NNS	O
for	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
preoperative	JJ	O
?-blockers	NNS	O
with	IN	O
those	DT	O
of	IN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

RESULTS	VB	O
The	DT	O
study	NN	O
group	NN	O
had	VBD	O
12,855	CD	O
patients	NNS	O
,	,	O
of	IN	O
whom	WP	O
7,967	CD	O
(	(	O
62.0	CD	O
%	NN	O
)	)	O
were	VBD	O
treated	VBN	O
preoperatively	RB	O
with	IN	O
?-blockers	NNS	O
.	.	O

Using	VBG	O
propensity	NN	O
matching	NN	O
,	,	O
we	PRP	O
selected	VBD	O
two	CD	O
matched	JJ	O
groups	NNS	O
of	IN	O
4,474	CD	O
patients	NNS	O
with	IN	O
preoperative	JJ	O
?-blocker	NN	O
use	NN	O
and	CC	O
4,474	CD	O
not	RB	O
using	VBG	O
preoperative	JJ	O
?-blockers	NNS	O
.	.	O

In	IN	O
the	DT	O
unmatched	JJ	O
cohort	NN	O
,	,	O
only	RB	O
deep	JJ	O
sternal	JJ	O
infection	NN	O
(	(	O
0.3	CD	O
%	NN	O
versus	IN	O
0.5	CD	O
%	NN	O
without	IN	O
?-blockers	NNS	O
;	:	O
p=0.032	NN	O
)	)	O
,	,	O
pneumonia	NN	O
(	(	O
1.9	CD	O
%	NN	O
versus	IN	O
2.4	CD	O
%	NN	O
without	IN	O
?-blockers	NNS	O
;	:	O
p=0.039	NN	O
)	)	O
,	,	O
and	CC	O
intraoperative	JJ	O
blood	NN	O
usage	NN	O
(	(	O
37.2	CD	O
%	NN	O
versus	IN	O
34.1	CD	O
%	NN	O
without	IN	O
?-blockers	NNS	O
;	:	O
p	VB	O
<	$	O
0.001	CD	O
)	)	O
reached	VBD	O
statistically	RB	O
significant	JJ	O
difference	NN	O
.	.	O

In	IN	O
the	DT	O
matched	JJ	O
groups	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
adverse	JJ	O
event	NN	O
rates	NNS	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
?-blockers	NNS	O
and	CC	O
those	DT	O
who	WP	O
were	VBD	O
not	RB	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
requiring	VBG	O
intraoperative	JJ	O
blood	NN	O
product	NN	O
use	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
among	IN	O
?-blocker-treated	JJ	O
patients	NNS	O
(	(	O
p=0.004	NN	O
)	)	O
.	.	O

Calculating	VBG	O
the	DT	O
adjusted	VBN	O
odds	NNS	O
ratios	NNS	O
showed	VBD	O
that	IN	O
in	IN	O
the	DT	O
matched	JJ	O
groups	NNS	O
,	,	O
the	DT	O
preoperative	JJ	O
use	NN	O
of	IN	O
?-blockers	NNS	O
was	VBD	O
not	RB	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
mortality	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
rational	NN	O
for	IN	O
preoperative	JJ	O
?-blockade	JJ	O
exists	NNS	O
.	.	O

However	RB	O
,	,	O
as	IN	O
with	IN	O
any	DT	O
medical	JJ	O
intervention	NN	O
,	,	O
its	PRP$	O
application	NN	O
should	MD	O
be	VB	O
tailored	VBN	O
to	TO	O
specific	JJ	O
clinical	JJ	O
scenarios	NNS	O
.	.	O

With	IN	O
no	DT	O
differences	NNS	O
in	IN	O
mortality	NN	O
or	CC	O
morbidity	NN	O
,	,	O
our	PRP$	O
findings	NNS	O
do	VBP	O
not	RB	O
support	VB	O
preoperative	JJ	O
?-blockade	NN	O
as	IN	O
a	DT	O
useful	JJ	O
quality	NN	O
indicator	NN	O
for	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
FemCap	NNP	O
,	,	O
a	DT	O
new	JJ	O
vaginal	JJ	O
barrier	NN	O
contraceptive	NN	O
,	,	O
and	CC	O
the	DT	O
Ortho	NNP	O
All-Flex	NNP	O
diaphragm	NN	O
.	.	O

The	DT	O
FemCap	NNP	O
Investigators	NNP	O
'	POS	O
Group	NNP	O
.	.	O

The	DT	O
FemCap	NNP	O
is	VBZ	O
a	DT	O
new	JJ	O
silicone	NN	O
rubber	NN	O
barrier	RBR	O
contraceptive	JJ	O
shaped	VBN	O
like	IN	O
a	DT	O
sailor	NN	O
's	POS	O
hat	NN	O
,	,	O
with	IN	O
a	DT	O
dome	NN	O
that	WDT	O
covers	VBZ	O
the	DT	O
cervix	NN	O
,	,	O
a	DT	O
rim	NN	O
that	WDT	O
fits	VBZ	O
into	IN	O
the	DT	O
fornices	NNS	O
,	,	O
and	CC	O
a	DT	O
brim	NN	O
that	WDT	O
conforms	VBZ	O
to	TO	O
the	DT	O
vaginal	JJ	O
walls	NNS	O
around	IN	O
the	DT	O
cervix	NN	O
.	.	O

It	PRP	O
was	VBD	O
designed	VBN	O
to	TO	O
result	VB	O
in	IN	O
fewer	JJR	O
dislodgments	NNS	O
and	CC	O
less	JJR	O
pressure	NN	O
on	IN	O
the	DT	O
urethra	NN	O
than	IN	O
the	DT	O
cervical	JJ	O
cap	NN	O
and	CC	O
diaphragm	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
to	TO	O
require	VB	O
less	JJR	O
clinician	JJ	O
time	NN	O
for	IN	O
fitting	VBG	O
.	.	O

This	DT	O
was	VBD	O
a	DT	O
phase	NN	O
II/III	NNP	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
open-label	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
of	IN	O
841	CD	SampleSize
women	NNS	Sex
at	IN	O
risk	NN	Condition
for	IN	Condition
pregnancy	NN	Condition
.	.	O

A	DT	O
subset	NN	O
of	IN	O
42	CD	SampleSize
women	NNS	SampleSize
at	IN	O
one	CD	O
site	NN	O
underwent	JJ	O
colposcopy	NN	Condition
.	.	O

Women	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
use	VB	O
the	DT	O
FemCap	NNP	O
or	CC	O
Ortho	NNP	O
All-Flex	NNP	O
contraceptive	NN	O
diaphragm	NN	O
,	,	O
both	DT	O
with	IN	O
2	CD	O
%	NN	O
nonoxynol-9	JJ	O
spermicide	NN	O
,	,	O
for	IN	O
28	CD	O
weeks	NNS	O
.	.	O

The	DT	O
objectives	NNS	O
were	VBD	O
to	TO	O
compare	VB	O
the	DT	O
two	CD	O
devices	NNS	O
with	IN	O
regard	NN	O
to	TO	O
their	PRP$	O
safety	NN	O
and	CC	O
acceptability	NN	O
and	CC	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
probability	NN	O
of	IN	O
pregnancy	NN	O
among	IN	O
FemCap	NNP	O
users	NNS	O
was	VBD	O
no	DT	O
worse	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
diaphragm	NN	O
(	(	O
meaning	VBG	O
not	RB	O
more	RBR	O
than	IN	O
6	CD	O
percentage	NN	O
points	NNS	O
higher	JJR	O
)	)	O
.	.	O

The	DT	O
6-month	JJ	O
Kaplan-Meier	NNP	O
cumulative	NN	O
unadjusted	VBD	O
typical	JJ	O
use	NN	O
pregnancy	NN	O
probabilities	NNS	O
were	VBD	O
13.5	CD	O
%	NN	O
among	IN	O
FemCap	NNP	O
users	NNS	O
and	CC	O
7.9	CD	O
%	NN	O
among	IN	O
diaphragm	JJ	O
users	NNS	O
.	.	O

The	DT	O
adjusted	JJ	O
risk	NN	O
of	IN	O
pregnancy	NN	O
among	IN	O
FemCap	NNP	O
users	NNS	O
was	VBD	O
1.96	CD	O
times	NNS	O
that	WDT	O
among	IN	O
diaphragm	JJ	O
users	NNS	O
,	,	O
with	IN	O
an	DT	O
upper	JJ	O
95	CD	O
%	NN	O
confidence	NN	O
limit	NN	O
of	IN	O
3.01	CD	O
.	.	O

Clinical	JJ	O
equivalence	NN	O
(	(	O
noninferiority	NN	O
)	)	O
of	IN	O
the	DT	O
FemCap	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
diaphragm	NN	O
,	,	O
as	IN	O
defined	VBN	O
in	IN	O
this	DT	O
study	NN	O
,	,	O
would	MD	O
mean	VB	O
that	IN	O
the	DT	O
true	JJ	O
risk	NN	O
of	IN	O
pregnancy	NN	O
among	IN	O
FemCap	NNP	O
users	NNS	O
was	VBD	O
no	DT	O
more	JJR	O
than	IN	O
1.73	CD	O
times	NNS	O
the	DT	O
pregnancy	NN	O
risk	NN	O
of	IN	O
diaphragm	NN	O
users	NNS	O
.	.	O

Because	IN	O
the	DT	O
observed	JJ	O
upper	JJ	O
95	CD	O
%	NN	O
confidence	NN	O
limit	NN	O
(	(	O
and	CC	O
even	RB	O
the	DT	O
point	NN	O
estimate	NN	O
)	)	O
exceeded	VBD	O
1.73	CD	O
,	,	O
the	DT	O
probability	NN	O
of	IN	O
pregnancy	NN	O
among	IN	O
FemCap	NNP	O
users	NNS	O
,	,	O
compared	VBN	O
with	IN	O
that	DT	O
among	IN	O
diaphragm	JJ	O
users	NNS	O
,	,	O
did	VBD	O
not	RB	O
meet	VB	O
the	DT	O
definition	NN	O
of	IN	O
clinical	JJ	O
equivalence	NN	O
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

The	DT	O
FemCap	NNP	O
was	VBD	O
believed	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
fewer	JJR	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
.	.	O

More	JJR	O
women	NNS	O
reported	VBD	O
problems	NNS	O
with	IN	O
the	DT	O
FemCap	NNP	O
with	IN	O
regard	NN	O
to	TO	O
insertion	NN	O
,	,	O
dislodgement	NN	O
,	,	O
and	CC	O
especially	RB	O
removal	JJ	O
,	,	O
although	IN	O
their	PRP$	O
general	JJ	O
assessments	NNS	O
were	VBD	O
positive	JJ	O
.	.	O

The	DT	O
two	CD	O
devices	NNS	O
were	VBD	O
comparable	JJ	O
with	IN	O
regard	NN	O
to	TO	O
safety	NN	O
and	CC	O
acceptability	NN	O
,	,	O
but	CC	O
a	DT	O
6-point	JJ	O
difference	NN	O
in	IN	O
the	DT	O
true	JJ	O
6-month	JJ	O
pregnancy	NN	O
probabilities	NNS	O
of	IN	O
the	DT	O
two	CD	O
devices	NNS	O
could	MD	O
not	RB	O
be	VB	O
ruled	VBN	O
out	RP	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
design	NN	O
modifications	NNS	O
can	MD	O
simplify	VB	O
insertion	NN	O
and	CC	O
removal	NN	O
.	.	O

Types	NNS	O
of	IN	O
parent	NN	Condition
verbal	JJ	O
responsiveness	NN	O
that	WDT	O
predict	VBP	O
language	NN	O
in	IN	O
young	JJ	Condition
children	NNS	Condition
with	IN	Condition
autism	NN	Condition
spectrum	NN	Condition
disorder	NN	Condition
.	.	Condition

PURPOSE	VB	O
This	DT	O
study	NN	O
examined	VBD	O
short-term	JJ	O
predictive	JJ	O
associations	NNS	O
between	IN	O
5	CD	O
different	JJ	O
types	NNS	O
of	IN	O
parent	NN	O
verbal	JJ	O
responsiveness	NN	O
and	CC	O
later	RB	O
spoken	JJ	O
vocabulary	NN	O
for	IN	O
32	CD	O
young	JJ	O
children	NNS	O
with	IN	O
a	DT	O
confirmed	JJ	O
diagnosis	NN	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
Parent	NNP	O
verbal	JJ	O
utterances	NNS	O
were	VBD	O
coded	VBN	O
from	IN	O
videotapes	NNS	O
of	IN	O
naturalistic	JJ	O
parent-child	JJ	O
play	NN	O
sessions	NNS	O
using	VBG	O
interval	JJ	O
and	CC	O
event-based	JJ	O
coding	NN	O
.	.	O

A	DT	O
vocabulary	JJ	O
difference	NN	O
score	NN	O
,	,	O
calculated	VBD	O
using	VBG	O
the	DT	O
MacArthur	NNP	O
Communicative	NNP	O
Development	NNP	O
Inventories	NNP	O
(	(	O
L.	NNP	O
Fenson	NNP	O
et	FW	O
al.	NN	O
,	,	O
1993	CD	O
)	)	O
,	,	O
was	VBD	O
used	VBN	O
as	IN	O
the	DT	O
outcome	NN	O
measure	NN	O
of	IN	O
spoken	JJ	O
vocabulary	JJ	O
6	CD	O
months	NNS	O
later	RB	O
.	.	O

RESULTS	VB	O
Parent	JJ	O
follow-in	JJ	O
comments	NNS	O
and	CC	O
follow-in	JJ	O
directives	NNS	O
predicted	VBD	O
spoken	JJ	O
vocabulary	JJ	O
after	IN	O
controlling	VBG	O
for	IN	O
child	JJ	O
engagement	NN	O
.	.	O

Parent	NNP	O
expansions	NNS	O
of	IN	O
child	NN	O
verbal	JJ	O
utterances	NNS	O
predicted	VBD	O
spoken	JJ	O
vocabulary	JJ	O
after	IN	O
controlling	VBG	O
for	IN	O
child	NN	O
talkativeness	NN	O
.	.	O

When	WRB	O
entered	VBN	O
together	RB	O
into	IN	O
a	DT	O
regression	NN	O
analysis	NN	O
,	,	O
metrics	NNS	O
that	IN	O
represented	VBD	O
(	(	O
a	DT	O
)	)	O
the	DT	O
number	NN	O
of	IN	O
parent	NN	O
utterances	NNS	O
following	VBG	O
into	IN	O
the	DT	O
child	NN	O
's	POS	O
focus	NN	O
of	IN	O
attention	NN	O
and	CC	O
(	(	O
b	NN	O
)	)	O
the	DT	O
number	NN	O
of	IN	O
parent	NN	O
utterances	NNS	O
responding	VBG	O
to	TO	O
child	VB	O
verbal	JJ	O
communication	NN	O
acts	NNS	O
both	DT	O
accounted	VBD	O
for	IN	O
unique	JJ	O
variance	NN	O
in	IN	O
predicting	VBG	O
change	NN	O
in	IN	O
spoken	JJ	O
vocabulary	NN	O
from	IN	O
Time	NNP	O
1	CD	O
to	TO	O
Time	NNP	O
2	CD	O
.	.	O

CONCLUSION	NNP	O
Parent	NNP	O
verbal	JJ	O
utterances	NNS	O
that	WDT	O
follow	VBP	O
into	IN	O
the	DT	O
child	NN	O
's	POS	O
current	JJ	O
focus	NN	O
of	IN	O
attention	NN	O
or	CC	O
respond	NN	O
to	TO	O
child	VB	O
verbal	JJ	O
communication	NN	O
acts	NNS	O
may	MD	O
facilitate	VB	O
the	DT	O
process	NN	O
of	IN	O
early	JJ	O
vocabulary	JJ	O
acquisition	NN	O
by	IN	O
mitigating	VBG	O
the	DT	O
need	NN	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
to	TO	O
use	VB	O
attention-following	JJ	O
as	IN	O
a	DT	O
word-learning	JJ	O
strategy	NN	O
.	.	O

Lack	NN	O
of	IN	O
effect	NN	O
of	IN	O
a	DT	O
low-fat	JJ	O
,	,	O
high-fiber	JJ	O
diet	NN	O
on	IN	O
the	DT	O
recurrence	NN	O
of	IN	O
colorectal	JJ	O
adenomas	NN	O
.	.	O

Polyp	NNP	O
Prevention	NNP	O
Trial	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
dietary	JJ	O
intervention	NN	O
can	MD	O
inhibit	VB	O
the	DT	O
development	NN	O
of	IN	O
recurrent	NN	O
colorectal	NN	O
adenomas	NN	O
,	,	O
which	WDT	O
are	VBP	O
precursors	NNS	O
of	IN	O
most	JJS	O
large-bowel	JJ	O
cancers	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	RB	O
assigned	VBD	O
2079	CD	SampleSize
men	NNS	Sex
and	CC	O
women	NNS	Sex
who	WP	O
were	VBD	O
35	CD	Age
years	NNS	O
of	IN	O
age	NN	O
or	CC	O
older	JJR	O
and	CC	O
who	WP	O
had	VBD	O
had	VBN	O
one	CD	O
or	CC	O
more	JJR	O
histologically	RB	O
confirmed	VBN	O
colorectal	JJ	Condition
adenomas	NN	Condition
removed	VBD	O
within	IN	O
six	CD	O
months	NNS	O
before	IN	O
randomization	NN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
:	:	O
an	DT	O
intervention	NN	O
group	NN	O
given	VBN	O
intensive	JJ	O
counseling	NN	O
and	CC	O
assigned	VBD	O
to	TO	O
follow	VB	O
a	DT	O
diet	NN	O
that	WDT	O
was	VBD	O
low	JJ	O
in	IN	O
fat	NN	O
(	(	O
20	CD	O
percent	NN	O
of	IN	O
total	JJ	O
calories	NNS	O
)	)	O
and	CC	O
high	JJ	O
in	IN	O
fiber	NN	O
(	(	O
18	CD	O
g	NN	O
of	IN	O
dietary	JJ	O
fiber	NN	O
per	IN	O
1000	CD	O
kcal	NN	O
)	)	O
and	CC	O
fruits	NNS	O
and	CC	O
vegetables	NNS	O
(	(	O
3.5	CD	O
servings	NNS	O
per	IN	O
1000	CD	O
kcal	NN	O
)	)	O
,	,	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
given	VBN	O
a	DT	O
standard	JJ	O
brochure	NN	O
on	IN	O
healthy	JJ	O
eating	NN	O
and	CC	O
assigned	VBD	O
to	TO	O
follow	VB	O
their	PRP$	O
usual	JJ	O
diet	NN	O
.	.	O

Subjects	NNS	O
entered	VBD	O
the	DT	O
study	NN	O
after	IN	O
undergoing	VBG	O
complete	JJ	O
colonoscopy	NN	O
and	CC	O
removal	NN	O
of	IN	O
adenomatous	JJ	O
polyps	NNS	O
;	:	O
they	PRP	O
remained	VBD	O
in	IN	O
the	DT	O
study	NN	O
for	IN	O
approximately	RB	O
four	CD	O
years	NNS	O
,	,	O
undergoing	VBG	O
colonoscopy	NN	O
one	CD	O
and	CC	O
four	CD	O
years	NNS	O
after	IN	O
randomization	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
1905	CD	SampleSize
of	IN	O
the	DT	O
randomized	JJ	O
subjects	NNS	O
(	(	O
91.6	CD	O
percent	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Of	IN	O
the	DT	O
958	CD	O
subjects	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
and	CC	O
the	DT	O
947	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
,	,	O
39.7	CD	O
percent	NN	O
and	CC	O
39.5	CD	O
percent	NN	O
,	,	O
respectively	RB	O
,	,	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
recurrent	NN	O
adenoma	NN	O
;	:	O
the	DT	O
unadjusted	JJ	O
risk	NN	O
ratio	NN	O
was	VBD	O
1.00	CD	O
(	(	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.90	CD	O
to	TO	O
1.12	CD	O
)	)	O
.	.	O

Among	IN	O
subjects	NNS	O
with	IN	O
recurrent	NN	O
adenomas	NN	O
,	,	O
the	DT	O
mean	NN	O
(	(	O
+/-SE	JJ	O
)	)	O
number	NN	O
of	IN	O
such	JJ	O
lesions	NNS	O
was	VBD	O
1.85+/-0.08	JJ	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
and	CC	O
1.84+/-0.07	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
recurrence	NN	O
of	IN	O
large	JJ	O
adenomas	NNS	O
(	(	O
with	IN	O
a	DT	O
maximal	JJ	O
diameter	NN	O
of	IN	O
at	IN	O
least	JJS	O
1	CD	O
cm	NN	O
)	)	O
and	CC	O
advanced	JJ	O
adenomas	NN	O
(	(	O
defined	VBN	O
as	IN	O
lesions	NNS	O
that	WDT	O
had	VBD	O
a	DT	O
maximal	JJ	O
diameter	NN	O
of	IN	O
at	IN	O
least	JJS	O
1	CD	O
cm	NN	O
or	CC	O
at	IN	O
least	JJS	O
25	CD	O
percent	NN	O
villous	JJ	O
elements	NNS	O
or	CC	O
evidence	NN	O
of	IN	O
high-grade	JJ	O
dysplasia	NN	O
,	,	O
including	VBG	O
carcinoma	NN	O
)	)	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Adopting	VBG	O
a	DT	O
diet	NN	O
that	WDT	O
is	VBZ	O
low	JJ	O
in	IN	O
fat	NN	O
and	CC	O
high	JJ	O
in	IN	O
fiber	NN	O
,	,	O
fruits	NNS	O
,	,	O
and	CC	O
vegetables	NNS	O
does	VBZ	O
not	RB	O
influence	VB	O
the	DT	O
risk	NN	O
of	IN	O
recurrence	NN	O
of	IN	O
colorectal	JJ	O
adenomas	NN	O
.	.	O

Use	NNP	O
of	IN	O
recombinant	JJ	O
human	JJ	O
granulocyte	NN	O
colony-stimulating	NN	O
factor	NN	O
to	TO	O
increase	VB	O
chemotherapy	JJ	O
dose-intensity	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
in	IN	O
very	RB	O
high-risk	JJ	O
childhood	NN	Age
acute	NN	Condition
lymphoblastic	JJ	Condition
leukemia	NN	Condition
.	.	O

PURPOSE	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
recombinant	JJ	O
human	JJ	O
granulocyte	NN	O
colony-stimulating	NN	O
factor	NN	O
(	(	O
[	JJ	O
G-CSF	NNP	O
]	NNP	O
lenogastrim	NN	O
)	)	O
can	MD	O
increase	VB	O
the	DT	O
chemotherapy	JJ	O
dose-intensity	NN	O
(	(	O
CDI	NNP	O
)	)	O
delivered	VBD	O
during	IN	O
consolidation	NN	O
chemotherapy	NN	O
of	IN	O
childhood	NN	Age
acute	NN	Condition
lymphoblastic	JJ	Condition
leukemia	NN	Condition
(	(	O
ALL	DT	Condition
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Sixty-seven	NNP	SampleSize
children	NNS	Age
with	IN	O
very	RB	O
high-risk	JJ	Condition
ALL	NNP	Condition
were	VBD	O
randomized	VBN	O
(	(	O
slow	JJ	O
early	JJ	O
response	NN	O
to	TO	O
therapy	VB	O
,	,	O
55	CD	O
patients	NNS	O
;	:	O
translocation	NN	O
t	NN	O
(	(	O
9	CD	O
;	:	O
22	CD	O
)	)	O
or	CC	O
t	NN	O
(	(	O
4	CD	O
;	:	O
11	CD	O
)	)	O
,	,	O
12	CD	O
patients	NNS	O
)	)	O
.	.	O

Consolidation	NNP	O
consisted	VBD	O
of	IN	O
six	CD	O
courses	NNS	O
of	IN	O
chemotherapy	NN	O
;	:	O
the	DT	O
first	JJ	O
,	,	O
third	JJ	O
,	,	O
and	CC	O
fifth	JJ	O
courses	NNS	O
were	VBD	O
a	DT	O
combination	NN	O
of	IN	O
high-dose	JJ	O
cytarabine	NN	O
,	,	O
etoposide	RB	O
,	,	O
and	CC	O
dexamethasone	NN	O
(	(	O
R3	NNP	O
)	)	O
,	,	O
whereas	VBD	O
the	DT	O
second	JJ	O
,	,	O
fourth	JJ	O
,	,	O
and	CC	O
sixth	JJ	O
courses	NNS	O
included	VBD	O
vincristine	NN	O
,	,	O
prednisone	NN	O
,	,	O
cyclophosphamide	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
and	CC	O
methotrexate	NN	O
(	(	O
COPADM	NNP	O
)	)	O
.	.	O

G-CSF	NNP	O
was	VBD	O
given	VBN	O
after	IN	O
each	DT	O
course	NN	O
,	,	O
and	CC	O
the	DT	O
next	JJ	O
scheduled	JJ	O
course	NN	O
was	VBD	O
started	VBN	O
as	RB	O
soon	RB	O
as	IN	O
neutrophil	JJ	O
count	NN	O
was	VBD	O
>	JJ	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
and	CC	O
platelet	NN	O
count	NN	O
was	VBD	O
>	JJ	O
100	CD	O
x	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
.	.	O

CDI	NNP	O
was	VBD	O
calculated	VBN	O
using	VBG	O
the	DT	O
interval	NN	O
from	IN	O
day	NN	O
1	CD	O
of	IN	O
the	DT	O
first	JJ	O
course	NN	O
to	TO	O
hematologic	VB	O
recovery	NN	O
after	IN	O
the	DT	O
fifth	JJ	O
course	NN	O
(	(	O
100	CD	O
%	NN	O
CDI	NNP	O
=	NNP	O
105-day	JJ	O
interval	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
CDI	NNP	O
was	VBD	O
significantly	RB	O
increased	VBN	O
in	IN	O
the	DT	O
G-CSF	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
non-G-CSF	JJ	O
group	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
105	CD	O
+/-	JJ	O
5	CD	O
%	NN	O
v	JJ	O
91	CD	O
+/-	JJ	O
4	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

This	DT	O
higher	JJR	O
intensity	NN	O
was	VBD	O
a	DT	O
result	NN	O
of	IN	O
shorter	JJR	O
post-R3	NN	O
intervals	NNS	O
in	IN	O
the	DT	O
G-CSF	NNP	O
group	NN	O
,	,	O
whereas	IN	O
the	DT	O
post-COPADM	JJ	O
intervals	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
reduced	VBN	O
.	.	O

After	IN	O
the	DT	O
R3	NNP	O
courses	NNS	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
days	NNS	O
with	IN	O
fever	NN	O
and	CC	O
intravenous	JJ	O
antibiotics	NNS	O
and	CC	O
duration	NN	O
of	IN	O
hospitalization	NN	O
were	VBD	O
significantly	RB	O
decreased	VBN	O
by	IN	O
G-CSF	NNP	O
,	,	O
whereas	JJ	O
reductions	NNS	O
observed	VBD	O
after	IN	O
COPADM	NNP	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Duration	NN	O
of	IN	O
granulocytopenia	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
G-CSF	NNP	O
group	NN	O
,	,	O
but	CC	O
thrombocytopenia	NN	O
was	VBD	O
prolonged	VBN	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
platelet	NN	O
transfusions	NNS	O
was	VBD	O
increased	VBN	O
.	.	O

Finally	RB	O
,	,	O
the	DT	O
3-year	JJ	O
probability	NN	O
of	IN	O
event-free	JJ	O
survival	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
G-CSF	NNP	O
can	MD	O
increase	VB	O
CDI	NNP	O
in	IN	O
high-risk	JJ	Condition
childhood	NN	Condition
ALL	NNP	Condition
.	.	O

Its	PRP$	O
effects	NNS	O
depend	VBP	O
on	IN	O
the	DT	O
chemotherapy	NN	O
regimen	NNS	O
given	VBN	O
before	IN	O
G-CSF	NNP	O
administration	NN	O
.	.	O

In	IN	O
our	PRP$	O
study	NN	O
,	,	O
a	DT	O
higher	JJR	O
CDI	NNP	O
did	VBD	O
not	RB	O
improve	VB	O
disease	NN	O
control	NN	O
.	.	O

A	DT	O
replication	NN	O
and	CC	O
extension	NN	O
of	IN	O
the	DT	O
PEERS	NNPS	O
intervention	NN	O
:	:	O
examining	JJ	O
effects	NNS	O
on	IN	O
social	JJ	O
skills	NNS	O
and	CC	O
social	JJ	O
anxiety	NN	O
in	IN	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
Program	NNP	O
for	IN	O
the	DT	O
Education	NNP	O
and	CC	O
Enrichment	NNP	O
of	IN	O
Relational	NNP	O
Skills	NNP	O
(	(	O
PEERS	NNS	O
:	:	O
Laugeson	NNP	O
et	CC	O
al	NN	O
.	.	O

in	IN	O
J	NNP	O
Autism	NNP	O
Dev	NNP	O
Disord	NNP	O
39	CD	O
(	(	O
4	CD	O
)	)	O
:596-606	NN	O
,	,	O
2009	CD	O
)	)	O
.	.	O

PEERS	CC	O
focuses	VBZ	O
on	IN	O
improving	VBG	O
friendship	JJ	O
quality	NN	O
and	CC	O
social	JJ	O
skills	NNS	O
among	IN	O
adolescents	NNS	Age
with	IN	Age
higher-functioning	JJ	Age
ASD	NNP	Age
.	.	Age

58	CD	O
participants	NNS	O
aged	VBN	O
11-16	JJ	O
years-old	JJ	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
an	DT	O
immediate	JJ	O
treatment	NN	O
or	CC	O
waitlist	NN	O
comparison	NN	O
group	NN	O
.	.	O

Results	NNP	O
revealed	VBD	O
,	,	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
waitlist	NN	O
group	NN	O
,	,	O
that	IN	O
the	DT	O
experimental	JJ	O
treatment	NN	O
group	NN	O
significantly	RB	O
improved	VBN	O
their	PRP$	O
knowledge	NN	O
of	IN	O
PEERS	NNP	O
concepts	NNS	O
and	CC	O
friendship	NN	O
skills	NNS	O
,	,	O
increased	VBN	O
in	IN	O
their	PRP$	O
amount	NN	O
of	IN	O
get-togethers	NNS	O
,	,	O
and	CC	O
decreased	VBN	O
in	IN	O
their	PRP$	O
levels	NNS	O
of	IN	O
social	JJ	O
anxiety	NN	O
,	,	O
core	NN	O
autistic	NN	O
symptoms	NNS	O
,	,	O
and	CC	O
problem	NN	O
behaviors	NNS	O
from	IN	O
pre-to	JJ	O
post-PEERS	NNS	O
.	.	O

This	DT	O
study	NN	O
provides	VBZ	O
the	DT	O
first	JJ	O
independent	JJ	O
replication	NN	O
and	CC	O
extension	NN	O
of	IN	O
the	DT	O
empirically-supported	JJ	O
PEERS	NNP	O
social	JJ	O
skills	NNS	O
intervention	NN	O
for	IN	O
adolescents	NNS	Age
with	IN	Age
ASD	NNP	Age
.	.	Age

Arterial	NNP	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
and	CC	O
venous	JJ	O
thrombosis	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
population-based	JJ	O
,	,	O
prospective	JJ	O
study	NN	O
(	(	O
the	DT	O
HUNT	NNP	O
2	CD	O
)	)	O
.	.	O

BACKGROUND	NNP	O
An	DT	O
explanation	NN	O
for	IN	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
stroke	NN	O
in	IN	O
patients	NNS	O
with	IN	O
venous	JJ	O
thrombosis	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
risk	NN	O
factors	NNS	O
for	IN	O
arterial	JJ	O
cardiovascular	JJ	O
disease	NN	O
also	RB	O
increase	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
venous	JJ	O
thrombosis	NN	O
.	.	O

DESIGN	NNP	O
AND	CC	O
METHODS	NNP	O
Cases	NNP	O
who	WP	O
had	VBD	O
a	DT	O
first	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
n=515	JJ	O
)	)	O
and	CC	O
matched	VBN	O
controls	NNS	O
(	(	O
n=1,505	NN	O
)	)	O
were	VBD	O
identified	VBN	O
from	IN	O
a	DT	O
population-based	JJ	O
,	,	O
nested	JJ	O
,	,	O
case-cohort	JJ	O
study	NN	O
(	(	O
the	DT	O
HUNT	NNP	O
2	CD	O
study	NN	O
)	)	O
comprising	VBG	O
71	CD	O
%	NN	O
(	(	O
n=66,140	JJ	O
)	)	O
of	IN	O
the	DT	O
adult	NN	O
residents	NNS	O
of	IN	O
Nord-Tr?ndelag	NNP	O
County	NNP	O
in	IN	O
Norway	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
age-	JJ	O
and	CC	O
sex-adjusted	JJ	O
odds	NNS	O
ratio	NN	O
of	IN	O
venous	JJ	O
thrombosis	NN	O
for	IN	O
subjects	NNS	O
with	IN	O
concentrations	NNS	O
of	IN	O
C-reactive	JJ	O
protein	NN	O
in	IN	O
the	DT	O
highest	JJS	O
quintile	NN	O
was	VBD	O
1.6	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
1.2-2.2	JJ	O
)	)	O
compared	VBN	O
to	TO	O
subjects	NNS	O
with	IN	O
C-reactive	JJ	O
protein	NN	O
in	IN	O
the	DT	O
lowest	JJS	O
quintile	NN	O
.	.	O

This	DT	O
association	NN	O
was	VBD	O
strongest	VBN	O
in	IN	O
subjects	NNS	O
who	WP	O
experienced	VBD	O
venous	JJ	O
thrombosis	NN	O
within	IN	O
a	DT	O
year	NN	O
after	IN	O
blood	NN	O
sampling	VBG	O
with	IN	O
a	DT	O
three-fold	JJ	O
increased	JJ	O
risk	NN	O
of	IN	O
participants	NNS	O
in	IN	O
the	DT	O
highest	JJS	O
versus	NN	O
the	DT	O
lowest	JJS	O
quintile	NN	O
.	.	O

Having	VBG	O
first	JJ	O
degree	JJ	O
relatives	NNS	O
who	WP	O
had	VBD	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
before	IN	O
the	DT	O
age	NN	O
of	IN	O
60	CD	O
years	NNS	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
venous	JJ	O
thrombosis	NN	O
compared	VBN	O
to	TO	O
not	RB	O
having	VBG	O
a	DT	O
positive	JJ	O
family	NN	O
history	NN	O
[	NNP	O
odds	VBZ	O
ratio	NN	O
1.3	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
1.1-1.6	JJ	O
)	)	O
]	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
the	DT	O
highest	JJS	O
quintile	NN	O
had	VBD	O
half	PDT	O
the	DT	O
risk	NN	O
of	IN	O
developing	VBG	O
venous	JJ	O
thrombosis	NN	O
compared	VBN	O
to	TO	O
subjects	NNS	O
whose	WP$	O
blood	NN	O
pressure	NN	O
was	VBD	O
in	IN	O
the	DT	O
lowest	JJS	O
quintile	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
associations	NNS	O
between	IN	O
the	DT	O
risk	NN	O
of	IN	O
venous	JJ	O
thrombosis	NN	O
and	CC	O
total	JJ	O
cholesterol	NN	O
,	,	O
low	JJ	O
density	NN	O
lipoprotein-cholesterol	NN	O
,	,	O
high	JJ	O
density	NN	O
lipoprotein-cholesterol	NN	O
,	,	O
triglycerides	NNS	O
,	,	O
glucose	NN	O
or	CC	O
smoking	NN	O
.	.	O

We	PRP	O
confirmed	VBD	O
the	DT	O
positive	JJ	O
association	NN	O
between	IN	O
obesity	NN	O
and	CC	O
venous	JJ	O
thrombosis	NN	O
.	.	O

CONCLUSIONS	NNP	O
C-reactive	JJ	O
protein	NN	O
and	CC	O
a	DT	O
family	NN	O
history	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
subsequent	JJ	O
venous	JJ	O
thrombosis	NN	O
.	.	O

Blood	NNP	O
pressure	NN	O
was	VBD	O
inversely	RB	O
correlated	VBN	O
to	TO	O
venous	JJ	O
thrombosis	NN	O
.	.	O

These	DT	O
findings	NNS	O
should	MD	O
be	VB	O
confirmed	VBN	O
by	IN	O
further	JJ	O
investigations	NNS	O
.	.	O

Therapeutic	JJ	O
effects	NNS	O
of	IN	O
combined	JJ	O
treatment	NN	O
using	VBG	O
tetracycline-immobilized	JJ	O
collagen	NN	O
film	NN	O
and	CC	O
root	NN	O
planing	NN	O
in	IN	O
periodontal	JJ	O
furcation	NN	O
pockets	NNS	O
.	.	O

46	CD	O
upper	JJ	O
and	CC	O
lower	JJR	O
molars	NNS	O
with	IN	O
furcation	NN	O
grade	NN	O
II	NNP	O
involvement	NN	O
were	VBD	O
selected	VBN	O
from	IN	O
16	CD	O
patients	NNS	O
with	IN	O
periodontal	JJ	O
disease	NN	O
.	.	O

The	DT	O
teeth	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
following	VBG	O
groups	NNS	O
according	VBG	O
to	TO	O
treatment	NN	O
;	:	O
(	(	O
1	CD	O
)	)	O
4	CD	O
consecutive	JJ	O
administrations	NNS	O
of	IN	O
tetracycline-immobilized	JJ	O
cross-linked	JJ	O
collagen	NN	O
film	NN	O
(	(	O
TC	NNP	O
film	NN	O
)	)	O
at	IN	O
intervals	NNS	O
of	IN	O
1	CD	O
week	NN	O
(	(	O
TC	NNP	O
group	NN	O
)	)	O
;	:	O
(	(	O
2	CD	O
)	)	O
1	CD	O
root	NN	O
planing	VBG	O
treatment	NN	O
(	(	O
RP	NNP	O
group	NN	O
)	)	O
;	:	O
(	(	O
3	CD	O
)	)	O
combination	NN	O
treatment	NN	O
(	(	O
TC	NNP	O
+	NNP	O
RP	NNP	O
group	NN	O
)	)	O
;	:	O
(	(	O
4	CD	O
)	)	O
no	DT	O
treatment	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
.	.	O

The	DT	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
each	DT	O
treatment	NN	O
were	VBD	O
compared	VBN	O
both	DT	O
clinically	RB	O
and	CC	O
microbiologically	RB	O
.	.	O

Records	NNS	O
of	IN	O
plaque	NN	O
index	NN	O
,	,	O
gingival	NN	O
index	NN	O
,	,	O
bleeding	VBG	O
on	IN	O
probing	VBG	O
,	,	O
probing	VBG	O
depth	NN	O
,	,	O
probing	VBG	O
attachment	JJ	O
level	NN	O
and	CC	O
microscopic	NN	O
counts	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
0	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
marked	JJ	O
decreases	NNS	O
in	IN	O
probing	VBG	O
depth	NN	O
and	CC	O
density	NN	O
of	IN	O
micro-organisms	NN	O
in	IN	O
both	CC	O
the	DT	O
RP	NNP	O
and	CC	O
TC	NNP	O
+	NNP	O
RP	NNP	O
groups	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
TC	NNP	O
+	NNP	O
RP	NNP	O
group	NN	O
was	VBD	O
characterized	VBN	O
by	IN	O
a	DT	O
decreased	JJ	O
rate	NN	O
of	IN	O
bleeding	VBG	O
on	IN	O
pocket	NN	O
probing	NN	O
and	CC	O
an	DT	O
increased	JJ	O
probing	NN	O
attachment	NN	O
gain	NN	O
.	.	O

The	DT	O
above	JJ	O
findings	NNS	O
demonstrated	VBD	O
that	IN	O
root	NN	O
planning	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
furcation	NN	O
involvement	NN	O
and	CC	O
that	IN	O
the	DT	O
effects	NNS	O
are	VBP	O
enhanced	VBN	O
by	IN	O
the	DT	O
local	JJ	O
administration	NN	O
of	IN	O
TC	NNP	O
films	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
varicella-zoster	JJ	O
virus	NN	O
infection	NN	O
in	IN	O
severely	RB	O
immunocompromised	JJ	O
patients	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
comparison	NN	O
of	IN	O
acyclovir	NN	O
and	CC	O
vidarabine	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
,	,	O
we	PRP	O
compared	VBN	O
intravenous	JJ	O
acyclovir	NNS	O
and	CC	O
vidarabine	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
varicella-zoster	JJ	O
virus	NN	O
infection	NN	O
in	IN	O
severely	RB	O
immunocompromised	JJ	O
patients	NNS	O
who	WP	O
presented	VBD	O
within	IN	O
72	CD	O
hours	NNS	O
of	IN	O
onset	NN	O
of	IN	O
the	DT	O
infection	NN	O
.	.	O

Eleven	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Cutaneous	JJ	O
dissemination	NN	O
of	IN	O
infection	NN	O
occurred	VBD	O
in	IN	O
none	NN	O
of	IN	O
the	DT	O
10	CD	O
acyclovir	NN	O
recipients	NNS	O
and	CC	O
in	IN	O
5	CD	O
of	IN	O
the	DT	O
10	CD	O
vidarabine	NN	O
recipients	NNS	O
who	WP	O
had	VBD	O
presented	VBN	O
with	IN	O
localized	JJ	O
dermatomal	JJ	O
disease	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.016	CD	O
)	)	O
.	.	O

As	IN	O
compared	VBN	O
with	IN	O
vidarabine	NN	O
,	,	O
acyclovir	JJ	O
treatment	NN	O
shortened	VBD	O
the	DT	O
median	JJ	O
periods	NNS	O
during	IN	O
which	WDT	O
cultures	NNS	O
were	VBD	O
positive	JJ	O
for	IN	O
the	DT	O
virus	NN	O
(	(	O
four	CD	O
vs.	FW	O
seven	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
and	CC	O
new	JJ	O
lesions	NNS	O
formed	VBN	O
(	(	O
three	CD	O
vs.	IN	O
six	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

Acyclovir	NNP	O
also	RB	O
shortened	VBD	O
the	DT	O
median	JJ	O
interval	NN	O
until	IN	O
the	DT	O
first	JJ	O
decrease	NN	O
in	IN	O
pain	NN	O
(	(	O
4	CD	O
vs.	FW	O
7	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
,	,	O
the	DT	O
pustulation	NN	O
of	IN	O
all	DT	O
lesions	NNS	O
(	(	O
4	CD	O
vs.	FW	O
7	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0004	CD	O
)	)	O
,	,	O
the	DT	O
crusting	NN	O
of	IN	O
all	DT	O
lesions	NNS	O
(	(	O
7	CD	O
vs.	FW	O
17	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
complete	JJ	O
healing	NN	O
of	IN	O
lesions	NNS	O
(	(	O
17	CD	O
vs.	FW	O
28	CD	O
days	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
acyclovir	NN	O
reduced	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
fever	NN	O
(	(	O
two	CD	O
vs.	FW	O
eight	CD	O
patients	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.015	CD	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
acyclovir	NN	O
is	VBZ	O
better	JJR	O
than	IN	O
vidarabine	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
varicella-zoster	JJ	O
infection	NN	O
in	IN	O
immunocompromised	JJ	O
patients	NNS	O
.	.	O

The	DT	O
ScanBrit	NNP	O
randomised	VBD	O
,	,	O
controlled	VBD	O
,	,	O
single-blind	JJ	O
study	NN	O
of	IN	O
a	DT	O
gluten-	JJ	O
and	CC	O
casein-free	JJ	O
dietary	JJ	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

There	EX	O
is	VBZ	O
increasing	VBG	O
interest	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
gluten-	JJ	O
and	CC	O
casein-free	JJ	O
diets	NNS	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASDs	NNP	O
)	)	O
.	.	O

We	PRP	O
report	VBP	O
results	NNS	O
from	IN	O
a	DT	O
two-stage	NN	O
,	,	O
24-month	JJ	O
,	,	O
randomised	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
incorporating	VBG	O
an	DT	O
adaptive	JJ	O
'catch-up	NN	O
'	POS	O
design	NN	O
and	CC	O
interim	JJ	O
analysis	NN	O
.	.	O

Stage	NN	O
1	CD	O
of	IN	O
the	DT	O
trial	NN	O
saw	VBD	O
72	CD	O
Danish	JJ	O
children	NNS	O
(	(	O
aged	VBN	Age
4	CD	Age
years	NNS	Age
to	TO	Age
10	CD	Age
years	NNS	Age
11	CD	Age
months	NNS	Age
)	)	O
assigned	VBD	O
to	TO	O
diet	VB	O
(	(	O
A	DT	O
)	)	O
or	CC	O
non-diet	JJ	O
(	(	O
B	NNP	O
)	)	O
groups	NNS	O
by	IN	O
stratified	JJ	O
randomisation	NN	O
.	.	O

Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule	NNP	O
(	(	O
ADOS	NNP	O
)	)	O
and	CC	O
the	DT	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
GARS	NNP	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
core	NN	O
autism	NN	O
behaviours	NNS	O
,	,	O
Vineland	NNP	O
Adaptive	NNP	O
Behaviour	NNP	O
Scales	NNP	O
(	(	O
VABS	NNP	O
)	)	O
to	TO	O
ascertain	VB	O
developmental	JJ	O
level	NN	O
,	,	O
and	CC	O
Attention-Deficit	NNP	O
Hyperactivity	NNP	O
Disorder	NNP	O
-	:	O
IV	NNP	O
scale	NN	O
(	(	O
ADHD-IV	NNP	O
)	)	O
to	TO	O
determine	VB	O
inattention	NN	O
and	CC	O
hyperactivity	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
tested	VBN	O
at	IN	O
baseline	NN	O
,	,	O
8	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
.	.	O

Based	VBN	O
on	IN	O
per	IN	O
protocol	NN	O
repeated	VBN	O
measures	NNS	O
analysis	NN	O
,	,	O
data	NNS	O
for	IN	O
26	CD	O
diet	JJ	O
children	NNS	O
and	CC	O
29	CD	O
controls	NNS	O
were	VBD	O
available	JJ	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

At	IN	O
this	DT	O
point	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
to	TO	O
mean	VB	O
diet	JJ	O
group	NN	O
scores	NNS	O
(	(	O
time*treatment	JJ	O
interaction	NN	O
)	)	O
on	IN	O
sub-domains	NNS	O
of	IN	O
ADOS	NNP	O
,	,	O
GARS	NNP	O
and	CC	O
ADHD-IV	NNP	O
measures	NNS	O
.	.	O

Surpassing	VBG	O
of	IN	O
predefined	JJ	O
statistical	JJ	O
thresholds	NNS	O
as	IN	O
evidence	NN	O
of	IN	O
improvement	NN	O
in	IN	O
group	NN	O
A	NNP	O
at	IN	O
12	CD	O
months	NNS	O
sanctioned	VBD	O
the	DT	O
re-assignment	NN	O
of	IN	O
group	NN	O
B	NNP	O
participants	NNS	O
to	TO	O
active	JJ	O
dietary	JJ	O
treatment	NN	O
.	.	O

Stage	NN	O
2	CD	O
data	NNS	O
for	IN	O
18	CD	O
group	NN	O
A	NNP	O
and	CC	O
17	CD	O
group	NN	O
B	NNP	O
participants	NNS	O
were	VBD	O
available	JJ	O
at	IN	O
24	CD	O
months	NNS	O
.	.	O

Multiple	NNP	O
scenario	NN	O
analysis	NN	O
based	VBN	O
on	IN	O
inter-	JJ	O
and	CC	O
intra-group	JJ	O
comparisons	NNS	O
showed	VBD	O
some	DT	O
evidence	NN	O
of	IN	O
sustained	JJ	O
clinical	JJ	O
group	NN	O
improvements	NNS	O
although	IN	O
possibly	RB	O
indicative	JJ	O
of	IN	O
a	DT	O
plateau	NN	O
effect	NN	O
for	IN	O
intervention	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
dietary	JJ	O
intervention	NN	O
may	MD	O
positively	RB	O
affect	VB	O
developmental	JJ	O
outcome	NN	O
for	IN	O
some	DT	O
children	NNS	O
diagnosed	VBN	O
with	IN	O
ASD	NNP	O
.	.	O

In	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
placebo	NN	O
condition	NN	O
to	TO	O
the	DT	O
current	JJ	O
investigation	NN	O
,	,	O
we	PRP	O
are	VBP	O
,	,	O
however	RB	O
,	,	O
unable	JJ	O
to	TO	O
disqualify	VB	O
potential	JJ	O
effects	NNS	O
derived	VBN	O
from	IN	O
intervention	NN	O
outside	IN	O
of	IN	O
dietary	JJ	O
changes	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
ascertain	VB	O
potential	JJ	O
best-	NN	O
and	CC	O
non-responders	NNS	O
to	TO	O
intervention	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
registered	VBN	O
with	IN	O
ClincialTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00614198	NNP	O
.	.	O

Placebo-controlled	JJ	O
acute	JJ	O
dosage	NN	O
naltrexone	NN	O
study	NN	O
in	IN	O
young	JJ	Condition
autistic	JJ	Condition
children	NNS	Condition
.	.	Condition

In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
trial	NN	O
23	CD	O
autistic	JJ	O
children	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
single	JJ	O
40-mg	JJ	O
dose	NN	O
of	IN	O
the	DT	O
opiate	JJ	O
antagonist	NN	O
naltrexone	NN	O
.	.	O

Drug	JJ	O
effects	NNS	O
were	VBD	O
monitored	VBN	O
by	IN	O
detailed	JJ	O
playroom	NN	O
observations	NNS	O
,	,	O
actometers	NNS	O
,	,	O
and	CC	O
parents	NNS	O
'	POS	O
checklist	NN	O
ratings	NNS	O
(	(	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
,	,	O
social	JJ	O
items	NNS	O
and	CC	O
target	NN	O
behaviors	NNS	O
)	)	O
.	.	O

Naltrexone	CD	O
treatment	NN	O
failed	VBD	O
to	TO	O
produce	VB	O
significant	JJ	O
changes	NNS	O
in	IN	O
social	JJ	O
behavior	NN	O
,	,	O
but	CC	O
it	PRP	O
did	VBD	O
reduce	VB	O
irritability	NN	O
and	CC	O
target	NN	O
scores	NNS	O
on	IN	O
behavior	JJ	O
checklists	NNS	O
.	.	O

The	DT	O
playroom	NN	O
data	NNS	O
indicated	VBD	O
that	IN	O
naltrexone	NN	O
significantly	RB	O
affected	VBD	O
indices	NNS	O
of	IN	O
activity	NN	O
and	CC	O
attention	NN	O
.	.	O

Placebo-controlled	JJ	O
pilot	NN	O
trial	NN	O
of	IN	O
mecamylamine	NN	O
for	IN	O
treatment	NN	O
of	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorders	NNS	Condition
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
possible	JJ	O
benefits	NNS	O
of	IN	O
a	DT	O
nicotinic	JJ	O
acetylcholine	NN	O
receptor	NN	O
(	(	O
nAChR	JJ	O
)	)	O
agent	NN	O
for	IN	O
autistic	JJ	O
symptoms	NNS	O
based	VBN	O
on	IN	O
postmortem	NN	O
observation	NN	O
of	IN	O
nAChR	JJ	O
abnormalities	NNS	O
(	(	O
deficient	JJ	O
?4?2	NN	O
nAChRs	NN	O
,	,	O
excess	JJ	O
?7	NNP	O
nAChRs	NN	O
)	)	O
in	IN	O
brains	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
autism	NN	O
.	.	O

METHOD	NNP	O
Mecamylamine	NNP	O
,	,	O
because	IN	O
of	IN	O
its	PRP$	O
safety	NN	O
record	NN	O
in	IN	O
children	NNS	O
with	IN	O
other	JJ	O
disorders	NNS	O
,	,	O
was	VBD	O
chosen	VBN	O
for	IN	O
this	DT	O
first	JJ	O
exploration	NN	O
.	.	O

Twenty	NNP	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
age	NN	O
4-12	CD	O
years	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
for	IN	O
14	CD	O
weeks	NNS	O
to	TO	O
placebo	VB	O
(	(	O
n=8	NN	O
)	)	O
or	CC	O
mecamylamine	NN	O
(	(	O
n=12	JJ	O
)	)	O
in	IN	O
ascending	VBG	O
fixed	JJ	O
doses	NNS	O
:	:	O
0.5	CD	O
mg/day	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
,	,	O
2.5	CD	O
mg	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
,	,	O
then	RB	O
5	CD	O
mg/day	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Improvement	NNP	O
was	VBD	O
rated	VBN	O
by	IN	O
a	DT	O
blinded	JJ	O
independent	JJ	O
evaluator	NN	O
.	.	O

Because	IN	O
of	IN	O
small	JJ	O
sample	NN	O
,	,	O
data	NNS	O
analysis	NN	O
was	VBD	O
descriptive	JJ	O
.	.	O

RESULTS	NNP	O
Eighteen	JJ	O
participants	NNS	O
(	(	O
10	CD	O
mecamylamine	NN	O
,	,	O
8	CD	O
placebo	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

All	DT	O
doses	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
;	:	O
the	DT	O
only	JJ	O
side	NN	O
effect	NN	O
of	IN	O
note	NN	O
was	VBD	O
constipation	NN	O
(	(	O
50	CD	O
%	NN	O
compared	VBN	O
with	IN	O
25	CD	O
%	NN	O
of	IN	O
placebo	NN	O
group	NN	O
)	)	O
.	.	O

Three	CD	O
children	NNS	O
had	VBD	O
clinically	RB	O
nonsignificant	JJ	O
electrocardiographic	JJ	O
QT	NNP	O
prolongation	NN	O
.	.	O

Both	DT	O
groups	NNS	O
showed	VBD	O
modest	JJ	O
to	TO	O
moderate	VB	O
improvement	NN	O
,	,	O
but	CC	O
differences	NNS	O
between	IN	O
groups	NNS	O
were	VBD	O
negligible	JJ	O
.	.	O

On	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
,	,	O
the	DT	O
Ohio	NNP	O
Autism	NNP	O
Clinical	NNP	O
Impressions	NNP	O
Scale	NNP	O
,	,	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
showed	VBD	O
improvement	NN	O
at	IN	O
some	DT	O
point	NN	O
(	(	O
but	CC	O
only	RB	O
40	CD	O
%	NN	O
sustained	VBD	O
it	PRP	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
62	CD	O
%	NN	O
on	IN	O
placebo	NN	O
.	.	O

Of	IN	O
the	DT	O
four	CD	O
in	IN	O
active	JJ	O
treatment	NN	O
that	WDT	O
sustained	VBD	O
improvement	NN	O
,	,	O
three	CD	O
had	VBD	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
0.13-0.15	JJ	O
mg/kg/day	NN	O
,	,	O
while	IN	O
those	DT	O
who	WP	O
regressed	VBD	O
had	VBD	O
doses	NNS	O
?0.18	JJ	O
mg/kg/day	NN	O
.	.	O

Graphed	VBN	O
means	NNS	O
suggested	VBD	O
better	RBR	O
outcome	NN	O
with	IN	O
lower	JJR	O
mg/kg	NN	O
and	CC	O
longer	JJR	O
medication	NN	O
duration	NN	O
.	.	O

Four	CD	O
parents	NNS	O
spontaneously	RB	O
reported	VBD	O
reduced	JJ	O
hyperactivity	NN	O
and	CC	O
irritability	NN	O
and	CC	O
better	JJR	O
verbalization	NN	O
and	CC	O
continued	JJ	O
mecamylamine	NN	O
at	IN	O
their	PRP$	O
own	JJ	O
expense	NN	O
.	.	O

CONCLUSION	NNP	O
Mecamylamine	NNP	O
appeared	VBD	O
to	TO	O
be	VB	O
safe	JJ	O
,	,	O
but	CC	O
not	RB	O
very	RB	O
effective	JJ	O
in	IN	O
autism	NN	O
.	.	O

The	DT	O
suggestion	NN	O
of	IN	O
better	JJR	O
results	NNS	O
at	IN	O
lower	JJR	O
doses	NNS	O
and	CC	O
longer	JJR	O
exposure	NN	O
warrants	NNS	O
consideration	NN	O
for	IN	O
future	JJ	O
trials	NNS	O
.	.	O

The	DT	O
next	JJ	O
step	NN	O
would	MD	O
be	VB	O
exploration	NN	O
of	IN	O
a	DT	O
more	RBR	O
specific	JJ	O
?4?2	NNP	O
nAChR	JJ	O
agonist	NN	O
,	,	O
such	JJ	O
as	IN	O
varenicline	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
placebo	NN	O
awareness	NN	O
on	IN	O
stimulant	JJ	O
drug	NN	O
response	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
trial	NN	O
.	.	O

RATIONALE	NNP	O
Critics	NNPS	O
have	VBP	O
called	VBN	O
into	IN	O
question	NN	O
findings	NNS	O
from	IN	O
double-blind	JJ	O
placebo-controlled	JJ	O
studies	NNS	O
because	IN	O
subjects	NNS	O
are	VBP	O
given	VBN	O
drug	NN	O
administration	NN	O
instructions	NNS	O
informing	VBG	O
them	PRP	O
of	IN	O
a	DT	O
placebo	JJ	O
condition	NN	O
.	.	O

The	DT	O
assertion	NN	O
that	IN	O
these	DT	O
drug	NN	O
administration	NN	O
instructions	NNS	O
bias	VBP	O
estimates	NNS	O
of	IN	O
effectiveness	NN	O
has	VBZ	O
undergone	RB	O
surprisingly	RB	O
little	JJ	O
empirical	JJ	O
investigation	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
drug	NN	O
administration	NN	O
instructions	NNS	O
informing	VBG	O
subjects	NNS	O
of	IN	O
a	DT	O
placebo	JJ	O
condition	NN	O
affect	VBP	O
the	DT	O
drug	NN	O
response	NN	O
and	CC	O
affect	VB	O
the	DT	O
saliva	JJ	O
concentration	NN	O
of	IN	O
the	DT	O
stimulant	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
assessed	VBD	O
caffeine	JJ	Condition
responses	NNS	Condition
and	CC	Condition
levels	NNS	Condition
of	IN	Condition
saliva	JJ	Condition
concentration	NN	Condition
of	IN	Condition
caffeine	NN	Condition
in	IN	O
52	CD	O
subjects	NNS	O
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
two	CD	O
drug	NN	O
administration	NN	O
instructions	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
placebo-informed	JJ	O
instructions	NNS	O
(	(	O
i.e.	NN	O
,	,	O
individuals	NNS	O
informed	VBD	O
of	IN	O
the	DT	O
placebo	NN	O
)	)	O
analogous	JJ	O
to	TO	O
those	DT	O
used	VBN	O
in	IN	O
double-blind	JJ	O
studies	NNS	O
and	CC	O
(	(	O
b	NN	O
)	)	O
placebo-uninformed	JJ	O
instructions	NNS	O
(	(	O
i.e.	NN	O
,	,	O
individuals	NNS	O
informed	VBD	O
they	PRP	O
are	VBP	O
taking	VBG	O
an	DT	O
active	JJ	O
stimulant	NN	O
)	)	O
.	.	O

RESULTS	VBN	O
On	IN	O
most	JJS	O
measures	NNS	O
(	(	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
hand	NN	O
steadiness	NN	O
,	,	O
reaction	NN	O
time	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
tension	NN	O
)	)	O
,	,	O
drug	NN	O
administration	NN	O
instructions	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
influence	VB	O
caffeine	JJ	O
response	NN	O
.	.	O

Instructions	NNP	O
also	RB	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
saliva	JJ	O
concentration	NN	O
of	IN	O
caffeine	NN	O
.	.	O

However	RB	O
,	,	O
only	RB	O
individuals	NNS	O
who	WP	O
were	VBD	O
uninformed	VBN	O
of	IN	O
the	DT	O
placebo	NN	O
condition	NN	O
showed	VBD	O
significant	JJ	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
vigor	NN	O
increases	NNS	O
with	IN	O
125	CD	O
mg	NNS	O
caffeine	NN	O
,	,	O
and	CC	O
significant	JJ	O
hand	NN	O
steadiness	NN	O
impairment	NN	O
and	CC	O
vigor	NN	O
increases	NNS	O
with	IN	O
325	CD	O
mg	NNS	O
caffeine	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
overall	JJ	O
findings	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
limited	JJ	O
bias	NN	O
is	VBZ	O
introduced	VBN	O
by	IN	O
drug	NN	O
administration	NN	O
instructions	NNS	O
.	.	O

The	DT	O
results	NNS	O
do	VBP	O
not	RB	O
support	VB	O
any	DT	O
suggestion	NN	O
that	IN	O
information	NN	O
about	IN	O
the	DT	O
existence	NN	O
of	IN	O
a	DT	O
placebo	NN	O
condition	NN	O
dramatically	RB	O
influences	VBZ	O
conclusions	NNS	O
drawn	VBP	O
about	IN	O
drug	NN	O
responses	NNS	O
in	IN	O
placebo-controlled	JJ	O
trials	NNS	O
.	.	O

Evaluation	NN	O
of	IN	O
umbilical	JJ	O
cord	NN	O
serum	NN	O
therapy	NN	O
for	IN	O
persistent	JJ	Condition
corneal	JJ	Condition
epithelial	JJ	Condition
defects	NNS	Condition
.	.	Condition

AIMS	NNP	O
To	TO	O
evaluate	VB	O
umbilical	JJ	O
cord	NN	O
serum	NN	O
therapy	NN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
promoting	VBG	O
the	DT	O
healing	NN	O
of	IN	O
persistent	JJ	Condition
corneal	JJ	Condition
epithelial	JJ	Condition
defects	NNS	Condition
.	.	Condition

METHODS	NNP	O
Umbilical	NNP	O
cord	NN	O
serum	NN	O
or	CC	O
autologous	JJ	O
serum	NN	O
drops	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
promote	VB	O
the	DT	O
healing	NN	O
of	IN	O
persistent	JJ	O
epithelial	JJ	O
defects	NNS	O
.	.	O

The	DT	O
study	NN	O
design	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

60	CD	O
eyes	NNS	O
of	IN	O
59	CD	O
patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
31	CD	O
in	IN	O
the	DT	O
cord	NN	O
serum	NN	O
group	NN	O
and	CC	O
29	CD	O
in	IN	O
the	DT	O
autologous	JJ	O
serum	NN	O
control	NN	O
group	NN	O
.	.	O

Epithelial	JJ	O
defects	NNS	O
measuring	VBG	O
at	IN	O
least	JJS	O
2	CD	O
mm	NN	O
in	IN	O
linear	JJ	O
dimension	NN	O
resistant	NN	O
to	TO	O
conventional	JJ	O
medical	JJ	O
management	NN	O
were	VBD	O
included	VBN	O
.	.	O

Serial	JJ	O
measurements	NNS	O
of	IN	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
epithelial	JJ	O
defects-namely	RB	O
,	,	O
two	CD	O
maximum	JJ	O
linear	JJ	O
dimensions	NNS	O
perpendicular	VBP	O
to	TO	O
each	DT	O
other	JJ	O
,	,	O
and	CC	O
the	DT	O
area	NN	O
and	CC	O
perimeter	NN	O
was	VBD	O
done	VBN	O
at	IN	O
start	NN	O
of	IN	O
therapy	NN	O
and	CC	O
follow	VB	O
up	RP	O
days	NNS	O
3	CD	O
,	,	O
7	CD	O
,	,	O
14	CD	O
,	,	O
21	CD	O
.	.	O

Rate	NN	O
of	IN	O
healing	NN	O
of	IN	O
the	DT	O
epithelial	JJ	O
defects	NNS	O
were	VBD	O
measured	VBN	O
as	IN	O
percentage	NN	O
decrease	NN	O
from	IN	O
the	DT	O
baseline	NN	O
parameter	NN	O
at	IN	O
each	DT	O
subsequent	NN	O
follow	VBP	O
up	RB	O
.	.	O

The	DT	O
data	NNS	O
were	VBD	O
analysed	VBN	O
by	IN	O
the	DT	O
non-parametric	JJ	O
Wilcoxon	NNP	O
rank	NN	O
sum	NN	O
test	NN	O
using	VBG	O
STATA	NNP	O
7.0	CD	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
percentage	NN	O
decrease	NN	O
in	IN	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
epithelial	JJ	O
defect	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
cord	NN	O
serum	NN	O
group	NN	O
at	IN	O
days	NNS	O
7	CD	O
,	,	O
14	CD	O
and	CC	O
21	CD	O
(	(	O
p	NN	O
<	RB	O
0.05	CD	O
)	)	O
when	WRB	O
measured	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
area	NN	O
and	CC	O
perimeter	NN	O
.	.	O

A	DT	O
greater	JJR	O
number	NN	O
of	IN	O
patients	NNS	O
showed	VBD	O
complete	JJ	O
re-epithelialisation	NN	O
with	IN	O
umbilical	JJ	O
cord	NN	O
serum	NN	O
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
than	IN	O
with	IN	O
autologous	JJ	O
serum	NN	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
(	(	O
Pearson	NNP	O
chi	VBZ	O
=	NNP	O
0.19	CD	O
)	)	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
patients	NNS	O
reported	VBD	O
any	DT	O
side	NN	O
effects	NNS	O
or	CC	O
discomfort	NN	O
with	IN	O
either	DT	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Umbilical	NNP	O
cord	NN	O
serum	NN	O
leads	VBZ	O
to	TO	O
faster	RBR	O
healing	NN	O
of	IN	O
the	DT	O
persistent	JJ	O
corneal	NN	O
epithelial	JJ	O
defects	NNS	O
refractory	NN	O
to	TO	O
all	DT	O
medical	JJ	O
management	NN	O
compared	VBN	O
to	TO	O
autologous	JJ	O
serum	NN	O
.	.	O

Development	NNP	O
of	IN	O
an	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
for	IN	O
the	DT	O
identification	NN	O
of	IN	O
auditory	NN	O
processing	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	CC	O
One	CD	O
type	NN	O
of	IN	O
test	NN	O
commonly	RB	O
used	VBD	O
to	TO	O
examine	VB	O
auditory	JJ	O
processing	NN	O
disorders	NNS	O
(	(	O
APD	NNP	O
)	)	O
is	VBZ	O
the	DT	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
(	(	O
LPFST	NNP	O
)	)	O
,	,	O
of	IN	O
which	WDT	O
there	EX	O
are	VBP	O
various	JJ	O
versions	NNS	O
.	.	O

In	IN	O
LPFSTs	NNP	O
,	,	O
a	DT	O
monaural	JJ	O
,	,	O
low-redundancy	JJ	O
speech	NN	O
sample	NN	O
is	VBZ	O
distorted	VBN	O
by	IN	O
using	VBG	O
filtering	VBG	O
to	TO	O
modify	VB	O
its	PRP$	O
frequency	NN	O
content	NN	O
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
richness	NN	O
of	IN	O
the	DT	O
neural	JJ	O
pathways	NNS	O
in	IN	O
the	DT	O
auditory	NN	O
system	NN	O
and	CC	O
the	DT	O
redundancy	NN	O
of	IN	O
acoustic	JJ	O
information	NN	O
in	IN	O
spoken	JJ	O
language	NN	O
,	,	O
a	DT	O
normal	JJ	O
listener	NN	O
is	VBZ	O
able	JJ	O
to	TO	O
recognize	VB	O
speech	NN	O
even	RB	O
when	WRB	O
parts	NNS	O
of	IN	O
the	DT	O
signal	NN	O
are	VBP	O
missing	VBG	O
,	,	O
whereas	IN	O
this	DT	O
ability	NN	O
is	VBZ	O
often	RB	O
impaired	VBN	O
in	IN	O
listeners	NNS	O
with	IN	O
APD	NNP	O
.	.	O

One	CD	O
limitation	NN	O
of	IN	O
the	DT	O
various	JJ	O
versions	NNS	O
of	IN	O
the	DT	O
LPFST	NNP	O
is	VBZ	O
that	IN	O
they	PRP	O
are	VBP	O
carried	VBN	O
out	IN	O
using	VBG	O
a	DT	O
constant	JJ	O
level	NN	O
of	IN	O
low-pass	JJ	O
filtering	NN	O
(	(	O
e.g	NN	O
.	.	O

a	DT	O
fixed	JJ	O
1kHz	CD	O
corner	NN	O
frequency	NN	O
)	)	O
which	WDT	O
makes	VBZ	O
them	PRP	O
prone	VB	O
to	TO	O
ceiling	NN	O
and	CC	O
floor	NN	O
effects	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
counter	VB	O
these	DT	O
effects	NNS	O
by	IN	O
modifying	VBG	O
the	DT	O
LPFST	NNP	O
using	VBG	O
a	DT	O
computer-based	JJ	O
adaptive	JJ	O
procedure	NN	O
,	,	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
performance	NN	O
of	IN	O
normal-hearing	JJ	O
participants	NNS	O
of	IN	O
varying	VBG	O
ages	NNS	O
on	IN	O
the	DT	O
test	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
preliminary	JJ	O
study	NN	O
,	,	O
33	CD	O
adults	NNS	O
and	CC	O
30	CD	O
children	NNS	O
(	(	O
aged	VBN	O
8-11	CD	O
years	NNS	O
)	)	O
with	IN	O
no	DT	O
known	JJ	O
history	NN	O
of	IN	O
listening	VBG	O
difficulties	NNS	O
were	VBD	O
tested	VBN	O
.	.	O

The	DT	O
University	NNP	O
of	IN	O
Canterbury	NNP	O
Adaptive	NNP	O
Speech	NNP	O
Test	NNP	O
(	(	O
UCAST	NNP	O
)	)	O
platform	NN	O
was	VBD	O
used	VBN	O
to	TO	O
administer	VB	O
a	DT	O
four-alternative	JJ	O
forced-choice	JJ	O
adaptive	JJ	O
test	NN	O
that	WDT	O
altered	VBD	O
a	DT	O
low-pass	JJ	O
filter	NN	O
(	(	O
LPF	NNP	O
)	)	O
to	TO	O
track	VB	O
the	DT	O
corner	NN	O
frequency	NN	O
at	IN	O
which	WDT	O
participants	NNS	O
correctly	RB	O
identified	VBN	O
a	DT	O
certain	JJ	O
percentage	NN	O
of	IN	O
the	DT	O
word	NN	O
stimuli	NN	O
.	.	O

RESULTS	NNP	O
Findings	NNP	O
on	IN	O
the	DT	O
University	NNP	O
of	IN	O
Canterbury	NNP	O
Adaptive	NNP	O
Speech	NNP	O
Test-Filtered	NNP	O
Words	NNP	O
(	(	O
UCAST-FW	NNP	O
)	)	O
indicated	VBD	O
a	DT	O
significant	JJ	O
maturational	JJ	O
effect	NN	O
.	.	O

Adult	NN	O
participants	NNS	O
performed	VBD	O
significantly	RB	O
better	RBR	O
on	IN	O
the	DT	O
UCAST-FW	NNP	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
child	NN	O
participants	NNS	O
.	.	O

The	DT	O
UCAST-FW	JJ	O
test	NN	O
was	VBD	O
reliable	JJ	O
over	IN	O
repeated	JJ	O
administrations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
An	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
such	JJ	O
as	IN	O
the	DT	O
UCAST-FW	NNP	O
is	VBZ	O
sensitive	JJ	O
to	TO	O
maturational	JJ	O
changes	NNS	O
in	IN	O
auditory	NN	O
processing	NN	O
ability	NN	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
of	IN	O
the	DT	O
Tele-Airway	NNP	O
Management	NNP	O
System	NNP	O
in	IN	O
a	DT	O
hospital	NN	O
emergency	NN	O
department	NN	O
.	.	O

We	PRP	O
developed	VBD	O
a	DT	O
telemedicine	NN	O
system	NN	O
for	IN	O
remote	JJ	O
guidance	NN	O
of	IN	O
emergency	NN	O
airway	NN	O
management	NN	O
called	VBD	O
the	DT	O
Tele-Airway	NNP	O
Management	NNP	O
System	NNP	O
(	(	O
TAMS	NNP	O
)	)	O
.	.	O

In	IN	O
a	DT	O
pilot	NN	O
study	NN	O
we	PRP	O
examined	VBD	O
the	DT	O
usefulness	NN	O
of	IN	O
the	DT	O
TAMS	NNP	O
for	IN	O
intubations	NNS	O
of	IN	O
actual	JJ	O
patients	NNS	O
in	IN	O
a	DT	O
hospital	NN	O
emergency	NN	O
department	NN	O
.	.	O

Twenty-five	JJ	SampleSize
patients	NNS	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
either	DT	O
to	TO	O
a	DT	O
TAMS	NNP	O
group	NN	O
or	CC	O
to	TO	O
an	DT	O
on-scene	JJ	O
directed	NN	O
(	(	O
OSD	NNP	O
)	)	O
group	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
12	CD	SampleSize
were	VBD	O
intubated	VBN	O
using	VBG	O
the	DT	O
TAMS	NNP	O
.	.	O

The	DT	O
mean	JJ	O
time	NN	O
to	TO	O
intubation	NN	O
(	(	O
TAMS	NNP	O
62	CD	O
s	NN	O
vs.	FW	O
OSD	NNP	O
56	CD	O
s	NN	O
)	)	O
and	CC	O
the	DT	O
success	NN	O
rate	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
oesophageal	JJ	O
intubations	NNS	O
in	IN	O
the	DT	O
TAMS	NNP	O
group	NN	O
and	CC	O
four	CD	O
in	IN	O
the	DT	O
OSD	NNP	O
group	NN	O
,	,	O
but	CC	O
this	DT	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.36	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
mechanical	JJ	O
or	CC	O
technical	JJ	O
errors	NNS	O
such	JJ	O
as	IN	O
disconnection	NN	O
during	IN	O
use	NN	O
of	IN	O
the	DT	O
TAMS	NNP	O
.	.	O

The	DT	O
pilot	NN	O
study	NN	O
demonstrated	VBD	O
the	DT	O
feasibility	NN	O
of	IN	O
the	DT	O
TAMS	NNP	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
OSD	NNP	O
.	.	O

However	RB	O
,	,	O
a	DT	O
larger	JJR	O
study	NN	O
will	MD	O
be	VB	O
required	VBN	O
to	TO	O
determine	VB	O
non-superiority	NN	O
or	CC	O
equivalence	NN	O
.	.	O

Intranasal	NNP	O
oxytocin	PRP	O
improves	VBZ	O
emotion	NN	O
recognition	NN	O
for	IN	O
youth	NN	Age
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorders	NNS	Condition
.	.	O

BACKGROUND	VB	O
A	NNP	O
diagnostic	JJ	O
hallmark	NN	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
is	VBZ	O
a	DT	O
qualitative	JJ	O
impairment	NN	O
in	IN	O
social	JJ	O
communication	NN	O
and	CC	O
interaction	NN	O
.	.	O

Deficits	NNS	O
in	IN	O
the	DT	O
ability	NN	O
to	TO	O
recognize	VB	O
the	DT	O
emotions	NNS	O
of	IN	O
others	NNS	O
are	VBP	O
believed	VBN	O
to	TO	O
contribute	VB	O
to	TO	O
this	DT	O
.	.	O

There	EX	O
is	VBZ	O
currently	RB	O
no	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
these	DT	O
problems	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
,	,	O
we	PRP	O
administered	VBD	O
oxytocin	RP	O
nasal	JJ	O
spray	NN	O
(	(	O
18	CD	O
or	CC	O
24	CD	O
IU	NNPS	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
to	TO	O
16	CD	SampleSize
male	NN	Sex
youth	NN	Age
aged	VBD	Age
12	CD	Age
to	TO	Age
19	CD	Age
who	WP	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
Autistic	NNP	Condition
or	CC	Condition
Asperger	NNP	Condition
's	POS	Condition
Disorder	NNP	Condition
.	.	O

Participants	NNS	O
then	RB	O
completed	VBD	O
the	DT	O
Reading	VBG	O
the	DT	O
Mind	NNP	O
in	IN	O
the	DT	O
Eyes	NNP	O
Task	NNP	O
,	,	O
a	DT	O
widely	RB	O
used	VBN	O
and	CC	O
reliable	JJ	O
test	NN	O
of	IN	O
emotion	NN	O
recognition	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
comparison	NN	O
with	IN	O
placebo	NN	O
,	,	O
oxytocin	JJ	O
administration	NN	O
improved	VBD	O
performance	NN	O
on	IN	O
the	DT	O
Reading	VBG	O
the	DT	O
Mind	NNP	O
in	IN	O
the	DT	O
Eyes	NNP	O
Task	NNP	O
.	.	O

This	DT	O
effect	NN	O
was	VBD	O
also	RB	O
shown	VBN	O
when	WRB	O
analysis	NN	O
was	VBD	O
restricted	VBN	O
to	TO	O
the	DT	O
younger	JJR	Age
participants	NNS	O
aged	VBD	O
12	CD	Age
to	TO	Age
15	CD	Age
who	WP	O
received	VBD	O
the	DT	O
lower	JJR	O
dose	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
provides	VBZ	O
the	DT	O
first	JJ	O
evidence	NN	O
that	IN	O
oxytocin	JJ	O
nasal	NN	O
spray	NN	O
improves	VBZ	O
emotion	NN	O
recognition	NN	O
in	IN	O
young	JJ	O
people	NNS	O
diagnosed	VBN	O
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorders	NNS	Condition
.	.	Condition

Findings	NNS	O
suggest	VBP	O
the	DT	O
potential	NN	O
of	IN	O
earlier	JJR	O
intervention	NN	O
and	CC	O
further	JJ	O
evaluation	NN	O
of	IN	O
oxytocin	JJ	O
nasal	JJ	O
spray	NN	O
as	IN	O
a	DT	O
treatment	NN	O
to	TO	O
improve	VB	O
social	JJ	O
communication	NN	O
and	CC	O
interaction	NN	O
in	IN	O
young	JJ	O
people	NNS	O
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorders	NNS	Condition
.	.	O

Maternal	JJ	O
breast-milk	NN	O
and	CC	O
intestinal	JJ	O
bifidobacteria	NNS	O
guide	VBP	O
the	DT	O
compositional	JJ	O
development	NN	O
of	IN	O
the	DT	O
Bifidobacterium	NNP	O
microbiota	NN	O
in	IN	O
infants	NNS	O
at	IN	O
risk	NN	O
of	IN	O
allergic	JJ	O
disease	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
sources	NNS	O
and	CC	O
the	DT	O
impact	NN	O
of	IN	O
maternal	JJ	O
bacteria	NNS	O
on	IN	O
the	DT	O
initial	JJ	O
inoculum	NN	O
of	IN	O
the	DT	O
intestinal	JJ	O
microflora	NN	O
of	IN	O
newborn	JJ	O
infants	NNS	O
remain	VBP	O
elusive	JJ	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
assess	VB	O
the	DT	O
association	NN	O
between	IN	O
maternal	JJ	O
breast-milk	NN	O
and	CC	O
fecal	JJ	O
bifidobacteria	NN	O
and	CC	O
infants	NNS	O
'	POS	O
fecal	JJ	O
bifidobacteria	NN	O
.	.	O

METHODS	NNP	O
Sixty-one	JJ	O
mother-infant	JJ	O
pairs	NNS	O
were	VBD	O
included	VBN	O
,	,	O
special	JJ	O
emphasis	NN	O
being	VBG	O
placed	VBN	O
on	IN	O
the	DT	O
maternal	JJ	O
allergic	NN	O
status	NN	O
.	.	O

Bifidobacteria	NNP	O
were	VBD	O
analysed	VBN	O
by	IN	O
a	DT	O
direct	JJ	O
PCR	NNP	O
method	NN	O
in	IN	O
fecal	JJ	O
samples	NNS	O
from	IN	O
mothers	NNS	O
at	IN	O
30-35	JJ	O
weeks	NNS	O
of	IN	O
gestation	NN	O
and	CC	O
from	IN	O
infants	NNS	O
at	IN	O
1	CD	O
month	NN	O
of	IN	O
age	NN	O
and	CC	O
from	IN	O
breast-milk	JJ	O
samples	NNS	O
1	CD	O
month	NN	O
post-partum	NN	O
.	.	O

RESULTS	NNP	O
Fecal	NNP	O
Bifidobacterium	NNP	O
adolescentis	NN	O
and	CC	O
Bifidobacterium	NNP	O
bifidum	NN	O
colonization	NN	O
frequencies	NNS	O
and	CC	O
counts	NNS	O
among	IN	O
mother-infant	JJ	O
pairs	NNS	O
correlated	VBN	O
significantly	RB	O
(	(	O
P=0.005	NNP	O
and	CC	O
0.02	CD	O
for	IN	O
frequencies	NNS	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
P=0.002	NNP	O
and	CC	O
0.01	CD	O
for	IN	O
counts	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Only	JJ	O
infants	NNS	O
of	IN	O
allergic	NN	O
,	,	O
atopic	NN	O
mothers	NNS	O
were	VBD	O
colonized	VBN	O
with	IN	O
B.	NNP	O
adolescentis	NN	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
breast-milk	NN	O
samples	NNS	O
contained	VBN	O
bifidobacteria	NNS	O
[	NNP	O
median	JJ	O
1.4	CD	O
x	JJ	O
10	CD	O
(	(	O
3	CD	O
)	)	O
bacterial	JJ	O
cells/mL	NN	O
;	:	O
interquartile	JJ	O
range	NN	O
(	(	O
IQR	NNP	O
)	)	O
48.7-3.8	CD	O
x	$	O
10	CD	O
(	(	O
3	CD	O
)	)	O
]	NN	O
.	.	O

Bifidobacterium	NNP	O
longum	NN	O
was	VBD	O
the	DT	O
most	RBS	O
frequently	RB	O
detected	VBN	O
species	NNS	O
in	IN	O
breast-milk	NN	O
.	.	O

Allergic	NNP	O
mothers	NNS	O
had	VBD	O
significantly	RB	O
lower	JJR	O
amounts	NNS	O
of	IN	O
bifidobacteria	NN	O
in	IN	O
breast-milk	NN	O
compared	VBN	O
with	IN	O
non-allergic	JJ	O
mothers	NNS	O
[	VBP	O
median	JJ	O
1.3	CD	O
x	JJ	O
10	CD	O
(	(	O
3	CD	O
)	)	O
bacterial	NN	O
cells/mL	NN	O
(	(	O
IQR	NNP	O
22.4-3.0	CD	O
x	NNP	O
10	CD	O
(	(	O
3	CD	O
)	)	O
)	)	O
vs.	FW	O
5.6	CD	O
x	$	O
10	CD	O
(	(	O
3	CD	O
)	)	O
bacterial	NN	O
cells/mL	NN	O
(	(	O
1.8	CD	O
x	RB	O
10	CD	O
(	(	O
3	CD	O
)	)	O
-1.8	NN	O
x	$	O
10	CD	O
(	(	O
4	CD	O
)	)	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
(	(	O
P=0.004	NNP	O
)	)	O
]	NN	O
,	,	O
and	CC	O
their	PRP$	O
infants	NNS	O
had	VBD	O
concurrently	RB	O
lower	JJR	O
counts	NNS	O
of	IN	O
bifidobacteria	NN	O
in	IN	O
feces	NNS	O
[	VBP	O
3.9	CD	O
x	JJ	O
10	CD	O
(	(	O
8	CD	O
)	)	O
bacterial	NN	O
cells/g	NN	O
(	(	O
IQR	NNP	O
6.5	CD	O
x	NN	O
10	CD	O
(	(	O
6	CD	O
)	)	O
-1.5	NN	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
)	)	O
in	IN	O
infants	NNS	O
of	IN	O
allergic	JJ	O
mothers	NNS	O
,	,	O
vs.	FW	O
2.5	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
bacterial	NN	O
cells/g	NN	O
(	(	O
6.5	CD	O
x	RB	O
10	CD	O
(	(	O
8	CD	O
)	)	O
-3.2	NN	O
x	$	O
10	CD	O
(	(	O
10	CD	O
)	)	O
)	)	O
in	IN	O
infants	NNS	O
of	IN	O
non-allergic	JJ	O
mothers	NNS	O
,	,	O
P=0.013	NNP	O
]	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Breast-milk	NNP	O
contains	VBZ	O
significant	JJ	O
numbers	NNS	O
of	IN	O
bifidobacteria	NN	O
and	CC	O
the	DT	O
maternal	JJ	O
allergic	NN	O
status	NN	O
further	RBR	O
deranges	VBZ	O
the	DT	O
counts	NNS	O
of	IN	O
bifidobacteria	NN	O
in	IN	O
breast-milk	NN	O
.	.	O

Maternal	NNP	O
fecal	JJ	O
and	CC	O
breast-milk	JJ	O
bifidobacterial	JJ	O
counts	NNS	O
impacted	VBN	O
on	IN	O
the	DT	O
infants	NNS	O
'	POS	O
fecal	JJ	O
Bifidobacterium	NN	O
levels	NNS	O
.	.	O

Breast-milk	NNP	O
bacteria	NN	O
should	MD	O
thus	RB	O
be	VB	O
considered	VBN	O
an	DT	O
important	JJ	O
source	NN	O
of	IN	O
bacteria	NNS	O
in	IN	O
the	DT	O
establishment	NN	O
of	IN	O
infantile	JJ	O
intestinal	JJ	O
microbiota	NN	O
.	.	O

Skin	NNP	O
manifestations	NNS	O
of	IN	O
inhaled	JJ	O
corticosteroids	NNS	O
in	IN	O
COPD	NNP	Condition
patients	NNS	Condition
:	:	Condition
results	NNS	O
from	IN	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
define	VB	O
the	DT	O
relationship	NN	O
between	IN	O
skin	NN	O
bruising	NN	O
(	(	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
cutaneous	JJ	O
manifestations	NNS	O
)	)	O
and	CC	O
inhaled	VBN	O
corticosteroid	NN	O
(	(	O
ICS	NNP	O
)	)	O
therapy	NN	O
vs	NN	O
placebo	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
COPD	NNP	O
who	WP	O
were	VBD	O
participating	VBG	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

To	TO	O
explore	VB	O
the	DT	O
relationship	NN	O
between	IN	O
easy	JJ	O
skin	NN	O
bruising	NN	O
and	CC	O
other	JJ	O
systemic	JJ	O
effects	NNS	O
of	IN	O
ICS	NNP	O
therapy	NN	O
,	,	O
including	VBG	O
adrenal	JJ	O
suppression	NN	O
and	CC	O
loss	NN	O
of	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Double-blind	NNP	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
triamcinolone	NN	O
acetonide	NN	O
(	(	O
1200	CD	O
microg	FW	O
daily	RB	O
)	)	O
vs	NN	O
placebo	NN	O
in	IN	O
participants	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
.	.	O

SETTING	NNP	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
,	,	O
a	DT	O
clinical	JJ	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
ICS	NNP	O
compared	VBN	O
to	TO	O
placebo	VB	O
in	IN	O
1,116	CD	O
participants	NNS	O
in	IN	O
10	CD	O
centers	NNS	O
over	IN	O
>	$	O
3.5	CD	O
to	TO	O
4.5	CD	O
years	NNS	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
1,116	CD	O
smokers	NNS	O
or	CC	O
recent	JJ	O
ex-smokers	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
(	(	O
age	NN	O
range	NN	O
,	,	O
40	CD	O
to	TO	O
69	CD	O
years	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
56.3	CD	O
years	NNS	O
;	:	O
37.2	CD	O
%	NN	O
female	NN	O
)	)	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
RESULTS	NNP	O
Every	NNP	O
6	CD	O
months	NNS	O
,	,	O
a	DT	O
structured	JJ	O
questionnaire	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
elicit	VB	O
reports	NNS	O
of	IN	O
any	DT	O
bruising	NN	O
and/or	NN	O
skin	NN	O
rashes	NNS	O
,	,	O
slow	JJ	O
healing	NN	O
of	IN	O
cuts	NNS	O
or	CC	O
sores	NNS	O
,	,	O
or	CC	O
other	JJ	O
skin	JJ	O
changes	NNS	O
.	.	O

Compliance	NN	O
with	IN	O
inhaler	NN	O
use	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
canister	NN	O
weighing	VBG	O
.	.	O

A	DT	O
significantly	RB	O
higher	JJR	O
proportion	NN	O
of	IN	O
ICS	NNP	O
than	IN	O
placebo	NN	O
participants	NNS	O
who	WP	O
complied	VBD	O
with	IN	O
using	VBG	O
their	PRP$	O
inhaler	NN	O
reported	VBD	O
easy	JJ	O
bruising	NN	O
(	(	O
11.2	CD	O
%	NN	O
vs	JJ	O
3.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
the	DT	O
slow	JJ	O
healing	NN	O
of	IN	O
skin	NN	O
cuts	NNS	O
or	CC	O
sores	NNS	O
(	(	O
2.4	CD	O
%	NN	O
vs	JJ	O
0.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Older	JJR	O
men	NNS	O
in	IN	O
the	DT	O
ICS	NNP	O
group	NN	O
with	IN	O
good	JJ	O
inhaler	NN	O
compliance	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
at	IN	O
the	DT	O
greatest	JJS	O
risk	NN	O
of	IN	O
bruising	VBG	O
.	.	O

In	IN	O
those	DT	O
participants	NNS	O
undergoing	VBG	O
serial	JJ	O
measurements	NNS	O
of	IN	O
adrenal	JJ	O
function	NN	O
and	CC	O
BMD	NNP	O
,	,	O
no	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	O
bruising	NN	O
and	CC	O
either	CC	O
the	DT	O
suppression	NN	O
of	IN	O
adrenal	JJ	O
function	NN	O
or	CC	O
the	DT	O
loss	NN	O
of	IN	O
BMD	NNP	O
as	IN	O
systemic	JJ	O
complications	NNS	O
of	IN	O
ICS	NNP	O
use	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
moderate-to-high	JJ	O
doses	NNS	O
of	IN	O
ICSs	NNP	O
result	NN	O
in	IN	O
an	DT	O
increased	JJ	O
incidence	NN	O
of	IN	O
easy	JJ	O
bruising	NN	O
and	CC	O
impairment	NN	O
in	IN	O
skin	NN	O
healing	NN	O
in	IN	O
middle-aged	JJ	O
to	TO	O
elderly	JJ	O
persons	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

No	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	O
bruising	NN	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
systemic	JJ	O
toxicity	NN	O
from	IN	O
the	DT	O
use	NN	O
of	IN	O
ICSs	NNP	O
.	.	O

Reduction	NN	O
of	IN	O
isoflurane	NN	O
MAC	NNP	O
by	IN	O
fentanyl	NN	O
or	CC	O
remifentanil	NN	O
in	IN	O
rats	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
main	JJ	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
three	CD	O
different	JJ	O
infusion	NN	O
rates	NNS	O
of	IN	O
fentanyl	NN	O
and	CC	O
remifentanil	NN	O
on	IN	O
the	DT	O
minimum	JJ	O
alveolar	JJ	O
concentration	NN	O
(	(	O
MAC	NNP	O
)	)	O
of	IN	O
isoflurane	NN	O
in	IN	O
the	DT	O
rat	NN	O
.	.	O

A	DT	O
secondary	JJ	O
objective	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
cardiovascular	NN	O
and	CC	O
respiratory	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
opioid	JJ	O
drugs	NNS	O
.	.	O

ANIMAL	NNP	O
POPULATION	NNP	O
Thirty-seven	NNP	SampleSize
male	NN	Sex
Wistar	NNP	O
rats	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
six	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
For	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
anaesthesia	NN	O
was	VBD	O
induced	VBN	O
with	IN	O
5	CD	O
%	NN	O
isoflurane	NN	O
in	IN	O
oxygen	NN	O
using	VBG	O
an	DT	O
induction	NN	O
chamber	NN	O
.	.	O

A	DT	O
14-gauge	JJ	O
catheter	NN	O
was	VBD	O
used	VBN	O
for	IN	O
endotracheal	JJ	O
intubation	NN	O
,	,	O
and	CC	O
anaesthesia	NN	O
was	VBD	O
maintained	VBN	O
with	IN	O
isoflurane	NN	O
delivered	VBN	O
in	IN	O
oxygen	NN	O
via	IN	O
a	DT	O
T-piece	NNP	O
breathing	NN	O
system	NN	O
.	.	O

A	DT	O
baseline	JJ	O
determination	NN	O
of	IN	O
the	DT	O
minimum	JJ	O
alveolar	JJ	O
concentration	NN	O
of	IN	O
isoflurane	NN	O
(	(	O
MACISO	NNP	O
)	)	O
was	VBD	O
made	VBN	O
for	IN	O
each	DT	O
animal	NN	O
.	.	O

Fentanyl	NNP	O
(	(	O
15	CD	O
,	,	O
30	CD	O
,	,	O
60	CD	O
micro	NN	O
g	JJ	O
kg-1	JJ	O
hour-1	NN	O
)	)	O
or	CC	O
remifentanil	NN	O
(	(	O
60	CD	O
,	,	O
120	CD	O
,	,	O
240	CD	O
micro	NN	O
g	JJ	O
kg-1	JJ	O
hour-1	NN	O
)	)	O
were	VBD	O
infused	VBN	O
intravenously	RB	O
into	IN	O
a	DT	O
previously	RB	O
cannulated	VBN	O
tail	NN	O
vein	NN	O
.	.	O

Thirty	NNP	O
minutes	NNS	O
after	IN	O
the	DT	O
infusion	NN	O
started	VBD	O
,	,	O
a	DT	O
second	JJ	O
MACISO	NNP	O
(	(	O
MACISO+drug	NNP	O
)	)	O
was	VBD	O
determined	VBN	O
.	.	O

The	DT	O
carotid	NN	O
artery	NN	O
was	VBD	O
cannulated	VBN	O
to	TO	O
monitor	VB	O
the	DT	O
arterial	JJ	O
pressure	NN	O
and	CC	O
to	TO	O
take	VB	O
samples	NNS	O
for	IN	O
arterial	JJ	O
gas	NN	O
measurements	NNS	O
.	.	O

Cardiovascular	NNP	O
(	(	O
heart	NN	O
rate	NN	O
and	CC	O
arterial	JJ	O
pressure	NN	O
)	)	O
and	CC	O
respiratory	NN	O
(	(	O
respiratory	JJ	O
rate	NN	O
and	CC	O
presence/absence	NN	O
of	IN	O
apnoea	NN	O
)	)	O
effects	NNS	O
after	IN	O
opioid	JJ	O
infusion	NN	O
were	VBD	O
also	RB	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Fentanyl	NNP	O
(	(	O
15	CD	O
,	,	O
30	CD	O
,	,	O
60	CD	O
micro	NN	O
g	JJ	O
kg-1	JJ	O
hour-1	NN	O
)	)	O
and	CC	O
remifentanil	NN	O
(	(	O
60	CD	O
,	,	O
120	CD	O
,	,	O
240	CD	O
micro	NN	O
g	JJ	O
kg-1	JJ	O
hour-1	NN	O
)	)	O
similarly	RB	O
reduced	VBN	O
isoflurane	NN	O
MAC	NNP	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
fashion	NN	O
:	:	O
by	IN	O
10	CD	O
%	NN	O
at	IN	O
lower	JJR	O
doses	NNS	O
,	,	O
25	CD	O
%	NN	O
at	IN	O
medium	NN	O
doses	NNS	O
and	CC	O
by	IN	O
60	CD	O
%	NN	O
at	IN	O
higher	JJR	O
doses	NNS	O
of	IN	O
both	DT	O
the	DT	O
drugs	NNS	O
.	.	O

Both	DT	O
opioids	NNS	O
reduced	VBD	O
the	DT	O
respiratory	NN	O
rate	NN	O
in	IN	O
a	DT	O
similar	JJ	O
way	NN	O
for	IN	O
all	DT	O
doses	NNS	O
tested	VBN	O
.	.	O

No	DT	O
episodes	NNS	O
of	IN	O
apnoea	NN	O
were	VBD	O
recorded	VBN	O
in	IN	O
the	DT	O
remifentanil	NN	O
groups	NNS	O
,	,	O
while	IN	O
administration	NN	O
of	IN	O
fentanyl	NN	O
resulted	VBN	O
in	IN	O
apnoea	NN	O
in	IN	O
three	CD	O
animals	NNS	O
(	(	O
one	CD	O
at	IN	O
each	DT	O
dose	JJ	O
level	NN	O
)	)	O
.	.	O

The	DT	O
effects	NNS	O
on	IN	O
the	DT	O
cardiovascular	JJ	O
system	NN	O
were	VBD	O
similar	JJ	O
with	IN	O
both	DT	O
drugs	NNS	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
intraoperative	JJ	O
use	NN	O
of	IN	O
remifentanil	NN	O
in	IN	O
the	DT	O
rat	NN	O
reduces	VBZ	O
the	DT	O
MAC	NNP	O
of	IN	O
isoflurane	NN	O
,	,	O
and	CC	O
that	IN	O
this	DT	O
anaesthetic	JJ	O
sparing	NN	O
effect	NN	O
is	VBZ	O
dose-dependent	JJ	O
and	CC	O
similar	JJ	O
to	TO	O
that	DT	O
produced	VBN	O
by	IN	O
fentanyl	NN	O
at	IN	O
the	DT	O
doses	NNS	O
tested	VBN	O
.	.	O

CLINICAL	JJ	O
RELEVANCE	NNP	O
The	DT	O
use	NN	O
of	IN	O
remifentanil	NN	O
during	IN	O
inhalant	JJ	O
anaesthesia	NN	O
in	IN	O
the	DT	O
rat	NN	O
can	MD	O
be	VB	O
considered	VBN	O
an	DT	O
intravenous	JJ	O
alternative	NN	O
to	TO	O
fentanyl	VB	O
,	,	O
providing	VBG	O
similar	JJ	O
reduction	NN	O
in	IN	O
isoflurane	NN	O
requirements	NNS	O
.	.	O

Due	NNP	O
to	TO	O
its	PRP$	O
rapid	JJ	O
offset	NN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
alternative	JJ	O
pain	NN	O
relief	NN	O
be	VB	O
instituted	VBN	O
before	IN	O
it	PRP	O
is	VBZ	O
discontinued	VBN	O
.	.	O

Primary	JJ	O
capsulectomy	NN	O
,	,	O
anterior	JJ	O
vitrectomy	NN	O
,	,	O
lensectomy	NN	O
,	,	O
and	CC	O
posterior	JJ	O
chamber	NN	O
lens	NNS	O
implantation	NN	O
in	IN	O
children	NNS	Age
:	:	O
limbal	JJ	O
versus	NN	O
pars	NNS	O
plana	VBP	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
limbal	JJ	O
versus	NN	O
a	DT	O
pars	NNS	O
plana	VBP	O
approach	NN	O
for	IN	O
primary	JJ	O
posterior	JJ	O
capsulectomy	NN	O
and	CC	O
anterior	JJ	O
vitrectomy	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
childhood	NN	Age
cataract	NN	Condition
.	.	O

SETTING	NNP	O
Department	NNP	O
of	IN	O
Ophthalmology	NNP	O
,	,	O
Labbafinejad	NNP	O
Medical	NNP	O
Center	NNP	O
,	,	O
Tehran	NNP	O
,	,	O
Iran	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	NN	O
,	,	O
controlled	VBN	O
,	,	O
double-masked	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
45	CD	O
eyes	NNS	O
was	VBD	O
conducted	VBN	O
.	.	O

After	IN	O
being	VBG	O
matched	VBN	O
,	,	O
38	CD	O
eyes	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
and	CC	O
were	VBD	O
divided	VBN	O
into	IN	O
2	CD	O
equal	JJ	O
groups	NNS	O
for	IN	O
data	NNS	O
analysis	NN	O
.	.	O

All	DT	O
eyes	NNS	O
had	VBD	O
lensectomy	NN	O
and	CC	O
posterior	JJ	O
chamber	NN	O
intraocular	JJ	O
lens	NNS	O
(	(	O
PC	NNP	O
IOL	NNP	O
)	)	O
implantation	NN	O
.	.	O

Primary	JJ	O
posterior	JJ	O
capsulectomy	NN	O
and	CC	O
anterior	JJ	O
vitrectomy	NN	O
were	VBD	O
performed	VBN	O
through	IN	O
the	DT	O
limbus	NN	O
in	IN	O
half	NN	O
of	IN	O
the	DT	O
eyes	NNS	O
and	CC	O
the	DT	O
pars	NNS	O
plana	VBP	O
in	IN	O
the	DT	O
other	JJ	O
half	NN	O
.	.	O

Main	NNP	O
outcome	NN	O
measures	NNS	O
included	VBD	O
visual	JJ	O
acuity	NN	O
,	,	O
estimated	VBN	O
red	JJ	O
reflex	NN	O
,	,	O
postsurgical	JJ	O
inflammatory	NN	O
reaction	NN	O
,	,	O
corneal	JJ	O
clarity	NN	O
,	,	O
posterior	JJ	O
synechias	NN	O
,	,	O
iris	JJ	O
capture	NN	O
,	,	O
IOL	NNP	O
position	NN	O
,	,	O
capsulectomy	JJ	O
size	NN	O
,	,	O
glaucoma	NN	O
,	,	O
cystoid	JJ	O
macular	NN	O
edema	NN	O
,	,	O
retinal	JJ	O
tear	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
refraction	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
2	CD	O
approaches	NNS	O
in	IN	O
the	DT	O
outcome	NN	O
measures	NNS	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
anatomic	JJ	O
and	CC	O
visual	JJ	O
results	NNS	O
were	VBD	O
encouraging	VBG	O
when	WRB	O
posterior	JJ	O
capsulectomy	NN	O
and	CC	O
anterior	JJ	O
vitrectomy	NN	O
,	,	O
using	VBG	O
a	DT	O
limbal	NN	O
or	CC	O
pars	NNS	O
plana	IN	O
approach	NN	O
,	,	O
were	VBD	O
combined	VBN	O
with	IN	O
lensectomy	NN	O
and	CC	O
PC	NN	O
IOL	NNP	O
implantation	NN	O
in	IN	O
children	NNS	Age
.	.	O

The	DT	O
application	NN	O
of	IN	O
these	DT	O
techniques	NNS	O
depends	VBZ	O
on	IN	O
surgeon	JJ	O
experience	NN	O
and	CC	O
skill	NN	O
.	.	O

Loss	NNP	O
of	IN	O
tooth	JJ	O
substance	NN	O
during	IN	O
root	NN	O
planing	VBG	O
with	IN	O
various	JJ	O
periodontal	JJ	O
instruments	NNS	O
:	:	O
an	DT	O
in	IN	O
vitro	NN	O
study	NN	O
.	.	O

Ultrasonic	JJ	O
and	CC	O
power-driven	JJ	O
instrumentation	NN	O
is	VBZ	O
gaining	VBG	O
in	IN	O
significance	NN	O
as	IN	O
an	DT	O
acceptable	JJ	O
alternative	NN	O
to	TO	O
manual	JJ	O
periodontal	JJ	O
root	NN	O
treatment	NN	O
.	.	O

Some	DT	O
question	NN	O
whether	IN	O
they	PRP	O
do	VBP	O
not	RB	O
remove	VB	O
too	RB	O
much	JJ	O
tooth	DT	O
substance	NN	O
.	.	O

Various	JJ	O
ultrasonic	JJ	O
scalers	NNS	O
,	,	O
hand	NN	O
instruments	NNS	O
and	CC	O
two	CD	O
power-driven	JJ	O
systems	NNS	O
were	VBD	O
compared	VBN	O
by	IN	O
assessing	VBG	O
the	DT	O
loss	NN	O
of	IN	O
tooth	JJ	O
substance	NN	O
due	JJ	O
to	TO	O
root	VB	O
instrumentation	NN	O
.	.	O

Quantitative	JJ	O
analysis	NN	O
of	IN	O
this	DT	O
effect	NN	O
of	IN	O
the	DT	O
instruments	NNS	O
used	VBN	O
was	VBD	O
performed	VBN	O
on	IN	O
20	CD	SampleSize
freshly	RB	O
extracted	VBN	O
,	,	O
non-periodontally	RB	O
involved	VBN	O
,	,	O
large	JJ	O
human	JJ	O
molars	NNS	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
study	NN	O
,	,	O
40	CD	SampleSize
specimens	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
four	CD	O
groups	NNS	O
of	IN	O
treatment	NN	O
:	:	O
combined	VBN	O
use	NN	O
of	IN	O
ultrasonic	JJ	O
scaler	NN	O
and	CC	O
Periopolisher	NNP	O
diamond-coated	JJ	O
inserts	NNS	O
(	(	O
US-POL	NNP	O
)	)	O
,	,	O
hand	NN	O
instruments	NNS	O
(	(	O
MANUAL	NNP	O
)	)	O
,	,	O
Perioplaner-Periopolisher	NNP	O
system	NN	O
(	(	O
PPL-POL	NNP	O
)	)	O
and	CC	O
Periokit	NNP	O
ultrasonic-designed	JJ	O
scalers	NNS	O
(	(	O
PERIOKIT	NNP	O
)	)	O
.	.	O

The	DT	O
second	JJ	O
study	NN	O
involved	VBN	O
two	CD	O
treatment	NN	O
groups	NNS	O
,	,	O
ultrasonic	JJ	O
scaler	NN	O
alone	RB	O
and	CC	O
hand	NN	O
instruments	NNS	O
,	,	O
each	DT	O
allocated	VBN	O
with	IN	O
20	CD	O
teeth	NNS	O
(	(	O
small	JJ	O
root	NN	O
fragments	NNS	O
)	)	O
.	.	O

An	DT	O
unpaired	JJ	O
two-tailed	JJ	O
t	NN	O
test	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
for	IN	O
both	DT	O
studies	NNS	O
to	TO	O
compare	VB	O
the	DT	O
average	JJ	O
weight	JJ	O
loss	NN	O
of	IN	O
root	JJ	O
substance	NN	O
with	IN	O
the	DT	O
modes	NNS	O
of	IN	O
instrumentation	NN	O
.	.	O

The	DT	O
level	NN	O
of	IN	O
significance	NN	O
was	VBD	O
set	VBN	O
at	IN	O
p	JJ	O
<	NNP	O
or=0.05	NN	O
.	.	O

The	DT	O
overall	JJ	O
results	NNS	O
of	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
experimental	JJ	O
trials	NNS	O
did	VBD	O
not	RB	O
reveal	VB	O
obvious	JJ	O
differences	NNS	O
in	IN	O
weight	JJ	O
loss	NN	O
between	IN	O
the	DT	O
manual	JJ	O
,	,	O
ultrasonic	JJ	O
or	CC	O
power-driven	JJ	O
root	NN	O
treatments	NNS	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
these	DT	O
two	CD	O
comparative	NN	O
studies	NNS	O
,	,	O
the	DT	O
power-driven	JJ	O
inserts	NNS	O
or	CC	O
the	DT	O
various	JJ	O
ultrasonic	JJ	O
scalers	NNS	O
tested	VBD	O
did	VBD	O
not	RB	O
remove	VB	O
more	RBR	O
tooth	JJ	O
substance	NN	O
than	IN	O
conventional	JJ	O
hand	NN	O
instruments	NNS	O
.	.	O

They	PRP	O
may	MD	O
thus	RB	O
be	VB	O
a	DT	O
useful	JJ	O
alternative	NN	O
for	IN	O
the	DT	O
debridement	NN	O
of	IN	O
root	NN	O
surfaces	NNS	O
.	.	O

Changing	VBG	O
Childbirth	NN	O
:	:	O
a	DT	O
pilot	NN	O
project	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
outcomes	NNS	O
of	IN	O
an	DT	O
adapted	JJ	O
pilot	NN	O
Changing	NNP	O
Childbirth	NNP	O
initiative	JJ	O
providing	VBG	O
continuity	NN	O
of	IN	O
care	NN	O
by	IN	O
a	DT	O
group	NN	O
of	IN	O
known	VBN	O
midwives	NNS	O
with	IN	O
traditional	JJ	O
maternity	NN	O
care	NN	O
.	.	O

DESIGN	NNP	O
Between-groups	NNP	O
trial	NN	O
to	TO	O
compare	VB	O
levels	NNS	O
of	IN	O
satisfaction	NN	O
and	CC	O
clinical	JJ	O
outcomes	NNS	O
for	IN	O
two	CD	O
groups	NNS	O
of	IN	O
women	NNS	O
,	,	O
cared	VBD	O
for	IN	O
either	DT	O
under	IN	O
this	DT	O
Changing	NNP	O
Childbirth	NNP	O
scheme	NN	O
or	CC	O
the	DT	O
traditional	JJ	O
model	NN	O
of	IN	O
care	NN	O
.	.	O

METHOD	NNP	O
Of	IN	O
the	DT	O
200	CD	SampleSize
women	NNS	SampleSize
who	WP	O
agreed	VBD	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
project	NN	O
,	,	O
100	CD	SampleSize
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
pilot	NN	O
scheme	NN	O
and	CC	O
100	CD	SampleSize
to	TO	O
the	DT	O
traditional	JJ	O
care	NN	O
package	NN	O
.	.	O

During	IN	O
the	DT	O
postpartum	JJ	O
period	NN	O
,	,	O
information	NN	O
was	VBD	O
collected	VBN	O
via	IN	O
a	DT	O
questionnaire	NN	O
about	IN	O
participants	NNS	O
'	POS	O
levels	NNS	O
of	IN	O
satisfaction	NN	O
with	IN	O
a	DT	O
variety	NN	O
of	IN	O
aspects	NNS	O
of	IN	O
care	NN	O
provided	VBN	O
during	IN	O
the	DT	O
antenatal	JJ	O
,	,	O
delivery	NN	O
and	CC	O
postpartum	NN	O
periods	NNS	O
.	.	O

Data	NNS	O
about	IN	O
clinical	JJ	O
outcomes	NNS	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
also	RB	O
obtained	VBN	O
.	.	O

RESULTS	JJ	O
Women	NNP	O
in	IN	O
the	DT	O
pilot	NN	O
group	NN	O
had	VBD	O
significantly	RB	O
more	RBR	O
continuity	NN	O
of	IN	O
care	NN	O
throughout	IN	O
each	DT	O
of	IN	O
the	DT	O
three	CD	O
periods	NNS	O
,	,	O
were	VBD	O
generally	RB	O
more	RBR	O
satisfied	JJ	O
with	IN	O
their	PRP$	O
care	NN	O
,	,	O
felt	VBD	O
that	IN	O
they	PRP	O
had	VBD	O
more	JJR	O
choice	NN	O
over	IN	O
a	DT	O
variety	NN	O
of	IN	O
aspects	NNS	O
of	IN	O
care	NN	O
and	CC	O
experienced	VBD	O
no	DT	O
compromise	NN	O
in	IN	O
clinical	JJ	O
outcomes	NNS	O
(	(	O
P	NNP	O
=	VBZ	O
0.05	CD	O
or	CC	O
less	JJR	O
in	IN	O
each	DT	O
case	NN	O
)	)	O
.	.	O

IMPLICATIONS	NNP	O
FOR	NNP	O
PRACTICE	NNP	O
Many	NNP	O
previous	JJ	O
attempts	NNS	O
to	TO	O
introduce	VB	O
the	DT	O
Changing	NNP	O
Childbirth	NNP	O
initiative	NN	O
have	VBP	O
revealed	VBN	O
significant	JJ	O
problems	NNS	O
,	,	O
particularly	RB	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
continuity	NN	O
of	IN	O
carer	NN	O
requirement	NN	O
.	.	O

Taking	VBG	O
account	NN	O
of	IN	O
local	JJ	O
health	NN	O
care	NN	O
needs	NNS	O
and	CC	O
existing	VBG	O
provision	NN	O
,	,	O
the	DT	O
present	JJ	O
study	NN	O
adapted	VBD	O
this	DT	O
concept	NN	O
to	TO	O
continuity	NN	O
of	IN	O
care	NN	O
.	.	O

This	DT	O
did	VBD	O
not	RB	O
apparently	RB	O
affect	VBP	O
any	DT	O
of	IN	O
the	DT	O
guiding	VBG	O
principles	NNS	O
contained	VBN	O
in	IN	O
the	DT	O
original	JJ	O
document	NN	O
,	,	O
and	CC	O
yet	RB	O
enhanced	VBN	O
satisfaction	NN	O
.	.	O

It	PRP	O
would	MD	O
appear	VB	O
that	IN	O
the	DT	O
Changing	NNP	O
Childbirth	NNP	O
agenda	NN	O
can	MD	O
be	VB	O
adapted	VBN	O
and	CC	O
integrated	VBN	O
with	IN	O
local	JJ	O
health	NN	O
care	NN	O
situations	NNS	O
without	IN	O
sacrificing	VBG	O
any	DT	O
of	IN	O
the	DT	O
overarching	JJ	O
principles	NNS	O
.	.	O

Heparin-coated	JJ	O
cardiopulmonary	JJ	O
bypass	NN	O
circuits	NNS	O
reduce	VB	O
circulating	VBG	O
complement	JJ	O
factors	NNS	O
and	CC	O
interleukin-6	NN	O
in	IN	O
paediatric	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

Children	NNP	O
are	VBP	O
sensitive	JJ	O
to	TO	O
the	DT	O
inflammatory	JJ	O
side	NN	O
effects	NNS	O
of	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
(	(	O
CPB	NNP	O
)	)	O
.	.	O

Our	PRP$	O
intention	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
if	IN	O
the	DT	O
biocompatibility	NN	O
benefits	NNS	O
of	IN	O
heparin-coated	JJ	O
CPB	NNP	O
circuits	NNS	O
apply	VBP	O
to	TO	O
children	NNS	O
.	.	O

In	IN	O
20	CD	O
operations	NNS	O
,	,	O
19	CD	O
children	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
heparin-coated	JJ	O
(	(	O
group	NN	O
HC	NNP	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
standard	JJ	O
(	(	O
group	NN	O
C	NNP	O
,	,	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
bypass	NN	O
circuits	NNS	O
.	.	O

Plasma	NNP	O
levels	NNS	O
of	IN	O
acute	JJ	O
phase	NN	O
reactants	NNS	O
,	,	O
interleukins	NNS	O
,	,	O
granulocytic	JJ	O
proteins	NNS	O
and	CC	O
complement	JJ	O
factors	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

All	DT	O
were	VBD	O
significantly	RB	O
elevated	VBN	O
after	IN	O
CPB	NNP	O
.	.	O

Levels	NNP	O
of	IN	O
complement	NN	O
factor	NN	O
C3a	NNP	O
(	(	O
851	CD	O
(	(	O
791-959	CD	O
)	)	O
ng/ml	FW	O
[	JJ	O
median	NN	O
with	IN	O
quartiles	NNS	O
]	VBP	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
497	CD	O
(	(	O
476-573	JJ	O
)	)	O
ng/ml	NN	O
in	IN	O
group	NN	O
HC	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
Terminal	NNP	O
Complement	NNP	O
Complex	NNP	O
(	(	O
114	CD	O
(	(	O
71-130	CD	O
)	)	O
AU/ml	NNP	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
35.5	CD	O
(	(	O
28.9-51.4	JJ	O
)	)	O
AU/ml	NNP	O
in	IN	O
group	NN	O
HC	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
interleukin-6	NN	O
(	(	O
570	CD	O
(	(	O
203-743	JJ	O
)	)	O
pg/ml	NN	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
168	CD	O
(	(	O
111-206	CD	O
)	)	O
pg/ml	NN	O
in	IN	O
group	NN	O
HC	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.005	CD	O
)	)	O
,	,	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
group	NN	O
HC	NNP	O
.	.	O

Heparin-coated	JJ	O
CPB	NNP	O
circuits	NNS	O
improve	VBP	O
the	DT	O
biocompatibility	NN	O
of	IN	O
CPB	NNP	O
during	IN	O
heart	NN	O
surgery	NN	O
in	IN	O
the	DT	O
paediatric	JJ	O
patient	NN	O
population	NN	O
,	,	O
as	IN	O
reflected	VBN	O
by	IN	O
significantly	RB	O
reduced	VBN	O
levels	NNS	O
of	IN	O
circulating	VBG	O
complement	JJ	O
factors	NNS	O
and	CC	O
interleukin-6	NN	O
.	.	O

Effects	NNS	O
of	IN	O
two	CD	O
types	NNS	O
of	IN	O
social	JJ	O
support	NN	O
and	CC	O
education	NN	O
on	IN	O
adaptation	NN	O
to	TO	O
early-stage	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
.	.	O

A	DT	O
Roy	NNP	O
adaptation	NN	O
model-based	JJ	O
support	NN	O
and	CC	O
education	NN	O
intervention	NN	O
for	IN	O
women	NNS	Sex
with	IN	O
early-stage	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
was	VBD	O
tested	VBN	O
in	IN	O
a	DT	O
three-group	JJ	O
,	,	O
three-phase	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
a	DT	O
sample	NN	O
of	IN	O
125	CD	SampleSize
women	NNS	Sex
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
received	VBD	O
13	CD	O
months	NNS	O
of	IN	O
combined	JJ	O
individual	JJ	O
telephone	NN	O
and	CC	O
in-person	NN	O
group	NN	O
support	NN	O
and	CC	O
education	NN	O
,	,	O
Control	NNP	O
Group	NNP	O
1	CD	O
received	VBD	O
13	CD	O
months	NNS	O
of	IN	O
telephone-only	JJ	O
individual	JJ	O
support	NN	O
and	CC	O
education	NN	O
,	,	O
and	CC	O
Control	NNP	O
Group	NNP	O
2	CD	O
received	VBD	O
one-time	RB	O
mailed	JJ	O
educational	JJ	O
information	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
and	CC	O
Control	NNP	O
Group	NNP	O
1	CD	O
reported	VBD	O
less	JJR	O
mood	NN	O
disturbance	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
all	DT	O
three	CD	O
phases	NNS	O
,	,	O
less	JJR	O
loneliness	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
Phases	NNP	O
II	NNP	O
and	CC	O
III	NNP	O
,	,	O
and	CC	O
a	DT	O
higher-quality	NN	O
relationship	NN	O
with	IN	O
a	DT	O
significant	JJ	O
other	JJ	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
Phase	NNP	O
II	NNP	O
than	IN	O
did	VBD	O
Control	NNP	O
Group	NNP	O
2	CD	O
.	.	O

No	DT	O
group	NN	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
cancer-related	JJ	O
worry	NN	O
or	CC	O
well-being	NN	O
.	.	O

The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
individual	JJ	O
telephone	NN	O
support	NN	O
may	MD	O
provide	VB	O
an	DT	O
effective	JJ	O
alternative	NN	O
to	TO	O
in-person	JJ	O
support	NN	O
groups	NNS	O
.	.	O

Further	NNP	O
study	NN	O
of	IN	O
telephone	NN	O
interventions	NNS	O
is	VBZ	O
recommended	VBN	O
using	VBG	O
ethnically	RB	O
and	CC	O
economically	RB	O
heterogeneous	JJ	O
samples	NNS	O
.	.	O

A	DT	O
pharmacy	NN	O
discharge	NN	O
plan	NN	O
for	IN	O
hospitalized	JJ	O
elderly	JJ	Age
patients	NNS	Age
--	:	O
a	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
to	TO	O
investigate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
pharmacy	NN	O
discharge	NN	O
plan	NN	O
in	IN	O
elderly	JJ	Age
hospitalized	JJ	O
patients	NNS	O
.	.	O

DESIGN	NNP	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SUBJECTS	NNP	O
AND	CC	O
SETTINGS	NNP	O
we	PRP	O
randomized	VBD	O
patients	NNS	O
aged	VBN	O
75	CD	Age
years	NNS	Age
and	CC	Age
older	JJR	Age
on	IN	O
four	CD	O
or	CC	O
more	JJR	O
medicines	NNS	O
who	WP	O
had	VBD	O
been	VBN	O
discharged	VBN	O
from	IN	O
three	CD	O
acute	JJ	O
general	JJ	O
and	CC	O
one	CD	O
long-stay	JJ	O
hospital	NN	O
to	TO	O
a	DT	O
pharmacy	NN	O
intervention	NN	O
or	CC	O
usual	JJ	O
care	NN	O
.	.	O

INTERVENTIONS	VBZ	O
the	DT	O
hospital	NN	O
pharmacist	NN	O
developed	VBD	O
discharge	NN	O
plans	NNS	O
which	WDT	O
gave	VBD	O
details	NNS	O
of	IN	O
medication	NN	O
and	CC	O
support	NN	O
required	VBN	O
by	IN	O
the	DT	O
patient	NN	O
.	.	O

A	DT	O
copy	NN	O
was	VBD	O
given	VBN	O
to	TO	O
the	DT	O
patient	NN	O
and	CC	O
to	TO	O
all	DT	O
relevant	JJ	O
professionals	NNS	O
and	CC	O
carers	NNS	O
.	.	O

This	DT	O
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
domiciliary	JJ	O
assessment	NN	O
by	IN	O
a	DT	O
community	NN	O
pharmacist	NN	O
.	.	O

In	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
patients	NNS	O
were	VBD	O
discharged	VBN	O
from	IN	O
hospital	NN	O
following	VBG	O
standard	JJ	O
procedures	NNS	O
that	WDT	O
included	VBD	O
a	DT	O
discharge	NN	O
letter	NN	O
to	TO	O
the	DT	O
general	JJ	O
practitioner	NN	O
listing	VBG	O
current	JJ	O
medications	NNS	O
.	.	O

OUTCOMES	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
re-admission	NN	O
to	TO	O
hospital	VB	O
within	IN	O
6	CD	O
months	NNS	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
the	DT	O
number	NN	O
of	IN	O
deaths	NNS	O
,	,	O
attendance	NN	O
at	IN	O
hospital	JJ	O
outpatient	NN	O
clinics	NNS	O
and	CC	O
general	JJ	O
practice	NN	O
and	CC	O
proportion	NN	O
of	IN	O
days	NNS	O
in	IN	O
hospital	NN	O
over	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
,	,	O
together	RB	O
with	IN	O
patients	NNS	O
'	POS	O
general	JJ	O
well-being	NN	O
,	,	O
satisfaction	NN	O
with	IN	O
the	DT	O
service	NN	O
and	CC	O
knowledge	NN	O
of	IN	O
and	CC	O
adherence	NN	O
to	TO	O
prescribed	VB	O
medication	NN	O
.	.	O

RESULTS	NNP	O
we	PRP	O
recruited	VBD	O
362	CD	O
patients	NNS	O
,	,	O
of	IN	O
whom	WP	O
181	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
each	DT	O
group	NN	O
.	.	O

We	PRP	O
collected	VBD	O
hospital	NN	O
and	CC	O
general	JJ	O
practice	NN	O
data	NNS	O
on	IN	O
at	IN	O
least	JJS	O
91	CD	O
and	CC	O
72	CD	O
%	NN	O
of	IN	O
patients	NNS	O
respectively	RB	O
at	IN	O
each	DT	O
follow-up	JJ	O
point	NN	O
and	CC	O
interviewed	VBD	O
between	IN	O
43	CD	O
and	CC	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
subjects	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
re-admitted	JJ	O
to	TO	O
hospital	VB	O
between	IN	O
baseline	NN	O
and	CC	O
3	CD	O
months	NNS	O
or	CC	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
we	PRP	O
found	VBD	O
no	DT	O
evidence	NN	O
to	TO	O
suggest	VB	O
that	IN	O
the	DT	O
co-ordinated	JJ	O
hospital	NN	O
and	CC	O
community	NN	O
pharmacy	NN	O
care	NN	O
discharge	NN	O
plans	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
in	IN	O
this	DT	O
study	NN	O
influence	NN	O
outcomes	NNS	O
.	.	O

Influence	NN	O
of	IN	O
special-effect	JJ	O
contact	NN	O
lenses	NNS	O
(	(	O
Crazy	NNP	O
Lenses	NNP	O
)	)	O
on	IN	O
visual	JJ	O
function	NN	O
.	.	O

PURPOSE	NNP	O
Special-effect	JJ	O
contact	NN	O
lenses	NNS	O
(	(	O
opaque	NN	O
,	,	O
tinted	VBD	O
soft	JJ	O
contact	NN	O
lenses	VBZ	O
that	IN	O
incorporate	JJ	O
decorative	JJ	O
images	NNS	O
such	JJ	O
as	IN	O
cateyes	NNS	O
,	,	O
stars	NNS	O
,	,	O
or	CC	O
hearts	NNS	O
to	TO	O
alter	VB	O
eye	NN	O
color	NN	O
and	CC	O
structure	NN	O
)	)	O
have	VBP	O
become	VBN	O
increasingly	RB	O
popular	JJ	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
such	JJ	O
lenses	NNS	O
impair	VBP	O
visual	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
A	DT	O
clear	JJ	O
soft	JJ	O
contact	NN	O
lens	NNS	O
and	CC	O
a	DT	O
special-effect	JJ	O
soft	JJ	O
contact	NN	O
lens	NNS	O
(	(	O
Crazy	NNP	O
lens	VBZ	O
,	,	O
)	)	O
were	VBD	O
fit	JJ	O
in	IN	O
changing	VBG	O
sequence	NN	O
in	IN	O
nine	CD	SampleSize
healthy	JJ	Condition
subjects	NNS	O
.	.	O

The	DT	O
parameters	NNS	O
studied	VBD	O
included	VBN	O
:	:	O
visual	JJ	O
acuity	NN	O
,	,	O
contrast	NN	O
sensitivity	NN	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
)	)	O
,	,	O
visual	JJ	O
field	NN	O
,	,	O
and	CC	O
mesopic	NN	O
vision	NN	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
following	JJ	O
parameters	NNS	O
displayed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Visual	JJ	O
acuity	NN	O
was	VBD	O
decreased	VBN	O
to	TO	O
0.9	CD	O
+/-	JJ	O
0.23	CD	O
in	IN	O
the	DT	O
Crazy	NNP	O
lens	VBZ	O
group	NN	O
as	IN	O
compared	VBN	O
with	IN	O
1.2	CD	O
+/-	JJ	O
0.13	CD	O
in	IN	O
the	DT	O
clear	JJ	O
lens	NNS	O
group	NN	O
.	.	O

Goldmann	NNP	O
visual	JJ	O
field	NN	O
displayed	VBD	O
a	DT	O
significant	JJ	O
constriction	NN	O
of	IN	O
the	DT	O
isopters	NNS	O
:	:	O
III/4	NNP	O
,	,	O
I/4	NNP	O
,	,	O
and	CC	O
I/3	NNP	O
.	.	O

Mesopic	NNP	O
vision	NN	O
without	IN	O
glare	NN	O
was	VBD	O
reduced	VBN	O
from	IN	O
1:2.5	CD	O
to	TO	O
1:7.4	CD	O
.	.	O

Contrast	NNP	O
sensitivity	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
a	DT	O
photopic	JJ	O
condition	NN	O
with	IN	O
and	CC	O
without	IN	O
glare	NN	O
and	CC	O
in	IN	O
a	DT	O
scotopic	JJ	O
condition	NN	O
without	IN	O
glare	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
special-effect	JJ	O
lenses	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
lens	NNS	O
wearing	VBG	O
comfort	NN	O
.	.	O

CONCLUSIONS	NNP	O
Special-effect	JJ	O
contact	NN	O
lenses	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
of	IN	O
many	JJ	O
visual	JJ	O
functions	NNS	O
,	,	O
including	VBG	O
visual	JJ	O
acuity	NN	O
and	CC	O
contrast	NN	O
sensitivity	NN	O
.	.	O

For	IN	O
some	DT	O
wearers	NNS	O
this	DT	O
may	MD	O
interfere	VB	O
with	IN	O
activities	NNS	O
where	WRB	O
excellent	JJ	O
vision	NN	O
is	VBZ	O
crucial	JJ	O
,	,	O
such	JJ	O
as	IN	O
driving	VBG	O
a	DT	O
car	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
risedronate	NN	O
on	IN	O
vertebral	JJ	O
fractures	NNS	O
in	IN	O
women	NNS	Sex
with	IN	O
established	VBN	O
postmenopausal	NN	Condition
osteoporosis	NN	Condition
.	.	O

Vertebral	JJ	O
Efficacy	NN	O
with	IN	O
Risedronate	NNP	O
Therapy	NNP	O
(	(	O
VERT	NNP	O
)	)	O
Study	NNP	O
Group	NNP	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
,	,	O
double-masked	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
risedronate	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
vertebral	JJ	O
fractures	NNS	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
established	VBN	Condition
osteoporosis	NN	Condition
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
80	CD	O
study	NN	O
centers	NNS	O
in	IN	O
Europe	NNP	O
and	CC	O
Australia	NNP	O
.	.	O

Postmenopausal	NNP	O
women	NNS	O
(	(	O
n	JJ	O
=	NN	O
1226	CD	O
)	)	O
with	IN	O
two	CD	Condition
or	CC	Condition
more	JJR	Condition
prevalent	JJ	Condition
vertebral	JJ	Condition
fractures	NNS	Condition
received	VBD	O
risedronate	JJ	O
2.5	CD	O
or	CC	O
5	CD	O
mg/day	NN	O
or	CC	O
placebo	NN	O
;	:	O
all	DT	O
subjects	NNS	O
also	RB	O
received	VBD	O
elemental	JJ	O
calcium	NN	O
1000	CD	O
mg/day	NN	O
,	,	O
and	CC	O
up	RB	O
to	TO	O
500	CD	O
IU/day	NNP	O
vitamin	FW	O
D	NNP	O
if	IN	O
baseline	NN	O
levels	NNS	O
were	VBD	O
low	JJ	O
.	.	O

The	DT	O
study	NN	O
duration	NN	O
was	VBD	O
3	CD	O
years	NNS	O
;	:	O
however	RB	O
,	,	O
the	DT	O
2.5	CD	O
mg	NN	O
group	NN	O
was	VBD	O
discontinued	VBN	O
by	IN	O
protocol	NN	O
amendment	NN	O
after	IN	O
2	CD	O
years	NNS	O
.	.	O

Lateral	JJ	O
spinal	JJ	O
radiographs	NN	O
were	VBD	O
taken	VBN	O
annually	RB	O
for	IN	O
assessment	NN	O
of	IN	O
vertebral	JJ	O
fractures	NNS	O
,	,	O
and	CC	O
bone	RB	O
mineral	JJ	O
density	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
dual-energy	JJ	O
X-ray	JJ	O
absorptiometry	NN	O
at	IN	O
6-month	JJ	O
intervals	NNS	O
.	.	O

Risedronate	VB	O
5	CD	O
mg	NN	O
reduced	VBD	O
the	DT	O
risk	NN	O
of	IN	O
new	JJ	O
vertebral	JJ	O
fractures	NNS	O
by	IN	O
49	CD	O
%	NN	O
over	IN	O
3	CD	O
years	NNS	O
compared	VBN	O
with	IN	O
control	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
61	CD	O
%	NN	O
was	VBD	O
seen	VBN	O
within	IN	O
the	DT	O
first	JJ	O
year	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
fracture	NN	O
reduction	NN	O
with	IN	O
risedronate	NN	O
2.5	CD	O
mg	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
in	IN	O
the	DT	O
5	CD	O
mg	NN	O
group	NN	O
over	IN	O
2	CD	O
years	NNS	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
nonvertebral	JJ	O
fractures	NNS	O
was	VBD	O
reduced	VBN	O
by	IN	O
33	CD	O
%	NN	O
compared	VBN	O
with	IN	O
control	NN	O
over	IN	O
3	CD	O
years	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.06	CD	O
)	)	O
.	.	O

Risedronate	NNP	O
significantly	RB	O
increased	VBD	O
bone	JJ	O
mineral	JJ	O
density	NN	O
at	IN	O
the	DT	O
spine	NN	O
and	CC	O
hip	NN	O
within	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
adverse-event	JJ	O
profile	NN	O
of	IN	O
risedronate	NN	O
,	,	O
including	VBG	O
gastrointestinal	JJ	O
adverse	JJ	O
events	NNS	O
,	,	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
control	NN	O
.	.	O

Risedronate	NNP	O
5	CD	O
mg	NN	O
provides	VBZ	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
therapy	NN	O
for	IN	O
severe	JJ	Condition
postmenopausal	NN	Condition
osteoporosis	NN	Condition
,	,	O
reducing	VBG	O
the	DT	O
incidence	NN	O
of	IN	O
vertebral	JJ	O
fractures	NNS	O
and	CC	O
improving	VBG	O
bone	NN	O
density	NN	O
in	IN	O
women	NNS	O
with	IN	O
established	VBN	Condition
disease	NN	Condition
.	.	O

Mediastinal	JJ	O
lymphadenectomy	NN	O
in	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
:	:	O
effectiveness	NN	O
in	IN	O
patients	NNS	O
with	IN	O
or	CC	O
without	IN	O
nodal	JJ	O
micrometastases	NNS	O
-	:	O
results	NNS	O
of	IN	O
a	DT	O
preliminary	JJ	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
So	RB	O
far	RB	O
it	PRP	O
has	VBZ	O
not	RB	O
clearly	RB	O
been	VBN	O
demonstrated	VBN	O
that	IN	O
systematic	JJ	O
mediastinal	JJ	O
lymphadenectomy	NN	O
improves	VBZ	O
survival	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
.	.	O

One	CD	O
explanation	NN	O
might	MD	O
be	VB	O
that	IN	O
in	IN	O
some	DT	O
patients	NNS	O
an	DT	O
early	JJ	O
spread	NN	O
of	IN	O
tumor	NN	O
cells	NNS	O
has	VBZ	O
occurred	VBN	O
which	WDT	O
might	MD	O
not	RB	O
be	VB	O
curable	JJ	O
by	IN	O
surgical	JJ	O
means	NNS	O
.	.	O

To	TO	O
test	VB	O
this	DT	O
hypothesis	NN	O
lymph	VBZ	O
nodes	NNS	O
of	IN	O
patients	NNS	O
which	WDT	O
were	VBD	O
treated	VBN	O
either	RB	O
by	IN	O
lymph	NN	O
node	NN	O
sampling	VBG	O
or	CC	O
systematic	JJ	O
lymphadenectomy	NN	O
were	VBD	O
screened	VBN	O
for	IN	O
micrometastatic	JJ	O
spread	NN	O
of	IN	O
tumor	NN	O
cells	NNS	O
and	CC	O
the	DT	O
influence	NN	O
of	IN	O
nodal	JJ	O
micrometastases	NNS	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
lymphadenectomy	NN	O
was	VBD	O
analyzed	VBN	O
.	.	O

METHODS	NNP	O
Lymph	NNP	O
nodes	NNS	O
from	IN	O
patients	NNS	O
(	(	O
n=94	NN	O
)	)	O
which	WDT	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
lymph	NN	O
node	NN	O
sampling	NN	O
(	(	O
LS	NNP	O
,	,	O
n=41	NN	O
)	)	O
versus	NN	O
radical	JJ	O
systematic	JJ	O
lymphadenectomy	NN	O
(	(	O
LA	NNP	O
,	,	O
n=53	RB	O
)	)	O
were	VBD	O
screened	VBN	O
by	IN	O
immunohistochemistry	NN	O
for	IN	O
disseminated	JJ	O
tumor	NN	O
cells	NNS	O
using	VBG	O
the	DT	O
antibody	NN	O
Ber-Ep4	NNP	O
.	.	O

The	DT	O
median	JJ	O
observation	NN	O
time	NN	O
was	VBD	O
longer	JJR	O
than	IN	O
5	CD	O
years	NNS	O
and	CC	O
follow-up	JJ	O
data	NNS	O
were	VBD	O
available	JJ	O
from	IN	O
all	DT	O
94	CD	O
patients	NNS	O
.	.	O

Kaplan-Meier	NNP	O
curves	NNS	O
were	VBD	O
calculated	VBN	O
and	CC	O
tested	VBN	O
for	IN	O
statistical	JJ	O
significance	NN	O
using	VBG	O
the	DT	O
log-rank	JJ	O
test	NN	O
.	.	O

RESULTS	NNP	O
Standard	NNP	O
histopathological	JJ	O
analysis	NN	O
revealed	VBD	O
no	DT	O
lymph	NN	O
node	RB	O
involvement	NN	O
(	(	O
pN0	NN	O
)	)	O
in	IN	O
61	CD	O
patients	NNS	O
,	,	O
pN1	JJ	O
disease	NN	O
in	IN	O
13	CD	O
patients	NNS	O
and	CC	O
pN2	JJ	O
disease	NN	O
in	IN	O
20	CD	O
patients	NNS	O
without	IN	O
significant	JJ	O
differences	NNS	O
between	IN	O
LA	NNP	O
and	CC	O
LS	NNP	O
with	IN	O
respect	NN	O
to	TO	O
T-stage	NN	O
,	,	O
N-stage	NN	O
or	CC	O
age	NN	O
and	CC	O
sex	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

By	IN	O
immunohistochemistry	NN	O
a	DT	O
minimal	JJ	O
nodal	JJ	O
spread	NN	O
of	IN	O
tumor	NN	O
cells	NNS	O
was	VBD	O
detected	VBN	O
in	IN	O
21	CD	O
out	IN	O
of	IN	O
94	CD	O
patients	NNS	O
(	(	O
LS	NNP	O
,	,	O
n=10	NN	O
(	(	O
24	CD	O
%	NN	O
)	)	O
;	:	O
LA	NNP	O
,	,	O
n=11	NN	O
(	(	O
21	CD	O
%	NN	O
)	)	O
)	)	O
.	.	O

Similar	JJ	O
to	TO	O
the	DT	O
entire	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
also	RB	O
in	IN	O
the	DT	O
subset	NN	O
of	IN	O
patients	NNS	O
with	IN	O
nodal	JJ	O
micrometastases	VBZ	O
the	DT	O
type	NN	O
of	IN	O
lymphadenectomy	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
influence	VB	O
the	DT	O
long-term	JJ	O
survival	NN	O
(	(	O
P=0.27	NNP	O
and	CC	O
P=0.39	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
negative	JJ	O
immunohistochemical	JJ	O
analysis	NN	O
systematic	JJ	O
lymphadenectomy	NN	O
resulted	VBD	O
in	IN	O
an	DT	O
improved	JJ	O
overall	JJ	O
survival	NN	O
(	(	O
P=0.044	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
Our	PRP$	O
data	NNS	O
provide	VB	O
some	DT	O
evidence	NN	O
that	IN	O
systematic	JJ	O
lymphadenectomy	NN	O
improves	VBZ	O
survival	JJ	O
in	IN	O
patients	NNS	O
without	IN	O
an	DT	O
early	JJ	O
locoregional	JJ	O
spread	NN	O
of	IN	O
cancer	NN	O
cells	NNS	O
.	.	O

As	RB	O
long	RB	O
as	IN	O
these	DT	O
patients	NNS	O
can	MD	O
not	RB	O
be	VB	O
identified	VBN	O
preoperatively	RB	O
all	DT	O
patients	NNS	O
should	MD	O
undergo	VB	O
a	DT	O
systematic	JJ	O
mediastinal	JJ	O
lymphadenectomy	NN	O
.	.	O

Chronic	NNP	O
fatigue	NN	O
syndrome	NN	O
versus	NN	O
neuroendocrineimmune	JJ	O
dysfunction	NN	O
syndrome	NN	O
:	:	O
differential	JJ	O
attributions	NNS	O
.	.	O

Since	IN	O
1988	CD	O
,	,	O
when	WRB	O
the	DT	O
term	NN	O
chronic	JJ	O
fatigue	NN	O
syndrome	NN	O
(	(	O
CFS	NNP	O
)	)	O
was	VBD	O
coined	VBN	O
,	,	O
considerable	JJ	O
discussion	NN	O
has	VBZ	O
occurred	VBN	O
about	IN	O
stigma	NN	O
associated	VBN	O
with	IN	O
this	DT	O
diagnostic	JJ	O
term	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
patients	NNS	Condition
with	IN	Condition
CFS	NNP	Condition
have	VBP	O
felt	VBN	O
that	IN	O
this	DT	O
term	NN	O
trivializes	VBZ	O
the	DT	O
serious	JJ	O
nature	NN	O
of	IN	O
this	DT	O
disorder	NN	O
.	.	O

A	DT	O
Name	NN	O
Change	NNP	O
Work	NNP	O
group	NN	O
,	,	O
appointed	VBN	O
by	IN	O
the	DT	O
CFS	NNP	O
Coordinating	NNP	O
Committee	NNP	O
,	,	O
developed	VBD	O
an	DT	O
umbrella	JJ	O
term	NN	O
:	:	O
chronic	JJ	O
neuroendocrineimmune	JJ	O
dysfunction	NN	O
syndrome	NN	O
(	(	O
CNDS	NNP	O
)	)	O
,	,	O
and	CC	O
proposed	VBD	O
that	IN	O
there	EX	O
would	MD	O
be	VB	O
sub-types	JJ	O
under	IN	O
this	DT	O
term	NN	O
,	,	O
one	CD	O
being	VBG	O
CFS	NNP	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
attributions	NNS	O
of	IN	O
this	DT	O
new	JJ	O
umbrella	JJ	O
term	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
CFS	NNP	O
.	.	O

Nurses	NNS	O
and	CC	O
physician	JJ	O
assistants	NNS	O
(	(	O
PAs	NNP	O
)	)	O
were	VBD	O
presented	VBN	O
a	DT	O
case	NN	O
study	NN	O
of	IN	O
a	DT	O
patient	NN	O
with	IN	O
symptoms	NNS	O
of	IN	O
CFS	NNP	O
.	.	O

They	PRP	O
were	VBD	O
told	VBN	O
that	IN	O
the	DT	O
patient	NN	O
had	VBD	O
either	CC	O
chronic	JJ	O
fatigue	NN	O
syndrome	NN	O
,	,	O
chronic	JJ	O
neuroendocrineimmune	JJ	O
dysfunction	NN	O
syndrome	NN	O
,	,	O
or	CC	O
chronic	JJ	O
neuroendocrineimmune	JJ	O
dysfunction	NN	O
syndrome	NN	O
,	,	O
which	WDT	O
had	VBD	O
formerly	RB	O
been	VBN	O
called	VBN	O
chronic	JJ	O
fatigue	NN	O
syndrome	NN	O
.	.	O

The	DT	O
different	JJ	O
terms	NNS	O
led	VBD	O
to	TO	O
different	JJ	O
attributions	NNS	O
,	,	O
with	IN	O
PA	NNP	O
respondents	NNS	O
rating	NN	O
the	DT	O
CNDS	NNP	O
label	NN	O
as	IN	O
more	RBR	O
severe	JJ	O
.	.	O

Results	VB	O
suggest	VBP	O
that	IN	O
a	DT	O
more	RBR	O
medical	JJ	O
sounding	VBG	O
term	NN	O
(	(	O
CNDS	NNP	O
)	)	O
may	MD	O
lead	VB	O
to	TO	O
attributions	NNS	O
that	IN	O
this	DT	O
syndrome	NN	O
is	VBZ	O
a	DT	O
more	RBR	O
serious	JJ	O
,	,	O
disabling	VBG	O
illness	NN	O
.	.	O

The	DT	O
policy	NN	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Hypnosis	NNP	O
treatment	NN	O
for	IN	O
severe	JJ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
:	:	O
investigation	NN	O
of	IN	O
mechanism	NN	O
and	CC	O
effects	NNS	O
on	IN	O
symptoms	NNS	O
.	.	O

Hypnosis	NNP	O
improves	VBZ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
(	(	O
IBS	NNP	O
)	)	O
,	,	O
but	CC	O
the	DT	O
mechanism	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

Possible	JJ	O
physiological	JJ	O
and	CC	O
psychological	JJ	O
mechanisms	NNS	O
were	VBD	O
investigated	VBN	O
in	IN	O
two	CD	O
studies	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
severe	JJ	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
received	VBD	O
seven	CD	O
biweekly	JJ	O
hypnosis	NN	O
sessions	NNS	O
and	CC	O
used	VBD	O
hypnosis	NN	O
audiotapes	NNS	O
at	IN	O
home	NN	O
.	.	O

Rectal	JJ	O
pain	NN	O
thresholds	NNS	O
and	CC	O
smooth	JJ	O
muscle	NN	O
tone	NN	O
were	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
barostat	NN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
in	IN	O
18	CD	O
patients	NNS	O
(	(	O
study	VB	O
I	PRP	O
)	)	O
,	,	O
and	CC	O
treatment	NN	O
changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
skin	JJ	O
conductance	NN	O
,	,	O
finger	NN	O
temperature	NN	O
,	,	O
and	CC	O
forehead	JJ	O
electromyographic	JJ	O
activity	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
24	CD	O
patients	NNS	O
(	(	O
study	VB	O
II	NNP	O
)	)	O
.	.	O

Somatization	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
depression	NN	O
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O

All	DT	O
central	JJ	O
IBS	NNP	O
symptoms	NNS	O
improved	VBN	O
substantially	RB	O
from	IN	O
treatment	NN	O
in	IN	O
both	DT	O
studies	NNS	O
.	.	O

Rectal	JJ	O
pain	NN	O
thresholds	NNS	O
,	,	O
rectal	JJ	O
smooth	JJ	O
muscle	NN	O
tone	NN	O
,	,	O
and	CC	O
autonomic	JJ	O
functioning	NN	O
(	(	O
except	IN	O
sweat	NN	O
gland	VBP	O
reactivity	NN	O
)	)	O
were	VBD	O
unaffected	VBN	O
by	IN	O
hypnosis	NN	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
somatization	NN	O
and	CC	O
psychological	JJ	O
distress	NN	O
showed	VBD	O
large	JJ	O
decreases	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
hypnosis	NN	O
improves	NNS	O
IBS	NNP	O
symptoms	NNS	O
through	IN	O
reductions	NNS	O
in	IN	O
psychological	JJ	O
distress	NN	O
and	CC	O
somatization	NN	O
.	.	O

Improvements	NNS	O
were	VBD	O
unrelated	JJ	O
to	TO	O
changes	NNS	O
in	IN	O
the	DT	O
physiological	JJ	O
parameters	NNS	O
measured	VBD	O
.	.	O

Randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
collaborative	JJ	O
care	NN	O
management	NN	O
of	IN	O
depression	NN	O
among	IN	O
low-income	JJ	O
patients	NNS	O
with	IN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
Alleviating	NNP	O
Depression	NNP	O
Among	IN	O
Patients	NNPS	O
With	IN	O
Cancer	NNP	O
(	(	O
ADAPt-C	NNP	O
)	)	O
collaborative	NN	O
care	NN	O
management	NN	O
for	IN	O
major	JJ	O
depression	NN	O
or	CC	O
dysthymia	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Study	NNP	O
patients	NNS	O
included	VBD	O
472	CD	O
low-income	JJ	O
,	,	O
predominantly	RB	O
female	JJ	O
Hispanic	JJ	O
patients	NNS	O
with	IN	O
cancer	NN	O
age	NN	O
>	VBD	O
or=	JJ	O
18	CD	O
years	NNS	O
with	IN	O
major	JJ	O
depression	NN	O
(	(	O
49	CD	O
%	NN	O
)	)	O
,	,	O
dysthymia	NN	O
(	(	O
5	CD	O
%	NN	O
)	)	O
,	,	O
or	CC	O
both	DT	O
(	(	O
46	CD	O
%	NN	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
242	CD	O
)	)	O
or	CC	O
enhanced	VBN	O
usual	JJ	O
care	NN	O
(	(	O
EUC	NNP	O
;	:	O
n	CC	O
=	VB	O
230	CD	O
)	)	O
.	.	O

Intervention	NN	O
patients	NNS	O
had	VBD	O
access	NN	O
for	IN	O
up	IN	O
to	TO	O
12	CD	O
months	NNS	O
to	TO	O
a	DT	O
depression	NN	O
clinical	JJ	O
specialist	NN	O
(	(	O
supervised	VBN	O
by	IN	O
a	DT	O
psychiatrist	NN	O
)	)	O
who	WP	O
offered	VBD	O
education	NN	O
,	,	O
structured	VBD	O
psychotherapy	NN	O
,	,	O
and	CC	O
maintenance/relapse	NN	O
prevention	NN	O
support	NN	O
.	.	O

The	DT	O
psychiatrist	NN	O
prescribed	VBD	O
antidepressant	JJ	O
medications	NNS	O
for	IN	O
patients	NNS	O
preferring	VBG	O
or	CC	O
assessed	VBN	O
to	TO	O
require	VB	O
medication	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
12	CD	O
months	NNS	O
,	,	O
63	CD	O
%	NN	O
of	IN	O
intervention	NN	O
patients	NNS	O
had	VBD	O
a	DT	O
50	CD	O
%	NN	O
or	CC	O
greater	JJR	O
reduction	NN	O
in	IN	O
depressive	JJ	O
symptoms	NNS	O
from	IN	O
baseline	NN	O
as	IN	O
assessed	VBN	O
by	IN	O
the	DT	O
Patient	NNP	O
Health	NNP	O
Questionnaire-9	NNP	O
(	(	O
PHQ-9	NNP	O
)	)	O
depression	NN	O
scale	NN	O
compared	VBN	O
with	IN	O
50	CD	O
%	NN	O
of	IN	O
EUC	NNP	O
patients	NNS	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NNP	O
=	VBZ	O
1.98	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.16	CD	O
to	TO	O
3.38	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Improvement	NN	O
was	VBD	O
also	RB	O
found	VBN	O
for	IN	O
5-point	JJ	O
decrease	NN	O
in	IN	O
PHQ-9	NNP	O
score	NN	O
among	IN	O
72.2	CD	O
%	NN	O
of	IN	O
intervention	NN	O
patients	NNS	O
compared	VBN	O
with	IN	O
59.7	CD	O
%	NN	O
of	IN	O
EUC	NNP	O
patients	NNS	O
(	(	O
OR	NNP	O
=	VBZ	O
1.99	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.14	CD	O
to	TO	O
3.50	CD	O
;	:	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

Intervention	NN	O
patients	NNS	O
also	RB	O
experienced	VBD	O
greater	JJR	O
rates	NNS	O
of	IN	O
depression	NN	O
treatment	NN	O
(	(	O
72.3	CD	O
%	NN	O
v	JJ	O
10.4	CD	O
%	NN	O
of	IN	O
EUC	NNP	O
patients	NNS	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
and	CC	O
significantly	RB	O
better	JJR	O
quality-of-life	JJ	O
outcomes	NNS	O
,	,	O
including	VBG	O
social/family	RB	O
(	(	O
adjusted	VBN	O
mean	NN	O
difference	NN	O
between	IN	O
groups	NNS	O
,	,	O
2.7	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.22	CD	O
to	TO	O
4.17	CD	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
emotional	JJ	O
(	(	O
adjusted	JJ	O
mean	NN	O
difference	NN	O
,	,	O
1.29	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.26	CD	O
to	TO	O
2.22	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
,	,	O
functional	JJ	O
(	(	O
adjusted	JJ	O
mean	NN	O
difference	NN	O
,	,	O
1.34	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.08	CD	O
to	TO	O
2.59	CD	O
;	:	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
,	,	O
and	CC	O
physical	JJ	O
well-being	NN	O
(	(	O
adjusted	VBN	O
mean	NN	O
difference	NN	O
,	,	O
2.79	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.49	CD	O
to	TO	O
5.1	CD	O
;	:	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
ADAPt-C	NNP	O
collaborative	JJ	O
care	NN	O
is	VBZ	O
feasible	JJ	O
and	CC	O
results	NNS	O
in	IN	O
significant	JJ	O
reduction	NN	O
in	IN	O
depressive	JJ	O
symptoms	NNS	O
,	,	O
improvement	NN	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
lower	JJR	O
pain	NN	O
levels	NNS	O
compared	VBN	O
with	IN	O
EUC	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
depressive	JJ	O
disorders	NNS	O
in	IN	O
a	DT	O
low-income	JJ	O
,	,	O
predominantly	RB	O
Hispanic	JJ	O
population	NN	O
in	IN	O
public	JJ	O
sector	NN	O
oncology	NN	O
clinics	NNS	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
zengjing	VBG	O
no	DT	O
.	.	O

1	CD	O
capsule	NN	O
on	IN	O
morphology	NN	O
and	CC	O
motility	NN	O
of	IN	O
sperm	NN	O
in	IN	O
patients	NNS	O
with	IN	O
oligospermia	JJ	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
explore	VB	O
the	DT	O
effect	NN	O
of	IN	O
Zengjing	VBG	O
Capsule	NNP	O
No	NNP	O
.	.	O

1	CD	O
(	(	O
ZJC1	NNP	O
)	)	O
on	IN	O
morphology	NN	O
and	CC	O
motility	NN	O
of	IN	O
sperm	NN	O
in	IN	O
patients	NNS	O
with	IN	O
oligospermia	NN	O
(	(	O
OSM	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Seventy-two	JJ	O
OSM	NNP	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
2	CD	O
groups	NNS	O
by	IN	O
a	DT	O
randomizing	JJ	O
digital	NN	O
table	NN	O
,	,	O
the	DT	O
treated	VBN	O
group	NN	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
they	PRP	O
were	VBD	O
treated	VBN	O
respectively	RB	O
by	IN	O
ZJC1	NNP	O
and	CC	O
Wuzi	NNP	O
Yanzong	NNP	O
Pill	NNP	O
(	(	O
WYP	NNP	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
of	IN	O
density	NN	O
,	,	O
motility	NN	O
and	CC	O
morphology	NN	O
of	IN	O
sperm	NN	O
in	IN	O
patients	NNS	O
before	IN	O
and	CC	O
after	IN	O
3-month	JJ	O
treatment	NN	O
were	VBD	O
examined	VBN	O
using	VBG	O
computerized	JJ	O
WLJY-9000	CD	O
colour	JJ	O
semen	NNS	O
analysis	NN	O
system	NN	O
with	IN	O
refined	JJ	O
Papanicolaou	NNP	O
's	POS	O
stain	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
density	NN	O
,	,	O
motility	NN	O
and	CC	O
morphology	NN	O
of	IN	O
sperm	NN	O
were	VBD	O
improved	VBN	O
and	CC	O
sperm	JJ	O
deformity	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
decreased	VBN	O
after	IN	O
treatment	NN	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
but	CC	O
the	DT	O
effects	NNS	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
were	VBD	O
better	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
ZJC1	NNP	O
can	MD	O
enhance	VB	O
the	DT	O
density	NN	O
and	CC	O
motility	NN	O
of	IN	O
sperm	NN	O
and	CC	O
reduce	VB	O
the	DT	O
sperm	JJ	O
deformity	NN	O
rate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
OSM	NNP	O
.	.	O

Fentanyl	NNP	O
supplementation	NN	O
to	TO	O
inhalation	NN	Condition
anaesthesia	NN	Condition
.	.	O

In	IN	O
eight	CD	SampleSize
out	IN	O
of	IN	O
15	CD	SampleSize
healthy	JJ	Condition
patients	NNS	O
undergoing	VBG	O
body	NN	O
surface	NN	O
surgery	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
fentanyl	JJ	O
infusion	NN	O
on	IN	O
a	DT	O
conventional	JJ	O
thiopentone	NN	O
,	,	O
nitrous	JJ	O
oxide	NN	O
,	,	O
oxygen	NN	O
and	CC	O
halothane	NN	O
anaesthetic	NN	O
was	VBD	O
studied	VBN	O
.	.	O

The	DT	O
fentanyl	JJ	O
infusion	NN	O
(	(	O
2	CD	O
micrograms/kg/hour	NN	O
)	)	O
reduced	VBD	O
the	DT	O
induction	NN	O
dose	NN	O
of	IN	O
thiopentone	NN	O
and	CC	O
caused	VBD	O
marked	JJ	O
respiratory	JJ	O
depression	NN	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
patients	NNS	O
'	POS	O
response	NN	O
to	TO	O
surgery	NN	O
.	.	O

The	DT	O
mean	JJ	O
arterial	JJ	O
pressures	NNS	O
and	CC	O
pulse	JJ	O
rates	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
each	DT	O
group	NN	O
throughout	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
operation	NN	O
.	.	O

The	DT	O
fentanyl	NN	O
made	VBD	O
no	DT	O
difference	NN	O
to	TO	O
the	DT	O
patients	NNS	O
'	POS	O
postoperative	JJ	O
analgesic	JJ	O
requirements	NNS	O
or	CC	O
to	TO	O
their	PRP$	O
recovery	NN	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
.	.	O

Children	NNP	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

I	PRP	O
:	:	O
comparison	NN	O
of	IN	O
placebo	NN	O
and	CC	O
single	JJ	O
dose	NN	O
of	IN	O
human	JJ	O
synthetic	JJ	O
secretin	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
human	JJ	O
synthetic	JJ	O
secretin	NN	O
(	(	O
HSS	NNP	O
)	)	O
on	IN	O
behaviour	NN	O
and	CC	O
communication	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
using	VBG	O
an	DT	O
objective	JJ	O
measure	NN	O
of	IN	O
communication	NN	O
and	CC	O
social	JJ	O
reciprocity	NN	O
and	CC	O
standardised	VBD	O
rating	NN	O
scales	NNS	O
.	.	O

METHODS	NNP	O
Randomised	VBD	O
,	,	O
crossover	NN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
and	CC	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
human	JJ	O
synthetic	JJ	O
secretin	NN	O
(	(	O
HSS	NNP	O
)	)	O
2	CD	O
CU/kg	NNP	O
.	.	O

The	DT	O
62	CD	O
subjects	NNS	O
(	(	O
3-8	CD	O
years	NNS	O
)	)	O
were	VBD	O
assigned	VBN	O
to	TO	O
group	NN	O
1	CD	O
(	(	O
saline	JJ	O
placebo/HSS	NN	O
)	)	O
or	CC	O
group	NN	O
2	CD	O
(	(	O
HSS/saline	NNP	O
placebo	NN	O
)	)	O
.	.	O

Diagnosis	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
ADI-R	NNP	O
(	(	O
Autism	NNP	O
Diagnostic	NNP	O
Interview-Revised	JJ	O
)	)	O
algorithm	NN	O
.	.	O

Severity	NN	O
of	IN	O
symptoms	NNS	O
was	VBD	O
rated	VBN	O
using	VBG	O
the	DT	O
CARS	NNP	O
(	(	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
)	)	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
Communication	NNP	O
and	CC	O
Symbolic	NNP	O
Behavior	NNP	O
Scale	NNP	O
(	(	O
CSBS	NNP	O
)	)	O
,	,	O
Ritvo	NNP	O
Real-life	NNP	O
Rating	NNP	O
Scale	NNP	O
,	,	O
weekly	JJ	O
Global	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
GBRS	NNP	O
)	)	O
by	IN	O
parents	NNS	O
and	CC	O
teachers	NNS	O
,	,	O
and	CC	O
daily	JJ	O
log	NN	O
of	IN	O
gastrointestinal	JJ	O
symptoms	NNS	O
.	.	O

The	DT	O
communication	NN	O
subscale	NN	O
of	IN	O
the	DT	O
CSBS	NNP	O
,	,	O
specifying	VBG	O
communication	NN	O
function	NN	O
,	,	O
reciprocity	NN	O
,	,	O
and	CC	O
social-affective	JJ	O
signalling	NN	O
was	VBD	O
videotaped	VBN	O
and	CC	O
scored	VBN	O
by	IN	O
a	DT	O
blinded	JJ	O
,	,	O
trained	JJ	O
observer	RB	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
one	CD	O
children	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

After	IN	O
randomisation	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
gender	NN	O
,	,	O
race	NN	O
,	,	O
age	NN	O
,	,	O
and	CC	O
parent	NN	O
and	CC	O
teacher	NN	O
GBRS	NNP	O
and	CC	O
Ritvo	NNP	O
Scale	NNP	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
secretin	FW	O
treatment	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
significant	JJ	O
improvement	NN	O
of	IN	O
CSBS	NNP	O
standard	JJ	O
scores	NNS	O
from	IN	O
baseline	NN	O
to	TO	O
2	CD	O
or	CC	O
4	CD	O
weeks	NNS	O
post-infusion	NN	O
.	.	O

Five	CD	O
children	NNS	O
showed	VBD	O
clinical	JJ	O
improvement	NN	O
in	IN	O
standard	JJ	O
scores	NNS	O
:	:	O
two	CD	O
after	IN	O
HSS	NNP	O
and	CC	O
three	CD	O
after	IN	O
placebo	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
gastrointestinal	NN	O
symptoms	NNS	O
after	IN	O
HSS	NNP	O
or	CC	O
saline	JJ	O
placebo	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intravenous	JJ	O
human	JJ	O
secretin	NN	O
is	VBZ	O
not	RB	O
effective	JJ	O
in	IN	O
changing	VBG	O
behaviour	NN	O
and	CC	O
communication	NN	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
when	WRB	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

Helicobacter	NNP	Condition
pylori	JJ	Condition
eradication	NN	O
in	IN	O
children	NNS	Age
and	CC	O
adolescents	NNS	Age
by	IN	O
a	DT	O
once	RB	O
daily	JJ	O
6-day	JJ	O
treatment	NN	O
with	IN	O
or	CC	O
without	IN	O
a	DT	O
proton	NN	O
pump	NN	O
inhibitor	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
trial	NN	O
.	.	O

AIM	NNP	O
To	TO	O
evaluate	VB	O
two	CD	O
simplified	JJ	O
Helicobacter	NNP	O
pylori	NN	O
eradication	NN	O
treatment	NN	O
alternatives	NNS	O
for	IN	O
children	NNS	Age
and	CC	O
adolescents	NNS	Age
.	.	O

METHODS	NNP	O
Study	NNP	O
subjects	NNS	O
were	VBD	O
identified	VBN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
and	CC	O
immunoblot	NN	O
in	IN	O
a	DT	O
family	NN	O
screening	VBG	O
project	NN	O
.	.	O

Helicobacter	NNP	Condition
pylori	NN	Condition
infected	VBD	O
10-21	JJ	Age
year	NN	O
olds	NNS	O
were	VBD	O
offered	VBN	O
treatment	NN	O
,	,	O
individuals	NNS	O
with	IN	O
abdominal	JJ	Condition
pain	NN	Condition
underwent	JJ	O
upper	JJ	O
endoscopy	NN	O
and	CC	O
those	DT	O
with	IN	O
peptic	JJ	Condition
ulcers	NNS	Condition
were	VBD	O
excluded	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
azithromycin	JJ	O
500	CD	O
mg	JJ	O
daily	JJ	O
and	CC	O
tinidazole	JJ	O
500	CD	O
mg	NN	O
two	CD	O
tablets	NNS	O
daily	RB	O
in	IN	O
combination	NN	O
with	IN	O
lansoprasole	JJ	O
30	CD	O
mg	JJ	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
(	(	O
ATL-group	NNP	O
)	)	O
or	CC	O
with	IN	O
placebo	NN	O
(	(	O
ATP-group	NNP	O
)	)	O
.	.	O

Urea	JJ	O
Breath	NNP	O
Test	NNP	O
was	VBD	O
performed	VBN	O
at	IN	O
inclusion	NN	O
and	CC	O
after	IN	O
a	DT	O
minimum	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
after	IN	O
end	NN	O
of	IN	O
therapy	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
total	JJ	O
,	,	O
131	CD	SampleSize
individuals	NNS	O
were	VBD	O
randomized	VBN	O
,	,	O
of	IN	O
whom	WP	O
31	CD	SampleSize
(	(	SampleSize
24	CD	SampleSize
%	NN	SampleSize
)	)	SampleSize
had	VBD	O
undergone	JJ	O
upper	JJ	O
endoscopy	NN	O
.	.	O

Full	NNP	O
compliance	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
93	CD	O
%	NN	O
(	(	O
122	CD	O
of	IN	O
131	CD	O
)	)	O
.	.	O

The	DT	O
intention-to-treat	JJ	O
eradication	NN	O
rate	NN	O
was	VBD	O
67	CD	O
%	NN	O
(	(	O
44	CD	O
of	IN	O
66	CD	O
)	)	O
and	CC	O
58	CD	O
%	NN	O
(	(	O
38	CD	O
of	IN	O
65	CD	O
)	)	O
for	IN	O
the	DT	O
ATL-	NNP	O
and	CC	O
the	DT	O
ATP-group	NNP	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	VB	O
The	DT	O
double-blind	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
did	VBD	O
not	RB	O
identify	VB	O
a	DT	O
simplified	VBN	O
,	,	O
successful	JJ	O
once	RB	O
daily	JJ	O
H.	NNP	O
pylori	NN	O
treatment	NN	O
for	IN	O
children	NNS	Age
and	CC	O
adolescents	NNS	Age
.	.	O

Thus	RB	O
,	,	O
twice	RB	O
daily	JJ	O
proton	NN	O
pump	NN	O
inhibitor	NN	O
(	(	O
PPI	NNP	O
)	)	O
-based	VBD	O
triple	JJ	O
therapies	NNS	O
for	IN	O
7	CD	O
days	NNS	O
remain	VBP	O
as	IN	O
the	DT	O
choice	NN	O
of	IN	O
treatment	NN	O
in	IN	O
children	NNS	Age
.	.	O

Further	NNP	O
,	,	O
powerful	JJ	O
and	CC	O
controlled	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
elucidate	VB	O
the	DT	O
best	JJS	O
treatment	NN	O
strategies	NNS	O
for	IN	O
H.	NNP	O
pylori	JJ	O
eradication	NN	O
in	IN	O
this	DT	O
age	NN	O
group	NN	O
.	.	O

Efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
antibiotics	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
H.	NNP	O
pylori	JJ	O
eradication	NN	O
.	.	O

BACKGROUND/AIMS	NNP	O
Helicobacter	NNP	O
pylori	NN	O
(	(	O
H.	NNP	O
pylori	NN	O
)	)	O
infection	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
common	JJ	O
gastrointestinal	JJ	O
diseases	NNS	O
.	.	O

An	DT	O
increasing	VBG	O
number	NN	O
of	IN	O
people	NNS	O
undergo	JJ	O
different	JJ	O
treatment	NN	O
options	NNS	O
.	.	O

Unfortunately	RB	O
,	,	O
H.	NNP	O
pylori	FW	O
therapy	NN	O
may	MD	O
be	VB	O
troublesome	JJ	O
for	IN	O
drug	NN	O
side	NN	O
effects	NNS	O
and	CC	O
inefficacious	JJ	O
for	IN	O
resistance	NN	O
to	TO	O
antibiotics	NNS	O
.	.	O

METHODOLOGY	NNP	O
One	CD	SampleSize
hundred	CD	SampleSize
and	CC	SampleSize
ninety-three	JJ	SampleSize
(	(	SampleSize
193	CD	SampleSize
)	)	SampleSize
H.	NNP	O
pylori-positive	JJ	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
7-day	JJ	O
treatments	NNS	O
:	:	O
Group	NNP	O
A	NNP	O
(	(	O
N	NNP	O
=	NNP	O
64	CD	SampleSize
)	)	O
:	:	O
amoxicillin	NN	O
,	,	O
clarithromycin	NN	O
and	CC	O
rabeprazole	NN	O
;	:	O
Group	NNP	Condition
B	NNP	Condition
(	(	O
N	NNP	O
=	NNP	O
64	CD	SampleSize
)	)	SampleSize
:	:	O
tinidazole	NN	O
,	,	O
clarithromycin	NN	O
and	CC	O
ranitidine	NN	O
bismuth	NN	O
citrate	NN	O
;	:	O
Group	NNP	O
C	NNP	O
(	(	O
N	NNP	O
=	NNP	O
65	CD	SampleSize
)	)	O
:	:	O
tinidazole	NN	O
,	,	O
clarithromycin	NN	O
and	CC	O
rabeprazole	JJ	O
Eradication	NNP	O
was	VBD	O
assessed	VBN	O
by	IN	O
13C-Urea	JJ	O
Breath	NNP	O
Test	NNP	O
6-8	JJ	O
weeks	NNS	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
therapy	NN	O
.	.	O

Not-eradicated	JJ	O
patients	NNS	O
underwent	VBD	O
a	DT	O
second	JJ	O
cycle	NN	O
with	IN	O
tinidazole	NN	O
,	,	O
tetracycline	NN	O
,	,	O
bismuth	NN	O
and	CC	O
rabeprazole	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
complete	VB	O
a	DT	O
validated	JJ	O
questionnaire	NN	O
regarding	VBG	O
presence	NN	O
and	CC	O
intensity	NN	O
of	IN	O
drug	NN	O
side	NN	O
effects	NNS	O
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
eighty-eight	JJ	O
out	IN	O
of	IN	O
the	DT	O
193	CD	O
H.	NNP	O
pylori-positive	JJ	O
patients	NNS	O
(	(	O
96	CD	O
%	NN	O
)	)	O
completed	VBD	O
therapy	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
eradication	NN	O
rates	NNS	O
was	VBD	O
observed	VBN	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
both	DT	O
in	IN	O
intention	NN	O
to	TO	O
treat	VB	O
analysis	NN	O
and	CC	O
in	IN	O
per	IN	O
protocol	NN	O
analysis	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
occurred	VBD	O
among	IN	O
groups	NNS	O
after	IN	O
the	DT	O
first-line	JJ	O
regimens	NNS	O
:	:	O
48	CD	O
%	NN	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
44	CD	O
%	NN	O
in	IN	O
group	NN	O
B	NNP	O
and	CC	O
46	CD	O
%	NN	O
in	IN	O
group	NN	O
C.	NNP	O
Twenty-two	NNP	O
out	IN	O
of	IN	O
the	DT	O
193	CD	O
enrolled	JJ	O
subjects	NNS	O
(	(	O
11	CD	O
%	NN	O
)	)	O
were	VBD	O
not	RB	O
eradicated	VBN	O
after	IN	O
the	DT	O
first-line	JJ	O
therapy	NN	O
.	.	O

Among	IN	O
them	PRP	O
,	,	O
86	CD	O
%	NN	O
were	VBD	O
successfully	RB	O
eradicated	VBN	O
by	IN	O
the	DT	O
tinidazole	NN	O
,	,	O
tetracycline	NN	O
,	,	O
bismuth	NN	O
and	CC	O
rabeprazole	JJ	O
therapy	NN	O
.	.	O

Moreover	RB	O
,	,	O
during	IN	O
quadruple	JJ	O
therapy	NN	O
,	,	O
a	DT	O
higher	JJR	O
prevalence	NN	O
and	CC	O
intensity	NN	O
of	IN	O
side	NN	O
effects	NNS	O
than	IN	O
in	IN	O
each	DT	O
one	CD	O
of	IN	O
the	DT	O
groups	NNS	O
submitted	VBD	O
to	TO	O
the	DT	O
first-line	JJ	O
triple	JJ	O
therapy	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
that	IN	O
triple	JJ	O
rabeprazole-based	JJ	O
eradicating	NN	O
regimens	NNS	O
are	VBP	O
effective	JJ	O
and	CC	O
safe	JJ	O
.	.	O

Incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
seems	VBZ	O
low	JJ	O
and	CC	O
similar	JJ	O
in	IN	O
different	JJ	O
three-drug	JJ	O
regimens	NNS	O
used	VBN	O
.	.	O

Quadruple	JJ	O
therapy	NN	O
,	,	O
which	WDT	O
appear	VBP	O
highly	RB	O
efficacious	JJ	O
as	IN	O
a	DT	O
second	JJ	O
line	NN	O
therapy	NN	O
,	,	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
significantly	RB	O
higher	JJR	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
first-line	JJ	O
treatment	NN	O
.	.	O

[	JJ	O
Triple	NNP	O
therapy	NN	O
regimens	VBZ	O
involving	VBG	O
H2	NNP	O
blockaders	NNS	O
for	IN	O
therapy	NN	O
of	IN	O
Helicobacter	NNP	O
pylori	FW	O
infections	NNS	O
]	VBP	O
.	.	O

Comparison	NNP	O
of	IN	O
ranitidine	NN	O
and	CC	O
lansoprazole	NN	O
in	IN	O
short-term	JJ	O
low-dose	JJ	O
triple	NN	O
therapy	NN	O
for	IN	O
Helicobacter	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
two	CD	O
1-week	JJ	O
low-dose	JJ	O
triple-therapy	JJ	O
drug	NN	O
regimens	NNS	O
involving	VBG	O
antisecretory	NN	O
drugs	NNS	O
for	IN	O
Helicobacter	NNP	O
pylori	JJ	O
infection	NN	O
,	,	O
99	CD	SampleSize
patients	NNS	O
with	IN	O
H.	NNP	O
pylori	FW	O
infection	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
either	DT	O
lansoprazole	NN	O
(	(	O
LPZ	NNP	O
)	)	O
or	CC	O
ranitidine	NN	O
(	(	O
RNT	NNP	O
)	)	O
used	VBD	O
together	RB	O
with	IN	O
clarithromycin	NN	O
(	(	O
CAM	NNP	O
)	)	O
and	CC	O
metrinidazole	$	O
(	(	O
MTZ	NNP	O
)	)	O
.	.	O

The	DT	O
drug	NN	O
combination	NN	O
and	CC	O
administration	NN	O
periods	NNS	O
in	IN	O
the	DT	O
PPI	NNP	O
group	NN	O
were	VBD	O
LPZ	NNP	O
30	CD	O
mg	NN	O
,	,	O
CAM	NNP	O
400	CD	O
mg	NN	O
,	,	O
MTZ	NNP	O
500	CD	O
mg	NN	O
(	(	O
LCM	NNP	O
group	NN	O
)	)	O
.	.	O

The	DT	O
ranitidine	NN	O
group	NN	O
received	VBD	O
RNT	NNP	O
300	CD	O
mg	NN	O
,	,	O
CAM	NNP	O
400	CD	O
mg	NN	O
,	,	O
MTZ	NNP	O
500	CD	O
mg	NN	O
(	(	O
RCM	NNP	O
group	NN	O
)	)	O
.	.	O

The	DT	O
cure	NN	O
rate	NN	O
of	IN	O
H.	NNP	O
pylori	FW	O
infection	NN	O
was	VBD	O
88	CD	O
%	NN	O
in	IN	O
the	DT	O
LCM	NNP	O
group	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
79-97	CD	O
and	CC	O
92	CD	O
%	NN	O
in	IN	O
the	DT	O
RCM	NNP	O
group	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
84-99	CD	O
.	.	O

Cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
for	IN	O
anxiety	NN	Condition
in	IN	Condition
children	NNS	Condition
with	IN	Condition
autism	NN	Condition
spectrum	NN	Condition
disorders	NNS	Condition
:	:	Condition
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
often	RB	O
present	JJ	O
with	IN	O
comorbid	NN	O
anxiety	NN	O
disorders	NNS	O
that	WDT	O
cause	VBP	O
significant	JJ	O
functional	JJ	O
impairment	NN	O
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
a	DT	O
modular	JJ	O
cognitive	JJ	O
behavioral	JJ	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
program	NN	O
for	IN	O
children	NNS	O
with	IN	O
this	DT	O
profile	NN	O
.	.	O

A	DT	O
standard	JJ	O
CBT	NNP	O
program	NN	O
was	VBD	O
augmented	VBN	O
with	IN	O
multiple	JJ	O
treatment	NN	O
components	NNS	O
designed	VBN	O
to	TO	O
accommodate	VB	O
or	CC	O
remediate	VB	O
the	DT	O
social	JJ	O
and	CC	O
adaptive	JJ	O
skill	NN	O
deficits	NNS	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
that	WDT	O
could	MD	O
pose	VB	O
barriers	NNS	O
to	TO	O
anxiety	VB	O
reduction	NN	O
.	.	O

METHOD	NNP	O
Forty	NNP	O
children	NNS	O
(	(	O
7-11	CD	O
years	NNS	O
old	JJ	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
16	CD	O
sessions	NNS	O
of	IN	O
CBT	NNP	O
or	CC	O
a	DT	O
3-month	JJ	O
waitlist	NN	O
(	(	O
36	CD	O
completed	VBN	O
treatment	NN	O
or	CC	O
waitlist	NN	O
)	)	O
.	.	O

Therapists	NNS	O
worked	VBD	O
with	IN	O
individual	JJ	O
families	NNS	O
.	.	O

The	DT	O
CBT	NNP	O
model	NN	O
emphasized	VBD	O
behavioral	JJ	O
experimentation	NN	O
,	,	O
parent-training	NN	O
,	,	O
and	CC	O
school	NN	O
consultation	NN	O
.	.	O

Independent	JJ	O
evaluators	NNS	O
blind	VBP	O
to	TO	O
treatment	NN	O
condition	NN	O
conducted	VBN	O
structured	JJ	O
diagnostic	JJ	O
interviews	NNS	O
and	CC	O
parents	NNS	O
and	CC	O
children	NNS	O
completed	VBN	O
anxiety	NN	O
symptom	NN	O
checklists	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
posttreatment/postwaitlist	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
intent-to-treat	JJ	O
analyses	NNS	O
,	,	O
78.5	CD	O
%	NN	O
of	IN	O
the	DT	O
CBT	NNP	O
group	NN	O
met	VBD	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NNP	O
scale	NN	O
criteria	NNS	O
for	IN	O
positive	JJ	O
treatment	NN	O
response	NN	O
at	IN	O
posttreatment	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
only	RB	O
8.7	CD	O
%	NN	O
of	IN	O
the	DT	O
waitlist	NN	O
group	NN	O
.	.	O

CBT	NNP	O
also	RB	O
outperformed	VBD	O
the	DT	O
waitlist	NN	O
on	IN	O
diagnostic	JJ	O
outcomes	NNS	O
and	CC	O
parent	NN	O
reports	NNS	O
of	IN	O
child	NN	O
anxiety	NN	O
,	,	O
but	CC	O
not	RB	O
children	NNS	O
's	POS	O
self-reports	NNS	O
.	.	O

Treatment	NN	O
gains	NNS	O
were	VBD	O
maintained	VBN	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
CBT	NNP	O
manual	JJ	O
employed	VBN	O
in	IN	O
this	DT	O
study	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
adaptations	NNS	O
of	IN	O
an	DT	O
evidence-based	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Remission	NN	O
of	IN	O
anxiety	NN	O
disorders	NNS	O
appears	VBZ	O
to	TO	O
be	VB	O
an	DT	O
achievable	JJ	O
goal	NN	O
among	IN	O
high-functioning	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
on	IN	O
hemostatic	JJ	O
variables	NNS	O
in	IN	O
women	NNS	Sex
with	IN	O
angiographically	RB	Condition
verified	VBN	Condition
coronary	JJ	Condition
artery	NN	Condition
disease	NN	Condition
:	:	O
results	NNS	O
from	IN	O
the	DT	O
estrogen	NN	O
in	IN	O
women	NNS	Sex
with	IN	O
atherosclerosis	NN	Condition
study	NN	O
.	.	O

Data	NNP	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
on	IN	O
hemostasis	NN	O
are	VBP	O
inconsistent	JJ	O
,	,	O
and	CC	O
there	EX	O
are	VBP	O
few	JJ	O
data	NNS	O
in	IN	O
women	NNS	Sex
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

In	IN	O
a	DT	O
single-center	NN	O
,	,	O
open	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
,	,	O
118	CD	SampleSize
postmenopausal	JJ	O
women	NNS	Sex
with	IN	O
angiographically	RB	Condition
verified	VBN	Condition
coronary	JJ	Condition
artery	NN	Condition
disease	NN	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
hormone	VB	O
replacement	NN	O
therapy	NN	O
,	,	O
given	VBN	O
as	IN	O
long-cycle	JJ	O
transdermal	JJ	O
17-beta-estradiol	JJ	O
(	(	O
50	CD	O
microg/24	RB	O
hour	NN	O
)	)	O
for	IN	O
3	CD	O
months	NNS	O
with	IN	O
sequential	JJ	O
medroxy-progesterone	NN	O
acetate	NN	O
for	IN	O
14	CD	O
days	NNS	O
,	,	O
or	CC	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
receiving	VBG	O
no	DT	O
therapy	NN	O
.	.	O

Hemostatic	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
3	CD	O
and	CC	O
12	CD	O
months	NNS	O
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
coagulation	NN	O
inhibitors	NNS	O
antithrombin	VBP	O
,	,	O
protein	JJ	O
C	NNP	O
,	,	O
and	CC	O
protein	NN	O
S	NNP	O
,	,	O
but	CC	O
not	RB	O
tissue	VB	O
factor	NN	O
pathway	NN	O
inhibitor	NN	O
,	,	O
decreased	VBN	O
significantly	RB	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
group	NN	O
at	IN	O
both	DT	O
3	CD	O
and	CC	O
12	CD	O
months	NNS	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
absolute	NN	O
decreases	VBZ	O
within	IN	O
the	DT	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
group	NN	O
were	VBD	O
3	CD	O
to	TO	O
10	CD	O
%	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
the	DT	O
coagulation	NN	O
products	NNS	O
prothrombin	VBP	O
fragment	JJ	O
1+2	CD	O
or	CC	O
thrombin-antithrombin	JJ	O
complex	NN	O
or	CC	O
for	IN	O
D-dimer	NNP	O
,	,	O
although	IN	O
there	EX	O
were	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
the	DT	O
levels	NNS	O
within	IN	O
the	DT	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
group	NN	O
.	.	O

Levels	NNP	O
of	IN	O
fibrinogen	NN	O
,	,	O
activated	VBD	O
factor	NN	O
VII	NNP	O
,	,	O
and	CC	O
factor	NN	O
VII	NNP	O
antigen	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
influenced	VBN	O
by	IN	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
treatment	NN	O
.	.	O

Similarly	RB	O
,	,	O
nonsignificant	JJ	O
changes	NNS	O
were	VBD	O
detected	VBN	O
for	IN	O
the	DT	O
fibrinolytic	JJ	O
parameters	NNS	O
tissue	VBP	O
plasminogen	JJ	O
activator	NN	O
activity	NN	O
,	,	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
antigen	NN	O
,	,	O
and	CC	O
global	JJ	O
fibrinolytic	JJ	O
activity	NN	O
,	,	O
but	CC	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
type	VBD	O
1	CD	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
group	NN	O
due	JJ	O
to	TO	O
a	DT	O
questionable	JJ	O
increase	NN	O
in	IN	O
the	DT	O
levels	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
treatment	NN	O
with	IN	O
transdermal	JJ	O
estradiol	NNS	O
combined	VBN	O
with	IN	O
long-cycle	NN	O
progestins	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
no	DT	O
net	JJ	O
activation	NN	O
of	IN	O
coagulation	NN	O
despite	IN	O
reduced	JJ	O
levels	NNS	O
of	IN	O
coagulation	NN	O
inhibitors	NNS	O
.	.	O

Diet	NNP	O
and	CC	O
vitamin	NNP	O
D	NNP	O
status	NN	O
among	IN	O
pregnant	JJ	Condition
Pakistani	NNP	Condition
women	NNS	Sex
in	IN	O
Oslo	NNP	O
.	.	O

OBJECTIVES	NNP	O
In	IN	O
the	DT	O
present	JJ	O
study	NN	O
the	DT	O
diet	NN	O
and	CC	O
the	DT	O
nutritional	JJ	O
status	NN	O
of	IN	O
pregnant	JJ	Condition
Pakistani	NNP	O
immigrant	NN	O
women	NNS	Sex
have	VBP	O
been	VBN	O
compared	VBN	O
with	IN	O
a	DT	O
group	NN	O
of	IN	O
Norwegian	JJ	Condition
women	NNS	Sex
.	.	O

DESIGN	VB	O
A	DT	O
cross-sectional	JJ	O
survey	NN	O
of	IN	O
women	NNS	Sex
in	IN	O
the	DT	O
18th	CD	Condition
week	NN	Condition
of	IN	Condition
pregnancy	NN	Condition
.	.	O

SETTING	NNP	O
Women	NNP	Sex
referred	VBD	O
to	TO	O
routine	VB	O
ultrasound	JJ	O
examination	NN	O
at	IN	O
Aker	NNP	O
and	CC	O
Ullev?l	NNP	O
Hospitals	NNP	O
in	IN	O
Norway	NNP	O
.	.	O

SUBJECTS	NNP	O
All	NNP	O
(	(	O
58	CD	O
)	)	O
healthy	JJ	O
women	NNS	O
of	IN	O
Pakistani	NNP	O
origin	NN	O
referred	VBD	O
from	IN	O
October	NNP	O
of	IN	O
1991	CD	O
to	TO	O
January	NNP	O
of	IN	O
1992	CD	O
were	VBD	O
included	VBN	O
,	,	O
of	IN	O
whom	WP	O
38	CD	O
(	(	O
66	CD	O
%	NN	O
)	)	O
participated	VBD	O
.	.	O

Forty-five	JJ	O
Norwegian	JJ	O
women	NNS	O
were	VBD	O
randomly	RB	O
included	VBN	O
in	IN	O
the	DT	O
same	JJ	O
period	NN	O
and	CC	O
38	CD	O
(	(	O
84	CD	O
%	NN	O
)	)	O
of	IN	O
these	DT	O
women	NNS	O
participated	VBD	O
.	.	O

RESULTS	VB	O
The	DT	O
serum	NN	O
levels	NNS	O
of	IN	O
25-hydroxyvitamin	JJ	O
D3	NNP	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
Pakistanis	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
Norwegians	NNPS	O
(	(	O
median	JJ	O
19	CD	O
nmol/l	JJ	O
vs	NN	O
55	CD	O
nmol/l	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
83	CD	O
%	NN	O
of	IN	O
the	DT	O
Pakistani	NNP	O
women	NNS	O
had	VBD	O
25-hydroxyvitamin	JJ	O
D3	NNP	O
levels	NNS	O
below	IN	O
the	DT	O
reference	NN	O
value	NN	O
(	(	O
<	JJ	O
30	CD	O
nmol/l	NN	O
)	)	O
.	.	O

The	DT	O
Pakistanis	NNP	O
had	VBD	O
higher	JJR	O
levels	NNS	O
of	IN	O
serum	NN	O
parathyroid	NN	O
hormone	NN	O
(	(	O
median	JJ	O
2.6	CD	O
vs	NN	O
1.6	CD	O
pmol/l	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
Pakistanis	NNP	O
also	RB	O
had	VBD	O
a	DT	O
lower	JJR	O
dietary	JJ	O
intake	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
Norwegians	NNPS	O
(	(	O
median	JJ	O
2.2	CD	O
vs	NN	O
3.3	CD	O
micrograms/day	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
lower	JJR	O
total	JJ	O
intake	NN	O
,	,	O
including	VBG	O
supplements	NNS	O
(	(	O
median	JJ	O
2.9	CD	O
vs	NN	O
7.0	CD	O
micrograms/day	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Among	IN	O
the	DT	O
Pakistanis	NNP	O
a	DT	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
dietary	JJ	O
intake	NN	O
of	IN	O
margarine	NN	O
,	,	O
the	DT	O
main	JJ	O
source	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
in	IN	O
the	DT	O
diet	NN	O
,	,	O
and	CC	O
the	DT	O
concentration	NN	O
of	IN	O
25-hydroxyvitamin	JJ	O
D3	NNP	O
in	IN	O
serum	NN	O
,	,	O
r	NN	O
=	NN	O
0.48	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
Pakistanis	NNP	O
avoided	VBD	O
any	DT	O
direct	JJ	O
sunshine	NN	O
exposure	NN	O
,	,	O
and	CC	O
no	DT	O
relation	NN	O
between	IN	O
outdoor	JJ	O
activity	NN	O
and	CC	O
serum	JJ	O
level	NN	O
of	IN	O
25-hydroxyvitamin	JJ	O
D3	NNP	O
was	VBD	O
found	VBN	O
.	.	O

The	DT	O
Pakistani	NNP	O
women	NNS	O
had	VBD	O
a	DT	O
lower	JJR	O
intake	NN	O
of	IN	O
calcium	NN	O
than	IN	O
the	DT	O
Norwegians	NNPS	O
(	(	O
median	JJ	O
793	CD	O
vs	NN	O
1134	CD	O
mg/day	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
This	DT	O
study	NN	O
has	VBZ	O
shown	VBN	O
that	IN	O
Pakistani	NNP	O
women	NNS	O
living	VBG	O
in	IN	O
Oslo	NNP	O
are	VBP	O
at	IN	O
great	JJ	O
risk	NN	O
of	IN	O
developing	VBG	O
vitamin	JJ	O
D	NNP	O
deficiency	NN	O
during	IN	O
pregnancy	NN	O
.	.	O

The	DT	O
main	JJ	O
reasons	NNS	O
for	IN	O
this	DT	O
are	VBP	O
avoidance	NN	O
of	IN	O
sun	NN	O
exposure	NN	O
,	,	O
a	DT	O
low	JJ	O
dietary	JJ	O
intake	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
,	,	O
and	CC	O
no	DT	O
or	CC	O
little	JJ	O
use	NN	O
of	IN	O
supplementation	NN	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
indomethacin	NN	O
in	IN	O
uremic	JJ	O
pericarditis	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
impact	NN	O
of	IN	O
indomethacin	NN	O
on	IN	O
the	DT	O
course	NN	O
of	IN	O
uremic	JJ	O
pericarditis	NN	O
we	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
double	JJ	O
blind	NN	O
study	NN	O
in	IN	O
which	WDT	O
24	CD	O
patients	NNS	O
with	IN	O
endstage	NN	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
and	CC	O
pericarditis	NN	O
randomly	RB	O
received	VBD	O
indomethacin	JJ	O
,	,	O
25	CD	O
mg	NN	O
four	CD	O
times	NNS	O
daily	RB	O
,	,	O
(	(	O
11	CD	O
patients	NNS	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
(	(	O
13	CD	O
patients	NNS	O
)	)	O
for	IN	O
a	DT	O
3-week	JJ	O
period	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBN	O
peritoneal	JJ	O
or	CC	O
hemodialysis	NN	O
treatment	NN	O
concurrently	RB	O
with	IN	O
the	DT	O
study	NN	O
drug	NN	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
the	DT	O
placebo	NN	O
,	,	O
indomethacin	NN	O
produced	VBD	O
an	DT	O
immediate	JJ	O
and	CC	O
sustained	JJ	O
reduction	NN	O
of	IN	O
fever	NN	O
in	IN	O
all	DT	O
but	CC	O
one	CD	O
patient	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
indomethacin	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
duration	NN	O
of	IN	O
chest	NN	O
pain	NN	O
(	(	O
mean	JJ	O
days	NNS	O
+/-	JJ	O
SE	NNP	O
:	:	O
placebo	NN	O
1.4	CD	O
+/-	JJ	O
0.6	CD	O
,	,	O
indomethacin	JJ	O
5.5	CD	O
+/-	JJ	O
3.3	CD	O
)	)	O
,	,	O
duration	NN	O
of	IN	O
pericardial	JJ	O
friction	NN	O
rub	NN	O
(	(	O
placebo	JJ	O
10.3	CD	O
+/-	JJ	O
1.7	CD	O
,	,	O
indomethacin	JJ	O
16.0	CD	O
+/-	JJ	O
3.8	CD	O
)	)	O
,	,	O
or	CC	O
on	IN	O
the	DT	O
amount	NN	O
of	IN	O
pericardial	JJ	O
effusion	NN	O
.	.	O

Further	NNP	O
,	,	O
indomethacin	NN	O
did	VBD	O
not	RB	O
diminish	VB	O
the	DT	O
need	NN	O
for	IN	O
invasive	JJ	O
surgical	JJ	O
procedures	NNS	O
for	IN	O
relief	NN	O
of	IN	O
tamponade	NN	O
(	(	O
three	CD	O
of	IN	O
13	CD	O
placebo	NN	O
patients	NNS	O
,	,	O
two	CD	O
of	IN	O
11	CD	O
indomethacin	JJ	O
patients	NNS	O
)	)	O
or	CC	O
result	NN	O
in	IN	O
decreased	JJ	O
mortality	NN	O
rate	NN	O
.	.	O

Death	NNP	O
(	(	O
not	RB	O
due	RB	O
to	TO	O
pericarditis	NN	O
)	)	O
occurred	VBD	O
in	IN	O
two	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
indomethacin	NN	O
and	CC	O
one	CD	O
patient	NN	O
who	WP	O
received	VBD	O
the	DT	O
placebo	NN	O
.	.	O

In	IN	O
our	PRP$	O
patients	NNS	O
pericarditis	VBP	O
encompassed	VBD	O
a	DT	O
wide	JJ	O
spectrum	NN	O
ranging	VBG	O
from	IN	O
a	DT	O
mild	JJ	O
illness	NN	O
of	IN	O
several	JJ	O
days	NNS	O
duration	NN	O
to	TO	O
a	DT	O
painful	JJ	O
and	CC	O
debilitating	JJ	O
disease	NN	O
lasting	JJ	O
weeks	NNS	O
and	CC	O
requiring	VBG	O
surgical	JJ	O
intervention	NN	O
.	.	O

Although	IN	O
the	DT	O
size	NN	O
of	IN	O
our	PRP$	O
population	NN	O
prohibits	VBZ	O
definitive	JJ	O
conclusions	NNS	O
,	,	O
it	PRP	O
would	MD	O
appear	VB	O
that	IN	O
,	,	O
except	IN	O
for	IN	O
fever	NN	O
,	,	O
the	DT	O
manifestations	NNS	O
and	CC	O
natural	JJ	O
history	NN	O
of	IN	O
this	DT	O
illness	NN	O
are	VBP	O
unaffected	VBN	O
by	IN	O
indomethacin	NN	O
.	.	O

Predicting	VBG	O
the	DT	O
effect	NN	O
of	IN	O
anthelmintic	JJ	O
treatment	NN	O
on	IN	O
milk	NN	O
production	NN	O
of	IN	O
dairy	NN	O
cattle	NNS	O
in	IN	O
Canada	NNP	O
using	VBG	O
an	DT	O
Ostertagia	NNP	O
ostertagi	NN	O
ELISA	NNP	O
from	IN	O
individual	JJ	O
milk	NN	O
samples	NNS	O
.	.	O

Gastrointestinal	NNP	Condition
nematodes	NNS	Condition
,	,	O
such	JJ	O
as	IN	O
Ostertagia	NNP	Condition
ostertagi	NN	Condition
and	CC	O
several	JJ	Condition
species	NNS	Condition
of	IN	Condition
Cooperia	NNP	Condition
,	,	O
are	VBP	O
ubiquitous	JJ	O
in	IN	O
temperate	NN	O
climates	NNS	O
and	CC	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
detrimental	JJ	O
effects	NNS	O
on	IN	O
production	NN	O
in	IN	O
adult	NN	O
dairy	NN	O
cattle	NNS	O
.	.	O

A	DT	O
published	VBN	O
meta-analysis	NN	O
demonstrated	VBD	O
that	IN	O
overall	JJ	O
,	,	O
producers	NNS	O
lose	VBP	O
approximately	RB	O
0.35	CD	O
kg	NNS	O
of	IN	O
milk	NN	O
per	IN	O
parasitized	VBN	O
cow	NN	O
per	IN	O
day	NN	O
.	.	O

Enzyme-linked	JJ	O
immunosorbent	NN	O
assays	NNS	O
(	(	O
ELISAs	NNP	O
)	)	O
have	VBP	O
the	DT	O
ability	NN	O
to	TO	O
quantify	VB	O
nematode	JJ	O
infections	NNS	O
in	IN	O
cattle	NNS	O
,	,	O
and	CC	O
thus	RB	O
,	,	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
amount	NN	O
of	IN	O
milk	NN	O
production	NN	O
loss	NN	O
due	JJ	O
to	TO	O
differing	VBG	O
levels	NNS	O
of	IN	O
parasitism	NN	O
at	IN	O
the	DT	O
individual	JJ	O
cow	NN	O
level	NN	O
.	.	O

ELISA	JJ	O
results	NNS	O
from	IN	O
individual	JJ	O
cow	NN	O
milk	NN	O
samples	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
predict	VB	O
milk	NN	O
production	NN	O
response	NN	O
following	VBG	O
a	DT	O
randomized	JJ	O
anthelmintic	JJ	O
treatment	NN	O
in	IN	O
a	DT	O
large	JJ	O
field	NN	O
trial	NN	O
.	.	O

To	TO	O
increase	VB	O
statistical	JJ	O
power	NN	O
,	,	O
the	DT	O
data	NNS	O
collected	VBN	O
from	IN	O
this	DT	O
field	NN	O
trial	NN	O
was	VBD	O
pooled	VBN	O
with	IN	O
data	NNS	O
from	IN	O
two	CD	O
other	JJ	O
published	VBN	O
field	NN	O
trials	NNS	O
to	TO	O
form	VB	O
an	DT	O
individual	JJ	O
patient	NN	O
data	NNS	O
meta-analysis	NN	O
(	(	O
IPDMA	NNP	O
)	)	O
.	.	O

The	DT	O
ability	NN	O
to	TO	O
predict	VB	O
the	DT	O
effect	NN	O
of	IN	O
anthelmintic	JJ	O
treatment	NN	O
on	IN	O
milk	NN	O
production	NN	O
depends	VBZ	O
on	IN	O
the	DT	O
level	NN	O
of	IN	O
parasitism	NN	O
quantified	VBN	O
by	IN	O
an	DT	O
ELISA	NNP	O
measuring	NN	O
milk	NN	O
antibodies	NNS	O
against	IN	O
O.	NNP	O
ostertagi	NN	O
,	,	O
and	CC	O
reported	VBD	O
as	IN	O
optical	JJ	O
density	NN	O
ratios	NNS	O
(	(	O
ODRs	NNP	O
)	)	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
estimates	NNS	O
from	IN	O
the	DT	O
interaction	NN	O
between	IN	O
ODR	NNP	O
and	CC	O
treatment	NN	O
on	IN	O
milk	NN	O
production	NN	O
were	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
how	WRB	O
well	RB	O
the	DT	O
ODR	NNP	O
predicted	VBD	O
the	DT	O
response	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

It	PRP	O
was	VBD	O
anticipated	VBN	O
that	IN	O
the	DT	O
relationship	NN	O
between	IN	O
milk	NN	O
production	NN	O
and	CC	O
ODR	NNP	O
was	VBD	O
unlikely	JJ	O
to	TO	O
be	VB	O
linear	JJ	O
,	,	O
so	IN	O
fractional	JJ	O
polynomials	NNS	O
were	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
continuous	JJ	O
ODR	NNP	O
values	NNS	O
.	.	O

The	DT	O
interaction	NN	O
in	IN	O
the	DT	O
field	NN	O
trial	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
(	(	O
p=0.138	NN	O
)	)	O
toward	IN	O
a	DT	O
beneficial	JJ	O
treatment	NN	O
effect	NN	O
when	WRB	O
the	DT	O
individual	JJ	O
ODR	NNP	O
values	NNS	O
,	,	O
measured	VBN	O
in	IN	O
late	JJ	O
lactation	NN	O
and	CC	O
using	VBG	O
Svanovir	NNP	O
(	(	O
?	.	O
)	)	O
,	,	O
were	VBD	O
greater	JJR	O
than	IN	O
0.12	CD	O
.	.	O

When	WRB	O
individual	JJ	O
data	NNS	O
from	IN	O
two	CD	O
other	JJ	O
similar	JJ	O
studies	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
an	DT	O
IPDMA	NNP	O
,	,	O
the	DT	O
interaction	NN	O
terms	NNS	O
became	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
p=0.009	NN	O
)	)	O
indicating	NN	O
that	IN	O
there	EX	O
is	VBZ	O
a	DT	O
beneficial	JJ	O
treatment	NN	O
effect	NN	O
when	WRB	O
ODR	NNP	O
values	NNS	O
are	VBP	O
slightly	RB	O
elevated	VBN	O
.	.	O

A	DT	O
graph	NN	O
was	VBD	O
used	VBN	O
to	TO	O
demonstrate	VB	O
the	DT	O
treatment	NN	O
effect	NN	O
(	(	O
the	DT	O
estimated	VBN	O
difference	NN	O
of	IN	O
kg/cow/day	NN	O
of	IN	O
milk	NN	O
yield	NN	O
between	IN	O
the	DT	O
treated	VBN	O
and	CC	O
placebo	JJ	O
cows	NNS	O
)	)	O
,	,	O
with	IN	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
,	,	O
as	IN	O
the	DT	O
ODR	NNP	O
values	NNS	O
increase	NN	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
note	VB	O
that	IN	O
the	DT	O
methods	NNS	O
of	IN	O
quantifying	VBG	O
the	DT	O
ODR	NNP	O
values	NNS	O
differed	VBD	O
between	IN	O
the	DT	O
three	CD	O
studies	NNS	O
in	IN	O
the	DT	O
IPDMA	NNP	O
,	,	O
therefore	RB	O
some	DT	O
caution	NN	O
should	MD	O
be	VB	O
used	VBN	O
when	WRB	O
using	VBG	O
these	DT	O
final	JJ	O
estimated	VBN	O
values	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
shape	NN	O
and	CC	O
magnitude	NN	O
of	IN	O
the	DT	O
treatment	NN	O
effects	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
other	JJ	O
fixed	JJ	O
model	NN	O
estimates	NNS	O
,	,	O
were	VBD	O
very	RB	O
similar	JJ	O
between	IN	O
the	DT	O
field	NN	O
trial	NN	O
and	CC	O
the	DT	O
IPDMA	NNP	O
suggesting	VBG	O
that	IN	O
any	DT	O
bias	NN	O
would	MD	O
likely	RB	O
be	VB	O
minimal	JJ	O
.	.	O

Changes	NNS	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
sexual	JJ	O
health	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
low-dose	JJ	O
peginterferon	NN	O
therapy	NN	O
and	CC	O
disease	NN	O
progression	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
hepatitis	NN	Condition
C.	NNP	Condition
BACKGROUND	NNP	O
Primary	NNP	O
analysis	NN	O
of	IN	O
the	DT	O
Hepatitis	NNP	Condition
C	NNP	Condition
Antiviral	NNP	O
Long-Term	NNP	O
Treatment	NNP	O
against	IN	O
Cirrhosis	NNP	Condition
(	(	O
HALT-C	NNP	Condition
)	)	O
Trial	NNP	O
showed	VBD	O
long-term	JJ	O
peginterferon	NN	O
therapy	NN	O
did	VBD	O
not	RB	O
reduce	VB	O
complications	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
hepatitis	NN	Condition
C	NNP	Condition
and	CC	O
advanced	JJ	Condition
fibrosis	NN	Condition
or	CC	O
cirrhosis	NN	Condition
.	.	O

AIM	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
long-term	JJ	O
peginterferon	NN	O
therapy	NN	O
and	CC	O
disease	NN	O
progression	NN	O
on	IN	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
HRQOL	NNP	O
)	)	O
,	,	O
symptoms	NNS	O
and	CC	O
sexual	JJ	O
health	NN	O
in	IN	O
HALT-C	NNP	O
patients	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
517	CD	Condition
HALT-C	JJ	Condition
patients	NNS	O
received	VBD	O
peginterferon	JJ	O
alfa-2a	JJ	O
(	(	O
90	CD	O
microg/week	NN	O
)	)	O
;	:	O
532	CD	Condition
received	VBD	O
no	DT	O
additional	JJ	O
treatment	NN	O
for	IN	O
3.5	CD	O
years	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
outcomes	NNS	O
of	IN	O
death	NN	O
,	,	O
hepatocellular	JJ	O
carcinoma	NN	O
and	CC	O
hepatic	JJ	O
decompensation	NN	O
.	.	O

Sexual	JJ	O
health	NN	O
,	,	O
SF-36	NNP	O
scores	NNS	O
and	CC	O
symptoms	NNS	O
were	VBD	O
serially	RB	O
assessed	VBN	O
by	IN	O
repeated-measures	NNS	O
analyses	NNS	O
of	IN	O
covariance	NN	O
.	.	O

RESULTS	JJ	O
Patients	NNS	O
with	IN	O
cirrhosis	NN	Condition
(	(	O
n	JJ	O
=	NNP	O
427	CD	O
)	)	O
reported	VBD	O
lower	JJR	O
general	JJ	O
well-being	NN	O
and	CC	O
more	JJR	O
fatigue	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
than	IN	O
patients	NNS	O
with	IN	O
fibrosis	NN	Condition
(	(	O
n	JJ	O
=	NNP	O
622	CD	O
)	)	O
.	.	O

Physical	JJ	O
scores	NNS	O
declined	VBD	O
significantly	RB	O
over	IN	O
time	NN	O
,	,	O
independent	JJ	O
of	IN	O
treatment	NN	O
,	,	O
and	CC	O
patients	NNS	O
with	IN	O
cirrhosis	NN	O
reported	VBD	O
lower	JJR	O
scores	NNS	O
.	.	O

Vitality	NNP	O
scores	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
those	DT	O
with	IN	O
cirrhosis	NN	O
,	,	O
and	CC	O
treated	VBD	O
patients	NNS	O
experienced	VBD	O
a	DT	O
greater	JJR	O
decline	NN	O
over	IN	O
time	NN	O
than	IN	O
untreated	JJ	O
patients	NNS	O
;	:	O
HRQOL	NNP	O
rebounded	VBD	O
after	IN	O
treatment	NN	O
ended	VBN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
clinical	JJ	O
outcome	NN	O
had	VBD	O
significantly	RB	O
greater	JJR	O
declines	NNS	O
in	IN	O
all	DT	O
SF-36	NNP	O
and	CC	O
symptom	JJ	O
scores	NNS	O
.	.	O

Among	IN	O
men	NNS	O
,	,	O
Sexual	NNP	O
Health	NNP	O
scores	NNS	O
were	VBD	O
significantly	RB	O
worse	JJR	O
in	IN	O
treated	JJ	O
patients	NNS	O
and	CC	O
in	IN	O
those	DT	O
with	IN	O
a	DT	O
clinical	JJ	O
outcome	NN	O
.	.	O

CONCLUSION	NNP	O
Clinical	NNP	O
progression	NN	O
of	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
and	CC	O
maintenance	NN	O
peginterferon	NN	O
therapy	NN	O
led	VBD	O
to	TO	O
worsening	VBG	O
of	IN	O
symptoms	NNS	O
,	,	O
HRQOL	NNP	O
and	CC	O
,	,	O
in	IN	O
men	NNS	Condition
,	,	O
sexual	JJ	O
health	NN	O
in	IN	O
a	DT	O
large	JJ	O
patient	NN	O
cohort	NN	O
followed	VBD	O
up	RB	O
over	IN	O
4	CD	O
years	NNS	O
(	(	O
NCT00006164	NNP	O
)	)	O
.	.	O

Zoledronic	JJ	O
acid	NN	O
significantly	RB	O
reduces	VBZ	O
skeletal	JJ	O
complications	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
Japanese	JJ	O
women	NNS	Condition
with	IN	O
bone	NN	O
metastases	NNS	O
from	IN	O
breast	NN	Condition
cancer	NN	Condition
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
zoledronic	JJ	O
acid	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bone	NN	O
metastases	NNS	O
from	IN	O
breast	NN	O
cancer	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Women	NNP	O
with	IN	O
bone	NN	O
metastases	NNS	O
(	(	O
N	NNP	SampleSize
=	NNP	SampleSize
228	CD	SampleSize
)	)	SampleSize
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
4	CD	O
mg	NN	O
zoledronic	JJ	O
acid	NN	O
(	(	O
n	JJ	O
=	NNP	O
114	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
114	CD	O
)	)	O
via	IN	O
15-minute	JJ	O
infusions	NNS	O
every	DT	O
4	CD	O
weeks	NNS	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
skeletal-related	JJ	O
event	NN	O
(	(	O
SRE	NNP	O
)	)	O
rate	NN	O
ratio	NN	O
between	IN	O
treatment	NN	O
groups	NNS	O
.	.	O

An	DT	O
SRE	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
pathologic	JJ	O
fracture	NN	O
,	,	O
spinal	JJ	O
cord	NN	O
compression	NN	O
,	,	O
and	CC	O
radiation	NN	O
or	CC	O
surgery	NN	O
to	TO	O
bone	VB	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
SRE	NNP	O
,	,	O
time-to-first	JJ	O
SRE	NNP	O
,	,	O
and	CC	O
Andersen-Gill	NNP	O
multiple-event	JJ	O
analysis	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
SRE	NNP	O
rate	NN	O
ratio	NN	O
at	IN	O
1	CD	O
year	NN	O
(	(	O
excluding	VBG	O
HCM	NNP	O
and	CC	O
adjusted	VBN	O
for	IN	O
prior	JJ	O
fracture	NN	O
)	)	O
was	VBD	O
0.61	CD	O
(	(	O
permutation	NN	O
test	NN	O
;	:	O
P	NNP	O
=	NNP	O
.027	NNP	O
)	)	O
,	,	O
indicating	VBG	O
that	IN	O
zoledronic	JJ	O
acid	NN	O
reduced	VBD	O
the	DT	O
rate	NN	O
of	IN	O
SRE	NNP	O
by	IN	O
39	CD	O
%	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
SRE	NNP	O
(	(	O
excluding	VBG	O
HCM	NNP	O
)	)	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
20	CD	O
%	NN	O
by	IN	O
zoledronic	JJ	O
acid	NN	O
(	(	O
29.8	CD	O
%	NN	O
v	JJ	O
49.6	CD	O
%	NN	O
for	IN	O
placebo	NN	O
;	:	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
.	.	O

Zoledronic	JJ	O
acid	NN	O
significantly	RB	O
delayed	VBN	O
time-to-first	JJ	O
SRE	NNP	O
(	(	O
median	JJ	O
not	RB	O
reached	VBN	O
v	RB	O
364	CD	O
days	NNS	O
;	:	O
Cox	NNP	O
regression	NN	O
;	:	O
P	NNP	O
=	NNP	O
.007	NNP	O
)	)	O
and	CC	O
reduced	VBD	O
the	DT	O
risk	NN	O
of	IN	O
SREs	NNP	O
by	IN	O
41	CD	O
%	NN	O
in	IN	O
multiple	JJ	O
event	NN	O
analysis	NN	O
(	(	O
risk	NN	O
ratio	NN	O
=	NNP	O
0.59	CD	O
;	:	O
P	NNP	O
=	NNP	O
.019	NNP	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Zoledronic	JJ	O
acid	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
a	DT	O
safety	NN	O
profile	NN	O
similar	JJ	O
to	TO	O
placebo	VB	O
.	.	O

No	DT	O
patient	NN	O
treated	VBD	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
had	VBD	O
grade	VBN	O
3	CD	O
or	CC	O
4	CD	O
serum	JJ	O
creatinine	NN	O
increase	NN	O
.	.	O

CONCLUSION	NNP	O
Zoledronic	NNP	O
acid	NN	O
significantly	RB	O
reduced	VBD	O
skeletal	JJ	O
complications	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
across	IN	O
multiple	JJ	O
end	NN	O
points	NNS	O
in	IN	O
Japanese	JJ	O
women	NNS	O
with	IN	O
bone	NN	O
metastases	NNS	O
from	IN	O
breast	NN	O
cancer	NN	O
.	.	O

First-line	JJ	O
cisplatin	NN	O
with	IN	O
docetaxel	NN	O
or	CC	O
vinorelbine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
:	:	O
a	DT	O
quality	NN	O
of	IN	O
life	NN	O
directed	VBN	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
of	IN	O
Gruppo	NNP	O
Oncologico	NNP	O
Italia	NNP	O
Meridionale	NNP	O
.	.	O

BACKGROUND	NNP	O
Quality	NNP	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
has	VBZ	O
gained	VBN	O
greater	JJR	O
importance	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
metastatic	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
due	JJ	O
to	TO	O
the	DT	O
palliative	JJ	O
nature	NN	O
of	IN	O
treatment	NN	O
.	.	O

Docetaxel	NNP	O
(	(	O
DCT	NNP	O
)	)	O
and	CC	O
cisplatin	NN	O
(	(	O
CDDP	NNP	O
)	)	O
doublet	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
to	TO	O
a	DT	O
better	JJR	O
QoL	NNP	O
than	IN	O
the	DT	O
weekly	JJ	O
vinorelbine	NN	O
(	(	O
VNR	NNP	O
)	)	O
and	CC	O
CDDP	NNP	O
regimen	NNS	O
.	.	O

Recently	RB	O
a	DT	O
newer	NN	O
more	RBR	O
tolerated	JJ	O
schedule	NN	O
of	IN	O
the	DT	O
VNR/CDDP	NNP	O
regimen	NN	O
has	VBZ	O
been	VBN	O
published	VBN	O
and	CC	O
is	VBZ	O
widely	RB	O
employed	VBN	O
in	IN	O
medical	JJ	O
practice	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
these	DT	O
regimens	NNS	O
on	IN	O
patients	NNS	O
'	POS	O
QoL	NNP	O
as	RB	O
well	RB	O
as	IN	O
symptoms	NNS	O
control	NN	O
and	CC	O
type	NN	O
and	CC	O
grading	VBG	O
chemo-related	JJ	O
side-effects	NNS	O
has	VBZ	O
been	VBN	O
compared	VBN	O
prospectically	RB	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
received	VBD	O
CDDP	NNP	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
plus	CC	O
DCT	NNP	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
every	DT	O
weeks	NNS	O
(	(	O
arm	IN	O
A	NNP	O
)	)	O
or	CC	O
CDDP	$	O
80	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
plus	CC	O
VNR	NNP	O
30	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
day	NN	O
1	CD	O
and	CC	O
8	CD	O
every	DT	O
3	CD	O
weeks	NNS	O
(	(	O
arm	NN	O
B	NNP	O
)	)	O
.	.	O

G-CSF	NNP	O
and/or	JJ	O
EPO	NNP	O
were	VBD	O
employed	VBN	O
as	IN	O
needed	VBN	O
.	.	O

Health-related	JJ	O
QoL	NNP	O
was	VBD	O
assessed	VBN	O
at	IN	O
entry	NN	O
and	CC	O
after	IN	O
every	DT	O
cycle	NN	O
by	IN	O
the	DT	O
EORTC-QLQ-C30	NNP	O
and	CC	O
LC13	NNP	O
questionnaires	NNS	O
,	,	O
toxicity	NN	O
by	IN	O
the	DT	O
NCI-NCCN	NNP	O
CTC	NNP	O
vs	NN	O
2	CD	O
,	,	O
and	CC	O
intent-to-treat	JJ	O
objective	JJ	O
response	NN	O
by	IN	O
the	DT	O
Recist	NNP	O
criteria	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
QoL	NNP	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
37	CD	O
pts	NNS	O
(	(	O
88	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
and	CC	O
39	CD	O
pts	NNS	O
(	(	O
87	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
one	NN	O
.	.	O

Baseline	JJ	O
mean	JJ	O
scores	NNS	O
and	CC	O
rates	NNS	O
at	IN	O
which	WDT	O
pts	NNS	O
failed	VBD	O
to	TO	O
complete	VB	O
QoL	NNP	O
assessment	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Global	NNP	O
health	NN	O
status	NN	O
of	IN	O
the	DT	O
EORTC	NNP	O
QLQ-C30	NNP	O
scale	NN	O
and	CC	O
specific	JJ	O
symptoms	NNS	O
control	NN	O
(	(	O
LC13	NNP	O
module	NN	O
)	)	O
improved	VBD	O
during	IN	O
treatment	NN	O
without	IN	O
any	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
.	.	O

Emotional	JJ	O
functioning	NN	O
remained	VBD	O
stable	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
during	IN	O
treatment	NN	O
,	,	O
whereas	JJ	O
physical	JJ	O
and	CC	O
role	NN	O
improved	VBN	O
slightly	RB	O
.	.	O

In	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
14	CD	O
pts	NNS	O
(	(	O
33	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CL	NNP	O
24-40	CD	O
%	NN	O
)	)	O
had	VBD	O
PR	NNP	O
,	,	O
and	CC	O
10	CD	O
(	(	O
24	CD	O
%	NN	O
)	)	O
SD	NNP	O
for	IN	O
a	DT	O
57	CD	O
%	NN	O
TGCR	NNP	O
.	.	O

In	IN	O
the	DT	O
VNR/CDDP	NNP	O
arm	NN	O
12	CD	O
pts	NNS	O
(	(	O
27	CD	O
%	NN	O
)	)	O
achieved	VBD	O
PR	NNP	O
,	,	O
18	CD	O
(	(	O
41	CD	O
%	NN	O
)	)	O
SD	VBZ	O
a	DT	O
68	CD	O
%	NN	O
TGCR	NNP	O
.	.	O

Differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Median	JJ	O
time-to-progression	NN	O
was	VBD	O
4.2	CD	O
months	NNS	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	O
arm	NN	O
and	CC	O
4.5	CD	O
months	NNS	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
one	CD	O
,	,	O
and	CC	O
median	JJ	O
overall	JJ	O
survival	NN	O
was	VBD	O
12.1	CD	O
(	(	O
range	VB	O
1-26+	JJ	O
months	NNS	O
)	)	O
and	CC	O
12.5	CD	O
months	NNS	O
(	(	O
range	VB	O
1-28+	JJ	O
months	NNS	O
)	)	O
for	IN	O
DCT/CDDP	NNP	O
and	CC	O
VNR/CDDP	NNP	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Febrile	NNP	O
neutropenia	JJ	O
rate	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
arm	NN	O
(	(	O
p=0.02	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
G3-4	NNP	O
anemia	NN	O
(	(	O
p=0.005	NN	O
)	)	O
and	CC	O
G-CSF/EPO	NNP	O
use	NN	O
(	(	O
p=0.019	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Global	NNP	O
and	CC	O
specific	JJ	O
health-related	JJ	O
QoL	NNP	O
data	NNS	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
with	IN	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
.	.	O

Efficacy	NN	O
measures	NNS	O
,	,	O
overall	JJ	O
response	NN	O
rate	NN	O
,	,	O
time-to-progression	NN	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
equivalent	JJ	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

However	RB	O
,	,	O
severe	JJ	O
anemia	NN	O
and	CC	O
febrile	JJ	O
neutropenia	NN	O
are	VBP	O
statistically	RB	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
VNR/CDDP	NNP	O
arm	NN	O
than	IN	O
in	IN	O
the	DT	O
DCT/CDDP	NNP	O
one	NN	O
.	.	O

These	DT	O
data	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
treatment	NN	O
decision-making	NN	O
for	IN	O
pts	NNS	O
with	IN	O
advanced	JJ	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
and	CC	O
for	IN	O
the	DT	O
design	NN	O
of	IN	O
future	JJ	O
trials	NNS	O
with	IN	O
chemotherapy	NN	O
plus	CC	O
biologics	NNS	O
.	.	O

Parenting	VBG	Condition
stress	NN	Condition
in	IN	O
the	DT	O
infant	JJ	O
aphakia	NN	O
treatment	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
parenting	VBG	Condition
stress	NN	Condition
following	VBG	O
infants	NNS	Age
'	POS	O
cataract	NN	O
extraction	NN	O
surgery	NN	O
,	,	O
and	CC	O
to	TO	O
determine	VB	O
if	IN	O
levels	NNS	O
of	IN	O
stress	NN	O
differ	NN	O
between	IN	O
2	CD	O
treatments	NNS	O
for	IN	O
unilateral	JJ	O
congenital	JJ	O
cataract	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
At	IN	O
surgery	NN	O
,	,	O
an	DT	O
intraocular	JJ	O
lens	NNS	O
(	(	O
IOL	NNP	O
)	)	O
was	VBD	O
implanted	VBN	O
or	CC	O
children	NNS	O
were	VBD	O
left	VBN	O
aphakic	NN	O
,	,	O
treated	VBD	O
with	IN	O
contact	NN	O
lens	NNS	O
(	(	O
CL	NNP	O
)	)	O
.	.	O

Stress	JJ	O
measures	NNS	O
were	VBD	O
administered	VBN	O
3	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
and	CC	O
at	IN	O
the	DT	O
first	JJ	O
visit	NN	O
after	IN	O
the	DT	O
visual	JJ	O
acuity	NN	O
(	(	O
VA	NNP	O
)	)	O
assessment	NN	O
done	VBN	O
at	IN	O
12	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

RESULTS	NNP	O
Caregivers	NNPS	O
in	IN	O
the	DT	O
IOL	NNP	O
group	NN	O
reported	VBD	O
higher	JJR	O
levels	NNS	O
of	IN	O
stress	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
CL	NNP	O
group	NN	O
3	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
no	DT	O
group	NN	O
differences	VBZ	O
in	IN	O
stress	NN	O
scores	NNS	O
at	IN	O
the	DT	O
post-VA	JJ	O
assessment	NN	O
.	.	O

Stress	NNP	O
scores	NNS	O
did	VBD	O
not	RB	O
change	VB	O
differentially	RB	O
for	IN	O
participants	NNS	O
assigned	VBN	O
to	TO	O
IOL	NNP	O
versus	NN	O
CL	NNP	O
treatments	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Treatment	NNP	O
assignment	NN	O
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
significant	JJ	O
impact	NN	O
on	IN	O
caregiver	NN	O
stress	NN	O
during	IN	O
infancy	NN	Age
or	CC	O
on	IN	O
the	DT	O
change	NN	O
in	IN	O
stress	NN	O
during	IN	O
the	DT	O
child	NN	O
's	POS	O
first	JJ	O
2	CD	O
years	NNS	O
of	IN	O
life	NN	O
.	.	O

Assessing	VBG	O
the	DT	O
bioequivalence	NN	O
of	IN	O
topical	JJ	O
retinoid	NN	O
products	NNS	O
by	IN	O
pharmacodynamic	JJ	O
assay	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
develop	VB	O
a	DT	O
simple	JJ	O
pharmacodynamic	NN	O
(	(	O
PD	NNP	O
)	)	O
assay	VBP	O
for	IN	O
the	DT	O
evaluation	NN	O
of	IN	O
the	DT	O
bioequivalence	NN	O
of	IN	O
topically	RB	O
applied	VBN	O
retinoid	NN	O
products	NNS	O
.	.	O

METHODS	NNP	O
Daily	NNP	O
applications	NNS	O
of	IN	O
products	NNS	O
containing	VBG	O
tretinoin	NN	O
or	CC	O
adapalene	NN	O
were	VBD	O
made	VBN	O
to	TO	O
the	DT	O
forearms	NNS	O
of	IN	O
human	JJ	O
subjects	NNS	O
for	IN	O
up	IN	O
to	TO	O
21	CD	O
days	NNS	O
.	.	O

Percutaneous	JJ	O
absorption	NN	O
was	VBD	O
enhanced	VBN	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
polyethylene	NN	O
film	NN	O
occlusion	NN	O
(	(	O
5	CD	O
h	NN	O
)	)	O
.	.	O

Pharmacologic	NNP	O
activity	NN	O
was	VBD	O
assessed	VBN	O
through	IN	O
the	DT	O
daily	JJ	O
measurement	NN	O
of	IN	O
three	CD	O
cutaneous	JJ	O
responses	NNS	O
intimately	RB	O
linked	VBN	O
to	TO	O
retinoid-induced	JJ	O
changes	NNS	O
in	IN	O
epidermal	JJ	O
differentiation	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
erythema	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
exfoliation	NN	O
(	(	O
scaling/peeling	VBG	O
)	)	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
increased	VBD	O
transepidermal	JJ	O
water	NN	O
loss	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
PD	NNP	O
model	NN	O
exhibited	VBD	O
the	DT	O
sensitivity	NN	O
and	CC	O
specificity	NN	O
required	VBN	O
to	TO	O
function	VB	O
as	IN	O
a	DT	O
bioequivalence	NN	O
surrogate	NN	O
.	.	O

It	PRP	O
was	VBD	O
possible	JJ	O
to	TO	O
differentiate	VB	O
between	IN	O
:	:	O
(	(	O
1	CD	O
)	)	O
three	CD	O
concentrations	NNS	O
of	IN	O
tretinoin	NN	O
in	IN	O
a	DT	O
commercial	JJ	O
cream	NN	O
product	NN	O
line	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
two	CD	O
concentrations	NNS	O
of	IN	O
tretinoin	NN	O
in	IN	O
a	DT	O
commercial	JJ	O
gel	NN	O
product	NN	O
line	NN	O
;	:	O
(	(	O
3	CD	O
)	)	O
different	JJ	O
vehicles	NNS	O
(	(	O
gel	NN	O
vs.	FW	O
cream	NN	O
)	)	O
containing	VBG	O
the	DT	O
same	JJ	O
concentration	NN	O
of	IN	O
tretinoin	NN	O
,	,	O
and	CC	O
(	(	O
4	CD	O
)	)	O
tretinoin	NN	O
and	CC	O
adapalene	NN	O
at	IN	O
the	DT	O
same	JJ	O
concentration	NN	O
.	.	O

The	DT	O
applicability	NN	O
of	IN	O
this	DT	O
model	NN	O
for	IN	O
bioequivalence	NN	O
testing	NN	O
was	VBD	O
established	VBN	O
by	IN	O
showing	VBG	O
that	IN	O
it	PRP	O
had	VBD	O
sufficient	JJ	O
power	NN	O
to	TO	O
determine	VB	O
that	DT	O
three	CD	O
test	NN	O
tretinoin	NN	O
cream	NN	O
products	NNS	O
and	CC	O
two	CD	O
approved	VBD	O
generic	JJ	O
tretinoin	NN	O
gel	NN	O
products	NNS	O
were	VBD	O
equivalent	JJ	O
to	TO	O
their	PRP$	O
corresponding	JJ	O
reference	NN	O
products	NNS	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
surrogate	NN	O
PD	NNP	O
model	NN	O
to	TO	O
assess	VB	O
retinoid	JJ	O
bioequivalence	NN	O
has	VBZ	O
been	VBN	O
developed	VBN	O
.	.	O

[	VB	O
A	DT	O
multicenter	NN	O
,	,	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
of	IN	O
intravenous	JJ	O
diltiazem	NNS	O
in	IN	O
treatment	NN	O
of	IN	O
unstable	JJ	O
angina	NN	Condition
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
clinical	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
intravenous	JJ	O
diltiazem	NNS	O
compared	VBN	O
with	IN	O
nitroglycerin	NN	O
in	IN	O
the	DT	O
patients	NNS	O
with	IN	O
unstable	JJ	Condition
angina	JJ	Condition
pectoris	NN	Condition
.	.	O

METHODS	NNP	O
A	NNP	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
open-label	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
213	CD	SampleSize
eligible	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
either	RB	O
to	TO	O
diltiazem	VB	O
or	CC	O
nitroglycerin	VB	O
treatment	NN	O
.	.	O

The	DT	O
diltiazem	NN	O
was	VBD	O
administered	VBN	O
from	IN	O
100	CD	O
microg/min	NN	O
at	IN	O
the	DT	O
initiation	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
largest	JJS	O
dosage	NN	O
was	VBD	O
200	CD	O
-	:	O
300	CD	O
microg/min	NN	O
;	:	O
the	DT	O
nitroglycerin	NN	O
was	VBD	O
administered	VBN	O
from	IN	O
20	CD	O
microg/min	NN	O
at	IN	O
the	DT	O
initiation	NN	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
largest	JJS	O
dosage	NN	O
was	VBD	O
80	CD	O
-	:	O
100	CD	O
microg/min	NN	O
.	.	O

Intravenous	JJ	O
infusion	NN	O
was	VBD	O
kept	VBN	O
over	IN	O
48	CD	O
hours	NNS	O
.	.	O

The	DT	O
endpoints	NNS	O
included	VBD	O
refractory	JJ	O
angina	NN	O
pectoris	NN	O
,	,	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
death	NN	O
,	,	O
emergency	NN	O
PTCA	NNP	O
and	CC	O
CABG	NNP	O
.	.	O

RESULTS	NNP	O
(	(	O
1	CD	O
)	)	O
Intravenous	NNP	O
diltiazem	NN	O
was	VBD	O
effective	JJ	O
on	IN	O
the	DT	O
improvement	NN	O
of	IN	O
symptom	NN	O
and	CC	O
electrocardiogram	NN	O
,	,	O
and	CC	O
its	PRP$	O
effects	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
intravenous	JJ	O
nitroglycerin	NN	O
.	.	O

(	(	O
2	CD	O
)	)	O
Compared	VBN	O
with	IN	O
nitroglycerin	NN	O
,	,	O
intravenous	JJ	O
diltiazem	NN	O
lowered	VBD	O
heart	NN	O
rate	NN	O
and	CC	O
myocardial	JJ	O
oxygen	NN	O
consumption	NN	O
index	NN	O
(	(	O
systolic	JJ	O
pressure	NN	O
x	JJ	O
heart	NN	O
rate	NN	O
)	)	O
to	TO	O
more	RBR	O
extent	JJ	O
significantly	RB	O
.	.	O

(	(	O
3	CD	O
)	)	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
onsets	NNS	O
of	IN	O
refractory	JJ	O
angina	NNS	O
pectoris	NN	O
were	VBD	O
reduced	VBN	O
more	RBR	O
significantly	RB	O
in	IN	O
the	DT	O
diltiazem	NN	O
group	NN	O
than	IN	O
in	IN	O
nitroglycerin	JJ	O
group	NN	O
[	VBD	O
4	CD	O
(	(	O
3.8	CD	O
%	NN	O
)	)	O
vs	NN	O
13	CD	O
(	(	O
11.9	CD	O
%	NN	O
)	)	O
,	,	O
RR	NNP	O
0.32	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.11	CD	O
-	:	O
0.96	CD	O
)	)	O
,	,	O
P	NNP	O
<	VBZ	O
0.05	CD	O
]	NN	O
.	.	O

(	(	O
4	CD	O
)	)	O
The	DT	O
patients	NNS	O
whose	WP$	O
heart	NN	O
rate	NN	O
were	VBD	O
reduced	VBN	O
significantly	RB	O
(	(	O
<	JJ	O
or=	RB	O
50	CD	O
beats	NNS	O
per	IN	O
minute	NN	O
)	)	O
in	IN	O
the	DT	O
diltiazem	NN	O
group	NN	O
were	VBD	O
more	JJR	O
than	IN	O
in	IN	O
the	DT	O
nitroglycerin	JJ	O
group	NN	O
[	VBD	O
8	CD	O
(	(	O
7.7	CD	O
%	NN	O
)	)	O
vs	NN	O
0	CD	O
(	(	O
0	CD	O
%	NN	O
)	)	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	NN	O
.	.	O

But	CC	O
these	DT	O
patients	NNS	O
could	MD	O
tolerate	VB	O
the	DT	O
lower	JJR	O
heart	NN	O
rate	NN	O
very	RB	O
well	RB	O
in	IN	O
the	DT	O
diltiazem	NN	O
group	NN	O
.	.	O

(	(	O
5	CD	O
)	)	O
The	DT	O
needs	NNS	O
of	IN	O
beta	NN	O
receptor	NN	O
blocker	NN	O
or	CC	O
calcium	NN	O
antagonists	NNS	O
were	VBD	O
reduced	VBN	O
more	RBR	O
significantly	RB	O
in	IN	O
the	DT	O
diltiazem	NN	O
group	NN	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
nitroglycerin	JJ	O
group	NN	O
[	VBD	O
2	CD	O
(	(	O
1.9	CD	O
%	NN	O
)	)	O
vs	NN	O
13	CD	O
(	(	O
11.9	CD	O
%	NN	O
)	)	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	NN	O
.	.	O

CONCLUSION	NNP	O
Intravenous	NNP	O
diltiazem	NN	O
therapy	NN	O
is	VBZ	O
effective	JJ	O
and	CC	O
safe	JJ	O
for	IN	O
patients	NNS	O
with	IN	O
unstable	JJ	O
angina	JJ	O
pectoris	NN	O
.	.	O

It	PRP	O
may	MD	O
significantly	RB	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
refractory	JJ	O
angina	JJ	O
pectoris	NNS	O
compared	VBN	O
with	IN	O
intravenous	JJ	O
nitroglycerin	NNS	O
.	.	O

LEGO	NNP	O
therapy	NN	O
and	CC	O
the	DT	O
social	JJ	O
use	NN	O
of	IN	O
language	NN	O
programme	NN	O
:	:	O
an	DT	O
evaluation	NN	O
of	IN	O
two	CD	O
social	JJ	O
skills	NNS	O
interventions	NNS	O
for	IN	O
children	NNS	Age
with	IN	O
high	JJ	Condition
functioning	VBG	Condition
autism	NN	Condition
and	CC	O
Asperger	NNP	Condition
Syndrome	NNP	Condition
.	.	O

LEGO	NNP	O
therapy	NN	O
and	CC	O
the	DT	O
Social	NNP	O
Use	NNP	O
of	IN	O
Language	NNP	O
Programme	NNP	O
(	(	O
SULP	NNP	O
)	)	O
were	VBD	O
evaluated	VBN	O
as	IN	O
social	JJ	O
skills	NNS	O
interventions	NNS	O
for	IN	O
6-11	JJ	Age
year	NN	O
olds	NNS	O
with	IN	O
high	JJ	Condition
functioning	VBG	Condition
autism	NN	Condition
and	CC	O
Asperger	NNP	Condition
Syndrome	NNP	Condition
.	.	O

Children	NNP	O
were	VBD	O
matched	VBN	O
on	IN	O
CA	NNP	O
,	,	O
IQ	NNP	O
,	,	O
and	CC	O
autistic	JJ	O
symptoms	NNS	O
before	IN	O
being	VBG	O
randomly	RB	O
assigned	VBN	O
to	TO	O
LEGO	NNP	O
or	CC	O
SULP	NNP	O
.	.	O

Therapy	NNP	O
occurred	VBD	O
for	IN	O
1	CD	O
h/week	NN	O
over	IN	O
18	CD	O
weeks	NNS	O
.	.	O

A	DT	O
no-intervention	JJ	O
control	NN	O
group	NN	O
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
LEGO	NNP	O
therapy	NN	O
group	NN	O
improved	VBD	O
more	JJR	O
than	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
on	IN	O
autism-specific	JJ	O
social	JJ	O
interaction	NN	O
scores	NNS	O
(	(	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
)	)	O
.	.	O

Maladaptive	JJ	O
behaviour	NN	O
decreased	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
the	DT	O
LEGO	NNP	O
and	CC	O
SULP	NNP	O
groups	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
non-significant	JJ	O
trend	NN	O
for	IN	O
SULP	NNP	O
and	CC	O
LEGO	NNP	O
groups	NNS	O
to	TO	O
improve	VB	O
more	JJR	O
than	IN	O
the	DT	O
no-intervention	JJ	O
group	NN	O
in	IN	O
communication	NN	O
and	CC	O
socialisation	NN	O
skills	NNS	O
.	.	O

Direct	JJ	O
aortic	JJ	O
cannulation	NN	O
in	IN	O
minimally	RB	O
invasive	JJ	O
mitral-valve	JJ	Condition
operations	NNS	Condition
.	.	O

The	DT	O
minimally	RB	O
invasive	JJ	O
Port-Access	NNP	O
(	(	O
Heartport	NNP	O
,	,	O
Redwood	NNP	O
City	NNP	O
,	,	O
CA	NNP	O
)	)	O
approach	NN	O
in	IN	O
mitral-valve	JJ	O
operations	NNS	O
originally	RB	O
required	VBN	O
femoral	JJ	O
arterial	JJ	O
cannulation	NN	O
,	,	O
which	WDT	O
is	VBZ	O
considered	VBN	O
a	DT	O
disadvantage	NN	O
,	,	O
especially	RB	O
in	IN	O
patients	NNS	O
with	IN	O
peripheral	JJ	O
vessel	NN	O
disease	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
20	CD	SampleSize
patients	NNS	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
,	,	O
to	TO	O
undergo	VB	O
either	RB	O
standard	JJ	O
femoral	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
direct	JJ	O
aortic	JJ	O
cannulation	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

Pre-	JJ	O
and	CC	O
postoperative	JJ	O
data	NNS	O
as	RB	O
well	RB	O
as	IN	O
markers	NNS	O
for	IN	O
myocardial	JJ	O
damage	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

Postoperatively	RB	O
,	,	O
patients	NNS	O
of	IN	O
group	NN	O
B	NNP	O
showed	VBD	O
lower	JJR	O
levels	NNS	O
of	IN	O
damage	NN	O
,	,	O
indicating	VBG	O
that	IN	O
direct	JJ	O
aortic	JJ	O
cannulation	NN	O
might	MD	O
provide	VB	O
better	JJR	O
myocardial	JJ	O
protection	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
the	DT	O
direct	JJ	O
aortic	JJ	O
cannulation	NN	O
technique	NN	O
may	MD	O
eliminate	VB	O
complications	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
standard	JJ	O
femoral	JJ	O
artery	NN	O
cannulation	NN	O
.	.	O

Impact	NN	O
of	IN	O
dronedarone	NN	O
on	IN	O
hospitalization	NN	O
burden	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
ATHENA	NNP	O
study	NN	O
.	.	O

AIMS	NNP	O
Cardiovascular	NNP	O
(	(	O
CV	NNP	O
)	)	O
hospitalization	NN	O
is	VBZ	O
a	DT	O
predictor	NN	O
of	IN	O
CV	NNP	O
mortality	NN	O
and	CC	O
has	VBZ	O
a	DT	O
negative	JJ	O
impact	NN	O
on	IN	O
patients	NNS	O
'	POS	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
of	IN	O
A	NNP	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
parallel-arm	JJ	O
Trial	NNP	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
dronedarone	NN	O
400	CD	O
mg	NN	O
bid	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
cardiovascular	JJ	O
Hospitalization	NNP	O
or	CC	O
death	NN	O
from	IN	O
any	DT	O
cause	NN	O
in	IN	O
patiENTs	NN	O
with	IN	O
Atrial	NNP	O
fibrillation/atrial	JJ	O
flutter	NN	O
(	(	O
ATHENA	NNP	O
)	)	O
,	,	O
a	DT	O
composite	NN	O
of	IN	O
first	JJ	O
CV	NNP	O
hospitalization	NN	O
or	CC	O
death	NN	O
from	IN	O
any	DT	O
cause	NN	O
,	,	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
dronedarone	NN	O
.	.	O

This	DT	O
post	NN	O
hoc	NN	O
analysis	NN	O
evaluated	VBD	O
the	DT	O
secondary	JJ	O
endpoint	NN	O
of	IN	O
CV	NNP	O
hospitalization	NN	O
and	CC	O
the	DT	O
clinical	JJ	O
benefit	NN	O
of	IN	O
dronedarone	NN	O
on	IN	O
the	DT	O
number	NN	O
and	CC	O
duration	NN	O
of	IN	O
CV	NNP	O
hospitalizations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
ATHENA	NNP	O
was	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
in	IN	O
4628	CD	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
paroxysmal/persistent	NN	O
AF	NNP	O
and	CC	O
additional	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
treated	VBN	O
with	IN	O
placebo	NN	O
or	CC	O
dronedarone	NN	O
.	.	O

Dronedarone	NNP	O
treatment	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
risk	NN	O
of	IN	O
first	JJ	O
CV	NNP	O
hospitalization	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
,	,	O
while	IN	O
the	DT	O
risk	NN	O
of	IN	O
first	JJ	O
non-CV	JJ	O
hospitalization	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.77	CD	O
)	)	O
.	.	O

About	IN	O
half	NN	O
of	IN	O
the	DT	O
CV	NNP	O
hospitalizations	NNS	O
were	VBD	O
AF-related	JJ	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
duration	NN	O
of	IN	O
hospital	JJ	O
stay	NN	O
of	IN	O
four	CD	O
nights	NNS	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
any	DT	O
hospitalization	NN	O
for	IN	O
AF	NNP	O
[	NNP	O
hazard	NN	O
ratio	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
0.626	CD	O
(	(	O
0.546-0.719	NN	O
)	)	O
]	NN	O
and	CC	O
duration	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
dronedarone	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

Dronedarone	NNP	O
treatment	NN	O
reduced	VBD	O
total	JJ	O
hospitalizations	NNS	O
for	IN	O
acute	JJ	O
coronary	JJ	O
syndrome	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0105	CD	O
)	)	O
and	CC	O
the	DT	O
time	NN	O
between	IN	O
the	DT	O
first	JJ	O
AF/atrial	NNP	O
flutter	NN	O
recurrence	NN	O
and	CC	O
CV	NNP	O
hospitalization/death	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0048	CD	O
)	)	O
.	.	O

Hospitalization	NNP	O
burden	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
across	IN	O
all	DT	O
levels	NNS	O
of	IN	O
care	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Cumulative	JJ	O
incidence	NN	O
data	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
effects	NNS	O
of	IN	O
dronedarone	NN	O
persisted	VBN	O
for	IN	O
at	IN	O
least	JJS	O
24	CD	O
months	NNS	O
.	.	O

CONCLUSION	NNP	O
Dronedarone	NNP	O
reduced	VBD	O
the	DT	O
risk	NN	O
for	IN	O
CV	NNP	O
hospitalization	NN	O
and	CC	O
the	DT	O
total	JJ	O
hospitalization	NN	O
burden	NN	O
in	IN	O
this	DT	O
patient	NN	O
group	NN	O
.	.	O

The	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
under	IN	O
ClinicalTrials.gov	NNP	O
#	#	O
NCT	NNP	O
00174785	CD	O
.	.	O

[	JJ	O
Mitomycin	NNP	O
C	NNP	O
plus	CC	O
HCFU	NNP	O
adjuvant	VBP	O
chemotherapy	NN	O
for	IN	O
noncuratively	RB	O
resected	VBN	O
cases	NNS	O
of	IN	O
colorectal	JJ	O
carcinoma	NN	O
.	.	O

(	(	O
Second	JJ	O
report	NN	O
)	)	O
:	:	O
5-year	JJ	O
survival	NN	O
rate	NN	O
.	.	O

Cooperative	NNP	O
Study	NNP	O
Group	NNP	O
of	IN	O
Kyushu	NNP	O
and	CC	O
Chugoku	NNP	O
for	IN	O
HCFU	NNP	O
Adjuvant	NNP	O
Chemotherapy	NNP	O
]	NNP	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
examine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
employing	VBG	O
mitomycin	JJ	O
C	NNP	O
(	(	O
MMC	NNP	O
)	)	O
and	CC	O
carmofur	NN	O
(	(	O
HCFU	NNP	O
)	)	O
for	IN	O
patients	NNS	O
with	IN	O
noncuratively	RB	Condition
resected	VBN	Condition
colorectal	JJ	Condition
carcinoma	NN	Condition
,	,	O
a	DT	O
cooperative	JJ	O
study	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
54	CD	SampleSize
institutions	NNS	O
in	IN	O
the	DT	O
Kyushu	NNP	O
and	CC	O
Chugoku	NNP	O
areas	NNS	O
of	IN	O
Japan	NNP	O
.	.	O

The	DT	O
criteria	NNS	O
for	IN	O
patient	JJ	O
selection	NN	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
1	CD	O
)	)	O
Age	NNP	Age
of	IN	Age
75	CD	Age
years	NNS	O
or	CC	O
less	JJR	O
and	CC	O
not	RB	O
accompanied	VBN	O
by	IN	O
any	DT	O
serious	JJ	O
disease	NN	O
.	.	O

2	CD	O
)	)	O
Macroscopic	NNP	O
diagnosis	NN	O
as	IN	O
being	VBG	O
noncuratively	RB	O
resected	VBN	O
on	IN	O
completion	NN	O
of	IN	O
the	DT	O
surgical	JJ	O
procedure	NN	O
.	.	O

3	CD	O
)	)	O
Definitive	JJ	O
diagnosis	NN	O
of	IN	O
colorectal	JJ	O
carcinomas	NN	O
,	,	O
histologically	RB	O
.	.	O

4	CD	O
)	)	O
No	DT	O
synchronous	JJ	O
or	CC	O
metachronous	JJ	O
double	JJ	O
cancer	NN	O
.	.	O

The	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
consisted	VBN	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
Group	NNP	O
A	NNP	O
,	,	O
the	DT	O
MMC	NNP	O
group	NN	O
received	VBD	O
bolus	RB	O
intravenous	JJ	O
injections	NNS	O
of	IN	O
20	CD	O
mg	NNS	O
MMC	NNP	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
operation	NN	O
and	CC	O
10	CD	O
mg	NN	O
the	DT	O
next	JJ	O
day	NN	O
,	,	O
followed	VBN	O
by	IN	O
10	CD	O
mg	NNS	O
every	DT	O
4	CD	O
weeks	NNS	O
until	IN	O
a	DT	O
total	NN	O
of	IN	O
100	CD	O
mg	NNS	O
had	VBD	O
been	VBN	O
administered	VBN	O
.	.	O

In	IN	O
Group	NNP	O
B	NNP	O
,	,	O
the	DT	O
MMC	NNP	O
+	NNP	O
HCFU	NNP	O
group	NN	O
received	VBD	O
the	DT	O
same	JJ	O
treatment	NN	O
in	IN	O
Group	NNP	O
A	NNP	O
,	,	O
but	CC	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
600	CD	O
mg/day	NN	O
of	IN	O
HCFU	NNP	O
from	IN	O
the	DT	O
second	JJ	O
week	NN	O
,	,	O
orally	RB	O
for	IN	O
at	IN	O
least	JJS	O
one	CD	O
year	NN	O
.	.	O

Concerning	VBG	O
the	DT	O
69-month	JJ	O
survival	NN	O
rate	NN	O
,	,	O
a	DT	O
better	JJR	O
result	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
MMC	NNP	O
+	NNP	O
HCFU	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
MMC	NNP	O
only	RB	O
group	NN	O
(	(	O
generalized	VBN	O
Wilcoxon	NNP	O
test	NN	O
:	:	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Significantly	RB	O
better	JJR	O
survival	NN	O
rates	NNS	O
were	VBD	O
obtained	VBN	O
in	IN	O
those	DT	O
cases	NNS	O
with	IN	O
disseminating	VBG	O
peritoneal	JJ	O
metastasis	NN	O
,	,	O
hepatic	JJ	O
metastasis	NN	O
and	CC	O
stage	NN	O
V	NNP	O
cancer	NN	O
in	IN	O
the	DT	O
MMC	NNP	O
+	NNP	O
HCFU	NNP	O
group	NN	O
as	IN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
MMC	NNP	O
only	RB	O
group	NN	O
.	.	O

No	DT	O
significant	JJ	O
side	NN	O
effects	NNS	O
due	JJ	O
to	TO	O
the	DT	O
combined	JJ	O
administration	NN	O
of	IN	O
HCFU	NNP	O
were	VBD	O
recognized	VBN	O
.	.	O

The	DT	O
combined	JJ	O
administration	NN	O
of	IN	O
MMC	NNP	O
and	CC	O
HCFU	NNP	O
was	VBD	O
suggested	VBN	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
adjuvant	NN	O
chemotherapy	NN	O
for	IN	O
noncuratively	RB	O
resected	VBN	O
cases	NNS	O
of	IN	O
colorectal	JJ	O
carcinoma	NN	O
.	.	O

Intraperitoneal	NNP	O
application	NN	O
of	IN	O
bupivacaine	NN	O
plus	CC	O
morphine	NN	O
for	IN	O
pain	NN	O
relief	NN	O
after	IN	O
laparoscopic	JJ	Condition
cholecystectomy	NN	Condition
.	.	Condition

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
Intraperitoneal	NNP	O
administration	NN	O
of	IN	O
a	DT	O
local	JJ	O
anaesthetic	NN	O
in	IN	O
combination	NN	O
with	IN	O
an	DT	O
opioid	NN	O
,	,	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
postoperative	JJ	O
pain	NN	O
,	,	O
has	VBZ	O
already	RB	O
been	VBN	O
reported	VBN	O
except	IN	O
after	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
aimed	VBN	O
at	IN	O
assessing	VBG	O
the	DT	O
analgesic	JJ	O
effect	NN	O
of	IN	O
the	DT	O
intraperitoneal	JJ	O
administration	NN	O
of	IN	O
bupivacaine	NN	O
and	CC	O
morphine	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

METHODS	NNP	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
,	,	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	JJ	O
manner	NN	O
,	,	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
injections	NNS	O
was	VBD	O
given	VBN	O
intraperitoneally	RB	O
.	.	O

There	EX	O
were	VBD	O
30	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
:	:	O
Group	NNP	O
1	CD	O
,	,	O
physiological	JJ	O
saline	NN	O
30	CD	O
mL	NN	O
;	:	O
Group	NNP	O
2	CD	O
,	,	O
bupivacaine	VBP	O
0.25	CD	O
%	NN	O
30	CD	O
mL	NN	O
;	:	O
Group	NNP	O
3	CD	O
,	,	O
bupivacaine	VBP	O
0.25	CD	O
%	NN	O
30	CD	O
mL	NN	O
plus	CC	O
morphine	JJ	O
2	CD	O
mg	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
Group	NNP	O
2	CD	O
received	VBD	O
2	CD	O
mg	NNS	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
morphine	NN	O
in	IN	O
2	CD	O
mL	NNS	O
saline	NN	O
,	,	O
and	CC	O
Groups	NNP	O
1	CD	O
and	CC	O
3	CD	O
,	,	O
2	CD	O
mL	NN	O
saline	NN	O
intravenously	RB	O
.	.	O

Patients	NNS	O
'	POS	O
postoperative	JJ	O
pain	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
and	CC	O
a	DT	O
verbal	JJ	O
rating	NN	O
score	NN	O
.	.	O

The	DT	O
postoperative	JJ	O
analgesic	JJ	O
requirement	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
total	JJ	O
dose	NN	O
of	IN	O
metamizol	NN	O
administered	VBN	O
by	IN	O
an	DT	O
i.v	NN	O
.	.	O

patient-controlled	JJ	O
analgesia	NN	O
(	(	O
PCA	NNP	O
)	)	O
device	NN	O
.	.	O

Pain	NNP	O
,	,	O
vital	JJ	O
signs	NNS	O
,	,	O
supplemental	JJ	O
analgesic	JJ	O
consumption	NN	O
and	CC	O
side-effects	NNS	O
were	VBD	O
recorded	VBN	O
for	IN	O
all	DT	O
patients	NNS	O
for	IN	O
24	CD	O
h.	JJ	O
RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
regarding	VBG	O
pain	NN	O
scores	NNS	O
(	(	O
at	IN	O
rest	NN	O
and	CC	O
coughing	VBG	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
except	IN	O
in	IN	O
the	DT	O
first	JJ	O
2	CD	O
h	NN	O
,	,	O
when	WRB	O
scores	NNS	O
were	VBD	O
lower	JJR	O
for	IN	O
patients	NNS	O
receiving	VBG	O
intraperitoneal	JJ	O
bupivacaine	NN	O
plus	CC	O
i.v	NN	O
.	.	O

morphine	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Supplemental	JJ	O
consumption	NN	O
of	IN	O
metamizol	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
Group	NNP	O
3	CD	O
than	IN	O
in	IN	O
Group	NNP	O
1	CD	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
h	NN	O
after	IN	O
surgery	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
cumulative	JJ	O
doses	NNS	O
of	IN	O
metamizol	NN	O
were	VBD	O
also	RB	O
lower	JJR	O
in	IN	O
Group	NNP	O
2	CD	O
than	IN	O
in	IN	O
Groups	NNP	O
1	CD	O
and	CC	O
3	CD	O
over	IN	O
the	DT	O
entire	JJ	O
study	NN	O
(	(	O
2025	CD	O
+/-	NN	O
1044	CD	O
mg	NN	O
vs.	FW	O
4925	CD	O
+/-	JJ	O
1238	CD	O
and	CC	O
4125	CD	O
+/-	JJ	O
1276mg	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
,	,	O
the	DT	O
intraperitoneal	JJ	O
administration	NN	O
of	IN	O
morphine	JJ	O
plus	CC	O
bupivacaine	JJ	O
0.25	CD	O
%	NN	O
reduced	VBD	O
the	DT	O
analgesic	JJ	O
requirements	NNS	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
postoperative	JJ	O
hours	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
intraperitoneal	JJ	O
bupivacaine	JJ	O
0.25	CD	O
%	NN	O
and	CC	O
i.v	NN	O
.	.	O

morphine	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
pain	NN	O
after	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

Investigation	NN	O
of	IN	O
erosion	NN	O
and	CC	O
abrasion	NN	O
on	IN	O
enamel	NN	O
and	CC	O
dentine	NN	O
:	:	O
a	DT	O
model	NN	O
in	IN	O
situ	JJ	O
using	VBG	O
toothpastes	NNS	O
of	IN	O
different	JJ	O
abrasivity	NN	O
.	.	O

BACKGROUND	NNP	O
Studies	NNPS	O
in	IN	O
vitro	JJ	O
suggest	VBP	O
that	IN	O
abrasion	NN	O
and	CC	O
erosion	NN	O
may	MD	O
act	VB	O
synergistically	RB	O
to	TO	O
produce	VB	O
wear	NN	O
of	IN	O
enamel	NN	O
and	CC	O
dentine	NN	O
.	.	O

Methods	NNS	O
in	IN	O
situ	NN	O
are	VBP	O
recently	RB	O
available	JJ	O
to	TO	O
study	VB	O
separately	RB	O
erosion	NN	O
and	CC	O
abrasion	NN	O
of	IN	O
dental	JJ	O
tissues	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
combine	VB	O
two	CD	O
in	IN	O
situ	NN	O
protocols	NNS	O
to	TO	O
study	VB	O
the	DT	O
interplay	NN	O
between	IN	O
erosion	NN	O
and	CC	O
abrasion	NN	O
of	IN	O
enamel	NN	O
and	CC	O
dentine	NN	O
.	.	O

METHOD	NNP	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
single-blind	JJ	O
,	,	O
randomised	JJ	O
,	,	O
five-treatment	JJ	O
cross-over	NN	O
design	NN	O
involving	VBG	O
15	CD	SampleSize
healthy	JJ	O
volunteers	NNS	O
.	.	O

During	IN	O
each	DT	O
10-day	JJ	O
study	NN	O
period	NN	O
,	,	O
subjects	NNS	O
wore	VBP	O
from	IN	O
0900	CD	O
to	TO	O
1700	CD	O
h	NN	O
an	DT	O
upper	JJ	O
removable	JJ	O
acrylic	JJ	O
appliance	NN	O
holding	VBG	O
one	CD	O
polished	JJ	O
enamel	NN	O
and	CC	O
one	CD	O
polished	VBN	O
dentine	NN	O
specimen	NNS	O
.	.	O

The	DT	O
specimen	JJ	O
treatment	NN	O
regimens	NNS	O
were	VBD	O
:	:	O
1	CD	O
.	.	O

Drinking	NN	O
water	NN	O
and	CC	O
brushing	NN	O
with	IN	O
toothpaste	NN	O
A	NNP	O
.	.	O

2	CD	O
.	.	O

Drinking	NN	O
water	NN	O
and	CC	O
brushing	NN	O
with	IN	O
toothpaste	NN	O
B	NNP	O
.	.	O

3	CD	O
.	.	O

Drinking	VBG	O
orange	NN	O
juice	NN	O
.	.	O

4	CD	O
.	.	O

Drinking	VBG	O
orange	NN	O
juice	NN	O
and	CC	O
brushing	VBG	O
with	IN	O
toothpaste	NN	O
A	NNP	O
.	.	O

5	CD	O
.	.	O

Drinking	VBG	O
orange	NN	O
juice	NN	O
and	CC	O
brushing	VBG	O
with	IN	O
toothpaste	NN	O
B	NNP	O
.	.	O

Drinking	NN	O
and	CC	O
brushing	VBG	O
times	NNS	O
were	VBD	O
around	IN	O
0900	CD	O
,	,	O
1100	CD	O
,	,	O
1300	CD	O
and	CC	O
1500	CD	O
h.	NN	O
Drinks	NNP	O
were	VBD	O
consumed	VBN	O
as	IN	O
250	CD	O
ml	NN	O
over	IN	O
10	CD	O
min	NNS	O
and	CC	O
brushing	VBG	O
ex	JJ	O
vivo	NN	O
for	IN	O
1	CD	O
min	NNS	O
to	TO	O
each	DT	O
specimen	NNS	O
.	.	O

Measurement	NN	O
of	IN	O
tissue	NN	O
loss	NN	O
was	VBD	O
made	VBN	O
on	IN	O
days	NNS	O
5	CD	O
and	CC	O
10	CD	O
of	IN	O
each	DT	O
period	NN	O
using	VBG	O
a	DT	O
profilometer	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
treatments	NNS	O
produced	VBD	O
increasing	VBG	O
tissue	NN	O
loss	NN	O
over	IN	O
time	NN	O
,	,	O
which	WDT	O
was	VBD	O
considerably	RB	O
greater	JJR	O
for	IN	O
dentine	NN	O
than	IN	O
enamel	NN	O
.	.	O

For	IN	O
enamel	NN	O
,	,	O
the	DT	O
data	NNS	O
at	IN	O
days	NNS	O
5	CD	O
and	CC	O
10	CD	O
showed	VBD	O
a	DT	O
significant	JJ	O
effect	NN	O
for	IN	O
erosion	NN	O
(	(	O
i.e	NN	O
.	.	O

orange	NN	O
juice	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
erosive	JJ	O
than	IN	O
water	NN	O
)	)	O
,	,	O
but	CC	O
no	DT	O
significant	JJ	O
effect	NN	O
for	IN	O
abrasion	NN	O
(	(	O
i.e	NN	O
.	.	O

no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
toothpaste	NN	O
treatments	NNS	O
)	)	O
.	.	O

The	DT	O
combined	JJ	O
orange	NN	O
juice	NN	O
and	CC	O
toothpaste	NN	O
effects	NNS	O
were	VBD	O
directional	JJ	O
for	IN	O
synergy	NN	O
but	CC	O
did	VBD	O
not	RB	O
reach	VB	O
significance	NN	O
.	.	O

For	IN	O
dentine	NN	O
at	IN	O
day	NN	O
10	CD	O
,	,	O
many	JJ	O
specimens	NNS	O
exceeded	VBD	O
the	DT	O
50	CD	O
microm	NN	O
set	VBN	O
limit	NN	O
of	IN	O
the	DT	O
profilometer	NN	O
and	CC	O
only	RB	O
day	NN	O
5	CD	O
data	NNS	O
were	VBD	O
considered	VBN	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
effects	NNS	O
for	IN	O
erosion	NN	O
(	(	O
orange	JJ	O
juice	NN	O
produced	VBD	O
significantly	RB	O
more	JJR	O
erosion	NN	O
than	IN	O
water	NN	O
)	)	O
and	CC	O
for	IN	O
abrasion	NN	O
(	(	O
paste	NN	O
A	DT	O
was	VBD	O
significantly	RB	O
more	RBR	O
abrasive	JJ	O
to	TO	O
dentine	VB	O
than	IN	O
paste	NN	O
B	NNP	O
)	)	O
.	.	O

The	DT	O
synergy	JJ	O
effect	NN	O
could	MD	O
not	RB	O
be	VB	O
examined	VBN	O
for	IN	O
dentine	NN	O
due	JJ	O
to	TO	O
the	DT	O
truncation	NN	O
effect	NN	O
as	IN	O
the	DT	O
set	NN	O
limit	NN	O
of	IN	O
the	DT	O
profilometer	NN	O
was	VBD	O
exceeded	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Erosion	NNP	O
increases	VBZ	O
the	DT	O
susceptibility	NN	O
of	IN	O
enamel	NN	O
to	TO	O
toothpaste	VB	O
abrasion	NN	O
.	.	O

Dentine	NNP	O
is	VBZ	O
considerably	RB	O
more	RBR	O
susceptible	JJ	O
than	IN	O
enamel	NN	O
to	TO	O
erosion	NN	O
and	CC	O
abrasion	NN	O
alone	RB	O
or	CC	O
combined	VBN	O
.	.	O

Dentine	NNP	O
loss	NN	O
appears	VBZ	O
to	TO	O
correlate	VB	O
with	IN	O
toothpaste	NN	O
abrasivity	NN	O
(	(	O
RDA	NNP	O
value	NN	O
)	)	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	O
therapy	NN	O
program	NN	O
for	IN	O
behaviorally	RB	Condition
disordered	VBN	Condition
mentally	RB	Condition
handicapped	JJ	Condition
patients	NNS	O
on	IN	O
staff	NN	O
personnel	NNS	O
in	IN	O
residential	JJ	O
care	NN	O
]	NNP	O
.	.	O

This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
an	DT	O
intensive	JJ	O
therapy	NN	O
program	NN	O
designed	VBN	O
for	IN	O
mentally	RB	Condition
handicapped	JJ	Condition
persons	NNS	O
with	IN	O
severely	RB	O
disturbed	VBN	O
or	CC	O
autistic	JJ	Condition
behavior	NN	Condition
on	IN	O
their	PRP$	O
staff	NN	O
personal	JJ	O
which	WDT	O
had	VBD	O
an	DT	O
active	JJ	O
role	NN	O
in	IN	O
the	DT	O
program	NN	O
.	.	O

The	DT	O
staff	NN	O
members	NNS	O
rated	VBD	O
their	PRP$	O
professional	JJ	O
competence	NN	O
,	,	O
quality	NN	O
of	IN	O
interaction	NN	O
with	IN	O
the	DT	O
client	NN	O
,	,	O
team	JJ	O
culture	NN	O
and	CC	O
work	NN	O
satisfaction	NN	O
before	IN	O
and	CC	O
after	IN	O
being	VBG	O
engaged	VBN	O
in	IN	O
the	DT	O
program	NN	O
,	,	O
with	IN	O
additional	JJ	O
ratings	NNS	O
of	IN	O
their	PRP$	O
personal	JJ	O
aims	NNS	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
program	NN	O
.	.	O

Three	NNP	O
sets	NNS	O
of	IN	O
data	NNS	O
were	VBD	O
obtained	VBN	O
with	IN	O
the	DT	O
program	NN	O
being	VBG	O
conducted	VBN	O
three	CD	O
times	NNS	O
in	IN	O
a	DT	O
row	NN	O
.	.	O

The	DT	O
testings	NNS	O
of	IN	O
the	DT	O
related	VBN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
independent	JJ	O
samples	NNS	O
show	VBP	O
differentiated	JJ	O
program	NN	O
effects	NNS	O
.	.	O

The	DT	O
main	JJ	O
effect	NN	O
is	VBZ	O
an	DT	O
increase	NN	O
of	IN	O
the	DT	O
professional	JJ	O
competence	NN	O
and	CC	O
quality	NN	O
of	IN	O
interaction	NN	O
,	,	O
especially	RB	O
by	IN	O
the	DT	O
qualified	JJ	O
staff	NN	O
members	NNS	O
.	.	O

Trainees	NNP	O
put	VBD	O
emphasis	NN	O
on	IN	O
the	DT	O
development	NN	O
of	IN	O
their	PRP$	O
personal	JJ	O
relationship	NN	O
with	IN	O
the	DT	O
client	NN	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
impact	NN	O
of	IN	O
learning	VBG	O
processes	NNS	O
specific	JJ	O
to	TO	O
the	DT	O
roles	NNS	O
of	IN	O
the	DT	O
staff	NN	O
members	NNS	O
and	CC	O
motivational	JJ	O
factors	NNS	O
on	IN	O
learning	NN	O
and	CC	O
therapy	NN	O
outcome	NN	O
,	,	O
along	IN	O
with	IN	O
institutional	JJ	O
conditions	NNS	O
influencing	VBG	O
successful	JJ	O
learning	NN	O
.	.	O

Thus	VB	O
the	DT	O
program	NN	O
facilitates	VBZ	O
the	DT	O
professional	JJ	O
and	CC	O
interpersonal	JJ	O
learning	NN	O
process	NN	O
of	IN	O
staff	NN	O
members	NNS	O
in	IN	O
a	DT	O
specific	JJ	O
way	NN	O
with	IN	O
success	NN	O
as	RB	O
well	RB	O
as	IN	O
with	IN	O
limitations	NNS	O
.	.	O

Reactive	JJ	O
balance	NN	O
adjustments	NNS	O
to	TO	O
unexpected	JJ	O
perturbations	NNS	O
during	IN	O
human	JJ	O
walking	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
investigation	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
unexpected	JJ	O
forward	NN	O
perturbations	NNS	O
(	(	O
FP	NNP	O
)	)	O
during	IN	O
gait	NN	O
on	IN	O
lower	JJR	O
extremity	NN	O
joint	NN	O
mechanics	NNS	O
and	CC	O
muscle	NN	O
Electromyographic	NNP	O
(	(	O
EMG	NNP	O
)	)	O
patterns	VBZ	O
in	IN	O
healthy	JJ	Condition
adults	NNS	Age
.	.	O

The	DT	O
muscles	NNS	O
surrounding	VBG	O
the	DT	O
hip	NN	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
most	RBS	O
important	JJ	O
in	IN	O
maintaining	VBG	O
control	NN	O
of	IN	O
the	DT	O
trunk	NN	O
and	CC	O
preventing	VBG	O
collapse	NN	O
in	IN	O
response	NN	O
to	TO	O
the	DT	O
FP	NNP	O
.	.	O

Distinct	NNP	O
lower	JJR	O
extremity	NN	O
joint	JJ	O
moment	NN	O
and	CC	O
power	NN	O
patterns	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
response	NN	O
to	TO	O
the	DT	O
FP	NNP	O
but	CC	O
an	DT	O
overall	JJ	O
positive	JJ	O
moment	NN	O
of	IN	O
support	NN	O
(	(	O
M	NNP	O
(	(	O
s	PRP	O
)	)	O
)	)	O
was	VBD	O
maintained	VBN	O
.	.	O

Therefore	RB	O
,	,	O
reactive	JJ	O
balance	NN	O
control	NN	O
was	VBD	O
a	DT	O
synchronized	JJ	O
effort	NN	O
of	IN	O
the	DT	O
lower	JJR	O
extremity	NN	O
joints	NNS	O
to	TO	O
prevent	VB	O
collapse	NN	O
during	IN	O
the	DT	O
FP	NNP	O
.	.	O

Local	JJ	O
immunotherapy	NN	O
by	IN	O
inhalation	NN	O
of	IN	O
a	DT	O
powder	NN	O
extract	NN	O
in	IN	O
asthma	NN	O
due	JJ	O
to	TO	O
house	NN	O
dust	NN	O
mite	NN	O
Dermatophagoides	NNP	O
pteronyssinus	NN	O
:	:	O
a	DT	O
double-blind	JJ	O
comparison	NN	O
with	IN	O
parenteral	JJ	O
immunotherapy	NN	O
.	.	O

To	TO	O
verify	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
the	DT	O
tolerability	NN	O
of	IN	O
local	JJ	O
immunotherapy	NN	O
(	(	O
LI	NNP	O
)	)	O
by	IN	O
inhalation	NN	O
of	IN	O
a	DT	O
powder	NN	O
extract	NN	O
of	IN	O
house	NN	O
dust	NN	O
mite	NN	O
(	(	O
HDM	NNP	O
)	)	O
,	,	O
in	IN	O
comparison	NN	O
with	IN	O
parenteral	JJ	O
immunotherapy	NN	O
(	(	O
PI	NNP	O
)	)	O
by	IN	O
injection	NN	O
,	,	O
10	CD	O
patients	NNS	O
with	IN	O
asthma	NNS	O
due	JJ	O
to	TO	O
HDM	NNP	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
blind	JJ	O
fashion	NN	O
.	.	O

5	CD	O
patients	NNS	O
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
underwent	NN	O
LI	NNP	O
and	CC	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
placebo	NN	O
,	,	O
5	CD	O
patients	NNS	O
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
underwent	NN	O
PI	NNP	O
and	CC	O
inhalation	NN	O
of	IN	O
lactose	NN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
each	DT	O
inhalation	NN	O
was	VBD	O
preceded	VBN	O
by	IN	O
premedication	NN	O
with	IN	O
disodium	NN	O
cromoglycate	NN	O
(	(	O
DSCG	NNP	O
)	)	O
(	(	O
40	CD	O
mg	NN	O
)	)	O
.	.	O

In	IN	O
Group	NNP	O
A	NNP	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
symptoms	NNS	O
score	NN	O
and	CC	O
in	IN	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
(	(	O
PEF	NNP	O
)	)	O
-derived	VBD	O
parameters	NNS	O
was	VBD	O
observed	VBN	O
already	RB	O
after	IN	O
3	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
,	,	O
and	CC	O
2	CD	O
patients	NNS	O
lost	VBD	O
the	DT	O
late	JJ	O
component	NN	O
of	IN	O
the	DT	O
bronchial	JJ	O
response	NN	O
to	TO	O
the	DT	O
challenge	NN	O
with	IN	O
HDM	NNP	O
.	.	O

No	NNP	O
significant	JJ	O
variation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
bronchial	JJ	O
responsiveness	NN	O
to	TO	O
methacholine	VB	O
and	CC	O
ultrasonically	RB	O
nebulized	VBN	O
distilled	JJ	O
water	NN	O
(	(	O
UNDW	NNP	O
)	)	O
and	CC	O
in	IN	O
immunologic	JJ	O
humoral	JJ	O
and	CC	O
cellular	JJ	O
parameters	NNS	O
in	IN	O
peripheral	JJ	O
blood	NN	O
after	IN	O
treatment	NN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

No	DT	O
local	JJ	O
important	JJ	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
Group	NNP	O
A	NNP	O
and	CC	O
no	DT	O
systemic	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
LI	NNP	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
PI	NNP	O
,	,	O
but	CC	O
more	RBR	O
rapid	JJ	O
in	IN	O
its	PRP$	O
action	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
asthma	NNS	O
due	JJ	O
to	TO	O
HDM	NNP	O
.	.	O

Moreover	RB	O
,	,	O
LI	NNP	O
is	VBZ	O
locally	RB	O
well	RB	O
tolerated	VBN	O
,	,	O
providing	VBG	O
DSCG	NNP	O
is	VBZ	O
inhaled	VBN	O
before	IN	O
each	DT	O
therapeutic	JJ	O
inhalation	NN	O
,	,	O
and	CC	O
does	VBZ	O
not	RB	O
induce	VB	O
systemic	JJ	O
side	NN	O
effects	NNS	O
.	.	O

Acid	NNP	O
resistance	NN	O
of	IN	O
enamel	JJ	Condition
subsurface	NN	Condition
lesions	NNS	Condition
remineralized	VBN	O
by	IN	O
a	DT	O
sugar-free	JJ	O
chewing	NN	O
gum	NN	O
containing	VBG	O
casein	JJ	O
phosphopeptide-amorphous	JJ	O
calcium	NN	O
phosphate	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
clinical	JJ	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
acid	JJ	O
resistance	NN	O
of	IN	O
enamel	JJ	Condition
lesions	NNS	Condition
remineralized	VBN	O
in	IN	O
situ	NN	O
by	IN	O
a	DT	O
sugar-free	JJ	O
chewing	NN	O
gum	NN	O
containing	VBG	O
casein	JJ	O
phosphopeptide-amorphous	JJ	O
calcium	NN	O
phosphate	NN	O
nanocomplexes	NNS	O
(	(	O
CPP-ACP	JJ	O
:	:	O
Recaldent	NN	O
)	)	O
.	.	O

The	DT	O
study	NN	O
utilized	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
crossover	VB	O
design	NN	O
with	IN	O
two	CD	O
treatments	NNS	O
:	:	O
(	(	O
i	NN	O
)	)	O
sugar-free	JJ	O
gum	NN	O
containing	VBG	O
18.8	CD	O
mg	NN	O
of	IN	O
CPP-ACP	NNP	O
,	,	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
sugar-free	JJ	O
gum	NN	O
not	RB	O
containing	VBG	O
CPP-ACP	NNP	O
as	IN	O
control	NN	O
.	.	O

Subjects	NNS	O
wore	RBR	O
removable	JJ	O
palatal	JJ	O
appliances	NNS	O
with	IN	O
insets	NNS	O
of	IN	O
human	JJ	O
enamel	NN	O
containing	VBG	O
demineralized	JJ	O
subsurface	NN	Condition
lesions	NNS	Condition
and	CC	O
chewed	VBD	O
the	DT	O
gum	NN	O
for	IN	O
20	CD	O
min	NN	O
4	CD	O
times	NNS	O
per	IN	O
day	NN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

After	IN	O
each	DT	O
treatment	NN	O
the	DT	O
enamel	NN	O
slabs	NN	O
were	VBD	O
removed	VBN	O
and	CC	O
half	NN	O
of	IN	O
each	DT	O
lesion	NN	O
challenged	VBD	O
with	IN	O
acid	NN	O
in	IN	O
vitro	NN	O
for	IN	O
8	CD	O
or	CC	O
16	CD	O
h.	VBP	O
The	DT	O
level	NN	O
of	IN	O
remineralization	NN	O
was	VBD	O
determined	VBN	O
using	VBG	O
microradiography	NN	O
.	.	O

The	DT	O
gum	NN	O
containing	VBG	O
CPP-ACP	NNP	O
produced	VBD	O
approximately	RB	O
twice	JJ	O
the	DT	O
level	NN	O
of	IN	O
remineralization	NN	O
as	IN	O
the	DT	O
control	NN	O
sugar-free	JJ	O
gum	NN	O
.	.	O

The	DT	O
8-	JJ	O
and	CC	O
16-hour	JJ	O
acid	NN	O
challenge	NN	O
of	IN	O
the	DT	O
lesions	NNS	O
remineralized	VBN	O
with	IN	O
the	DT	O
control	NN	O
gum	NN	O
resulted	VBD	O
in	IN	O
65.4	CD	O
and	CC	O
88.0	CD	O
%	NN	O
reductions	NNS	O
,	,	O
respectively	RB	O
,	,	O
of	IN	O
deposited	JJ	O
mineral	NN	O
,	,	O
while	IN	O
for	IN	O
the	DT	O
CPP-ACP-remineralized	JJ	O
lesions	NNS	O
the	DT	O
corresponding	JJ	O
reductions	NNS	O
were	VBD	O
30.5	CD	O
and	CC	O
41.8	CD	O
%	NN	O
.	.	O

The	DT	O
acid	NN	O
challenge	NN	O
after	IN	O
in	IN	O
situ	JJ	O
remineralization	NN	O
for	IN	O
both	DT	O
control	NN	O
and	CC	O
CPP-ACP-treated	JJ	O
lesions	NNS	O
resulted	VBD	O
in	IN	O
demineralization	NN	O
underneath	IN	O
the	DT	O
remineralized	JJ	O
zone	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
remineralized	JJ	O
mineral	NN	O
was	VBD	O
more	RBR	O
resistant	JJ	O
to	TO	O
subsequent	JJ	O
acid	NN	O
challenge	NN	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
sugar-free	JJ	O
gum	NN	O
containing	VBG	O
CPP-ACP	NNP	O
is	VBZ	O
superior	JJ	O
to	TO	O
an	DT	O
equivalent	JJ	O
gum	NN	O
not	RB	O
containing	VBG	O
CPP-ACP	NNP	O
in	IN	O
remineralization	NN	O
of	IN	O
enamel	JJ	O
subsurface	NN	O
lesions	NNS	O
in	IN	O
situ	NN	O
with	IN	O
mineral	NN	O
that	WDT	O
is	VBZ	O
more	RBR	O
resistant	JJ	O
to	TO	O
subsequent	JJ	O
acid	NN	O
challenge	NN	O
.	.	O

Radiotherapy	NNP	O
and	CC	O
CCNU	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
high-grade	JJ	O
supratentorial	JJ	O
astrocytomas	NN	O
.	.	O

Forty-one	CD	SampleSize
consecutive	JJ	O
patients	NNS	O
with	IN	O
supratentorial	JJ	Condition
primary	JJ	Condition
brain	NN	Condition
tumors	NNS	Condition
(	(	O
38	CD	SampleSize
Grade	NNP	Condition
III	NNP	Condition
and	CC	Condition
IV	NNP	Condition
astrocytomas	RB	Condition
,	,	O
one	CD	SampleSize
giant-cell	NN	Condition
astrocytoma	NN	Condition
,	,	O
and	CC	O
two	CD	SampleSize
cases	NNS	O
with	IN	O
insufficient	JJ	O
tissue	NN	O
for	IN	O
diagnosis	NN	O
)	)	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
within	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
surgery	NN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
therapeutic	JJ	O
groups	NNS	O
.	.	O

Group	NNP	O
1	CD	O
(	(	O
15	CD	O
patients	NNS	O
)	)	O
received	VBD	O
radiation	NN	O
therapy	NN	O
totaling	VBG	O
4000	CD	O
to	TO	O
4500	CD	O
rads	NNS	O
in	IN	O
4	CD	O
to	TO	O
5	CD	O
weeks	NNS	O
.	.	O

Group	NNP	O
2	CD	O
(	(	O
13	CD	O
patients	NNS	O
)	)	O
received	VBD	O
1-	JJ	O
(	(	O
2-chloroethyl	JJ	O
)	)	O
-3-cyclohexyl-1-nitrosourea	FW	O
CCNU	NNP	O
)	)	O
130	CD	O
mg/sq	JJ	O
m	NNS	O
orally	RB	O
every	DT	O
6	CD	O
weeks	NNS	O
.	.	O

Group	NNP	O
3	CD	O
(	(	O
13	CD	O
patients	NNS	O
)	)	O
received	VBD	O
radiation	NN	O
therapy	NN	O
plus	CC	O
CCNU	NNP	O
as	IN	O
for	IN	O
Groups	NNP	O
1	CD	O
and	CC	O
2	CD	O
.	.	O

When	WRB	O
the	DT	O
disease	NN	O
progressed	VBD	O
,	,	O
patients	NNS	O
in	IN	O
Groups	NNP	O
1	CD	O
and	CC	O
2	CD	O
were	VBD	O
crossed	VBN	O
over	IN	O
to	TO	O
receive	VB	O
CCNU	NNP	O
and	CC	O
irradiation	NN	O
respectively	RB	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
time	NN	O
in	IN	O
these	DT	O
groups	NNS	O
was	VBD	O
188	CD	O
,	,	O
259	CD	O
,	,	O
and	CC	O
252	CD	O
days	NNS	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
survival	NN	O
263	CD	O
,	,	O
262	CD	O
,	,	O
and	CC	O
329	CD	O
days	NNS	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
from	IN	O
diagnosis	NN	O
to	TO	O
crossover	VB	O
(	(	O
Groups	NNP	O
1	CD	O
and	CC	O
2	CD	O
)	)	O
or	CC	O
to	TO	O
progression	NN	O
(	(	O
Group	NNP	O
3	CD	O
)	)	O
was	VBD	O
163	CD	O
,	,	O
99	CD	O
,	,	O
and	CC	O
220	CD	O
days	NNS	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
time	NN	O
was	VBD	O
172	CD	O
,	,	O
108	CD	O
,	,	O
and	CC	O
231	CD	O
days	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
means	NNS	O
or	CC	O
medians	NNS	O
in	IN	O
any	DT	O
of	IN	O
these	DT	O
situations	NNS	O
.	.	O

Can	MD	O
acupuncture	VB	O
ease	VB	O
the	DT	O
symptoms	NNS	O
of	IN	O
menopause	NN	Condition
?	.	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
2-group	JJ	O
clinical	JJ	O
study	NN	O
,	,	O
acupuncture	NN	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
menopausal	NN	Condition
hot	JJ	Condition
flushes	NNS	Condition
,	,	O
sleep	JJ	Condition
disturbances	NNS	Condition
,	,	O
and	CC	O
mood	NN	Condition
changes	NNS	Condition
.	.	O

The	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
consisted	VBD	O
of	IN	O
specific	JJ	O
acupuncture	NN	O
body	NN	O
points	NNS	O
related	VBN	O
to	TO	O
menopausal	VB	O
symptoms	NNS	O
.	.	O

The	DT	O
comparison	JJ	O
acupuncture	NN	O
treatment	NN	O
consisted	VBN	O
of	IN	O
a	DT	O
treatment	NN	O
designated	VBN	O
as	IN	O
a	DT	O
general	JJ	O
tonic	NN	O
specifically	RB	O
designed	VBN	O
to	TO	O
benefit	VB	O
the	DT	O
flow	NN	O
of	IN	O
Ch'i	NNP	O
(	(	O
energy	NN	O
)	)	O
.	.	O

Results	NNS	O
from	IN	O
the	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
mean	JJ	O
monthly	JJ	O
hot	JJ	O
flush	NN	O
severity	NN	O
for	IN	O
site-specific	JJ	O
acupuncture	NN	O
.	.	O

The	DT	O
comparison	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
in	IN	O
severity	NN	O
from	IN	O
baseline	NN	O
over	IN	O
the	DT	O
treatment	NN	O
phase	NN	O
.	.	O

Sleep	JJ	O
disturbances	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
declined	VBD	O
over	IN	O
the	DT	O
study	NN	O
.	.	O

Mood	NNP	O
changes	NNS	O
in	IN	O
both	DT	O
the	DT	O
experimental	JJ	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
and	CC	O
the	DT	O
comparison	NN	O
acupuncture	NN	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
baseline	NN	O
and	CC	O
the	DT	O
third	JJ	O
month	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Acupuncture	NNP	O
using	VBG	O
menopausal-specific	JJ	O
sites	NNS	O
holds	VBZ	O
promise	NN	O
for	IN	O
nonhormonal	JJ	O
relief	NN	O
of	IN	O
hot	JJ	O
flushes	NNS	O
and	CC	O
sleep	JJ	O
disturbances	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
dalcetrapib	NN	O
on	IN	O
atherosclerotic	JJ	O
disease	NN	O
using	VBG	O
novel	JJ	O
non-invasive	JJ	O
multimodality	NN	O
imaging	NN	O
(	(	O
dal-PLAQUE	JJ	O
)	)	O
:	:	O
a	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Dalcetrapib	NNP	O
modulates	VBZ	O
cholesteryl	VBP	O
ester	NN	O
transfer	NN	O
protein	NN	O
(	(	O
CETP	NNP	O
)	)	O
activity	NN	O
to	TO	O
raise	VB	O
high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
HDL-C	NNP	O
)	)	O
.	.	O

After	IN	O
the	DT	O
failure	NN	O
of	IN	O
torcetrapib	NN	O
it	PRP	O
was	VBD	O
unknown	JJ	O
if	IN	O
HDL	NNP	O
produced	VBN	O
by	IN	O
interaction	NN	O
with	IN	O
CETP	NNP	O
had	VBD	O
pro-atherogenic	JJ	O
or	CC	O
pro-inflammatory	JJ	O
properties	NNS	O
.	.	O

dal-PLAQUE	NN	O
is	VBZ	O
the	DT	O
first	JJ	O
multicentre	NN	O
study	NN	O
using	VBG	O
novel	JJ	O
non-invasive	JJ	O
multimodality	NN	O
imaging	VBG	O
to	TO	O
assess	VB	O
structural	JJ	O
and	CC	O
inflammatory	JJ	O
indices	NNS	O
of	IN	O
atherosclerosis	NN	O
as	IN	O
primary	JJ	O
endpoints	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
phase	NN	O
2b	CD	O
,	,	O
double-blind	NN	O
,	,	O
multicentre	JJ	O
trial	NN	O
,	,	O
patients	NNS	O
(	(	Age
aged	VBN	Age
18-75	CD	Age
years	NNS	Age
)	)	Age
with	IN	Condition
,	,	Condition
or	CC	Condition
with	IN	Condition
high	JJ	Condition
risk	NN	Condition
of	IN	Condition
,	,	Condition
coronary	JJ	Condition
heart	NN	Condition
disease	NN	Condition
were	VBD	O
randomly	RB	O
assigned	VBN	O
(	(	O
1:1	CD	O
)	)	O
to	TO	O
dalcetrapib	VB	O
600	CD	O
mg/day	NN	O
or	CC	O
placebo	NN	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
done	VBN	O
with	IN	O
a	DT	O
computer-generated	JJ	O
randomisation	NN	O
code	NN	O
and	CC	O
was	VBD	O
stratified	VBN	O
by	IN	O
centre	NN	O
.	.	O

Patients	NNS	O
and	CC	O
investigators	NNS	O
were	VBD	O
masked	VBN	O
to	TO	O
treatment	NN	O
.	.	O

Coprimary	JJ	O
endpoints	NNS	O
were	VBD	O
MRI-assessed	JJ	O
indices	NNS	O
(	(	O
total	JJ	O
vessel	NN	O
area	NN	O
,	,	O
wall	JJ	O
area	NN	O
,	,	O
wall	NN	O
thickness	NN	O
,	,	O
and	CC	O
normalised	VBD	O
wall	NN	O
index	NN	O
[	JJ	O
average	JJ	O
carotid	NN	O
]	NN	O
)	)	O
after	IN	O
24	CD	O
months	NNS	O
and	CC	O
(	(	O
18	CD	O
)	)	O
F-fluorodeoxyglucose	NNP	O
(	(	O
(	(	O
18	CD	O
)	)	O
F-FDG	NN	O
)	)	O
PET/CT	NNP	O
assessment	NN	O
of	IN	O
arterial	JJ	O
inflammation	NN	O
within	IN	O
an	DT	O
index	NN	O
vessel	NN	O
(	(	O
right	JJ	O
carotid	NN	O
,	,	O
left	VBD	O
carotid	NN	O
,	,	O
or	CC	O
ascending	VBG	O
thoracic	JJ	O
aorta	NN	O
)	)	O
after	IN	O
6	CD	O
months	NNS	O
,	,	O
with	IN	O
no-harm	JJ	O
boundaries	NNS	O
established	VBN	O
before	IN	O
unblinding	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
NCT00655473	NNP	O
.	.	O

FINDINGS	NNP	O
189	CD	SampleSize
patients	NNS	O
were	VBD	O
screened	VBN	O
and	CC	O
130	CD	SampleSize
randomly	RB	O
assigned	VBN	SampleSize
to	TO	O
placebo	VB	O
(	(	O
66	CD	SampleSize
patients	NNS	O
)	)	O
or	CC	O
dalcetrapib	NN	O
(	(	O
64	CD	SampleSize
patients	NNS	O
)	)	O
.	.	O

For	IN	O
the	DT	O
coprimary	JJ	O
MRI	NNP	O
and	CC	O
PET/CT	NNP	O
endpoints	NNS	O
,	,	O
CIs	NNP	O
were	VBD	O
below	IN	O
the	DT	O
no-harm	JJ	O
boundary	NN	O
or	CC	O
the	DT	O
adverse	JJ	O
change	NN	O
was	VBD	O
numerically	RB	O
lower	JJR	O
in	IN	O
the	DT	O
dalcetrapib	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

MRI-derived	JJ	O
change	NN	O
in	IN	O
total	JJ	O
vessel	JJ	O
area	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
patients	NNS	O
given	VBN	O
dalcetrapib	NNS	O
compared	VBN	O
with	IN	O
those	DT	O
given	VBN	O
placebo	NNS	O
after	IN	O
24	CD	O
months	NNS	O
;	:	O
absolute	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
relative	NN	O
to	TO	O
placebo	VB	O
was	VBD	O
-4?01	JJ	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
90	CD	O
%	NN	O
CI	NNP	O
-7?23	NNP	O
to	TO	O
-0?80	VB	O
;	:	O
nominal	JJ	O
p=0?04	NN	O
)	)	O
.	.	O

The	DT	O
PET/CT	NNP	O
measure	NN	O
of	IN	O
index	NN	O
vessel	JJ	O
most-diseased-segment	JJ	O
target-to-background	NN	O
ratio	NN	O
(	(	O
TBR	NNP	O
)	)	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
,	,	O
but	CC	O
carotid	JJ	O
artery	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
7	CD	O
%	NN	O
reduction	NN	O
in	IN	O
most-diseased-segment	JJ	O
TBR	NNP	O
in	IN	O
the	DT	O
dalcetrapib	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
-7?3	NNP	O
[	RB	O
90	CD	O
%	NN	O
CI	NNP	O
-13?5	NNP	O
to	TO	O
-0?8	VB	O
]	NNP	O
;	:	O
nominal	JJ	O
p=0?07	NN	O
)	)	O
.	.	O

Dalcetrapib	NNP	O
did	VBD	O
not	RB	O
increase	VB	O
office	NN	O
blood	NN	O
pressure	NN	O
and	CC	O
the	DT	O
frequency	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

INTERPRETATION	NNP	O
Dalcetrapib	NNP	O
showed	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
a	DT	O
pathological	JJ	O
effect	NN	O
related	VBN	O
to	TO	O
the	DT	O
arterial	JJ	O
wall	NN	O
over	IN	O
24	CD	O
months	NNS	O
.	.	O

Moreover	RB	O
,	,	O
this	DT	O
trial	NN	O
suggests	VBZ	O
possible	JJ	O
beneficial	JJ	O
vascular	JJ	O
effects	NNS	O
of	IN	O
dalcetrapib	NN	O
,	,	O
including	VBG	O
the	DT	O
reduction	NN	O
in	IN	O
total	JJ	O
vessel	JJ	O
enlargement	NN	O
over	IN	O
24	CD	O
months	NNS	O
,	,	O
but	CC	O
long-term	JJ	O
safety	NN	O
and	CC	O
clinical	JJ	O
outcomes	NNS	O
efficacy	NN	O
of	IN	O
dalcetrapib	NNS	O
need	VBP	O
to	TO	O
be	VB	O
analysed	VBN	O
.	.	O

FUNDING	NN	O
F	NNP	O
Hoffmann-La	NNP	O
Roche	NNP	O
Ltd	NNP	O
.	.	O

[	JJ	O
Pharmacological	NNP	O
correction	NN	O
of	IN	O
free	JJ	O
radical	JJ	O
disturbances	NNS	O
and	CC	O
endotoxicosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diffuse	NN	O
peritonitis	NN	O
at	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
]	NNP	O
.	.	O

The	DT	O
examination	NN	O
and	CC	O
treatment	NN	O
of	IN	O
64	CD	O
patients	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
inclusion	NN	O
of	IN	O
complex	JJ	O
antioxidant	NN	O
cytoflavin	NN	O
in	IN	O
intensive	JJ	O
therapy	NN	O
at	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
of	IN	O
diffuse	NN	O
peritonitis	NN	O
allows	VBZ	O
the	DT	O
hypoxia	NN	O
degree	NN	O
to	TO	O
be	VB	O
decreased	VBN	O
that	IN	O
in	IN	O
its	PRP$	O
turn	NN	O
results	NNS	O
in	IN	O
quicker	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
antioxidant	JJ	O
system	NN	O
and	CC	O
decreased	JJ	O
activity	NN	O
of	IN	O
peroxidation	NN	O
and	CC	O
endotoxicosis	NN	O
level	NN	O
.	.	O

The	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
of	IN	O
diffuse	NN	O
peritonitis	NN	O
with	IN	O
cytoflavin	NN	O
included	VBN	O
in	IN	O
intensive	JJ	O
therapy	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
shorter	JJR	O
terms	NNS	O
of	IN	O
artificial	JJ	O
lung	NN	O
ventilation	NN	O
,	,	O
shorter	JJR	O
time	NN	O
of	IN	O
staying	VBG	O
in	IN	O
critical	JJ	O
condition	NN	O
,	,	O
more	RBR	O
favorable	JJ	O
course	NN	O
of	IN	O
complications	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
amantadine	NN	O
and	CC	O
pemoline	NN	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
multiple	JJ	O
sclerosis	NN	O
.	.	O

BACKGROUND	NNP	O
Amantadine	NNP	O
hydrochloride	NN	O
and	CC	O
pemoline	NN	O
,	,	O
both	DT	O
frequently	RB	O
used	VBN	O
to	TO	O
treat	VB	O
the	DT	O
fatigue	NN	O
of	IN	O
multiple	JJ	O
sclerosis	NN	O
(	(	O
MS	NNP	O
)	)	O
,	,	O
may	MD	O
also	RB	O
improve	VB	O
attention	NN	O
and	CC	O
other	JJ	O
cognitive	JJ	O
functions	NNS	O
in	IN	O
MS.	NNP	O
To	TO	O
our	PRP$	O
knowledge	NN	O
,	,	O
these	DT	O
agents	NNS	O
have	VBP	O
never	RB	O
been	VBN	O
compared	VBN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
patients	NNS	O
with	IN	O
MS	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
amantadine	NN	O
and	CC	O
pemoline	NN	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
MS.	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
45	CD	O
ambulatory	JJ	O
patients	NNS	O
with	IN	O
MS	NNP	O
and	CC	O
severe	JJ	O
fatigue	NN	O
were	VBD	O
treated	VBN	O
for	IN	O
6	CD	O
weeks	NNS	O
with	IN	O
amantadine	NN	O
,	,	O
pemoline	NN	O
,	,	O
or	CC	O
placebo	NN	O
using	VBG	O
a	DT	O
parallel	JJ	O
group	NN	O
design	NN	O
.	.	O

They	PRP	O
underwent	VBD	O
comprehensive	JJ	O
neuropsychological	JJ	O
testing	NN	O
to	TO	O
determine	VB	O
treatment	NN	O
effects	NNS	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
.	.	O

Primary	JJ	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
tests	NNS	O
of	IN	O
attention	NN	O
(	(	O
Digit	NNP	O
Span	NNP	O
,	,	O
Trail	NNP	O
Making	NNP	O
Test	NNP	O
,	,	O
and	CC	O
Symbol	NNP	O
Digit	NNP	O
Modalities	NNP	O
Test	NNP	O
)	)	O
,	,	O
verbal	JJ	O
memory	NN	O
(	(	O
Selective	JJ	O
Reminding	NNP	O
Test	NNP	O
)	)	O
,	,	O
nonverbal	JJ	O
memory	NN	O
(	(	O
Benton	NNP	O
Visual	NNP	O
Retention	NNP	O
Test	NNP	O
)	)	O
,	,	O
and	CC	O
motor	NN	O
speed	NN	O
(	(	O
Finger	NNP	O
Tapping	NNP	O
Test	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Fatigue	NNP	O
did	VBD	O
not	RB	O
significantly	RB	O
correlate	VB	O
with	IN	O
any	DT	O
of	IN	O
the	DT	O
neuropsychological	JJ	O
outcome	NN	O
measures	NNS	O
at	IN	O
baseline	NN	O
or	CC	O
after	IN	O
treatment	NN	O
.	.	O

All	DT	O
three	CD	O
treatment	NN	O
groups	NNS	O
improved	VBN	O
on	IN	O
tests	NNS	O
of	IN	O
attention	NN	O
(	(	O
P	NNP	O
<	NNP	O
.003	NNP	O
)	)	O
,	,	O
verbal	JJ	O
memory	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
and	CC	O
motor	NN	O
speed	NN	O
(	(	O
P	NNP	O
<	NNP	O
.002	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
amantadine	NN	O
,	,	O
pemoline	NN	O
,	,	O
and	CC	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
Cognitive	NNP	O
functioning	NN	O
in	IN	O
MS	NNP	O
is	VBZ	O
independent	JJ	O
of	IN	O
fatigue	NN	O
.	.	O

Neither	CC	O
amantadine	JJ	O
nor	CC	O
pemoline	JJ	O
enhances	NNS	O
cognitive	JJ	O
performance	NN	O
in	IN	O
MS	NNP	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Epidural	JJ	O
fentanyl-bupivacaine	JJ	O
compared	VBN	O
with	IN	O
clonidine-bupivacaine	NN	O
for	IN	O
analgesia	NN	O
in	IN	O
labour	NN	O
.	.	O

Alpha-adrenergic	JJ	O
agonists	NNS	O
produce	VBP	O
pain	NN	O
relief	NN	O
through	IN	O
an	DT	O
opioid	JJ	O
independent	JJ	O
mechanism	NN	O
and	CC	O
may	MD	O
be	VB	O
alternatives	NNS	O
to	TO	O
opioids	NNS	O
for	IN	O
combination	NN	O
with	IN	O
local	JJ	O
anaesthetics	NNS	O
for	IN	O
analgesia	NN	O
during	IN	O
labour	NN	O
.	.	O

We	PRP	O
studied	VBD	O
41	CD	SampleSize
pregnant	JJ	O
women	NNS	Sex
.	.	O

Epidural	JJ	O
block	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
75	CD	O
microg	NNS	O
clonidine	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
50	CD	O
microg	NNS	O
fentanyl	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
combined	VBN	O
with	IN	O
0.125	CD	O
%	NN	O
bupivacaine	NN	O
(	(	O
10	CD	O
mL	NN	O
)	)	O
.	.	O

Maternal	JJ	O
vital	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Analgesia	NNP	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
;	:	O
sedation	NN	O
was	VBD	O
scored	VBN	O
using	VBG	O
a	DT	O
five-point	JJ	O
scale	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
maternal	JJ	O
vital	JJ	O
parameters	NNS	O
,	,	O
fetal	JJ	O
heart	NN	O
rate	NN	O
(	(	O
FHR	NNP	O
)	)	O
or	CC	O
Apgar	NNP	O
scores	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Analgesia	NNP	O
lasted	VBD	O
longer	RBR	O
in	IN	O
the	DT	O
bupivacaine-clonidine	JJ	O
group	NN	O
(	(	O
139.4	CD	O
+/-	JJ	O
31	CD	O
min	NN	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
bupivacaine-fentanyl	JJ	O
group	NN	O
(	(	O
127.9	CD	O
+/-	JJ	O
48	CD	O
min	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.42	CD	O
)	)	O
.	.	O

Additional	JJ	O
analgesic	JJ	O
requirement	NN	O
was	VBD	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
fentanyl-bupivacaine	JJ	O
group	NN	O
and	CC	O
total	JJ	O
bupivacaine	NN	O
requirement	NN	O
was	VBD	O
less	RBR	O
in	IN	O
the	DT	O
clonidine-bupivacaine	JJ	O
group	NN	O
(	(	O
22.5	CD	O
+/-	JJ	O
12.5	CD	O
mg	NN	O
vs.	FW	O
30.9	CD	O
+/-	JJ	O
12.8	CD	O
mg	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

This	DT	O
small	JJ	O
study	NN	O
confirms	VBZ	O
that	IN	O
this	DT	O
combination	NN	O
of	IN	O
bupivacaine	NN	O
and	CC	O
clonidine	NN	O
provides	VBZ	O
satisfactory	JJ	O
analgesia	NN	O
for	IN	O
first-stage	JJ	O
labour	NN	O
,	,	O
and	CC	O
of	IN	O
longer	JJR	O
duration	NN	O
than	IN	O
bupivacaine-fentanyl	NN	O
.	.	O

A	DT	O
phase	NN	O
II	NNP	O
study	NN	O
of	IN	O
cetuximab	NN	O
,	,	O
capecitabine	NN	O
and	CC	O
radiotherapy	NN	O
in	IN	O
neoadjuvant	JJ	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
locally	RB	Condition
advanced	VBN	Condition
resectable	JJ	Condition
rectal	JJ	Condition
cancer	NN	Condition
.	.	O

BACKGROUND	NNP	O
Neoadjuvant	NNP	O
chemoradiotherapy	NN	O
(	(	O
CRT	NNP	O
)	)	O
reduces	VBZ	O
local	JJ	O
tumor	NN	O
recurrence	NN	O
in	IN	O
locally	RB	O
advanced	JJ	O
rectal	JJ	O
cancer	NN	O
(	(	O
LARC	NNP	O
)	)	O
.	.	O

This	DT	O
phase	NN	O
II	NNP	O
study	NN	O
assessed	VBD	O
neoadjuvant	JJ	O
cetuximab	NN	O
with	IN	O
capecitabine-based	JJ	O
CRT	NNP	O
in	IN	O
LARC	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
stage	NN	Condition
II/III	NNP	Condition
LARC	NNP	Condition
received	VBD	O
capecitabine	JJ	O
1250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
intravenous	JJ	O
cetuximab	NNS	O
400	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
at	IN	O
week	NN	O
3	CD	O
,	,	O
then	RB	O
weekly	RB	O
intravenous	JJ	O
250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
cetuximab	NN	O
plus	CC	O
CRT	NNP	O
including	VBG	O
capecitabine	NN	O
825	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
twice	RB	O
daily	RB	O
(	(	O
including	VBG	O
weekends	NNS	O
during	IN	O
radiotherapy	NN	O
)	)	O
with	IN	O
radiotherapy	NN	O
of	IN	O
45	CD	O
Gy	NNP	O
(	(	O
25	CD	O
x	RB	O
1.8	CD	O
Gy	NNP	O
)	)	O
,	,	O
5	CD	O
days	NNS	O
a	DT	O
week	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
.	.	O

Total	JJ	O
mesorectal	JJ	O
excision	NN	O
was	VBD	O
scheduled	VBN	O
4-6	JJ	O
weeks	NNS	O
following	VBG	O
completion	NN	O
of	IN	O
CRT	NNP	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
pathological	JJ	O
complete	JJ	O
response	NN	O
(	(	O
pCR	NN	O
)	)	O
.	.	O

RESULTS	JJ	O
Thirty-seven	JJ	SampleSize
patients	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
safety	NN	O
and	CC	O
efficacy	NN	O
.	.	O

TMN	NNP	O
staging	VBG	O
at	IN	O
baseline	NN	O
was	VBD	O
:	:	O
T4N2	NNP	O
,	,	O
11	CD	O
%	NN	O
;	:	O
T3N2	NNP	O
,	,	O
40	CD	O
%	NN	O
;	:	O
T2N2	NNP	O
,	,	O
3	CD	O
%	NN	O
;	:	O
T3N1	NNP	O
,	,	O
35	CD	O
%	NN	O
;	:	O
T2N1	NNP	O
,	,	O
3	CD	O
%	NN	O
and	CC	O
T3N0	NNP	O
8	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
included	VBD	O
,	,	O
grade	VBD	O
1/2	CD	O
acneiform	NN	O
skin	NN	O
rash	NN	O
(	(	O
86	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
grade	VBD	O
3	CD	O
radiodermatitis	NN	O
,	,	O
(	(	O
16	CD	O
%	NN	O
)	)	O
,	,	O
diarrhea	NN	O
(	(	O
11	CD	O
%	NN	O
)	)	O
and	CC	O
hypersensitivity	NN	O
(	(	O
5	CD	O
%	NN	O
)	)	O
.	.	O

pCR	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
3	CD	O
patients	NNS	O
(	(	O
8	CD	O
%	NN	O
)	)	O
.	.	O

Overall-	JJ	O
,	,	O
T-	JJ	O
and	CC	O
N-downstaging	JJ	O
rates	NNS	O
were	VBD	O
73	CD	O
%	NN	O
,	,	O
57	CD	O
%	NN	O
and	CC	O
81	CD	O
%	NN	O
respectively	RB	O
.	.	O

Total	JJ	O
sphincter	JJ	O
preservation	NN	O
rate	NN	O
was	VBD	O
76	CD	O
%	NN	O
,	,	O
and	CC	O
53	CD	O
%	NN	O
in	IN	O
17	CD	SampleSize
patients	NNS	O
whose	WP$	O
tumors	NNS	O
were	VBD	O
located	VBN	O
within	IN	O
5	CD	O
cm	NN	O
from	IN	O
the	DT	O
anal	JJ	O
verge	NN	O
.	.	O

Non-fatal	JJ	O
perioperative	JJ	O
complications	NNS	O
occurred	VBD	O
in	IN	O
13	CD	O
patients	NNS	O
(	(	O
35	CD	O
%	NN	O
)	)	O
with	IN	O
delayed	VBN	O
wound	NN	O
healing	VBG	O
occurring	VBG	O
in	IN	O
6	CD	O
patients	NNS	O
(	(	O
16	CD	O
%	NN	O
)	)	O
.	.	O

One	CD	O
death	NN	O
was	VBD	O
recorded	VBN	O
due	JJ	O
to	TO	O
sepsis	VB	O
following	VBG	O
colonic	JJ	O
necrosis	NN	O
.	.	O

CONCLUSION	NNP	O
Neoadjuvant	NNP	O
cetuximab	NN	O
with	IN	O
capecitabine-based	JJ	O
CRT	NNP	O
is	VBZ	O
tolerable	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
resectable	JJ	Condition
LARC	NNP	Condition
.	.	O

Whilst	NNP	O
the	DT	O
pCR	NN	O
rate	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
recent	JJ	O
reports	NNS	O
,	,	O
a	DT	O
high	JJ	O
pathological	JJ	O
downstaging	VBG	O
rate	NN	O
was	VBD	O
achieved	VBN	O
.	.	O

Allopurinol	NNP	O
use	NN	O
yields	NNS	O
potentially	RB	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
inflammatory	JJ	O
indices	NNS	O
in	IN	O
those	DT	O
with	IN	O
recent	JJ	O
ischemic	JJ	O
stroke	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Elevated	NNP	O
serum	NN	O
uric	JJ	O
acid	NN	O
level	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
poor	JJ	O
outcome	NN	O
and	CC	O
increased	VBD	O
risk	NN	O
of	IN	O
recurrent	NN	O
events	NNS	O
after	IN	O
stroke	NN	O
.	.	O

The	DT	O
xanthine	JJ	O
oxidase	NN	O
inhibitor	NN	O
allopurinol	NN	O
lowers	NNS	O
uric	JJ	O
acid	NN	O
but	CC	O
also	RB	O
attenuates	VBZ	O
expression	NN	O
of	IN	O
inflammatory	JJ	O
adhesion	NN	O
molecules	NNS	O
in	IN	O
murine	NN	O
models	NNS	O
,	,	O
reduces	NNS	O
oxidative	VBP	O
stress	NN	O
in	IN	O
the	DT	O
vasculature	NN	O
,	,	O
and	CC	O
improves	VBZ	O
endothelial	JJ	O
function	NN	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
allopurinol	JJ	O
alters	NNS	O
expression	NN	O
of	IN	O
inflammatory	NN	O
markers	NNS	O
after	IN	O
acute	JJ	O
ischemic	JJ	O
stroke	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
effect	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
'	POS	O
treatment	NN	O
with	IN	O
high-	NN	O
(	(	O
300	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
)	)	O
or	CC	O
low-	JJ	O
(	(	O
100	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
)	)	O
dose	NN	O
allopurinol	NN	O
on	IN	O
levels	NNS	O
of	IN	O
uric	JJ	O
acid	NN	O
and	CC	O
circulating	VBG	O
inflammatory	JJ	O
markers	NNS	O
after	IN	O
ischemic	JJ	O
stroke	NN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
enrolled	VBD	O
50	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
ischemic	JJ	O
stroke	NN	O
(	(	O
17	CD	O
,	,	O
17	CD	O
,	,	O
and	CC	O
16	CD	O
in	IN	O
the	DT	O
high	JJ	O
,	,	O
low	JJ	O
,	,	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Mean	NNP	O
(	(	O
+/-SD	NNP	O
)	)	O
age	NN	O
was	VBD	O
70	CD	O
(	(	O
+/-13	JJ	O
)	)	O
years	NNS	O
.	.	O

Groups	NNP	O
had	VBD	O
similar	JJ	O
characteristics	NNS	O
at	IN	O
baseline	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Uric	NNP	O
acid	NN	O
levels	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
at	IN	O
both	DT	O
7	CD	O
days	NNS	O
and	CC	O
6	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
(	(	O
by	IN	O
0.14	CD	O
mmol/L	NNS	O
at	IN	O
6	CD	O
weeks	NNS	O
,	,	O
P=0.002	NNP	O
)	)	O
.	.	O

Intercellular	JJ	O
adhesion	NN	O
molecule-1	JJ	O
concentration	NN	O
(	(	O
ng/mL	JJ	O
)	)	O
rose	VBD	O
by	IN	O
51.2	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
rose	VBD	O
slightly	RB	O
(	(	O
by	IN	O
10.6	CD	O
)	)	O
in	IN	O
the	DT	O
low-dose	JJ	O
allopurinol	NN	O
group	NN	O
,	,	O
but	CC	O
fell	VBD	O
in	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
(	(	O
by	IN	O
2.6	CD	O
;	:	O
difference	NN	O
between	IN	O
groups	NNS	O
P=0.012	NNP	O
,	,	O
Kruskal-Wallis	NNP	O
test	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Allopurinol	NNP	O
treatment	NN	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
and	CC	O
attenuates	VBZ	O
the	DT	O
rise	NN	O
in	IN	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
levels	NNS	O
seen	VBN	O
after	IN	O
stroke	NN	O
.	.	O

Uric	JJ	O
acid	NN	O
levels	NNS	O
were	VBD	O
lowered	VBN	O
with	IN	O
high	JJ	O
doses	NNS	O
.	.	O

These	DT	O
findings	NNS	O
support	NN	O
further	JJ	O
evaluation	NN	O
of	IN	O
allopurinol	NN	O
as	IN	O
a	DT	O
preventive	JJ	O
measure	NN	O
after	IN	O
stroke	NN	O
.	.	O

PROCLAIM	NN	O
:	:	O
pilot	NN	O
study	NN	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
clopidogrel	NN	O
on	IN	O
inflammatory	JJ	O
markers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	JJ	O
receiving	VBG	O
low-dose	JJ	O
aspirin	NN	O
.	.	O

Metabolic	NNP	O
syndrome	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
intravascular	JJ	O
inflammation	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
inflammatory	NN	O
biomarkers	NNS	O
and	CC	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
ischemic	JJ	O
atherothrombotic	JJ	O
events	NNS	O
.	.	O

Evidence	NN	O
suggests	VBZ	O
that	IN	O
atherothrombosis	NN	O
and	CC	O
intravascular	JJ	O
inflammation	NN	O
share	NN	O
predictive	JJ	O
biomarkers	NNS	O
,	,	O
including	VBG	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
,	,	O
CD40	NNP	O
ligand	NN	O
,	,	O
P-selectin	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
pro-brain	JJ	O
natriuretic	JJ	O
peptide	NN	O
.	.	O

Patients	NNS	O
who	WP	O
had	VBD	O
metabolic	JJ	O
syndrome	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
clopidogrel	NN	O
75	CD	O
mg/day	JJ	O
plus	CC	O
aspirin	JJ	O
81	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
89	CD	O
)	)	O
or	CC	O
placebo	JJ	O
plus	CC	O
aspirin	JJ	O
81	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
92	CD	O
)	)	O
for	IN	O
9	CD	O
weeks	NNS	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
each	DT	O
treatment	NN	O
in	IN	O
suppression	NN	O
of	IN	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

Change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
levels	NNS	O
of	IN	O
high-sensitivity	NN	O
C-reactive	JJ	O
protein	NN	O
,	,	O
CD40	NNP	O
ligand	NN	O
,	,	O
P-selectin	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
pro-brain	JJ	O
natriuretic	JJ	O
peptide	NN	O
at	IN	O
6	CD	O
weeks	NNS	O
was	VBD	O
assessed	VBN	O
to	TO	O
evaluate	VB	O
each	DT	O
treatment	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
at	IN	O
Week	JJ	O
6	CD	O
in	IN	O
model-adjusted	JJ	O
CD40-ligand	NNP	O
levels	NNS	O
in	IN	O
favor	NN	O
of	IN	O
clopidogrel	NN	O
plus	CC	O
aspirin	JJ	O
compared	VBN	O
with	IN	O
placebo	NN	O
plus	CC	O
aspirin	NN	O
in	IN	O
both	DT	O
the	DT	O
intent-to-treat	JJ	O
population	NN	O
(	(	O
difference	NN	O
between	IN	O
least-squares	NNS	O
means	NNS	O
=	VBP	O
-186.5	NNP	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-342.3	NN	O
to	TO	O
-30.8	VB	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
and	CC	O
the	DT	O
per-protocol	JJ	O
population	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
treatment	NN	O
arms	NNS	O
for	IN	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
,	,	O
P-selectin	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
pro-brain	JJ	O
natriuretic	JJ	O
peptide	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
deaths	NNS	O
or	CC	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
either	DT	O
treatment	NN	O
arm	NN	O
.	.	O

Data	NNS	O
from	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
clopidogrel	NN	O
can	MD	O
decrease	VB	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
CD40-ligand	NNP	O
biomarker	NN	O
.	.	O

Effects	NNS	O
of	IN	O
piracetam	NN	O
on	IN	O
regional	JJ	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
mental	JJ	O
functions	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
organic	JJ	O
dementia	NN	Condition
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
piracetam	NN	O
(	(	O
Nootropil	NNP	O
,	,	O
UCB6215	NNP	O
)	)	O
on	IN	O
mental	JJ	O
functions	NNS	O
and	CC	O
on	IN	O
regional	JJ	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
(	(	O
rCBF	NN	O
)	)	O
were	VBD	O
investigated	VBN	O
in	IN	O
eight	CD	SampleSize
patients	NNS	O
in	IN	O
the	DT	O
presenile	JJ	Age
age	NN	O
who	WP	O
displayed	VBD	O
symptoms	NNS	O
of	IN	O
moderate	JJ	O
dementia	NN	Condition
.	.	O

The	DT	O
double-blind	JJ	O
crossover	NN	O
design	NN	O
included	VBD	O
nine	CD	O
measurement	NN	O
occasions	NNS	O
,	,	O
each	DT	O
involving	VBG	O
rCBF	NN	O
measurement	NN	O
by	IN	O
the	DT	O
133-Xe	JJ	O
inhalation	NN	O
method	NN	O
,	,	O
ratings	NNS	O
of	IN	O
symptoms	NNS	O
of	IN	O
dementia	NN	O
,	,	O
personality	NN	O
changes	NNS	O
,	,	O
and	CC	O
side	NN	O
effects	NNS	O
,	,	O
and	CC	O
a	DT	O
psychometric	JJ	O
investigation	NN	O
.	.	O

Three	CD	O
investigations	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
each	DT	O
of	IN	O
three	CD	O
treatment	NN	O
periods	NNS	O
.	.	O

The	DT	O
first	JJ	O
investigation	NN	O
in	IN	O
a	DT	O
period	NN	O
was	VBD	O
made	VBN	O
without	IN	O
medication	NN	O
.	.	O

Then	RB	O
either	DT	O
placebo	NN	O
or	CC	O
piracetam	VB	O
4.8	CD	O
g/day	NN	O
or	CC	O
9.6	CD	O
g/day	NN	O
was	VBD	O
given	VBN	O
during	IN	O
four	CD	O
weeks	NNS	O
with	IN	O
measurements	NNS	O
after	IN	O
2	CD	O
weekks	NN	O
and	CC	O
4	CD	O
weeks	NNS	O
.	.	O

There	EX	O
were	VBD	O
intervals	NNS	O
of	IN	O
4	CD	O
weeks	NNS	O
without	IN	O
medication	NN	O
between	IN	O
the	DT	O
treatment	NN	O
periods	NNS	O
.	.	O

Piracetam	NNP	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
either	CC	O
mental	JJ	O
functions	NNS	O
or	CC	O
rCBF	NN	O
.	.	O

Early	JJ	O
withdrawal	NN	O
of	IN	O
calcineurin	NN	O
inhibitors	NNS	O
and	CC	O
everolimus	JJ	O
monotherapy	NN	O
in	IN	O
de	FW	O
novo	FW	O
liver	NN	Condition
transplant	NN	Condition
recipients	VBZ	O
preserves	VBZ	O
renal	JJ	O
function	NN	O
.	.	O

We	PRP	O
designed	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
to	TO	O
assess	VB	O
whether	IN	O
the	DT	O
early	JJ	O
withdrawal	NN	O
of	IN	O
cyclosporine	NN	O
(	(	O
CsA	NNP	O
)	)	O
followed	VBN	O
by	IN	O
the	DT	O
initiation	NN	O
of	IN	O
everolimus	NN	O
(	(	O
Evr	NNP	O
)	)	O
monotherapy	NN	O
in	IN	O
de	FW	Condition
novo	FW	Condition
liver	FW	Condition
transplantation	NN	Condition
(	(	Condition
LT	NNP	Condition
)	)	Condition
patients	NNS	O
would	MD	O
result	VB	O
in	IN	O
superior	JJ	O
renal	JJ	O
function	NN	O
compared	VBN	O
to	TO	O
a	DT	O
CsA-based	JJ	O
immunosuppression	NN	O
protocol	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
CsA	NNP	O
for	IN	O
the	DT	O
first	JJ	O
10	CD	O
days	NNS	O
and	CC	O
then	RB	O
randomized	VBN	O
to	TO	O
receive	VB	O
Evr	NNP	O
in	IN	O
combination	NN	O
with	IN	O
CsA	NNP	O
up	RB	O
to	TO	O
day	NN	O
30	CD	O
,	,	O
then	RB	O
either	DT	O
continued	VBN	O
on	IN	O
Evr	NNP	O
monotherapy	NN	O
(	(	O
Evr	NNP	O
group	NN	O
)	)	O
or	CC	O
maintained	VBN	O
on	IN	O
CsA	NNP	O
with/without	NN	O
mycophenolate	NN	O
mofetil	NN	O
(	(	O
CsA	NNP	O
group	NN	O
)	)	O
in	IN	O
case	NN	O
of	IN	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
(	(	O
CKD	NNP	O
)	)	O
.	.	O

Seventy-eight	JJ	SampleSize
patients	NNS	O
were	VBD	O
randomized	VBN	O
(	(	O
Evr	NNP	O
n	RB	O
=	VBZ	O
52	CD	O
;	:	O
CsA	NNP	O
n	VBD	O
=	NNP	O
26	CD	O
)	)	O
.	.	O

The	DT	O
1-year	JJ	O
freedom	NN	O
from	IN	O
efficacy	NN	O
failure	NN	O
in	IN	O
Evr	NNP	O
group	NN	O
was	VBD	O
75	CD	O
%	NN	O
versus	IN	O
69.2	CD	O
%	NN	O
in	IN	O
CsA	NNP	O
group	NN	O
,	,	O
p	VBP	O
=	JJ	O
0.36	CD	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
patient	JJ	O
survival	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Mean	NNP	O
modification	NN	O
of	IN	O
diet	NN	O
in	IN	O
renal	JJ	O
disease	NN	O
(	(	O
MDRD	NNP	O
)	)	O
was	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
Evr	NNP	O
group	NN	O
at	IN	O
12	CD	O
months	NNS	O
(	(	O
87.7	CD	O
?	.	O
26.1	CD	O
vs.	IN	O
59.9	CD	O
?	.	O
12.6	CD	O
mL/min	NN	O
;	:	O
p	CC	O
<	VB	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
CKD	NNP	O
stage	NN	O
?	.	O
3	CD	O
(	(	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
<	$	O
60	CD	O
mL/min	NN	O
)	)	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
CsA	NNP	O
group	NN	O
at	IN	O
1	CD	O
year	NN	O
(	(	O
52.2	CD	O
%	NN	O
vs.	FW	O
15.4	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
early	JJ	O
withdrawal	NN	O
of	IN	O
CsA	NNP	O
followed	VBN	O
by	IN	O
Evr	NNP	O
monotherapy	NN	O
in	IN	O
de	FW	O
novo	FW	O
LT	NNP	O
patients	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
an	DT	O
improvement	NN	O
in	IN	O
renal	JJ	O
function	NN	O
,	,	O
with	IN	O
a	DT	O
similar	JJ	O
incidence	NN	O
of	IN	O
rejection	NN	O
and	CC	O
major	JJ	O
complications	NNS	O
.	.	O

Omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
supplementation	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	Condition
:	:	O
a	DT	O
double-blind	JJ	O
randomized	NN	O
,	,	O
placebo-controlled	JJ	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
increasing	VBG	O
evidence	NN	O
that	IN	O
fatty	JJ	O
acid	JJ	O
deficiencies	NNS	O
or	CC	O
imbalances	NNS	O
may	MD	O
contribute	VB	O
to	TO	O
childhood	VB	O
neurodevelopmental	JJ	Condition
disorders	NNS	Condition
.	.	Condition

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
6-week	JJ	O
pilot	NN	O
trial	NN	O
investigating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
1.5	CD	O
g/d	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
(	(	O
.84	JJ	O
g/d	NN	O
eicosapentaenoic	NN	O
acid	NN	O
,	,	O
.7	NNP	O
g/d	NN	O
docosahexaenoic	NN	O
acid	NN	O
)	)	O
supplementation	NN	O
in	IN	O
13	CD	SampleSize
children	NNS	O
(	(	O
aged	VBN	Age
5	CD	Age
to	TO	Age
17	CD	Age
years	NNS	Age
)	)	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
accompanied	VBN	O
by	IN	O
severe	JJ	Condition
tantrums	NNS	Condition
,	,	Condition
aggression	NN	Condition
,	,	Condition
or	CC	Condition
self-injurious	JJ	Condition
behavior	NN	Condition
.	.	O

The	DT	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
at	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
observed	VBD	O
an	DT	O
advantage	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	O
and	CC	O
stereotypy	NN	O
,	,	O
each	DT	O
with	IN	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
.	.	O

Repeated-measures	NNS	O
ANOVA	NNP	O
indicated	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
superiority	NN	O
of	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
over	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	O
.	.	O

No	DT	O
clinically	RB	O
relevant	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
elicited	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	VBZ	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
provide	VBP	O
preliminary	JJ	O
evidence	NN	O
that	IN	O
omega-3	JJ	O
fatty	JJ	O
acids	NNS	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
therapeutic	JJ	O
efficacy	NN	O
of	IN	O
phonophoresis	NN	O
and	CC	O
iontophoresis	NN	O
using	VBG	O
dexamethasone	NN	O
sodium	NN	O
phosphate	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
knee	JJ	O
osteoarthritis	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
Many	NNP	O
treatment	NN	O
options	NNS	O
,	,	O
including	VBG	O
non-pharmacological	JJ	O
and	CC	O
pharmacological	JJ	O
measures	NNS	O
,	,	O
have	VBP	O
been	VBN	O
recommended	VBN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

Among	IN	O
the	DT	O
non-pharmacological	JJ	O
approach	NN	O
is	VBZ	O
physiotherapy	NN	O
,	,	O
which	WDT	O
involves	VBZ	O
the	DT	O
use	NN	O
of	IN	O
physical	JJ	O
modalities	NNS	O
like	IN	O
,	,	O
heat	NN	O
therapy	NN	O
,	,	O
exercise	NN	O
therapy	NN	O
,	,	O
electrical	JJ	O
stimulation	NN	O
,	,	O
therapeutic	JJ	O
ultrasound	NN	O
,	,	O
iontophoresis	NN	O
,	,	O
and	CC	O
phonophoresis	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
therefore	RB	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
0.4	CD	O
%	NN	O
Dexamethasone	NNP	O
sodium	NN	O
phosphate	NN	O
(	(	O
DEX-P	NNP	O
)	)	O
phonophoresis	NN	O
(	(	O
PH	NNP	O
)	)	O
with	IN	O
0.4	CD	O
%	NN	O
DEX-P	JJ	O
iontophoresis	NN	O
(	(	O
ION	NNP	O
)	)	O
therapy	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
knee	JJ	O
joint	JJ	O
OA	NNP	O
.	.	O

METHODS	NNP	O
Fifty	NNP	O
patients	NNS	O
(	(	O
19	CD	O
males	NNS	O
and	CC	O
31	CD	O
females	NNS	O
)	)	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
53.6	CD	O
+/-	JJ	O
8.9	CD	O
years	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
PH	NNP	O
or	CC	O
ION	NNP	O
groups	NNS	O
with	IN	O
25	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Ultrasound	NNP	O
waves	VBZ	O
of	IN	O
1	CD	O
MHz	NNP	O
frequency	NN	O
was	VBD	O
applied	VBN	O
for	IN	O
5	CD	O
minutes	NNS	O
to	TO	O
the	DT	O
target	NN	O
knee	NN	O
,	,	O
so	RB	O
also	RB	O
was	VBD	O
the	DT	O
direct	JJ	O
current	JJ	O
for	IN	O
10	CD	O
minutes	NNS	O
for	IN	O
10	CD	O
sessions	NNS	O
treatment	NN	O
period	NN	O
.	.	O

Western	JJ	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
University	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
scores	VBZ	O
,	,	O
20	CD	O
meters	NNS	O
ambulatory	JJ	O
time	NN	O
,	,	O
and	CC	O
knee	VB	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
were	VBD	O
evaluated	VBN	O
before	IN	O
and	CC	O
after	IN	O
therapy	NN	O
as	IN	O
the	DT	O
outcome	NN	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
two	CD	O
weeks	NNS	O
,	,	O
significant	JJ	O
improvement	NN	O
in	IN	O
total	JJ	O
WOMAC	NNP	O
scores	NNS	O
was	VBD	O
observed	VBN	O
in	IN	O
15	CD	O
(	(	O
60	CD	O
%	NN	O
)	)	O
and	CC	O
16	CD	O
(	(	O
64	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
PH	NNP	O
and	CC	O
ION	NNP	O
groups	NNS	O
respectively	RB	O
,	,	O
indicating	VBG	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
improvement	NN	O
rate	NN	O
.	.	O

Twenty	NNP	O
(	(	O
20	CD	O
)	)	O
metres	NNS	O
ambulatory	JJ	O
time	NN	O
and	CC	O
knee	NN	O
range	NN	O
of	IN	O
motion	NN	O
also	RB	O
improved	VBN	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
yet	RB	O
these	DT	O
variables	NNS	O
showed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
therapeutic	JJ	O
modalities	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
and	CC	O
generally	RB	O
well	RB	O
tolerated	VBN	O
after	IN	O
10	CD	O
treatment	NN	O
sessions	NNS	O
.	.	O

DEX-P	JJ	O
phonophoresis	NN	O
was	VBD	O
not	RB	O
superior	JJ	O
to	TO	O
DEX-P	JJ	O
iontophoresis	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
OA	NNP	O
of	IN	O
the	DT	O
knee	NN	O
.	.	O

Stapled	VBN	O
hemorrhoidopexy	NN	O
vs.	FW	O
Harmonic	NNP	O
Scalpel	NNP	O
hemorrhoidectomy	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

PURPOSE	VB	O
A	NNP	O
randomized	JJ	O
trial	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
stapled	VBN	O
hemorrhoidopexy	NN	O
with	IN	O
excisional	JJ	O
hemorrhoidectomy	NN	O
in	IN	O
which	WDT	O
the	DT	O
Harmonic	NNP	O
Scalpel	NNP	O
was	VBD	O
used	VBN	O
.	.	O

METHODS	JJ	O
Patients	NNS	O
with	IN	O
Grade	NNP	O
III	NNP	O
hemorrhoids	NNS	O
who	WP	O
were	VBD	O
employed	VBN	O
during	IN	O
the	DT	O
trial	NN	O
period	NN	O
were	VBD	O
recruited	VBN	O
and	CC	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
Harmonic	NNP	O
Scalpel	NNP	O
hemorrhoidectomy	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
stapled	VBD	O
hemorrhoidopexy	NN	O
.	.	O

All	DT	O
operations	NNS	O
were	VBD	O
performed	VBN	O
by	IN	O
a	DT	O
single	JJ	O
surgeon	NN	O
.	.	O

In	IN	O
the	DT	O
stapled	JJ	O
group	NN	O
,	,	O
the	DT	O
doughnut	NN	O
obtained	VBN	O
was	VBD	O
sent	VBN	O
for	IN	O
histopathologic	JJ	O
examination	NN	O
to	TO	O
determine	VB	O
whether	IN	O
smooth	JJ	O
muscles	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
specimen	NNS	O
.	.	O

Operative	NNP	O
data	NN	O
and	CC	O
complications	NNS	O
were	VBD	O
recorded	VBN	O
,	,	O
and	CC	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
through	IN	O
a	DT	O
structured	JJ	O
pro	JJ	O
forma	NN	O
protocol	NN	O
.	.	O

An	DT	O
independent	JJ	O
assessor	NN	O
was	VBD	O
assigned	VBN	O
to	TO	O
obtain	VB	O
postoperative	JJ	O
pain	NN	O
scores	NNS	O
and	CC	O
satisfaction	NN	O
scores	NNS	O
at	IN	O
six-month	JJ	O
follow-up	JJ	O
.	.	O

Patients	NNS	O
were	VBD	O
also	RB	O
administered	VBN	O
a	DT	O
simple	JJ	O
questionnaire	NN	O
at	IN	O
follow-up	JJ	O
to	TO	O
assess	VB	O
continence	NN	O
functions	NNS	O
.	.	O

RESULTS	NNP	O
Over	IN	O
a	DT	O
20-month	JJ	O
period	NN	O
,	,	O
88	CD	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
matched	VBN	O
for	IN	O
age	NN	O
and	CC	O
gender	NN	O
distribution	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
identified	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
operation	NN	O
time	NN	O
,	,	O
blood	NN	O
loss	NN	O
,	,	O
day	NN	O
of	IN	O
first	JJ	O
bowel	NN	O
movement	NN	O
after	IN	O
surgery	NN	O
,	,	O
and	CC	O
complication	NN	O
rates	NNS	O
.	.	O

Despite	IN	O
a	DT	O
similar	JJ	O
parenteral	NN	O
and	CC	O
oral	JJ	O
analgesic	JJ	O
requirement	NN	O
,	,	O
the	DT	O
stapled	VBN	O
group	NN	O
had	VBD	O
a	DT	O
significantly	RB	O
better	RBR	O
pain	NN	O
score	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
;	:	O
these	DT	O
patients	NNS	O
also	RB	O
had	VBD	O
a	DT	O
significantly	RB	O
shorter	JJR	O
length	NN	O
of	IN	O
stay	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
on	IN	O
average	NN	O
resumed	VBN	O
work	NN	O
nine	CD	O
days	NNS	O
earlier	RBR	O
than	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
the	DT	O
Harmonic	NNP	O
Scalpel	NNP	O
(	(	O
6.7	CD	O
vs.	FW	O
15.6	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Although	IN	O
88	CD	O
percent	NN	O
of	IN	O
doughnuts	NNS	O
obtained	VBN	O
in	IN	O
the	DT	O
stapled	JJ	O
group	NN	O
contained	VBD	O
some	DT	O
smooth	JJ	O
muscle	NN	O
fibers	NNS	O
,	,	O
no	DT	O
association	NN	O
was	VBD	O
found	VBN	O
between	IN	O
smooth	JJ	O
muscle	NN	O
incorporation	NN	O
and	CC	O
postoperative	JJ	O
continence	NN	O
function	NN	O
,	,	O
and	CC	O
as	IN	O
a	DT	O
whole	JJ	O
the	DT	O
continence	NN	O
outcomes	NNS	O
of	IN	O
the	DT	O
stapled	VBN	O
group	NN	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
after	IN	O
Harmonic	NNP	O
Scalpel	NNP	O
hemorrhoidectomy	NN	O
.	.	O

Finally	RB	O
,	,	O
at	IN	O
six-month	JJ	O
follow-up	JJ	O
,	,	O
patients	NNS	O
who	WP	O
underwent	VBP	O
the	DT	O
stapled	JJ	O
procedure	NN	O
had	VBD	O
significantly	RB	O
better	JJR	O
satisfaction	NN	O
scores	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Stapled	NNP	O
hemorrhoidopexy	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
procedure	NN	O
for	IN	O
Grade	NNP	O
III	NNP	O
hemorrhoidal	JJ	O
disease	NN	O
.	.	O

Patients	NNS	O
derive	JJ	O
greater	JJR	O
short-term	JJ	O
benefits	NNS	O
of	IN	O
reduced	JJ	O
pain	NN	O
,	,	O
shorter	JJR	O
length	NN	O
of	IN	O
stay	NN	O
,	,	O
and	CC	O
earlier	JJR	O
resumption	NN	O
to	TO	O
work	VB	O
.	.	O

Long-term	JJ	O
follow-up	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
determine	VB	O
whether	IN	O
these	DT	O
initial	JJ	O
results	NNS	O
are	VBP	O
lasting	VBG	O
.	.	O

An	DT	O
analysis	NN	O
of	IN	O
the	DT	O
radiation	NN	O
related	VBN	O
morbidity	NN	O
observed	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
neutron	NN	O
therapy	NN	O
for	IN	O
bladder	NN	Condition
cancer	NN	Condition
.	.	Condition

This	DT	O
report	NN	O
is	VBZ	O
an	DT	O
analysis	NN	O
of	IN	O
the	DT	O
morbidity	NN	O
in	IN	O
the	DT	O
bladder	NN	O
and	CC	O
bowel	NN	O
observed	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
d	NN	O
(	(	O
15	CD	O
)	)	O
+Be	NN	O
neutrons	NNS	O
versus	VBP	O
megavoltage	NN	O
photons	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bladder	NN	O
cancer	NN	O
.	.	O

Acute	JJ	O
reactions	NNS	O
in	IN	O
the	DT	O
bladder	NN	O
and	CC	O
bowel	NN	O
were	VBD	O
significantly	RB	O
worse	JJR	O
after	IN	O
photon	NN	O
therapy	NN	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
photons	NNS	O
45.7	CD	O
%	NN	O
had	VBD	O
severe	JJ	O
reactions	NNS	O
in	IN	O
the	DT	O
bladder	NN	O
compared	VBN	O
with	IN	O
10.6	CD	O
%	NN	O
after	IN	O
neutron	JJ	O
therapy	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Severe	NNP	O
acute	JJ	O
bowel	NN	O
reactions	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
8.5	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
after	IN	O
photon	NN	O
therapy	NN	O
compared	VBN	O
with	IN	O
3.8	CD	O
%	NN	O
after	IN	O
neutron	JJ	O
therapy	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Late	JJ	O
reactions	NNS	O
were	VBD	O
significantly	RB	O
worse	JJR	O
after	IN	O
neutrons	NNS	O
.	.	O

Severe	NNP	O
late	JJ	O
reactions	NNS	O
in	IN	O
the	DT	O
bladder	NN	O
were	VBD	O
seen	VBN	O
in	IN	O
58.5	CD	O
%	NN	O
of	IN	O
patients	NNS	O
after	IN	O
neutron	JJ	O
therapy	NN	O
and	CC	O
in	IN	O
40.5	CD	O
%	NN	O
after	IN	O
photon	NN	O
therapy	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
bowel	NN	O
they	PRP	O
were	VBD	O
observed	VBN	O
in	IN	O
53.3	CD	O
%	NN	O
of	IN	O
patients	NNS	O
after	IN	O
neutron	JJ	O
therapy	NN	O
compared	VBN	O
with	IN	O
8	CD	O
%	NN	O
after	IN	O
photon	NN	O
therapy	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
disparity	NN	O
in	IN	O
the	DT	O
degree	NN	O
of	IN	O
early	JJ	O
and	CC	O
late	JJ	O
complications	NNS	O
makes	VBZ	O
assessment	NN	O
of	IN	O
RBE	NNP	O
values	NNS	O
difficult	JJ	O
.	.	O

It	PRP	O
is	VBZ	O
estimated	VBN	O
that	IN	O
for	IN	O
bladder	NN	O
morbidity	NN	O
the	DT	O
RBE	NNP	O
value	NN	O
,	,	O
for	IN	O
photon	NN	O
dose	JJ	O
fractions	NNS	O
of	IN	O
2.75	CD	O
Gy	NNP	O
,	,	O
is	VBZ	O
less	JJR	O
than	IN	O
3.3	CD	O
for	IN	O
early	JJ	O
reactions	NNS	O
and	CC	O
equal	JJ	O
to	TO	O
3.4	CD	O
for	IN	O
late	JJ	O
effects	NNS	O
.	.	O

The	DT	O
respective	JJ	O
RBE	NNP	O
values	NNS	O
for	IN	O
early	RB	O
and	CC	O
late	JJ	O
effects	NNS	O
in	IN	O
the	DT	O
bowel	NN	O
are	VBP	O
less	JJR	O
than	IN	O
3.4	CD	O
and	CC	O
3.8	CD	O
.	.	O

Roles	NNS	O
of	IN	O
adapalene	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	Condition
versicolor	NN	Condition
.	.	O

BACKGROUND	NNP	O
Ketoconazole	NNP	O
is	VBZ	O
a	DT	O
typical	JJ	O
treatment	NN	O
available	JJ	O
for	IN	O
pityriasis	NN	Condition
versicolor	NN	Condition
;	:	O
tretinoin	CC	O
cream	NN	O
is	VBZ	O
effective	JJ	O
,	,	O
too	RB	O
.	.	O

Adapalene	NNP	O
gel	NN	O
is	VBZ	O
a	DT	O
tretinoin	JJ	O
derivative	NN	O
and	CC	O
has	VBZ	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
irritation	NN	O
compared	VBN	O
with	IN	O
other	JJ	O
topical	JJ	O
retinoid	NN	O
products	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
reports	NNS	O
on	IN	O
adapalene	NN	O
gel	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	Condition
versicolor	NN	Condition
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
adapalene	NN	O
gel	NN	O
comparing	VBG	O
the	DT	O
treatment	NN	O
with	IN	O
adapalene	JJ	O
gel	NNS	O
and	CC	O
2	CD	O
%	NN	O
ketoconazole	JJ	O
cream	NN	O
in	IN	O
pityriasis	NN	Condition
versicolor	NN	Condition
.	.	O

METHODS	NNP	O
Eighty	NNP	SampleSize
patients	NNS	O
suffering	VBG	O
from	IN	O
pityriasis	NN	Condition
versicolor	NN	Condition
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
one	CD	O
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
2	CD	O
%	NN	O
ketoconazole	JJ	O
cream	NN	O
topically	RB	O
twice	JJ	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
,	,	O
adapalene	JJ	O
gel	NN	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
other	JJ	O
group	NN	O
in	IN	O
a	DT	O
similar	JJ	O
fashion	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
efficacy	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

No	DT	O
major	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
either	CC	O
.	.	O

CONCLUSION	NNP	O
Adapalene	NNP	O
was	VBD	O
the	DT	O
favorable	JJ	O
option	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pityriasis	NN	Condition
versicolor	NN	Condition
.	.	O

The	DT	O
probable	JJ	O
therapeutic	JJ	O
mechanism	NN	O
of	IN	O
adapalene	NN	O
is	VBZ	O
also	RB	O
discussed	VBN	O
.	.	O

Long-term	JJ	O
psychosocial	NN	O
and	CC	O
health	NN	O
economy	NN	O
consequences	NNS	O
of	IN	O
ADHD	NNP	Condition
,	,	O
autism	NN	Condition
,	,	O
and	CC	O
reading-writing	JJ	Condition
disorder	NN	Condition
:	:	O
a	DT	O
prospective	JJ	O
service	NN	O
evaluation	NN	O
project	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
evaluate	VB	O
psychosocial	JJ	O
,	,	O
societal	JJ	O
,	,	O
and	CC	O
family	NN	O
cost	NN	O
consequences	NNS	O
of	IN	O
a	DT	O
psychoeducational	JJ	O
intervention	NN	O
program	NN	O
.	.	O

METHODS	NNP	O
Sixty	NNP	SampleSize
boys	VBZ	Age
with	IN	O
ADHD	NNP	Condition
,	,	O
Asperger	NNP	Condition
syndrome/high-functioning	JJ	Condition
autism	NN	Condition
(	(	Condition
AS/HFA	NNP	Condition
)	)	Condition
,	,	O
and	CC	O
reading	NN	Condition
and	CC	Condition
writing	VBG	Condition
disorder	NN	Condition
(	(	Condition
RD/WD	NNP	Condition
)	)	Condition
were	VBD	O
allocated	VBN	O
to	TO	O
participate	VB	O
in	IN	O
a	DT	O
service	NN	O
evaluation	NN	O
project	NN	O
.	.	O

Every	DT	O
other	JJ	O
boy	NN	O
in	IN	O
each	DT	O
diagnostic	JJ	O
group	NN	O
was	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
either	RB	O
(	(	O
a	DT	O
)	)	O
a	DT	O
special	JJ	O
education	NN	O
program	NN	O
(	(	O
clinical	JJ	O
index	NN	O
group	NN	O
)	)	O
or	CC	O
(	(	O
b	NN	O
)	)	O
follow-up	NN	O
without	IN	O
the	DT	O
special	JJ	O
education	NN	O
program	NN	O
(	(	O
clinical	JJ	O
comparison	NN	O
group	NN	O
)	)	O
.	.	O

Nine	CD	O
years	NNS	O
after	IN	O
initial	JJ	O
assessments	NNS	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
psychosocial	NN	O
and	CC	O
economic	JJ	O
resource	NN	O
consequences	NNS	O
over	IN	O
time	NN	O
was	VBD	O
studied	VBN	O
.	.	O

RESULTS	NNP	O
ADHD	NNP	O
,	,	O
AS/HFA	NNP	O
,	,	O
and	CC	O
RD/WD	NNP	O
all	DT	O
had	VBD	O
severe	JJ	O
impact	NN	O
on	IN	O
family	NN	O
life	NN	O
quality	NN	O
.	.	O

The	DT	O
societal	JJ	O
costs	NNS	O
were	VBD	O
high	JJ	O
,	,	O
but	CC	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
resource	NN	O
use	NN	O
or	CC	O
in	IN	O
total	JJ	O
costs	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
clinical	JJ	O
index	NN	O
and	CC	O
the	DT	O
comparison	NN	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
underscore	VBP	O
the	DT	O
very	RB	O
long-term	JJ	O
need	NN	O
for	IN	O
support	NN	O
including	VBG	O
individually	RB	O
tailored	VBN	O
reevaluations	NNS	O
and	CC	O
carefully	RB	O
monitored	VBN	O
intervention	NN	O
programs	NNS	O
adapted	VBD	O
to	TO	O
family	NN	O
needs	NNS	O
and	CC	O
severity	NN	O
of	IN	O
child	NN	O
disorder	NN	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
donepezil	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
:	:	O
neuropsychological	JJ	O
measures	NNS	O
.	.	O

OBJECTIVE	NNP	O
There	EX	O
has	VBZ	O
been	VBN	O
recent	JJ	O
interest	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
cognitive	JJ	O
enhancing	VBG	O
drugs	NNS	O
,	,	O
such	JJ	O
as	IN	O
cholinesterase	NN	O
inhibitors	NNS	O
,	,	O
as	IN	O
a	DT	O
possible	JJ	O
treatment	NN	O
for	IN	O
executive	NN	O
functioning	NN	O
(	(	O
EF	NNP	O
)	)	O
deficits	NNS	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
tolerability	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
efficacy	NN	O
of	IN	O
donepezil	NN	O
on	IN	O
EF	NNP	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

METHOD	NNP	O
Thirty-four	JJ	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
age	NN	O
range	NN	O
8-17	CD	O
years	NNS	O
;	:	O
IQ	NNP	O
>	NNP	O
75	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
10-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
donepezil	NN	O
(	(	O
doses	NNS	O
of	IN	O
5	CD	O
and	CC	O
10	CD	O
mg	NN	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
10-week	JJ	O
open	JJ	O
label	NN	O
trial	NN	O
for	IN	O
placebo	NN	O
nonresponders	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
effect	NN	O
of	IN	O
donepezil	NN	O
treatment	NN	O
on	IN	O
EF	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

Despite	IN	O
improvement	NN	O
on	IN	O
a	DT	O
number	NN	O
of	IN	O
EF	NNP	O
measures	NNS	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
between-group	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
(	(	O
with	IN	O
gains	NNS	O
observed	VBN	O
for	IN	O
both	DT	O
the	DT	O
placebo	NN	O
and	CC	O
donepezil	NN	O
groups	NNS	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
short-term	JJ	O
treatment	NN	O
with	IN	O
donepezil	NN	O
may	MD	O
have	VB	O
limited	VBN	O
impact	NN	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
ASD	NNP	O
.	.	O

Future	NNP	O
controlled	VBD	O
trials	NNS	O
may	MD	O
need	VB	O
to	TO	O
consider	VB	O
a	DT	O
longer	RBR	O
treatment	NN	O
period	NN	O
to	TO	O
detect	VB	O
significant	JJ	O
gains	NNS	O
on	IN	O
EF	NNP	O
measures	NNS	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
ofloxacin	NN	O
and	CC	O
cefixime	NN	O
for	IN	O
treatment	NN	O
of	IN	O
typhoid	JJ	Condition
fever	NN	Condition
in	IN	O
children	NNS	Age
.	.	O

The	DT	O
Dong	NNP	O
Nai	NNP	O
Pediatric	NNP	O
Center	NNP	O
Typhoid	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
concerns	NNS	O
about	IN	O
safety	NN	O
in	IN	O
children	NNS	O
,	,	O
fluoroquinolone	NN	O
antibiotics	NNS	O
have	VBP	O
become	VBN	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
in	IN	O
patients	NNS	O
with	IN	O
multidrug-resistant	JJ	Condition
typhoid	NN	Condition
fever	NN	Condition
in	IN	O
Vietnam	NNP	O
.	.	O

However	RB	O
,	,	O
quinolone-resistant	JJ	O
strains	NNS	O
of	IN	O
Salmonella	NNP	O
typhi	NN	O
have	VBP	O
recently	RB	O
been	VBN	O
reported	VBN	O
from	IN	O
Vietnam	NNP	O
;	:	O
and	CC	O
if	IN	O
quinolone	JJ	O
resistance	NN	O
becomes	NNS	O
established	VBN	O
,	,	O
alternative	JJ	O
oral	JJ	O
treatment	NN	O
options	NNS	O
will	MD	O
be	VB	O
needed	VBN	O
.	.	O

OBJECTIVE	NNP	O
Cefixime	NNP	O
,	,	O
an	DT	O
orally	RB	O
administered	VBN	O
third	JJ	O
generation	NN	O
cephalosporin	NN	O
,	,	O
was	VBD	O
compared	VBN	O
with	IN	O
ofloxacin	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
uncomplicated	JJ	O
typhoid	NN	O
fever	NN	O
in	IN	O
children	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
an	DT	O
open	JJ	O
trial	NN	O
children	NNS	Age
with	IN	O
suspected	JJ	O
typhoid	NN	Condition
fever	NN	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
ofloxacin	NN	O
(	(	O
10	CD	O
mg/kg/day	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
)	)	O
for	IN	O
5	CD	O
days	NNS	O
or	CC	O
cefixime	NN	O
(	(	O
20	CD	O
mg/kg/day	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
)	)	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
S.	NNP	O
typhi	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
82	CD	SampleSize
patients	NNS	O
(	(	O
44	CD	O
in	IN	O
the	DT	O
cefixime	NN	O
group	NN	O
,	,	O
38	CD	O
in	IN	O
the	DT	O
ofloxacin	JJ	O
group	NN	O
)	)	O
and	CC	O
70	CD	SampleSize
(	(	O
85	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
isolates	NNS	O
were	VBD	O
multidrug-resistant	JJ	O
.	.	O

Median	JJ	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
range	NN	O
)	)	O
fever	NN	O
clearance	NN	O
times	NNS	O
were	VBD	O
4.4	CD	O
(	(	O
4	CD	O
to	TO	O
5.2	CD	O
,	,	O
0.2	CD	O
to	TO	O
9.9	CD	O
)	)	O
days	NNS	O
for	IN	O
ofloxacin	JJ	O
recipients	NNS	O
and	CC	O
8.5	CD	O
(	(	O
4.2	CD	O
to	TO	O
9	CD	O
,	,	O
1.8	CD	O
to	TO	O
15.2	CD	O
)	)	O
days	NNS	O
for	IN	O
cefixime-treated	JJ	O
patients	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
11	CD	O
treatment	NN	O
failures	NNS	O
(	(	O
10	CD	O
acute	NN	O
and	CC	O
one	CD	O
relapse	NN	O
)	)	O
in	IN	O
the	DT	O
cefixime	NN	O
group	NN	O
and	CC	O
1	CD	O
acute	NN	O
treatment	NN	O
failure	NN	O
in	IN	O
the	DT	O
ofloxacin	NN	O
group	NN	O
(	(	O
mean	JJ	O
difference	NN	O
,	,	O
22	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
9	CD	O
to	TO	O
36	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Short	NNP	O
course	NN	O
treatment	NN	O
with	IN	O
cefixime	NN	O
may	MD	O
provide	VB	O
a	DT	O
useful	JJ	O
alternative	JJ	O
treatment	NN	O
in	IN	O
cases	NNS	O
of	IN	O
uncomplicated	JJ	Condition
typhoid	NN	Condition
fever	NN	Condition
in	IN	O
children	NNS	Age
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
less	RBR	O
effective	JJ	O
than	IN	O
short	JJ	O
course	NN	O
treatment	NN	O
with	IN	O
ofloxacin	NN	O
.	.	O

Faulty	NNP	O
Japanese	JJ	O
sentences	NNS	O
are	VBP	O
judged	VBN	O
more	RBR	O
grammatical	JJ	O
when	WRB	O
punctuation	NN	O
is	VBZ	O
used	VBN	O
:	:	O
negative	JJ	O
implications	NNS	O
for	IN	O
Chomsky	NNP	O
's	POS	O
principle	NN	O
of	IN	O
Full	NNP	O
Interpretation	NNP	O
.	.	O

88	CD	SampleSize
adult	JJ	Age
Japanese	JJ	O
speakers	NNS	O
judged	VBD	O
the	DT	O
grammaticality	NN	O
of	IN	O
isolated	JJ	O
simple	JJ	O
bitransitive	JJ	O
sentences	NNS	O
involving	VBG	O
an	DT	O
uninterpretable	JJ	O
extra	JJ	O
argument	NN	O
in	IN	O
addition	NN	O
to	TO	O
three	CD	O
legitimate	JJ	O
arguments	NNS	O
.	.	O

The	DT	O
sentences	NNS	O
thus	RB	O
violated	VBD	O
Chomsky	NNP	O
's	POS	O
principle	NN	O
of	IN	O
Full	NNP	O
Interpretation	NNP	O
which	WDT	O
prohibits	VBZ	O
the	DT	O
structure	NN	O
building	NN	O
of	IN	O
a	DT	O
sentence	NN	O
including	VBG	O
uninterpretable	JJ	O
elements	NNS	O
.	.	O

The	DT	O
primary	JJ	O
variable	NN	O
of	IN	O
interest	NN	O
was	VBD	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
punctuation	NN	O
,	,	O
i.e.	FW	O
,	,	O
commas	NN	O
,	,	O
which	WDT	O
enclosed	VBD	O
the	DT	O
extra	JJ	O
argument	NN	O
.	.	O

Findings	NNS	O
showed	VBD	O
that	IN	O
sentences	NNS	O
with	IN	O
punctuation	NN	O
were	VBD	O
judged	VBN	O
more	RBR	O
grammatical	JJ	O
than	IN	O
the	DT	O
ones	NNS	O
without	IN	O
punctuation	NN	O
,	,	O
with	IN	O
an	DT	O
average	JJ	O
score	NN	O
of	IN	O
judged	JJ	O
grammaticality	NN	O
exceeding	VBG	O
3	CD	O
on	IN	O
a	DT	O
7-point	JJ	O
scale	NN	O
(	(	O
1	CD	O
=least	RB	O
grammatical	JJ	O
;	:	O
7=most	CD	O
grammatical	NN	O
)	)	O
.	.	O

This	DT	O
score	NN	O
would	MD	O
not	RB	O
be	VB	O
expected	VBN	O
if	IN	O
the	DT	O
speakers	NNS	O
possess	NN	O
and	CC	O
judge	NN	O
the	DT	O
sentences	NNS	O
in	IN	O
conformity	NN	O
with	IN	O
the	DT	O
principle	NN	O
of	IN	O
Full	NNP	O
Interpretation	NNP	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
albuterol	JJ	O
solution	NN	O
nebulized	VBN	O
versus	NN	O
albuterol	NN	O
powder	NN	O
given	VBN	O
by	IN	O
breath	NN	O
activated	VBN	O
metered	VBD	O
dose	JJ	O
inhaler	NN	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
nebulized	JJ	O
vs	NN	O
powdered	VBD	O
albuterol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
exacerbated	JJ	Condition
bronchial	JJ	Condition
asthma	NN	Condition
who	WP	Condition
required	VBD	Condition
hospitalization	NN	Condition
.	.	O

From	IN	Condition
January	NNP	Condition
to	TO	Condition
May	NNP	Condition
1990	CD	Condition
known	NN	O
asthmatics	NNS	O
admitted	VBN	O
with	IN	O
acute	JJ	Condition
exacerbation	NN	Condition
were	VBD	O
included	VBN	O
by	IN	O
established	VBN	O
criteria	NNS	O
.	.	O

Two	CD	O
groups	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

Group	NNP	O
I	PRP	O
for	IN	O
Albuterol	NNP	O
powder	NN	O
200	CD	O
micrograms	NNS	O
inhaled	VBD	O
q	RB	O
4	CD	O
hours	NNS	O
.	.	O

Group	NNP	O
II	NNP	O
with	IN	O
Albuterol	NNP	O
nebulized	JJ	O
solution	NN	O
2.5	CD	O
mg	NN	O
inhaled	VBD	O
q	RB	O
4	CD	O
hrs	NN	O
.	.	O

Force	NNP	O
Vital	NNP	O
Capacity	NNP	O
and	CC	O
Force	NNP	O
Expiratory	NNP	O
Volume	NN	O
in	IN	O
one	CD	O
second	NN	O
were	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
pressure	NN	O
differential	JJ	O
transducer	NN	O
upon	IN	O
admission	NN	O
,	,	O
30	CD	O
minutes	NNS	O
and	CC	O
24-hours	JJ	O
following	NN	O
therapies	NNS	O
.	.	O

Absolute	NNP	O
FEV1	NNP	O
improvement	NN	O
was	VBD	O
calculated	VBN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
student	NN	O
's	POS	O
T-Test	NNP	O
and	CC	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
Test	NNP	O
with	IN	O
significance	NN	O
established	VBN	O
at	IN	O
p	NN	O
>	VBP	O
0.01	CD	O
%	NN	O
.	.	O

Fifteen	JJ	SampleSize
patients	NNS	O
enrolled	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
two	CD	O
patients	NNS	O
of	IN	O
group	NN	O
I	PRP	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
statistic	JJ	O
analysis	NN	O
due	JJ	O
to	TO	O
refusal	VB	O
to	TO	O
continue	VB	O
with	IN	O
the	DT	O
therapy	NN	O
.	.	O

Both	DT	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
with	IN	O
respect	NN	O
to	TO	O
sex	NN	O
,	,	O
asthma	JJ	O
exacerbations/year	NN	O
,	,	O
smoking	VBG	O
history	NN	O
and	CC	O
hospital	JJ	O
length	NN	O
of	IN	O
stay	NN	O
.	.	O

FVC	NNP	O
and	CC	O
FEV1	NNP	O
were	VBD	O
comparable	JJ	O
also	RB	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
there	EX	O
were	VBD	O
significant	JJ	O
difference	NN	O
when	WRB	O
the	DT	O
absolute	NN	O
improvement	NN	O
were	VBD	O
compared	VBN	O
.	.	O

The	DT	O
mean	JJ	O
+/-	JJ	O
SE	NNP	O
for	IN	O
FEV1	NNP	O
absolute	JJ	O
improvement	NN	O
at	IN	O
the	DT	O
first	JJ	O
30	CD	O
min	NN	O
was	VBD	O
0.42	CD	O
+/-	JJ	O
0.08	CD	O
lts	NNS	O
for	IN	O
the	DT	O
Group	NNP	O
I	PRP	O
versus	VBP	O
0.65	CD	O
+/-	JJ	O
0.6	CD	O
lts	NNS	O
in	IN	O
the	DT	O
Group	NNP	O
II	NNP	O
.	.	O

In	IN	O
the	DT	O
next	JJ	O
24	CD	O
hours	NNS	O
,	,	O
Group	NNP	O
I	PRP	O
was	VBD	O
0.16	CD	O
+/-	JJ	O
0.2	CD	O
lts	NNS	O
versus	JJ	O
0.30	CD	O
+/-	JJ	O
0.7	CD	O
lts	NNS	O
in	IN	O
Group	NNP	O
II	NNP	O
(	(	O
p	JJ	O
>	NNP	O
.01	NNP	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
although	IN	O
the	DT	O
dose	JJ	O
equivalence	NN	O
of	IN	O
both	DT	O
delivery	NN	O
systems	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
established	VBN	O
in	IN	O
our	PRP$	O
study	NN	O
,	,	O
the	DT	O
nebulized	JJ	O
solution	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
of	IN	O
hospitalization	NN	O
than	IN	O
the	DT	O
dry	JJ	O
powder	NN	O
.	.	O

Effect	NN	O
of	IN	O
beta-blocking	NN	O
drugs	NNS	O
on	IN	O
beta-cell	NN	O
function	NN	O
and	CC	O
insulin	NN	O
sensitivity	NN	O
in	IN	O
hypertensive	JJ	O
non-diabetic	JJ	O
patients	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
two	CD	O
beta-blocking	JJ	O
drugs	NNS	O
on	IN	O
endogenous	JJ	O
insulin	NN	O
secretion	NN	O
and	CC	O
insulin	NN	O
sensitivity	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
cross-over	NN	O
study	NN	O
in	IN	O
13	CD	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
each	DT	O
of	IN	O
three	CD	O
2-week	JJ	O
treatment	NN	O
periods	NNS	O
with	IN	O
propranolol	JJ	O
80	CD	O
mg	NN	O
b.i.d.	NN	O
,	,	O
atenolol	RB	O
50	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

and	CC	O
placebo	JJ	O
b.i.d	NN	O
.	.	O

Endogenous	JJ	O
insulin	NN	O
secretion	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
measuring	VBG	O
serum	JJ	O
insulin	NN	O
and	CC	O
C-peptide	NNP	O
before	IN	O
and	CC	O
6	CD	O
min	NN	O
after	IN	O
iv	JJ	O
administration	NN	O
of	IN	O
glucagon	NN	O
;	:	O
insulin	JJ	O
sensitivity	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
measuring	VBG	O
insulin	NN	O
binding	VBG	O
to	TO	O
erythrocytes	NNS	O
,	,	O
and	CC	O
as	IN	O
the	DT	O
glucose	JJ	O
disappearance	NN	O
rate	NN	O
(	(	O
KITT	NNP	O
)	)	O
after	IN	O
i.v	NN	O
.	.	O

insulin	NN	O
.	.	O

Fasting	VBG	O
concentrations	NNS	O
of	IN	O
serum	JJ	O
free	JJ	O
fatty	NN	O
acids	NNS	O
(	(	O
S-FFA	NNP	O
)	)	O
and	CC	O
plasma	JJ	O
gastric	JJ	O
inhibitory	NN	O
polypeptide	NN	O
(	(	O
P-GIP	NNP	O
)	)	O
were	VBD	O
also	RB	O
recorded	VBN	O
during	IN	O
the	DT	O
three	CD	O
study	NN	O
periods	NNS	O
.	.	O

Both	DT	O
propranolol	NN	O
and	CC	O
atenolol	NN	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
and	CC	O
S-FFA	NNP	O
concentrations	NNS	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
and	CC	O
all	DT	O
patients	NNS	O
showed	VBD	O
measurable	JJ	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
propranolol	NN	O
and	CC	O
atenolol	NN	O
.	.	O

The	DT	O
results	NNS	O
can	MD	O
be	VB	O
considered	VBN	O
representative	JJ	O
,	,	O
therefore	RB	O
,	,	O
of	IN	O
clinical	JJ	O
beta-blockade	NN	O
.	.	O

The	DT	O
two	CD	O
drugs	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
influence	VB	O
the	DT	O
fasting	NN	O
blood	NN	O
glucose	JJ	O
level	NN	O
.	.	O

There	EX	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
fasting	VBG	O
and	CC	O
glucagon-stimulated	JJ	O
serum	NN	O
C-peptide	NNP	O
concentration	NN	O
during	IN	O
propranolol	JJ	O
therapy	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
p	JJ	O
=	NN	O
0.037	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.030	CD	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
although	IN	O
this	DT	O
was	VBD	O
not	RB	O
reflected	VBN	O
by	IN	O
a	DT	O
significant	JJ	O
change	NN	O
in	IN	O
serum	JJ	O
insulin	NN	O
.	.	O

Propranolol	NNP	O
and	CC	O
atenolol	RB	O
did	VBD	O
not	RB	O
significantly	RB	O
influence	JJ	O
insulin	NN	O
binding	NN	O
to	TO	O
erythrocytes	NNS	O
,	,	O
but	CC	O
they	PRP	O
clearly	RB	O
reduced	VBD	O
the	DT	O
glucose	JJ	O
disappearance	NN	O
rate	NN	O
KITT	NNP	O
was	VBD	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
p	JJ	O
=	NN	O
0.0036	CD	O
and	CC	O
p	VB	O
=	NNP	O
0.0003	CD	O
)	)	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
findings	NNS	O
support	VBP	O
the	DT	O
view	NN	O
that	IN	O
beta-blocking	JJ	O
drugs	NNS	O
can	MD	O
influence	VB	O
glucose	JJ	O
metabolism	NN	O
by	IN	O
mechanisms	NNS	O
other	JJ	O
than	IN	O
inhibition	NN	O
of	IN	O
endogenous	JJ	O
insulin	NN	O
secretion	NN	O
.	.	O

Supporting	VBG	O
families	NNS	O
in	IN	O
challenging	VBG	O
contexts	NN	O
:	:	O
the	DT	O
CAPEDP	NNP	O
project	NN	O
.	.	O

Although	IN	O
France	NNP	O
has	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
generous	JJ	O
health	NN	O
and	CC	O
social	JJ	O
care	NN	O
systems	NNS	O
for	IN	O
infant	NN	O
and	CC	O
maternal	JJ	O
well-being	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
,	,	O
professionals	NNS	O
have	VBP	O
been	VBN	O
increasingly	RB	O
concerned	VBN	O
by	IN	O
the	DT	O
rising	VBG	O
number	NN	O
of	IN	O
children	NNS	O
being	VBG	O
referred	VBN	O
for	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
.	.	O

The	DT	O
present	JJ	O
article	NN	O
describes	VBZ	O
the	DT	O
first	JJ	O
home-visiting	JJ	O
program	NN	O
in	IN	O
France	NNP	O
to	TO	O
specifically	RB	O
target	VB	O
mental	JJ	O
health	NN	O
questions	NNS	O
in	IN	O
families	NNS	O
living	VBG	O
in	IN	O
vulnerable	JJ	O
contexts	NN	O
.	.	O

The	DT	O
CAPEDP	NNP	O
project	NN	O
,	,	O
involving	VBG	O
440	CD	O
women	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
,	,	O
took	VBD	O
place	NN	O
in	IN	O
Paris	NNP	O
and	CC	O
its	PRP$	O
inner	JJ	O
suburbs	NNS	O
from	IN	O
2006	CD	O
to	TO	O
2011	CD	O
.	.	O

To	TO	O
be	VB	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
,	,	O
women	NNS	O
had	VBD	O
to	TO	O
be	VB	O
(	(	O
i	NN	O
)	)	O
under	IN	O
26	CD	O
years	NNS	O
old	JJ	O
,	,	O
(	(	O
ii	NN	O
)	)	O
less	JJR	O
that	IN	O
27	CD	O
weeks	NNS	O
pregnant	JJ	O
,	,	O
(	(	O
iii	NN	O
)	)	O
sufficiently	RB	O
fluent	VBN	O
in	IN	O
French	JJ	O
to	TO	O
give	VB	O
truly	NN	O
informed	JJ	O
consent	NN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
study	NN	O
and	CC	O
benefit	NN	O
from	IN	O
the	DT	O
intervention	NN	O
and	CC	O
(	(	O
iv	NN	O
)	)	O
presenting	VBG	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	JJ	O
social	JJ	O
vulnerability	NN	O
factors	NNS	O
:	:	O
low	JJ	O
income	NN	O
,	,	O
low	JJ	O
educational	JJ	O
level	NN	O
,	,	O
and/or	RB	O
intending	VBG	O
to	TO	O
bring	VB	O
up	RP	O
the	DT	O
child	NN	O
without	IN	O
the	DT	O
child	NN	O
's	POS	O
father	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
44	CD	O
home	NN	O
visits	NNS	O
from	IN	O
the	DT	O
third	JJ	O
trimester	NN	O
of	IN	O
pregnancy	NN	O
through	IN	O
to	TO	O
the	DT	O
child	NN	O
's	POS	O
second	JJ	O
birthday	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
to	TO	O
promote	VB	O
infant	JJ	O
mental	JJ	O
health	NN	O
and	CC	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
infant	JJ	O
mental	JJ	O
health	NN	O
problems	NNS	O
at	IN	O
the	DT	O
age	NN	O
of	IN	O
two	CD	O
years	NNS	O
.	.	O

The	DT	O
intervention	NN	O
paid	VBD	O
particular	JJ	O
attention	NN	O
to	TO	O
postnatal	JJ	O
maternal	JJ	O
depression	NN	O
and	CC	O
promoting	VBG	O
parenting	VBG	O
skills	NNS	O
and	CC	O
attachment	JJ	O
security	NN	O
,	,	O
particularly	RB	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
video	NN	O
during	IN	O
home-visits	NNS	O
.	.	O

A	DT	O
major	JJ	O
issue	NN	O
was	VBD	O
that	IN	O
of	IN	O
adapting	VBG	O
international	JJ	O
best	JJS	O
practice	NN	O
recommendations	NNS	O
with	IN	O
regard	NN	O
to	TO	O
home-visiting	JJ	O
programs	NNS	O
to	TO	O
the	DT	O
particularities	NNS	O
of	IN	O
the	DT	O
existing	VBG	O
French	JJ	O
social	JJ	O
and	CC	O
health	NN	O
care	NN	O
system	NN	O
.	.	O

An	DT	O
original	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
to	TO	O
use	VB	O
trained	JJ	O
clinical	JJ	O
psychologists	NNS	O
to	TO	O
conduct	VB	O
all	DT	O
home	NN	O
visits	NNS	O
.	.	O

Randomized	VBN	O
evaluation	NN	O
of	IN	O
octreotide	JJ	O
vs	FW	O
prochlorperazine	NN	O
for	IN	O
ED	NNP	O
treatment	NN	O
of	IN	O
migraine	NN	O
headache	NN	O
.	.	O

UNLABELLED	JJ	O
Patients	NNS	O
with	IN	O
headaches	NNS	O
account	VBP	O
for	IN	O
approximately	RB	O
2	CD	O
%	NN	O
of	IN	O
all	DT	O
ED	NNP	O
visits	NNS	O
,	,	O
with	IN	O
migraines	NNS	O
being	VBG	O
the	DT	O
most	RBS	O
common	JJ	O
defined	VBD	O
primary	JJ	O
headache	NN	O
syndrome	NN	O
.	.	O

Our	PRP$	O
goals	NNS	O
were	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
intravenous	JJ	O
octreotide	NN	O
(	(	O
OC	NNP	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
migraines	NNS	O
,	,	O
when	WRB	O
compared	VBN	O
to	TO	O
standard	VB	O
therapy	NN	O
with	IN	O
prochlorperazine	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
as	IN	O
a	DT	O
double-blinded	JJ	O
,	,	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

Each	DT	O
subject	NN	O
received	VBD	O
either	CC	O
100	CD	O
microg	NN	O
of	IN	O
octreotide	NN	O
or	CC	O
10	CD	O
mg	NN	O
of	IN	O
prochlorperazine	NN	O
intravenously	RB	O
for	IN	O
a	DT	O
2-minute	JJ	O
period	NN	O
.	.	O

RESULTS	NNP	O
Comparison	NNP	O
of	IN	O
the	DT	O
change	NN	O
in	IN	O
median	JJ	O
visual	JJ	O
analog	NN	O
scale	NN	O
scores	NNS	O
for	IN	O
60	CD	O
minutes	NNS	O
demonstrated	VBD	O
that	IN	O
octreotide	NN	O
was	VBD	O
less	RBR	O
effective	JJ	O
at	IN	O
reducing	VBG	O
pain	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
and	CC	O
producing	VBG	O
clinical	JJ	O
success	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Restlessness	JJ	O
consistent	JJ	O
with	IN	O
akathisia	NN	O
was	VBD	O
noted	VBN	O
by	IN	O
35	CD	O
%	NN	O
of	IN	O
the	DT	O
PC	NN	O
group	NN	O
and	CC	O
8	CD	O
%	NN	O
of	IN	O
the	DT	O
OC	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

At	IN	O
60	CD	O
minutes	NNS	O
,	,	O
rescue	NN	O
medication	NN	O
was	VBD	O
required	VBN	O
by	IN	O
48	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
OC	NNP	O
group	NN	O
,	,	O
whereas	RB	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
PC	NNP	O
group	NN	O
required	VBD	O
such	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

All	DT	O
44	CD	O
patients	NNS	O
were	VBD	O
contacted	VBN	O
for	IN	O
follow-up	NN	O
at	IN	O
48	CD	O
to	TO	O
72	CD	O
hours	NNS	O
after	IN	O
enrollment	NN	O
.	.	O

At	IN	O
that	DT	O
time	NN	O
,	,	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
prochlorperazine	NN	O
and	CC	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
octreotide	JJ	O
patients	NNS	O
had	VBD	O
experienced	VBN	O
some	DT	O
headache	NN	O
recurrence	NN	O
(	(	O
P	NNP	O
=	NNP	O
.1	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Prochlorperazine	NNP	O
was	VBD	O
statistically	RB	O
superior	JJ	O
to	TO	O
octreotide	VB	O
in	IN	O
clinical	JJ	O
success	NN	O
rate	NN	O
and	CC	O
decrease	NN	O
in	IN	O
pain	NN	O
in	IN	O
migraine	NN	O
patients	NNS	O
but	CC	O
caused	VBD	O
more	JJR	O
restlessness	NN	O
and	CC	O
sedation	NN	O
.	.	O

Effects	NNS	O
of	IN	O
supervised	JJ	O
exercise	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
Postoperative	NNP	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
has	VBZ	O
a	DT	O
number	NN	O
of	IN	O
associated	JJ	O
complications	NNS	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
could	MD	O
mitigate	VB	O
the	DT	O
complications	NNS	O
that	WDT	O
occur	VBP	O
during	IN	O
radiotherapy	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty	NNP	O
women	NNS	O
were	VBD	O
randomized	VBN	O
before	IN	O
radiotherapy	NN	O
after	IN	O
various	JJ	O
operations	NNS	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
exercise	NN	O
group	NN	O
performed	VBD	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
therapy	NN	O
for	IN	O
50	CD	O
min	NN	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
.	.	O

Twenty-three	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
asked	VBN	O
to	TO	O
perform	VB	O
self-shoulder	JJ	O
stretching	VBG	O
exercise	NN	O
.	.	O

The	DT	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
Quality	NNP	O
of	IN	O
Life-BREF	NNP	O
(	(	O
WHOQOL-BREF	NNP	O
)	)	O
,	,	O
brief	JJ	O
fatigue	JJ	O
inventory	NN	O
(	(	O
BFI	NNP	O
)	)	O
,	,	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
of	IN	O
the	DT	O
shoulder	NN	O
,	,	O
and	CC	O
pain	NN	O
score	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
radiotherapy	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
noted	VBD	O
at	IN	O
baseline	NN	O
between	IN	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
exercise	NN	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
WHOQOL-BREF	NNP	O
and	CC	O
shoulder	NN	O
ROM	NNP	O
and	CC	O
decrease	NN	O
in	IN	O
BFI	NNP	O
and	CC	O
pain	NN	O
score	NN	O
after	IN	O
radiotherapy	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
showed	VBD	O
decrease	NN	O
in	IN	O
the	DT	O
WHOQOL-BREF	NNP	O
and	CC	O
shoulder	NN	O
ROM	NNP	O
and	CC	O
increase	VB	O
in	IN	O
BFI	NNP	O
and	CC	O
pain	NN	O
score	NN	O
after	IN	O
radiotherapy	NN	O
.	.	O

There	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
WHOQOL	NNP	O
,	,	O
BFI	NNP	O
,	,	O
shoulder	NN	O
ROM	NNP	O
,	,	O
and	CC	O
pain	VB	O
score	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Patients	NNPS	O
receiving	VBG	O
radiotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
may	MD	O
benefit	VB	O
in	IN	O
physical	JJ	O
and	CC	O
psychological	JJ	O
aspects	NNS	O
from	IN	O
supervised	VBN	O
moderate-intensity	NN	O
exercise	NN	O
therapy	NN	O
.	.	O

Recovery	NN	O
after	IN	O
prolonged	JJ	Condition
anaesthesia	NN	Condition
for	IN	O
acoustic	JJ	Condition
neuroma	NN	Condition
surgery	NN	Condition
:	:	O
desflurane	NN	O
versus	IN	O
isoflurane	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
33	CD	SampleSize
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
desflurane	NN	O
(	(	O
D	NNP	O
)	)	O
or	CC	O
isoflurane	NN	O
(	(	O
I	PRP	O
)	)	O
for	IN	O
acoustic	JJ	Condition
neuroma	NN	Condition
surgery	NN	O
.	.	O

The	DT	O
time	NN	O
from	IN	O
end	NN	O
of	IN	O
the	DT	O
procedure	NN	O
to	TO	O
spontaneous	JJ	O
breathing	NN	O
,	,	O
extubation	NN	O
,	,	O
eye-opening	JJ	O
,	,	O
hand-squeezing	JJ	O
to	TO	O
command	VB	O
,	,	O
and	CC	O
ability	NN	O
to	TO	O
state	NN	O
name	NN	O
,	,	O
birthdate	NN	O
and	CC	O
phone	NN	O
number	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

The	DT	O
Steward	NNP	O
recovery	NN	O
score	NN	O
was	VBD	O
also	RB	O
recorded	VBN	O
every	DT	O
five	CD	O
minutes	NNS	O
during	IN	O
the	DT	O
first	JJ	O
20	CD	O
minutes	NNS	O
postoperatively	RB	O
and	CC	O
then	RB	O
every	DT	O
10	CD	O
to	TO	O
15	CD	O
minutes	NNS	O
.	.	O

Groups	NNP	O
were	VBD	O
similar	JJ	O
regarding	VBG	O
patient	NN	O
characteristics	NNS	O
,	,	O
depth	NN	O
of	IN	O
anaesthesia	NN	O
,	,	O
sufentanil	JJ	O
total	NN	O
dose	NN	O
,	,	O
anaesthesia	JJ	O
duration	NN	O
(	(	O
D	NNP	O
:	:	O
349.1	CD	O
+/-	JJ	O
19.1	CD	O
min	NN	O
;	:	O
I	PRP	O
:	:	O
349.2	CD	O
+/-	JJ	O
22.9	CD	O
min	NN	O
)	)	O
,	,	O
haemodynamic/respiratory	JJ	O
parameters	NNS	O
,	,	O
and	CC	O
surgical	JJ	O
conditions	NNS	O
(	(	O
assessed	VBN	O
by	IN	O
a	DT	O
bleeding	NN	O
score	NN	O
)	)	O
.	.	O

The	DT	O
emergence	NN	O
time	NN	O
in	IN	O
the	DT	O
D	NNP	O
group	NN	O
was	VBD	O
significantly	RB	O
faster	JJR	O
than	IN	O
the	DT	O
I	PRP	O
group	NN	O
(	(	O
D	NNP	O
:	:	O
14.9	CD	O
+/-	JJ	O
2.4	CD	O
min	NN	O
vs	NN	O
I	PRP	O
:	:	O
29.2	CD	O
+/-	JJ	O
2.4	CD	O
min	NN	O
for	IN	O
eye-opening	NN	O
)	)	O
.	.	O

Full	JJ	O
recovery	NN	O
also	RB	O
occurred	VBD	O
earlier	RBR	O
in	IN	O
the	DT	O
D	NNP	O
group	NN	O
(	(	O
D	NNP	O
:	:	O
22.1	CD	O
+/-	JJ	O
3.1	CD	O
min	NN	O
vs	NN	O
I	PRP	O
:	:	O
37.6	CD	O
+/-	JJ	O
4.0	CD	O
min	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.005	CD	O
for	IN	O
stating	VBG	O
name	NN	O
)	)	O
.	.	O

Steward	JJ	O
recovery	NN	O
scores	NNS	O
were	VBD	O
also	RB	O
better	RBR	O
during	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
hour	NN	O
in	IN	O
the	DT	O
D	NNP	O
group	NN	O
(	(	O
D	NNP	O
:	:	O
40	CD	O
min	NN	O
vs	NN	O
I	PRP	O
:	:	O
90	CD	O
min	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.005	CD	O
for	IN	O
100	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
Steward	NNP	O
score	NN	O
of	IN	O
6	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
desflurane	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
similar	JJ	O
operating	NN	O
conditions	NNS	O
and	CC	O
faster	RBR	O
postoperative	JJ	O
recovery	NN	O
following	VBG	O
acoustic	JJ	Condition
neuroma	NN	Condition
surgery	NN	O
.	.	O

The	DT	O
faster	JJ	O
recovery	NN	O
following	VBG	O
desflurane	NN	O
may	MD	O
be	VB	O
desirable	JJ	O
after	IN	O
long	JJ	O
surgical	JJ	O
procedures	NNS	O
,	,	O
enabling	VBG	O
the	DT	O
patient	NN	O
's	POS	O
full	JJ	O
cooperation	NN	O
and	CC	O
facilitating	VBG	O
early	JJ	O
diagnosis	NN	O
of	IN	O
any	DT	O
potential	JJ	O
neurological	JJ	O
deficit	NN	O
.	.	O

Asthma	NN	O
:	:	O
communication	NN	O
between	IN	O
hospital	NN	O
and	CC	O
general	JJ	Condition
practitioners	NNS	Condition
.	.	O

OBJECTIVE	NN	O
To	TO	O
assess	VB	O
whether	IN	O
efforts	NNS	O
to	TO	O
actively	RB	O
involve	VB	O
General	NNP	O
Practitioners	NNP	O
(	(	O
GPs	NNP	O
)	)	O
in	IN	O
the	DT	O
postdischarge	NN	O
care	NN	O
of	IN	O
their	PRP$	O
paediatric	JJ	O
asthma	NN	O
patients	NNS	O
improved	VBD	O
their	PRP$	O
satisfaction	NN	O
with	IN	O
communication	NN	O
with	IN	O
hospital	JJ	O
staff	NN	O
.	.	O

METHODOLOGY	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
involving	VBG	O
60	CD	O
patients	NNS	O
admitted	VBN	O
to	TO	O
the	DT	O
Royal	NNP	O
Children	NNP	O
's	POS	O
Hospital	NNP	O
,	,	O
Melbourne	NNP	O
,	,	O
with	IN	O
acute	JJ	Condition
asthma	NN	Condition
and	CC	O
an	DT	O
identifiable	JJ	O
GP	NNP	O
.	.	O

The	DT	O
GPs	NNP	O
of	IN	O
the	DT	O
intervention	NN	O
patients	NNS	O
were	VBD	O
telephoned	VBN	O
during	IN	O
the	DT	O
admission	NN	O
.	.	O

Intervention	NN	O
patients	NNS	O
and	CC	O
their	PRP$	O
GPs	NNP	O
received	VBD	O
printed	JJ	O
information	NN	O
detailing	VBG	O
the	DT	O
care	NN	O
the	DT	O
patient	NN	O
received	VBD	O
in	IN	O
hospital	NN	O
and	CC	O
the	DT	O
recommended	VBN	O
postdischarge	NN	O
care	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
standardized	JJ	O
educational	JJ	O
booklets	NNS	O
about	IN	O
asthma	NN	O
.	.	O

Follow-up	JJ	O
appointments	NNS	O
were	VBD	O
made	VBN	O
for	IN	O
intervention	NN	O
patients	NNS	O
to	TO	O
attend	VB	O
their	PRP$	O
GPs	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
GPs	NNP	O
of	IN	O
intervention	NN	O
patients	NNS	O
were	VBD	O
more	RBR	O
satisfied	JJ	O
when	WRB	O
compared	VBN	O
to	TO	O
the	DT	O
GPs	NNP	O
receiving	VBG	O
a	DT	O
standard	JJ	O
level	NN	O
of	IN	O
communication	NN	O
(	(	O
96.4	CD	O
%	NN	O
vs	JJ	O
48.3	CD	O
%	NN	O
of	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
GPs	NNP	O
,	,	O
respectively	RB	O
,	,	O
described	VBD	O
the	DT	O
communication	NN	O
as	IN	O
good	JJ	O
or	CC	O
extremely	RB	O
good	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
intervention	NN	O
group	NN	O
GPs	NNP	O
believed	VBD	O
they	PRP	O
were	VBD	O
more	JJR	O
involved	JJ	O
after	IN	O
discharge	NN	O
(	(	O
75.0	CD	O
%	NN	O
vs	JJ	O
44.8	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
and	CC	O
had	VBD	O
greater	JJR	O
understanding	NN	O
of	IN	O
their	PRP$	O
patient	NN	O
's	POS	O
hospitalisation	NN	O
(	(	O
96.4	CD	O
%	NN	O
vs	JJ	O
62.1	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

These	DT	O
differences	NNS	O
were	VBD	O
noted	VBN	O
despite	IN	O
there	EX	O
being	VBG	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
follow-up	JJ	O
attendance	NN	O
with	IN	O
GPs	NNP	O
for	IN	O
intervention	NN	O
and	CC	O
control	NN	O
patients	NNS	O
(	(	O
85.7	CD	O
%	NN	O
vs	JJ	O
72.4	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.2	CD	O
)	)	O
.	.	O

Qualitative	JJ	O
data	NNS	O
supported	VBD	O
these	DT	O
findings	NNS	O
with	IN	O
GPs	NNP	O
expressing	VBG	O
approval	NN	O
of	IN	O
the	DT	O
intervention	NN	O
used	VBN	O
.	.	O

CONCLUSION	NNP	O
Efforts	NNPS	O
to	TO	O
actively	RB	O
involve	VB	O
GPs	NNP	O
in	IN	O
the	DT	O
postdischarge	NN	O
care	NN	O
of	IN	O
their	PRP$	O
paediatric	JJ	O
patients	NNS	O
with	IN	O
asthma	JJ	O
resulted	VBN	O
in	IN	O
a	DT	O
marked	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
satisfaction	NN	O
with	IN	O
the	DT	O
communication	NN	O
with	IN	O
medical	JJ	O
staff	NN	O
at	IN	O
the	DT	O
Royal	NNP	O
Children	NNP	O
's	POS	O
Hospital	NNP	O
,	,	O
Melbourne	NNP	O
.	.	O

The	DT	O
study	NN	O
had	VBD	O
insufficient	JJ	O
power	NN	O
to	TO	O
demonstrate	VB	O
a	DT	O
difference	NN	O
in	IN	O
morbidity	NN	O
.	.	O

Buprenorphine	NNP	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
naloxone	NN	O
in	IN	O
non-dependent	JJ	O
humans	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
concurrent	NN	O
naloxone	NN	O
on	IN	O
the	DT	O
opioid	JJ	O
agonist	JJ	O
effects	NNS	O
of	IN	O
buprenorphine	NN	O
,	,	O
a	DT	O
mixed	JJ	O
agonist-antagonist	JJ	O
marketed	VBN	O
as	IN	O
an	DT	O
analgesic	JJ	O
and	CC	O
under	IN	O
development	NN	O
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
drug	NN	O
abuse	NN	O
.	.	O

In	IN	O
a	DT	O
residential	JJ	O
laboratory	NN	O
seven	CD	SampleSize
non-physically-dependent	JJ	O
opioid	JJ	Condition
abuser	NN	Condition
volunteers	NNS	O
received	VBD	O
intramuscular	JJ	O
buprenorphine	NN	O
(	(	O
0.4	CD	O
mg	NN	O
or	CC	O
0.8	CD	O
mg/70	NNS	O
kg	NN	O
)	)	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
naloxone	NN	O
(	(	O
0.4	CD	O
mg	NN	O
or	CC	O
0.8	CD	O
mg/70	NNS	O
kg	NN	O
)	)	O
versus	NN	O
placebo	NN	O
.	.	O

Buprenorphine	NNP	O
produced	VBD	O
dose-related	JJ	O
opioid	JJ	O
agonist	NN	O
effects	NNS	O
on	IN	O
physiological	JJ	O
and	CC	O
subjective	JJ	O
measures	NNS	O
.	.	O

Concurrent	NNP	O
naloxone	RB	O
attenuated	VBD	O
the	DT	O
opioid	JJ	O
agonist	JJ	O
effects	NNS	O
of	IN	O
buprenorphine	NN	O
.	.	O

Thus	RB	O
,	,	O
a	DT	O
combination	NN	O
product	NN	O
of	IN	O
buprenorphine	NN	O
and	CC	O
naloxone	NN	O
may	MD	O
have	VB	O
lower	JJR	O
abuse	NN	O
liability	NN	O
than	IN	O
buprenorphine	VB	O
alone	JJ	O
.	.	O

Preservative-free	JJ	O
ocular	JJ	O
hydrating	VBG	O
agents	NNS	O
in	IN	O
symptomatic	JJ	Condition
contact	NN	Condition
lens	VBZ	Condition
wearers	NNS	Condition
:	:	O
saline	NN	O
versus	IN	O
PVP	NNP	O
solution	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
two	CD	O
preservative-free	JJ	O
hydrating	VBG	O
agents	NNS	O
,	,	O
in	IN	O
multidose	NN	O
(	(	O
ABAK	NNP	O
)	)	O
bottles	NNS	O
,	,	O
in	IN	O
contact	NN	Condition
lens	NN	Condition
wearers	NNS	Condition
experiencing	VBG	O
symptoms	NNS	O
of	IN	O
ocular	JJ	Condition
dryness	NN	Condition
.	.	O

METHODS	NNP	O
The	DT	O
endpoint	NN	O
of	IN	O
this	DT	O
4-week	JJ	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
comparing	VBG	O
a	DT	O
2	CD	O
%	NN	O
polyvinylpyrrolidone	NN	O
(	(	O
PVP	NNP	O
)	)	O
solution	NN	O
with	IN	O
a	DT	O
0.9	CD	O
%	NN	O
NaCl	NNP	O
solution	NN	O
was	VBD	O
to	TO	O
assess	VB	O
ocular	JJ	O
discomfort	NN	O
using	VBG	O
a	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
.	.	O

A	DT	O
biomicroscopic	NN	O
examination	NN	O
and	CC	O
a	DT	O
test	NN	O
of	IN	O
tolerability	NN	O
on	IN	O
instillation	NN	O
were	VBD	O
also	RB	O
performed	VBN	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Thirty-nine	JJ	SampleSize
subjects	NNS	O
were	VBD	O
enrolled	VBN	O
(	(	O
23	CD	SampleSize
PVP	NNP	O
;	:	O
16	CD	SampleSize
NaCl	NNP	O
)	)	O
.	.	O

The	DT	O
average	JJ	O
age	NN	O
was	VBD	O
30	CD	Age
;	:	O
subjects	NNS	O
were	VBD	O
predominantly	RB	O
female	JJ	Sex
,	,	O
and	CC	O
mostly	RB	O
wore	VBD	Condition
frequent-replacement	JJ	Condition
contact	NN	Condition
lenses	NNS	Condition
.	.	O

They	PRP	O
were	VBD	O
all	DT	O
exposed	VBN	O
to	TO	O
environmental	JJ	O
factors	NNS	O
such	JJ	O
as	IN	O
routine	JJ	O
use	NN	O
of	IN	O
video	NN	O
monitors	NNS	O
or	CC	O
air	NN	O
conditioning	NN	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
at	IN	O
baseline	NN	O
(	(	O
D0	NNP	O
)	)	O
.	.	O

Both	DT	O
PVP	NNP	O
and	CC	O
NaCl	NNP	O
improved	VBD	O
the	DT	O
comfort	NN	O
of	IN	O
contact	NN	O
lens	NNS	O
wear	VBP	O
(	(	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
,	,	O
with	IN	O
no	DT	O
difference	NN	O
between	IN	O
them	PRP	O
(	(	O
P	NNP	O
=	NNP	O
0.25	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
daily	JJ	O
duration	NN	O
of	IN	O
lens	NNS	O
wear	JJ	O
and	CC	O
the	DT	O
daily	JJ	O
number	NN	O
of	IN	O
instillations	NNS	O
to	TO	O
relieve	VB	O
discomfort	NN	O
(	(	O
4.2	CD	O
+/-	JJ	O
2.0	CD	O
for	IN	O
PVP	NNP	O
ABAK	NNP	O
;	:	O
4.6	CD	O
+/-	JJ	O
1.9	CD	O
for	IN	O
NaCl	NNP	O
ABAK	NNP	O
)	)	O
were	VBD	O
comparable	JJ	O
.	.	O

However	RB	O
,	,	O
PVP	NNP	O
use	NN	O
led	VBD	O
to	TO	O
more	RBR	O
favorable	JJ	O
evolution	NN	O
of	IN	O
fluorescein-staining	JJ	O
corneal	NN	O
punctuations	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.028	CD	O
)	)	O
.	.	O

Safety	NN	O
was	VBD	O
good	JJ	O
,	,	O
with	IN	O
minimal	JJ	O
adverse	JJ	O
events	NNS	O
considered	VBN	O
unrelated	JJ	O
to	TO	O
the	DT	O
products	NNS	O
.	.	O

Lens	NNP	O
wettability	NN	O
was	VBD	O
excellent	JJ	O
,	,	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
clinically	RB	O
relevant	JJ	O
deposits	NNS	O
.	.	O

Most	JJS	O
subjects	NNS	O
also	RB	O
found	VBD	O
the	DT	O
ABAK	NNP	O
bottles	NNS	O
convenient	NN	O
.	.	O

CONCLUSIONS	NNP	O
Ocular	NNP	O
hydration	NN	O
improves	VBZ	O
comfort	NN	O
in	IN	O
contact	NN	O
lens	NN	O
wearers	NNS	O
.	.	O

NaCl	NNP	O
is	VBZ	O
an	DT	O
appropriate	JJ	O
first-line	JJ	O
treatment	NN	O
,	,	O
but	CC	O
for	IN	O
subjects	NNS	O
with	IN	O
fluorescein-staining	JJ	O
punctuations	NNS	O
,	,	O
lubrication	NN	O
with	IN	O
PVP	NNP	O
is	VBZ	O
preferable	JJ	O
.	.	O

[	JJ	O
Treatment	NNP	O
of	IN	O
hyperhomocysteinemia	NN	O
and	CC	O
endothelial	JJ	O
dysfunction	NN	O
in	IN	O
renal-transplant	JJ	Condition
recipients	NNS	Condition
with	IN	O
vitamin	NN	O
B	NNP	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
vitamin	NN	O
B	NNP	O
on	IN	O
treatment	NN	O
of	IN	O
hyperhomocysteinemia	NN	O
and	CC	O
endothelial	JJ	O
dysfunction	NN	O
in	IN	O
renal-transplant	JJ	Condition
recipients	NNS	Condition
.	.	Condition

METHODS	NNP	O
Thirty-six	NNP	O
stable	JJ	O
hyperhomocysteinemic	JJ	O
renal-transplant	JJ	O
recipients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
vitamin	VB	O
treatment	NN	O
(	(	O
group	NN	O
A	NNP	O
,	,	O
n	JJ	O
=	NN	O
18	CD	O
,	,	O
folic	JJ	O
acid	VBP	O
5	CD	O
mg/d	NN	O
,	,	O
vitamin	NN	O
B	NNP	O
(	(	O
6	CD	O
)	)	O
50	CD	O
mg/d	NN	O
,	,	O
B	NNP	O
(	(	O
12	CD	O
)	)	O
1000	CD	O
microg/d	NN	O
)	)	O
or	CC	O
controlled	VBN	O
group	NN	O
(	(	O
group	NN	O
B	NNP	O
,	,	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

All	DT	O
subjects	NNS	O
underwent	JJ	O
assessment	NN	O
of	IN	O
levels	NNS	O
for	IN	O
creatinine	NN	O
,	,	O
creatinine	JJ	O
clearance	NN	O
,	,	O
average	JJ	O
pressure	NN	O
,	,	O
total	JJ	O
cholesterol	NN	O
,	,	O
triglyceride	NN	O
and	CC	O
fasting	JJ	O
homocysteine	NN	O
.	.	O

Endothelial	JJ	O
function	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
high-resolution	NN	O
vascular	JJ	O
ultrasound	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
levels	NNS	O
of	IN	O
homocysteine	NN	O
markedly	RB	O
decreased	VBD	O
in	IN	O
group	NN	O
A	NNP	O
[	NNP	O
(	(	O
13	CD	O
+/-	JJ	O
4	CD	O
)	)	O
micromol/L	NN	O
vs	NN	O
(	(	O
20	CD	O
+/-	JJ	O
5	CD	O
)	)	O
micromol/L	NN	O
,	,	O
t	EX	O
=	JJ	O
5.3	CD	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	NN	O
after	IN	O
treatment	NN	O
,	,	O
whereas	IN	O
no	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
group	NN	O
B	NNP	O
.	.	O

In	IN	O
group	NN	O
A	NNP	O
,	,	O
endothelium	NN	O
dependent	JJ	O
[	NNP	O
(	(	O
12	CD	O
+/-	JJ	O
5	CD	O
)	)	O
%	NN	O
vs	NN	O
(	(	O
9	CD	O
+/-	JJ	O
5	CD	O
)	)	O
%	NN	O
,	,	O
t	JJ	O
=	NN	O
2.9	CD	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	NN	O
and	CC	O
independent	JJ	O
[	NNP	O
(	(	O
18	CD	O
+/-	JJ	O
4	CD	O
)	)	O
%	NN	O
vs	NN	O
(	(	O
12	CD	O
+/-	JJ	O
5	CD	O
)	)	O
%	NN	O
,	,	O
t	JJ	O
=	NN	O
3.4	CD	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	JJ	O
vasodilatation	NN	O
responses	NNS	O
significantly	RB	O
increased	VBD	O
after	IN	O
treatment	NN	O
,	,	O
no	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
group	NN	O
B.	NNP	O
Endothelium	NNP	O
dependent	NN	O
[	NNP	O
(	(	O
9	CD	O
+/-	JJ	O
6	CD	O
)	)	O
%	NN	O
,	,	O
t	JJ	O
=	NN	O
2.8	CD	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	NN	O
and	CC	O
independent	JJ	O
[	NNP	O
(	(	O
12	CD	O
+/-	JJ	O
5	CD	O
)	)	O
%	NN	O
,	,	O
t	JJ	O
=	NN	O
3.5	CD	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
]	JJ	O
vasodilatation	NN	O
responses	NNS	O
of	IN	O
group	NN	O
A	NNP	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
of	IN	O
group	NN	O
B	NNP	O
after	IN	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Vitamin	NNP	O
B	NNP	O
supplementation	NN	O
can	MD	O
reduce	VB	O
the	DT	O
levels	NNS	O
of	IN	O
homocysteine	NN	O
and	CC	O
improve	VB	O
the	DT	O
endothelial	JJ	O
function	NN	O
in	IN	O
hyperhomocysteinemic	JJ	O
renal-transplant	JJ	O
recipients	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
fluoxetine	NN	O
alone	RB	O
vs.	FW	O
fluoxetine	JJ	O
plus	CC	O
local	JJ	O
lidocaine	NN	O
ointment	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
premature	JJ	Condition
ejaculation	NN	Condition
.	.	O

OBJECTIVE	CC	O
The	DT	O
present	JJ	O
study	NN	O
compares	VBZ	O
the	DT	O
efficacy	NN	O
and	CC	O
side	JJ	O
effects	NNS	O
of	IN	O
fluoxetine	NN	O
alone	RB	O
vs.	FW	O
fluoxetine	JJ	O
plus	CC	O
local	JJ	O
lidocaine	NN	O
ointment	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
premature	JJ	O
ejaculation	NN	O
.	.	O

METHODS	NNP	O
Forty-three	JJ	SampleSize
patients	NNS	O
suffering	VBG	O
from	IN	O
premature	JJ	O
ejaculation	NN	O
were	VBD	O
studied	VBN	O
.	.	O

The	DT	O
exclusion	NN	O
criteria	NNS	O
were	VBD	O
erectile	JJ	O
dysfunction	NN	O
,	,	O
loss	NN	O
of	IN	O
libido	NN	O
,	,	O
alcohol	NN	O
and	CC	O
substance	NN	O
abuse	NN	O
,	,	O
mental	JJ	O
retardation	NN	O
,	,	O
diabetes	VBZ	O
mellitus	NN	O
,	,	O
thyroid	JJ	O
disease	NN	O
,	,	O
hypotension	NN	O
,	,	O
previous	JJ	O
use	NN	O
of	IN	O
these	DT	O
drugs	NNS	O
and	CC	O
urogenital	JJ	O
infections	NNS	O
.	.	O

The	DT	O
patients	NNS	O
'	POS	O
ages	NNS	O
ranged	VBD	O
from	IN	O
19	CD	Age
to	TO	Age
48	CD	Age
years	NNS	Age
(	(	O
mean	JJ	O
age	NN	O
28	CD	Age
+/-	JJ	Age
1.6	CD	Age
)	)	O
.	.	O

They	PRP	O
had	VBD	O
regular	JJ	O
sexual	JJ	O
lives	NNS	O
.	.	O

They	PRP	O
had	VBD	O
normal	JJ	O
psychiatric	JJ	O
consultation	NN	O
and	CC	O
the	DT	O
Glombock	NNP	O
Rast	NNP	O
Sexual	NNP	O
Satisfactory	NNP	O
Test	NNP	O
(	(	O
GRISS	NNP	O
)	)	O
psychiatric	JJ	O
test	NN	O
were	VBD	O
in	IN	O
accordance	NN	O
with	IN	O
premature	JJ	O
ejaculation	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
.	.	O

Twenty-six	JJ	O
patients	NNS	O
,	,	O
aged	VBD	O
21	CD	O
to	TO	O
36	CD	O
years	NNS	O
(	(	O
mean	JJ	O
age	NN	O
27	CD	O
)	)	O
,	,	O
received	VBD	O
only	RB	O
fluoxetine	JJ	O
20	CD	O
mg/day	NN	O
(	(	O
1	CD	O
capsule	NN	O
)	)	O
for	IN	O
a	DT	O
week	NN	O
which	WDT	O
was	VBD	O
later	RBR	O
increased	VBN	O
to	TO	O
40	CD	O
mg/day	NN	O
(	(	O
2	CD	O
capsules	NNS	O
)	)	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
,	,	O
aged	VBD	O
19	CD	O
to	TO	O
48	CD	O
years	NNS	O
(	(	O
mean	JJ	O
age	NN	O
31	CD	O
)	)	O
,	,	O
were	VBD	O
given	VBN	O
fluoxetine	JJ	O
20	CD	O
mg/day	JJ	O
plus	CC	O
local	JJ	O
application	NN	O
of	IN	O
lidocaine	JJ	O
ointment	NN	O
.	.	O

The	DT	O
patients	NNS	O
and	CC	O
partners	NNS	O
were	VBD	O
re-evaluated	JJ	O
8	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
classified	VBN	O
as	IN	O
unsuccessful	JJ	O
,	,	O
improvement	NN	O
and	CC	O
cure	NN	O
.	.	O

The	DT	O
chi-square	JJ	O
test	NN	O
was	VBD	O
used	VBN	O
for	IN	O
statistical	JJ	O
analysis	NN	O
.	.	O

In	IN	O
the	DT	O
fluoxetine	NN	O
group	NN	O
,	,	O
8	CD	O
(	(	O
30.8	CD	O
%	NN	O
)	)	O
patients	NNS	O
cured	VBD	O
,	,	O
11	CD	O
(	(	O
42.2	CD	O
%	NN	O
)	)	O
showed	VBD	O
improvement	NN	O
and	CC	O
there	EX	O
were	VBD	O
7	CD	O
failures	NNS	O
(	(	O
26.9	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
combination	NN	O
treatment	NN	O
group	NN	O
,	,	O
9	CD	O
(	(	O
52.9	CD	O
%	NN	O
)	)	O
patients	NNS	O
cured	VBN	O
,	,	O
improvement	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
5	CD	O
(	(	O
29.4	CD	O
%	NN	O
)	)	O
and	CC	O
failure	NN	O
in	IN	O
3	CD	O
(	(	O
17.6	CD	O
%	NN	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
in	IN	O
group	NN	O
I	PRP	O
were	VBD	O
observed	VBN	O
in	IN	O
6	CD	O
patients	NNS	O
(	(	O
23	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
5	CD	O
(	(	O
29.4	CD	O
%	NN	O
)	)	O
in	IN	O
group	NN	O
II	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
according	VBG	O
to	TO	O
the	DT	O
side	NN	O
effects	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.01	CD	O
)	)	O
.	.	O

No	UH	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
due	JJ	O
to	TO	O
side	VB	O
effects	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
combination	NN	O
of	IN	O
fluoxetine	JJ	O
plus	CC	O
local	JJ	O
application	NN	O
of	IN	O
lidocaine	JJ	O
ointment	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
fluoxetine	VB	O
alone	RB	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
premature	JJ	O
ejaculation	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
results	NNS	O
should	MD	O
be	VB	O
confirmed	VBN	O
in	IN	O
further	JJ	O
studies	NNS	O
with	IN	O
a	DT	O
placebo	NN	O
group	NN	O
to	TO	O
rule	VB	O
out	IN	O
the	DT	O
placebo	NN	O
effect	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
alfentanil	NN	O
,	,	O
fentanyl	NN	O
and	CC	O
sufentanil	NN	O
for	IN	O
total	JJ	O
intravenous	JJ	O
anaesthesia	NN	O
with	IN	O
propofol	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
.	.	O

We	PRP	O
have	VBP	O
studied	VBN	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
alfentanil	NN	O
,	,	O
fentanyl	NN	O
and	CC	O
sufentanil	VB	O
together	RB	O
with	IN	O
propofol	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
(	(	O
CABG	NNP	O
)	)	O
.	.	O

Sixty	JJ	O
patients	NNS	O
(	(	O
age	NN	O
40-73	CD	O
yr	NN	O
,	,	O
56	CD	O
male	NN	O
)	)	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
receive	VB	O
alfentanil	NN	O
,	,	O
fentanyl	NN	O
or	CC	O
sufentanil	NN	O
and	CC	O
propofol	NN	O
.	.	O

Plasma	NNP	O
concentrations	NNS	O
of	IN	O
these	DT	O
drugs	NNS	O
and	CC	O
times	NNS	O
for	IN	O
the	DT	O
plasma	NN	O
concentration	NN	O
to	TO	O
decrease	VB	O
by	IN	O
50	CD	O
%	NN	O
(	(	O
t50	NN	O
)	)	O
and	CC	O
80	CD	O
%	NN	O
(	(	O
t80	NN	O
)	)	O
after	IN	O
cessation	NN	O
of	IN	O
the	DT	O
infusion	NN	O
were	VBD	O
determined	VBN	O
.	.	O

Times	NNS	O
were	VBD	O
recorded	VBN	O
to	TO	O
awakening	VBG	O
and	CC	O
tracheal	JJ	O
extubation	NN	O
.	.	O

Total	JJ	O
dose	NN	O
and	CC	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
propofol	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

Mean	NNP	O
total	JJ	O
doses	NNS	O
of	IN	O
alfentanil	NN	O
,	,	O
fentanyl	NN	O
and	CC	O
sufentanil	NN	O
were	VBD	O
443	CD	O
,	,	O
45	CD	O
and	CC	O
4.4	CD	O
micrograms	NNS	O
kg-1	JJ	O
,	,	O
respectively	RB	O
.	.	O

Time	NN	O
to	TO	O
awakening	VBG	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
.	.	O

In	IN	O
patients	NNS	O
receiving	VBG	O
fentanyl	NN	O
,	,	O
the	DT	O
trachea	NN	O
was	VBD	O
extubated	VBN	O
on	IN	O
average	JJ	O
2	CD	O
h	NN	O
later	RB	O
than	IN	O
in	IN	O
those	DT	O
receiving	VBG	O
sufentanil	NN	O
and	CC	O
3	CD	O
h	NN	O
later	RB	O
than	IN	O
in	IN	O
those	DT	O
receiving	VBG	O
alfentanil	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
t80	NN	O
of	IN	O
fentanyl	NN	O
was	VBD	O
longer	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
than	IN	O
that	DT	O
of	IN	O
alfentanil	NN	O
or	CC	O
sufentanil	NN	O
,	,	O
and	CC	O
there	RB	O
was	VBD	O
a	DT	O
linear	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
t80	NN	O
of	IN	O
the	DT	O
opioid	NN	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
tracheal	VB	O
extubation	NN	O
(	(	O
r	JJ	O
=	VBZ	O
0.51	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
t50	NN	O
values	NNS	O
for	IN	O
these	DT	O
opioids	NNS	O
were	VBD	O
similar	JJ	O
and	CC	O
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
recovery	NN	O
time	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
patients	NNS	O
undergoing	VBG	O
CABG	NNP	O
and	CC	O
who	WP	O
were	VBD	O
anaesthetized	VBN	O
with	IN	O
fentanyl	NN	O
and	CC	O
propofol	NN	O
needed	VBN	O
mechanical	JJ	O
ventilatory	NN	O
support	NN	O
for	IN	O
a	DT	O
significantly	RB	O
longer	JJR	O
time	NN	O
than	IN	O
those	DT	O
receiving	VBG	O
alfentanil	NN	O
or	CC	O
sufentanil	NN	O
and	CC	O
propofol	NN	O
.	.	O

On	IN	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
interindividual	JJ	O
variation	NN	O
observed	VBD	O
,	,	O
the	DT	O
time	NN	O
to	TO	O
tracheal	VB	O
extubation	NN	O
was	VBD	O
most	RBS	O
predictable	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
alfentanil	NN	O
and	CC	O
most	RBS	O
variable	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
fentanyl	NN	O
,	,	O
a	DT	O
finding	NN	O
which	WDT	O
may	MD	O
be	VB	O
important	JJ	O
if	IN	O
the	DT	O
patients	NNS	O
are	VBP	O
transferred	VBN	O
to	TO	O
a	DT	O
step-down	JJ	O
unit	NN	O
on	IN	O
the	DT	O
evening	NN	O
of	IN	O
the	DT	O
operation	NN	O
.	.	O

Similar	JJ	O
compliance	NN	O
and	CC	O
effect	NN	O
of	IN	O
treatment	NN	O
in	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
resulting	VBG	O
from	IN	O
intravenous	JJ	O
drug	NN	O
use	NN	O
in	IN	O
comparison	NN	O
with	IN	O
other	JJ	O
infection	NN	O
causes	NNS	O
.	.	O

OBJECTIVES	NNP	O
There	EX	O
is	VBZ	O
some	DT	O
reluctance	NN	O
to	TO	O
treat	VB	O
intravenous	JJ	O
drug	NN	O
users	NNS	O
(	(	O
IVDUs	NNP	O
)	)	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
(	(	O
CHC	NNP	O
)	)	O
because	IN	O
of	IN	O
presumed	JJ	O
lower	JJR	O
compliance	NN	O
and	CC	O
response	NN	O
to	TO	O
antiviral	JJ	O
therapy	NN	O
.	.	O

We	PRP	O
intended	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
compliance	NN	O
and	CC	O
response	NN	O
to	TO	O
antiviral	JJ	O
treatment	NN	O
for	IN	O
CHC	NNP	O
in	IN	O
IVDUs	NNP	O
compared	VBN	O
with	IN	O
non-IVDUs	JJ	O
.	.	O

METHODS	VB	O
A	DT	O
retrospective	JJ	O
cohort	NN	O
study	NN	O
--	:	O
secondary	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
treatment	NN	O
trial	NN	O
--	:	O
was	VBD	O
performed	VBN	O
in	IN	O
Belgium	NNP	O
and	CC	O
The	DT	O
Netherlands	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
406	CD	O
previously	RB	O
untreated	JJ	O
CHC	NNP	O
patients	NNS	O
,	,	O
including	VBG	O
98	CD	O
(	(	O
24	CD	O
%	NN	O
)	)	O
IVDUs	NNP	O
,	,	O
were	VBD	O
studied	VBN	O
for	IN	O
compliance	NN	O
(	(	O
presentation	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
)	)	O
,	,	O
complete	JJ	O
response	NN	O
(	(	O
alanine	JJ	O
aminotransferase	NN	O
within	IN	O
normal	JJ	O
limits	NNS	O
and	CC	O
serum	NN	O
hepatitis	NN	O
C	NNP	O
virus	NN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
negative	JJ	O
)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
therapy	NN	O
and	CC	O
sustained	VBD	O
virological	JJ	O
response	NN	O
(	(	O
SVR	NNP	O
)	)	O
.	.	O

RESULTS	JJ	O
Non-compliance	NNP	O
(	(	O
8.2	CD	O
%	NN	O
)	)	O
in	IN	O
IVDUs	NNP	O
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
non-IVDUs	JJ	O
(	(	O
6.8	CD	O
%	NN	O
)	)	O
(	(	O
relative	JJ	O
risk=1.20	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval=0.55-2.62	NN	O
)	)	O
.	.	O

Complete	JJ	O
response	NN	O
after	IN	O
controlling	VBG	O
for	IN	O
hepatitis	NN	O
C	NNP	O
virus	NN	O
was	VBD	O
similar	JJ	O
(	(	O
relative	JJ	O
risk=1.19	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval=0.89-1.60	NN	O
)	)	O
.	.	O

Controlling	VBG	O
for	IN	O
treatment	NN	O
arm	NN	O
,	,	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
presence	NN	O
of	IN	O
cirrhosis	NN	O
or	CC	O
hepatitis	NN	O
C	NNP	O
virus	NN	O
viral	JJ	O
load	NN	O
before	IN	O
treatment	NN	O
did	VBD	O
not	RB	O
change	VB	O
these	DT	O
results	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
marginally	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
sustained	JJ	O
virological	JJ	O
response	NN	O
between	IN	O
IVDUs	NNP	O
(	(	O
46.6	CD	O
%	NN	O
)	)	O
and	CC	O
non-IVDUs	JJ	O
(	(	O
34.6	CD	O
%	NN	O
)	)	O
(	(	O
relative	JJ	O
risk=1.35	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval=1.00-1.81	NN	O
)	)	O
,	,	O
also	RB	O
disappearing	VBG	O
after	IN	O
adjusting	VBG	O
for	IN	O
genotype	NN	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
compliance	NN	O
or	CC	O
sustained	VBN	O
virological	JJ	O
response	NN	O
was	VBD	O
found	VBN	O
between	IN	O
active	JJ	O
and	CC	O
non-active	JJ	O
IVDUs	NNP	O
or	CC	O
between	IN	O
IVDU	NNP	O
patients	NNS	O
in	IN	O
or	CC	O
without	IN	O
a	DT	O
methadone	NN	O
maintenance	NN	O
program	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
group	NN	O
of	IN	O
Benelux	NNP	O
patients	NNS	O
,	,	O
IVDUs	NNP	O
showed	VBD	O
similar	JJ	O
compliance	NN	O
and	CC	O
response	NN	O
to	TO	O
treatment	NN	O
with	IN	O
interferon	NN	O
and	CC	O
ribavirin	NN	O
compared	VBN	O
with	IN	O
other	JJ	O
patients	NNS	O
with	IN	O
CHC	NNP	O
infection	NN	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
no	RB	O
longer	RBR	O
justifiable	JJ	O
to	TO	O
withhold	VB	O
treatment	NN	O
to	TO	O
chronic	VB	O
hepatitis	NN	O
C	NNP	O
patients	NNS	O
who	WP	O
use	VBP	O
intravenous	JJ	O
drugs	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
calcanean	JJ	O
bone	NN	O
mineral	NN	O
occurring	VBG	O
spontaneously	RB	O
and	CC	O
during	IN	O
hormone	JJ	O
replacement	NN	O
therapy	NN	O
in	IN	O
early	JJ	O
post-menopausal	JJ	O
women	NNS	O
.	.	O

The	DT	O
spontaneous	JJ	O
calcanean	JJ	O
bone	NN	O
loss	NN	O
occurring	VBG	O
in	IN	O
healthy	JJ	O
early	JJ	O
post-menopausal	JJ	O
women	NNS	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
hormone	NN	O
replacement	NN	O
therapies	NNS	O
(	(	O
HRT	NNP	O
's	POS	O
)	)	O
were	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
longitudinal	JJ	O
study	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
right	NN	O
and	CC	O
left	VBD	O
calcanean	JJ	O
BMC	NNP	O
or	CC	O
BMD	NNP	O
(	(	O
p	JJ	O
>	NNP	O
0.15	CD	O
)	)	O
.	.	O

The	DT	O
spontaneous	JJ	O
bone	NN	O
loss	NN	O
was	VBD	O
similar	JJ	O
at	IN	O
all	PDT	O
the	DT	O
skeletal	JJ	O
sites	NNS	O
measured	VBD	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
spontaneous	JJ	O
loss	NN	O
in	IN	O
calcanean	JJ	O
BMD	NNP	O
of	IN	O
1.6	CD	O
%	NN	O
over	IN	O
one	CD	O
year	NN	O
.	.	O

Both	DT	O
HRT	NNP	O
's	POS	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
prevented	VBD	O
the	DT	O
bone	NN	O
loss	NN	O
from	IN	O
all	DT	O
skeletal	JJ	O
sites	NNS	O
irrespective	VBP	O
of	IN	O
the	DT	O
weight-bearing	NN	O
or	CC	O
content	NN	O
of	IN	O
trabecular	JJ	O
bone	NN	O
,	,	O
and	CC	O
(	(	O
for	IN	O
the	DT	O
weight-bearing	JJ	O
bones	NNS	O
)	)	O
there	EX	O
was	VBD	O
even	RB	O
a	DT	O
gain	NN	O
in	IN	O
calcanean	JJ	O
BMC	NNP	O
and	CC	O
BMD	NNP	O
and	CC	O
spinal	JJ	O
BMD	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Bone	NNP	O
mineral	NN	O
of	IN	O
the	DT	O
calcaneus	NN	O
and	CC	O
the	DT	O
spine	NN	O
correlated	VBN	O
equally	RB	O
to	TO	O
body	NN	O
weight	NN	O
(	(	O
r	VB	O
approximately	RB	O
0.4	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
whereas	WP	O
bone	RB	O
mineral	NN	O
in	IN	O
the	DT	O
forearm	NN	O
was	VBD	O
not	RB	O
correlated	VBN	O
to	TO	O
body	VB	O
weight	NN	O
.	.	O

The	DT	O
correlations	NNS	O
between	IN	O
the	DT	O
changes	NNS	O
in	IN	O
bone	NN	O
mineral	NN	O
at	IN	O
the	DT	O
sites	NNS	O
measured	VBN	O
were	VBD	O
all	DT	O
significant	JJ	O
(	(	O
r	VB	O
approximately	RB	O
0.2-0.4	JJ	O
)	)	O
.	.	O

Caries	NNS	O
preventive	JJ	O
effects	NNS	O
of	IN	O
toothpastes	NNS	O
containing	VBG	O
monofluorophosphate	NN	O
and	CC	O
trimetaphosphate	NN	O
:	:	O
a	DT	O
3-year	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
caries-preventive	JJ	O
effects	NNS	O
of	IN	O
two	CD	O
toothpastes	NNS	O
were	VBD	O
tested	VBN	O
in	IN	O
a	DT	O
3-year	JJ	O
clinical	JJ	O
trial	NN	O
involving	VBG	O
1319	CD	SampleSize
children	NNS	O
aged	VBN	O
11-13	CD	Age
years	NNS	Age
.	.	O

The	DT	O
test	NN	O
toothpastes	NNS	O
were	VBD	O
:	:	O
1	CD	O
)	)	O
a	DT	O
low	JJ	O
abrasion	NN	O
paste	NN	O
containing	VBG	O
0.8	CD	O
%	NN	O
sodium	NN	O
monofluorophosphate	NN	O
(	(	O
MFP	NNP	O
)	)	O
,	,	O
and	CC	O
2	CD	O
)	)	O
a	DT	O
paste	NN	O
containing	VBG	O
3	CD	O
%	NN	O
sodium	NN	O
trimetaphosphate	NN	O
(	(	O
TMP	NNP	O
)	)	O
.	.	O

The	DT	O
control	NN	O
toothpaste	NN	O
was	VBD	O
a	DT	O
conventional	JJ	O
,	,	O
moderately	RB	O
abrasive	JJ	O
paste	NN	O
containing	VBG	O
0.8	CD	O
%	NN	O
sodium	NN	O
monofluorophosphate	NN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
examined	VBN	O
clinically	RB	O
and	CC	O
radiologically	RB	O
each	DT	O
year	NN	O
.	.	O

Toothpaste	NN	O
was	VBD	O
supplied	VBN	O
to	TO	O
the	DT	O
children	NNS	O
's	POS	O
homes	NNS	O
,	,	O
and	CC	O
its	PRP$	O
use	NN	O
was	VBD	O
unsupervised	JJ	O
.	.	O

Caries	NNS	O
increments	NNS	O
after	IN	O
3	CD	O
years	NNS	O
,	,	O
in	IN	O
terms	NNS	O
of	IN	O
DMF	NNP	O
teeth	NNS	O
and	CC	O
DMF	NNP	O
surfaces	NNS	O
,	,	O
showed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
MFP	NNP	O
test	NN	O
group	NN	O
(	(	SampleSize
444	CD	SampleSize
children	NNS	O
)	)	O
and	CC	O
the	DT	O
MFP	NNP	O
control	NN	O
group	NN	O
(	(	O
450	CD	SampleSize
children	NNS	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
TMP	NNP	O
test	NN	O
group	NN	O
(	(	O
425	CD	SampleSize
children	NNS	O
)	)	O
had	VBD	O
significantly	RB	O
higher	JJR	O
caries	NNS	O
increments	NNS	O
than	IN	O
the	DT	O
MFP	NNP	O
control	NN	O
group	NN	O
.	.	O

All	DT	O
three	CD	O
groups	NNS	O
of	IN	O
children	NNS	O
showed	VBD	O
some	DT	O
improvement	NN	O
in	IN	O
oral	JJ	O
hygiene	NN	O
and	CC	O
in	IN	O
gingival	JJ	O
health	NN	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Effect	NN	O
of	IN	O
perioperative	JJ	O
parecoxib	NN	O
on	IN	O
postoperative	JJ	O
pain	NN	O
and	CC	O
local	JJ	O
inflammation	NN	O
factors	NNS	O
PGE2	NNP	O
and	CC	O
IL-6	NNP	O
for	IN	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
postoperative	JJ	O
pain	NN	O
management	NN	O
and	CC	O
the	DT	O
concentration	NN	O
change	NN	O
of	IN	O
PGE-2	NNP	O
and	CC	O
IL-6	NNP	O
of	IN	O
joint	JJ	O
fluid	NN	O
with	IN	O
parecoxib	NN	O
after	IN	O
postoperative	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
.	.	O

In	IN	O
the	DT	O
study	NN	O
,	,	O
100	CD	SampleSize
patients	NNS	O
experiencing	VBG	O
primary	JJ	Condition
TKA	NNP	Condition
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
study	NN	O
group	NN	O
,	,	O
receiving	VBG	O
parecoxib	NN	O
sodium	NN	O
(	(	O
40	CD	O
mg	NN	O
)	)	O
intravenously	RB	O
(	(	O
IV	NNP	O
)	)	O
at	IN	O
the	DT	O
completion	NN	O
of	IN	O
surgery	NN	O
and	CC	O
once	RB	O
every	DT	O
12	CD	O
h	NN	O
for	IN	O
totally	RB	O
6	CD	O
times	NNS	O
postoperatively	RB	O
,	,	O
and	CC	O
placebo	NN	O
group	NN	O
,	,	O
receiving	VBG	O
normal	JJ	O
saline	JJ	O
2	CD	O
mL	NN	O
IV	NNP	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
points	NNS	O
.	.	O

Efficacy	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
total	JJ	O
amount	NN	O
of	IN	O
morphine	NN	O
consumed	VBN	O
,	,	O
pain	VBP	O
intensity	NN	O
,	,	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
,	,	O
the	DT	O
concentration	NN	O
change	NN	O
of	IN	O
PGE-2	NNP	O
and	CC	O
IL-6	NNP	O
of	IN	O
joint	JJ	O
fluid	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
(	(	O
PONV	NNP	O
)	)	O
postoperatively	RB	O
.	.	O

Patients	NNS	O
in	IN	O
study	NN	O
group	NN	O
consumed	VBD	O
significantly	RB	O
less	JJR	O
morphine	NN	O
,	,	O
experienced	VBD	O
significant	JJ	O
less	JJR	O
pain	NN	O
scores	NNS	O
,	,	O
and	CC	O
obtained	VBD	O
significantly	RB	O
more	RBR	O
ROM	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
placebo	NN	O
group	NN	O
during	IN	O
3	CD	O
days	NNS	O
postoperatively	RB	O
.	.	O

The	DT	O
concentration	NN	O
of	IN	O
PGE-2	NNP	O
and	CC	O
IL-6	NNP	O
of	IN	O
joint	JJ	O
fluid	NN	O
in	IN	O
study	NN	O
group	NN	O
are	VBP	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
during	IN	O
24	CD	O
h	NNS	O
postoperatively	RB	O
.	.	O

The	DT	O
overall	JJ	O
incidence	NN	O
of	IN	O
PONV	NNP	O
was	VBD	O
low	JJ	O
and	CC	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
demonstrated	VBD	O
that	IN	O
the	DT	O
perioperative	JJ	O
administration	NN	O
of	IN	O
parecoxib	NN	O
after	IN	O
primary	JJ	O
TKA	NNP	O
resulted	VBD	O
in	IN	O
significantly	RB	O
improved	VBN	O
postoperative	JJ	O
analgesic	JJ	O
management	NN	O
as	IN	O
defined	VBN	O
by	IN	O
reduction	NN	O
in	IN	O
opioid	JJ	O
requirement	NN	O
,	,	O
lower	JJR	O
pain	NN	O
scores	NNS	O
and	CC	O
ROM	NNP	O
,	,	O
and	CC	O
significantly	RB	O
lowered	VBD	O
local	JJ	O
inflammation	NN	O
factors	NNS	O
PGE2	NNP	O
and	CC	O
IL-6	NNP	O
.	.	O

Effect	NN	O
of	IN	O
zoledronic	JJ	O
acid	NN	O
on	IN	O
disseminated	JJ	O
tumour	NN	O
cells	NNS	O
in	IN	O
women	NNS	Sex
with	IN	O
locally	RB	Condition
advanced	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
:	:	O
an	DT	O
open	JJ	O
label	NN	O
,	,	O
randomised	VBN	O
,	,	O
phase	VB	O
2	CD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Treatment	NNP	O
with	IN	O
bisphosphonates	NNS	O
decreases	NNS	O
bone	VBP	O
loss	NN	O
and	CC	O
can	MD	O
increase	VB	O
disease-free	JJ	O
survival	NN	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	Condition
cancer	NN	Condition
.	.	O

The	DT	O
aim	NN	O
of	IN	O
our	PRP$	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
zoledronic	JJ	O
acid	NN	O
on	IN	O
clearance	NN	O
of	IN	O
disseminated	JJ	O
tumour	NN	O
cells	NNS	O
(	(	O
DTCs	NNP	O
)	)	O
from	IN	O
the	DT	O
bone	NN	O
marrow	NN	O
in	IN	O
women	NNS	Sex
undergoing	VBG	O
neoadjuvant	JJ	Condition
chemotherapy	NN	Condition
for	IN	O
breast	NN	Condition
cancer	NN	Condition
.	.	O

METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
recruited	VBN	O
for	IN	O
this	DT	O
open-label	JJ	O
,	,	O
phase	VB	O
2	CD	O
randomised	JJ	O
trial	NN	O
between	IN	O
March	NNP	O
17	CD	O
,	,	O
2003	CD	O
,	,	O
and	CC	O
May	NNP	O
19	CD	O
,	,	O
2006	CD	O
,	,	O
at	IN	O
a	DT	O
single	JJ	O
centre	NN	O
.	.	O

Eligible	JJ	O
patients	NNS	O
had	VBD	O
clinical	JJ	Condition
stage	NN	Condition
II-III	NNP	Condition
(	(	Condition
>	CD	Condition
or	CC	Condition
=	VB	Condition
T2	NNP	Condition
and/or	JJ	Condition
>	NN	Condition
or	CC	Condition
=	VB	Condition
N1	NNP	Condition
)	)	Condition
newly	RB	Condition
diagnosed	VBN	Condition
breast	NN	Condition
cancer	NN	Condition
,	,	O
Eastern	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
performance	NN	O
status	NN	O
of	IN	O
0	CD	O
or	CC	O
1	CD	O
,	,	O
and	CC	O
normal	JJ	O
cardiac	NN	O
,	,	O
renal	JJ	O
,	,	O
and	CC	O
liver	JJ	O
function	NN	O
.	.	O

120	CD	SampleSize
women	NNS	Sex
were	VBD	O
randomly	RB	O
assigned	VBN	O
,	,	O
using	VBG	O
allocation	NN	O
concealment	NN	O
,	,	O
to	TO	O
receive	VB	O
4	CD	O
mg	NN	O
zoledronic	JJ	O
acid	NN	O
intravenously	RB	O
every	DT	O
3	CD	O
weeks	NNS	O
(	(	O
n=60	NN	O
)	)	O
,	,	O
or	CC	O
no	DT	O
zoledronic	JJ	O
acid	NN	O
(	(	O
n=60	JJ	O
)	)	O
,	,	O
for	IN	O
1	CD	O
year	NN	O
concomitant	NN	O
with	IN	O
four	CD	O
cycles	NNS	O
of	IN	O
neoadjuvant	JJ	O
epirubicin	NN	O
(	(	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
plus	CC	O
docetaxel	JJ	O
(	(	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
and	CC	O
two	CD	O
cycles	NNS	O
of	IN	O
adjuvant	JJ	O
epirubicin	JJ	O
plus	CC	O
docetaxel	JJ	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
detectable	JJ	O
DTCs	NNP	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

Final	NNP	O
analysis	NN	O
was	VBD	O
done	VBN	O
1	CD	O
year	NN	O
after	IN	O
the	DT	O
last	JJ	O
patient	NN	O
was	VBD	O
enrolled	VBN	O
.	.	O

Analyses	NNS	O
were	VBD	O
done	VBN	O
for	IN	O
all	DT	O
patients	NNS	O
with	IN	O
available	JJ	O
data	NNS	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00242203	NNP	O
.	.	O

FINDINGS	NNP	O
Of	IN	O
the	DT	O
120	CD	SampleSize
patients	NNS	O
initially	RB	O
enrolled	VBD	O
,	,	O
one	CD	SampleSize
withdrew	NN	O
after	IN	O
signing	VBG	O
consent	NN	O
and	CC	O
one	CD	SampleSize
patient	NN	O
's	POS	O
baseline	NN	O
bone	NN	O
marrow	NN	O
was	VBD	O
not	RB	O
available	JJ	O
.	.	O

Both	DT	O
of	IN	O
these	DT	O
patients	NNS	O
were	VBD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

At	IN	O
3	CD	O
months	NNS	O
,	,	O
109	CD	SampleSize
bone-marrow	NN	O
samples	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
analysis	NN	O
.	.	O

In	IN	O
the	DT	O
zoledronic	JJ	O
acid	NN	O
group	NN	O
,	,	O
bone	NN	O
marrow	NN	O
was	VBD	O
not	RB	O
collected	VBN	O
from	IN	O
one	CD	O
patient	NN	O
because	IN	O
of	IN	O
disease	NN	O
progression	NN	O
,	,	O
one	CD	O
patient	NN	O
was	VBD	O
taken	VBN	O
off	RP	O
study	NN	O
because	IN	O
of	IN	O
severe	JJ	O
diarrhoea	NN	O
,	,	O
and	CC	O
two	CD	O
patients	NNS	O
had	VBD	O
not	RB	O
consented	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
surgery	NN	O
.	.	O

In	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
bone	NN	O
marrow	NN	O
was	VBD	O
not	RB	O
collected	VBN	O
from	IN	O
two	CD	O
patients	NNS	O
because	IN	O
of	IN	O
disease	NN	O
progression	NN	O
,	,	O
one	CD	O
patient	NN	O
withdrew	VBD	O
consent	NN	O
,	,	O
and	CC	O
three	CD	O
patients	NNS	O
were	VBD	O
not	RB	O
consented	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
surgery	NN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
DTCs	NNP	O
were	VBD	O
detected	VBN	O
in	IN	O
26	CD	O
of	IN	O
60	CD	O
patients	NNS	O
in	IN	O
the	DT	O
zoledronic	JJ	O
acid	NN	O
group	NN	O
and	CC	O
28	CD	O
of	IN	O
58	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

At	IN	O
3	CD	O
months	NNS	O
,	,	O
17	CD	O
of	IN	O
56	CD	O
patients	NNS	O
receiving	VBG	O
zoledronic	JJ	O
acid	NN	O
versus	IN	O
25	CD	O
of	IN	O
53	CD	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
zoledronic	JJ	O
acid	NN	O
had	VBD	O
detectable	JJ	O
DTCs	NNP	O
(	(	O
p=0.054	NN	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
grade	NN	O
3-4	JJ	O
toxicities	NNS	O
were	VBD	O
infection	NN	O
(	(	O
five	CD	O
of	IN	O
60	CD	O
patients	NNS	O
in	IN	O
the	DT	O
zoledronic	JJ	O
acid	NN	O
group	NN	O
and	CC	O
six	CD	O
of	IN	O
59	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
)	)	O
and	CC	O
thrombosis	NN	O
(	(	O
five	CD	O
of	IN	O
60	CD	O
in	IN	O
the	DT	O
zoledronic	JJ	O
acid	NN	O
and	CC	O
two	CD	O
of	IN	O
59	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
one	CD	O
documented	JJ	O
case	NN	O
of	IN	O
osteonecrosis	NN	O
in	IN	O
the	DT	O
zoledronic	JJ	O
acid	NN	O
group	NN	O
.	.	O

INTERPRETATION	NNP	O
Zoledronic	NNP	O
acid	NN	O
administered	VBD	O
with	IN	O
chemotherapy	NN	O
resulted	VBN	O
in	IN	O
a	DT	O
decreased	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
DTCs	NNP	O
detected	VBD	O
in	IN	O
the	DT	O
bone	NN	O
marrow	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
surgery	NN	O
.	.	O

Our	PRP$	O
study	NN	O
supports	VBZ	O
the	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
antimetastatic	JJ	O
effects	NNS	O
of	IN	O
zoledronic	JJ	O
acid	NN	O
may	MD	O
be	VB	O
through	IN	O
effects	NNS	O
on	IN	O
DTCs	NNP	O
.	.	O

FUNDING	NN	O
Novartis	NN	O
Pharmaceuticals	NNP	O
and	CC	O
Pfizer	NNP	O
Inc	NNP	O
.	.	O

The	DT	O
aging	VBG	O
motor	NN	O
system	NN	O
as	IN	O
a	DT	O
model	NN	O
for	IN	O
plastic	JJ	O
changes	NNS	O
of	IN	O
GABA-mediated	NNP	O
intracortical	JJ	O
inhibition	NN	O
and	CC	O
their	PRP$	O
behavioral	JJ	O
relevance	NN	O
.	.	O

Since	IN	O
GABAA-mediated	JJ	O
intracortical	JJ	O
inhibition	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
underlie	VB	O
plastic	NN	O
changes	NNS	O
throughout	IN	O
the	DT	O
lifespan	NN	O
from	IN	O
development	NN	O
to	TO	O
aging	VBG	O
,	,	O
here	RB	O
,	,	O
the	DT	O
aging	VBG	O
motor	NN	O
system	NN	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
model	NN	O
to	TO	O
analyze	VB	O
the	DT	O
interdependence	NN	O
of	IN	O
plastic	JJ	O
alterations	NNS	O
within	IN	O
the	DT	O
inhibitory	JJ	O
motorcortical	JJ	O
network	NN	O
and	CC	O
level	NN	O
of	IN	O
behavioral	JJ	O
performance	NN	O
.	.	O

Double-pulse	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
dpTMS	NN	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
inhibition	NN	O
by	IN	O
means	NNS	O
of	IN	O
short-interval	JJ	O
intracortical	JJ	O
inhibition	NN	O
(	(	O
SICI	NNP	O
)	)	O
of	IN	O
the	DT	O
contralateral	JJ	O
primary	JJ	O
motor	NN	O
cortex	NN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
64	CD	O
healthy	JJ	O
right-handed	JJ	O
human	JJ	O
subjects	NNS	O
covering	VBG	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
the	DT	O
adult	NN	O
lifespan	NN	O
(	(	O
age	NN	O
range	NN	O
20-88	CD	O
years	NNS	O
,	,	O
mean	VB	O
47.6	CD	O
?	.	O
20.7	CD	O
,	,	O
34	CD	O
female	NN	O
)	)	O
.	.	O

SICI	NNP	O
was	VBD	O
evaluated	VBN	O
during	IN	O
resting	VBG	O
state	NN	O
and	CC	O
in	IN	O
an	DT	O
event-related	JJ	O
condition	NN	O
during	IN	O
movement	NN	O
preparation	NN	O
in	IN	O
a	DT	O
visually	RB	O
triggered	VBN	O
simple	JJ	O
reaction	NN	O
time	NN	O
task	NN	O
.	.	O

In	IN	O
a	DT	O
subgroup	NN	O
(	(	O
N	NNP	O
=	NNP	O
23	CD	O
)	)	O
,	,	O
manual	JJ	O
motor	NN	O
performance	NN	O
was	VBD	O
tested	VBN	O
with	IN	O
tasks	NNS	O
of	IN	O
graded	VBN	O
dexterous	JJ	O
demand	NN	O
.	.	O

Weak	JJ	O
resting-state	JJ	O
inhibition	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
overall	JJ	O
lower	JJR	O
manual	JJ	O
motor	NN	O
performance	NN	O
.	.	O

Better	RBR	O
event-related	JJ	O
modulation	NN	O
of	IN	O
inhibition	NN	O
correlated	VBN	O
with	IN	O
better	JJR	O
performance	NN	O
in	IN	O
more	RBR	O
demanding	JJ	O
tasks	NNS	O
,	,	O
in	IN	O
which	WDT	O
fast	RB	O
alternating	VBG	O
activation	NN	O
of	IN	O
cortical	JJ	O
representations	NNS	O
are	VBP	O
necessary	JJ	O
.	.	O

Declining	VBG	O
resting-state	JJ	O
inhibition	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
weakened	JJ	O
event-related	JJ	O
modulation	NN	O
of	IN	O
inhibition	NN	O
.	.	O

Therefore	NN	O
,	,	O
reduced	VBD	O
resting-state	JJ	O
inhibition	NN	O
might	MD	O
lead	VB	O
to	TO	O
a	DT	O
subsequent	JJ	O
loss	NN	O
of	IN	O
modulatory	JJ	O
capacity	NN	O
,	,	O
possibly	RB	O
reflecting	VBG	O
malfunctioning	VBG	O
precision	NN	O
in	IN	O
GABAAergic	NNP	O
neurotransmission	NN	O
;	:	O
the	DT	O
consequence	NN	O
is	VBZ	O
an	DT	O
inevitable	JJ	O
decline	NN	O
in	IN	O
motor	NN	O
function	NN	O
.	.	O

Effect	NN	O
of	IN	O
n-3	JJ	O
polyunsaturated	JJ	O
fatty	JJ	O
acid	NNS	O
intake	VBP	O
on	IN	O
phospholipid	JJ	O
fatty	JJ	O
acid	JJ	O
composition	NN	O
in	IN	O
plasma	NN	O
and	CC	O
erythrocytes	NNS	O
.	.	O

To	TO	O
characterize	VB	O
the	DT	O
time	NN	O
course	NN	O
of	IN	O
plasma	NN	O
and	CC	O
red	JJ	O
blood	NN	O
cell	NN	O
(	(	O
RBC	NNP	O
)	)	O
changes	NNS	O
after	IN	O
n-3	JJ	O
polyunsaturated	JJ	O
fatty	JJ	O
acid	NN	O
(	(	O
PUFA	NNP	O
)	)	O
supplementation	NN	O
,	,	O
20	CD	Condition
healthy	JJ	Condition
male	NN	Condition
volunteers	NNS	Condition
were	VBD	Condition
randomly	RB	Condition
assigned	VBN	Condition
to	TO	O
receive	VB	O
either	DT	O
four	CD	O
1-g	JJ	O
capsules	NNS	O
of	IN	O
n-3	JJ	O
PUFA	NNP	O
ethyl	NN	O
esters	NNS	O
or	CC	O
four	CD	O
1-g	JJ	O
capsules	NNS	O
of	IN	O
olive	JJ	O
oil	NN	O
(	(	O
as	IN	O
placebo	NN	O
)	)	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
4	CD	O
mo	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
3-mo	JJ	O
washout	NN	O
period	NN	O
.	.	O

Fatty	NNP	O
acids	NNS	O
of	IN	O
plasma	NN	O
and	CC	O
RBC	NNP	O
phospholipid	JJ	O
fractions	NNS	O
were	VBD	O
analyzed	VBN	O
at	IN	O
0	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
4	CD	O
mo	NN	O
of	IN	O
treatment	NN	O
and	CC	O
at	IN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
mo	NN	O
of	IN	O
washout	NN	O
.	.	O

During	IN	O
n-3	JJ	O
PUFA	NNP	O
supplementation	NN	O
,	,	O
accumulations	NNS	O
of	IN	O
eicosapentaenoic	NN	O
(	(	O
EPA	NNP	O
)	)	O
,	,	O
docosapentaenoic	FW	O
(	(	O
DPA	NNP	O
)	)	O
,	,	O
and	CC	O
docosahexaenoic	NN	O
(	(	O
DHA	NNP	O
)	)	O
acids	NNS	O
were	VBD	O
marked	VBN	O
after	IN	O
2	CD	O
mo	NN	O
with	IN	O
differences	NNS	O
among	IN	O
different	JJ	O
fractions	NNS	O
of	IN	O
plasma	NN	O
and	CC	O
RBCs	NNP	O
in	IN	O
further	JJ	O
accumulation	NN	O
up	RB	O
to	TO	O
4	CD	O
mo	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
months	NNS	O
of	IN	O
the	DT	O
washout	NN	O
,	,	O
slight	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
changes	NNS	O
of	IN	O
various	JJ	O
fatty	JJ	O
acids	NNS	O
among	IN	O
different	JJ	O
phospholipid	JJ	O
fractions	NNS	O
,	,	O
but	CC	O
after	IN	O
3	CD	O
mo	NN	O
of	IN	O
washout	NN	O
,	,	O
only	RB	O
minor	JJ	O
alterations	NNS	O
were	VBD	O
still	RB	O
detectable	JJ	O
with	IN	O
respect	NN	O
to	TO	O
pretreatment	VB	O
values	NNS	O
.	.	O

These	DT	O
data	NNS	O
confirm	VBP	O
the	DT	O
complex	JJ	O
relations	NNS	O
among	IN	O
different	JJ	O
fatty	JJ	O
acid	NN	O
pools	NNS	O
after	IN	O
n-3	JJ	O
PUFA	NNP	O
supplementation	NN	O
.	.	O

Effect	NN	O
of	IN	O
a	DT	O
ferrule	NN	O
and	CC	O
increased	VBD	O
clinical	JJ	O
crown	NN	O
length	NN	O
on	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
fracture	NN	O
resistance	NN	O
of	IN	O
premolars	NNS	O
restored	VBN	O
using	VBG	O
two	CD	O
dowel-and-core	JJ	O
systems	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
crown-lengthening	JJ	O
ferrule	NN	O
on	IN	O
the	DT	O
fracture	NN	O
resistance	NN	O
of	IN	O
endodontically-treated	JJ	O
teeth	NNS	O
restored	VBN	O
with	IN	O
two	CD	O
dowel-core	JJ	O
systems	NNS	O
.	.	O

Thirty-two	NNP	SampleSize
extracted	VBD	O
mandibular	JJ	O
first	JJ	O
premolars	NNS	O
were	VBD	O
sectioned	VBN	O
perpendicular	JJ	O
to	TO	O
the	DT	O
long	JJ	O
axis	NN	O
at	IN	O
a	DT	O
point	NN	O
1.0	CD	O
mm	NN	O
occlusal	NN	O
to	TO	O
the	DT	O
buccal	JJ	O
cementoenamel	NN	O
junction	NN	O
.	.	O

Following	VBG	O
endodontic	JJ	O
treatment	NN	O
,	,	O
the	DT	O
teeth	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
four	CD	O
groups	NNS	O
:	:	O
cast	VBN	O
Ni-Cr	JJ	O
alloy	NN	O
dowel-core	NN	O
with	IN	O
no	DT	O
ferrule	NN	O
(	(	O
Group	NNP	O
A1	NNP	O
)	)	O
,	,	O
cast	VBD	O
Ni-Cr	JJ	O
alloy	NN	O
dowel-core	NN	O
with	IN	O
2.0	CD	O
mm	NNS	O
ferrule	NN	O
(	(	O
Group	NNP	O
A2	NNP	O
)	)	O
,	,	O
prefabricated	VBN	O
carbon	NN	O
fiber-reinforced	JJ	O
dowel-resin	NN	O
core	NN	O
with	IN	O
no	DT	O
ferrule	NN	O
(	(	O
Group	NNP	O
B1	NNP	O
)	)	O
and	CC	O
carbon	JJ	O
fiber-reinforced	JJ	O
dowel-resin	NN	O
core	NN	O
with	IN	O
2.0	CD	O
mm	NNS	O
ferrule	NN	O
(	(	O
Group	NNP	O
B2	NNP	O
)	)	O
.	.	O

Each	DT	O
specimen	NN	O
was	VBD	O
embedded	VBN	O
in	IN	O
a	DT	O
self-cured	JJ	O
acrylic	JJ	O
resin	NN	O
block	NN	O
from	IN	O
2.0	CD	O
mm	JJ	O
apical	JJ	O
to	TO	O
the	DT	O
margins	NNS	O
of	IN	O
a	DT	O
cast	JJ	O
Ni-Cr	JJ	O
alloy	NN	O
crown	NN	O
,	,	O
then	RB	O
loaded	VBD	O
at	IN	O
150	CD	O
degrees	NNS	O
from	IN	O
the	DT	O
long	JJ	O
axis	NN	O
in	IN	O
a	DT	O
universal	JJ	O
testing	VBG	O
machine	NN	O
at	IN	O
a	DT	O
crosshead	JJ	O
speed	NN	O
of	IN	O
1.0	CD	O
mm/minute	NN	O
until	IN	O
fracture	NN	O
.	.	O

The	DT	O
data	NNS	O
were	VBD	O
recorded	VBN	O
and	CC	O
analyzed	VBN	O
using	VBG	O
ANOVA	NNP	O
and	CC	O
Fisher	NNP	O
's	POS	O
exact	NN	O
tests	NNS	O
,	,	O
with	IN	O
alpha	JJ	O
=	$	O
0.05	CD	O
.	.	O

Mean	JJ	O
failure	NN	O
loads	NNS	O
(	(	O
kN	NN	O
)	)	O
for	IN	O
the	DT	O
A1	NNP	O
,	,	O
A2	NNP	O
,	,	O
B1	NNP	O
and	CC	O
B2	NNP	O
Groups	NNP	O
were	VBD	O
:	:	O
1.46	CD	O
(	(	O
S.D	NNP	O
.	.	O

0.45	CD	O
)	)	O
,	,	O
1.07	CD	O
(	(	O
0.21	CD	O
)	)	O
,	,	O
1.13	CD	O
(	(	O
0.30	CD	O
)	)	O
and	CC	O
1.02	CD	O
(	(	O
0.27	CD	O
)	)	O
.	.	O

The	DT	O
teeth	NNS	O
restored	VBD	O
with	IN	O
cast	JJ	O
Ni-Cr	JJ	O
dowel-cores	NNS	O
and	CC	O
2.0	CD	O
mm	NN	O
ferrules	NNS	O
demonstrated	VBD	O
significantly	RB	O
lower	JJR	O
fracture	NN	O
strengths	NNS	O
,	,	O
p	VBP	O
=	JJ	O
0.04	CD	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
root	NN	O
fracture	NN	O
patterns	VBZ	O
between	IN	O
the	DT	O
two	CD	O
dowel	NN	O
systems	NNS	O
,	,	O
with	IN	O
the	DT	O
carbon	NN	O
fiber-reinforced	JJ	O
dowel-resin	NN	O
core	NN	O
system	NN	O
,	,	O
being	VBG	O
the	DT	O
less	JJS	O
severe	JJ	O
p	NN	O
<	VBD	O
0.05	CD	O
.	.	O

Crown	NNP	O
lengthening	VBG	O
with	IN	O
a	DT	O
2.0	CD	O
mm	NN	O
apical	JJ	O
extended	VBD	O
ferrule	NN	O
resulted	VBD	O
in	IN	O
reduced	JJ	O
fracture	NN	O
strengths	NNS	O
for	IN	O
endodontically-treated	JJ	O
teeth	NNS	O
restored	VBN	O
using	VBG	O
two	CD	O
dowel-core	JJ	O
systems	NNS	O
and	CC	O
cast	JJ	O
metal	NN	O
crowns	NNS	O
.	.	O

The	DT	O
carbon	NN	O
fiber-reinforced	JJ	O
dowel-resin	NN	O
core	NN	O
system	NN	O
reduced	VBD	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
root	NN	Condition
fractures	NNS	Condition
.	.	O

Deliberate	NNP	O
hypotension	NN	O
in	IN	O
patients	NNS	O
with	IN	O
intracranial	JJ	Condition
arteriovenous	JJ	Condition
malformations	NNS	Condition
:	:	O
esmolol	NN	O
compared	VBN	O
with	IN	O
isoflurane	NN	O
and	CC	O
sodium	NN	O
nitroprusside	RB	O
.	.	O

Thirty	JJ	SampleSize
patients	NNS	O
undergoing	VBG	O
resection	NN	O
of	IN	O
arteriovenous	JJ	Condition
malformations	NNS	Condition
with	IN	O
deliberate	JJ	O
hypotension	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
of	IN	O
3	CD	O
hypotensive	JJ	O
agents	NNS	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
isoflurane	NN	O
and	CC	O
nitrous	JJ	O
oxide	NN	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

Mean	NNP	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
reduced	VBN	O
20	CD	O
%	NN	O
to	TO	O
60-65	JJ	O
mm	NN	O
Hg	NNP	O
with	IN	O
use	NN	O
of	IN	O
either	DT	O
isoflurane	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
4	CD	O
%	NN	O
)	)	O
,	,	O
sodium	JJ	O
nitroprusside	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
micrograms.kg-1.min-1	NN	O
)	)	O
,	,	O
or	CC	O
esmolol	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
24	CD	O
mg/min	NN	O
)	)	O
.	.	O

Esmolol	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
from	IN	O
6.2	CD	O
+/-	JJ	O
1.3	CD	O
to	TO	O
3.8	CD	O
+/-	JJ	O
0.8	CD	O
L/min	NNP	O
,	,	O
which	WDT	O
,	,	O
because	IN	O
of	IN	O
a	DT	O
22	CD	O
%	NN	O
increase	NN	O
in	IN	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
,	,	O
far	RB	O
exceeded	VBD	O
the	DT	O
reduction	NN	O
in	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
.	.	O

Systemic	NNP	O
vascular	JJ	O
resistance	NN	O
increased	VBD	O
despite	IN	O
a	DT	O
32	CD	O
%	NN	O
decrease	NN	O
in	IN	O
plasma	JJ	O
renin	NN	O
activity	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
with	IN	O
sodium	JJ	O
nitroprusside	NN	O
or	CC	O
isoflurane	NN	O
,	,	O
the	DT	O
decrease	NN	O
in	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
decreases	NNS	O
in	IN	O
systemic	JJ	O
vascular	JJ	O
resistance	NN	O
of	IN	O
similar	JJ	O
magnitude	NN	O
,	,	O
with	IN	O
no	DT	O
change	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
.	.	O

Plasma	NNP	O
renin	NN	O
activity	NN	O
levels	NNS	O
increased	VBD	O
48	CD	O
%	NN	O
with	IN	O
sodium	NN	O
nitroprusside	NN	O
and	CC	O
126	CD	O
%	NN	O
with	IN	O
isoflurane	NN	O
.	.	O

Heart	NNP	O
rate	NN	O
increased	VBD	O
13	CD	O
%	NN	O
with	IN	O
sodium	NN	O
nitroprusside	NN	O
,	,	O
remained	VBD	O
unchanged	JJ	O
with	IN	O
isoflurane	NN	O
,	,	O
and	CC	O
decreased	VBD	O
23	CD	O
%	NN	O
with	IN	O
esmolol	NN	O
.	.	O

Although	IN	O
esmolol	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
primary	JJ	O
hypotensive	JJ	O
agent	NN	O
,	,	O
the	DT	O
potential	NN	O
for	IN	O
marked	JJ	O
myocardial	JJ	O
depression	NN	O
must	MD	O
be	VB	O
recognized	VBN	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
pharmacologic	NN	O
properties	NNS	O
for	IN	O
the	DT	O
different	JJ	O
hypotensive	JJ	O
agents	NNS	O
suggest	VBP	O
that	IN	O
combinations	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
may	MD	O
provide	VB	O
a	DT	O
pharmacologic	NN	O
profile	NN	O
superior	JJ	O
to	TO	O
either	DT	O
agent	NN	O
alone	RB	O
.	.	O

Noradrenergic	NNP	O
moderation	NN	O
of	IN	O
working	VBG	O
memory	NN	O
impairments	NNS	O
in	IN	O
adults	NNS	Age
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorder	NN	Condition
.	.	O

In	IN	O
addition	NN	O
to	TO	O
having	VBG	O
difficulties	NNS	O
with	IN	O
social	JJ	O
communications	NNS	O
,	,	O
individuals	NNS	O
with	IN	O
an	DT	O
autism	NN	Condition
spectrum	NN	Condition
disorder	NN	Condition
(	(	Condition
ASD	NNP	Condition
)	)	Condition
often	RB	O
also	RB	O
experience	JJ	O
impairment	NN	O
in	IN	O
higher-order	NN	O
,	,	O
executive	NN	O
skills	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
pharmacological	JJ	O
modulation	NN	O
of	IN	O
the	DT	O
norepinephrine	NN	O
system	NN	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
such	JJ	O
impairments	NNS	O
.	.	O

A	DT	O
sample	NN	O
of	IN	O
14	CD	SampleSize
high-functioning	JJ	O
adults	NNS	Age
with	IN	O
ASD	NNP	Condition
and	CC	O
a	DT	O
demographically-matched	JJ	O
comparison	NN	O
group	NN	O
of	IN	O
13	CD	SampleSize
typically	RB	O
developing	VBG	O
individuals	NNS	O
participated	VBN	O
.	.	O

An	DT	O
AX	NNP	O
continuous	JJ	O
performance	NN	O
test	NN	O
(	(	O
AX-CPT	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
working	VBG	O
memory	NN	O
and	CC	O
inhibitory	NN	O
control	NN	O
.	.	O

AX-CPT	JJ	O
performance	NN	O
was	VBD	O
assessed	VBN	O
following	VBG	O
administration	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
propranolol	NN	O
(	(	O
a	DT	O
beta	NN	O
adrenergic	JJ	O
antagonist	NN	O
)	)	O
and	CC	O
following	VBG	O
placebo	NN	O
(	(	O
sugar	NN	O
pill	NN	O
)	)	O
administration	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
ASD	NNP	Condition
performed	VBD	O
more	RBR	O
poorly	RB	O
than	IN	O
non-ASD	JJ	O
individuals	NNS	O
in	IN	O
the	DT	O
working	JJ	O
memory	NN	O
condition	NN	O
(	(	O
BX	NNP	O
trials	NNS	O
)	)	O
.	.	O

Importantly	RB	O
,	,	O
administration	NN	O
of	IN	O
propranolol	NN	O
attenuated	VBN	O
this	DT	O
impairment	NN	O
,	,	O
with	IN	O
the	DT	O
ASD	NNP	O
group	NN	O
performing	VBG	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
propranolol	NN	O
condition	NN	O
than	IN	O
the	DT	O
placebo	JJ	O
condition	NN	O
.	.	O

Working	VBG	O
memory	NN	O
performance	NN	O
of	IN	O
the	DT	O
non-ASD	JJ	O
group	NN	O
was	VBD	O
unaffected	VBN	O
by	IN	O
propranolol/placebo	JJ	O
administration	NN	O
.	.	O

No	DT	O
group	NN	O
or	CC	O
medication	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
the	DT	O
inhibition	NN	O
condition	NN	O
(	(	O
AY	NNP	O
trials	NNS	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
findings	NNS	O
suggest	VBP	O
that	IN	O
norepinephrine	NN	O
may	MD	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
some	DT	O
,	,	O
but	CC	O
not	RB	O
necessarily	RB	O
all	RB	O
,	,	O
cognitive	JJ	O
impairments	NNS	O
associated	VBN	O
with	IN	O
ASD	NNP	O
.	.	O

Additional	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
fully	RB	O
understand	VB	O
whether	IN	O
this	DT	O
role	NN	O
is	VBZ	O
primarily	RB	O
causal	JJ	O
or	CC	O
compensatory	NN	O
in	IN	O
nature	NN	O
.	.	O

Do	VB	O
physicians	NNS	O
'	POS	O
implicit	JJ	O
views	NNS	O
of	IN	O
African	JJ	O
Americans	NNPS	O
affect	VBP	O
clinical	JJ	O
decision	NN	O
making	NN	O
?	.	O
BACKGROUND	NNP	O
Total	NNP	O
knee	FW	O
replacement	NN	O
(	(	O
TKR	NNP	O
)	)	O
is	VBZ	O
a	DT	O
cost-effective	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
severe	JJ	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

While	IN	O
prevalence	NN	O
of	IN	O
OA	NNP	Condition
is	VBZ	O
higher	JJR	O
among	IN	O
blacks	NNS	O
than	IN	O
whites	NNS	O
,	,	O
TKR	NNP	O
rates	NNS	O
are	VBP	O
lower	JJR	O
among	IN	O
blacks	NNS	O
.	.	O

Physicians	NNPS	O
'	POS	O
implicit	JJ	O
preferences	NNS	O
might	MD	O
explain	VB	O
racial	JJ	O
differences	NNS	O
in	IN	O
TKR	NNP	O
recommendation	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
whether	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
implicit	JJ	O
racial	JJ	O
bias	NN	O
predicts	VBZ	O
physician	JJ	O
recommendation	NN	O
of	IN	O
TKR	NNP	O
for	IN	O
black	JJ	O
and	CC	O
white	JJ	O
patients	NNS	O
with	IN	O
OA	NNP	O
and	CC	O
to	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
web-based	JJ	O
instrument	NN	O
as	IN	O
an	DT	O
intervention	NN	O
to	TO	O
decrease	VB	O
the	DT	O
effect	NN	O
of	IN	O
implicit	JJ	O
racial	JJ	O
bias	NN	O
on	IN	O
physician	JJ	O
recommendation	NN	O
of	IN	O
TKR	NNP	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
web-based	JJ	O
study	NN	O
,	,	O
543	CD	SampleSize
family	NN	O
and	CC	O
internal	JJ	O
medicine	NN	O
physicians	NNS	O
were	VBD	O
given	VBN	O
a	DT	O
scenario	NN	O
describing	VBG	O
either	CC	O
a	DT	O
black	JJ	O
or	CC	O
white	JJ	O
patient	NN	O
with	IN	O
severe	JJ	O
OA	NNP	O
refractory	NN	O
to	TO	O
medical	JJ	O
treatment	NN	O
.	.	O

Questionnaires	VBZ	O
evaluating	VBG	O
the	DT	O
likelihood	NN	O
of	IN	O
recommending	VBG	O
TKR	NNP	O
,	,	O
perceived	VBD	O
medical	JJ	O
cooperativeness	NN	O
,	,	O
and	CC	O
measures	NNS	O
of	IN	O
implicit	JJ	O
racial	JJ	O
bias	NN	O
were	VBD	O
administered	VBN	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
included	VBD	O
TKR	NNP	O
recommendation	NN	O
,	,	O
implicit	JJ	O
racial	JJ	O
preference	NN	O
,	,	O
and	CC	O
medical	JJ	O
cooperativeness	NN	O
stereotypes	NNS	O
measured	VBN	O
with	IN	O
implicit	JJ	O
association	NN	O
tests	NNS	O
.	.	O

RESULTS	NNP	O
Subjects	NNPS	O
displayed	VBD	O
a	DT	O
strong	JJ	O
implicit	JJ	O
preference	NN	O
for	IN	O
whites	NNS	O
over	IN	O
blacks	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
and	CC	O
associated	VBN	O
medically	RB	O
cooperative	JJ	O
with	IN	O
whites	NNS	O
over	IN	O
blacks	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

Physicians	NNPS	O
reported	VBD	O
significantly	RB	O
greater	JJR	O
liking	VBG	O
for	IN	O
whites	NNS	O
over	IN	O
blacks	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
and	CC	O
reported	VBD	O
believing	VBG	O
whites	NNS	O
were	VBD	O
more	RBR	O
medically	RB	O
cooperative	JJ	O
than	IN	O
blacks	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

Participants	NNS	O
reported	VBD	O
providing	VBG	O
similar	JJ	O
care	NN	O
for	IN	O
white	JJ	O
and	CC	O
black	JJ	O
patients	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.10	NNP	O
)	)	O
but	CC	O
agreed	VBD	O
that	IN	O
subconscious	JJ	O
biases	NNS	O
could	MD	O
influence	VB	O
their	PRP$	O
treatment	NN	O
decisions	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
recommendation	NN	O
for	IN	O
TKR	NNP	O
when	WRB	O
the	DT	O
patient	NN	O
was	VBD	O
black	JJ	O
(	(	O
47	CD	O
%	NN	O
)	)	O
versus	NN	O
white	JJ	O
(	(	O
38	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
.439	NNP	O
)	)	O
,	,	O
and	CC	O
neither	DT	O
implicit	JJ	O
nor	CC	O
explicit	JJ	O
racial	JJ	O
biases	NNS	O
predicted	VBD	O
differential	JJ	O
treatment	NN	O
recommendations	NNS	O
by	IN	O
race	NN	O
(	(	O
all	DT	O
P	NNP	O
>	NNP	O
.06	NNP	O
)	)	O
.	.	O

Although	IN	O
participants	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
recommend	VB	O
TKR	NNP	O
when	WRB	O
completing	VBG	O
the	DT	O
implicit	JJ	O
association	NN	O
test	NN	O
before	IN	O
the	DT	O
decision	NN	O
,	,	O
patient	JJ	O
race	NN	O
was	VBD	O
not	RB	O
significant	JJ	O
in	IN	O
the	DT	O
association	NN	O
(	(	O
P	NNP	O
=	NNP	O
.960	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Physicians	NNPS	O
possessed	VBD	O
explicit	NN	O
and	CC	O
implicit	JJ	O
racial	JJ	O
biases	NNS	O
,	,	O
but	CC	O
those	DT	O
biases	NNS	O
did	VBD	O
not	RB	O
predict	VB	O
treatment	NN	O
recommendations	NNS	O
.	.	O

Clinicians	NNPS	O
'	POS	O
biases	NNS	O
about	IN	O
the	DT	O
medical	JJ	O
cooperativeness	NN	O
of	IN	O
blacks	NNS	O
versus	VBP	O
whites	NNS	O
,	,	O
however	RB	O
,	,	O
may	MD	O
have	VB	O
influenced	VBN	O
treatment	NN	O
decisions	NNS	O
.	.	O

A	DT	O
phase	NN	O
III	NNP	O
clinical	JJ	O
trial	NN	O
of	IN	O
exercise	NN	O
modalities	NNS	O
on	IN	O
treatment	NN	O
side-effects	NNS	O
in	IN	O
men	NNS	Sex
receiving	VBG	O
therapy	NN	O
for	IN	O
prostate	NN	Condition
cancer	NN	Condition
.	.	O

BACKGROUND	NNP	O
Androgen	NNP	O
deprivation	NN	O
therapy	NN	O
(	(	O
ADT	NNP	O
)	)	O
is	VBZ	O
accompanied	VBN	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
adverse	JJ	O
side	NN	O
effects	NNS	O
including	VBG	O
reduced	VBD	O
bone	JJ	O
mass	NN	O
and	CC	O
increased	VBD	O
risk	NN	O
for	IN	O
fracture	NN	O
,	,	O
reduced	VBN	O
lean	JJ	O
mass	NN	O
and	CC	O
muscle	NN	O
strength	NN	O
,	,	O
mood	NN	O
disturbance	NN	O
and	CC	O
increased	VBD	O
fat	JJ	O
mass	NN	O
compromising	VBG	O
physical	JJ	O
functioning	NN	O
,	,	O
independence	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
investigation	NN	O
is	VBZ	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
long	JJ	O
term	NN	O
exercise	NN	O
on	IN	O
reversing	VBG	O
musculoskeletal-related	JJ	O
side	NN	O
effects	NNS	O
,	,	O
and	CC	O
cardiovascular	JJ	O
and	CC	O
diabetes	VBZ	O
risk	NN	O
factors	NNS	O
in	IN	O
men	NNS	O
receiving	VBG	O
androgen	NN	Condition
deprivation	NN	Condition
for	IN	O
their	PRP$	O
prostate	NN	O
cancer	NN	O
.	.	O

Specifically	RB	O
,	,	O
we	PRP	O
aim	VBP	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
12-month	JJ	O
exercise	NN	O
program	NN	O
designed	VBN	O
to	TO	O
load	VB	O
the	DT	O
musculoskeletal	NN	O
system	NN	O
and	CC	O
reduce	VB	O
cardiovascular	NN	O
and	CC	O
diabetes	VBZ	O
disease	JJ	O
progression	NN	O
on	IN	O
the	DT	O
following	JJ	O
primary	JJ	O
endpoints	NNS	O
:	:	O
1	CD	O
)	)	O
bone	NN	O
mineral	JJ	O
density	NN	O
;	:	O
2	CD	O
)	)	O
cardiorespiratory	NN	O
function	NN	O
and	CC	O
maximal	JJ	O
oxygen	NN	O
capacity	NN	O
;	:	O
3	CD	O
)	)	O
body	NN	O
composition	NN	O
(	(	O
lean	JJ	O
mass	NN	O
and	CC	O
fat	JJ	O
mass	NN	O
)	)	O
;	:	O
4	CD	O
)	)	O
blood	NN	O
pressure	NN	O
and	CC	O
cardiovascular	JJ	O
function	NN	O
;	:	O
5	CD	O
)	)	O
lipids	NNS	O
and	CC	O
glycemic	JJ	O
control	NN	O
;	:	O
and	CC	O
6	CD	O
)	)	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
psychological	JJ	O
distress	NN	O
.	.	O

METHODS/DESIGN	NNP	O
Multi-site	NNP	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
195	CD	SampleSize
men	NNS	Sex
(	(	O
65	CD	O
subjects	NNS	O
per	IN	O
arm	NN	O
)	)	O
undergoing	NN	O
treatment	NN	O
for	IN	O
prostate	NN	Condition
cancer	NN	Condition
involving	VBG	Condition
ADT	NNP	Condition
in	IN	O
the	DT	O
cities	NNS	O
of	IN	O
Perth	NNP	O
and	CC	O
Brisbane	NNP	O
in	IN	O
Australia	NNP	O
.	.	O

Participants	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
to	TO	O
(	(	O
1	CD	O
)	)	O
resistance/impact	NN	O
loading	VBG	O
exercise	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
resistance/cardiovascular	NN	O
exercise	NN	O
groups	NNS	O
and	CC	O
(	(	O
3	CD	O
)	)	O
usual	JJ	O
care/delayed	VBN	O
exercise	NN	O
.	.	O

Participants	NNS	O
will	MD	O
then	RB	O
undergo	VB	O
progressive	JJ	O
training	NN	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

Measurements	NNS	O
for	IN	O
primary	JJ	O
and	CC	O
secondary	JJ	O
endpoints	NNS	O
will	MD	O
take	VB	O
place	NN	O
at	IN	O
baseline	NN	O
,	,	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
(	(	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
)	)	O
.	.	O

DISCUSSION	VB	O
The	DT	O
principal	JJ	O
outcome	NN	O
of	IN	O
this	DT	O
project	NN	O
will	MD	O
be	VB	O
the	DT	O
determination	NN	O
of	IN	O
the	DT	O
strength	NN	O
of	IN	O
effect	NN	O
of	IN	O
exercise	NN	O
on	IN	O
the	DT	O
well	NN	O
established	VBN	O
musculoskeletal	NN	O
,	,	O
cardiovascular	JJ	O
and	CC	O
insulin	JJ	O
metabolism	NN	O
side	NN	O
effects	NNS	O
of	IN	O
androgen	NN	O
deprivation	NN	O
in	IN	O
prostate	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

As	IN	O
this	DT	O
project	NN	O
is	VBZ	O
much	RB	O
longer	JJR	O
term	NN	O
than	IN	O
previous	JJ	O
investigations	NNS	O
in	IN	O
the	DT	O
area	NN	O
of	IN	O
exercise	NN	O
and	CC	O
cancer	NN	O
,	,	O
we	PRP	O
will	MD	O
gain	VB	O
knowledge	NN	O
as	IN	O
to	TO	O
the	DT	O
continuing	VBG	O
effects	NNS	O
of	IN	O
exercise	NN	O
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
specifically	RB	O
targeting	VBG	O
bone	NN	O
density	NN	O
,	,	O
cardiovascular	JJ	O
function	NN	O
,	,	O
lean	JJ	O
and	CC	O
fat	JJ	O
mass	NN	O
,	,	O
physical	JJ	O
function	NN	O
and	CC	O
falls	VBZ	O
risk	NN	O
as	IN	O
primary	JJ	O
study	NN	O
endpoints	NNS	O
.	.	O

In	IN	O
terms	NNS	O
of	IN	O
advancement	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
care	NN	O
,	,	O
we	PRP	O
expect	VBP	O
dissemination	NN	O
of	IN	O
the	DT	O
knowledge	NN	O
gained	VBN	O
from	IN	O
this	DT	O
project	NN	O
to	TO	O
reduce	VB	O
fracture	NN	O
risk	NN	O
,	,	O
improve	VB	O
physical	JJ	O
and	CC	O
functional	JJ	O
ability	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
ultimately	RB	O
survival	JJ	O
rate	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRY	NNP	O
A	NNP	O
Phase	NNP	O
III	NNP	O
clinical	JJ	O
trial	NN	O
of	IN	O
exercise	NN	O
modalities	NNS	O
on	IN	O
treatment	NN	O
side-effects	NNS	O
in	IN	O
men	NNS	O
receiving	VBG	O
therapy	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
;	:	O
ACTRN12609000200280	NNP	O
.	.	O

Oral	JJ	O
S-adenosylmethionine	NNP	O
in	IN	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
intrahepatic	JJ	Condition
cholestasis	NN	Condition
.	.	Condition

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Parenteral	JJ	O
S-adenosylmethionine	JJ	O
proved	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
reversing	VBG	O
intrahepatic	JJ	O
cholestasis	NN	O
in	IN	O
pregnant	JJ	O
women	NNS	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
findings	NNS	O
,	,	O
a	DT	O
prospective	JJ	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
was	VBD	O
planned	VBN	O
to	TO	O
assess	VB	O
whether	IN	O
oral	JJ	O
S-adenosylmethionine	NNP	O
is	VBZ	O
effective	JJ	O
in	IN	O
cholestatic	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	O
liver	NN	O
disease	NN	O
.	.	O

Accordingly	RB	O
,	,	O
220	CD	O
inpatients	NNS	O
(	(	O
26	CD	O
%	NN	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
,	,	O
68	CD	O
%	NN	O
cirrhosis	NN	O
,	,	O
6	CD	O
%	NN	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
)	)	O
with	IN	O
stable	JJ	O
(	(	O
1	CD	O
month	NN	O
or	CC	O
more	JJR	O
)	)	O
at	IN	O
least	JJS	O
twofold	JJ	O
increases	NNS	O
in	IN	O
serum	JJ	O
total	NN	O
and	CC	O
conjugated	VBD	O
bilirubin	NN	O
and	CC	O
alkaline	JJ	O
phosphatase	NN	O
volunteered	VBD	O
for	IN	O
the	DT	O
trial	NN	O
.	.	O

Serum	NNP	O
markers	NNS	O
of	IN	O
cholestasis	NN	O
significantly	RB	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
decreased	VBN	O
after	IN	O
oral	JJ	O
S-adenosylmethionine	JJ	O
administration	NN	O
(	(	O
1600	CD	O
mg/day	NN	O
)	)	O
,	,	O
and	CC	O
their	PRP$	O
values	NNS	O
were	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
lower	JJR	O
than	IN	O
the	DT	O
corresponding	JJ	O
values	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

S-adenosylmethionine	NNP	O
significantly	RB	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
improved	VBN	O
subjective	JJ	O
symptoms	NNS	O
such	JJ	O
as	IN	O
pruritus	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
feeling	NN	O
of	IN	O
being	VBG	O
unwell	JJ	O
,	,	O
whereas	JJ	O
placebo	NN	O
was	VBD	O
ineffective	JJ	O
.	.	O

Two	CD	O
patients	NNS	O
in	IN	O
the	DT	O
S-adenosylmethionine	NNP	O
group	NN	O
and	CC	O
9	CD	O
controls	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
withdrew	NN	O
from	IN	O
the	DT	O
trial	NN	O
for	IN	O
reduced	VBN	O
compliance	NN	O
because	IN	O
of	IN	O
inefficacy	NN	O
of	IN	O
treatment	NN	O
.	.	O

Oral	JJ	O
S-adenosylmethionine	NNP	O
was	VBD	O
tolerated	VBN	O
to	TO	O
the	DT	O
same	JJ	O
extent	NN	O
as	IN	O
placebo	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
short-term	JJ	O
administration	NN	O
of	IN	O
oral	JJ	O
S-adenosylmethionine	NNP	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
in	IN	O
improving	VBG	O
clinical	JJ	O
and	CC	O
laboratory	JJ	O
measures	NNS	O
of	IN	O
intrahepatic	JJ	O
cholestasis	NN	O
and	CC	O
offers	VBZ	O
a	DT	O
new	JJ	O
therapeutic	JJ	O
modality	NN	O
for	IN	O
the	DT	O
symptomatic	JJ	O
management	NN	O
of	IN	O
this	DT	O
syndrome	NN	O
.	.	O

Kata	NNP	O
techniques	NNS	O
training	VBG	O
consistently	RB	O
decreases	VBZ	O
stereotypy	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
14	CD	O
weeks	NNS	O
of	IN	O
Kata	NNP	O
techniques	NNS	O
training	VBG	O
on	IN	O
stereotypic	JJ	O
behaviors	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
were	VBD	O
investigated	VBN	O
.	.	O

The	DT	O
study	NN	O
included	VBD	O
30	CD	O
eligible	JJ	O
(	(	O
diagnosed	JJ	O
ASD	NNP	O
,	,	O
school	NN	O
age	NN	O
)	)	O
children	NNS	O
with	IN	O
ages	NNS	O
ranging	VBG	O
from	IN	O
5	CD	O
to	TO	O
16	CD	O
years	NNS	O
whom	WP	O
they	PRP	O
assigned	VBD	O
to	TO	O
an	DT	O
exercise	NN	O
(	(	O
n=15	JJ	O
)	)	O
or	CC	O
a	DT	O
no-exercise	JJ	O
control	NN	O
group	NN	O
(	(	O
n=15	RB	O
)	)	O
.	.	O

Participants	NNS	O
of	IN	O
the	DT	O
exercise	NN	O
group	NN	O
received	VBD	O
Kata	NNP	O
techniques	NNS	O
instruction	VBP	O
four	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
14	CD	O
weeks	NNS	O
(	(	O
56	CD	O
sessions	NNS	O
)	)	O
.	.	O

Stereotypy	NNP	O
was	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
(	(	O
pre-intervention	NN	O
)	)	O
,	,	O
week	NN	O
14	CD	O
(	(	O
post-intervention	NN	O
)	)	O
,	,	O
and	CC	O
at	IN	O
one	CD	O
month	NN	O
follow	VB	O
up	RP	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
Kata	NNP	O
techniques	NNS	O
training	VBG	O
significantly	RB	O
reduced	VBN	O
stereotypy	NN	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
.	.	O

Following	VBG	O
participation	NN	O
in	IN	O
Kata	NNP	O
techniques	NNS	O
training	NN	O
,	,	O
stereotypy	NN	O
decreased	VBN	O
from	IN	O
baseline	NN	O
levels	NNS	O
by	IN	O
a	DT	O
M	NNP	O
of	IN	O
42.54	CD	O
%	NN	O
across	IN	O
participants	NNS	O
.	.	O

Interestingly	NNP	O
,	,	O
after	IN	O
30	CD	O
days	NNS	O
of	IN	O
no	DT	O
practice	NN	O
,	,	O
stereotypy	NN	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
remained	VBD	O
significantly	RB	O
decreased	VBN	O
compared	VBN	O
to	TO	O
pre-intervention	NN	O
time	NN	O
.	.	O

The	DT	O
participants	NNS	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
did	VBD	O
not	RB	O
show	VB	O
significant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
stereotypy	NN	O
.	.	O

Teaching	VBG	O
martial	JJ	O
arts	NNS	O
techniques	NNS	O
to	TO	O
children	NNS	O
with	IN	O
ASD	NNP	O
for	IN	O
a	DT	O
long	JJ	O
period	NN	O
of	IN	O
time	NN	O
consistently	RB	O
decreased	VBN	O
their	PRP$	O
stereotypic	NN	O
behaviors	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
bulimia	NN	Condition
nervosa	NN	Condition
with	IN	O
lithium	JJ	O
carbonate	NN	O
.	.	O

A	DT	O
controlled	JJ	O
study	NN	O
.	.	O

Ninety-one	CD	O
female	JJ	O
bulimic	JJ	O
outpatients	NNS	O
received	VBD	O
lithium	JJ	O
carbonate	NN	O
or	CC	O
placebo	NN	O
on	IN	O
a	DT	O
random	JJ	O
basis	NN	O
,	,	O
after	IN	O
being	VBG	O
separated	VBN	O
into	IN	O
depressed	JJ	Condition
and	CC	O
nondepressed	JJ	O
subgroups	NNS	O
,	,	O
in	IN	O
an	DT	O
8-week	JJ	O
double-blind	JJ	O
trial	NN	O
.	.	O

Sixty-eight	JJ	SampleSize
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
experienced	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
bulimic	JJ	O
episodes	NNS	O
after	IN	O
the	DT	O
8	CD	O
weeks	NNS	O
.	.	O

Lithium	NNP	O
,	,	O
in	IN	O
a	DT	O
dosage	NN	O
yielding	VBG	O
relatively	RB	O
low	JJ	O
plasma	NN	O
levels	NNS	O
,	,	O
was	VBD	O
not	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
.	.	O

However	RB	O
,	,	O
depression	NN	O
and	CC	O
other	JJ	O
psychopathologies	NNS	O
decreased	VBN	O
with	IN	O
improvement	NN	O
in	IN	O
bulimic	JJ	O
behavior	NN	O
.	.	O

Detection	NN	O
rates	NNS	O
of	IN	O
cancer	NN	O
,	,	O
high	JJ	O
grade	NN	O
PIN	NNP	O
and	CC	O
atypical	JJ	O
lesions	NNS	O
suspicious	JJ	O
for	IN	O
cancer	NN	O
in	IN	O
the	DT	O
European	NNP	O
Randomized	NNP	O
Study	NNP	O
of	IN	O
Screening	NNP	Condition
for	IN	Condition
Prostate	NNP	Condition
Cancer	NNP	Condition
.	.	O

THE	NNP	O
AIM	NNP	O
OF	IN	O
THE	NNP	O
STUDY	NNP	O
This	DT	O
article	NN	O
presents	VBZ	O
the	DT	O
incidence	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
,	,	O
isolated	VBN	O
high	JJ	O
grade	NN	O
prostatic	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
(	(	O
PIN	NNP	O
)	)	O
and	CC	O
atypical	JJ	O
lesions	NNS	O
suspicious	JJ	O
for	IN	O
prostate	NN	O
cancer	NN	O
(	(	O
LSPC	NNP	O
)	)	O
during	IN	O
subsequent	JJ	O
screening	VBG	O
rounds	NNS	O
in	IN	O
the	DT	O
centres	NNS	O
of	IN	O
five	CD	O
of	IN	O
the	DT	O
countries	NNS	O
participating	VBG	O
in	IN	O
the	DT	O
European	NNP	O
Randomized	NNP	O
Study	NNP	O
of	IN	O
Screening	NNP	O
for	IN	O
Prostate	NNP	O
Cancer	NNP	O
(	(	O
ERSPC	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
and	CC	O
predictive	JJ	O
value	NN	O
of	IN	O
high	JJ	O
grade	NN	O
PIN	NNP	O
and	CC	O
LSPC	NNP	O
for	IN	O
prostate	NN	O
cancer	NN	O
in	IN	O
subsequent	JJ	O
biopsy	NN	O
following	VBG	O
these	DT	O
diagnoses	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Study	NNP	O
group	NN	O
consisted	VBD	O
of	IN	O
56,653	CD	SampleSize
screened	JJ	O
men	NNS	Sex
in	IN	O
the	DT	O
ERSPC	NNP	O
centres	NNS	O
of	IN	O
Finland	NNP	O
,	,	O
Italy	NNP	O
,	,	O
Netherlands	NNP	O
,	,	O
Sweden	NNP	O
and	CC	O
Switzerland	NNP	O
,	,	O
who	WP	O
underwent	VBD	O
3-7	JJ	O
screening	NN	O
rounds	NNS	O
at	IN	O
2-4	JJ	O
year	NN	O
interval	NN	O
.	.	O

Data	NNP	O
for	IN	O
prostate	NN	O
cancer	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
ERSPC	NNP	O
central	JJ	O
database	NN	O
.	.	O

Data	NNP	O
for	IN	O
high	JJ	O
grade	NN	O
PIN	NNP	Condition
and	CC	O
LSPC	NNP	Condition
were	VBD	O
gathered	VBN	O
from	IN	O
each	DT	O
ERSPC	NNP	O
centre	NN	O
.	.	O

Detection	NNP	O
rates	NNS	O
of	IN	O
subsequent	JJ	O
prostate	NN	O
cancer	NN	O
in	IN	O
the	DT	O
first	JJ	O
re-biopsy	NN	O
after	IN	O
these	DT	O
diagnoses	NNS	O
were	VBD	O
determined	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
average	JJ	O
cancer	NN	O
detection	NN	O
rate	NN	O
was	VBD	O
3.5	CD	O
%	NN	O
,	,	O
3.2	CD	O
%	NN	O
and	CC	O
3.5	CD	O
%	NN	O
for	IN	O
the	DT	O
completed	VBN	O
rounds	NNS	O
1	CD	O
,	,	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
all	DT	O
five	CD	O
centres	NNS	O
.	.	O

Incidence	NN	O
of	IN	O
high	JJ	O
grade	NN	O
PIN	NNP	O
increased	VBD	O
from	IN	O
1.5	CD	O
%	NN	O
in	IN	O
the	DT	O
first	JJ	O
round	NN	O
to	TO	O
5.0	CD	O
%	NN	O
in	IN	O
the	DT	O
third	JJ	O
round	NN	O
,	,	O
varying	VBG	O
among	IN	O
centres	NNS	O
in	IN	O
the	DT	O
first	JJ	O
round	NN	O
between	IN	O
0.8	CD	O
%	NN	O
and	CC	O
7.6	CD	O
%	NN	O
.	.	O

The	DT	O
cancer	NN	O
detection	NN	O
rate	NN	O
in	IN	O
the	DT	O
first	JJ	O
re-biopsy	NN	O
after	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
high	JJ	O
grade	NN	O
PIN	NNP	O
was	VBD	O
12.9	CD	O
%	NN	O
.	.	O

Incidence	NN	O
of	IN	O
LSPC	NNP	O
was	VBD	O
2.4	CD	O
%	NN	O
,	,	O
2.7	CD	O
%	NN	O
,	,	O
2.2	CD	O
%	NN	O
and	CC	O
2.6	CD	O
%	NN	O
in	IN	O
the	DT	O
first	JJ	O
,	,	O
second	JJ	O
,	,	O
third	JJ	O
and	CC	O
fourth	JJ	O
round	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
cancer	NN	O
detection	NN	O
rate	NN	O
at	IN	O
the	DT	O
first	JJ	O
re-biopsy	NN	O
after	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
LSPC	NNP	O
was	VBD	O
in	IN	O
average	JJ	O
33.8	CD	O
%	NN	O
.	.	O

CONCLUSIONS	NNP	O
Cancer	NNP	O
detection	NN	O
rate	NN	O
was	VBD	O
stable	JJ	O
during	IN	O
the	DT	O
three	CD	O
screening	VBG	O
rounds	NNS	O
.	.	O

The	DT	O
wide	JJ	O
variation	NN	O
in	IN	O
frequency	NN	O
in	IN	O
particular	JJ	O
of	IN	O
high	JJ	O
grade	NN	O
PIN	NNP	O
among	IN	O
the	DT	O
ERSPC	NNP	O
centres	VBZ	O
suggests	VBZ	O
a	DT	O
considerable	JJ	O
inter-observer	JJ	O
variation	NN	O
.	.	O

The	DT	O
average	JJ	O
comparatively	RB	O
low	JJ	O
detection	NN	O
rate	NN	O
of	IN	O
isolated	JJ	O
high	JJ	O
grade	NN	O
PIN	NNP	O
in	IN	O
the	DT	O
first	JJ	O
screening	NN	O
round	NN	O
may	MD	O
be	VB	O
screening-related	JJ	O
,	,	O
while	IN	O
its	PRP$	O
consistent	JJ	O
increase	NN	O
during	IN	O
three	CD	O
screening	VBG	O
rounds	NNS	O
could	MD	O
be	VB	O
the	DT	O
consequence	NN	O
of	IN	O
a.o	NN	O
.	.	O

previous	JJ	O
screening	NN	O
and	CC	O
ageing	NN	O
of	IN	O
the	DT	O
population	NN	O
.	.	O

The	DT	O
observed	JJ	O
low	JJ	O
risk	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
after	IN	O
isolated	VBN	O
high	JJ	O
grade	NN	O
PIN	NNP	O
in	IN	O
this	DT	O
screening	NN	O
setting	NN	O
is	VBZ	O
in	IN	O
line	NN	O
with	IN	O
the	DT	O
current	JJ	O
recommendation	NN	O
to	TO	O
abstain	VB	O
from	IN	O
early	JJ	O
repeat	NN	O
biopsies	NNS	O
after	IN	O
this	DT	O
diagnosis	NN	O
.	.	O

The	DT	O
association	NN	O
of	IN	O
LSPC	NNP	O
with	IN	O
high	JJ	O
incidence	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
in	IN	O
re-biopsies	NNS	O
confirms	NNS	O
the	DT	O
need	NN	O
for	IN	O
early	JJ	O
repeat	NN	O
biopsies	NNS	O
and	CC	O
follow-up	NN	O
of	IN	O
these	DT	O
men	NNS	O
.	.	O

The	DT	O
low	JJ	O
percentage	NN	O
of	IN	O
LSPC	NNP	O
(	(	O
<	VB	O
3	CD	O
%	NN	O
of	IN	O
biopsies	NNS	O
)	)	O
throughout	IN	O
all	DT	O
rounds	NNS	O
is	VBZ	O
reassuring	VBG	O
as	IN	O
it	PRP	O
limits	VBZ	O
the	DT	O
biopsy	NN	O
burden	NN	O
in	IN	O
a	DT	O
screening	NN	O
setting	NN	O
.	.	O

Beta-carotene	NNP	O
in	IN	O
HIV	NNP	Condition
infection	NN	Condition
.	.	Condition

beta-Carotene	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
have	VB	O
an	DT	O
immunostimulatory	JJ	O
effect	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
beta-carotene	JJ	O
supplementation	NN	O
can	MD	O
increase	VB	O
CD4	NNP	O
counts	NNS	O
in	IN	O
HIV-infected	JJ	Condition
patients	NNS	O
.	.	O

Our	PRP$	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
test	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
beta-carotene	NN	O
in	IN	O
raising	VBG	O
CD4	NNP	O
counts	NNS	O
in	IN	O
HIV-infected	JJ	Condition
patients	NNS	O
.	.	O

Twenty-one	CD	SampleSize
HIV-seropositive	JJ	Condition
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
beta-carotene	NN	O
,	,	O
180	CD	O
mg/day	NN	O
or	CC	O
placebo	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
,	,	O
and	CC	O
then	RB	O
crossed	VBD	O
over	IN	O
to	TO	O
receive	VB	O
the	DT	O
alternative	JJ	O
treatment	NN	O
for	IN	O
the	DT	O
following	JJ	O
4	CD	O
weeks	NNS	O
.	.	O

beta-Carotene	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
total	JJ	O
WBC	NNP	O
count	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
%	NN	O
change	NN	O
in	IN	O
CD4	NNP	O
count	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
%	NN	O
change	NN	O
in	IN	O
CD4/CD8	NNP	O
ratios	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
absolute	JJ	O
CD4	NNP	O
count	NN	O
,	,	O
absolute	JJ	O
CD4/CD8	NNP	O
ratio	NN	O
,	,	O
and	CC	O
total	JJ	O
and	CC	O
B-lymphocytes	NNP	O
all	DT	O
increased	VBN	O
on	IN	O
carotene	NN	O
and	CC	O
fell	VBD	O
during	IN	O
placebo	NN	O
,	,	O
but	CC	O
these	DT	O
differences	NNS	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
.	.	O

No	DT	O
toxicity	NN	O
was	VBD	O
observed	VBN	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

beta-Carotene	JJ	O
appears	VBZ	O
to	TO	O
have	VB	O
an	DT	O
immunostimulatory	JJ	O
effect	NN	O
in	IN	O
HIV-infected	JJ	Condition
patients	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
demonstrate	VB	O
whether	IN	O
beta-carotene	NN	O
has	VBZ	O
a	DT	O
role	NN	O
as	IN	O
adjunct	JJ	O
therapy	NN	O
in	IN	O
treatment	NN	O
of	IN	O
HIV-infected	JJ	Condition
patients	NNS	O
.	.	O

Prospective	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
macrolide	NN	O
antibiotic	JJ	O
dirithromycin	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Helicobacter	NNP	Condition
pylori	NN	Condition
.	.	O

BACKGROUND	NNP	O
Macrolide	NNP	O
antibiotics	NNS	O
are	VBP	O
active	JJ	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	NN	O
against	IN	O
Helicobacter	NNP	Condition
pylori	NN	Condition
.	.	O

We	PRP	O
assessed	VBD	O
a	DT	O
newer	JJR	O
macrolide	NN	O
,	,	O
dirithromycin	NN	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
H.	NNP	O
pylori	FW	O
in	IN	O
two	CD	O
separate	JJ	O
studies	NNS	O
.	.	O

METHODS	NNP	O
Volunteers	NNPS	O
with	IN	O
H.	NNP	O
pylori	FW	O
infection	NN	O
(	(	O
by	IN	O
13C-urea	JJ	O
breath	NN	O
test	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
2-week	JJ	O
treatment	NN	O
regimens	NNS	O
.	.	O

Study	NNP	O
1	CD	O
:	:	O
dirithromycin	NN	O
500	CD	O
mg	NN	O
q.d.s.	NN	O
,	,	O
dirithromycin	VBZ	O
500	CD	O
mg	NN	O
q.d.s	NN	O
.	.	O

plus	CC	O
omeprazole	JJ	O
40	CD	O
mg	JJ	O
q.d.s.	NN	O
,	,	O
or	CC	O
dirithromycin	VB	O
500	CD	O
mg	NN	O
q.d.s	NN	O
.	.	O

plus	CC	O
metronidazole	JJ	O
500	CD	O
mg	NN	O
t.d.s	NN	O
.	.	O

Study	CC	O
2	CD	O
:	:	O
dirithromycin	NN	O
500	CD	O
mg	NN	O
q.d.s	NN	O
.	.	O

plus	CC	O
omeprazole	JJ	O
20	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
dirithromycin	NN	O
1000	CD	O
mg	NN	O
q.d.s	NN	O
.	.	O

plus	CC	O
omeprazole	JJ	O
20	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
or	CC	O
amoxycillin	RB	O
500	CD	O
mg	NN	O
q.d.s	NN	O
.	.	O

plus	CC	O
omepirazole	JJ	O
20	CD	O
mg	NN	O
b.d	NN	O
.	.	O

Four	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
completion	NN	O
of	IN	O
therapy	NN	O
a	DT	O
repeat	NN	O
13C-urea	JJ	O
breath	NN	O
test	NN	O
was	VBD	O
done	VBN	O
to	TO	O
assess	VB	O
for	IN	O
cure	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
patient	NN	O
taking	VBG	O
dirithromycin	JJ	O
alone	RB	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
omeprazole	JJ	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
achieved	VBD	O
cure	NN	O
of	IN	O
their	PRP$	O
infection	NN	O
.	.	O

Eradication	NN	O
of	IN	O
H.	NNP	O
pylori	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
one	CD	O
of	IN	O
seven	CD	O
patients	NNS	O
taking	VBG	O
dirithromycin	JJ	O
plus	CC	O
metronidazole	JJ	O
.	.	O

Five	CD	O
of	IN	O
10	CD	O
patients	NNS	O
taking	VBG	O
omeprazole-amoxycillin	JJ	O
dual	JJ	O
therapy	NN	O
had	VBD	O
their	PRP$	O
H.	NNP	O
pylori	NN	O
infection	NN	O
cured	VBD	O
(	(	O
P	NNP	O
=	VBZ	O
0.0007	CD	O
vs.	NN	O
patients	NNS	O
taking	VBG	O
dirithromycin	JJ	O
plus	CC	O
omeprazole	JJ	O
)	)	O
.	.	O

Eleven	NNP	O
(	(	O
47	CD	O
%	NN	O
)	)	O
of	IN	O
32	CD	O
patients	NNS	O
taking	VBG	O
dirithromycin	JJ	O
alone	RB	O
or	CC	O
combined	VBN	O
with	IN	O
omeprazole	JJ	O
reported	VBD	O
side-effects	NNS	O
,	,	O
but	CC	O
only	RB	O
two	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
stopped	VBD	O
therapy	NN	O
prematurely	RB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
side-effects	NNS	O
.	.	O

CONCLUSION	NNP	O
No	NNP	O
subject	JJ	O
taking	VBG	O
dirithromycin	NN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
omeprazole	NN	O
had	VBD	O
their	PRP$	O
H.	NNP	O
pylori	NN	O
infection	NN	O
cured	VBD	O
.	.	O

Dirithromycin	NNP	O
,	,	O
in	IN	O
the	DT	O
regimen	NNS	O
used	VBN	O
,	,	O
shows	VBZ	O
little	JJ	O
promise	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
H.	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

Relationship	NN	O
between	IN	O
subjective	JJ	O
effects	NNS	O
and	CC	O
drug	NN	O
preferences	NNS	O
:	:	O
ethanol	NN	O
and	CC	O
diazepam	NN	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
subjective	JJ	O
effects	NNS	O
and	CC	O
drug	NN	O
preferences	NNS	O
in	IN	O
normal	JJ	Condition
volunteers	NNS	O
was	VBD	O
explored	VBN	O
in	IN	O
a	DT	O
meta-analysis	NN	O
of	IN	O
several	JJ	O
previously	RB	O
published	VBN	O
studies	NNS	O
.	.	O

Subjective	JJ	O
effects	NNS	O
of	IN	O
,	,	O
and	CC	O
preference	NN	O
for	IN	O
,	,	O
ethanol	NN	O
and	CC	O
diazepam	NN	O
vs.	FW	O
placebo	NN	O
were	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
choice	NN	O
procedure	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
grouped	VBN	O
according	VBG	O
to	TO	O
their	PRP$	O
drug	NN	O
choices	NNS	O
:	:	O
'non-choosers	NNS	O
'	POS	O
never	RB	O
chose	JJ	O
drug	NN	O
,	,	O
whereas	IN	O
'choosers	NNS	O
'	POS	O
always	RB	O
chose	JJ	O
drug	NN	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
compared	VBN	O
on	IN	O
their	PRP$	O
subjective	JJ	O
responses	NNS	O
to	TO	O
drug	NN	O
and	CC	O
on	IN	O
demographic	JJ	O
variables	NNS	O
.	.	O

Ethanol	NNP	O
decreased	VBD	O
Arousal	NNP	O
,	,	O
Elation	NNP	O
,	,	O
Positive	NNP	O
Mood	NNP	O
and	CC	O
Vigor	NNP	O
,	,	O
and	CC	O
increased	VBD	O
Anxiety	NNP	O
,	,	O
Depression	NNP	O
and	CC	O
Fatigue	NNP	O
in	IN	O
the	DT	O
non-choosers	NNS	O
,	,	O
whereas	IN	O
it	PRP	O
increased	VBD	O
Arousal	NNP	O
and	CC	O
Vigor	NNP	O
in	IN	O
the	DT	O
choosers	NNS	O
.	.	O

Ethanol	JJ	O
choosers	NNS	O
were	VBD	O
also	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
males	NNS	Sex
and/or	IN	O
full-time	JJ	O
students	NNS	O
than	IN	O
non-choosers	NNS	O
.	.	O

Diazepam	NNP	O
produced	VBD	O
sedative-like	JJ	O
effects	NNS	O
in	IN	O
both	DT	O
choosers	NNS	O
and	CC	O
non-choosers	NNS	O
,	,	O
but	CC	O
markedly	RB	O
decreased	VBD	O
Anxiety	NNP	O
and	CC	O
increased	VBD	O
Friendliness	NNP	O
in	IN	O
choosers	NNS	O
only	RB	O
.	.	O

Diazepam	NNP	O
choice	NN	O
was	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
more	RBR	O
frequent	JJ	O
recreational	JJ	O
use	NN	O
of	IN	O
marijuana	NN	O
and	CC	O
stimulants	NNS	O
.	.	O

Thus	RB	O
,	,	O
both	DT	O
demographic	JJ	O
variables	NNS	O
and	CC	O
subjective	JJ	O
drug	NN	O
effects	NNS	O
were	VBD	O
related	VBN	O
to	TO	O
drug	NN	O
preference	NN	O
.	.	O

A	DT	O
crossover	NN	O
study	NN	O
of	IN	O
risperidone	NN	O
in	IN	O
children	NNS	O
,	,	O
adolescents	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
mental	JJ	O
retardation	NN	O
.	.	O

Risperidone	NN	O
has	VBZ	O
shown	VBN	O
safety	NN	O
and	CC	O
efficacy	NN	O
for	IN	O
aggressive	JJ	O
and	CC	O
destructive	JJ	O
behaviors	NNS	O
in	IN	O
short-term	JJ	O
studies	NNS	O
.	.	O

This	DT	O
longer-duration	NN	O
study	NN	O
includes	VBZ	O
a	DT	O
broad	JJ	O
sample	NN	O
.	.	O

Forty	NNP	O
subjects	NNS	O
,	,	O
aged	VBN	O
8-56	CD	O
years	NNS	O
(	(	O
mean=22	NN	O
)	)	O
,	,	O
all	DT	O
with	IN	O
mental	JJ	O
retardation	NN	O
and	CC	O
36	CD	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
participated	VBD	O
in	IN	O
this	DT	O
22-week	JJ	O
crossover	NN	O
study	NN	O
,	,	O
with	IN	O
24	CD	O
weeks	NNS	O
of	IN	O
open	JJ	O
maintenance	NN	O
thereafter	RB	O
.	.	O

Of	IN	O
40	CD	O
subjects	NNS	O
,	,	O
23	CD	O
(	(	O
57.5	CD	O
%	NN	O
)	)	O
responded	VBD	O
fully	RB	O
(	(	O
50	CD	O
%	NN	O
decrease	NN	O
in	IN	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community	NNP	O
Irritability	NNP	O
subscale	NNP	O
score	NN	O
)	)	O
,	,	O
while	IN	O
35	CD	O
subjects	NNS	O
(	(	O
87.5	CD	O
%	NN	O
)	)	O
showed	VBD	O
a	DT	O
25	CD	O
%	NN	O
decrease	NN	O
.	.	O

Gender	NNP	O
,	,	O
mood	NN	O
disorder	NN	O
,	,	O
and	CC	O
antiseizure	NN	O
medications	NNS	O
did	VBD	O
not	RB	O
alter	VB	O
response	NN	O
.	.	O

Increased	VBN	O
appetite	NN	O
and	CC	O
weight	JJ	O
gain	NN	O
were	VBD	O
common	JJ	O
.	.	O

Low	JJ	O
dose	JJ	O
risperidone	NN	O
was	VBD	O
effective	JJ	O
for	IN	O
aggressive	JJ	O
behavior	NN	O
in	IN	O
persons	NNS	O
with	IN	O
MR.	NNP	O
More	NNP	O
long-term	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
,	,	O
incorporating	VBG	O
weight	NN	O
control	NN	O
interventions	NNS	O
.	.	O

Response	NNP	O
prediction	NN	O
in	IN	O
metastasised	JJ	O
colorectal	NN	O
cancer	NN	O
using	VBG	O
intratumoural	JJ	O
thymidylate	JJ	O
synthase	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomised	JJ	O
multicentre	NN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Molecular	NNP	O
markers	NNS	O
to	TO	O
predict	VB	O
response	NN	O
to	TO	O
5-fluorouracil	JJ	O
(	(	O
FU	NNP	O
)	)	O
-based	VBD	O
treatment	NN	O
of	IN	O
recurrent	NN	O
or	CC	O
metastasised	VBN	O
colorectal	JJ	O
cancer	NN	O
(	(	O
mCRC	NN	O
)	)	O
are	VBP	O
not	RB	O
established	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
trial	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
value	NN	O
of	IN	O
thymidylate	JJ	O
synthase	NN	O
(	(	O
TS	NNP	O
)	)	O
,	,	O
a	DT	O
key	JJ	O
enzyme	NN	O
of	IN	O
DNA	NNP	O
synthesis	NN	O
and	CC	O
target	NN	O
of	IN	O
5-FU	JJ	O
,	,	O
to	TO	O
predict	VB	O
response	NN	O
to	TO	O
chemotherapy	NN	O
of	IN	O
mCRC	NN	O
.	.	O

METHODS	NNP	O
Tumour	NNP	O
tissue	NN	O
was	VBD	O
obtained	VBN	O
from	IN	O
168	CD	O
patients	NNS	O
with	IN	O
mCRC	NN	O
for	IN	O
relative	JJ	O
thymidylate	NN	O
synthase	NN	O
(	(	O
TS	NNP	O
)	)	O
mRNA	NN	O
quantitation	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
5-FU/folinic	JJ	O
acid	NN	O
(	(	O
FA	NNP	O
,	,	O
FUFA	NNP	O
)	)	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
irinotecan	JJ	O
5-fluorouracil/folinic	JJ	O
acid	NN	O
and	CC	O
irinotecan	JJ	O
(	(	O
FOLFIRI	NNP	O
)	)	O
stratified	VBN	O
by	IN	O
TS	NNP	O
(	(	O
low	JJ	O
versus	RB	O
high	JJ	O
)	)	O
.	.	O

Primary	JJ	O
end-point	NN	O
was	VBD	O
overall	JJ	O
response	NN	O
to	TO	O
first-line	JJ	O
treatment	NN	O
among	IN	O
TS	NNP	O
high	JJ	O
patients	NNS	O
.	.	O

All	DT	O
parties	NNS	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
randomisation	NN	O
centre	NN	O
,	,	O
were	VBD	O
blinded	VBN	O
for	IN	O
TS	NNP	O
status	NN	O
.	.	O

RESULTS	NNP	O
Biopsies	NNP	O
(	(	O
n=168	RB	O
)	)	O
were	VBD	O
taken	VBN	O
without	IN	O
complications	NNS	O
.	.	O

TS	NN	O
levels	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
147	CD	O
patients	NNS	O
(	(	O
87.5	CD	O
%	NN	O
)	)	O
.	.	O

Analysing	VBG	O
response	NN	O
to	TO	O
FUFA	NNP	O
and	CC	O
FOLFIRI	NNP	O
in	IN	O
the	DT	O
per	NN	O
protocol	NN	O
set	VBN	O
(	(	O
n=119	NN	O
)	)	O
after	IN	O
un-blinding	JJ	O
TS	NNP	O
in	IN	O
the	DT	O
data	NN	O
base	NN	O
revealed	VBD	O
a	DT	O
trend	NN	O
to	TO	O
better	JJR	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
(	(	O
9/19	CD	O
,	,	O
47	CD	O
%	NN	O
)	)	O
in	IN	O
TS	NNP	O
high	JJ	O
compared	VBN	O
to	TO	O
FUFA	NNP	O
(	(	O
5/23	CD	O
,	,	O
22	CD	O
%	NN	O
,	,	O
p=0.077	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
biopsies	NNS	O
taken	VBN	O
from	IN	O
liver	JJ	O
lesions	NNS	O
(	(	O
n=91	NN	O
)	)	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
and	CC	O
FUFA	NNP	O
in	IN	O
TS	NNP	O
high	NN	O
was	VBD	O
53	CD	O
%	NN	O
(	(	O
9/17	CD	O
)	)	O
and	CC	O
18	CD	O
%	NN	O
(	(	O
3/17	CD	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
p=0.035	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
low	JJ	O
TS	NNP	O
,	,	O
no	DT	O
remarkable	JJ	O
difference	NN	O
in	IN	O
overall	JJ	O
response	NN	O
to	TO	O
FOLFIRI	NNP	O
and	CC	O
FUFA	NNP	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Taking	VBG	O
a	DT	O
pre-treatment	JJ	O
biopsy	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
feasible	JJ	O
procedure	NN	O
in	IN	O
mCRC	NN	O
.	.	O

After	IN	O
validation	NN	O
of	IN	O
our	PRP$	O
data	NNS	O
in	IN	O
a	DT	O
larger	JJR	O
group	NN	O
TS	NNP	O
determination	NN	O
may	MD	O
have	VB	O
the	DT	O
potential	NN	O
to	TO	O
better	JJR	O
help	NN	O
direct	VB	O
systemic	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
primarily	RB	O
non-resectable	JJ	O
mCRC	NN	O
.	.	O

Effect	NN	O
of	IN	O
two	CD	O
monophasic	JJ	O
oral	JJ	O
contraceptives	NNS	O
containing	VBG	O
gestodene	NN	O
or	CC	O
desogestrel	NN	O
on	IN	O
serum	NN	O
lipoprotein	NN	O
lipid	JJ	O
levels	NNS	O
.	.	O

Forty-nine	NNP	SampleSize
healthy	JJ	O
women	NNS	Sex
aged	VBN	O
20-35	JJ	Age
years	NNS	O
who	WP	O
had	VBD	O
not	RB	O
been	VBN	O
pregnant	JJ	O
or	CC	O
using	VBG	O
an	DT	O
oral	JJ	O
contraceptive	NN	O
(	(	O
OC	NNP	O
)	)	O
for	IN	O
the	DT	O
previous	JJ	O
3	CD	O
months	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
one	CD	O
group	NN	O
taking	VBG	O
an	DT	O
OC	NNP	O
containing	VBG	O
75	CD	O
micrograms	NNS	O
gestodene	NN	O
(	(	O
GTD	NNP	O
)	)	O
and	CC	O
30	CD	O
micrograms	NNS	O
ethinyl	VBP	O
estradiol	NN	O
(	(	O
EE	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
using	VBG	O
an	DT	O
OC	NNP	O
with	IN	O
150	CD	O
micrograms	NNS	O
desogestrel	NN	O
(	(	O
DSG	NNP	O
)	)	O
and	CC	O
30	CD	O
micrograms	NNS	O
EE	NNP	O
.	.	O

Fasting	VBG	O
blood	NN	O
samples	NNS	O
were	VBD	O
taken	VBN	O
before	RB	O
treatment	NN	O
,	,	O
and	CC	O
after	IN	O
cycles	NNS	O
3	CD	O
and	CC	O
6	CD	O
,	,	O
between	IN	O
the	DT	O
18th	CD	O
and	CC	O
the	DT	O
22nd	CD	O
day	NN	O
of	IN	O
the	DT	O
cycle	NN	O
.	.	O

Blood	NNP	O
lipoprotein	JJ	O
lipid	JJ	O
levels	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Serum	NNP	O
total	JJ	O
cholesterol	NN	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
first	JJ	O
three	CD	O
cycles	NNS	O
,	,	O
serum	JJ	O
triglyceride	NN	O
increased	VBN	O
by	IN	O
46	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
and	CC	O
HDL-cholesterol	NNP	O
by	IN	O
14	CD	O
%	NN	O
and	CC	O
8	CD	O
%	NN	O
in	IN	O
the	DT	O
GTD	NNP	O
and	CC	O
DSG	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
serum	NN	O
LDL	NNP	O
level	NN	O
decreased	VBN	O
by	IN	O
6.2	CD	O
%	NN	O
and	CC	O
11.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Between	VB	O
the	DT	O
third	JJ	O
and	CC	O
sixth	JJ	O
cycle	NN	O
,	,	O
no	DT	O
further	JJ	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
,	,	O
nor	CC	O
did	VBD	O
these	DT	O
changes	NNS	O
differ	VBP	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
both	DT	O
OC	NNP	O
preparations	NNS	O
exerted	VBD	O
small	JJ	O
and	CC	O
probably	RB	O
favorable	JJ	O
effects	NNS	O
on	IN	O
serum	NN	O
lipoprotein	NN	O
lipid	JJ	O
levels	NNS	O
.	.	O

Differences	NNS	O
in	IN	O
reach	NN	O
and	CC	O
attrition	NN	O
between	IN	O
Web-based	JJ	O
and	CC	O
print-delivered	JJ	O
tailored	JJ	O
interventions	NNS	O
among	IN	O
adults	NNS	Age
over	IN	Age
50	CD	Age
years	NNS	Age
of	IN	Age
age	NN	Age
:	:	O
clustered	VBN	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
Internet	NNP	O
has	VBZ	O
the	DT	O
potential	JJ	O
to	TO	O
provide	VB	O
large	JJ	O
populations	NNS	O
with	IN	O
individual	JJ	O
health	NN	O
promotion	NN	O
advice	NN	O
at	IN	O
a	DT	O
relatively	RB	O
low	JJ	O
cost	NN	O
.	.	O

Despite	IN	O
the	DT	O
high	JJ	O
rates	NNS	O
of	IN	O
Internet	NNP	O
access	NN	O
,	,	O
actual	JJ	O
reach	NN	O
by	IN	O
Web-based	JJ	O
interventions	NNS	O
is	VBZ	O
often	RB	O
disappointingly	RB	O
low	JJ	O
,	,	O
and	CC	O
differences	NNS	O
in	IN	O
use	NN	O
between	IN	O
demographic	JJ	O
subgroups	NNS	O
are	VBP	O
present	JJ	O
.	.	O

Furthermore	RB	O
,	,	O
Web-based	JJ	O
interventions	NNS	O
often	RB	O
have	VBP	O
to	TO	O
deal	VB	O
with	IN	O
high	JJ	O
rates	NNS	O
of	IN	O
attrition	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
assess	VB	O
user	JJ	O
characteristics	NNS	O
related	VBN	O
to	TO	O
participation	NN	O
and	CC	O
attrition	NN	O
when	WRB	O
comparing	VBG	O
Web-based	JJ	O
and	CC	O
print-delivered	JJ	O
tailored	JJ	O
interventions	NNS	O
containing	VBG	O
similar	JJ	O
content	NN	O
and	CC	O
thereby	RB	O
to	TO	O
provide	VB	O
recommendations	NNS	O
in	IN	O
choosing	VBG	O
the	DT	O
appropriate	JJ	O
delivery	NN	O
mode	NN	O
for	IN	O
a	DT	O
particular	JJ	O
target	NN	O
audience	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
studied	VBD	O
the	DT	O
distribution	NN	O
of	IN	O
a	DT	O
Web-based	JJ	O
and	CC	O
a	DT	O
print-delivered	JJ	O
version	NN	O
of	IN	O
the	DT	O
Active	NNP	O
Plus	NNP	O
intervention	NN	O
in	IN	O
a	DT	O
clustered	JJ	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
recruited	VBN	O
via	IN	O
direct	JJ	O
mailing	NN	O
within	IN	O
the	DT	O
participating	VBG	O
Municipal	NNP	O
Health	NNP	O
Council	NNP	O
regions	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
the	DT	O
printed	VBN	O
or	CC	O
Web-based	VBN	O
intervention	NN	O
by	IN	O
their	PRP$	O
region	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
answers	NNS	O
given	VBN	O
in	IN	O
a	DT	O
prior	JJ	O
assessment	NN	O
,	,	O
participants	NNS	O
received	VBD	O
tailored	JJ	O
advice	NN	O
on	IN	O
3	CD	O
occasions	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
within	IN	O
2	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
baseline	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
2	CD	O
months	NNS	O
after	IN	O
the	DT	O
baseline	NN	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
within	IN	O
4	CD	O
months	NNS	O
after	IN	O
the	DT	O
baseline	NN	O
(	(	O
based	VBN	O
on	IN	O
a	DT	O
second	JJ	O
assessment	NN	O
at	IN	O
3	CD	O
months	NNS	O
)	)	O
.	.	O

The	DT	O
baseline	NN	O
(	(	O
printed	VBN	O
or	CC	O
Web-based	VBN	O
)	)	O
results	NNS	O
were	VBD	O
analyzed	JJ	O
using	VBG	O
ANOVA	NNP	O
and	CC	O
chi-square	JJ	O
tests	NNS	O
to	TO	O
establish	VB	O
the	DT	O
differences	NNS	O
in	IN	O
user	JJ	O
characteristics	NNS	O
between	IN	O
both	DT	O
intervention	NN	O
groups	NNS	O
.	.	O

We	PRP	O
used	VBD	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
to	TO	O
study	VB	O
the	DT	O
interaction	NN	O
between	IN	O
the	DT	O
user	NN	O
characteristics	NNS	O
and	CC	O
the	DT	O
delivery	NN	O
mode	NN	O
in	IN	O
the	DT	O
prediction	NN	O
of	IN	O
dropout	NN	O
rate	NN	O
within	IN	O
the	DT	O
intervention	NN	O
period	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
printed	JJ	O
intervention	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
higher	JJR	O
participation	NN	O
rate	NN	O
(	(	O
19	CD	O
%	NN	O
)	)	O
than	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
(	(	O
12	CD	O
%	NN	O
)	)	O
.	.	O

Participants	NNS	O
of	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
were	VBD	O
significantly	RB	O
younger	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
more	RBR	O
often	RB	O
men	NNS	O
(	(	O
P=.01	NNP	O
)	)	O
,	,	O
had	VBD	O
a	DT	O
higher	JJR	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
a	DT	O
lower	JJR	O
intention	NN	O
to	TO	O
be	VB	O
physically	RB	O
active	JJ	O
(	(	O
P=.03	NNP	O
)	)	O
than	IN	O
participants	NNS	O
of	IN	O
the	DT	O
printed	VBN	O
intervention	NN	O
.	.	O

The	DT	O
dropout	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
group	NN	O
(	(	O
53	CD	O
%	NN	O
)	)	O
compared	VBN	O
to	TO	O
the	DT	O
print-delivered	JJ	O
intervention	NN	O
(	(	O
39	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

A	DT	O
low	JJ	O
intention	NN	O
to	TO	O
be	VB	O
physically	RB	O
active	JJ	O
was	VBD	O
a	DT	O
strong	JJ	O
predictor	NN	O
for	IN	O
dropout	NN	O
within	IN	O
both	DT	O
delivery	NN	O
modes	FW	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
difference	NN	O
in	IN	O
dropout	NN	O
rate	NN	O
between	IN	O
the	DT	O
Web-based	JJ	O
and	CC	O
the	DT	O
printed	JJ	O
intervention	NN	O
was	VBD	O
not	RB	O
explained	VBN	O
by	IN	O
user	JJ	O
characteristics	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
reach	NN	O
of	IN	O
the	DT	O
same	JJ	O
tailored	JJ	O
physical	JJ	O
activity	NN	O
(	(	O
PA	NNP	O
)	)	O
intervention	NN	O
in	IN	O
a	DT	O
printed	JJ	O
or	CC	O
Web-based	JJ	O
delivery	NN	O
mode	NN	O
differed	VBD	O
between	IN	O
sociodemographic	JJ	O
subgroups	NNS	O
of	IN	O
participants	NNS	O
over	IN	O
50	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

Although	IN	O
the	DT	O
reach	NN	O
of	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
is	VBZ	O
lower	JJR	O
,	,	O
Web-based	JJ	O
interventions	NNS	O
can	MD	O
be	VB	O
a	DT	O
good	JJ	O
channel	NN	O
to	TO	O
reach	VB	O
high-risk	JJ	O
populations	NNS	O
(	(	O
lower	JJR	O
PA	NNP	O
intention	NN	O
and	CC	O
higher	JJR	O
BMI	NNP	O
)	)	O
.	.	O

While	IN	O
the	DT	O
dropout	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
group	NN	O
,	,	O
no	DT	O
specific	JJ	O
user	NN	O
characteristics	NNS	O
explained	VBD	O
the	DT	O
difference	NN	O
in	IN	O
dropout	NN	O
rates	NNS	O
between	IN	O
the	DT	O
delivery	NN	O
modes	NN	O
.	.	O

More	JJR	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
determine	VB	O
what	WP	O
caused	VBD	O
the	DT	O
high	JJ	O
rate	NN	O
of	IN	O
dropout	NN	O
in	IN	O
the	DT	O
Web-based	JJ	O
intervention	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Dutch	NNP	O
Trial	NNP	O
Register	NNP	O
(	(	O
NTR	NNP	O
)	)	O
:	:	O
2297	CD	O
:	:	O
http	NN	O
:	:	O
//www.trialregister.nl/trialreg/admin/rctview.asp	NN	O
?	.	O
TC=2297	NNP	O
(	(	O
Archived	VBN	O
by	IN	O
WebCite	NNP	O
at	IN	O
http	NN	O
:	:	O
//www.webcitation.org/65TkwoESp	NN	O
)	)	O
.	.	O

A	DT	O
web-based	JJ	O
approach	NN	O
to	TO	O
address	VB	O
cardiovascular	JJ	Condition
risks	NNS	Condition
in	IN	O
managers	NNS	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
examine	VB	O
whether	IN	O
a	DT	O
Web-based	JJ	O
health	NN	O
and	CC	O
leadership	NN	O
development	NN	O
program	NN	O
--	:	O
designed	VBN	O
specifically	RB	O
for	IN	O
managers	NNS	O
--	:	O
was	VBD	O
associated	VBN	O
with	IN	O
changes	NNS	O
in	IN	O
self-reported	JJ	O
and	CC	O
biometric	JJ	O
indicators	NNS	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
within	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
randomized	VBN	O
control	NN	O
trial	NN	O
.	.	O

METHODS	VB	O
A	DT	O
total	NN	O
of	IN	O
145	CD	SampleSize
managers	NNS	O
from	IN	O
8	CD	O
organizations	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
6-month	JJ	O
Internet-based	JJ	O
program	NN	O
or	CC	O
a	DT	O
control	JJ	O
condition	NN	O
.	.	O

They	PRP	O
completed	VBD	O
pre-	NN	O
and	CC	O
posttest	NN	O
assessments	NNS	O
that	WDT	O
included	VBD	O
both	DT	O
self-reported	JJ	O
attitudes	NNS	O
(	(	O
on	IN	O
diet	NN	O
,	,	O
exercise	NN	O
,	,	O
and	CC	O
mental	JJ	O
health	NN	O
)	)	O
and	CC	O
biometric	JJ	O
measures	NNS	O
(	(	O
eg	NN	O
,	,	O
body	NN	O
weight	NN	O
,	,	O
waist	JJ	O
circumference	NN	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
intervention	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
improvements	NNS	O
in	IN	O
dietary	JJ	O
attitudes	NNS	O
,	,	O
dietary	JJ	O
self-efficacy	NN	O
,	,	O
and	CC	O
exercise	NN	O
,	,	O
and	CC	O
reductions	NNS	O
in	IN	O
distress	NN	O
symptoms	NNS	O
.	.	O

Women	NNS	O
in	IN	O
the	DT	O
program	NN	O
reduced	VBD	O
their	PRP$	O
waist	NN	O
circumference	NN	O
significantly	RB	O
more	RBR	O
than	IN	O
controls	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
program	NN	O
showed	VBD	O
promise	NN	O
for	IN	O
reducing	VBG	O
cardiovascular	JJ	O
disease	NN	O
risk	NN	O
factors	NNS	O
.	.	O

Similar	JJ	O
results	NNS	O
across	IN	O
diverse	JJ	O
organizations	NNS	O
suggest	VBP	O
the	DT	O
program	NN	O
may	MD	O
be	VB	O
useful	JJ	O
across	IN	O
industry	NN	O
types	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
fluoxetine	NN	O
and	CC	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
obesity	NN	Condition
.	.	Condition

Our	PRP$	O
study	NN	O
aims	VBZ	O
at	IN	O
assessing	VBG	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
fluoxetine	NN	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
obesity	NN	O
using	VBG	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
design	NN	O
.	.	O

We	PRP	O
studied	VBD	O
42	CD	SampleSize
obese	JJ	O
women	NNS	O
(	(	O
body	NN	O
mass	NN	O
index	NN	O
35.9	CD	O
+/-	JJ	O
5.3	CD	O
kg/m2	NN	O
)	)	O
.	.	O

The	DT	O
obese	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
start	VB	O
treatment	NN	O
with	IN	O
fluoxetine	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
for	IN	O
3	CD	O
months	NNS	O
(	(	O
period	NN	O
1	CD	O
)	)	O
.	.	O

After	IN	O
a	DT	O
1-month	JJ	O
washout	NN	O
period	NN	O
,	,	O
treatment	NN	O
was	VBD	O
crossed	VBN	O
for	IN	O
the	DT	O
following	JJ	O
3	CD	O
months	NNS	O
(	(	O
period	NN	O
2	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
weight	JJ	O
loss	NN	O
when	WRB	O
the	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
fluoxetine	NN	O
(	(	O
group	NN	O
A	NNP	O
period	NN	O
1	CD	O
and	CC	O
group	NN	O
B	NNP	O
period	NN	O
2	CD	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
placebo	NN	O
(	(	O
group	NN	O
B	NNP	O
period	NN	O
1	CD	O
and	CC	O
group	NN	O
A	NNP	O
period	NN	O
2	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
monthly	JJ	O
weight	NN	O
reduction	NN	O
during	IN	O
both	DT	O
treatments	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
we	PRP	O
demonstrated	VBD	O
that	IN	O
serotoninergic	JJ	O
drugs	NNS	O
such	JJ	O
as	IN	O
fluoxetine	JJ	O
need	VBP	O
further	JJ	O
investigation	NN	O
before	IN	O
being	VBG	O
used	VBN	O
indiscriminately	RB	O
in	IN	O
obese	JJ	O
subjects	NNS	O
.	.	O

Motion	NN	O
aftereffects	NNS	O
with	IN	O
horizontally	RB	O
moving	VBG	O
sound	NN	O
sources	NNS	O
in	IN	O
the	DT	O
free	JJ	O
field	NN	O
.	.	O

A	DT	O
horizontally	RB	O
moving	VBG	O
sound	NN	O
was	VBD	O
presented	VBN	O
to	TO	O
an	DT	O
observer	NN	O
seated	VBN	O
in	IN	O
the	DT	O
center	NN	O
of	IN	O
an	DT	O
anechoic	JJ	O
chamber	NN	O
.	.	O

The	DT	O
sound	NN	O
,	,	O
either	CC	O
a	DT	O
500-Hz	JJ	O
low-pass	JJ	O
noise	NN	O
or	CC	O
a	DT	O
6300-Hz	JJ	O
high-pass	NN	O
noise	NN	O
,	,	O
repeatedly	RB	O
traversed	VBD	O
a	DT	O
semicircular	JJ	O
arc	NN	O
in	IN	O
the	DT	O
observer	NN	O
's	POS	O
front	JJ	O
hemifield	NN	O
at	IN	O
ear	JJ	O
level	NN	O
(	(	O
distance	NN	O
:	:	O
1.5	CD	O
m	NN	O
)	)	O
.	.	O

At	IN	O
10-sec	JJ	O
intervals	NNS	O
this	DT	O
adaptor	NN	O
was	VBD	O
interrupted	VBN	O
,	,	O
and	CC	O
a	DT	O
750-msec	JJ	O
moving	NN	O
probe	NN	O
(	(	O
a	DT	O
500-Hz	JJ	O
low-pass	JJ	O
noise	NN	O
)	)	O
was	VBD	O
presented	VBN	O
from	IN	O
a	DT	O
horizontal	JJ	O
arc	NN	O
1.6	CD	O
m	NN	O
in	IN	O
front	NN	O
of	IN	O
the	DT	O
observer	NN	O
.	.	O

During	IN	O
a	DT	O
run	NN	O
,	,	O
the	DT	O
adaptor	NN	O
was	VBD	O
presented	VBN	O
at	IN	O
a	DT	O
constant	JJ	O
velocity	NN	O
(	(	O
-200	JJ	O
degrees	NNS	O
to	TO	O
+200	VB	O
degrees/sec	NN	O
)	)	O
,	,	O
while	IN	O
probes	NNS	O
with	IN	O
velocities	NNS	O
varying	VBG	O
from	IN	O
-10	JJ	O
degrees	NNS	O
to	TO	O
+10	VB	O
degrees/sec	NN	O
were	VBD	O
presented	VBN	O
in	IN	O
a	DT	O
random	JJ	O
order	NN	O
.	.	O

Observers	NNS	O
judged	VBD	O
the	DT	O
direction	NN	O
of	IN	O
motion	NN	O
(	(	O
left	VBD	O
or	CC	O
right	JJ	O
)	)	O
of	IN	O
each	DT	O
probe	NN	O
.	.	O

As	IN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
stimuli	NNS	O
presented	VBN	O
over	IN	O
headphones	NNS	O
(	(	O
Grantham	NNP	O
&	CC	O
Wightman	NNP	O
,	,	O
1979	CD	O
)	)	O
,	,	O
an	DT	O
auditory	JJ	O
motion	NN	O
aftereffect	NN	O
(	(	O
MAE	NNP	O
)	)	O
occurred	VBD	O
:	:	O
subjects	NNS	O
responded	VBD	O
left	VBN	O
to	TO	O
probes	VB	O
more	RBR	O
often	RB	O
when	WRB	O
the	DT	O
adaptor	NN	O
moved	VBD	O
right	RB	O
than	IN	O
when	WRB	O
it	PRP	O
moved	VBD	O
left	RB	O
.	.	O

When	WRB	O
the	DT	O
adaptor	NN	O
and	CC	O
probe	NN	O
were	VBD	O
spectrally	RB	O
the	DT	O
same	JJ	O
,	,	O
the	DT	O
MAE	NNP	O
was	VBD	O
greater	JJR	O
than	IN	O
when	WRB	O
they	PRP	O
were	VBD	O
from	IN	O
different	JJ	O
spectral	JJ	O
regions	NNS	O
;	:	O
the	DT	O
magnitude	NN	O
of	IN	O
this	DT	O
difference	NN	O
depended	VBD	O
on	IN	O
adaptor	NN	O
speed	NN	O
and	CC	O
was	VBD	O
subject-dependent	NN	O
.	.	O

It	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
there	EX	O
are	VBP	O
two	CD	O
components	NNS	O
underlying	VBG	O
the	DT	O
auditory	JJ	O
MAE	NNP	O
:	:	O
(	(	O
1	CD	O
)	)	O
a	DT	O
generalized	JJ	O
bias	NN	O
to	TO	O
respond	VB	O
that	DT	O
probes	NNS	O
move	VBP	O
in	IN	O
the	DT	O
direction	NN	O
opposite	NN	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
adaptor	NN	O
,	,	O
independent	JJ	O
of	IN	O
their	PRP$	O
spectra	NN	O
;	:	O
and	CC	O
(	(	O
2	CD	O
)	)	O
a	DT	O
loss	NN	O
of	IN	O
sensitivity	NN	O
to	TO	O
the	DT	O
velocity	NN	O
of	IN	O
moving	VBG	O
sounds	NNS	O
after	IN	O
prolonged	JJ	O
exposure	NN	O
to	TO	O
moving	VBG	O
sounds	NNS	O
having	VBG	O
the	DT	O
same	JJ	O
spectral	JJ	O
content	NN	O
.	.	O

Effects	NNS	O
of	IN	O
two	CD	O
combined	JJ	O
oral	JJ	O
contraceptives	NNS	O
containing	VBG	O
ethinyl	NN	O
estradiol	$	O
20	CD	O
microg	NN	O
combined	VBN	O
with	IN	O
either	DT	O
drospirenone	NN	O
or	CC	O
desogestrel	NN	O
on	IN	O
lipids	NNS	O
,	,	O
hemostatic	JJ	O
parameters	NNS	O
and	CC	O
carbohydrate	JJ	O
metabolism	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
ethinyl	NN	O
estradiol	NN	O
20	CD	O
microg/drospirenone	NN	O
3	CD	O
mg	NN	O
(	(	O
EE	NNP	O
20	CD	O
microg/DRSP	NN	O
3	CD	O
mg	NN	O
)	)	O
administered	VBD	O
according	VBG	O
to	TO	O
a	DT	O
24/4	JJ	O
regimen	NN	O
with	IN	O
ethinyl	JJ	O
estradiol	NN	O
20	CD	O
microg/desogestrel	NN	O
150	CD	O
microg	NN	O
(	(	O
EE	NNP	O
20	CD	O
microg/DSG	NN	O
150	CD	O
microg	NN	O
)	)	O
administered	VBD	O
according	VBG	O
to	TO	O
the	DT	O
conventional	JJ	O
21/7	CD	O
regimen	NNS	O
on	IN	O
lipid	JJ	O
,	,	O
carbohydrate	NN	O
and	CC	O
hemostatic	JJ	O
parameters	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
In	IN	O
this	DT	O
open-label	JJ	O
study	NN	O
,	,	O
healthy	JJ	O
women	NNS	Sex
were	VBD	O
randomized	VBN	O
to	TO	O
EE	VB	O
20	CD	O
microg/DRSP	NN	O
3	CD	O
mg	NN	O
or	CC	O
EE	NNP	O
20	CD	O
microg/DSG	NN	O
150	CD	O
microg	NN	O
for	IN	O
seven	CD	O
cycles	NNS	O
.	.	O

Mean	JJ	O
differences	NNS	O
in	IN	O
high-density	NN	O
lipoprotein	NN	O
(	(	O
HDL	NNP	O
)	)	O
-	:	O
and	CC	O
low-density	JJ	O
lipoprotein	NN	O
(	(	O
LDL	NNP	O
)	)	O
-cholesterol	NN	O
levels	NNS	O
at	IN	O
cycle	NN	O
7	CD	O
compared	VBN	O
to	TO	O
baseline	VB	O
were	VBD	O
assessed	VBN	O
.	.	O

Secondary	JJ	O
variables	NNS	O
included	VBD	O
changes	NNS	O
in	IN	O
other	JJ	O
lipid	JJ	O
,	,	O
hemostatic	JJ	O
and	CC	O
carbohydrate	JJ	O
parameters	NNS	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
treatments	NNS	O
increased	VBD	O
HDL-cholesterol	NNP	O
,	,	O
but	CC	O
decreased	VBD	O
LDL-cholesterol	NNP	O
by	IN	O
a	DT	O
comparable	JJ	O
extent	NN	O
.	.	O

Although	IN	O
slightly	RB	O
elevated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
blood	NN	O
glucose	NN	O
and	CC	O
C-peptide	JJ	O
levels	NNS	O
measured	VBN	O
during	IN	O
oral	JJ	O
glucose	JJ	O
tolerance	NN	O
tests	NNS	O
were	VBD	O
within	IN	O
normal	JJ	O
reference	NN	O
ranges	VBZ	O
at	IN	O
cycle	NN	O
7	CD	O
.	.	O

Overall	JJ	O
,	,	O
the	DT	O
differences	NNS	O
in	IN	O
lipid	JJ	O
,	,	O
hemostatic	JJ	O
or	CC	O
carbohydrate	JJ	O
parameters	NNS	O
were	VBD	O
not	RB	O
significant	JJ	O
between	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
.	.	O

CONCLUSION	NNP	O
EE	NNP	O
20	CD	O
microg/DRSP	NN	O
3	CD	O
mg	NN	O
has	VBZ	O
a	DT	O
good	JJ	O
safety	NN	O
profile	NN	O
comparable	JJ	O
with	IN	O
EE	NNP	O
20	CD	O
microg/DSG	NN	O
150	CD	O
microg	NN	O
.	.	O

VLDL	NNP	O
,	,	O
apolipoproteins	VBZ	O
B	NNP	O
,	,	O
CIII	NNP	O
,	,	O
and	CC	O
E	NNP	O
,	,	O
and	CC	O
risk	NN	O
of	IN	O
recurrent	JJ	O
coronary	JJ	O
events	NNS	O
in	IN	O
the	DT	O
Cholesterol	NNP	O
and	CC	O
Recurrent	NNP	O
Events	NNP	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Plasma	NNP	O
triglyceride	NN	O
concentration	NN	O
has	VBZ	O
been	VBN	O
an	DT	O
inconsistent	JJ	O
independent	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
,	,	O
perhaps	RB	O
because	IN	O
of	IN	O
the	DT	O
metabolic	JJ	O
heterogeneity	NN	O
among	IN	O
VLDL	NNP	O
particles	NNS	O
,	,	O
the	DT	O
main	JJ	O
carriers	NNS	O
of	IN	O
triglycerides	NNS	O
in	IN	O
plasma	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
nested	JJ	O
case-control	NN	O
study	NN	O
in	IN	O
the	DT	O
Cholesterol	NNP	O
and	CC	O
Recurrent	NNP	O
Events	NNP	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
,	,	O
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
pravastatin	NN	O
in	IN	O
4159	CD	SampleSize
patients	NNS	O
with	IN	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
average	JJ	O
LDL	NNP	O
concentrations	NNS	O
at	IN	O
baseline	NN	O
(	(	O
115	CD	O
to	TO	O
174	CD	O
mg/dL	NNS	O
,	,	O
mean	VBP	O
139	CD	O
mg/dL	NN	O
)	)	O
.	.	O

Baseline	NNP	O
concentrations	NNS	O
of	IN	O
VLDL-apolipoprotein	NNP	O
(	(	O
apo	NN	O
)	)	O
B	NNP	O
(	(	O
the	DT	O
VLDL	NNP	O
particle	NN	O
concentration	NN	O
)	)	O
,	,	O
VLDL	NNP	O
lipids	NNS	O
,	,	O
and	CC	O
apoCIII	NN	O
and	CC	O
apoE	NN	O
in	IN	O
VLDL+LDL	NNP	O
and	CC	O
in	IN	O
HDL	NNP	O
were	VBD	O
compared	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
either	CC	O
a	DT	O
myocardial	JJ	Condition
infarction	NN	Condition
or	CC	O
coronary	JJ	Condition
death	NN	Condition
(	(	O
cases	NNS	O
,	,	O
n=418	NN	SampleSize
)	)	O
with	IN	O
those	DT	O
in	IN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
cardiovascular	JJ	O
event	NN	O
(	(	O
control	NN	O
subjects	VBZ	O
,	,	O
n=370	NN	SampleSize
)	)	O
in	IN	O
5	CD	O
years	NNS	O
of	IN	O
follow-up	JJ	O
.	.	O

VLDL-cholesterol	NN	O
,	,	O
VLDL-triglyceride	NNP	O
,	,	O
VLDL-apoB	NNP	O
,	,	O
apoCIII	NN	O
and	CC	O
apoE	NN	O
in	IN	O
VLDL+LDL	NNP	O
and	CC	O
apoE	NN	O
in	IN	O
HDL	NNP	O
were	VBD	O
all	DT	O
interrelated	VBN	O
,	,	O
and	CC	O
each	DT	O
was	VBD	O
a	DT	O
univariate	JJ	O
predictor	NN	O
of	IN	O
subsequent	JJ	O
coronary	JJ	O
events	NNS	O
.	.	O

The	DT	O
significant	JJ	O
independent	JJ	O
predictors	NNS	O
were	VBD	O
VLDL-apoB	NNP	O
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	VBZ	O
3.2	CD	O
for	IN	O
highest	JJS	O
to	TO	O
lowest	JJS	O
quintiles	NNS	O
,	,	O
P	NNP	O
:	:	O
=0.04	NN	O
)	)	O
,	,	O
apoCIII	RB	O
in	IN	O
VLDL+LDL	NNP	O
(	(	O
RR	NNP	O
2.3	CD	O
,	,	O
P	NNP	O
:	:	O
=0.04	NN	O
)	)	O
,	,	O
and	CC	O
apoE	NN	O
in	IN	O
HDL	NNP	O
(	(	O
RR	NNP	O
1.8	CD	O
,	,	O
P	NNP	O
:	:	O
=0.02	NN	O
)	)	O
.	.	O

Plasma	NNP	O
triglycerides	NNS	O
,	,	O
a	DT	O
univariate	JJ	O
predictor	NN	O
of	IN	O
coronary	JJ	O
events	NNS	O
(	(	O
RR	NNP	O
1.6	CD	O
,	,	O
P	NNP	O
:	:	O
=0.03	NN	O
)	)	O
,	,	O
was	VBD	O
not	RB	O
related	VBN	O
to	TO	O
coronary	JJ	O
events	NNS	O
(	(	O
RR	NNP	O
1.3	CD	O
,	,	O
P	NNP	O
:	:	O
=0.6	NN	O
)	)	O
when	WRB	O
apoCIII	NN	O
in	IN	O
VLDL+LDL	NNP	O
was	VBD	O
included	VBN	O
in	IN	O
the	DT	O
model	NN	O
,	,	O
whereas	JJ	O
apoCIII	NN	O
remained	VBD	O
significant	JJ	O
.	.	O

Adjustment	NN	O
for	IN	O
LDL-	NNP	O
and	CC	O
HDL-cholesterol	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
these	DT	O
results	NNS	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
VLDL	NNP	O
particles	NNS	O
and	CC	O
apoCIII	NN	O
in	IN	O
VLDL	NNP	O
and	CC	O
LDL	NNP	O
are	VBP	O
more	RBR	O
specific	JJ	O
measures	NNS	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
risk	NN	O
than	IN	O
plasma	JJ	O
triglycerides	NNS	O
perhaps	RB	O
because	IN	O
their	PRP$	O
known	VBN	O
metabolic	NN	O
properties	NNS	O
link	VBP	O
them	PRP	O
more	RBR	O
closely	RB	O
to	TO	O
atherosclerosis	NN	O
.	.	O

Randomized	NNP	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
systemic	JJ	O
interferon	NN	O
with	IN	O
diathermocoagulation	NN	O
in	IN	O
primary	JJ	O
multiple	NNS	O
and	CC	O
widespread	JJ	O
anogenital	JJ	O
condyloma	NN	O
.	.	O

Two	CD	O
hundred	VBD	O
three	CD	O
patients	NNS	O
(	(	O
median	JJ	O
age	NN	O
26	CD	O
years	NNS	O
;	:	O
range	VB	O
18-45	JJ	O
)	)	O
with	IN	O
untreated	JJ	O
multiple	NNS	O
and	CC	O
widespread	JJ	O
anogenital	JJ	O
condyloma	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
study	NN	O
arms	NNS	O
in	IN	O
order	NN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
,	,	O
toxicity	NN	O
,	,	O
and	CC	O
tolerability	NN	O
of	IN	O
recombinant	JJ	O
interferon	NN	O
alpha-2b	NN	O
with	IN	O
those	DT	O
of	IN	O
diathermocoagulation	NN	O
.	.	O

Of	IN	O
200	CD	O
evaluable	JJ	O
patients	NNS	O
,	,	O
51	CD	O
were	VBD	O
treated	VBN	O
intramuscularly	RB	O
(	(	O
IM	NNP	O
)	)	O
with	IN	O
3	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
U	NNP	O
(	(	O
3	CD	O
MU	NNP	O
)	)	O
/m2	VBP	O
daily	JJ	O
for	IN	O
3	CD	O
weeks	NNS	O
(	(	O
total	JJ	O
dose	RB	O
63	CD	O
MU/m2	NNP	O
)	)	O
,	,	O
50	CD	O
received	VBD	O
subcutaneous	JJ	O
thrice-weekly	JJ	O
injections	NNS	O
of	IN	O
3	CD	O
MU/m2	NNP	O
for	IN	O
4	CD	O
weeks	NNS	O
(	(	O
total	JJ	O
dose	RB	O
36	CD	O
MU/m2	NNP	O
)	)	O
,	,	O
51	CD	O
underwent	JJ	O
diathermocoagulation	NN	O
,	,	O
and	CC	O
48	CD	O
were	VBD	O
not	RB	O
treated	VBN	O
and	CC	O
were	VBD	O
used	VBN	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Six	NNP	O
months	NNS	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
(	(	O
complete	JJ	O
and	CC	O
partial	JJ	O
responses	NNS	O
)	)	O
was	VBD	O
70	CD	O
%	NN	O
:	:	O
57	CD	O
and	CC	O
82	CD	O
%	NN	O
for	IN	O
patients	NNS	O
receiving	VBG	O
interferon	JJ	O
alpha-2b	NN	O
(	(	O
IM	NNP	O
and	CC	O
subcutaneously	RB	O
)	)	O
and	CC	O
diathermocoagulation	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
8	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
from	IN	O
therapy	NN	O
,	,	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
complete	JJ	O
response	NN	O
were	VBD	O
found	VBN	O
among	IN	O
the	DT	O
different	JJ	O
types	NNS	O
of	IN	O
treatment	NN	O
:	:	O
20	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
35	CD	O
%	NN	O
for	IN	O
the	DT	O
two	CD	O
interferon	NN	O
groups	NNS	O
and	CC	O
the	DT	O
diathermocoagulation	NN	O
group	NN	O
,	,	O
respectively	RB	O
.	.	O

Fifteen	NNP	O
and	CC	O
two	CD	O
complete	JJ	O
responders	NNS	O
in	IN	O
the	DT	O
cauterization	NN	O
and	CC	O
interferon	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
,	,	O
experienced	VBD	O
disease	NN	O
recurrence	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
.01	NN	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
given	VBN	O
interferon	JJ	O
therapy	NN	O
complained	VBD	O
of	IN	O
flu-like	NN	O
symptoms	NNS	O
,	,	O
which	WDT	O
declined	VBD	O
progressively	RB	O
after	IN	O
the	DT	O
first	JJ	O
week	NN	O
of	IN	O
treatment	NN	O
.	.	O

Fatigue	NNP	O
,	,	O
lasting	VBG	O
as	RB	O
long	RB	O
as	IN	O
patients	NNS	O
received	VBD	O
interferon	NN	O
,	,	O
was	VBD	O
the	DT	O
most	RBS	O
prevalent	JJ	O
chronic	JJ	O
side	NN	O
effect	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
systemic	JJ	O
recombinant	JJ	O
interferon	NN	O
alpha-2b	NN	O
is	VBZ	O
active	JJ	O
in	IN	O
treating	VBG	O
patients	NNS	O
with	IN	O
primary	JJ	O
condyloma	NN	O
lesions	NNS	O
and	CC	O
does	VBZ	O
so	RB	O
as	RB	O
well	RB	O
as	IN	O
cauterization	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Beneficial	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
diabetes	NN	O
specific	JJ	O
formula	NN	O
on	IN	O
insulin	NN	O
sensitivity	NN	O
and	CC	O
free	JJ	O
fatty	NN	O
acid	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
mellitus	RB	O
.	.	O

BACKGROUND	VB	O
This	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
diabetes	NN	O
specific	JJ	O
formula	NN	O
(	(	O
Diason	NNP	O
low	JJ	O
energy	NN	O
:	:	O
313.8	CD	O
kJ/100	NNS	O
ml	NN	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
a	DT	O
standard	JJ	O
formula	NN	O
,	,	O
on	IN	O
insulin	NN	O
sensitivity	NN	O
,	,	O
serum	JJ	O
C	NNP	O
peptide	NN	O
,	,	O
serum	JJ	O
lipids	NNS	O
and	CC	O
free	JJ	O
fatty	NN	O
acid	NN	O
(	(	O
FFA	NNP	O
)	)	O
in	IN	O
type	NN	O
2	CD	O
diabetics	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
total	NN	O
of	IN	O
71	CD	O
type	NN	O
2	CD	O
diabetics	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Enteral	NNP	O
formulas	NNS	O
were	VBD	O
given	VBN	O
orally	RB	O
as	IN	O
the	DT	O
sole	JJ	O
source	NN	O
of	IN	O
nutrition	NN	O
to	TO	O
the	DT	O
subjects	NNS	O
for	IN	O
6	CD	O
days	NNS	O
.	.	O

Venous	JJ	O
blood	NN	O
samples	NNS	O
(	(	O
0.5	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
hours	NNS	O
)	)	O
were	VBD	O
collected	VBN	O
at	IN	O
day-7	NN	O
after	IN	O
a	DT	O
75	CD	O
g	JJ	O
oral	JJ	O
glucose	JJ	O
tolerance	NN	O
test	NN	O
(	(	O
OGTT	NNP	O
)	)	O
,	,	O
day	NN	O
1	CD	O
after	IN	O
a	DT	O
standard	JJ	O
test	NN	O
meal	NN	O
(	(	O
1673.6	CD	O
kJ	NN	O
)	)	O
and	CC	O
after	IN	O
6	CD	O
days	NNS	O
of	IN	O
either	CC	O
the	DT	O
test	NN	O
diabetes	VBZ	O
specific	JJ	O
formula	NN	O
or	CC	O
a	DT	O
standard	JJ	O
formula	NN	O
.	.	O

Plasma	NNP	O
glucose	NN	O
,	,	O
serum	JJ	O
insulin	NN	O
,	,	O
C	NNP	O
peptide	NN	O
and	CC	O
lipids	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
After	IN	O
the	DT	O
intervention	NN	O
period	NN	O
,	,	O
the	DT	O
diabetes	NNS	O
specific	JJ	O
formula	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significantly	RB	O
lower	JJR	O
postprandial	JJ	O
rise	NN	O
in	IN	O
blood	NN	O
glucose	JJ	O
concentrations	NNS	O
at	IN	O
0.5	CD	O
hour	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
1	CD	O
hour	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
;	:	O
significantly	RB	O
lower	JJR	O
peak	JJ	O
height	NN	O
of	IN	O
plasma	NN	O
glucose	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
;	:	O
significantly	RB	O
lower	JJR	O
plasma	NN	O
insulin	NN	O
concentrations	NNS	O
at	IN	O
0.5	CD	O
hour	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
1	CD	O
hour	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
2	CD	O
hours	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
;	:	O
and	CC	O
a	DT	O
significantly	RB	O
lower	JJR	O
plasma	NN	O
insulin	NN	O
peak	NN	O
compared	VBN	O
to	TO	O
controls	NNS	O
;	:	O
both	DT	O
OGTT	NNP	O
and	CC	O
a	DT	O
standard	JJ	O
test	NN	O
meal	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
glucose	NN	O
and	CC	O
insulin	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
after	IN	O
the	DT	O
diabetes	NNS	O
specific	JJ	O
formula	NN	O
compared	VBN	O
to	TO	O
the	DT	O
standard	JJ	O
formula	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
.	.	O

The	DT	O
C	NNP	O
peptide	NN	O
level	NN	O
was	VBD	O
lower	JJR	O
after	IN	O
6	CD	O
days	NNS	O
of	IN	O
both	DT	O
nutrition	NN	O
formulas	NNS	O
compare	VBP	O
to	TO	O
75	CD	O
g	NN	O
OGTT	NNP	O
,	,	O
but	CC	O
not	RB	O
different	JJ	O
from	IN	O
the	DT	O
standard	NN	O
mixed	JJ	O
meal	NN	O
.	.	O

Both	DT	O
formulas	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
summary	JJ	O
the	DT	O
diabetes	NNS	O
specific	JJ	O
formula	NN	O
with	IN	O
a	DT	O
relatively	RB	O
high	JJ	O
monounsaturated	VBN	O
fatty	JJ	O
acid	NN	O
and	CC	O
high	JJ	O
multi	NN	O
fiber	NN	O
proportion	NN	O
significantly	RB	O
improved	VBN	O
glycemic	JJ	O
control	NN	O
.	.	O

On	IN	O
top	NN	O
of	IN	O
this	DT	O
,	,	O
the	DT	O
insulin	NN	O
sensitivity	NN	O
(	(	O
HOMA-IS	NNP	O
)	)	O
was	VBD	O
significantly	RB	O
improved	VBN	O
and	CC	O
may	MD	O
therefore	VB	O
directly	RB	O
improve	VB	O
the	DT	O
impact	NN	O
on	IN	O
long	JJ	O
term	NN	O
complications	NNS	O
.	.	O

The	DT	O
disease	NN	O
specific	JJ	O
formula	NN	O
should	MD	O
therefore	RB	O
be	VB	O
the	DT	O
preferred	JJ	O
option	NN	O
to	TO	O
be	VB	O
used	VBN	O
by	IN	O
diabetic	JJ	O
and	CC	O
hyperglycemic	JJ	O
patients	NNS	O
in	IN	O
need	NN	O
of	IN	O
nutritional	JJ	O
support	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
local	JJ	O
anaesthetics	NNS	O
for	IN	O
venepuncture	NN	Condition
.	.	O

AIM	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
EMLA	NNP	O
cream	NN	O
and	CC	O
Ametop	NNP	O
gel	NN	O
in	IN	O
providing	VBG	O
analgesia	NN	O
for	IN	O
venous	JJ	Condition
cannulation	NN	Condition
.	.	O

METHODS	NNP	O
Single	NNP	O
blind	NN	O
study	NN	O
in	IN	O
120	CD	SampleSize
children	NNS	Age
.	.	O

RESULTS	NNP	O
Both	NNP	O
anaesthetic	JJ	O
agents	NNS	O
produced	VBN	O
adequate	JJ	O
analgesia	NN	O
.	.	O

However	RB	O
,	,	O
Ametop	NNP	O
gel	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
,	,	O
with	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
pain	NN	O
scores	NNS	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
two	CD	O
artificial	JJ	O
tear	JJ	O
formulations	NNS	O
for	IN	O
dry	JJ	O
eye	NN	O
through	IN	O
high-resolution	JJ	O
optical	JJ	O
coherence	NN	O
tomography	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
two	CD	O
artificial	JJ	O
eye-drop	JJ	O
formulations	NNS	O
by	IN	O
analysing	VBG	O
the	DT	O
lower	JJR	O
tear	NN	O
film	NN	O
meniscus	NN	O
volume	NN	O
through	IN	O
a	DT	O
commercial	JJ	O
high-resolution	NN	O
spectral-domain	JJ	O
optical	JJ	O
coherence	NN	O
tomographer	NN	O
.	.	O

METHODS	NNP	O
Twenty	NNP	O
dry	JJ	O
eye	NN	O
patients	NNS	O
(	(	O
12	CD	O
men	NNS	O
,	,	O
eight	CD	O
women	NNS	O
,	,	O
aged	VBD	O
57.5	CD	O
?	.	O
8.4	CD	O
years	NNS	O
)	)	O
with	IN	O
refractive	JJ	O
errors	NNS	O
from	IN	O
-2.50	NN	O
to	TO	O
+0.75	VB	O
D	NNP	O
(	(	O
mean	JJ	O
-1.34	NNP	O
?	.	O
1.02	CD	O
D	NNP	O
)	)	O
and	CC	O
cylinders	NNS	O
lower	JJR	O
than	IN	O
1.00	CD	O
D	NNP	O
were	VBD	O
examined	VBN	O
.	.	O

Tear	JJ	O
meniscus	NN	O
volume	NN	O
was	VBD	O
measured	VBN	O
before	IN	O
,	,	O
immediately	RB	O
after	IN	O
and	CC	O
10	CD	O
,	,	O
30	CD	O
and	CC	O
60	CD	O
minutes	NNS	O
after	IN	O
instillation	NN	O
using	VBG	O
the	DT	O
Copernicus	NNP	O
high-resolution	NN	O
spectral-domain	JJ	O
optical	JJ	O
coherence	NN	O
tomographer	NN	O
(	(	O
Optopol	NNP	O
Tech	NNP	O
SA	NNP	O
,	,	O
Zawiercie	NNP	O
,	,	O
Poland	NNP	O
)	)	O
.	.	O

Volume	NN	O
was	VBD	O
calculated	VBN	O
from	IN	O
the	DT	O
local	JJ	O
area	NN	O
obtained	VBN	O
from	IN	O
tomograms	NNS	O
considering	VBG	O
a	DT	O
regular	JJ	O
distribution	NN	O
of	IN	O
the	DT	O
tear	JJ	O
meniscus	NN	O
across	IN	O
the	DT	O
eyelid	NN	O
.	.	O

Ten	CD	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
first	VB	O
receive	VB	O
either	DT	O
polyethylene	NN	O
glycol	NN	O
(	(	O
Blink	NNP	O
Intensive	NNP	O
,	,	O
Abbot	NNP	O
Medical	NNP	O
Optics	NNP	O
Inc	NNP	O
,	,	O
CA	NNP	O
,	,	O
USA	NNP	O
)	)	O
or	CC	O
hypromellose	JJ	O
(	(	O
Artific	NNP	O
,	,	O
Farma-Lepori	NNP	O
SA	NNP	O
,	,	O
Barcelona	NNP	O
,	,	O
Spain	NNP	O
)	)	O
three	CD	O
times	NNS	O
daily	RB	O
in	IN	O
both	DT	O
eyes	NNS	O
for	IN	O
one	CD	O
month	NN	O
.	.	O

Measures	NNS	O
were	VBD	O
then	RB	O
repeated	VBN	O
and	CC	O
after	IN	O
a	DT	O
one-week	JJ	O
wash-out	JJ	O
period	NN	O
they	PRP	O
were	VBD	O
switched	VBN	O
to	TO	O
the	DT	O
other	JJ	O
eye-drop	NN	O
for	IN	O
another	DT	O
month	NN	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
baseline	NN	O
volume	NN	O
was	VBD	O
0.38	CD	O
?	.	O
0.10	CD	O
?L	NN	O
,	,	O
while	IN	O
mean	JJ	O
baseline	NN	O
volume	NN	O
after	IN	O
the	DT	O
wash-out	JJ	O
period	NN	O
was	VBD	O
slightly	RB	O
higher	JJR	O
,	,	O
0.39	CD	O
?	.	O
0.10	CD	O
?L	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.638	CD	O
)	)	O
.	.	O

Analysis	NN	O
of	IN	O
variance	NN	O
showed	VBD	O
significant	JJ	O
differences	NNS	O
in	IN	O
meniscus	NN	O
volume	NN	O
with	IN	O
time	NN	O
after	IN	O
instillation	NN	O
with	IN	O
both	DT	O
formulations	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
mean	JJ	O
volume	NN	O
decreasing	VBG	O
with	IN	O
time	NN	O
.	.	O

At	IN	O
30	CD	O
and	CC	O
60	CD	O
minutes	NNS	O
following	VBG	O
instillation	NN	O
,	,	O
values	NNS	O
decreased	VBD	O
to	TO	O
almost	RB	O
baseline	VB	O
(	(	O
average	JJ	O
difference	NN	O
0.02	CD	O
?	.	O
0.03	CD	O
?L	NN	O
at	IN	O
t	NN	O
(	(	O
30	CD	O
)	)	O
,	,	O
p	JJ	O
=	NN	O
0.016	CD	O
and	CC	O
0.01	CD	O
?	.	O
0.01	CD	O
?L	NN	O
at	IN	O
t	NN	O
(	(	O
60	CD	O
)	)	O
,	,	O
p	JJ	O
=	NNP	O
0.098	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
An	DT	O
increase	NN	O
in	IN	O
tear	JJ	O
film	NN	O
meniscus	NN	O
volume	NN	O
in	IN	O
dry	JJ	O
eyes	NNS	O
from	IN	O
the	DT	O
use	NN	O
of	IN	O
eye-drops	NNS	O
has	VBZ	O
been	VBN	O
shown	VBN	O
.	.	O

High	JJ	O
resolution	NN	O
imaging	NN	O
of	IN	O
lower	JJR	O
tear	NN	O
film	NN	O
meniscus	NN	O
with	IN	O
clinical	JJ	O
optical	JJ	O
coherence	NN	O
tomography	NN	O
systems	NNS	O
provides	VBZ	O
useful	JJ	O
measures	NNS	O
of	IN	O
tear	JJ	O
volume	NN	O
.	.	O

Both	DT	O
formulations	NNS	O
assessed	VBN	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
are	VBP	O
efficient	JJ	O
in	IN	O
increasing	VBG	O
tear	JJ	O
meniscus	NN	O
volume	NN	O
and	CC	O
reducing	VBG	O
dry	JJ	O
eye	NN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
,	,	O
although	IN	O
results	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
increase	NN	O
in	IN	O
meniscus	JJ	O
volume	NN	O
were	VBD	O
higher	JJR	O
with	IN	O
the	DT	O
polyethylene	NN	O
glycol	NN	O
formulation	NN	O
.	.	O

PTK2	NNP	O
expression	NN	O
and	CC	O
immunochemotherapy	JJ	O
outcome	NN	O
in	IN	O
chronic	JJ	Condition
lymphocytic	JJ	Condition
leukemia	NN	Condition
.	.	O

Addition	NN	O
of	IN	O
rituximab	NN	O
(	(	O
R	NNP	O
)	)	O
to	TO	O
fludarabine	VB	O
and	CC	O
cyclophosphamide	VB	O
(	(	O
FC	NNP	O
)	)	O
has	VBZ	O
significantly	RB	O
improved	VBN	O
patient	JJ	O
outcomes	NNS	O
in	IN	O
chronic	JJ	Condition
lymphocytic	JJ	Condition
leukemia	NN	Condition
(	(	O
CLL	NNP	Condition
)	)	O
.	.	O

Whether	NNP	O
baseline	NN	O
gene	NN	O
expression	NN	O
can	MD	O
identify	VB	O
patients	NNS	O
who	WP	O
will	MD	O
benefit	VB	O
from	IN	O
immunochemotherapy	NN	O
over	IN	O
chemotherapy	NN	O
alone	RB	O
has	VBZ	O
not	RB	O
been	VBN	O
determined	VBN	O
.	.	O

We	PRP	O
assessed	VBD	O
genome-wide	JJ	O
expression	NN	O
of	IN	O
300	CD	SampleSize
pretreatment	NN	O
specimens	NNS	O
from	IN	O
a	DT	O
subset	NN	O
of	IN	O
552	CD	SampleSize
patients	NNS	O
in	IN	O
REACH	NNP	O
,	,	O
a	DT	O
study	NN	O
of	IN	O
FC	NNP	O
or	CC	O
R-FC	NNP	O
in	IN	O
relapsed	JJ	O
CLL	NNP	Condition
.	.	O

An	DT	O
independent	JJ	O
test	NN	O
set	NN	O
was	VBD	O
derived	VBN	O
from	IN	O
282	CD	O
pretreatment	NN	O
specimens	NNS	O
from	IN	O
CLL8	NNP	O
,	,	O
a	DT	O
study	NN	O
of	IN	O
FC	NNP	O
or	CC	O
R-FC	NNP	O
in	IN	O
treatment-na?ve	JJ	O
patients	NNS	O
.	.	O

Genes	NNP	O
specific	JJ	O
for	IN	O
benefit	NN	O
from	IN	O
R-FC	NNP	O
were	VBD	O
determined	VBN	O
by	IN	O
assessing	VBG	O
treatment-gene	JJ	O
interactions	NNS	O
in	IN	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
models	NNS	O
.	.	O

REACH	JJ	O
patients	NNS	O
with	IN	O
higher	JJR	O
pretreatment	NN	O
protein	NN	O
tyrosine	JJ	O
kinase	NN	O
2	CD	O
(	(	O
PTK2	NNP	O
)	)	O
messenger	NN	O
RNA	NNP	O
levels	NNS	O
derived	VBN	O
greater	JJR	O
benefit	NN	O
from	IN	O
R-FC	NNP	O
,	,	O
with	IN	O
significant	JJ	O
improvements	NNS	O
in	IN	O
progression-free	JJ	O
survival	NN	O
,	,	O
independent	JJ	O
of	IN	O
known	JJ	O
prognostic	JJ	O
factors	NNS	O
in	IN	O
a	DT	O
multivariate	NN	O
model	NN	O
.	.	O

Examination	NN	O
of	IN	O
PTK2	NNP	O
gene	NN	O
expression	NN	O
in	IN	O
CLL8	NNP	O
patients	NNS	O
yielded	VBD	O
similar	JJ	O
results	NNS	O
.	.	O

Furthermore	NNP	O
,	,	O
PTK2	NNP	O
inhibition	NN	O
blunted	VBD	O
R-dependent	NNP	O
cell	NN	O
death	NN	O
in	IN	O
vitro	NN	O
.	.	O

This	DT	O
retrospective	JJ	O
analysis	NN	O
from	IN	O
2	CD	O
independent	JJ	O
trials	NNS	O
revealed	VBD	O
that	IN	O
increased	VBD	O
PTK2	NNP	O
expression	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
improved	JJ	O
outcomes	NNS	O
for	IN	O
CLL	NNP	O
patients	NNS	O
treated	VBD	O
with	IN	O
R-FC	NNP	O
vs	NN	O
FC	NNP	O
.	.	O

PTK2	NNP	O
expression	NN	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
biomarker	NN	O
for	IN	O
patient	JJ	O
selection	NN	O
in	IN	O
future	JJ	O
trials	NNS	O
.	.	O

These	DT	O
trials	NNS	O
were	VBD	O
registered	VBN	O
at	IN	O
www.clinicaltrials.gov	NN	O
as	IN	O
#	#	O
NCT00090051	NNP	O
(	(	O
REACH	NNP	O
)	)	O
and	CC	O
#	#	O
NCT00281918	NNP	O
(	(	O
CLL8	NNP	O
)	)	O
.	.	O

MSL-109	NNP	O
adjuvant	JJ	O
therapy	NN	O
for	IN	O
cytomegalovirus	NN	Condition
retinitis	NN	Condition
in	IN	O
patients	NNS	O
with	IN	O
acquired	JJ	O
immunodeficiency	NN	O
syndrome	NN	O
:	:	O
the	DT	O
Monoclonal	NNP	O
Antibody	NNP	O
Cytomegalovirus	NNP	O
Retinitis	NNP	O
Trial	NNP	O
.	.	O

The	DT	O
Studies	NNPS	O
of	IN	O
Ocular	JJ	Condition
Complications	NNS	Condition
of	IN	O
AIDS	NNP	O
Research	NNP	O
Group	NNP	O
.	.	O

AIDS	NNP	O
Clinical	JJ	O
Trials	NNP	O
Group	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
an	DT	O
intravenous	JJ	O
human	JJ	O
monoclonal	NN	O
antibody	NN	O
to	TO	O
cytomegalovirus	VB	O
(	(	O
CMV	NNP	O
)	)	O
,	,	O
MSL-109	NNP	O
,	,	O
as	IN	O
adjuvant	JJ	O
treatment	NN	O
for	IN	O
CMV	NNP	O
retinitis	NN	O
.	.	O

METHODS	NNP	O
Two	CD	SampleSize
hundred	VBD	SampleSize
nine	CD	SampleSize
patients	NNS	O
with	IN	O
acquired	JJ	Condition
immunodeficiency	NN	Condition
syndrome	NN	Condition
and	CC	O
active	JJ	O
CMV	NNP	Condition
retinitis	NN	Condition
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
phase	NN	O
2/3	CD	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Patients	NNS	O
received	VBD	O
adjuvant	JJ	O
treatment	NN	O
with	IN	O
MSL-109	NNP	O
,	,	O
60	CD	O
mg	NN	O
intravenously	RB	O
every	DT	O
2	CD	O
weeks	NNS	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Randomization	NN	O
was	VBD	O
stratified	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
whether	IN	O
patients	NNS	O
had	VBD	O
untreated	VBN	O
or	CC	O
relapsed	VBN	O
retinitis	NN	O
.	.	O

Primary	JJ	O
drug	NN	O
therapy	NN	O
for	IN	O
CMV	NNP	O
retinitis	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
the	DT	O
treating	NN	O
physician	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
rates	NNS	O
of	IN	O
retinitis	NN	O
progression	NN	O
,	,	O
as	IN	O
evaluated	VBN	O
in	IN	O
a	DT	O
masked	JJ	O
fashion	NN	O
,	,	O
were	VBD	O
3.04/person-year	JJ	O
in	IN	O
the	DT	O
MSL-109-treated	NNP	O
group	NN	O
and	CC	O
3.05/person-year	JJ	O
in	IN	O
the	DT	O
placebo-treated	JJ	O
group	NN	O
(	(	O
P=.98	NNP	O
;	:	O
Wald	NNP	O
test	NN	O
)	)	O
;	:	O
the	DT	O
median	JJ	O
times	NNS	O
to	TO	O
progression	NN	O
were	VBD	O
67	CD	O
days	NNS	O
in	IN	O
the	DT	O
MSL-109-treated	NNP	O
group	NN	O
and	CC	O
65	CD	O
days	NNS	O
in	IN	O
the	DT	O
placebo-treated	JJ	O
group	NN	O
.	.	O

No	DT	O
differences	NNS	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
rates	NNS	O
of	IN	O
increase	NN	O
in	IN	O
retinal	JJ	O
area	NN	O
involved	VBN	O
by	IN	O
CMV	NNP	O
,	,	O
visual	JJ	O
field	NN	O
loss	NN	O
,	,	O
or	CC	O
visual	JJ	O
acuity	NN	O
outcomes	NNS	O
.	.	O

The	DT	O
mortality	NN	O
rate	NN	O
in	IN	O
the	DT	O
MSL-109-treated	NNP	O
group	NN	O
was	VBD	O
0.68/person-year	JJ	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
placebo-treated	JJ	O
group	NN	O
,	,	O
0.31/person-year	JJ	O
(	(	O
P=.01	NNP	O
)	)	O
.	.	O

The	DT	O
mortality	NN	O
difference	NN	O
was	VBD	O
not	RB	O
explained	VBN	O
by	IN	O
differences	NNS	O
in	IN	O
baseline	NN	O
variables	NNS	O
or	CC	O
in	IN	O
concurrent	JJ	O
antiretroviral	JJ	O
therapy	NN	O
.	.	O

Among	IN	O
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	Condition
retinitis	NN	Condition
,	,	O
mortality	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
(	(	O
MSL-109	NNP	O
,	,	O
0.41/person-year	JJ	O
;	:	O
placebo	NN	O
,	,	O
0.42/person-year	JJ	O
;	:	O
P=.95	NNP	O
)	)	O
,	,	O
whereas	JJ	O
among	IN	O
patients	NNS	O
with	IN	O
relapsed	JJ	O
retinitis	NN	O
the	DT	O
MSL-109-treated	NNP	O
group	NN	O
had	VBD	O
a	DT	O
greater	JJR	O
mortality	NN	O
rate	NN	O
(	(	O
MSL-109	NNP	O
,	,	O
0.83/person-year	JJ	O
;	:	O
placebo	NN	O
,	,	O
0.24/person-year	JJ	O
;	:	O
P=.003	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
mortality	NN	O
rate	NN	O
in	IN	O
the	DT	O
placebo-treated	JJ	O
patients	NNS	O
with	IN	O
relapsed	JJ	O
CMV	NNP	O
retinitis	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo-treated	JJ	O
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
CMV	NNP	O
retinitis	NN	O
and	CC	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
other	JJ	O
trials	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
relapsed	JJ	O
CMV	NNP	O
retinitis	NN	O
.	.	O

CONCLUSIONS	NNP	O
Intravenous	NNP	O
MSL-109	NNP	O
,	,	O
60	CD	O
mg	NN	O
every	DT	O
2	CD	O
weeks	NNS	O
,	,	O
appeared	VBD	O
to	TO	O
be	VB	O
ineffective	JJ	O
adjuvant	JJ	O
therapy	NN	O
for	IN	O
CMV	NNP	O
retinitis	NN	O
.	.	O

The	DT	O
mortality	NN	O
rate	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
MSL-109-treated	NNP	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
reasons	NNS	O
for	IN	O
this	DT	O
difference	NN	O
remain	NN	O
uncertain	JJ	O
.	.	O

2-Chloroprocaine	JJ	O
antagonism	NN	O
of	IN	O
epidural	JJ	O
morphine	NN	O
analgesia	NN	O
.	.	O

BACKGROUND	NNP	O
2-Chloroprocaine	JJ	O
(	(	O
2-CP	JJ	O
)	)	O
used	VBN	O
for	IN	O
lumbar	JJ	O
epidural	JJ	O
anesthesia	NN	O
(	(	O
LEA	NNP	O
)	)	O
reportedly	RB	O
decreases	VBZ	O
the	DT	O
efficacy	NN	O
of	IN	O
epidural	JJ	O
morphine	NN	O
(	(	O
EM	NNP	O
)	)	O
administered	VBD	O
for	IN	O
post-cesarean	JJ	Condition
section	NN	Condition
(	(	Condition
CS	NNP	Condition
)	)	Condition
analgesia	NN	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
supplemental	JJ	O
i.v	NN	O
.	.	O

morphine	VB	O
self-administered	JJ	O
by	IN	O
the	DT	O
patient	NN	O
via	IN	O
the	DT	O
patient-controlled	JJ	O
analgesia	NN	O
device	NN	O
(	(	O
PCA	NNP	O
)	)	O
is	VBZ	O
used	VBN	O
to	TO	O
study	VB	O
the	DT	O
interaction	NN	O
between	IN	O
EM	NNP	O
and	CC	O
2-CP	JJ	O
.	.	O

METHODS	NNP	O
Forty-two	JJ	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
elective	JJ	O
CS	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
equal	JJ	O
groups	NNS	O
,	,	O
and	CC	O
received	VBD	O
2-CP	JJ	O
,	,	O
2-CP	JJ	O
+	NN	O
epinephrine	NN	O
(	(	O
Epi	NNP	O
,	,	O
5	CD	O
micrograms.ml-1	NN	O
)	)	O
or	CC	O
2	CD	O
%	NN	O
lidocaine	NN	O
(	(	O
Lido	NNP	O
)	)	O
with	IN	O
Epi	NNP	O
for	IN	O
LEA	NNP	O
.	.	O

All	DT	Condition
patients	NNS	Condition
received	VBD	Condition
5	CD	O
mg	NNS	O
EM	NNP	O
and	CC	O
i.v	NN	O
.	.	O

PCA	NNP	O
morphine	NN	O
for	IN	O
postoperative	JJ	O
pain	NN	O
.	.	O

Cumulative	JJ	O
amount	NN	O
of	IN	O
i.v	NN	O
.	.	O

morphine	NN	O
used	VBN	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
amount	NN	O
of	IN	O
the	DT	O
drug	NN	O
used	VBN	O
during	IN	O
each	DT	O
2-h	JJ	O
period	NN	O
were	VBD	O
noted	VBN	O
.	.	O

Nonparametric	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
and	CC	O
Chi-squared	JJ	O
analysis	NN	O
were	VBD	O
used	VBN	O
for	IN	O
statistical	JJ	O
comparisons	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
cumulative	JJ	O
24-h	JJ	O
i.v	NN	O
.	.	O

PCA	NNP	O
morphine	JJ	O
requirement	NN	O
in	IN	O
the	DT	O
2-CP	JJ	O
,	,	O
2-CP+Epi	JJ	O
and	CC	O
Lido+Epi	NNP	O
groups	NNS	O
respectively	RB	O
was	VBD	O
20.5	CD	O
+/-	JJ	O
24	CD	O
,	,	O
33.1.5	CD	O
+/-	JJ	O
27	CD	O
and	CC	O
4.07	CD	O
+/-	JJ	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
.	.	O

The	DT	O
Lido	NNP	O
+	NNP	O
Epi	NNP	O
group	NN	O
used	VBD	O
significantly	RB	O
less	JJR	O
morphine	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
compared	VBN	O
to	TO	O
either	DT	O
of	IN	O
the	DT	O
2-CP	JJ	O
groups	NNS	O
with	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
2-CP	JJ	O
groups	NNS	O
.	.	O

The	DT	O
maximum	JJ	O
i.v	NN	O
.	.	O

PCA	NNP	O
morphine	NN	O
use	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
first	JJ	O
4	CD	O
hours	NNS	O
following	VBG	O
surgery	NN	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Analgesic	NNP	O
efficacy	NN	O
of	IN	O
EM	NNP	O
is	VBZ	O
decreased	VBN	O
when	WRB	O
2-CP	JJ	O
is	VBZ	O
used	VBN	O
for	IN	O
LEA	NNP	O
compared	VBN	O
to	TO	O
when	WRB	O
Lido	NNP	O
+	NNP	O
Epi	NNP	O
is	VBZ	O
used	VBN	O
.	.	O

Human	NNP	O
primary	JJ	O
visual	JJ	O
cortex	NN	O
(	(	O
V1	NNP	O
)	)	O
is	VBZ	O
selective	JJ	O
for	IN	O
second-order	JJ	O
spatial	JJ	O
frequency	NN	O
.	.	O

A	DT	O
variety	NN	O
of	IN	O
cues	NNS	O
can	MD	O
differentiate	VB	O
objects	NNS	O
from	IN	O
their	PRP$	O
surrounds	NNS	O
.	.	O

These	DT	O
include	VBP	O
first-order	NN	O
cues	NNS	O
such	JJ	O
as	IN	O
luminance	NN	O
modulations	NNS	O
and	CC	O
second-order	NN	O
cues	NNS	O
involving	VBG	O
modulations	NNS	O
of	IN	O
orientation	NN	O
and	CC	O
contrast	NN	O
.	.	O

Human	NNP	O
sensitivity	NN	O
to	TO	O
first-order	JJ	O
modulations	NNS	O
is	VBZ	O
well	RB	O
described	VBN	O
by	IN	O
a	DT	O
computational	JJ	O
model	NN	O
involving	VBG	O
spatially	RB	O
localized	VBN	O
filters	NNS	O
that	WDT	O
are	VBP	O
selective	JJ	O
for	IN	O
orientation	NN	O
and	CC	O
spatial	JJ	O
frequency	NN	O
(	(	O
SF	NNP	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
widely	RB	O
held	VBN	O
that	IN	O
first-order	JJ	O
modulations	NNS	O
are	VBP	O
represented	VBN	O
by	IN	O
the	DT	O
firing	VBG	O
rates	NNS	O
of	IN	O
simple	JJ	O
and	CC	O
complex	JJ	O
cells	NNS	O
(	(	O
first-order	JJ	O
neurons	NNS	O
)	)	O
in	IN	O
primary	JJ	O
visual	JJ	O
cortex	NN	O
(	(	O
V1	NNP	O
)	)	O
that	IN	O
,	,	O
likewise	RB	O
,	,	O
have	VBP	O
spatially	RB	O
localized	VBN	O
receptive	JJ	O
fields	NNS	O
that	WDT	O
are	VBP	O
selective	JJ	O
for	IN	O
orientation-	JJ	O
and	CC	O
SF	NNP	O
.	.	O

Human	NNP	O
sensitivity	NN	O
to	TO	O
second-order	JJ	O
modulations	NNS	O
is	VBZ	O
well	RB	O
described	VBN	O
by	IN	O
a	DT	O
filter-rectify-filter	NN	O
(	(	O
FRF	NNP	O
)	)	O
model	NN	O
,	,	O
with	IN	O
first-	JJ	O
and	CC	O
second-order	JJ	O
filters	NNS	O
selective	VBP	O
for	IN	O
orientation	NN	O
and	CC	O
SF	NNP	O
.	.	O

However	RB	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
how	WRB	O
neuronal	JJ	O
activity	NN	O
in	IN	O
visual	JJ	O
cortex	NN	O
represents	VBZ	O
second-order	JJ	O
modulations	NNS	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
FRF	NNP	O
model	NN	O
by	IN	O
using	VBG	O
an	DT	O
functional	JJ	O
(	(	O
f	JJ	O
)	)	O
MRI-adaptation	NN	O
protocol	NN	O
to	TO	O
characterize	VB	O
the	DT	O
selectivity	NN	O
of	IN	O
activity	NN	O
in	IN	O
visual	JJ	O
cortex	NN	O
to	TO	O
second-order	NN	O
,	,	O
orientation-defined	JJ	O
gratings	NNS	O
of	IN	O
two	CD	O
different	JJ	O
SFs	NNP	O
.	.	O

fMRI	NN	O
responses	NNS	O
throughout	IN	O
early	JJ	O
visual	JJ	O
cortex	NN	O
exhibited	VBD	O
selective	JJ	O
adaptation	NN	O
to	TO	O
these	DT	O
stimuli	NNS	O
.	.	O

The	DT	O
low-SF	JJ	O
grating	NN	O
was	VBD	O
a	DT	O
more	RBR	O
effective	JJ	O
adapter	NN	O
than	IN	O
the	DT	O
high-SF	JJ	O
grating	NN	O
,	,	O
incompatible	JJ	O
with	IN	O
the	DT	O
FRF	NNP	O
model	NN	O
.	.	O

To	TO	O
explain	VB	O
the	DT	O
results	NNS	O
,	,	O
we	PRP	O
extended	VBD	O
the	DT	O
FRF	NNP	O
model	NN	O
by	IN	O
incorporating	VBG	O
normalization	NN	O
,	,	O
yielding	VBG	O
a	DT	O
filter-rectify-normalize-filter	JJ	O
model	NN	O
,	,	O
in	IN	O
which	WDT	O
normalization	NN	O
enhances	VBZ	O
selectivity	NN	O
for	IN	O
second-order	JJ	O
SF	NNP	O
but	CC	O
only	RB	O
for	IN	O
low	JJ	O
spatial	JJ	O
frequencies	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
neurons	NNS	O
in	IN	O
human	JJ	O
visual	JJ	O
cortex	NN	O
are	VBP	O
selective	JJ	O
for	IN	O
second-order	NN	O
SF	NNP	O
,	,	O
that	IN	O
normalization	NN	O
(	(	O
surround	JJ	O
suppression	NN	O
)	)	O
contributes	VBZ	O
to	TO	O
this	DT	O
selectivity	NN	O
,	,	O
and	CC	O
that	IN	O
the	DT	O
selectivity	NN	O
in	IN	O
higher	JJR	O
visual	JJ	O
areas	NNS	O
is	VBZ	O
simply	RB	O
fed	JJ	O
forward	RB	O
from	IN	O
V1	NNP	O
.	.	O

A	DT	O
potent	JJ	O
oral	JJ	O
P-selectin	NNP	O
blocking	NN	O
agent	NN	O
improves	VBZ	O
microcirculatory	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
a	DT	O
marker	NN	O
of	IN	O
endothelial	JJ	O
cell	NN	O
injury	NN	O
in	IN	O
patients	NNS	O
with	IN	O
sickle	JJ	Condition
cell	NN	Condition
disease	NN	Condition
.	.	O

Abnormal	JJ	O
blood	NN	O
flow	NN	O
accounts	NNS	O
for	IN	O
most	JJS	O
of	IN	O
the	DT	O
clinical	JJ	O
morbidity	NN	O
of	IN	O
sickle	NN	O
cell	NN	O
disease	NN	O
(	(	O
SCD	NNP	O
)	)	O
[	VBD	O
1,2	CD	O
]	NNP	O
.	.	O

Most	JJS	O
notably	RB	O
,	,	O
occlusion	NN	O
of	IN	O
flow	NN	O
in	IN	O
the	DT	O
microvasculature	NN	O
causes	VBZ	O
the	DT	O
acute	NN	O
pain	NN	O
crises	NNS	O
[	VBP	O
3	CD	O
]	NN	O
that	WDT	O
are	VBP	O
the	DT	O
commonest	NN	O
cause	NN	O
for	IN	O
patients	NNS	O
with	IN	O
SCD	NNP	Condition
to	TO	O
seek	VB	O
medical	JJ	O
attention	NN	O
[	VBD	O
4	CD	O
]	NN	O
and	CC	O
major	JJ	O
determinants	NNS	O
of	IN	O
their	PRP$	O
quality	NN	O
of	IN	O
life	NN	O
[	$	O
5	CD	O
]	NNP	O
.	.	O

Based	VBN	O
on	IN	O
evidence	NN	O
that	IN	O
endothelial	JJ	O
P-selectin	NNP	O
is	VBZ	O
central	JJ	O
to	TO	O
the	DT	O
abnormal	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
SCD	NNP	O
we	PRP	O
provide	VBP	O
results	NNS	O
from	IN	O
four	CD	O
of	IN	O
our	PRP$	O
studies	NNS	O
that	WDT	O
are	VBP	O
germane	VBN	O
to	TO	O
microvascular	VB	O
blood	NN	O
flow	NN	O
in	IN	O
SCD	NNP	O
.	.	O

A	DT	O
proof-of-principle	JJ	O
study	NN	O
established	VBD	O
that	IN	O
doses	NNS	O
of	IN	O
heparin	NN	O
lower	JJR	O
than	IN	O
what	WP	O
are	VBP	O
used	VBN	O
for	IN	O
anticoagulation	NN	O
but	CC	O
sufficient	JJ	O
to	TO	O
block	VB	O
P-selectin	NNP	O
improved	JJ	O
microvascular	JJ	O
blood	NN	O
flow	NN	O
inpatients	NNS	O
with	IN	O
SCD	NNP	Condition
.	.	O

An	DT	O
in	IN	O
vitro	NN	O
study	NN	O
showed	VBD	O
that	IN	O
Pentosan	NNP	O
Polysulfate	NNP	O
Sodium	NNP	O
(	(	O
PPS	NNP	O
)	)	O
had	VBD	O
greater	JJR	O
P-selectin	JJ	O
blocking	NN	O
activity	NN	O
than	IN	O
heparin	NN	O
.	.	O

A	DT	O
Phase	NN	O
I	PRP	O
clinical	VBP	O
study	NN	O
demonstrated	VBD	O
that	IN	O
a	DT	O
single	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
PPS	NNP	O
increased	VBD	O
microvascular	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
patients	NNS	O
with	IN	O
SCD	NNP	O
.	.	O

A	NNP	O
Phase	NNP	O
II	NNP	O
clinical	JJ	O
study	NN	O
that	WDT	O
was	VBD	O
not	RB	O
completed	VBN	O
documented	VBD	O
that	IN	O
daily	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
PPS	NNP	O
administered	VBD	O
for	IN	O
8	CD	O
weeks	NNS	O
lowered	VBD	O
plasma	JJ	O
levels	NNS	O
of	IN	O
sVCAM-1	NN	O
and	CC	O
tended	VBD	O
to	TO	O
improve	VB	O
microvascular	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
patients	NNS	O
with	IN	O
SCD	NNP	O
.	.	O

These	DT	O
data	NNS	O
support	NN	O
the	DT	O
concept	NN	O
that	IN	O
P-selectin	NNP	O
on	IN	O
the	DT	O
microvascular	JJ	O
endothelium	NN	O
is	VBZ	O
critical	JJ	O
to	TO	O
both	DT	O
acute	JJ	O
vascular	NN	O
occlusion	NN	O
and	CC	O
chronically	RB	O
impaired	JJ	O
microvascular	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
SCD	NNP	O
.	.	O

They	PRP	O
also	RB	O
demonstrate	VBP	O
that	IN	O
oral	JJ	O
PPS	NNP	O
is	VBZ	O
beneficial	JJ	O
to	TO	O
microvascular	VB	O
sickle	NN	O
cell	NN	O
blood	NN	O
flow	NN	O
and	CC	O
has	VBZ	O
potential	JJ	O
as	IN	O
an	DT	O
efficacious	JJ	O
agent	NN	O
for	IN	O
long-term	JJ	O
prophylactic	JJ	O
therapy	NN	O
of	IN	O
SCD	NNP	O
.	.	O

Economic	JJ	O
evaluation	NN	O
of	IN	O
aquatic	JJ	O
exercise	NN	O
for	IN	O
persons	NNS	O
with	IN	O
osteoarthritis	NN	Condition
.	.	O

OBJECTIVES	NNP	O
To	TO	O
estimate	VB	O
cost	NN	O
and	CC	O
outcomes	NNS	O
of	IN	O
the	DT	O
Arthritis	NNP	O
Foundation	NNP	O
aquatic	JJ	O
exercise	NN	O
classes	NNS	O
from	IN	O
the	DT	O
societal	JJ	O
perspective	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
trial	NN	O
of	IN	O
20-week	JJ	O
aquatic	JJ	O
classes	NNS	O
.	.	O

Cost	NN	O
per	IN	O
quality-adjusted	JJ	O
life	NN	O
year	NN	O
(	(	O
QALY	NNP	O
)	)	O
gained	VBD	O
was	VBD	O
estimated	VBN	O
using	VBG	O
trial	NN	O
data	NNS	O
.	.	O

Sample	NNP	O
size	NN	O
was	VBD	O
based	VBN	O
on	IN	O
80	CD	O
%	NN	O
power	NN	O
to	TO	O
reject	VB	O
the	DT	O
null	JJ	O
hypothesis	NN	O
that	IN	O
the	DT	O
cost/QALY	NN	O
gained	VBD	O
would	MD	O
not	RB	O
exceed	VB	O
$	$	O
50,000	CD	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
Recruited	VBD	O
249	CD	SampleSize
adults	NNS	Age
from	IN	O
Washington	NNP	O
State	NNP	O
aged	VBD	Age
55	CD	Age
to	TO	Age
75	CD	Age
with	IN	O
a	DT	O
doctor-confirmed	JJ	O
diagnosis	NN	O
of	IN	O
osteoarthritis	NN	Condition
to	TO	O
participate	VB	O
in	IN	O
aquatic	JJ	O
classes	NNS	O
.	.	O

The	DT	O
Quality	NN	O
of	IN	O
Well-Being	NNP	O
Scale	NNP	O
(	(	O
QWB	NNP	O
)	)	O
and	CC	O
Current	NNP	O
Health	NNP	O
Desirability	NNP	O
Rating	NNP	O
(	(	O
CHDR	NNP	O
)	)	O
were	VBD	O
used	VBN	O
for	IN	O
economic	JJ	O
evaluation	NN	O
,	,	O
supplemented	VBN	O
by	IN	O
the	DT	O
arthritis-specific	JJ	O
Health	NNP	O
Assessment	NNP	O
Questionnaire	NNP	O
(	(	O
HAQ	NNP	O
)	)	O
,	,	O
Center	NNP	O
for	IN	O
Epidemiologic	NNP	O
Studies-Depression	NNP	O
Scale	NNP	O
(	(	O
CES-D	NNP	O
)	)	O
,	,	O
and	CC	O
Perceived	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
Scale	NNP	O
(	(	O
PQOL	NNP	O
)	)	O
collected	VBD	O
at	IN	O
baseline	NN	O
and	CC	O
postclass	NN	O
.	.	O

Outcome	NNP	O
results	NNS	O
applied	VBD	O
to	TO	O
life	NN	O
expectancy	NN	O
tables	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
QALYs	NNP	O
.	.	O

Use	NNP	O
of	IN	O
health	NN	O
care	NN	O
facilities	NNS	O
was	VBD	O
assessed	VBN	O
from	IN	O
diaries/questionnaires	NNS	O
and	CC	O
Medicare	NNP	O
reimbursement	NN	O
rates	NNS	O
used	VBD	O
to	TO	O
estimate	VB	O
costs	NNS	O
.	.	O

Nonparametric	NNP	O
bootstrap	NN	O
sampling	NN	O
of	IN	O
costs/QALY	NN	O
ratios	NNS	O
established	VBD	O
the	DT	O
95	CD	O
%	NN	O
CI	NNP	O
around	IN	O
the	DT	O
estimates	NNS	O
.	.	O

RESULTS	NNP	O
Aquatic	JJ	O
exercisers	NNS	O
reported	VBD	O
equal	JJ	O
(	(	O
QWB	NNP	O
)	)	O
or	CC	O
better	JJR	O
(	(	O
CHDR	NNP	O
,	,	O
HAQ	NNP	O
,	,	O
PQOL	NNP	O
)	)	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Outcomes	NNS	O
improved	VBN	O
with	IN	O
regular	JJ	O
class	NN	O
attendance	NN	O
.	.	O

Costs/QALY	NNP	O
gained	VBD	O
discounted	VBN	O
at	IN	O
3	CD	O
%	NN	O
were	VBD	O
$	$	O
205,186	CD	O
using	VBG	O
the	DT	O
QWB	NNP	O
and	CC	O
$	$	O
32,643	CD	O
using	VBG	O
the	DT	O
CHRD	NNP	O
.	.	O

CONCLUSION	NNP	O
Aquatic	NNP	O
exercise	NN	O
exceeded	VBD	O
$	$	O
50,000	CD	O
per	IN	O
QALY	NN	O
gained	VBN	O
using	VBG	O
the	DT	O
community-weighted	JJ	O
outcome	NN	O
but	CC	O
fell	VBD	O
below	IN	O
this	DT	O
arbitrary	JJ	O
budget	NN	O
constraint	NN	O
when	WRB	O
using	VBG	O
the	DT	O
participant-weighted	JJ	O
measure	NN	O
.	.	O

Confidence	NN	O
intervals	NNS	O
around	IN	O
these	DT	O
ratios	NNS	O
suggested	VBD	O
wide	JJ	O
variability	NN	O
of	IN	O
cost	NN	O
effectiveness	NN	O
of	IN	O
aquatic	JJ	O
exercise	NN	O
.	.	O

Local	JJ	O
warming	NN	O
and	CC	O
insertion	NN	O
of	IN	O
peripheral	JJ	O
venous	JJ	O
cannulas	NNS	O
:	:	O
single	JJ	O
blinded	VBD	O
prospective	JJ	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
and	CC	O
single	JJ	O
blinded	VBD	O
randomised	VBN	O
crossover	RB	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
local	JJ	O
warming	NN	O
of	IN	O
the	DT	O
lower	JJR	O
arm	NN	O
and	CC	O
hand	NN	O
facilitates	NNS	O
peripheral	VBP	O
venous	JJ	O
cannulation	NN	O
.	.	O

DESIGN	NNP	O
Single	NNP	O
blinded	VBD	O
prospective	JJ	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
and	CC	O
single	JJ	O
blinded	VBD	O
randomised	VBN	O
crossover	RB	O
trial	NN	O
.	.	O

SETTING	NNP	O
Neurosurgical	JJ	O
unit	NN	O
and	CC	O
haematology	NN	O
ward	NN	O
of	IN	O
university	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	CC	O
100	CD	SampleSize
neurosurgical	JJ	O
patients	NNS	O
and	CC	O
40	CD	SampleSize
patients	NNS	O
with	IN	O
leukaemia	NNS	Condition
who	WP	O
required	VBD	O
chemotherapy	NN	O
.	.	O

INTERVENTIONS	NNP	O
Neurosurgical	JJ	O
patients	NNS	O
'	POS	O
hands	NNS	O
and	CC	O
forearms	NNS	O
were	VBD	O
covered	VBN	O
for	IN	O
15	CD	O
minutes	NNS	O
with	IN	O
a	DT	O
carbon	NN	O
fibre	NN	O
heating	VBG	O
mitt	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
active	JJ	O
warming	NN	O
at	IN	O
52	CD	O
degrees	NNS	O
C	NNP	O
or	CC	O
passive	JJ	O
insulation	NN	O
(	(	O
heater	NN	O
not	RB	O
activated	VBN	O
)	)	O
.	.	O

The	DT	O
same	JJ	O
warming	NN	O
system	NN	O
was	VBD	O
used	VBN	O
for	IN	O
10	CD	O
minutes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
leukaemia	NN	O
.	.	O

They	PRP	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
active	JJ	O
warming	NN	O
or	CC	O
passive	JJ	O
insulation	NN	O
on	IN	O
day	NN	O
1	CD	O
and	CC	O
given	VBN	O
alternative	JJ	O
treatment	NN	O
during	IN	O
the	DT	O
subsequent	JJ	O
visit	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
PRIMARY	NNP	O
:	:	O
success	NN	O
rate	NN	O
for	IN	O
insertion	NN	O
of	IN	O
18	CD	O
gauge	NN	O
cannula	NN	O
into	IN	O
vein	NN	O
on	IN	O
back	NN	O
of	IN	O
hand	NN	O
.	.	O

SECONDARY	NN	O
:	:	O
time	NN	O
required	VBN	O
for	IN	O
successful	JJ	O
cannulation	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
neurosurgical	JJ	O
patients	NNS	O
,	,	O
it	PRP	O
took	VBD	O
36	CD	O
seconds	NNS	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
31	CD	O
to	TO	O
40	CD	O
seconds	NNS	O
)	)	O
to	TO	O
insert	VB	O
a	DT	O
cannula	NN	O
in	IN	O
the	DT	O
active	JJ	O
warming	NN	O
group	NN	O
and	CC	O
62	CD	O
(	(	O
50	CD	O
to	TO	O
74	CD	O
)	)	O
seconds	NNS	O
in	IN	O
the	DT	O
passive	JJ	O
insulation	NN	O
group	NN	O
(	(	O
P=0.002	NNP	O
)	)	O
.	.	O

Three	NNP	O
(	(	O
6	CD	O
%	NN	O
)	)	O
first	RB	O
attempts	VBZ	O
failed	VBN	O
in	IN	O
the	DT	O
active	JJ	O
warming	VBG	O
group	NN	O
compared	VBN	O
with	IN	O
14	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
passive	JJ	O
insulation	NN	O
group	NN	O
(	(	O
P=0.008	NNP	O
)	)	O
.	.	O

The	DT	O
crossover	NN	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
leukaemia	NN	O
showed	VBD	O
that	IN	O
insertion	NN	O
time	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
20	CD	O
seconds	NNS	O
(	(	O
8	CD	O
to	TO	O
32	CD	O
,	,	O
P=0.013	NNP	O
)	)	O
with	IN	O
active	JJ	O
warming	NN	O
and	CC	O
that	IN	O
failure	NN	O
rates	NNS	O
at	IN	O
first	JJ	O
attempt	NN	O
were	VBD	O
6	CD	O
%	NN	O
with	IN	O
warming	VBG	O
and	CC	O
30	CD	O
%	NN	O
with	IN	O
passive	JJ	O
insulation	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Local	NNP	O
warming	VBG	O
facilitates	VBZ	O
the	DT	O
insertion	NN	O
of	IN	O
peripheral	JJ	O
venous	JJ	O
cannulas	NNS	O
,	,	O
reducing	VBG	O
both	DT	O
time	NN	O
and	CC	O
number	NN	O
of	IN	O
attempts	NNS	O
required	VBN	O
.	.	O

This	DT	O
may	MD	O
decrease	VB	O
the	DT	O
time	NN	O
staff	NN	O
spend	VBP	O
inserting	VBG	O
cannulas	NN	O
,	,	O
reduce	VB	O
supply	NN	O
costs	NNS	O
,	,	O
and	CC	O
improve	VB	O
patient	JJ	O
satisfaction	NN	O
.	.	O

Improved	VBN	O
fibrinolysis	NN	O
after	IN	O
1-year	JJ	O
treatment	NN	O
with	IN	O
HMG	NNP	O
CoA	NNP	O
reductase	NN	O
inhibitors	NNS	O
in	IN	O
patients	NNS	Condition
with	IN	Condition
coronary	JJ	Condition
heart	NN	Condition
disease	NN	Condition
.	.	O

The	DT	O
study	NN	O
was	VBD	O
aimed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
different	JJ	O
statins	NNS	O
on	IN	O
the	DT	O
levels	NNS	O
of	IN	O
haemostatic	JJ	O
variables	NNS	O
reflecting	VBG	O
procoagulant	NN	O
and	CC	O
fibrinolytic	JJ	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
,	,	O
with	IN	O
the	DT	O
hypothesis	NN	O
that	WDT	O
statins	VBZ	O
might	MD	O
beneficially	RB	O
modify	VB	O
these	DT	O
levels	NNS	O
.	.	O

Fifty-eight	JJ	SampleSize
patients	NNS	SampleSize
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
atorvastatin	NN	O
(	(	O
n=28	JJ	O
)	)	O
or	CC	O
simvastatin	NN	O
(	(	O
n=30	JJ	O
)	)	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
in	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
20	CD	O
mg/day	NN	O
.	.	O

Fasting	VBG	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
before	IN	O
and	CC	O
after	IN	O
12-month	JJ	O
treatment	NN	O
for	IN	O
determinations	NNS	O
of	IN	O
fibrinogen	NN	O
,	,	O
prothrombin	JJ	O
fragment	NN	O
1+2	CD	O
(	(	O
F1+2	NNP	O
)	)	O
,	,	O
plasma	JJ	O
D-dimer	NNP	O
,	,	O
soluble	JJ	O
tissue	NN	O
factor	NN	O
,	,	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
(	(	O
tPA	NN	O
)	)	O
antigen	NN	O
,	,	O
tPA	NN	O
activity	NN	O
,	,	O
plasminogen	NN	O
activator	NN	O
inhibitor	JJ	O
type-1	JJ	O
activity	NN	O
(	(	O
PAI-1	NNP	O
activity	NN	O
)	)	O
and	CC	O
serum	JJ	O
D-dimer	NNP	O
as	IN	O
a	DT	O
global	JJ	O
test	NN	O
of	IN	O
fibrinolytic	JJ	O
activity	NN	O
.	.	O

In	IN	O
the	DT	O
total	JJ	O
population	NN	O
,	,	O
improved	VBN	O
fibrinolytic	JJ	O
activity	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
1	CD	O
year	NN	O
with	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
D-dimer	NNP	O
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
tPA	JJ	O
activity	NN	O
(	(	O
P=.024	NNP	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
tPA	NN	O
antigen	NN	O
(	(	O
P=.048	NNP	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
measured	JJ	O
coagulation	NN	O
variables	NNS	O
.	.	O

Separately	RB	O
examined	VBD	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	O
profile	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
atorvastatin	NN	O
group	NN	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
serum	JJ	O
D-dimer	NNP	O
(	(	O
P=.005	NNP	O
)	)	O
,	,	O
a	DT	O
borderline	JJ	O
increase	NN	O
in	IN	O
tPA	JJ	O
activity	NN	O
(	(	O
P=.083	NNP	O
)	)	O
and	CC	O
a	DT	O
borderline	NN	O
reduction	NN	O
in	IN	O
tPA	NN	O
antigen	NN	O
(	(	O
P=.069	NNP	O
)	)	O
.	.	O

Within	IN	O
the	DT	O
simvastatin	NN	O
group	NN	O
,	,	O
a	DT	O
reduction	NN	O
in	IN	O
prothrombin	NN	O
F1+2	NNP	O
was	VBD	O
observed	VBN	O
(	(	O
P=.038	NNP	O
)	)	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
changes	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
global	JJ	O
fibrinolysis	NN	O
(	(	O
serum	JJ	O
D-dimer	NNP	O
,	,	O
P=.046	NNP	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	O
profile	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
statin	NN	O
treatment	NN	O
,	,	O
most	RBS	O
pronounced	JJ	O
with	IN	O
atorvastatin	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
drugs	NNS	O
promote	VBP	O
a	DT	O
profibrinolytic	JJ	O
profile	NN	O
,	,	O
and	CC	O
may	MD	O
in	IN	O
part	NN	O
explain	VBP	O
the	DT	O
benefit	NN	O
of	IN	O
statin	NN	O
treatment	NN	O
rendered	VBN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CHD	NNP	O
.	.	O

Age-related	JJ	O
response	NN	O
to	TO	O
two	CD	O
Haemophilus	NNP	O
influenzae	NN	O
type	NN	O
b	NN	O
vaccines	NNS	O
.	.	O

Two	CD	O
types	NNS	O
of	IN	O
Hib	NNP	O
vaccines	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
efficacy	NN	O
and	CC	O
safety	NN	O
in	IN	O
71	CD	O
normal	JJ	O
children	NNS	O
in	IN	O
three	CD	O
age	NN	O
groups	NNS	O
:	:	O
36	CD	O
to	TO	O
72	CD	O
months	NNS	O
,	,	O
15	CD	O
to	TO	O
18	CD	O
months	NNS	O
,	,	O
and	CC	O
6	CD	O
to	TO	O
8	CD	O
months	NNS	O
.	.	O

One	CD	O
vaccine	NN	O
contained	VBD	O
the	DT	O
Hib-specific	NNP	O
capsular	JJ	O
polysaccharide	NN	O
,	,	O
PRP	NNP	O
;	:	O
the	DT	O
second	JJ	O
vaccine	NN	O
contained	VBN	O
PRP	NNP	O
combined	VBN	O
with	IN	O
pertussis	NN	O
vaccine	NN	O
,	,	O
PRP-P.	NNP	O
A	NNP	O
third	JJ	O
vaccine	NN	O
,	,	O
DTP	NNP	O
,	,	O
was	VBD	O
administered	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
for	IN	O
each	DT	O
age	NN	O
.	.	O

Anti-PRP	NNP	O
antibody	NN	O
levels	NNS	O
were	VBD	O
greater	JJR	O
after	IN	O
vaccination	NN	O
with	IN	O
PRP-P	NNP	O
than	IN	O
after	IN	O
PRP	NNP	O
in	IN	O
all	DT	O
three	CD	O
age	NN	O
groups	NNS	O
.	.	O

Immunoresponsiveness	NN	O
to	TO	O
both	DT	O
vaccines	NNS	O
increased	VBD	O
with	IN	O
age	NN	O
.	.	O

A	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
was	VBD	O
seen	VBN	O
with	IN	O
both	DT	O
PRP	NNP	O
(	(	O
15	CD	O
%	NN	O
)	)	O
and	CC	O
PRP-P	NNP	O
(	(	O
20	CD	O
%	NN	O
)	)	O
than	IN	O
with	IN	O
DTP	NNP	O
(	(	O
56	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
PRP-P	NNP	O
is	VBZ	O
both	DT	O
well	RB	O
tolerated	VBN	O
clinically	RB	O
and	CC	O
has	VBZ	O
greater	JJR	O
immunogenicity	NN	O
than	IN	O
PRP	NNP	O
.	.	O

A	DT	O
web-based	JJ	O
patient	NN	O
activation	NN	O
intervention	NN	O
to	TO	O
improve	VB	O
hypertension	NN	O
care	NN	O
:	:	O
study	NN	O
design	NN	O
and	CC	O
baseline	NN	O
characteristics	NNS	O
in	IN	O
the	DT	O
web	NN	O
hypertension	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
the	DT	O
known	JJ	O
health	NN	O
risks	NNS	O
of	IN	O
hypertension	NN	O
,	,	O
many	JJ	O
hypertensive	JJ	Condition
patients	NNS	O
still	RB	O
have	VBP	O
uncontrolled	VBN	O
blood	NN	O
pressure	NN	O
.	.	O

Clinical	JJ	O
inertia	NN	O
,	,	O
the	DT	O
tendency	NN	O
of	IN	O
physicians	NNS	O
not	RB	O
to	TO	O
intensify	VB	O
treatment	NN	O
,	,	O
is	VBZ	O
a	DT	O
common	JJ	O
barrier	NN	O
in	IN	O
controlling	VBG	O
chronic	JJ	O
diseases	NNS	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
aimed	VBN	O
at	IN	O
determining	VBG	O
the	DT	O
impact	NN	O
of	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
ask	VB	O
providers	NNS	O
to	TO	O
make	VB	O
changes	NNS	O
to	TO	O
their	PRP$	O
care	NN	O
through	IN	O
tailored	VBN	O
feedback	NN	O
.	.	O

METHODS	NNP	O
Diagnosed	VBD	O
hypertensive	JJ	Condition
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
RCT	NNP	O
and	CC	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
study	NN	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
the	DT	O
intervention	NN	O
condition	NN	O
--	:	O
Web-based	JJ	O
hypertension	NN	O
feedback	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
's	POS	O
self-report	NN	O
of	IN	O
health	NN	O
variables	NNS	O
and	CC	O
previous	JJ	O
BP	NNP	O
measurements	NNS	O
,	,	O
to	TO	O
prompt	VB	O
them	PRP	O
to	TO	O
ask	VB	O
questions	NNS	O
during	IN	O
their	PRP$	O
next	JJ	O
physician	NN	O
's	POS	O
visit	NN	O
about	IN	O
hypertension	NN	O
care	NN	O
(	(	O
2	CD	O
)	)	O
the	DT	O
control	NN	O
condition	NN	O
--	:	O
Web-based	JJ	O
preventive	JJ	O
health	NN	O
feedback	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
individual	NN	O
's	POS	O
self-report	NN	O
of	IN	O
receiving	VBG	O
preventive	JJ	O
care	NN	O
(	(	O
e.g.	UH	O
,	,	O
pap	JJ	O
testing	VBG	O
)	)	O
,	,	O
to	TO	O
prompt	VB	O
them	PRP	O
to	TO	O
ask	VB	O
questions	NNS	O
during	IN	O
their	PRP$	O
next	JJ	O
physician	NN	O
's	POS	O
visit	NN	O
about	IN	O
preventive	JJ	O
care	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
the	DT	O
study	NN	O
is	VBZ	O
change	VBN	O
in	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
change	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
with	IN	O
controlled	VBN	O
blood	NN	O
pressure	NN	O
.	.	O

CONCLUSION	NNP	O
Five	CD	SampleSize
hundred	VBD	SampleSize
participants	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
baseline	JJ	O
characteristics	NNS	O
include	VBP	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
60.0	CD	Age
years	NNS	Age
;	:	O
57.6	CD	O
%	NN	O
female	NN	Sex
;	:	O
and	CC	O
77.6	CD	O
%	NN	O
white	JJ	O
.	.	O

Overall	JJ	O
37.7	CD	O
%	NN	O
participants	NNS	O
had	VBD	O
uncontrolled	VBN	Condition
blood	NN	Condition
pressure	NN	Condition
;	:	O
the	DT	O
mean	NN	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
was	VBD	O
in	IN	O
the	DT	O
obese	JJ	O
range	NN	O
(	(	O
32.4	CD	O
)	)	O
and	CC	O
21.8	CD	O
%	NN	O
had	VBD	O
diabetes	NNS	Condition
.	.	O

By	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
become	VB	O
involved	VBN	O
in	IN	O
their	PRP$	O
own	JJ	O
care	NN	O
,	,	O
we	PRP	O
believe	VBP	O
the	DT	O
addition	NN	O
of	IN	O
the	DT	O
web-based	JJ	O
intervention	NN	O
will	MD	O
improve	VB	O
blood	NN	O
pressure	NN	O
control	NN	O
compared	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
who	WP	O
receive	VBP	O
web-based	JJ	O
preventive	JJ	O
messages	NNS	O
unrelated	VBN	O
to	TO	O
hypertension	NN	O
.	.	O

Feedlot	NNP	O
performance	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
of	IN	O
Holstein	NNP	Condition
steers	NNS	Sex
as	IN	O
affected	VBN	O
by	IN	O
source	NN	O
of	IN	O
dietary	JJ	O
protein	NN	O
and	CC	O
level	NN	O
of	IN	O
ruminally	RB	O
protected	VBN	O
lysine	NN	O
and	CC	O
methionine	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
source	NN	O
of	IN	O
dietary	JJ	O
CP	NNP	O
and	CC	O
level	NN	O
of	IN	O
ruminally	RB	O
protected	VBN	O
lysine	NN	O
and	CC	O
methionine	NN	O
(	(	O
RPLM	NNP	O
)	)	O
on	IN	O
feedlot	NN	O
performance	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
of	IN	O
Holstein	NNP	Condition
steers	NNS	Condition
during	IN	O
a	DT	O
growing-finishing	JJ	O
trial	NN	O
(	(	O
266	CD	O
d	NN	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
168	CD	SampleSize
Holstein	NNP	Condition
steers	NNS	Condition
(	(	O
182.7	CD	Condition
+/-	JJ	Condition
27.5	CD	Condition
kg	NN	Condition
)	)	O
were	VBD	O
used	VBN	O
in	IN	O
a	DT	O
completely	RB	O
randomized	JJ	O
design	NN	O
experiment	NN	O
(	(	O
eight	CD	O
treatments	NNS	O
;	:	O
three	CD	O
pens	NNS	O
of	IN	O
seven	CD	O
steers/treatment	NN	O
)	)	O
.	.	O

Steers	NNPS	O
were	VBD	O
given	VBN	O
ad	NN	O
libitum	NN	O
access	NN	O
to	TO	O
high-concentrate	JJ	O
diets	NNS	O
(	(	O
13	CD	O
%	NN	O
CP	NNP	O
)	)	O
containing	VBG	O
71	CD	O
%	NN	O
whole	JJ	O
shelled	VBN	O
corn	NN	O
,	,	O
10	CD	O
%	NN	O
corn	NN	O
silage	NN	O
,	,	O
4	CD	O
%	NN	O
condensed	JJ	O
distillers	NNS	O
solubles	NNS	O
,	,	O
and	CC	O
15	CD	O
%	NN	O
protein	NN	O
supplements	NNS	O
(	(	O
DM	NNP	O
basis	NN	O
)	)	O
.	.	O

Treatments	NNS	O
were	VBD	O
arranged	VBN	O
as	IN	O
a	DT	O
2	CD	O
x	NN	O
4	CD	O
factorial	JJ	O
.	.	O

The	DT	O
main	JJ	O
factors	NNS	O
were	VBD	O
two	CD	O
sources	NNS	O
of	IN	O
dietary	JJ	O
CP	NNP	O
and	CC	O
four	CD	O
levels	NNS	O
of	IN	O
RPLM	NNP	O
.	.	O

The	DT	O
sources	NNS	O
of	IN	O
dietary	JJ	O
CP	NNP	O
were	VBD	O
soybean	JJ	O
meal	NN	O
(	(	O
SBM	NNP	O
)	)	O
or	CC	O
SBM	NNP	O
and	CC	O
urea	JJ	O
(	(	O
SBM-U	NNP	O
)	)	O
.	.	O

Urea-N	NNP	O
replaced	VBD	O
50	CD	O
%	NN	O
of	IN	O
SBM-N	NNP	O
in	IN	O
the	DT	O
SBM-U	NNP	O
diet	NN	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
RPLM	NNP	O
were	VBD	O
0	CD	O
,	,	O
5	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
15	CD	O
g	NN	O
per	IN	O
steer	NN	O
daily	RB	O
.	.	O

No	UH	O
interactions	NNS	O
(	(	O
P	NNP	O
>	NNP	O
.10	NNP	O
)	)	O
between	IN	O
source	NN	O
of	IN	O
dietary	JJ	O
CP	NNP	O
and	CC	O
level	NN	O
of	IN	O
RPLM	NNP	O
were	VBD	O
observed	VBN	O
for	IN	O
feedlot	NN	O
performance	NN	O
or	CC	O
carcass	NN	O
characteristics	NNS	O
.	.	O

Feedlot	NNP	O
performance	NN	O
showed	VBD	O
an	DT	O
advantage	NN	O
(	(	O
P	NNP	O
<	NNP	O
.10	NNP	O
)	)	O
to	TO	O
feeding	VBG	O
SMB	NNP	O
during	IN	O
the	DT	O
first	JJ	O
84	CD	O
d	NN	O
of	IN	O
the	DT	O
trial	NN	O
and	CC	O
an	DT	O
advantage	NN	O
to	TO	O
feeding	VBG	O
SBM-U	NNP	O
during	IN	O
the	DT	O
last	JJ	O
98	CD	O
d	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

However	RB	O
,	,	O
feedlot	JJ	O
performance	NN	O
for	IN	O
the	DT	O
whole	JJ	O
trial	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
(	(	O
except	IN	O
for	IN	O
fat	JJ	O
thickness	NN	O
)	)	O
were	VBD	O
not	RB	O
affected	VBN	O
(	(	O
P	NNP	O
>	NNP	O
.10	NNP	O
)	)	O
by	IN	O
the	DT	O
source	NN	O
of	IN	O
dietary	JJ	O
CP	NNP	O
.	.	O

Steers	NNP	O
fed	VBD	O
diets	NNS	O
containing	VBG	O
SBM-U	NNP	O
had	VBD	O
12	CD	O
%	NN	O
less	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.10	NNP	O
)	)	O
fat	VBZ	O
thickness	JJ	O
than	IN	O
those	DT	O
fed	JJ	O
diets	NNS	O
containing	VBG	O
SBM	NNP	O
.	.	O

Supplementation	NN	O
of	IN	O
diets	NNS	O
with	IN	O
increasing	VBG	O
levels	NNS	O
of	IN	O
RPLM	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
(	(	O
P	NNP	O
>	NNP	O
.10	NNP	O
)	)	O
ADG	NNP	O
or	CC	O
carcass	NN	O
characteristics	NNS	O
.	.	O

However	RB	O
,	,	O
DMI	NNP	O
and	CC	O
gain	NN	O
:	:	O
feed	NN	O
showed	VBD	O
cubic	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.10	NNP	O
)	)	O
responses	VBZ	O
to	TO	O
increasing	VBG	O
dietary	JJ	O
level	NN	O
of	IN	O
RPLM	NNP	O
.	.	O

Supplementation	NN	O
of	IN	O
RPLM	NNP	O
at	IN	O
the	DT	O
10	CD	O
g/d	NNS	O
level	NN	O
improved	VBD	O
gain	NN	O
:	:	O
feed	VBN	O
by	IN	O
12	CD	O
%	NN	O
during	IN	O
the	DT	O
last	JJ	O
98	CD	O
d	NN	O
of	IN	O
the	DT	O
trial	NN	O
,	,	O
and	CC	O
this	DT	O
was	VBD	O
a	DT	O
direct	JJ	O
response	NN	O
to	TO	O
the	DT	O
cubic	JJ	O
effects	NNS	O
of	IN	O
RPLM	NNP	O
on	IN	O
DMI	NNP	O
.	.	O

Results	NNP	O
suggest	VBP	O
a	DT	O
cost	NN	O
advantage	NN	O
for	IN	O
replacing	VBG	O
50	CD	O
%	NN	O
of	IN	O
SBM-N	NNP	O
with	IN	O
that	DT	O
from	IN	O
urea	JJ	O
in	IN	O
high-corn	JJ	O
diets	NNS	O
without	IN	O
negative	JJ	O
effects	NNS	O
on	IN	O
feedlot	NN	O
performance	NN	O
or	CC	O
carcass	NN	O
characteristics	NNS	O
of	IN	O
growing-finishing	JJ	O
Holstein	NNP	Condition
steers	NNS	Condition
with	IN	O
extended	JJ	O
feeding	NN	O
periods	NNS	O
(	(	O
266	CD	O
d	NN	O
)	)	O
.	.	O

These	DT	O
types	NNS	O
of	IN	O
diets	NNS	O
seem	VBP	O
to	TO	O
meet	VB	O
the	DT	O
amino	NN	O
acid	NN	O
requirements	NNS	O
and	CC	O
are	VBP	O
not	RB	O
limiting	VBG	O
in	IN	O
lysine	NN	O
and	CC	O
methionine	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
ebrotidine	NN	O
and	CC	O
ranitidine	NN	O
combined	VBN	O
with	IN	O
amoxicillin	NN	O
and	CC	O
metronidazole	NN	O
in	IN	O
the	DT	O
eradication	NN	O
of	IN	O
Helicobacter	NNP	O
pylori	NN	O
in	IN	O
patients	NNS	O
with	IN	O
duodenal	JJ	Condition
ulcer	NN	Condition
.	.	O

This	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
phase	VB	O
III	NNP	O
clinical	JJ	O
trial	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
two	CD	O
parallel	JJ	O
groups	NNS	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
ebrotidine	NN	O
(	(	O
N-	JJ	O
[	NN	O
(	(	O
E	NNP	O
)	)	O
-	:	O
[	JJ	O
[	JJ	O
2-	JJ	O
[	NN	O
[	NNP	O
[	NNP	O
2-	JJ	O
[	NNP	O
(	(	O
diaminomethylene	NN	O
)	)	O
amino	NN	O
]	JJ	O
-4-thiazolyl	NNP	O
]	NNP	O
methyl	NN	O
]	NNP	O
thio	NN	O
]	NNP	O
ethyl	VBZ	O
]	NNP	O
amino	NN	O
]	NNP	O
methylene	NN	O
]	NNP	O
-4-bromo-benzenesulfonamide	NNP	O
,	,	O
CAS	NNP	O
100981-43-9	CD	O
,	,	O
FI-3542	NNP	O
)	)	O
400	CD	O
mg	NN	O
and	CC	O
ranitidine	VB	O
300	CD	O
mg	NN	O
given	VBN	O
in	IN	O
single	JJ	O
evening	NN	O
dose	NN	O
,	,	O
combined	VBN	O
with	IN	O
amoxicillin	JJ	O
750	CD	O
mg	NN	O
and	CC	O
metronidazole	$	O
500	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
,	,	O
in	IN	O
the	DT	O
eradication	NN	O
of	IN	O
Helicobacter	NNP	O
pylori	NN	O
in	IN	O
patients	NNS	O
with	IN	O
duodenal	JJ	O
ulcer	NN	O
.	.	O

Thirty	JJ	O
patients	NNS	O
were	VBD	O
included	VBN	O
,	,	O
divided	VBN	O
into	IN	O
two	CD	SampleSize
groups	NNS	SampleSize
of	IN	SampleSize
15	CD	SampleSize
,	,	O
to	TO	O
whom	WP	O
one	CD	O
of	IN	O
the	DT	O
study	NN	O
therapies	NNS	O
was	VBD	O
administered	VBN	O
based	VBN	O
on	IN	O
a	DT	O
randomization	NN	O
code	NN	O
.	.	O

Clinical	JJ	O
and	CC	O
endoscopic	JJ	O
controls	NNS	O
were	VBD	O
performed	VBN	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
seen	VBN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
demographic	JJ	O
parameters	NNS	O
and	CC	O
clinical	JJ	O
histories	NNS	O
.	.	O

They	PRP	O
were	VBD	O
both	DT	O
perfectly	RB	O
homogeneous	JJ	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
eradication	NN	O
of	IN	O
both	DT	O
therapies	NNS	O
in	IN	O
both	DT	O
the	DT	O
antrum	NN	O
and	CC	O
gastric	JJ	O
body	NN	O
samples	NNS	O
(	(	O
over	IN	O
80	CD	O
%	NN	O
eradication	NN	O
)	)	O
,	,	O
allowing	VBG	O
the	DT	O
results	NNS	O
to	TO	O
be	VB	O
classified	VBN	O
as	IN	O
satisfactory	NN	O
.	.	O

Moreover	RB	O
,	,	O
perfect	JJ	O
control	NN	O
was	VBD	O
achieved	VBN	O
through	IN	O
the	DT	O
study	NN	O
of	IN	O
clinical	JJ	O
symptoms	NNS	O
,	,	O
which	WDT	O
even	RB	O
disappeared	VBD	O
in	IN	O
some	DT	O
cases	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
healing	VBG	O
rate	NN	O
of	IN	O
the	DT	O
duodenal	JJ	O
ulcer	NN	O
after	IN	O
four	CD	O
weeks	NNS	O
,	,	O
86.7	CD	O
%	NN	O
being	VBG	O
achieved	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Differential	JJ	O
inhibition	NN	O
of	IN	O
bronchoconstriction	NN	O
by	IN	O
the	DT	O
calcium	NN	O
channel	NN	O
blockers	NNS	O
,	,	O
verapamil	NN	O
and	CC	O
nifedipine	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
the	DT	O
calcium	NN	O
channel	NN	O
blocking	VBG	O
agents	NNS	O
can	MD	O
inhibit	VB	O
experimentally	RB	O
induced	JJ	O
bronchoconstriction	NN	O
in	IN	O
asthmatics	NNS	Condition
,	,	O
but	CC	O
their	PRP$	O
protective	JJ	O
action	NN	O
has	VBZ	O
been	VBN	O
variable	JJ	O
.	.	O

To	TO	O
clarify	VB	O
the	DT	O
influence	NN	O
of	IN	O
stimulus	NN	O
intensity	NN	O
and	CC	O
choice	NN	O
of	IN	O
calcium	NN	O
blocker	NN	O
on	IN	O
these	DT	O
reported	VBN	O
differences	NNS	O
in	IN	O
outcome	NN	O
,	,	O
we	PRP	O
performed	VBD	O
noncumulative	JJ	O
thermal	JJ	O
stimulus-response	JJ	O
curves	NNS	O
using	VBG	O
isocapnic	JJ	O
hyperventilation	NN	O
of	IN	O
cold	JJ	O
air	NN	O
in	IN	O
8	CD	SampleSize
asthmatics	NNS	Condition
.	.	O

Subjects	NNS	O
received	VBD	O
pretreatment	JJ	O
with	IN	O
orally	RB	O
administered	VBN	O
nifedipine	NN	O
(	(	O
20	CD	O
mg	NN	O
)	)	O
,	,	O
intravenously	RB	O
administered	VBN	O
verapamil	NN	O
(	(	O
10	CD	O
mg	NN	O
bolus	NN	O
followed	VBN	O
by	IN	O
a	DT	O
continuous	JJ	O
infusion	NN	O
)	)	O
,	,	O
or	CC	O
appropriate	JJ	O
placebos	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
fashion	NN	O
.	.	O

Verapamil	NNP	O
afforded	VBD	O
no	DT	O
consistent	JJ	O
protection	NN	O
against	IN	O
the	DT	O
thermal	JJ	O
challenges	NNS	O
,	,	O
whereas	NNS	O
nifedipine	VBP	O
significantly	RB	O
blunted	VBN	O
the	DT	O
bronchoconstrictor	NN	O
response	NN	O
to	TO	O
stimuli	NNS	O
of	IN	O
low	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
and	CC	O
middle	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.03	CD	O
)	)	O
intensity	NN	O
.	.	O

At	IN	O
the	DT	O
highest	JJS	O
thermal	JJ	O
burden	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
nifedipine	NN	O
was	VBD	O
inconsistent	JJ	O
and	CC	O
not	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
that	DT	O
of	IN	O
placebo	NN	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
protection	NN	O
from	IN	O
bronchoconstriction	NN	O
afforded	VBN	O
by	IN	O
the	DT	O
calcium	NN	O
channel	NN	O
blockers	NNS	O
depends	VBZ	O
on	IN	O
the	DT	O
choice	NN	O
of	IN	O
agent	NN	O
and	CC	O
the	DT	O
intensity	NN	O
of	IN	O
the	DT	O
bronchoconstricting	NN	O
stimulus	NN	O
,	,	O
and	CC	O
they	PRP	O
raise	VBP	O
the	DT	O
possibility	NN	O
that	IN	O
the	DT	O
contribution	NN	O
of	IN	O
transmembrane	NN	O
calcium	NN	O
ion	NN	O
influx	NN	O
to	TO	O
the	DT	O
pathogenesis	NN	O
of	IN	O
bronchoconstriction	NN	O
may	MD	O
vary	VB	O
according	VBG	O
to	TO	O
stimulus	JJ	O
intensity	NN	O
.	.	O

Measuring	VBG	O
the	DT	O
impact	NN	O
of	IN	O
patient	JJ	O
counseling	NN	O
in	IN	O
the	DT	O
outpatient	JJ	O
pharmacy	NN	O
setting	NN	O
:	:	O
the	DT	O
research	NN	O
design	NN	O
of	IN	O
the	DT	O
Kaiser	NNP	O
Permanente/USC	NNP	O
patient	NN	O
consultation	NN	O
study	NN	O
.	.	O

This	DT	O
article	NN	O
describes	VBZ	O
the	DT	O
research	NN	O
method	NN	O
used	VBN	O
to	TO	O
measure	VB	O
the	DT	O
impact	NN	O
of	IN	O
three	CD	O
alternative	JJ	O
models	NNS	O
of	IN	O
patient	JJ	O
counseling	NN	O
in	IN	O
the	DT	O
outpatient	JJ	O
pharmacy	NN	O
setting	VBG	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
pharmacies	NNS	O
operated	VBN	O
by	IN	O
the	DT	O
Southern	NNP	O
California	NNP	O
region	NN	O
Kaiser	NNP	O
Permanente	NNP	O
Medical	NNP	O
Care	NNP	O
Program	NNP	O
.	.	O

Both	DT	O
random	JJ	O
assignment	NN	O
and	CC	O
large-scale	JJ	O
geographic	JJ	O
area	NN	O
research	NN	O
designs	NNS	O
were	VBD	O
used	VBN	O
.	.	O

The	DT	O
presentation	NN	O
of	IN	O
the	DT	O
research	NN	O
design	NN	O
includes	VBZ	O
discussions	NNS	O
of	IN	O
data	NNS	O
collection	NN	O
and	CC	O
patient	JJ	O
sampling	VBG	O
methods	NNS	O
;	:	O
the	DT	O
measurement	NN	O
of	IN	O
patient	JJ	O
outcomes	NNS	O
,	,	O
including	VBG	O
measures	NNS	O
of	IN	O
health	NN	O
care	NN	O
costs	NNS	O
and	CC	O
utilization	NN	O
,	,	O
patient	JJ	O
functional	JJ	O
status	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Demographic	NNP	O
data	NNS	O
are	VBP	O
presented	VBN	O
for	IN	O
the	DT	O
study	NN	O
population	NN	O
,	,	O
including	VBG	O
an	DT	O
analysis	NN	O
of	IN	O
potential	JJ	O
biased	JJ	O
selection	NN	O
of	IN	O
patients	NNS	O
electing	VBG	O
to	TO	O
participate	VB	O
in	IN	O
random	JJ	O
assignment	NN	O
.	.	O

Data	NNS	O
are	VBP	O
also	RB	O
presented	VBN	O
documenting	VBG	O
potential	JJ	O
selection	NN	O
bias	NN	O
across	IN	O
geographically	RB	O
determined	VBN	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
geographic	JJ	O
area	NN	O
design	NN	O
arm	NN	O
.	.	O

Finally	RB	O
,	,	O
the	DT	O
article	NN	O
presents	VBZ	O
the	DT	O
analysis	NN	O
plan	NN	O
for	IN	O
the	DT	O
study	NN	O
and	CC	O
discusses	NNS	O
study	VBP	O
limitations	NNS	O
.	.	O

[	JJ	O
Obstetrical	NNP	O
analgesia	NN	O
with	IN	O
tramadol	JJ	O
]	NN	O
.	.	O

Parenteral	JJ	O
analgesia	NN	O
with	IN	O
Tramal	NNP	O
was	VBD	O
performed	VBN	O
in	IN	O
23	CD	O
normal	JJ	O
deliveries	NNS	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
group	NN	O
of	IN	O
normal	JJ	O
deliveries	NNS	O
in	IN	O
which	WDT	O
analgesia	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
pethidine	NN	O
.	.	O

Both	DT	O
medicaments	NNS	O
excerted	VBD	O
an	DT	O
identical	JJ	O
analgetic	JJ	O
efficiency	NN	O
.	.	O

No	DT	O
adverse	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
Tramal	NNP	O
concerning	VBG	O
the	DT	O
follow-up	NN	O
of	IN	O
labour	NN	O
or	CC	O
the	DT	O
newborn	JJ	O
.	.	O

Tramal	JJ	O
can	MD	O
be	VB	O
recommended	VBN	O
for	IN	O
obstetrical	JJ	O
analgesia	NN	O
since	IN	O
it	PRP	O
does	VBZ	O
not	RB	O
excert	VB	O
inhibitory	JJ	O
effects	NNS	O
upon	IN	O
the	DT	O
respiratory	NN	O
center	NN	O
.	.	O

Neurocognitive	JJ	O
outcomes	NNS	O
in	IN	O
off-pump	JJ	O
versus	NN	O
on-pump	JJ	O
bypass	NN	O
surgery	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Cognitive	NNP	O
difficulties	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
after	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
using	VBG	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
cognitive	JJ	O
benefit	NN	O
of	IN	O
off-pump	JJ	O
surgery	NN	O
remains	VBZ	O
unclear	JJ	O
.	.	O

METHODS	NNP	O
Consecutively	RB	O
listed	VBD	O
candidates	NNS	O
for	IN	O
elective	JJ	O
bypass	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
off-pump	JJ	O
or	CC	O
on-pump	JJ	O
techniques	NNS	O
(	(	O
n	JJ	O
=	NNP	O
107	CD	O
)	)	O
.	.	O

A	DT	O
battery	NN	O
of	IN	O
11	CD	O
standardized	JJ	O
neuropsychological	JJ	O
tests	NNS	O
was	VBD	O
administered	VBN	O
before	IN	O
surgery	NN	O
,	,	O
and	CC	O
again	RB	O
at	IN	O
2	CD	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
compared	VBN	O
using	VBG	O
a	DT	O
range	NN	O
of	IN	O
statistical	JJ	O
procedures	NNS	O
,	,	O
including	VBG	O
growth	NN	O
modeling	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
cognitive	JJ	O
test	NN	O
scores	NNS	O
between	IN	O
the	DT	O
off-pump	JJ	O
and	CC	O
on-pump	JJ	O
groups	NNS	O
using	VBG	O
t	JJ	O
tests	NNS	O
at	IN	O
any	DT	O
of	IN	O
the	DT	O
time	NN	O
points	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
off-pump	JJ	O
and	CC	O
on-pump	JJ	O
groups	NNS	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
cognitive	JJ	O
deficits	NNS	O
at	IN	O
2	CD	O
months	NNS	O
or	CC	O
6	CD	O
months	NNS	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
that	WDT	O
fewer	JJR	O
off-pump	NN	O
patients	NNS	O
showed	VBD	O
impairment	JJ	O
on	IN	O
one	CD	O
test	NN	O
of	IN	O
verbal	JJ	O
fluency	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

When	WRB	O
the	DT	O
pattern	NN	O
of	IN	O
cognitive	JJ	O
change	NN	O
over	IN	O
time	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
was	VBD	O
compared	VBN	O
using	VBG	O
sophisticated	JJ	O
modeling	NN	O
techniques	NNS	O
,	,	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
again	RB	O
comparable	JJ	O
,	,	O
except	IN	O
for	IN	O
results	NNS	O
on	IN	O
the	DT	O
test	NN	O
of	IN	O
verbal	JJ	O
fluency	NN	O
,	,	O
in	IN	O
which	WDT	O
the	DT	O
off-pump	NN	O
group	NN	O
showed	VBD	O
more	RBR	O
rapid	JJ	O
postsurgical	JJ	O
cognitive	NN	O
gains	NNS	O
than	IN	O
the	DT	O
on-pump	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
off-pump	JJ	O
group	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
generally	RB	O
comparable	JJ	O
to	TO	O
the	DT	O
on-pump	JJ	O
group	NN	O
in	IN	O
terms	NNS	O
of	IN	O
short-term	JJ	O
and	CC	O
long-term	JJ	O
postsurgical	JJ	O
neurocognitive	JJ	O
outcomes	NNS	O
.	.	O

Naltrexone	NN	O
in	IN	O
young	JJ	O
autistic	JJ	O
children	NNS	O
:	:	O
replication	NN	O
study	NN	O
and	CC	O
learning	NN	O
measures	NNS	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
expanded	VBD	O
upon	RB	O
previous	JJ	O
work	NN	O
on	IN	O
naltrexone	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
in	IN	O
young	JJ	O
autistic	JJ	O
children	NNS	O
and	CC	O
assessed	JJ	O
performance	NN	O
on	IN	O
learning	VBG	O
measures	NNS	O
.	.	O

METHOD	NNP	O
Eleven	NNP	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBD	O
3.0	CD	O
to	TO	O
8.3	CD	O
years	NNS	O
,	,	O
were	VBD	O
studied	VBN	O
in	IN	O
home	NN	O
,	,	O
school	NN	O
,	,	O
and	CC	O
outpatient	JJ	O
laboratory	NN	O
,	,	O
bringing	VBG	O
to	TO	O
24	CD	O
the	DT	O
combined	VBN	O
study	NN	O
sample	NN	O
.	.	O

Naltrexone	NNP	O
,	,	O
1.0	CD	O
mg/kg	NN	O
,	,	O
was	VBD	O
given	VBN	O
daily	RB	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
.	.	O

Dependent	JJ	O
measures	NNS	O
were	VBD	O
parent	NN	O
and	CC	O
teacher	RB	O
Clinical	JJ	O
Global	NNP	O
Impressions	NNP	O
(	(	O
CGI	NNP	O
)	)	O
and	CC	O
Naltrexone	NNP	O
Side	NNP	O
Effects	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
SE	NNP	O
)	)	O
,	,	O
Conners	NNPS	O
Parent	NNP	O
Impulsivity/Hyperactivity	NNP	O
Factor	NNP	O
,	,	O
Teacher	NNP	O
Hyperactivity	NNP	O
Factor	NNP	O
,	,	O
laboratory	NN	O
CGI	NNP	O
,	,	O
and	CC	O
analysis	NN	O
of	IN	O
videotaped	JJ	O
behavior	NN	O
.	.	O

Learning	VBG	O
measures	NNS	O
were	VBD	O
the	DT	O
Early	JJ	O
Intervention	NNP	O
Developmental	NNP	O
Profile-Language	NNP	O
and	CC	O
paired-associate	JJ	O
learning	NN	O
.	.	O

RESULTS	JJ	O
Comparisons	NNPS	O
between	IN	O
naltrexone	NN	O
and	CC	O
baseline	NN	O
,	,	O
but	CC	O
not	RB	O
naltrexone	RB	O
and	CC	O
placebo	NN	O
,	,	O
on	IN	O
parent	NN	O
and	CC	O
teacher	NN	O
ratings	NNS	O
showed	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

Three	CD	O
of	IN	O
11	CD	O
subjects	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
or	CC	O
more	JJR	O
settings	NNS	O
.	.	O

Side	JJ	O
effects	NNS	O
were	VBD	O
mild	JJ	O
.	.	O

Administering	VBG	O
naltrexone	NN	O
was	VBD	O
a	DT	O
challenge	NN	O
.	.	O

The	DT	O
combined	JJ	O
study	NN	O
sample	NN	O
showed	VBD	O
improvement	NN	O
on	IN	O
all	DT	O
parent	NN	O
measures	NNS	O
and	CC	O
on	IN	O
Teacher	NNP	O
CGI	NNP	O
and	CC	O
SE-Restlessness	NNP	O
compared	VBN	O
with	IN	O
baseline	NN	O
and	CC	O
placebo	NN	O
.	.	O

Eleven	NNP	O
of	IN	O
the	DT	O
24	CD	O
children	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
or	CC	O
more	JJR	O
settings	NNS	O
.	.	O

Scores	NNS	O
on	IN	O
learning	VBG	O
measures	NNS	O
did	VBD	O
not	RB	O
change	VB	O
across	IN	O
conditions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Naltrexone	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
modest	JJ	O
improvement	NN	O
of	IN	O
behavior	NN	O
in	IN	O
11	CD	O
of	IN	O
24	CD	O
children	NNS	O
,	,	O
but	CC	O
learning	VBG	O
did	VBD	O
not	RB	O
improve	VB	O
.	.	O

Intra-luminal	JJ	O
nicotine	NN	O
reduces	NNS	O
smooth	JJ	O
muscle	NN	O
tone	NN	O
and	CC	O
contractile	NN	O
activity	NN	O
in	IN	O
the	DT	O
distal	JJ	O
large	JJ	O
bowel	NN	O
.	.	O

BACKGROUND	NNP	O
Nicotine	NNP	O
may	MD	O
be	VB	O
of	IN	O
therapeutic	JJ	O
value	NN	O
in	IN	O
ulcerative	JJ	O
colitis	NN	O
(	(	O
UC	NNP	O
)	)	O
,	,	O
although	IN	O
its	PRP$	O
mechanism	NN	O
of	IN	O
action	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
solution	NN	O
of	IN	O
nicotine	NN	O
on	IN	O
sustained	JJ	O
resting	NN	O
pressure	NN	O
(	(	O
tone	NN	O
)	)	O
and	CC	O
contractile	JJ	O
activity	NN	O
in	IN	O
the	DT	O
human	JJ	O
colon	NN	O
.	.	O

METHODS	NNP	O
Ten	NNP	O
healthy	JJ	O
volunteers	NNS	O
,	,	O
and	CC	O
seven	CD	O
with	IN	O
UC	NNP	O
in	IN	O
symptomatic	JJ	O
remission	NN	O
took	VBD	O
part	NN	O
;	:	O
all	DT	O
were	VBD	O
non-smokers	NNS	O
.	.	O

All	DT	O
17	CD	O
subjects	NNS	O
were	VBD	O
given	VBN	O
nicotine	JJ	O
or	CC	O
placebo	JJ	O
solution	NN	O
on	IN	O
two	CD	O
separate	JJ	O
occasions	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
sequence	NN	O
.	.	O

A	DT	O
water-perfused	JJ	O
manometry	NN	O
catheter	NN	O
,	,	O
with	IN	O
openings	NNS	O
at	IN	O
5	CD	O
,	,	O
10	CD	O
and	CC	O
15	CD	O
cm	NN	O
from	IN	O
the	DT	O
tip	NN	O
,	,	O
was	VBD	O
placed	VBN	O
by	IN	O
rigid	JJ	O
sigmoidoscopy	NN	O
in	IN	O
the	DT	O
recto-sigmoid	JJ	O
region	NN	O
.	.	O

Baseline	NNP	O
tone	NN	O
and	CC	O
activity	NN	O
were	VBD	O
measured	VBN	O
for	IN	O
15	CD	O
min	NNS	O
prior	RB	O
to	TO	O
instillation	NN	O
of	IN	O
20	CD	O
ml	NN	O
of	IN	O
saline	JJ	O
alone	NN	O
or	CC	O
with	IN	O
nicotine	JJ	O
,	,	O
1.2	CD	O
mg	NN	O
,	,	O
at	IN	O
pH	JJ	O
4.5	CD	O
.	.	O

Observations	NNS	O
were	VBD	O
made	VBN	O
over	IN	O
the	DT	O
subsequent	JJ	O
15-20	JJ	O
min	NN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
spontaneous	JJ	O
activity	NN	O
in	IN	O
all	DT	O
subjects	NNS	O
showed	VBD	O
both	DT	O
high-	JJ	O
and	CC	O
low-frequency	JJ	O
components	NNS	O
;	:	O
in	IN	O
three	CD	O
patients	NNS	O
with	IN	O
UC	NNP	O
,	,	O
the	DT	O
low-frequency	NN	O
activity	NN	O
was	VBD	O
of	IN	O
high	JJ	O
amplitude	NN	O
.	.	O

The	DT	O
nicotine	NN	O
reduced	VBD	O
both	DT	O
tone	NN	O
and	CC	O
activity	NN	O
in	IN	O
all	DT	O
subjects	NNS	O
,	,	O
with	IN	O
reduction	NN	O
or	CC	O
abolition	NN	O
of	IN	O
the	DT	O
large	JJ	O
contractions	NNS	O
in	IN	O
UC	NNP	O
.	.	O

Tone	NN	O
in	IN	O
all	DT	O
17	CD	O
subjects	NNS	O
was	VBD	O
reduced	VBN	O
significantly	RB	O
at	IN	O
3	CD	O
min	NN	O
after	IN	O
nicotine	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.000015	CD	O
,	,	O
sign	JJ	O
test	NN	O
)	)	O
;	:	O
the	DT	O
rate	NN	O
of	IN	O
recovery	NN	O
varied	VBN	O
in	IN	O
individuals	NNS	O
.	.	O

Results	NNS	O
from	IN	O
normals	NNS	O
and	CC	O
UC	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
from	IN	O
each	DT	O
other	JJ	O
.	.	O

No	DT	O
significant	JJ	O
change	NN	O
in	IN	O
tone	NN	O
or	CC	O
activity	NN	O
was	VBD	O
observed	VBN	O
with	IN	O
the	DT	O
saline	JJ	O
solution	NN	O
.	.	O

CONCLUSION	NNP	O
Intra-luminal	JJ	O
nicotine	NN	O
significantly	RB	O
reduces	VBZ	O
both	DT	O
smooth	JJ	O
muscle	NN	O
tone	NN	O
and	CC	O
contractile	NN	O
activity	NN	O
in	IN	O
the	DT	O
recto-sigmoid	JJ	O
colon	NN	O
in	IN	O
both	DT	O
normal	JJ	O
subjects	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
UC	NNP	O
.	.	O

Efficacy	NN	O
of	IN	O
omeprazole	JJ	O
versus	NN	O
high-dose	JJ	O
famotidine	NN	O
for	IN	O
prevention	NN	O
of	IN	O
exercise-induced	JJ	O
gastritis	NN	O
in	IN	O
racing	VBG	O
Alaskan	NNP	O
sled	VBD	O
dogs	NNS	O
.	.	O

BACKGROUND	NNP	O
Omeprazole	NNP	O
and	CC	O
famotidine	VB	O
both	DT	O
reduce	VB	O
severity	NN	O
of	IN	O
exercise-induced	JJ	O
gastritis	NN	O
,	,	O
but	CC	O
administering	VBG	O
famotidine	NN	O
is	VBZ	O
easier	JJR	O
than	IN	O
administering	VBG	O
omeprazole	JJ	O
during	IN	O
racing	VBG	O
competition	NN	O
.	.	O

HYPOTHESIS	NNP	O
Famotidine	NNP	O
is	VBZ	O
more	RBR	O
efficacious	JJ	O
than	IN	O
no	DT	O
treatment	NN	O
in	IN	O
reducing	VBG	O
severity	NN	O
of	IN	O
exercise-induced	JJ	O
gastritis	NN	O
;	:	O
and	CC	O
high-dose	JJ	O
famotidine	NN	O
is	VBZ	O
more	RBR	O
efficacious	JJ	O
than	IN	O
omeprazole	NN	O
in	IN	O
reducing	VBG	O
severity	NN	O
of	IN	O
exercise-induced	JJ	O
gastritis	NN	O
.	.	O

ANIMALS	NNP	O
Experiment	VBD	O
1	CD	O
:	:	O
Randomized	VBN	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
36	CD	SampleSize
sled	VBD	O
dogs	NNS	O
(	(	O
3-8	CD	O
years	NNS	O
)	)	O
;	:	O
Experiment	JJ	O
2	CD	O
:	:	O
Randomized	VBN	O
positive-control	NN	O
study	NN	O
,	,	O
52	CD	SampleSize
sled	VBD	O
dogs	NNS	O
(	(	O
2-8	CD	O
years	NNS	O
)	)	O
.	.	O

METHODS	NNP	O
Experiment	JJ	O
1	CD	O
:	:	O
Equal	JJ	O
numbers	NNS	O
of	IN	O
dogs	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
famotidine	VB	O
(	(	O
20	CD	O
mg	RB	O
q24h	NN	O
)	)	O
or	CC	O
no	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

Gastroscopy	NNP	O
was	VBD	O
performed	VBN	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
dogs	NNS	O
ran	VBD	O
330	CD	O
miles	NNS	O
.	.	O

Mucosal	NNP	O
appearance	NN	O
was	VBD	O
blindly	RB	O
scored	VBN	O
by	IN	O
previously	RB	O
described	VBN	O
scoring	VBG	O
system	NN	O
.	.	O

Experiment	JJ	O
2	CD	O
:	:	O
Equal	JJ	O
numbers	NNS	O
of	IN	O
dogs	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
omeprazole	VB	O
(	(	O
20	CD	O
mg	RB	O
q24h	NN	O
)	)	O
or	CC	O
high-dose	JJ	O
famotidine	NN	O
(	(	O
40	CD	O
mg	RB	O
q12h	NN	O
)	)	O
groups	NNS	O
.	.	O

Gastroscopy	NNP	O
was	VBD	O
performed	VBN	O
48	CD	O
hours	NNS	O
before	IN	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
dogs	NNS	O
ran	VBD	O
300	CD	O
miles	NNS	O
.	.	O

Mucosal	NNP	O
appearance	NN	O
was	VBD	O
blindly	RB	O
scored	VBN	O
by	IN	O
previously	RB	O
described	VBN	O
scoring	VBG	O
system	NN	O
.	.	O

RESULTS	NNP	O
Famotidine	NNP	O
reduced	VBD	O
the	DT	O
prevalence	NN	O
of	IN	O
clinically	RB	O
relevant	JJ	O
,	,	O
exercise-induced	JJ	O
gastric	JJ	O
lesions	NNS	O
compared	VBN	O
with	IN	O
no	DT	O
treatment	NN	O
(	(	O
7/16	CD	O
versus	NN	O
11/16	CD	O
,	,	O
P	NNP	O
=	NNP	O
.031	NNP	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
high-dose	JJ	O
famotidine	NN	O
,	,	O
omeprazole	VBP	O
significantly	RB	O
decreased	VBN	O
the	DT	O
severity	NN	O
(	(	O
0.4	CD	O
versus	NN	O
1.2	CD	O
,	,	O
P	NNP	O
=	NNP	O
.0002	NNP	O
)	)	O
and	CC	O
prevalence	NN	O
(	(	O
2/23	CD	O
versus	NN	O
7/21	CD	O
,	,	O
P	NNP	O
=	NNP	O
.049	NNP	O
)	)	O
of	IN	O
gastric	JJ	O
lesions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
Although	IN	O
famotidine	NN	O
provides	VBZ	O
some	DT	O
benefit	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
exercise-induced	JJ	O
gastric	JJ	O
lesions	NNS	O
,	,	O
omeprazole	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
famotidine	VB	O
in	IN	O
preventing	VBG	O
gastritis	NN	O
in	IN	O
dogs	NNS	O
running	VBG	O
300	CD	O
miles	NNS	O
.	.	O

Routine	NNP	O
administration	NN	O
of	IN	O
omeprazole	NN	O
is	VBZ	O
recommended	VBN	O
to	TO	O
prevent	VB	O
stress-associated	JJ	O
gastric	JJ	O
disease	NN	O
in	IN	O
exercising	VBG	O
and	CC	O
racing	VBG	O
Alaskan	NNP	O
sled	VBD	O
dogs	NNS	O
.	.	O

Different	JJ	O
loss	NN	O
of	IN	O
BMD	NNP	O
using	VBG	O
uncemented	JJ	O
press-fit	NN	O
and	CC	O
whole	JJ	O
polyethylene	NN	O
cups	NNS	O
fixed	VBN	O
with	IN	O
cement	NN	O
:	:	O
repeated	VBN	O
DXA	NNP	O
studies	NNS	O
in	IN	O
96	CD	O
hips	NNS	O
randomized	VBN	O
to	TO	O
3	CD	O
types	NNS	O
of	IN	O
fixation	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
cemented	JJ	O
THA	NNP	O
,	,	O
aseptic	JJ	O
loosening	NN	O
of	IN	O
the	DT	O
cup	NN	O
is	VBZ	O
more	RBR	O
common	JJ	O
than	IN	O
loosening	NN	O
of	IN	O
the	DT	O
stem	NN	O
,	,	O
while	IN	O
periprosthetic	JJ	O
osteolysis	NN	O
of	IN	O
the	DT	O
socket	NN	O
resulting	VBG	O
in	IN	O
difficult	JJ	O
reconstruction	NN	O
problems	NNS	O
has	VBZ	O
emerged	VBN	O
as	IN	O
the	DT	O
most	RBS	O
significant	JJ	O
problem	NN	O
with	IN	O
cementless	JJ	O
cup	NN	O
fixation	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
90	CD	O
patients	NNS	O
(	(	O
96	CD	O
hips	NNS	O
)	)	O
scheduled	VBN	O
for	IN	O
THA	NNP	O
were	VBD	O
stratified	VBN	O
in	IN	O
three	CD	O
groups	NNS	O
according	VBG	O
to	TO	O
the	DT	O
method	NN	O
of	IN	O
fixation	NN	O
of	IN	O
the	DT	O
acetabular	JJ	O
component	NN	O
:	:	O
acrylic	JJ	O
bone	NN	O
cement	NN	O
with	IN	O
fluoride	NN	O
(	(	O
Cemex-F	NNP	O
)	)	O
,	,	O
porous-coated	JJ	O
press-fit	JJ	O
cup	NN	O
with	IN	O
ceramic	JJ	O
coating	NN	O
(	(	O
Trilogy	NNP	O
,	,	O
uncemented	VBD	O
)	)	O
and	CC	O
acrylic	JJ	O
cement	NN	O
with	IN	O
gentamicin	NN	O
(	(	O
Palacos	NNP	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
the	DT	O
Spectron	NNP	O
EF	NNP	O
stem	NN	O
.	.	O

Acetabular	NNP	O
bone	VBD	O
mineral	JJ	O
density	NN	O
was	VBD	O
measured	VBN	O
with	IN	O
dual-energy	JJ	O
X-ray	JJ	O
absorptiometry	NN	O
(	(	O
DXA	NNP	O
)	)	O
1	CD	O
week	NN	O
postoperatively	RB	O
,	,	O
and	CC	O
after	IN	O
12	CD	O
and	CC	O
24	CD	O
months	NNS	O
.	.	O

The	DT	O
periprosthetic	JJ	O
BMD	NNP	O
was	VBD	O
evaluated	VBN	O
in	IN	O
5	CD	O
ROIs	NNP	O
positioned	VBD	O
around	IN	O
the	DT	O
acetabular	JJ	O
component	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
uncemented	JJ	O
sockets	NNS	O
,	,	O
the	DT	O
BMD	NNP	O
had	VBD	O
decreased	VBN	O
proximally	RB	O
and	CC	O
medially	RB	O
to	TO	O
the	DT	O
cup	NN	O
after	IN	O
2	CD	O
years	NNS	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
significant	JJ	O
in	IN	O
the	DT	O
proximal	JJ	O
region	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
Palacos	NNP	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
with	IN	O
cemented	JJ	O
components	NNS	O
after	IN	O
2	CD	O
years	NNS	O
.	.	O

Stepwise	NN	O
linear	JJ	O
regression	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
loss	NN	O
of	IN	O
periprosthetic	JJ	O
BMD	NNP	O
in	IN	O
the	DT	O
proximal	JJ	O
high-pressure	NN	O
region	NN	O
after	IN	O
2	CD	O
years	NNS	O
increased	VBD	O
with	IN	O
higher	RBR	O
postoperative	JJ	O
BMD	NNP	O
and	CC	O
when	WRB	O
the	DT	O
uncemented	JJ	O
design	NN	O
had	VBD	O
been	VBN	O
used	VBN	O
.	.	O

INTERPRETATION	NNP	O
Contrary	NNP	O
to	TO	O
previous	JJ	O
studies	NNS	O
of	IN	O
cemented	JJ	O
stems	NNS	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
fluoride	JJ	O
cement	NN	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
periprosthetic	JJ	O
BMD	NNP	O
2	CD	O
years	NNS	O
after	IN	O
the	DT	O
examination	NN	O
.	.	O

Increased	VBN	O
loss	NN	O
of	IN	O
BMD	NNP	O
with	IN	O
use	NN	O
of	IN	O
uncemented	JJ	O
press-fit	JJ	O
cups	NNS	O
in	IN	O
the	DT	O
region	NN	O
in	IN	O
which	WDT	O
osteolytic	JJ	O
lesions	NNS	O
are	VBP	O
commonly	RB	O
found	VBN	O
suggests	VBZ	O
that	IN	O
stress	NN	O
shielding	NN	O
may	MD	O
initiate	VB	O
the	DT	O
development	NN	O
of	IN	O
this	DT	O
complication	NN	O
.	.	O

Longer	JJR	O
follow-up	NN	O
will	MD	O
,	,	O
however	RB	O
,	,	O
be	VB	O
necessary	JJ	O
to	TO	O
substantiate	VB	O
this	DT	O
hypothesis	NN	O
.	.	O

Skin	NNP	O
improvement	NN	O
with	IN	O
two	CD	O
different	JJ	O
oestroprogestins	NNS	O
in	IN	O
patients	NNS	O
affected	VBN	O
by	IN	O
acne	NN	Condition
and	CC	O
polycystic	JJ	Condition
ovary	JJ	Condition
syndrome	NN	Condition
:	:	Condition
clinical	JJ	O
and	CC	O
instrumental	JJ	O
evaluation	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
it	PRP	O
is	VBZ	O
accepted	VBN	O
that	IN	O
acne	NN	O
is	VBZ	O
mostly	RB	O
caused	VBN	O
by	IN	O
an	DT	O
hyper-responsiveness	NN	O
of	IN	O
the	DT	O
pilo-sebaceous	JJ	O
unit	NN	O
to	TO	O
normal	JJ	O
circulating	VBG	O
androgen	NN	O
hormones	NNS	O
,	,	O
in	IN	O
a	DT	O
few	JJ	O
patients	NNS	O
,	,	O
especially	RB	O
women	NNS	Sex
,	,	O
acneic	JJ	O
lesions	NNS	O
can	MD	O
be	VB	O
associated	VBN	O
with	IN	O
increased	JJ	O
serum	NN	O
androgen	NN	O
levels	NNS	O
(	(	O
hyperandrogenism	NN	O
)	)	O
,	,	O
of	IN	O
which	WDT	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
is	VBZ	O
the	DT	O
most	RBS	O
common	JJ	O
cause	NN	O
.	.	O

In	IN	O
women	NNS	Sex
with	IN	O
acne	NN	Condition
and	CC	O
proven	JJ	O
PCOS	NNP	O
therapy	NN	O
with	IN	O
estroprogestins	NNS	O
(	(	O
EPs	NNP	O
)	)	O
can	MD	O
be	VB	O
an	DT	O
excellent	JJ	O
option	NN	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
two	CD	O
estroprogestins	NNS	O
(	(	O
EPs	NNP	O
)	)	O
,	,	O
ethinyl-estradiol	JJ	O
(	(	O
EE	NNP	O
)	)	O
30	CD	O
mcg/drospirenone	NN	O
(	(	O
DRSP	NNP	O
)	)	O
3	CD	O
mg	NN	O
,	,	O
and	CC	O
ethinyl-estradiol	NN	O
(	(	O
EE	NNP	O
)	)	O
30	CD	O
mcg/chlormadinone	NN	O
acetate	NN	O
(	(	O
CMA	NNP	O
)	)	O
2	CD	O
mg	NN	O
,	,	O
both	DT	O
on	IN	O
increased	VBN	O
serum	NN	O
androgen	NN	O
levels	NNS	O
and	CC	O
on	IN	O
several	JJ	O
skin	NN	O
parameters	NNS	O
in	IN	O
women	NNS	Sex
affected	VBN	O
by	IN	O
mild	NN	Condition
to	TO	Condition
severe	VB	Condition
acne	NN	Condition
and	CC	O
polycystic	JJ	Condition
ovary	JJ	Condition
syndrome	NN	Condition
(	(	Condition
PCOS	NNP	Condition
)	)	Condition
.	.	O

METHODS	NNP	O
Fifty-nine	JJ	SampleSize
women	NNS	Sex
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
EE/DRSP	NNP	O
(	(	O
n	JJ	O
=	NNP	O
32	CD	O
)	)	O
or	CC	O
EE/CMA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
for	IN	O
six	CD	O
months	NNS	O
.	.	O

Evaluation	NN	O
of	IN	O
serum	NN	O
androgen	NN	O
levels	NNS	O
,	,	O
grading	NN	O
of	IN	O
acne	NN	O
and	CC	O
hirsutism	NN	O
(	(	O
respectively	RB	O
with	IN	O
Pillsbury	NNP	O
and	CC	O
Ferriman-Gallwey	NNP	O
score	NN	O
)	)	O
and	CC	O
non-invasive	JJ	O
assessment	NN	O
of	IN	O
skin	JJ	O
hydration	NN	O
,	,	O
transepidermal	JJ	O
water	NN	O
loss	NN	O
(	(	O
TEWL	NNP	O
)	)	O
and	CC	O
skin	JJ	O
homogeneity	NN	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
,	,	O
at	IN	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
(	(	O
end	NN	O
of	IN	O
treatment	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
showed	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
of	IN	O
skin	NN	O
and	CC	O
hormonal	JJ	O
parameters	NNS	O
,	,	O
although	IN	O
EE/DRSP	NNP	O
showed	VBD	O
a	DT	O
more	RBR	O
potent	JJ	O
effect	NN	O
on	IN	O
acne	NN	O
and	CC	O
seborrhea	NN	O
.	.	O

CONCLUSIONS	NNP	O
Estroprogestins	NNP	O
represent	VBP	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
treatment	NN	O
in	IN	O
women	NNS	Sex
with	IN	O
acne	NN	O
and	CC	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
.	.	O

Nevertheless	RB	O
,	,	O
the	DT	O
combination	NN	O
EE	NNP	O
30	CD	O
mcg/DRSP	NN	O
3	CD	O
mg	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
more	RBR	O
potent	JJ	O
therapeutic	JJ	O
option	NN	O
.	.	O

[	JJ	O
Efficacy	NNP	O
of	IN	O
paliperidone	NN	O
extended-release	JJ	O
tablets	NNS	O
in	IN	O
the	DT	O
improvement	NN	O
of	IN	O
social	JJ	O
functions	NNS	O
in	IN	O
schizophrenics	NNS	Condition
:	:	O
a	DT	O
randomized	NN	O
and	CC	O
controlled	VBD	O
study	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
explore	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
paliperidone	NN	O
extended-release	JJ	O
tablets	NNS	O
in	IN	O
the	DT	O
improvement	NN	O
of	IN	O
social	JJ	O
functions	NNS	O
in	IN	O
schizophrenics	NNS	Condition
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
81	CD	Condition
schizophrenics	NNS	Condition
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
study	NN	O
group	NN	O
with	IN	O
paliperidone	NN	O
extended-release	JJ	O
tablets	NNS	O
and	CC	O
control	NN	O
group	NN	O
with	IN	O
risperidone	NN	O
for	IN	O
a	DT	O
12-week	JJ	O
treatment	NN	O
.	.	O

They	PRP	O
were	VBD	O
assessed	VBN	O
and	CC	O
analyzed	VBN	O
by	IN	O
positive	JJ	O
and	CC	O
negative	JJ	O
symptoms	NNS	O
scales	NNS	O
(	(	O
PANSS	NNP	O
)	)	O
,	,	O
social	JJ	O
disability	NN	O
screening	VBG	O
schedule	NN	O
(	(	O
SDSS	NNP	O
)	)	O
and	CC	O
treatment	NN	O
emergent	NN	O
symptom	NN	O
scale	NN	O
(	(	O
TESS	NNP	O
)	)	O
at	IN	O
baseline	NN	O
,	,	O
6	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
and	CC	O
12	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
study	NN	O
group	NN	O
,	,	O
the	DT	O
factors	NNS	O
and	CC	O
total	JJ	O
scores	NNS	O
of	IN	O
PANSS	NNP	O
in	IN	O
the	DT	O
12	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
of	IN	O
treatment	NN	O
[	NNP	O
(	(	O
12.0	CD	O
?	.	O
2.8	CD	O
)	)	O
,	,	O
(	(	O
12.1	CD	O
?	.	O
3.6	CD	O
)	)	O
,	,	O
(	(	O
26.2	CD	O
?	.	O
5.0	CD	O
)	)	O
,	,	O
(	(	O
50.2	CD	O
?	.	O
8.7	CD	O
)	)	O
]	NN	O
were	VBD	O
all	DT	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
at	IN	O
baseline	JJ	O
[	NNP	O
(	(	O
24.7	CD	O
?	.	O
5.3	CD	O
)	)	O
,	,	O
(	(	O
23.8	CD	O
?	.	O
3.6	CD	O
)	)	O
,	,	O
(	(	O
45.0	CD	O
?	.	O
2.9	CD	O
)	)	O
,	,	O
(	(	O
93.5	CD	O
?	.	O
6.8	CD	O
)	)	O
]	NN	O
(	(	O
t	JJ	O
=	NNP	O
9.60-16.78	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
study	NN	O
group	NN	O
,	,	O
the	DT	O
positive	JJ	O
factor	NN	O
,	,	O
negative	JJ	O
factor	NN	O
and	CC	O
total	JJ	O
scores	NNS	O
of	IN	O
PANSS	NNP	O
in	IN	O
the	DT	O
12	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
of	IN	O
treatment	NN	O
[	NNP	O
(	(	O
12.0	CD	O
?	.	O
2.8	CD	O
)	)	O
,	,	O
(	(	O
12.1	CD	O
?	.	O
3.6	CD	O
)	)	O
,	,	O
(	(	O
50.2	CD	O
?	.	O
8.7	CD	O
)	)	O
]	NN	O
were	VBD	O
all	DT	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
6	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
of	IN	O
treatment	NN	O
[	NNP	O
(	(	O
14.2	CD	O
?	.	O
1.8	CD	O
)	)	O
,	,	O
(	(	O
14.6	CD	O
?	.	O
2.4	CD	O
)	)	O
,	,	O
(	(	O
56.5	CD	O
?	.	O
6.4	CD	O
)	)	O
]	NN	O
(	(	O
t	JJ	O
=	NNP	O
2.58-4.26	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
12	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
factors	NNS	O
and	CC	O
total	JJ	O
scores	NNS	O
of	IN	O
PANSS	NNP	O
in	IN	O
study	NN	O
group	NN	O
[	NNP	O
(	(	O
12.0	CD	O
?	.	O
2.8	CD	O
)	)	O
,	,	O
(	(	O
12.1	CD	O
?	.	O
3.6	CD	O
)	)	O
,	,	O
(	(	O
26.2	CD	O
?	.	O
5.0	CD	O
)	)	O
,	,	O
(	(	O
50.2	CD	O
?	.	O
8.7	CD	O
)	)	O
]	NN	O
were	VBD	O
all	DT	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
control	NN	O
group	NN	O
[	NNP	O
(	(	O
16.9	CD	O
?	.	O
4.9	CD	O
)	)	O
,	,	O
(	(	O
18.7	CD	O
?	.	O
5.3	CD	O
)	)	O
,	,	O
(	(	O
32.5	CD	O
?	.	O
5.1	CD	O
)	)	O
,	,	O
(	(	O
68.1	CD	O
?	.	O
13.0	CD	O
)	)	O
]	NN	O
(	(	O
t	JJ	O
=	NNP	O
-4.28	NNP	O
--	:	O
5.67	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
study	NN	O
group	NN	O
,	,	O
the	DT	O
total	JJ	O
scores	NNS	O
of	IN	O
SDSS	NNP	O
in	IN	O
the	DT	O
12	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
of	IN	O
treatment	NN	O
(	(	O
5.93	CD	O
?	.	O
2.78	CD	O
)	)	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
at	IN	O
baseline	NN	O
(	(	O
13.9	CD	O
?	.	O
3.4	CD	O
)	)	O
(	(	O
t	JJ	O
=	NN	O
10.83	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
study	NN	O
group	NN	O
,	,	O
the	DT	O
total	JJ	O
scores	NNS	O
of	IN	O
SDSS	NNP	O
in	IN	O
the	DT	O
12	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
of	IN	O
treatment	NN	O
(	(	O
5.9	CD	O
?	.	O
2.8	CD	O
)	)	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
6	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
of	IN	O
treatment	NN	O
(	(	O
7.6	CD	O
?	.	O
2.9	CD	O
)	)	O
(	(	O
t	JJ	O
=	NN	O
5.21	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

But	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
control	NN	O
group	NN	O
(	(	O
t	JJ	O
=	NN	O
1.88	CD	O
,	,	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
12	CD	O
(	(	O
th	NN	O
)	)	O
weekend	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
total	JJ	O
scores	NNS	O
of	IN	O
SDSS	NNP	O
in	IN	O
study	NN	O
group	NN	O
(	(	O
5.9	CD	O
?	.	O
2.8	CD	O
)	)	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
control	NN	O
group	NN	O
(	(	O
8.8	CD	O
?	.	O
2.9	CD	O
)	)	O
(	(	O
t	JJ	O
=	NNP	O
-4.49	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	UH	O
severe	JJ	O
adverse	JJ	O
effect	NN	O
was	VBD	O
reported	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Paliperidone	NNP	O
extended-release	JJ	O
tablets	NNS	O
are	VBP	O
effective	JJ	O
to	TO	O
improve	VB	O
social	JJ	O
functions	NNS	O
and	CC	O
psychiatric	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenics	NNS	O
.	.	O

Green	JJ	O
banana-supplemented	JJ	O
diet	NN	O
in	IN	O
the	DT	O
home	NN	O
management	NN	O
of	IN	O
acute	NN	O
and	CC	O
prolonged	JJ	Condition
diarrhoea	NN	Condition
in	IN	O
children	NNS	Age
:	:	O
a	DT	O
community-based	JJ	O
trial	NN	O
in	IN	O
rural	JJ	O
Bangladesh	NNP	O
.	.	O

SUMMARY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
green	JJ	O
banana	NN	O
in	IN	O
the	DT	O
home	NN	O
management	NN	O
of	IN	O
acute	NN	O
(	(	O
<	JJ	O
7	CD	O
days	NNS	O
)	)	O
or	CC	O
prolonged	VBN	O
(	(	O
?	.	O
7	CD	O
days	NNS	O
)	)	O
diarrhoea	VBP	O
at	IN	O
the	DT	O
community	NN	O
level	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
cluster	NN	O
randomized	VBD	O
field	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
2968	CD	SampleSize
Bangladeshi	NNP	O
rural	JJ	O
children	NNS	O
6-36	JJ	Age
months	NNS	Age
old	JJ	Age
.	.	O

Wards	NNP	O
(	(	O
villages	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
a	DT	O
standard	JJ	O
care	NN	O
group	NN	O
or	CC	O
a	DT	O
standard	JJ	O
care	NN	O
plus	CC	O
green	JJ	O
banana	NN	O
group	NN	O
where	WRB	O
mothers	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
add	VB	O
cooked	JJ	O
green	JJ	O
banana	NN	O
to	TO	O
the	DT	O
diets	NNS	O
of	IN	O
diarrhoeal	JJ	O
children	NNS	O
.	.	O

Through	IN	O
a	DT	O
village-based	JJ	O
surveillance	NN	O
system	NN	O
,	,	O
diarrhoeal	JJ	O
morbidity	NN	O
data	NNS	O
(	(	O
severity	NN	O
,	,	O
duration	NN	O
,	,	O
compliance	NN	O
)	)	O
were	VBD	O
collected	VBN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Treatment	JJ	O
effects	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
analysing	VBG	O
cumulative	JJ	O
probability	NN	O
of	IN	O
cure	NN	O
by	IN	O
testing	VBG	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
models	NNS	O
and	CC	O
relative	JJ	O
risk	NN	O
(	(	O
RR	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
cumulative	JJ	O
probability	NN	O
of	IN	O
cure	NN	O
was	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
different	JJ	O
in	IN	O
children	NNS	O
receiving	VBG	O
GB	NNP	O
for	IN	O
both	DT	O
acute	JJ	O
[	NNP	O
hazard	NN	O
ratio	NN	O
(	(	O
HR	NNP	O
)	)	O
=	VBZ	O
0.63	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.56-0.67	NN	O
)	)	O
]	NN	O
and	CC	O
prolonged	VBD	O
diarrhoea	NNS	O
[	NNP	O
HR	NNP	O
=	VBZ	O
0.38	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.26-0.59	NN	O
)	)	O
]	NN	O
.	.	O

The	DT	O
recovery	NN	O
rates	NNS	O
of	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
diarrhoea	NN	O
receiving	VBG	O
GB	NNP	O
(	(	O
vs.	FW	O
control	NN	O
)	)	O
were	VBD	O
significantly	RB	O
more	JJR	O
by	IN	O
day	NN	O
3	CD	O
:	:	O
79.9	CD	O
%	NN	O
vs	NN	O
.	.	O

53.3	CD	O
%	NN	O
[	NN	O
(	(	O
RR	NNP	O
)	)	O
=	VBD	O
0.47	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.41-0.55	JJ	O
]	NN	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
day	NN	O
7	CD	O
:	:	O
96.6	CD	O
%	NN	O
vs	NN	O
.	.	O

89.1	CD	O
%	NN	O
(	(	O
RR	NNP	O
=	NNP	O
0.32	CD	O
;	:	O
0.22-0.46	JJ	O
)	)	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Children	NNP	O
with	IN	O
prolonged	JJ	O
diarrhoea	NN	O
receiving	VBG	O
green	JJ	O
banana	NN	O
had	VBD	O
significantly	RB	O
higher	JJR	O
recovery	NN	O
rates	NNS	O
by	IN	O
day	NN	O
10	CD	O
:	:	O
79.8	CD	O
%	NN	O
vs	NN	O
.	.	O

51.9	CD	O
%	NN	O
(	(	O
RR	NNP	O
=	NNP	O
0.42	CD	O
;	:	O
0.23-0.73	JJ	O
)	)	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
day	NN	O
14	CD	O
:	:	O
93.6	CD	O
%	NN	O
vs	NN	O
.	.	O

67.2	CD	O
%	NN	O
(	(	O
RR	NNP	O
=	NNP	O
0.22	CD	O
;	:	O
0.08-0.54	JJ	O
)	)	O
,	,	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	O
green	JJ	O
banana-supplemented	JJ	O
diet	NN	O
hastened	VBD	O
recovery	NN	O
of	IN	O
acute	NN	O
and	CC	O
prolonged	VBD	O
childhood	NN	O
diarrhoea	NN	O
managed	VBD	O
at	IN	O
home	NN	O
in	IN	O
rural	JJ	O
Bangladesh	NNP	O
.	.	O

Paclitaxel	NNP	O
(	(	O
175	CD	O
mg/m2	NN	O
)	)	O
plus	CC	O
carboplatin	NN	O
(	(	O
6	CD	O
AUC	NNP	O
)	)	O
versus	NN	O
paclitaxel	NN	O
(	(	O
225	CD	O
mg/m2	NN	O
)	)	O
plus	CC	O
carboplatin	NN	O
(	(	O
6	CD	O
AUC	NNP	O
)	)	O
in	IN	O
advanced	JJ	O
non-small-cell	JJ	Condition
lung	NN	Condition
cancer	NN	Condition
(	(	Condition
NSCLC	NNP	Condition
)	)	Condition
:	:	O
a	DT	O
multicenter	NN	O
randomized	VBN	O
trial	NN	O
.	.	O

Hellenic	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
HeCOG	NNP	O
)	)	O
.	.	O

PURPOSE	VB	O
The	DT	O
combination	NN	O
of	IN	O
paclitaxel	NN	O
and	CC	O
carboplatin	NN	O
has	VBZ	O
become	VBN	O
a	DT	O
widely	RB	O
used	VBN	O
regimen	NNS	O
in	IN	O
NSCLC	NNP	O
due	JJ	O
to	TO	O
phase	VB	O
II	NNP	O
reports	NNS	O
of	IN	O
moderate	JJ	O
toxicity	NN	O
,	,	O
reasonable	JJ	O
activity	NN	O
and	CC	O
easy	JJ	O
outpatient	JJ	O
administration	NN	O
.	.	O

Purpose	NNP	O
of	IN	O
our	PRP$	O
present	JJ	O
prospective	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
dose	JJ	O
response	NN	O
relationship	NN	O
of	IN	O
paclitaxel	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Since	IN	O
July	NNP	O
1996	CD	O
,	,	O
198	CD	SampleSize
patients	NNS	O
with	IN	O
non-operable	JJ	Condition
NSCLC	NNP	Condition
and	CC	O
measurable	JJ	O
disease	NN	O
without	IN	O
previous	JJ	O
chemotherapy	NN	O
entered	VBD	O
the	DT	O
trial	NN	O
.	.	O

Ninety	NNP	SampleSize
nine	CD	SampleSize
patients	NNS	O
(	(	O
group	NN	O
A	DT	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
paclitaxel	NN	O
175	CD	O
mg/m2	NN	O
in	IN	O
three-hour	JJ	O
infusion	NN	O
plus	CC	O
carboplatin	NN	O
dosed	VBD	O
to	TO	O
an	DT	O
area	NN	O
under	IN	O
the	DT	O
concentration-time	JJ	O
curve	NN	O
of	IN	O
6	CD	O
every	DT	O
3	CD	O
weeks	NNS	O
and	CC	O
99	CD	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
to	TO	O
receive	VB	O
the	DT	O
same	JJ	O
regimen	NN	O
with	IN	O
paclitaxel	NN	O
increased	VBN	O
to	TO	O
225	CD	O
mg/m2	NN	O
.	.	O

Eligibility	NNP	O
criteria	NNS	O
included	VBD	O
WHO	NNP	O
performance	NN	O
status	NN	O
0-2	CD	O
,	,	O
documented	VBN	O
inoperable	JJ	O
stage	NN	O
IIIA	NNP	O
and	CC	O
IIIB	NNP	O
,	,	O
IV	NNP	O
,	,	O
no	DT	O
brain	NN	O
metastasis	NN	O
,	,	O
no	DT	O
prior	JJ	O
chemotherapy	NN	O
and	CC	O
adequate	JJ	O
renal	NN	O
and	CC	O
hepatic	JJ	O
function	NN	O
.	.	O

Patients	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
well-matched	JJ	O
with	IN	O
baseline	JJ	O
disease	NN	O
characteristics	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
group	NN	O
A	NNP	O
with	IN	O
90	CD	O
evaluable	JJ	O
patients	NNS	O
,	,	O
the	DT	O
response	NN	O
rate	NN	O
was	VBD	O
25.6	CD	O
%	NN	O
(	(	O
6	CD	O
CR	NNP	O
,	,	O
17	CD	O
PR	NNP	O
)	)	O
whereas	VBP	O
in	IN	O
group	NN	O
B	NNP	O
with	IN	O
88	CD	O
evaluable	JJ	O
patients	NNS	O
,	,	O
the	DT	O
response	NN	O
rate	NN	O
was	VBD	O
31.8	CD	O
%	NN	O
(	(	O
3	CD	O
CR	NNP	O
,	,	O
25	CD	O
PR	NNP	O
)	)	O
,	,	O
P	NNP	O
=	VBZ	O
0.733	CD	O
.	.	O

Median	JJ	O
time	NN	O
to	TO	O
progression	NN	O
favored	VBD	O
the	DT	O
high-dose	JJ	O
paclitaxel	NN	O
(	(	O
4.3	CD	O
vs.	FW	O
6.4	CD	O
months	NNS	O
,	,	O
P	NNP	O
=	NNP	O
0.044	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
9.5	CD	O
months	NNS	O
for	IN	O
group	NN	O
A	NNP	O
versus	NN	O
11.4	CD	O
months	NNS	O
for	IN	O
group	NN	O
B	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.16	CD	O
)	)	O
.	.	O

The	DT	O
one-year	JJ	O
survival	NN	O
was	VBD	O
37	CD	O
%	NN	O
for	IN	O
group	NN	O
A	NNP	O
and	CC	O
44	CD	O
%	NN	O
for	IN	O
group	NN	O
B	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.35	CD	O
)	)	O
.	.	O

The	DT	O
best	JJS	O
prognostic	JJ	O
factor	NN	O
for	IN	O
one-year	JJ	O
survival	NN	O
was	VBD	O
the	DT	O
response	NN	O
rate	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

With	IN	O
a	DT	O
relative	JJ	O
dose	JJ	O
intensity	NN	O
of	IN	O
paclitaxel	NN	O
0.94	CD	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
neurotoxicity	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
and	CC	O
leucopenia	$	O
(	(	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
were	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
group	NN	O
B	NNP	O
patients	NNS	O
.	.	O

No	DT	O
toxic	JJ	O
death	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Higher	NNP	O
dose	VBD	O
paclitaxel	JJ	O
prolongs	NNS	O
the	DT	O
median	JJ	O
time	NN	O
to	TO	O
progression	NN	O
but	CC	O
causes	VBZ	O
more	JJR	O
neurotoxicity	NN	O
and	CC	O
leucopenia	NN	O
.	.	O

The	DT	O
better	JJR	O
response	NN	O
rate	NN	O
,	,	O
the	DT	O
longer	JJR	O
overall	JJ	O
and	CC	O
better	JJR	O
one-year	JJ	O
survival	NN	O
seen	VBN	O
with	IN	O
the	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
paclitaxel	NNS	O
are	VBP	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Effect	NN	O
of	IN	O
vitamin	NN	O
K2	NNP	O
on	IN	O
the	DT	O
recurrence	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hepatocellular	JJ	Condition
carcinoma	NN	Condition
.	.	O

BACKGROUND/AIMS	NNP	O
Vitamin	NNP	O
K2	NNP	O
(	(	O
VK2	NNP	O
)	)	O
appears	VBZ	O
to	TO	O
have	VB	O
a	DT	O
potent	JJ	O
inhibitory	NN	O
activity	NN	O
for	IN	O
cell	NN	O
growth	NN	O
including	VBG	O
HCC	NNP	O
cells	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
whether	IN	O
VK2	NNP	O
could	MD	O
reduce	VB	O
incidence	NN	O
of	IN	O
tumor	NN	O
recurrence	NN	O
after	IN	O
treatment	NN	O
of	IN	O
HCC	NNP	O
.	.	O

Forty-five	JJ	O
patients	NNS	O
with	IN	O
cured	JJ	O
or	CC	O
possibly	RB	O
cured	VBN	O
HCC	NNP	Condition
were	VBD	O
randomly	RB	O
selected	VBN	O
,	,	O
assigning	VBG	O
patients	NNS	O
to	TO	O
treatment	NN	O
(	(	O
n=21	JJ	O
)	)	O
or	CC	O
control	VB	O
group	NN	O
(	(	O
n=24	CC	O
)	)	O
with	IN	O
randomization	NN	O
list	NN	O
.	.	O

METHODOLOGY	NNP	O
For	IN	O
the	DT	O
treatment	NN	O
group	NN	O
,	,	O
forty-five	JJ	O
mg	NN	O
of	IN	O
Glakay	NNP	O
was	VBD	O
given	VBN	O
orally	RB	O
every	DT	O
day	NN	O
after	IN	O
therapy	NN	O
for	IN	O
HCC	NNP	O
.	.	O

No	CC	O
patients	NNS	O
complained	VBD	O
of	IN	O
adverse	JJ	O
effects	NNS	O
.	.	O

Abdominal	NNP	O
ultrasonography	NN	O
and	CC	O
dynamic	JJ	O
CT	NNP	O
were	VBD	O
performed	VBN	O
at	IN	O
3-month	JJ	O
intervals	NNS	O
.	.	O

Recurrence	NNP	O
was	VBD	O
confirmed	VBN	O
by	IN	O
abdominal	JJ	O
angiography	NN	O
.	.	O

RESULTS	NNP	O
Recurrence	NNP	O
of	IN	O
HCC	NNP	O
occurred	VBD	O
in	IN	O
7	CD	O
cases	NNS	O
(	(	O
33.3	CD	O
%	NN	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
group	NN	O
and	CC	O
12	CD	O
cases	NNS	O
(	(	O
50.0	CD	O
%	NN	O
)	)	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
during	IN	O
mean	JJ	O
observation	NN	O
periods	NNS	O
of	IN	O
19.5	CD	O
and	CC	O
16.5	CD	O
months	NNS	O
,	,	O
respectively	RB	O
.	.	O

Administration	NNP	O
of	IN	O
VK2	NNP	O
was	VBD	O
not	RB	O
an	DT	O
independent	JJ	O
variable	NN	O
for	IN	O
the	DT	O
recurrence	NN	O
on	IN	O
univariate	JJ	O
analysis	NN	O
.	.	O

Cumulative	JJ	O
incidence	NN	O
of	IN	O
HCC	NNP	O
recurrence	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
and	CC	O
the	DT	O
cumulative	JJ	O
survival	NN	O
rate	NN	O
tended	VBD	O
to	TO	O
be	VB	O
high	JJ	O
in	IN	O
treatment	NN	O
group	NN	O
(	(	O
p	IN	O
=0.054	NN	O
)	)	O
.	.	O

Cox	NNP	O
regression	NN	O
analysis	NN	O
revealed	VBD	O
that	IN	O
serum	NN	O
albumin	JJ	O
concentration	NN	O
alone	RB	O
was	VBD	O
an	DT	O
independent	JJ	O
factor	NN	O
affecting	VBG	O
the	DT	O
recurrence	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
VK2	NNP	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
prevent	VB	O
recurrence	NN	O
of	IN	O
HCC	NNP	O
after	IN	O
curative	JJ	O
treatment	NN	O
.	.	O

Our	PRP$	O
study	NN	O
is	VBZ	O
preliminary	JJ	O
and	CC	O
large-scale	JJ	O
trials	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
VK2	NNP	O
is	VBZ	O
of	IN	O
benefit	NN	O
to	TO	O
decrease	VB	O
the	DT	O
recurrence	NN	O
of	IN	O
HCC	NNP	O
.	.	O

Improved	NNP	O
responsiveness	NN	O
of	IN	O
PCOS	NNP	O
patients	NNS	O
to	TO	O
clomiphene	VB	O
after	IN	O
CYP17a	NNP	O
inhibitor	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
CYP17a	NNP	O
inhibitor	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
on	IN	O
clomiphene	NN	O
responsiveness	NN	O
in	IN	O
PCOS	NNP	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Prospective	JJ	O
analysis	NN	O
was	VBD	O
employed	VBN	O
with	IN	O
the	DT	O
setup	NN	O
at	IN	O
Alexandria	NNP	O
IVF/ICSI	NNP	O
center	NN	O
.	.	O

Ninety-seven	JJ	O
insulin-resistant	JJ	O
PCOS	NNP	O
patients	NNS	O
undergoing	VBG	O
ovulation	NN	O
induction	NN	O
using	VBG	O
clomiphene	JJ	O
citrate	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
,	,	O
by	IN	O
random	JJ	O
number	NN	O
table	NN	O
,	,	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
first	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
received	VBN	O
ketoconazole	NN	O
(	(	O
400	CD	O
mg	NNS	O
daily	RB	O
)	)	O
till	NN	O
correction	NN	O
of	IN	O
metabolic	JJ	O
syndrome	NN	O
followed	VBN	O
by	IN	O
clomiphene	NN	O
(	(	O
100	CD	O
mg/day	NN	O
)	)	O
;	:	O
the	DT	O
second	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
48	CD	O
)	)	O
receiving	VBG	O
clomiphene	NN	O
without	IN	O
ketoconazole	JJ	O
pretreatment	NN	O
.	.	O

Main	NNP	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
incidence	NN	O
of	IN	O
clomiphene	NN	O
resistance	NN	O
,	,	O
monofollicular	JJ	O
response	NN	O
,	,	O
fasting	VBG	O
insulin/glucose	JJ	O
ratio	NN	O
,	,	O
serum	NN	O
testosterone	NN	O
,	,	O
and	CC	O
pregnancy	NN	O
rates	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
ketoconazole	NN	O
group	NN	O
showed	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
higher	JJR	O
incidence	NN	O
of	IN	O
monofollicular	JJ	O
response	NN	O
(	(	O
38	CD	O
%	NN	O
)	)	O
,	,	O
higher	JJR	O
pregnancy	NN	O
rates	NNS	O
,	,	O
and	CC	O
significantly	RB	O
less	JJR	O
marked	JJ	O
antiestrogenic	NN	O
manifestations	NNS	O
than	IN	O
did	VBD	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

They	PRP	O
also	RB	O
had	VBD	O
significantly	RB	O
lower	JJR	O
incidence	NN	O
of	IN	O
clomiphene	NN	O
resistance	NN	O
(	(	O
11.6	CD	O
%	NN	O
)	)	O
,	,	O
lower	JJR	O
serum	NN	O
testosterone	NN	O
levels	NNS	O
,	,	O
less	JJR	O
hyperinsulinaemia	NN	O
,	,	O
than	IN	O
did	VBD	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Ketoconazole	NNP	O
improved	VBD	O
clomiphene	JJ	O
responsivenss	NN	O
in	IN	O
PCOS	NNP	O
patients	NNS	O
and	CC	O
attenuated	VBD	O
its	PRP$	O
untoward	JJ	O
biological	JJ	O
effects	NNS	O
.	.	O

Adherence	NN	O
to	TO	O
moderate-intensity	NN	O
exercise	NN	O
during	IN	O
breast	NN	Condition
cancer	NN	Condition
therapy	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
aims	NNS	O
of	IN	O
this	DT	O
pilot	NN	O
study	NN	O
were	VBD	O
the	DT	O
following	JJ	O
:	:	O
1	CD	O
)	)	O
to	TO	O
examine	VB	O
patterns	NNS	O
of	IN	O
adherence	NN	O
to	TO	O
a	DT	O
brisk	JJ	O
walking	VBG	O
program	NN	O
in	IN	O
women	NNS	Condition
receiving	VBG	O
adjuvant	JJ	Condition
chemotherapy	NN	Condition
or	CC	Condition
radiation	NN	Condition
therapy	NN	Condition
for	IN	O
newly	RB	O
diagnosed	VBN	O
breast	NN	O
cancer	NN	O
using	VBG	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
experimental	JJ	O
design	NN	O
;	:	O
2	CD	O
)	)	O
to	TO	O
examine	VB	O
the	DT	O
influence	NN	O
of	IN	O
disease	NN	O
symptoms	NNS	O
and	CC	O
treatment	NN	O
side	NN	O
effects	NNS	O
on	IN	O
exercise	NN	O
levels	NNS	O
;	:	O
and	CC	O
3	CD	O
)	)	O
to	TO	O
suggest	VB	O
methods	NNS	O
that	WDT	O
may	MD	O
improve	VB	O
future	NN	O
clinical	JJ	O
trials	NNS	O
of	IN	O
moderate-intensity	NN	O
exercise	NN	O
in	IN	O
similar	JJ	O
populations	NNS	O
.	.	O

DESCRIPTION	NNP	O
OF	IN	O
STUDY	NNP	O
Fifty-two	NNP	SampleSize
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
breast	NN	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
usual	JJ	O
care	NN	O
or	CC	O
usual	JJ	O
care	NN	O
plus	CC	O
exercise	NN	O
.	.	O

Those	DT	O
assigned	VBN	O
to	TO	O
the	DT	O
exercise	NN	O
group	NN	O
received	VBD	O
a	DT	O
standardized	JJ	O
,	,	O
self-administered	JJ	O
,	,	O
home-based	JJ	O
brisk	NN	O
walking	VBG	O
intervention	NN	O
in	IN	O
addition	NN	O
to	TO	O
usual	JJ	O
care	NN	O
.	.	O

Each	DT	O
day	NN	O
subjects	VBZ	O
completed	VBN	O
self-report	JJ	O
diary	JJ	O
forms	NNS	O
that	WDT	O
elicited	VBD	O
information	NN	O
about	IN	O
activity	NN	O
levels	NNS	O
,	,	O
and	CC	O
the	DT	O
occurrence	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
side	JJ	O
effects	NNS	O
during	IN	O
cancer	NN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Analyses	NNP	O
of	IN	O
self-reported	JJ	O
daily	JJ	O
activity	NN	O
levels	NNS	O
revealed	VBD	O
a	DT	O
diffusion	NN	O
of	IN	O
treatment	NN	O
effect	NN	O
.	.	O

Fifty	NNP	O
percent	NN	O
of	IN	O
the	DT	O
usual-care	JJ	O
group	NN	O
reported	VBD	O
maintaining	NN	O
or	CC	O
increasing	VBG	O
their	PRP$	O
physical	JJ	O
activity	NN	O
to	TO	O
a	DT	O
moderate-intensity	JJ	O
level	NN	O
,	,	O
while	IN	O
33	CD	O
%	NN	O
of	IN	O
the	DT	O
exercise	NN	O
group	NN	O
did	VBD	O
not	RB	O
exercise	NN	O
at	IN	O
the	DT	O
prescribed	NN	O
levels	NNS	O
.	.	O

Analyses	NNS	O
of	IN	O
self-reported	JJ	O
disease	NN	O
symptoms	NNS	O
and	CC	O
treatment	NN	O
side	NN	O
effects	NNS	O
did	VBD	O
not	RB	O
reveal	VB	O
clinically	RB	O
meaningful	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CLINICAL	JJ	O
IMPLICATIONS	NNP	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
women	NNS	O
who	WP	O
exercised	VBD	O
regularly	RB	O
before	RB	O
receiving	VBG	O
a	DT	O
breast	NN	O
cancer	NN	O
diagnosis	NN	O
attempted	VBD	O
to	TO	O
maintain	VB	O
their	PRP$	O
exercise	NN	O
programs	NNS	O
.	.	O

Women	NNS	O
who	WP	O
lead	VBP	O
sedentary	JJ	O
lifestyles	NNS	O
may	MD	O
benefit	VB	O
from	IN	O
a	DT	O
structured	JJ	O
exercise	NN	O
program	NN	O
that	WDT	O
includes	VBZ	O
information	NN	O
and	CC	O
support	NN	O
related	VBN	O
to	TO	O
exercise	VB	O
adherence	NN	O
strategies	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
glucagon-like	JJ	O
peptide-1	JJ	O
(	(	O
7-36	JJ	O
)	)	O
amide	NN	O
on	IN	O
motility	NN	O
and	CC	O
sensation	NN	O
of	IN	O
the	DT	O
proximal	JJ	Condition
stomach	NN	Condition
in	IN	O
humans	NNS	O
.	.	O

BACKGROUND	NNP	O
Glucagon-like	JJ	O
peptide-1	NN	O
(	(	O
7-36	JJ	O
)	)	O
amide	NN	O
(	(	O
GLP-1	NNP	O
)	)	O
retards	NNS	O
gastric	JJ	O
emptying	NN	O
,	,	O
reduces	NNS	O
food	NN	O
intake	NN	O
,	,	O
and	CC	O
inhibits	VBZ	O
antroduodenal	JJ	O
and	CC	O
stimulates	VBZ	O
pyloric	JJ	O
motility	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
synthetic	JJ	O
GLP-1	NNP	O
on	IN	O
fundus	NN	O
tone	NN	O
and	CC	O
volume	NN	O
waves	NNS	O
,	,	O
gastric	JJ	O
compliance	NN	O
,	,	O
and	CC	O
perception	NN	O
of	IN	O
gastric	JJ	O
distension	NN	O
.	.	O

SUBJECTS	NNP	O
Eleven	NNP	SampleSize
healthy	JJ	Condition
male	NN	Sex
volunteers	NNS	O
.	.	O

METHODS	NNP	O
Background	NNP	O
infusions	NNS	O
were	VBD	O
saline	JJ	O
,	,	O
or	CC	O
GLP-1	NNP	O
at	IN	O
0.3	CD	O
or	CC	O
0.9	CD	O
pmol/	JJ	O
kg/min	NN	O
on	IN	O
separate	JJ	O
days	NNS	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Interdigestive	JJ	O
fundus	NN	O
motility	NN	O
was	VBD	O
recorded	VBN	O
by	IN	O
barostat	NN	O
(	(	O
maximum	JJ	O
capacity	NN	O
of	IN	O
intragastric	JJ	O
bag	NN	O
1200	CD	O
ml	NN	O
)	)	O
during	IN	O
basal	NN	O
and	CC	O
peptide	JJ	O
periods	NNS	O
of	IN	O
60	CD	O
minutes	NNS	O
each	DT	O
.	.	O

Thereafter	RB	O
stepwise	JJ	O
isobaric	JJ	O
distensions	NNS	O
were	VBD	O
performed	VBN	O
with	IN	O
ongoing	JJ	O
peptide	NN	O
infusion	NN	O
,	,	O
and	CC	O
gastric	JJ	O
sensation	NN	O
was	VBD	O
scored	VBN	O
.	.	O

RESULTS	NNP	O
Low	NNP	O
and	CC	O
high	JJ	O
loads	NNS	O
of	IN	O
GLP-1	NNP	O
induced	JJ	O
physiological	JJ	O
and	CC	O
supraphysiological	JJ	O
plasma	NN	O
immunoreactivities	NNS	O
,	,	O
respectively	RB	O
.	.	O

GLP-1	NNP	O
dose	NN	O
dependently	RB	O
diminished	VBD	O
fundus	JJ	O
tone	NN	O
(	(	O
162.9	CD	O
(	(	O
15.0	CD	O
)	)	O
and	CC	O
259.5	CD	O
(	(	O
17.2	CD	O
)	)	O
v	NN	O
121.1	CD	O
(	(	O
6.0	CD	O
)	)	O
ml	NN	O
with	IN	O
saline	NN	O
;	:	O
p	CC	O
<	VB	O
0.0001	CD	O
)	)	O
.	.	O

It	PRP	O
greatly	RB	O
reduced	VBD	O
volume	NN	O
waves	NNS	O
and	CC	O
total	JJ	O
volume	NN	O
displaced	VBN	O
by	IN	O
these	DT	O
events	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Gastric	NNP	O
compliance	NN	O
derived	VBD	O
from	IN	O
isobaric	JJ	O
distension	NN	O
rose	VBD	O
in	IN	O
a	DT	O
dose	NN	O
related	JJ	O
manner	NN	O
(	(	O
42.6	CD	O
(	(	O
5.5	CD	O
)	)	O
and	CC	O
63.6	CD	O
(	(	O
7.7	CD	O
)	)	O
v	NN	O
27.0	CD	O
(	(	O
3.5	CD	O
)	)	O
ml/mm	NN	O
Hg	NNP	O
;	:	O
p=0.0004	NN	O
)	)	O
with	IN	O
a	DT	O
concomitant	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
pressure	NN	O
at	IN	O
half	JJ	O
maximum	JJ	O
bag	NN	O
volume	NN	O
(	(	O
6.4	CD	O
(	(	O
0.4	CD	O
)	)	O
and	CC	O
5.5	CD	O
(	(	O
0.4	CD	O
)	)	O
v	NN	O
7.2	CD	O
(	(	O
0.1	CD	O
)	)	O
mm	NN	O
Hg	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.0001	CD	O
)	)	O
.	.	O

GLP-1	NNP	O
did	VBD	O
not	RB	O
change	VB	O
perception	NN	O
of	IN	O
isobaric	JJ	O
distension	NN	O
but	CC	O
reduced	VBD	O
the	DT	O
perception	NN	O
score	RB	O
related	VBN	O
to	TO	O
corresponding	VBG	O
bag	NN	O
volume	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
GLP-1	NNP	O
is	VBZ	O
a	DT	O
candidate	JJ	O
physiological	JJ	O
inhibitory	NN	O
regulator	NN	O
of	IN	O
fundus	JJ	O
motility	NN	O
.	.	O

It	PRP	O
allows	VBZ	O
the	DT	O
stomach	NN	O
to	TO	O
afford	VB	O
a	DT	O
larger	JJR	O
volume	NN	O
without	IN	O
increase	NN	O
in	IN	O
sensation	NN	O
.	.	O

Double-blind	JJ	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
aprindine	NN	O
and	CC	O
digoxin	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
symptomatic	JJ	Condition
atrial	JJ	Condition
fibrillation	NN	Condition
.	.	O

A	DT	O
multicenter	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
trial	NN	O
compared	VBN	O
the	DT	O
preventive	JJ	O
effect	NN	O
of	IN	O
aprindine	NN	O
and	CC	O
digoxin	NN	O
on	IN	O
the	DT	O
recurrence	NN	O
of	IN	O
atrial	JJ	Condition
fibrillation	NN	Condition
(	(	Condition
AF	NNP	Condition
)	)	O
with	IN	O
placebo	NN	O
,	,	O
and	CC	O
also	RB	O
compare	VBP	O
the	DT	O
effectiveness	NN	O
of	IN	O
these	DT	O
2	CD	O
drugs	NNS	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
AF	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
symptomatic	JJ	Condition
paroxysmal	NN	Condition
or	CC	O
persistent	JJ	Condition
AF	NNP	Condition
who	WP	O
had	VBD	O
converted	VBN	O
to	TO	O
sinus	VB	Condition
rhythm	NN	Condition
(	(	Condition
SR	NNP	Condition
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
aprindine	NN	O
(	(	O
40	CD	O
mg/day	NN	O
)	)	O
,	,	O
digoxin	NN	O
(	(	O
0.25	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
and	CC	O
followed	VBD	O
up	RP	O
on	IN	O
an	DT	O
outpatient	JJ	O
basis	NN	O
every	DT	O
2	CD	O
weeks	NNS	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Of	IN	O
the	DT	O
141	CD	SampleSize
patients	NNS	O
from	IN	O
36	CD	SampleSize
participating	VBG	O
centers	NNS	O
,	,	O
47	CD	SampleSize
were	VBD	SampleSize
given	VBN	SampleSize
aprindine	NN	SampleSize
,	,	O
47	CD	SampleSize
digoxin	NN	SampleSize
,	,	O
and	CC	O
47	CD	SampleSize
were	VBD	SampleSize
on	IN	SampleSize
placebo	NN	SampleSize
.	.	O

After	IN	O
the	DT	O
6-month	JJ	O
follow-up	NN	O
,	,	O
the	DT	O
Kaplan-Meier	NNP	O
estimates	NNS	O
of	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
remaining	VBG	O
free	JJ	O
of	IN	O
recurrent	JJ	O
symptomatic	JJ	O
AF	NNP	O
on	IN	O
aprindine	NN	O
,	,	O
digoxin	NN	O
and	CC	O
placebo	NN	O
were	VBD	O
33.3	CD	O
%	NN	O
,	,	O
29.2	CD	O
%	NN	O
and	CC	O
21.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
patients	NNS	O
remaining	VBG	O
in	IN	O
SR	NNP	O
for	IN	O
15	CD	O
days	NNS	O
after	IN	O
from	IN	O
the	DT	O
start	NN	O
of	IN	O
follow-up	NN	O
,	,	O
freedom	NN	O
from	IN	O
recurrence	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
prevalent	JJ	O
in	IN	O
the	DT	O
aprindine	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
p=0.0414	NN	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
digoxin	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
neither	CC	O
aprindine	JJ	O
nor	CC	O
digoxin	NN	O
had	VBD	O
a	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
preventing	VBG	O
relapse	NN	O
of	IN	O
symptomatic	JJ	O
AF	NNP	O
;	:	O
however	RB	O
,	,	O
recurrence	NN	O
of	IN	O
AF	NNP	O
occurred	VBD	O
later	RBR	O
with	IN	O
aprindine	NN	O
than	IN	O
with	IN	O
placebo	NN	O
or	CC	O
digoxin	NN	O
.	.	O

A	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
multicenter	NN	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
study	NN	O
of	IN	O
a	DT	O
refrigerator-stable	JJ	O
formulation	NN	O
of	IN	O
Zostavax	NNP	O
.	.	O

The	DT	O
vaccine	NN	O
Zostavax	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
prevent	VB	O
herpes	NNS	O
zoster	NNP	O
(	(	O
HZ	NNP	O
)	)	O
and	CC	O
postherpetic	JJ	O
neuralgia	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
for	IN	O
individuals	NNS	O
>	CD	O
or	CC	O
=60	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
safety	NN	O
and	CC	O
the	DT	O
immunogenicity	NN	O
of	IN	O
a	DT	O
refrigerator-stable	JJ	O
formulation	NN	O
(	(	O
Zostavax	NNP	O
refrigerated	VBD	O
)	)	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
current	JJ	O
formulation	NN	O
(	(	O
Zostavax	NNP	O
frozen	RB	O
)	)	O
in	IN	O
subjects	NNS	O
>	VBP	O
or	CC	O
=50	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

Subjects	VBZ	O
with	IN	O
a	DT	O
negative	JJ	O
history	NN	O
for	IN	O
HZ	NNP	O
were	VBD	O
randomized	VBN	O
1:1	CD	O
to	TO	O
receive	VB	O
one	CD	O
dose	NN	O
of	IN	O
either	DT	O
formulation	NN	O
.	.	O

Enrollment	NN	O
was	VBD	O
stratified	VBN	O
1:2	CD	O
by	IN	O
age	NN	O
(	(	O
50	CD	O
to	TO	O
59	CD	O
years	NNS	O
and	CC	O
>	NN	O
or	CC	O
=60	CD	O
years	NNS	O
)	)	O
.	.	O

Safety	NN	O
was	VBD	O
evaluated	VBN	O
for	IN	O
28	CD	O
days	NNS	O
postvaccination	NN	O
.	.	O

Varicella-zoster	JJ	O
virus	NN	O
(	(	O
VZV	NNP	O
)	)	O
antibody	NN	O
responses	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
glycoprotein	JJ	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
gpELISA	NN	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoints	NNS	O
were	VBD	O
the	DT	O
VZV	NNP	O
antibody	NN	O
geometric	JJ	O
mean	NN	O
titer	NN	O
(	(	O
GMT	NNP	O
;	:	O
day	NN	O
28	CD	O
)	)	O
,	,	O
the	DT	O
VZV	NNP	O
antibody	NN	O
geometric	JJ	O
mean	NN	O
rise	NN	O
(	(	O
GMR	NNP	O
;	:	O
days	NNS	O
1	CD	O
to	TO	O
28	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
vaccine-related	JJ	O
serious	JJ	O
adverse	JJ	O
experiences	NNS	O
(	(	O
AEs	NNP	O
)	)	O
over	IN	O
28	CD	O
days	NNS	O
.	.	O

The	DT	O
refrigerated	JJ	O
(	(	O
n	JJ	O
=	NNP	O
182	CD	O
)	)	O
and	CC	O
frozen	JJ	O
(	(	O
n	JJ	O
=	NNP	O
185	CD	O
)	)	O
formulations	NNS	O
induced	VBD	O
similar	JJ	O
GMTs	NNP	O
(	(	O
727.4	CD	O
and	CC	O
834.4	CD	O
gpELISA	NN	O
units/ml	NN	O
,	,	O
respectively	RB	O
)	)	O
;	:	O
the	DT	O
estimated	VBN	O
GMT	NNP	O
ratio	NN	O
(	(	O
refrigerated	VBN	O
formulation/frozen	RB	O
formulation	NN	O
)	)	O
was	VBD	O
0.87	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.71	CD	O
to	TO	O
1.07	CD	O
)	)	O
.	.	O

The	DT	O
GMRs	NNPS	O
were	VBD	O
2.6-	JJ	O
and	CC	O
2.9-fold	JJ	O
,	,	O
respectively	RB	O
.	.	O

No	DT	O
vaccine-related	JJ	O
serious	JJ	O
AEs	NNP	O
were	VBD	O
reported	VBN	O
in	IN	O
either	DT	O
group	NN	O
,	,	O
and	CC	O
the	DT	O
safety	NN	O
profiles	NNS	O
of	IN	O
the	DT	O
formulations	NNS	O
were	VBD	O
generally	RB	O
similar	JJ	O
.	.	O

The	DT	O
frequencies	NNS	O
of	IN	O
injection-site	JJ	O
AEs	NNP	O
during	IN	O
follow-up	JJ	O
were	VBD	O
35.6	CD	O
%	NN	O
and	CC	O
46.4	CD	O
%	NN	O
in	IN	O
the	DT	O
refrigerated	JJ	O
and	CC	O
the	DT	O
frozen	JJ	O
formulation	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
were	VBD	O
generally	RB	O
mild	VBN	O
.	.	O

The	DT	O
frequencies	NNS	O
of	IN	O
systemic	JJ	O
AEs	NNP	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
and	CC	O
those	DT	O
of	IN	O
vaccine-related	JJ	O
AEs	NNP	O
were	VBD	O
approximately	RB	O
6	CD	O
%	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
refrigerator-stable	JJ	O
formulation	NN	O
of	IN	O
Zostavax	NNP	O
has	VBZ	O
an	DT	O
acceptable	JJ	O
safety	NN	O
profile	NN	O
and	CC	O
is	VBZ	O
as	RB	O
immunogenic	JJ	O
as	IN	O
the	DT	O
frozen	JJ	O
formulation	NN	O
;	:	O
thus	RB	O
,	,	O
the	DT	O
vaccine	NN	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
clinical	JJ	O
settings	NNS	O
where	WRB	O
freezer	NN	O
availability	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

Functional	JJ	O
outcome	NN	O
following	VBG	O
intramedullary	JJ	O
nailing	NN	O
of	IN	O
the	DT	O
femur	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
comparison	NN	O
of	IN	O
piriformis	NN	O
fossa	NN	O
and	CC	O
greater	JJR	O
trochanteric	JJ	O
entry	NN	O
portals	NNS	O
.	.	O

BACKGROUND	IN	O
The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
prospectively	RB	O
compare	VB	O
the	DT	O
functional	JJ	O
outcome	NN	O
of	IN	O
intramedullary	JJ	O
nailing	NN	O
of	IN	O
the	DT	O
femur	NN	O
performed	VBD	O
with	IN	O
use	NN	O
of	IN	O
a	DT	O
trochanteric	NN	O
and	CC	O
a	DT	O
piriformis	NN	O
fossa	NN	O
entry	NN	O
portal	NN	O
.	.	O

METHODS	NNP	O
One	CD	Condition
hundred	CD	Condition
and	CC	Condition
ten	JJ	Condition
patients	NNS	Condition
with	IN	O
a	DT	O
femoral	JJ	Condition
shaft	NN	Condition
fracture	NN	Condition
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

Fifty-four	CD	SampleSize
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
Group	NNP	O
A	NNP	O
(	(	O
piriformis	JJ	O
fossa	NN	O
portal	NN	O
)	)	O
and	CC	O
fifty-six	JJ	SampleSize
to	TO	O
Group	NNP	O
B	NNP	O
(	(	O
trochanteric	JJ	O
portal	NN	O
)	)	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
Osteoarthritis	NNP	O
Index	NNP	O
hip	NN	O
function	NN	O
score	NN	O
,	,	O
pain	NN	O
,	,	O
and	CC	O
blinded	VBD	O
functional	JJ	O
evaluation	NN	O
by	IN	O
a	DT	O
physical	JJ	O
therapist	NN	O
.	.	O

RESULTS	NNP	O
Most	JJS	O
measures	NNS	O
of	IN	O
hip	NN	O
function	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
WOMAC	NNP	O
score	NN	O
at	IN	O
three	CD	O
,	,	O
six	CD	O
,	,	O
and	CC	O
twelve	JJ	O
months	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
piriformis	NN	O
fossa	NN	O
and	CC	O
trochanteric	JJ	O
nailing	NN	O
groups	NNS	O
.	.	O

Functional	JJ	O
tests	NNS	O
included	VBD	O
the	DT	O
chair	NN	O
stand	VBP	O
test	NN	O
and	CC	O
the	DT	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
test	NN	O
.	.	O

Patients	NNS	O
in	IN	O
Group	NNP	O
B	NNP	O
had	VBD	O
significantly	RB	O
better	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
chair	NN	O
stand	VBP	O
test	NN	O
(	(	O
13.3	CD	O
compared	VBN	O
with	IN	O
11.1	CD	O
in	IN	O
Group	NNP	O
A	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
at	IN	O
six	CD	O
months	NNS	O
postoperatively	RB	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
at	IN	O
twelve	JJ	O
months	NNS	O
(	(	O
14.0	CD	O
compared	VBN	O
with	IN	O
13.6	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
on	IN	O
the	DT	O
timed	VBN	O
up	RP	O
and	CC	O
go	VB	O
test	NN	O
at	IN	O
either	DT	O
six	CD	O
or	CC	O
twelve	VB	O
months	NNS	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
also	RB	O
did	VBD	O
not	RB	O
differ	VB	O
on	IN	O
the	DT	O
muscle	NN	O
strength	NN	O
testing	VBG	O
.	.	O

Intraoperative	JJ	O
parameters	NNS	O
differed	VBD	O
significantly	RB	O
between	IN	O
the	DT	O
groups	NNS	O
with	IN	O
respect	NN	O
to	TO	O
operative	JJ	O
time	NN	O
,	,	O
fluoroscopy	JJ	O
time	NN	O
,	,	O
and	CC	O
incision	NN	O
length	NN	O
,	,	O
with	IN	O
the	DT	O
difference	NN	O
favoring	VBG	O
Group	NNP	O
B	NNP	O
for	IN	O
each	DT	O
parameter	NN	O
.	.	O

Analog	NNP	O
pain	VBP	O
scale	JJ	O
values	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
Group	NNP	O
A	NNP	O
(	(	O
2.49	CD	O
)	)	O
and	CC	O
Group	NNP	O
B	NNP	O
(	(	O
2.15	CD	O
)	)	O
at	IN	O
twelve	JJ	O
months	NNS	O
postoperatively	RB	O
.	.	O

CONCLUSIONS	JJ	O
Patients	NNPS	O
in	IN	O
our	PRP$	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
trochanteric	JJ	O
nailing	VBG	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
hip	NN	O
function	NN	O
at	IN	O
one	CD	O
year	NN	O
postoperatively	RB	O
compared	VBN	O
with	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
intramedullary	JJ	O
nailing	VBG	O
through	IN	O
the	DT	O
piriformis	NN	O
fossa	NN	O
.	.	O

The	DT	O
values	NNS	O
of	IN	O
several	JJ	O
intraoperative	JJ	O
parameters	NNS	O
were	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
trochanteric	JJ	O
nailing	NN	O
group	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
functional	JJ	O
hip	NN	O
outcome	NN	O
of	IN	O
femoral	JJ	O
intramedullary	JJ	O
nailing	NN	O
performed	VBN	O
through	IN	O
the	DT	O
greater	JJR	O
trochanter	NN	O
is	VBZ	O
equal	JJ	O
to	TO	O
that	DT	O
of	IN	O
intramedullary	JJ	O
nailing	NN	O
performed	VBN	O
through	IN	O
the	DT	O
piriformis	NN	O
fossa	NN	O
.	.	O

Sleep-anticipating	JJ	O
effects	NNS	O
of	IN	O
melatonin	NN	O
in	IN	O
the	DT	O
human	JJ	O
brain	NN	O
.	.	O

Melatonin	NNP	O
,	,	O
the	DT	O
hormone	NN	O
produced	VBN	O
nocturnally	RB	O
by	IN	O
the	DT	O
pineal	NN	O
gland	NN	O
,	,	O
is	VBZ	O
an	DT	O
endogenous	JJ	O
regulator	NN	O
of	IN	O
the	DT	O
sleep-wake	JJ	O
cycle	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
melatonin	NN	O
on	IN	O
brain	NN	O
activities	NNS	O
and	CC	O
their	PRP$	O
relation	NN	O
to	TO	O
induction	NN	O
of	IN	O
sleepiness	NN	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
functional	JJ	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
(	(	O
fMRI	NN	O
)	)	O
study	NN	O
.	.	O

Melatonin	NNP	O
,	,	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
reduced	VBN	O
task-related	JJ	O
activity	NN	O
in	IN	O
the	DT	O
rostro-medial	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
occipital	JJ	O
cortex	NN	O
during	IN	O
a	DT	O
visual-search	JJ	O
task	NN	O
and	CC	O
in	IN	O
the	DT	O
auditory	JJ	O
cortex	NN	O
during	IN	O
a	DT	O
music	NN	O
task	NN	O
.	.	O

These	DT	O
effects	NNS	O
correlated	VBD	O
with	IN	O
subjective	JJ	O
measurements	NNS	O
of	IN	O
fatigue	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
melatonin	NN	O
enhanced	VBD	O
the	DT	O
activation	NN	O
in	IN	O
the	DT	O
left	NN	O
parahippocampus	NN	O
in	IN	O
an	DT	O
autobiographic	JJ	O
memory	NN	O
task	NN	O
.	.	O

Results	VB	O
demonstrate	NN	O
that	IN	O
melatonin	NN	O
modulates	NNS	O
brain	NN	O
activity	NN	O
in	IN	O
a	DT	O
manner	NN	O
resembling	VBG	O
actual	JJ	O
sleep	NN	O
although	IN	O
subjects	NNS	O
are	VBP	O
fully	RB	O
awake	RB	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
fatigue	NN	O
inducing	VBG	O
effect	NN	O
of	IN	O
melatonin	NN	O
on	IN	O
brain	NN	O
activity	NN	O
is	VBZ	O
essentially	RB	O
different	JJ	O
from	IN	O
that	DT	O
of	IN	O
sleep	JJ	O
deprivation	NN	O
thus	RB	O
revealing	VBG	O
differences	NNS	O
between	IN	O
fatigues	NNS	O
related	VBN	O
to	TO	O
the	DT	O
circadian	JJ	O
sleep	NN	O
regulation	NN	O
as	IN	O
opposed	VBN	O
to	TO	O
increased	VBN	O
homeostatic	JJ	O
sleep	NN	O
need	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
highlight	VBD	O
the	DT	O
role	NN	O
of	IN	O
melatonin	NN	O
in	IN	O
priming	VBG	O
sleep-associated	JJ	O
brain	NN	O
activation	NN	O
patterns	NNS	O
in	IN	O
anticipation	NN	O
of	IN	O
sleep	NN	O
.	.	O

Clinical	JJ	O
evaluation	NN	O
of	IN	O
imidapril	NN	O
in	IN	O
congestive	JJ	Condition
heart	NN	Condition
failure	NN	Condition
in	IN	Condition
dogs	NNS	Condition
:	:	Condition
results	NNS	O
of	IN	O
the	DT	O
EFFIC	NNP	O
study	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
clinical	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
imidapril	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
dogs	NNS	Condition
that	WDT	Condition
presented	VBD	Condition
with	IN	Condition
mild	NN	Condition
to	TO	Condition
severe	VB	Condition
congestive	JJ	Condition
heart	NN	Condition
failure	NN	Condition
(	(	Condition
New	NNP	Condition
York	NNP	Condition
Heart	NNP	Condition
Association	NNP	Condition
stage	NN	Condition
II	NNP	Condition
to	TO	Condition
IV	NNP	Condition
)	)	Condition
by	IN	O
comparing	VBG	O
the	DT	O
success	NN	O
rate	NN	O
of	IN	O
imidapril	NN	O
with	IN	O
a	DT	O
positive	JJ	O
control	NN	O
by	IN	O
a	DT	O
non-inferiority	JJ	O
approach	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
good	JJ	O
,	,	O
clinical	JJ	O
practice	NN	O
compliant	NN	O
,	,	O
multicentre	NN	O
study	NN	O
(	(	O
EFFIC	NNP	O
study	NN	O
)	)	O
enrolled	VBD	O
142	CD	O
client-owned	JJ	O
dogs	NNS	O
and	CC	O
was	VBD	O
conducted	VBN	O
in	IN	O
20	CD	O
locations	NNS	O
in	IN	O
France	NNP	O
,	,	O
Belgium	NNP	O
and	CC	O
Germany	NNP	O
.	.	O

Dogs	NNP	Condition
of	IN	Condition
various	JJ	Condition
breed	NN	Condition
,	,	Condition
age	NN	Condition
and	CC	Condition
weight	NN	Condition
were	VBD	Condition
included	VBN	Condition
in	IN	Condition
the	DT	Condition
study	NN	Condition
.	.	Condition

These	DT	O
dogs	NNS	O
were	VBD	O
randomised	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
that	WDT	O
were	VBD	O
treated	VBN	O
for	IN	O
84	CD	O
days	NNS	O
with	IN	O
either	DT	O
the	DT	O
test	NN	O
product	NN	O
,	,	O
imidapril	NN	O
,	,	O
or	CC	O
the	DT	O
positive	JJ	O
control	NN	O
,	,	O
benazepril	NN	O
,	,	O
and	CC	O
followed	VBD	O
up	RP	O
in	IN	O
parallel	NN	O
over	IN	O
this	DT	O
period	NN	O
.	.	O

Both	DT	O
treatments	NNS	O
were	VBD	O
administered	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.25	CD	O
mg/kg	NN	O
once	RB	O
a	DT	O
day	NN	O
with	IN	O
the	DT	O
possibility	NN	O
of	IN	O
doubling	VBG	O
this	DT	O
dose	NN	O
to	TO	O
0.5	CD	O
mg/kg	NN	O
if	IN	O
considered	VBN	O
necessary	JJ	O
from	IN	O
a	DT	O
clinical	JJ	O
point	NN	O
of	IN	O
view	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
concomitant	JJ	O
treatment	NN	O
was	VBD	O
given	VBN	O
to	TO	O
dogs	NNS	O
presenting	VBG	O
with	IN	O
pulmonary	JJ	O
oedema	NN	O
and/or	NN	O
ascites	NNS	O
,	,	O
supraventricular	JJ	O
tachyarrhythmia	NN	O
and/or	NN	O
dilated	VBD	O
cardiomyopathy	NN	O
.	.	O

The	DT	O
evolution	NN	O
of	IN	O
the	DT	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
stage	NN	O
and	CC	O
the	DT	O
functional	JJ	O
signs	NNS	O
score	NN	O
were	VBD	O
evaluated	VBN	O
as	IN	O
primary	JJ	O
efficacy	NN	O
criteria	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
success	NN	O
rate	NN	O
in	IN	O
the	DT	O
imidapril	NN	O
group	NN	O
was	VBD	O
66	CD	O
compared	VBN	O
with	IN	O
68	CD	O
per	IN	O
cent	NN	O
in	IN	O
the	DT	O
benazepril	NN	O
group	NN	O
.	.	O

Regarding	VBG	O
safety	NN	O
,	,	O
35	CD	O
dogs	NNS	O
in	IN	O
each	DT	O
group	NN	O
experienced	VBD	O
at	IN	O
least	JJS	O
one	CD	O
adverse	JJ	O
event	NN	O
.	.	O

Nine	NNP	O
dogs	NNS	O
in	IN	O
each	DT	O
group	NN	O
experienced	VBD	O
at	IN	O
least	JJS	O
one	CD	O
serious	JJ	O
adverse	JJ	O
event	NN	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
these	DT	O
results	NNS	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CLINICAL	JJ	O
SIGNIFICANCE	NNP	O
Imidapril	NNP	O
is	VBZ	O
as	RB	O
efficacious	JJ	O
and	CC	O
safe	JJ	O
as	IN	O
the	DT	O
reference	NN	O
product	NN	O
,	,	O
benazepril	NN	O
.	.	O

A	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
nonlinear	JJ	O
frequency	NN	O
compression	NN	O
versus	IN	O
conventional	JJ	O
processing	NN	O
in	IN	O
hearing	VBG	O
aids	NNS	O
:	:	O
speech	NN	O
and	CC	O
language	NN	O
of	IN	O
children	NNS	Age
at	IN	Age
three	CD	Age
years	NNS	Age
of	IN	Age
age	NN	Age
.	.	Age

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
nonlinear	JJ	O
frequency	NN	O
compression	NN	O
(	(	O
NLFC	NNP	O
)	)	O
on	IN	O
children	NNS	O
's	POS	O
development	NN	O
of	IN	O
speech	NN	O
and	CC	O
language	NN	O
at	IN	O
three	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
population-based	JJ	O
longitudinal	JJ	O
study	NN	O
on	IN	O
outcomes	NNS	O
of	IN	O
children	NNS	O
with	IN	O
hearing	VBG	O
impairment	NN	O
(	(	O
LOCHI	NNP	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
fitting	VBG	O
with	IN	O
NLFC	NNP	O
(	(	O
Phonak	NNP	O
Naida	NNP	O
V	NNP	O
SP	NNP	O
or	CC	O
UP	NNP	O
)	)	O
or	CC	O
with	IN	O
conventional	JJ	O
processing	NN	O
in	IN	O
hearing	VBG	O
aids	NNS	O
,	,	O
prescribed	VBN	O
by	IN	O
using	VBG	O
either	CC	O
the	DT	O
NAL	NNP	O
or	CC	O
the	DT	O
DSL	NNP	O
formula	NN	O
.	.	O

Standardized	JJ	O
tests	NNS	O
of	IN	O
speech	NN	O
production	NN	O
,	,	O
receptive	JJ	O
and	CC	O
expressive	JJ	O
language	NN	O
were	VBD	O
administered	VBN	O
,	,	O
and	CC	O
parent	NN	O
ratings	NNS	O
were	VBD	O
collected	VBN	O
.	.	O

All	DT	O
assessments	NNS	O
were	VBD	O
double-blinded	JJ	O
.	.	O

STUDY	NNP	O
SAMPLE	NNP	O
Participants	NNP	O
were	VBD	O
44	CD	O
of	IN	O
the	DT	O
450	CD	O
children	NNS	O
in	IN	O
the	DT	O
LOCHI	NNP	O
cohort	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
to	TO	O
children	NNS	O
using	VBG	O
conventional	JJ	O
processing	NN	O
,	,	O
receptive	JJ	O
and	CC	O
expressive	JJ	O
language	NN	O
was	VBD	O
higher	JJR	O
but	CC	O
receptive	JJ	O
vocabulary	NN	O
and	CC	O
consonant	JJ	O
articulation	NN	O
scores	NNS	O
were	VBD	O
lower	JJR	O
for	IN	O
children	NNS	O
who	WP	O
use	VBP	O
NLFC	NNP	O
.	.	O

There	EX	O
was	VBD	O
increased	VBN	O
substitution	NN	O
of	IN	O
affricates	NNS	O
by	IN	O
fricatives	NNS	O
for	IN	O
children	NNS	O
using	VBG	O
NLFC	NNP	O
,	,	O
compared	VBN	O
to	TO	O
children	NNS	O
using	VBG	O
conventional	JJ	O
amplification	NN	O
.	.	O

After	IN	O
allowing	VBG	O
for	IN	O
the	DT	O
effect	NN	O
of	IN	O
multiple	JJ	O
demographic	JJ	O
variables	NNS	O
,	,	O
the	DT	O
difference	NN	O
in	IN	O
global	JJ	O
language	NN	O
scores	NNS	O
between	IN	O
groups	NNS	O
was	VBD	O
not	RB	O
significant	JJ	O
(	(	O
effect	NN	O
:	:	O
0.8	CD	O
[	$	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
-	:	O
6.7	CD	O
,	,	O
8.3	CD	O
]	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
insufficient	JJ	O
evidence	NN	O
to	TO	O
indicate	VB	O
a	DT	O
difference	NN	O
in	IN	O
language	NN	O
ability	NN	O
between	IN	O
children	NNS	O
using	VBG	O
NLFC	NNP	O
and	CC	O
those	DT	O
using	VBG	O
conventional	JJ	O
amplification	NN	O
.	.	O

What	WP	O
is	VBZ	O
the	DT	O
optimum	JJ	O
maximal	JJ	O
gonadotropin	NN	O
dosage	NN	O
used	VBN	O
in	IN	O
microdose	JJ	Condition
flare-up	JJ	Condition
cycles	NNS	Condition
in	IN	Condition
poor	JJ	Condition
responders	NNS	Condition
?	.	O
OBJECTIVE	NNP	O
To	TO	O
find	VB	O
out	RP	O
the	DT	O
optimum	JJ	O
maximal	JJ	O
dosage	NN	O
of	IN	O
recombinant	JJ	O
follicle	NN	O
stimulating	VBG	O
hormone	NN	O
(	(	O
rFSH	NN	O
)	)	O
in	IN	O
microdose	JJ	O
gonadotropin-releasing	JJ	O
hormone	NN	O
analog	NN	O
(	(	O
GnRH-a	NNP	O
)	)	O
flare	NN	O
cycles	NNS	O
in	IN	O
poor	JJ	O
responders	NNS	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
randomized	VBD	O
study	NN	O
.	.	O

SETTING	NNP	O
Private	NNP	O
infertility	NN	O
clinic	NN	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
total	NN	O
of	IN	O
119	CD	O
women	NNS	O
were	VBD	O
taken	VBN	O
into	IN	O
the	DT	O
study	NN	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
The	DT	O
study	NN	O
group	NN	O
underwent	VBD	O
a	DT	O
microdose	JJ	O
protocol	NN	O
with	IN	O
a	DT	O
GnRH-agonist	JJ	O
followed	VBN	O
by	IN	O
rFSH	JJ	O
administration	NN	O
.	.	O

On	IN	O
the	DT	O
third	JJ	O
day	NN	O
of	IN	O
GnRH-a	NNP	O
administration	NN	O
,	,	O
119	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
three	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
daily	JJ	O
fixed	VBN	O
doses	NNS	O
of	IN	O
300	CD	O
IU	NNP	O
of	IN	O
rFSH	NN	O
(	(	O
group	NN	O
A	NNP	O
,	,	O
n	JJ	O
=	NNP	O
38	CD	O
)	)	O
,	,	O
or	CC	O
450	CD	O
IU	NNP	O
of	IN	O
rFSH	NN	O
(	(	O
group	NN	O
B	NNP	O
,	,	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
,	,	O
or	CC	O
600	CD	O
IU	NNP	O
of	IN	O
rFSH	NN	O
(	(	O
group	NN	O
C	NNP	O
,	,	O
n	JJ	O
=	NNP	O
42	CD	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Peak	NNP	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
levels	NNS	O
,	,	O
days	NNS	O
of	IN	O
stimulation	NN	O
with	IN	O
rFSH	NN	O
,	,	O
total	JJ	O
rFSH	NN	O
dosage	NN	O
,	,	O
total	JJ	O
number	NN	O
of	IN	O
oocytes	NNS	O
retrieved	VBN	O
,	,	O
M2	NNP	O
oocytes	VBZ	O
retrieved	VBN	O
,	,	O
total	JJ	O
number	NN	O
of	IN	O
embryos	NN	O
,	,	O
number	NN	O
of	IN	O
embryos	NN	O
transferred	VBN	O
,	,	O
number	NN	O
of	IN	O
Grade-1	NNP	O
embryos	NN	O
transferred	VBD	O
,	,	O
clinical	JJ	O
pregnancy	NN	O
rate	NN	O
(	(	O
positive	JJ	O
fetal	JJ	O
cardiac	JJ	O
activity	NN	O
)	)	O
,	,	O
and	CC	O
cancellation	NN	O
rates	NNS	O
of	IN	O
stimulation	NN	O
and	CC	O
embryo	NN	O
transfer	NN	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
Clinical	NNP	O
pregnancy	NN	O
rates	NNS	O
were	VBD	O
13.1	CD	O
%	NN	O
,	,	O
15.3	CD	O
%	NN	O
,	,	O
and	CC	O
16.1	CD	O
%	NN	O
for	IN	O
group	NN	O
A	NNP	O
,	,	O
group	NN	O
B	NNP	O
,	,	O
and	CC	O
group	NN	O
C	NNP	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
age	NN	O
,	,	O
peak	JJ	O
serum	NN	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
concentration	NN	O
,	,	O
days	NNS	O
of	IN	O
stimulation	NN	O
with	IN	O
rFSH	NN	O
,	,	O
total	JJ	O
number	NN	O
of	IN	O
M2	NNP	O
oocytes	VBZ	O
retrieved	VBN	O
,	,	O
number	NN	O
of	IN	O
embryos	NN	O
transferred	VBN	O
,	,	O
clinical	JJ	O
pregnancy	NN	O
rates	NNS	O
,	,	O
and	CC	O
cancellation	NN	O
rates	NNS	O
of	IN	O
stimulation	NN	O
and	CC	O
embryo	NN	O
transfer	NN	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
except	IN	O
for	IN	O
total	JJ	O
rFSH	JJ	O
dosage	NN	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
There	EX	O
is	VBZ	O
no	DT	O
need	NN	O
to	TO	O
use	VB	O
doses	NNS	O
above	IN	O
300	CD	O
IU	NNP	O
of	IN	O
rFSH	NN	O
to	TO	O
increase	VB	O
the	DT	O
pregnancy	NN	O
rate	NN	O
in	IN	O
microdose	JJ	O
cycles	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
because	IN	O
the	DT	O
duration	NN	O
of	IN	O
stimulation	NN	O
does	VBZ	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
groups	NNS	O
,	,	O
the	DT	O
usage	NN	O
of	IN	O
300	CD	O
IU	NNP	O
rFSH	NN	O
in	IN	O
microdose	JJ	O
cycles	NNS	O
results	NNS	O
in	IN	O
less	JJR	O
total	JJ	O
amount	NN	O
of	IN	O
rFSH	NN	O
consumed	VBN	O
in	IN	O
a	DT	O
cycle	NN	O
compared	VBN	O
with	IN	O
higher	JJR	O
dosages	NNS	O
,	,	O
and	CC	O
this	DT	O
would	MD	O
obviously	RB	O
cost	VB	O
less	JJR	O
money	NN	O
to	TO	O
the	DT	O
patients	NNS	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
intramammary	JJ	O
tilmicosin	NN	O
at	IN	O
drying-off	NN	O
,	,	O
and	CC	O
other	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
new	JJ	O
intramammary	JJ	O
infections	NNS	O
during	IN	O
the	DT	O
dry	JJ	O
period	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
intramammary	JJ	O
infusion	NN	O
,	,	O
containing	VBG	O
tilmicosin	NN	O
phosphate	NN	O
,	,	O
to	TO	O
an	DT	O
infusion	NN	O
of	IN	O
a	DT	O
negative	JJ	O
control	NN	O
intramammary	JJ	O
placebo	NN	O
for	IN	O
preventing	VBG	O
new	JJ	O
intramammary	JJ	O
infections	NNS	O
(	(	O
IMI	NNP	O
)	)	O
during	IN	O
the	DT	O
dry	JJ	O
period	NN	O
.	.	O

Cows	NNS	Condition
were	VBD	O
enrolled	VBN	O
from	IN	O
24	CD	O
dairy	NN	O
herds	NNS	O
from	IN	O
three	CD	O
geographical	JJ	O
regions	NNS	O
of	IN	O
Canada	NNP	O
.	.	O

Data	NNP	O
from	IN	O
248	CD	SampleSize
cows	NNS	O
and	CC	O
938	CD	O
bacteriologically	RB	O
negative	JJ	O
quarters	NNS	O
at	IN	O
drying-off	NN	O
are	VBP	O
summarized	VBN	O
.	.	O

Overall	JJ	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
new	JJ	O
IMI	NNP	O
during	IN	O
the	DT	O
dry	JJ	O
period	NN	O
was	VBD	O
16.7	CD	O
%	NN	O
of	IN	O
quarters	NNS	O
.	.	O

The	DT	O
new	JJ	O
infection	NN	O
rates	NNS	O
for	IN	O
quarters	NNS	O
that	WDT	O
received	VBD	O
intramammary	JJ	O
tilmicosin	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
intramammary	JJ	O
placebo	NN	O
were	VBD	O
14.4	CD	O
and	CC	O
19.4	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
new	JJ	O
IMI	NNP	O
was	VBD	O
caused	VBN	O
by	IN	O
coagulase-negative	JJ	O
staphylococci	NN	O
(	(	O
49	CD	O
%	NN	O
)	)	O
and	CC	O
environmental	JJ	O
streptococcal	JJ	O
organisms	NNS	O
(	(	O
26.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
probability	NN	O
for	IN	O
quarters	NNS	O
to	TO	O
develop	VB	O
new	JJ	O
IMI	NNP	O
in	IN	O
the	DT	O
dry	JJ	O
period	NN	O
was	VBD	O
significantly	RB	O
increased	VBN	O
when	WRB	O
cows	NNS	O
had	VBD	O
higher	JJR	O
milk	NN	O
production	NN	O
before	IN	O
drying-off	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
when	WRB	O
cows	NNS	O
had	VBD	O
longer	RBR	O
dry	JJ	O
periods	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
when	WRB	O
dry	JJ	O
cows	NNS	O
were	VBD	O
housed	VBN	O
in	IN	O
tie-stall	JJ	O
barns	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Higher	JJR	O
parity	NN	O
cows	NNS	O
and	CC	O
those	DT	O
that	WDT	O
had	VBD	O
a	DT	O
linear	JJ	O
score	NN	O
somatic	JJ	O
cell	NN	O
count	NN	O
(	(	O
SCC	NNP	O
)	)	O
above	IN	O
4	CD	O
on	IN	O
the	DT	O
last	JJ	O
DHI	NNP	O
test	NN	O
were	VBD	O
also	RB	O
at	IN	O
increased	VBN	O
risk	NN	O
for	IN	O
new	JJ	O
IMI	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.10	CD	O
)	)	O
.	.	O

Administration	NN	O
of	IN	O
intramammary	JJ	O
tilmicosin	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
an	DT	O
efficacious	JJ	O
therapy	NN	O
for	IN	O
prevention	NN	O
of	IN	O
new	JJ	O
IMI	NNP	O
;	:	O
however	RB	O
,	,	O
there	EX	O
is	VBZ	O
currently	RB	O
no	DT	O
approved	VBD	O
intramammary	JJ	O
formulation	NN	O
of	IN	O
this	DT	O
product	NN	O
available	JJ	O
.	.	O

Use	NNP	O
of	IN	O
blanket	NN	O
dry	JJ	O
cow	NN	O
antibiotic	JJ	O
therapy	NN	O
compared	VBN	O
to	TO	O
selective	VB	O
dry	JJ	O
cow	NN	O
therapy	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
importance	NN	O
of	IN	O
identifying	VBG	O
risk	NN	O
factors	NNS	O
and	CC	O
managing	VBG	O
the	DT	O
environment	NN	O
of	IN	O
dry	JJ	O
cows	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Comparison	NNP	O
between	IN	O
intermittent	JJ	O
mandatory	JJ	O
ventilation	NN	O
and	CC	O
synchronized	JJ	O
intermittent	NN	O
mandatory	JJ	O
ventilation	NN	O
with	IN	O
pressure	NN	O
support	NN	O
in	IN	O
children	NNS	Age
.	.	O

OBJECTIVE	NN	O
To	TO	O
compare	VB	O
intermittent	JJ	O
mandatory	JJ	O
ventilation	NN	O
(	(	O
IMV	NNP	O
)	)	O
with	IN	O
synchronized	JJ	O
intermittent	JJ	O
mandatory	NN	O
ventilation	NN	O
plus	CC	O
pressure	NN	O
support	NN	O
(	(	O
SIMV+PS	NNP	O
)	)	O
in	IN	O
terms	NNS	O
of	IN	O
time	NN	O
on	IN	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
duration	NN	O
of	IN	O
weaning	VBG	O
and	CC	O
length	NN	O
of	IN	O
stay	NN	O
in	IN	O
a	DT	O
pediatric	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
PICU	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
enrolled	VBD	O
children	NNS	Age
aged	VBN	O
28	CD	Age
days	NNS	Age
to	TO	Age
4	CD	Age
years	NNS	Age
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
a	DT	O
PICU	NNP	O
between	IN	O
October	NNP	O
of	IN	O
2005	CD	O
and	CC	O
June	NNP	O
of	IN	O
2007	CD	O
and	CC	O
put	VB	O
on	IN	O
mechanical	JJ	O
ventilation	NN	O
(	(	O
MV	NNP	O
)	)	O
for	IN	O
more	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
by	IN	O
drawing	VBG	O
lots	NNS	O
:	:	O
IMV	NNP	O
group	NN	O
(	(	O
IMVG	NNP	O
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
and	CC	O
SIMV+PS	NNP	O
group	NN	O
(	(	O
SIMVG	NNP	O
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
.	.	O

Children	NNP	Age
were	VBD	O
excluded	VBN	O
if	IN	O
they	PRP	O
had	VBD	O
undergone	JJ	O
tracheotomy	NN	O
or	CC	O
had	VBD	O
chronic	JJ	Condition
respiratory	NN	Condition
diseases	NNS	Condition
.	.	Condition

Data	NNS	O
on	IN	O
oxygenation	NN	O
and	CC	O
ventilation	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
admission	NN	O
and	CC	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
weaning	VBG	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
indication	NN	O
for	IN	O
MV	NNP	O
,	,	O
PRISM	NNP	O
score	NN	O
,	,	O
Comfort	NNP	O
scale	NN	O
,	,	O
use	NN	O
of	IN	O
sedatives	NNS	O
or	CC	O
ventilation	NN	O
and	CC	O
oxygenation	NN	O
parameters	NNS	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
on	IN	O
MV	NNP	O
was	VBD	O
5	CD	O
days	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.120	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
for	IN	O
duration	NN	O
of	IN	O
weaning	VBG	O
[	JJ	O
IMVG	NNP	O
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	O
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.262	CD	O
]	NN	O
or	CC	O
length	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
[	JJ	O
IMVG	NNP	O
:	:	O
8	CD	O
days	NNS	O
(	(	O
2-22	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	O
:	:	O
6	CD	O
days	NNS	O
(	(	O
3-20	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.113	CD	O
]	NNP	O
.	.	O

CONCLUSION	NNP	O
Among	IN	O
the	DT	O
children	NNS	Age
studied	VBN	O
here	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
IMV	NNP	O
and	CC	O
SIMV+PS	NNP	O
in	IN	O
terms	NNS	O
of	IN	O
time	NN	O
on	IN	O
MV	NNP	O
,	,	O
duration	NN	O
of	IN	O
weaning	VBG	O
or	CC	O
time	NN	O
spent	VBN	O
in	IN	O
the	DT	O
PICU	NNP	O
.	.	O

ClinicalTrials.govID	NN	O
:	:	O
NCT00549809	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
insufficient	JJ	O
sleep	NN	O
on	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
:	:	O
a	DT	O
24-h	JJ	O
study	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
acute	JJ	O
sleep	JJ	O
deprivation	NN	O
during	IN	O
the	DT	O
first	JJ	O
part	NN	O
of	IN	O
the	DT	O
night	NN	O
on	IN	O
24-h	JJ	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
(	(	O
ABPM	NNP	O
)	)	O
was	VBD	O
studied	VBN	O
in	IN	O
36	CD	O
never-treated	JJ	O
mild	NN	O
to	TO	O
moderate	VB	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

According	VBG	O
to	TO	O
a	DT	O
crossover	NN	O
design	NN	O
,	,	O
they	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
have	VB	O
either	DT	O
sleep	JJ	O
deprivation	NN	O
or	CC	O
a	DT	O
full	JJ	O
night	NN	O
's	POS	O
sleep	NN	O
1	CD	O
week	NN	O
apart	RB	O
,	,	O
during	IN	O
which	WDT	O
they	PRP	O
were	VBD	O
monitored	VBN	O
with	IN	O
ABPM	NNP	O
.	.	O

Urine	NNP	O
samples	NNS	O
for	IN	O
analysis	NN	O
of	IN	O
nocturnal	JJ	O
urinary	JJ	O
excretion	NN	O
of	IN	O
norepinephrine	NN	O
were	VBD	O
collected	VBN	O
.	.	O

During	IN	O
the	DT	O
sleep-deprivation	JJ	O
day	NN	O
,	,	O
both	DT	O
mean	JJ	O
24-h	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
mean	JJ	O
24-h	JJ	O
heart	NN	O
rate	NN	O
were	VBD	O
higher	JJR	O
in	IN	O
comparison	NN	O
with	IN	O
those	DT	O
recorded	VBN	O
during	IN	O
the	DT	O
routine	JJ	O
workday	NN	O
,	,	O
the	DT	O
difference	NN	O
being	VBG	O
more	RBR	O
pronounced	JJ	O
during	IN	O
the	DT	O
nighttime	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Urinary	JJ	O
excretion	NN	O
of	IN	O
norepinephrine	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
at	IN	O
night	NN	O
during	IN	O
sleep	JJ	O
deprivation	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Blood	NNP	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
significantly	RB	O
increased	VBN	O
in	IN	O
the	DT	O
morning	NN	O
after	IN	O
a	DT	O
sleep-insufficient	JJ	O
night	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
lack	NN	O
of	IN	O
sleep	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
may	MD	O
increase	VB	O
sympathetic	JJ	O
nervous	JJ	O
activity	NN	O
during	IN	O
the	DT	O
night	NN	O
and	CC	O
the	DT	O
following	JJ	O
morning	NN	O
,	,	O
leading	VBG	O
to	TO	O
increased	VBN	O
blood	NN	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
.	.	O

This	DT	O
situation	NN	O
might	MD	O
represent	VB	O
an	DT	O
increased	VBN	O
risk	NN	O
for	IN	O
both	DT	O
target	NN	O
organ	JJ	O
damage	NN	O
and	CC	O
acute	JJ	O
cardiovascular	JJ	O
diseases	NNS	O
.	.	O

Social	JJ	O
stories	NNS	O
:	:	O
mechanisms	NNS	O
of	IN	O
effectiveness	NN	O
in	IN	O
increasing	VBG	O
game	NN	O
play	NN	O
skills	NNS	O
in	IN	O
children	NNS	Age
diagnosed	VBN	O
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorder	NN	Condition
using	VBG	O
a	DT	O
pretest	NN	O
posttest	NN	O
repeated	VBD	O
measures	NNS	O
randomized	VBN	O
control	NN	O
group	NN	O
design	NN	O
.	.	O

An	DT	O
increasing	VBG	O
body	NN	O
of	IN	O
literature	NN	O
has	VBZ	O
indicated	VBN	O
that	IN	O
social	JJ	O
stories	NNS	O
are	VBP	O
an	DT	O
effective	JJ	O
way	NN	O
to	TO	O
teach	VB	O
individuals	NNS	O
diagnosed	VBN	O
with	IN	O
autism	NN	Condition
appropriate	JJ	O
social	JJ	O
behavior	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
two	CD	O
formats	NNS	O
of	IN	O
a	DT	O
social	JJ	O
story	NN	O
targeting	VBG	O
the	DT	O
improvement	NN	O
of	IN	O
social	JJ	O
skills	NNS	O
during	IN	O
game	NN	O
play	NN	O
using	VBG	O
a	DT	O
pretest	NN	O
posttest	NN	O
repeated	VBD	O
measures	NNS	O
randomized	VBN	O
control	NN	O
group	NN	O
design	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
45	CD	SampleSize
children	NNS	O
diagnosed	VBN	O
with	IN	O
Autism	NNP	Condition
Spectrum	NNP	Condition
Disorder	NNP	Condition
(	(	Condition
ASD	NNP	Condition
)	)	Condition
ages	VBZ	O
7-14	CD	Age
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
standard	VB	O
,	,	O
directive	JJ	O
,	,	O
or	CC	O
control	VB	O
story	NN	O
conditions	NNS	O
.	.	O

Results	NNS	O
demonstrated	VBD	O
that	IN	O
the	DT	O
standard	NN	O
and	CC	O
directive	JJ	O
story	NN	O
formats	NNS	O
were	VBD	O
equally	RB	O
as	IN	O
effective	JJ	O
in	IN	O
eliciting	VBG	O
,	,	O
generalizing	VBG	O
and	CC	O
maintaining	VBG	O
the	DT	O
targeted	VBN	O
social	JJ	O
skills	NNS	O
in	IN	O
participants	NNS	O
who	WP	O
had	VBD	O
prior	JJ	O
game	NN	O
play	NN	O
experience	NN	O
and	CC	O
Verbal	NNP	O
Comprehension	NNP	O
Index	NNP	O
(	(	O
VCI	NNP	O
)	)	O
scores	VBZ	O
from	IN	O
the	DT	O
WISC-IV	JJ	O
intelligence	NN	O
test	NN	O
in	IN	O
the	DT	O
borderline	NN	O
range	NN	O
or	CC	O
above	NN	O
.	.	O

A	DT	O
pilot	NN	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
DIR/Floortime?	NNP	O
parent	NN	O
training	NN	O
intervention	NN	O
for	IN	O
pre-school	JJ	Age
children	NNS	Age
with	IN	O
autistic	JJ	Condition
spectrum	NN	Condition
disorders	NNS	Condition
.	.	O

This	DT	O
pilot	NN	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
test	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
adding	VBG	O
home-based	JJ	O
Developmental	NNP	O
,	,	O
Individual-Difference	NNP	O
,	,	O
Relationship-Based	JJ	O
(	(	O
DIR	NNP	O
)	)	O
/Floortime?	VBZ	O
intervention	NN	O
to	TO	O
the	DT	O
routine	JJ	O
care	NN	O
of	IN	O
preschool	NN	O
children	NNS	O
with	IN	O
autistic	JJ	Condition
spectrum	NN	Condition
disorder	NN	Condition
.	.	O

Measures	NNS	O
of	IN	O
functional	JJ	O
emotional	JJ	O
development	NN	O
and	CC	O
symptom	JJ	O
severity	NN	O
were	VBD	O
taken	VBN	O
.	.	O

It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
after	IN	O
the	DT	O
parents	NNS	O
added	VBD	O
home-based	JJ	O
DIR/Floortime?	NNP	O
intervention	NN	O
at	IN	O
an	DT	O
average	NN	O
of	IN	O
15.2	CD	O
hours/week	NN	O
for	IN	O
three	CD	O
months	NNS	O
,	,	O
the	DT	O
intervention	NN	O
group	NN	O
made	VBD	O
significantly	RB	O
greater	JJR	O
gains	NNS	O
in	IN	O
all	DT	O
three	CD	O
measures	NNS	O
employed	VBN	O
in	IN	O
the	DT	O
study	NN	O
:	:	O
Functional	NNP	O
Emotional	NNP	O
Assessment	NNP	O
Scale	NNP	O
(	(	O
FEAS	NNP	O
)	)	O
(	(	O
F	NNP	O
=	NNP	O
5.1	CD	O
,	,	O
p	NN	O
=	NNP	O
.031	NNP	O
)	)	O
,	,	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
F	NNP	O
=	NNP	O
2.1	CD	O
,	,	O
p	NN	O
=	NNP	O
.002	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
Functional	NNP	O
Emotional	NNP	O
Questionnaires	NNP	O
(	(	O
F	NNP	O
=	NNP	O
6.8	CD	O
,	,	O
p	NN	O
=	NNP	O
.006	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
confirms	VBZ	O
the	DT	O
positive	JJ	O
results	NNS	O
obtained	VBN	O
by	IN	O
a	DT	O
previous	JJ	O
DIR	NNP	O
pilot	NN	O
study	NN	O
(	(	O
Solomon	NNP	O
et	RB	O
al.	RB	O
,	,	O
2007	CD	O
)	)	O
.	.	O

Pharmacokinetic	JJ	O
properties	NNS	O
of	IN	O
YM17E	NNP	O
,	,	O
an	DT	O
inhibitor	NN	O
of	IN	O
acyl	NN	O
coenzyme	NN	O
A	DT	O
:	:	O
cholesterol	NN	O
acyl	NN	O
transferase	NN	O
,	,	O
and	CC	O
serum	VB	O
cholesterol	NN	O
levels	NNS	O
in	IN	O
healthy	JJ	Condition
volunteers	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
single	JJ	O
and	CC	O
repeat	JJ	O
oral	JJ	O
dose	NN	O
study	NN	O
of	IN	O
YM17E	NNP	O
,	,	O
a	DT	O
novel	JJ	O
inhibitor	NN	O
of	IN	O
acyl	NN	O
coenzyme	NN	O
A	NNP	O
(	(	O
CoA	NNP	O
)	)	O
:	:	O
cholesterol	NN	O
acyltransferase	NN	O
,	,	O
in	IN	O
healthy	JJ	O
male	NN	Sex
volunteers	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
pharmacokinetic	JJ	O
profile	NN	O
,	,	O
tolerability	NN	O
and	CC	O
effect	NN	O
of	IN	O
the	DT	O
drug	NN	O
on	IN	O
serum	NN	O
cholesterol	NN	O
.	.	O

In	IN	O
the	DT	O
single	JJ	O
administration	NN	O
study	NN	O
,	,	O
YM17E	NNP	O
was	VBD	O
administered	VBN	O
after	IN	O
a	DT	O
meal	NN	O
to	TO	O
two	CD	O
groups	NNS	O
of	IN	O
subjects	NNS	O
(	(	O
each	DT	O
containing	VBG	O
six	CD	SampleSize
subjects	NNS	O
taking	VBG	O
the	DT	O
drug	NN	O
and	CC	O
three	CD	SampleSize
taking	VBG	O
placebo	NN	O
)	)	O
receiving	VBG	O
3	CD	O
,	,	O
60	CD	O
and	CC	O
300	CD	O
mg	NN	O
or	CC	O
15	CD	O
,	,	O
60	CD	O
and	CC	O
450	CD	O
mg	NN	O
YM17E	NNP	O
,	,	O
respectively	RB	O
.	.	O

Plasma	NNP	O
concentrations	NNS	O
of	IN	O
unchanged	JJ	O
drug	NN	O
following	VBG	O
single	JJ	O
oral	JJ	O
administration	NN	O
at	IN	O
3-300	JJ	O
mg	NN	O
after	IN	O
a	DT	O
meal	NN	O
increased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
plasma	NN	O
concentrations	NNS	O
after	IN	O
administration	NN	O
of	IN	O
450	CD	O
mg	NNS	O
were	VBD	O
almost	RB	O
the	DT	O
same	JJ	O
as	IN	O
after	IN	O
300	CD	O
mg	NN	O
.	.	O

Unchanged	VBD	O
YM17E	NNP	O
was	VBD	O
not	RB	O
detected	VBN	O
in	IN	O
urine	NN	O
after	IN	O
single	JJ	O
administration	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
it	PRP	O
was	VBD	O
excreted	VBN	O
via	IN	O
the	DT	O
bile	NN	O
or	CC	O
urine	NN	O
after	IN	O
metabolism	NN	O
.	.	O

Five	CD	O
active	JJ	O
metabolites	NNS	O
(	(	O
M1	NNP	O
,	,	O
M2-a	NNP	O
,	,	O
M2-b	NNP	O
,	,	O
M3	NNP	O
and	CC	O
M4	NNP	O
)	)	O
were	VBD	O
observed	VBN	O
in	IN	O
plasma	NN	O
at	IN	O
concentrations	NNS	O
comparable	JJ	O
to	TO	O
those	DT	O
of	IN	O
unchanged	JJ	O
YM17E	NNP	O
.	.	O

Their	PRP$	O
plasma	JJ	O
concentrations	NNS	O
increased	VBD	O
in	IN	O
a	DT	O
slightly	RB	O
greater	JJR	O
than	IN	O
dose-dependent	JJ	O
manner	NN	O
from	IN	O
3	CD	O
to	TO	O
300	CD	O
mg	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
food	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
an	DT	O
open	JJ	O
crossover	NN	O
design	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
washout	NN	O
period	NN	O
.	.	O

Twelve	NNP	O
subjects	VBZ	O
received	VBD	O
150	CD	O
mg	NNS	O
YM17E	VBN	O
in	IN	O
both	DT	O
the	DT	O
fasted	VBN	O
and	CC	O
post-prandial	JJ	O
states	NNS	O
.	.	O

The	DT	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
after	IN	O
fasting	VBG	O
were	VBD	O
closely	RB	O
similar	JJ	O
to	TO	O
those	DT	O
after	IN	O
a	DT	O
meal	NN	O
,	,	O
showing	VBG	O
that	IN	O
bioavailability	NN	O
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
food	NN	O
intake	NN	O
.	.	O

In	IN	O
the	DT	O
repeated	JJ	O
oral	JJ	O
dose	NN	O
study	NN	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
test	JJ	O
drug	NN	O
at	IN	O
150	CD	O
mg	NN	O
or	CC	O
300	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	RB	O
6	CD	O
each	DT	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
3	CD	O
)	)	O
twice	RB	O
a	DT	O
day	NN	O
(	(	O
after	IN	O
breakfast	NN	O
and	CC	O
after	IN	O
dinner	NN	O
)	)	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

On	IN	O
days	NNS	O
1	CD	O
and	CC	O
7	CD	O
,	,	O
the	DT	O
subjects	NNS	O
received	VBD	O
YM17E	NNP	O
once	RB	O
a	DT	O
day	NN	O
(	(	O
after	IN	O
breakfast	NN	O
)	)	O
for	IN	O
evaluation	NN	O
of	IN	O
pharmacokinetic	JJ	O
properties	NNS	O
.	.	O

After	IN	O
repeated	VBN	O
oral	JJ	O
administration	NN	O
of	IN	O
150	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
plasma	JJ	O
concentrations	NNS	O
reached	VBD	O
steady	JJ	O
state	NN	O
by	IN	O
day	NN	O
5	CD	O
(	(	O
mean	JJ	O
Cmin	NNP	O
48.6	CD	O
ng.ml-1	NN	O
)	)	O
.	.	O

After	IN	O
repeated	JJ	O
administration	NN	O
of	IN	O
300	CD	O
mg	NN	O
b.d.	NN	O
,	,	O
plasma	JJ	O
concentrations	NNS	O
prior	RB	O
to	TO	O
each	DT	O
daily	JJ	O
morning	NN	O
dose	NN	O
increased	VBD	O
up	RB	O
to	TO	O
the	DT	O
5th	JJ	O
day	NN	O
(	(	O
mean	JJ	O
Cmin	NNP	O
166.6	CD	O
ng.ml-1	NN	O
)	)	O
and	CC	O
then	RB	O
tended	VBD	O
to	TO	O
decrease	VB	O
until	IN	O
the	DT	O
7th	JJ	O
day	NN	O
.	.	O

No	DT	O
significant	JJ	O
signs	NNS	O
,	,	O
symptoms	NNS	O
or	CC	O
changes	NNS	O
in	IN	O
serum	NN	O
cholesterol	NN	O
levels	NNS	O
were	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
single	JJ	O
and	CC	O
repeated	JJ	O
oral	JJ	O
dose	NN	O
studies	NNS	O
at	IN	O
150	CD	O
mg	NN	O
b.d	NN	O
.	.	O

Although	IN	O
statistical	JJ	O
analysis	NN	O
was	VBD	O
not	RB	O
conducted	VBN	O
because	IN	O
of	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
subjects	NNS	O
,	,	O
all	DT	O
subjects	NNS	O
receiving	VBG	O
repeated	VBD	O
oral	JJ	O
administration	NN	O
of	IN	O
300	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
showed	VBD	O
a	DT	O
25	CD	O
%	NN	O
decrease	NN	O
in	IN	O
serum	NN	O
cholesterol	NN	O
level	NN	O
on	IN	O
day	NN	O
7	CD	O
,	,	O
but	CC	O
also	RB	O
the	DT	O
simultaneous	JJ	O
occurrence	NN	O
of	IN	O
diarrhoea	NN	O
.	.	O

Long-term	JJ	O
efficacy	NN	O
of	IN	O
subcutaneous	JJ	O
sumatriptan	NNS	O
using	VBG	O
a	DT	O
novel	JJ	O
self-injector	NN	O
.	.	O

An	DT	O
open	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
investigated	VBD	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
acceptability	NN	O
to	TO	O
patients	NNS	O
of	IN	O
subcutaneous	JJ	O
sumatriptan	JJ	O
6	CD	O
mg	NN	O
,	,	O
administered	VBN	O
using	VBG	O
a	DT	O
novel	NN	O
cartridge	NN	O
system	NN	O
self-injector	NN	O
,	,	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	Condition
.	.	O

Eighty	NNP	O
patients	NNS	O
treated	VBD	O
all	DT	O
migraine	NN	Condition
attacks	NNS	O
for	IN	O
6	CD	O
months	NNS	O
at	IN	O
home	NN	O
with	IN	O
a	DT	O
subcutaneous	JJ	O
injection	NN	O
of	IN	O
sumatriptan	JJ	Condition
6	CD	O
mg.	NN	O
A	NNP	O
second	JJ	O
injection	NN	O
could	MD	O
be	VB	O
taken	VBN	O
after	IN	O
1	CD	O
to	TO	O
24	CD	O
hours	NNS	O
if	IN	O
relief	NN	O
was	VBD	O
inadequate	JJ	O
,	,	O
or	CC	O
if	IN	O
the	DT	O
headache	NN	O
recurred	VBD	O
,	,	O
and	CC	O
rescue	NN	O
medication	NN	O
could	MD	O
be	VB	O
taken	VBN	O
1	CD	O
hour	NN	O
after	IN	O
the	DT	O
second	JJ	O
injection	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
percentage	NN	O
of	IN	O
attacks	NNS	O
in	IN	O
which	WDT	O
headache	NN	O
improved	VBD	O
from	IN	O
severe	JJ	O
or	CC	O
moderate	JJ	O
before	IN	O
treatment	NN	O
to	TO	O
mild	VB	O
or	CC	O
absent	VB	O
at	IN	O
1	CD	O
hour	NN	O
after	IN	O
the	DT	O
first	JJ	O
injection	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1566	CD	O
attacks	NNS	O
were	VBD	O
treated	VBN	O
by	IN	O
the	DT	O
80	CD	O
patients	NNS	O
and	CC	O
69	CD	O
patients	NNS	O
completed	VBD	O
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Headache	NNP	O
relief	NN	O
was	VBD	O
reported	VBN	O
1	CD	O
hour	NN	O
after	IN	O
the	DT	O
first	JJ	O
injection	NN	O
in	IN	O
a	DT	O
mean	NN	O
of	IN	O
78	CD	O
%	NN	O
of	IN	O
attacks	NNS	O
(	(	O
83	CD	O
%	NN	O
in	IN	O
the	DT	O
first	JJ	O
3	CD	O
months	NNS	O
and	CC	O
76	CD	O
%	NN	O
in	IN	O
the	DT	O
second	JJ	O
3	CD	O
months	NNS	O
)	)	O
.	.	O

A	DT	O
second	JJ	O
injection	NN	O
was	VBD	O
required	VBN	O
in	IN	O
a	DT	O
mean	NN	O
of	IN	O
40	CD	O
%	NN	O
of	IN	O
attacks	NNS	O
,	,	O
and	CC	O
headache	NN	O
was	VBD	O
mild	JJ	O
or	CC	O
absent	JJ	O
1	CD	O
hour	NN	O
after	IN	O
the	DT	O
second	JJ	O
injection	NN	O
in	IN	O
a	DT	O
mean	NN	O
of	IN	O
77	CD	O
%	NN	O
of	IN	O
attacks	NNS	O
.	.	O

Rescue	NNP	O
medication	NN	O
was	VBD	O
required	VBN	O
after	IN	O
the	DT	O
second	JJ	O
injection	NN	O
in	IN	O
a	DT	O
mean	NN	O
of	IN	O
14	CD	O
%	NN	O
of	IN	O
attacks	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
87	CD	O
%	NN	O
of	IN	O
patients	NNS	O
said	VBD	O
that	IN	O
they	PRP	O
would	MD	O
take	VB	O
the	DT	O
medication	NN	O
again	RB	O
,	,	O
and	CC	O
at	IN	O
each	DT	O
clinic	JJ	O
visit	NN	O
over	IN	O
80	CD	O
%	NN	O
said	VBD	O
that	IN	O
they	PRP	O
found	VBD	O
the	DT	O
injector	NN	O
easy	NN	O
to	TO	O
use	VB	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
reported	VBN	O
previously	RB	O
with	IN	O
sumatriptan	NNS	O
and	CC	O
were	VBD	O
mostly	RB	O
mild	JJ	O
to	TO	O
moderate	VB	O
in	IN	O
intensity	NN	O
,	,	O
short-lived	JJ	O
,	,	O
and	CC	O
resolved	VBD	O
spontaneously	RB	O
.	.	O

Subcutaneous	JJ	O
sumatriptan	JJ	O
6	CD	O
mg	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
,	,	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
well	RB	O
accepted	VBN	O
,	,	O
long-term	JJ	O
,	,	O
acute	JJ	O
treatment	NN	O
for	IN	O
migraine	NN	O
when	WRB	O
self-injected	JJ	O
by	IN	O
patients	NNS	O
using	VBG	O
the	DT	O
novel	JJ	O
self-injector	NN	O
.	.	O

Obesity	NN	O
and	CC	O
mortality	NN	O
in	IN	O
men	NNS	O
with	IN	O
locally	RB	Condition
advanced	JJ	Condition
prostate	NN	Condition
cancer	NN	Condition
:	:	Condition
analysis	NN	O
of	IN	O
RTOG	NNP	O
85-31	JJ	O
.	.	O

BACKGROUND	NNP	O
Greater	NNP	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
shorter	JJR	O
time	NN	O
to	TO	O
prostate-specific	JJ	O
antigen	NN	O
(	(	O
PSA	NNP	O
)	)	O
failure	NN	O
following	VBG	O
radical	JJ	O
prostatectomy	NN	O
and	CC	O
radiation	NN	O
therapy	NN	O
(	(	O
RT	NNP	O
)	)	O
.	.	O

Whether	NNP	O
BMI	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
prostate	JJ	O
cancer-specific	JJ	O
mortality	NN	O
(	(	O
PCSM	NNP	O
)	)	O
was	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
large	JJ	O
randomized	JJ	O
trial	NN	O
of	IN	O
men	NNS	Age
treated	VBN	O
with	IN	O
RT	NNP	O
and	CC	O
androgen	JJ	Condition
deprivation	NN	Condition
therapy	NN	Condition
(	(	Condition
ADT	NNP	Condition
)	)	Condition
for	IN	Condition
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Between	NNP	O
1987	CD	O
and	CC	O
1992	CD	O
,	,	O
945	CD	O
eligible	JJ	O
men	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
phase	NN	O
3	CD	O
trial	NN	O
(	(	O
RTOG	NNP	O
85-31	CD	O
)	)	O
and	CC	O
randomized	VBN	O
to	TO	O
RT	NNP	O
and	CC	O
immediate	JJ	O
goserelin	NN	O
or	CC	O
RT	NNP	O
alone	RB	O
followed	VBD	O
by	IN	O
goserelin	NN	O
at	IN	O
recurrence	NN	O
.	.	O

Height	NNP	O
and	CC	O
weight	VBN	O
data	NNS	O
were	VBD	O
available	JJ	O
at	IN	O
baseline	NN	O
for	IN	O
788	CD	O
(	(	O
83	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
.	.	O

Cox	NNP	O
regression	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
relations	NNS	O
between	IN	O
BMI	NNP	O
and	CC	O
all-cause	JJ	O
mortality	NN	O
,	,	O
PCSM	NNP	O
,	,	O
and	CC	O
nonprostate	JJ	O
cancer	NN	O
mortality	NN	O
.	.	O

Covariates	NNS	O
included	VBD	O
age	NN	O
,	,	O
race	NN	O
,	,	O
treatment	NN	O
arm	NN	O
,	,	O
history	NN	O
of	IN	O
prostatectomy	NN	O
,	,	O
nodal	JJ	O
involvement	NN	O
,	,	O
Gleason	NNP	O
score	NN	O
,	,	O
clinical	JJ	O
stage	NN	O
,	,	O
and	CC	O
BMI	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
5-year	JJ	O
PCSM	NNP	O
rate	NN	O
for	IN	O
men	NNS	O
with	IN	O
BMI	NNP	O
<	NNP	O
25	CD	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
was	VBD	O
6.5	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
13.1	CD	O
%	NN	O
and	CC	O
12.2	CD	O
%	NN	O
in	IN	O
men	NNS	O
with	IN	O
BMI	NNP	O
>	NNP	O
or	CC	O
=25	VB	O
to	TO	O
<	VB	O
30	CD	O
and	CC	O
BMI	NNP	O
>	NNP	O
or	CC	O
=30	NNP	O
,	,	O
respectively	RB	O
(	(	O
Gray	NNP	O
's	POS	O
P	NNP	O
=	NNP	O
.005	NNP	O
)	)	O
.	.	O

In	IN	O
multivariate	NN	O
analyses	NNS	O
,	,	O
greater	JJR	O
BMI	NNP	O
was	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
higher	JJR	O
PCSM	NNP	O
(	(	O
for	IN	O
BMI	NNP	O
>	NNP	O
or	CC	O
=25	VB	O
to	TO	O
<	VB	O
30	CD	O
,	,	O
hazard	RB	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
1.52	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.02-2.27	JJ	O
,	,	O
P	NNP	O
=	NNP	O
.04	NNP	O
;	:	O
for	IN	O
BMI	NNP	O
>	NNP	O
or	CC	O
=30	NNP	O
,	,	O
HR	NNP	O
1.64	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01-2.66	JJ	O
,	,	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
.	.	O

BMI	NNP	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
nonprostate	JJ	O
cancer	NN	O
or	CC	O
all-cause	JJ	O
mortality	NN	O
.	.	O

CONCLUSIONS	NNP	O
Greater	NNP	O
baseline	NN	O
BMI	NNP	O
is	VBZ	O
independently	RB	O
associated	VBN	O
with	IN	O
higher	JJR	O
PCSM	NN	O
in	IN	O
men	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
mechanism	NN	O
(	(	O
s	NN	O
)	)	O
for	IN	O
increased	VBN	O
cancer-specific	JJ	O
mortality	NN	O
and	CC	O
to	TO	O
assess	VB	O
whether	IN	O
weight	JJ	O
loss	NN	O
after	IN	O
prostate	JJ	O
cancer	NN	O
diagnosis	NN	O
alters	NNS	O
disease	VBP	O
course	NN	O
.	.	O

An	DT	O
in	IN	O
vitro	NN	O
comparative	JJ	O
analysis	NN	O
:	:	O
scanning	NN	O
electron	NN	O
microscopy	NN	O
of	IN	O
dentin/restoration	NN	O
interfaces	NNS	O
.	.	O

One	CD	SampleSize
hundred	VBD	SampleSize
maxillary	JJ	O
premolar	JJ	O
teeth	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
ten	VB	O
groups	NNS	O
.	.	O

Each	DT	O
group	NN	O
was	VBD	O
restored	VBN	O
with	IN	O
one	CD	O
of	IN	O
ten	JJ	O
different	JJ	O
restorative	NN	O
techniques	NNS	O
.	.	O

The	DT	O
teeth	NNS	O
were	VBD	O
stored	VBN	O
in	IN	O
deionized	JJ	O
water	NN	O
for	IN	O
7d	CD	O
prior	JJ	O
to	TO	O
longitudinal	JJ	O
sectioning	NN	O
in	IN	O
a	DT	O
mesio-distal	JJ	O
plane	NN	O
.	.	O

Following	VBG	O
sectioning	NN	O
,	,	O
ten	JJ	O
specimens	NNS	O
from	IN	O
each	DT	O
group	NN	O
were	VBD	O
chosen	VBN	O
at	IN	O
random	NN	O
from	IN	O
the	DT	O
20	CD	O
available	JJ	O
sections	NNS	O
.	.	O

The	DT	O
sectioned	JJ	O
surfaces	NNS	O
were	VBD	O
polished	VBN	O
using	VBG	O
600-grit	JJ	O
SiC	NNP	O
abrasive	JJ	O
paper	NN	O
and	CC	O
etched	VBD	O
for	IN	O
10	CD	O
s	NN	O
with	IN	O
50	CD	O
%	NN	O
phosphoric	JJ	O
acid	NN	O
to	TO	O
remove	VB	O
the	DT	O
smear	JJ	O
layer	NN	O
produced	VBN	O
by	IN	O
sectioning	VBG	O
.	.	O

Five	CD	O
tooth	JJ	O
sections	NNS	O
from	IN	O
the	DT	O
dentin	NN	O
bonding	VBG	O
resin	NN	O
groups	NNS	O
were	VBD	O
allowed	VBN	O
to	TO	O
dry	VB	O
at	IN	O
20	CD	O
degrees	NNS	O
C	NNP	O
for	IN	O
24h	CD	O
.	.	O

The	DT	O
glass	NN	O
ionomer-based	JJ	O
groups	NNS	O
were	VBD	O
reimmersed	VBN	O
in	IN	O
deionized	JJ	O
water	NN	O
during	IN	O
this	DT	O
period	NN	O
.	.	O

The	DT	O
remaining	VBG	O
five	CD	O
sections	NNS	O
from	IN	O
each	DT	O
group	NN	O
were	VBD	O
replicated	VBN	O
using	VBG	O
an	DT	O
addition-cure	JJ	O
vinyl	NN	O
polysiloxane	NN	O
impression	NN	O
material	NN	O
and	CC	O
an	DT	O
epoxy	JJ	O
resin	NN	O
.	.	O

A	DT	O
comparison	NN	O
was	VBD	O
made	VBN	O
of	IN	O
the	DT	O
sections	NNS	O
and	CC	O
the	DT	O
replicas	NN	O
.	.	O

All	DT	O
tooth	JJ	O
specimens	NNS	O
were	VBD	O
sputter-coated	JJ	O
with	IN	O
gold	NN	O
for	IN	O
4	CD	O
min	NNS	O
and	CC	O
examined	VBD	O
using	VBG	O
a	DT	O
scanning	VBG	O
electron	NN	O
microscope	NN	O
.	.	O

Replicas	NNPS	O
were	VBD	O
gold-coated	JJ	O
for	IN	O
3	CD	O
min	NN	O
.	.	O

Different	JJ	O
tooth/restoration	NN	O
interfaces	NNS	O
,	,	O
associated	VBN	O
with	IN	O
different	JJ	O
materials	NNS	O
,	,	O
were	VBD	O
observed	VBN	O
.	.	O

A	DT	O
marked	JJ	O
difference	NN	O
between	IN	O
the	DT	O
replicas	NN	O
and	CC	O
tooth	JJ	O
sections	NNS	O
was	VBD	O
observed	VBN	O
for	IN	O
glass	NN	O
ionomer-based	JJ	O
restorations	NNS	O
but	CC	O
not	RB	O
for	IN	O
resin-based	JJ	O
bonding	NN	O
systems	NNS	O
.	.	O

Representative	JJ	O
samples	NNS	O
of	IN	O
replicas	NN	O
and	CC	O
specimens	NNS	O
are	VBP	O
shown	VBN	O
,	,	O
and	CC	O
the	DT	O
significance	NN	O
of	IN	O
the	DT	O
observed	JJ	O
differences	NNS	O
is	VBZ	O
discussed	VBN	O
.	.	O

Multiple	JJ	O
doses	NNS	O
of	IN	O
secretin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	Condition
:	:	O
a	DT	O
controlled	VBN	O
study	NN	O
.	.	O

UNLABELLED	NNP	O
Dramatic	JJ	O
effects	NNS	O
on	IN	O
autistic	JJ	O
behaviour	NN	O
after	IN	O
repeated	VBN	O
injections	NNS	O
of	IN	O
the	DT	O
gastrointestinal	JJ	O
hormone	NN	O
secretin	NN	O
have	VBP	O
been	VBN	O
referred	VBN	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
case	NN	O
reports	NNS	O
.	.	O

In	IN	O
the	DT	O
absence	NN	O
of	IN	O
curative	JJ	O
and	CC	O
effective	JJ	O
treatments	NNS	O
for	IN	O
this	DT	O
disabling	JJ	O
condition	NN	O
,	,	O
this	DT	O
information	NN	O
has	VBZ	O
created	VBN	O
new	JJ	O
hope	NN	O
among	IN	O
parents	NNS	O
.	.	O

Although	IN	O
controlled	JJ	O
studies	NNS	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
mainly	RB	O
one	CD	O
single	JJ	O
dose	NN	O
have	VBP	O
not	RB	O
documented	VBN	O
any	DT	O
effect	NN	O
,	,	O
many	JJ	O
children	NNS	Age
still	RB	O
continue	VBP	O
to	TO	O
receive	VB	O
secretin	NN	O
.	.	O

Six	NNP	SampleSize
children	NNS	O
enrolled	VBD	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
in	IN	O
which	WDT	O
each	DT	O
child	NN	O
was	VBD	O
its	PRP$	O
own	JJ	O
control	NN	O
.	.	O

Human	NNP	O
synthetic	JJ	O
secretin	NN	O
,	,	O
mean	VBP	O
dose	JJ	O
3.4	CD	O
clinical	JJ	O
units	NNS	O
,	,	O
and	CC	O
placebo	NN	O
were	VBD	O
administered	VBN	O
intravenously	RB	O
in	IN	O
randomized	JJ	O
order	NN	O
every	DT	O
4th	CD	O
wk	NN	O
,	,	O
on	IN	O
three	CD	O
occasions	NNS	O
each	DT	O
.	.	O

The	DT	O
measurement	JJ	O
instruments	NNS	O
were	VBD	O
the	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
and	CC	O
the	DT	O
aberrant	JJ	O
behaviour	NN	O
checklist	NN	O
(	(	O
ABC	NNP	O
)	)	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
placebo	NN	O
in	IN	O
3	CD	O
out	IN	O
of	IN	O
6	CD	O
children	NNS	Age
and	CC	O
for	IN	O
secretin	NN	O
in	IN	O
one	CD	O
child	NN	O
,	,	O
using	VBG	O
parental	JJ	O
ratings	NNS	O
only	RB	O
(	(	O
VAS	NNP	O
scores	VBZ	O
)	)	O
.	.	O

Differences	NNS	O
were	VBD	O
small	JJ	O
and	CC	O
lacked	JJ	O
clinical	JJ	O
significance	NN	O
,	,	O
which	WDT	O
was	VBD	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
overall	JJ	O
impression	NN	O
of	IN	O
the	DT	O
parents	NNS	O
and	CC	O
teachers	NNS	O
and	CC	O
visual	JJ	O
inspection	NN	O
of	IN	O
graphs	NN	O
.	.	O

CONCLUSION	NN	O
In	IN	O
this	DT	O
placebo-controlled	JJ	O
study	NN	O
,	,	O
multiple	JJ	O
doses	NNS	O
of	IN	O
secretin	NN	O
did	VBD	O
not	RB	O
produce	VB	O
any	DT	O
symptomatic	JJ	O
improvement	NN	O
.	.	O

Skeletal	JJ	O
muscle	NN	O
total	JJ	O
creatine	NN	O
content	NN	O
and	CC	O
creatine	NN	O
transporter	NN	O
gene	NN	O
expression	NN	O
in	IN	O
vegetarians	NNS	O
prior	JJ	O
to	TO	O
and	CC	O
following	VBG	O
creatine	JJ	O
supplementation	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
vegetarianism	NN	O
on	IN	O
skeletal	JJ	O
muscle	NN	O
total	JJ	O
creatine	NN	O
(	(	O
TCr	NNP	O
)	)	O
content	NN	O
and	CC	O
creatine	NN	O
transporter	NN	O
(	(	O
CreaT	NNP	O
)	)	O
gene	NN	O
expression	NN	O
,	,	O
prior	RB	O
to	TO	O
and	CC	O
during	IN	O
5	CD	O
d	NN	O
of	IN	O
Cr	NNP	O
supplementation	NN	O
(	(	O
CrS	NNP	O
)	)	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
crossover	NN	O
design	NN	O
,	,	O
7	CD	O
vegetarians	NNS	O
(	(	O
VEG	NNP	O
)	)	O
and	CC	O
nonvegetarians	NNS	O
(	(	O
NVEG	NNP	O
)	)	O
were	VBD	O
assigned	VBN	O
Cr	NNP	O
or	CC	O
placebo	NN	O
supplements	NNS	O
for	IN	O
5	CD	O
d	NN	O
and	CC	O
after	IN	O
5	CD	O
wk	NN	O
,	,	O
received	VBD	O
the	DT	O
alternative	JJ	O
treatment	NN	O
.	.	O

Muscle	NNP	O
sampling	VBG	O
occurred	VBD	O
before	IN	O
,	,	O
and	CC	O
after	IN	O
1	CD	O
and	CC	O
5	CD	O
d	NN	O
of	IN	O
treatment	NN	O
ingestion	NN	O
.	.	O

Basal	NNP	O
muscle	NN	O
TCr	NNP	O
content	NN	O
was	VBD	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
VEG	NNP	O
compared	VBN	O
with	IN	O
NVEG	NNP	O
.	.	O

Muscle	NNP	O
TCr	NNP	O
increased	VBD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
throughout	IN	O
the	DT	O
Cr	NNP	O
trial	NN	O
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
was	VBD	O
greater	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
VEG	NNP	O
compared	VBN	O
with	IN	O
NVEG	NNP	O
,	,	O
at	IN	O
days	NNS	O
1	CD	O
and	CC	O
5	CD	O
.	.	O

CreaT	NNP	O
gene	NN	O
expression	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
VEG	NNP	O
and	CC	O
NVEG	NNP	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
VEG	NNP	O
have	VBP	O
a	DT	O
lower	JJR	O
muscle	NN	O
TCr	NNP	O
content	NN	O
and	CC	O
an	DT	O
increased	VBN	O
capacity	NN	O
to	TO	O
load	VB	O
Cr	NNP	O
into	IN	O
muscle	NN	O
following	VBG	O
CrS	NNP	O
.	.	O

Muscle	NNP	O
CreaT	NNP	O
gene	NN	O
expression	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
affected	VBN	O
by	IN	O
vegetarianism	NN	O
.	.	O

Testosterone	NN	O
and	CC	O
gonadotropins	NNS	O
but	CC	O
not	RB	O
estrogen	RB	O
associated	VBN	O
with	IN	O
spatial	JJ	O
ability	NN	O
in	IN	O
women	NNS	Sex
suffering	VBG	O
from	IN	O
schizophrenia	NN	Condition
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
association	NN	O
between	IN	O
estrogen	NN	O
and	CC	O
spatial	JJ	O
ability	NN	O
tasks	NNS	O
in	IN	O
women	NNS	Sex
suffering	VBG	O
from	IN	O
schizophrenia	NN	Condition
.	.	O

For	IN	O
this	DT	O
purpose	NN	O
,	,	O
a	DT	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
three-time	JJ	O
cross-over	NN	O
study	NN	O
using	VBG	O
17beta-estradiol	JJ	O
combined	VBN	O
with	IN	O
norethisterone	JJ	O
acetate	NN	O
for	IN	O
replacement	NN	O
therapy	NN	O
and	CC	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
a	DT	O
naturalistic	JJ	O
maintenance	NN	O
antipsychotic	JJ	O
treatment	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
8	CD	O
months	NNS	O
.	.	O

Nineteen	JJ	SampleSize
women	NNS	Sex
(	(	O
mean	JJ	O
age=38.0	NN	Age
years	NNS	Age
,	,	O
SD=9.9	NNP	O
years	NNS	O
)	)	O
with	IN	O
schizophrenia	NN	Condition
hospitalized	VBN	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
or	CC	O
repeatedly	RB	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Sex	NNP	O
hormones	VBZ	O
-	:	O
17beta-estradiol	JJ	O
,	,	O
luteinizing	VBG	O
hormone	NN	O
(	(	O
LH	NNP	O
)	)	O
,	,	O
follicle-stimulating	JJ	O
hormone	NN	O
(	(	O
FSH	NNP	O
)	)	O
,	,	O
prolactin	NN	O
,	,	O
testosterone	NN	O
,	,	O
and	CC	O
dehydroepiandrosterone	NN	O
sulfate	NN	O
-	:	O
were	VBD	O
measured	VBN	O
and	CC	O
the	DT	O
patients	NNS	O
completed	VBD	O
a	DT	O
neuropsychological	JJ	O
test	NN	O
in	IN	O
the	DT	O
last	JJ	O
two	CD	O
active	JJ	O
drug	NN	O
and/or	NN	O
placebo	NN	O
phases	NNS	O
.	.	O

Three	CD	O
different	JJ	O
spatial	JJ	O
ability	NN	O
tasks	NNS	O
-	:	O
spatial	JJ	O
orientation	NN	O
,	,	O
spatial	JJ	O
visualization	NN	O
,	,	O
and	CC	O
flexibility	NN	O
of	IN	O
closure	NN	O
-	:	O
were	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
paper-and-pencil	JJ	O
test	NN	O
.	.	O

No	DT	O
association	NN	O
between	IN	O
estrogen	NN	O
and	CC	O
spatial	JJ	O
ability	NN	O
was	VBD	O
found	VBN	O
;	:	O
however	RB	O
,	,	O
in	IN	O
an	DT	O
additional	JJ	O
exploratory	NN	O
data	NNS	O
analysis	NN	O
,	,	O
high	JJ	O
levels	NNS	O
of	IN	O
testosterone	NN	O
,	,	O
LH	NNP	O
,	,	O
and	CC	O
FSH	NNP	O
correlated	VBD	O
significantly	RB	O
with	IN	O
performance	NN	O
in	IN	O
the	DT	O
flexibility	NN	O
of	IN	O
closure	NN	O
task	NN	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
very	RB	O
first	JJ	O
study	NN	O
,	,	O
based	VBN	O
on	IN	O
estrogen	NN	O
intervention	NN	O
instead	RB	O
of	IN	O
physiological	JJ	O
hormone	NN	O
changes	NNS	O
,	,	O
to	TO	O
examine	VB	O
the	DT	O
association	NN	O
between	IN	O
estrogen	NN	O
and	CC	O
spatial	JJ	O
ability	NN	O
in	IN	O
women	NNS	Sex
with	IN	O
schizophrenia	NN	Condition
.	.	O

The	DT	O
effect	NN	O
of	IN	O
halothane	NN	O
and	CC	O
isoflurane	NN	O
on	IN	O
plasma	JJ	O
cytokine	NN	O
levels	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
halothane	NN	O
vs.	FW	O
isoflurane	NN	O
on	IN	O
cytokine	JJ	O
production	NN	O
during	IN	O
minor	JJ	O
elective	JJ	O
surgery	NN	O
.	.	O

Forty	NNP	O
adult	NN	O
patients	NNS	O
,	,	O
ASA	NNP	O
I-II	NNP	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
halothane	NN	O
or	CC	O
isoflurane	NN	O
.	.	O

Venous	JJ	O
samples	NNS	O
for	IN	O
interleukin	NN	O
(	(	O
IL	NNP	O
)	)	O
-1beta	NN	O
,	,	O
IL-2	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
tumour	JJ	O
necrosis	NN	O
factor-alpha	NN	O
(	(	O
TNF-alpha	NNP	O
)	)	O
and	CC	O
interferon-gamma	JJ	O
(	(	O
IFN-gamma	NNP	O
)	)	O
were	VBD	O
taken	VBN	O
before	RB	O
anaesthesia	JJ	O
,	,	O
before	IN	O
incision	NN	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
anaesthesia	NN	O
and	CC	O
24	CD	O
h	NN	O
postoperatively	RB	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
IL-6	NNP	O
and	CC	O
TNF-alpha	NNP	O
levels	NNS	O
remained	VBD	O
low	JJ	O
throughout	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

Before	IN	O
incision	NN	O
,	,	O
in	IN	O
both	DT	O
groups	NNS	O
IL-1beta	NNP	O
and	CC	O
IFN-gamma	NNP	O
showed	VBD	O
a	DT	O
decrease	NN	O
(	(	O
p	JJ	O
<	VBP	O
0.01	CD	O
for	IN	O
IL-1beta	NNP	O
in	IN	O
isoflurane	NN	O
group	NN	O
and	CC	O
p	NN	O
<	VBP	O
0.05	CD	O
for	IN	O
the	DT	O
others	NNS	O
)	)	O
compared	VBN	O
with	IN	O
pre-induction	NN	O
.	.	O

By	IN	O
the	DT	O
end	NN	O
of	IN	O
anaesthesia	NN	O
and	CC	O
surgery	NN	O
,	,	O
IL-1beta	NNP	O
had	VBD	O
increased	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
IFN-gamma	NNP	O
had	VBD	O
decreased	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
both	DT	O
groups	NNS	O
compared	VBN	O
with	IN	O
pre-incisional	JJ	O
levels	NNS	O
.	.	O

By	IN	O
24	CD	O
h	NNS	O
postoperatively	RB	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
IL-1beta	NNP	O
had	VBD	O
decreased	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
whereas	JJ	O
IFN-gamma	NNP	O
had	VBD	O
increased	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
end	NN	O
of	IN	O
anaesthesia	NN	O
and	CC	O
surgery	NN	O
level	NN	O
.	.	O

Pre-incisionally	RB	O
,	,	O
IL-2	NNP	O
increased	VBD	O
in	IN	O
the	DT	O
halothane	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
whereas	IN	O
it	PRP	O
decreased	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
isoflurane	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
pre-induction	NN	O
level	NN	O
.	.	O

By	IN	O
the	DT	O
end	NN	O
of	IN	O
anaesthesia	NN	O
and	CC	O
surgery	NN	O
and	CC	O
by	IN	O
24	CD	O
h	NN	O
postoperatively	RB	O
,	,	O
IL-2	NNP	O
had	VBD	O
decreased	VBN	O
significantly	RB	O
in	IN	O
the	DT	O
halothane	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
whereas	IN	O
it	PRP	O
increased	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
isoflurane	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
compared	VBN	O
with	IN	O
pre-incision	NN	O
and	CC	O
end	NN	O
of	IN	O
anaesthesia	NN	O
and	CC	O
surgery	NN	O
levels	NNS	O
,	,	O
respectively	RB	O
.	.	O

Are	NNP	O
oral	JJ	O
cathartics	NNS	O
of	IN	O
value	NN	O
in	IN	O
optimizing	VBG	O
the	DT	O
gallium	NN	O
scan	JJ	O
?	.	O
Concise	NNP	O
communication	NN	O
.	.	O

The	DT	O
normal	JJ	O
intestinal	JJ	O
secretion	NN	O
of	IN	O
9-15	CD	O
%	NN	O
of	IN	O
an	DT	O
administered	VBN	O
dose	NN	O
of	IN	O
gallium-67	NN	O
may	MD	O
prevent	VB	O
early	JJ	O
detection	NN	O
of	IN	O
intra-abdominal	JJ	O
disease	NN	O
.	.	O

We	PRP	O
randomized	VBD	Condition
50	CD	SampleSize
patients	NNS	O
to	TO	O
receive	VB	O
either	DT	O
no	DT	O
bowel	NN	O
preparation	NN	O
or	CC	O
30	CD	O
cc	NN	O
of	IN	O
milk	NN	O
of	IN	O
magnesia	JJ	O
plus	CC	O
5	CD	O
cc	NN	O
of	IN	O
cascara	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
frequency	NN	O
with	IN	O
which	WDT	O
gallium	NN	O
interfered	VBD	O
with	IN	O
readings	NNS	O
or	CC	O
time	NN	O
to	TO	O
complete	VB	O
the	DT	O
study	NN	O
.	.	O

Intensive	JJ	O
induction	NN	O
chemotherapy	NN	O
for	IN	O
small	JJ	O
cell	NN	O
anaplastic	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
lung	NN	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
intensive	JJ	O
induction	NN	O
chemotherapy	NN	O
in	IN	O
small	JJ	O
cell	NN	O
cancer	NN	O
of	IN	O
the	DT	O
lung	NN	O
remains	VBZ	O
unclear	JJ	O
.	.	O

Twenty-eight	JJ	SampleSize
newly	RB	O
diagnosed	VBN	O
patients	NNS	O
with	IN	O
small	JJ	Condition
cell	NN	Condition
lung	NN	Condition
cancer	NN	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
high-dose	JJ	O
or	CC	O
standard-dose	JJ	O
cyclophosphamide	NN	O
,	,	O
vincristine	NN	O
,	,	O
and	CC	O
semustine	NN	O
in	IN	O
a	DT	O
trial	NN	O
where	WRB	O
the	DT	O
dose	NN	O
of	IN	O
induction	NN	O
chemotherapy	NN	O
was	VBD	O
the	DT	O
sole	JJ	O
treatment	NN	O
variable	JJ	O
.	.	O

Complete	JJ	O
responses	NNS	O
(	(	O
CR	NNP	O
)	)	O
were	VBD	O
achieved	VBN	O
in	IN	O
57	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
high-dose	JJ	O
therapy	NN	O
as	IN	O
compared	VBN	O
to	TO	O
21	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
standard-dose	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
severe	JJ	O
toxicity	NN	O
in	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
median	JJ	O
survival	NN	O
was	VBD	O
not	RB	O
improved	VBN	O
(	(	O
36	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
vs	VBD	O
43	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
standard-dose	JJ	O
group	NN	O
)	)	O
;	:	O
however	RB	O
,	,	O
the	DT	O
median	JJ	O
survival	NN	O
in	IN	O
patients	NNS	O
achieving	VBG	O
CR	NNP	O
was	VBD	O
prolonged	VBN	O
(	(	O
92	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
high-dose	JJ	O
group	NN	O
vs	VBD	O
50	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
standard-dose	JJ	O
group	NN	O
)	)	O
.	.	O

These	DT	O
effects	NNS	O
were	VBD	O
most	RBS	O
pronounced	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
extensive	JJ	O
disease	NN	O
;	:	O
a	DT	O
CR	NNP	O
after	IN	O
induction	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
five	CD	O
of	IN	O
nine	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
high	JJ	O
doses	NNS	O
but	CC	O
not	RB	O
in	IN	O
any	DT	O
of	IN	O
those	DT	O
treated	VBN	O
with	IN	O
standard	JJ	O
doses	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

A	NNP	O
small	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
appear	VBP	O
to	TO	O
benefit	VB	O
by	IN	O
achieving	VBG	O
a	DT	O
long-term	JJ	O
remission	NN	O
with	IN	O
intensive	JJ	O
induction	NN	O
chemotherapy	NN	O
,	,	O
but	CC	O
this	DT	O
effect	NN	O
may	MD	O
be	VB	O
offset	VBN	O
by	IN	O
increased	JJ	O
morbidity	NN	O
.	.	O

[	JJ	O
Neoton	NNP	O
and	CC	O
thrombolytic	JJ	O
therapy	NN	O
of	IN	O
myocardial	JJ	Condition
infarction	NN	Condition
]	NNP	O
.	.	O

AIM	NNP	O
To	TO	O
evaluate	VB	O
neoton	JJ	O
therapy	NN	O
effects	NNS	O
in	IN	O
acute	JJ	Condition
myocardial	JJ	Condition
infarction	NN	Condition
(	(	Condition
MI	NNP	Condition
)	)	Condition
on	IN	O
systolic	JJ	O
function	NN	O
of	IN	O
the	DT	O
left	JJ	O
ventricle	NN	O
,	,	O
arrhythmia	NN	Condition
and	CC	O
clinical	JJ	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
on	IN	O
thrombolytic	JJ	O
therapy	NN	O
(	(	O
TLT	NNP	O
)	)	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
106	CD	SampleSize
males	NNS	Sex
with	IN	O
Q-MI	NNP	Condition
entered	VBD	O
the	DT	O
study	NN	O
.	.	O

47	CD	O
received	VBD	O
treatment	NN	O
without	IN	O
TLT	NNP	O
and	CC	O
neoton	NN	O
,	,	O
30	CD	O
patients	NNS	O
received	VBD	O
TLT	NNP	O
with	IN	O
streptokinase	JJ	O
preparations	NNS	O
,	,	O
29	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
streptokinase	JJ	O
preparations	NNS	O
and	CC	O
neoton	NN	O
.	.	O

Left	NNP	O
ventricular	JJ	O
systolic	JJ	O
function	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
echocardiography	NN	O
on	IN	O
day	NN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
7	CD	O
,	,	O
14	CD	O
,	,	O
21	CD	O
and	CC	O
28	CD	O
;	:	O
arrhythmia	NN	O
was	VBD	O
analysed	VBN	O
at	IN	O
Holter	NNP	O
monitoring	VBG	O
in	IN	O
day	NN	O
1	CD	O
and	CC	O
2	CD	O
of	IN	O
MI	NNP	O
.	.	O

RESULTS	NNP	O
TLT	NNP	O
failed	VBD	O
to	TO	O
arrest	VB	O
progression	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
dilation	NN	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
hospital	NN	O
stay	NN	O
.	.	O

Patients	NNS	O
given	VBN	O
neoton	NNS	O
in	IN	O
acute	JJ	O
period	NN	O
of	IN	O
MI	NNP	O
had	VBD	O
no	DT	O
increase	NN	O
in	IN	O
the	DT	O
end	NN	O
systolic	NN	O
and	CC	O
diastolic	JJ	O
volumes	NNS	O
of	IN	O
the	DT	O
left	JJ	O
ventricle	NN	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
first	JJ	O
months	NNS	O
after	IN	O
MI	NNP	O
onset	NN	O
.	.	O

Antiarrhythmic	NNP	O
action	NN	O
of	IN	O
neoton	NN	O
manifested	VBN	O
on	IN	O
MI	NNP	O
day	NN	O
2	CD	O
.	.	O

CONCLUSION	NNP	O
Neoton	NNP	O
given	VBN	O
to	TO	O
MI	NNP	O
patients	NNS	O
receiving	VBG	O
TLT	NNP	O
prevents	NNS	O
progression	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
systolic	JJ	O
dysfunction	NN	O
and	CC	O
establishment	NN	O
of	IN	O
predictors	NNS	O
of	IN	O
unfavourable	JJ	O
outcome	NN	O
.	.	O

Randomised	VBN	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
rhesus-human	JJ	O
reassortant	JJ	O
rotavirus	NN	O
vaccine	NN	O
for	IN	O
prevention	NN	O
of	IN	O
severe	JJ	O
rotavirus	NN	O
gastroenteritis	NN	O
.	.	O

BACKGROUND	NNP	O
Rotavirus	NNP	O
is	VBZ	O
the	DT	O
most	RBS	O
common	JJ	O
cause	NN	O
of	IN	O
acute	JJ	O
childhood	NN	O
gastroenteritis	NN	O
.	.	O

Vaccination	NN	O
with	IN	O
live	JJ	O
oral	JJ	O
heterologous	JJ	O
rotavirus	NN	O
vaccines	NNS	O
may	MD	O
prevent	VB	O
rotavirus	NN	O
gastroenteritis	NN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
rhesus-human	JJ	O
reassortant	JJ	O
rotavirus	NN	O
tetravalent	NN	O
vaccine	NN	O
(	(	O
RRV-TV	NNP	O
)	)	O
against	IN	O
severe	JJ	O
rotavirus	NN	O
gastroenteritis	NN	O
in	IN	O
Finnish	JJ	O
children	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
placebo-controlled	JJ	O
double-blind	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
Placebo	NNP	O
or	CC	O
RRV-TV	NNP	O
(	(	O
titre	JJ	O
4x10	CD	O
(	(	O
5	CD	O
)	)	O
plaque-forming	JJ	O
units	NNS	O
)	)	O
was	VBD	O
given	VBN	O
to	TO	O
infants	NNS	O
at	IN	O
ages	NNS	O
2	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
5	CD	O
months	NNS	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
one	CD	O
or	CC	O
two	CD	O
rotavirus	JJ	O
epidemic	JJ	O
seasons	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
protection	NN	O
against	IN	O
severe	JJ	O
rotavirus	NN	O
gastroenteritis	NN	O
(	(	O
score	JJ	O
>	NN	O
or	CC	O
=11	NN	O
on	IN	O
a	DT	O
20-point	JJ	O
severity	NN	O
scale	NN	O
)	)	O
.	.	O

2398	CD	SampleSize
children	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
received	VBN	O
at	IN	O
least	JJS	O
one	CD	O
dose	NN	O
of	IN	O
RRV-TV	NNP	O
(	(	O
n=1191	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=1207	JJ	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
analysis	NN	O
was	VBD	O
based	VBN	O
on	IN	O
children	NNS	O
who	WP	O
received	VBD	O
three	CD	O
doses	NNS	O
of	IN	O
RRV-TV	NNP	O
(	(	O
n=1128	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=1145	JJ	O
)	)	O
.	.	O

FINDINGS	$	O
256	CD	O
episodes	NNS	O
of	IN	O
rotavirus	NN	O
gastroenteritis	NN	O
occurred	VBD	O
at	IN	O
any	DT	O
time	NN	O
during	IN	O
the	DT	O
study	NN	O
;	:	O
65	CD	O
were	VBD	O
among	IN	O
1191	CD	O
RRV-TV	JJ	O
recipients	NNS	O
,	,	O
and	CC	O
191	CD	O
among	IN	O
1207	CD	O
placebo	NN	O
recipients	NNS	O
(	(	O
vaccine	JJ	O
efficacy	NN	O
66	CD	O
%	NN	O
[	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
55-74	JJ	O
]	NN	O
;	:	O
intention-to-treat	JJ	O
analysis	NN	O
)	)	O
.	.	O

226	CD	O
episodes	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
analysis	NN	O
of	IN	O
fully	RB	O
vaccinated	VBN	O
children	NNS	O
(	(	O
54	CD	O
among	IN	O
1128	CD	O
RRV-TV	JJ	O
recipients	NNS	O
,	,	O
172	CD	O
among	IN	O
1145	CD	O
placebo	NN	O
recipients	NNS	O
;	:	O
vaccine	VB	O
efficacy	NN	O
68	CD	O
%	NN	O
[	JJ	O
57-76	JJ	O
]	NN	O
)	)	O
.	.	O

100	CD	O
episodes	NNS	O
were	VBD	O
severe	JJ	O
,	,	O
eight	CD	O
in	IN	O
RRV-TV	NNP	O
recipients	NNS	O
and	CC	O
92	CD	O
in	IN	O
placebo	NN	O
recipients	NNS	O
(	(	O
vaccine	JJ	O
efficacy	NN	O
91	CD	O
%	NN	O
[	JJ	O
82-96	JJ	O
]	NN	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
RRV-TV	NNP	O
vaccine	NN	O
was	VBD	O
highly	RB	O
effective	JJ	O
against	IN	O
severe	JJ	O
rotavirus	NN	O
gastroenteritis	NN	O
in	IN	O
young	JJ	O
children	NNS	O
.	.	O

Incorporation	NN	O
of	IN	O
this	DT	O
vaccine	NN	O
into	IN	O
routine	JJ	O
immunisation	NN	O
schedules	NNS	O
of	IN	O
infants	NNS	O
could	MD	O
reduce	VB	O
severe	JJ	O
rotavirus	NN	O
gastroenteritis	NN	O
by	IN	O
90	CD	O
%	NN	O
and	CC	O
severe	JJ	O
gastroenteritis	NN	O
of	IN	O
all	DT	O
causes	NNS	O
in	IN	O
young	JJ	O
children	NNS	O
by	IN	O
60	CD	O
%	NN	O
.	.	O

Direct	JJ	O
renin	NN	O
inhibition	NN	O
improves	VBZ	O
parasympathetic	JJ	O
function	NN	O
in	IN	O
diabetes	NNS	Condition
.	.	O

AIM	VB	O
The	DT	O
renin-angiotensin-aldosterone	NN	O
system	NN	O
(	(	O
RAAS	NNP	O
)	)	O
and	CC	O
autonomic	JJ	O
nervous	JJ	O
system	NN	O
regulate	VB	O
the	DT	O
cardiovascular	JJ	O
system	NN	O
.	.	O

Blockade	NN	O
of	IN	O
the	DT	O
RAAS	NNP	O
may	MD	O
slow	VB	O
the	DT	O
progression	NN	O
of	IN	O
end-organ	JJ	O
damage	NN	O
.	.	O

Direct	JJ	O
renin	NN	O
inhibition	NN	O
offers	VBZ	O
a	DT	O
means	NN	O
for	IN	O
blocking	VBG	O
the	DT	O
RAAS	NNP	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
direct	JJ	O
renin	NN	O
inhibition	NN	O
on	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
,	,	O
60	CD	SampleSize
individuals	NNS	O
with	IN	O
diabetes	NNS	Condition
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
300	CD	O
mg	NN	O
of	IN	O
aliskiren	NN	O
or	CC	O
placebo	NN	O
once	RB	O
daily	JJ	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
a	DT	O
change	NN	O
in	IN	O
tests	NNS	O
of	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
.	.	O

Autonomic	NNP	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
power	NN	O
spectral	JJ	O
analysis	NN	O
and	CC	O
RR-variation	NNP	O
during	IN	O
deep	JJ	O
breathing	NN	O
[	JJ	O
i.e	NN	O
.	.	O

mean	VB	O
circular	JJ	O
resultant	NN	O
(	(	O
MCR	NNP	O
)	)	O
,	,	O
expiration/inspiration	NN	O
(	(	O
E/I	NNP	O
)	)	O
ratio	NN	O
]	NN	O
.	.	O

The	DT	O
MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
assess	NN	O
parasympathetic	JJ	O
function	NN	O
.	.	O

Secondary	JJ	O
measures	NNS	O
included	VBD	O
change	NN	O
in	IN	O
biochemical	JJ	O
parameters	NNS	O
[	VBP	O
e.g	NN	O
.	.	O

plasma	JJ	O
renin	NN	O
activity	NN	O
,	,	O
leptin	NN	O
and	CC	O
interleukin-6	JJ	O
]	NN	O
.	.	O

Change	NN	O
in	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
blood	NN	O
analytes	NNS	O
were	VBD	O
analysed	VBN	O
by	IN	O
a	DT	O
mixed	JJ	O
effects	NNS	O
model	NN	O
for	IN	O
repeated	JJ	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
treatment	NN	O
groups	NNS	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
aliskiren	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
blood	NN	O
pressure	NN	O
was	VBD	O
reduced	VBN	O
as	RB	O
well	RB	O
as	IN	O
plasma	JJ	O
renin	NN	O
activity	NN	O
[	VBP	O
from	IN	O
2.4	CD	O
?	.	O
3.8	CD	O
(	(	O
mean	VB	O
?	.	O
standard	JJ	O
deviation	NN	O
)	)	O
to	TO	O
0.5	CD	O
?	.	O
0.4	CD	O
?g/l/h	NN	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
]	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
(	(	O
aliskiren	VB	O
?	.	O
visit	NN	O
)	)	O
for	IN	O
MCR	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
E/I	NNP	O
ratio	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
indicating	VBG	O
improvement	NN	O
in	IN	O
MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
for	IN	O
those	DT	O
on	IN	O
aliskiren	NNS	O
.	.	O

MCR	NNP	O
means	VBZ	O
,	,	O
baseline	VB	O
vs.	IN	O
follow-up	JJ	O
,	,	O
were	VBD	O
41.8	CD	O
?	.	O
19.7	CD	O
vs.	IN	O
50.8	CD	O
?	.	O
26.1	CD	O
(	(	O
aliskiren	NN	O
)	)	O
and	CC	O
38.2	CD	O
?	.	O
23.6	CD	O
vs.	IN	O
37.5	CD	O
?	.	O
24.1	CD	O
(	(	O
placebo	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Parasympathetic	NNP	O
function	NN	O
(	(	O
i.e	JJ	O
.	.	O

MCR	NNP	O
and	CC	O
E/I	NNP	O
ratio	NN	O
)	)	O
was	VBD	O
enhanced	VBN	O
by	IN	O
downregulation	NN	O
of	IN	O
the	DT	O
RAAS	NNP	O
.	.	O

[	RB	O
Preoperative	NNP	O
chemotherapy	NN	O
of	IN	O
esophageal	JJ	O
cancer	NN	O
]	NNP	O
.	.	O

A	NNP	O
series	NN	O
of	IN	O
25	CD	O
patients	NNS	O
with	IN	O
advanced	JJ	O
esophageal	NN	O
cancer	NN	O
treated	VBN	O
from	IN	O
Mar	NNP	O
.	.	O

1981	CD	O
to	TO	O
Sep.	VB	O
1982	CD	O
by	IN	O
preoperative	JJ	O
chemotherapy	NN	O
plus	CC	O
surgery	NN	O
is	VBZ	O
reported	VBN	O
.	.	O

All	PDT	O
the	DT	O
patients	NNS	O
came	VBD	O
from	IN	O
the	DT	O
hospitals	NNS	O
of	IN	O
the	DT	O
cooperative	JJ	O
research	NN	O
group	NN	O
and	CC	O
were	VBD	O
randomized	VBN	O
into	IN	O
chemotherapy	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

They	PRP	O
were	VBD	O
proved	VBN	O
by	IN	O
X-ray	NNP	O
,	,	O
cytology	NN	O
and	CC	O
histopathology	NN	O
prior	RB	O
to	TO	O
treatment	NN	O
.	.	O

By	IN	O
histology	NN	O
,	,	O
22	CD	O
cases	NNS	O
were	VBD	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
,	,	O
1	CD	O
adenocarcinoma	NN	O
and	CC	O
2	CD	O
squamous	JJ	O
adenocarcinoma	NN	O
.	.	O

The	DT	O
COF	NNP	O
chemotherapy	NN	O
consisted	VBD	O
of	IN	O
Vincristine	NNP	O
1	CD	O
mg	NN	O
,	,	O
cyclophosphamide	RB	O
600	CD	O
mg	NNS	O
and	CC	O
5-fluorouracil	JJ	O
500	CD	O
mg	NN	O
IV	NNP	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
8	CD	O
with	IN	O
or	CC	O
without	IN	O
the	DT	O
addition	NN	O
of	IN	O
Pingyangmycin	NNP	O
,	,	O
a	DT	O
drug	NN	O
equivalent	NN	O
to	TO	O
Bleomycin	NNP	O
A5	NNP	O
,	,	O
at	IN	O
the	DT	O
dose	NN	O
of	IN	O
10	CD	O
mg	NNS	O
IM	NNP	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
and	CC	O
8	CD	O
.	.	O

The	DT	O
interval	NN	O
between	IN	O
the	DT	O
ending	VBG	O
of	IN	O
chemotherapy	NN	O
and	CC	O
the	DT	O
surgical	JJ	O
resection	NN	O
was	VBD	O
5-6	JJ	O
days	NNS	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
preoperative	JJ	O
chemotherapy	NN	O
caused	VBD	O
no	DT	O
myelosuppression	NN	O
,	,	O
but	CC	O
merely	RB	O
mild	JJ	O
gastrointestinal	JJ	O
symptoms	NNS	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
operated	VBN	O
and	CC	O
resected	VBN	O
without	IN	O
difficulty	NN	O
.	.	O

The	DT	O
subjective	JJ	O
improvement	NN	O
in	IN	O
various	JJ	O
degrees	NNS	O
and	CC	O
the	DT	O
shrinkage	NN	O
of	IN	O
tumor	NN	O
in	IN	O
the	DT	O
X-ray	JJ	O
films	NNS	O
were	VBD	O
present	JJ	O
in	IN	O
5/25	CD	O
cases	NNS	O
who	WP	O
received	VBD	O
preoperative	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
histopathological	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
chemotherapy	NN	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
16	CD	O
specimens	NNS	O
)	)	O
were	VBD	O
different	JJ	O
.	.	O

In	IN	O
the	DT	O
chemotherapy	NN	O
group	NN	O
,	,	O
excessive	JJ	O
keratinization	NN	O
in	IN	O
the	DT	O
squamous	JJ	O
component	NN	O
of	IN	O
the	DT	O
esophageal	NN	O
cancerous	JJ	O
tissue	NN	O
appeared	VBD	O
in	IN	O
the	DT	O
resected	JJ	O
specimens	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
degeneration	NN	O
and	CC	O
necrosis	NN	O
in	IN	O
the	DT	O
squamous	JJ	O
epithelium	NN	O
adjacent	NN	O
to	TO	O
carcinoma	VB	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
chemotherapy	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
suggested	VBD	O
that	IN	O
such	JJ	O
combined	JJ	O
modality	NN	O
is	VBZ	O
worth	IN	O
further	JJ	O
study	NN	O
.	.	O

Behavioral	JJ	O
changes	NNS	O
in	IN	O
autistic	JJ	O
individuals	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
wearing	VBG	O
ambient	JJ	O
transitional	JJ	O
prism	NN	O
lenses	NNS	O
.	.	O

A	DT	O
double-blind	JJ	O
crossover	NN	O
design	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
wearing	VBG	O
ambient	JJ	O
lenses	NNS	O
to	TO	O
reduce	VB	O
the	DT	O
behavioral	JJ	O
symptoms	NNS	O
of	IN	O
autism	NN	O
.	.	O

Eighteen	NNP	O
autistic	JJ	O
individuals	NNS	O
,	,	O
ranging	VBG	O
in	IN	O
age	NN	O
from	IN	O
7	CD	O
to	TO	O
18	CD	O
years	NNS	O
,	,	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Behavior	NNP	O
,	,	O
attention	NN	O
,	,	O
and	CC	O
orientation	NN	O
were	VBD	O
evaluated	VBN	O
at	IN	O
1	CD	O
1/2	CD	O
months	NNS	O
,	,	O
2	CD	O
months	NNS	O
,	,	O
3	CD	O
months	NNS	O
,	,	O
and	CC	O
4	CD	O
months	NNS	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	O
condition	NN	O
,	,	O
the	DT	O
results	NNS	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
behavior	JJ	O
problems	NNS	O
at	IN	O
the	DT	O
1	CD	O
1/2	CD	O
and	CC	O
2	CD	O
month	NN	O
assessment	NN	O
periods	NNS	O
and	CC	O
a	DT	O
slight	JJ	O
loss	NN	O
of	IN	O
these	DT	O
benefits	NNS	O
at	IN	O
the	DT	O
3	CD	O
and	CC	O
4	CD	O
month	NN	O
assessment	NN	O
periods	NNS	O
.	.	O

These	DT	O
findings	NNS	O
support	VBP	O
the	DT	O
prediction	NN	O
that	WDT	O
ambient	JJ	O
lenses	NNS	O
,	,	O
worn	VBN	O
without	IN	O
engaging	VBG	O
in	IN	O
visual-motor	NN	O
exercises	NNS	O
,	,	O
have	VBP	O
positive	JJ	O
effects	NNS	O
on	IN	O
autistic	JJ	O
individuals	NNS	O
.	.	O

Correlation	NN	O
of	IN	O
adenosinergic	JJ	O
activity	NN	O
with	IN	O
superior	JJ	O
efficacy	NN	O
of	IN	O
clozapine	NN	O
for	IN	O
treatment	NN	O
of	IN	O
chronic	JJ	O
schizophrenia	NN	Condition
:	:	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
It	PRP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
that	IN	O
a	DT	O
deficit	NN	O
of	IN	O
adenosinergic	JJ	O
activity	NN	O
could	MD	O
contribute	VB	O
to	TO	O
the	DT	O
pathophysiology	NN	O
of	IN	O
schizophrenia	NN	O
.	.	O

The	DT	O
authors	NNS	O
undertook	VBP	O
this	DT	O
study	NN	O
to	TO	O
further	RBR	O
evaluate	VB	O
the	DT	O
level	NN	O
of	IN	O
adenosine	JJ	O
deaminase	NN	O
(	(	O
ADA	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
schizophrenia	NN	Condition
treated	VBN	O
with	IN	O
monotherapy	NN	O
of	IN	O
haloperidol	NN	O
,	,	O
risperidone	NN	O
or	CC	O
clozapine	NN	O
and	CC	O
correlation	NN	O
between	IN	O
the	DT	O
ADA	NNP	O
level	NN	O
with	IN	O
response	NN	O
to	TO	O
treatment	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
trial	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
8-week	JJ	O
,	,	O
double	JJ	O
blind	NN	O
study	NN	O
of	IN	O
parallel	JJ	O
groups	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
schizophrenia	NN	Condition
.	.	O

Eligible	JJ	O
participants	NNS	O
in	IN	O
the	DT	O
study	NN	O
were	VBD	O
51	CD	SampleSize
patients	NNS	SampleSize
with	IN	O
chronic	JJ	Condition
schizophrenia	NN	Condition
with	IN	O
ages	NNS	O
ranging	VBG	O
from	IN	O
20	CD	Age
to	TO	Age
45	CD	Age
years	NNS	Age
.	.	O

All	DT	O
participants	NNS	O
were	VBD	O
inpatients	NNS	O
,	,	O
in	IN	O
the	DT	O
active	JJ	O
phase	NN	O
of	IN	O
illness	NN	O
,	,	O
and	CC	O
met	VBD	O
DSM-IV-TR	NNP	O
criteria	NNS	O
for	IN	O
schizophrenia	NN	Condition
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
(	(	O
17	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
)	)	O
to	TO	O
risperidone	VB	O
(	(	O
6	CD	O
mg/day	NN	O
)	)	O
or	CC	O
haloperidol	$	O
15	CD	O
mg/day	NN	O
or	CC	O
clozapine	NN	O
(	(	O
300	CD	O
mg/day	NN	O
)	)	O
.	.	O

Serum	NNP	O
ADA	NNP	O
activity	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
week	NN	O
8	CD	O
.	.	O

RESULTS	VB	O
The	DT	O
plasma	JJ	O
levels	NNS	O
of	IN	O
ADA	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
schizophrenia	NN	O
who	WP	O
received	VBD	O
clozapine	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
haloperidol	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
response	NN	O
to	TO	O
treatment	NN	O
was	VBD	O
positively	RB	O
correlated	VBN	O
with	IN	O
plasma	NN	O
levels	NNS	O
of	IN	O
ADA	NNP	O
only	RB	O
in	IN	O
the	DT	O
clozapine	NN	O
group	NN	O
(	(	O
r	NN	O
=	VBZ	O
0.46	CD	O
and	CC	O
p	VB	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
indicate	VBP	O
an	DT	O
increased	JJ	O
activity	NN	O
of	IN	O
the	DT	O
enzyme	NN	O
ADA	NNP	O
in	IN	O
the	DT	O
serum	NN	O
of	IN	O
schizophrenic	JJ	O
patients	NNS	O
being	VBG	O
treated	VBN	O
with	IN	O
clozapine	NN	O
and	CC	O
this	DT	O
increase	NN	O
may	MD	O
be	VB	O
correlated	VBN	O
with	IN	O
clozapine	NN	O
's	POS	O
superior	JJ	O
antipsychotic	JJ	O
efficacy	NN	O
.	.	O

Predictive	JJ	O
validity	NN	O
of	IN	O
a	DT	O
medication	NN	O
adherence	NN	O
measure	NN	O
in	IN	O
an	DT	O
outpatient	JJ	O
setting	NN	O
.	.	O

This	DT	O
study	NN	O
examines	VBZ	O
the	DT	O
psychometric	JJ	O
properties	NNS	O
and	CC	O
tests	VBZ	O
the	DT	O
concurrent	NN	O
and	CC	O
predictive	JJ	O
validity	NN	O
of	IN	O
a	DT	O
structured	JJ	O
,	,	O
self-reported	JJ	O
medication	NN	O
adherence	NN	O
measure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	Condition
.	.	O

The	DT	O
authors	NNS	O
also	RB	O
assessed	VBD	O
various	JJ	O
psychosocial	JJ	O
determinants	NNS	O
of	IN	O
adherence	NN	O
,	,	O
such	JJ	O
as	IN	O
knowledge	NN	O
,	,	O
social	JJ	O
support	NN	O
,	,	O
satisfaction	NN	O
with	IN	O
care	NN	O
,	,	O
and	CC	O
complexity	NN	O
of	IN	O
the	DT	O
medical	JJ	O
regimen	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1367	CD	SampleSize
patients	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
;	:	O
mean	JJ	O
age	NN	O
was	VBD	O
52.5	CD	Age
years	NNS	Age
,	,	O
40.8	CD	O
%	NN	O
were	VBD	O
male	JJ	Sex
,	,	O
76.5	CD	O
%	NN	O
were	VBD	O
black	JJ	O
,	,	O
50.8	CD	O
%	NN	O
graduated	VBN	O
from	IN	O
high	JJ	O
school	NN	O
,	,	O
26	CD	O
%	NN	O
were	VBD	O
married	VBN	O
,	,	O
and	CC	O
54.1	CD	O
%	NN	O
had	VBD	O
income	NN	O
<	NNP	O
$	$	O
5,000	CD	O
.	.	O

The	DT	O
8-item	JJ	O
medication	NN	O
adherence	NN	O
scale	NN	O
was	VBD	O
reliable	JJ	O
(	(	O
alpha=.83	NN	O
)	)	O
and	CC	O
significantly	RB	O
associated	VBN	O
with	IN	O
blood	NN	O
pressure	NN	O
control	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Using	VBG	O
a	DT	O
cutpoint	NN	O
of	IN	O
<	$	O
6	CD	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
the	DT	O
measure	NN	O
to	TO	O
identify	VB	O
patients	NNS	O
with	IN	O
poor	JJ	O
blood	NN	O
pressure	NN	O
control	NN	O
was	VBD	O
estimated	VBN	O
to	TO	O
be	VB	O
93	CD	O
%	NN	O
,	,	O
and	CC	O
the	DT	O
specificity	NN	O
was	VBD	O
53	CD	O
%	NN	O
.	.	O

The	DT	O
medication	NN	O
adherence	NN	O
measure	NN	O
proved	VBD	O
to	TO	O
be	VB	O
reliable	JJ	O
,	,	O
with	IN	O
good	JJ	O
concurrent	NN	O
and	CC	O
predictive	JJ	O
validity	NN	O
in	IN	O
primarily	RB	O
low-income	JJ	O
,	,	O
minority	NN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
and	CC	O
might	MD	O
function	VB	O
as	IN	O
a	DT	O
screening	VBG	O
tool	NN	O
in	IN	O
outpatient	JJ	O
settings	NNS	O
with	IN	O
other	JJ	O
patient	NN	O
groups	NNS	O
.	.	O

The	DT	O
additional	JJ	O
value	NN	O
of	IN	O
a	DT	O
night	NN	O
splint	NN	O
to	TO	O
eccentric	VB	O
exercises	NNS	O
in	IN	O
chronic	JJ	O
midportion	NN	O
Achilles	NNP	O
tendinopathy	NN	Condition
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

AIM	NNP	O
To	TO	O
assess	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
night	NN	O
splint	NN	O
is	VBZ	O
of	IN	O
added	JJ	O
benefit	NN	O
on	IN	O
functional	JJ	O
outcome	NN	O
in	IN	O
treating	VBG	O
chronic	JJ	Condition
midportion	NN	Condition
Achilles	NNP	Condition
tendinopathy	NN	Condition
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
single-blind	JJ	O
,	,	O
prospective	JJ	O
,	,	O
single	JJ	O
centre	NN	O
,	,	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
set	NN	O
in	IN	O
the	DT	O
Sports	NNP	O
Medical	NNP	O
Department	NNP	O
,	,	O
The	DT	O
Hague	NNP	O
Medical	NNP	O
Centre	NNP	O
,	,	O
The	DT	O
Netherlands	NNP	O
.	.	O

Inclusion	NNP	O
criteria	NNS	O
were	VBD	O
:	:	O
age	NN	O
18-70	CD	Age
years	NNS	Age
,	,	O
active	JJ	Condition
participation	NN	Condition
in	IN	Condition
sports	NNS	Condition
,	,	O
and	CC	O
tendon	VB	Condition
pain	NN	Condition
localised	VBN	Condition
at	IN	Condition
2-7	JJ	Condition
cm	NN	Condition
from	IN	Condition
distal	JJ	Condition
insertion	NN	Condition
.	.	O

Exclusion	NN	O
criteria	NNS	O
were	VBD	O
:	:	O
insertional	JJ	O
disorders	NNS	O
,	,	O
partial	JJ	O
or	CC	O
complete	JJ	O
ruptures	NNS	O
,	,	O
or	CC	O
systemic	JJ	O
illness	NN	O
.	.	O

70	CD	O
tendons	NNS	O
were	VBD	O
included	VBN	O
and	CC	O
randomised	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
eccentric	JJ	O
exercises	NNS	O
with	IN	O
a	DT	O
night	NN	O
splint	NN	O
(	(	O
night	NN	O
splint	NN	O
group	NN	O
,	,	O
n	RB	O
=	VBZ	O
36	CD	O
)	)	O
or	CC	O
eccentric	JJ	O
exercises	NNS	O
only	RB	O
(	(	O
eccentric	JJ	O
group	NN	O
,	,	O
n	RB	O
=	VBZ	O
34	CD	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
Both	DT	O
groups	NNS	O
completed	VBD	O
a	DT	O
12-week	JJ	O
heavy-load	NN	O
eccentric	JJ	O
training	NN	O
programme	NN	O
.	.	O

One	CD	O
group	NN	O
received	VBD	O
a	DT	O
night	NN	O
splint	NN	O
in	IN	O
addition	NN	O
to	TO	O
eccentric	JJ	O
exercises	NNS	O
.	.	O

At	IN	O
baseline	NN	O
and	CC	O
follow-up	NN	O
at	IN	O
12	CD	O
weeks	NNS	O
,	,	O
patient	JJ	O
satisfaction	NN	O
,	,	O
Victorian	NNP	O
Institute	NNP	O
of	IN	O
Sport	NNP	O
Assessment-Achilles	NNP	O
questionnaire	NN	O
(	(	O
VISA-A	NNP	O
)	)	O
score	NN	O
and	CC	O
reported	VBD	O
compliance	NN	O
were	VBD	O
recorded	VBN	O
by	IN	O
a	DT	O
single-blind	NN	O
trained	JJ	O
researcher	NN	O
who	WP	O
was	VBD	O
blinded	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
patient	JJ	O
satisfaction	NN	O
in	IN	O
the	DT	O
eccentric	JJ	O
group	NN	O
was	VBD	O
63	CD	O
%	NN	O
compared	VBN	O
with	IN	O
48	CD	O
%	NN	O
in	IN	O
the	DT	O
night	NN	O
splint	NN	O
group	NN	O
.	.	O

The	DT	O
VISA-A	NNP	O
score	NN	O
significantly	RB	O
improved	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
;	:	O
in	IN	O
the	DT	O
eccentric	JJ	O
group	NN	O
from	IN	O
50.1	CD	O
to	TO	O
68.8	CD	O
(	(	O
p	NN	O
=	RB	O
0.001	CD	O
)	)	O
and	CC	O
in	IN	O
the	DT	O
night	NN	O
splint	NN	O
group	NN	O
from	IN	O
49.4	CD	O
to	TO	O
67.0	CD	O
(	(	O
p	NN	O
<	RB	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
VISA-A	NNP	O
score	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.815	CD	O
)	)	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.261	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	O
night	NN	O
splint	NN	O
is	VBZ	O
not	RB	O
beneficial	JJ	O
in	IN	O
addition	NN	O
to	TO	O
eccentric	VB	O
exercises	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
midportion	NN	O
Achilles	NNP	O
tendinopathy	NN	O
.	.	O

Impact	NN	O
of	IN	O
interviewer	NN	O
's	POS	O
body	NN	O
mass	NN	O
index	NN	O
on	IN	O
underreporting	VBG	O
energy	NN	O
intake	NN	O
in	IN	O
overweight	NN	Condition
and	CC	Condition
obese	JJ	Condition
women	NNS	Sex
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
if	IN	O
overweight	JJ	Condition
and	CC	O
obese	JJ	Condition
women	NNS	Sex
provide	VBP	O
more	JJR	O
accurate	JJ	O
reports	NNS	O
of	IN	O
their	PRP$	O
energy	NN	O
intake	NN	O
by	IN	O
1	CD	O
)	)	O
in-person	NN	O
recall	NN	O
with	IN	O
an	DT	O
obese	JJ	O
interviewer	NN	O
,	,	O
2	CD	O
)	)	O
in-person	NN	O
recall	NN	O
with	IN	O
a	DT	O
lean	JJ	O
interviewer	NN	O
,	,	O
or	CC	O
3	CD	O
)	)	O
telephone	NN	O
recall	NN	O
with	IN	O
an	DT	O
unknown	JJ	O
interviewer	NN	O
.	.	O

RESEARCH	NNP	O
METHODS	NNP	O
AND	NNP	O
PROCEDURES	NNP	O
Eighty-eight	NNP	SampleSize
overweight	NN	Condition
and	CC	O
obese	JJ	Condition
women	NNS	Sex
participated	VBD	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Subjects	NNS	O
completed	VBD	O
one	CD	O
telephone-administered	JJ	O
multiple-pass	JJ	O
24-hour	JJ	O
recall	NN	O
(	(	O
MP24R	NNP	O
)	)	O
with	IN	O
an	DT	O
unknown	JJ	O
interviewer	NN	O
and	CC	O
were	VBD	O
then	RB	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
in-person	JJ	O
MP24R	NNP	O
with	IN	O
either	CC	O
a	DT	O
lean	JJ	O
or	CC	O
obese	JJ	O
interviewer	NN	O
to	TO	O
gather	VB	O
reported	VBN	O
energy	NN	O
intake	NN	O
(	(	O
rEI	NN	O
)	)	O
.	.	O

Basal	NNP	O
metabolic	JJ	O
rate	NN	O
(	(	O
BMR	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
Deltrac	NNP	O
monitor	NN	O
,	,	O
and	CC	O
physical	JJ	O
activity	NN	O
(	(	O
EEPA	NNP	O
)	)	O
was	VBD	O
estimated	VBN	O
using	VBG	O
a	DT	O
Caltrac	NNP	O
accelerometer	NN	O
.	.	O

Therefore	RB	O
,	,	O
estimated	VBD	O
energy	NN	O
expenditure	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
:	:	O
estTEE	NN	O
=	NNP	O
(	(	O
BMR	NNP	O
+	NNP	O
EEPA	NNP	O
)	)	O
x	VBD	O
1.10	CD	O
.	.	O

RESULTS	VB	O
No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
in-person	JJ	O
interview	NN	O
modes	NNS	O
for	IN	O
subject	JJ	O
age	NN	O
,	,	O
weight	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
,	,	O
percentage	NN	O
of	IN	O
body	NN	O
fat	NN	O
,	,	O
total	JJ	O
energy	NN	O
expenditure	NN	O
,	,	O
rEI	NN	O
,	,	O
and	CC	O
misreporting	NN	O
of	IN	O
energy	NN	O
intake	NN	O
.	.	O

In-person	NNP	O
recall	NN	O
data	NNS	O
were	VBD	O
combined	VBN	O
for	IN	O
comparison	NN	O
with	IN	O
the	DT	O
telephone	NN	O
recalls	VBZ	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
in-person	JJ	O
and	CC	O
telephone	NN	O
recalls	NNS	O
for	IN	O
rEI	NN	O
and	CC	O
misreporting	NN	O
.	.	O

Mean	NNP	O
reported	VBD	O
energy	NN	O
intake	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
estimated	VBN	O
total	JJ	O
energy	NN	O
expenditure	NN	O
for	IN	O
the	DT	O
telephone	NN	O
recalls	NNS	O
and	CC	O
combined	VBN	O
(	(	O
lean	JJ	O
and	CC	O
obese	JJ	O
modes	NNS	O
)	)	O
in-person	NN	O
recalls	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
found	VBD	O
that	IN	O
interviewer	NN	O
body	NN	O
mass	NN	O
index	NN	O
had	VBD	O
no	DT	O
impact	NN	O
on	IN	O
self-reported	JJ	O
energy	NN	O
intake	NN	O
during	IN	O
an	DT	O
in-person	JJ	O
MP24R	NNP	O
,	,	O
and	CC	O
that	IN	O
telephone	NN	O
recall	NN	O
data	NNS	O
were	VBD	O
comparable	JJ	O
with	IN	O
in-person	JJ	O
recalls	NNS	O
.	.	O

Underreporting	NNP	O
was	VBD	O
a	DT	O
widespread	JJ	O
problem	NN	O
(	(	O
approximately	RB	O
26	CD	O
%	NN	O
)	)	O
for	IN	O
all	DT	O
modes	NNS	O
in	IN	O
this	DT	O
sample	NN	O
.	.	O

Effect	NN	O
of	IN	O
simvastatin	NN	O
and	CC	O
fenofibrate	NN	O
on	IN	O
endothelium	NN	O
in	IN	O
Type	NNP	Condition
2	CD	Condition
diabetes	NNS	Condition
.	.	O

Statins	NNS	O
and	CC	O
fibrates	NNS	O
influence	VBP	O
endothelial	JJ	O
activity	NN	O
and	CC	O
consequently	RB	O
atherogenesis	NN	O
but	CC	O
the	DT	O
mechanisms	NNS	O
are	VBP	O
not	RB	O
well	RB	O
understood	RB	O
.	.	O

Twenty	NNP	SampleSize
Type	NNP	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	Condition
dyslipidemia	NN	Condition
were	VBD	O
treated	VBN	O
3	CD	O
months	NNS	O
with	IN	O
simvastatin	NN	O
(	(	O
20	CD	O
mg	NNS	O
daily	RB	O
)	)	O
and	CC	O
then	RB	O
3	CD	O
months	NNS	O
with	IN	O
fenofibrate	NN	O
(	(	O
200	CD	O
mg	NNS	O
daily	RB	O
)	)	O
with	IN	O
2	CD	O
months	NNS	O
of	IN	O
wash-out	NN	O
between	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
.	.	O

Laboratory	JJ	O
parameters	NNS	O
of	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
fibrinolysis	NN	O
and	CC	O
endothelial	JJ	O
function	NN	O
were	VBD	O
evaluated	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
treatment	NN	O
period	NN	O
.	.	O

The	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
serum	JJ	O
total	JJ	O
and	CC	O
LDL-cholesterol	JJ	O
concentrations	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
caused	VBN	O
by	IN	O
simvastatin	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	JJ	O
N-acetyl-beta-glucosaminidase	JJ	O
activity	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
ascorbic	JJ	O
acid	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
plasminogen	JJ	O
activator	NN	O
inhibitor	NN	O
(	(	O
PAI-1	NNP	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
vonWillebrand	FW	O
factor	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
E-selectin	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
concentrations	NNS	O
and	CC	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
plasma	NN	O
glutathione	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
levels	NNS	O
.	.	O

Fenofibrate	NNP	O
caused	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
serum	JJ	O
triglyceride	JJ	O
concentration	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
plasma	NN	O
malondialdehyde	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
plasma	JJ	O
PAI-1	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
P-selectin	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
concentrations	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
simvastatin	NN	O
and	CC	O
fenofibrate	NN	O
interact	NN	O
,	,	O
by	IN	O
different	JJ	O
mechanisms	NNS	O
,	,	O
with	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
a	DT	O
key	JJ	O
factor	NN	O
in	IN	O
the	DT	O
modification	NN	O
of	IN	O
fibrinolysis	NN	O
and	CC	O
endothelial	JJ	O
function	NN	O
in	IN	O
Type	NNP	O
2	CD	O
diabetes	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
encoding	VBG	O
in	IN	O
hypnosis	NN	O
and	CC	O
post-hypnotic	JJ	O
suggestion	NN	O
on	IN	O
academic	JJ	O
performance	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
proactive	JJ	O
learning	NN	O
in	IN	O
hypnosis	NN	Condition
,	,	O
post-hypnotic	JJ	O
suggestion	NN	O
,	,	O
and	CC	O
academic	JJ	O
performance	NN	O
.	.	O

Participants	NNS	O
(	(	O
N	NNP	O
=	NNP	O
56	CD	SampleSize
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
or	CC	O
a	DT	O
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
hypnotized	VBN	O
and	CC	O
read	VB	O
a	DT	O
passage	NN	O
while	IN	O
in	IN	O
hypnosis	NN	O
.	.	O

Concurrently	RB	O
,	,	O
they	PRP	O
were	VBD	O
given	VBN	O
a	DT	O
post-hypnotic	JJ	O
suggestion	NN	O
,	,	O
which	WDT	O
attempted	VBD	O
to	TO	O
aid	VB	O
recognition	NN	O
and	CC	O
performance	NN	O
on	IN	O
a	DT	O
test	NN	O
immediately	RB	O
following	VBG	O
the	DT	O
hypnosis	NN	O
session	NN	O
.	.	O

Both	DT	O
groups	NNS	O
completed	VBD	O
a	DT	O
multiple-choice	JJ	O
test	NN	O
based	VBN	O
on	IN	O
the	DT	O
aforementioned	JJ	O
passage	NN	O
.	.	O

An	DT	O
analysis	NN	O
of	IN	O
covariance	NN	O
discerned	VBD	O
the	DT	O
effect	NN	O
of	IN	O
proactive	JJ	O
learning	NN	O
and	CC	O
post-hypnotic	JJ	O
suggestion	NN	O
on	IN	O
test	NN	O
performance	NN	O
,	,	O
while	IN	O
controlling	VBG	O
for	IN	O
the	DT	O
variance	NN	O
introduced	VBN	O
by	IN	O
scholastic	JJ	O
aptitude	NN	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
ACT	NNP	O
.	.	O

Results	NNP	O
indicated	VBD	O
that	IN	O
the	DT	O
hypnosis	NN	O
sessions	NNS	O
predicted	VBD	O
significantly	RB	O
impaired	JJ	O
test	NN	O
performance	NN	O
.	.	O

Effect	NN	O
of	IN	O
hydrochlorothiazide	NN	O
therapy	NN	O
on	IN	O
cardiac	JJ	Condition
arrhythmias	NN	Condition
in	IN	Condition
African-American	JJ	Condition
men	NNS	Condition
with	IN	Condition
systemic	JJ	Condition
hypertension	NN	Condition
and	CC	Condition
moderate	VB	Condition
to	TO	Condition
severe	VB	Condition
left	JJ	Condition
ventricular	JJ	Condition
hypertrophy	NN	Condition
.	.	O

The	DT	O
effect	NN	O
of	IN	O
hydrochlorothiazide	NN	O
therapy	NN	O
on	IN	O
ventricular	JJ	O
arrhythmias	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
45	CD	O
hypertensive	JJ	O
African-American	JJ	O
men	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
left	VBN	O
ventricular	JJ	O
(	(	O
LV	NNP	O
)	)	O
hypertrophy	NN	O
.	.	O

After	IN	O
medication	NN	O
washout	NN	O
,	,	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
placebo	NN	O
followed	VBN	O
by	IN	O
hydrochlorothiazide	NN	O
.	.	O

Clinical	NNP	O
,	,	O
biochemical	JJ	O
,	,	O
and	CC	O
48-hour	JJ	O
ambulatory	NN	O
electrocardiographic	JJ	O
data	NN	O
was	VBD	O
collected	VBN	O
after	IN	O
each	DT	O
treatment	NN	O
phase	NN	O
.	.	O

Signal-averaged	JJ	O
electrocardiograms	NNS	O
were	VBD	O
recorded	VBN	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
24	CD	O
patients	NNS	O
.	.	O

Average	JJ	O
LV	NNP	O
posterior	NN	O
wall	NN	O
thickness	NN	O
was	VBD	O
15	CD	O
+/-	JJ	O
1.1	CD	O
mm	NN	O
,	,	O
septum	VBD	O
16	CD	O
+/-	JJ	O
2	CD	O
mm	NN	O
,	,	O
LV	NNP	O
mass	VBD	O
420	CD	O
+/-	JJ	O
90	CD	O
g	NN	O
,	,	O
and	CC	O
LV	NNP	O
mass	NNP	O
index	NN	O
212	CD	O
=	NN	O
51	CD	O
g/m2	NN	O
.	.	O

Systolic	NNP	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
was	VBD	O
168	CD	O
+/-	JJ	O
18	CD	O
mm	NN	O
Hg	NNP	O
after	IN	O
the	DT	O
placebo	NN	O
phase	NN	O
and	CC	O
146	CD	O
+/-	JJ	O
15	CD	O
mm	NN	O
Hg	NNP	O
after	IN	O
hydrochlorothiazide	NN	O
;	:	O
diastolic	JJ	O
BP	NNP	O
was	VBD	O
103	CD	O
+/-	JJ	O
6	CD	O
mm	NN	O
Hg	NNP	O
and	CC	O
89	CD	O
+/-	JJ	O
9	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
respectively	RB	O
.	.	O

Serum	NNP	O
potassium	NN	O
decreased	VBD	O
significantly	RB	O
from	IN	O
4.2	CD	O
+/-	JJ	O
0.4	CD	O
mmol/L	NN	O
to	TO	O
3.7	CD	O
+/-	JJ	O
0.6	CD	O
mmol/L	NN	O
after	IN	O
hydrochlorothiazide	JJ	O
therapy	NN	O
.	.	O

The	DT	O
average	JJ	O
hourly	JJ	O
incidence	NN	O
of	IN	O
ventricular	JJ	O
premature	NN	O
contractions	NNS	O
was	VBD	O
22	CD	O
with	IN	O
placebo	NN	O
and	CC	O
25	CD	O
with	IN	O
hydrochlorothiazide	NN	O
.	.	O

There	EX	O
were	VBD	O
3	CD	O
and	CC	O
1	CD	O
couplets	NNS	O
and	CC	O
0.2	CD	O
and	CC	O
0.2	CD	O
runs	NNS	O
of	IN	O
ventricular	JJ	O
tachycardia	NN	O
per	IN	O
patient	NN	O
per	IN	O
hour	NN	O
,	,	O
respectively	RB	O
.	.	O

Variables	NNS	O
of	IN	O
signal-averaged	JJ	O
electrocardiography	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
2	CD	O
treatments	NNS	O
.	.	O

Thus	RB	O
,	,	O
in	IN	O
hypertensive	JJ	O
African-American	JJ	O
men	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
hydrochlorothiazide	NN	O
does	VBZ	O
not	RB	O
worsen	VB	O
ventricular	JJ	O
arrhythmias	NNS	O
or	CC	O
signal-averaged	JJ	O
electrocardiographic	JJ	O
variables	NNS	O
.	.	O

Low	JJ	O
doses	NNS	O
of	IN	O
ketazolam	NN	O
in	IN	O
anxiety	NN	Condition
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

A	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
between-patient	JJ	O
trial	NN	O
comparing	VBG	O
two	CD	O
doses	NNS	O
of	IN	O
ketazolam	NN	O
(	(	O
15	CD	O
and	CC	O
30	CD	O
mg	NN	O
)	)	O
with	IN	O
placebo	NN	O
,	,	O
each	DT	O
given	VBN	O
once	RB	O
daily	JJ	O
,	,	O
in	IN	O
the	DT	O
evening	NN	O
,	,	O
to	TO	O
92	CD	SampleSize
outpatients	NNS	O
affected	VBN	O
by	IN	O
generalized	JJ	O
anxiety	NN	Condition
disorders	NNS	Condition
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
month	NN	O
,	,	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

After	IN	O
1-week	JJ	O
washout	NN	O
period	NN	O
47	CD	SampleSize
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
ketazolam	VB	O
15	CD	O
mg	NN	O
,	,	O
and	CC	O
45	CD	O
to	TO	O
placebo	VB	O
for	IN	O
15	CD	O
days	NNS	O
(	(	O
first	JJ	O
period	NN	O
)	)	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
this	DT	O
period	NN	O
,	,	O
if	IN	O
the	DT	O
patient	NN	O
experienced	VBD	O
a	DT	O
decrease	NN	O
on	IN	O
the	DT	O
total	JJ	O
Hamilton	NNP	O
Anxiety	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
HAM-A	NNP	O
)	)	O
of	IN	O
at	IN	O
least	JJS	O
25	CD	O
%	NN	O
of	IN	O
basal	NN	O
value	NN	O
,	,	O
the	DT	O
treatment	NN	O
was	VBD	O
kept	VBN	O
unchanged	JJ	O
for	IN	O
a	DT	O
further	JJ	O
15	CD	O
days	NNS	O
,	,	O
otherwise	RB	O
15	CD	O
mg	NN	O
of	IN	O
ketazolam	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
the	DT	O
previous	JJ	O
treatment	NN	O
(	(	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

Anxiety	NN	O
was	VBD	O
rated	VBN	O
after	IN	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
with	IN	O
the	DT	O
Italian	JJ	O
HAM-A	NNP	O
scale	NN	O
and	CC	O
with	IN	O
a	DT	O
4-point	JJ	O
scale	NN	O
(	(	O
patient	NN	O
's	POS	O
assessment	NN	O
)	)	O
.	.	O

Seventy-eight	JJ	SampleSize
patients	NNS	O
completed	VBD	O
the	DT	O
first	JJ	O
period	NN	O
and	CC	O
75	CD	SampleSize
the	DT	O
whole	NN	O
study	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
period	NN	O
the	DT	O
percentage	NN	O
of	IN	O
responders	NNS	O
was	VBD	O
almost	RB	O
identical	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
but	CC	O
during	IN	O
the	DT	O
second	JJ	O
period	NN	O
a	DT	O
further	JJ	O
slight	NN	O
improvement	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
early	JJ	O
placebo	NN	O
responders	NNS	O
,	,	O
while	IN	O
the	DT	O
HAM-A	NNP	O
score	NN	O
of	IN	O
patients	NNS	O
on	IN	O
ketazolam	NNS	O
continued	VBN	O
to	TO	O
improve	VB	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Likewise	VB	O
a	DT	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
difference	NN	O
between	IN	O
treatments	NNS	O
was	VBD	O
observed	VBN	O
,	,	O
on	IN	O
the	DT	O
4-point	JJ	O
scale	NN	O
,	,	O
in	IN	O
the	DT	O
population	NN	O
as	IN	O
a	DT	O
whole	NN	O
(	(	O
end	NN	O
of	IN	O
first	JJ	O
period	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
responder	NN	O
patients	NNS	O
(	(	O
end	JJ	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

Tolerability	NN	O
was	VBD	O
good	JJ	O
,	,	O
except	IN	O
in	IN	O
1	CD	O
patient	NN	O
on	IN	O
placebo	NN	O
,	,	O
who	WP	O
was	VBD	O
withdrawn	VBN	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
severe	JJ	O
headache	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
single-dose	JJ	O
versus	NN	O
conventional-dose	JJ	O
antibiotic	JJ	O
treatment	NN	O
of	IN	O
bacteriuria	NN	Condition
in	IN	Condition
elderly	JJ	Condition
women	NNS	Condition
.	.	Condition

The	DT	O
efficacy	NN	O
of	IN	O
single-dose	JJ	O
antibiotic	JJ	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bacteriuria	NN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
non-catheterized	JJ	O
elderly	JJ	O
women	NNS	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
conventional	JJ	O
7-10	JJ	O
day	NN	O
courses	NNS	O
of	IN	O
antibiotic	JJ	O
therapy	NN	O
.	.	O

Thirty-one	JJ	O
women	NNS	O
received	VBD	O
single-dose	JJ	O
treatment	NN	O
and	CC	O
22	CD	O
conventional-dose	JJ	O
treatment	NN	O
.	.	O

The	DT	O
cure	NN	O
rates	NNS	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
single-dose	JJ	O
treatments	NNS	O
were	VBD	O
52	CD	O
%	NN	O
and	CC	O
38	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
cure	NN	O
rates	NNS	O
for	IN	O
the	DT	O
conventional-dose	JJ	O
treatments	NNS	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
were	VBD	O
59	CD	O
%	NN	O
and	CC	O
52	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
place	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
single-dose	JJ	O
antibiotic	JJ	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
selected	VBN	O
elderly	JJ	O
women	NNS	O
with	IN	O
bacteriuria	NN	O
,	,	O
but	CC	O
larger	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

Immunotherapy	NNP	O
maintenance	NN	O
in	IN	O
acute	JJ	Condition
non-lymphocytic	JJ	Condition
leukaemia	NN	Condition
.	.	Condition

Between	NNP	O
January	NNP	O
1975	CD	O
and	CC	O
December	NNP	O
1977	CD	O
,	,	O
264	CD	O
adult	NN	O
patients	NNS	O
with	IN	O
acute	JJ	O
non-lymphocytic	JJ	O
leukaemia	NN	O
entered	VBD	O
the	DT	O
Australian	JJ	O
National	NNP	O
Leukaemia	NNP	O
Trial	NNP	O
.	.	O

Of	IN	O
251	CD	O
evaluable	JJ	O
patients	NNS	O
,	,	O
three	CD	O
induction	NN	O
regimens	VBZ	O
achieved	VBN	O
similar	JJ	O
complete	JJ	O
response	NN	O
(	(	O
CR	NNP	O
)	)	O
rates	NNS	O
.	.	O

CROP	NNP	O
(	(	O
cytosine	JJ	O
arabinoside	NN	O
,	,	O
daunorubicin	NN	O
,	,	O
vincristine	NN	O
,	,	O
prednisolone	NN	O
)	)	O
produced	VBD	O
CR	NNP	O
in	IN	O
41	CD	O
%	NN	O
of	IN	O
patients	NNS	O
,	,	O
7	CD	O
and	CC	O
3	CD	O
(	(	O
cytosine	NN	O
arabinoside	RB	O
,	,	O
daunorubicin	NN	O
)	)	O
in	IN	O
42	CD	O
%	NN	O
and	CC	O
7	CD	O
and	CC	O
3	CD	O
plus	CC	O
hydroxyurea	NN	O
in	IN	O
52	CD	O
%	NN	O
.	.	O

Remission	NNP	O
duration	NN	O
and	CC	O
survival	NN	O
were	VBD	O
similar	JJ	O
when	WRB	O
induction	NN	O
regimens	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

Forty-five	JJ	O
patients	NNS	O
reaching	VBG	O
maintenance	NN	O
therapy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
either	DT	O
chemo-immunotherapy	NN	O
(	(	O
BCG	NNP	O
plus	CC	O
intradermal	JJ	O
leukaemic	JJ	O
blast	NN	O
cells	NNS	O
)	)	O
or	CC	O
chemotherapy	VB	O
alone	RB	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
CR	NNP	O
in	IN	O
these	DT	O
two	CD	O
groups	NNS	O
was	VBD	O
almost	RB	O
identical	JJ	O
,	,	O
though	IN	O
patients	NNS	O
receiving	VBG	O
chemotherapy	NN	O
alone	RB	O
had	VBD	O
prolonged	VBN	O
survival	NN	O
(	(	O
median	JJ	O
161	CD	O
weeks	NNS	O
)	)	O
when	WRB	O
compared	VBN	O
to	TO	O
the	DT	O
chemo-immunotherapy	JJ	O
group	NN	O
(	(	O
84	CD	O
weeks	NNS	O
,	,	O
p	VBP	O
=	JJ	O
0	CD	O
.	.	O

07	CD	O
)	)	O
.	.	O

Institutions	NNS	O
with	IN	O
less	JJR	O
developed	JJ	O
supportive	NN	O
facilities	NNS	O
reported	VBD	O
lower	JJR	O
CR	NNP	O
rates	NNS	O
(	(	O
p	VB	O
=	RB	O
0	CD	O
.	.	O

04	CD	O
)	)	O
.	.	O

Leucocytosis	NNP	O
(	(	O
greater	JJR	O
than	IN	O
100	CD	O
X	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/1	NN	O
)	)	O
and	CC	O
older	JJR	O
age	NN	O
(	(	O
greater	JJR	O
than	IN	O
50	CD	O
years	NNS	O
)	)	O
were	VBD	O
associated	VBN	O
with	IN	O
shortened	JJ	O
survival	NN	O
.	.	O

The	DT	O
Trial	NNP	O
has	VBZ	O
failed	VBN	O
to	TO	O
show	VB	O
any	DT	O
advantage	NN	O
for	IN	O
this	DT	O
form	NN	O
of	IN	O
immunotherapy	NN	O
.	.	O

Folic	JJ	O
acid-based	JJ	O
intervention	NN	O
in	IN	O
non-ST	JJ	Condition
elevation	NN	Condition
acute	NN	Condition
coronary	JJ	Condition
syndromes	NNS	Condition
.	.	Condition

Homocysteinemia	NNP	O
is	VBZ	O
a	DT	O
risk	NN	O
factor	NN	O
for	IN	O
cardiovascular	JJ	O
diseases	NNS	O
.	.	O

Folic	NNP	O
acid	NN	O
combined	VBN	O
with	IN	O
vitamins	NNS	O
B	NNP	O
(	(	O
6	CD	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
12	CD	O
)	)	O
is	VBZ	O
effective	JJ	O
in	IN	O
lowering	VBG	O
homocysteine	NN	O
levels	NNS	O
.	.	O

This	DT	O
randomized	VBD	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
folic	JJ	O
acid-based	JJ	O
supplement	NN	O
on	IN	O
secondary	JJ	O
prevention	NN	O
of	IN	O
clinical	JJ	O
events	NNS	O
in	IN	O
non-ST-segment	JJ	O
elevation	NN	O
acute	NN	O
coronary	JJ	O
syndromes	NNS	O
.	.	O

The	DT	O
study	NN	O
comprised	VBD	O
240	CD	O
patients	NNS	O
with	IN	O
either	DT	O
unstable	JJ	O
angina	NN	O
or	CC	O
non-ST-elevation	JJ	O
myocardial	JJ	O
infarction	NN	O
in	IN	O
the	DT	O
previous	JJ	O
2	CD	O
weeks	NNS	O
who	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
folate	NN	O
group	NN	O
(	(	O
n	JJ	O
=116	NN	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
group	NN	O
(	(	O
n	JJ	O
=124	NN	O
)	)	O
.	.	O

The	DT	O
folate	NN	O
group	NN	O
received	VBD	O
1	CD	O
mg	NNS	O
folic	JJ	O
acid	RB	O
,	,	O
400	CD	O
microg	NN	O
vitamin	NN	O
B	NNP	O
(	(	O
12	CD	O
)	)	O
,	,	O
and	CC	O
10	CD	O
mg	NN	O
vitamin	NN	O
B	NNP	O
(	(	O
6	CD	O
)	)	O
daily	RB	O
.	.	O

Clinical	JJ	O
outcomes	NNS	O
within	IN	O
6	CD	O
months	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

The	DT	O
composite	JJ	O
endpoint	NN	O
of	IN	O
death	NN	O
,	,	O
nonfatal	JJ	O
acute	NN	O
coronary	JJ	O
syndrome	NN	O
,	,	O
and	CC	O
serious	JJ	O
re-hospitalization	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
folate	NN	O
group	NN	O
;	:	O
serious	JJ	O
re-hospitalization	NN	O
alone	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
this	DT	O
group	NN	O
.	.	O

Advanced	NNP	O
age	NN	O
and	CC	O
diabetes	NNS	O
increased	VBD	O
susceptibility	NN	O
to	TO	O
the	DT	O
composite	JJ	O
outcome	NN	O
.	.	O

Folic	JJ	O
acid-based	JJ	O
supplementation	NN	O
is	VBZ	O
not	RB	O
beneficial	JJ	O
and	CC	O
may	MD	O
even	RB	O
be	VB	O
harmful	JJ	O
in	IN	O
the	DT	O
secondary	JJ	O
prevention	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
unstable	JJ	O
angina	NNS	O
and	CC	O
non-ST-elevation	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
on	IN	O
the	DT	O
safety	NN	O
of	IN	O
such	JJ	O
supplements	NNS	O
are	VBP	O
suggested	VBN	O
.	.	O

Controlled	VBN	O
Clinical	JJ	O
Trials	NNS	O
Registry	NNP	O
no	DT	O
.	.	O

ISRCTN30249553	NNP	O
.	.	O

Effectiveness	NN	O
of	IN	O
once-daily	JJ	O
monotherapy	NN	O
with	IN	O
a	DT	O
new	JJ	O
nifedipine	NN	O
sustained	VBN	O
release	NN	O
calcium	NN	O
antagonist	NN	O
.	.	O

Data	NNS	O
from	IN	O
2	CD	Condition
separate	JJ	Condition
multicenter	NN	Condition
,	,	O
double-blind	JJ	O
clinical	JJ	O
studies	NNS	O
following	VBG	O
the	DT	O
same	JJ	O
protocol	NN	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
selection	NN	O
of	IN	O
doses	NNS	O
,	,	O
were	VBD	O
pooled	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
fixed	JJ	O
doses	NNS	O
of	IN	O
a	DT	O
new	JJ	O
sustained-release	NN	O
(	(	O
SR	NNP	O
)	)	O
formulation	NN	O
of	IN	O
nifedipine	JJ	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
388	CD	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
uncomplicated	JJ	O
essential	JJ	O
hypertension	NN	O
.	.	O

After	IN	O
a	DT	O
3-6	JJ	O
week	NN	O
placebo	NN	O
washout	IN	O
period	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
placebo	NN	O
or	CC	O
nifedipine	JJ	O
SR-20	JJ	O
mg	NN	O
(	(	O
study	NN	O
I	PRP	O
only	RB	O
)	)	O
,	,	O
50	CD	O
mg	NN	O
,	,	O
100	CD	O
mg	NN	O
,	,	O
or	CC	O
150	CD	O
mg	NN	O
(	(	O
study	VB	O
II	NNP	O
only	RB	O
)	)	O
.	.	O

Among	IN	O
the	DT	O
278	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
6	CD	O
weeks	NNS	O
of	IN	O
active	JJ	O
therapy	NN	O
,	,	O
mean	JJ	O
supine	VBP	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
reductions	NNS	O
from	IN	O
pretreatment	JJ	O
baseline	NN	O
were	VBD	O
5.9	CD	O
,	,	O
9.3	CD	O
,	,	O
9.2	CD	O
,	,	O
11.1	CD	O
,	,	O
and	CC	O
13.2	CD	O
mm	NN	O
Hg	NNP	O
in	IN	O
the	DT	O
placebo	NN	O
,	,	O
20-	JJ	O
,	,	O
50-	JJ	O
,	,	O
100-	JJ	O
,	,	O
and	CC	O
150-mg	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
reductions	NNS	O
achieved	VBN	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
nifedipine	JJ	O
SR	NNP	O
groups	NNS	O
were	VBD	O
statistically	RB	O
significant	JJ	O
versus	NN	O
baseline	NN	O
values	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

All	DT	O
nifedipine-SR	JJ	O
doses	NNS	O
reduced	VBN	O
supine	JJ	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
significantly	RB	O
more	RBR	O
than	IN	O
placebo	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
linear	JJ	O
relationship	NN	O
between	IN	O
the	DT	O
log	NN	O
of	IN	O
the	DT	O
dose	NN	O
and	CC	O
the	DT	O
blood	NN	O
pressure	NN	O
reduction	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Automated	VBN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
recordings	NNS	O
performed	VBN	O
in	IN	O
221	CD	O
of	IN	O
the	DT	O
patients	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
blood	NN	O
pressure	NN	O
was	VBD	O
lowered	VBN	O
evenly	RB	O
through	IN	O
the	DT	O
entire	JJ	O
24-hour	JJ	O
dosing	NN	O
period	NN	O
.	.	O

The	DT	O
doses	NNS	O
that	WDT	O
were	VBD	O
effective	JJ	O
and	CC	O
associated	VBN	O
with	IN	O
the	DT	O
fewest	JJS	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
20	CD	O
mg	NNS	O
and	CC	O
50	CD	O
mg	NN	O
once	RB	O
daily	RB	O
.	.	O

Oral	JJ	O
ganciclovir	NN	O
dosing	VBG	O
in	IN	O
transplant	NN	O
recipients	NNS	O
and	CC	O
dialysis	NN	O
patients	NNS	O
based	VBN	O
on	IN	O
renal	JJ	O
function	NN	O
.	.	O

BACKGROUND	NNP	O
An	DT	O
oral	JJ	O
formulation	NN	O
of	IN	O
ganciclovir	NN	O
(	(	O
GCV	NNP	O
)	)	O
was	VBD	O
recently	RB	O
approved	VBN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
cytomegalovirus	NN	O
disease	NN	O
in	IN	O
solid	JJ	O
organ	NN	O
transplant	JJ	O
recipients	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
GCV	NNP	O
and	CC	O
to	TO	O
test	VB	O
a	DT	O
dosing	NN	O
algorithm	NN	O
in	IN	O
transplant	NN	O
and	CC	O
dialysis	NN	O
patients	NNS	O
with	IN	O
different	JJ	O
levels	NNS	O
of	IN	O
renal	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
Pharmacokinetic	JJ	O
studies	NNS	O
were	VBD	O
carried	VBN	O
out	IN	O
in	IN	O
23	CD	SampleSize
patients	NNS	SampleSize
who	WP	O
were	VBD	O
either	CC	O
a	DT	O
recipient	NN	O
of	IN	O
an	DT	O
organ	JJ	O
transplant	NN	O
or	CC	O
on	IN	O
hemodialysis	NN	O
.	.	O

Drug	NNP	O
dosing	NN	O
was	VBD	O
established	VBN	O
by	IN	O
the	DT	O
following	VBG	O
algorithm	NN	O
based	VBN	O
on	IN	O
calculated	JJ	O
creatinine	NN	O
clearance	NN	O
(	(	O
CrCl	NNP	O
)	)	O
:	:	O
CrCl	NNP	O
=	NNP	O
[	NNP	O
(	(	O
140-age	JJ	O
)	)	O
x	FW	O
body	NN	O
weight	VBD	O
]	JJ	O
/	NNP	O
(	(	O
72	CD	O
x	NNP	O
Cr	NNP	O
)	)	O
x	VBZ	O
0.85	CD	O
for	IN	O
women	NNS	O
that	WDT	O
is	VBZ	O
,	,	O
CrCl	NNP	O
>	VBZ	O
50	CD	O
ml/min	NN	O
,	,	O
1000	CD	O
mg	NN	O
every	DT	O
8	CD	O
hr	NN	O
;	:	O
CrCl	NNP	O
of	IN	O
25-50	JJ	O
ml/min	NN	O
,	,	O
1000	CD	O
mg	NN	O
every	DT	O
24	CD	O
hr	NN	O
;	:	O
CrCl	NNP	O
of	IN	O
10-24	JJ	O
ml/	NN	O
min	NN	O
,	,	O
500	CD	O
mg	NN	O
every	DT	O
day	NN	O
;	:	O
CrCl	NNP	O
<	VBD	O
10	CD	O
ml/min	NN	O
(	(	O
or	CC	O
on	IN	O
dialysis	NN	O
)	)	O
,	,	O
500	CD	O
mg	NN	O
every	DT	O
other	JJ	O
day	NN	O
after	IN	O
dialysis	NN	O
.	.	O

GCV	NNP	O
was	VBD	O
taken	VBN	O
within	IN	O
30	CD	O
min	NNS	O
after	IN	O
a	DT	O
meal	NN	O
.	.	O

The	DT	O
patients	NNS	O
received	VBD	O
oral	JJ	O
GCV	NNP	O
for	IN	O
between	IN	O
12	CD	O
days	NNS	O
and	CC	O
14	CD	O
weeks	NNS	O
.	.	O

Serum	NNP	O
specimens	VBZ	O
(	(	O
or	CC	O
plasma	NN	O
from	IN	O
patients	NNS	O
on	IN	O
hemodialysis	NN	O
)	)	O
obtained	VBD	O
at	IN	O
steady	JJ	O
state	NN	O
were	VBD	O
analyzed	VBN	O
for	IN	O
GCV	NNP	O
concentrations	NNS	O
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
.	.	O

In	IN	O
nine	CD	O
of	IN	O
the	DT	O
transplant	NN	O
recipients	NNS	O
,	,	O
absolute	JJ	O
bioavailability	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
comparing	VBG	O
GCV	NNP	O
levels	NNS	O
after	IN	O
single	JJ	O
oral	JJ	O
and	CC	O
intravenous	JJ	O
doses	NNS	O
of	IN	O
GCV	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
following	JJ	O
GCV	NNP	O
concentrations	NNS	O
(	(	O
mean	JJ	O
+/-SD	NN	O
)	)	O
were	VBD	O
determined	VBN	O
:	:	O
with	IN	O
CrCl	NNP	O
of	IN	O
>	NNP	O
or	CC	O
=70	NNP	O
ml/min	NN	O
,	,	O
the	DT	O
minimum	JJ	O
steady-state	JJ	O
concentration	NN	O
(	(	O
Cmin	NNP	O
)	)	O
and	CC	O
maximum	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
were	VBD	O
0.78+/-0.46	JJ	O
microg/ml	NN	O
and	CC	O
1.42+/-0.37	JJ	O
microg/ml	NN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
a	DT	O
24-hr	JJ	O
area	NN	O
under	IN	O
the	DT	O
concentration	NN	O
time	NN	O
curve	NN	O
(	(	O
AUC0-24	NNP	O
)	)	O
of	IN	O
24.7+/-7.8	JJ	O
microg	NN	O
x	NNP	O
hr/ml	NN	O
;	:	O
with	IN	O
CrCl	NNP	O
of	IN	O
50-69	JJ	O
ml/min	NN	O
,	,	O
the	DT	O
Cmin	NNP	O
and	CC	O
Cmax	NNP	O
were	VBD	O
1.93+/-0.48	JJ	O
and	CC	O
2.57+/-0.39	JJ	O
microg/ml	NN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
an	DT	O
AUC0-24	NNP	O
of	IN	O
52.1+/-10.1	JJ	O
microg	NN	O
x	NNP	O
hr/ml	NN	O
;	:	O
with	IN	O
CrCl	NNP	O
of	IN	O
25-50	JJ	O
ml/min	NN	O
,	,	O
the	DT	O
Cmin	NNP	O
and	CC	O
Cmax	NNP	O
were	VBD	O
0.41+/-0.27	JJ	O
and	CC	O
1.17+/-0.32	JJ	O
microg/ml	NN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
an	DT	O
AUC0-24	NNP	O
of	IN	O
14.6+/-7.4	JJ	O
microg	NN	O
x	NNP	O
hr/ml	NN	O
.	.	O

For	IN	O
one	CD	O
patient	NN	O
with	IN	O
a	DT	O
CrCl	NNP	O
of	IN	O
23.8	CD	O
ml/min	NN	O
,	,	O
the	DT	O
Cmin	NNP	O
and	CC	O
Cmax	NNP	O
were	VBD	O
0.32	CD	O
and	CC	O
0.7	CD	O
microg/ml	NN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
an	DT	O
AUC0-24	NNP	O
of	IN	O
10.7	CD	O
microg	NNS	O
x	JJ	O
hr/ml	NN	O
.	.	O

With	IN	O
CrCl	NNP	O
of	IN	O
<	NNP	O
10	CD	O
ml/min	NN	O
,	,	O
the	DT	O
mean	JJ	O
Cmin	NNP	O
and	CC	O
Cmax	NNP	O
were	VBD	O
0.75+/-0.42	JJ	O
and	CC	O
1.59+/-0.55	JJ	O
microg/ml	NN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
AUC0-24	NNP	O
of	IN	O
64.6+/-18.8	JJ	O
microg	NN	O
x	NNP	O
hr/ml	NN	O
.	.	O

Absolute	NNP	O
bioavailability	NN	O
,	,	O
for	IN	O
the	DT	O
nine	CD	O
patients	NNS	O
so	RB	O
analyzed	JJ	O
,	,	O
was	VBD	O
7.2+/-2.4	JJ	O
%	NN	O
.	.	O

For	IN	O
those	DT	O
patients	NNS	O
with	IN	O
end-stage	JJ	Condition
renal	JJ	Condition
failure	NN	Condition
,	,	O
GCV	NNP	O
concentrations	NNS	O
fell	VBD	O
during	IN	O
dialysis	NN	O
from	IN	O
a	DT	O
mean	NN	O
of	IN	O
1.47+/-0.48	JJ	O
microg/ml	NN	O
before	IN	O
dialysis	NN	O
to	TO	O
0.69+/-0.38	JJ	O
microg/ml	NN	O
after	IN	O
dialysis	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
bioavailability	NN	O
of	IN	O
oral	JJ	O
GCV	NNP	O
in	IN	O
transplant	JJ	O
patients	NNS	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
observed	VBN	O
in	IN	O
human	JJ	Condition
immunodeficiency	NN	Condition
virus-infected	JJ	Condition
patients	NNS	O
.	.	O

However	RB	O
,	,	O
levels	NNS	O
between	IN	O
0.5	CD	O
and	CC	O
1	CD	O
microg/ml	NN	O
(	(	O
within	IN	O
the	DT	O
IC50	NNP	O
of	IN	O
most	JJS	O
cytomegalovirus	JJ	O
isolates	NNS	O
)	)	O
could	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
tolerable	JJ	O
oral	JJ	O
doses	NNS	O
.	.	O

The	DT	O
proposed	VBN	O
dosing	NN	O
algorithm	NN	O
resulted	VBD	O
in	IN	O
adequate	JJ	O
levels	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
CrCl	NNP	O
greater	JJR	O
than	IN	O
50	CD	O
ml/min	NNS	O
and	CC	O
for	IN	O
patients	NNS	O
on	IN	O
dialysis	NN	O
.	.	O

For	IN	O
patients	NNS	O
with	IN	O
CrCl	NNP	O
between	IN	O
10	CD	O
and	CC	O
50	CD	O
ml/min	NN	O
,	,	O
the	DT	O
levels	NNS	O
achieved	VBN	O
were	VBD	O
low	JJ	O
and	CC	O
these	DT	O
patients	NNS	O
would	MD	O
likely	RB	O
benefit	VB	O
from	IN	O
increased	JJ	O
doses	NNS	O
.	.	O

New	NNP	O
hope	NN	O
for	IN	O
children	NNS	Age
with	IN	O
Kawasaki	NNP	Condition
disease	NN	O
.	.	O

Kawasaki	NNP	O
disease	NN	O
is	VBZ	O
now	RB	O
the	DT	O
most	RBS	O
common	JJ	O
cause	NN	O
of	IN	O
acquired	VBN	O
heart	NN	Condition
disease	NN	O
in	IN	O
America	NNP	O
's	POS	O
children	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
an	DT	O
acute	JJ	O
febrile	NN	O
illness	NN	O
that	WDT	O
may	MD	O
cause	VB	O
coronary	JJ	O
artery	NN	O
aneurysm	NN	O
formation	NN	O
in	IN	O
infected	JJ	O
children	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
intravenous	JJ	O
administration	NN	O
of	IN	O
gamma	JJ	O
globulin	NN	O
(	(	O
IVGG	NNP	O
)	)	O
plus	CC	O
aspirin	JJ	O
versus	NN	O
aspirin	NN	O
alone	RB	O
upon	IN	O
coronary	JJ	O
aneurysm	NN	O
formation	NN	O
show	VBP	O
a	DT	O
decrease	NN	O
in	IN	O
coronary	JJ	O
aneurysm	NN	O
formation	NN	O
from	IN	O
the	DT	O
usual	JJ	O
20	CD	O
%	NN	O
-30	NN	O
%	NN	O
to	TO	O
3	CD	O
%	NN	O
.	.	O

Administration	NNP	O
of	IN	O
IVGG	NNP	O
presents	VBZ	O
some	DT	O
unique	JJ	O
challenges	NNS	O
for	IN	O
nurses	NNS	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
pediatric	JJ	O
nurse	NN	O
must	MD	O
educate	VB	O
parents	NNS	O
and	CC	O
children	NNS	O
about	IN	O
this	DT	O
disease	NN	O
to	TO	O
prepare	VB	O
them	PRP	O
for	IN	O
discharge	NN	O
and	CC	O
long-term	JJ	O
follow-up	JJ	O
care	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
a	DT	O
psychological	JJ	O
intervention	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
non-metastatic	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
psychological	JJ	O
intervention	NN	O
had	VBD	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
behaviour	NN	O
of	IN	O
women	NNS	Sex
diagnosed	VBN	O
with	IN	O
breast	NN	Condition
cancer	NN	Condition
.	.	O

36	CD	SampleSize
consecutive	JJ	O
patients	NNS	O
with	IN	O
non-metastatic	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
assigned	VBD	O
to	TO	O
surgery	VB	O
and	CC	O
systemic	VB	O
chemotherapy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
psychological	JJ	O
intervention	NN	O
(	(	O
weekly	JJ	O
cognitive	VBP	O
individual	JJ	O
psychotherapy	NN	O
and	CC	O
bimonthly	JJ	O
family	NN	O
counselling	VBG	O
)	)	O
or	CC	O
standard	JJ	O
follow-up	NN	O
.	.	O

Personality	NNP	O
(	(	O
16-PF	JJ	O
and	CC	O
IIQ	NNP	O
)	)	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
FLIC	NNP	O
)	)	O
,	,	O
and	CC	O
depression	NN	O
(	(	O
BDI	NNP	O
)	)	O
scores	NNS	O
were	VBD	O
the	DT	O
endpoints	NNS	O
for	IN	O
this	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
at	IN	O
diagnosis	NN	O
,	,	O
and	CC	O
up	RB	O
to	TO	O
9	CD	O
months	NNS	O
after	IN	O
diagnosis	NN	O
.	.	O

Cognitive	JJ	O
psychotherapy	NN	O
and	CC	O
family	NN	O
counselling	NN	O
improved	VBD	O
both	DT	O
depression	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
indexes	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Better	NNP	O
emotional	JJ	O
coping	NN	O
behaviours	NNS	O
were	VBD	O
also	RB	O
revealed	VBN	O
by	IN	O
some	DT	O
changes	NNS	O
in	IN	O
personality	NN	O
traits	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

Individual	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
short	JJ	O
theory	NN	O
of	IN	O
mind	NN	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Having	VBG	O
a	DT	O
'theory	NN	O
of	IN	O
mind	NN	O
'	''	O
,	,	O
or	CC	O
having	VBG	O
the	DT	O
ability	NN	O
to	TO	O
attribute	VB	O
mental	JJ	O
states	NNS	O
to	TO	O
oneself	VB	O
or	CC	O
others	NNS	O
,	,	O
is	VBZ	O
considered	VBN	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
central	JJ	O
domains	NNS	O
of	IN	O
impairment	NN	O
among	IN	O
children	NNS	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Many	JJ	O
interventions	NNS	O
focus	VBP	O
on	IN	O
improving	VBG	O
theory	NN	O
of	IN	O
mind	NN	O
skills	NNS	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Nonetheless	NNP	O
,	,	O
the	DT	O
empirical	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
effect	NN	O
of	IN	O
these	DT	O
interventions	NNS	O
is	VBZ	O
limited	JJ	O
.	.	O

The	DT	O
main	JJ	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
examine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
short	JJ	O
theory	NN	O
of	IN	O
mind	NN	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

A	DT	O
second	JJ	O
objective	NN	O
is	VBZ	O
to	TO	O
determine	VB	O
which	WDT	O
subgroups	NNS	O
within	IN	O
the	DT	O
autism	NN	O
spectrum	JJ	O
profit	NN	O
most	JJS	O
from	IN	O
the	DT	O
intervention	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
is	VBZ	O
a	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

One	CD	O
hundred	VBD	O
children	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
aged	VBD	O
7	CD	O
to	TO	O
12	CD	O
years	NNS	O
will	MD	O
be	VB	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
or	CC	O
a	DT	O
waiting	JJ	O
list	NN	O
control	NN	O
group	NN	O
.	.	O

Outcome	NNP	O
measures	VBZ	O
include	VBP	O
the	DT	O
completion	NN	O
of	IN	O
theory	NN	O
of	IN	O
mind	NN	O
and	CC	O
emotion	NN	O
understanding	NN	O
tasks	NNS	O
,	,	O
and	CC	O
parent	NN	O
and	CC	O
teacher	NN	O
questionnaires	NNS	O
on	IN	O
children	NNS	O
's	POS	O
social	JJ	O
skills	NNS	O
.	.	O

Follow-up	NNP	O
data	NN	O
for	IN	O
the	DT	O
intervention	NN	O
group	NN	O
will	MD	O
be	VB	O
collected	VBN	O
6	CD	O
months	NNS	O
after	IN	O
the	DT	O
interventions	NNS	O
.	.	O

DISCUSSION	NNP	O
This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
theory	NN	O
of	IN	O
mind	NN	O
intervention	NN	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Hypotheses	NNP	O
,	,	O
strengths	NNS	O
,	,	O
and	CC	O
limitations	NNS	O
of	IN	O
the	DT	O
study	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Netherlands	NNP	O
Trial	NNP	O
Register	NNP	O
NTR2327	NNP	O
.	.	O

Controlled	VBN	O
study	NN	O
on	IN	O
the	DT	O
therapeutic	JJ	O
efficacy	NN	O
of	IN	O
propionyl-L-carnitine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
congestive	JJ	Condition
heart	NN	Condition
failure	NN	Condition
.	.	O

A	DT	O
double-blind	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
of	IN	O
propionyl-L-carnitine	NN	O
(	(	O
CAS	NNP	O
17298-37-2	CD	O
)	)	O
versus	NN	O
placebo	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
a	DT	O
group	NN	O
of	IN	O
60	CD	SampleSize
patients	NNS	O
with	IN	O
mild	JJ	Condition
to	TO	O
moderate	VB	Condition
(	(	Condition
II	NNP	Condition
and	CC	Condition
III	NNP	Condition
NYHA	NNP	Condition
class	NN	Condition
)	)	Condition
congestive	JJ	Condition
heart	NN	Condition
failure	NN	Condition
.	.	O

The	DT	O
group	NN	O
was	VBD	O
made	VBN	O
up	IN	O
of	IN	O
men	NNS	Sex
and	CC	O
women	NNS	Sex
aged	VBD	O
between	IN	Age
48	CD	Age
and	CC	Age
73	CD	Age
years	NNS	Age
in	IN	O
chronic	JJ	Condition
treatment	NN	Condition
with	IN	O
digitalis	NN	O
and	CC	O
diuretics	NNS	O
for	IN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
and	CC	O
who	WP	O
still	RB	O
displayed	VBD	O
symptoms	NNS	O
.	.	O

Thirty	NN	O
of	IN	O
these	DT	O
patients	NNS	O
were	VBD	O
chosen	VBN	O
randomly	RB	O
and	CC	O
for	IN	O
180	CD	O
days	NNS	O
,	,	O
500	CD	O
mg	NN	O
of	IN	O
propionyl-L-carnitine	NN	O
was	VBD	O
orally	RB	O
administered	VBN	O
,	,	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
in	IN	O
addition	NN	O
to	TO	O
their	PRP$	O
usual	JJ	O
treatment	NN	O
.	.	O

At	IN	O
basal	JJ	O
conditions	NNS	O
and	CC	O
after	IN	O
30	CD	O
,	,	O
90	CD	O
and	CC	O
180	CD	O
days	NNS	O
the	DT	O
maximum	JJ	O
exercise	NN	O
time	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
an	DT	O
exercise	NN	O
tolerance	NN	O
test	NN	O
performed	VBD	O
on	IN	O
an	DT	O
ergometer	NN	O
bicycle	NN	O
and	CC	O
the	DT	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
was	VBD	O
tested	VBN	O
by	IN	O
means	NNS	O
of	IN	O
bidimensional	JJ	O
echocardiography	NN	O
.	.	O

After	IN	O
one	CD	O
month	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
propionyl-L-carnitine	NN	O
,	,	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
showed	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
the	DT	O
values	NNS	O
of	IN	O
both	DT	O
tests	NNS	O
,	,	O
increases	NNS	O
which	WDT	O
became	VBD	O
even	RB	O
more	RBR	O
evident	JJ	O
after	IN	O
90	CD	O
and	CC	O
180	CD	O
days	NNS	O
.	.	O

At	IN	O
the	DT	O
stated	VBN	O
times	NNS	O
the	DT	O
increases	NNS	O
in	IN	O
the	DT	O
maximum	JJ	O
exercise	NN	O
time	NN	O
were	VBD	O
16.4	CD	O
%	NN	O
,	,	O
22.9	CD	O
%	NN	O
,	,	O
and	CC	O
25.9	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
increased	VBN	O
by	IN	O
8.4	CD	O
%	NN	O
,	,	O
11.6	CD	O
%	NN	O
and	CC	O
13.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

On	IN	O
the	DT	O
basis	NN	O
of	IN	O
these	DT	O
results	NNS	O
,	,	O
having	VBG	O
studied	VBN	O
the	DT	O
particular	JJ	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
propionyl-L-carnitine	NN	O
the	DT	O
authors	NNS	O
conclude	VBP	O
that	IN	O
it	PRP	O
represents	VBZ	O
a	DT	O
drug	NN	O
of	IN	O
undoubted	JJ	O
therapeutic	JJ	O
interest	NN	O
in	IN	O
patients	NNS	O
with	IN	O
congestive	JJ	Condition
heart	NN	Condition
failure	NN	Condition
,	,	O
in	IN	O
whom	WP	O
it	PRP	O
could	MD	O
be	VB	O
efficaciously	RB	O
administered	VBN	O
along	IN	O
with	IN	O
a	DT	O
standard	JJ	O
pharmacological	JJ	O
therapy	NN	O
.	.	O

Protection	NN	O
of	IN	O
man	NN	O
from	IN	O
natural	JJ	O
infection	NN	O
with	IN	O
influenza	JJ	O
A2	NNP	O
Hong	NNP	O
Kong	NNP	O
virus	NN	O
by	IN	O
amantadine	NN	O
:	:	O
a	DT	O
controlled	JJ	O
field	NN	O
trial	NN	O
.	.	O

Prophylactic	JJ	O
administration	NN	O
of	IN	O
amantadine	NN	O
in	IN	O
doses	NNS	O
of	IN	O
100	CD	O
mg.	NN	O
twice	RB	O
a	DT	O
day	NN	O
offered	VBN	O
statistically	RB	O
significant	JJ	O
protection	NN	O
against	IN	O
influenza	JJ	O
A2	NNP	O
infection	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
field	NN	O
trial	NN	O
involving	VBG	O
391	CD	SampleSize
medical	JJ	Condition
student	NN	Condition
volunteers	NNS	Condition
during	IN	O
the	DT	O
influenza	JJ	O
A2	NNP	O
Hong	NNP	O
Kong	NNP	O
epidemic	VBP	O
in	IN	O
Helsinki	NNP	O
in	IN	O
the	DT	O
winter	NN	O
of	IN	O
1969	CD	O
.	.	O

Serologically	RB	O
verified	JJ	O
influenza	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
complement	JJ	O
fixation	NN	O
and/or	NN	O
haemagglutination	NN	O
inhibition	NN	O
,	,	O
occurred	VBD	O
in	IN	O
27	CD	O
out	IN	O
of	IN	O
192	CD	SampleSize
students	NNS	SampleSize
in	IN	SampleSize
the	DT	SampleSize
amantadine	NN	SampleSize
group	NN	SampleSize
against	IN	O
57	CD	O
out	IN	O
of	IN	O
199	CD	SampleSize
in	IN	SampleSize
the	DT	SampleSize
placebo	NN	SampleSize
group	NN	SampleSize
,	,	O
giving	VBG	O
a	DT	O
protection	NN	O
rate	NN	O
of	IN	O
52	CD	O
%	NN	O
.	.	O

Influence	NN	O
of	IN	O
diets	NNS	O
rich	JJ	O
in	IN	O
Maillard	NNP	O
reaction	NN	O
products	NNS	O
on	IN	O
calcium	NN	O
bioavailability	NN	O
.	.	O

Assays	NNS	O
in	IN	O
male	JJ	Sex
adolescents	NNS	Age
and	CC	O
in	IN	O
Caco-2	NNP	O
cells	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
the	DT	O
high	JJ	O
intake	NN	O
of	IN	O
Maillard	NNP	O
reaction	NN	O
products	NNS	O
(	(	O
MRP	NNP	O
)	)	O
on	IN	O
calcium	NN	O
availability	NN	O
in	IN	O
adolescents	NNS	O
and	CC	O
across	IN	O
Caco-2	NNP	O
cell	NN	O
monolayers	NNS	O
were	VBD	O
examined	VBN	O
.	.	O

In	IN	O
a	DT	O
2	CD	O
week	NN	O
randomized	VBN	O
two-period	JJ	O
crossover	NN	O
trial	NN	O
,	,	O
18	CD	SampleSize
male	NN	Sex
adolescents	NNS	Age
consumed	VBD	O
two	CD	O
diets	NNS	O
,	,	O
named	VBN	O
white	JJ	O
diet	NN	O
(	(	O
WD	NNP	O
)	)	O
and	CC	O
brown	JJ	O
diet	NN	O
(	(	O
BD	NNP	O
)	)	O
,	,	O
which	WDT	O
were	VBD	O
poor	JJ	O
and	CC	O
rich	JJ	O
in	IN	O
MRP	NNP	O
,	,	O
respectively	RB	O
.	.	O

A	DT	O
3	CD	O
day	NN	O
balance	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
period	NN	O
,	,	O
and	CC	O
fasting	VBG	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
.	.	O

Calcium	NNP	O
solubility	NN	O
and	CC	O
absorption	NN	O
across	IN	O
Caco-2	NNP	O
cells	NNS	O
were	VBD	O
studied	VBN	O
after	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
digestion	NN	O
of	IN	O
the	DT	O
diets	NNS	O
.	.	O

The	DT	O
in	IN	O
vitro	NN	O
assay	NN	O
showed	VBD	O
similar	JJ	O
solubility	NN	O
after	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
digestion	NN	O
and	CC	O
similar	JJ	O
transport	NN	O
across	IN	O
Caco-2	NNP	O
cells	NNS	O
.	.	O

In	IN	O
accordance	NN	O
,	,	O
calcium	NN	O
bioavailability	NN	O
in	IN	O
adolescents	NNS	O
did	VBD	O
not	RB	O
vary	JJ	O
between	IN	O
the	DT	O
diets	NNS	O
(	(	O
%	NN	O
WD	NNP	O
=	VBZ	O
40.4	CD	O
+/-	JJ	O
5.1	CD	O
,	,	O
%	NN	O
BD	NNP	O
=	VBZ	O
38.2	CD	O
+/-	JJ	O
3.6	CD	O
)	)	O
.	.	O

Serum	NNP	O
and	CC	O
urine	JJ	O
biochemical	JJ	O
parameters	NNS	O
related	VBN	O
to	TO	O
calcium	NN	O
status	NN	O
and	CC	O
bone	NN	O
metabolism	NN	O
remained	VBD	O
unaltered	JJ	O
.	.	O

Only	RB	O
deoxypyridinoline	JJ	O
values	NNS	O
were	VBD	O
significantly	RB	O
lower	JJR	O
after	IN	O
consumption	NN	O
of	IN	O
the	DT	O
BD	NNP	O
(	(	O
13.0	CD	O
+/-	JJ	O
1.1	CD	O
compared	VBN	O
to	TO	O
18.3	CD	O
+/-	JJ	O
2.1	CD	O
nM/Mm	JJ	O
Cr	NNP	O
in	IN	O
the	DT	O
WD	NNP	O
)	)	O
,	,	O
possibly	RB	O
indicative	JJ	O
of	IN	O
less	RBR	O
efficient	JJ	O
bone	NN	O
turnover	NN	O
during	IN	O
this	DT	O
period	NN	O
.	.	O

As	IN	O
calcium	NN	O
acquired	VBD	O
during	IN	O
adolescence	NN	O
is	VBZ	O
essential	JJ	O
to	TO	O
maximize	VB	O
peak	JJ	O
bone	NN	O
mass	NN	O
and	CC	O
to	TO	O
prevent	VB	O
osteoporosis	NN	O
,	,	O
possible	JJ	O
long-term	JJ	O
effects	NNS	O
of	IN	O
excessive	JJ	O
MRP	NNP	O
intake	NN	O
during	IN	O
this	DT	O
period	NN	O
warrant	JJ	O
attention	NN	O
.	.	O

Training	VBG	O
referential	JJ	O
communicative	JJ	O
skills	NNS	O
to	TO	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
reports	VBZ	O
the	DT	O
effects	NNS	O
of	IN	O
referential	JJ	O
communication	NN	O
training	NN	O
in	IN	O
individuals	NNS	O
formally	RB	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
20	CD	O
children	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
M	NNP	O
age	NN	O
=	VBD	O
14.3	CD	O
yr.	NN	O
,	,	O
SD	NNP	O
=	NNP	O
4.2	CD	O
;	:	O
6	CD	O
girls	NNS	O
,	,	O
14	CD	O
boys	NNS	O
)	)	O
in	IN	O
the	DT	O
role	NN	O
of	IN	O
speakers	NNS	O
and	CC	O
20	CD	O
control	NN	O
children	NNS	O
,	,	O
who	WP	O
acted	VBD	O
as	IN	O
listeners	NNS	O
.	.	O

They	PRP	O
were	VBD	O
all	DT	O
enrolled	VBN	O
in	IN	O
mainstream	JJ	O
compulsory	NN	O
education	NN	O
.	.	O

Inclusion/exclusion	NNP	O
criteria	NNS	O
were	VBD	O
defined	VBN	O
according	VBG	O
to	TO	O
the	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
ASD	NNP	O
,	,	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
additional	JJ	O
or	CC	O
associated	JJ	O
disability	NN	O
,	,	O
previous	JJ	O
training	NN	O
in	IN	O
referential	JJ	O
communication	NN	O
,	,	O
and	CC	O
any	DT	O
drug	NN	O
treatment	NN	O
.	.	O

Speakers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
(	(	O
trained	JJ	O
vs	NN	O
untrained	VBD	O
)	)	O
.	.	O

Linguistic	JJ	O
age	NN	O
,	,	O
cognitive	JJ	O
level	NN	O
and	CC	O
autistic	JJ	O
symptoms	NNS	O
were	VBD	O
analyzed	VBN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
the	DT	O
Peabody	NNP	O
Picture	NNP	O
Vocabulary	NNP	O
Test	NNP	O
(	(	O
PPVT	NNP	O
)	)	O
,	,	O
the	DT	O
Wechsler	NNP	O
Intelligence	NNP	O
Scale	NNP	O
(	(	O
WISC-R	NNP	O
or	CC	O
WAIS-III	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
Autistic	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
.	.	O

Communicative	JJ	O
abilities	NNS	O
were	VBD	O
analyzed	VBN	O
through	IN	O
two	CD	O
indexes	NNS	O
related	VBN	O
to	TO	O
message	VB	O
complexity	NN	O
and	CC	O
self-regulation	NN	O
.	.	O

The	DT	O
trained	JJ	O
group	NN	O
was	VBD	O
trained	VBN	O
in	IN	O
referential	JJ	O
communication	NN	O
tasks	NNS	O
(	(	O
task	NN	O
analysis	NN	O
,	,	O
role	NN	O
taking	NN	O
,	,	O
and	CC	O
task	JJ	O
evaluation	NN	O
)	)	O
,	,	O
while	IN	O
the	DT	O
untrained	JJ	O
group	NN	O
took	VBD	O
part	NN	O
in	IN	O
a	DT	O
communicative	JJ	O
game	NN	O
but	CC	O
without	IN	O
any	DT	O
specific	JJ	O
communicative	JJ	O
training	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
complexity	NN	O
of	IN	O
emitted	JJ	O
messages	NNS	O
had	VBD	O
improved	VBN	O
statistically	RB	O
significantly	RB	O
in	IN	O
the	DT	O
trained	JJ	O
group	NN	O
as	IN	O
an	DT	O
effect	NN	O
of	IN	O
training	NN	O
.	.	O

Ecological	JJ	O
referential	JJ	O
communication	NN	O
is	VBZ	O
shown	VBN	O
to	TO	O
be	VB	O
an	DT	O
appropriate	JJ	O
paradigm	NN	O
for	IN	O
studying	VBG	O
the	DT	O
communicative	JJ	O
process	NN	O
and	CC	O
its	PRP$	O
products	NNS	O
and	CC	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
develop	VB	O
and	CC	O
implement	VB	O
a	DT	O
training	NN	O
program	NN	O
focused	VBN	O
on	IN	O
those	DT	O
skills	NNS	O
in	IN	O
which	WDT	O
individuals	NNS	O
with	IN	O
ASD	NNP	O
are	VBP	O
most	RBS	O
deficient	JJ	O
.	.	O

Pregabalin	NNP	O
versus	NN	O
naltrexone	NN	O
in	IN	O
alcohol	NN	Condition
dependence	NN	Condition
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
comparison	JJ	O
trial	NN	O
.	.	O

Pregabalin	NNP	O
(	(	O
PRE	NNP	O
)	)	O
acts	VBZ	O
as	IN	O
a	DT	O
presynaptic	JJ	O
inhibitor	NN	O
of	IN	O
the	DT	O
release	NN	O
of	IN	O
excessive	JJ	O
levels	NNS	O
of	IN	O
excitatory	NN	O
neurotransmitters	NNS	O
by	IN	O
selectively	RB	O
binding	VBG	O
to	TO	O
the	DT	O
alpha	NN	O
(	(	O
2	CD	O
)	)	O
-delta	NN	O
subunit	NN	O
of	IN	O
voltage-gated	JJ	O
calcium	NN	O
channels	NNS	O
.	.	O

In	IN	O
this	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
comparison	NN	O
trial	NN	O
with	IN	O
naltrexone	NN	O
(	(	O
NAL	NNP	O
)	)	O
,	,	O
we	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
PRE	NNP	O
on	IN	O
alcohol	NN	O
drinking	NN	O
indices	NNS	O
.	.	O

Craving	VBG	O
reduction	NN	O
and	CC	O
improvement	NN	O
of	IN	O
psychiatric	JJ	O
symptoms	NNS	O
were	VBD	O
the	DT	O
secondary	JJ	O
endpoints	NNS	O
.	.	O

Seventy-one	CD	Condition
alcohol-dependent	JJ	O
subjects	NNS	O
were	VBD	O
detoxified	VBN	O
and	CC	O
subsequently	RB	O
randomised	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
receiving	VBG	O
50	CD	O
mg	NN	O
of	IN	O
NAL	NNP	O
or	CC	O
150-450	JJ	O
mg	NN	O
of	IN	O
PRE	NNP	O
.	.	O

Craving	NNP	O
(	(	O
VAS	NNP	O
;	:	O
OCDS	NNP	O
)	)	O
,	,	O
withdrawal	NN	O
(	(	O
CIWA-Ar	NNP	O
)	)	O
and	CC	O
psychiatric	JJ	O
symptoms	NNS	O
(	(	O
SCL-90-R	NNP	O
)	)	O
rating	NN	O
scales	NNS	O
were	VBD	O
applied	VBN	O
.	.	O

Alcohol	NNP	O
drinking	NN	O
indices	NNS	O
and	CC	O
craving	VBG	O
scores	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
NAL	NNP	O
,	,	O
PRE	NNP	O
resulted	VBD	O
in	IN	O
greater	JJR	O
improvement	NN	O
of	IN	O
specific	JJ	O
symptoms	NNS	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
anxiety	NN	O
,	,	O
hostility	NN	O
and	CC	O
psychoticism	NN	O
,	,	O
and	CC	O
survival	JJ	O
function	NN	O
(	(	O
duration	NN	O
of	IN	O
abstinence	NN	O
from	IN	O
alcohol	NN	O
)	)	O
.	.	O

PRE	NNP	O
also	RB	O
resulted	VBD	O
in	IN	O
better	RBR	O
outcome	NN	O
in	IN	O
patients	NNS	O
reporting	VBG	O
a	DT	O
comorbid	NN	Condition
psychiatric	JJ	Condition
disorder	NN	Condition
.	.	O

Results	NNS	O
from	IN	O
this	DT	O
study	NN	O
globally	RB	O
place	VBP	O
PRE	NNP	O
within	IN	O
the	DT	O
same	JJ	O
range	NN	O
of	IN	O
efficacy	NN	O
as	IN	O
that	DT	O
of	IN	O
NAL	NNP	O
.	.	O

The	DT	O
mechanism	NN	O
involved	VBN	O
in	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
PRE	NNP	O
in	IN	O
relapse	NN	O
prevention	NN	O
could	MD	O
be	VB	O
less	RBR	O
related	JJ	O
to	TO	O
alcohol	VB	O
craving	NN	O
and	CC	O
more	RBR	O
associated	JJ	O
with	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
comorbid	NN	O
psychiatric	JJ	O
symptomatology	NN	O
.	.	O

[	JJ	O
Evaluation	NNP	O
of	IN	O
Stepping	NNP	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
:	:	O
Interims	NNP	O
analysis	NN	O
of	IN	O
the	DT	O
Stepping-Stones-SPC-Multicentric	NNP	O
Study	NNP	O
]	NNP	O
.	.	O

Stepping	VBG	O
Stones	JJ	O
Triple	NNP	O
P	NNP	O
is	VBZ	O
a	DT	O
behavioural	JJ	O
parenting	NN	O
training	NN	O
for	IN	O
families	NNS	O
with	IN	O
a	DT	O
handicapped	JJ	Condition
child	NN	Age
,	,	O
which	WDT	O
has	VBZ	O
already	RB	O
been	VBN	O
successfully	RB	O
evaluated	VBN	O
in	IN	O
its	PRP$	O
country	NN	O
of	IN	O
origin	NN	O
,	,	O
Australia	NNP	O
.	.	O

Within	IN	O
a	DT	O
multicentric	JJ	O
study	NN	O
of	IN	O
several	JJ	O
Social	NNP	O
Pediatric	NNP	O
Centers	NNP	O
(	(	O
SPCs	NNP	O
)	)	O
and	CC	O
further	JJ	O
clinics/institutions	NNS	O
in	IN	O
Germany	NNP	O
,	,	O
it	PRP	O
has	VBZ	O
been	VBN	O
established	VBN	O
as	IN	O
a	DT	O
group	NN	O
parenting	VBG	O
training	NN	O
(	(	O
3-7	JJ	O
families	NNS	O
per	IN	O
training	NN	O
)	)	O
.	.	O

Statistical	JJ	O
analysis	NN	O
proved	VBD	O
significant	JJ	O
effects	NNS	O
concerning	VBG	O
dysfunctional	JJ	O
parenting	NN	O
,	,	O
parental	JJ	O
stress	NN	O
and	CC	O
child	VB	O
behaviour	NN	O
problems	NNS	O
as	RB	O
well	RB	O
as	IN	O
little	JJ	O
side	NN	O
effects	NNS	O
and	CC	O
a	DT	O
positive	JJ	O
acceptance	NN	O
of	IN	O
stepping	VBG	O
stones	NNS	O
by	IN	O
the	DT	O
families	NNS	O
.	.	O

Prophylactic	JJ	O
use	NN	O
of	IN	O
amifostine	NN	O
to	TO	O
prevent	VB	O
radiochemotherapy-induced	JJ	O
mucositis	NN	O
and	CC	O
xerostomia	NN	O
in	IN	O
head-and-neck	JJ	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
prophylactic	JJ	O
properties	NNS	O
of	IN	O
amifostine	NN	O
against	IN	O
acute	JJ	O
and	CC	O
late	JJ	O
toxicities	NNS	O
from	IN	O
radiochemotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
head-and-neck	JJ	O
cancer	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
Fifty	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
conventional	JJ	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
(	(	O
2-Gy	JJ	O
fractions	NNS	O
,	,	O
5	CD	O
days	NNS	O
weekly	RB	O
,	,	O
to	TO	O
a	DT	O
total	NN	O
of	IN	O
60-74	JJ	O
Gy	NNP	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
tumor	NN	O
localization	NN	O
and	CC	O
TNM	NNP	O
classification	NN	O
)	)	O
and	CC	O
carboplatin	NN	O
(	(	O
90	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
infusion	NN	O
once	RB	O
per	IN	O
week	NN	O
before	IN	O
RT	NNP	O
)	)	O
.	.	O

Amifostine	NNP	O
(	(	O
300	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
was	VBD	O
administered	VBN	O
in	IN	O
the	DT	O
study	NN	O
group	NN	O
only	RB	O
15-30	JJ	O
min	NN	O
before	IN	O
RT	NNP	O
for	IN	O
6-7.5	JJ	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
study	NN	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
grading	NN	O
of	IN	O
acute	NN	O
and	CC	O
late	JJ	O
nonhematologic	NN	O
toxicities	NNS	O
(	(	O
mucositis	NN	O
,	,	O
dysphagia	NN	O
,	,	O
xerostomia	NN	O
)	)	O
induced	VBN	O
by	IN	O
radiochemotherapy	NN	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
treatment	NN	O
duration	NN	O
,	,	O
hematologic	JJ	O
toxicity	NN	O
,	,	O
and	CC	O
clinical	JJ	O
outcome	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
treatment	NN	O
duration	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
amifostine-treated	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.013	CD	O
)	)	O
,	,	O
because	IN	O
treatment	NN	O
interruptions	NNS	O
were	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Acute	NNP	O
toxicities	NNS	O
(	(	O
mucositis	NN	O
and	CC	O
dysphagia	NN	O
)	)	O
were	VBD	O
less	JJR	O
severe	JJ	O
in	IN	O
the	DT	O
amifostine-treated	JJ	O
group	NN	O
.	.	O

By	IN	O
Week	JJ	O
3	CD	O
,	,	O
all	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
experienced	VBD	O
Grade	NNP	O
2	CD	O
mucositis	NN	O
compared	VBN	O
with	IN	O
only	RB	O
9	CD	O
%	NN	O
in	IN	O
the	DT	O
amifostine-treated	JJ	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

By	IN	O
Week	JJ	O
5	CD	O
,	,	O
52.2	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
experienced	VBD	O
Grade	NNP	O
4	CD	O
mucositis	NN	O
compared	VBN	O
with	IN	O
4.5	CD	O
%	NN	O
in	IN	O
the	DT	O
amifostine-treated	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0006	CD	O
)	)	O
.	.	O

Similar	JJ	O
results	NNS	O
were	VBD	O
obtained	VBN	O
for	IN	O
dysphagia	NN	O
.	.	O

At	IN	O
3	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
only	RB	O
27	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
study	NN	O
group	NN	O
experienced	VBD	O
Grade	NNP	O
2	CD	O
xerostomia	NN	O
compared	VBN	O
with	IN	O
73.9	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Eighteen	JJ	O
months	NNS	O
after	IN	O
cessation	NN	O
of	IN	O
therapy	NN	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
Grade	NNP	O
2	CD	O
xerostomia	NN	O
was	VBD	O
4.5	CD	O
%	NN	O
vs.	FW	O
30.4	CD	O
%	NN	O
for	IN	O
each	DT	O
respective	JJ	O
treatment	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.047	CD	O
)	)	O
.	.	O

Cytoprotection	NN	O
with	IN	O
amifostine	NN	O
did	VBD	O
not	RB	O
affect	VB	O
treatment	NN	O
outcome	NN	O
,	,	O
with	IN	O
90.9	CD	O
%	NN	O
complete	JJ	O
responses	NNS	O
in	IN	O
the	DT	O
amifostine-treated	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
78.3	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.414	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Amifostine	NNP	O
was	VBD	O
effective	JJ	O
in	IN	O
reducing	VBG	O
mucositis	NN	O
and	CC	O
dysphagia	NN	O
resulting	VBG	O
from	IN	O
radiochemotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
head-and-neck	JJ	O
cancer	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
amifostine	NN	O
reduced	VBD	O
the	DT	O
severity	NN	O
of	IN	O
late	JJ	O
xerostomia	NN	O
,	,	O
a	DT	O
side	NN	O
effect	NN	O
of	IN	O
RT	NNP	O
with	IN	O
long-lasting	JJ	O
consequences	NNS	O
.	.	O

Amifostine	NNP	O
treatment	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
clinical	JJ	O
outcome	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
a	DT	O
stage-of-change	NN	O
oriented	VBN	O
smoking	VBG	O
cessation	NN	O
intervention	NN	O
in	IN	O
infertile	NN	Condition
and	CC	O
pregnant	JJ	Condition
women	NNS	Sex
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
a	DT	O
stage-of-change	NN	O
oriented	VBN	O
smoking	VBG	O
cessation	NN	O
intervention	NN	O
for	IN	O
infertile	NN	O
and	CC	O
pregnant	JJ	O
women	NNS	O
,	,	O
compared	VBN	O
with	IN	O
standard	NN	O
of	IN	O
care	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NNP	O
Three	CD	O
university	NN	O
teaching	VBG	O
hospitals	NNS	O
in	IN	O
Hamilton	NNP	O
,	,	O
Ontario	NNP	O
,	,	O
Canada	NNP	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
Infertile	NNP	O
women	NNS	O
at	IN	O
their	PRP$	O
first	JJ	O
visit	NN	O
to	TO	O
a	DT	O
tertiary	JJ	O
referral	JJ	O
infertility	NN	O
clinic	NN	O
(	(	O
n	JJ	O
=	NNP	O
94	CD	SampleSize
)	)	O
and	CC	O
new	JJ	O
patients	NNS	O
seeking	VBG	O
pre-natal	JJ	O
care	NN	O
(	(	O
n	JJ	O
=	NNP	O
110	CD	SampleSize
)	)	O
who	WP	O
had	VBD	O
smoked	VBN	O
>	NNP	O
/=	$	O
3	CD	O
cigarettes	NNS	O
in	IN	O
the	DT	O
past	JJ	O
six	CD	O
months	NNS	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
three	CD	O
to	TO	O
five	CD	O
minute	NN	O
scripted	VBN	O
intervention	NN	O
and	CC	O
booklet	NN	O
specific	NN	O
to	TO	O
the	DT	O
woman	NN	O
's	POS	O
stage-of-change	NN	O
in	IN	O
the	DT	O
smoking	NN	O
continuum	NN	O
,	,	O
versus	JJ	O
standard	NN	O
of	IN	O
care	NN	O
.	.	O

Exhaled	VBN	O
carbon-monoxide	NN	O
(	(	O
CO	NNP	O
)	)	O
monitoring	NN	O
was	VBD	O
used	VBN	O
to	TO	O
validate	VB	O
exposure	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Delta	NNP	O
stage-of-change	NN	O
and	CC	O
rate	NN	O
of	IN	O
maintained	VBN	O
cessation	NN	O
at	IN	O
12	CD	O
months	NNS	O
post	VBN	O
follow-up	JJ	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
Intervention	NNP	O
and	CC	O
control	NN	O
were	VBD	O
similarly	RB	O
effective	JJ	O
for	IN	O
infertile	JJ	O
women	NNS	O
:	:	O
the	DT	O
rate	NN	O
of	IN	O
maintained	VBN	O
cessation	NN	O
rose	VBD	O
significantly	RB	O
from	IN	O
4	CD	O
%	NN	O
to	TO	O
24	CD	O
%	NN	O
over	IN	O
twelve	JJ	O
months	NNS	O
,	,	O
with	IN	O
a	DT	O
mean	JJ	O
delta	NN	O
stage-of-change	NN	O
0.28	CD	O
.	.	O

In	IN	O
prenatal	JJ	O
women	NNS	O
,	,	O
neither	CC	O
approach	NN	O
was	VBD	O
effective	JJ	O
.	.	O

Maintained	VBN	O
cessation	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
from	IN	O
0	CD	O
to	TO	O
12	CD	O
months	NNS	O
(	(	O
19	CD	O
%	NN	O
to	TO	O
18	CD	O
%	NN	O
)	)	O
.	.	O

Mean	JJ	O
delta	JJ	O
stage-of-change	NN	O
declined	VBN	O
by	IN	O
-0.62	NNP	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
For	IN	O
infertile	JJ	O
women	NNS	O
,	,	O
basic	JJ	O
information	NN	O
describing	VBG	O
the	DT	O
impact	NN	O
of	IN	O
smoking	VBG	O
on	IN	O
fertility	NN	O
,	,	O
along	IN	O
with	IN	O
exhaled	JJ	O
CO	NNP	O
monitoring	NN	O
and	CC	O
a	DT	O
more	RBR	O
intensive	JJ	O
intervention	NN	O
were	VBD	O
both	DT	O
highly	RB	O
effective	JJ	O
.	.	O

In	IN	O
pregnant	JJ	O
women	NNS	O
neither	CC	O
approach	NN	O
was	VBD	O
beneficial	JJ	O
,	,	O
with	IN	O
some	DT	O
evidence	NN	O
of	IN	O
post-partum	JJ	O
relapse	NN	O
.	.	O

Cardiovascular	JJ	O
and	CC	O
behavioral	JJ	O
effects	NNS	O
of	IN	O
aerobic	JJ	O
exercise	NN	O
training	NN	O
in	IN	O
healthy	JJ	O
older	JJR	Age
men	NNS	Sex
and	CC	Sex
women	NNS	Sex
.	.	O

The	DT	O
cardiovascular	JJ	O
and	CC	O
behavioral	JJ	O
adaptations	NNS	O
associated	VBN	O
with	IN	O
a	DT	O
4-month	JJ	O
program	NN	O
of	IN	O
aerobic	JJ	O
exercise	NN	O
training	NN	O
were	VBD	O
examined	VBN	O
in	IN	O
101	CD	SampleSize
older	JJR	Age
men	NNS	O
and	CC	O
women	NNS	O
(	(	O
mean	JJ	O
age	NN	O
=	VBD	O
67	CD	O
years	NNS	O
)	)	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
Aerobic	NNP	O
Exercise	NNP	O
group	NN	O
,	,	O
a	DT	O
Yoga	NNP	O
and	CC	O
Flexibility	NNP	O
control	NN	O
group	NN	O
,	,	O
or	CC	O
a	DT	O
Waiting	JJ	O
List	NNP	O
control	NN	O
group	NN	O
.	.	O

Prior	NNP	O
to	TO	O
and	CC	O
following	VBG	O
the	DT	O
4-month	JJ	O
program	NN	O
,	,	O
subjects	VBZ	O
underwent	JJ	O
comprehensive	JJ	O
physiological	NN	O
and	CC	O
psychological	JJ	O
evaluations	NNS	O
.	.	O

Physiological	JJ	O
measures	NNS	O
included	VBD	O
measurement	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
,	,	O
lipids	NNS	O
,	,	O
bone	NN	O
density	NN	O
,	,	O
and	CC	O
cardiorespiratory	JJ	O
fitness	NN	O
including	VBG	O
direct	JJ	O
measurements	NNS	O
of	IN	O
peak	NN	O
oxygen	NN	O
consumption	NN	O
(	(	O
VO2	NNP	O
)	)	O
and	CC	O
anaerobic	JJ	O
threshold	NN	O
.	.	O

Psychological	JJ	O
measures	NNS	O
included	VBD	O
measures	NNS	O
of	IN	O
mood	NN	O
,	,	O
psychiatric	JJ	O
symptoms	NNS	O
,	,	O
and	CC	O
neuropsychological	JJ	O
functioning	NN	O
.	.	O

This	DT	O
study	NN	O
demonstrated	VBD	O
that	IN	O
4	CD	O
months	NNS	O
of	IN	O
aerobic	JJ	O
exercise	NN	O
training	NN	O
produced	VBD	O
an	DT	O
overall	JJ	O
11.6	CD	O
%	NN	O
improvement	NN	O
in	IN	O
peak	NN	O
VO2	NNP	O
and	CC	O
a	DT	O
13	CD	O
%	NN	O
increase	NN	O
in	IN	O
anaerobic	JJ	O
threshold	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
Yoga	NNP	O
and	CC	O
Waiting	NNP	O
List	NNP	O
control	NN	O
groups	NNS	O
experienced	VBD	O
no	DT	O
change	NN	O
in	IN	O
cardiorespiratory	NN	O
fitness	NN	O
.	.	O

Other	JJ	O
favorable	JJ	O
physiological	JJ	O
changes	NNS	O
observed	VBN	O
among	IN	O
aerobic	JJ	O
exercise	NN	O
participants	NNS	O
included	VBD	O
lower	JJR	O
cholesterol	NN	O
levels	NNS	O
,	,	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
levels	NNS	O
,	,	O
and	CC	O
for	IN	O
subjects	NNS	O
at	IN	O
risk	NN	O
for	IN	O
bone	NN	O
fracture	NN	O
,	,	O
a	DT	O
trend	NN	O
toward	IN	O
an	DT	O
increase	NN	O
in	IN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
.	.	O

Although	IN	O
few	JJ	O
significant	JJ	O
psychological	JJ	O
changes	NNS	O
could	MD	O
be	VB	O
attributed	VBN	O
to	TO	O
aerobic	VB	O
exercise	NN	O
training	NN	O
,	,	O
participants	NNS	O
in	IN	O
the	DT	O
two	CD	O
active	JJ	O
treatment	NN	O
groups	NNS	O
perceived	VBD	O
themselves	PRP	O
as	IN	O
improving	VBG	O
on	IN	O
a	DT	O
number	NN	O
of	IN	O
psychological	JJ	O
and	CC	O
behavioral	JJ	O
dimensions	NNS	O
.	.	O

Efficacy	NN	O
of	IN	O
bepotastine	NN	O
besilate	NN	O
ophthalmic	JJ	O
solution	NN	O
1.5	CD	O
%	NN	O
for	IN	O
seasonal	JJ	Condition
allergic	JJ	Condition
conjunctivitis	NN	Condition
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
natural	JJ	O
exposure	NN	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

Allergic	NNP	O
conjunctivitis	NN	O
(	(	O
AC	NNP	O
)	)	O
affects	VBZ	O
an	DT	O
estimated	JJ	O
20	CD	O
%	NN	O
of	IN	O
the	DT	O
population	NN	O
in	IN	O
the	DT	O
Western	JJ	O
world	NN	O
,	,	O
with	IN	O
a	DT	O
large	JJ	O
fraction	NN	O
suffering	VBG	O
due	JJ	O
to	TO	O
seasonal	JJ	O
or	CC	O
perennial	JJ	O
allergen	NN	O
exposures	NNS	O
.	.	O

Bepotastine	NNP	O
besilate	NN	O
ophthalmic	JJ	O
solution	NN	O
(	(	O
BBOS	NNP	O
)	)	O
1.5	CD	O
%	NN	O
,	,	O
a	DT	O
dual-acting	JJ	O
histamine	NN	O
(	(	O
H	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
receptor	NN	O
antagonist	NN	O
and	CC	O
mast	NN	O
cell	NN	O
stabilizer	NN	O
,	,	O
is	VBZ	O
indicated	VBN	O
for	IN	O
itching	VBG	O
associated	VBN	O
with	IN	O
AC	NNP	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
for	IN	O
reducing	VBG	O
ocular	JJ	Condition
itching	NN	Condition
associated	VBN	O
with	IN	O
AC	NNP	Condition
in	IN	O
subjects	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
natural	JJ	O
exposure	NN	O
trial	NN	O
.	.	O

Eligible	JJ	O
subjects	NNS	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
double-masked	JJ	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
natural	JJ	O
exposure	NN	O
clinical	JJ	O
trial	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
or	CC	O
placebo	NN	O
eyedrops	NNS	O
on	IN	O
a	DT	O
1:1	CD	O
basis	NN	O
and	CC	O
instilled	VBD	O
1	CD	O
drop	NN	O
of	IN	O
the	DT	O
test	NN	O
agent	NN	O
into	IN	O
both	DT	O
eyes	NNS	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
ocular	JJ	O
itching	NN	O
scores	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
were	VBD	O
evaluated	VBN	O
based	VBN	O
on	IN	O
subject-assessed	JJ	O
severity	NN	O
of	IN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
itching	NN	O
.	.	O

Subject-reported	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
also	RB	O
recorded	VBN	O
for	IN	O
safety	NN	O
.	.	O

Treatment	NN	O
with	IN	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
significantly	RB	O
reduced	VBN	O
instantaneous	JJ	O
and	CC	O
reflective	JJ	O
ocular	JJ	O
itching	NN	O
scores	NNS	O
from	IN	O
baseline	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
over	IN	O
the	DT	O
2-week	JJ	O
study	NN	O
period	NN	O
(	(	O
p	JJ	O
=	NN	O
0.007	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.005	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

BBOS	$	O
1.5	CD	O
%	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
AEs	NNP	O
were	VBD	O
generally	RB	O
transient	JJ	O
and	CC	O
mild	JJ	O
.	.	O

This	DT	O
clinical	JJ	O
study	NN	O
indicates	VBZ	O
BBOS	NNP	O
1.5	CD	O
%	NN	O
effectively	RB	O
and	CC	O
safely	RB	O
treated	VBD	O
ocular	JJ	O
itching	NN	O
in	IN	O
a	DT	O
natural	JJ	O
exposure	NN	O
allergy	NN	O
study	NN	O
and	CC	O
is	VBZ	O
a	DT	O
useful	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
ocular	JJ	O
itching	NN	O
associated	VBN	O
with	IN	O
AC	NNP	O
.	.	O

(	(	O
ClinicalTrials.gov	NNP	O
identifier	VBZ	O
number	NN	O
:	:	O
NCT01174823	NNP	O
.	.	O

)	)	O
The	DT	O
gluten-free	JJ	O
,	,	O
casein-free	JJ	O
diet	NN	O
in	IN	O
autism	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
preliminary	JJ	O
double	NN	O
blind	VB	O
clinical	JJ	O
trial	NN	O
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
gluten-free	JJ	O
and	CC	O
casein-free	JJ	O
(	(	O
GFCF	NNP	O
)	)	O
diet	NN	O
in	IN	O
treating	VBG	O
autism	NN	O
using	VBG	O
a	DT	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
repeated	VBD	O
measures	NNS	O
crossover	RB	O
design	NN	O
.	.	O

The	DT	O
sample	NN	O
included	VBD	O
15	CD	O
children	NNS	O
aged	VBN	O
2-16	CD	O
years	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Data	NNP	O
on	IN	O
autistic	JJ	O
symptoms	NNS	O
and	CC	O
urinary	JJ	O
peptide	NN	O
levels	NNS	O
were	VBD	O
collected	VBN	O
in	IN	O
the	DT	O
subjects	NNS	O
'	POS	O
homes	NNS	O
over	IN	O
the	DT	O
12	CD	O
weeks	NNS	O
that	IN	O
they	PRP	O
were	VBD	O
on	IN	O
the	DT	O
diet	JJ	O
.	.	O

Group	NNP	O
data	VBD	O
indicated	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
findings	NNS	O
even	RB	O
though	IN	O
several	JJ	O
parents	NNS	O
reported	VBD	O
improvement	NN	O
in	IN	O
their	PRP$	O
children	NNS	O
.	.	O

Although	IN	O
preliminary	JJ	O
,	,	O
this	DT	O
study	NN	O
demonstrates	VBZ	O
how	WRB	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
the	DT	O
GFCF	NNP	O
diet	NN	O
can	MD	O
be	VB	O
conducted	VBN	O
,	,	O
and	CC	O
suggests	VBZ	O
directions	NNS	O
for	IN	O
future	JJ	O
research	NN	O
.	.	O

Improving	VBG	O
maternal	JJ	O
mental	JJ	Condition
health	NN	Condition
after	IN	O
a	DT	O
child	NN	Condition
's	POS	Condition
diagnosis	NN	Condition
of	IN	Condition
autism	NN	Condition
spectrum	JJ	Condition
disorder	NN	Condition
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

IMPORTANCE	VBZ	O
The	DT	O
prevalence	NN	O
of	IN	O
psychological	JJ	O
distress	NN	O
among	IN	O
mothers	NNS	Condition
of	IN	O
children	NNS	Condition
with	IN	Condition
autism	NN	Condition
spectrum	NN	Condition
disorder	NN	Condition
(	(	Condition
ASD	NNP	Condition
)	)	Condition
suggests	VBZ	O
a	DT	O
need	NN	O
for	IN	O
interventions	NNS	O
that	WDT	O
address	VBP	O
parental	JJ	O
mental	JJ	O
health	NN	O
during	IN	O
the	DT	O
critical	JJ	O
period	NN	O
after	IN	O
the	DT	O
child	NN	O
's	POS	O
autism	NN	O
diagnosis	NN	O
when	WRB	O
parents	NNS	O
are	VBP	O
learning	VBG	O
to	TO	O
navigate	VB	O
the	DT	O
complex	JJ	O
system	NN	O
of	IN	O
autism	NN	O
services	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
whether	IN	O
a	DT	O
brief	JJ	O
cognitive	JJ	O
behavioral	JJ	O
intervention	NN	O
,	,	O
problem-solving	JJ	O
education	NN	O
(	(	O
PSE	NNP	O
)	)	O
,	,	O
decreases	VBZ	O
parenting	VBG	O
stress	NN	O
and	CC	O
maternal	JJ	O
depressive	NN	O
symptoms	NNS	O
during	IN	O
the	DT	O
period	NN	O
immediately	RB	O
following	VBG	O
a	DT	O
child	NN	O
's	POS	O
diagnosis	NN	O
of	IN	O
ASD	NNP	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
A	NNP	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
compared	VBN	O
6	CD	O
sessions	NNS	O
of	IN	O
PSE	NNP	O
with	IN	O
usual	JJ	O
care	NN	O
.	.	O

Settings	NNP	O
included	VBD	O
an	DT	O
autism	NN	O
clinic	NN	O
and	CC	O
6	CD	O
community-based	JJ	O
early	JJ	O
intervention	NN	O
programs	NNS	O
that	WDT	O
primarily	RB	O
serve	VBP	O
low-income	JJ	O
families	NNS	O
.	.	O

Participants	NNS	O
were	VBD	O
mothers	NNS	Sex
of	IN	O
122	CD	SampleSize
young	JJ	O
children	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
34	CD	O
months	NNS	O
)	)	O
who	WP	O
recently	RB	O
received	VBD	O
a	DT	O
diagnosis	NN	Condition
of	IN	Condition
ASD	NNP	Condition
.	.	O

Among	IN	O
mothers	NNS	O
assessed	VBN	O
for	IN	O
eligibility	NN	O
,	,	O
17.0	CD	O
%	NN	O
declined	VBD	O
participation	NN	O
.	.	O

We	PRP	O
report	VBP	O
outcomes	NNS	O
after	IN	O
3	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
(	(	O
immediate	JJ	O
postdiagnosis	NN	O
period	NN	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
Problem-solving	JJ	O
education	NN	O
is	VBZ	O
a	DT	O
brief	JJ	O
,	,	O
cognitive	JJ	O
intervention	NN	O
delivered	VBN	O
in	IN	O
six	CD	O
30-minute	JJ	O
individualized	VBN	O
sessions	NNS	O
by	IN	O
existing	VBG	O
staff	NN	O
(	(	O
early	JJ	O
intervention	NN	O
programs	NNS	O
)	)	O
or	CC	O
research	NN	O
staff	NN	O
without	IN	O
formal	JJ	O
mental	JJ	O
health	NN	O
training	NN	O
(	(	O
autism	NN	O
clinic	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
AND	NNP	O
MEASURES	NNP	O
Primary	NNP	O
outcomes	NNS	O
were	VBD	O
parental	JJ	O
stress	NN	O
and	CC	O
maternal	JJ	O
depressive	NN	O
symptoms	NNS	O
.	.	O

RESULTS	NNP	O
Fifty-nine	JJ	SampleSize
mothers	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
PSE	NNP	O
and	CC	O
63	CD	O
to	TO	O
receive	VB	O
usual	JJ	O
care	NN	O
.	.	O

The	DT	O
follow-up	JJ	O
rate	NN	O
was	VBD	O
91.0	CD	O
%	NN	O
.	.	O

Most	JJS	O
intervention	NN	O
mothers	NNS	O
(	(	O
78.0	CD	O
%	NN	O
)	)	O
received	VBD	O
the	DT	O
full	JJ	O
PSE	NNP	O
course	NN	O
.	.	O

At	IN	O
the	DT	O
3-month	JJ	O
follow-up	JJ	O
assessment	NN	O
,	,	O
PSE	NNP	O
mothers	NNS	O
were	VBD	O
significantly	RB	O
less	RBR	O
likely	JJ	O
than	IN	O
those	DT	O
serving	VBG	O
as	RB	O
controls	NNS	O
to	TO	O
have	VB	O
clinically	RB	O
significant	JJ	O
parental	JJ	O
stress	NN	O
(	(	O
3.8	CD	O
%	NN	O
vs	JJ	O
29.3	CD	O
%	NN	O
;	:	O
adjusted	VBN	O
relative	JJ	O
risk	NN	O
[	NNP	O
aRR	NN	O
]	NNP	O
,	,	O
0.17	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.04	CD	O
to	TO	O
0.65	CD	O
)	)	O
.	.	O

For	IN	O
depressive	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
risk	NN	O
reduction	NN	O
in	IN	O
clinically	RB	O
significant	JJ	O
symptoms	NNS	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
(	(	O
5.7	CD	O
%	NN	O
vs	JJ	O
22.4	CD	O
%	NN	O
;	:	O
aRR	CC	O
,	,	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.10	CD	O
to	TO	O
1.08	CD	O
)	)	O
;	:	O
however	RB	O
,	,	O
the	DT	O
reduction	NN	O
in	IN	O
mean	JJ	O
depressive	NN	O
symptoms	NNS	O
was	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
Quick	NNP	O
Inventory	NNP	O
of	IN	O
Depressive	NNP	O
Symptomatology	NNP	O
score	NN	O
,	,	O
4.6	CD	O
with	IN	O
PSE	NNP	O
vs	FW	O
6.9	CD	O
with	IN	O
usual	JJ	O
care	NN	O
;	:	O
adjusted	VBN	O
mean	NN	O
difference	NN	O
,	,	O
-1.67	NNP	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-3.17	NNP	O
to	TO	O
-0.18	VB	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
AND	CC	O
RELEVANCE	NNP	O
The	DT	O
positive	JJ	O
effects	NNS	O
of	IN	O
PSE	NNP	O
in	IN	O
reducing	VBG	O
parenting	VBG	O
stress	NN	O
and	CC	O
depressive	JJ	O
symptoms	NNS	O
during	IN	O
the	DT	O
critical	JJ	O
postdiagnosis	NN	O
period	NN	O
,	,	O
when	WRB	O
parents	NNS	O
are	VBP	O
asked	VBN	O
to	TO	O
navigate	VB	O
a	DT	O
complex	JJ	O
service	NN	O
delivery	NN	O
system	NN	O
,	,	O
suggest	VBP	O
that	IN	O
it	PRP	O
may	MD	O
have	VB	O
a	DT	O
place	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

Further	NNP	O
work	NN	O
will	MD	O
monitor	VB	O
these	DT	O
families	NNS	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
9	CD	O
months	NNS	O
to	TO	O
determine	VB	O
the	DT	O
trajectory	NN	O
of	IN	O
outcomes	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT01021384	NN	O
.	.	O

Local	JJ	O
delivery	NN	O
of	IN	O
a	DT	O
recombinant	NN	O
adenoassociated	VBN	O
vector	NN	O
containing	VBG	O
a	DT	O
tumour	JJ	O
necrosis	NN	O
factor	NN	O
alpha	IN	O
antagonist	JJ	O
gene	NN	O
in	IN	O
inflammatory	JJ	O
arthritis	NN	O
:	:	O
a	DT	O
phase	NN	O
1	CD	O
dose-escalation	NN	O
safety	NN	O
and	CC	O
tolerability	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
,	,	O
an	DT	O
adenoassociated	JJ	O
virus	NN	O
serotype	NN	O
2	CD	O
vector	NN	O
containing	VBG	O
the	DT	O
cDNA	NN	O
for	IN	O
the	DT	O
human	JJ	O
tumour	JJ	O
necrosis	NN	O
factor-immunoglobulin	JJ	O
Fc	NNP	O
fusion	NN	O
gene	NN	O
(	(	O
tgAAC94	NN	O
)	)	O
,	,	O
in	IN	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
phase	JJ	O
1	CD	O
,	,	O
dose-escalation	NN	O
study	NN	O
,	,	O
15	CD	Condition
subjects	NNS	Condition
with	IN	Condition
inflammatory	JJ	Condition
arthritis	NN	Condition
(	(	Condition
14	CD	Condition
with	IN	Condition
rheumatoid	JJ	Condition
arthritis	NN	Condition
and	CC	Condition
1	CD	Condition
with	IN	Condition
ankylosing	VBG	Condition
spondylitis	NN	Condition
)	)	Condition
not	RB	Condition
receiving	VBG	Condition
tumour	JJ	Condition
necrosis	NN	Condition
factor	NN	Condition
alpha	NN	Condition
(	(	Condition
TNFalpha	NNP	Condition
)	)	Condition
inhibitors	NNS	Condition
with	IN	Condition
persistent	JJ	Condition
moderate	NN	Condition
(	(	Condition
grade	JJ	Condition
2	CD	Condition
)	)	Condition
or	CC	Condition
severe	JJ	Condition
(	(	Condition
grade	JJ	Condition
3	CD	Condition
)	)	Condition
swelling	NN	Condition
in	IN	Condition
a	DT	Condition
target	NN	Condition
joint	NN	Condition
due	JJ	Condition
to	TO	Condition
inflammatory	JJ	Condition
arthritis	NN	Condition
received	VBD	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
at	IN	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
10	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
or	CC	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
11	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
DNase	NNP	O
resistant	JJ	O
particles	NNS	O
per	IN	O
ml	NN	O
joint	NN	O
volume	NN	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
into	IN	O
a	DT	O
knee	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
or	CC	O
ankle	NN	O
(	(	O
n	JJ	O
=	NNP	O
1	CD	O
)	)	O
.	.	O

Safety	NN	O
was	VBD	O
assessed	VBN	O
through	IN	O
adverse	JJ	O
event	NN	O
monitoring	NN	O
.	.	O

As	IN	O
a	DT	O
secondary	JJ	O
objective	NN	O
,	,	O
changes	NNS	O
in	IN	O
injected	JJ	O
joint	NN	O
tenderness	NN	O
and	CC	O
swelling	VBG	O
scores	NNS	O
,	,	O
each	DT	O
measured	VBN	O
on	IN	O
a	DT	O
four-point	JJ	O
scale	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Intra-articular	JJ	O
injections	NNS	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
no	DT	O
major	JJ	O
safety	NN	O
issues	NNS	O
.	.	O

One	CD	O
event	NN	O
,	,	O
mild	JJ	O
knee	NN	O
pruritus	NN	O
,	,	O
was	VBD	O
considered	VBN	O
probably	RB	O
related	VBN	O
.	.	O

Synovial	JJ	O
fluid	NN	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
protein	NN	O
was	VBD	O
not	RB	O
detected	VBN	O
(	(	O
nor	CC	O
expected	VBN	O
)	)	O
at	IN	O
the	DT	O
doses	NNS	O
used	VBN	O
.	.	O

At	IN	O
12	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
,	,	O
a	DT	O
two-point	JJ	O
decrease	NN	O
in	IN	O
swelling	VBG	O
was	VBD	O
noted	VBN	O
in	IN	O
2/11	CD	O
and	CC	O
2/4	CD	O
subjects	NNS	O
injected	VBN	O
with	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
and	CC	O
placebo	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intra-articular	JJ	O
rAAV2-TNFR	NN	O
:	:	O
Fc	CD	O
appears	VBZ	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
subjects	NNS	O
without	IN	O
concurrent	JJ	O
systemic	JJ	O
TNFalpha	NNP	O
antagonist	NN	O
use	NN	O
.	.	O

It	PRP	O
is	VBZ	O
thus	RB	O
feasible	JJ	O
to	TO	O
proceed	VB	O
with	IN	O
larger	JJR	O
trials	NNS	O
to	TO	O
further	JJ	O
test	NN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
local	JJ	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
gene	NN	O
transfer	NN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
modality	NN	O
for	IN	O
patients	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

The	DT	O
Social	NNP	O
Communication	NNP	O
Assessment	NNP	O
for	IN	O
Toddlers	NNP	O
with	IN	O
Autism	NNP	O
(	(	O
SCATA	NNP	O
)	)	O
:	:	O
an	DT	O
instrument	NN	O
to	TO	O
measure	VB	O
the	DT	O
frequency	NN	O
,	,	O
form	NN	O
and	CC	O
function	NN	O
of	IN	O
communication	NN	O
in	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

The	DT	O
Social	NNP	O
Communication	NNP	O
Assessment	NNP	O
for	IN	O
Toddlers	NNP	O
with	IN	O
Autism	NNP	O
(	(	O
SCATA	NNP	O
)	)	O
was	VBD	O
designed	VBN	O
to	TO	O
measure	VB	O
non-verbal	JJ	O
communication	NN	O
,	,	O
including	VBG	O
early	JJ	O
and	CC	O
atypical	JJ	O
communication	NN	O
,	,	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Each	DT	O
communicative	JJ	O
act	NN	O
is	VBZ	O
scored	VBN	O
according	VBG	O
to	TO	O
its	PRP$	O
form	NN	O
,	,	O
function	NN	O
,	,	O
role	NN	O
and	CC	O
complexity	NN	O
.	.	O

The	DT	O
SCATA	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
communicative	JJ	O
ability	NN	O
longitudinally	RB	O
in	IN	O
two	CD	O
samples	NNS	O
of	IN	O
toddlers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Overall	JJ	O
frequency	NN	O
of	IN	O
non-verbal	JJ	O
communicative	JJ	O
acts	NNS	O
did	VBD	O
not	RB	O
change	NN	O
between	IN	O
the	DT	O
two	CD	O
assessments	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
form	NN	O
and	CC	O
complexity	NN	O
,	,	O
the	DT	O
function	NN	O
and	CC	O
the	DT	O
role	NN	O
the	DT	O
child	NN	O
took	VBD	O
in	IN	O
the	DT	O
interaction	NN	O
did	VBD	O
change	VB	O
with	IN	O
time	NN	O
.	.	O

Both	DT	O
frequency	NN	O
and	CC	O
function	NN	O
of	IN	O
communicative	JJ	O
acts	NNS	O
in	IN	O
toddlerhood	NN	O
were	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
later	JJ	O
language	NN	O
ability	NN	O
:	:	O
social	JJ	O
acts	NNS	O
,	,	O
comments	NNS	O
and	CC	O
initiations	NNS	O
showed	VBD	O
greater	JJR	O
predictive	JJ	O
association	NN	O
than	IN	O
requests	NNS	O
and	CC	O
responses	NNS	O
.	.	O

Perispinal	JJ	O
analgesia	NN	O
for	IN	O
labour	NN	O
followed	VBN	O
by	IN	O
patient-controlled	JJ	O
infusion	NN	O
with	IN	O
bupivacaine	NN	O
and	CC	O
sufentanil	NN	O
:	:	O
combined	VBN	O
spinal-epidural	JJ	O
vs.	FW	O
epidural	JJ	O
analgesia	NN	O
alone	RB	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
Combined	NNP	O
spinal-epidural	JJ	O
is	VBZ	O
an	DT	O
alternative	JJ	O
technique	NN	O
to	TO	O
epidural	JJ	O
analgesia	NN	O
for	IN	O
labour	NN	O
,	,	O
but	CC	O
its	PRP$	O
benefits	NNS	O
are	VBP	O
not	RB	O
clearly	RB	O
identified	VBN	O
.	.	O

METHODS	VB	O
A	DT	O
prospective	JJ	O
,	,	O
blinded	VBD	O
,	,	O
randomized	VBD	O
study	NN	O
was	VBD	O
undertaken	JJ	O
involving	VBG	O
113	CD	SampleSize
women	NNS	Sex
attending	VBG	O
a	DT	O
university	NN	O
hospital	NN	O
obstetric	JJ	O
department	NN	O
.	.	O

Analgesia	NNP	O
was	VBD	O
initiated	VBN	O
with	IN	O
intrathecal	JJ	O
bupivacaine	NN	O
0.25	CD	O
%	NN	O
1	CD	O
mL	NN	O
+	NNP	O
sufentanil	VBD	O
5	CD	O
microg	NN	O
in	IN	O
the	DT	O
combined	JJ	O
spinal-epidural	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
54	CD	O
)	)	O
,	,	O
and	CC	O
with	IN	O
bupivacaine	JJ	O
0.125	CD	O
%	NN	O
+	JJ	O
epinephrine	NN	O
2.5	CD	O
microg	NN	O
mL	NN	O
(	(	O
-1	NNP	O
)	)	O
+	VBD	O
sufentanil	$	O
7.5	CD	O
microg	NN	O
in	IN	O
the	DT	O
epidural	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
59	CD	O
)	)	O
.	.	O

In	IN	O
both	DT	O
cases	NNS	O
this	DT	O
was	VBD	O
followed	VBN	O
by	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
with	IN	O
bupivacaine	JJ	O
0.125	CD	O
%	NN	O
(	(	O
+	JJ	O
sufentanil	NN	O
0.25	CD	O
microg	NN	O
mL	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
.	.	O

Duration	NN	O
of	IN	O
labour	NN	O
,	,	O
quality	NN	O
of	IN	O
analgesia	NN	O
and	CC	O
side-effects	NNS	O
were	VBD	O
compared	VBN	O
between	IN	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
combined	JJ	O
spinal-epidural	JJ	O
group	NN	O
,	,	O
the	DT	O
onset	NN	O
of	IN	O
analgesia	NN	O
was	VBD	O
faster	RBR	O
(	(	O
5	CD	O
vs.	FW	O
15	CD	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
the	DT	O
consumption	NN	O
of	IN	O
bupivacaine	NN	O
was	VBD	O
lower	JJR	O
(	(	O
7.5	CD	O
vs.	FW	O
11.3	CD	O
mg	NN	O
h	NN	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
there	EX	O
was	VBD	O
less	JJR	O
unilateral	JJ	O
analgesia	NN	O
(	(	O
14.8	CD	O
%	NN	O
vs.	FW	O
40.7	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
epidural	JJ	O
group	NN	O
.	.	O

The	DT	O
characteristics	NNS	O
of	IN	O
labour	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
combined	JJ	O
spinal-epidural	JJ	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
posterior	JJ	O
presentation	NN	O
(	(	O
25.9	CD	O
%	NN	O
vs.	FW	O
10	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
pruritus	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
hypotension	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
,	,	O
somnolence	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
nausea	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
and	CC	O
one	CD	O
case	NN	O
of	IN	O
meningitis	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
combined	JJ	O
spinal-epidural	JJ	O
technique	NN	O
provided	VBD	O
more	RBR	O
effective	JJ	O
analgesia	NN	O
during	IN	Condition
labour	JJR	Condition
than	IN	O
epidural	JJ	O
analgesia	NN	O
alone	RB	O
but	CC	O
offered	VBN	O
no	DT	O
other	JJ	O
advantage	NN	O
.	.	O

It	PRP	O
induced	VBD	O
more	RBR	O
adverse	JJ	O
effects	NNS	O
and	CC	O
this	DT	O
should	MD	O
be	VB	O
considered	VBN	O
before	IN	O
routinely	RB	O
using	VBG	O
the	DT	O
combined	JJ	O
spinal-epidural	JJ	O
technique	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
four	CD	O
continuously	RB	O
administered	VBN	O
progestogen	NN	O
plus	CC	O
oestradiol	JJ	O
combinations	NNS	O
for	IN	O
climacteric	JJ	O
complaints	NNS	O
.	.	O

Sixty	NNP	O
women	NNS	O
with	IN	O
climacteric	JJ	O
complaints	NNS	O
who	WP	O
had	VBD	O
not	RB	O
menstruated	VBN	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
year	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
four	CD	O
hormonal	JJ	O
replacement	NN	O
regimens	NNS	O
.	.	O

All	DT	O
four	CD	O
formulations	NNS	O
were	VBD	O
administered	VBN	O
daily	RB	O
and	CC	O
continuously	RB	O
and	CC	O
each	DT	O
contained	VBD	O
2	CD	O
mg	NN	O
of	IN	O
micronized	JJ	O
oestradiol-17	JJ	O
beta	NN	O
in	IN	O
combination	NN	O
with	IN	O
either	DT	O
norethisterone	NN	O
acetate	NN	O
1	CD	O
mg	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
0.5	CD	O
mg	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
or	CC	O
megestrol	VB	O
acetate	JJ	O
5	CD	O
mg	NN	O
(	(	O
group	NN	O
C	NNP	O
)	)	O
or	CC	O
2.5	CD	O
mg	NN	O
(	(	O
group	NN	O
D	NNP	O
)	)	O
.	.	O

The	DT	O
clinical	JJ	O
efficacy	NN	O
was	VBD	O
the	DT	O
same	JJ	O
although	IN	O
the	DT	O
alleviation	NN	O
of	IN	O
vasomotor	NN	O
symptoms	NNS	O
was	VBD	O
somewhat	RB	O
slower	JJR	O
in	IN	O
those	DT	O
women	NNS	O
receiving	VBG	O
preparation	NN	O
A	NNP	O
.	.	O

The	DT	O
endometrium	NN	O
was	VBD	O
atrophied	VBN	O
in	IN	O
nearly	RB	O
all	DT	O
biopsies	NNS	O
.	.	O

Irregular	JJ	O
uterine	JJ	O
bleeding	NN	O
was	VBD	O
almost	RB	O
entirely	RB	O
confined	VBN	O
to	TO	O
the	DT	O
earlier	JJR	O
phase	NN	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
was	VBD	O
substantially	RB	O
less	JJR	O
with	IN	O
the	DT	O
formulation	NN	O
containing	VBG	O
1	CD	O
mg	JJ	O
norethisterone	NN	O
acetate	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
a	DT	O
continuous	JJ	O
oestradiol-progestogen	JJ	O
combination	NN	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
long-term	JJ	O
treatment	NN	O
of	IN	O
climacteric	JJ	O
complaints	NNS	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
and	CC	O
that	IN	O
after	IN	O
4	CD	O
months	NNS	O
the	DT	O
clinical	JJ	O
efficacy	NN	O
is	VBZ	O
the	DT	O
same	JJ	O
irrespective	NN	O
of	IN	O
the	DT	O
type	NN	O
and	CC	O
dose	NN	O
of	IN	O
progestogen	NN	O
administered	VBN	O
.	.	O

[	IN	O
The	DT	O
application	NN	O
of	IN	O
naphcon	JJ	O
eye	NN	O
drops	NNS	O
during	IN	O
Lasik	NNP	O
surgery	NN	O
]	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
Naphcon	NNP	O
eye	NN	O
drops	NNS	O
for	IN	O
preventing	VBG	O
conjunctival	JJ	Condition
bleeding	NN	Condition
during	IN	O
Lasik	NNP	O
surgery	NN	O
.	.	O

METHODS	NNP	O
One	CD	SampleSize
hundred	VBN	SampleSize
cases	NNS	O
(	(	O
200	CD	O
eyes	NNS	O
)	)	O
were	VBD	O
divided	VBN	O
into	IN	O
treating	VBG	O
group	NN	O
and	CC	O
control	NN	O
group	NN	O
randomly	RB	O
according	VBG	O
to	TO	O
using	VBG	O
and	CC	O
not	RB	O
using	VBG	O
Naphcon	NNP	O
eye	NN	O
drops	NNS	O
before	IN	O
Lasik	NNP	O
surgery	NN	O
.	.	O

Treating	VBG	O
group	NN	O
patients	NNS	O
received	VBD	O
three	CD	O
times	NNS	O
Naphcon	NNP	O
eye	NN	O
drops	NNS	O
during	IN	O
15	CD	O
minutes	NNS	O
before	IN	O
surgery	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
incidence	NN	O
of	IN	O
conjunctival	JJ	O
bleeding	VBG	O
from	IN	O
treating	VBG	O
and	CC	O
control	VB	O
group	NN	O
were	VBD	O
8	CD	O
%	NN	O
and	CC	O
15	CD	O
%	NN	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
significant	JJ	O
statistical	JJ	O
difference	NN	O
between	IN	O
them	PRP	O
.	.	O

CONCLUSION	NNP	O
Naphcon	NNP	O
eye	NN	O
drop	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
agent	NN	O
to	TO	O
prevent	VB	O
conjunctival	JJ	Condition
bleeding	NN	Condition
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
an	DT	O
interim	JJ	O
methadone	NN	O
maintenance	NN	O
clinic	NN	O
.	.	O

BACKGROUND	NNP	O
Interim	NNP	O
methadone	NN	O
maintenance	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
method	NN	O
of	IN	O
providing	VBG	O
clinically	RB	O
effective	JJ	O
services	NNS	O
to	TO	O
heroin	VB	Condition
addicts	NNS	Condition
waiting	VBG	O
for	IN	O
treatment	NN	O
in	IN	O
standard	JJ	O
comprehensive	JJ	O
methadone	NN	O
maintenance	NN	O
programs	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
clinic	NN	O
that	WDT	O
provided	VBD	O
initial	JJ	O
medical	JJ	O
evaluation	NN	O
,	,	O
methadone	NN	O
medication	NN	O
,	,	O
and	CC	O
AIDS	NNP	O
education	NN	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
include	VB	O
formal	JJ	O
drug	NN	O
abuse	NN	O
counseling	NN	O
or	CC	O
other	JJ	O
social	JJ	O
support	NN	O
services	NNS	O
was	VBD	O
established	VBN	O
in	IN	O
New	NNP	O
York	NNP	O
City	NNP	O
.	.	O

A	NNP	O
sample	NN	O
of	IN	O
301	CD	SampleSize
volunteer	NN	O
subjects	NNS	O
recruited	VBN	O
from	IN	O
the	DT	O
waiting	VBG	O
list	NN	O
for	IN	O
treatment	NN	O
in	IN	O
the	DT	O
Beth	NNP	O
Israel	NNP	O
methadone	NN	O
program	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
immediate	VB	O
entry	NN	O
into	IN	O
the	DT	O
interim	JJ	O
clinic	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
initial	JJ	O
levels	NNS	O
of	IN	O
illicit	JJ	O
drug	NN	O
use	NN	O
across	IN	O
the	DT	O
experimental	JJ	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

One-month	JJ	O
urinalysis	JJ	O
follow-up	NN	O
data	NNS	O
showed	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
heroin	NN	O
use	NN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
from	IN	O
63	CD	O
%	NN	O
positive	JJ	O
at	IN	O
intake	NN	O
to	TO	O
29	CD	O
%	NN	O
positive	JJ	O
)	)	O
with	IN	O
no	DT	O
change	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
62	CD	O
%	NN	O
to	TO	O
60	CD	O
%	NN	O
positive	JJ	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
change	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
cocaine	NN	O
urinalyses	NNS	O
(	(	O
approximately	RB	O
70	CD	O
%	NN	O
positive	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
at	IN	O
intake	NN	O
and	CC	O
follow-up	NN	O
)	)	O
.	.	O

A	DT	O
higher	JJR	O
percentage	NN	O
of	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
were	VBD	O
in	IN	O
treatment	NN	O
at	IN	O
16-month	JJ	O
follow-up	NN	O
(	(	O
72	CD	O
%	NN	O
vs	JJ	O
56	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Limited	NNP	O
services	NNS	O
interim	VBP	O
methadone	JJ	O
maintenance	NN	O
can	MD	O
reduce	VB	O
heroin	NNS	O
use	VBP	O
among	IN	O
persons	NNS	O
awaiting	VBG	O
entry	NN	O
into	IN	O
comprehensive	JJ	O
treatment	NN	O
and	CC	O
increase	VB	O
the	DT	O
percentage	NN	O
entering	VBG	O
treatment	NN	O
.	.	O

Breaking	VBG	O
it	PRP	O
down	RP	O
is	VBZ	O
better	RBR	O
:	:	O
haptic	JJ	O
decomposition	NN	O
of	IN	O
complex	JJ	O
movements	NNS	O
aids	NNS	O
in	IN	O
robot-assisted	JJ	O
motor	NN	O
learning	NN	O
.	.	O

Training	VBG	O
with	IN	O
haptic	JJ	O
guidance	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
technique	NN	O
for	IN	O
learning	VBG	O
complex	JJ	O
movements	NNS	O
in	IN	O
rehabilitation	NN	O
and	CC	O
sports	NNS	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
unclear	JJ	O
how	WRB	O
to	TO	O
best	VB	O
deliver	RB	O
guidance-based	JJ	O
training	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	IN	O
breaking	VBG	O
down	RP	O
a	DT	O
complex	JJ	O
movement	NN	O
,	,	O
similar	JJ	O
to	TO	O
a	DT	O
tennis	NN	O
backhand	NN	O
,	,	O
into	IN	O
simpler	NN	O
parts	NNS	O
and	CC	O
then	RB	O
using	VBG	O
haptic	JJ	O
feedback	NN	O
from	IN	O
a	DT	O
robotic	JJ	O
exoskeleton	NN	O
would	MD	O
help	VB	O
the	DT	O
motor	NN	O
system	NN	O
learn	VBP	O
the	DT	O
movement	NN	O
.	.	O

We	PRP	O
also	RB	O
examined	VBD	O
how	WRB	O
the	DT	O
particular	JJ	O
form	NN	O
of	IN	O
the	DT	O
decomposition	NN	O
affected	VBD	O
learning	NN	O
.	.	O

Three	CD	O
groups	NNS	O
of	IN	O
unimpaired	JJ	Condition
participants	NNS	O
trained	VBN	O
with	IN	O
the	DT	O
target	NN	O
arm	JJ	O
movement	NN	O
broken	VBD	O
down	RB	O
in	IN	O
three	CD	O
ways	NNS	O
:	:	O
1	CD	O
)	)	O
elbow	NN	O
flexion/extension	NN	O
and	CC	O
the	DT	O
unified	JJ	O
shoulder	NN	O
motion	NN	O
independently	RB	O
(	(	O
anatomical	JJ	O
decomposition	NN	O
)	)	O
,	,	O
2	CD	O
)	)	O
three	CD	O
component	JJ	O
shoulder	NN	O
motions	NNS	O
in	IN	O
Euler	NNP	O
coordinates	NNS	O
and	CC	O
elbow	JJ	O
flexion/extension	NN	O
(	(	O
Euler	NNP	O
decomposition	NN	O
)	)	O
,	,	O
or	CC	O
3	CD	O
)	)	O
the	DT	O
motion	NN	O
of	IN	O
the	DT	O
tip	NN	O
of	IN	O
the	DT	O
elbow	NN	O
and	CC	O
motion	NN	O
of	IN	O
the	DT	O
hand	NN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
elbow	NN	O
,	,	O
independently	RB	O
(	(	O
visual	JJ	O
decomposition	NN	O
)	)	O
.	.	O

A	DT	O
control	NN	O
group	NN	O
practiced	VBD	O
the	DT	O
same	JJ	O
number	NN	O
of	IN	O
movements	NNS	O
,	,	O
but	CC	O
experienced	VBD	O
the	DT	O
target	NN	O
motion	NN	O
only	RB	O
,	,	O
achieving	VBG	O
eight	CD	O
times	NNS	O
more	RBR	O
direct	JJ	O
practice	NN	O
with	IN	O
this	DT	O
motion	NN	O
.	.	O

Despite	IN	O
less	JJR	O
experience	NN	O
with	IN	O
the	DT	O
target	NN	O
motion	NN	O
,	,	O
part	NN	O
training	NN	O
was	VBD	O
better	RBR	O
,	,	O
but	CC	O
only	RB	O
when	WRB	O
the	DT	O
arm	NN	O
trajectory	NN	O
was	VBD	O
decomposed	VBN	O
into	IN	O
anatomical	JJ	O
components	NNS	O
.	.	O

Varying	VBG	O
robotic	JJ	O
movement	NN	O
training	NN	O
to	TO	O
include	VB	O
practice	NN	O
of	IN	O
simpler	NN	O
,	,	O
anatomically-isolated	JJ	O
motions	NNS	O
may	MD	O
enhance	VB	O
its	PRP$	O
efficacy	NN	O
.	.	O

A	DT	O
prospective	JJ	O
multicenter	NN	O
randomized	VBD	O
comparative	JJ	O
study	NN	O
between	IN	O
the	DT	O
U-	NNP	O
and	CC	O
H-type	NNP	O
methods	NNS	O
of	IN	O
the	DT	O
TVT	NNP	O
SECUR	NNP	O
procedure	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
female	JJ	Sex
stress	NN	Condition
urinary	JJ	Condition
incontinence	NN	Condition
:	:	O
1-year	JJ	O
follow-up	NN	O
.	.	O

BACKGROUND	NNP	O
No	NNP	O
studies	NNS	O
have	VBP	O
been	VBN	O
published	VBN	O
comparing	VBG	O
the	DT	O
U-	JJ	O
and	CC	O
H-type	JJ	O
methods	NNS	O
of	IN	O
the	DT	O
TVT	NNP	O
SECUR	NNP	O
(	(	O
TVT-S	NNP	O
)	)	O
procedure	NN	O
.	.	O

OBJECTIVE	CC	O
Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
two	CD	O
types	NNS	O
of	IN	O
TVT-S	NNP	O
for	IN	O
female	JJ	Sex
stress	NN	Condition
urinary	JJ	Condition
incontinence	NN	Condition
(	(	Condition
SUI	NNP	Condition
)	)	Condition
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
Women	NNP	Sex
with	IN	O
urodynamic	JJ	Condition
SUI	NNP	Condition
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
12-mo	JJ	O
multicenter	NN	O
randomized	VBN	O
study	NN	O
.	.	O

INTERVENTION	NNP	O
Subjects	NNPS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
the	DT	O
U-	JJ	O
or	CC	O
H-type	JJ	O
method	NN	O
of	IN	O
TVT-S.	JJ	O
MEASUREMENTS	NNP	O
Pre-	NNP	O
and	CC	O
postoperative	JJ	O
evaluations	NNS	O
included	VBD	O
a	DT	O
standing	VBG	O
stress	NN	O
test	NN	O
,	,	O
the	DT	O
Sandvik	NNP	O
questionnaire	NN	O
,	,	O
the	DT	O
Incontinence	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
(	(	O
I-QOL	NNP	O
)	)	O
questionnaire	NN	O
,	,	O
and	CC	O
the	DT	O
International	NNP	O
Consultation	NNP	O
on	IN	O
Incontinence	NNP	O
Questionnaire-Female	NNP	O
Lower	NNP	O
Urinary	NNP	O
Tract	NNP	O
Symptoms	NNP	O
(	(	O
ICIQ-FLUTS	NNP	O
)	)	O
.	.	O

Patients	NNS	O
'	POS	O
satisfaction	NN	O
and	CC	O
complications	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

Objective	NNP	O
and	CC	O
subjective	JJ	O
cures	NNS	O
were	VBD	O
defined	VBN	O
as	IN	O
no	DT	O
leakage	NN	O
on	IN	O
the	DT	O
stress	JJ	O
test	NN	O
and	CC	O
responses	NNS	O
on	IN	O
the	DT	O
Sandvik	NNP	O
questionnaire	NN	O
,	,	O
respectively	RB	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
surgical	JJ	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
.	.	O

RESULTS	NNP	O
AND	NNP	O
LIMITATIONS	NNP	O
Of	IN	O
285	CD	SampleSize
women	NNS	Sex
,	,	O
144	CD	SampleSize
had	VBD	O
the	DT	O
U-type	JJ	O
method	NN	O
and	CC	O
141	CD	SampleSize
had	VBD	O
the	DT	O
H-type	JJ	O
method	NN	O
.	.	O

Objective	JJ	O
cure	NN	O
rates	NNS	O
were	VBD	O
87.5	CD	O
%	NN	O
for	IN	O
the	DT	O
U-type	JJ	O
method	NN	O
and	CC	O
80.1	CD	O
%	NN	O
for	IN	O
the	DT	O
H-type	NNP	O
method	NN	O
(	(	O
p=0.091	NN	O
)	)	O
.	.	O

Subjective	JJ	O
cure	NN	O
rates	NNS	O
were	VBD	O
77.1	CD	O
%	NN	O
for	IN	O
the	DT	O
U-type	JJ	O
method	NN	O
and	CC	O
75.7	CD	O
%	NN	O
for	IN	O
the	DT	O
H-type	NNP	O
method	NN	O
(	(	O
p=0.786	NN	O
)	)	O
.	.	O

Improvement	NN	O
in	IN	O
I-QOL	NNP	O
and	CC	O
domain	NN	O
scores	NNS	O
of	IN	O
the	DT	O
ICIQ-FLUTS	NNP	O
(	(	O
filling	VBG	O
and	CC	O
incontinence	NN	O
sum	NN	O
,	,	O
QOL	NNP	O
score	NN	O
)	)	O
,	,	O
and	CC	O
patients	NNS	O
'	POS	O
satisfaction	NN	O
favored	VBD	O
the	DT	O
U-type	JJ	O
method	NN	O
.	.	O

There	EX	O
were	VBD	O
three	CD	O
cases	NNS	O
of	IN	O
intraoperative	JJ	O
vaginal	JJ	O
wall	NN	O
perforation	NN	O
,	,	O
one	CD	O
case	NN	O
of	IN	O
increased	VBN	O
bleeding	NN	O
,	,	O
and	CC	O
three	CD	O
cases	NNS	O
of	IN	O
temporary	JJ	O
postoperative	JJ	O
retention	NN	O
.	.	O

A	DT	O
power	NN	O
calculation	NN	O
was	VBD	O
not	RB	O
performed	VBN	O
,	,	O
and	CC	O
some	DT	O
baseline	NN	O
characteristics	NNS	O
were	VBD	O
not	RB	O
balanced	VBN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
methods	NNS	O
of	IN	O
TVT-S	NNP	O
provided	VBD	O
comparable	JJ	O
cure	NN	O
rates	NNS	O
for	IN	O
female	JJ	O
SUI	NNP	Condition
.	.	O

However	RB	O
,	,	O
QOL	NNP	O
and	CC	O
treatment	NN	O
satisfaction	NN	O
favored	VBD	O
the	DT	O
U-type	JJ	O
method	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
The	DT	O
protocol	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
not	RB	O
registered	VBN	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
dopexamine	NN	O
in	IN	O
splanchnic	JJ	O
perfusion	NN	O
during	IN	O
surgery	NN	O
of	IN	O
the	DT	O
abdominal	JJ	O
aorta	NN	O
]	NNP	O
.	.	O

Abdominal	NNP	O
aortic	JJ	O
surgery	NN	O
has	VBZ	O
significant	JJ	O
effects	NNS	O
on	IN	O
cardiac	NN	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
dopexamine	NN	O
,	,	O
an	DT	O
inodilator	JJ	O
drug	NN	O
,	,	O
on	IN	O
hemodynamic	JJ	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
with	IN	O
measurement	NN	O
of	IN	O
gastric	JJ	O
intramucosal	NN	O
pH	NN	O
,	,	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
gastric	JJ	O
tonometry	NN	O
,	,	O
during	IN	O
abdominal	JJ	O
aneurysm	JJ	O
resection	NN	O
.	.	O

Twenty-five	JJ	O
patients	NNS	O
undergoing	VBG	O
excision	NN	O
of	IN	O
an	DT	O
aortic	JJ	O
abdominal	JJ	O
aneurysm	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
Group	NNP	O
II	NNP	O
patients	NNS	O
received	VBD	O
dopexamine	JJ	O
infusion	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
microgram/kg/m	NN	O
,	,	O
and	CC	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.5	CD	O
micrograms/kg/m	NN	O
from	IN	O
declamping	VBG	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
surgery	NN	O
.	.	O

Whereas	NNP	O
Group	NNP	O
I	PRP	O
patients	NNS	O
did	VBD	O
not	RB	O
receive	VB	O
a	DT	O
dopexamine	JJ	O
infusion	NN	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	VBG	O
the	DT	O
intramucosal	NN	O
pH	VBZ	O
value	NN	O
decreased	VBN	O
in	IN	O
Group	NNP	O
I	PRP	O
patients	NNS	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
Group	NNP	O
II	NNP	O
patients	NNS	O
.	.	O

Heart	NNP	O
rate	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
,	,	O
and	CC	O
mixed	JJ	O
venous	JJ	O
oxygen	NN	O
saturation	NN	O
increased	VBD	O
significantly	RB	O
during	IN	O
dopexamine	JJ	O
infusion	NN	O
,	,	O
whereas	JJ	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
was	VBD	O
reduced	VBN	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
dopexamine	NN	O
was	VBD	O
a	DT	O
useful	JJ	O
agent	NN	O
in	IN	O
improving	VBG	O
splanchnic	JJ	O
blood	NN	O
flow	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
venous	JJ	O
saturation	NN	O
.	.	O

Also	RB	O
,	,	O
since	IN	O
the	DT	O
drug	NN	O
produces	VBZ	O
dose	RB	O
related	JJ	O
hemodynamic	JJ	O
changes	NNS	O
of	IN	O
rapid	JJ	O
onset	NN	O
and	CC	O
reversibility	NN	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
interrupt	VB	O
the	DT	O
infusion	NN	O
before	IN	O
aortic	JJ	O
declamping	NN	O
to	TO	O
avoid	VB	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
intramucosal	NN	O
pH	VBZ	O
value	NN	O
.	.	O

Dairy	NN	O
products	NNS	O
do	VBP	O
not	RB	O
lead	VB	O
to	TO	O
alterations	NNS	O
in	IN	O
body	NN	O
weight	NN	O
or	CC	O
fat	JJ	O
mass	NN	O
in	IN	O
young	JJ	Sex
women	NNS	Sex
in	IN	O
a	DT	O
1-y	JJ	O
intervention	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	JJ	O
results	NNS	O
suggested	VBD	O
that	IN	O
increased	VBD	O
intake	NN	O
of	IN	O
dairy	NN	O
calcium	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
reduced	JJ	O
weight	NN	O
and	CC	O
fat	JJ	O
mass	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
long-term	JJ	O
increases	NNS	O
in	IN	O
consumption	NN	O
of	IN	O
dairy	NN	O
calcium	NN	O
alter	NN	O
body	NN	O
weight	NN	O
and	CC	O
fat	JJ	O
mass	NN	O
in	IN	O
young	JJ	Age
,	,	O
healthy	JJ	O
women	NNS	Age
.	.	O

DESIGN	NNP	O
We	PRP	O
used	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
1-y	JJ	O
intervention	NN	O
for	IN	O
dairy	NN	O
calcium	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
155	CD	SampleSize
young	JJ	O
(	(	O
aged	VBN	O
18-30	CD	Age
y	NN	O
)	)	O
,	,	O
healthy	JJ	O
,	,	O
normal-weight	JJ	O
women	NNS	O
with	IN	O
intake	NN	O
of	IN	O
dietary	JJ	O
calcium	NN	O
<	VBZ	O
800	CD	O
mg/d	NN	O
and	CC	O
energy	NN	O
intake	VBP	O
<	CD	O
/=	JJ	O
2200	CD	O
kcal/d	NN	O
.	.	O

Women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
:	:	O
1	CD	O
)	)	O
control	NN	O
:	:	O
continue	NN	O
established	VBD	O
dietary	JJ	O
intake	NN	O
;	:	O
2	CD	O
)	)	O
medium	NN	O
dairy	NN	O
:	:	O
substitute	NN	O
dairy	NN	O
products	NNS	O
to	TO	O
achieve	VB	O
intake	NN	O
of	IN	O
calcium	NN	O
of	IN	O
approximately	RB	O
1000-1100	JJ	O
mg/d	NN	O
and	CC	O
maintain	VB	O
isocaloric	JJ	O
intake	NN	O
;	:	O
3	CD	O
)	)	O
high	JJ	O
dairy	NN	O
:	:	O
substitute	NN	O
dairy	NN	O
products	NNS	O
to	TO	O
achieve	VB	O
intake	NN	O
of	IN	O
calcium	NN	O
of	IN	O
1300-1400	JJ	O
mg/d	NN	O
and	CC	O
maintain	VB	O
isocaloric	JJ	O
intake	NN	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
1-y	JJ	O
changes	NNS	O
in	IN	O
body	NN	O
weight	NN	O
(	(	O
in	IN	O
kg	NN	O
)	)	O
and	CC	O
fat	JJ	O
mass	NN	O
(	(	O
in	IN	O
kg	NN	O
)	)	O
.	.	O

One	CD	SampleSize
hundred	VBD	SampleSize
thirty-five	JJ	SampleSize
women	NNS	O
completed	VBD	O
the	DT	O
trial	NN	O
.	.	O

RESULTS	JJ	O
Mean	NNP	O
intakes	NNS	O
of	IN	O
calcium	NN	O
during	IN	O
the	DT	O
intervention	NN	O
were	VBD	O
742.4	CD	O
+/-	JJ	O
321.5	CD	O
,	,	O
1026.4	CD	O
+/-	JJ	O
311.3	CD	O
,	,	O
and	CC	O
1131.29	CD	O
+/-	JJ	O
337.2	CD	O
mg/d	NN	O
for	IN	O
the	DT	O
control	NN	O
,	,	O
medium-dairy	NN	O
,	,	O
and	CC	O
high-dairy	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
mean	JJ	O
1-y	JJ	O
change	NN	O
in	IN	O
body	NN	O
weight	NN	O
between	IN	O
the	DT	O
control	NN	O
,	,	O
medium-dairy	NN	O
,	,	O
and	CC	O
high-dairy	JJ	O
groups	NNS	O
(	(	O
0.8	CD	O
+/-	JJ	O
2.8	CD	O
,	,	O
0.7	CD	O
+/-	JJ	O
3.0	CD	O
,	,	O
and	CC	O
1.5	CD	O
+/-	JJ	O
4.1	CD	O
kg	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
0.45	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
mean	JJ	O
1-y	JJ	O
change	NN	O
in	IN	O
fat	JJ	O
mass	NN	O
between	IN	O
the	DT	O
control	NN	O
,	,	O
medium-dairy	NN	O
,	,	O
and	CC	O
high-dairy	JJ	O
groups	NNS	O
(	(	O
-0.5	JJ	O
+/-	JJ	O
2.5	CD	O
,	,	O
0.3	CD	O
+/-	JJ	O
2.7	CD	O
,	,	O
and	CC	O
0.5	CD	O
+/-	JJ	O
3.5	CD	O
kg	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
0.26	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Increased	VBD	O
intake	NN	O
of	IN	O
dairy	NN	O
products	NNS	O
does	VBZ	O
not	RB	O
alter	VB	O
body	NN	O
weight	NN	O
or	CC	O
fat	JJ	O
mass	NN	O
in	IN	O
young	JJ	Age
,	,	O
healthy	JJ	O
women	NNS	Age
over	IN	O
1	CD	O
y	NNS	O
.	.	O

Elevated	JJ	O
concentration	NN	O
of	IN	O
placental	JJ	O
growth	NN	O
factor	NN	O
(	(	O
PlGF	NNP	O
)	)	O
and	CC	O
long	JJ	O
term	NN	O
risk	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
coronary	JJ	O
syndrome	NN	O
in	IN	O
the	DT	O
PROVE	NNP	O
IT-TIMI	NNP	O
22	CD	O
trial	NN	O
.	.	O

Placental	JJ	O
growth	NN	O
factor	NN	O
(	(	O
PlGF	NNP	O
)	)	O
,	,	O
a	DT	O
member	NN	O
of	IN	O
the	DT	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
(	(	O
VEGF	NNP	O
)	)	O
family	NN	O
,	,	O
acts	VBZ	O
via	IN	O
the	DT	O
flt-1	JJ	O
receptor	NN	O
and	CC	O
promotes	VBZ	O
endothelial	JJ	O
activation	NN	O
and	CC	O
macrophage	NN	O
recruitment	NN	O
into	IN	O
atherosclerotic	JJ	O
lesions	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
relationship	NN	O
of	IN	O
PlGF	NNP	O
with	IN	O
cardiovascular	JJ	O
outcomes	NNS	O
in	IN	O
a	DT	O
large	JJ	O
cohort	NN	O
of	IN	O
patients	NNS	O
presenting	VBG	O
across	IN	O
the	DT	O
spectrum	NN	O
of	IN	O
ACS	NNP	O
.	.	O

PlGF	NNP	O
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
(	(	O
n	JJ	O
=	NNP	O
3,761	CD	O
)	)	O
and	CC	O
at	IN	O
four-months	JJ	O
(	(	O
n	JJ	O
=	NNP	O
3,369	CD	O
)	)	O
in	IN	O
patients	NNS	Condition
randomized	VBN	Condition
to	TO	Condition
atorvastatin	VB	Condition
80	CD	Condition
mg	NN	Condition
or	CC	Condition
pravastatin	NN	Condition
40	CD	Condition
mg	NN	Condition
after	IN	Condition
ACS	NNP	Condition
in	IN	Condition
the	DT	O
PROVE	NNP	O
IT-TIMI	NNP	O
22	CD	O
trial	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
,	,	O
unstable	JJ	O
angina	NN	O
,	,	O
revascularization	NN	O
or	CC	O
stroke	NN	O
(	(	O
mean	JJ	O
follow-up	JJ	O
24	CD	O
months	NNS	O
)	)	O
.	.	O

Elevated	VBN	O
baseline	NN	O
PlGF	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
the	DT	O
primary	JJ	O
endpoint	NN	O
through	IN	O
2	CD	O
years	NNS	O
(	(	O
Q1	NNP	O
vs.	FW	O
Q5	NNP	O
:	:	O
18.7	CD	O
vs.	IN	O
29.3	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
death	NN	O
or	CC	O
MI	NNP	O
was	VBD	O
also	RB	O
higher	JJR	O
in	IN	O
patients	NNS	O
with	IN	O
elevated	JJ	O
baseline	NN	O
PlGF	NNP	O
(	(	O
Q1	NNP	O
vs.	FW	O
Q5	NNP	O
:	:	O
7.0	CD	O
vs.	IN	O
11.6	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.029	CD	O
)	)	O
.	.	O

Adjusting	VBG	O
for	IN	O
baseline	NN	O
characteristics	NNS	O
and	CC	O
risk	NN	O
factors	NNS	O
,	,	O
elevated	VBD	O
baseline	NN	O
PlGF	NNP	O
was	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
the	DT	O
risk	NN	O
of	IN	O
the	DT	O
primary	JJ	O
endpoint	NN	O
(	(	O
adjusted-HR	JJ	O
for	IN	O
Q5	NNP	O
vs.	FW	O
Q1	NNP	O
1.45	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.16-1.83	CD	O
;	:	O
p	CC	O
=	VB	O
0.001	CD	O
)	)	O
.	.	O

Elevated	VBN	O
PlGF	NNP	O
at	IN	O
four	CD	O
months	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
risk	NN	O
of	IN	O
death	NN	O
or	CC	O
MI	NNP	O
(	(	O
Adjusted	NNP	O
HR	NNP	O
Q5	NNP	O
vs.	IN	O
Q1	NNP	O
2.79	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.37-5.68	JJ	O
;	:	O
p	VB	O
=	$	O
0.005	CD	O
)	)	O
,	,	O
and	CC	O
higher	JJR	O
risk	NN	O
of	IN	O
the	DT	O
primary	JJ	O
endpoint	NN	O
(	(	O
Adjusted	NNP	O
HR	NNP	O
Q5	NNP	O
vs.	IN	O
Q1	NNP	O
1.78	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.26-2.51	JJ	O
;	:	O
p	VB	O
=	$	O
0.001	CD	O
)	)	O
.	.	O

Higher	JJR	O
concentration	NN	O
of	IN	O
PlGF	NNP	O
after	IN	O
ACS	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
long-term	JJ	O
risk	NN	O
of	IN	O
recurrent	JJ	O
cardiovascular	JJ	O
events	NNS	O
independent	JJ	O
of	IN	O
traditional	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

This	DT	O
association	NN	O
is	VBZ	O
present	JJ	O
early	JJ	O
after	IN	O
ACS	NNP	O
and	CC	O
appears	VBZ	O
to	TO	O
be	VB	O
stronger	JJR	O
at	IN	O
four	CD	O
months	NNS	O
.	.	O

Mandibular	JJ	O
advancement	NN	O
splint	NN	O
improves	VBZ	O
indices	NNS	O
of	IN	O
obstructive	JJ	Condition
sleep	NN	Condition
apnoea	NN	Condition
and	CC	Condition
snoring	VBG	Condition
but	CC	O
side	JJ	O
effects	NNS	O
are	VBP	O
common	JJ	O
.	.	O

AIM	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
mandibular	JJ	O
advancement	NN	O
splint	NN	O
(	(	O
MAS	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
obstructive	JJ	O
sleep	JJ	O
apnoea	NN	O
syndrome	NN	O
(	(	O
OSAS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Nineteen	NNP	SampleSize
patients	NNS	O
using	VBG	O
a	DT	O
MAS	NNP	O
for	IN	O
symptomatic	JJ	O
OSAS	NNP	O
underwent	NN	O
polysomnography	NN	O
,	,	O
with	IN	O
MAS	NNP	O
use	NN	O
randomised	VBD	O
to	TO	O
one	CD	O
half	NN	O
of	IN	O
the	DT	O
night	NN	O
.	.	O

Indices	NNS	O
of	IN	O
snoring	VBG	O
and	CC	O
OSAS	NNP	O
were	VBD	O
compared	VBN	O
.	.	O

Side	NNP	O
effects	NNS	O
,	,	O
compliance	NN	O
and	CC	O
treatment	NN	O
response	NN	O
were	VBD	O
evaluated	VBN	O
by	IN	O
questionnaire	NN	O
.	.	O

RESULTS	NNP	O
Use	NNP	O
of	IN	O
the	DT	O
MAS	NNP	O
improved	VBD	O
total	JJ	O
respiratory	NN	O
disturbance	NN	O
index	NN	O
(	(	O
RDI	NNP	O
)	)	O
from	IN	O
22.2	CD	O
+/-	JJ	O
19.8	CD	O
(	(	O
SD	NNP	O
)	)	O
events	NNS	O
per	IN	O
hour	NN	O
to	TO	O
16.5	CD	O
+/-	JJ	O
21.4/hr	CD	O
(	(	O
p	NN	O
=	RB	O
0.03	CD	O
)	)	O
,	,	O
supine	JJ	O
RDI	NNP	O
(	(	O
30.8	CD	O
+/-	JJ	O
23.8/hr	CD	O
to	TO	O
18.8	CD	O
+/-	JJ	O
22.1/hr	CD	O
,	,	O
p	NN	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
arousal	JJ	O
index	NN	O
(	(	O
25.2	CD	O
+/-	JJ	O
18.9/hr	CD	O
to	TO	O
19.3	CD	O
+/-	JJ	O
14.2/hr	CD	O
,	,	O
p	NN	O
=	NNP	O
0.01	CD	O
)	)	O
and	CC	O
snoring	VBG	O
intensity	NN	O
(	(	O
52.7	CD	O
+/-	JJ	O
4.1	CD	O
to	TO	O
50.7	CD	O
+/-	JJ	O
2.7	CD	O
dB	NN	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
but	CC	O
not	RB	O
total	JJ	O
snore	NN	O
frequency	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Using	VBG	O
polysomnographic	JJ	O
criteria	NNS	O
,	,	O
MAS	NNP	O
treatment	NN	O
was	VBD	O
completely	RB	O
successful	JJ	O
in	IN	O
four	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
partially	RB	O
successful	JJ	O
in	IN	O
ten	NN	O
(	(	O
52.6	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
failure	NN	O
in	IN	O
five	CD	O
(	(	O
26.3	CD	O
%	NN	O
)	)	O
.	.	O

Treatment	NN	O
over	IN	O
a	DT	O
median	NN	O
of	IN	O
6.5	CD	O
weeks	NNS	O
(	(	O
range	VB	O
2-48	CD	O
)	)	O
was	VBD	O
perceived	VBN	O
as	IN	O
beneficial	JJ	O
by	IN	O
ten	NN	O
of	IN	O
eleven	JJ	O
partners	NNS	O
.	.	O

Fifteen	JJ	O
patients	NNS	O
(	(	O
79	CD	O
%	NN	O
)	)	O
reported	VBD	O
side	JJ	O
effects	NNS	O
,	,	O
9	CD	O
(	(	O
46	CD	O
%	NN	O
)	)	O
did	VBD	O
not	RB	O
use	VB	O
the	DT	O
device	NN	O
every	DT	O
night	NN	O
and	CC	O
four	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
used	VBD	O
the	DT	O
device	NN	O
less	JJR	O
than	IN	O
three	CD	O
nights	NNS	O
per	IN	O
week	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
use	NN	O
of	IN	O
the	DT	O
MAS	NNP	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
indices	NNS	O
of	IN	O
OSAS	NNP	O
and	CC	O
snoring	VBG	O
.	.	O

However	RB	O
,	,	O
a	DT	O
significant	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
had	VBD	O
difficulty	NN	O
tolerating	NN	O
and	CC	O
regularly	RB	O
using	VBG	O
the	DT	O
device	NN	O
.	.	O

Increasing	VBG	O
the	DT	O
reach	NN	O
of	IN	O
health	NN	O
sponsorship	NN	O
:	:	O
using	VBG	O
a	DT	O
sponsorship	JJ	O
kit	NN	O
to	TO	O
promote	VB	O
health	NN	O
.	.	O

In	IN	O
Australia	NNP	O
,	,	O
a	DT	O
tobacco	NN	O
tax	NN	O
provides	VBZ	O
funding	NN	O
for	IN	O
Healthway	NNP	O
,	,	O
the	DT	O
Western	NNP	O
Australian	NNP	O
Health	NNP	O
Promotion	NNP	O
Foundation	NNP	O
.	.	O

Healthway	NNP	O
provides	VBZ	O
sponsorships	NNS	O
for	IN	O
the	DT	O
arts	NNS	O
and	CC	O
racing	NN	O
and	CC	O
sporting	VBG	O
events	NNS	O
to	TO	O
replace	VB	O
funds	NNS	O
previously	RB	O
provided	VBN	O
by	IN	O
tobacco	NN	O
companies	NNS	O
.	.	O

These	DT	O
sponsorships	NNS	O
provide	VBP	O
visibility	NN	O
for	IN	O
Healthway	NNP	O
and	CC	O
positive	JJ	O
health	NN	O
messages	NNS	O
.	.	O

Normally	RB	O
,	,	O
Healthway	NNP	O
staff	NN	O
attends	VBZ	O
these	DT	O
events	NNS	O
to	TO	O
help	VB	O
promote	VB	O
health	NN	O
messages	NNS	O
.	.	O

To	TO	O
reduce	VB	O
Healthway	NNP	O
staff	NN	O
time	NN	O
spent	VBN	O
helping	VBG	O
event	NN	O
organizers	NNS	O
promote	VBP	O
health	NN	O
messages	NNS	O
,	,	O
Healthway	NNP	O
developed	VBD	O
a	DT	O
sponsor	JJ	O
kit	NN	O
of	IN	O
promotional	JJ	O
materials	NNS	O
which	WDT	O
communicate	VBP	O
health	NN	O
messages	NNS	O
without	IN	O
requiring	VBG	O
Healthway	NNP	O
staff	NN	O
to	TO	O
attend	VB	O
events	NNS	O
.	.	O

Recognition	NNP	O
,	,	O
awareness	NN	O
,	,	O
comprehension	NN	O
,	,	O
and	CC	O
acceptance	NN	O
of	IN	O
health	NN	O
messages	NNS	O
was	VBD	O
comparable	JJ	O
at	IN	O
events	NNS	O
that	WDT	O
featured	VBD	O
Healthway	NNP	O
staff	NN	O
versus	IN	O
the	DT	O
sponsor	NN	O
kits	NNS	O
,	,	O
but	CC	O
the	DT	O
average	JJ	O
cost	NN	O
of	IN	O
the	DT	O
sponsorship	NN	O
kits	NNS	O
was	VBD	O
only	RB	O
40	CD	O
%	NN	O
of	IN	O
the	DT	O
cost	NN	O
when	WRB	O
Healthway	NNP	O
staff	NN	O
was	VBD	O
featured	VBN	O
.	.	O

Naltrexone	NN	O
in	IN	O
autistic	JJ	Condition
children	NNS	Age
:	:	O
a	DT	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
critically	RB	O
the	DT	O
effects	NNS	O
of	IN	O
naltrexone	NN	O
on	IN	O
behavioral	JJ	O
symptoms	NNS	O
and	CC	O
learning	VBG	O
in	IN	O
autistic	JJ	Condition
children	NNS	O
,	,	O
and	CC	O
its	PRP$	O
safety	NN	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
preliminary	JJ	O
report	NN	O
on	IN	O
18	CD	SampleSize
children	NNS	Age
,	,	O
ages	VBZ	O
3.08	CD	Age
to	TO	O
7.99	CD	Age
years	NNS	O
,	,	O
who	WP	O
completed	VBD	O
this	DT	O
ongoing	JJ	O
study	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
naltrexone	CD	O
or	CC	O
placebo	NN	O
and	CC	O
received	VBD	O
daily	JJ	O
doses	NNS	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
21	CD	O
days	NNS	O
.	.	O

Naltrexone	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	O
according	VBG	O
to	TO	O
blind	VB	O
Clinical	JJ	O
Global	NNP	O
Consensus	NNP	O
Ratings	NNP	O
(	(	O
unpublished	JJ	O
scale	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
other	JJ	O
behavioral	JJ	O
rating	NN	O
measures	NNS	O
did	VBD	O
not	RB	O
confirm	VB	O
this	DT	O
result	NN	O
.	.	O

There	EX	O
was	VBD	O
only	RB	O
a	DT	O
suggestion	NN	O
that	IN	O
naltrexone	NN	O
reduced	VBD	O
fidgety	NN	O
and	CC	O
hyperactive	JJ	O
behavior	NN	O
and	CC	O
tended	VBD	O
to	TO	O
alleviate	VB	O
overall	JJ	O
symptomatology	NN	O
in	IN	O
older	JJR	O
children	NNS	O
.	.	O

Naltrexone	NN	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
affect	VB	O
discrimination	NN	O
learning	VBG	O
.	.	O

Results	NNS	O
are	VBP	O
preliminary	JJ	O
and	CC	O
,	,	O
owing	VBG	O
to	TO	O
the	DT	O
small	JJ	O
sample	NN	O
size	NN	O
,	,	O
can	MD	O
be	VB	O
considered	VBN	O
only	RB	O
suggestive	JJ	O
until	IN	O
this	DT	O
study	NN	O
is	VBZ	O
completed	VBN	O
or	CC	O
replication	NN	O
is	VBZ	O
obtained	VBN	O
from	IN	O
independent	JJ	O
research	NN	O
.	.	O

A	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
on	IN	O
the	DT	O
influence	NN	O
of	IN	O
acetaminophen	NN	O
,	,	O
diclofenac	NN	O
,	,	O
or	CC	O
naproxen	RB	O
on	IN	O
aspirin-induced	JJ	O
inhibition	NN	O
of	IN	O
platelet	NN	O
aggregation	NN	O
.	.	O

Nonsteroidal	NNP	O
anti-inflammatory	JJ	O
drugs	NNS	O
(	(	O
NSAID	NNP	O
)	)	O
may	MD	O
interfere	VB	O
with	IN	O
aspirin	NN	O
(	(	O
acetylsalicylic	JJ	O
acid	NN	O
)	)	O
and	CC	O
increase	VB	O
the	DT	O
risk	NN	O
for	IN	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

The	DT	O
clinical	JJ	O
relevance	NN	O
is	VBZ	O
uncertain	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
analyse	VB	O
the	DT	O
influence	NN	O
of	IN	O
a	DT	O
co-administration	NN	O
of	IN	O
aspirin	NN	O
and	CC	O
NSAID	NNP	O
on	IN	O
platelet	NN	O
aggregation	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
,	,	O
eleven	RB	O
healthy	JJ	O
volunteers	NNS	O
were	VBD	O
studied	VBN	O
during	IN	O
4	CD	O
separate	JJ	O
study	NN	O
periods	NNS	O
of	IN	O
4	CD	O
days	NNS	O
each	DT	O
.	.	O

Individuals	NNS	O
were	VBD	O
treated	VBN	O
on	IN	O
each	DT	O
occasion	NN	O
with	IN	O
100	CD	O
mg	NNS	O
aspirin	JJ	O
daily	RB	O
in	IN	O
combination	NN	O
with	IN	O
either	DT	O
3	CD	O
x	VBD	O
1	CD	O
g	NN	O
acetaminophen	NN	O
,	,	O
3	CD	O
x	NN	O
50	CD	O
mg	NN	O
diclofenac	NN	O
,	,	O
3	CD	O
x	NN	O
250	CD	O
mg	NN	O
naproxen	NN	O
,	,	O
or	CC	O
3	CD	O
x	JJ	O
1	CD	O
placebo	NN	O
.	.	O

Primary	JJ	O
hemostasis	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
platelet	NN	O
function	NN	O
analyser	NN	O
(	(	O
PFA-100	NNP	O
)	)	O
,	,	O
which	WDT	O
measures	VBZ	O
the	DT	O
closure	NN	O
time	NN	O
(	(	O
CT	NNP	O
)	)	O
of	IN	O
a	DT	O
collagen-	JJ	O
and	CC	O
epinephrine-coated	JJ	O
pore	NN	O
by	IN	O
aggregating	VBG	O
platelets	NNS	O
in	IN	O
flowing	VBG	O
blood	NN	O
.	.	O

Naproxen	NNP	O
enhanced	VBD	O
the	DT	O
anti-aggregatory	JJ	O
action	NN	O
of	IN	O
aspirin	NN	O
after	IN	O
24	CD	O
h	NN	O
(	(	O
CT	NNP	O
rising	VBG	O
from	IN	O
104+/-16	JJ	O
s	NN	O
at	IN	O
baseline	NN	O
to	TO	O
212+/-69	JJ	O
s	NN	O
at	IN	O
24	CD	O
h	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	O
seen	VBN	O
with	IN	O
any	DT	O
other	JJ	O
drug	NN	O
combination	NN	O
.	.	O

Diclofenac	NNP	O
reduced	VBD	O
the	DT	O
anti-aggregatory	JJ	O
action	NN	O
of	IN	O
aspirin	NN	O
in	IN	O
the	DT	O
first	JJ	O
two	CD	O
days	NNS	O
,	,	O
since	IN	O
the	DT	O
CT	NNP	O
did	VBD	O
not	RB	O
rise	VB	O
significantly	RB	O
(	(	O
109+/-19	JJ	O
s	NN	O
,	,	O
148+/-56	JJ	O
s	NN	O
,	,	O
and	CC	O
168+/-66	JJ	O
s	NN	O
at	IN	O
0	CD	O
h	NN	O
,	,	O
24	CD	O
h	NN	O
,	,	O
48	CD	O
h	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Acetaminophen	NNP	O
had	VBD	O
no	DT	O
effect	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

After	IN	O
4	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
platelet	NN	O
aggregation	NN	O
was	VBD	O
similarly	RB	O
inhibited	VBN	O
by	IN	O
all	DT	O
combinations	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
co-administration	NN	O
of	IN	O
NSAID	NNP	O
and	CC	O
aspirin	NN	O
may	MD	O
interfere	VB	O
with	IN	O
platelet	NN	O
inhibition	NN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
a	DT	O
treatment	NN	O
with	IN	O
an	DT	O
increase	NN	O
of	IN	O
naproxen	JJ	O
and	CC	O
a	DT	O
decrease	NN	O
of	IN	O
diclofenac	NN	O
.	.	O

This	DT	O
effect	NN	O
is	VBZ	O
lost	VBN	O
after	IN	O
4	CD	O
days	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
a	DT	O
regular	JJ	O
daily	JJ	O
co-administration	NN	O
of	IN	O
NSAID	NNP	O
does	VBZ	O
not	RB	O
have	VB	O
an	DT	O
influence	NN	O
on	IN	O
platelet	NN	O
inhibition	NN	O
by	IN	O
aspirin	NN	O
.	.	O

Theta	NNP	O
burst	JJS	O
stimulation	NN	O
in	IN	O
the	DT	O
rehabilitation	NN	O
of	IN	O
the	DT	O
upper	JJ	O
limb	NN	O
:	:	O
a	DT	O
semirandomized	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
chronic	JJ	O
stroke	NN	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Noninvasive	NNP	O
cortical	JJ	O
stimulation	NN	O
could	MD	O
represent	VB	O
an	DT	O
add-on	JJ	O
treatment	NN	O
to	TO	O
enhance	VB	O
motor	NN	O
recovery	NN	O
after	IN	O
stroke	NN	O
.	.	O

However	RB	O
,	,	O
its	PRP$	O
clinical	JJ	O
value	NN	O
,	,	O
including	VBG	O
anticipated	VBN	O
size	NN	O
and	CC	O
duration	NN	O
of	IN	O
the	DT	O
treatment	NN	O
effects	NNS	O
,	,	O
remains	VBZ	O
largely	RB	O
unknown	JJ	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
authors	NNS	O
designed	VBD	O
a	DT	O
small	JJ	O
semi-randomized	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
explore	VB	O
whether	IN	O
long-lasting	JJ	O
clinically	RB	O
important	JJ	O
gains	NNS	O
can	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
adding	VBG	O
theta	JJ	O
burst	JJ	O
stimulation	NN	O
(	(	O
TBS	NNP	O
)	)	O
,	,	O
a	DT	O
form	NN	O
of	IN	O
repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
TMS	NNP	O
)	)	O
,	,	O
to	TO	O
a	DT	O
rehabilitation	NN	O
program	NN	O
for	IN	O
the	DT	O
hand	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
41	CD	O
chronic	JJ	O
stroke	NN	O
patients	NNS	O
received	VBD	O
excitatory	JJ	O
TBS	NNP	O
to	TO	O
the	DT	O
ipsilesional	NN	O
hemisphere	NN	O
or	CC	O
inhibitory	NN	O
TBS	NNP	O
to	TO	O
the	DT	O
contralesional	NN	O
hemisphere	NN	O
in	IN	O
2	CD	O
centers	NNS	O
;	:	O
each	DT	O
active	JJ	O
group	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
group	NN	O
receiving	VBG	O
sham	NN	O
TBS	NNP	O
.	.	O

TBS	NNP	O
was	VBD	O
followed	VBN	O
by	IN	O
physical	JJ	O
therapy	NN	O
for	IN	O
10	CD	O
working	JJ	O
days	NNS	O
.	.	O

Patients	NNS	O
and	CC	O
therapists	NNS	O
were	VBD	O
blinded	VBN	O
to	TO	O
the	DT	O
type	NN	O
of	IN	O
TBS	NNP	O
.	.	O

Primary	NNP	O
outcome	JJ	O
measures	NNS	O
(	(	O
9-hole	CD	O
Peg	NNP	O
Test	NNP	O
[	VBD	O
9HPT	CD	O
]	NN	O
,	,	O
Jebsen	NNP	O
Taylor	NNP	O
Test	NNP	O
[	NNP	O
JTT	NNP	O
]	NNP	O
,	,	O
and	CC	O
grip	NN	O
and	CC	O
pinch-grip	JJ	O
dynamometry	NN	O
)	)	O
were	VBD	O
assessed	VBN	O
4	CD	O
,	,	O
30	CD	O
,	,	O
and	CC	O
90	CD	O
days	NNS	O
post	RB	O
treatment	NN	O
.	.	O

The	DT	O
clinically	RB	O
important	JJ	O
difference	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
maximum	JJ	O
score	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
and	CC	O
sham	NN	O
groups	NNS	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
outcome	NN	O
measures	NNS	O
.	.	O

All	DT	O
patients	NNS	O
achieved	VBN	O
small	JJ	O
sustainable	JJ	O
improvements	NNS	O
--	:	O
9HPT	CD	O
,	,	O
5	CD	O
%	NN	O
of	IN	O
maximum	NN	O
(	(	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
=	VBD	O
3	CD	O
%	NN	O
-7	NNP	O
%	NN	O
)	)	O
;	:	O
JTT	NNP	O
,	,	O
5.7	CD	O
%	NN	O
(	(	O
CI	NNP	O
=	RB	O
3	CD	O
%	NN	O
-8	NNP	O
%	NN	O
)	)	O
;	:	O
and	CC	O
grip	VB	O
strength	NN	O
,	,	O
6	CD	O
%	NN	O
(	(	O
CI	NNP	O
=	RB	O
2	CD	O
%	NN	O
-10	NNP	O
%	NN	O
)	)	O
--	:	O
all	DT	O
below	IN	O
the	DT	O
defined	VBN	O
clinically	RB	O
important	JJ	O
level	NN	O
.	.	O

CONCLUSIONS	NNP	O
Cortical	NNP	O
stimulation	NN	O
did	VBD	O
not	RB	O
augment	VB	O
the	DT	O
gains	NNS	O
from	IN	O
a	DT	O
late	JJ	O
rehabilitation	NN	O
program	NN	O
.	.	O

The	DT	O
effect	NN	O
size	NN	O
anticipated	VBN	O
by	IN	O
the	DT	O
authors	NNS	O
was	VBD	O
overestimated	VBN	O
.	.	O

These	DT	O
results	NNS	O
can	MD	O
improve	VB	O
the	DT	O
design	NN	O
of	IN	O
future	JJ	O
work	NN	O
on	IN	O
therapeutic	JJ	O
uses	NNS	O
of	IN	O
TMS	NNP	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
disposition	NN	O
of	IN	O
carvedilol	NN	O
in	IN	O
humans	NNS	O
.	.	O

Pharmacokinetics	NNS	O
of	IN	O
carvedilol	NN	O
(	(	O
C	NNP	O
)	)	O
have	VBP	O
been	VBN	O
studied	VBN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
after	IN	O
a	DT	O
single	JJ	O
i.v	NN	O
.	.	O

and	CC	O
oral	JJ	O
administration	NN	O
,	,	O
and	CC	O
the	DT	O
metabolic	JJ	O
disposition	NN	O
after	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
14C-labeled	JJ	O
drug	NN	O
.	.	O

C	NNP	O
demonstrates	VBZ	O
dose-linear	JJ	O
behavior	NN	O
.	.	O

The	DT	O
absolute	JJ	O
bioavailability	NN	O
reaches	VBZ	O
24	CD	O
%	NN	O
probably	RB	O
due	JJ	O
to	TO	O
a	DT	O
first-pass	JJ	O
effect	NN	O
.	.	O

After	IN	O
a	DT	O
50	CD	O
mg	JJ	O
oral	JJ	O
dose	NN	O
,	,	O
maximum	JJ	O
concentrations	NNS	O
of	IN	O
66	CD	O
micrograms/l	NNS	O
are	VBP	O
achieved	VBN	O
within	IN	O
1.2	CD	O
h.	JJ	O
C	NNP	O
is	VBZ	O
extensively	RB	O
distributed	VBN	O
to	TO	O
the	DT	O
tissues	NNS	O
(	(	O
Vz	NNP	O
=	VBZ	O
132	CD	O
l	NN	O
)	)	O
and	CC	O
eliminated	VBN	O
primarily	RB	O
by	IN	O
hepatic	JJ	O
metabolism	NN	O
(	(	O
total	JJ	O
clearance	NN	O
590	CD	O
ml/min	NN	O
,	,	O
renal	JJ	O
clearance	NN	O
4	CD	O
ml/min	NN	O
)	)	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
longer	RBR	O
half-life	NN	O
of	IN	O
6.4	CD	O
h	NN	O
after	IN	O
oral	JJ	O
administration	NN	O
in	IN	O
contrast	NN	O
to	TO	O
2.4	CD	O
h	NN	O
after	IN	O
i.v	NN	O
.	.	O

administration	NN	O
,	,	O
C	NNP	O
is	VBZ	O
assumed	VBN	O
to	TO	O
be	VB	O
absorption	JJ	O
dependent	JJ	O
since	IN	O
no	DT	O
sustained-release	JJ	O
formulation	NN	O
was	VBD	O
used	VBN	O
.	.	O

The	DT	O
half-life	NN	O
of	IN	O
radioactivity	NN	O
in	IN	O
plasma	NN	O
is	VBZ	O
39	CD	O
h	NN	O
;	:	O
16	CD	O
%	NN	O
of	IN	O
C	NNP	O
is	VBZ	O
excreted	VBN	O
in	IN	O
urine	NN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
metabolites	NNS	O
and	CC	O
only	RB	O
0.3	CD	O
%	NN	O
unchanged	JJ	O
.	.	O

The	DT	O
urinary	JJ	O
metabolites	NNS	O
consist	VBP	O
of	IN	O
carvedilol	NN	O
glucuronide	NN	O
(	(	O
5.2	CD	O
%	NN	O
of	IN	O
the	DT	O
dose	NN	O
)	)	O
,	,	O
cleavage	JJ	O
products	NNS	O
of	IN	O
the	DT	O
beta-blocking	JJ	O
side	NN	O
chain	NN	O
(	(	O
2.1	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
ring-hydroxylated	JJ	O
forms	NNS	O
(	(	O
2.9	CD	O
%	NN	O
)	)	O
.	.	O

Sixty	NNP	O
percent	NN	O
of	IN	O
the	DT	O
dose	NN	O
is	VBZ	O
recovered	VBN	O
in	IN	O
the	DT	O
feces	NNS	O
.	.	O

A	DT	O
demethylated	JJ	O
product	NN	O
of	IN	O
C	NNP	O
exhibits	VBZ	O
only	RB	O
minor	JJ	O
beta-blocking	JJ	O
activity	NN	O
.	.	O

This	DT	O
metabolite	NN	O
is	VBZ	O
detected	VBN	O
in	IN	O
plasma	NN	O
in	IN	O
concentrations	NNS	O
ten	VBP	O
times	NNS	O
lower	JJR	O
than	IN	O
the	DT	O
parent	NN	O
compound	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
diclofenac	JJ	O
sodium	NN	O
and	CC	O
morphine	NN	O
sulphate	NN	O
for	IN	O
postoperative	JJ	O
analgesia	NN	O
after	IN	O
day	NN	O
case	NN	O
inguinal	JJ	Condition
hernia	NN	Condition
surgery	NN	Condition
.	.	O

Postoperative	NNP	O
pain	NN	O
may	MD	O
be	VB	O
a	DT	O
significant	JJ	O
reason	NN	O
for	IN	O
delayed	JJ	O
discharge	NN	O
from	IN	O
hospital	NN	O
,	,	O
increased	VBN	O
morbidity	NN	O
and	CC	O
reduced	JJ	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
ambulatory	JJ	Condition
hernia	NN	Condition
surgery	NN	Condition
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
two	CD	O
postoperative	JJ	O
oral	JJ	O
analgesic	NN	O
protocols	NNS	O
after	IN	O
day	NN	Condition
case	NN	Condition
inguinal	JJ	Condition
hernia	NN	Condition
repair	NN	Condition
;	:	O
30	CD	O
mg	NN	O
morphine	NN	O
sulphate	NN	O
(	(	O
MST	NNP	O
)	)	O
and	CC	O
10	CD	O
mg	NNS	O
metoclopramide	RB	O
every	DT	O
8	CD	O
h	NN	O
for	IN	O
48	CD	O
h	NN	O
or	CC	O
75	CD	O
mg	NNS	O
diclofenac	JJ	O
twice	RB	O
daily	RB	O
for	IN	O
48	CD	O
h.	PDT	O
The	DT	O
pain	NN	O
reported	VBD	O
in	IN	O
the	DT	O
MST	NNP	O
group	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
on	IN	O
both	DT	O
the	DT	O
day	NN	O
of	IN	O
operation	NN	O
and	CC	O
the	DT	O
first	JJ	O
postoperative	JJ	O
day	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
,	,	O
Mann-Whitney	NNP	O
U	NNP	O
test	NN	O
)	)	O
.	.	O

A	DT	O
significantly	RB	O
higher	JJR	O
proportion	NN	O
of	IN	O
patients	NNS	Condition
taking	VBG	Condition
MST	NNP	Condition
complained	VBD	O
of	IN	O
nausea	NN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
operation	NN	O
and	CC	O
on	IN	O
the	DT	O
1st	CD	O
postoperative	JJ	O
day	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
,	,	O
chi	RB	O
2	CD	O
)	)	O
.	.	O

The	DT	O
time	NN	O
taken	VBN	O
to	TO	O
walk	VB	O
,	,	O
dress	NN	O
and	CC	O
leave	VBP	O
home	NN	O
alone	RB	O
were	VBD	O
achieved	VBN	O
in	IN	O
a	DT	O
significantly	RB	O
shorter	JJR	O
duration	NN	O
in	IN	O
patients	NNS	O
taking	VBG	O
diclofenac	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
diclofenac	NN	O
provides	VBZ	O
effective	JJ	O
analgesia	NN	O
,	,	O
has	VBZ	O
a	DT	O
more	RBR	O
acceptable	JJ	O
side-effect	JJ	O
profile	NN	O
than	IN	O
morphine	JJ	O
sulphate	NN	O
and	CC	O
is	VBZ	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
after	IN	O
ambulatory	NN	O
hernia	NN	O
surgery	NN	O
.	.	O

Components	NNS	O
of	IN	O
working	VBG	O
memory	NN	O
and	CC	O
visual	JJ	O
selective	JJ	O
attention	NN	O
.	.	O

Load	NNP	O
theory	NN	O
(	(	O
Lavie	NNP	O
,	,	O
N.	NNP	O
,	,	O
Hirst	NNP	O
,	,	O
A.	NNP	O
,	,	O
De	NNP	O
Fockert	NNP	O
,	,	O
J.	NNP	O
W.	NNP	O
,	,	O
&	CC	O
Viding	NNP	O
,	,	O
E.	NNP	O
[	NNP	O
2004	CD	O
]	NNP	O
.	.	O

Load	NNP	O
theory	NN	O
of	IN	O
selective	JJ	O
attention	NN	O
and	CC	O
cognitive	JJ	O
control	NN	O
.	.	O

Journal	NNP	O
of	IN	O
Experimental	NNP	O
Psychology	NNP	O
:	:	O
General	NNP	O
,	,	O
133	CD	O
,	,	O
339-354	JJ	O
.	.	O

)	)	O
proposes	VBZ	O
that	IN	O
control	NN	O
of	IN	O
attention	NN	O
depends	VBZ	O
on	IN	O
the	DT	O
amount	NN	O
and	CC	O
type	NN	O
of	IN	O
load	NN	O
that	WDT	O
is	VBZ	O
imposed	VBN	O
by	IN	O
current	JJ	O
processing	NN	O
.	.	O

Specifically	RB	O
,	,	O
perceptual	JJ	O
load	NN	O
should	MD	O
lead	VB	O
to	TO	O
efficient	JJ	O
distractor	NN	O
rejection	NN	O
,	,	O
whereas	IN	O
working	VBG	O
memory	NN	O
load	NN	O
(	(	O
dual-task	JJ	O
coordination	NN	O
)	)	O
should	MD	O
hinder	VB	O
distractor	NN	O
rejection	NN	O
.	.	O

Studies	NNPS	O
support	VBP	O
load	NN	O
theory	NN	O
's	POS	O
prediction	NN	O
that	IN	O
working	VBG	O
memory	NN	O
load	NN	O
will	MD	O
lead	VB	O
to	TO	O
larger	JJR	O
distractor	NN	O
effects	NNS	O
;	:	O
however	RB	O
,	,	O
these	DT	O
studies	NNS	O
used	VBD	O
secondary	JJ	O
tasks	NNS	O
that	WDT	O
required	VBD	O
only	RB	O
verbal	JJ	O
working	VBG	O
memory	NN	O
and	CC	O
the	DT	O
central	JJ	O
executive	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
which	WDT	O
other	JJ	O
working	VBG	O
memory	NN	O
components	NNS	O
(	(	O
visual	JJ	O
,	,	O
spatial	JJ	O
,	,	O
and	CC	O
phonological	JJ	O
)	)	O
influence	NN	O
visual	JJ	Condition
selective	JJ	Condition
attention	NN	Condition
.	.	O

Subjects	NNS	O
completed	VBD	O
an	DT	O
attentional	JJ	O
capture	NN	O
task	NN	O
alone	RB	O
(	(	O
single-task	JJ	O
)	)	O
or	CC	O
while	IN	O
engaged	VBN	O
in	IN	O
a	DT	O
working	JJ	O
memory	NN	O
task	NN	O
(	(	O
dual-task	JJ	O
)	)	O
.	.	O

Results	CC	O
showed	VBD	O
that	IN	O
along	IN	O
with	IN	O
the	DT	O
central	JJ	O
executive	NN	O
,	,	O
visual	JJ	O
and	CC	O
spatial	JJ	O
working	VBG	O
memory	NN	O
influenced	VBD	O
selective	JJ	O
attention	NN	O
,	,	O
but	CC	O
phonological	JJ	O
working	VBG	O
memory	NN	O
did	VBD	O
not	RB	O
.	.	O

Specifically	RB	O
,	,	O
attentional	JJ	O
capture	NN	O
was	VBD	O
larger	JJR	O
when	WRB	O
visual	JJ	O
or	CC	O
spatial	JJ	O
working	VBG	O
memory	NN	O
was	VBD	O
loaded	VBN	O
,	,	O
but	CC	O
phonological	JJ	O
working	VBG	O
memory	NN	O
load	NN	O
did	VBD	O
not	RB	O
affect	VB	O
attentional	JJ	O
capture	NN	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
load	NN	O
theory	NN	O
and	CC	O
suggest	VBP	O
specific	JJ	O
components	NNS	O
of	IN	O
working	VBG	O
memory	NN	O
influence	NN	O
visual	JJ	O
selective	JJ	O
attention	NN	O
.	.	O

ARIX	NN	O
:	:	O
a	DT	O
randomised	JJ	O
trial	NN	O
of	IN	O
acupuncture	NN	O
v	FW	O
oral	JJ	O
care	NN	O
sessions	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
xerostomia	NN	Condition
following	VBG	O
treatment	NN	O
of	IN	O
head	NN	Condition
and	CC	Condition
neck	NN	Condition
cancer	NN	Condition
.	.	O

BACKGROUND	NNP	O
Radiation	NNP	O
treatment	NN	O
of	IN	O
head	NN	Condition
and	CC	Condition
neck	NN	Condition
cancer	NN	Condition
can	MD	O
cause	VB	O
chronic	JJ	Condition
xerostomia	NN	Condition
which	WDT	O
impairs	VBZ	O
patients	NNS	O
'	POS	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

The	DT	O
study	NN	O
reported	VBD	O
here	RB	O
examined	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
acupuncture	NN	O
in	IN	O
alleviating	VBG	O
xerostomia	NN	O
symptoms	NNS	O
especially	RB	O
dry	JJ	O
mouth	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
145	CD	SampleSize
patients	NNS	O
with	IN	O
chronic	JJ	Condition
radiation-induced	JJ	Condition
xerostomia	NN	Condition
>	$	O
18	CD	O
months	NNS	O
after	IN	O
treatments	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
seven	CD	O
UK	NNP	O
cancer	NN	O
centres	NNS	O
.	.	O

The	DT	O
study	NN	O
employed	VBD	O
a	DT	O
randomised	JJ	O
crossover	NN	O
design	NN	O
with	IN	O
participants	NNS	O
receiving	VBG	O
two	CD	O
group	NN	O
sessions	NNS	O
of	IN	O
oral	JJ	O
care	NN	O
education	NN	O
and	CC	O
eight	CD	O
of	IN	O
acupuncture	NN	O
using	VBG	O
standardised	VBN	O
methods	NNS	O
.	.	O

Patient-reported	JJ	O
outcome	NN	O
(	(	O
PROs	NNP	O
)	)	O
measures	NNS	O
were	VBD	O
completed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
weeks	NNS	O
5	CD	O
,	,	O
9	CD	O
,	,	O
13	CD	O
,	,	O
17	CD	O
,	,	O
and	CC	O
21	CD	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
improvement	NN	O
in	IN	O
dry	JJ	O
mouth	NN	O
.	.	O

OBJECTIVE	NNP	O
saliva	NN	O
measurements	NNS	O
were	VBD	O
also	RB	O
carried	VBN	O
out	RP	O
.	.	O

RESULTS	JJ	O
Acupuncture	NNP	O
compared	VBN	O
with	IN	O
oral	JJ	O
care	NN	O
,	,	O
produced	VBD	O
significant	JJ	O
reductions	NNS	O
in	IN	O
patient	JJ	O
reports	NNS	O
of	IN	O
severe	JJ	O
dry	JJ	O
mouth	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
2.01	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.031	CD	O
)	)	O
sticky	NN	O
saliva	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
1.67	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.048	CD	O
)	)	O
,	,	O
needing	VBG	O
to	TO	O
sip	VB	O
fluids	NNS	O
to	TO	O
swallow	VB	O
food	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
2.08	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
and	CC	O
in	IN	O
waking	VBG	O
up	RP	O
at	IN	O
night	NN	O
to	TO	O
drink	VB	O
(	(	O
OR	NNP	O
=	VBZ	O
1.71	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
either	DT	O
stimulated	VBD	O
or	CC	O
unstimulated	JJ	O
saliva	NN	O
measurements	NNS	O
over	IN	O
time	NN	O
.	.	O

CONCLUSION	NNP	O
Eight	NNP	O
sessions	NNS	O
of	IN	O
weekly	JJ	O
group	NN	O
acupuncture	NN	O
compared	VBN	O
with	IN	O
group	NN	O
oral	JJ	O
care	NN	O
education	NN	O
provide	VBP	O
significantly	RB	O
better	JJR	O
relief	NN	O
of	IN	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
chronic	JJ	Condition
radiation-induced	JJ	Condition
xerostomia	NN	Condition
.	.	Condition

Clomipramine	NNP	O
versus	NN	O
haloperidol	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autistic	JJ	Condition
disorder	NN	Condition
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Clomipramine	NNP	O
,	,	O
haloperidol	NN	O
,	,	O
and	CC	O
placebo	NN	O
were	VBD	O
compared	VBN	O
with	IN	O
baseline	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	Condition
,	,	O
and	CC	O
overall	JJ	O
outcome	NN	O
,	,	O
specific	JJ	O
symptoms	NNS	O
,	,	O
and	CC	O
side	JJ	O
effects	NNS	O
were	VBD	O
examined	VBN	O
.	.	O

It	PRP	O
was	VBD	O
hypothesized	VBN	O
that	IN	O
clomipramine	NN	O
would	MD	O
be	VB	O
better	RB	O
tolerated	VBN	O
than	IN	O
haloperidol	NN	O
and	CC	O
prove	VB	O
superior	JJ	O
on	IN	O
a	DT	O
measure	NN	O
of	IN	O
stereotypy	NN	O
.	.	O

Individuals	NNS	O
with	IN	O
a	DT	O
DSM-IV	JJ	O
diagnosis	NN	O
of	IN	O
autistic	JJ	Condition
disorder	NN	Condition
(	(	O
mean	JJ	O
age	NN	O
,	,	O
16.3	CD	O
years	NNS	O
;	:	O
range	NN	O
,	,	O
10-36	JJ	O
years	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
,	,	O
by	IN	O
using	VBG	O
a	DT	O
Latin	NNP	O
square	NN	O
design	NN	O
,	,	O
to	TO	O
the	DT	O
following	JJ	O
7-week	JJ	O
trials	NNS	O
:	:	O
placebo	NN	O
,	,	O
clomipramine	NN	Condition
(	(	O
mean	JJ	O
daily	RB	O
dose	RB	O
,	,	O
128.4	CD	O
mg	NN	O
;	:	O
range	NN	O
,	,	O
100-150	JJ	O
mg	NN	O
)	)	O
,	,	O
or	CC	O
haloperidol	NN	O
(	(	O
mean	JJ	O
daily	RB	O
dose	RB	O
,	,	O
1.3	CD	O
mg	NN	O
;	:	O
range	NN	O
,	,	O
1-1.5	JJ	O
mg	NN	O
)	)	O
.	.	O

Data	NNP	O
on	IN	O
36	CD	SampleSize
subjects	NNS	O
were	VBD	O
analyzed	VBN	O
and	CC	O
taken	VBN	O
together	RB	O
;	:	O
the	DT	O
results	NNS	O
favored	VBD	O
haloperidol	NN	O
.	.	O

In	IN	O
those	DT	O
patients	NNS	O
who	WP	O
were	VBD	O
able	JJ	O
to	TO	O
complete	VB	O
a	DT	O
full	JJ	O
therapeutic	JJ	O
trial	NN	O
,	,	O
clomipramine	NN	O
proved	VBD	O
comparable	JJ	O
to	TO	O
haloperidol	VB	O
in	IN	O
terms	NNS	O
of	IN	O
improvement	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
.	.	O

However	RB	O
,	,	O
significantly	RB	O
fewer	JJR	O
individuals	NNS	O
receiving	VBG	O
clomipramine	NN	O
versus	NN	O
haloperidol	NN	O
were	VBD	O
able	JJ	O
to	TO	O
complete	VB	O
the	DT	O
trial	NN	O
(	(	O
37.5	CD	O
%	NN	O
vs.	FW	O
69.7	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
for	IN	O
reasons	NNS	O
related	VBN	O
to	TO	O
both	DT	O
side	NN	O
effects	NNS	O
and	CC	O
efficacy	NN	O
or	CC	O
behavior	NN	O
problems	NNS	O
.	.	O

In	IN	O
the	DT	O
intent-to-treat	JJ	O
sample	NN	O
,	,	O
which	WDT	O
is	VBZ	O
perhaps	RB	O
more	RBR	O
clinically	RB	O
relevant	JJ	O
,	,	O
only	RB	O
haloperidol	VBZ	O
proved	VBN	O
superior	JJ	O
to	TO	O
baseline	VB	O
on	IN	O
a	DT	O
global	JJ	O
measure	NN	O
of	IN	O
autistic	JJ	O
symptom	NN	O
severity	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
specific	JJ	O
measures	NNS	O
for	IN	O
irritability	NN	O
and	CC	O
hyperactivity	NN	O
.	.	O

Clomipramine	NNP	O
did	VBD	O
not	RB	O
seem	VB	O
more	RBR	O
effective	JJ	O
on	IN	O
a	DT	O
measure	NN	O
of	IN	O
stereotypy	NN	O
,	,	O
nor	CC	O
was	VBD	O
it	PRP	O
better	RBR	O
tolerated	VBN	O
.	.	O

Randomized	VBN	O
trial	NN	O
comparing	VBG	O
induction	NN	O
chemotherapy	NN	O
versus	NN	O
induction	NN	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
maintenance	NN	O
chemotherapy	NN	O
in	IN	O
small-cell	JJ	Condition
lung	NN	Condition
cancer	NN	Condition
.	.	O

European	JJ	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
.	.	O

PURPOSE	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
European	NNP	O
Lung	NNP	O
Cancer	NNP	O
Working	NNP	O
Party	NNP	O
(	(	O
ELCWP	NNP	O
)	)	O
performed	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
with	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
to	TO	O
determine	VB	O
if	IN	O
maintenance	NN	O
chemotherapy	NN	O
with	IN	O
12	CD	O
courses	NNS	O
of	IN	O
etoposide	NN	O
(	(	O
120	CD	O
mg/m2	NN	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
3	CD	O
)	)	O
and	CC	O
vindesine	NN	O
(	(	O
3	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
3	CD	O
)	)	O
could	MD	O
improve	VB	O
progression-free	JJ	O
survival	NN	O
in	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
SCLC	NNP	O
)	)	O
patients	NNS	O
who	WP	O
responded	VBD	O
to	TO	O
six	CD	O
courses	NNS	O
of	IN	O
induction	NN	O
chemotherapy	NN	O
with	IN	O
ifosfamide	NN	O
,	,	O
etoposide	RB	O
,	,	O
and	CC	O
an	DT	O
anthracycline	NN	O
(	(	O
doxorubicin	NN	O
or	CC	O
epirubicin	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Among	IN	O
235	CD	SampleSize
eligible	JJ	O
patients	NNS	O
initially	RB	O
registered	VBD	O
,	,	O
91	CD	SampleSize
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
maintenance	NN	O
therapy	NN	O
,	,	O
including	VBG	O
seven	CD	SampleSize
patients	NNS	O
who	WP	O
were	VBD	O
no	RB	O
longer	RBR	O
responding	VBG	O
.	.	O

Among	IN	O
84	CD	O
randomized	JJ	O
responders	NNS	O
,	,	O
progression-free	JJ	O
survival	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
by	IN	O
maintenance	NN	O
therapy	NN	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
(	(	O
maintenance	NN	O
v	IN	O
follow-up	JJ	O
)	)	O
of	IN	O
25	CD	O
versus	NNS	O
12	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
second	JJ	O
randomization	NN	O
,	,	O
but	CC	O
survival	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
increased	VBN	O
(	(	O
P	NNP	O
=	NNP	O
.10	NNP	O
)	)	O
,	,	O
with	IN	O
median	JJ	O
durations	NNS	O
of	IN	O
48	CD	O
and	CC	O
38	CD	O
weeks	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
a	DT	O
multi-variate	JJ	O
analysis	NN	O
that	WDT	O
took	VBD	O
into	IN	O
account	NN	O
disease	NN	O
extent	NN	O
,	,	O
maintenance	NN	O
therapy	NN	O
,	,	O
Karnofsky	NNP	O
performance	NN	O
status	NN	O
(	(	O
PS	NNP	O
)	)	O
,	,	O
and	CC	O
absolute	JJ	O
dose-intensity	NN	O
(	(	O
ADI	NNP	O
)	)	O
of	IN	O
anthracycline	NN	O
given	VBN	O
during	IN	O
induction	NN	O
,	,	O
limited	JJ	O
disease	NN	O
(	(	O
LD	NNP	O
)	)	O
and	CC	O
maintenance	NN	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
independent	JJ	O
positive	JJ	O
predictors	NNS	O
of	IN	O
survival	NN	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
conclude	VBP	O
that	DT	O
maintenance	NN	O
chemotherapy	NN	O
in	IN	O
responding	VBG	O
patients	NNS	O
is	VBZ	O
beneficial	JJ	O
in	IN	O
SCLC	NNP	O
.	.	O

Impact	NN	O
of	IN	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blocker	NN	O
therapy	NN	O
(	(	O
olmesartan	JJ	O
or	CC	O
valsartan	NN	O
)	)	O
on	IN	O
coronary	JJ	O
atherosclerotic	JJ	O
plaque	NN	O
volume	NN	O
measured	VBN	O
by	IN	O
intravascular	JJ	O
ultrasound	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	Condition
angina	JJ	Condition
pectoris	NN	Condition
.	.	O

Coronary	JJ	O
plaques	NNS	O
can	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
some	DT	O
medications	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
2	CD	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
(	(	O
olmesartan	NN	O
at	IN	O
20	CD	O
mg/day	NN	O
or	CC	O
valsartan	NN	O
at	IN	O
80	CD	O
mg/day	NN	O
)	)	O
on	IN	O
coronary	JJ	O
plaque	NN	O
by	IN	O
coronary	JJ	O
intravascular	JJ	O
ultrasound	NN	O
.	.	O

One	CD	SampleSize
hundred	VBD	SampleSize
hypertensive	JJ	Condition
patients	NNS	O
with	IN	O
stable	JJ	Condition
angina	NNS	Condition
pectoris	NNS	Condition
who	WP	O
underwent	VBP	O
elective	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
were	VBD	O
randomly	RB	O
selected	VBN	O
to	TO	O
receive	VB	O
1	CD	O
of	IN	O
the	DT	O
2	CD	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
after	IN	O
coronary	JJ	O
intervention	NN	O
.	.	O

Nontarget	NNP	O
coronary	JJ	O
lesions	NNS	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
stenosis	NN	O
were	VBD	O
measured	VBN	O
by	IN	O
volumetric	JJ	O
intravascular	JJ	O
ultrasound	NN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
both	CC	O
the	DT	O
olmesartan	NN	O
and	CC	O
the	DT	O
valsartan	NN	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
examined	JJ	O
coronary	JJ	O
plaque	NN	O
volume	NN	O
(	(	O
46.2	CD	O
?	.	O
24.1	CD	O
mm?	NN	O
at	IN	O
baseline	NN	O
vs	NN	O
41.6	CD	O
?	.	O
21.1	CD	O
mm?	NN	O
at	IN	O
6	CD	O
months	NNS	O
:	:	O
4.7	CD	O
%	NN	O
decrease	NN	O
,	,	O
p	VBP	O
=	JJ	O
0.0002	CD	O
;	:	O
and	CC	O
47.2	CD	O
?	.	O
32.7	CD	O
mm?	NN	O
at	IN	O
baseline	NN	O
vs	NN	O
42.5	CD	O
?	.	O
30.2	CD	O
mm?	NN	O
at	IN	O
6	CD	O
months	NNS	O
:	:	O
4.8	CD	O
%	NN	O
decrease	NN	O
,	,	O
p	VBP	O
=	JJ	O
0.002	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
of	IN	O
plaque	JJ	O
regression	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.96	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
coronary	JJ	O
plaque	NN	O
volume	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NNS	O
pectoris	NN	O
who	WP	O
received	VBD	O
olmesartan	PRP	O
or	CC	O
valsartan	VB	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
reduction	NN	O
of	IN	O
plaque	NN	O
volume	NN	O
achieved	VBN	O
by	IN	O
these	DT	O
2	CD	O
medications	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
body	NN	O
weight	JJ	O
changes	NNS	O
and	CC	O
endurance	NN	O
training	NN	O
on	IN	O
24h	CD	O
substrate	JJ	O
oxidation	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
exercise	NN	O
training	NN	O
and	CC	O
dietary	JJ	O
macronutrient	NN	O
composition	NN	O
on	IN	O
24	CD	O
h	NN	O
substrate	JJ	O
oxidation	NN	O
in	IN	O
male	NN	Sex
,	,	O
obese	JJ	Condition
subjects	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
16	CD	O
month	NN	O
exercise	NN	O
intervention	NN	O
study	NN	O
was	VBD	O
executed	VBN	O
,	,	O
including	VBG	O
a	DT	O
weight	JJ	O
loss	NN	O
period	NN	O
with	IN	O
a	DT	O
very	RB	O
low	JJ	O
energy	NN	O
diet	NN	O
(	(	O
VLED	NNP	O
)	)	O
for	IN	O
2	CD	O
months	NNS	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

SUBJECTS	NNP	O
Twelve	NNP	SampleSize
male	NN	O
,	,	O
obese	JJ	Condition
subjects	NNS	O
(	(	O
age	NN	O
36.3+/-5.1	CD	Age
y	NN	O
;	:	O
body	NN	O
weight	VBD	O
94.6+/-13.9	CD	O
kg	NN	O
;	:	O
body	NN	O
mass	NN	O
index	NN	O
,	,	O
BMI	NNP	O
30.8+/-3.0	NNP	O
kg/m2	NN	O
)	)	O
and	CC	O
in	IN	O
an	DT	O
additional	JJ	O
study	NN	O
15	CD	O
lean	JJ	O
,	,	O
well-trained	JJ	O
subjects	NNS	O
(	(	O
age	NN	O
36.2+/-7.2	CD	Age
y	NN	O
;	:	O
body	NN	O
weight	VBD	O
72.2+/-5.9	JJ	O
kg	NN	O
;	:	O
BMI	NNP	O
22.3+/-1.7	CD	O
kg/m2	NN	O
)	)	O
participated	VBD	O
.	.	O

MEASUREMENTS	NNP	O
Substrate	NNP	O
oxidation	NN	O
was	VBD	O
measured	VBN	O
during	IN	O
a	DT	O
standardized	JJ	O
36	CD	O
h	NN	O
stay	NN	O
in	IN	O
the	DT	O
respiration	NN	O
chamber	NN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
0	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
at	IN	O
4	CD	O
,	,	O
10	CD	O
and	CC	O
16	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
respiration	NN	O
chamber	NN	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
high-fat	NN	O
(	(	O
Hi.F	NNP	O
)	)	O
diet	NN	O
(	(	O
60	CD	O
%	NN	O
of	IN	O
energy	NN	O
(	(	O
En	NNP	O
%	NN	O
)	)	O
fat	NN	O
)	)	O
or	CC	O
a	DT	O
reduced-fat	JJ	O
(	(	O
Red.F	NNP	O
)	)	O
diet	NN	O
(	(	O
30	CD	O
En	NNP	O
%	NN	O
fat	NN	O
)	)	O
.	.	O

The	DT	O
well-trained	JJ	O
group	NN	O
was	VBD	O
measured	VBN	O
once	RB	O
in	IN	O
the	DT	O
respiration	NN	O
chamber	NN	O
for	IN	O
36	CD	O
h	NN	O
according	VBG	O
to	TO	O
the	DT	O
same	JJ	O
protocol	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
any	DT	O
time	NN	O
point	NN	O
,	,	O
independent	JJ	O
of	IN	O
the	DT	O
diet	NN	O
consumed	VBD	O
,	,	O
the	DT	O
24	CD	O
h	NN	O
carbohydrate	NN	O
(	(	O
CHO	NNP	O
)	)	O
balances	NNS	O
in	IN	O
the	DT	O
chamber	NN	O
were	VBD	O
mostly	RB	O
negative	JJ	O
(	(	O
means	NNS	O
ranging	VBG	O
from	IN	O
+31	NN	O
to	TO	O
-98	VB	O
g/d	NN	O
)	)	O
and	CC	O
the	DT	O
fat	JJ	O
balances	NNS	O
mostly	RB	O
positive	JJ	O
(	(	O
means	NNS	O
ranging	VBG	O
from	IN	O
-26	NN	O
to	TO	O
+38	VB	O
g/d	NN	O
)	)	O
for	IN	O
the	DT	O
obese	NN	O
a	DT	O
well	RB	O
as	IN	O
for	IN	O
the	DT	O
lean	JJ	O
,	,	O
well-trained	JJ	O
group	NN	O
.	.	O

For	IN	O
both	DT	O
diets	NNS	O
an	DT	O
increased	JJ	O
shortage	NN	O
of	IN	O
70	CD	O
g	NN	O
of	IN	O
CHO	NNP	O
was	VBD	O
found	VBN	O
at	IN	O
16	CD	O
months	NNS	O
compared	VBN	O
with	IN	O
4	CD	O
months	NNS	O
,	,	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
fat	JJ	O
balance	NN	O
of	IN	O
33	CD	O
g	NN	O
during	IN	O
the	DT	O
same	JJ	O
time	NN	O
period	NN	O
in	IN	O
the	DT	O
obese	JJ	O
subjects	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
CHO	NNP	O
oxidation	NN	O
had	VBD	O
increased	VBN	O
with	IN	O
12	CD	O
months	NNS	O
endurance	RB	O
training	VBG	O
.	.	O

In	IN	O
the	DT	O
well-trained	JJ	O
group	NN	O
the	DT	O
24h	CD	O
CHO	NNP	O
balance	NN	O
was	VBD	O
even	RB	O
more	RBR	O
negative	JJ	O
for	IN	O
both	DT	O
types	NNS	O
of	IN	O
diet	NN	O
(	(	O
-103	UH	O
to	TO	O
-185	VB	O
g/d	NN	O
for	IN	O
the	DT	O
Red.F	NNP	O
and	CC	O
Hi.F	NNP	O
diet	NN	O
,	,	O
respectively	RB	O
)	)	O
under	IN	O
similar	JJ	O
conditions	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
trained	JJ	O
obese	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
changes	NNS	O
in	IN	O
24	CD	O
h	NN	O
substrate	JJ	O
utilization	NN	O
in	IN	O
the	DT	O
obese	JJ	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
the	DT	O
well-trained	JJ	O
group	NN	O
,	,	O
suggest	VBP	O
that	IN	O
endurance	NN	O
training	NN	O
increased	VBD	O
the	DT	O
reliance	NN	O
on	IN	O
carbohydrate	NN	O
oxidation	NN	O
and	CC	O
therefore	RB	O
did	VBD	O
not	RB	O
increase	VB	O
24	CD	O
fat	JJ	O
oxidation	NN	O
.	.	O

Comparative	NNP	O
study	NN	O
of	IN	O
actinic	JJ	Condition
keratosis	NN	Condition
treatment	NN	O
with	IN	O
3	CD	O
%	NN	O
diclofenac	JJ	O
sodium	NN	O
and	CC	O
5	CD	O
%	NN	O
5-fluorouracil	JJ	O
.	.	O

BACKGROUND	NNP	O
Actinic	NNP	Condition
keratosis	NN	Condition
is	VBZ	O
a	DT	O
frequent	JJ	O
lesion	NN	O
which	WDT	O
occurs	VBZ	O
in	IN	O
sunlight	NN	O
exposed	VBN	O
areas	NNS	O
.	.	O

Diclofenac	NNP	O
sodium	NN	O
and	CC	O
5-Fluorouracil	JJ	O
are	VBP	O
effective	JJ	O
,	,	O
non-invasive	JJ	O
and	CC	O
easy-to-apply	JJ	O
topical	JJ	O
treatment	NN	O
options	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
assess	VB	O
and	CC	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
3	CD	O
%	NN	O
diclofenac	JJ	O
sodium	NN	O
associated	VBN	O
with	IN	O
2.5	CD	O
%	NN	O
hyaluronic	JJ	O
acid	NN	O
and	CC	O
of	IN	O
5	CD	O
%	NN	O
5-Fluorouracil	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
actinic	JJ	O
keratosis	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
patient	NN	O
's	POS	O
degree	NN	O
of	IN	O
satisfaction	NN	O
and	CC	O
tolerability	NN	O
.	.	O

METHODS	NNP	O
28	CD	SampleSize
patients	NNS	SampleSize
with	IN	O
a	DT	O
clinical	JJ	Condition
diagnosis	NN	Condition
of	IN	Condition
actinic	JJ	Condition
keratosis	NN	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
diclofenac	JJ	O
sodium	NN	O
or	CC	O
5-Fluorouracil	JJ	O
and	CC	O
were	VBD	O
clinically	RB	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
as	RB	O
well	RB	O
as	IN	O
8	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

Modified	NNP	O
versions	NNS	O
of	IN	O
the	DT	O
Investigator	NNP	O
and	CC	O
Patient	NNP	O
Global	NNP	O
Improvement	NNP	O
Scores	NNP	O
were	VBD	O
used	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
average	JJ	O
number	NN	O
of	IN	O
lesions	NNS	O
in	IN	O
the	DT	O
diclofenac	NN	O
sodium	NN	O
group	NN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
was	VBD	O
13.6	CD	O
and	CC	O
6.6	CD	O
(	(	O
p	NN	O
<	RB	O
0,001	CD	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
17.4	CD	O
and	CC	O
3.15	CD	O
(	(	O
p	NN	O
<	RB	O
0.001	CD	O
)	)	O
in	IN	O
the	DT	O
5-Fluorouracil	JJ	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
lesions	NNS	O
in	IN	O
the	DT	O
5-Fluorouracil	JJ	O
group	NN	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
diclofenac	NN	O
sodium	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

To	TO	O
the	DT	O
non-blinded	JJ	O
physician	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
higher	JJR	O
satisfactory	JJ	O
therapeutic	JJ	O
response	NN	O
in	IN	O
the	DT	O
5-Fluorouracil	JJ	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
;	:	O
to	TO	O
the	DT	O
blinded	JJ	O
physician	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
higher	JJR	O
satisfactory	JJ	O
response	NN	O
in	IN	O
this	DT	O
same	JJ	O
group	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p=0.09	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
high	JJ	O
degree	NN	O
of	IN	O
satisfaction	NN	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
73	CD	O
%	NN	O
in	IN	O
the	DT	O
diclofenac	NN	O
sodium	NN	O
group	NN	O
and	CC	O
77	CD	O
%	NN	O
in	IN	O
the	DT	O
5-Fluorouracil	JJ	O
group	NN	O
;	:	O
p=0.827	NN	O
)	)	O
.	.	O

Regarding	VBG	O
adverse	JJ	O
effects	NNS	O
,	,	O
the	DT	O
diclofenac	NN	O
sodium	NN	O
group	NN	O
presented	VBD	O
a	DT	O
higher	JJR	O
degree	NN	O
of	IN	O
satisfaction	NN	O
(	(	O
93.3	CD	O
%	NN	O
vs	JJ	O
38.4	CD	O
%	NN	O
;	:	O
p=0.008	NN	O
)	)	O
.	.	O

Erythema	NNP	O
,	,	O
edema	NN	O
,	,	O
crusts	NNS	O
and	CC	O
itching	VBG	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
5-Fluorouracil	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
concluded	VBD	O
that	IN	O
5-Fluorouracil	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
;	:	O
however	RB	O
,	,	O
it	PRP	O
showed	VBD	O
lower	JJR	O
tolerability	NN	O
than	IN	O
diclofenac	JJ	O
sodium	NN	O
.	.	O

Treatment	NN	O
of	IN	O
acute	NN	Condition
otitis	NN	Condition
media	NNS	Condition
in	IN	Condition
children	NNS	Condition
under	IN	Condition
2	CD	Condition
years	NNS	Condition
of	IN	Condition
age	NN	Condition
.	.	Condition

BACKGROUND	NNP	O
Recommendations	NNP	O
vary	VBP	O
regarding	VBG	O
immediate	JJ	O
antimicrobial	JJ	O
treatment	NN	O
versus	NN	O
watchful	JJ	O
waiting	VBG	O
for	IN	O
children	NNS	O
younger	JJR	O
than	IN	O
2	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
acute	JJ	O
otitis	NN	O
media	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBN	O
291	CD	O
children	NNS	O
6	CD	O
to	TO	O
23	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
with	IN	O
acute	JJ	O
otitis	NN	O
media	NNS	O
diagnosed	VBN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
stringent	NN	O
criteria	NNS	O
,	,	O
to	TO	O
receive	VB	O
amoxicillin-clavulanate	NN	O
or	CC	O
placebo	NN	O
for	IN	O
10	CD	O
days	NNS	O
.	.	O

We	PRP	O
measured	VBD	O
symptomatic	JJ	O
response	NN	O
and	CC	O
rates	NNS	O
of	IN	O
clinical	JJ	O
failure	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
the	DT	O
children	NNS	O
who	WP	O
received	VBD	O
amoxicillin-clavulanate	NN	O
,	,	O
35	CD	O
%	NN	O
had	VBD	O
initial	JJ	O
resolution	NN	O
of	IN	O
symptoms	NNS	O
by	IN	O
day	NN	O
2	CD	O
,	,	O
61	CD	O
%	NN	O
by	IN	O
day	NN	O
4	CD	O
,	,	O
and	CC	O
80	CD	O
%	NN	O
by	IN	O
day	NN	O
7	CD	O
;	:	O
among	IN	O
children	NNS	O
who	WP	O
received	VBD	O
placebo	NN	O
,	,	O
28	CD	O
%	NN	O
had	VBD	O
initial	JJ	O
resolution	NN	O
of	IN	O
symptoms	NNS	O
by	IN	O
day	NN	O
2	CD	O
,	,	O
54	CD	O
%	NN	O
by	IN	O
day	NN	O
4	CD	O
,	,	O
and	CC	O
74	CD	O
%	NN	O
by	IN	O
day	NN	O
7	CD	O
(	(	O
P=0.14	NNP	O
for	IN	O
the	DT	O
overall	JJ	O
comparison	NN	O
)	)	O
.	.	O

For	IN	O
sustained	JJ	O
resolution	NN	O
of	IN	O
symptoms	NNS	O
,	,	O
the	DT	O
corresponding	JJ	O
values	NNS	O
were	VBD	O
20	CD	O
%	NN	O
,	,	O
41	CD	O
%	NN	O
,	,	O
and	CC	O
67	CD	O
%	NN	O
with	IN	O
amoxicillin-clavulanate	JJ	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
14	CD	O
%	NN	O
,	,	O
36	CD	O
%	NN	O
,	,	O
and	CC	O
53	CD	O
%	NN	O
with	IN	O
placebo	NN	O
(	(	O
P=0.04	NNP	O
for	IN	O
the	DT	O
overall	JJ	O
comparison	NN	O
)	)	O
.	.	O

Mean	JJ	O
symptom	NN	O
scores	NNS	O
over	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
were	VBD	O
lower	JJR	O
for	IN	O
the	DT	O
children	NNS	O
treated	VBN	O
with	IN	O
amoxicillin-clavulanate	JJ	O
than	IN	O
for	IN	O
those	DT	O
who	WP	O
received	VBD	O
placebo	NN	O
(	(	O
P=0.02	NNP	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
clinical	JJ	O
failure	NN	O
--	:	O
defined	VBD	O
as	IN	O
the	DT	O
persistence	NN	O
of	IN	O
signs	NNS	O
of	IN	O
acute	JJ	O
infection	NN	O
on	IN	O
otoscopic	JJ	O
examination	NN	O
--	:	O
was	VBD	O
also	RB	O
lower	JJR	O
among	IN	O
the	DT	O
children	NNS	O
treated	VBN	O
with	IN	O
amoxicillin-clavulanate	JJ	O
than	IN	O
among	IN	O
those	DT	O
who	WP	O
received	VBD	O
placebo	NN	O
:	:	O
4	CD	O
%	NN	O
versus	IN	O
23	CD	O
%	NN	O
at	IN	O
or	CC	O
before	IN	O
the	DT	O
visit	NN	O
on	IN	O
day	NN	O
4	CD	O
or	CC	O
5	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
16	CD	O
%	NN	O
versus	IN	O
51	CD	O
%	NN	O
at	IN	O
or	CC	O
before	IN	O
the	DT	O
visit	NN	O
on	IN	O
day	NN	O
10	CD	O
to	TO	O
12	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Mastoiditis	NNP	O
developed	VBD	O
in	IN	O
one	CD	O
child	NN	O
who	WP	O
received	VBD	O
placebo	NN	O
.	.	O

Diarrhea	NNP	O
and	CC	O
diaper-area	JJ	O
dermatitis	NN	O
were	VBD	O
more	JJR	O
common	JJ	O
among	IN	O
children	NNS	O
who	WP	O
received	VBD	O
amoxicillin-clavulanate	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
either	DT	O
group	NN	O
in	IN	O
the	DT	O
rates	NNS	O
of	IN	O
nasopharyngeal	JJ	O
colonization	NN	O
with	IN	O
nonsusceptible	JJ	O
Streptococcus	NNP	O
pneumoniae	NN	O
.	.	O

CONCLUSIONS	NNP	O
Among	IN	O
children	NNS	O
6	CD	O
to	TO	O
23	CD	O
months	NNS	O
of	IN	O
age	NN	O
with	IN	O
acute	JJ	O
otitis	NN	O
media	NNS	O
,	,	O
treatment	NN	O
with	IN	O
amoxicillin-clavulanate	NN	O
for	IN	O
10	CD	O
days	NNS	O
tended	VBD	O
to	TO	O
reduce	VB	O
the	DT	O
time	NN	O
to	TO	O
resolution	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
reduced	VBD	O
the	DT	O
overall	JJ	O
symptom	NN	O
burden	NN	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
persistent	JJ	O
signs	NNS	O
of	IN	O
acute	JJ	O
infection	NN	O
on	IN	O
otoscopic	JJ	O
examination	NN	O
.	.	O

(	(	O
Funded	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Institute	NNP	O
of	IN	O
Allergy	NNP	O
and	CC	O
Infectious	NNP	O
Diseases	NNP	O
;	:	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00377260	NNP	O
.	.	O

)	)	O
.	.	O

Accuracy	NN	O
of	IN	O
pelvic	JJ	Condition
radiotherapy	NN	Condition
:	:	O
prospective	JJ	O
analysis	NN	O
of	IN	O
90	CD	SampleSize
patients	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
trial	NN	O
of	IN	O
blocked	VBN	O
versus	FW	O
standard	JJ	O
radiotherapy	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
accuracy	NN	O
of	IN	O
pelvic	JJ	O
radiotherapy	NN	O
during	IN	O
a	DT	O
trial	NN	O
of	IN	O
blocked	JJ	O
radiotherapy	NN	O
at	IN	O
the	DT	O
Royal	NNP	O
Marsden	NNP	O
Hospital	NNP	O
,	,	O
UK	NNP	O
.	.	O

Prospective	JJ	O
evaluation	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
90	CD	SampleSize
patients	NNS	O
receiving	VBG	O
CT	NNP	O
planned	VBD	O
pelvic	JJ	Condition
radiotherapy	NN	Condition
using	VBG	O
weekly	JJ	O
anterior-posterior	JJ	O
and	CC	O
lateral	JJ	O
portal	JJ	O
films	NNS	O
.	.	O

Field	NNP	O
placement	JJ	O
errors	NNS	O
(	(	O
FPEs	NNP	O
)	)	O
were	VBD	O
calculated	VBN	O
by	IN	O
comparing	VBG	O
field	NN	O
centres	NNS	O
of	IN	O
each	DT	O
film	NN	O
with	IN	O
a	DT	O
designated	JJ	O
point	NN	O
of	IN	O
interest	NN	O
.	.	O

Data	NNP	O
was	VBD	O
evaluated	VBN	O
to	TO	O
calculate	VB	O
the	DT	O
overall	JJ	O
treatment	NN	O
simulator	NN	O
differences	NNS	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
error	JJ	O
free	JJ	O
treatments	NNS	O
,	,	O
and	CC	O
mean	VB	O
treatment-simulator	JJ	O
position	NN	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
role	NN	O
of	IN	O
systematic	JJ	O
versus	NN	O
random	JJ	O
errors	NNS	O
.	.	O

Age	NNP	O
,	,	O
weight	NN	O
,	,	O
disease	NN	O
site	NN	O
,	,	O
position	NN	O
of	IN	O
treatment	NN	O
,	,	O
fractionation	NN	O
,	,	O
blocked	VBD	O
versus	JJ	O
conventional	JJ	O
techniques	NNS	O
were	VBD	O
assessed	VBN	O
for	IN	O
their	PRP$	O
effect	NN	O
on	IN	O
treatment	NN	O
accuracy	NN	O
.	.	O

The	DT	O
mean	JJ	O
absolute	NN	O
error	NN	O
between	IN	O
treatment	NN	O
and	CC	O
simulator	NN	O
films	NNS	O
was	VBD	O
anterior	JJ	O
right-left	NN	O
(	(	O
ARL	NNP	O
)	)	O
0.25	CD	O
cm	NN	O
,	,	O
anterior	JJ	O
superior-inferior	JJ	O
(	(	O
ASI	NNP	O
)	)	O
0.32	CD	O
cm	NN	O
,	,	O
lateral	JJ	O
anterior-posterior	JJ	O
(	(	O
LAP	NNP	O
)	)	O
0.42	CD	O
cm	NN	O
,	,	O
and	CC	O
lateral	JJ	O
superior-inferior	JJ	O
(	(	O
LSI	NNP	O
)	)	O
0.28	CD	O
cm	NN	O
.	.	O

On	IN	O
average	JJ	O
the	DT	O
field	NN	O
centre	NN	O
was	VBD	O
displaced	VBN	O
by	IN	O
0.66	CD	O
cm	NN	O
(	(	O
standard	JJ	O
deviation	NN	O
,	,	O
S.D	NNP	O
.	.	O

=	VB	O
0.34	CD	O
)	)	O
from	IN	O
that	DT	O
intended	VBN	O
.	.	O

On	IN	O
each	DT	O
treatment	NN	O
day	NN	O
29	CD	O
%	NN	O
of	IN	O
anterior	JJ	O
films	NNS	O
and	CC	O
45	CD	O
%	NN	O
of	IN	O
lateral	JJ	O
films	NNS	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
0.5	CD	O
cm	NN	O
error	NN	O
.	.	O

Overall	JJ	O
59	CD	O
%	NN	O
of	IN	O
treatments	NNS	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
0.5	CD	O
cm	NN	O
error	NN	O
and	CC	O
9	CD	O
%	NN	O
a	DT	O
1.0	CD	O
cm	NN	O
error	NN	O
.	.	O

The	DT	O
field	NN	O
centre	NN	O
was	VBD	O
more	JJR	O
than	IN	O
0.5	CD	O
cm	NN	O
from	IN	O
the	DT	O
position	NN	O
intended	VBN	O
in	IN	O
66	CD	O
%	NN	O
of	IN	O
treatments	NNS	O
and	CC	O
over	IN	O
1	CD	O
cm	NNS	O
for	IN	O
14	CD	O
%	NN	O
of	IN	O
treatments	NNS	O
.	.	O

Analysis	NN	O
of	IN	O
variance	NN	O
showed	VBD	O
that	IN	O
both	DT	O
random	NN	O
and	CC	O
systematic	JJ	O
errors	NNS	O
occurred	VBD	O
in	IN	O
all	DT	O
directions	NNS	O
.	.	O

Though	IN	O
random	JJ	O
errors	NNS	O
were	VBD	O
of	IN	O
similar	JJ	O
magnitude	NN	O
in	IN	O
all	DT	O
direction	NN	O
(	(	O
variance	NN	O
sigma	NN	O
2	CD	O
=	JJ	O
0.06-0.09	JJ	O
cm2	NN	O
)	)	O
;	:	O
systematic	JJ	O
errors	NNS	O
showed	VBD	O
a	DT	O
4-fold	JJ	O
variation	NN	O
being	VBG	O
greatest	JJS	O
in	IN	O
the	DT	O
LAP	NNP	O
direction	NN	O
(	(	O
sigma	JJ	O
2	CD	O
=	JJ	O
0.19	CD	O
cm2	NN	O
)	)	O
and	CC	O
least	JJS	O
the	DT	O
ARL	NNP	O
direction	NN	O
(	(	O
sigma	JJ	O
2	CD	O
=	JJ	O
0.048	CD	O
cm2	NN	O
)	)	O
.	.	O

No	DT	O
factor	NN	O
consistently	RB	O
predicted	VBN	O
for	IN	O
worse	JJR	O
outcome	NN	O
in	IN	O
all	DT	O
directions	NNS	O
.	.	O

Hypofractionated	VBN	O
treatments	NNS	O
were	VBD	O
less	JJR	O
accurate	JJ	O
in	IN	O
the	DT	O
LSI	NNP	O
direction	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Systematic	JJ	O
errors	NNS	O
were	VBD	O
associated	VBN	O
in	IN	O
the	DT	O
ARL	NNP	O
direction	NN	O
with	IN	O
hypofractionation	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
,	,	O
in	IN	O
the	DT	O
LSI	NNP	O
direction	NN	O
with	IN	O
weight	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.03	CD	O
)	)	O
and	CC	O
age	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
significant	JJ	O
random	NN	O
and	CC	O
systematic	JJ	O
errors	NNS	O
can	MD	O
occur	VB	O
during	IN	O
pelvic	JJ	O
radiotherapy	NN	O
especially	RB	O
in	IN	O
the	DT	O
LAP	NNP	O
direction	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
customised	JJ	O
immobilisation	NN	O
device	NN	O
,	,	O
to	TO	O
cover	VB	O
95	CD	O
%	NN	O
of	IN	O
errors	NNS	O
,	,	O
margins	NNS	O
of	IN	O
0.6	CD	O
cm	NN	O
for	IN	O
RL	NNP	O
and	CC	O
SI	NNP	O
directions	NNS	O
and	CC	O
0.9	CD	O
cm	NN	O
for	IN	O
AP	NNP	O
direction	NN	O
should	MD	O
be	VB	O
allowed	VBN	O
between	IN	O
the	DT	O
planning	NN	O
and	CC	O
clinical	JJ	O
target	NN	O
volumes	NNS	O
.	.	O

However	RB	O
,	,	O
ideally	RB	O
,	,	O
each	DT	O
centre	NN	O
should	MD	O
determine	VB	O
their	PRP$	O
own	JJ	O
margin	NN	O
requirements	NNS	O
according	VBG	O
to	TO	O
local	JJ	O
clinical	JJ	O
practice	NN	O
.	.	O

FloSeal	NNP	O
hemostatic	JJ	O
matrix	NN	O
in	IN	O
persistent	JJ	Condition
epistaxis	NN	Condition
:	:	Condition
prospective	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
Although	IN	O
most	JJS	O
cases	NNS	O
of	IN	O
epistaxis	NN	O
are	VBP	O
managed	VBN	O
conservatively	RB	O
,	,	O
occasionally	RB	O
they	PRP	O
can	MD	O
progress	VB	O
to	TO	O
significant	JJ	O
hemorrhage	NN	O
requiring	VBG	O
more	JJR	O
involved	JJ	O
management	NN	O
or	CC	O
surgery	NN	O
.	.	O

Endoscopic	NNP	O
ligation	NN	O
surgery	NN	O
is	VBZ	O
the	DT	O
current	JJ	O
institutional	JJ	O
standard	NN	O
of	IN	O
care	NN	O
for	IN	O
patients	NNS	O
who	WP	O
fail	VBP	O
conservative	JJ	O
management	NN	O
.	.	O

However	RB	O
,	,	O
surgical	JJ	O
ligation	NN	O
requires	VBZ	O
availability	NN	O
of	IN	O
surgical	JJ	O
resources	NNS	O
and	CC	O
patients	NNS	O
who	WP	O
are	VBP	O
able	JJ	O
to	TO	O
withstand	VB	O
an	DT	O
anesthetic	JJ	O
.	.	O

This	DT	O
study	NN	O
's	POS	O
objective	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
FloSeal	NNP	O
hemostatic	JJ	O
matrix	NN	O
(	(	O
Baxter	NNP	O
Healthcare	NNP	O
Corporation	NNP	O
,	,	O
Hayward	NNP	O
,	,	O
CA	NNP	O
)	)	O
in	IN	O
epistaxis	JJ	O
refractory	NN	O
to	TO	O
nasal	VB	O
packing	VBG	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
epistaxis	NN	O
patients	NNS	O
whose	WP$	O
nasal	JJ	O
hemorrhage	NN	O
persisted	VBD	O
despite	IN	O
adequate	JJ	O
nasal	NNS	O
packing	VBG	O
by	IN	O
the	DT	O
otolaryngology-head	JJ	O
and	CC	O
neck	NN	O
surgery	NN	O
team	NN	O
.	.	O

Once	RB	O
enrolled	JJ	O
,	,	O
patients	NNS	O
are	VBP	O
given	VBN	O
a	DT	O
trial	NN	O
of	IN	O
intranasal	JJ	O
FloSeal	NNP	O
hemostatic	JJ	O
matrix	NN	O
to	TO	O
abort	VB	O
the	DT	O
epistaxis	NN	O
.	.	O

Should	MD	O
this	DT	O
fail	NN	O
,	,	O
patients	NNS	O
then	RB	O
proceed	VBP	O
with	IN	O
surgical	JJ	O
clipping	NN	O
.	.	O

RESULTS	VB	O
Our	PRP$	O
prospective	JJ	O
cohort	NN	O
demonstrated	VBD	O
significant	JJ	O
success	NN	O
in	IN	O
80	CD	Condition
%	NN	Condition
of	IN	Condition
patients	NNS	Condition
with	IN	Condition
persistent	JJ	Condition
epistaxis	NN	Condition
,	,	O
who	WP	O
would	MD	O
have	VB	O
otherwise	RB	O
been	VBN	O
taken	VBN	O
to	TO	O
the	DT	O
operating	NN	O
theatre	NN	O
,	,	O
avoiding	VBG	O
the	DT	O
need	NN	O
for	IN	O
further	JJ	O
surgical	JJ	O
intervention	NN	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
enrolled	JJ	O
patients	NNS	O
with	IN	O
persistent	JJ	O
nasal	JJ	O
hemorrhage	NN	O
were	VBD	O
adequately	RB	O
managed	VBN	O
with	IN	O
the	DT	O
hemostatic	JJ	O
matrix	NN	O
alone	RB	O
and	CC	O
were	VBD	O
discharged	VBN	O
from	IN	O
hospital	NN	O
in	IN	O
a	DT	O
timeframe	NN	O
comparable	JJ	O
to	TO	O
that	DT	O
of	IN	O
surgical	JJ	O
managment	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
revealed	VBD	O
a	DT	O
highly	RB	O
effective	JJ	O
tool	NN	O
in	IN	O
the	DT	O
otolaryngologist	NN	O
's	POS	O
management	NN	O
of	IN	O
persistent	JJ	O
epistaxis	NN	O
.	.	O

Given	VBN	O
the	DT	O
ease	NN	O
of	IN	O
use	NN	O
,	,	O
decreased	VBN	O
morbidity	NN	O
to	TO	O
the	DT	O
patient	NN	O
,	,	O
and	CC	O
cost-effectiveness	NN	O
,	,	O
FloSeal	NNP	O
hemostatic	JJ	O
matrix	NN	O
could	MD	O
change	VB	O
clinical	JJ	O
practice	NN	O
in	IN	O
managing	VBG	O
this	DT	O
common	JJ	O
condition	NN	O
.	.	O

Adjuvant	JJ	O
therapy	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
:	:	O
the	DT	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
experience	NN	O
.	.	O

The	DT	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
compared	VBN	O
one	CD	O
year	NN	O
of	IN	O
adjuvant	JJ	O
combination	NN	O
chemotherapy	NN	O
with	IN	O
continuous	JJ	O
CMFVP	NNP	O
(	(	O
cyclophosphamide	NN	O
,	,	O
methotrexate	NN	O
,	,	O
5-fluorouracil	JJ	O
,	,	O
vincristine	NN	O
,	,	O
and	CC	O
prednisone	NN	O
)	)	O
to	TO	O
two	CD	O
years	NNS	O
of	IN	O
intermittent	JJ	O
L-phenylalanine	JJ	O
mustard	NN	O
(	(	O
L-PAM	NNP	O
)	)	O
in	IN	O
women	NNS	Sex
with	IN	O
operable	JJ	O
breast	NN	Condition
cancer	NN	Condition
with	IN	O
histologically	RB	O
positive	JJ	O
axillary	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

In	IN	O
fully	RB	O
and	CC	O
partially	RB	O
evaluable	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
68-month	JJ	O
median	JJ	O
follow-up	NN	O
,	,	O
treatment	NN	O
failures	NNS	O
have	VBP	O
occurred	VBN	O
in	IN	O
27	CD	O
%	NN	O
of	IN	O
172	CD	SampleSize
receiving	VBG	O
CMFVP	NNP	O
and	CC	O
47	CD	O
%	NN	O
of	IN	O
186	CD	SampleSize
women	NNS	O
given	VBN	O
L-PAM	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

The	DT	O
advantage	NN	O
for	IN	O
women	NNS	O
receiving	VBG	O
CMFVP	NNP	O
was	VBD	O
seen	VBN	O
for	IN	O
all	DT	O
subsets	NNS	O
regardless	RB	O
of	IN	O
menopausal	NN	O
status	NN	O
except	IN	O
among	IN	O
women	NNS	O
who	WP	O
were	VBD	O
premenopausal	NN	Condition
and	CC	O
had	VBD	O
1-3	JJ	O
positive	JJ	O
nodes	NNS	O
.	.	O

Based	VBN	O
on	IN	O
this	DT	O
study	NN	O
,	,	O
a	DT	O
second	JJ	O
study	NN	O
was	VBD	O
implemented	VBN	O
using	VBG	O
both	DT	O
the	DT	O
estrogen-receptor	NN	O
(	(	O
ER	NNP	O
)	)	O
content	NN	O
of	IN	O
the	DT	O
primary	JJ	O
tumor	NN	O
and	CC	O
axillary	JJ	O
nodal	NN	O
status	NN	O
to	TO	O
select	VB	O
therapy	NN	O
.	.	O

Effects	NNS	O
of	IN	O
maternal	JJ	O
and	CC	O
dietary	JJ	O
selenium	NN	O
(	(	O
Se-enriched	NNP	O
yeast	NN	O
)	)	O
on	IN	O
the	DT	O
expression	NN	O
of	IN	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
and	CC	O
CyclinB1	NNP	O
of	IN	O
germ	JJ	O
cells	NNS	O
of	IN	O
their	PRP$	O
offspring	NN	O
in	IN	O
goats	NNS	Condition
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
selenium	NN	O
on	IN	O
the	DT	O
expression	NN	O
of	IN	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
and	CC	O
CyclinB1	NNP	O
(	(	O
two	CD	O
components	NNS	O
of	IN	O
MPF	NNP	O
regulating	VBG	O
cell	NN	O
cycle	NN	O
)	)	O
of	IN	O
germ	JJ	O
cells	NNS	O
of	IN	O
their	PRP$	O
offspring	NN	O
in	IN	O
goats	NNS	O
.	.	O

A	DT	O
herd	NN	O
of	IN	O
119	CD	SampleSize
Taihang	NNP	O
Black	NNP	O
Goats	NNP	O
,	,	O
which	WDT	O
was	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
4	CD	O
treatments	NNS	O
,	,	O
received	VBD	O
experimental	JJ	O
diet	JJ	O
with	IN	O
different	JJ	O
Se	NNP	O
levels	NNS	O
(	(	O
from	IN	O
Se-enriched	NNP	O
yeast	NN	O
)	)	O
for	IN	O
174d	CD	O
.	.	O

The	DT	O
four	CD	O
treatments	NNS	O
,	,	O
fed	VBN	O
with	IN	O
a	DT	O
basal	NN	O
diet	JJ	O
,	,	O
were	VBD	O
supplemented	VBN	O
with	IN	O
0	CD	O
(	(	O
control	NN	O
)	)	O
,	,	O
0.5	CD	O
,	,	O
2	CD	O
and	CC	O
4	CD	O
mgkg??	NN	O
DM	NNP	O
Se	NNP	O
.	.	O

Testis	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
from	IN	O
the	DT	O
young	JJ	O
male	NN	O
goats	NNS	O
of	IN	O
each	DT	O
treatment	NN	O
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
30d	CD	O
after	IN	O
weaning	VBG	O
)	)	O
for	IN	O
mRNA	NN	O
expression	NN	O
using	VBG	O
real-time	JJ	O
PCR	NNP	O
and	CC	O
for	IN	O
protein	JJ	O
expression	NN	O
by	IN	O
immunohistochemistry	NN	O
assay	NN	O
.	.	O

Results	NNP	O
show	VBP	O
that	IN	O
a	DT	O
significant	JJ	O
decrease	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
mRNA	JJ	O
expression	NN	O
of	IN	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
and	CC	O
CyclinB1	NNP	O
in	IN	O
the	DT	O
testis	NN	O
of	IN	O
Se-deficient	NNP	O
(	(	O
Group	NNP	O
1	CD	O
)	)	O
and	CC	O
Se-excess	NNP	O
(	(	O
Group	NNP	O
4	CD	O
)	)	O
animals	NNS	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
Groups	NNP	O
2	CD	O
and	CC	O
3	CD	O
.	.	O

However	RB	O
,	,	O
no	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
mRNA	JJ	O
expression	NN	O
of	IN	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
between	IN	O
Se-deficient	NNP	O
(	(	O
Group	NNP	O
1	CD	O
)	)	O
and	CC	O
Se-excess	NNP	O
(	(	O
Group	NNP	O
4	CD	O
)	)	O
.	.	O

Also	RB	O
the	DT	O
immunohistochemistry	NN	O
assay	NN	O
detected	VBD	O
similar	JJ	O
results	NNS	O
of	IN	O
protein	JJ	O
expression	NN	O
of	IN	O
these	DT	O
two	CD	O
genes	NNS	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
,	,	O
that	DT	O
maternal	JJ	O
and	CC	O
dietary	JJ	O
Se-induced	NNP	O
oxidative	JJ	O
stress	NN	O
can	MD	O
modulate	VB	O
the	DT	O
mRNA	NN	O
and	CC	O
protein	JJ	O
expression	NN	O
of	IN	O
the	DT	O
cell	NN	O
cycle	NN	O
related	VBN	O
genes	NNS	O
(	(	O
p34	NN	O
(	(	O
cdc2	NN	O
)	)	O
and	CC	O
CyclinB1	NNP	O
)	)	O
in	IN	O
the	DT	O
testis	NN	O
of	IN	O
their	PRP$	O
offspring	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
Se	NNP	O
deficiency	NN	O
and	CC	O
Se	NNP	O
excess	NN	O
could	MD	O
prevent	VB	O
the	DT	O
completion	NN	O
of	IN	O
the	DT	O
cell	NN	O
cycle	NN	O
.	.	O

Randomised	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
graded	JJ	O
exercise	NN	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
chronic	JJ	Condition
fatigue	NN	Condition
syndrome	NN	Condition
.	.	O

OBJECTIVE	UH	O
To	TO	O
test	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
graded	JJ	O
aerobic	JJ	O
exercise	NN	O
programme	NN	O
in	IN	O
the	DT	O
chronic	JJ	Condition
fatigue	NN	Condition
syndrome	NN	Condition
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
controlled	VBN	O
trial	NN	O
with	IN	O
control	NN	O
treatment	NN	O
crossover	NN	O
after	IN	O
the	DT	O
first	JJ	O
follow	VB	O
up	RP	O
examination	NN	O
.	.	O

SETTING	NN	O
Chronic	NNP	O
fatigue	NN	O
clinic	NN	O
in	IN	O
a	DT	O
general	JJ	O
hospital	NN	O
department	NN	O
of	IN	O
psychiatry	NN	O
.	.	O

SUBJECTS	NNP	O
66	CD	SampleSize
patients	NNS	O
with	IN	O
the	DT	O
chronic	JJ	Condition
fatigue	NN	Condition
syndrome	NN	Condition
who	WP	O
had	VBD	O
neither	CC	O
a	DT	O
psychiatric	JJ	Condition
disorder	NN	Condition
nor	CC	O
appreciable	JJ	Condition
sleep	JJ	Condition
disturbance	NN	Condition
.	.	O

INTERVENTIONS	NNP	O
Random	NNP	O
allocation	NN	O
to	TO	O
12	CD	O
weeks	NNS	O
of	IN	O
either	DT	O
graded	VBN	O
aerobic	NN	O
exercise	NN	O
or	CC	O
flexibility	NN	O
exercises	NNS	O
and	CC	O
relaxation	NN	O
therapy	NN	O
.	.	O

Patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
flexibility	NN	O
programme	NN	O
were	VBD	O
invited	VBN	O
to	TO	O
cross	VB	O
over	IN	O
to	TO	O
the	DT	O
exercise	NN	O
programme	NN	O
afterwards	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
self	NN	O
rated	VBN	O
clinical	JJ	O
global	JJ	O
impression	NN	O
change	NN	O
score	NN	O
,	,	O
very	RB	O
much	JJ	O
better	RBR	O
or	CC	O
much	RB	O
better	JJR	O
being	VBG	O
considered	VBN	O
as	IN	O
clinically	RB	O
important	JJ	O
.	.	O

RESULTS	VB	O
Four	CD	O
patients	NNS	O
receiving	VBG	O
exercise	NN	O
and	CC	O
three	CD	O
receiving	VBG	O
flexibility	NN	O
treatment	NN	O
dropped	VBD	O
out	RP	O
before	IN	O
completion	NN	O
.	.	O

15	CD	O
of	IN	O
29	CD	O
patients	NNS	O
rated	VBN	O
themselves	PRP	O
as	IN	O
better	JJR	O
after	IN	O
completing	VBG	O
exercise	NN	O
treatment	NN	O
compared	VBN	O
with	IN	O
eight	CD	O
of	IN	O
30	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
flexibility	NN	O
treatment	NN	O
.	.	O

Analysis	NN	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
gave	VBD	O
similar	JJ	O
results	NNS	O
(	(	O
17/33	CD	O
v	RB	O
9/33	CD	O
patients	NNS	O
better	RBR	O
)	)	O
.	.	O

Fatigue	NNP	O
,	,	O
functional	JJ	O
capacity	NN	O
,	,	O
and	CC	O
fitness	NN	O
were	VBD	O
significantly	RB	O
better	RBR	O
after	IN	O
exercise	NN	O
than	IN	O
after	IN	O
flexibility	NN	O
treatment	NN	O
.	.	O

12	CD	O
of	IN	O
22	CD	O
patients	NNS	O
who	WP	O
crossed	VBD	O
over	IN	O
to	TO	O
exercise	VB	O
after	IN	O
flexibility	NN	O
treatment	NN	O
rated	VBN	O
themselves	PRP	O
as	IN	O
better	JJR	O
after	IN	O
completing	VBG	O
exercise	NN	O
treatment	NN	O
32	CD	O
of	IN	O
47	CD	O
patients	NNS	O
rated	VBN	O
themselves	PRP	O
as	IN	O
better	JJR	O
three	CD	O
months	NNS	O
after	IN	O
completing	VBG	O
supervised	JJ	O
exercise	NN	O
treatment	NN	O
35	CD	O
of	IN	O
47	CD	O
patients	NNS	O
rated	VBN	O
themselves	PRP	O
as	IN	O
better	JJR	O
one	CD	O
year	NN	O
after	IN	O
completing	VBG	O
supervised	JJ	O
exercise	NN	O
treatment	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
appropriately	RB	O
prescribed	VBN	O
graded	VBN	O
aerobic	JJ	O
exercise	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
the	DT	O
chronic	JJ	Condition
fatigue	NN	Condition
syndrome	NN	Condition
.	.	O

Use	NNP	O
of	IN	O
a	DT	O
DNAemia	NNP	O
cut-off	NN	O
for	IN	O
monitoring	VBG	O
human	JJ	O
cytomegalovirus	NN	O
infection	NN	O
reduces	VBZ	O
the	DT	O
number	NN	O
of	IN	O
preemptively	RB	O
treated	VBN	O
children	NNS	O
and	CC	O
young	JJ	O
adults	NNS	O
receiving	VBG	O
hematopoietic	JJ	O
stem-cell	JJ	O
transplantation	NN	O
compared	VBN	O
with	IN	O
qualitative	JJ	O
pp65	NN	O
antigenemia	NN	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
the	DT	O
use	NN	O
of	IN	O
quantitative	JJ	O
DNAemia	NNP	O
versus	NN	O
positive	JJ	O
antigenemia	NN	O
for	IN	O
starting	VBG	O
preemptive	JJ	O
antihuman	NN	O
cytomegalovirus	NN	O
(	(	O
HCMV	NNP	O
)	)	O
therapy	NN	O
in	IN	O
hematopoietic	JJ	O
stem-cell	JJ	O
transplantation	NN	O
(	(	O
HSCT	NNP	O
)	)	O
recipients	NNS	O
.	.	O

In	IN	O
the	DT	O
DNAemia	NNP	O
arm	NN	O
,	,	O
antiviral	JJ	O
therapy	NN	O
was	VBD	O
initiated	VBN	O
on	IN	O
reaching	VBG	O
a	DT	O
DNAemia	NNP	O
cut-off	NN	O
of	IN	O
10	CD	O
000	CD	O
DNA	NNP	O
copies/mL	NN	O
of	IN	O
whole	JJ	O
blood	NN	O
,	,	O
whereas	NNS	O
in	IN	O
the	DT	O
antigenemia	NN	O
arm	NN	O
,	,	O
therapy	NN	O
was	VBD	O
started	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
positive	JJ	O
antigenemia	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
in	IN	O
the	DT	O
2	CD	O
arms	NNS	O
.	.	O

On	IN	O
the	DT	O
whole	NN	O
,	,	O
178	CD	O
patients	NNS	O
(	(	O
89	CD	O
in	IN	O
each	DT	O
arm	NN	O
)	)	O
,	,	O
receiving	VBG	O
unmanipulated	JJ	O
HSCT	NNP	O
from	IN	O
either	CC	O
a	DT	O
relative	NN	O
or	CC	O
an	DT	O
unrelated	JJ	O
donor	NN	O
,	,	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
HCMV	NNP	O
infection	NN	O
was	VBD	O
comparable	JJ	O
in	IN	O
DNAemia	NNP	O
and	CC	O
antigenemia	NN	O
arms	NNS	O
(	(	O
34	CD	O
%	NN	O
vs	JJ	O
42	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
=	NNP	O
.259	NNP	O
)	)	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
DNAemia	NNP	O
arm	NN	O
(	(	O
18	CD	O
%	NN	O
vs	JJ	O
31	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
.026	NNP	O
)	)	O
.	.	O

No	DT	O
patient	NN	O
developed	VBD	O
HCMV	NNP	O
disease	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
a	DT	O
DNAemia	NNP	O
cut-off	NN	O
avoids	NNS	O
unnecessary	JJ	O
antiviral	JJ	O
treatment	NN	O
.	.	O

Role	NNP	O
of	IN	O
oxidized	VBN	O
regenerated	VBN	O
cellulose	NN	O
in	IN	O
preventing	VBG	O
infections	NNS	O
at	IN	O
the	DT	O
surgical	JJ	O
site	NN	O
:	:	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
in	IN	O
98	CD	Condition
patients	NNS	Condition
affected	VBN	Condition
by	IN	Condition
a	DT	Condition
dirty	NN	Condition
wound	NN	Condition
.	.	Condition

AIM	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
whether	IN	O
oxidized	JJ	O
regenerated	VBN	O
cellulose	NN	O
(	(	O
ORC	NNP	O
)	)	O
,	,	O
applied	VBN	O
to	TO	O
dirty	VB	O
surgical	JJ	O
wounds	NNS	O
,	,	O
is	VBZ	O
able	JJ	O
to	TO	O
reduce	VB	O
the	DT	O
microbial	JJ	O
load	NN	O
and	CC	O
,	,	O
consequently	RB	O
,	,	O
the	DT	O
infection	NN	O
rate	NN	O
as	IN	O
compared	VBN	O
to	TO	O
conventional	JJ	O
local	JJ	O
wound	NN	O
treatment	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
98	CD	O
patients	NNS	O
who	WP	O
underwent	VBP	O
intestinal	JJ	O
recanalization	NN	O
procedures	NNS	O
between	IN	O
December	NNP	O
2003	CD	O
and	CC	O
December	NNP	O
2008	CD	O
,	,	O
with	IN	O
the	DT	O
stoma	NN	O
as	IN	O
the	DT	O
surgical	JJ	O
site	NN	O
.	.	O

Authors	NNS	O
considered	VBD	O
several	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
SSI	NNP	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
group	NN	O
A	NNP	O
(	(	O
50	CD	O
patients	NNS	O
)	)	O
,	,	O
the	DT	O
surgical	JJ	O
wound	NN	O
,	,	O
previous	JJ	O
site	NN	O
of	IN	O
the	DT	O
stoma	NN	O
,	,	O
was	VBD	O
packed	VBN	O
with	IN	O
ORC	NNP	O
,	,	O
whereas	RB	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
48	CD	O
patients	NNS	O
)	)	O
gauze	VBP	O
soaked	VBN	O
in	IN	O
iodine	NN	O
was	VBD	O
used	VBN	O
.	.	O

Microbial	JJ	O
contamination	NN	O
was	VBD	O
evaluated	VBN	O
with	IN	O
three	CD	O
swabs	NNS	O
(	(	O
in	IN	O
subcutaneous	JJ	O
tissue	NN	O
and	CC	O
the	DT	O
dermis	NN	O
)	)	O
,	,	O
in	IN	O
the	DT	O
operating	NN	O
room	NN	O
before	IN	O
wound	NN	O
packing	NN	O
and	CC	O
on	IN	O
the	DT	O
2nd	CD	O
and	CC	O
3rd	CD	O
postoperative	JJ	O
day	NN	O
(	(	O
before	IN	O
suturing	VBG	O
the	DT	O
skin	NN	O
)	)	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
cases	NNS	O
of	IN	O
wound	NN	O
dehiscence	NN	O
and	CC	O
no	DT	O
clinically	RB	O
evident	JJ	O
superficial	NN	O
or	CC	O
deep	JJ	O
surgical	JJ	O
site	NN	O
infections	NNS	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Analysis	NN	O
of	IN	O
all	DT	O
data	NNS	O
revealed	VBD	O
that	IN	O
there	EX	O
was	VBD	O
no	DT	O
or	CC	O
reduced	VBN	O
bacterial	JJ	O
contamination	NN	O
in	IN	O
the	DT	O
second	JJ	O
and	CC	O
third	JJ	O
swab	NN	O
in	IN	O
33	CD	O
patients	NNS	O
(	(	O
66	CD	O
%	NN	O
)	)	O
of	IN	O
Group	NNP	O
A	NNP	O
versus	NN	O
12	CD	O
patients	NNS	O
(	(	O
25	CD	O
%	NN	O
)	)	O
of	IN	O
Group	NNP	O
B	NNP	O
.	.	O

CONCLUSION	NNP	O
Although	IN	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
consider	VB	O
all	DT	O
factors	NNS	O
which	WDT	O
can	MD	O
have	VB	O
an	DT	O
influence	NN	O
on	IN	O
SSI	NNP	O
and	CC	O
use	VB	O
all	PDT	O
the	DT	O
means	NNS	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
SSI	NNP	O
,	,	O
there	EX	O
is	VBZ	O
a	DT	O
rationale	NN	O
for	IN	O
using	VBG	O
ORC	NNP	O
to	TO	O
prevent	VB	O
this	DT	O
kind	NN	O
of	IN	O
infection	NN	O
,	,	O
especially	RB	O
in	IN	O
patients	NNS	O
who	WP	O
undergo	VBP	O
dirty	JJ	O
surgery	NN	O
.	.	O

Effects	NNS	O
of	IN	O
fenoterol	NN	O
on	IN	O
inspiratory	JJ	O
effort	NN	O
sensation	NN	O
and	CC	O
fatigue	NN	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
fenoterol	NN	O
on	IN	O
the	DT	O
relationship	NN	O
between	IN	O
inspiratory	NN	O
effort	NN	O
sensation	NN	O
(	(	O
IES	NNP	O
)	)	O
and	CC	O
inspiratory	JJ	O
muscle	NN	O
fatigue	NN	O
induced	VBN	O
by	IN	O
inspiratory	NN	O
threshold	NN	O
loading	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
threshold	NN	O
was	VBD	O
60	CD	O
%	NN	O
of	IN	O
maximal	JJ	O
static	JJ	O
inspiratory	NN	O
mouth	NN	O
pressure	NN	O
(	(	O
PI	NNP	O
,	,	O
mmax	NN	O
)	)	O
at	IN	O
functional	JJ	O
residual	JJ	O
capacity	NN	O
,	,	O
and	CC	O
the	DT	O
duty	NN	O
cycle	NN	O
was	VBD	O
0.5	CD	O
.	.	O

Subjects	NNS	O
continued	VBD	O
the	DT	O
threshold	NN	O
loaded	VBD	O
breathing	NN	O
until	IN	O
the	DT	O
target	NN	O
mouth	NN	O
pressure	NN	O
could	MD	O
no	RB	O
longer	RB	O
be	VB	O
maintained	VBN	O
(	(	O
endurance	JJ	O
time	NN	O
)	)	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
IES	NNP	O
was	VBD	O
scored	VBN	O
with	IN	O
a	DT	O
modified	JJ	O
Borg	NNP	O
scale	NN	O
.	.	O

Either	CC	O
fenoterol	NN	O
(	(	O
5	CD	O
mg	NN	O
)	)	O
or	CC	O
a	DT	O
placebo	NN	O
was	VBD	O
given	VBN	O
orally	RB	O
2	CD	O
h	NN	O
before	IN	O
loading	VBG	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
crossover	NN	O
protocol	NN	O
.	.	O

The	DT	O
endurance	NN	O
time	NN	O
with	IN	O
fenoterol	NN	O
(	(	O
34.4	CD	O
+/-	JJ	O
8.6	CD	O
min	NN	O
)	)	O
was	VBD	O
longer	JJR	O
than	IN	O
that	DT	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
22.2	CD	O
+/-	JJ	O
7.1	CD	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	O
of	IN	O
high-	JJ	O
to	TO	O
low-frequency	JJ	O
power	NN	O
of	IN	O
the	DT	O
diaphragmatic	JJ	O
electromyogram	NN	O
(	(	O
EMGdi	NNP	O
)	)	O
decreased	VBD	O
during	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
less	RBR	O
with	IN	O
fenoterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
EMGdi	NNP	O
also	RB	O
decreased	VBD	O
with	IN	O
loading	NN	O
;	:	O
the	DT	O
decrease	NN	O
was	VBD	O
greater	JJR	O
on	IN	O
fenoterol	NN	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
PI	NNP	O
,	,	O
mmax	NN	O
and	CC	O
maximal	JJ	O
transdiaphragmatic	JJ	O
pressure	NN	O
(	(	O
Pdi	NNP	O
)	)	O
were	VBD	O
similarly	RB	O
decreased	VBN	O
after	IN	O
loading	VBG	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
the	DT	O
IES	NNP	O
rose	VBD	O
with	IN	O
time	NN	O
during	IN	O
loading	VBG	O
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
was	VBD	O
lower	JJR	O
with	IN	O
fenoterol	NN	O
than	IN	O
with	IN	O
the	DT	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
ratio	NN	O
of	IN	O
Pdi	NNP	O
to	TO	O
integrated	JJ	O
activity	NN	O
of	IN	O
the	DT	O
EMGdi	NNP	O
increased	VBD	O
with	IN	O
fenoterol	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Fenoterol	NNP	O
treatment	NN	O
increased	VBD	O
both	DT	O
superimposed	VBN	O
Pdi	NNP	O
twitch	NN	O
and	CC	O
Pdi	NNP	O
twitch	NN	O
of	IN	O
relaxed	JJ	O
diaphragm	NN	O
and	CC	O
decreased	VBD	O
the	DT	O
value	NN	O
of	IN	O
(	(	O
1-superimposed	JJ	O
Pdi	NNP	O
twitch/Pdi	NN	O
twitch	NN	O
of	IN	O
relaxed	JJ	O
diaphragm	NN	O
)	)	O
.	.	O

Thus	IN	O
we	PRP	O
conclude	VBP	O
that	IN	O
in	IN	O
normal	JJ	O
subjects	NNS	O
fenoterol	JJ	O
reduces	NNS	O
diaphragmatic	JJ	O
fatigue	NN	O
and	CC	O
decreases	VBZ	O
the	DT	O
motor	NN	O
command	NN	O
to	TO	O
the	DT	O
diaphragm	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
decrease	NN	O
in	IN	O
IES	NNP	O
during	IN	O
inspiratory	JJ	O
threshold	JJ	O
loading	NN	O
and	CC	O
a	DT	O
prolongation	NN	O
of	IN	O
endurance	NN	O
.	.	O

[	RB	O
4	CD	O
years	NNS	O
'	POS	O
experience	NN	O
with	IN	O
a	DT	O
balloon-expandable	JJ	O
endoprosthesis	NN	O
.	.	O

Experimental	JJ	O
and	CC	O
clinical	JJ	O
application	NN	O
]	NNP	O
.	.	O

During	IN	O
a	DT	O
4-year	JJ	O
period	NN	O
of	IN	O
clinical	JJ	O
application	NN	O
of	IN	O
the	DT	O
balloon-expandable	JJ	O
Palmaz	NNP	O
stent	NN	O
,	,	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
stent	JJ	O
implantation	NN	O
and	CC	O
traditional	JJ	O
balloon	NN	O
angioplasty	NN	O
of	IN	O
iliac	JJ	O
arteries	NNS	O
in	IN	O
arterial	JJ	O
occlusive	JJ	O
disease	NN	O
was	VBD	O
started	VBN	O
.	.	O

The	DT	O
first	JJ	O
long-term	JJ	O
results	NNS	O
,	,	O
recorded	VBD	O
after	IN	O
2	CD	O
years	NNS	O
,	,	O
indicate	VBP	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
complication	NN	O
rate	NN	O
(	(	O
after	IN	O
stenting	VBG	O
2/62	CD	O
and	CC	O
after	IN	O
angioplasty	JJ	O
5/69	CD	O
)	)	O
and	CC	O
patency	NN	O
(	(	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
70	CD	O
%	NN	O
of	IN	O
original	JJ	O
lumen	NNS	O
size	NN	O
upon	IN	O
stent	JJ	O
implantation	NN	O
or	CC	O
balloon	NN	O
inflation	NN	O
:	:	O
95	CD	O
%	NN	O
after	IN	O
stenting	VBG	O
and	CC	O
72	CD	O
%	NN	O
after	IN	O
angioplasty	NN	O
)	)	O
.	.	O

Clinical	JJ	O
improvement	NN	O
after	IN	O
2	CD	O
years	NNS	O
was	VBD	O
89	CD	O
%	NN	O
after	IN	O
stenting	VBG	O
and	CC	O
70	CD	O
%	NN	O
after	IN	O
angioplasty	NN	O
.	.	O

Parallel	NNP	O
to	TO	O
the	DT	O
clinical	JJ	O
trials	NNS	O
,	,	O
experimental	JJ	O
canine	NN	O
artery	NN	O
stenting	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
differences	NNS	O
in	IN	O
the	DT	O
long-term	JJ	O
patency	NN	O
of	IN	O
stents	NNS	O
exposed	VBN	O
to	TO	O
restricted	VBN	O
flow	NN	O
.	.	O

Significant	JJ	O
differences	NNS	O
in	IN	O
neointimal	JJ	O
healing	NN	O
were	VBD	O
found	VBN	O
between	IN	O
normally	RB	O
perfused	VBN	O
stents	NNS	O
and	CC	O
stents	NNS	O
with	IN	O
artificially	RB	O
reduced	VBN	O
flow	NN	O
:	:	O
during	IN	O
the	DT	O
total	JJ	O
observation	NN	O
period	NN	O
of	IN	O
6	CD	O
months	NNS	O
the	DT	O
neointimal	JJ	O
height	NN	O
was	VBD	O
up	RB	O
to	TO	O
200	CD	O
%	NN	O
higher	JJR	O
in	IN	O
flow-restricted	JJ	O
stents	NNS	O
,	,	O
while	IN	O
the	DT	O
histological	JJ	O
composition	NN	O
of	IN	O
the	DT	O
neointima	NN	O
was	VBD	O
the	DT	O
same	JJ	O
as	IN	O
with	IN	O
normally	RB	O
perfused	VBN	O
stents	NNS	O
.	.	O

Prospective	JJ	O
study	NN	O
of	IN	O
C-reactive	NNP	O
protein	NN	O
,	,	O
homocysteine	NN	O
,	,	O
and	CC	O
plasma	VB	O
lipid	JJ	O
levels	NNS	O
as	IN	O
predictors	NNS	O
of	IN	O
sudden	JJ	O
cardiac	JJ	O
death	NN	O
.	.	O

BACKGROUND	NNP	O
Sudden	NNP	O
cardiac	JJ	O
death	NN	O
(	(	O
SCD	NNP	O
)	)	O
is	VBZ	O
an	DT	O
important	JJ	O
cause	NN	O
of	IN	O
mortality	NN	O
even	RB	O
among	IN	O
apparently	RB	O
healthy	JJ	O
populations	NNS	O
.	.	O

However	RB	O
,	,	O
our	PRP$	O
ability	NN	O
to	TO	O
identify	VB	O
those	DT	O
at	IN	O
risk	NN	O
for	IN	O
SCD	NNP	O
in	IN	O
the	DT	O
general	JJ	O
population	NN	O
is	VBZ	O
poor	JJ	O
,	,	O
and	CC	O
more	RBR	O
specific	JJ	O
markers	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
To	TO	O
compare	VB	O
and	CC	O
contrast	VB	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
homocysteine	NN	O
,	,	O
and	CC	O
lipids	NNS	O
as	IN	O
long-term	JJ	O
predictors	NNS	O
of	IN	O
SCD	NNP	O
,	,	O
we	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
nested	JJ	O
,	,	O
case-control	JJ	O
analysis	NN	O
involving	VBG	O
97	CD	SampleSize
cases	NNS	O
of	IN	O
SCD	NNP	Condition
among	IN	O
apparently	RB	O
healthy	JJ	O
men	NNS	Sex
enrolled	VBN	O
in	IN	O
the	DT	O
Physician	NNP	O
's	POS	O
Health	NNP	O
Study	NNP	O
.	.	O

Of	IN	O
these	DT	O
plasma	JJ	O
markers	NNS	O
measured	VBD	O
,	,	O
only	RB	O
baseline	JJ	O
CRP	NNP	O
levels	NNS	O
were	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
the	DT	O
risk	NN	O
of	IN	O
SCD	NNP	O
over	IN	O
the	DT	O
ensuing	VBG	O
17	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
(	(	O
P	NNP	O
for	IN	O
trend=0.001	NN	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
risk	NN	O
associated	VBN	O
with	IN	O
CRP	NNP	O
levels	NNS	O
was	VBD	O
primarily	RB	O
seen	VBN	O
among	IN	O
men	NNS	O
in	IN	O
the	DT	O
highest	JJS	O
quartile	NN	O
,	,	O
who	WP	O
were	VBD	O
at	IN	O
a	DT	O
2.78-fold	JJ	O
increased	JJ	O
risk	NN	O
of	IN	O
SCD	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.35	CD	O
to	TO	O
5.72	CD	O
)	)	O
compared	VBN	O
with	IN	O
men	NNS	O
in	IN	O
the	DT	O
lowest	JJS	O
quartile	NN	O
.	.	O

These	DT	O
results	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
altered	VBN	O
in	IN	O
analyses	NNS	O
that	WDT	O
(	(	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
matching	JJ	O
variables	NNS	O
of	IN	O
age	NN	O
and	CC	O
smoking	NN	O
status	NN	O
)	)	O
controlled	VBD	O
for	IN	O
lipid	JJ	O
parameters	NNS	O
,	,	O
homocysteine	NN	O
,	,	O
and	CC	O
multiple	JJ	O
cardiac	JJ	O
risk	NN	O
factors	NNS	O
(	(	O
relative	JJ	O
risk	NN	O
for	IN	O
highest	JJS	O
versus	NN	O
lowest	JJS	O
quartile	NN	O
2.65	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.79	CD	O
to	TO	O
8.83	CD	O
;	:	O
P	NNP	O
for	IN	O
trend=0.03	NN	O
)	)	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
the	DT	O
positive	JJ	O
relationship	NN	O
observed	VBD	O
for	IN	O
CRP	NNP	O
,	,	O
neither	DT	O
homocysteine	NN	O
nor	CC	O
lipid	JJ	O
levels	NNS	O
were	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
risk	NN	O
of	IN	O
SCD	NNP	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
prospective	JJ	O
data	NNS	O
suggest	VBP	O
that	IN	O
CRP	NNP	O
levels	NNS	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
identifying	VBG	O
apparently	RB	O
healthy	JJ	O
men	NNS	O
who	WP	O
are	VBP	O
at	IN	O
an	DT	O
increased	VBN	O
long-term	JJ	Condition
risk	NN	Condition
of	IN	Condition
SCD	NNP	Condition
.	.	O

The	DT	O
evolving	VBG	O
clinical	JJ	O
status	NN	O
of	IN	O
patients	NNS	O
after	IN	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
:	:	O
the	DT	O
importance	NN	O
of	IN	O
post-hospital	JJ	O
data	NNS	O
for	IN	O
mortality	NN	O
prediction	NN	O
.	.	O

Studies	NNPS	O
predicting	VBG	O
mortality	NN	O
after	IN	O
myocardial	JJ	Condition
infarction	NN	Condition
(	(	Condition
MI	NNP	Condition
)	)	O
usually	RB	O
rely	VBP	O
on	IN	O
in-hospital	JJ	O
data	NNS	O
,	,	O
and	CC	O
combine	NN	O
patients	NNS	Condition
admitted	VBN	Condition
for	IN	Condition
the	DT	Condition
first	JJ	Condition
MI	NNP	Condition
with	IN	Condition
recurrent	JJ	Condition
MI	NNP	Condition
patients	NNS	Condition
.	.	O

Since	IN	O
treatment	NN	O
decisions	NNS	O
are	VBP	O
often	RB	O
made	VBN	O
or	CC	O
modified	VBN	O
at	IN	O
the	DT	O
first	JJ	O
outpatient	NN	O
clinic	JJ	O
visit	NN	O
,	,	O
this	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
importance	NN	O
of	IN	O
post-hospital	JJ	O
data	NNS	O
on	IN	O
mortality	NN	O
prediction	NN	O
after	IN	O
a	DT	O
first	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
.	.	O

An	DT	O
inception	NN	O
cohort	NN	O
of	IN	O
patients	NNS	Condition
enrolled	VBN	Condition
in	IN	Condition
the	DT	Condition
Beta-Blocker	NNP	Condition
in	IN	Condition
Heart	NNP	Condition
Attack	NNP	Condition
Trial	NNP	Condition
(	(	O
n	JJ	O
=	NN	O
2830	CD	SampleSize
)	)	O
was	VBD	O
included	VBN	O
.	.	O

Forty-three	JJ	O
variables	NNS	O
(	(	O
including	VBG	O
in-hospital	JJ	O
and	CC	O
post-hospital	JJ	O
data	NNS	O
)	)	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
stepwise	NN	O
logistic	JJ	O
regression	NN	O
.	.	O

Ten	CD	O
variables	NNS	O
were	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
1-year	JJ	O
mortality	NN	O
:	:	O
five	CD	O
used	VBN	O
in-hospital	JJ	O
data	NNS	O
(	(	O
history	NN	O
of	IN	O
hypertension	NN	O
,	,	O
hypercholesterolemia	NN	O
,	,	O
congestive	JJ	O
heart	NN	O
failure	NN	O
[	NNP	O
CHF	NNP	O
]	NNP	O
,	,	O
ventricular	JJ	O
tachycardia	NN	O
,	,	O
and	CC	O
age	NN	O
)	)	O
;	:	O
and	CC	O
five	CD	O
variables	NNS	O
depended	VBN	O
on	IN	O
post-hospital	JJ	O
data	NNS	O
collected	VBN	O
at	IN	O
the	DT	O
first	JJ	O
outpatient	JJ	O
visit	NN	O
(	(	O
CHF	NNP	O
after	IN	O
discharge	NN	O
,	,	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
functional	JJ	O
class	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
pulmonary	JJ	O
rates	NNS	O
,	,	O
and	CC	O
smoking	NN	O
)	)	O
.	.	O

Two	CD	O
predictive	JJ	O
systems	NNS	O
were	VBD	O
developed	VBN	O
that	IN	O
partitioned	JJ	O
patients	NNS	O
into	IN	O
one	CD	O
of	IN	O
four	CD	O
classes	NNS	O
with	IN	O
distinct	JJ	O
mortality	NN	O
risks	NNS	O
:	:	O
a	DT	O
composite	JJ	O
system	NN	O
using	VBG	O
the	DT	O
10	CD	O
in-	JJ	O
and	CC	O
post-hospital	JJ	O
variables	NNS	O
,	,	O
and	CC	O
a	DT	O
system	NN	O
using	VBG	O
only	RB	O
the	DT	O
5	CD	O
in-hospital	JJ	O
variables	NNS	O
.	.	O

Mortality	NNP	O
risk	NN	O
for	IN	O
the	DT	O
composite	JJ	O
system	NN	O
classes	NNS	O
ranged	VBD	O
from	IN	O
0.6	CD	O
to	TO	O
20.0	CD	O
%	NN	O
(	(	O
I	PRP	O
[	VBP	O
n	JJ	O
=	$	O
861	CD	O
]	NNP	O
,	,	O
0.6	CD	O
%	NN	O
;	:	O
II	NNP	O
[	NNP	O
n	RB	O
=	VBZ	O
1151	CD	O
]	NN	O
,	,	O
2.3	CD	O
%	NN	O
;	:	O
III	NNP	O
[	NNP	O
n	MD	O
=698	VB	O
]	NNP	O
,	,	O
4.3	CD	O
%	NN	O
;	:	O
IV	NNP	O
[	NNP	O
n	VBD	O
=	$	O
120	CD	O
]	NNP	O
,	,	O
20.0	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
the	DT	O
range	NN	O
of	IN	O
mortality	NN	O
risk	NN	O
using	VBG	O
the	DT	O
in-hospital	JJ	O
data	NNS	O
only	RB	O
system	NN	O
was	VBD	O
less	JJR	O
(	(	O
1	CD	O
to	TO	O
8.3	CD	O
%	NN	O
)	)	O
.	.	O

Most	JJS	O
importantly	RB	O
,	,	O
a	DT	O
distinct	JJ	O
gradient	NN	O
within	IN	O
each	DT	O
class	NN	O
of	IN	O
the	DT	O
in-hospital	JJ	O
data	NNS	O
only	RB	O
system	NN	O
was	VBD	O
created	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
the	DT	O
post-hospital	JJ	O
data	NN	O
.	.	O

This	DT	O
study	NN	O
demonstrates	VBZ	O
that	IN	O
risk	NN	O
stratification	NN	O
after	IN	O
an	DT	O
acute	NN	O
first	RB	O
MI	NNP	O
is	VBZ	O
improved	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
post-hospital	JJ	O
data	NNS	O
.	.	O

Hypotensive	JJ	O
effects	NNS	O
and	CC	O
influence	NN	O
on	IN	O
serum	NN	O
lipids	NNS	O
of	IN	O
SQ29,852	NNP	O
,	,	O
a	DT	O
new	JJ	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitor	NN	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
:	:	O
a	DT	O
comparison	NN	O
with	IN	O
atenolol	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
SQ29,852	NNP	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
,	,	O
a	DT	O
new	JJ	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitor	NN	O
,	,	O
and	CC	O
atenolol	NN	O
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
,	,	O
monotherapies	NNS	O
were	VBD	O
compared	VBN	O
in	IN	O
46	CD	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
essential	JJ	O
hypertension	NN	O
.	.	O

Both	DT	O
SQ29,852	NNP	O
(	(	O
mean	VBP	O
dose	RB	O
15.0	CD	O
+/-	JJ	O
5.1	CD	O
mg/day	NN	O
)	)	O
and	CC	O
atenolol	$	O
(	(	O
mean	VB	O
dose	RB	O
37.5	CD	O
+/-	JJ	O
18.5	CD	O
mg/day	NN	O
)	)	O
significantly	RB	O
decreased	VBN	O
both	DT	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressures	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
serum	NN	O
lipids	NNS	O
,	,	O
apolipoproteins	NNS	O
,	,	O
lipoproteins	VBZ	O
or	CC	O
atherosclerotic	JJ	O
indices	NNS	O
after	IN	O
both	DT	O
SQ29,852	NNP	O
and	CC	O
atenolol	RB	O
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
significant	JJ	O
inter-group	JJ	O
differences	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
side	NN	O
effects	NNS	O
or	CC	O
abnormal	JJ	O
laboratory	NN	O
tests	NNS	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
SQ29,852	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	O
antihypertensive	JJ	O
drug	NN	O
without	IN	O
adverse	JJ	O
effect	NN	O
on	IN	O
lipid	JJ	O
metabolism	NN	O
.	.	O

[	NN	O
Mitoxantrone	NNP	O
(	(	O
MTX	NNP	O
)	)	O
versus	NN	O
mitomycin	NN	O
C	NNP	O
(	(	O
MMC	NNP	O
)	)	O
in	IN	O
the	DT	O
ablative	JJ	O
treatment	NN	O
of	IN	O
Ta	NNP	Condition
,	,	Condition
T1	NNP	Condition
superficial	JJ	Condition
bladder	NN	Condition
tumors	NNS	Condition
.	.	O

Phase	NNP	O
III	NNP	O
,	,	O
randomized	VBD	O
prospective	JJ	O
study	NN	O
]	NNP	O
.	.	O

A	NNP	O
prospective	JJ	O
randomized	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
ablation	NN	O
capacity	NN	O
of	IN	O
mitoxantrone	NN	O
in	IN	O
Ta-T1	NNP	O
superficial	JJ	O
bladder	NN	O
tumors	NNS	O
versus	VBP	O
mitomycin	JJ	O
C	NNP	O
,	,	O
a	DT	O
drug	NN	O
whose	WP$	O
intravesical	JJ	O
ablation	NN	O
properties	NNS	O
are	VBP	O
well-known	JJ	O
.	.	O

Fifty-seven	JJ	O
patients	NNS	O
comprised	VBD	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
tumor	NN	O
was	VBD	O
not	RB	O
completely	RB	O
resected	VBN	O
when	WRB	O
the	DT	O
patient	NN	O
underwent	JJ	O
TUR	NNP	O
.	.	O

This	DT	O
residual	JJ	O
tumor	NN	O
was	VBD	O
used	VBN	O
as	IN	O
control	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
either	DT	O
20	CD	O
mg	NN	O
Mitoxantrone	NNP	O
or	CC	O
40	CD	O
mg	NNS	O
mitomycin	JJ	O
C	NNP	O
weekly	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
and	CC	O
two	CD	O
other	JJ	O
instillations	NNS	O
every	DT	O
15	CD	O
days	NNS	O
in	IN	O
50	CD	O
ml	NNS	O
saline	JJ	O
solution	NN	O
.	.	O

Response	NNP	O
to	TO	O
therapy	NN	O
was	VBD	O
evaluated	VBN	O
between	IN	O
the	DT	O
4th	CD	O
and	CC	O
8th	CD	O
week	NN	O
and	CC	O
classified	VBD	O
as	IN	O
complete	JJ	O
response	NN	O
(	(	O
CR	NNP	O
)	)	O
,	,	O
defined	VBD	O
as	IN	O
no	DT	O
gross	JJ	O
and	CC	O
microscopic	JJ	O
evidence	NN	O
of	IN	O
residual	JJ	O
tumor	NN	O
,	,	O
or	CC	O
no	DT	O
response	NN	O
(	(	O
NR	NNP	O
)	)	O
or	CC	O
therapeutic	JJ	O
failure	NN	O
.	.	O

CR	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
77.7	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
mitomycin	JJ	O
C	NNP	O
and	CC	O
in	IN	O
50	CD	O
%	NN	O
in	IN	O
those	DT	O
that	WDT	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
Mitoxantrone	NNP	O
.	.	O

Treatment	NNP	O
was	VBD	O
discontinued	VBN	O
because	IN	O
of	IN	O
side	NN	O
effects	NNS	O
in	IN	O
15	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
mitomycin	JJ	O
C	NNP	O
and	CC	O
in	IN	O
63.4	CD	O
%	NN	O
of	IN	O
those	DT	O
who	WP	O
received	VBD	O
Mitoxantrone	NNP	O
.	.	O

We	PRP	O
can	MD	O
conclude	VB	O
from	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
that	IN	O
Mitoxantrone	NNP	O
is	VBZ	O
a	DT	O
useful	JJ	O
agent	NN	O
for	IN	O
ablation	NN	O
therapy	NN	O
of	IN	O
superficial	JJ	O
bladder	NN	O
tumors	NNS	O
,	,	O
although	IN	O
the	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
severe	JJ	O
side	NN	O
effects	NNS	O
warrants	NNS	O
its	PRP$	O
limited	JJ	O
use	NN	O
and	CC	O
at	IN	O
high	JJ	O
dilutions	NNS	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
10	CD	O
%	NN	O
HES	NNP	O
130/0.4	CD	O
versus	NN	O
10	CD	O
%	NN	O
HES	NNP	O
200/0.5	CD	O
for	IN	O
plasma	NN	O
volume	NN	O
expansion	NN	O
in	IN	O
cardiac	JJ	O
surgery	NN	O
patients	NNS	O
.	.	O

AIM	NNP	O
Hydroxyethyl	NNP	O
starch	NN	O
(	(	O
HES	NNP	O
)	)	O
solutions	NNS	O
are	VBP	O
frequently	RB	O
used	VBN	O
for	IN	O
perioperative	JJ	O
volume	NN	O
replacement	NN	O
.	.	O

Whereas	NNP	O
older	JJR	O
HES	NNP	O
specimen	NNS	O
tended	VBD	O
to	TO	O
accumulate	VB	O
in	IN	O
the	DT	O
plasma	NN	O
and	CC	O
to	TO	O
cause	VB	O
negative	JJ	O
effects	NNS	O
on	IN	O
hemostasis	NN	O
,	,	O
more	RBR	O
recent	JJ	O
products	NNS	O
,	,	O
e.g.	NN	O
,	,	O
HES	NNP	O
130/0.4	CD	O
,	,	O
are	VBP	O
characterised	VBN	O
by	IN	O
improved	JJ	O
pharmacological	JJ	O
properties	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
10	CD	O
%	NN	O
HES	NNP	O
130/0.4	CD	O
and	CC	O
10	CD	O
%	NN	O
HES	NNP	O
200/0.5	CD	O
.	.	O

METHODS	NN	O
In	IN	O
this	DT	O
post-hoc	JJ	O
analysis	NN	O
of	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
multi-center	JJ	O
therapeutic	JJ	O
equivalence	NN	O
trial	NN	O
,	,	O
76	CD	O
patients	NNS	O
undergoing	JJ	O
elective	JJ	O
on-pump	JJ	O
cardiac	NN	O
surgery	NN	O
received	VBD	O
perioperative	JJ	O
volume	NN	O
replacement	NN	O
using	VBG	O
either	CC	O
10	CD	O
%	NN	O
HES	NNP	O
130/0.4	CD	O
(	(	O
N.=37	NNP	O
)	)	O
or	CC	O
10	CD	O
%	NN	O
HES	NNP	O
200/0.5	CD	O
(	(	O
N.=39	NNP	O
)	)	O
up	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
20	CD	O
mL	JJ	O
kg-1	NN	O
.	.	O

RESULTS	NNP	O
Equivalent	NNP	O
volumes	NNS	O
of	IN	O
investigational	JJ	O
medication	NN	O
were	VBD	O
infused	VBN	O
until	IN	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
administration	NN	O
(	(	O
1577	CD	O
vs.	IN	O
1540	CD	O
mL	NN	O
;	:	O
treatment	NN	O
difference	NN	O
37	CD	O
[	JJ	O
-150	NN	O
;	:	O
223	CD	O
]	NNP	O
mL	NN	O
;	:	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
for	IN	O
equivalence	NN	O
)	)	O
.	.	O

Whereas	NNP	O
standard	JJ	O
laboratory	NN	O
tests	NNS	O
of	IN	O
coagulation	NN	O
were	VBD	O
comparable	JJ	O
between	IN	O
groups	NNS	O
,	,	O
von	FW	O
Willebrand	NNP	O
factor	NN	O
activity	NN	O
on	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
morning	NN	O
tended	VBD	O
to	TO	O
be	VB	O
higher	JJR	O
following	VBG	O
treatment	NN	O
with	IN	O
10	CD	O
%	NN	O
HES	NNP	O
130/0.4	CD	O
as	IN	O
compared	VBN	O
to	TO	O
10	CD	O
%	NN	O
HES	NNP	O
200/0.5	CD	O
(	(	O
P=0.025	NNP	O
)	)	O
with	IN	O
this	DT	O
difference	NN	O
being	VBG	O
statistically	RB	O
significant	JJ	O
only	RB	O
in	IN	O
the	DT	O
per-protocol	JJ	O
analysis	NN	O
(	(	O
P=0.02	NNP	O
)	)	O
.	.	O

Treatment	JJ	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
concerning	VBG	O
other	JJ	O
safety	NN	O
parameters	NNS	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
drug	NN	O
reactions	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
renal	JJ	O
function	NN	O
was	VBD	O
well	RB	O
preserved	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Ten	CD	O
percent	NN	O
HES	NNP	O
130/0.4	CD	O
was	VBD	O
equally	RB	O
effective	JJ	O
and	CC	O
safe	JJ	O
as	IN	O
compared	VBN	O
to	TO	O
10	CD	O
%	NN	O
HES	NNP	O
200/0.5	CD	O
for	IN	O
volume	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
cardiovascular	JJ	O
surgery	NN	O
.	.	O

Postoperative	JJ	O
coagulation	NN	O
and	CC	O
renal	JJ	O
function	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
standard	JJ	O
laboratory	NN	O
tests	NNS	O
,	,	O
were	VBD	O
similar	JJ	O
among	IN	O
groups	NNS	O
.	.	O

Using	VBG	O
the	DT	O
virtual	JJ	O
reality-cognitive	JJ	O
rehabilitation	NN	O
approach	NN	O
to	TO	O
improve	VB	O
contextual	JJ	O
processing	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	Condition
.	.	O

BACKGROUND	NNP	O
This	DT	O
pilot	NN	O
study	NN	O
investigated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
novel	JJ	O
virtual	JJ	O
reality-cognitive	JJ	O
rehabilitation	NN	O
(	(	O
VR-CR	NNP	O
)	)	O
intervention	NN	O
to	TO	O
improve	VB	O
contextual	JJ	O
processing	NN	O
of	IN	O
objects	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	Condition
.	.	O

Previous	JJ	O
research	NN	O
supports	VBZ	O
that	IN	O
children	NNS	O
with	IN	O
autism	NN	Condition
show	NN	O
deficits	NNS	O
in	IN	O
contextual	JJ	O
processing	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
deficits	NNS	O
in	IN	O
its	PRP$	O
elementary	JJ	O
components	NNS	O
:	:	O
abstraction	NN	O
and	CC	O
cognitive	JJ	O
flexibility	NN	O
.	.	O

METHODS	NNP	O
Four	CD	SampleSize
children	NNS	O
with	IN	O
autism	NN	Condition
participated	VBN	O
in	IN	O
a	DT	O
multiple-baseline	JJ	O
,	,	O
single-subject	JJ	O
study	NN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
taught	JJ	O
how	WRB	O
to	TO	O
see	VB	O
objects	NNS	O
in	IN	O
context	NN	O
by	IN	O
reinforcing	VBG	O
attention	NN	O
to	TO	O
pivotal	JJ	O
contextual	JJ	O
information	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
children	NNS	O
demonstrated	VBD	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
contextual	JJ	O
processing	NN	O
and	CC	O
cognitive	JJ	O
flexibility	NN	O
.	.	O

Mixed	JJ	O
results	NNS	O
were	VBD	O
found	VBN	O
on	IN	O
the	DT	O
control	NN	O
test	NN	O
and	CC	O
changes	NNS	O
in	IN	O
context-related	JJ	O
behaviours	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Larger-scale	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
usability	NN	O
in	IN	O
comprehensive	JJ	O
educational	JJ	O
programs	NNS	O
.	.	O

Safety	NN	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
changes	NNS	O
in	IN	O
amyloid	JJ	O
beta	NN	O
concentrations	NNS	O
after	IN	O
administration	NN	O
of	IN	O
a	DT	O
gamma-secretase	JJ	O
inhibitor	NN	O
in	IN	O
volunteers	NNS	O
.	.	O

Amyloid	NNP	O
beta	NN	O
(	(	O
Abeta	NNP	O
)	)	O
may	MD	O
play	VB	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
Alzheimer	NNP	O
disease	NN	O
.	.	O

A	DT	O
functional	JJ	O
gamma-secretase	NN	O
inhibitor	NN	O
,	,	O
LY450139	NNP	O
,	,	O
was	VBD	O
developed	VBN	O
that	IN	O
inhibits	NNS	O
Abeta	NNP	O
formation	NN	O
in	IN	O
whole	JJ	O
cell	NN	O
assays	NNS	O
,	,	O
transgenic	JJ	O
mice	NN	O
,	,	O
and	CC	O
beagle	JJ	O
dogs	NNS	O
.	.	O

The	DT	O
authors	NNS	O
wished	VBD	O
to	TO	O
determine	VB	O
the	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
this	DT	O
drug	NN	O
,	,	O
and	CC	O
the	DT	O
reduction	NN	O
of	IN	O
Abeta	NNP	O
in	IN	O
plasma	NN	O
and	CC	O
cerebrospinal	JJ	O
fluid	NN	O
(	(	O
CSF	NNP	O
)	)	O
after	IN	O
multiple	JJ	O
doses	NNS	O
.	.	O

Volunteer	NNP	O
subjects	NNS	O
(	(	O
N	NNP	O
=	NNP	O
37	CD	O
)	)	O
were	VBD	O
studied	VBN	O
using	VBG	O
doses	NNS	O
from	IN	O
5	CD	O
to	TO	O
50	CD	O
mg/day	NN	O
given	VBN	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Plasma	NNP	O
and	CC	O
CSF	NNP	O
concentrations	NNS	O
of	IN	O
LY450139	NNP	O
,	,	O
Abeta	NNP	O
(	(	O
1-40	JJ	O
)	)	O
and	CC	O
Abeta	NNP	O
(	(	O
1-X	JJ	O
)	)	O
(	(	O
Abeta	NNP	O
(	(	O
total	JJ	O
)	)	O
)	)	O
were	VBD	O
determined	VBN	O
,	,	O
and	CC	O
safety	NN	O
and	CC	O
tolerability	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

The	DT	O
plasma	JJ	O
half-life	NN	O
of	IN	O
LY450139	NNP	O
was	VBD	O
approximately	RB	O
2.5	CD	O
hours	NNS	O
.	.	O

Pharmacokinetic	JJ	O
analyses	NNS	O
showed	VBD	O
a	DT	O
linear	JJ	O
relationship	NN	O
between	IN	O
dose	NN	O
and	CC	O
plasma	JJ	O
concentrations	NNS	O
,	,	O
with	IN	O
a	DT	O
Cmax	NNP	O
of	IN	O
828	CD	O
+/-	JJ	O
19.2	CD	O
ng/mL	NN	O
after	IN	O
a	DT	O
50-mg	JJ	O
dose	NN	O
.	.	O

Plasma	NNP	O
Abeta	NNP	O
concentrations	NNS	O
decreased	VBD	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
manner	NN	O
over	IN	O
a	DT	O
6-hour	JJ	O
interval	NN	O
following	VBG	O
drug	NN	O
administration	NN	O
,	,	O
with	IN	O
a	DT	O
maximum	JJ	O
decrease	NN	O
of	IN	O
approximately	RB	O
40	CD	O
%	NN	O
relative	JJ	O
to	TO	O
baseline	VB	O
.	.	O

After	IN	O
returning	VBG	O
to	TO	O
baseline	VB	O
,	,	O
Abeta	NNP	O
concentrations	NNS	O
were	VBD	O
transiently	RB	O
increased	VBN	O
.	.	O

CSF	NNP	O
Abeta	NNP	O
concentrations	NNS	O
were	VBD	O
unchanged	JJ	O
.	.	O

Adverse	JJ	O
events	NNS	O
reported	VBN	O
by	IN	O
subjects	NNS	O
taking	VBG	O
5-mg	JJ	O
,	,	O
20-mg	JJ	O
,	,	O
or	CC	O
40-mg	JJ	O
doses	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
reported	VBN	O
by	IN	O
subjects	NNS	O
taking	VBG	O
placebo	NN	O
.	.	O

Two	CD	O
of	IN	O
7	CD	O
subjects	NNS	O
taking	VBG	O
50	CD	O
mg/day	NN	O
experienced	VBD	O
adverse	JJ	O
events	NNS	O
that	WDT	O
may	MD	O
have	VB	O
been	VBN	O
drug	NN	O
related	VBN	O
.	.	O

In	IN	O
this	DT	O
phase	NN	O
1	CD	O
volunteer	NN	O
study	NN	O
,	,	O
reported	VBD	O
adverse	JJ	O
events	NNS	O
after	IN	O
taking	VBG	O
LY450139	NNP	O
were	VBD	O
manageable	JJ	O
.	.	O

A	DT	O
dose-dependent	JJ	O
reduction	NN	O
in	IN	O
plasma	NN	O
Abeta	NNP	O
was	VBD	O
demonstrated	VBN	O
,	,	O
and	CC	O
changes	NNS	O
in	IN	O
plasma	NN	O
Abeta	NNP	O
concentrations	NNS	O
were	VBD	O
temporally	RB	O
related	VBN	O
to	TO	O
the	DT	O
pharmacokinetic	JJ	O
characteristics	NNS	O
of	IN	O
LY450139	NNP	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
weight	NN	O
training	NN	O
on	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
and	CC	O
bone	NN	O
turnover	NN	O
in	IN	O
postmenopausal	JJ	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
with	IN	O
bone	JJ	O
loss	NN	O
:	:	O
a	DT	O
24-month	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

SUMMARY	VB	O
This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
24	CD	O
months	NNS	O
of	IN	O
weight	JJ	O
training	NN	O
exercises	NNS	O
enhanced	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
risedronate	NN	O
,	,	O
calcium	NN	O
,	,	O
and	CC	O
vitamin	NN	O
D	NNP	O
in	IN	O
maintaining	VBG	O
or	CC	O
improving	VBG	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
in	IN	O
223	CD	O
postmenopausal	NN	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
.	.	O

Subjects	NNS	O
who	WP	O
were	VBD	O
>	NNP	O
or	CC	O
=50	CD	O
%	NN	O
adherent	NN	O
to	TO	O
exercise	VB	O
had	VBN	O
no	DT	O
improvement	NN	O
in	IN	O
BMD	NNP	O
but	CC	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
lose	VB	O
BMD	NNP	O
.	.	O

INTRODUCTION	NNP	O
This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
(	(	O
1	CD	O
)	)	O
postmenopausal	NN	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
(	(	O
BCS	NNP	O
)	)	O
with	IN	O
bone	NN	O
loss	NN	O
taking	VBG	O
24	CD	O
months	NNS	O
of	IN	O
risedronate	NN	O
,	,	O
calcium	NN	O
,	,	O
and	CC	O
vitamin	NN	O
D	NNP	O
had	VBD	O
increased	VBN	O
bone	RB	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
at	IN	O
the	DT	O
total	JJ	O
hip	NN	O
,	,	O
femoral	JJ	O
neck	NN	O
,	,	O
L1-L4	NNP	O
spine	NN	O
,	,	O
total	JJ	O
radius	NN	O
and	CC	O
33	CD	O
%	NN	O
radius	NN	O
,	,	O
and	CC	O
decreased	VBD	O
bone	NN	O
turnover	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
subjects	NNS	O
who	WP	O
also	RB	O
participated	VBD	O
in	IN	O
strength/weight	JJ	O
training	NN	O
(	(	O
ST	NNP	O
)	)	O
exercises	NNS	O
had	VBD	O
greater	JJR	O
increases	NNS	O
in	IN	O
BMD	NNP	O
and	CC	O
greater	JJR	O
decreases	NNS	O
in	IN	O
bone	NN	O
turnover	NN	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
subjects	NNS	O
who	WP	O
also	RB	O
exercised	VBD	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
preserve	VB	O
(	(	O
at	IN	O
least	JJS	O
maintain	NN	O
)	)	O
BMD	NNP	O
.	.	O

METHODS	NNP	O
Postmenopausal	NNP	O
BCS	NNP	O
(	(	O
223	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
exercise	VB	O
plus	JJ	O
medication	NN	O
or	CC	O
medication	NN	O
only	RB	O
groups	NNS	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
24	CD	O
months	NNS	O
of	IN	O
1,200	CD	O
mg	NN	O
of	IN	O
calcium	NN	O
and	CC	O
400	CD	O
IU	NNP	O
of	IN	O
vitamin	NNP	O
D	NNP	O
daily	RB	O
and	CC	O
35	CD	O
mg	NN	O
of	IN	O
risedronate	JJ	O
weekly	JJ	O
,	,	O
and	CC	O
the	DT	O
exercise	NN	O
group	NN	O
additionally	RB	O
had	VBD	O
ST	NNP	O
exercises	NNS	O
twice	RB	O
weekly	RB	O
.	.	O

RESULTS	NNP	O
After	IN	O
24	CD	O
months	NNS	O
,	,	O
women	NNS	O
who	WP	O
took	VBD	O
medications	NNS	O
without	IN	O
exercising	VBG	O
had	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
BMD	NNP	O
at	IN	O
the	DT	O
total	JJ	O
hip	NN	O
(	(	O
+1.81	CD	O
%	NN	O
)	)	O
and	CC	O
spine	NN	O
(	(	O
+2.85	CD	O
%	NN	O
)	)	O
and	CC	O
significant	JJ	O
decreases	NNS	O
in	IN	O
Alkphase	NNP	O
B	NNP	O
(	(	O
-8.7	NNP	O
%	NN	O
)	)	O
and	CC	O
serum	JJ	O
NTx	NNP	O
(	(	O
-16.7	NNP	O
%	NN	O
)	)	O
.	.	O

Women	NNS	O
who	WP	O
also	RB	O
exercised	VBD	O
had	VBD	O
additional	JJ	O
increases	NNS	O
in	IN	O
BMD	NNP	O
at	IN	O
the	DT	O
femoral	JJ	O
neck	NN	O
(	(	O
+0.29	CD	O
%	NN	O
)	)	O
,	,	O
total	JJ	O
hip	NN	O
(	(	O
+0.34	CD	O
%	NN	O
)	)	O
,	,	O
spine	NN	O
(	(	O
+0.23	CD	O
%	NN	O
)	)	O
,	,	O
total	JJ	O
radius	NN	O
(	(	O
+0.30	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
additional	JJ	O
decreases	NNS	O
in	IN	O
Alkphase	NNP	O
B	NNP	O
(	(	O
-2.4	NNP	O
%	NN	O
)	)	O
and	CC	O
Serum	NNP	O
NTx	NNP	O
(	(	O
-6.5	NNP	O
%	NN	O
)	)	O
.	.	O

Additional	JJ	O
changes	NNS	O
in	IN	O
BMD	NNP	O
and	CC	O
bone	NN	O
turnover	NN	O
with	IN	O
exercise	NN	O
were	VBD	O
not	RB	O
significant	JJ	O
.	.	O

Subjects	NNS	O
who	WP	O
were	VBD	O
>	NNP	O
or	CC	O
=50	CD	O
%	NN	O
adherent	NN	O
to	TO	O
exercise	VB	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
lose	VB	O
BMD	NNP	O
at	IN	O
the	DT	O
total	JJ	O
hip	NN	O
(	(	O
chi-square	JJ	O
[	NN	O
1	CD	O
]	NNP	O
=	NNP	O
4.66	CD	O
,	,	O
p	NN	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
femoral	JJ	O
neck	NN	O
(	(	O
chi-square	JJ	O
[	NN	O
1	CD	O
]	NNP	O
=	NNP	O
4.63	CD	O
,	,	O
p	NN	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Strength/weight	NNP	O
training	NN	O
exercises	NNS	O
may	MD	O
prevent	VB	O
loss	NN	O
of	IN	O
BMD	NNP	O
in	IN	O
postmenopausal	NN	O
BCS	NNP	O
at	IN	O
risk	NN	O
for	IN	O
bone	NN	O
loss	NN	O
.	.	O

Serum	NNP	O
biochemical	JJ	O
characteristics	NNS	O
of	IN	O
Beluga	NNP	O
,	,	O
Huso	NNP	O
huso	NN	O
(	(	O
L.	NNP	O
)	)	O
,	,	O
in	IN	O
response	NN	O
to	TO	O
blood	NN	O
sampling	NN	O
after	IN	O
clove	NN	O
powder	NN	O
solution	NN	O
exposure	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
anesthesia	NN	O
on	IN	O
serum	NN	O
parameters	NNS	O
,	,	O
Beluga	NNP	O
,	,	O
Huso	NNP	O
huso	NN	O
(	(	O
L.	NNP	O
)	)	O
were	VBD	O
blood-sampled	JJ	O
immediately	RB	O
without	IN	O
anesthesia	NN	O
(	(	O
control	NN	O
)	)	O
or	CC	O
subjected	VBN	O
to	TO	O
following	VBG	O
anesthesia	JJ	O
procedure	NN	O
:	:	O
40	CD	O
,	,	O
120	CD	O
,	,	O
and	CC	O
240	CD	O
s	NN	O
exposure	NN	O
to	TO	O
3,000	CD	O
,	,	O
700	CD	O
,	,	O
and	CC	O
500	CD	O
mg	NN	O
l??	NN	O
clove	NN	O
solution	NN	O
,	,	O
respectively	RB	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
after	IN	O
these	DT	O
periods	NNS	O
,	,	O
when	WRB	O
fish	NN	O
were	VBD	O
immobile	JJ	O
and	CC	O
reached	VBD	O
stage	NN	O
4	CD	O
anesthesia	NN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
cortisol	NN	O
and	CC	O
glucose	JJ	O
levels	NNS	O
were	VBD	O
significantly	RB	O
high	JJ	O
in	IN	O
700	CD	O
and	CC	O
500	CD	O
but	CC	O
not	RB	O
3,000	CD	O
mg	NNS	O
l??	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
control	VB	O
.	.	O

Serum	NNP	O
lactate	NN	O
levels	NNS	O
were	VBD	O
significantly	RB	O
high	JJ	O
in	IN	O
500	CD	O
mg	NNS	O
l??	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
control	VB	O
group	NN	O
.	.	O

Lactate	NNP	O
levels	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
differed	VBN	O
between	IN	O
control	NN	O
,	,	O
3,000	CD	O
,	,	O
and	CC	O
700	CD	O
mg	NN	O
l??	NN	O
groups	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
serum	NN	O
levels	NNS	O
of	IN	O
cholesterol	NN	O
,	,	O
total	JJ	O
protein	NN	O
,	,	O
lactate	JJ	O
dehydrogenase	NN	O
,	,	O
aspartate	JJ	O
aminotransferase	NN	O
,	,	O
alanine	JJ	O
aminotransferase	NN	O
,	,	O
Na?	NNP	O
,	,	O
Cl?	NNP	O
,	,	O
K?	NNP	O
,	,	O
and	CC	O
Ca??	NNP	O
.	.	O

Results	NNP	O
suggest	VBP	O
that	IN	O
rapid	JJ	O
anesthesia	NN	O
with	IN	O
higher	JJR	O
dose	NN	O
is	VBZ	O
better	JJR	O
than	IN	O
slow	JJ	O
anesthesia	NN	O
with	IN	O
lower	JJR	O
dose	NN	O
for	IN	O
blood	NN	O
sampling	NN	O
in	IN	O
Beluga	NNP	O
.	.	O

Immediately	RB	O
restored	VBN	O
,	,	O
single-tapered	JJ	O
implants	NNS	Condition
in	IN	Condition
the	DT	Condition
anterior	JJ	Condition
maxilla	NN	Condition
:	:	O
prosthodontic	JJ	O
and	CC	O
aesthetic	JJ	O
outcomes	NNS	O
after	IN	O
1	CD	O
year	NN	O
.	.	O

BACKGROUND	NNP	O
Conventional	NNP	O
implant	JJ	O
protocols	NNS	O
advocate	VBP	O
a	DT	O
two-stage	NN	O
technique	NN	O
with	IN	O
a	DT	O
load-free	JJ	O
,	,	O
submerged	VBD	O
healing	JJ	O
period	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
immediate	JJ	O
restoration	NN	O
of	IN	O
single	JJ	O
implants	NNS	O
may	MD	O
be	VB	O
a	DT	O
viable	JJ	O
treatment	NN	O
option	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
prosthodontic	JJ	Condition
and	CC	O
aesthetic	JJ	Condition
peri-implant	JJ	Condition
mucosal	NN	O
outcomes	NNS	O
of	IN	O
immediately	RB	O
restored	VBN	O
,	,	O
Southern	JJ	Condition
single-tapered	JJ	Condition
implants	NNS	Condition
in	IN	Condition
the	DT	Condition
anterior	JJ	Condition
maxilla	NN	Condition
after	IN	O
1	CD	O
year	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Participants	NNP	O
(	(	O
mean	JJ	O
age	NN	O
:	:	O
43.25	CD	O
years	NNS	O
;	:	O
range	NN	O
:	:	O
23-71	JJ	O
years	NNS	O
)	)	O
satisfying	VBG	O
specified	VBN	O
inclusion	NN	O
criteria	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
conventional	JJ	O
two-stage	JJ	O
restoration	NN	O
(	(	O
control	NN	O
group	NN	O
;	:	O
n=14	CC	O
)	)	O
and	CC	O
immediate	JJ	O
restoration	NN	O
groups	NNS	O
(	(	O
test	NN	O
group	NN	O
;	:	O
n	CC	O
=14	NN	O
)	)	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

Tapered	VBN	O
,	,	O
roughened-surface	JJ	O
Southern	JJ	O
implants	NNS	O
were	VBD	O
placed	VBN	O
using	VBG	O
a	DT	O
standardized	JJ	O
technique	NN	O
,	,	O
and	CC	O
implant	JJ	O
level	NN	O
bone	NN	O
impressions	NNS	O
were	VBD	O
made	VBN	O
.	.	O

Provisional	JJ	O
screw-retained	JJ	O
crowns	NNS	O
,	,	O
out	IN	O
of	IN	O
occlusion	NN	O
,	,	O
were	VBD	O
placed	VBN	O
at	IN	O
second-stage	NN	O
surgery	NN	O
after	IN	O
26	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
conventional	JJ	O
restoration	NN	O
group	NN	O
,	,	O
and	CC	O
within	IN	O
4	CD	O
hours	NNS	O
of	IN	O
implant	JJ	O
placement	NN	O
for	IN	O
the	DT	O
immediate	JJ	O
restoration	NN	O
group	NN	O
.	.	O

Both	DT	O
groups	NNS	O
had	VBD	O
definitive	JJ	O
screw-retained	JJ	O
metal-ceramic	JJ	O
crowns	NNS	O
placed	VBN	O
in	IN	O
occlusion	NN	O
8	CD	O
weeks	NNS	O
later	RB	O
.	.	O

Peri-implant	JJ	O
mucosal	NN	O
response	NN	O
and	CC	O
papilla	NN	O
index	NN	O
were	VBD	O
recorded	VBN	O
4	CD	O
weeks	NNS	O
after	IN	O
definitive	JJ	O
crown	JJ	O
placement	NN	O
to	TO	O
allow	VB	O
for	IN	O
mucosal	JJ	O
maturation	NN	O
and	CC	O
at	IN	O
1	CD	O
year	NN	O
.	.	O

Prosthodontic	NNP	O
and	CC	O
aesthetic	JJ	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
established	VBN	O
criteria	NNS	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
within	IN	O
,	,	O
or	CC	O
between	IN	O
,	,	O
the	DT	O
control	NN	O
and	CC	O
test	NN	O
groups	NNS	O
for	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
bone	NN	O
quality	NN	O
or	CC	O
quantity	NN	O
,	,	O
implant	JJ	O
stability	NN	O
measurements	NNS	O
at	IN	O
surgery	NN	O
,	,	O
or	CC	O
implant	JJ	O
length	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
implant	JJ	O
success	NN	O
rate	NN	O
as	IN	O
determined	VBN	O
by	IN	O
radiographic	JJ	O
bone	NN	O
loss	NN	O
and	CC	O
stability	NN	O
tests	NNS	O
after	IN	O
1	CD	O
year	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
prosthodontic	JJ	O
maintenance	NN	O
,	,	O
peri-implant	JJ	O
mucosal	NN	O
response	NN	O
,	,	O
and	CC	O
papilla	NN	O
index	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
over	IN	O
1	CD	O
year	NN	O
.	.	O

CONCLUSIONS	NNP	O
Tapered	NNP	O
,	,	O
roughened-surface	JJ	O
implants	NNS	O
immediately	RB	O
restored	VBN	O
with	IN	O
single	JJ	O
provisional	JJ	O
crowns	NNS	O
at	IN	O
surgery	NN	O
and	CC	O
definitive	JJ	O
crowns	NNS	O
8	CD	O
weeks	NNS	O
later	RB	O
were	VBD	O
as	IN	O
prosthodontically	RB	O
and	CC	O
aesthetically	RB	O
successful	JJ	O
as	IN	O
conventionally	RB	O
restored	VBN	O
two-stage	JJ	O
implants	NNS	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
service	NN	O
.	.	O

Restoring	VBG	O
single	JJ	O
implants	NNS	O
immediately	RB	O
with	IN	O
screw-retained	JJ	O
crowns	NNS	O
is	VBZ	O
an	DT	O
efficient	JJ	O
procedure	NN	O
,	,	O
but	CC	O
the	DT	O
short-term	JJ	O
outcome	NN	O
is	VBZ	O
by	IN	O
no	DT	O
means	NNS	O
superior	VBP	O
to	TO	O
a	DT	O
conventional	JJ	O
two-stage	JJ	O
approach	NN	O
.	.	O

Histamine	NNP	Condition
intolerance-like	NN	Condition
symptoms	NNS	Condition
in	IN	O
healthy	JJ	Condition
volunteers	NNS	O
after	IN	O
oral	JJ	O
provocation	NN	O
with	IN	O
liquid	JJ	O
histamine	NN	O
.	.	O

Histamine	NNP	O
in	IN	O
food	NN	O
at	IN	O
non-toxic	JJ	O
doses	NNS	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
to	TO	O
be	VB	O
a	DT	O
major	JJ	O
cause	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
causing	NN	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	O
,	,	O
hypotension	NN	O
,	,	O
headache	NN	O
,	,	O
pruritus	NN	O
and	CC	O
flush	NN	O
(	(	O
histamine	JJ	O
intolerance	NN	O
)	)	O
.	.	O

Histamine-rich	JJ	O
foods	NNS	O
such	JJ	O
as	IN	O
cheese	NN	O
,	,	O
sausages	NNS	O
,	,	O
sauerkraut	NN	O
,	,	O
tuna	NN	O
,	,	O
tomatoes	NNS	O
,	,	O
and	CC	O
alcoholic	JJ	O
beverages	NNS	O
may	MD	O
contain	VB	O
histamine	VB	O
up	IN	O
to	TO	O
500	CD	O
mg/kg	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
in	IN	O
10	CD	SampleSize
healthy	JJ	O
females	NNS	Sex
(	(	O
age	NN	O
range	NN	O
22-36	CD	Age
years	NNS	Age
,	,	O
mean	JJ	O
29.1	CD	O
+/-	JJ	O
5.4	CD	O
)	)	O
who	WP	O
were	VBD	O
hospitalized	VBN	O
and	CC	O
challenged	VBN	O
on	IN	O
two	CD	O
consecutive	JJ	O
days	NNS	O
with	IN	O
placebo	NN	O
(	(	O
peppermint	JJ	O
tea	NN	O
)	)	O
or	CC	O
75	CD	O
mg	NN	O
of	IN	O
pure	JJ	O
histamine	NN	O
(	(	O
equaling	VBG	O
124	CD	O
mg	JJ	O
histamine	NN	O
dihydrochloride	NN	O
,	,	O
dissolved	VBN	O
in	IN	O
peppermint	NN	O
tea	NN	O
)	)	O
.	.	O

Objective	JJ	O
parameters	NNS	O
(	(	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
skin	JJ	O
temperature	NN	O
,	,	O
peak	VB	O
flow	NN	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
total	JJ	O
clinical	JJ	O
symptom	NN	O
score	NN	O
using	VBG	O
a	DT	O
standardized	VBN	O
protocol	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
received	VBD	O
a	DT	O
histamine-free	JJ	O
diet	NN	O
also	RB	O
low	JJ	O
in	IN	O
allergen	NN	O
24	CD	O
hours	NNS	O
before	IN	O
hospitalization	NN	O
and	CC	O
over	IN	O
the	DT	O
whole	JJ	O
observation	NN	O
period	NN	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
at	IN	O
baseline	NN	O
,	,	O
10	CD	O
,	,	O
20	CD	O
,	,	O
40	CD	O
,	,	O
and	CC	O
80	CD	O
minutes	NNS	O
,	,	O
and	CC	O
histamine	NN	O
and	CC	O
the	DT	O
histamine-degrading	JJ	O
enzyme	NN	O
diamine	NN	O
oxidase	NN	O
(	(	O
DAO	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

After	IN	O
histamine	JJ	O
challenge	NN	O
,	,	O
5	CD	O
of	IN	O
10	CD	O
subjects	NNS	O
showed	VBD	O
no	DT	O
reaction	NN	O
.	.	O

One	CD	O
individual	NN	O
experienced	VBD	O
tachycardia	NN	O
,	,	O
mild	JJ	O
hypotension	NN	O
after	IN	O
20	CD	O
minutes	NNS	O
,	,	O
sneezing	VBG	O
,	,	O
itching	NN	O
of	IN	O
the	DT	O
nose	NN	O
,	,	O
and	CC	O
rhinorrhea	NN	O
after	IN	O
60	CD	O
minutes	NNS	O
.	.	O

Four	CD	O
subjects	NNS	O
experienced	VBD	O
delayed	JJ	O
symptoms	NNS	O
like	IN	O
diarrhea	NN	O
(	(	O
4x	CD	O
)	)	O
,	,	O
flatulence	NN	O
(	(	O
3x	CD	O
)	)	O
,	,	O
headache	NN	O
(	(	O
3x	CD	O
)	)	O
,	,	O
pruritus	NN	O
(	(	O
2x	CD	O
)	)	O
and	CC	O
ocular	JJ	O
symptoms	NNS	O
(	(	O
1x	CD	O
)	)	O
starting	VBG	O
3	CD	O
to	TO	O
24	CD	O
hours	NNS	O
after	IN	O
provocation	NN	O
.	.	O

No	DT	O
subject	NN	O
reacted	VBD	O
to	TO	O
placebo	VB	O
.	.	O

No	DT	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
histamine	NN	O
and	CC	O
DAO	NNP	O
levels	NNS	O
within	IN	O
the	DT	O
first	JJ	O
80	CD	O
minutes	NNS	O
in	IN	O
non-reactors	NNS	O
as	RB	O
well	RB	O
as	IN	O
reactors	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
challenge	NN	O
with	IN	O
histamine	JJ	O
versus	NN	O
challenge	NN	O
with	IN	O
placebo	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
75	CD	O
mg	NN	O
of	IN	O
pure	NN	O
liquid	JJ	O
oral	JJ	O
histamine	NN	O
--	:	O
a	DT	O
dose	JJ	O
found	VBN	O
in	IN	O
normal	JJ	O
meals	NNS	O
--	:	O
can	MD	O
provoke	VB	O
immediate	JJ	O
as	RB	O
well	RB	O
as	IN	O
delayed	VBN	O
symptoms	NNS	O
in	IN	O
50	CD	O
%	NN	O
of	IN	O
healthy	JJ	O
females	NNS	Sex
without	IN	O
a	DT	O
history	NN	O
of	IN	O
food	NN	O
intolerance	NN	O
.	.	O

Influence	NN	O
of	IN	O
sentinel	NN	O
lymph	NN	O
node	JJ	O
tumor	NN	O
burden	NN	O
on	IN	O
survival	NN	O
in	IN	O
melanoma	NN	Condition
.	.	O

BACKGROUND	NNP	O
Completion	NNP	O
lymph	NN	O
node	NN	O
dissection	NN	O
(	(	O
CLND	NNP	O
)	)	O
is	VBZ	O
the	DT	O
standard	JJ	O
procedure	NN	O
for	IN	O
patients	NNS	O
with	IN	O
positive	JJ	Condition
sentinel	NNS	Condition
lymph	NN	Condition
nodes	NNS	Condition
(	(	O
SLN	NNP	O
)	)	O
.	.	O

With	IN	O
extensive	JJ	O
pathological	JJ	O
workup	NN	O
,	,	O
increased	VBD	O
numbers	NNS	O
of	IN	O
small	JJ	O
metastatic	JJ	O
deposits	NNS	O
are	VBP	O
detected	VBN	O
in	IN	O
SLN	NNP	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
prognostic	JJ	O
significance	NN	O
of	IN	O
SLN	NNP	O
metastatic	JJ	O
deposits	NNS	O
<	VBP	O
or	CC	O
=	VBP	O
0.2	CD	O
mm	NNS	O
in	IN	O
patients	NNS	O
treated	VBN	O
in	IN	O
a	DT	O
referral	JJ	O
cancer	NN	O
center	NN	O
in	IN	O
Brazil	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
stage	NN	O
I/II	NNP	O
melanoma	NN	Condition
,	,	O
consecutively	RB	O
submitted	VBN	O
to	TO	O
a	DT	O
SLN	NNP	O
procedure	NN	O
by	IN	O
the	DT	O
same	JJ	O
surgeon	NN	O
from	IN	O
2000	CD	O
to	TO	O
2006	CD	O
,	,	O
were	VBD	O
evaluated	VBN	O
.	.	O

All	DT	O
positive	JJ	O
SLN	NNP	O
and	CC	O
randomly	RB	O
selected	VBN	O
negative	JJ	O
cases	NNS	O
were	VBD	O
reviewed	VBN	O
by	IN	O
two	CD	O
pathologists	NNS	O
.	.	O

Different	NNP	O
prognostic	JJ	O
factors	NNS	O
and	CC	O
SLN	NNP	O
tumor	NN	O
burden	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

Additional	JJ	O
positive	JJ	O
non-SLN	NN	O
after	IN	O
CLND	NNP	O
,	,	O
and	CC	O
disease	VB	O
outcome	NN	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
381	CD	SampleSize
patients	NNS	O
who	WP	O
underwent	VBP	O
SLN	NNP	Condition
biopsy	NN	Condition
,	,	O
103	CD	SampleSize
(	(	O
27	CD	O
%	NN	O
)	)	O
were	VBD	O
positive	JJ	O
.	.	O

The	DT	O
mean/median	JJ	O
Breslow	NNP	O
tumor	NN	O
thickness	NN	O
in	IN	O
the	DT	O
overall	JJ	O
group	NN	O
was	VBD	O
3.4/2.0	CD	O
mm	NN	O
and	CC	O
in	IN	O
the	DT	O
SLN	NNP	O
positive	JJ	O
patients	NNS	O
was	VBD	O
5.72/4.0	CD	O
mm	NN	O
.	.	O

Among	IN	O
these	DT	O
patients	NNS	O
,	,	O
48	CD	O
(	(	O
47	CD	O
%	NN	O
)	)	O
had	VBD	O
metastatic	JJ	O
deposits	NNS	O
>	VBP	O
2	CD	O
mm	NN	O
(	(	O
macrometastasis	NN	O
)	)	O
,	,	O
49	CD	O
(	(	O
47	CD	O
%	NN	O
)	)	O
had	VBD	O
metastatic	JJ	O
deposits	NNS	O
<	VBP	O
or	CC	O
=2	VBP	O
mm	NNS	O
but	CC	O
>	$	O
0.2	CD	O
mm	NN	O
(	(	O
micrometastasis	NN	O
)	)	O
,	,	O
and	CC	O
6	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
had	VBD	O
metastatic	JJ	O
deposits	NNS	O
<	VBP	O
or	CC	O
=0.2	VBP	O
mm	NNS	O
(	(	O
submicrometastasis	NN	O
)	)	O
.	.	O

Additional	JJ	O
positive	JJ	O
non-SLN	NNS	O
were	VBD	O
detected	VBN	O
in	IN	O
29	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
macrometastasis	NN	O
,	,	O
in	IN	O
25	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
micrometastasis	NN	O
,	,	O
and	CC	O
in	IN	O
0	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
submicrometastases	NNS	O
.	.	O

At	IN	O
median	JJ	O
follow-up	NN	O
of	IN	O
35	CD	O
months	NNS	O
,	,	O
the	DT	O
estimated	VBN	O
3-year	JJ	O
overall	JJ	O
survival	NN	O
was	VBD	O
92	CD	O
%	NN	O
for	IN	O
negative	JJ	O
SLN	NNP	O
,	,	O
64	CD	O
%	NN	O
for	IN	O
micrometastases	NNS	O
,	,	O
53	CD	O
%	NN	O
for	IN	O
macrometastases	NNS	O
,	,	O
and	CC	O
100	CD	O
%	NN	O
for	IN	O
submicrometastases	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
patients	NNS	O
with	IN	O
SLN	NNP	O
metastatic	JJ	O
deposits	NNS	O
<	VBP	O
or	CC	O
=0.2	VBP	O
mm	NNS	O
had	VBD	O
no	DT	O
additional	JJ	O
positive	JJ	O
non-SLNs	NN	O
,	,	O
and	CC	O
no	DT	O
recurrences	NNS	O
or	CC	O
deaths	NNS	O
were	VBD	O
recorded	VBN	O
,	,	O
suggesting	VBG	O
that	IN	O
their	PRP$	O
prognosis	NN	O
is	VBZ	O
equivalent	JJ	O
to	TO	O
that	DT	O
of	IN	O
patients	NNS	O
with	IN	O
negative	JJ	O
SLN	NNP	O
.	.	O

Improved	VBN	O
adherence	NN	O
with	IN	O
once-daily	JJ	O
versus	NN	O
twice-daily	RB	O
dosing	NN	O
of	IN	O
mometasone	NN	O
furoate	NN	O
administered	VBD	O
via	IN	O
a	DT	O
dry	JJ	O
powder	NN	O
inhaler	NN	O
:	:	O
a	DT	O
randomized	JJ	O
open-label	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Poor	NNP	O
adherence	NN	O
with	IN	O
prescribed	JJ	O
asthma	JJ	O
medication	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
barrier	NN	O
to	TO	O
positive	JJ	O
treatment	NN	O
outcomes	RB	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
once-daily	JJ	O
administration	NN	O
of	IN	O
mometasone	NN	O
furoate	NN	O
administered	VBD	O
via	IN	O
a	DT	O
dry	JJ	O
powder	NN	O
inhaler	NN	O
(	(	O
MF-DPI	NNP	O
)	)	O
on	IN	O
treatment	NN	O
adherence	NN	O
compared	VBN	O
with	IN	O
a	DT	O
twice-daily	JJ	O
administration	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
12-week	JJ	O
open-label	NN	O
study	NN	O
designed	VBN	O
to	TO	O
mimic	VB	O
an	DT	O
actual	JJ	O
clinical	JJ	O
setting	NN	O
in	IN	O
patients	NNS	O
>	JJ	Age
or=12	CD	Age
years	NNS	Age
old	JJ	Age
with	IN	O
mild-to-moderate	JJ	Condition
persistent	JJ	Condition
asthma	NN	Condition
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
MF-DPI	NNP	O
400	CD	O
microg	NN	O
once-daily	RB	O
in	IN	O
the	DT	O
evening	NN	O
or	CC	O
MF-DPI	JJ	O
200	CD	O
microg	JJ	O
twice-daily	RB	O
.	.	O

Adherence	NNP	O
was	VBD	O
assessed	VBN	O
primarily	RB	O
using	VBG	O
the	DT	O
number	NN	O
of	IN	O
actual	JJ	O
administered	VBN	O
doses	NNS	O
reported	VBN	O
from	IN	O
the	DT	O
device	NN	O
counter	NN	O
divided	VBN	O
by	IN	O
the	DT	O
number	NN	O
of	IN	O
scheduled	JJ	O
doses	NNS	O
.	.	O

Self-reports	NNS	O
were	VBD	O
also	RB	O
used	VBN	O
to	TO	O
determine	VB	O
adherence	NN	O
.	.	O

Health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
healthcare	JJ	O
resource	NN	O
utilization	NN	O
,	,	O
and	CC	O
days	NNS	O
missed	VBN	O
from	IN	O
work	NN	O
or	CC	O
school	NN	O
were	VBD	O
also	RB	O
reported	VBN	O
.	.	O

RESULTS	JJ	O
1233	CD	SampleSize
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

The	DT	O
mean	JJ	O
adherence	NN	O
rates	NNS	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
automatic	JJ	O
dose	NN	O
counter	NN	O
,	,	O
were	VBD	O
significantly	RB	O
better	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
MF-DPI	NNP	O
400	CD	O
microg	NN	O
once-daily	RB	O
in	IN	O
the	DT	O
evening	NN	O
(	(	O
93.3	CD	O
%	NN	O
)	)	O
than	IN	O
with	IN	O
MF-DPI	NNP	O
200	CD	O
microg	NN	O
twice-daily	RB	O
(	(	O
89.5	CD	O
%	NN	O
)	)	O
.	.	O

Mean	JJ	O
adherence	NN	O
rates	NNS	O
based	VBN	O
on	IN	O
self-reports	NNS	O
were	VBD	O
also	RB	O
significantly	RB	O
better	RBR	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
MF-DPI	NNP	O
400	CD	O
microg	NN	O
QD	NNP	O
PM	NNP	O
(	(	O
97.2	CD	O
%	NN	O
)	)	O
than	IN	O
with	IN	O
MF-DPI	NNP	O
200	CD	O
microg	NN	O
twice-daily	RB	O
(	(	O
95.3	CD	O
%	NN	O
)	)	O
.	.	O

Adherence	NN	O
rates	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
adolescents	NNS	O
(	(	O
12-17	CD	O
years	NNS	O
old	JJ	O
)	)	O
.	.	O

Health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
improved	VBN	O
by	IN	O
20	CD	O
%	NN	O
in	IN	O
patients	NNS	O
using	VBG	O
MF-DPI	JJ	O
once-daily	RB	O
in	IN	O
the	DT	O
evening	NN	O
and	CC	O
by	IN	O
14	CD	O
%	NN	O
in	IN	O
patients	NNS	O
using	VBG	O
MF-DPI	JJ	O
twice-daily	JJ	O
.	.	O

Very	RB	O
few	JJ	O
(	(	O
<	JJ	O
8	CD	O
%	NN	O
)	)	O
patients	NNS	O
missed	JJ	O
work/school	NN	O
.	.	O

CONCLUSION	NNP	O
Mean	NNP	O
adherence	NN	O
rates	NNS	O
were	VBD	O
greater	JJR	O
with	IN	O
a	DT	O
once-daily	JJ	O
dosing	VBG	O
regimen	NNS	O
of	IN	O
MF-DPI	NNP	O
than	IN	O
with	IN	O
a	DT	O
twice-daily	JJ	O
dosing	NN	O
regimen.This	NN	O
trial	NN	O
was	VBD	O
completed	VBN	O
prior	RB	O
to	TO	O
the	DT	O
ISMJE	NNP	O
requirements	NNS	O
for	IN	O
trial	NN	O
registration	NN	O
.	.	O

Effect	NN	O
of	IN	O
macronutrient	JJ	O
composition	NN	O
of	IN	O
the	DT	O
diet	NN	O
on	IN	O
the	DT	O
regulation	NN	O
of	IN	O
lipolysis	NN	O
in	IN	O
adipose	JJ	O
tissue	NN	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
exercise	NN	O
:	:	O
microdialysis	NN	O
study	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
elucidate	VB	O
,	,	O
using	VBG	O
a	DT	O
microdialysis	NN	O
technique	NN	O
,	,	O
whether	IN	O
modifications	NNS	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
fat	NN	O
in	IN	O
the	DT	O
diet	JJ	O
influence	NN	O
lipid	JJ	O
mobilization	NN	O
from	IN	O
adipose	JJ	O
tissue	NN	O
in	IN	O
situ	NN	O
.	.	O

Nine	NNP	O
healthy	JJ	Condition
volunteers	NNS	O
(	(	O
age	NN	Age
,	,	Age
23.4	CD	Age
+/-	JJ	Age
0.2	CD	Age
years	NNS	Age
;	:	O
body	NN	O
mas	VBZ	O
index	NN	O
[	NNP	O
BMI	NNP	O
]	NNP	O
,	,	O
23.5	CD	O
+/-	JJ	O
1.6	CD	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
were	VBD	O
fed	VBN	O
,	,	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
with	IN	O
a	DT	O
high-fat	JJ	O
diet	NN	O
(	(	O
HFD	NNP	O
)	)	O
(	(	O
65	CD	O
%	NN	O
of	IN	O
energy	NN	O
content	NN	O
fat	NN	O
,	,	O
15	CD	O
%	NN	O
protein	NN	O
,	,	O
20	CD	O
%	NN	O
carbohydrate	NN	O
)	)	O
or	CC	O
a	DT	O
high-carbohydrate	JJ	O
diet	NN	O
(	(	O
HCD	NNP	O
)	)	O
(	(	O
70	CD	O
%	NN	O
carbohydrate	NN	O
,	,	O
15	CD	O
%	NN	O
protein	NN	O
,	,	O
15	CD	O
%	NN	O
fat	NN	O
)	)	O
for	IN	O
5	CD	O
days	NNS	O
,	,	O
with	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
10	CD	O
days	NNS	O
between	IN	O
the	DT	O
diets	NNS	O
.	.	O

Subjects	NNS	O
were	VBD	O
studied	VBN	O
in	IN	O
the	DT	O
fasting	NN	O
state	NN	O
on	IN	O
the	DT	O
morning	NN	O
following	VBG	O
days	NNS	O
4	CD	O
and	CC	O
5	CD	O
of	IN	O
each	DT	O
diet	NN	O
.	.	O

We	PRP	O
measured	VBD	O
the	DT	O
concentration	NN	O
of	IN	O
extracellular	JJ	O
glycerol	NN	O
(	(	O
EGC	NNP	O
)	)	O
in	IN	O
adipose	JJ	O
tissue	NN	O
in	IN	O
response	NN	O
to	TO	O
(	(	O
1	CD	O
)	)	O
pharmacologic	NN	O
stimulation	NN	O
with	IN	O
isoprenaline	NN	O
(	(	O
1	CD	O
and	CC	O
10	CD	O
micromol/L	NN	O
)	)	O
in	IN	O
situ	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
stimulation	NN	O
with	IN	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
epinephrine	NN	O
(	(	O
0.0375	CD	O
microg/min/kg	NN	O
body	NN	O
weight	NN	O
)	)	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
submaximal	NN	O
aerobic	JJ	O
exercise	NN	O
(	(	O
50	CD	O
%	NN	O
V*O2max	NNP	O
,	,	O
60-minute	JJ	O
duration	NN	O
)	)	O
.	.	O

No	DT	O
effect	NN	O
of	IN	O
the	DT	O
diet	JJ	O
composition	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
increases	NNS	O
of	IN	O
EGC	NNP	O
in	IN	O
response	NN	O
to	TO	O
isoprenaline	VB	O
(	(	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
[	NNP	O
AUC	NNP	O
]	NN	O
:	:	O
HFD	NNP	O
,	,	O
1,534	CD	O
+/-	JJ	O
370	CD	O
micromol/90	NN	O
min	NN	O
;	:	O
HCD	NNP	O
,	,	O
1,108	CD	O
+/-	JJ	O
465	CD	O
micromol/90	NN	O
min	NN	O
;	:	O
not	RB	O
significant	JJ	O
[	NNP	O
NS	NNP	O
]	NNP	O
)	)	O
or	CC	O
epinephrine	JJ	O
stimulations	NNS	O
(	(	O
AUC	NNP	O
:	:	O
HFD	NNP	O
,	,	O
190	CD	O
+/-	JJ	O
92	CD	O
micromol/30	NN	O
min	NN	O
;	:	O
HCD	NNP	O
,	,	O
251	CD	O
+/-	JJ	O
298	CD	O
micromol/30	NN	O
min	NN	O
;	:	O
NS	NNP	O
)	)	O
.	.	O

The	DT	O
exercise-induced	JJ	O
increase	NN	O
in	IN	O
EGC	NNP	O
was	VBD	O
higher	RBR	O
during	IN	O
the	DT	O
HFD	NNP	O
(	(	O
AUC	NNP	O
:	:	O
HFD	NNP	O
,	,	O
1,641	CD	O
+/-	JJ	O
181	CD	O
micromol/60	NN	O
min	NN	O
;	:	O
HCD	NNP	O
,	,	O
963	CD	O
+/-	JJ	O
156	CD	O
micromol/60	NN	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
exercise-induced	JJ	O
response	NN	O
of	IN	O
norepinephrine	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
epinephrine	NN	O
(	(	O
P	NNP	O
=.056	NNP	O
)	)	O
and	CC	O
lower	JJR	O
insulinemia	NN	O
during	IN	O
exercise	NN	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
macronutrient	JJ	O
composition	NN	O
of	IN	O
diet	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
beta-adrenergic	JJ	O
responsiveness	NN	O
of	IN	O
adipose	JJ	O
tissue	NN	O
to	TO	O
catecholamine	VB	O
action	NN	O
at	IN	O
rest	NN	O
.	.	O

During	IN	O
exercise	NN	O
,	,	O
the	DT	O
HFD	NNP	O
promotes	VBZ	O
higher	JJR	O
lipolysis	NN	O
in	IN	O
adipose	JJ	O
tissue	NN	O
and	CC	O
this	DT	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
catecholamine	NN	O
response	NN	O
and	CC	O
lower	JJR	O
insulinemia	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
hand-sewn	NN	O
and	CC	O
stapled	VBD	O
esophagogastric	JJ	O
anastomosis	NN	O
after	IN	O
esophageal	JJ	O
resection	NN	O
for	IN	O
cancer	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
hand-sewn	JJ	O
and	CC	O
stapled	JJ	O
methods	NNS	O
in	IN	O
esophagogastric	JJ	O
anastomosis	NN	O
.	.	O

SUMMARY	NNP	O
BACKGROUND	NNP	O
DATA	NNP	O
After	IN	O
esophageal	JJ	O
resection	NN	O
for	IN	O
cancer	NN	O
,	,	O
the	DT	O
relative	JJ	O
merits	NNS	O
of	IN	O
the	DT	O
hand-sewn	NN	O
and	CC	O
the	DT	O
stapled	JJ	O
methods	NNS	O
of	IN	O
esophagogastric	JJ	O
anastomosis	NN	O
,	,	O
especially	RB	O
regarding	VBG	O
leakage	NN	O
and	CC	O
stricture	NN	O
rates	NNS	O
,	,	O
have	VBP	O
not	RB	O
adequately	RB	O
been	VBN	O
studied	VBN	O
.	.	O

METHODS	VB	O
A	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
undertaken	VBN	O
in	IN	O
122	CD	O
patients	NNS	O
with	IN	O
squamous	JJ	O
cell	NN	O
cancer	NN	O
of	IN	O
the	DT	O
thoracic	NN	O
esophagus	NN	O
who	WP	O
underwent	VBD	O
a	DT	O
Lewis-Tanner	JJ	O
esophagectomy	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
esophageal	VB	O
size	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
diameter	NN	O
of	IN	O
the	DT	O
divided	VBN	O
esophagus	NN	O
(	(	O
<	CD	O
or	CC	O
>	VB	O
or	CC	O
=	VB	O
30	CD	O
mm	NN	O
)	)	O
and	CC	O
then	RB	O
were	VBD	O
randomized	VBN	O
to	TO	O
have	VB	O
either	CC	O
a	DT	O
hand-sewn	NN	O
or	CC	O
a	DT	O
stapled	JJ	O
anastomosis	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
total	NN	O
operating	VBG	O
times	NNS	O
(	(	O
standard	JJ	O
error	NN	O
of	IN	O
the	DT	O
mean	NN	O
)	)	O
when	WRB	O
the	DT	O
hand-sewn	NN	O
and	CC	O
the	DT	O
stapled	JJ	O
methods	NNS	O
were	VBD	O
used	VBN	O
were	VBD	O
214	CD	O
(	(	O
4	CD	O
)	)	O
minutes	NNS	O
and	CC	O
217	CD	O
(	(	O
3.4	CD	O
)	)	O
minutes	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
not	RB	O
significant	JJ	O
[	NNP	O
NS	NNP	O
]	NNP	O
)	)	O
.	.	O

The	DT	O
respective	NN	O
in	IN	O
vivo	NN	O
proximal	JJ	O
resection	NN	O
margins	NNS	O
(	(	O
standard	JJ	O
error	NN	O
of	IN	O
the	DT	O
mean	NN	O
)	)	O
were	VBD	O
8	CD	O
(	(	O
0.4	CD	O
)	)	O
cm	NN	O
and	CC	O
7.6	CD	O
(	(	O
0.4	CD	O
)	)	O
cm	NN	O
(	(	O
p	JJ	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Leakage	VB	O
rates	NNS	O
were	VBD	O
1.6	CD	O
%	NN	O
and	CC	O
4.9	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Excluding	VBG	O
hospital	JJ	O
deaths	NNS	O
,	,	O
patients	NNS	O
with	IN	O
leakage	NN	O
or	CC	O
anastomotic	JJ	O
recurrence	NN	O
,	,	O
and	CC	O
those	DT	O
who	WP	O
received	VBD	O
radiation	NN	O
therapy	NN	O
to	TO	O
histologically	RB	O
infiltrated	JJ	O
resection	NN	O
margin	NN	O
,	,	O
anastomotic	JJ	O
stricture	NN	O
was	VBD	O
found	VBN	O
in	IN	O
5	CD	O
(	(	O
9.1	CD	O
%	NN	O
)	)	O
of	IN	O
55	CD	O
patients	NNS	O
in	IN	O
the	DT	O
hand-sewn	JJ	O
group	NN	O
and	CC	O
20	CD	O
(	(	O
40	CD	O
%	NN	O
)	)	O
of	IN	O
50	CD	O
in	IN	O
the	DT	O
stapler	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

The	DT	O
difference	NN	O
in	IN	O
stricture	NN	O
rates	NNS	O
was	VBD	O
significant	JJ	O
in	IN	O
small	JJ	O
as	RB	O
well	RB	O
as	IN	O
large	JJ	O
esophagi	NN	O
.	.	O

Anastomotic	JJ	O
recurrence	NN	O
developed	VBD	O
in	IN	O
only	RB	O
one	CD	O
patient	NN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
authors	NNS	O
conclude	VBP	O
that	IN	O
both	DT	O
methods	NNS	O
were	VBD	O
safe	JJ	O
,	,	O
but	CC	O
the	DT	O
stapled	JJ	O
technique	NN	O
resulted	VBD	O
in	IN	O
more	RBR	O
stricture	JJ	O
formation	NN	O
.	.	O

Central	JJ	O
neuronal	JJ	O
mechanisms	NNS	O
of	IN	O
gastric	JJ	O
electrical	JJ	O
stimulation	NN	O
in	IN	O
diabetic	JJ	O
gastroparesis	NN	Condition
.	.	O

OBJECTIVE	CC	O
The	DT	O
mechanisms	NNS	O
underlying	VBG	O
symptom	JJ	O
improvement	NN	O
in	IN	O
gastric	JJ	O
electrical	JJ	O
stimulation	NN	O
(	(	O
GES	NNP	O
)	)	O
are	VBP	O
not	RB	O
fully	RB	O
understood	JJ	O
.	.	O

Modulation	NN	O
of	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
excitability	NN	O
may	MD	O
be	VB	O
involved	VBN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
central	JJ	O
effects	NNS	O
of	IN	O
GES	NNP	O
,	,	O
including	VBG	O
the	DT	O
possible	JJ	O
modulation	NN	O
of	IN	O
the	DT	O
visceral	JJ	O
sensory	NN	O
nervous	JJ	O
system	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
gastric	JJ	O
electrical	JJ	O
stimulator	NN	O
was	VBD	O
implanted	VBN	O
in	IN	O
seven	CD	SampleSize
diabetic	JJ	Condition
patients	NNS	O
with	IN	O
medically	RB	Condition
refractory	JJ	Condition
gastroparesis	NN	Condition
.	.	O

A	DT	O
double-blinded	JJ	O
protocol	NN	O
was	VBD	O
used	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
patients	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
one	CD	O
month	NN	O
after	IN	O
recovery	NN	O
with	IN	O
the	DT	O
stimulator	NN	O
turned	VBD	O
on	IN	O
and	CC	O
off	IN	O
(	(	O
1-month	JJ	O
periods	NNS	O
)	)	O
.	.	O

The	DT	O
following	JJ	O
assessments	NNS	O
were	VBD	O
carried	VBN	O
out	IN	O
:	:	O
mechanical	JJ	O
,	,	O
thermal	JJ	O
and	CC	O
electrical	JJ	O
stimulations	NNS	O
with	IN	O
sensory	JJ	O
recordings	NNS	O
in	IN	O
the	DT	O
esophagus	NN	O
and	CC	O
duodenum	NN	O
,	,	O
and	CC	O
standardized	VBD	O
,	,	O
self-administered	JJ	O
,	,	O
daily	JJ	O
symptom	NN	O
questionnaires	NNS	O
.	.	O

RESULTS	NNP	O
No	NNP	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
baseline	NN	O
and	CC	O
the	DT	O
on-	JJ	O
and	CC	O
off	RP	O
periods	NNS	O
in	IN	O
overall	JJ	O
gut	NN	O
pain	NN	O
thresholds	NNS	O
across	IN	O
all	DT	O
stimulus	NN	O
modalities	NNS	O
in	IN	O
the	DT	O
esophagus	NN	O
(	(	O
p=0.63	NN	O
)	)	O
,	,	O
duodenum	NN	O
(	(	O
p=0.19	NN	O
)	)	O
or	CC	O
esophagus	JJ	O
and	CC	O
duodenum	NN	O
combined	VBN	O
(	(	O
p=0.76	NN	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
the	DT	O
sensory	JJ	O
response	NN	O
to	TO	O
mechanical	JJ	O
stimulation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
esophagus	NN	O
before	IN	O
(	(	O
all	DT	O
p	VBP	O
>	$	O
0.31	CD	O
)	)	O
and	CC	O
after	IN	O
(	(	O
all	DT	O
p	VBP	O
>	$	O
0.43	CD	O
)	)	O
smooth	FW	O
muscle	NN	O
relaxation	NN	O
with	IN	O
butylscopolamine	NN	O
.	.	O

Similar	JJ	O
findings	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
duodenum	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
thermal	JJ	O
sensitivity	NN	O
(	(	O
esophagus	JJ	O
(	(	O
p=0.67	NN	O
)	)	O
and	CC	O
duodenum	NN	O
(	(	O
p=0.17	NN	O
)	)	O
)	)	O
,	,	O
sensory	JJ	O
response	NN	O
to	TO	O
electrical	JJ	O
stimulation	NN	O
(	(	O
esophagus	JJ	O
(	(	O
p=0.57	NN	O
)	)	O
and	CC	O
duodenum	NN	O
(	(	O
p=0.52	NN	O
)	)	O
)	)	O
or	CC	O
induced	VBN	O
somatic	JJ	O
referred	VBD	O
pain	NN	O
areas	NNS	O
(	(	O
esophagus	NN	O
(	(	O
p=0.75	NN	O
)	)	O
and	CC	O
duodenum	NN	O
(	(	O
p=0.51	NN	O
)	)	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
induced	JJ	O
somatic	JJ	O
referred	VBD	O
pain	JJ	O
areas	NNS	O
or	CC	O
self-reported	JJ	O
symptoms	NNS	O
.	.	O

CONCLUSIONS	NNP	O
No	NNP	O
evidence	NN	O
was	VBD	O
found	VBN	O
for	IN	O
GES-induced	NNP	O
modulation	NN	O
of	IN	O
the	DT	O
visceral	JJ	O
sensory	NN	O
system	NN	O
and	CC	O
central	JJ	O
excitability	NN	O
.	.	O

However	RB	O
,	,	O
GES	NNP	O
has	VBZ	O
been	VBN	O
proven	VBN	O
to	TO	O
modulate	VB	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
in	IN	O
animal	JJ	O
studies	NNS	O
,	,	O
necessitating	VBG	O
further	JJ	O
human	JJ	O
experiments	NNS	O
in	IN	O
order	NN	O
unambiguously	RB	O
to	TO	O
establish	VB	O
the	DT	O
possible	JJ	O
central	JJ	O
effects	NNS	O
of	IN	O
GES	NNP	O
.	.	O

The	DT	O
course	NN	O
of	IN	O
depression	NN	Condition
in	IN	O
recent	JJ	O
onset	NN	O
rheumatoid	NN	Condition
arthritis	NN	Condition
:	:	O
the	DT	O
predictive	JJ	O
role	NN	O
of	IN	O
disability	NN	O
,	,	O
illness	JJ	O
perceptions	NNS	O
,	,	O
pain	NN	O
and	CC	O
coping	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
course	NN	O
of	IN	O
depression	NN	Condition
for	IN	O
patients	NNS	O
with	IN	O
recently	RB	O
diagnosed	VBN	O
rheumatoid	NN	Condition
arthritis	NN	Condition
(	(	Condition
RA	NNP	Condition
)	)	Condition
and	CC	O
to	TO	O
investigate	VB	O
predictors	NNS	O
of	IN	O
depression	NN	Condition
.	.	O

METHODS	NNP	O
Twenty-two	JJ	SampleSize
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
recently	RB	O
diagnosed	VBN	O
RA	NNP	Condition
of	IN	O
less	JJR	O
than	IN	O
2	CD	O
years	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
a	DT	O
variety	NN	O
of	IN	O
clinical	JJ	O
outcome	NN	O
and	CC	O
process	NN	O
measures	NNS	O
on	IN	O
six	CD	O
assessment	JJ	O
occasions	NNS	O
over	IN	O
a	DT	O
21-month	JJ	O
period	NN	O
.	.	O

These	DT	O
22	CD	SampleSize
patients	NNS	O
constituted	VBD	O
the	DT	O
control	NN	O
group	NN	O
of	IN	O
a	DT	O
controlled	VBN	O
trial	NN	O
and	CC	O
received	VBN	O
standard	JJ	O
outpatient	NN	O
clinic	JJ	O
treatment	NN	O
during	IN	O
follow-up	JJ	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
became	VBD	O
significantly	RB	O
more	RBR	O
depressed	JJ	Condition
over	IN	O
time	NN	O
.	.	O

A	DT	O
set	NN	O
of	IN	O
five	CD	O
factors	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
consistently	RB	O
predict	VB	O
depression	NN	O
at	IN	O
the	DT	O
following	JJ	O
assessment	NN	O
.	.	O

These	DT	O
were	VBD	O
initial	JJ	O
level	NN	O
of	IN	O
depression	NN	O
,	,	O
disability	NN	O
,	,	O
pain	NN	O
,	,	O
beliefs	VB	O
about	IN	O
the	DT	O
consequences	NNS	O
of	IN	O
arthritis	NN	O
and	CC	O
coping	VBG	O
strategies	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
confirm	VBP	O
the	DT	O
importance	NN	O
of	IN	O
psychological	JJ	O
factors	NNS	O
in	IN	O
early	JJ	O
RA	NNP	O
and	CC	O
their	PRP$	O
relative	JJ	O
independence	NN	O
from	IN	O
physical	JJ	O
findings	NNS	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
study	NN	O
to	TO	O
document	VB	O
the	DT	O
importance	NN	O
of	IN	O
illness	JJ	O
perceptions	NNS	O
in	IN	O
recent	JJ	O
onset	NN	O
RA	NNP	O
.	.	O

Bronchial	JJ	Condition
carcinoma	NN	Condition
.	.	O

II	NNP	O
.	.	O

Quantitative	JJ	O
measurements	NNS	O
of	IN	O
the	DT	O
quality	NN	O
of	IN	O
survival	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
of	IN	O
the	DT	O
result	NN	O
of	IN	O
therapy	NN	O
in	IN	O
inoperable	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
disease	NN	O
.	.	O

Forty-eight	JJ	SampleSize
bronchial	JJ	Condition
carcinoma	NN	Condition
patients	NNS	O
in	IN	O
clinicoanatomical	JJ	O
stage	NN	O
4	CD	O
of	IN	O
the	DT	O
disease	NN	O
(	(	O
advanced	JJ	O
disease	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
groups	NNS	O
for	IN	O
radiotherapy	NN	O
,	,	O
chemotherapy	NN	O
(	(	O
cyclophosphamide	NN	O
)	)	O
and	CC	O
placebo	JJ	O
treatment	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
survival	JJ	O
time	NN	O
and	CC	O
quality	NN	O
of	IN	O
survival	NN	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
time	NN	O
was	VBD	O
4.7	CD	O
months	NNS	O
for	IN	O
radiotherapy	NN	O
,	,	O
4.7	CD	O
months	NNS	O
for	IN	O
cyclophosphamide	NN	O
and	CC	O
1.7	CD	O
months	NNS	O
for	IN	O
placebo	NN	O
.	.	O

The	DT	O
median	JJ	O
total	JJ	O
sum	NN	O
of	IN	O
vitagram	NN	O
points	NNS	O
was	VBD	O
28.1	CD	O
for	IN	O
radiotherapy	NN	O
,	,	O
20.7	CD	O
for	IN	O
cyclophosphamide	NN	O
and	CC	O
6.8	CD	O
for	IN	O
placebo	NN	O
.	.	O

When	WRB	O
calculated	JJ	O
per	IN	O
month	NN	O
,	,	O
the	DT	O
median	JJ	O
sum	NN	O
of	IN	O
vitagram	NN	O
points	NNS	O
was	VBD	O
5.9	CD	O
for	IN	O
radiotherapy	NN	O
,	,	O
5.7	CD	O
for	IN	O
cyclophosphamide	NN	O
and	CC	O
4.8	CD	O
for	IN	O
placebo	NN	O
.	.	O

Statistically	RB	O
the	DT	O
results	NNS	O
give	VBP	O
no	DT	O
reason	NN	O
to	TO	O
believe	VB	O
that	IN	O
placebo	NN	O
is	VBZ	O
better	JJR	O
than	IN	O
radiotherapy	NN	O
,	,	O
but	CC	O
it	PRP	O
can	MD	O
not	RB	O
be	VB	O
excluded	VBN	O
that	IN	O
radiotherapy	NN	O
patients	NNS	O
could	MD	O
have	VB	O
a	DT	O
much	RB	O
longer	JJR	O
survival	NN	O
.	.	O

As	IN	O
for	IN	O
cyclophosphamide	NN	O
versus	NN	O
radiotherapy	NN	O
,	,	O
the	DT	O
differences	NNS	O
are	VBP	O
to	TO	O
uncertain	VB	O
for	IN	O
any	DT	O
conclusion	NN	O
to	TO	O
be	VB	O
drawn	VBN	O
.	.	O

Comparative	JJ	O
evaluation	NN	O
of	IN	O
percutaneous	JJ	O
laser	NN	O
and	CC	O
radiofrequency	NN	O
ablation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
HCC	NNP	Condition
smaller	JJR	O
than	IN	O
4	CD	O
cm	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
study	NN	O
was	VBD	O
done	VBN	O
to	TO	O
compare	VB	O
percutaneous	JJ	O
laser	NN	O
ablation	NN	O
(	(	O
PLA	NNP	O
)	)	O
and	CC	O
radiofrequency	NN	O
thermoablation	NN	O
(	(	O
RFA	NNP	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hepatocellular	JJ	Condition
carcinoma	NN	Condition
(	(	O
HCC	NNP	O
)	)	O
?	.	O
4	CD	O
cm	NN	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
liver	JJ	Condition
cirrhosis	NN	Condition
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
with	IN	O
single	JJ	O
HCC	NNP	O
?	.	O
4	CD	O
cm	NN	O
in	IN	O
diameter	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
treatments	NNS	O
:	:	O
15	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
PLA	NNP	O
,	,	O
using	VBG	O
a	DT	O
multifibre	NN	O
system	NN	O
connected	VBN	O
to	TO	O
a	DT	O
neodymium	JJ	O
yttrium-aluminium-garnet	NN	O
laser	NN	O
source	NN	O
;	:	O
15	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
RFA	NNP	O
,	,	O
using	VBG	O
an	DT	O
expandable	JJ	O
needle	JJ	O
electrode	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
up	RB	O
to	TO	O
12	CD	O
months	NNS	O
.	.	O

RESULTS	VB	O
A	NNP	O
complete	JJ	O
response	NN	O
was	VBD	O
obtained	VBN	O
in	IN	O
87	CD	O
%	NN	O
lesions	NNS	O
treated	VBN	O
with	IN	O
PLA	NNP	O
and	CC	O
in	IN	O
93	CD	O
%	NN	O
lesions	NNS	O
treated	VBN	O
with	IN	O
RFA	NNP	O
(	(	O
p	JJ	O
=	NNP	O
ns	NN	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
local	JJ	O
recurrence-free	JJ	O
survival	NN	O
rates	NNS	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
were	VBD	O
comparable	JJ	O
.	.	O

However	RB	O
,	,	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
recurrence	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
PLA	NNP	O
group	NN	O
for	IN	O
lesions	NNS	O
?	.	O
21	CD	O
mm	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0081	CD	O
)	)	O
.	.	O

A	DT	O
postablation	NN	O
syndrome	NN	O
was	VBD	O
documented	VBN	O
in	IN	O
13	CD	O
patients	NNS	O
(	(	O
1	CD	O
PLA	NNP	O
;	:	O
12	CD	O
RFA	NNP	O
)	)	O
.	.	O

Tumour	JJ	O
necrosis	NN	O
factor-?	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
RFA	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
RFA	NNP	O
is	VBZ	O
more	RBR	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HCC	NNP	O
compared	VBN	O
to	TO	O
PLA	NNP	O
for	IN	O
lesions	NNS	O
?	.	O
21	CD	O
mm	NN	O
.	.	O

However	RB	O
,	,	O
PLA	NNP	O
should	MD	O
be	VB	O
considered	VBN	O
a	DT	O
viable	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
HCC	NNP	O
?	.	O
20	CD	O
mm	NN	O
,	,	O
in	IN	O
view	NN	O
of	IN	O
the	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
complications	NNS	O
.	.	O

[	JJ	O
Structural	NNP	O
and	CC	O
immunohistochemical	JJ	O
changes	NNS	O
of	IN	O
conjunctiva	NN	O
induced	VBN	O
by	IN	O
topical	JJ	O
glaucoma	NN	O
medication	NN	O
]	NNP	O
.	.	O

PURPOSE	VB	O
The	DT	O
topical	JJ	O
medication	NN	O
represents	VBZ	O
the	DT	O
first	JJ	O
line	NN	O
therapy	NN	O
for	IN	O
the	DT	O
primary	JJ	O
open	JJ	O
angle	NN	O
glaucoma	NN	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
aimed	VBN	O
at	IN	O
assessing	VBG	O
the	DT	O
structural	JJ	O
and	CC	O
immunohistochemical	JJ	O
changes	NNS	O
of	IN	O
conjunctiva	NN	O
induced	VBN	O
by	IN	O
topical	JJ	O
glaucoma	NN	O
medication	NN	O
.	.	O

METHODS	NNP	O
For	IN	O
this	DT	O
purpose	NN	O
,	,	O
we	PRP	O
carried	VBD	O
out	RP	O
a	DT	O
40	CD	O
weeks	NNS	O
,	,	O
prospective	JJ	O
,	,	O
experimental	JJ	O
,	,	O
epidemiological-operational	JJ	O
and	CC	O
randomized	JJ	O
study	NN	O
enrolling	VBG	O
18	CD	O
patients	NNS	O
(	(	O
36	CD	O
eyes	NNS	O
)	)	O
with	IN	O
recently	RB	O
primary	JJ	Condition
open	JJ	Condition
angle	NN	Condition
glaucoma	NN	Condition
.	.	O

The	DT	O
eyes	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
treatment	NN	O
(	(	O
non-selective	JJ	O
beta	NN	O
blockers	NNS	O
or	CC	O
selective	JJ	O
,	,	O
prostaglandin	JJ	O
analogues	NNS	O
,	,	O
topical	JJ	O
carbonic	JJ	O
anhydrase	NN	O
inhibitors	NNS	O
)	)	O
in	IN	O
four	CD	O
groups	NNS	O
.	.	O

The	DT	O
assessment	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
comparison	NN	O
with	IN	O
control	NN	O
group	NN	O
(	(	O
4	CD	O
patients	NNS	O
)	)	O
who	WP	O
was	VBD	O
instilled	VBN	O
with	IN	O
natural	JJ	Condition
tears	NNS	Condition
(	(	O
with	IN	O
different	JJ	O
preservative	NN	O
)	)	O
.	.	O

Both	CC	O
the	DT	O
cytology	NN	O
and	CC	O
the	DT	O
conjunctival	NN	O
biopsy	NN	O
specimens	NNS	O
were	VBD	O
investigated	VBN	O
by	IN	O
histological	JJ	O
exams	NNS	O
and	CC	O
immunohistochemistry	NN	O
using	VBG	O
different	JJ	O
monoclonal	JJ	O
antibodies	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
collaboration	NN	O
with	IN	O
The	DT	O
National	NNP	O
Institute	NNP	O
of	IN	O
Research	NNP	O
and	CC	O
Development	NNP	O
in	IN	O
Pathology	NNP	O
and	CC	O
Biomedical	NNP	O
Sciences-	NNP	O
V.	NNP	O
Babes	NNP	O
-Bucharest	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
morphometric	JJ	O
analysis	NN	O
of	IN	O
histological	JJ	O
sections	NNS	O
of	IN	O
conjunctiva	NN	O
showed	VBD	O
the	DT	O
following	JJ	O
changes	NNS	O
:	:	O
squamous	JJ	O
metaplasia	NN	O
(	(	O
significant	JJ	O
increases	NNS	O
in	IN	O
the	DT	O
thickness	NN	O
and	CC	O
number	NN	O
of	IN	O
epithelial	JJ	O
cell	NN	O
layers	NNS	O
)	)	O
,	,	O
inflammation	NN	O
(	(	O
increase	VB	O
the	DT	O
number	NN	O
of	IN	O
lymphocytes	NNS	O
,	,	O
macrophages	NNS	O
and	CC	O
fibroblasts	NNS	O
)	)	O
and	CC	O
subconjunctival	JJ	O
fibrosis	NN	O
.	.	O

According	VBG	O
to	TO	O
the	DT	O
type	NN	O
of	IN	O
medication	NN	O
,	,	O
we	PRP	O
observed	VBD	O
the	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
subepithelial	JJ	O
collagen	NN	O
density	NN	O
and	CC	O
degenerative	JJ	O
changes	NNS	O
of	IN	O
fibrocytes	NNS	O
,	,	O
the	DT	O
reduction	NN	O
of	IN	O
extracellular	JJ	O
matrix	NN	O
and	CC	O
also	RB	O
the	DT	O
up-regulation	NN	O
of	IN	O
antibodies	NNS	O
against	IN	O
matrix	JJ	O
metalloproteinase	NN	O
and	CC	O
allergic	JJ	O
changes	NNS	O
.	.	O

According	VBG	O
to	TO	O
structural	JJ	O
changes	NNS	O
,	,	O
the	DT	O
immunohistochemistry	NN	O
confirmed	VBD	O
the	DT	O
tendency	NN	O
of	IN	O
chronic	JJ	O
inflammation	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
revealed	VBD	O
important	JJ	O
structural	JJ	O
and	CC	O
immunohistochemical	JJ	O
changes	NNS	O
of	IN	O
conjunctiva	NN	O
after	IN	O
topical	JJ	O
glaucoma	NN	O
medication	NN	O
.	.	O

The	DT	O
category	NN	O
and	CC	O
the	DT	O
intensity	NN	O
of	IN	O
these	DT	O
changes	NNS	O
are	VBP	O
dependent	JJ	O
on	IN	O
the	DT	O
sort	NN	O
of	IN	O
therapy	NN	O
and	CC	O
the	DT	O
topical	JJ	O
treatment	NN	O
period	NN	O
.	.	O

The	DT	O
findings	NNS	O
showed	VBD	O
that	IN	O
benzalkonium	NN	O
chloride	NN	O
(	(	O
the	DT	O
most	RBS	O
common	JJ	O
preservative	NN	O
of	IN	O
antiglaucoma	NN	O
drugs	NNS	O
)	)	O
is	VBZ	O
a	DT	O
major	JJ	O
factor	NN	O
for	IN	O
conjunctival	NN	O
metaplasia	NN	O
.	.	O

Rizatriptan	NNP	O
5	CD	O
mg	NN	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	Condition
in	IN	O
adolescents	NNS	Age
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
tolerability	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
in	IN	O
adolescent	JJ	O
migraineurs	NNS	O
.	.	O

METHODS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
aged	VBD	O
12	CD	Age
to	TO	Age
17	CD	Age
years	NNS	Age
received	VBD	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
149	CD	SampleSize
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
147	CD	SampleSize
)	)	O
for	IN	O
a	DT	O
moderate	JJ	O
or	CC	O
severe	JJ	O
headache	NN	O
and	CC	O
for	IN	O
up	RB	O
to	TO	O
two	CD	O
recurrences	NNS	O
.	.	O

Headache	NNP	O
severity	NN	O
,	,	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
associated	VBN	O
symptoms	NNS	O
,	,	O
and	CC	O
functional	JJ	O
disability	NN	O
were	VBD	O
assessed	VBN	O
over	IN	O
a	DT	O
4-hour	JJ	O
postdose	JJ	O
period	NN	O
,	,	O
and	CC	O
any	DT	O
adverse	JJ	O
events	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
measure	NN	O
was	VBD	O
pain-free	JJ	O
status	NN	O
at	IN	O
2	CD	O
hours	NNS	O
postdose	RB	O
.	.	O

RESULTS	NNP	O
Rizatriptan	NNP	O
5	CD	O
mg	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

The	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
adverse	JJ	O
events	NNS	O
(	(	O
all	DT	O
with	IN	O
incidence	NN	O
of	IN	O
5	CD	O
%	NN	O
or	CC	O
less	JJR	O
)	)	O
among	IN	O
patients	NNS	O
receiving	VBG	O
rizatriptan	NNS	O
were	VBD	O
dry	JJ	O
mouth	NN	O
,	,	O
dizziness	NN	O
,	,	O
asthenia/fatigue	NN	O
,	,	O
nausea	NN	O
,	,	O
and	CC	O
somnolence	NN	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
pain-free	JJ	O
at	IN	O
2	CD	O
hours	NNS	O
was	VBD	O
32	CD	O
%	NN	O
for	IN	O
rizatriptan	JJ	O
5	CD	O
mg	NN	O
versus	NN	O
28	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
P=.474	NNP	O
)	)	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
pain	NN	O
relief	NN	O
(	(	O
reduction	NN	O
of	IN	O
predose	JJ	O
pain	NN	O
intensity	NN	O
to	TO	O
mild	VB	O
or	CC	O
none	NN	O
)	)	O
at	IN	O
2	CD	O
hours	NNS	O
was	VBD	O
66	CD	O
%	NN	O
for	IN	O
rizatriptan	JJ	O
versus	NN	O
56	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
P=.079	NNP	O
)	)	O
.	.	O

Placebo	NNP	O
response	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
typically	RB	O
observed	VBN	O
in	IN	O
previous	JJ	O
studies	NNS	O
of	IN	O
rizatriptan	NN	O
in	IN	O
adults	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
rizatriptan	VBP	O
significantly	RB	O
improved	VBN	O
functional	JJ	O
disability	NN	O
at	IN	O
1.5	CD	O
and	CC	O
2	CD	O
hours	NNS	O
,	,	O
and	CC	O
nausea	NN	O
at	IN	O
1	CD	O
and	CC	O
1.5	CD	O
hours	NNS	O
.	.	O

Post	NNP	O
hoc	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
benefit	NN	O
of	IN	O
rizatriptan	JJ	O
versus	NN	O
placebo	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
pain	NN	O
relief	NN	O
when	WRB	O
their	PRP$	O
migraine	NN	O
attacks	NNS	O
were	VBD	O
treated	VBN	O
on	IN	O
weekends	NNS	O
(	(	O
65	CD	O
%	NN	O
versus	IN	O
36	CD	O
%	NN	O
,	,	O
P=.046	NNP	O
)	)	O
compared	VBN	O
with	IN	O
weekdays	NNS	O
(	(	O
66	CD	O
%	NN	O
versus	IN	O
61	CD	O
%	NN	O
,	,	O
P=.365	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
weekend	NN	O
placebo	NN	O
response	NN	O
rate	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
seen	VBN	O
in	IN	O
adults	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Rizatriptan	NNP	O
5	CD	O
mg	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
effective	JJ	O
on	IN	O
some	DT	O
measures	NNS	O
when	WRB	O
used	VBN	O
in	IN	O
adolescents	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
migraine	JJ	O
attack	NN	Condition
.	.	O

A	DT	O
prospective	JJ	O
double-blind	NN	O
,	,	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
of	IN	O
levocarnitine	NN	O
to	TO	O
treat	VB	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

BACKGROUND	NNP	O
L-carnitine	NNP	O
was	VBD	O
proposed	VBN	O
as	IN	O
a	DT	O
potential	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
diagnosed	VBN	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
to	TO	O
improve	VB	O
mitochondrial	JJ	O
dysfunction	NN	O
,	,	O
but	CC	O
no	DT	O
prior	JJ	O
randomized	VBN	O
controlled	VBN	O
trials	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
.	.	O

MATERIAL/METHODS	NNP	O
Thirty	NNP	O
subjects	NNS	O
diagnosed	VBD	O
with	IN	O
an	DT	O
ASD	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
a	DT	O
standardized	JJ	O
regimen	NN	O
(	(	O
50	CD	O
mg	RB	O
L-carnitine/kg	NNP	O
bodyweight/day	NN	O
)	)	O
of	IN	O
liquid	JJ	O
L-carnitine	NNP	O
(	(	O
n=19	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=11	JJ	O
)	)	O
for	IN	O
3-months	JJ	O
.	.	O

Measures	NNS	O
included	VBD	O
changes	NNS	O
in	IN	O
professionally	RB	O
completed	VBN	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
CARS	NNP	O
)	)	O
,	,	O
hand	NN	O
muscle	NN	O
testing	NN	O
,	,	O
and	CC	O
modified	VBD	O
clinical	JJ	O
global	JJ	O
impression	NN	O
(	(	O
CGI	NNP	O
)	)	O
forms	VBZ	O
;	:	O
parent	NN	O
completed	VBD	O
Autism	NNP	O
Treatment	NNP	O
Evaluation	NNP	O
Checklist	NNP	O
(	(	O
ATEC	NNP	O
)	)	O
,	,	O
treatment	NN	O
adherence	NN	O
measurement	NN	O
(	(	O
TAM	NNP	O
)	)	O
,	,	O
frequency	NN	O
and	CC	O
intensity	NN	O
of	IN	O
side	JJ	O
effect	NN	O
rating	NN	O
(	(	O
FISER	NNP	O
)	)	O
/global	VBD	O
rating	NN	O
of	IN	O
side	JJ	O
effect	NN	O
burden	NN	O
(	(	O
GRSEB	NNP	O
)	)	O
/patient	VBD	O
report	NN	O
of	IN	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
(	(	O
PRISE	NNP	O
)	)	O
forms	NNS	O
;	:	O
and	CC	O
lab	VB	O
testing	VBG	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
improvements	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
CARS	NNP	O
(	(	O
-2.03	NNP	O
,	,	O
95	CD	O
%	NN	O
CI=-3.7	NNP	O
to	TO	O
-0.31	VB	O
)	)	O
,	,	O
CGI	NNP	O
(	(	O
-0.69	NNP	O
,	,	O
95	CD	O
%	NN	O
CI=-1.1	NNP	O
to	TO	O
-0.06	VB	O
)	)	O
,	,	O
and	CC	O
ATEC	NNP	O
scores	NNS	O
.	.	O

Significant	JJ	O
correlations	NNS	O
between	IN	O
changes	NNS	O
in	IN	O
serum	JJ	O
free-carnitine	JJ	O
levels	NNS	O
and	CC	O
positive	JJ	O
clinical	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
hand	NN	O
muscle	NN	O
strength	NN	O
(	(	O
R2=0.23	NNP	O
,	,	O
P=0.046	NNP	O
)	)	O
,	,	O
cognitive	JJ	O
scores	NNS	O
(	(	O
R2=0.27	NNP	O
,	,	O
P=0.019	NNP	O
)	)	O
,	,	O
and	CC	O
CARS	NNP	O
scores	NNS	O
(	(	O
R2=0.20	NNP	O
,	,	O
P=0.047	NNP	O
)	)	O
.	.	O

Study	NNP	O
subjects	NNS	O
were	VBD	O
protocol-compliant	JJ	O
(	(	O
average	JJ	O
adherence	NN	O
was	VBD	O
>	JJ	O
85	CD	O
%	NN	O
)	)	O
and	CC	O
generally	RB	O
well-tolerated	VBD	O
the	DT	O
L-carnitine	JJ	O
therapy	NN	O
given	VBN	O
.	.	O

CONCLUSIONS	NNP	O
L-carnitine	JJ	O
therapy	NN	O
(	(	O
50	CD	O
mg/kilogram-bodyweight/day	NN	O
)	)	O
administered	VBD	O
for	IN	O
3-months	JJ	O
significantly	RB	O
improved	VBN	O
several	JJ	O
clinical	JJ	O
measurements	NNS	O
of	IN	O
ASD	NNP	O
severity	NN	O
,	,	O
but	CC	O
subsequent	JJ	O
studies	NNS	O
are	VBP	O
recommended	VBN	O
.	.	O

Videotaped	NNP	O
training	NN	O
in	IN	O
alcohol	NN	O
counseling	NN	O
for	IN	O
obstetric	JJ	O
care	NN	O
practitioners	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
videotaped	JJ	O
training	NN	O
for	IN	O
obstetric	JJ	O
care	NN	O
practitioners	NNS	O
in	IN	O
motivational	JJ	O
interviewing	NN	O
skills	NNS	O
that	WDT	O
could	MD	O
be	VB	O
used	VBN	O
in	IN	O
brief	JJ	O
patient	JJ	O
consultations	NNS	O
on	IN	O
problem	NN	O
drinking	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
health	NN	O
care	NN	O
practitioners	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
using	VBG	O
a	DT	O
20-minute	JJ	O
videotape	NN	O
to	TO	O
instruct	VB	O
them	PRP	O
in	IN	O
motivational	JJ	O
interviewing	NN	O
.	.	O

Participants	NNS	O
engaged	VBN	O
in	IN	O
a	DT	O
pretest	JJ	O
roleplay	NN	O
with	IN	O
an	DT	O
actress	NN	O
playing	VBG	O
a	DT	O
drinking	NN	O
pregnant	JJ	O
woman	NN	O
.	.	O

Those	DT	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
experimental	JJ	O
condition	NN	O
watched	VBD	O
the	DT	O
motivational	JJ	O
interviewing	NN	O
videotape	NN	O
.	.	O

Control	NNP	O
condition	NN	O
participants	NNS	O
watched	VBD	O
a	DT	O
20-minute	JJ	O
docudrama	NN	O
of	IN	O
a	DT	O
pregnant	JJ	O
problem	NN	O
drinker	NN	O
.	.	O

Both	DT	O
groups	NNS	O
then	RB	O
engaged	VBD	O
in	IN	O
a	DT	O
post-test	JJ	O
roleplay	NN	O
similar	JJ	O
to	TO	O
the	DT	O
pretest	NN	O
.	.	O

Behavioral	JJ	O
ratings	NNS	O
of	IN	O
the	DT	O
roleplays	NNS	O
and	CC	O
participant	JJ	O
evaluations	NNS	O
of	IN	O
the	DT	O
motivational	JJ	O
interviewing	NN	O
video	NN	O
constituted	VBD	O
the	DT	O
outcome	NN	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
Participant	NNP	O
evaluations	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
training	NN	O
video	NN	O
was	VBD	O
clear	JJ	O
in	IN	O
explaining	VBG	O
and	CC	O
demonstrating	VBG	O
the	DT	O
principles	NNS	O
and	CC	O
skills	NNS	O
of	IN	O
motivational	JJ	O
interviewing	NN	O
.	.	O

Change	NN	O
in	IN	O
behavioral	JJ	O
ratings	NNS	O
from	IN	O
pretest	NN	O
to	TO	O
post-test	NN	O
showed	VBD	O
significant	JJ	O
differences	NNS	O
in	IN	O
motivational	JJ	O
interviewing	NN	O
skills	NNS	O
between	IN	O
the	DT	O
experimental	JJ	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Obstetric	NNP	O
care	NN	O
practitioners	NNS	O
who	WP	O
viewed	VBD	O
the	DT	O
training	NN	O
video	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
showing	VBG	O
greater	JJR	O
empathy	NN	O
,	,	O
minimizing	VBG	O
patient	JJ	O
defensiveness	NN	O
,	,	O
and	CC	O
supporting	VBG	O
women	NNS	O
's	POS	O
beliefs	NNS	O
in	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
change	VB	O
.	.	O

CONCLUSION	NNP	O
Obstetric	NNP	O
care	NN	O
practitioners	NNS	O
can	MD	O
improve	VB	O
their	PRP$	O
alcohol	NN	O
intervention	NN	O
skills	NNS	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
20-minute	JJ	O
videotaped	JJ	O
instruction	NN	O
in	IN	O
motivational	JJ	O
interviewing	NN	O
.	.	O

Clinicians	NNPS	O
who	WP	O
improve	VBP	O
their	PRP$	O
skills	NNS	O
in	IN	O
motivational	JJ	O
interviewing	NN	O
can	MD	O
intervene	VB	O
more	RBR	O
effectively	RB	O
with	IN	O
their	PRP$	O
drinking	NN	O
pregnant	JJ	O
patients	NNS	O
.	.	O

Using	VBG	O
motivational	JJ	O
interviewing	NN	O
with	IN	O
this	DT	O
population	NN	O
holds	VBZ	O
promise	RB	O
for	IN	O
helping	VBG	O
prevent	JJ	O
alcohol-related	JJ	O
health	NN	O
problems	NNS	O
.	.	O

Need	NN	O
for	IN	O
insulin	NN	O
therapy	NN	O
in	IN	O
type	NN	Condition
II	NNP	Condition
diabetes	VBZ	Condition
mellitus	NN	Condition
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

To	TO	O
identify	VB	O
patients	NNS	O
with	IN	O
type	JJ	Condition
II	NNP	Condition
diabetes	VBZ	Condition
mellitus	NN	Condition
for	IN	O
whom	WP	O
insulin	NN	O
therapy	NN	O
is	VBZ	O
most	RBS	O
beneficial	JJ	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
in	IN	O
the	DT	O
general	JJ	O
medicine	NN	O
clinic	NN	O
of	IN	O
a	DT	O
university	NN	O
hospital	NN	O
.	.	O

Asymptomatic	NNP	O
,	,	O
obese	JJ	Condition
,	,	O
insulin-treated	JJ	O
patients	NNS	O
were	VBD	O
given	VBN	O
diet	JJ	O
and	CC	O
diabetes	VBZ	O
education	NN	O
and	CC	O
,	,	O
in	IN	O
half	NN	O
of	IN	O
these	DT	O
patients	NNS	O
,	,	O
insulin	JJ	O
therapy	NN	O
was	VBD	O
withdrawn	VBN	O
.	.	O

Over	IN	O
six	CD	O
months	NNS	O
,	,	O
patients	NNS	O
developing	VBG	O
hyperglycemic	JJ	O
symptoms	NNS	O
or	CC	O
acetonemia	NN	O
were	VBD	O
counted	VBN	O
as	IN	O
study	NN	O
failures	NNS	O
.	.	O

Failure	NN	O
criteria	NNS	O
developed	VBD	O
in	IN	O
13	CD	O
of	IN	O
25	CD	SampleSize
insulin-withdrawal	JJ	SampleSize
patients	NNS	O
,	,	O
at	IN	O
a	DT	O
median	NN	O
of	IN	O
four	CD	O
weeks	NNS	O
after	IN	O
withdrawal	NN	O
,	,	O
compared	VBN	O
with	IN	O
two	CD	O
of	IN	O
24	CD	SampleSize
control	NN	O
subjects	NNS	O
.	.	O

Elevated	VBN	O
stimulated	VBD	O
glucose	JJ	O
levels	NNS	O
predicted	VBD	O
the	DT	O
need	NN	O
for	IN	O
insulin	JJ	O
therapy	NN	O
.	.	O

Hyperglycemia	NNP	O
worsened	VBD	O
in	IN	O
insulin-withdrawal	JJ	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
meet	VB	O
study	JJ	O
failure	NN	O
criteria	NNS	O
,	,	O
but	CC	O
it	PRP	O
improved	VBD	O
in	IN	O
control	NN	O
patients	NNS	O
.	.	O

Study	NNP	O
patients	NNS	O
were	VBD	O
insulin	JJ	O
deficient	NN	O
as	IN	O
shown	VBN	O
by	IN	O
low	JJ	O
baseline	NN	O
C	NNP	O
peptide	NN	O
values	NNS	O
(	(	O
0.43	CD	O
+/-	JJ	O
0.05	CD	O
nmol/L	NN	O
)	)	O
.	.	O

The	DT	O
prompt	JJ	O
metabolic	JJ	O
decompensation	NN	O
precipitated	VBN	O
by	IN	O
insulin	NN	O
withdrawal	NN	O
suggests	VBZ	O
that	IN	O
insulin-deficient	JJ	O
patients	NNS	O
may	MD	O
benefit	VB	O
from	IN	O
insulin	NN	O
therapy	NN	O
and	CC	O
may	MD	O
need	VB	O
it	PRP	O
to	TO	O
prevent	VB	O
symptomatic	JJ	O
hyperglycemia	NN	O
.	.	O

Trial	NN	O
of	IN	O
(	(	O
+	NNP	O
)	)	O
-cyanidanol-3	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hepatitis	NN	Condition
B	NNP	Condition
chronic	NN	Condition
liver	NN	Condition
disease	NN	Condition
.	.	O

A	DT	O
double-blind	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
12	CD	O
months	NNS	O
'	POS	O
treatment	NN	O
with	IN	O
(	(	O
+	NN	O
)	)	O
-cyanidanol-3	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
26	CD	SampleSize
patients	NNS	SampleSize
with	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
liver	NN	O
disease	NN	O
.	.	O

Treatment	NN	O
did	VBD	O
not	RB	O
improve	VB	O
liver	RB	O
blood	NN	O
tests	NNS	O
nor	CC	O
histological	JJ	O
appearances	NNS	O
of	IN	O
the	DT	O
liver	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
trend	NN	O
towards	IN	O
reduction	NN	O
of	IN	O
serum	NN	O
titres	NNS	O
of	IN	O
hepatitis	NN	O
B	NNP	O
surface	NN	O
antigen	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
enoxaparin	NN	O
and	CC	O
standard	JJ	O
heparin	NN	O
in	IN	O
gynaecologic	JJ	O
oncologic	JJ	O
surgery	NN	O
:	:	O
a	DT	O
randomised	JJ	O
prospective	JJ	O
double-blind	NN	O
clinical	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
haemorrhagic	JJ	O
complications	NNS	O
and	CC	O
efficacy	NN	O
of	IN	O
enoxaparin	NN	O
,	,	O
a	DT	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
LMWH	NNP	O
)	)	O
,	,	O
and	CC	O
conventional	JJ	O
standard	NN	O
heparin	NN	O
(	(	O
SH	NNP	O
)	)	O
in	IN	O
gynaecological	JJ	O
oncologic	NN	O
surgery	NN	O
.	.	O

MATERIALS	NNP	O
METHODS	NNP	O
A	NNP	O
double	JJ	O
blind	NN	O
,	,	O
randomised	VBD	O
trial	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
102	CD	O
consecutive	JJ	O
women	NNS	O
undergoing	VBG	O
gynaecologic	JJ	O
cancer	NN	O
surgery	NN	O
with	IN	O
pelvic	NN	O
and	CC	O
paraaortic	JJ	O
lymphadenectomy	NN	O
.	.	O

The	DT	O
women	NNS	O
were	VBD	O
separated	VBN	O
into	IN	O
those	DT	O
who	WP	O
were	VBD	O
given	VBN	O
2,500	CD	O
IU	NNP	O
enoxaparin	NN	O
once	RB	O
daily	JJ	O
and	CC	O
SH	NNP	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
5,000	CD	O
IU	NNP	O
three	CD	O
times	NNS	O
daily	RB	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
analysed	VBN	O
for	IN	O
intraoperative	JJ	O
blood	NN	O
loss	NN	O
,	,	O
drainage	NN	O
,	,	O
transfusion	NN	O
requirements	NNS	O
,	,	O
perioperative	JJ	O
haemoglobin	NN	O
decrease	NN	O
,	,	O
wound	NN	O
haematoma	NN	O
,	,	O
and	CC	O
clinical	JJ	O
deep	NN	O
venous	JJ	O
thrombosis	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
for	IN	O
age	NN	O
,	,	O
weight	NN	O
,	,	O
and	CC	O
other	JJ	O
factors	NNS	O
,	,	O
which	WDT	O
could	MD	O
predispose	VB	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
DVT	NNP	O
)	)	O
and	CC	O
haemorrhage	NN	O
.	.	O

No	DT	O
patient	NN	O
developed	VBD	O
clinical	JJ	O
significant	JJ	O
DVT	NNP	O
,	,	O
wound	NN	O
haematoma	NN	O
or	CC	O
intra-abdominal	JJ	O
bleeding	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
bleeding	VBG	O
complications	NNS	O
between	IN	O
the	DT	O
two	CD	O
regimens	NNS	O
.	.	O

The	DT	O
antiFXa	JJ	O
level	NN	O
in	IN	O
the	DT	O
plasma	NN	O
was	VBD	O
correlated	VBN	O
strongly	RB	O
with	IN	O
patient	JJ	O
weight	NN	O
.	.	O

CONCLUSIONS	VB	O
A	NNP	O
dose	NN	O
of	IN	O
2,500	CD	O
IU	NNP	O
enoxaparin/day	NN	O
does	VBZ	O
not	RB	O
cause	VB	O
more	RBR	O
bleeding	JJ	O
complications	NNS	O
than	IN	O
SH	NNP	O
5,000	CD	O
IU	NNP	O
three	CD	O
times	NNS	O
daily	RB	O
when	WRB	O
used	VBN	O
to	TO	O
prevent	VB	O
thrombosis	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
enoxaparin	NN	O
must	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
weight	NN	O
.	.	O

Older	JJR	Age
patients	NNS	O
with	IN	O
chronic	JJ	Condition
myeloid	NN	Condition
leukemia	NN	Condition
(	(	O
?65	CD	O
years	NNS	O
)	)	O
profit	NN	O
more	RBR	O
from	IN	O
higher	JJR	O
imatinib	NN	O
doses	NNS	O
than	IN	O
younger	JJR	O
patients	NNS	O
:	:	O
a	DT	O
subanalysis	NN	O
of	IN	O
the	DT	O
randomized	JJ	O
CML-Study	NNP	O
IV	NNP	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
imatinib	NN	O
dose	NN	O
on	IN	O
response	NN	O
rates	NNS	O
and	CC	O
survival	NN	O
in	IN	O
older	JJR	O
patients	NNS	O
with	IN	O
chronic	JJ	O
myeloid	NN	O
leukemia	NN	O
in	IN	O
chronic	JJ	O
phase	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
well	RB	O
.	.	O

We	PRP	O
analyzed	VBD	O
data	NNS	O
from	IN	O
the	DT	O
German	JJ	O
CML-Study	NNP	O
IV	NNP	O
,	,	O
a	DT	O
randomized	JJ	O
five-arm	JJ	O
treatment	NN	O
optimization	NN	O
study	NN	O
in	IN	O
newly	RB	O
diagnosed	VBN	O
BCR-ABL-positive	JJ	O
chronic	JJ	O
myeloid	NN	O
leukemia	NN	O
in	IN	O
chronic	JJ	O
phase	NN	O
.	.	O

Patients	NNS	O
randomized	VBD	O
to	TO	O
imatinib	VB	O
400	CD	O
mg/day	NN	O
(	(	O
IM400	NNP	O
)	)	O
or	CC	O
imatinib	$	O
800	CD	O
mg/day	NN	O
(	(	O
IM800	NNP	O
)	)	O
and	CC	O
stratified	VBD	O
according	VBG	O
to	TO	O
age	NN	O
(	(	O
?65	CD	O
years	NNS	O
vs.	FW	O
<	RB	O
65	CD	O
years	NNS	O
)	)	O
were	VBD	O
compared	VBN	O
regarding	VBG	O
dose	RB	O
,	,	O
response	NN	O
,	,	O
adverse	JJ	O
events	NNS	O
,	,	O
rates	NNS	O
of	IN	O
progression	NN	O
,	,	O
and	CC	O
survival	NN	O
.	.	O

The	DT	O
full	JJ	O
800	CD	O
mg	NN	O
dose	NN	O
was	VBD	O
given	VBN	O
after	IN	O
a	DT	O
6-week	JJ	O
run-in	JJ	O
period	NN	O
with	IN	O
imatinib	JJ	O
400	CD	O
mg/day	NN	O
.	.	O

The	DT	O
dose	NN	O
could	MD	O
then	RB	O
be	VB	O
reduced	VBN	O
according	VBG	O
to	TO	O
tolerability	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
828	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
IM400	NNP	O
or	CC	O
IM800	NNP	O
.	.	O

Seven	NNP	O
hundred	VBD	O
eighty-four	JJ	O
patients	NNS	O
were	VBD	O
evaluable	JJ	O
(	(	O
IM400	NNP	O
,	,	O
382	CD	O
;	:	O
IM800	NNP	O
,	,	O
402	CD	O
)	)	O
.	.	O

One	CD	O
hundred	VBD	O
ten	JJ	O
patients	NNS	O
(	(	O
29	CD	O
%	NN	O
)	)	O
on	IN	O
IM400	NNP	O
and	CC	O
83	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
on	IN	O
IM800	NNP	O
were	VBD	O
?65	JJ	O
years	NNS	O
.	.	O

The	DT	O
median	JJ	O
dose	JJ	O
per	IN	O
day	NN	O
was	VBD	O
lower	JJR	O
for	IN	O
patients	NNS	O
?65	CD	O
years	NNS	O
on	IN	O
IM800	NNP	O
,	,	O
with	IN	O
the	DT	O
highest	JJS	O
median	JJ	O
dose	NN	O
in	IN	O
the	DT	O
first	JJ	O
year	NN	O
(	(	O
466	CD	O
mg/day	NN	O
for	IN	O
patients	NNS	O
?65	CD	O
years	NNS	O
vs.	FW	O
630	CD	O
mg/day	NN	O
for	IN	O
patients	NNS	O
<	JJ	O
65	CD	O
years	NNS	O
)	)	O
.	.	O

Older	JJR	O
patients	NNS	O
on	IN	O
IM800	NNP	O
achieved	VBD	O
major	JJ	O
molecular	JJ	O
remission	NN	O
and	CC	O
deep	JJ	O
molecular	JJ	O
remission	NN	O
as	IN	O
fast	NN	O
as	IN	O
younger	JJR	O
patients	NNS	O
,	,	O
in	IN	O
contrast	NN	O
to	TO	O
standard	VB	O
dose	JJ	O
imatinib	NN	O
with	IN	O
which	WDT	O
older	JJR	O
patients	NNS	O
achieved	VBD	O
remissions	NNS	O
much	RB	O
later	RBR	O
than	IN	O
younger	JJR	O
patients	NNS	O
.	.	O

Grades	NNP	O
3	CD	O
and	CC	O
4	CD	O
adverse	JJ	O
events	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
age	NN	O
groups	NNS	O
.	.	O

Five-year	JJ	O
relative	JJ	O
survival	NN	O
for	IN	O
older	JJR	O
patients	NNS	O
was	VBD	O
comparable	JJ	O
to	TO	O
that	DT	O
of	IN	O
younger	JJR	O
patients	NNS	O
.	.	O

We	PRP	O
suggest	VBP	O
that	IN	O
the	DT	O
optimal	JJ	O
dose	NN	O
for	IN	O
older	JJR	O
patients	NNS	O
is	VBZ	O
higher	JJR	O
than	IN	O
400	CD	O
mg/day	NN	O
.	.	O

ClinicalTrials.gov	NNP	O
identifier	NN	O
:	:	O
NCT00055874	NN	O
Comparison	NNP	O
of	IN	O
the	DT	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
epoetin	NN	O
zeta	NN	O
to	TO	O
epoetin	VB	O
alfa	NN	O
in	IN	O
the	DT	O
maintenance	NN	O
phase	NN	O
of	IN	O
renal	JJ	Condition
anaemia	NN	Condition
treatment	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
therapeutic	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
epoetin	JJ	O
zeta	NN	O
,	,	O
compared	VBN	O
with	IN	O
epoetin	NN	O
alfa	NN	O
,	,	O
in	IN	O
maintaining	VBG	O
target	NN	O
haemoglobin	NN	O
(	(	O
Hb	NNP	O
)	)	O
concentrations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
anaemia	NN	Condition
and	CC	O
chronic	JJ	Condition
kidney	NN	Condition
disease	NN	Condition
(	(	Condition
CKD	NNP	Condition
)	)	Condition
maintained	VBD	O
on	IN	O
haemodialysis	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
received	VBD	O
epoetin	JJ	O
zeta	NN	O
or	CC	O
epoetin	NN	O
alfa	NN	O
intravenously	RB	O
,	,	O
1-3	JJ	O
times/week	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
,	,	O
then	RB	O
the	DT	O
alternative	JJ	O
treatment	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
,	,	O
in	IN	O
this	DT	O
double-blind	NN	O
,	,	O
crossover	NN	O
,	,	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

Eligible	JJ	O
patients	NNS	O
were	VBD	O
18-75	CD	Age
years	NNS	Age
old	JJ	Age
with	IN	O
CKD	NNP	Condition
stage	NN	Condition
5	CD	Condition
maintained	VBN	O
on	IN	O
haemodialysis	NN	O
.	.	O

Patients	NNS	O
had	VBD	O
received	VBN	O
epoetin	NN	O
for	IN	O
>	NN	O
or	CC	O
=	$	O
3	CD	O
months	NNS	O
upon	IN	O
study	NN	O
entry	NN	O
and	CC	O
had	VBD	O
achieved	VBN	O
a	DT	O
target	NN	O
Hb	NNP	O
level	NN	O
of	IN	O
10.5-12.5	JJ	O
g/dL	NN	O
with	IN	O
a	DT	O
stable	JJ	O
epoetin	NN	O
dose	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Primary	NNP	O
efficacy	NN	O
endpoints	NNS	O
were	VBD	O
intra-individual	JJ	O
differences	NNS	O
(	(	O
test-reference	NN	O
)	)	O
in	IN	O
mean	JJ	O
Hb	NNP	O
levels	NNS	O
and	CC	O
mean	JJ	O
weekly	JJ	O
dose/kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

Safety	NN	O
endpoints	NNS	O
included	VBD	O
occurrence	NN	O
of	IN	O
neutralizing	VBG	O
anti-erythro	JJ	O
poietin	NN	O
antibodies	NNS	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
In	IN	O
total	JJ	O
,	,	O
313	CD	SampleSize
patients	NNS	SampleSize
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
epoetin	NN	O
zeta	NN	O
(	(	O
n	JJ	O
=	NNP	O
155	CD	O
)	)	O
or	CC	O
epoetin	JJ	O
alfa	NN	O
(	(	O
n	JJ	O
=	NNP	O
158	CD	O
)	)	O
;	:	O
146	CD	O
and	CC	O
145	CD	O
patients	NNS	O
(	(	O
respectively	RB	O
)	)	O
switched	VBD	O
treatment	NN	O
after	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Mean	NNP	O
(	(	O
range	NN	O
)	)	O
Hb	NNP	O
levels	NNS	O
were	VBD	O
11.35	CD	O
(	(	O
8.96-14.22	CD	O
)	)	O
g/dL	NN	O
and	CC	O
11.54	CD	O
(	(	O
8.74-13.84	CD	O
)	)	O
g/dL	NN	O
for	IN	O
patients	NNS	O
receiving	VBG	O
epoetin	JJ	O
zeta	NN	O
and	CC	O
epoetin	NN	O
alfa	NN	O
,	,	O
respectively	RB	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
[	NNP	O
test-reference	NN	O
]	NN	O
:	:	O
0.09-0.28	JJ	O
g/dL	NN	O
,	,	O
within	IN	O
the	DT	O
predefined	JJ	O
equivalence	NN	O
range	NN	O
of	IN	O
+/-0.6	NNP	O
g/dL	NN	O
)	)	O
.	.	O

Mean	NNP	O
(	(	O
range	NN	O
)	)	O
weekly	JJ	O
doses	NNS	O
were	VBD	O
92.68	CD	O
(	(	O
12.74-398.41	JJ	O
)	)	O
IU/kg/wk	NNP	O
and	CC	O
92.58	CD	O
(	(	O
10.53-393.07	JJ	O
)	)	O
IU/kg/wk	NNP	O
for	IN	O
patients	NNS	O
receiving	VBG	O
epoetin	JJ	O
zeta	NN	O
and	CC	O
epoetin	NN	O
alfa	NN	O
,	,	O
respectively	RB	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
test-reference	NN	O
]	NN	O
:	:	O
-4.67	NN	O
and	CC	O
4.29	CD	O
IU/kg/wk	NNP	O
,	,	O
within	IN	O
the	DT	O
equivalence	NN	O
range	NN	O
of	IN	O
+/-45.00	NNP	O
IU/kg/wk	NNP	O
)	)	O
.	.	O

Patients	NNPS	O
underwent	JJ	O
minor	JJ	O
nominal	JJ	O
dose	NN	O
adjustments	NNS	O
during	IN	O
treatment	NN	O
crossover	NN	O
.	.	O

AE	NNP	O
profile	NN	O
was	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
products	NNS	O
;	:	O
the	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
AEs	NNP	O
were	VBD	O
infections	NNS	O
and	CC	O
infestations	NNS	O
(	(	O
in	IN	O
26.5	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
epoetin	JJ	O
zeta	NN	O
and	CC	O
23.6	CD	O
%	NN	O
receiving	VBG	O
epoetin	JJ	O
alfa	NN	O
)	)	O
.	.	O

No	UH	O
patients	NNS	O
developed	VBD	O
neutralizing	VBG	O
anti-erythropoietin	JJ	O
antibodies	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Epoetin	NNP	O
zeta	NN	O
is	VBZ	O
therapeutically	RB	O
equivalent	JJ	O
to	TO	O
epoetin	VB	O
alfa	NN	O
in	IN	O
the	DT	O
maintenance	NN	O
of	IN	O
target	NN	O
Hb	NNP	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
renal	JJ	Condition
anaemia	NN	Condition
.	.	O

No	DT	O
unexpected	JJ	O
AEs	NNP	O
were	VBD	O
seen	VBN	O
.	.	O

Comparison	NNP	O
of	IN	O
tropisetron	NN	O
and	CC	O
granisetron	NN	O
in	IN	O
the	DT	O
control	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
children	NNS	Age
receiving	VBG	O
combined	JJ	O
cancer	NN	Condition
chemotherapy	NN	Condition
.	.	O

Tropisetron	NNP	O
and	CC	O
granisetron	NN	O
are	VBP	O
selective	JJ	O
serotonin	NN	O
(	(	O
5-HT3	JJ	O
)	)	O
antagonists	VBZ	O
that	WDT	O
have	VBP	O
been	VBN	O
proven	VBN	O
effective	JJ	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
adults	NNS	Age
and	CC	O
children	NNS	Age
receiving	VBG	O
cancer	NN	Condition
chemotherapy	NN	Condition
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
two	CD	O
agents	NNS	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
vomiting	VBG	O
and	CC	O
nausea	NN	O
in	IN	O
children	NNS	O
receiving	VBG	O
highly	RB	Condition
emetogenic	JJ	Condition
chemotherapy	NN	Condition
for	IN	O
various	JJ	O
malignancies	NNS	Condition
.	.	O

A	DT	O
total	NN	O
of	IN	O
51	CD	SampleSize
children	NNS	O
(	(	O
mean	JJ	O
age	NN	O
:	:	O
7.7	CD	Age
+/-	NN	Age
4.8	CD	Age
year	NN	Age
)	)	O
were	VBD	O
studied	VBN	O
in	IN	O
133	CD	O
chemotherapy	NN	O
cycles	NNS	O
.	.	O

In	IN	O
66	CD	O
chemotherapy	NN	O
cycles	NNS	O
,	,	O
the	DT	O
children	NNS	O
received	VBD	O
tropisetron	RP	O
as	IN	O
an	DT	O
antiemetic	JJ	O
agent	NN	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.2	CD	O
mg/kg/24	NNS	O
h	VBD	O
intravenously	RB	O
and	CC	O
,	,	O
in	IN	O
67	CD	O
cycles	NNS	O
,	,	O
they	PRP	O
received	VBD	O
granisetron	NN	O
40	CD	O
micrograms/kg/24	NN	O
h	NN	O
intravenously	RB	O
before	IN	O
cytotoxic	JJ	O
drug	NN	O
administration	NN	O
during	IN	O
the	DT	O
days	NNS	O
they	PRP	O
received	VBD	O
chemotherapy	NN	O
.	.	O

The	DT	O
response	NN	O
per	IN	O
24	CD	O
h	NN	O
of	IN	O
chemotherapy	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
complete	JJ	O
(	(	O
no	DT	O
nausea	NN	O
and	CC	O
vomiting	NN	O
)	)	O
,	,	O
partial	JJ	O
(	(	O
1-4	JJ	O
events	NNS	O
of	IN	O
vomiting	VBG	O
and/or	JJ	O
nausea	NN	O
)	)	O
,	,	O
and	CC	O
failure	NN	O
(	(	O
more	JJR	O
than	IN	O
4	CD	O
events	NNS	O
of	IN	O
vomiting	VBG	O
and/or	JJ	O
nausea	NN	O
)	)	O
.	.	O

Efficacy	NN	O
of	IN	O
antiemetic	JJ	O
therapy	NN	O
was	VBD	O
evaluated	VBN	O
as	IN	O
acute	NN	O
(	(	O
Day	NNP	O
1	CD	O
)	)	O
and	CC	O
overall	$	O
was	VBD	O
based	VBN	O
on	IN	O
the	DT	O
worst	JJS	O
day	NN	O
during	IN	O
the	DT	O
chemotherapy	NN	O
.	.	O

Complete	NNP	O
control	NN	O
of	IN	O
acute	JJ	O
vomiting	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
74	CD	O
%	NN	O
of	IN	O
tropisetron	NN	O
and	CC	O
88	CD	O
%	NN	O
of	IN	O
granisetron	NN	O
patients	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
and	CC	O
complete	JJ	O
control	NN	O
of	IN	O
acute	JJ	O
nausea	NN	O
in	IN	O
56	CD	O
%	NN	O
and	CC	O
82	CD	O
%	NN	O
respectively	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Overall	JJ	O
response	NN	O
by	IN	O
means	NNS	O
of	IN	O
complete	JJ	O
control	NN	O
of	IN	O
both	DT	O
vomiting	VBG	O
and	CC	O
nausea	NN	O
during	IN	O
the	DT	O
whole	JJ	O
therapy	NN	O
period	NN	O
was	VBD	O
29	CD	O
%	NN	O
of	IN	O
tropisetron	NN	O
group	NN	O
and	CC	O
55	CD	O
%	NN	O
of	IN	O
granisetron	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.007	CD	O
)	)	O
.	.	O

The	DT	O
statistical	JJ	O
analysis	NN	O
(	(	O
depending	VBG	O
on	IN	O
the	DT	O
emetogenicity	NN	O
of	IN	O
the	DT	O
chemotherapy	NN	O
cycles	NNS	O
)	)	O
showed	VBD	O
increased	JJ	O
efficacy	NN	O
of	IN	O
granisetron	NN	O
in	IN	O
highly	RB	O
(	(	O
grade	VB	O
3	CD	O
)	)	O
emetogenic	JJ	O
chemotherapy	NN	O
cycles	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
,	,	O
whereas	IN	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
very	RB	O
highly	RB	O
emetogenic	JJ	O
cycles	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.7	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
granisetron	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
tropisetron	RB	O
,	,	O
especially	RB	O
in	IN	O
patients	NNS	O
heavier	JJR	O
than	IN	O
25	CD	O
kg	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
few	JJ	O
and	CC	O
mild	JJ	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
tolerability	NN	O
of	IN	O
the	DT	O
two	CD	O
antiemetic	JJ	O
therapy	NN	O
modalities	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
granisetron	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
tropisetron	NN	O
in	IN	O
controlling	VBG	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
children	NNS	Age
receiving	VBG	O
highly	RB	Condition
emetogenic	JJ	Condition
chemotherapy	NN	Condition
.	.	O

This	DT	O
increased	VBD	O
antiemetic	JJ	O
efficacy	NN	O
of	IN	O
ganisetron	NN	O
might	MD	O
have	VB	O
been	VBN	O
related	VBN	O
to	TO	O
maximal	VB	O
dose	JJ	O
differences	NNS	O
according	VBG	O
to	TO	O
body	NN	O
weight	NN	O
.	.	O

Association	NNP	O
of	IN	O
efavirenz	JJ	O
hypersusceptibility	NN	O
with	IN	O
virologic	JJ	O
response	NN	O
in	IN	O
ACTG	NNP	O
368	CD	O
,	,	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
abacavir	NN	O
(	(	O
ABC	NNP	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
efavirenz	NN	O
(	(	O
EFV	NNP	O
)	)	O
and	CC	O
indinavir	NN	O
(	(	O
IDV	NNP	O
)	)	O
in	IN	O
HIV-infected	JJ	Condition
subjects	NNS	O
with	IN	O
prior	JJ	O
nucleoside	JJ	O
analog	NN	O
experience	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
association	NN	O
of	IN	O
efavirenz	JJ	O
hypersusceptibility	NN	O
(	(	O
EFV-HS	NNP	O
)	)	O
with	IN	O
clinical	JJ	O
outcome	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
EFV	NNP	O
plus	CC	O
indinavir	NN	O
(	(	O
EFV+IDV	NNP	O
)	)	O
vs.	FW	O
EFV+IDV	NNP	O
plus	CC	O
abacavir	NN	O
(	(	O
ABC	NNP	O
)	)	O
in	IN	O
283	CD	SampleSize
nucleoside-experienced	JJ	O
HIV-infected	JJ	Condition
patients	NNS	O
.	.	O

METHOD	NNP	O
AND	CC	O
RESULTS	NNP	O
Rates	NNS	O
of	IN	O
virologic	JJ	O
failure	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
arms	NNS	O
at	IN	O
week	NN	O
16	CD	O
(	(	O
p	JJ	O
=	NNP	O
.509	NNP	O
)	)	O
.	.	O

Treatment	JJ	O
discontinuations	NNS	O
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
ABC	NNP	O
arm	NN	O
(	(	O
p	JJ	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

Using	VBG	O
logistic	JJ	O
regression	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
association	NN	O
between	IN	O
virologic	JJ	O
failure	NN	O
and	CC	O
either	DT	O
baseline	NN	O
ABC	NNP	O
resistance	NN	O
or	CC	O
regimen	NNS	O
sensitivity	NN	O
score	NN	O
.	.	O

Using	VBG	O
3	CD	O
different	JJ	O
genotypic	NN	O
scoring	VBG	O
systems	NNS	O
,	,	O
EFV-HS	NNP	O
was	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
reduced	JJ	O
virologic	JJ	O
failure	NN	O
at	IN	O
week	NN	O
16	CD	O
,	,	O
independent	JJ	O
of	IN	O
treatment	NN	O
assignment	NN	O
.	.	O

In	IN	O
some	DT	O
patients	NNS	O
on	IN	O
the	DT	O
nucleoside-sparing	JJ	O
arm	NN	O
,	,	O
the	DT	O
nucleoside-resistance	JJ	O
mutation	NN	O
L74V	NNP	O
was	VBD	O
selected	VBN	O
for	IN	O
in	IN	O
combination	NN	O
with	IN	O
the	DT	O
uncommonly	JJ	O
occurring	VBG	O
EFV-resistance	JJ	O
mutations	NNS	O
K103N+L100I	NNP	O
;	:	O
L74V	NNP	O
was	VBD	O
not	RB	O
detected	VBN	O
as	IN	O
a	DT	O
minority	NN	O
variant	NN	O
,	,	O
using	VBG	O
clonal	JJ	O
sequence	NN	O
analysis	NN	O
,	,	O
when	WRB	O
the	DT	O
nucleoside-sparing	JJ	O
regimen	NN	O
was	VBD	O
initiated	VBN	O
.	.	O

CONCLUSION	NNP	O
Premature	NNP	O
treatment	NN	O
discontinuations	NNS	O
in	IN	O
the	DT	O
ABC	NNP	O
arm	NN	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
EFV-HS	NNP	O
HIV	NNP	O
variants	NNS	O
in	IN	O
this	DT	O
patient	NN	O
population	NN	O
likely	RB	O
made	VBD	O
it	PRP	O
difficult	JJ	O
to	TO	O
detect	VB	O
a	DT	O
benefit	NN	O
of	IN	O
adding	VBG	O
ABC	NNP	O
to	TO	O
EFV+IDV	NNP	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
L74V	NNP	O
,	,	O
when	WRB	O
combined	VBN	O
with	IN	O
K103N+L100I	NNP	O
,	,	O
may	MD	O
confer	VB	O
a	DT	O
selective	JJ	O
advantage	NN	O
to	TO	O
the	DT	O
virus	NN	O
that	WDT	O
is	VBZ	O
independent	JJ	O
of	IN	O
its	PRP$	O
effects	NNS	O
on	IN	O
nucleoside	JJ	O
resistance	NN	O
.	.	O

Topical	JJ	O
PUVA	NNP	O
,	,	O
etretinate	NN	O
,	,	O
and	CC	O
combined	VBN	O
PUVA	NNP	O
and	CC	O
etretinate	VB	O
for	IN	O
palmoplantar	JJ	O
pustulosis	NN	O
:	:	O
comparison	NN	O
of	IN	O
therapeutic	JJ	O
efficacy	NN	O
and	CC	O
the	DT	O
influences	NNS	O
of	IN	O
tonsillar	JJ	O
and	CC	O
dental	JJ	O
focal	JJ	O
infections	NNS	O
.	.	O

Twenty	CD	SampleSize
patients	NNS	O
with	IN	O
palmoplantar	JJ	Condition
pustulosis	NN	Condition
(	(	Condition
PPP	NNP	Condition
)	)	Condition
were	VBD	O
treated	VBN	O
with	IN	O
topical	JJ	O
PUVA	NNP	O
,	,	O
oral	JJ	O
etretinate	NN	O
(	(	O
Re	NNP	O
)	)	O
,	,	O
or	CC	O
combined	VBN	O
PUVA	NNP	O
and	CC	O
etretinate	VB	O
(	(	O
Re-PUVA	NNP	O
)	)	O
.	.	O

Re	NNP	O
and	CC	O
Re-PUVA	NNP	O
treated	VBD	O
sites	NNS	O
improved	VBN	O
and/or	RB	O
cleared	VBN	O
more	RBR	O
rapidly	RB	O
than	IN	O
PUVA	NNP	O
treated	VBD	O
sites	NNS	O
.	.	O

Complete	JJ	O
clearance	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
six	CD	O
of	IN	O
ten	NNS	O
sites	NNS	O
treated	VBD	O
with	IN	O
Re-PUVA	NNP	O
,	,	O
two	CD	O
of	IN	O
ten	NNS	O
with	IN	O
Re	NNP	O
,	,	O
and	CC	O
one	CD	O
of	IN	O
ten	NN	O
sites	NNS	O
with	IN	O
PUVA	NNP	O
within	IN	O
12	CD	O
weeks	NNS	O
.	.	O

UVA-control	NNP	O
sites	VBZ	O
failed	VBD	O
to	TO	O
be	VB	O
cleared	VBN	O
within	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Remission	NNP	O
periods	NNS	O
after	IN	O
stopping	VBG	O
the	DT	O
treatment	NN	O
were	VBD	O
1.5	CD	O
+/-	JJ	O
0.5	CD	O
weeks	NNS	O
(	(	O
n	JJ	O
=	NNP	O
2	CD	O
)	)	O
with	IN	O
Re	NNP	O
,	,	O
10.5	CD	O
+/-	JJ	O
11.4	CD	O
weeks	NNS	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
with	IN	O
Re-PUVA	NNP	O
,	,	O
and	CC	O
one	CD	O
year	NN	O
(	(	O
n	JJ	O
=	NNP	O
1	CD	O
)	)	O
with	IN	O
PUVA	NNP	O
.	.	O

These	DT	O
results	NNS	O
overall	VBP	O
suggested	VBD	O
that	IN	O
Re-PUVA	NNP	O
is	VBZ	O
the	DT	O
most	RBS	O
effective	JJ	O
treatment	NN	O
for	IN	O
PPP	NNP	O
.	.	O

Tonsillar	NNP	O
focal	JJ	O
infection	NN	O
(	(	O
TFI	NNP	O
)	)	O
and	CC	O
dental	JJ	O
focal	JJ	O
infection	NN	O
(	(	O
DFI	NNP	O
)	)	O
were	VBD	O
found	VBN	O
in	IN	O
6/20	CD	O
and	CC	O
17/20	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
focal	JJ	O
infection	NN	O
(	(	O
FI	NNP	O
)	)	O
,	,	O
TFI	NNP	O
and/or	VBZ	O
DFI	NNP	O
,	,	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
interfere	VB	O
with	IN	O
the	DT	O
therapeutic	JJ	O
activities	NNS	O
of	IN	O
Re	NNP	O
and/or	NN	O
PUVA	NNP	O
,	,	O
because	IN	O
the	DT	O
complete	JJ	O
clearance	NN	O
rates	NNS	O
and	CC	O
remission	NN	O
periods	NNS	O
in	IN	O
FI	NNP	O
(	(	O
+	NNP	O
)	)	O
patients	NNS	O
were	VBD	O
comparable	JJ	O
with	IN	O
those	DT	O
in	IN	O
FI	NNP	O
(	(	O
-	:	O
)	)	O
patients	NNS	O
.	.	O

Home	NNP	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
:	:	O
advantages	NNS	O
and	CC	O
limitations	NNS	O
.	.	O

Home	NNP	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
is	VBZ	O
a	DT	O
useful	JJ	O
tool	NN	O
for	IN	O
clinical	JJ	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	Condition
.	.	O

Its	PRP$	O
major	JJ	O
advantages	NNS	O
are	VBP	O
the	DT	O
ease	NN	O
with	IN	O
which	WDT	O
the	DT	O
techniques	NNS	O
can	MD	O
be	VB	O
learned	VBN	O
,	,	O
reproducibility	NN	O
of	IN	O
values	NNS	O
,	,	O
sensitivity	NN	O
of	IN	O
measurement	NN	O
and	CC	O
availability	NN	O
of	IN	O
normotensive	JJ	O
data	NNS	O
.	.	O

In	IN	O
spite	NN	O
of	IN	O
the	DT	O
ability	NN	O
to	TO	O
tell	VB	O
whether	IN	O
a	DT	O
subject	NN	O
has	VBZ	O
normal	JJ	O
or	CC	O
abnormal	JJ	O
values	NNS	O
,	,	O
because	IN	O
of	IN	O
the	DT	O
lack	NN	O
of	IN	O
prospective	JJ	O
mortality/morbidity	NN	O
data	NNS	O
,	,	O
home	NN	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
can	MD	O
not	RB	O
be	VB	O
used	VBN	O
to	TO	O
decide	VB	O
whether	IN	O
treatment	NN	O
is	VBZ	O
indicated	VBN	O
.	.	O

The	DT	O
treatment	NN	O
decision	NN	O
must	MD	O
be	VB	O
based	VBN	O
on	IN	O
repeated	VBN	O
clinic	JJ	O
blood	NN	O
pressure	NN	O
readings	NNS	O
.	.	O

After	IN	O
that	IN	O
the	DT	O
home	NN	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
exclude	VB	O
individuals	NNS	O
who	WP	O
are	VBP	O
at	IN	O
risk	NN	O
for	IN	O
side	NN	O
effects	NNS	O
due	JJ	O
to	TO	O
low	JJ	O
out-of-office	JJ	O
blood	NN	O
pressure	NN	O
readings	NNS	O
and	CC	O
to	TO	O
precisely	RB	O
monitor	VB	O
the	DT	O
blood	NN	O
pressure	NN	O
response	NN	O
to	TO	O
therapy	NN	O
.	.	O

Home	NNP	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
is	VBZ	O
frequently	RB	O
used	VBN	O
to	TO	O
find	VB	O
subjects	NNS	O
with	IN	O
'white-coat	NNP	O
'	POS	O
hypertension	NN	O
.	.	O

In	IN	O
our	PRP$	O
study	NN	O
of	IN	O
borderline	JJ	Condition
hypertension	NN	Condition
in	IN	O
Tecumseh	NNP	O
,	,	O
white-coat	JJ	O
hypertension	NN	O
is	VBZ	O
present	JJ	O
in	IN	O
7.1	CD	O
%	NN	O
of	IN	O
the	DT	O
whole	JJ	O
population	NN	O
and	CC	O
in	IN	O
58	CD	O
%	NN	O
of	IN	O
all	DT	O
subjects	NNS	O
with	IN	O
elevated	JJ	O
blood	NN	O
pressures	NNS	O
in	IN	O
the	DT	O
clinic	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
white-coat	JJ	O
hypertension	NN	O
in	IN	O
Tecumseh	NNP	O
appear	VBP	O
to	TO	O
be	VB	O
at	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
for	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
:	:	O
they	PRP	O
show	VBP	O
repeated	VBN	O
elevated	JJ	O
clinic	NN	O
readings	NNS	O
throughout	IN	O
their	PRP$	O
life	NN	O
time	NN	O
,	,	O
their	PRP$	O
parents	NNS	O
have	VBP	O
higher	JJR	O
blood	NN	O
pressure	NN	O
,	,	O
their	PRP$	O
high-density	NN	O
lipoprotein	NN	O
is	VBZ	O
decreased	VBN	O
and	CC	O
insulin	NN	O
,	,	O
cholesterol	NN	O
and	CC	O
triglycerides	NNS	O
are	VBP	O
elevated	VBN	O
.	.	O

Whereas	JJ	O
subjects	NNS	O
with	IN	O
white-coat	JJ	O
hypertension	NN	O
should	MD	O
not	RB	O
be	VB	O
treated	VBN	O
with	IN	O
antihypertensive	JJ	O
agents	NNS	O
,	,	O
they	PRP	O
must	MD	O
be	VB	O
followed	VBN	O
and	CC	O
managed	VBN	O
through	IN	O
non-pharmacologic	JJ	O
means	NNS	O
.	.	O

Pretreatment	NN	O
and	CC	O
co-administration	NN	O
of	IN	O
oral	JJ	O
anti-diabetic	JJ	O
agent	NN	O
with	IN	O
clomiphene	JJ	O
citrate	NN	O
or	CC	O
rFSH	NN	O
for	IN	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene-citrate-resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
.	.	O

AIM	IN	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
explore	VB	O
the	DT	O
result	NN	O
of	IN	O
pretreatment	NN	O
and	CC	O
concomitant	NN	O
use	NN	O
of	IN	O
metformin	NN	O
with	IN	O
clomiphene	JJ	O
citrate	NN	O
(	(	O
CC	NNP	O
)	)	O
and	CC	O
rFSH	NN	O
for	IN	O
ovulation	NN	O
induction	NN	O
in	IN	O
clomiphene-citrate-resistant	JJ	O
polycystic	JJ	O
ovary	JJ	O
syndrome	NN	O
(	(	O
PCOS	NNP	O
)	)	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
done	VBN	O
in	IN	O
the	DT	O
Dhaka	NNP	O
Medical	NNP	O
College	NNP	O
and	CC	O
Hospital	NNP	O
and	CC	O
the	DT	O
Infertility	NNP	O
Care	NNP	O
and	CC	O
Research	NNP	O
Centre	NNP	O
,	,	O
Dhaka	NNP	O
,	,	O
Bangladesh	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
165	CD	O
infertile	JJ	O
patients	NNS	O
with	IN	O
CC-resistant	JJ	O
PCOS	NNP	O
who	WP	O
attended	VBD	O
for	IN	O
treatment	NN	O
were	VBD	O
the	DT	O
target	NN	O
population	NN	O
for	IN	O
this	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
:	:	O
groups	NNS	O
A	DT	O
and	CC	O
B	NNP	O
were	VBD	O
given	VBN	O
metformin	NNS	O
and	CC	O
group	NN	O
C	NNP	O
was	VBD	O
the	DT	O
control	NN	O
.	.	O

Along	IN	O
with	IN	O
metformin	NN	O
,	,	O
group	NN	O
A	NNP	O
received	VBD	O
CC	NNP	O
and	CC	O
group	NN	O
B	NNP	O
received	VBD	O
rFSH	NN	O
.	.	O

Group	NNP	O
C	NNP	O
was	VBD	O
treated	VBN	O
with	IN	O
only	RB	O
rFSH	NN	O
.	.	O

Metformin	NNP	O
was	VBD	O
given	VBN	O
1500	CD	O
mg	JJ	O
daily	JJ	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Afterwards	NNS	O
CC	NNP	O
or	CC	O
rFSH	VB	O
were	VBD	O
added	VBN	O
for	IN	O
induction	NN	O
of	IN	O
ovulation	NN	O
along	IN	O
with	IN	O
metformin	NN	O
.	.	O

Six	NNP	O
ovulatory	JJ	O
cycles	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

Treatment	NNP	O
was	VBD	O
terminated	VBN	O
when	WRB	O
there	EX	O
was	VBD	O
no	DT	O
response	NN	O
with	IN	O
maximum	JJ	O
dose	NN	O
of	IN	O
CC	NNP	O
and	CC	O
rFSH	NN	O
or	CC	O
after	IN	O
six	CD	O
ovulatory	JJ	O
cycles	NNS	O
without	IN	O
pregnancy	NN	O
or	CC	O
after	IN	O
achieving	VBG	O
pregnancy	NN	O
.	.	O

A	DT	O
P-value	NNP	O
of	IN	O
<	NNP	O
0.5	CD	O
was	VBD	O
considered	VBN	O
as	IN	O
significant	JJ	O
.	.	O

RESULTS	NNP	O
Ovulation	NNP	O
(	(	O
89.09	CD	O
%	NN	O
)	)	O
and	CC	O
pregnancy	NN	O
(	(	O
54.55	CD	O
%	NN	O
)	)	O
rates	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
group	NN	O
B.	NNP	O
Ovulation	NNP	O
(	(	O
74.55	CD	O
%	NN	O
)	)	O
and	CC	O
pregnancy	NN	O
(	(	O
29.09	CD	O
%	NN	O
)	)	O
rates	NNS	O
were	VBD	O
also	RB	O
satisfactory	JJ	O
in	IN	O
group	NN	O
C	NNP	O
but	CC	O
a	DT	O
dose	NN	O
of	IN	O
rFSH	JJ	O
requirement	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.000	CD	O
)	)	O
.	.	O

In	IN	O
group	NN	O
A	NNP	O
,	,	O
both	DT	O
ovulation	NN	O
and	CC	O
pregnancy	NN	O
rate	NN	O
were	VBD	O
much	RB	O
lower	JJR	O
than	IN	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
(	(	O
27.27	CD	O
%	NN	O
and	CC	O
12.73	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Use	NNP	O
of	IN	O
metformin	NN	O
increases	VBZ	O
the	DT	O
response	NN	O
of	IN	O
ovulation-inducing	JJ	O
agents	NNS	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
safely	RB	O
in	IN	O
PCOS	NNP	O
.	.	O

Association	NNP	O
of	IN	O
race	NN	O
with	IN	O
complications	NNS	O
and	CC	O
prognosis	NN	O
following	VBG	O
acute	JJ	O
coronary	JJ	O
syndromes	NNS	O
.	.	O

The	DT	O
baseline	NN	O
characteristics	NNS	O
,	,	O
complications	NNS	O
,	,	O
and	CC	O
survival	NN	O
of	IN	O
489	CD	SampleSize
black	JJ	O
and	CC	O
6,890	CD	SampleSize
non-black	JJ	O
patients	NNS	O
with	IN	O
acute	JJ	O
coronary	JJ	Condition
syndromes	NNS	Condition
were	VBD	O
studied	VBN	O
.	.	O

Important	NNP	O
racial	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
demographic	JJ	O
features	NNS	O
,	,	O
atherosclerosis	NN	O
risk	NN	O
factors	NNS	O
,	,	O
and	CC	O
treatment	NN	O
strategies	NNS	O
;	:	O
however	RB	O
,	,	O
despite	IN	O
these	DT	O
differences	NNS	O
,	,	O
no	DT	O
independent	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
clinical	JJ	O
outcomes	NNS	O
according	VBG	O
to	TO	O
race	NN	O
.	.	O

The	DT	O
1-year	JJ	O
mortality	NN	O
rate	NN	O
was	VBD	O
2.9	CD	O
%	NN	O
for	IN	O
black	JJ	O
patients	NNS	O
and	CC	O
2.5	CD	O
%	NN	O
for	IN	O
non-black	JJ	O
patients	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.93	CD	O
)	)	O
.	.	O

A	DT	O
randomized	JJ	O
parallel	NN	O
study	NN	O
to	TO	O
assess	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
two	CD	O
different	JJ	O
dosing	VBG	O
regimens	NNS	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
superficial	JJ	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
.	.	O

OBJECTIVES	CC	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
two	CD	O
cycled	VBD	O
dosing	VBG	O
regimens	NNS	O
of	IN	O
imiquimod	JJ	O
5	CD	O
%	NN	O
cream	NN	O
for	IN	O
treatment	NN	O
of	IN	O
superficial	JJ	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
(	(	O
sBCC	NN	O
)	)	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
(	(	O
n	JJ	O
=	NNP	O
32	CD	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
regimens	NNS	O
:	:	O
8	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
once-daily	JJ	O
dosing	VBG	O
for	IN	O
alternate	JJ	O
weeks	NNS	O
(	(	O
R1	NNP	O
)	)	O
and	CC	O
5	CD	O
weeks	NNS	O
of	IN	O
once-daily	JJ	O
dosing	NN	O
with	IN	O
a	DT	O
1-week	JJ	O
interval	NN	O
in	IN	O
the	DT	O
middle	NN	O
of	IN	O
the	DT	O
course	NN	O
(	(	O
R2	NNP	O
)	)	O
.	.	O

Efficacy	NN	O
measures	NNS	O
were	VBD	O
tumour	JJ	O
clearance	NN	O
at	IN	O
weeks	NNS	O
19	CD	O
and	CC	O
52	CD	O
and	CC	O
measures	NNS	O
of	IN	O
patients	NNS	O
'	POS	O
acceptability	NN	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
from	IN	O
30	CD	O
patients	NNS	O
(	(	O
13	CD	O
females	NNS	O
)	)	O
,	,	O
14	CD	O
on	IN	O
R1	NNP	O
and	CC	O
16	CD	O
on	IN	O
R2	NNP	O
,	,	O
were	VBD	O
analysed	VBN	O
.	.	O

The	DT	O
results	NNS	O
revealed	VBD	O
an	DT	O
initial	JJ	O
clearance	NN	O
rate	NN	O
of	IN	O
64	CD	O
%	NN	O
at	IN	O
week	NN	O
19	CD	O
for	IN	O
R1	NNP	O
and	CC	O
81	CD	O
%	NN	O
for	IN	O
R2	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
:	:	O
-14	NN	O
%	NN	O
to	TO	O
45	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.21	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
clearance	NN	O
rates	NNS	O
at	IN	O
week	NN	O
52	CD	O
were	VBD	O
significantly	RB	O
different	JJ	O
:	:	O
43	CD	O
%	NN	O
for	IN	O
R1	NNP	O
and	CC	O
88	CD	O
%	NN	O
for	IN	O
R2	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
for	IN	O
difference	NN	O
:	:	O
11	CD	O
%	NN	O
to	TO	O
68	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
acceptability	NN	O
of	IN	O
treatment	NN	O
as	IN	O
measured	VBN	O
by	IN	O
composite	JJ	O
median	JJ	O
visual	JJ	O
analogue	NN	O
scores	NNS	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

CONCLUSION	NNP	O
Five	NNP	O
weeks	NNS	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	O
cream	NN	O
once	RB	O
daily	JJ	O
with	IN	O
a	DT	O
1-week	JJ	O
interval	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
but	CC	O
as	RB	O
well	RB	O
tolerated	VBN	O
as	IN	O
the	DT	O
8-week	JJ	O
alternate	NN	O
week	NN	O
regimen	NNS	O
for	IN	O
sBCC	NN	O
.	.	O

Effect	NN	O
of	IN	O
soy	NN	O
protein	NN	O
containing	VBG	O
isoflavones	NNS	O
on	IN	O
blood	NN	O
lipids	NNS	O
in	IN	O
moderately	RB	O
hypercholesterolemic	JJ	Condition
adults	NNS	Age
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Dietary	NNP	O
intake	NN	O
of	IN	O
soy	JJ	O
protein	NN	O
with	IN	O
isoflavones	NNS	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
reductions	NNS	O
in	IN	O
serum	NN	O
cholesterol	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
water-washed	JJ	O
soy	NN	O
protein	NN	O
concentrate	NN	O
with	IN	O
a	DT	O
milk-protein	JJ	O
based	VBN	O
control	NN	O
on	IN	O
blood	NN	O
lipid	JJ	O
levels	NNS	O
in	IN	O
hyperlipidemic	JJ	Condition
men	NNS	Sex
and	CC	O
women	NNS	Sex
.	.	Sex

METHODS	VB	O
A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
including	VBG	O
159	CD	SampleSize
subjects	NNS	O
.	.	O

After	IN	O
a	DT	O
3-week	JJ	O
run-in	JJ	O
period	NN	O
during	IN	O
which	WDT	O
all	DT	O
subjects	NNS	O
consumed	VBD	O
a	DT	O
milk	NN	O
protein-based	JJ	O
supplement	NN	O
,	,	O
participants	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
:	:	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
continued	VBN	O
milk	NN	O
protein	NN	O
)	)	O
and	CC	O
an	DT	O
intervention	NN	O
group	NN	O
(	(	O
soy	JJ	O
protein	NN	O
)	)	O
for	IN	O
a	DT	O
five-week	JJ	O
period	NN	O
.	.	O

Fasting	VBG	O
venous	JJ	O
blood	NN	O
draws	NN	O
for	IN	O
lipid	JJ	O
measurement	NN	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
towards	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
run-in	JJ	O
period	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
.	.	O

Blood	NNP	O
isoflavone	NN	O
concentrations	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
Blood	NNP	O
lipid	JJ	O
levels	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
at	IN	O
any	DT	O
point	NN	O
in	IN	O
time	NN	O
;	:	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
associations	NNS	O
between	IN	O
blood	NN	O
isoflavones	NNS	O
and	CC	O
lipid	JJ	O
levels	NNS	O
.	.	O

Significant	JJ	O
decreases	NNS	O
in	IN	O
total	JJ	O
cholesterol	NN	O
(	(	O
19	CD	O
mg/dL	NN	O
)	)	O
,	,	O
and	CC	O
LDL-cholesterol	NNP	O
(	(	O
11	CD	O
mg/dL	NN	O
)	)	O
,	,	O
were	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
run-in	JJ	O
period	NN	O
,	,	O
with	IN	O
no	DT	O
further	JJ	O
decreases	NNS	O
in	IN	O
lipids	NNS	O
during	IN	O
the	DT	O
intervention	NN	O
period	NN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
do	VBP	O
not	RB	O
support	VB	O
the	DT	O
hypothesis	NN	O
that	IN	O
water-washed	JJ	O
soy	NN	O
protein	NN	O
has	VBZ	O
an	DT	O
effect	NN	O
on	IN	O
blood	NN	O
lipids	NNS	O
.	.	O

Several	JJ	O
hypotheses	NNS	O
are	VBP	O
discussed	VBN	O
,	,	O
highlighting	VBG	O
the	DT	O
selective	JJ	O
nature	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
soy	NN	O
consumption	NN	O
in	IN	O
the	DT	O
population	NN	O
.	.	O

The	DT	O
cholesterol-lowering	JJ	O
effect	NN	O
during	IN	O
the	DT	O
run-in	JJ	O
period	NN	O
may	MD	O
be	VB	O
explained	VBN	O
by	IN	O
the	DT	O
regression	NN	O
to	TO	O
the	DT	O
mean	JJ	O
effect	NN	O
and	CC	O
by	IN	O
other	JJ	O
factors	NNS	O
related	VBN	O
to	TO	O
study	VB	O
participation	NN	O
,	,	O
mainly	RB	O
nutrient	JJ	O
displacement	NN	O
induced	VBN	O
by	IN	O
the	DT	O
protein	NN	O
supplement	NN	O
.	.	O

Effect	NN	O
of	IN	O
VX-770	NNP	O
in	IN	O
persons	NNS	O
with	IN	O
cystic	JJ	O
fibrosis	NN	O
and	CC	O
the	DT	O
G551D-CFTR	NNP	O
mutation	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
new	JJ	O
approach	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cystic	JJ	O
fibrosis	NN	O
involves	VBZ	O
improving	VBG	O
the	DT	O
function	NN	O
of	IN	O
mutant	JJ	O
cystic	JJ	O
fibrosis	NN	O
transmembrane	NN	O
conductance	NN	O
regulator	NN	O
(	(	O
CFTR	NNP	O
)	)	O
.	.	O

VX-770	NNP	O
,	,	O
a	DT	O
CFTR	NNP	O
potentiator	NN	O
,	,	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
increase	VB	O
the	DT	O
activity	NN	O
of	IN	O
wild-type	NN	O
and	CC	O
defective	JJ	O
cell-surface	NN	O
CFTR	NNP	O
in	IN	O
vitro	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
39	CD	O
adults	NNS	O
with	IN	O
cystic	JJ	O
fibrosis	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
G551D-CFTR	JJ	O
allele	NN	O
to	TO	O
receive	VB	O
oral	JJ	O
VX-770	NNP	O
every	DT	O
12	CD	O
hours	NNS	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
25	CD	O
,	,	O
75	CD	O
,	,	O
or	CC	O
150	CD	O
mg	NN	O
or	CC	O
placebo	NN	O
for	IN	O
14	CD	O
days	NNS	O
(	(	O
in	IN	O
part	NN	O
1	CD	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
or	CC	O
VX-770	JJ	O
every	DT	O
12	CD	O
hours	NNS	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
150	CD	O
or	CC	O
250	CD	O
mg	NN	O
or	CC	O
placebo	NN	O
for	IN	O
28	CD	O
days	NNS	O
(	(	O
in	IN	O
part	NN	O
2	CD	O
of	IN	O
the	DT	O
study	NN	O
)	)	O
.	.	O

RESULTS	VBN	O
At	IN	O
day	NN	O
28	CD	O
,	,	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
subjects	NNS	O
who	WP	O
received	VBD	O
150	CD	O
mg	NNS	O
of	IN	O
VX-770	NNP	O
,	,	O
the	DT	O
median	JJ	O
change	NN	O
in	IN	O
the	DT	O
nasal	JJ	O
potential	JJ	O
difference	NN	O
(	(	O
in	IN	O
response	NN	O
to	TO	O
the	DT	O
administration	NN	O
of	IN	O
a	DT	O
chloride-free	JJ	O
isoproterenol	JJ	O
solution	NN	O
)	)	O
from	IN	O
baseline	NN	O
was	VBD	O
-3.5	JJ	O
mV	NN	O
(	(	O
range	NN	O
,	,	O
-8.3	NNP	O
to	TO	O
0.5	CD	O
;	:	O
P=0.02	NNP	O
for	IN	O
the	DT	O
within-subject	JJ	O
comparison	NN	O
,	,	O
P=0.13	NNP	O
vs.	FW	O
placebo	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
median	JJ	O
change	NN	O
in	IN	O
the	DT	O
level	NN	O
of	IN	O
sweat	NN	O
chloride	NN	O
was	VBD	O
-59.5	JJ	O
mmol	NN	O
per	IN	O
liter	NN	O
(	(	O
range	NN	O
,	,	O
-66.0	NN	O
to	TO	O
-19.0	VB	O
;	:	O
P=0.008	NNP	O
within-subject	NN	O
,	,	O
P=0.02	NNP	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
percent	NN	O
of	IN	O
predicted	VBN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
1	CD	O
second	NN	O
was	VBD	O
8.7	CD	O
%	NN	O
(	(	O
range	NN	O
,	,	O
2.3	CD	O
to	TO	O
31.3	CD	O
;	:	O
P=0.008	NNP	O
for	IN	O
the	DT	O
within-subject	JJ	O
comparison	NN	O
,	,	O
P=0.56	NNP	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
withdrew	VBD	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

Six	NNP	O
severe	JJ	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
in	IN	O
two	CD	O
subjects	NNS	O
(	(	O
diffuse	IN	O
macular	NN	O
rash	NN	O
in	IN	O
one	CD	O
subject	NN	O
and	CC	O
five	CD	O
incidents	NNS	O
of	IN	O
elevated	VBN	O
blood	NN	O
and	CC	O
urine	JJ	O
glucose	NN	O
levels	NNS	O
in	IN	O
one	CD	O
subject	NN	O
with	IN	O
diabetes	NNS	O
)	)	O
.	.	O

All	DT	O
severe	JJ	O
adverse	JJ	O
events	NNS	O
resolved	VBN	O
without	IN	O
the	DT	O
discontinuation	NN	O
of	IN	O
VX-770	NNP	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
adverse-event	JJ	O
profile	NN	O
of	IN	O
VX-770	NNP	O
showed	VBD	O
that	IN	O
VX-770	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
within-subject	JJ	O
improvements	NNS	O
in	IN	O
CFTR	NNP	O
and	CC	O
lung	NN	O
function	NN	O
.	.	O

These	DT	O
findings	NNS	O
provide	VBP	O
support	NN	O
for	IN	O
further	JJ	O
studies	NNS	O
of	IN	O
pharmacologic	JJ	O
potentiation	NN	O
of	IN	O
CFTR	NNP	O
as	IN	O
a	DT	O
means	NN	O
to	TO	O
treat	VB	O
cystic	JJ	O
fibrosis	NN	O
.	.	O

(	(	O
Funded	VBN	O
by	IN	O
Vertex	NNP	O
Pharmaceuticals	NNP	O
and	CC	O
others	NNS	O
;	:	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00457821	NNP	O
.	.	O

)	)	O
.	.	O

An	DT	O
open-label	JJ	O
extension	NN	O
study	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
risperidone	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
long-term	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
risperidone	NN	O
in	IN	O
treating	VBG	O
irritability	NN	O
and	CC	O
related	JJ	O
behaviors	NNS	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
6	CD	O
month	NN	O
(	(	O
26	CD	O
week	NN	O
)	)	O
open-label	NN	O
extension	NN	O
(	(	O
OLE	NNP	O
)	)	O
study	NN	O
,	,	O
patients	NNS	O
(	(	O
5-17	JJ	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
who	WP	O
completed	VBD	O
the	DT	O
previous	JJ	O
fixed-dose	JJ	O
,	,	O
6	CD	O
week	NN	O
,	,	O
double-blind	JJ	O
[	NNP	O
DB	NNP	O
]	NNP	O
phase	NN	O
)	)	O
were	VBD	O
flexibly	RB	O
dosed	VBN	O
with	IN	O
risperidone	NN	O
based	VBN	O
on	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
maximum	JJ	O
allowed	VBD	O
dose	NN	O
was	VBD	O
1.25	CD	O
mg/day	NN	O
for	IN	O
those	DT	O
weighing	VBG	O
20	CD	O
to	TO	O
<	VB	O
45	CD	O
kg	NN	O
,	,	O
and	CC	O
1.75	CD	O
mg/day	NN	O
for	IN	O
those	DT	O
weighing	VBG	O
?	.	O
45	CD	O
kg	NN	O
.	.	O

The	DT	O
study	NN	O
primarily	RB	O
assessed	VBD	O
risperidone	NN	O
's	POS	O
safety	NN	O
;	:	O
efficacy	NN	O
was	VBD	O
assessed	VBN	O
as	IN	O
a	DT	O
secondary	JJ	O
end-point	NN	O
.	.	O

RESULTS	VB	O
Fifty-six	NNP	O
(	(	O
71	CD	O
%	NN	O
)	)	O
out	IN	O
of	IN	O
79	CD	O
enrolled	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
OLE	NNP	O
;	:	O
the	DT	O
most	RBS	O
common	JJ	O
discontinuations	NNS	O
were	VBD	O
for	IN	O
insufficient	JJ	O
response	NN	O
(	(	O
7	CD	O
[	RB	O
9	CD	O
%	NN	O
]	NN	O
)	)	O
or	CC	O
adverse	JJ	O
events	NNS	O
(	(	O
AE	NNP	O
)	)	O
(	(	O
5	CD	O
[	RB	O
6	CD	O
%	NN	O
]	NN	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
(	(	O
?	.	O
5	CD	O
%	NN	O
frequency	NN	O
in	IN	O
the	DT	O
total	JJ	O
group	NN	O
)	)	O
AEs	NNP	O
were	VBD	O
increased	VBN	O
appetite	RB	O
(	(	O
11	CD	O
%	NN	O
[	JJ	O
n=9	JJ	O
]	NN	O
)	)	O
;	:	O
increased	VBN	O
weight	NN	O
and	CC	O
vomiting	NN	O
(	(	O
9	CD	O
%	NN	O
[	JJ	O
n=7	JJ	O
]	NNP	O
each	DT	O
)	)	O
;	:	O
sedation	NN	O
,	,	O
pyrexia	NN	O
,	,	O
and	CC	O
upper	JJ	O
respiratory	NN	O
tract	NN	O
infection	NN	O
(	(	O
8	CD	O
%	NN	O
[	JJ	O
n=6	JJ	O
]	NNP	O
each	DT	O
)	)	O
;	:	O
nasopharyngitis	NN	O
(	(	O
6	CD	O
%	NN	O
[	JJ	O
n=5	JJ	O
]	NN	O
)	)	O
;	:	O
and	CC	O
somnolence	NN	O
and	CC	O
fatigue	NN	O
(	(	O
5	CD	O
%	NN	O
[	JJ	O
n=4	JJ	O
]	NNP	O
each	DT	O
)	)	O
.	.	O

Extrapyramidal	JJ	O
AEs	NNP	O
were	VBD	O
reported	VBN	O
in	IN	O
6	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
patients	NNS	O
.	.	O

Increase	NNP	O
in	IN	O
mean	JJ	O
weight	NN	O
(	(	O
11-15	CD	O
%	NN	O
)	)	O
and	CC	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
5-10	CD	O
%	NN	O
)	)	O
occurred	VBD	O
;	:	O
one	CD	O
patient	NN	O
discontinued	VBN	O
because	IN	O
of	IN	O
weight	JJ	O
increase	NN	O
.	.	O

One	CD	O
potentially	RB	O
prolactin-related	JJ	O
AE	NNP	O
(	(	O
irregular	JJ	O
menstruation	NN	O
)	)	O
was	VBD	O
reported	VBN	O
.	.	O

The	DT	O
risperidone	NN	O
high-dose	JJ	O
group	NN	O
had	VBD	O
the	DT	O
greatest	JJS	O
mean	JJ	O
improvement	NN	O
in	IN	O
sleep	JJ	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
24.6	CD	O
)	)	O
.	.	O

All	DT	O
groups	NNS	O
showed	VBD	O
additional	JJ	O
improvement	NN	O
in	IN	O
efficacy	NN	O
scale	JJ	O
scores	NNS	O
during	IN	O
the	DT	O
OLE	NNP	O
.	.	O

CONCLUSIONS	NNP	O
During	IN	O
this	DT	O
OLE	NNP	O
,	,	O
safety	NN	O
findings	NNS	O
with	IN	O
risperidone	NN	O
treatment	NN	O
(	(	O
maximum	JJ	O
weight-based	JJ	O
dose	NN	O
of	IN	O
1.25	CD	O
mg/day	NN	O
or	CC	O
1.75	CD	O
mg/day	NN	O
)	)	O
were	VBD	O
consistent	JJ	O
with	IN	O
those	DT	O
observed	VBN	O
in	IN	O
the	DT	O
DB	NNP	O
phase	NN	O
,	,	O
and	CC	O
with	IN	O
the	DT	O
current	JJ	O
safety	NN	O
information	NN	O
for	IN	O
risperidone	NN	O
in	IN	O
autistic	JJ	O
,	,	O
psychiatric	JJ	O
,	,	O
and	CC	O
behavioral	JJ	O
disorders	NNS	O
.	.	O

Patients	NNS	O
experienced	VBD	O
some	DT	O
additional	JJ	O
improvement	NN	O
in	IN	O
irritability	NN	O
and	CC	O
related	JJ	O
behaviors	NNS	O
.	.	O

CLINICAL	JJ	O
TRIALS	NNP	O
REGISTRY	NNP	O
This	DT	O
phase-4	JJ	O
study	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
(	(	O
NCT00576732	NNP	O
)	)	O
.	.	O

Evaluating	VBG	O
the	DT	O
impact	NN	O
of	IN	O
peer	NN	O
,	,	O
nurse	JJ	O
case-managed	JJ	O
,	,	O
and	CC	O
standard	JJ	O
HIV	NNP	O
risk-reduction	NN	O
programs	NNS	O
on	IN	O
psychosocial	JJ	O
and	CC	O
health-promoting	JJ	O
behavioral	JJ	O
outcomes	NNS	O
among	IN	O
homeless	JJ	O
women	NNS	Sex
.	.	O

Investigators	NNS	O
examined	VBD	O
the	DT	O
6-month	JJ	O
impact	NN	O
of	IN	O
three	CD	O
cognitive-behavioral	JJ	O
HIV	NNP	O
risk-reduction	NN	O
programs	NNS	O
on	IN	O
behavioral	JJ	O
factors	NNS	O
(	(	O
substance	NN	O
use	NN	O
and	CC	O
sexual	JJ	O
risk	NN	O
behaviors	NNS	O
)	)	O
and	CC	O
cognitive	JJ	O
and	CC	O
psychological	JJ	O
resources	NNS	O
of	IN	O
325	CD	SampleSize
women	NNS	Sex
who	WP	O
resided	VBD	O
in	IN	O
emergency	NN	O
or	CC	O
sober-living	NN	O
shelters	NNS	O
and	CC	O
their	PRP$	O
308	CD	SampleSize
intimate	JJ	O
sexual	JJ	O
partners	NNS	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
by	IN	O
shelter	NN	O
to	TO	O
a	DT	O
peer-mentored	JJ	O
,	,	O
a	DT	O
nurse	JJ	O
case-managed	JJ	O
,	,	O
or	CC	O
a	DT	O
standard	JJ	O
care	NN	O
HIV	NNP	O
risk-reduction	NN	O
program	NN	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
all	DT	O
groups	NNS	O
in	IN	O
all	DT	O
behavioral	JJ	O
factors	NNS	O
and	CC	O
cognitive	JJ	O
and	CC	O
psychological	JJ	O
resources	NNS	O
except	IN	O
for	IN	O
self-esteem	NN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
peer-mentored	JJ	O
and	CC	O
nurse	JJ	O
case-managed	JJ	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
from	IN	O
the	DT	O
standard	JJ	O
group	NN	O
in	IN	O
self-esteem	NN	O
,	,	O
life	NN	O
satisfaction	NN	O
,	,	O
psychological	JJ	O
well-being	NN	O
,	,	O
use	NN	O
of	IN	O
noninjection	NN	O
drugs	NNS	O
,	,	O
sex	NN	O
with	IN	O
multiple	JJ	O
partners	NNS	O
,	,	O
and	CC	O
unprotected	JJ	O
sex	NN	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
n	JJ	O
=	NNP	O
633	CD	O
)	)	O
.	.	O

It	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
a	DT	O
standard	JJ	O
approach	NN	O
by	IN	O
health	NN	O
care	NN	O
professionals	NNS	O
appears	VBZ	O
to	TO	O
effectively	RB	O
modify	VB	O
HIV	NNP	O
risk	NN	O
behaviors	NNS	O
for	IN	O
a	DT	O
majority	NN	O
of	IN	O
homeless	JJ	Condition
participants	NNS	O
and	CC	O
may	MD	O
have	VB	O
important	JJ	O
economic	JJ	O
and	CC	O
policy	NN	O
implications	NNS	O
.	.	O

Further	NNP	O
,	,	O
the	DT	O
impact	NN	O
of	IN	O
short-term	JJ	O
programs	NNS	O
that	WDT	O
address	VBP	O
psychological	JJ	O
vulnerabilities	NNS	O
of	IN	O
impoverished	JJ	Condition
populations	NNS	O
needs	NNS	O
to	TO	O
be	VB	O
studied	VBN	O
further	JJ	O
.	.	O

Cimetidine	NNP	O
as	IN	O
an	DT	O
immunomodulator	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
herpes	NNS	O
zoster	NN	O
.	.	O

As	IN	O
there	EX	O
is	VBZ	O
evidence	NN	O
of	IN	O
a	DT	O
possible	JJ	O
immunoregulatory	JJ	O
role	NN	O
for	IN	O
H2-histamine	NNP	O
receptor	NN	O
antagonists	NNS	O
,	,	O
we	PRP	O
carried	VBD	O
out	RP	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
in	IN	O
vivo	NN	O
and	CC	O
in	IN	O
vitro	JJ	O
effect	NN	O
of	IN	O
cimetidine	NN	O
,	,	O
an	DT	O
H2-blocker	NNP	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
herpes	NNS	O
zoster	JJ	O
infection	NN	O
.	.	O

Cimetidine	NNP	O
treatment	NN	O
shortened	VBD	O
the	DT	O
median	JJ	O
interval	NN	O
until	IN	O
the	DT	O
first	JJ	O
decrease	NN	O
in	IN	O
pain	NN	O
,	,	O
the	DT	O
median	JJ	O
interval	NN	O
until	IN	O
the	DT	O
complete	JJ	O
resolution	NN	O
of	IN	O
pain	NN	O
and	CC	O
promoted	VBN	O
faster	RBR	O
complete	JJ	O
healing	NN	O
of	IN	O
skin	NN	O
lesions	NNS	O
than	IN	O
symptomatic	JJ	O
treatment	NN	O
.	.	O

The	DT	O
immunological	JJ	O
trends	NNS	O
observed	VBN	O
in	IN	O
vitro	JJ	O
support	NN	O
an	DT	O
important	JJ	O
role	NN	O
for	IN	O
histamine	NN	O
in	IN	O
the	DT	O
induction	NN	O
of	IN	O
immunosuppression	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
response	NN	O
to	TO	O
the	DT	O
mitogen	NN	O
phytohemagglutinin	NN	O
.	.	O

This	DT	O
effect	NN	O
of	IN	O
histamine	NN	O
was	VBD	O
antagonized	VBN	O
by	IN	O
cimetidine	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
a	DT	O
short	JJ	O
nurse-based	JJ	O
and	CC	O
a	DT	O
long	JJ	O
multidisciplinary	JJ	O
version	NN	O
of	IN	O
structured	JJ	O
patient	JJ	O
education	NN	O
in	IN	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
.	.	O

OBJECTIVE	CC	O
Structured	NNP	O
multidisciplinary	JJ	O
patient	NN	O
group	NN	O
education	NN	O
has	VBZ	O
positive	JJ	O
effects	NNS	O
on	IN	O
symptoms	NNS	O
,	,	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
disease-related	JJ	O
knowledge	NN	O
in	IN	O
patients	NNS	O
with	IN	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
(	(	O
IBS	NNP	O
)	)	O
,	,	O
but	CC	O
few	JJ	O
studies	NNS	O
comparing	VBG	O
different	JJ	O
forms	NNS	O
of	IN	O
educational	JJ	O
interventions	NNS	O
are	VBP	O
available	JJ	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
long	JJ	O
multidisciplinary	JJ	O
group	NN	O
education	NN	O
with	IN	O
a	DT	O
short	JJ	O
nurse-based	JJ	O
group	NN	O
education	NN	O
with	IN	O
regard	NN	O
to	TO	O
symptoms	NNS	O
,	,	O
knowledge	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
satisfaction	NN	O
with	IN	O
the	DT	O
intervention	NN	O
in	IN	O
IBS	NNP	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
IBS	NNP	O
according	VBG	O
to	TO	O
the	DT	O
Rome	NNP	O
II	NNP	O
criteria	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
short	JJ	O
nurse-based	JJ	O
or	CC	O
a	DT	O
long	JJ	O
multidisciplinary-based	JJ	O
education	NN	O
.	.	O

The	DT	O
effects	NNS	O
were	VBD	O
evaluated	VBN	O
by	IN	O
self-administered	JJ	O
questionnaires	NNS	O
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
baseline	NN	O
,	,	O
and	CC	O
compared	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
No	NNP	O
differences	NNS	O
in	IN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
in	IN	O
the	DT	O
between-group	JJ	O
comparisons	NNS	O
at	IN	O
any	DT	O
of	IN	O
the	DT	O
follow-up	JJ	O
assessments	NNS	O
.	.	O

However	RB	O
,	,	O
positive	JJ	O
effects	NNS	O
on	IN	O
symptoms	NNS	O
,	,	O
knowledge	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
satisfaction	NN	O
with	IN	O
the	DT	O
intervention	NN	O
were	VBD	O
found	VBN	O
in	IN	O
both	CC	O
the	DT	O
short	JJ	O
and	CC	O
the	DT	O
long	JJ	O
version	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
short	JJ	O
,	,	O
nurse-based	JJ	O
educational	JJ	O
intervention	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
as	RB	O
efficacious	JJ	O
as	IN	O
a	DT	O
longer	RBR	O
multidisciplinary	JJ	O
version	NN	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
positive	JJ	O
effects	NNS	O
on	IN	O
patients	NNS	O
'	POS	O
well-being	NN	O
were	VBD	O
found	VBN	O
to	TO	O
a	DT	O
similar	JJ	O
extent	NN	O
.	.	O

This	DT	O
is	VBZ	O
an	DT	O
important	JJ	O
finding	NN	O
that	IN	O
,	,	O
from	IN	O
a	DT	O
cost-effective	JJ	O
perspective	NN	O
,	,	O
could	MD	O
contribute	VB	O
toward	IN	O
an	DT	O
optimized	JJ	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
IBS	NNP	O
.	.	O

Clinical	JJ	O
performance	NN	O
of	IN	O
the	DT	O
Reichert	NNP	O
AT550	NNP	O
:	:	O
a	DT	O
new	JJ	O
non-contact	JJ	O
tonometer	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
level	NN	O
of	IN	O
accuracy	NN	O
for	IN	O
measurements	NNS	O
of	IN	O
intra-ocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
obtained	VBD	O
with	IN	O
a	DT	O
new	JJ	O
non-contact	JJ	O
tonometer	NN	O
(	(	O
NCT	NNP	O
)	)	O
the	DT	O
Reichert	NNP	O
AT550	NNP	O
.	.	O

Measurements	NNS	O
were	VBD	O
compared	VBN	O
against	IN	O
those	DT	O
obtained	VBN	O
with	IN	O
the	DT	O
Reichert	NNP	O
Xpert	NNP	O
Plus	NNP	O
,	,	O
Goldmann	NNP	O
applanation	NN	O
tonometer	NN	O
and	CC	O
Perkins	NNP	O
tonometer	NN	O
.	.	O

Thirty-five	JJ	O
university	NN	O
students	NNS	O
were	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
four	CD	O
tonometers	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
order	NN	O
,	,	O
with	IN	O
non-contact	JJ	O
tonometry	NN	O
performed	VBD	O
first	RB	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
four	CD	O
measurement	NN	O
devices	NNS	O
had	VBD	O
its	PRP$	O
own	JJ	O
trained	JJ	O
clinical	JJ	O
observer	NN	O
.	.	O

Plots	NNP	O
of	IN	O
differences	NNS	O
of	IN	O
IOP	NNP	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
mean	NN	O
for	IN	O
each	DT	O
pair	NN	O
of	IN	O
instruments	NNS	O
were	VBD	O
obtained	VBN	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
when	WRB	O
comparing	VBG	O
the	DT	O
AT550	NNP	O
NCT	NNP	O
with	IN	O
contact	JJ	O
applanation	NN	O
tonometry	NN	O
(	(	O
AT	NNP	O
)	)	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
,	,	O
displaying	VBG	O
the	DT	O
closest	JJS	O
level	NN	O
of	IN	O
agreement	NN	O
(	(	O
as	IN	O
represented	VBN	O
by	IN	O
the	DT	O
lowest	JJS	O
mean	JJ	O
difference	NN	O
and	CC	O
the	DT	O
narrowest	JJS	O
confidence	NN	O
interval	NN	O
)	)	O
with	IN	O
the	DT	O
Goldmann	NNP	O
tonometer	NN	O
(	(	O
limits	NNS	O
of	IN	O
agreement	NN	O
,	,	O
0.12+/-2.17	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
readings	NNS	O
of	IN	O
IOP	NNP	O
with	IN	O
the	DT	O
AT550	NNP	O
NCT	NNP	O
are	VBP	O
clinically	RB	O
comparable	JJ	O
with	IN	O
those	DT	O
obtained	VBN	O
with	IN	O
Goldmann	NNP	O
tonometry	NN	O
in	IN	O
a	DT	O
population	NN	O
with	IN	O
IOP	NNP	O
within	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

Qigong	JJ	O
massage	NN	O
treatment	NN	O
for	IN	O
sensory	JJ	O
and	CC	O
self-regulation	JJ	O
problems	NNS	O
in	IN	O
young	JJ	Age
children	NNS	Age
with	IN	O
autism	NN	Condition
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Autism	NN	O
is	VBZ	O
commonly	RB	O
associated	VBN	O
with	IN	O
sensory	JJ	O
and	CC	O
self-regulatory	JJ	O
disturbances	NNS	O
.	.	O

This	DT	O
article	NN	O
presents	VBZ	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
study	NN	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
5-month	JJ	O
intervention	NN	O
directed	VBD	O
toward	IN	O
improving	VBG	O
sensory	JJ	O
impairment	NN	O
,	,	O
digestion	NN	O
,	,	O
and	CC	O
sleep	NN	O
in	IN	O
46	CD	SampleSize
children	NNS	Age
with	IN	O
autism	NN	Condition
<	NNP	O
age	NN	Age
6	CD	Age
.	.	O

The	DT	O
intervention	NN	O
,	,	O
Qigong	NNP	O
Sensory	NNP	O
Training	NNP	O
(	(	O
QST	NNP	O
)	)	O
,	,	O
is	VBZ	O
a	DT	O
qigong	JJ	O
massage	NN	O
intervention	NN	O
based	VBN	O
in	IN	O
Chinese	JJ	O
medicine	NN	O
.	.	O

It	PRP	O
is	VBZ	O
two-pronged	JJ	O
:	:	O
Trainers	NNS	O
work	VBP	O
with	IN	O
children	NNS	O
directly	RB	O
20	CD	O
times	NNS	O
over	IN	O
5	CD	O
months	NNS	O
,	,	O
and	CC	O
parents	NNS	O
give	VBP	O
the	DT	O
massage	NN	O
daily	RB	O
to	TO	O
their	PRP$	O
children	NNS	O
.	.	O

Improvement	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
two	CD	O
settings	NNS	O
--	:	O
preschool	NN	O
and	CC	O
home	NN	O
--	:	O
by	IN	O
teachers	NNS	O
(	(	O
blind	IN	O
to	TO	O
group	NN	O
)	)	O
and	CC	O
parents	NNS	O
.	.	O

Teacher	CC	O
evaluations	NNS	O
showed	VBD	O
that	IN	O
treated	JJ	O
children	NNS	O
had	VBD	O
significant	JJ	O
classroom	NN	O
improvement	NN	O
of	IN	O
social	JJ	O
and	CC	O
language	NN	O
skills	NNS	O
and	CC	O
reduction	NN	O
in	IN	O
autistic	JJ	O
behavior	NN	O
compared	VBN	O
with	IN	O
wait-list	JJ	O
control	NN	O
participants	NNS	O
.	.	O

These	DT	O
findings	NNS	O
were	VBD	O
confirmed	VBN	O
by	IN	O
parent	NN	O
data	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
gains	NNS	O
had	VBD	O
generalized	VBN	O
across	IN	O
contexts	NN	O
.	.	O

A	DT	O
model	NN	O
and	CC	O
supporting	VBG	O
data	NNS	O
for	IN	O
understanding	NN	O
and	CC	O
treating	VBG	O
sensory	JJ	O
and	CC	O
self-regulation	JJ	O
problems	NNS	O
in	IN	O
autism	NN	O
is	VBZ	O
presented	VBN	O
.	.	O

Comparison	NNP	O
of	IN	O
mastectomy	NN	O
with	IN	O
tamoxifen	NN	O
for	IN	O
treating	VBG	O
elderly	JJ	Age
patients	NNS	O
with	IN	O
operable	JJ	O
breast	NN	Condition
cancer	NN	Condition
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
Comparison	NNP	O
of	IN	O
tamoxifen	NN	O
and	CC	O
mastectomy	NN	O
in	IN	O
treatment	NN	O
of	IN	O
breast	NN	Condition
cancer	NN	Condition
in	IN	O
elderly	JJ	Age
patients	NNS	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
trial	NN	O
of	IN	O
treatment	NN	O
of	IN	O
operable	JJ	O
breast	NN	O
cancer	NN	O
by	IN	O
wedge	NN	O
mastectomy	NN	O
or	CC	O
tamoxifen	NN	O
,	,	O
with	IN	O
median	JJ	O
follow	VBP	O
up	RP	O
24	CD	O
and	CC	O
25	CD	O
months	NNS	O
respectively	RB	O
(	(	O
range	VB	O
1-63	CD	O
)	)	O
.	.	O

SETTING	NN	O
University	NNP	O
hospital	NN	O
;	:	O
most	JJS	O
patients	NNS	O
from	IN	O
primary	JJ	O
catchment	JJ	O
area	NN	O
.	.	O

PATIENTS	CC	O
135	CD	SampleSize
consecutive	JJ	O
patients	NNS	O
with	IN	O
breast	JJ	Condition
cancer	NN	Condition
aged	VBD	O
over	IN	O
70	CD	Age
with	IN	O
operable	JJ	O
tumours	NNS	Condition
(	(	O
less	JJR	O
than	IN	O
5	CD	O
cm	JJ	O
maximum	JJ	O
diameter	NN	O
)	)	O
;	:	O
68	CD	O
were	VBD	O
allocated	VBN	O
to	TO	O
tamoxifen	VB	O
group	NN	O
and	CC	O
67	CD	O
to	TO	O
mastectomy	VB	O
group	NN	O
.	.	O

Histological	JJ	O
diagnosis	NN	O
by	IN	O
biopsy	NN	O
.	.	O

Two	CD	O
incorrect	JJ	O
randomisations	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Patient	NNP	O
characteristics	NNS	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
and	CC	O
all	DT	O
under	IN	O
care	NN	O
of	IN	O
one	CD	O
surgical	JJ	O
team	NN	O
.	.	O

INTERVENTIONS	NNP	O
Mastectomy	NNP	O
group	NN	O
received	VBD	O
wedge	JJ	O
mastectomy	NN	O
plus	CC	O
excision	NN	O
of	IN	O
symptomatic	JJ	O
axillary	JJ	O
lymph	NN	O
nodes	NNS	O
.	.	O

Tamoxifen	NNP	O
group	NN	O
received	VBD	O
continuous	JJ	O
treatment	NN	O
with	IN	O
tamoxifen	JJ	O
20	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
.	.	O

Patients	NNS	O
in	IN	O
tamoxifen	JJ	O
group	NN	O
received	VBD	O
wedge	WP	O
mastectomy	NN	O
if	IN	O
there	EX	O
was	VBD	O
sign	NN	O
of	IN	O
local	JJ	O
progression	NN	O
.	.	O

Those	DT	O
in	IN	O
mastectomy	JJ	O
group	NN	O
received	VBD	O
further	JJ	O
excision	NN	O
or	CC	O
radiotherapy	NN	O
for	IN	O
locoregional	JJ	O
recurrence	NN	O
and	CC	O
when	WRB	O
local	JJ	O
treatments	NNS	O
had	VBD	O
been	VBN	O
exhausted	VBN	O
or	CC	O
metastatic	JJ	O
disease	NN	O
diagnosed	VBD	O
they	PRP	O
received	VBD	O
tamoxifen	NN	O
.	.	O

END	JJ	O
POINT	NNP	O
Treatment	NNP	O
efficacy	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
local	JJ	O
control	NN	O
of	IN	O
disease	NN	O
and	CC	O
by	IN	O
survival	NN	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Mortality	NNP	O
from	IN	O
metastatic	JJ	O
cancer	NN	O
in	IN	O
tamoxifen	NN	O
group	NN	O
was	VBD	O
7	CD	O
(	(	O
10.6	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
mastectomy	JJ	O
group	NN	O
10	CD	O
(	(	O
15.3	CD	O
%	NN	O
)	)	O
(	(	O
NS	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
mastectomy	JJ	O
group	NN	O
70	CD	O
%	NN	O
remained	VBD	O
alive	JJ	O
and	CC	O
free	JJ	O
of	IN	O
local	JJ	O
recurrence	NN	O
at	IN	O
24	CD	O
months	NNS	O
;	:	O
in	IN	O
tamoxifen	NN	O
group	NN	O
only	RB	O
47	CD	O
%	NN	O
remained	VBD	O
alive	JJ	O
and	CC	O
free	JJ	O
of	IN	O
local	JJ	O
progression	NN	O
.	.	O

In	IN	O
mastectomy	JJ	O
group	NN	O
locoregional	JJ	O
recurrence	NN	O
occurred	VBD	O
in	IN	O
16	CD	O
patients	NNS	O
and	CC	O
metastatic	JJ	O
disease	NN	O
in	IN	O
13	CD	O
;	:	O
in	IN	O
tamoxifen	NN	O
group	NN	O
locoregional	JJ	O
progression	NN	O
occurred	VBD	O
in	IN	O
29	CD	O
patients	NNS	O
and	CC	O
metastatic	JJ	O
disease	NN	O
in	IN	O
seven	CD	O
.	.	O

CONCLUSIONS	NNP	O
As	IN	O
a	DT	O
high	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
tamoxifen	NNS	O
eventually	RB	O
required	VBN	O
surgery	NN	O
treatment	NN	O
of	IN	O
elderly	JJ	Age
patients	NNS	O
with	IN	O
breast	JJ	Condition
cancer	NN	Condition
should	MD	O
include	VB	O
mastectomy	NN	O
.	.	O

Optimum	NNP	O
treatment	NN	O
may	MD	O
include	VB	O
both	DT	O
mastectomy	NNS	O
and	CC	O
tamoxifen	NN	O
.	.	O

The	DT	O
prevalence	NN	O
of	IN	O
IgE	NNP	O
sensitization	NN	O
to	TO	O
formaldehyde	VB	O
in	IN	O
asthmatic	JJ	Condition
children	NNS	O
.	.	O

BACKGROUND	NNP	O
Formaldehyde	NNP	O
(	(	O
FA	NNP	O
)	)	O
is	VBZ	O
well	RB	O
documented	VBN	O
as	IN	O
a	DT	O
cause	NN	O
of	IN	O
occupational	JJ	O
asthma	NN	O
.	.	O

Recently	RB	O
,	,	O
attention	NN	O
has	VBZ	O
been	VBN	O
paid	VBN	O
to	TO	O
FA	NNP	O
as	IN	O
an	DT	O
allergen	NN	O
and	CC	O
a	DT	O
pollutant	NN	O
that	WDT	O
enhances	VBZ	O
allergic	JJ	O
sensitization	NN	O
.	.	O

We	PRP	O
have	VBP	O
investigated	VBN	O
the	DT	O
prevalence	NN	O
of	IN	O
FA-specific	NNP	O
IgE	NNP	O
in	IN	O
asthmatic	JJ	O
children	NNS	O
and	CC	O
the	DT	O
correlation	NN	O
between	IN	O
IgE	NNP	O
sensitization	NN	O
to	TO	O
FA	NNP	O
and	CC	O
the	DT	O
severity	NN	O
of	IN	O
asthma	NN	O
.	.	O

METHODS	NNP	O
One	CD	SampleSize
hundred	CD	SampleSize
and	CC	SampleSize
fifty-five	JJ	SampleSize
children	NNS	O
were	VBD	O
investigated	VBN	O
,	,	O
122	CD	SampleSize
of	IN	O
them	PRP	O
asthmatic	JJ	O
and	CC	O
33	CD	SampleSize
nonallergic	NN	O
.	.	O

Specific	JJ	O
IgE	NNP	O
against	IN	O
FA	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
CAP	NNP	O
RAST	NNP	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
patients	NNS	O
answered	VBD	O
a	DT	O
questionnaire	NN	O
,	,	O
containing	VBG	O
questions	NNS	O
on	IN	O
clinical	JJ	O
features	NNS	O
of	IN	O
their	PRP$	O
asthma	NN	O
,	,	O
their	PRP$	O
living	NN	O
conditions	NNS	O
,	,	O
and	CC	O
symptoms	NNS	O
of	IN	O
mucosal	JJ	O
irritation	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
all	PDT	O
the	DT	O
subjects	NNS	O
assessed	VBN	O
,	,	O
FA-specific	NNP	O
IgE	NNP	O
was	VBD	O
detected	VBN	O
in	IN	O
only	RB	O
two	CD	O
asthmatics	NNS	O
,	,	O
and	CC	O
their	PRP$	O
IgE	NNP	O
levels	NNS	O
of	IN	O
FA	NNP	O
were	VBD	O
low	JJ	O
(	(	O
0.42	CD	O
and	CC	O
0.46	CD	O
UA/ml	NNP	O
)	)	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
two	CD	O
patients	NNS	O
with	IN	O
FA-specific	NNP	O
IgE	NNP	O
had	VBD	O
severe	JJ	O
asthma	NN	O
and	CC	O
frequent	JJ	O
symptoms	NNS	O
of	IN	O
mucosal	JJ	O
irritation	NN	O
,	,	O
but	CC	O
the	DT	O
other	JJ	O
had	VBD	O
mild	VBN	O
asthma	NNS	O
and	CC	O
only	RB	O
rare	JJ	O
symptoms	NNS	O
of	IN	O
mucosal	JJ	O
irritation	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
prevalence	NN	O
of	IN	O
IgE	NNP	O
sensitization	NN	O
to	TO	O
FA	NNP	O
appears	VBZ	O
very	RB	O
low	JJ	O
in	IN	O
Japanese	JJ	O
children	NNS	O
,	,	O
whether	IN	O
or	CC	O
not	RB	O
they	PRP	O
have	VBP	O
asthma	VBN	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
appears	VBZ	O
likely	JJ	O
that	IN	O
FA	NNP	O
is	VBZ	O
not	RB	O
one	CD	O
of	IN	O
the	DT	O
major	JJ	O
allergens	NNS	O
causing	VBG	O
childhood	NN	O
asthma	NN	O
.	.	O

Acustimulation	NNP	O
wrist	NN	O
bands	NNS	O
are	VBP	O
not	RB	O
effective	JJ	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
chemotherapy-induced	JJ	O
nausea	NN	O
in	IN	O
women	NNS	Sex
with	IN	O
breast	NN	Condition
cancer	NN	Condition
.	.	O

This	DT	O
experiment	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
acustimulation	NN	O
wrist	NN	O
band	NN	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
chemotherapy-induced	JJ	O
nausea	NN	O
using	VBG	O
a	DT	O
randomized	JJ	O
three-arm	JJ	O
clinical	JJ	O
trial	NN	O
(	(	O
active	JJ	O
acustimulation	NN	O
,	,	O
sham	JJ	O
acustimulation	NN	O
,	,	O
and	CC	O
no	DT	O
acustimulation	NN	O
)	)	O
in	IN	O
96	CD	SampleSize
women	NNS	Sex
with	IN	O
breast	NN	Condition
cancer	NN	Condition
who	WP	O
experienced	VBD	O
nausea	NN	Condition
at	IN	Condition
their	PRP$	Condition
first	JJ	Condition
chemotherapy	NN	Condition
treatment	NN	Condition
.	.	O

Five	CD	O
outcomes	NNS	O
related	VBN	O
to	TO	O
wrist	VB	O
band	NN	O
efficacy	NN	O
(	(	O
acute	JJ	O
nausea	NN	O
,	,	O
delayed	VBN	O
nausea	NN	O
,	,	O
vomiting	VBG	O
,	,	O
QOL	NNP	O
,	,	O
and	CC	O
total	JJ	O
amount	NN	O
of	IN	O
antiemetic	JJ	O
medication	NN	O
used	VBN	O
)	)	O
were	VBD	O
examined	VBN	O
.	.	O

The	DT	O
five	CD	O
outcomes	NNS	O
were	VBD	O
examined	VBN	O
separately	RB	O
using	VBG	O
analysis	NN	O
of	IN	O
covariance	NN	O
controlling	VBG	O
for	IN	O
age	NN	O
and	CC	O
severity	NN	O
of	IN	O
past	JJ	O
nausea	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
any	DT	O
of	IN	O
these	DT	O
study	NN	O
measures	NNS	O
among	IN	O
the	DT	O
three	CD	O
treatment	NN	O
conditions	NNS	O
(	(	O
P	NNP	O
>	VBZ	O
0.1	CD	O
for	IN	O
all	DT	O
)	)	O
.	.	O

Study	NNP	O
results	NNS	O
do	VBP	O
not	RB	O
support	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
acustimulation	NN	O
bands	NNS	O
are	VBP	O
efficacious	JJ	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
pharmacological	JJ	O
antiemetics	NNS	O
for	IN	O
control	NN	O
of	IN	O
chemotherapy-related	JJ	O
nausea	NN	O
in	IN	O
female	JJ	Sex
breast	NN	Condition
cancer	NN	Condition
patients	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
hypnotherapy	NN	O
with	IN	O
systematic	JJ	O
relaxation	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cigarette	NN	O
habituation	NN	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
methodological	JJ	O
deficiencies	NNS	O
in	IN	O
this	DT	O
area	NN	O
of	IN	O
research	NN	O
,	,	O
it	PRP	O
is	VBZ	O
impossible	JJ	O
to	TO	O
make	VB	O
any	DT	O
valid	JJ	O
conclusions	NNS	O
about	IN	O
whether	IN	O
hypnosis	NN	O
itself	PRP	O
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cigarette	NN	O
habituation	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
87	CD	SampleSize
volunteers	NNS	O
who	WP	O
wanted	VBD	O
to	TO	O
quit	VB	O
cigarette	NN	Condition
smoking	NN	Condition
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
the	DT	O
experimental	JJ	O
hypnosis	NN	O
group	NN	O
,	,	O
the	DT	O
comparison	NN	O
relaxation	NN	O
group	NN	O
,	,	O
and	CC	O
the	DT	O
waiting	VBG	O
list	NN	O
control	NN	O
group	NN	O
.	.	O

Ss	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
had	VBD	O
four	CD	O
weekly	JJ	O
50-minute	NN	O
,	,	O
individual	JJ	O
sessions	NNS	O
.	.	O

Four	CD	O
months	NNS	O
after	IN	O
the	DT	O
completion	NN	O
of	IN	O
treatment	NN	O
,	,	O
Ss	NNP	O
were	VBD	O
administered	VBN	O
a	DT	O
questionnaire	NN	O
and	CC	O
a	DT	O
hypnotic	JJ	O
susceptibility	NN	O
scale	NN	O
.	.	O

Ss	NNP	O
in	IN	O
the	DT	O
hypnosis	NN	O
group	NN	O
who	WP	O
were	VBD	O
in	IN	O
the	DT	O
upper	JJ	O
two-thirds	NNS	O
of	IN	O
the	DT	O
group	NN	O
in	IN	O
terms	NNS	O
of	IN	O
hypnotic	JJ	O
susceptibility	NN	O
reduced	VBD	O
their	PRP$	O
cigarette	NN	O
consumption	NN	O
substantially	RB	O
more	JJR	O
than	IN	O
Ss	NNP	O
in	IN	O
the	DT	O
relaxation	NN	O
group	NN	O
who	WP	O
were	VBD	O
in	IN	O
the	DT	O
upper	JJ	O
two-thirds	NNS	O
of	IN	O
the	DT	O
group	NN	O
in	IN	O
terms	NNS	O
of	IN	O
hypnotic	JJ	O
susceptibility	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
hypnotic	JJ	O
state	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
therapeutic	JJ	O
for	IN	O
individuals	NNS	O
who	WP	O
can	MD	O
enter	VB	O
medium	NN	O
or	CC	O
deep	JJ	O
states	NNS	O
of	IN	O
hypnosis	NN	O
.	.	O

[	NNS	O
Randomized	NNP	O
study	NN	O
on	IN	O
the	DT	O
long-term	JJ	O
adjuvant	JJ	O
chemotherapy	NN	O
with	IN	O
ftorafur	NN	O
and	CC	O
mitomycin	NN	O
C	NNP	O
for	IN	O
stomach	NN	O
cancer	NN	O
:	:	O
second	JJ	O
report	NN	O
]	NN	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
the	DT	O
usefulness	NN	O
of	IN	O
long-term	JJ	O
adjuvant	JJ	O
chemotherapy	NN	O
,	,	O
the	DT	O
Cooperative	NNP	O
Study	NNP	O
Group	NNP	O
of	IN	O
Surgical	NNP	O
Adjuvant	NNP	O
Chemotherapy	NNP	O
for	IN	O
Gastric	NNP	O
Cancer	NNP	O
adopted	VBD	O
as	IN	O
the	DT	O
second	JJ	O
cooperative	NN	O
study	NN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
on	IN	O
three	CD	O
groups	NNS	O
;	:	O
MMC	NNP	O
alone	RB	O
,	,	O
Futraful	NNP	O
alone	RB	O
and	CC	O
a	DT	O
combination	NN	O
of	IN	O
MMC	NNP	O
and	CC	O
Futraful	NNP	O
.	.	O

In	IN	O
the	DT	O
group	NN	O
of	IN	O
Futraful	NNP	O
alone	RB	O
the	DT	O
survival	NN	O
and	CC	O
disease-free	JJ	O
rate	NN	O
were	VBD	O
improved	VBN	O
in	IN	O
three	CD	O
years	NNS	O
after	IN	O
operation	NN	O
,	,	O
especially	RB	O
marked	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
advanced	JJ	O
stage	NN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
survival	NN	O
and	CC	O
disease-free	JJ	O
rate	NN	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
the	DT	O
combination	NN	O
therapy	NN	O
were	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
Futraful	NNP	O
alone	RB	O
,	,	O
and	CC	O
the	DT	O
relapse	NN	O
rate	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
former	JJ	O
.	.	O

Therefore	RB	O
,	,	O
a	DT	O
long-term	JJ	O
combined	JJ	O
adjuvant	JJ	O
chemotherapy	NN	O
with	IN	O
MMC	NNP	O
and	CC	O
Futraful	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
effective	JJ	O
chemotherapy	NN	O
regimens	NNS	O
for	IN	O
resectable	JJ	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
nitinol	JJ	O
tipless	NN	O
stone	NN	O
baskets	NNS	O
in	IN	O
an	DT	O
in	IN	O
vitro	JJ	O
caliceal	NN	O
model	NN	O
.	.	O

PURPOSE	NNP	O
Tipless	NNP	O
stone	NN	O
baskets	NNS	O
facilitate	VBP	O
caliceal	JJ	O
calculi	JJ	O
extraction	NN	O
during	IN	O
flexible	JJ	O
ureteroscopy	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
stone	NN	O
capture	NN	O
rate	NN	O
of	IN	O
9	CD	O
commercially	RB	O
available	JJ	O
tipless	NN	O
stone	NN	O
baskets	NNS	O
in	IN	O
an	DT	O
in	IN	O
vitro	NN	O
model	NN	O
using	VBG	O
novice	NN	O
and	CC	O
expert	NN	O
operators	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
Microvasive	NNP	O
Zerotip	NNP	O
(	(	O
2.4Fr	CD	O
,	,	O
3.0Fr	CD	O
)	)	O
,	,	O
Cook	NNP	O
N-Circle	NNP	O
(	(	O
2.2Fr	CD	O
,	,	O
3.0Fr	CD	O
,	,	O
3.2Fr	CD	O
)	)	O
,	,	O
Bard	NNP	O
Dimension	NNP	O
(	(	O
3.0Fr	CD	O
,	,	O
Sacred	NNP	O
Heart	NNP	O
Medical	NNP	O
Halo	NNP	O
(	(	O
1.9Fr	CD	O
)	)	O
,	,	O
Vantage	NNP	O
(	(	O
1.9Fr	CD	O
)	)	O
and	CC	O
Circon-ACMI	JJ	O
Sur-Catch-NT	NNP	O
(	(	O
3.0Fr	CD	O
)	)	O
were	VBD	O
tested	VBN	O
by	IN	O
3	CD	O
novice	NNS	O
and	CC	O
3	CD	O
experienced	VBD	O
basket	NN	O
operators	NNS	O
.	.	O

Each	DT	O
operator	NN	O
performed	VBD	O
stone	JJ	O
extraction	NN	O
of	IN	O
2	CD	O
,	,	O
5	CD	O
and	CC	O
8	CD	O
mm	NN	O
calculi	NN	O
(	(	O
size	NN	O
determined	VBN	O
by	IN	O
digital	JJ	O
caliper	NN	O
with	IN	O
3	CD	O
repetitions	NNS	O
of	IN	O
each	DT	O
basket	NN	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
extraction	NN	O
of	IN	O
the	DT	O
calculus	NN	O
from	IN	O
a	DT	O
convex	NN	O
based	VBN	O
test	NN	O
tube	NN	O
caliceal	NN	O
model	NN	O
was	VBD	O
recorded	VBN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	O
and	CC	O
Fisher	NNP	O
's	POS	O
pairwise	NN	O
comparisons	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
a	DT	O
learning	JJ	O
curve	NN	O
of	IN	O
27	CD	O
basket	NN	O
retrievals	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
stone	NN	O
capture	NN	O
times	NNS	O
between	IN	O
novice	NN	O
(	(	O
38	CD	O
+/-	JJ	O
54	CD	O
seconds	NNS	O
)	)	O
and	CC	O
expert	JJ	O
operators	NNS	O
(	(	O
32	CD	O
+/-	JJ	O
49	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.174	CD	O
)	)	O
.	.	O

For	IN	O
total	JJ	O
stone	NN	O
capture	NN	O
(	(	O
all	DT	O
sizes	NNS	O
)	)	O
the	DT	O
Sacred	NNP	O
Heart	NNP	O
Halo	NNP	O
resulted	VBD	O
in	IN	O
the	DT	O
most	RBS	O
rapid	JJ	O
stone	NN	O
extraction	NN	O
(	(	O
17	CD	O
+/-	JJ	O
14	CD	O
seconds	NNS	O
)	)	O
by	IN	O
novices	NNS	O
and	CC	O
experts	NNS	O
,	,	O
while	IN	O
the	DT	O
Sur-Catch	NNP	O
NT	NNP	O
resulted	VBD	O
in	IN	O
the	DT	O
slowest	JJS	O
stone	NN	O
extraction	NN	O
(	(	O
78	CD	O
+/-	JJ	O
90	CD	O
,	,	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
Halo	NNP	O
(	(	O
14	CD	O
+/-	JJ	O
9	CD	O
seconds	NNS	O
)	)	O
and	CC	O
Vantage	NNP	O
(	(	O
19	CD	O
+/-	JJ	O
12	CD	O
seconds	NNS	O
)	)	O
baskets	NNS	O
were	VBD	O
significantly	RB	O
faster	JJR	O
for	IN	O
2	CD	O
mm	NNS	O
calculi	NN	O
than	IN	O
the	DT	O
N-Circle	NNP	O
(	(	O
73	CD	O
+/-	JJ	O
60	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
,	,	O
Sur-Catch	NNP	O
(	(	O
169	CD	O
+/-	JJ	O
85	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.0005	CD	O
)	)	O
and	CC	O
Dimension	NNP	O
(	(	O
73	CD	O
+/-	JJ	O
70	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.017	CD	O
)	)	O
.	.	O

The	DT	O
Zerotip	NNP	O
functioned	VBD	O
well	RB	O
for	IN	O
2	CD	O
mm	NNS	O
calculi	NN	O
in	IN	O
the	DT	O
hands	NNS	O
of	IN	O
expert	NN	O
operators	NNS	O
(	(	O
15	CD	O
+/-	JJ	O
9	CD	O
seconds	NNS	O
)	)	O
but	CC	O
not	RB	O
novice	JJ	O
operators	NNS	O
(	(	O
94	CD	O
+/-	JJ	O
95	CD	O
seconds	NNS	O
)	)	O
.	.	O

The	DT	O
Sur-Catch	JJ	O
NT	NNP	O
was	VBD	O
significantly	RB	O
slower	JJR	O
for	IN	O
2	CD	O
mm	NNS	O
calculi	NN	O
than	IN	O
the	DT	O
N-Circle	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
Dimension	NNP	O
(	(	O
p	JJ	O
=.03	NN	O
)	)	O
,	,	O
Halo	NNP	O
(	(	O
p	JJ	O
=.0005	NN	O
)	)	O
,	,	O
Vantage	NNP	O
(	(	O
p	JJ	O
=.001	NN	O
)	)	O
and	CC	O
Zerotip	NNP	O
(	(	O
p	JJ	O
=.002	NN	O
)	)	O
.	.	O

For	IN	O
5	CD	O
mm	NNS	O
calculi	VBP	O
the	DT	O
Halo	NNP	O
was	VBD	O
superior	JJ	O
(	(	O
12	CD	O
+/-	JJ	O
8	CD	O
seconds	NNS	O
)	)	O
,	,	O
while	IN	O
the	DT	O
Zerotip	NNP	O
were	VBD	O
superior	JJ	O
for	IN	O
8	CD	O
mm	NNS	O
calculi	NN	O
(	(	O
8	CD	O
+/-	JJ	O
3	CD	O
seconds	NNS	O
)	)	O
compared	VBN	O
to	TO	O
the	DT	O
N-Circle	NNP	O
(	(	O
23	CD	O
+/-	JJ	O
28	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.026	CD	O
)	)	O
,	,	O
Halo	NNP	O
(	(	O
26	CD	O
+/-	JJ	O
18	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.021	CD	O
)	)	O
and	CC	O
Vantage	NNP	O
(	(	O
23	CD	O
+/-	JJ	O
15	CD	O
seconds	NNS	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
Sacred	NNP	O
Heart	NNP	O
Halo	NNP	O
and	CC	O
Vantage	NNP	O
baskets	NNS	O
resulted	VBD	O
in	IN	O
the	DT	O
most	RBS	O
expeditious	JJ	O
stone	NN	O
extraction	NN	O
,	,	O
especially	RB	O
for	IN	O
2	CD	O
to	TO	O
5	CD	O
mm	NNS	O
calculi	VBP	O
while	IN	O
the	DT	O
Microvasive	NNP	O
Zerotip	NNP	O
was	VBD	O
optimal	JJ	O
for	IN	O
8	CD	O
mm	NN	O
calculi	NN	O
.	.	O

The	DT	O
Sur-Catch	JJ	O
NT	NNP	O
had	VBD	O
the	DT	O
slowest	JJS	O
stone	JJ	O
capture	NN	O
rate	NN	O
for	IN	O
all	DT	O
stone	NN	O
sizes	VBZ	O
.	.	O

Caliceal	NNP	O
models	NNS	O
of	IN	O
stone	NN	O
basketing	NN	O
may	MD	O
be	VB	O
useful	JJ	O
to	TO	O
train	VB	O
novice	JJ	O
urology	NN	O
residents	NNS	O
and	CC	O
nursing	NN	O
assistants	NNS	O
.	.	O

Gemcitabine	NNP	O
and	CC	O
split-dose	JJ	O
paclitaxel	NN	O
or	CC	O
docetaxel	NN	O
in	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
randomised	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
activity	NN	O
and	CC	O
toxicity	NN	O
of	IN	O
split-dose	JJ	O
paclitaxel	NN	O
or	CC	O
docetaxel	NN	O
in	IN	O
combination	NN	O
with	IN	O
gemcitabine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
(	(	O
MBC	NNP	Condition
)	)	O
who	WP	O
had	VBD	O
previously	RB	Condition
received	VBN	Condition
anthracyclines	NNS	Condition
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
210	CD	SampleSize
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
gemcitabine	NN	O
1,250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
Days	VBZ	O
1	CD	O
and	CC	O
8	CD	O
and	CC	O
paclitaxel	VB	O
175	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
as	IN	O
a	DT	O
3-h	JJ	O
infusion	NN	O
on	IN	O
Day	NNP	O
1	CD	O
(	(	O
GP1	NNP	O
)	)	O
;	:	O
gemcitabine	$	O
1,000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
Days	VBZ	O
1	CD	O
and	CC	O
8	CD	O
and	CC	O
paclitaxel	VB	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
as	IN	O
a	DT	O
1-h	JJ	O
infusion	NN	O
on	IN	O
Days	NNP	O
1	CD	O
and	CC	O
8	CD	O
(	(	O
GP2	NNP	O
)	)	O
;	:	O
gemcitabine	$	O
1,000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
Days	VBZ	O
1	CD	O
and	CC	O
8	CD	O
and	CC	O
docetaxel	VB	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
as	IN	O
a	DT	O
1-h	JJ	O
infusion	NN	O
on	IN	O
Days	NNP	O
1	CD	O
and	CC	O
8	CD	O
(	(	O
GD	NNP	O
)	)	O
.	.	O

Cycles	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
3	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
204	CD	SampleSize
patients	NNS	O
evaluable	JJ	O
for	IN	O
response	NN	O
assessment	NN	O
,	,	O
the	DT	O
response	NN	O
rates	NNS	O
were	VBD	O
48.6	CD	O
%	NN	O
for	IN	O
GP1	NNP	O
,	,	O
52.2	CD	O
%	NN	O
for	IN	O
GP2	NNP	O
,	,	O
and	CC	O
52.3	CD	O
%	NN	O
for	IN	O
GD	NNP	O
.	.	O

Median	JJ	O
response	NN	O
duration	NN	O
,	,	O
time	NN	O
to	TO	O
treatment	NN	O
failure	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
were	VBD	O
similar	JJ	O
in	IN	O
each	DT	O
arm	NN	O
.	.	O

Median	JJ	O
TTP	NNP	O
for	IN	O
GP1	NNP	O
,	,	O
GP2	NNP	O
and	CC	O
GD	NNP	O
was	VBD	O
7.5	CD	O
,	,	O
7.0	CD	O
and	CC	O
7.4	CD	O
months	NNS	O
,	,	O
respectively	RB	O
.	.	O

For	IN	O
the	DT	O
208	CD	SampleSize
patients	NNS	O
evaluable	JJ	O
for	IN	O
safety	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
grade	NN	O
3/4	CD	O
toxicity	NN	O
for	IN	O
each	DT	O
regimen	NN	O
was	VBD	O
neutropaenia	RB	O
,	,	O
with	IN	O
64	CD	O
%	NN	O
,	,	O
57	CD	O
%	NN	O
,	,	O
and	CC	O
68	CD	O
%	NN	O
for	IN	O
GP1	NNP	O
,	,	O
GP2	NNP	O
,	,	O
and	CC	O
GD	NNP	O
,	,	O
respectively	RB	O
.	.	O

Grade	VB	O
4	CD	O
neutropaenia	NN	O
,	,	O
grade	VBD	O
3/4	CD	O
anaemia	NN	O
,	,	O
febrile	JJ	O
neutropaenia	NN	O
,	,	O
and	CC	O
diarrhoea	NNS	O
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
docetaxel	NN	O
arm	NN	O
,	,	O
as	IN	O
was	VBD	O
the	DT	O
use	NN	O
of	IN	O
intravenous	JJ	O
antibiotics	NNS	O
and	CC	O
blood	NN	O
transfusions	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
study	NN	O
confirmed	VBD	O
the	DT	O
high	JJ	O
activity	NN	O
of	IN	O
gemcitabine-taxane	JJ	O
combinations	NNS	O
in	IN	O
MBC	NNP	O
.	.	O

Split-dose	JJ	O
paclitaxel	NN	O
had	VBD	O
similar	JJ	O
activity	NN	O
and	CC	O
toxicity	NN	O
to	TO	O
the	DT	O
3-weekly	JJ	O
administration	NN	O
.	.	O

The	DT	O
split-dose	JJ	O
docetaxel	NN	O
regimen	NNS	O
had	VBD	O
similar	JJ	O
activity	NN	O
to	TO	O
the	DT	O
paclitaxel	NN	O
combinations	NNS	O
though	IN	O
associated	VBN	O
with	IN	O
higher	JJR	O
toxicity	NN	O
.	.	O

Prospective	NNP	O
randomised	VBD	O
study	NN	O
of	IN	O
double	JJ	O
hemi-body	JJ	O
irradiation	NN	O
with	IN	O
and	CC	O
without	IN	O
subsequent	JJ	O
maintenance	NN	O
recombinant	NN	O
alpha	VBD	O
2b	CD	O
interferon	NN	O
on	IN	O
survival	NN	O
in	IN	O
patients	NNS	O
with	IN	O
relapsed	JJ	O
multiple	JJ	O
myeloma	NN	O
.	.	O

Immediately	RB	O
before	IN	O
first	JJ	O
hemi-body	NN	O
irradiation	NN	O
,	,	O
59	CD	SampleSize
patients	NNS	O
with	IN	O
relapsed	JJ	O
multiple	JJ	O
myeloma	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
or	CC	O
not	RB	O
to	TO	O
receive	VB	O
subsequent	JJ	O
alpha-2b	JJ	O
interferon	NN	O
maintenance	NN	O
.	.	O

13	CD	O
patients	NNS	O
(	(	O
22	CD	O
%	NN	O
)	)	O
[	VBZ	O
8	CD	O
of	IN	O
31	CD	O
(	(	O
26	CD	O
%	NN	O
)	)	O
controls	VBZ	O
,	,	O
5	CD	O
of	IN	O
28	CD	O
(	(	O
18	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
interferon	NN	O
arm	NN	O
]	NN	O
received	VBD	O
single	JJ	O
hemi-body	JJ	O
irradiation	NN	O
alone	RB	O
due	JJ	O
to	TO	O
progressive	JJ	O
disease	NN	O
and/or	JJ	O
persistent	JJ	O
cytopoenias	NN	O
following	VBG	O
the	DT	O
initial	JJ	O
procedure	NN	O
.	.	O

Mean	JJ	O
time	NN	O
between	IN	O
upper	JJ	O
and	CC	O
lower	JJR	O
hemi-body	NN	O
irradiation	NN	O
was	VBD	O
69	CD	O
days	NNS	O
(	(	O
range	VB	O
35-294	NNP	O
)	)	O
.	.	O

Of	IN	O
23	CD	O
patients	NNS	O
randomised	VBN	O
to	TO	O
receive	VB	O
interferon	NN	O
and	CC	O
completing	VBG	O
double	JJ	O
hemi-body	JJ	O
irradiation	NN	O
,	,	O
15	CD	O
(	(	O
65	CD	O
%	NN	O
)	)	O
achieved	VBD	O
peripheral	JJ	O
blood	NN	O
counts	NNS	O
adequate	VBP	O
to	TO	O
allow	VB	O
interferon	JJ	O
administration	NN	O
as	IN	O
per	IN	O
study	NN	O
criteria	NNS	O
commencing	VBG	O
at	IN	O
a	DT	O
mean	JJ	O
116	CD	O
days	NNS	O
(	(	O
61-241	JJ	O
)	)	O
from	IN	O
time	NN	O
of	IN	O
study	NN	O
entry	NN	O
.	.	O

The	DT	O
mean	JJ	O
period	NN	O
of	IN	O
interferon	NN	O
therapy	NN	O
,	,	O
starting	VBG	O
at	IN	O
a	DT	O
mean	JJ	O
65	CD	O
days	NNS	O
(	(	O
26-160	JJ	O
)	)	O
post	NN	O
second	JJ	O
hemi-body	NN	O
irradiation	NN	O
,	,	O
is	VBZ	O
16.4	CD	O
months	NNS	O
(	(	O
2-33.5	JJ	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
median	JJ	O
survival	NN	O
durations	NNS	O
(	(	O
10	CD	O
months	NNS	O
)	)	O
from	IN	O
time	NN	O
of	IN	O
initial	JJ	O
radiotherapy	NN	O
between	IN	O
control	NN	O
and	CC	O
interferon	NN	O
patients	NNS	O
.	.	O

Single-dose	JJ	O
and	CC	O
multi-dose	JJ	O
clindamycin	NN	O
therapy	NN	O
fails	VBZ	O
to	TO	O
demonstrate	VB	O
efficacy	NN	O
in	IN	O
preventing	VBG	O
infectious	JJ	O
and	CC	O
inflammatory	JJ	O
complications	NNS	O
in	IN	O
third	JJ	Condition
molar	JJ	Condition
surgery	NN	Condition
.	.	Condition

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
single-	JJ	O
and	CC	O
multi-dose	JJ	O
(	(	O
5-day	JJ	O
)	)	O
clindamycin	NN	O
therapy	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
inflammatory	JJ	O
complications	NNS	O
in	IN	O
patients	NNS	Condition
undergoing	VBG	Condition
lower	JJR	Condition
third	JJ	Condition
molar	JJ	Condition
surgical	JJ	Condition
extraction	NN	Condition
with	IN	Condition
bone	NN	Condition
removal	NN	Condition
.	.	Condition

Patients	NNS	Condition
who	WP	O
qualified	VBD	O
for	IN	O
the	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-masked	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
single	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
clindamycin	NN	O
administered	VBN	O
preoperatively	RB	O
(	(	O
single-dose	JJ	O
group	NN	O
)	)	O
;	:	O
(	(	O
2	CD	O
)	)	O
clindamycin	NN	O
administered	VBD	O
preoperatively	RB	O
with	IN	O
continued	JJ	O
therapy	NN	O
for	IN	O
5	CD	O
days	NNS	O
(	(	O
5-day	JJ	O
group	NN	O
)	)	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
a	DT	O
placebo	NN	O
group	NN	O
.	.	O

The	DT	O
following	JJ	O
parameters	NNS	O
were	VBD	O
evaluated	VBN	O
on	IN	O
the	DT	O
first	JJ	O
,	,	O
second	JJ	O
and	CC	O
seventh	JJ	O
days	NNS	O
postsurgery	NN	O
:	:	O
trismus	NN	O
,	,	O
facial	JJ	O
swelling	NN	O
,	,	O
body	NN	O
temperature	NN	O
,	,	O
lymphadenopathy	JJ	O
,	,	O
alveolar	JJ	O
osteitis	NN	O
and	CC	O
subjective	JJ	O
pain	NN	O
sensations	NNS	O
.	.	O

There	EX	Condition
were	VBD	Condition
86	CD	Condition
patients	NNS	Condition
(	(	Condition
31	CD	Condition
in	IN	Condition
the	DT	Condition
single-dose	JJ	Condition
group	NN	Condition
,	,	Condition
28	CD	Condition
in	IN	Condition
the	DT	Condition
5-day	JJ	Condition
group	NN	Condition
and	CC	Condition
27	CD	Condition
in	IN	Condition
the	DT	Condition
placebo	NN	Condition
group	NN	Condition
)	)	Condition
enrolled	VBD	Condition
in	IN	Condition
the	DT	Condition
study	NN	Condition
.	.	Condition

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
postoperative	JJ	O
inflammatory	JJ	O
complications	NNS	O
in	IN	O
patients	NNS	O
during	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
days	NNS	O
postsurgery	NN	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
variation	NN	O
in	IN	O
body	NN	O
temperature	NN	O
was	VBD	O
reported	VBN	O
on	IN	O
the	DT	O
seventh	JJ	O
day	NN	O
.	.	O

Analysis	NN	O
of	IN	O
the	DT	O
postoperative	JJ	O
analgesic	JJ	O
intake	NN	O
did	VBD	O
not	RB	O
show	VB	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
examined	VBN	O
groups	NNS	O
.	.	O

Clindamycin	NNP	O
applied	VBD	O
in	IN	O
a	DT	O
single	JJ	O
preoperative	NN	O
dose	NN	O
of	IN	O
600	CD	O
mg	NN	O
with	IN	O
or	CC	O
without	IN	O
subsequent	JJ	O
5-day	JJ	O
therapy	NN	O
does	VBZ	O
not	RB	O
demonstrate	VB	O
efficacy	NN	O
in	IN	O
prophylaxis	NN	O
for	IN	O
postoperative	JJ	O
inflammatory	NN	O
complications	NNS	O
after	IN	O
third	JJ	O
molar	JJ	O
surgery	NN	O
.	.	O

Women	NNP	Condition
's	POS	Condition
responses	NNS	Condition
to	TO	Condition
information	NN	Condition
on	IN	Condition
mammographic	JJ	Condition
breast	NN	Condition
density	NN	Condition
.	.	Condition

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
negative	JJ	O
and	CC	O
positive	JJ	O
outcomes	NNS	O
of	IN	O
providing	VBG	O
mammographic	JJ	O
breast	NN	O
density	NN	O
(	(	O
MBD	NNP	O
)	)	O
information	NN	O
to	TO	O
participants	NNS	Condition
of	IN	Condition
a	DT	Condition
screening	JJ	Condition
program	NN	Condition
.	.	Condition

A	DT	O
randomized	JJ	O
experiment	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
a	DT	O
sample	NN	O
of	IN	O
618	CD	O
women	NNS	O
50	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
MBD	NNP	O
greater	JJR	O
than	IN	O
50	CD	O
%	NN	O
of	IN	O
breast	NN	O
volume	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
reporting	VBG	O
the	DT	O
presence	NN	O
of	IN	O
MBD	NNP	O
in	IN	O
the	DT	O
screening	NN	O
mammography	NN	O
results	NNS	O
letter	NN	O
that	WDT	O
was	VBD	O
sent	VBN	O
along	IN	O
with	IN	O
an	DT	O
information	NN	O
pamphlet	NN	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
controls	NNS	O
,	,	O
more	JJR	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
described	VBD	O
the	DT	O
term	NN	O
breast	NN	O
density	NN	O
correctly	RB	O
and	CC	O
recognized	VBD	O
it	PRP	O
as	IN	O
a	DT	O
risk	NN	O
factor	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Although	IN	O
at	IN	O
the	DT	O
4-week	JJ	O
follow-up	NN	O
the	DT	O
intervention	NN	O
group	NN	O
indicated	VBD	O
that	IN	O
they	PRP	O
were	VBD	O
very	RB	O
likely	JJ	O
to	TO	O
have	VB	O
an	DT	O
annual	JJ	O
clinical	JJ	O
breast	NN	O
examination	NN	O
more	RBR	O
frequently	RB	O
than	IN	O
controls	NNS	O
,	,	O
no	DT	O
differences	NNS	O
were	VBD	O
detected	VBN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
on	IN	O
other	JJ	O
behavioural	JJ	O
or	CC	O
psychological	JJ	O
measures	NNS	O
,	,	O
although	IN	O
at	IN	O
the	DT	O
4-week	JJ	O
follow-up	JJ	O
the	DT	O
control	NN	O
group	NN	O
perceived	VBD	O
their	PRP$	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
,	,	O
relative	VBP	O
to	TO	O
other	JJ	O
women	NNS	O
their	PRP$	O
age	NN	O
,	,	O
as	IN	O
a	DT	O
lot	NN	O
lower	JJR	O
than	IN	O
did	VBD	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
a	DT	O
feasible	JJ	O
and	CC	O
non-threatening	JJ	O
way	NN	O
to	TO	O
provide	VB	O
women	NNS	O
with	IN	O
important	JJ	O
personalized	VBN	O
information	NN	O
about	IN	O
breast	NN	O
cancer	NN	O
risk	NN	O
.	.	O

[	JJ	O
Postural	NNP	O
biofeedback	NN	O
and	CC	O
locomotion	NN	O
reeducation	NN	O
in	IN	Condition
stroke	NN	Condition
patients	NNS	Condition
]	VBP	Condition
.	.	O

AIMS	NNP	O
To	TO	O
compare	VB	O
,	,	O
in	IN	O
post-acute	JJ	O
hemiparetic	JJ	O
patients	NNS	O
,	,	O
gait	NN	O
improvement	NN	O
after	IN	O
conventional	JJ	O
physical	JJ	O
therapy	NN	O
alone	RB	O
or	CC	O
with	IN	O
a	DT	O
specialised	JJ	O
balance	NN	O
retraining	VBG	O
program	NN	O
.	.	O

PATIENTS	VB	O
Twenty-six	JJ	O
patients	NNS	O
within	IN	O
3	CD	O
months	NNS	O
of	IN	O
onset	NN	O
of	IN	O
stroke	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
physical	JJ	O
therapy	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
or	CC	O
therapy	NN	O
and	CC	O
retraining	NN	O
(	(	O
experimental	JJ	O
group	NN	O
)	)	O
,	,	O
most	JJS	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
with	IN	O
left	JJ	O
hemiplegia	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
was	VBD	O
significantly	RB	O
older	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

METHOD	NNP	O
Thirteen	NNP	O
patients	NNS	O
received	VBD	O
early	JJ	O
conventional	JJ	O
therapy	NN	O
,	,	O
and	CC	O
13	CD	O
received	VBD	O
therapy	NN	O
combined	VBN	O
with	IN	O
standing	VBG	O
balance	NN	O
training	NN	O
by	IN	O
biofeedback	NN	O
(	(	O
BPM	NNP	O
Monitor	NNP	O
)	)	O
.	.	O

Clinical	JJ	O
measures	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
entry	NN	O
(	(	O
J0	NNP	O
)	)	O
,	,	O
once	RB	O
when	WRB	O
subjects	NNS	O
began	VBD	O
to	TO	O
walk	VB	O
(	(	O
JM	NNP	O
)	)	O
and	CC	O
30	CD	O
days	NNS	O
later	RB	O
(	(	O
JM	NNP	O
+	NNP	O
30	CD	O
)	)	O
.	.	O

Gait	NNP	O
spatiotemporal	JJ	O
parameters	NNS	O
were	VBD	O
collected	VBN	O
by	IN	O
use	NN	O
of	IN	O
the	DT	O
Vicon	NNP	O
system	NN	O
at	IN	O
JM	NNP	O
and	CC	O
JM	NNP	O
+	NNP	O
30	CD	O
.	.	O

RESULTS	VB	O
Whatever	IN	O
the	DT	O
method	NN	O
of	IN	O
rehabilitation	NN	O
,	,	O
the	DT	O
clinical	JJ	O
scores	NNS	O
improved	VBN	O
significantly	RB	O
between	IN	O
J0	NNP	O
and	CC	O
JM	NNP	O
+	NNP	O
30	CD	O
,	,	O
except	IN	O
for	IN	O
spasticity	NN	O
.	.	O

The	DT	O
time	NN	O
between	IN	O
stroke	NN	O
and	CC	O
the	DT	O
beginning	NN	O
of	IN	O
walking	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
both	DT	O
groups	NNS	O
.	.	O

Gait	NNP	O
velocity	NN	O
increased	VBD	O
significantly	RB	O
between	IN	O
JM	NNP	O
and	CC	O
JM	NNP	O
+	NNP	O
30	CD	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
no	DT	O
difference	NN	O
between	IN	O
groups	NNS	O
.	.	O

The	DT	O
walking	NN	O
pattern	NN	O
was	VBD	O
improved	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
paretic	JJ	O
limb	NN	O
single	JJ	O
stance	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
significantly	RB	O
improved	VBD	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
reception	NN	O
double	JJ	O
stance	NN	O
on	IN	O
the	DT	O
paretic	JJ	O
limb	NN	O
between	IN	O
JM	NNP	O
and	CC	O
JM	NNP	O
+	NNP	O
30	CD	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
groups	NNS	O
demonstrated	VBD	O
improvement	NN	O
in	IN	O
the	DT	O
rehabilitation	NN	O
unit	NN	O
.	.	O

The	DT	O
benefits	NNS	O
of	IN	O
visual	JJ	O
biofeedback	NN	O
by	IN	O
forceplate	NN	O
system	NN	O
training	VBG	O
suggest	JJ	O
particular	JJ	O
improvement	NN	O
of	IN	O
anticipation	NN	O
equilibrium	NN	O
with	IN	O
conventional	JJ	O
therapy	NN	O
.	.	O

One	CD	O
quadrant	JJ	O
sub-Tenon	NN	O
's	POS	O
capsule	NN	O
anesthesia	NN	O
in	IN	O
anterior	JJ	Condition
segment	NN	Condition
surgery	NN	Condition
.	.	O

Reports	NNS	O
of	IN	O
complications	NNS	O
associated	VBN	O
with	IN	O
local	JJ	O
anesthesia	NN	O
in	IN	O
ophthalmic	JJ	Condition
surgery	NN	Condition
have	VBP	O
increased	VBN	O
conspicuously	RB	O
in	IN	O
recent	JJ	O
years	NNS	O
.	.	O

Sub-Tenon	NNP	O
's	POS	O
capsule	NN	O
anesthesia	NN	O
for	IN	O
anterior	JJ	O
segment	NN	O
surgery	NN	O
avoids	IN	O
the	DT	O
risks	NNS	O
of	IN	O
retrobulbar	NN	O
and	CC	O
peribulbar	NN	O
injections	NNS	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
sub-Tenon	NN	O
's	POS	O
and	CC	O
retrobulbar	NN	O
anesthesia	NN	O
.	.	O

Patients	NNS	O
undergoing	VBG	O
various	JJ	O
anterior	JJ	Condition
segment	NN	Condition
surgery	NN	Condition
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
sub-Tenon	NN	O
's	POS	O
or	CC	O
retrobulbar	NN	O
anesthesia	NN	O
;	:	O
300	CD	SampleSize
were	VBD	O
operated	VBN	O
with	IN	O
1-quadrant	JJ	Condition
sub-Tenon	NN	Condition
's	POS	Condition
anesthesia	NN	Condition
(	(	Condition
1-QST	JJ	Condition
)	)	Condition
and	CC	O
the	DT	O
results	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
270	CD	SampleSize
patients	NNS	SampleSize
operated	VBN	O
with	IN	O
retrobulbar	NN	Condition
anesthesia	NN	Condition
.	.	O

Retrobulbar	NNP	O
anesthesia	NN	O
consisted	VBD	O
of	IN	O
a	DT	O
2.5	CD	O
ml	NN	O
injection	NN	O
of	IN	O
a	DT	O
1:1	CD	O
mixture	NN	O
of	IN	O
2	CD	O
%	NN	O
lidocaine	NN	O
without	IN	O
epinephrine	NN	O
and	CC	O
0.5	CD	O
%	NN	O
bupivacaine	NN	O
.	.	O

Sub-Tenon	NNP	O
's	POS	O
anesthesia	NN	O
involved	VBN	O
direct	JJ	O
transconjunctival	JJ	O
infiltration	NN	O
of	IN	O
the	DT	O
same	JJ	O
local	JJ	O
anesthetic	JJ	O
directly	RB	O
into	IN	O
the	DT	O
sub-Tenon	NN	O
's	POS	O
space	NN	O
,	,	O
in	IN	O
the	DT	O
inferior-nasal	JJ	O
quadrant	NN	O
,	,	O
using	VBG	O
a	DT	O
blunt	NN	O
23-gauge	JJ	O
cannula	NN	O
.	.	O

Patients	NNS	O
undergoing	VBG	O
various	JJ	O
anterior	JJ	Condition
segment	NN	Condition
surgery	NN	Condition
procedures	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1-QST	CD	O
or	CC	O
retrobulbar	VB	O
anesthesia	NN	O
;	:	O
300	CD	O
patients	NNS	O
were	VBD	O
operated	VBN	O
with	IN	O
1-QST	JJ	O
and	CC	O
the	DT	O
results	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
270	CD	O
patients	NNS	O
operated	VBN	O
with	IN	O
retrobulbar	NN	O
anesthesia	NN	O
.	.	O

Preinjection	NN	O
mean	NN	O
(	(	O
+/-	JJ	O
SD	NNP	O
)	)	O
IOP	NNP	O
wer	$	O
12.9	CD	O
+/-	JJ	O
3.7	CD	O
mmHg	NN	O
in	IN	O
the	DT	O
retrobulbar	NN	O
and	CC	O
13.4	CD	O
+/-	JJ	O
3.2	CD	O
mmHg	NN	O
in	IN	O
the	DT	O
1-QST	JJ	O
patients	NNS	O
.	.	O

Preoperative	JJ	O
intraocular	JJ	O
pressures	NNS	O
were	VBD	O
8.7	CD	O
+/-	JJ	O
3.0	CD	O
mmHg	NN	O
in	IN	O
the	DT	O
retrobulbar	NN	O
and	CC	O
9.2	CD	O
+/-	JJ	O
3.2	CD	O
mmHg	NN	O
in	IN	O
1-QST	JJ	O
patients	NNS	O
.	.	O

Pre-	NNP	O
and	CC	O
postinjection	NN	O
IOP	NNP	O
for	IN	O
retrobulbar	NN	O
and	CC	O
1-QST	JJ	O
patients	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

Pain	NN	O
scores	NNS	O
for	IN	O
delivery	NN	O
of	IN	O
the	DT	O
anesthetic	JJ	O
,	,	O
using	VBG	O
a	DT	O
numerical	JJ	O
rating	NN	O
scale	NN	O
,	,	O
produced	VBD	O
a	DT	O
median	JJ	O
score	NN	O
of	IN	O
1	CD	O
for	IN	O
1-QST	JJ	O
and	CC	O
2	CD	O
for	IN	O
the	DT	O
retrobulbar	NN	O
technique	NN	O
.	.	O

For	IN	O
the	DT	O
subsequent	JJ	O
operative	JJ	O
procedure	NN	O
,	,	O
the	DT	O
median	JJ	O
score	NN	O
was	VBD	O
1	CD	O
for	IN	O
1-QST	JJ	O
and	CC	O
2	CD	O
for	IN	O
the	DT	O
retrobulbar	NN	O
patients	NNS	O
.	.	O

Complete	JJ	O
akinesia	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
41	CD	O
%	NN	O
with	IN	O
1-QST	JJ	O
and	CC	O
in	IN	O
69	CD	O
%	NN	O
of	IN	O
retrobulbar	NN	O
patients	NNS	O
.	.	O

1-QST	JJ	O
patients	NNS	O
with	IN	O
incomplete	JJ	O
akinesia	NN	O
most	RBS	O
often	RB	O
had	VBD	O
lateral	JJ	O
muscle	NN	O
function	NN	O
which	WDT	O
did	VBD	O
not	RB	O
interfere	VB	O
with	IN	O
the	DT	O
operation	NN	O
.	.	O

We	PRP	O
found	VBD	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
blunt	NN	O
cannula	NN	O
to	TO	O
deliver	VB	O
anesthetic	JJ	O
into	IN	O
the	DT	O
sub-Tenon	NN	O
's	POS	O
space	NN	O
as	IN	O
a	DT	O
simple	NN	O
,	,	O
safe	JJ	O
and	CC	O
effective	JJ	O
alternative	JJ	O
approach	NN	O
to	TO	O
traditional	JJ	O
retrobulbar	NN	O
anesthesia	NN	O
in	IN	O
anterior	JJ	O
segment	NN	O
surgery	NN	O
.	.	O

Effect	NN	O
of	IN	O
topical	JJ	O
anesthesia	NN	O
and	CC	O
age	NN	O
on	IN	O
pain	NN	O
scores	NNS	O
during	IN	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
screening	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
efficacy	NN	O
of	IN	O
topical	JJ	O
anesthesia	NN	O
during	IN	O
retinopathy	NN	Condition
of	IN	Condition
prematurity	NN	Condition
(	(	O
ROP	NNP	O
)	)	O
screening	NN	O
has	VBZ	O
been	VBN	O
a	DT	O
controversial	JJ	O
issue	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
proparacaine	NN	O
eye	NN	O
drops	NNS	O
(	(	O
0.5	CD	O
%	NN	O
)	)	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
Premature	NNP	O
Infant	NNP	O
Pain	NNP	O
Profile	NNP	O
(	(	O
PIPP	NNP	O
)	)	O
scores	VBZ	O
in	IN	O
40	CD	SampleSize
preterm	JJ	O
infants	NNS	Age
undergoing	VBG	O
ROP	NNP	Condition
screening	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
randomized	VBD	O
double	JJ	O
masked	JJ	O
cross-over	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
the	DT	O
neonatal	JJ	O
intensive	JJ	O
units	NNS	O
for	IN	O
infants	NNS	O
undergoing	VBG	O
routine	JJ	O
ROP	NNP	O
screening	VBG	O
exams	NNS	O
.	.	O

Baseline	NNP	O
PIPP	NNP	O
scores	NNS	O
and	CC	O
post-examination	NN	O
PIPP	NNP	O
scores	VBZ	O
at	IN	O
1	CD	O
and	CC	O
5	CD	O
min	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
:	:	O
(	(	O
1	CD	O
)	)	O
those	DT	O
receiving	VBG	O
saline	JJ	O
vs	NN	O
proparacaine	NN	O
eye	NN	O
drops	NNS	O
(	(	O
2	CD	O
)	)	O
first	RB	O
ROP	NNP	O
screening	VBG	O
vs	JJ	O
second	JJ	O
ROP	NNP	O
screening	NN	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
type	NN	O
of	IN	O
eye	NN	O
drops	NNS	O
used	VBN	O
.	.	O

Wilcoxon	NNP	O
signed-ranks	JJ	O
test	NN	O
was	VBD	O
used	VBN	O
to	TO	O
pair	VB	O
pain	NN	O
scores	NNS	O
.	.	O

RESULT	NNP	O
Forty	NNP	O
preterm	NN	O
infants	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Mean	NNP	O
gestational	JJ	O
age	NN	O
(	(	O
GA	NNP	O
)	)	O
at	IN	O
first	JJ	O
and	CC	O
second	JJ	O
examinations	NNS	O
was	VBD	O
33.3	CD	O
and	CC	O
35.3	CD	O
weeks	NNS	O
,	,	O
respectively	RB	O
.	.	O

Proparacaine	NNP	O
use	VBP	O
significantly	RB	O
lowered	VBN	O
mean	JJ	O
PIPP	NNP	O
scores	NNS	O
(	(	O
P=0.027	NNP	O
)	)	O
and	CC	O
delta	JJ	O
scores	NNS	O
(	(	O
P=0.013	NNP	O
)	)	O
at	IN	O
1	CD	O
min	NN	O
after	IN	O
examination	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
at	IN	O
5	CD	O
min	NN	O
after	IN	O
examination	NN	O
.	.	O

Second	JJ	O
examinations	NNS	O
showed	VBD	O
significantly	RB	O
lower	JJR	O
mean	JJ	O
PIPP	NNP	O
scores	NNS	O
after	IN	O
examination	NN	O
(	(	O
1	CD	O
min	NN	O
(	(	O
P=0.003	NNP	O
)	)	O
and	CC	O
5	CD	O
min	NN	O
(	(	O
P=0.025	NNP	O
)	)	O
)	)	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
type	NN	O
of	IN	O
drop	NN	O
used	VBN	O
.	.	O

CONCLUSION	NNP	O
Proparacaine	NNP	O
eye	NN	O
drops	NNS	O
offer	VBP	O
significant	JJ	O
relief	NN	O
of	IN	O
pain	NN	O
that	WDT	O
is	VBZ	O
apparently	RB	O
short	JJ	O
lived	VBD	O
.	.	O

Significantly	NNP	O
lower	JJR	O
PIPP	NNP	O
scores	NNS	O
at	IN	O
second	JJ	O
ROP	NNP	O
examinations	NNS	O
suggested	VBD	O
that	IN	O
infants	NNS	O
of	IN	O
older	JJR	O
GA	NNP	O
may	MD	O
have	VB	O
a	DT	O
greater	JJR	O
ability	NN	O
to	TO	O
tolerate	VB	O
ROP	NNP	O
screening	VBG	O
.	.	O

We	PRP	O
recommend	VBP	O
the	DT	O
use	NN	O
of	IN	O
proparacaine	NN	O
eye	NN	O
drops	NNS	O
for	IN	O
the	DT	O
short	JJ	O
term	NN	O
,	,	O
immediate	JJ	O
relief	NN	O
of	IN	O
pain	NN	O
during	IN	O
ROP	NNP	O
screening	VBG	O
in	IN	O
preterm	JJ	O
infants	NNS	O
of	IN	O
lesser	JJR	O
GA	NNP	O
.	.	O

Amphotericin	NNP	O
versus	NN	O
pentamidine	NN	O
in	IN	O
antimony-unresponsive	JJ	Condition
kala-azar	NN	Condition
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
amphotericin	NN	O
B	NNP	O
and	CC	O
pentamidine	JJ	O
isethionate	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
trial	NN	O
in	IN	O
120	CD	SampleSize
uncomplicated	JJ	O
and	CC	O
parasitologically	RB	O
confirmed	VBN	O
cases	NNS	O
of	IN	O
antimony-unresponsive	JJ	Condition
kala-azar	NN	Condition
.	.	O

Doses	NNS	O
were	VBD	O
twenty	JJ	O
intramuscular	JJ	O
injections	NNS	O
of	IN	O
pentamidine	NN	O
4	CD	O
mg/kg	NN	O
on	IN	O
alternate	JJ	O
days	NNS	O
or	CC	O
fourteen	JJ	O
definitive	JJ	O
doses	NNS	O
of	IN	O
amphotericin	JJ	O
0.5	CD	O
mg/kg	NN	O
infused	VBN	O
in	IN	O
5	CD	O
%	NN	O
dextrose	NN	O
on	IN	O
alternate	JJ	O
days	NNS	O
.	.	O

48	CD	O
(	(	O
80	CD	O
%	NN	O
)	)	O
patients	NNS	O
given	VBN	O
pentamidine	VBP	O
showed	VBN	O
initial	JJ	O
cure	NN	O
and	CC	O
46	CD	O
(	(	O
77	CD	O
%	NN	O
)	)	O
showed	VBD	O
definitive	JJ	O
cure	NN	O
compared	VBN	O
with	IN	O
60	CD	O
(	(	O
100	CD	O
%	NN	O
)	)	O
and	CC	O
59	CD	O
(	(	O
98	CD	O
%	NN	O
)	)	O
cases	NNS	O
,	,	O
respectively	RB	O
,	,	O
on	IN	O
amphotericin	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Amphotericin	NNP	O
also	RB	O
brought	VBD	O
about	RB	O
quicker	JJR	O
abatement	NN	O
of	IN	O
fever	NN	O
and	CC	O
more	JJR	O
complete	JJ	O
spleen	JJ	O
regression	NN	O
.	.	O

Processing	VBG	O
familiar	JJ	O
and	CC	O
unfamiliar	JJ	O
auditory	NN	O
stimuli	NN	O
during	IN	O
general	JJ	Condition
anesthesia	NN	Condition
.	.	O

We	PRP	O
tested	VBD	O
memory	NN	O
priming	NN	O
for	IN	O
auditory	JJ	O
stimuli	NNS	O
presented	VBN	O
during	IN	O
general	JJ	Condition
propofol-sufentanil	JJ	Condition
anesthesia	NN	Condition
in	IN	O
58	CD	SampleSize
patients	NNS	O
undergoing	JJ	O
day-case	JJ	Condition
arthroscopic	NN	Condition
surgery	NN	Condition
.	.	O

Stimuli	NNP	O
were	VBD	O
presented	VBN	O
via	IN	O
headphones	NNS	O
and	CC	O
consisted	VBN	O
of	IN	O
common	JJ	O
facts	NNS	O
(	(	O
Group	NNP	SampleSize
A	NNP	SampleSize
,	,	SampleSize
29	CD	SampleSize
patients	NNS	O
)	)	O
,	,	O
or	CC	O
familiar	JJ	O
or	CC	O
unfamiliar	JJ	O
full	JJ	O
names	NNS	O
of	IN	O
fictitious	JJ	O
people	NNS	O
(	(	O
GRoup	NNP	SampleSize
B	NNP	SampleSize
,	,	SampleSize
29	CD	SampleSize
patients	NNS	O
)	)	O
.	.	O

Group	NNP	O
A	NNP	O
was	VBD	O
expected	VBN	O
to	TO	O
give	VB	O
more	JJR	O
correct	JJ	O
answers	NNS	O
to	TO	O
questions	NNS	O
about	IN	O
the	DT	O
common	JJ	O
facts	NNS	O
than	IN	O
Group	NNP	O
B	NNP	O
,	,	O
when	WRB	O
tested	VBN	O
postoperatively	RB	O
,	,	O
and	CC	O
Group	NNP	O
B	NNP	O
to	TO	O
attribute	VB	O
more	JJR	O
fame	NN	O
to	TO	O
presented	VBN	O
names	NNS	O
than	IN	O
Group	NNP	O
A	NNP	O
(	(	O
famous	JJ	O
names	RB	O
test	NN	O
)	)	O
.	.	O

Because	IN	O
the	DT	O
process	NN	O
for	IN	O
learning	VBG	O
new	JJ	O
or	CC	O
unfamiliar	JJ	O
stimuli	NNS	O
(	(	O
elaboration	NN	O
)	)	O
in	IN	O
particular	JJ	O
may	MD	O
be	VB	O
impaired	VBN	O
under	IN	O
general	JJ	Condition
anesthesia	NN	Condition
,	,	O
more	JJR	O
memory	NN	O
priming	NN	O
was	VBD	O
expected	VBN	O
for	IN	O
familiar	JJ	O
than	IN	O
for	IN	O
unfamiliar	JJ	O
material	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
demonstrated	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
performance	NN	O
on	IN	O
common	JJ	O
facts	NNS	O
or	CC	O
in	IN	O
fame	NN	O
attributed	VBN	O
to	TO	O
the	DT	O
names	NNS	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
memory	NN	O
priming	NN	O
,	,	O
however	RB	O
,	,	O
was	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
measures	NNS	O
of	IN	O
preoperative	JJ	O
anxiety	NN	O
.	.	O

Wheelchair	NNP	O
skills	VBZ	O
training	NN	O
to	TO	O
improve	VB	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
among	IN	O
older	JJR	Age
adults	NNS	Age
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
wheelchair	NN	O
skills	NNS	O
training	VBG	O
on	IN	O
confidence	NN	O
in	IN	O
older	JJR	Age
adults	NNS	Age
who	WP	O
are	VBP	O
inexperienced	VBN	O
wheelchair	JJ	O
users	NNS	O
.	.	O

DESIGN	NNP	O
Parallel	NNP	O
group	NN	O
,	,	O
single-blind	JJ	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Research	NNP	O
laboratory	NN	O
in	IN	O
a	DT	O
rehabilitation	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
(	(	O
N=20	NNP	SampleSize
)	)	O
who	WP	O
were	VBD	O
community-living	JJ	O
older	JJR	Age
adults	NNS	Age
at	IN	O
least	JJS	O
65	CD	Age
years	NNS	Age
old	JJ	Age
(	(	O
mean	JJ	O
age	NN	O
,	,	O
70y	CD	Age
)	)	O
,	,	O
50	CD	O
%	NN	O
women	NNS	Sex
,	,	O
and	CC	O
who	WP	O
had	VBD	O
no	DT	O
experience	NN	O
of	IN	O
using	VBG	O
a	DT	O
wheelchair	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
n=10	JJ	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n=10	JJ	O
)	)	O
group	NN	O
.	.	O

INTERVENTIONS	VBZ	O
The	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
two	CD	O
1-hour	JJ	O
training	NN	O
sessions	NNS	O
that	WDT	O
followed	VBD	O
the	DT	O
Wheelchair	NNP	O
Skills	NNP	O
Training	NNP	O
Program	NNP	O
(	(	O
WSTP	NNP	O
)	)	O
protocol	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
received	VBD	O
a	DT	O
single	JJ	O
socialization	NN	O
contact	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
Wheelchair	NNP	O
Use	NNP	O
Confidence	NNP	O
Scale-Manual	JJ	O
(	(	O
WheelCon-M	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
.	.	O

The	DT	O
WheelCon-M	NNP	O
is	VBZ	O
a	DT	O
self-report	JJ	O
questionnaire	NN	O
that	WDT	O
comprises	VBZ	O
65	CD	O
items	NNS	O
in	IN	O
6	CD	O
conceptual	JJ	O
areas	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
1-way	JJ	O
between-groups	JJ	O
analysis	NN	O
of	IN	O
covariance	NN	O
revealed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
postintervention	NN	O
WheelCon-M	JJ	O
scores	NNS	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
F1,17=10.9	NNP	O
,	,	O
P=.004	NNP	O
)	)	O
after	IN	O
controlling	VBG	O
for	IN	O
baseline	JJ	O
WheelCon-M	JJ	O
scores	NNS	O
.	.	O

A	DT	O
large	JJ	O
effect	NN	O
size	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
(	(	O
partial	JJ	O
?	.	O
(	(	O
2	CD	O
)	)	O
=.39	NN	O
)	)	O
.	.	O

Secondary	JJ	O
analyses	NNS	O
revealed	VBD	O
that	IN	O
the	DT	O
WSTP	NNP	O
had	VBD	O
greater	JJR	O
effects	NNS	O
on	IN	O
confidence	NN	O
in	IN	O
areas	NNS	O
related	VBN	O
to	TO	O
maneuvering	VBG	O
around	IN	O
the	DT	O
physical	JJ	O
environment	NN	O
,	,	O
knowledge	NN	O
and	CC	O
problem	NN	O
solving	NN	O
,	,	O
advocacy	NN	O
,	,	O
and	CC	O
managing	VBG	O
emotions	NNS	O
than	IN	O
in	IN	O
areas	NNS	O
related	VBN	O
to	TO	O
performing	VBG	O
activities	NNS	O
and	CC	O
behaving	VBG	O
in	IN	O
social	JJ	O
situations	NNS	O
.	.	O

CONCLUSION	NNP	O
Two	CD	O
1-hour	JJ	O
WSTP	NNP	O
sessions	NNS	O
improve	VBP	O
confidence	NN	O
with	IN	O
using	VBG	O
a	DT	O
manual	JJ	O
wheelchair	NN	O
among	IN	O
older	JJR	O
adults	NNS	O
who	WP	O
are	VBP	O
inexperienced	VBN	O
wheelchair	JJ	O
users	NNS	O
.	.	O

A	DT	O
randomized	VBN	O
study	NN	O
comparing	VBG	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Ligaclip	NNP	O
with	IN	O
bipolar	JJ	O
energy	NN	O
to	TO	O
prevent	VB	O
lymphocele	NN	O
during	IN	O
laparoscopic	JJ	Condition
pelvic	JJ	Condition
lymphadenectomy	NN	Condition
for	IN	Condition
gynecologic	JJ	Condition
cancer	NN	Condition
.	.	Condition

OBJECTIVE	CC	O
This	DT	O
prospective	JJ	O
randomized	NN	O
pilot	NN	O
study	NN	O
compared	VBN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Ligaclip	NNP	O
(	(	O
Ethicon	NNP	O
Endo-Surgery	NNP	O
,	,	O
Cincinnati	NNP	O
,	,	O
OH	NNP	O
)	)	O
with	IN	O
bipolar	JJ	O
coagulation	NN	O
in	IN	O
preventing	VBG	O
lymphoceles	NNS	O
after	IN	O
laparoscopic	NN	O
pelvic	JJ	O
lymphadenectomy	NN	O
for	IN	O
gynecologic	JJ	O
cancer	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Thirty	NNP	O
patients	NNS	O
with	IN	O
gynecologic	JJ	O
malignancy	NN	O
,	,	O
who	WP	O
had	VBD	O
laparoscopic	VBN	O
pelvic	JJ	O
lymphadenectomy	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
for	IN	O
lymphadenectomy	NN	O
in	IN	O
1	CD	O
side	NN	O
of	IN	O
the	DT	O
pelvis	NN	O
using	VBG	O
the	DT	O
Ligaclip	NNP	O
,	,	O
whereas	RB	O
,	,	O
in	IN	O
the	DT	O
other	JJ	O
side	NN	O
,	,	O
the	DT	O
bipolar	JJ	O
coagulation	NN	O
to	TO	O
seal	VB	O
lymphatic	JJ	O
vessels	NNS	O
was	VBD	O
used	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
ultrasound	JJ	O
examination	NN	O
,	,	O
we	PRP	O
detected	VBD	O
lymphocele	NNS	O
in	IN	O
10	CD	O
patients	NNS	O
(	(	O
33	CD	O
%	NN	O
)	)	O
.	.	O

Lymphocele	NNP	O
developed	VBD	O
in	IN	O
9	CD	O
(	(	O
30	CD	O
%	NN	O
)	)	O
patients	NNS	O
on	IN	O
the	DT	O
side	NN	O
where	WRB	O
laparoscopic	NN	O
pelvic	JJ	O
lymphadenectomy	NN	O
was	VBD	O
perfomed	VBN	O
using	VBG	O
bipolar	JJ	O
coagulation	NN	O
,	,	O
and	CC	O
in	IN	O
1	CD	O
(	(	O
3.3	CD	O
%	NN	O
)	)	O
patient	NN	O
on	IN	O
the	DT	O
side	NN	O
where	WRB	O
laparoscopic	NN	O
pelvic	JJ	O
lymphadenectomy	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
Ligaclip	NNP	O
.	.	O

Univariate	NNP	O
analysis	NN	O
revealed	VBD	O
that	IN	O
the	DT	O
Ligaclip	NNP	O
's	POS	O
use	NN	O
compared	VBN	O
with	IN	O
electrocoagulation	NN	O
in	IN	O
the	DT	O
laparoscopic	NN	O
pelvic	JJ	O
lymphadenectomy	NN	O
is	VBZ	O
an	DT	O
independent	JJ	O
predictive	JJ	O
factor	NN	O
for	IN	O
development	NN	O
of	IN	O
lymphocele	NN	O
(	(	O
P	NNP	O
=	NNP	O
.006	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
This	DT	O
study	NN	O
demonstrates	VBZ	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Ligaclip	NNP	O
to	TO	O
close	VB	O
lymphatic	JJ	O
vessels	NNS	O
may	MD	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
lymphoceles	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
pelvic	JJ	O
lymphadenectomy	NN	O
.	.	O

Effect	NN	O
of	IN	O
L-ornithine-L-aspartate	NNP	O
on	IN	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
TIPS	NNP	O
undergoing	VBG	O
glutamine	JJ	O
challenge	NN	O
:	:	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
An	DT	O
oral	JJ	O
glutamine	NN	O
load	NN	O
in	IN	O
cirrhotic	JJ	O
patients	NNS	O
awaiting	VBG	O
liver	JJ	O
transplantation	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
cause	VB	O
a	DT	O
rise	NN	O
in	IN	O
blood	NN	O
ammonia	NN	O
and	CC	O
psychometric	NN	O
abnormalities	NNS	O
which	WDT	O
were	VBD	O
reversed	VBN	O
by	IN	O
hepatic	JJ	O
transplantation	NN	O
.	.	O

L-Ornithine-L-aspartate	NNP	O
(	(	O
LOLA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
ammonia	NN	O
and	CC	O
improve	VB	O
psychometric	JJ	O
function	NN	O
in	IN	O
patients	NNS	Condition
with	IN	Condition
hepatic	JJ	Condition
encephalopathy	NN	Condition
.	.	Condition

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
LOLA	NNP	O
in	IN	O
healthy	JJ	O
patients	NNS	O
with	IN	O
cirrhosis	NN	O
and	CC	O
no	DT	O
evidence	NN	O
of	IN	O
clinical	JJ	O
encephalopathy	NN	O
after	IN	O
challenging	VBG	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
by	IN	O
administration	NN	O
of	IN	O
oral	JJ	O
glutamine	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Eight	NNP	O
cirrhotics	NNS	O
(	(	O
Child	NNP	O
's	POS	O
B	NNP	O
or	CC	O
C	NNP	O
)	)	O
without	IN	O
transjugular	JJ	O
intrahepatic	JJ	O
portosystemic	JJ	O
shunts	NNS	O
(	(	O
TIPS	NNP	O
)	)	O
and	CC	O
seven	CD	O
with	IN	O
TIPS	NNP	O
underwent	JJ	O
two	CD	O
oral	JJ	O
glutamine	NN	O
(	(	O
20	CD	O
g	NN	O
)	)	O
challenges	VBZ	O
,	,	O
receiving	VBG	O
LOLA	NNP	O
(	(	O
5	CD	O
g	RB	O
intravenously	RB	O
)	)	O
on	IN	O
one	CD	O
occasion	NN	O
and	CC	O
placebo	NN	O
on	IN	O
the	DT	O
other	JJ	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Psychometric	JJ	O
tests	NNS	O
,	,	O
including	VBG	O
choice	NN	O
reaction	NN	O
time	NN	O
(	(	O
CRT	NNP	O
)	)	O
and	CC	O
number	NN	O
connection	NN	O
test	NN	O
,	,	O
were	VBD	O
performed	VBN	O
before	IN	O
and	CC	O
after	IN	O
glutamine	NN	O
,	,	O
together	RB	O
with	IN	O
electroencephalography	NN	O
and	CC	O
blood	NN	O
ammonia	NN	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
basal	NN	O
ammonia	NN	O
was	VBD	O
27	CD	O
(	(	O
SEM	NNP	O
5	CD	O
)	)	O
micromol/l	NN	O
in	IN	O
non-TIPS	JJ	O
and	CC	O
76	CD	O
(	(	O
10	CD	O
)	)	O
micromol/l	NN	O
in	IN	O
TIPS	NNP	O
patients	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Basal	NNP	O
CRT	NNP	O
2	CD	O
was	VBD	O
0.643	CD	O
(	(	O
0.033	CD	O
)	)	O
s	NN	O
in	IN	O
non-TIPS	JJ	O
and	CC	O
0.825	CD	O
(	(	O
0.076	CD	O
)	)	O
s	NN	O
in	IN	O
TIPS	NNP	O
patients	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.02	CD	O
)	)	O
.	.	O

In	IN	O
non-TIPS	JJ	O
patients	NNS	O
,	,	O
ammonia	NNS	O
increased	VBD	O
to	TO	O
36	CD	O
(	(	O
10	CD	O
)	)	O
micromol/l	NN	O
when	WRB	O
LOLA	NNP	O
was	VBD	O
administered	VBN	O
and	CC	O
to	TO	O
62	CD	O
(	(	O
13	CD	O
)	)	O
micromol/l	NN	O
with	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
alteration	NN	O
in	IN	O
psychometric	JJ	O
function	NN	O
in	IN	O
non-TIPS	JJ	O
patients	NNS	O
after	IN	O
glutamine	NN	O
when	WRB	O
LOLA	NNP	O
was	VBD	O
given	VBN	O
but	CC	O
when	WRB	O
placebo	NN	O
was	VBD	O
given	VBN	O
,	,	O
glutamine	NN	O
caused	VBN	O
prolongation	NN	O
of	IN	O
CRT	NNP	O
(	(	O
p=0.02	NN	O
)	)	O
.	.	O

Glutamine	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
psychometric	JJ	O
function	NN	O
in	IN	O
TIPS	NNP	O
patients	NNS	O
with	IN	O
or	CC	O
without	IN	O
LOLA	NNP	O
.	.	O

CONCLUSION	NNP	O
This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
LOLA	NNP	O
ameliorated	VBD	O
the	DT	O
deleterious	JJ	O
psychometric	JJ	O
effects	NNS	O
of	IN	O
glutamine	NN	O
in	IN	O
Child	NNP	O
's	POS	O
grade	NN	O
B	NNP	O
and	CC	O
C	NNP	O
patients	NNS	O
with	IN	O
cirrhosis	NN	O
without	IN	O
TIPS	NNP	O
and	CC	O
supports	VBZ	O
its	PRP$	O
use	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
in	IN	O
hepatic	JJ	O
encephalopathy	NN	O
.	.	O

Are	NNP	O
PRO	NNP	O
discharge	NN	O
screens	NNS	O
associated	VBN	O
with	IN	O
postdischarge	NN	O
adverse	JJ	O
outcomes	NNS	O
?	.	O
OBJECTIVE	IN	O
We	PRP	O
evaluate	VBP	O
whether	IN	O
patient	JJ	O
outcomes	NNS	O
may	MD	O
be	VB	O
affected	VBN	O
by	IN	O
possible	JJ	O
errors	NNS	O
in	IN	O
care	NN	O
at	IN	O
discharge	NN	O
as	IN	O
assessed	VBN	O
by	IN	O
Peer	NNP	O
Review	NNP	O
Organizations	NNP	O
(	(	O
PROs	NNP	O
)	)	O
.	.	O

DATA	NNP	O
SOURCES/STUDY	NNP	O
SETTING	NNP	O
The	DT	O
three	CD	O
data	NNS	O
sources	NNS	O
for	IN	O
the	DT	O
study	NN	O
were	VBD	O
(	(	O
1	CD	O
)	)	O
the	DT	O
generic	JJ	O
screen	NN	O
results	NNS	O
of	IN	O
a	DT	O
3	CD	O
percent	NN	O
random	JJ	O
sample	NN	O
of	IN	O
Medicare	NNP	O
beneficiaries	NNS	O
age	NN	O
65	CD	O
years	NNS	O
or	CC	O
older	JJR	O
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
California	NNP	O
hospitals	NNS	O
between	IN	O
1	CD	O
July	NNP	O
1987	CD	O
and	CC	O
30	CD	O
June	NNP	O
1988	CD	O
(	(	O
n	JJ	O
=	$	O
20,136	CD	O
patients	NNS	O
)	)	O
;	:	O
(	(	O
2	CD	O
)	)	O
the	DT	O
1987	CD	O
and	CC	O
1988	CD	O
California	NNP	O
Medicare	NNP	O
Provided	VBD	O
Analysis	NNP	O
and	CC	O
Review	NNP	O
(	(	O
MEDPAR	NNP	O
)	)	O
data	NN	O
files	NNS	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
the	DT	O
American	NNP	O
Hospital	NNP	O
Association	NNP	O
(	(	O
AHA	NNP	O
)	)	O
1988	CD	O
Annual	NNP	O
Survey	NNP	O
of	IN	O
Hospitals	NNP	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Multivariate	NNP	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
association	NN	O
between	IN	O
the	DT	O
results	NNS	O
of	IN	O
generic	JJ	O
discharge	NN	O
administered	VBN	O
by	IN	O
the	DT	O
PROs	NNP	O
and	CC	O
two	CD	O
patient	JJ	O
outcomes	NNS	O
:	:	O
mortality	NN	O
and	CC	O
readmission	NN	O
within	IN	O
30	CD	O
days	NNS	O
.	.	O

The	DT	O
analysis	NN	O
was	VBD	O
adjusted	VBN	O
for	IN	O
other	JJ	O
patient	JJ	O
characteristics	NNS	O
recorded	VBN	O
on	IN	O
the	DT	O
uniform	JJ	O
discharge	NN	O
abstract	NN	O
.	.	O

PRINCIPAL	NNP	O
FINDINGS	NNP	O
Four	NNP	O
discharge	NN	O
screens	NNS	O
indicated	VBD	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
an	DT	O
adverse	JJ	O
outcome-absence	NN	O
of	IN	O
documentation	NN	O
of	IN	O
discharge	NN	O
planning	NN	O
,	,	O
elevated	JJ	O
temperature	NN	O
,	,	O
abnormal	JJ	O
pulse	NN	O
,	,	O
and	CC	O
unaddressed	JJ	O
abnormal	JJ	O
test	NN	O
results	NNS	O
at	IN	O
discharge	NN	O
.	.	O

The	DT	O
other	JJ	O
three	CD	O
discharge	NN	O
screens	NNS	O
examined-abnormal	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
IV	NNP	O
fluids	NNS	O
or	CC	O
drugs	NNS	O
,	,	O
and	CC	O
wound	JJ	O
drainage	NN	O
before	IN	O
discharge-were	JJ	O
unrelated	JJ	O
to	TO	O
postdischarge	VB	O
adverse	JJ	O
outcomes	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Generic	NNP	O
discharge	NN	O
screens	NNS	O
based	VBN	O
on	IN	O
inadequate	JJ	O
discharge	NN	O
planning	NN	O
,	,	O
abnormal	JJ	O
pulse	NN	O
,	,	O
increased	JJ	O
temperature	NN	O
,	,	O
or	CC	O
unaddressed	JJ	O
abnormal	JJ	O
tests	NNS	O
may	MD	O
be	VB	O
important	JJ	O
indicators	NNS	O
of	IN	O
substandard	NN	O
care	NN	O
.	.	O

Other	JJ	O
discharge	NN	O
screens	NNS	O
apparently	RB	O
do	VBP	O
not	RB	O
detect	VB	O
errors	NNS	O
in	IN	O
care	NN	O
associated	VBN	O
with	IN	O
major	JJ	O
consequences	NNS	O
for	IN	O
patients	NNS	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
nefazodone	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
hospitalized	VBN	O
for	IN	O
major	JJ	Condition
depression	NN	Condition
.	.	O

BACKGROUND	IN	O
There	EX	O
are	VBP	O
few	JJ	O
published	VBN	O
placebo-controlled	JJ	O
clinical	JJ	O
trials	NNS	O
demonstrating	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
newer	NN	O
antidepressants	NNS	O
in	IN	O
markedly	RB	O
or	CC	O
severely	RB	Condition
depressed	JJ	Condition
hospitalized	JJ	O
patients	NNS	O
.	.	O

This	DT	O
study	NN	O
demonstrates	VBZ	O
the	DT	O
efficacy	NN	O
of	IN	O
nefazodone	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
hospitalized	VBN	O
for	IN	O
major	JJ	Condition
depression	NN	Condition
.	.	O

METHOD	NNP	O
Nefazodone	NNP	O
and	CC	O
placebo	VB	O
treatment	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
6-week	JJ	O
trial	NN	O
of	IN	O
120	CD	SampleSize
patients	NNS	O
hospitalized	VBN	O
for	IN	O
DSM-III-R	NNP	O
diagnosed	VBD	O
major	JJ	O
depression	NN	O
(	(	O
without	IN	O
psychosis	NN	Condition
)	)	O
at	IN	O
2	CD	O
study	NN	O
centers	NNS	O
.	.	O

Efficacy	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
standard	JJ	O
psychiatric	NN	O
rating	NN	O
scales	NNS	O
,	,	O
and	CC	O
patients	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
safety	NN	O
.	.	O

RESULTS	NNP	O
Nefazodone	NNP	O
treatment	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
(	(	O
p	JJ	O
<	NNP	O
.01	NNP	O
)	)	O
of	IN	O
the	DT	O
17-item	JJ	O
Hamilton	NNP	O
Rating	NNP	O
Scale	NNP	O
for	IN	O
Depression	NNP	O
(	(	O
HAM-D-17	NNP	O
)	)	O
total	NN	O
score	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
first	JJ	O
treatment	NN	O
week	NN	O
through	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
-12.2	NNP	O
nefazodone	RB	O
vs.	FW	O
-7.7	NNP	O
placebo	NN	O
)	)	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
trial	NN	O
,	,	O
significantly	RB	O
more	RBR	O
nefazodone-treated	JJ	O
patients	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
than	IN	O
placebo-treated	JJ	O
patients	NNS	O
(	(	O
29	CD	O
%	NN	O
)	)	O
had	VBD	O
responded	VBN	O
,	,	O
as	IN	O
indicated	VBN	O
by	IN	O
their	PRP$	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NN	O
score	NN	O
(	(	O
p	JJ	O
=	NNP	O
.021	NNP	O
)	)	O
or	CC	O
by	IN	O
a	DT	O
>	NN	O
or	CC	O
=	VB	O
50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
their	PRP$	O
HAM-D-17	JJ	O
scores	NNS	O
(	(	O
p	VB	O
=	NNP	O
.017	NNP	O
)	)	O
.	.	O

Significantly	RB	O
more	RBR	O
patients	NNS	O
treated	VBN	O
with	IN	O
nefazodone	NN	O
(	(	O
36	CD	O
%	NN	O
)	)	O
than	IN	O
placebo-treated	JJ	O
patients	NNS	O
(	(	O
14	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
HAM-D-17	NNP	O
score	NN	O
<	NN	O
or	CC	O
=	VB	O
10	CD	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
p	JJ	O
=	NNP	O
.004	NNP	O
)	)	O
.	.	O

Significant	JJ	O
treatment	NN	O
differences	NNS	O
(	(	O
p	JJ	O
<	NNP	O
.01	NNP	O
)	)	O
in	IN	O
favor	NN	O
of	IN	O
nefazodone	NN	O
were	VBD	O
also	RB	O
seen	VBN	O
in	IN	O
the	DT	O
Montgomery-Asberg	NNP	O
Depression	NNP	O
Rating	NNP	O
Scale	NNP	O
;	:	O
the	DT	O
HAM-D	NNP	O
retardation	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
sleep	JJ	O
disturbance	NN	O
factors	NNS	O
;	:	O
and	CC	O
HAM-D	NNP	O
item	NN	O
1	CD	O
(	(	O
depressed	JJ	O
mood	NN	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
dysthymia	NN	Condition
in	IN	O
addition	NN	O
to	TO	O
major	JJ	Condition
depression	NN	Condition
also	RB	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
(	(	O
p	JJ	O
<	NNP	O
.05	NNP	O
)	)	O
when	WRB	O
treated	VBN	O
with	IN	O
nefazodone	NN	O
,	,	O
with	IN	O
significant	JJ	O
differences	NNS	O
in	IN	O
response	NN	O
rates	NNS	O
seen	VBN	O
as	RB	O
early	RB	O
as	IN	O
week	NN	O
2	CD	O
and	CC	O
through	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

The	DT	O
mean	JJ	O
nefazodone	NN	O
dose	NN	O
was	VBD	O
491	CD	O
mg/day	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
week	NN	O
2	CD	O
and	CC	O
503	CD	O
mg/day	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

Nefazodone	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
discontinuing	VBG	O
owing	VBG	O
to	TO	O
adverse	JJ	O
events	NNS	O
was	VBD	O
small	JJ	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
safety	NN	O
issues	NNS	O
noted	VBN	O
in	IN	O
either	DT	O
treatment	NN	O
group	NN	O
.	.	O

Fewer	JJR	O
nefazodone-treated	JJ	O
than	IN	O
placebo-treated	JJ	O
patients	NNS	O
discontinued	VBN	O
owing	VBG	O
to	TO	O
lack	VB	O
of	IN	O
efficacy	NN	O
.	.	O

CONCLUSION	NNP	O
Nefazodone	NNP	O
was	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
marked	VBN	O
to	TO	O
severe	VB	O
major	JJ	Condition
depression	NN	Condition
in	IN	O
patients	NNS	O
requiring	VBG	O
hospitalization	NN	O
.	.	O

The	DT	O
clinical	JJ	O
benefit	NN	O
of	IN	O
nefazodone	NN	O
was	VBD	O
evident	JJ	O
as	RB	O
early	RB	O
as	IN	O
the	DT	O
first	JJ	O
week	NN	O
of	IN	O
treatment	NN	O
as	IN	O
judged	VBN	O
by	IN	O
several	JJ	O
measures	NNS	O
of	IN	O
efficacy	NN	O
,	,	O
with	IN	O
significant	JJ	O
differences	NNS	O
from	IN	O
placebo	NN	O
sustained	VBN	O
throughout	IN	O
the	DT	O
trial	NN	O
.	.	O

Effect	NN	O
of	IN	O
aldose	JJ	O
reductase	NN	O
inhibition	NN	O
on	IN	O
cardiovascular	JJ	O
reflex	NN	O
tests	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
definite	JJ	Condition
diabetic	JJ	Condition
autonomic	JJ	Condition
neuropathy	NN	Condition
over	IN	Condition
a	DT	Condition
period	NN	Condition
of	IN	Condition
2	CD	Condition
years	NNS	Condition
.	.	O

The	DT	O
potential	NN	O
of	IN	O
the	DT	O
aldose	JJ	O
reductase	NN	O
inhibitor	NN	O
tolrestat	NN	O
to	TO	O
ameliorate	VB	O
definite	JJ	O
diabetic	JJ	O
autonomic	NN	O
neuropathy	NN	O
(	(	O
DAN	NNP	O
)	)	O
,	,	O
as	IN	O
defined	VBN	O
by	IN	O
standard	JJ	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
tests	NNS	O
,	,	O
was	VBD	O
evaluated	VBN	O
in	IN	O
35	CD	SampleSize
patients	NNS	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
2	CD	O
years	NNS	O
,	,	O
with	IN	O
repeated	VBN	O
measurements	NNS	O
at	IN	O
3-month	JJ	O
intervals	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
tolrestat	NN	O
(	(	O
200	CD	O
mg	NN	O
a	DT	O
day	NN	O
)	)	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
placebo	NN	O
on	IN	O
35	CD	SampleSize
controls	NNS	Condition
with	IN	Condition
diabetes	NNS	Condition
mellitus	NNS	Condition
,	,	Condition
of	IN	Condition
similar	JJ	Condition
age	NN	Condition
,	,	Condition
gender	NN	Condition
,	,	Condition
and	CC	Condition
glycemic	JJ	Condition
control	NN	Condition
.	.	Condition

In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
a	DT	O
significant	JJ	O
deterioration	NN	O
of	IN	O
the	DT	O
indices	NNS	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
Valsalva	NNP	O
ratio	NN	O
,	,	O
was	VBD	O
recorded	VBN	O
,	,	O
while	IN	O
tolrestat	NN	O
induced	VBD	O
a	DT	O
significant	JJ	O
beneficial	JJ	O
change	NN	O
in	IN	O
the	DT	O
values	NNS	O
of	IN	O
most	JJS	O
standard	JJ	O
cardiovascular	JJ	O
reflex	NN	O
tests	NNS	O
,	,	O
in	IN	O
comparison	NN	O
to	TO	O
baseline	VB	O
and	CC	O
placebo	VB	O
.	.	O

The	DT	O
deep	JJ	O
breathing	NN	O
tests	NNS	O
(	(	O
expiration-inspiration	NN	O
ratio	NN	O
,	,	O
standard	JJ	O
deviation	NN	O
,	,	O
and	CC	O
mean	VB	O
circular	JJ	O
resultant	NN	O
of	IN	O
R-R	NNP	O
intervals	NNS	O
)	)	O
,	,	O
postural	JJ	O
index	NN	O
,	,	O
and	CC	O
postural	JJ	O
hypotension	NN	O
were	VBD	O
favorably	RB	O
affected	VBN	O
.	.	O

Three	CD	O
of	IN	O
35	CD	O
patients	NNS	O
on	IN	O
tolrestat	NN	O
(	(	O
8.6	CD	O
%	NN	O
)	)	O
developed	VBD	O
high	JJ	O
transaminases	NNS	O
levels	NNS	O
(	(	O
more	JJR	O
than	IN	O
threefold	VB	O
the	DT	O
upper	JJ	O
normal	JJ	O
limit	NN	O
)	)	O
and	CC	O
were	VBD	O
withdrawn	VBN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
tolrestat	NN	O
improved	VBD	O
autonomic	RB	O
nervous	JJ	O
system	NN	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
definite	JJ	O
DAN	NNP	O
,	,	O
in	IN	O
comparison	NN	O
to	TO	O
baseline	VB	O
and	CC	O
placebo	VB	O
.	.	O

The	DT	O
clinical	JJ	O
importance	NN	O
of	IN	O
this	DT	O
finding	NN	O
needs	VBZ	O
further	JJ	O
investigation	NN	O
.	.	O

Direct	JJ	O
and	CC	O
indirect	JJ	O
effects	NNS	O
of	IN	O
interdental	JJ	O
hygiene	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

Many	JJ	O
randomized	VBD	O
controlled	JJ	O
trials	NNS	O
(	(	O
RCTs	NNP	O
)	)	O
in	IN	O
dental	JJ	O
research	NN	O
test	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
interventions	NNS	O
on	IN	O
more	JJR	O
than	IN	O
one	CD	O
outcome	NN	O
variable	NN	O
.	.	O

Univariate	NNP	O
methods	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
t	JJ	O
test	NN	O
or	CC	O
analysis	NN	O
of	IN	O
covariance	NN	O
,	,	O
can	MD	O
not	RB	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
interventions	NNS	O
on	IN	O
multiple	JJ	O
outcomes	NNS	O
simultaneously	RB	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
use	VB	O
structural	JJ	O
equation	NN	O
modeling	NN	O
(	(	O
SEM	NNP	O
)	)	O
to	TO	O
re-analyze	VB	O
a	DT	O
RCT	NNP	O
,	,	O
comparing	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
pre-curved	JJ	O
interdental	JJ	O
brushes	NNS	O
and	CC	O
flossing	VBG	O
on	IN	O
probing	VBG	O
pocket	NN	O
depth	NN	O
(	(	O
PPD	NNP	O
)	)	O
,	,	O
plaque	JJ	O
indices	NNS	O
,	,	O
and	CC	O
bleeding	VBG	O
on	IN	O
probing	VBG	O
(	(	O
BOP	NNP	O
)	)	O
measured	VBD	O
at	IN	O
baseline	NN	O
,	,	O
intermediate	NN	O
,	,	O
and	CC	O
final	JJ	O
examinations	NNS	O
.	.	O

Results	NNS	O
of	IN	O
SEM	NNP	O
showed	VBD	O
that	IN	O
the	DT	O
observed	JJ	O
greater	JJR	O
reduction	NN	O
in	IN	O
PPD	NNP	O
and	CC	O
BOP	NNP	O
in	IN	O
persons	NNS	Condition
using	VBG	Condition
interdental	JJ	Condition
brushing	NN	Condition
than	IN	Condition
in	IN	Condition
those	DT	Condition
flossing	NN	Condition
is	VBZ	O
due	JJ	O
mainly	RB	O
to	TO	O
the	DT	O
greater	JJR	O
efficiency	NN	O
in	IN	O
plaque	NN	O
removal	NN	O
with	IN	O
the	DT	O
interdental	JJ	O
brushes	NNS	O
(	(	O
indirect	JJ	O
effect	NN	O
)	)	O
rather	RB	O
than	IN	O
to	TO	O
the	DT	O
compression	NN	O
of	IN	O
the	DT	O
interdental	JJ	O
papillae	NN	O
(	(	O
direct	JJ	O
effect	NN	O
)	)	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
smokers	NNS	Condition
showed	VBD	O
less	JJR	O
BOP	NNP	O
at	IN	O
baseline	NN	O
but	CC	O
also	RB	O
less	RBR	O
improvement	NN	O
in	IN	O
BOP	NNP	O
through	IN	O
direct	JJ	O
effects	NNS	O
.	.	O

Psychiatric	NNP	O
treatment	NN	O
of	IN	O
eczema	NN	Condition
:	:	O
a	DT	O
controlled	JJ	O
trial	NN	O
.	.	O

Seventy-two	JJ	SampleSize
patients	NNS	O
with	IN	O
eczema	NNS	Condition
were	VBD	O
randomly	RB	O
allotted	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
A	DT	O
,	,	O
those	DT	O
receiving	VBG	O
dermatological	JJ	O
treatment	NN	O
only	RB	O
,	,	O
and	CC	O
B	NNP	O
,	,	O
those	DT	O
receiving	VBG	O
the	DT	O
same	JJ	O
dermatological	JJ	O
treatment	NN	O
plus	CC	O
psychiatric	JJ	O
treatment	NN	O
,	,	O
limited	VBN	O
where	WRB	O
possible	JJ	O
to	TO	O
four	CD	O
months	NNS	O
.	.	O

Cases	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
at	IN	O
six-monthly	JJ	O
dermatological	JJ	O
assessments	NNS	O
,	,	O
57	CD	O
(	(	O
79	CD	O
%	NN	O
)	)	O
for	IN	O
18	CD	O
months	NNS	O
.	.	O

The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
overt	JJ	O
emotional	JJ	O
disturbance	NN	O
,	,	O
of	IN	O
new	JJ	O
psychological	JJ	O
or	CC	O
psychophysiological	JJ	O
symptoms	NNS	O
preceding	VBG	O
the	DT	O
rash	NN	O
by	IN	O
up	IN	O
to	TO	O
a	DT	O
year	NN	O
,	,	O
and	CC	O
of	IN	O
high	JJ	O
motivation	NN	O
for	IN	O
it	PRP	O
,	,	O
brief	JJ	O
psychiatric	JJ	O
treatment	NN	O
improves	VBZ	O
the	DT	O
outcome	NN	O
in	IN	O
eczema	NN	O
(	(	O
the	DT	O
proportion	NN	O
clear	JJ	O
at	IN	O
18	CD	O
months	NNS	O
was	VBD	O
about	IN	O
doubled	VBN	O
)	)	O
,	,	O
whereas	NNS	O
in	IN	O
their	PRP$	O
absence	NN	O
such	JJ	O
treatment	NN	O
may	MD	O
worsen	VB	O
it	PRP	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
anticholinergic	NN	O
and	CC	O
beta	VB	O
2-agonist	JJ	O
and	CC	O
combination	NN	O
therapy	NN	O
on	IN	O
respiratory	NN	O
impedance	NN	O
in	IN	O
COPD	NNP	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
three	CD	O
different	JJ	O
regimens	NNS	O
of	IN	O
inhaled	JJ	O
bronchodilators	NNS	O
on	IN	O
spirometry	NN	O
and	CC	O
respiratory	JJ	O
impedance	NN	O
as	IN	O
measured	VBN	O
with	IN	O
the	DT	O
technique	NN	O
of	IN	O
forced	JJ	O
oscillations	NNS	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
in	IN	O
22	CD	SampleSize
patients	NNS	O
with	IN	O
stable	JJ	Condition
chronic	JJ	Condition
obstructive	JJ	Condition
pulmonary	JJ	Condition
disease	NN	Condition
(	(	O
FEV1	NNP	Condition
less	JJR	Condition
than	IN	Condition
70	CD	Condition
percent	NN	Condition
predicted	VBN	Condition
)	)	O
.	.	O

On	IN	O
three	CD	O
trial	NN	O
days	NNS	O
,	,	O
patients	NNS	O
inhaled	VBD	O
,	,	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
40	CD	O
micrograms	NNS	O
ipratropium	JJ	O
bromide	NN	O
,	,	O
200	CD	O
micrograms	NNS	O
fenoterol	JJ	O
hydrobromide	NN	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
40	CD	O
micrograms	NNS	O
ipratropium	NN	O
and	CC	O
100	CD	O
micrograms	NNS	O
fenoterol	VBP	O
from	IN	O
a	DT	O
powder	NN	O
inhaler	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
second	JJ	O
dose	NN	O
of	IN	O
the	DT	O
same	JJ	O
drug	NN	O
after	IN	O
60	CD	O
min	NN	O
.	.	O

The	DT	O
effects	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
20	CD	O
,	,	O
40	CD	O
,	,	O
60	CD	O
,	,	O
and	CC	O
120	CD	O
min	NN	O
after	IN	O
the	DT	O
first	JJ	O
inhalation	NN	O
.	.	O

No	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
total	JJ	O
respiratory	NN	O
resistance	NN	O
at	IN	O
8	CD	O
Hz	NNP	O
(	(	O
Rrs	NNP	O
[	VBZ	O
8	CD	O
]	NN	O
)	)	O
was	VBD	O
observed	VBN	O
after	IN	O
ipratropium	NN	O
,	,	O
whereas	JJ	O
Rrs	NNP	O
(	(	O
8	CD	O
)	)	O
decreased	VBD	O
significantly	RB	O
20	CD	O
min	NNS	O
after	IN	O
fenoterol	NN	O
and	CC	O
40	CD	O
min	NN	O
after	IN	O
the	DT	O
combination	NN	O
regimen	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

All	DT	O
three	CD	O
studied	VBD	O
drugs	NNS	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
reactance	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
and	CC	O
decrease	NN	O
in	IN	O
resonant	JJ	O
frequency	NN	O
.	.	O

Both	DT	O
fenoterol	NN	O
(	(	O
delta	JJ	O
FEV1	NNP	O
34	CD	O
percent	NN	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
and	CC	O
the	DT	O
combination	NN	O
regimen	NNS	O
(	(	O
delta	JJ	O
FEV1	NNP	O
38	CD	O
percent	NN	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
resulted	VBD	O
in	IN	O
a	DT	O
significantly	RB	O
larger	JJR	O
increase	NN	O
in	IN	O
FEV1	NNP	O
than	IN	O
ipratropium	NN	O
alone	RB	O
(	(	O
delta	JJ	O
FEV1	NNP	O
17	CD	O
percent	NN	O
,	,	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

A	DT	O
second	JJ	O
dose	NN	O
of	IN	O
fenoterol	NN	O
and	CC	O
of	IN	O
the	DT	O
combination	NN	O
regimen	NNS	O
resulted	VBD	O
in	IN	O
a	DT	O
further	JJ	O
significant	JJ	O
increase	NN	O
in	IN	O
FEV1	NNP	O
after	IN	O
120	CD	O
min	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
second	JJ	O
dose	NN	O
of	IN	O
ipratropium	NN	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
a	DT	O
further	JJ	O
significant	JJ	O
increase	NN	O
in	IN	O
FEV1	NNP	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
respiratory	NN	O
impedance	NN	O
were	VBD	O
qualitatively	RB	O
similar	JJ	O
for	IN	O
all	DT	O
three	CD	O
drug	NN	O
regimens	NNS	O
,	,	O
but	CC	O
larger	JJR	O
in	IN	O
absolute	NN	O
terms	NNS	O
after	IN	O
fenoterol	NN	O
and	CC	O
the	DT	O
combination	NN	O
regimen	NNS	O
than	IN	O
after	IN	O
ipratropium	NN	O
.	.	O

The	DT	O
similar	JJ	O
effect	NN	O
of	IN	O
these	DT	O
drugs	NNS	O
on	IN	O
the	DT	O
reactance	NN	O
can	MD	O
be	VB	O
explained	VBN	O
by	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
capacitance	NN	O
of	IN	O
the	DT	O
respiratory	NN	O
system	NN	O
,	,	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
frequency	NN	O
dependence	NN	O
of	IN	O
resistance	NN	O
,	,	O
by	IN	O
assuming	VBG	O
a	DT	O
decrease	NN	O
in	IN	O
peripheral	JJ	O
airway	NN	O
resistance	NN	O
.	.	O

Interleukin-6	NNP	O
receptor	NN	O
inhibition	NN	O
with	IN	O
tocilizumab	NN	O
and	CC	O
attainment	NN	O
of	IN	O
disease	NN	O
remission	NN	O
in	IN	O
rheumatoid	JJ	Condition
arthritis	NN	Condition
:	:	Condition
the	DT	O
role	NN	O
of	IN	O
acute-phase	JJ	O
reactants	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
tocilizumab	NN	O
on	IN	O
rheumatoid	NN	Condition
arthritis	NN	Condition
(	(	Condition
RA	NNP	Condition
)	)	Condition
disease	NN	O
activity	NN	O
and	CC	O
remission	NN	O
assessment	NN	O
,	,	O
using	VBG	O
measures	NNS	O
that	WDT	O
do	VBP	O
or	CC	O
do	VB	O
not	RB	O
comprise	VB	O
acute-phase	JJ	O
reactants	NNS	O
.	.	O

METHODS	NNP	O
Simplified	NNP	O
Disease	NNP	O
Activity	NNP	O
Index	NNP	O
(	(	O
SDAI	NNP	O
)	)	O
scores	VBZ	O
,	,	O
Clinical	JJ	O
Disease	NNP	O
Activity	NNP	O
Index	NNP	O
(	(	O
CDAI	NNP	O
)	)	O
scores	VBZ	O
,	,	O
and	CC	O
the	DT	O
Disease	NNP	O
Activity	NNP	O
Score	NNP	O
in	IN	O
28	CD	O
joints	NNS	O
(	(	O
DAS28	NNP	O
)	)	O
were	VBD	O
calculated	VBN	O
using	VBG	O
data	NNS	O
from	IN	O
tocilizumab	JJ	O
trials	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
in	IN	O
whom	WP	O
disease	NN	O
had	VBD	O
remained	VBN	O
active	JJ	O
despite	IN	O
treatment	NN	O
with	IN	O
disease-modifying	JJ	O
antirheumatic	JJ	O
drugs	NNS	O
.	.	O

The	DT	O
CDAI	NNP	O
does	VBZ	O
not	RB	O
contain	VB	O
an	DT	O
acute-phase	JJ	O
reactant	NN	O
component	NN	O
.	.	O

Disease	NNP	O
activity	NN	O
states	NNS	O
,	,	O
including	VBG	O
remission	NN	O
,	,	O
were	VBD	O
defined	VBN	O
using	VBG	O
established	VBN	O
cut	NN	O
points	NNS	O
;	:	O
for	IN	O
the	DT	O
DAS28	NNP	O
,	,	O
an	DT	O
alternative	JJ	O
cut	NN	O
point	NN	O
of	IN	O
<	$	O
2.4	CD	O
was	VBD	O
also	RB	O
used	VBN	O
.	.	O

RESULTS	JJ	O
Changes	NNS	O
in	IN	O
the	DT	O
DAS28	NNP	O
,	,	O
the	DT	O
SDAI	NNP	O
score	NN	O
,	,	O
and	CC	O
the	DT	O
CDAI	NNP	O
score	NN	O
among	IN	O
patients	NNS	O
receiving	VBG	O
tocilizumab	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
among	IN	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
,	,	O
and	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
these	DT	O
changes	NNS	O
was	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
SDAI	NNP	O
and	CC	O
the	DT	O
CDAI	NNP	O
.	.	O

Among	IN	O
patients	NNS	O
who	WP	O
achieved	VBD	O
50	CD	O
%	NN	O
improvement	NN	O
in	IN	O
disease	NN	O
activity	NN	O
according	VBG	O
to	TO	O
the	DT	O
American	NNP	O
College	NNP	O
of	IN	O
Rheumatology	NNP	O
criteria	NNS	O
,	,	O
only	RB	O
?20	VBZ	O
%	NN	O
required	VBN	O
a	DT	O
reduction	NN	O
in	IN	O
acute-phase	JJ	O
reactant	NN	O
values	NNS	O
in	IN	O
order	NN	O
to	TO	O
fulfill	VB	O
the	DT	O
criteria	NNS	O
.	.	O

However	RB	O
,	,	O
DAS28	NNP	O
remission	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
(	(	O
even	RB	O
when	WRB	O
using	VBG	O
the	DT	O
lower	JJR	O
cut	NN	O
point	NN	O
)	)	O
than	IN	O
the	DT	O
SDAI	NNP	O
and	CC	O
CDAI	NNP	O
remission	NN	O
rates	NNS	O
.	.	O

Only	RB	O
a	DT	O
minority	NN	O
of	IN	O
tocilizumab-treated	JJ	O
patients	NNS	O
with	IN	O
DAS28	NNP	O
remission	NN	O
also	RB	O
had	VBD	O
disease	NN	O
remission	NN	O
according	VBG	O
to	TO	O
the	DT	O
SDAI	NNP	O
(	(	O
26	CD	O
%	NN	O
)	)	O
or	CC	O
CDAI	NNP	O
(	(	O
?21	NNP	O
%	NN	O
)	)	O
.	.	O

With	IN	O
infliximab	JJ	O
treatment	NN	O
,	,	O
SDAI	NNP	O
and	CC	O
CDAI	NNP	O
remission	NN	O
rates	NNS	O
were	VBD	O
of	IN	O
the	DT	O
same	JJ	O
magnitude	NN	O
as	IN	O
those	DT	O
observed	VBN	O
with	IN	O
tocilizumab	JJ	O
treatment	NN	O
,	,	O
and	CC	O
DAS28	NNP	O
remission	NN	O
rates	NNS	O
were	VBD	O
lower	JJR	O
.	.	O

Tocilizumab-treated	JJ	O
patients	NNS	O
with	IN	O
DAS28	NNP	O
remission	NN	O
but	CC	O
without	IN	O
CDAI	NNP	O
remission	NN	O
had	VBD	O
significantly	RB	O
higher	JJR	O
swollen	JJ	O
joint	JJ	O
counts	NNS	O
but	CC	O
lower	JJR	O
erythrocyte	NN	O
sedimentation	NN	O
rates	NNS	O
(	(	O
ESRs	NNP	O
)	)	O
compared	VBN	O
with	IN	O
patients	NNS	O
with	IN	O
SDAI	NNP	O
or	CC	O
CDAI	NNP	O
remission	NN	O
.	.	O

CONCLUSION	NNP	O
Disease	NNP	O
activity	NN	O
in	IN	O
RA	NNP	O
is	VBZ	O
reduced	VBN	O
by	IN	O
tocilizumab	NN	O
treatment	NN	O
,	,	O
irrespective	NN	O
of	IN	O
the	DT	O
type	NN	O
of	IN	O
composite	JJ	O
measure	NN	O
used	VBN	O
to	TO	O
evaluate	VB	O
disease	NN	O
activity	NN	O
.	.	O

Remission	NN	O
rates	NNS	O
were	VBD	O
much	RB	O
higher	JJR	O
using	VBG	O
the	DT	O
DAS28	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
SDAI	NNP	O
and	CC	O
CDAI	NNP	O
,	,	O
due	JJ	O
to	TO	O
the	DT	O
high	JJ	O
weight	NN	O
of	IN	O
the	DT	O
ESR	NNP	O
in	IN	O
the	DT	O
DAS28	NNP	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
tocilizumab	NN	O
on	IN	O
the	DT	O
ESR	NNP	O
.	.	O

Using	VBG	O
the	DT	O
stringent	NN	O
SDAI	NNP	O
and	CC	O
CDAI	NNP	O
criteria	NNS	O
,	,	O
however	RB	O
,	,	O
remission	NN	O
rates	NNS	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
tocilizumab	NNS	O
were	VBD	O
in	IN	O
the	DT	O
same	JJ	O
range	NN	O
as	IN	O
those	DT	O
seen	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
inhibitors	NNS	O
.	.	O

Simvastatin	NNP	O
and	CC	O
preparation	NN	O
of	IN	O
polyunsaturated	JJ	O
phospholipids	NNS	O
produce	VBP	O
similar	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
phospholipid	JJ	O
composition	NN	O
of	IN	O
high-density	NN	O
lipoproteins	NNS	O
during	IN	O
hypercholesterolemia	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
phospholipid	JJ	O
composition	NN	O
of	IN	O
high-density	NN	O
lipoproteins	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	Condition
heart	NN	Condition
disease	NN	Condition
and	CC	O
hypercholesterolemia	NN	O
treated	VBN	O
with	IN	O
simvastatin	NN	O
(	(	O
Zocor	NNP	O
,	,	O
inhibitor	NN	O
of	IN	O
the	DT	O
key	JJ	O
enzyme	NN	O
of	IN	O
cholesterol	NN	O
synthesis	NN	O
)	)	O
and	CC	O
preparation	NN	O
of	IN	O
polyunsaturated	JJ	O
phospholipids	NNS	O
(	(	O
lipostabil	JJ	O
forte	NN	O
)	)	O
.	.	O

Simvastatin	NNP	O
produced	VBD	O
a	DT	O
hypolipidemic	JJ	O
effect	NN	O
and	CC	O
modulates	VBZ	O
the	DT	O
phospholipid	JJ	O
composition	NN	O
of	IN	O
high-density	NN	O
lipoproteins	NNS	O
(	(	O
similarly	RB	O
to	TO	O
lipostabil	VB	O
forte	NN	O
)	)	O
.	.	O

These	DT	O
changes	NNS	O
contribute	VBP	O
to	TO	O
functional	JJ	O
activity	NN	O
of	IN	O
high-density	NN	O
lipoproteins	NNS	O
in	IN	O
the	DT	O
reverse	NN	O
cholesterol	NN	O
transport	NN	O
.	.	O

Feasibility	NN	O
and	CC	O
effects	NNS	O
of	IN	O
nurse	JJ	O
run	NN	O
clinics	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
epilepsy	NN	Condition
in	IN	O
general	JJ	O
practice	NN	O
:	:	O
randomised	VBN	O
controlled	JJ	O
trial	NN	O
.	.	O

Epilepsy	NNP	O
Care	NNP	O
Evaluation	NNP	O
Group	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
test	VB	O
the	DT	O
feasibility	NN	O
and	CC	O
effect	NN	O
of	IN	O
nurse	JJ	O
run	NN	O
epilepsy	NN	Condition
clinics	NNS	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
randomised	JJ	O
controlled	JJ	O
trial	NN	O
of	IN	O
nurse	JJ	O
run	NN	O
clinics	NNS	O
versus	VBP	O
usual	JJ	O
care	NN	O
.	.	O

SETTING	NN	O
Six	NNP	O
general	JJ	O
practices	NNS	O
in	IN	O
the	DT	O
South	NNP	O
Thames	NNPS	O
region	NN	O
.	.	O

SUBJECTS	NNP	O
251	CD	SampleSize
patients	NNS	O
aged	VBN	O
over	IN	O
15	CD	O
years	NNS	O
who	WP	O
were	VBD	O
taking	VBG	O
anti-epileptic	JJ	O
drugs	NNS	O
or	CC	O
had	VBD	O
a	DT	O
diagnosis	NN	O
of	IN	O
epilepsy	NN	Condition
and	CC	O
an	DT	O
attack	NN	O
in	IN	O
the	DT	O
past	JJ	O
two	CD	O
years	NNS	O
who	WP	O
met	VBD	O
specified	VBN	O
inclusion	NN	O
criteria	NNS	O
and	CC	O
had	VBD	O
responded	VBN	O
to	TO	O
a	DT	O
questionnaire	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Questionnaire	NNP	O
responses	NNS	O
and	CC	O
recording	NN	O
of	IN	O
key	JJ	O
variables	NNS	O
extracted	VBN	O
from	IN	O
the	DT	O
clinical	JJ	O
records	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
intervention	NN	O
.	.	O

RESULTS	CC	O
127	CD	SampleSize
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
a	DT	O
nurse	JJ	O
run	NN	O
clinic	NN	O
,	,	O
of	IN	O
whom	WP	O
106	CD	O
(	(	O
83	CD	O
%	NN	O
)	)	O
attended	VBD	O
.	.	O

The	DT	O
nurse	JJ	O
wrote	VBD	O
28	CD	O
letters	NNS	O
to	TO	O
the	DT	O
general	JJ	O
practitioners	NNS	O
suggesting	VBG	O
changes	NNS	O
in	IN	O
epilepsy	NN	O
management	NN	O
.	.	O

For	IN	O
this	DT	O
intervention	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
usual	JJ	O
care	NN	O
group	NN	O
there	EX	O
was	VBD	O
a	DT	O
highly	RB	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
level	NN	O
of	IN	O
advice	NN	O
recorded	VBN	O
as	IN	O
having	VBG	O
been	VBN	O
given	VBN	O
on	IN	O
drug	NN	O
compliance	NN	O
,	,	O
adverse	JJ	O
drug	NN	O
effects	NNS	O
,	,	O
driving	VBG	O
,	,	O
alcohol	NN	O
intake	NN	O
,	,	O
and	CC	O
self	PRP	O
help	VBP	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Nurse	NNP	O
run	VBP	O
clinics	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
epilepsy	NN	Condition
were	VBD	O
feasible	JJ	O
and	CC	O
well	RB	O
attended	VBD	O
.	.	O

Such	JJ	O
clinics	NNS	O
can	MD	O
significantly	RB	O
improve	VB	O
the	DT	O
level	NN	O
of	IN	O
advice	NN	O
and	CC	O
drug	NN	O
management	NN	O
recorded	VBN	O
.	.	O

Prevention	NN	O
of	IN	O
subsequent	JJ	O
exercise-induced	JJ	O
periinfarct	NN	O
ischemia	NN	O
by	IN	O
emergency	NN	O
coronary	JJ	O
angioplasty	NN	O
in	IN	O
acute	JJ	Condition
myocardial	JJ	Condition
infarction	NN	Condition
:	:	O
comparison	NN	O
with	IN	O
intracoronary	JJ	O
streptokinase	NN	O
.	.	O

To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
emergency	NN	O
percutaneous	JJ	O
transluminal	JJ	O
coronary	NN	O
angioplasty	NN	O
and	CC	O
intracoronary	JJ	O
streptokinase	NN	O
in	IN	O
preventing	VBG	O
exercise-induced	JJ	O
periinfarct	NN	O
ischemia	NN	O
,	,	O
28	CD	O
patients	NNS	O
presenting	VBG	O
within	IN	O
12	CD	O
hours	NNS	O
of	IN	O
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
of	IN	O
acute	JJ	Condition
myocardial	JJ	Condition
infarction	NN	Condition
were	VBD	O
prospectively	RB	O
randomized	VBN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
14	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
emergency	NN	O
angioplasty	NN	O
and	CC	O
14	CD	O
patients	NNS	O
received	VBD	O
intracoronary	JJ	O
streptokinase	NN	O
.	.	O

Recatheterization	NN	O
and	CC	O
submaximal	JJ	O
exercise	NN	O
thallium-201	JJ	O
single	JJ	O
photon	NN	O
emission	NN	O
computed	VBD	O
tomography	NN	O
were	VBD	O
performed	VBN	O
before	IN	O
hospital	JJ	O
discharge	NN	O
.	.	O

Periinfarct	NNP	O
ischemia	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
a	DT	O
reversible	JJ	O
thallium	NN	O
defect	NN	O
adjacent	NN	O
to	TO	O
a	DT	O
fixed	VBN	O
defect	NN	O
assessed	VBN	O
qualitatively	RB	O
.	.	O

Successful	JJ	O
reperfusion	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
86	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
emergency	NN	O
angioplasty	NN	O
and	CC	O
86	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
intracoronary	JJ	O
streptokinase	NN	O
(	(	O
p	JJ	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Residual	JJ	O
stenosis	NN	O
of	IN	O
the	DT	O
infarct-related	JJ	O
coronary	JJ	O
artery	NN	O
shown	VBN	O
at	IN	O
predischarge	NN	O
angiography	NN	O
was	VBD	O
43.8	CD	O
+/-	JJ	O
31.4	CD	O
%	NN	O
for	IN	O
the	DT	O
angioplasty	JJ	O
group	NN	O
and	CC	O
75.0	CD	O
+/-	JJ	O
15.6	CD	O
%	NN	O
for	IN	O
the	DT	O
streptokinase	NN	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
angioplasty	JJ	O
group	NN	O
,	,	O
9	CD	O
%	NN	O
developed	VBD	O
exercise-induced	JJ	O
periinfarct	NN	O
ischemia	NN	O
compared	VBN	O
with	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
streptokinase	NN	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
treated	VBN	O
with	IN	O
emergency	NN	O
angioplasty	NN	O
had	VBD	O
significantly	RB	O
less	RBR	O
severe	JJ	O
residual	JJ	O
coronary	JJ	O
stenosis	NN	O
and	CC	O
exercise-induced	JJ	O
periinfarct	NN	O
ischemia	NN	O
than	IN	O
did	VBD	O
those	DT	O
treated	VBN	O
with	IN	O
intracoronary	JJ	O
streptokinase	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
further	JJ	O
application	NN	O
of	IN	O
coronary	JJ	O
angioplasty	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Blockade	NN	O
of	IN	O
cytotoxic	JJ	O
T-lymphocyte	JJ	O
antigen-4	NN	O
by	IN	O
ipilimumab	JJ	O
results	NNS	O
in	IN	O
dysregulation	NN	O
of	IN	O
gastrointestinal	JJ	O
immunity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
melanoma	NN	Condition
.	.	O

Blockade	NNP	O
of	IN	O
cytotoxic	JJ	O
T-lymphocyte	JJ	O
antigen-4	NN	O
(	(	O
CTLA-4	NNP	O
)	)	O
by	IN	O
ipilimumab	NN	O
leads	NNS	O
to	TO	O
immune-mediated	JJ	O
tumor	NN	O
regression	NN	O
and	CC	O
immune-related	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
irAEs	NN	O
)	)	O
,	,	O
including	VBG	O
diarrhea	NN	O
and	CC	O
colitis	NN	O
.	.	O

The	DT	O
current	JJ	O
analyses	NNS	O
were	VBD	O
undertaken	JJ	O
to	TO	O
promote	VB	O
an	DT	O
understanding	NN	O
of	IN	O
the	DT	O
underlying	VBG	O
mechanism	NN	O
of	IN	O
action	NN	O
and	CC	O
to	TO	O
identify	VB	O
potential	JJ	O
biomarkers	NNS	O
that	WDT	O
could	MD	O
help	VB	O
in	IN	O
the	DT	O
prediction	NN	O
and	CC	O
management	NN	O
of	IN	O
ipilimumab-induced	JJ	O
gastrointestinal	JJ	O
irAEs	NN	O
.	.	O

Treatment-na?ve	CD	O
or	CC	O
previously	RB	O
treated	VBN	O
patients	NNS	O
with	IN	O
unresectable	JJ	O
stage	NN	O
III/IV	NNP	O
melanoma	NN	O
(	(	O
n	JJ	O
=	NNP	O
115	CD	O
)	)	O
received	VBD	O
open-label	JJ	O
ipilimumab	NN	O
(	(	O
10	CD	O
mg/kg	NN	O
every	DT	O
3	CD	O
weeks	NNS	O
for	IN	O
four	CD	O
doses	NNS	O
)	)	O
and	CC	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
concomitant	NN	O
blinded	VBN	O
prophylactic	JJ	O
oral	JJ	O
budesonide	NN	O
(	(	O
9	CD	O
mg/d	NN	O
with	IN	O
gradual	JJ	O
taper	NN	O
through	IN	O
week	NN	O
16	CD	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
histologic	JJ	O
assessment	NN	O
of	IN	O
bowel	NN	O
biopsies	NNS	O
and	CC	O
assessment	NN	O
of	IN	O
serologic	JJ	O
markers	NNS	O
of	IN	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
(	(	O
IBD	NNP	O
)	)	O
,	,	O
fecal	JJ	O
calprotectin	NN	O
levels	NNS	O
,	,	O
and	CC	O
polymorphisms	NNS	O
in	IN	O
immune-related	JJ	O
genes	NNS	O
.	.	O

Ipilimumab	NNP	O
resulted	VBD	O
in	IN	O
dysregulation	NN	O
of	IN	O
gastrointestinal	JJ	O
mucosal	NN	O
immunity	NN	O
as	IN	O
evidenced	VBN	O
by	IN	O
altered	JJ	O
antibody	NN	O
levels	NNS	O
to	TO	O
enteric	VB	O
flora	NNS	O
,	,	O
inflammatory	NN	O
cell	NN	O
infiltration	NN	O
into	IN	O
gastrointestinal	JJ	O
mucosa	NN	O
,	,	O
and	CC	O
increased	VBD	O
fecal	JJ	O
calprotectin	NN	O
associated	VBN	O
with	IN	O
diarrhea	NN	O
and	CC	O
clinical	JJ	O
evidence	NN	O
of	IN	O
colitis	NN	O
.	.	O

The	DT	O
pattern	NN	O
of	IN	O
ipilimumab-induced	JJ	O
antibody	NN	O
titers	NNS	O
to	TO	O
microbial	JJ	O
flora	NN	O
and	CC	O
the	DT	O
histologic	NN	O
features	NNS	O
and	CC	O
location	NN	O
of	IN	O
the	DT	O
inflammation	NN	O
were	VBD	O
distinct	JJ	O
from	IN	O
classic	JJ	O
IBD	NNP	O
.	.	O

Prophylactic	NNP	O
budesonide	NN	O
did	VBD	O
not	RB	O
prevent	VB	O
ipilimumab-induced	JJ	O
bowel	NN	O
inflammation	NN	O
.	.	O

Despite	IN	O
an	DT	O
observed	JJ	O
association	NN	O
between	IN	O
colonic	JJ	O
inflammation	NN	O
and	CC	O
grade	VB	O
2	CD	O
or	CC	O
higher	JJR	O
diarrhea	NN	O
,	,	O
no	DT	O
baseline	NN	O
biomarkers	NNS	O
could	MD	O
reliably	RB	O
predict	VB	O
development	NN	O
of	IN	O
gastrointestinal	JJ	O
toxicity	NN	O
.	.	O

Although	IN	O
classic	JJ	O
IBD	NNP	O
and	CC	O
ipilimumab-related	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
are	VBP	O
both	DT	O
immune	JJ	O
mediated	VBN	O
,	,	O
the	DT	O
observed	JJ	O
pattern	NN	O
of	IN	O
biomarkers	NNS	O
suggests	VBZ	O
ipilimumab-related	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
may	MD	O
be	VB	O
a	DT	O
distinct	JJ	O
clinicopathologic	NN	O
entity	NN	O
.	.	O

Chronopharmacology	NN	O
of	IN	O
enalapril	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
enalapril	NN	O
,	,	O
an	DT	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitor	NN	O
,	,	O
are	VBP	O
reported	VBN	O
to	TO	O
vary	VB	O
with	IN	O
the	DT	O
time	NN	O
of	IN	O
administration	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
examine	VB	O
whether	IN	O
the	DT	O
effect	NN	O
of	IN	O
enalapril	NN	O
on	IN	O
plasma	NN	O
bradykinin	NN	O
(	(	O
BK	NNP	O
)	)	O
,	,	O
substance	NN	O
P	NNP	O
and	CC	O
prostaglandin	VB	O
E2	NNP	O
(	(	O
PGE2	NNP	O
)	)	O
,	,	O
which	WDT	O
are	VBP	O
likely	JJ	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
enalapril-induced	JJ	O
cough	NN	O
,	,	O
might	MD	O
also	RB	O
be	VB	O
affected	VBN	O
by	IN	O
its	PRP$	O
time	NN	O
of	IN	O
administration	NN	O
.	.	O

Enalapril	NNP	O
5	CD	O
mg	NN	O
or	CC	O
placebo	NN	O
was	VBD	O
given	VBN	O
orally	RB	O
at	IN	O
10:00	CD	O
h	NN	O
(	(	O
day	NN	O
trial	NN	O
)	)	O
or	CC	O
22:00	CD	O
h	NN	O
(	(	O
night	NN	O
trial	NN	O
)	)	O
to	TO	O
12	CD	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
of	IN	O
total	JJ	O
drug	NN	O
(	(	O
enalapril	JJ	O
+	NNP	O
enalaprilat	NN	O
,	,	O
its	PRP$	O
active	JJ	O
metabolite	NN	O
)	)	O
during	IN	O
the	DT	O
day	NN	O
and	CC	O
night	NN	O
trials	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
at	IN	O
any	DT	O
time	NN	O
.	.	O

However	RB	O
,	,	O
serum	JJ	O
enalaprilat	NN	O
tended	VBD	O
to	TO	O
be	VB	O
higher	JJR	O
and	CC	O
its	PRP$	O
maximum	JJ	O
concentration	NN	O
greater	JJR	O
in	IN	O
the	DT	O
day	NN	O
trial	NN	O
than	IN	O
in	IN	O
the	DT	O
night	NN	O
trial	NN	O
.	.	O

Blood	NNP	O
pressure	NN	O
24	CD	O
h	NN	O
after	IN	O
administration	NN	O
of	IN	O
enalapril	NN	O
was	VBD	O
reduced	VBN	O
at	IN	O
22:00	CD	O
h	NN	O
,	,	O
but	CC	O
not	RB	O
at	IN	O
10:00	CD	O
h.	NN	O
Plasma	NNP	O
BK	NNP	O
tended	VBD	O
to	TO	O
increase	VB	O
following	VBG	O
enalapril	JJ	O
administration	NN	O
at	IN	O
10:00	CD	O
h	NN	O
,	,	O
but	CC	O
not	RB	O
at	IN	O
22:00	CD	O
h.	NN	O
Remarkable	JJ	O
increases	NNS	O
in	IN	O
plasma	NN	O
BK	NNP	O
were	VBD	O
observed	VBN	O
in	IN	O
two	CD	O
patients	NNS	O
in	IN	O
the	DT	O
day	NN	O
trial	NN	O
and	CC	O
one	CD	O
of	IN	O
them	PRP	O
also	RB	O
complained	VBD	O
of	IN	O
cough	NN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
such	JJ	O
increase	NN	O
in	IN	O
plasma	JJ	O
BK	NNP	O
or	CC	O
subsequent	JJ	O
adverse	JJ	O
effect	NN	O
were	VBD	O
recorded	VBN	O
in	IN	O
the	DT	O
night	NN	O
trial	NN	O
.	.	O

Plasma	NNP	O
substance	NN	O
P	NNP	O
and	CC	O
PGE2	NNP	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
following	VBG	O
enalapril	JJ	O
administration	NN	O
either	RB	O
in	IN	O
the	DT	O
day	NN	O
or	CC	O
night	NN	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
response	NN	O
of	IN	O
BK	NNP	O
to	TO	O
enalapril	VB	O
is	VBZ	O
affected	VBN	O
by	IN	O
the	DT	O
time	NN	O
of	IN	O
administration	NN	O
.	.	O

In	IN	O
patients	NNS	O
who	WP	O
complain	VBP	O
of	IN	O
cough	NN	O
during	IN	O
treatment	NN	O
with	IN	O
enalapril	NN	O
during	IN	O
the	DT	O
daytime	NN	O
,	,	O
this	DT	O
adverse	JJ	O
effect	NN	O
might	MD	O
be	VB	O
diminished	VBN	O
or	CC	O
eliminated	VBN	O
by	IN	O
a	DT	O
switch	NN	O
to	TO	O
night-time	JJ	O
administration	NN	O
.	.	O

Percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
in	IN	O
patients	NNS	O
with	IN	O
previous	JJ	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
grafting	NN	O
(	(	O
from	IN	O
the	DT	O
j-Cypher	JJ	O
Registry	NNP	O
)	)	O
.	.	O

A	DT	O
paucity	NN	O
of	IN	O
data	NNS	O
is	VBZ	O
available	JJ	O
from	IN	O
large-scale	JJ	O
studies	NNS	O
evaluating	VBG	O
the	DT	O
long-term	JJ	O
outcomes	NNS	O
of	IN	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
undergone	JJ	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
grafting	NN	O
(	(	O
CABG	NNP	O
)	)	O
in	IN	O
the	DT	O
drug-eluting	JJ	O
stent	NN	O
era	NN	O
.	.	O

Of	IN	O
12,812	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
undergone	JJ	O
sirolimus-eluting	JJ	O
stent	NN	O
implantation	NN	O
in	IN	O
the	DT	O
j-Cypher	JJ	O
registry	NN	O
,	,	O
919	CD	O
(	(	O
7.2	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
history	NN	O
of	IN	O
CABG	NNP	O
and	CC	O
had	VBD	O
significantly	RB	O
higher	JJR	O
crude	JJ	O
5-year	JJ	O
mortality	NN	O
(	(	O
19.9	CD	O
%	NN	O
vs	JJ	O
14.0	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

After	IN	O
adjusting	VBG	O
for	IN	O
confounders	NNS	O
,	,	O
the	DT	O
excess	JJ	O
risk	NN	O
of	IN	O
death	NN	O
was	VBD	O
no	RB	O
longer	RBR	O
significant	JJ	O
(	(	O
hazard	JJ	O
ratio	NN	O
0.99	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.83	CD	O
to	TO	O
1.18	CD	O
,	,	O
p	NN	O
=	NNP	O
0.90	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
adjusted	VBN	O
risk	NN	O
of	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
patients	NNS	O
with	IN	O
previous	JJ	O
CABG	NNP	O
than	IN	O
in	IN	O
those	DT	O
without	IN	O
(	(	O
hazard	NN	O
ratio	NN	O
1.25	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
1.06	CD	O
to	TO	O
1.47	CD	O
,	,	O
p	NN	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
with	IN	O
previous	JJ	O
CABG	NNP	O
,	,	O
those	DT	O
who	WP	O
had	VBD	O
undergone	JJ	O
?1	NNP	O
saphenous	JJ	O
vein	NN	O
graft	NN	O
intervention	NN	O
had	VBD	O
significantly	RB	O
higher	JJR	O
adjusted	JJ	O
risks	NNS	O
of	IN	O
cardiac	JJ	O
death	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
2.21	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
1.26	CD	O
to	TO	O
3.76	CD	O
,	,	O
p	NN	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
myocardial	JJ	O
infarction	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
2.56	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
1.10	CD	O
to	TO	O
5.60	CD	O
,	,	O
p	NN	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
target	NN	O
lesion	NN	O
revascularization	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
2.65	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
1.82	CD	O
to	TO	O
3.81	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
definite	JJ	O
stent	NN	O
thrombosis	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
7.70	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
1.99	CD	O
to	TO	O
29.1	CD	O
,	,	O
p	NN	O
=	NNP	O
0.004	CD	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
who	WP	O
underwent	VBP	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
only	RB	O
for	IN	O
the	DT	O
native	JJ	O
coronary	JJ	O
artery	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
adjusted	JJ	O
mortality	NN	O
was	VBD	O
similar	JJ	O
between	IN	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
previous	JJ	O
CABG	NNP	O
,	,	O
despite	IN	O
a	DT	O
significantly	RB	O
different	JJ	O
risk	NN	O
of	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
.	.	O

Among	IN	O
the	DT	O
patients	NNS	O
with	IN	O
previous	JJ	O
CABG	NNP	O
,	,	O
those	DT	O
with	IN	O
saphenous	JJ	O
vein	NN	O
graft	NN	O
intervention	NN	O
using	VBG	O
a	DT	O
first-generation	JJ	O
drug-eluting	JJ	O
stent	NN	O
had	VBD	O
worse	JJR	O
clinical	JJ	O
outcomes	NNS	O
than	IN	O
those	DT	O
with	IN	O
a	DT	O
native	JJ	O
coronary	JJ	O
artery	NN	O
target	NN	O
only	RB	O
.	.	O

Succinate	NNP	O
sumatriptan	JJ	O
evaluation	NN	O
by	IN	O
Doppler	NNP	O
echocardiography	NN	O
in	IN	O
patients	NNS	O
with	IN	O
migraine	NN	O
.	.	O

Recent	JJ	O
reports	NNS	O
show	VBP	O
that	IN	O
sumatriptan	JJ	O
administration	NN	O
increases	NNS	O
blood	VBP	O
pressure	NN	O
and	CC	O
vascular	JJ	O
resistance	NN	O
both	DT	O
in	IN	O
systemic	NN	O
and	CC	O
pulmonary	JJ	O
circulation	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
by	IN	O
echo-Doppler	NN	O
technique	NN	O
the	DT	O
hemodynamic	JJ	O
effects	NNS	O
of	IN	O
subcutaneous	JJ	O
sumatriptan	JJ	O
administration	NN	O
.	.	O

Forty-one	CD	O
migraine	JJ	O
subjects	NNS	O
(	(	O
26	CD	O
males	NNS	O
,	,	O
15	CD	O
females	NNS	O
)	)	O
,	,	O
mean	JJ	O
age	NN	O
36	CD	O
+/-	JJ	O
2	CD	O
years	NNS	O
(	(	O
range	VB	O
36-39	CD	O
years	NNS	O
)	)	O
,	,	O
and	CC	O
20	CD	O
healthy	JJ	O
control	NN	O
subjects	NNS	O
(	(	O
14	CD	O
males	NNS	O
,	,	O
six	CD	O
females	NNS	O
)	)	O
,	,	O
mean	JJ	O
age	NN	O
36	CD	O
+/-	JJ	O
2	CD	O
years	NNS	O
(	(	O
range	VB	O
36-39	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
(	(	O
double-blind	NN	O
)	)	O
to	TO	O
receiving	VBG	O
sumatriptan	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

After	IN	O
a	DT	O
2-week	JJ	O
complete	JJ	O
pharmacological	NN	O
washout	NN	O
,	,	O
clinical	JJ	O
examination	NN	O
,	,	O
electrocardiogram	NN	O
,	,	O
and	CC	O
Doppler	NNP	O
echocardiography	NN	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
,	,	O
15	CD	O
,	,	O
30	CD	O
,	,	O
45	CD	O
,	,	O
and	CC	O
60	CD	O
min	NN	O
after	IN	O
sumatriptan	NN	O
or	CC	O
placebo	JJ	O
administration	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
regarding	VBG	O
Doppler	NNP	O
echocardiographic	JJ	O
parameters	NNS	O
(	(	O
aortic	JJ	O
integral	NN	O
,	,	O
pulmonary	JJ	O
integral	JJ	O
,	,	O
end-systolic	JJ	O
and	CC	O
end-diastolic	JJ	O
diameters	NNS	O
)	)	O
and	CC	O
heart	NN	O
rate	NN	O
;	:	O
only	RB	O
a	DT	O
slight	NN	O
but	CC	O
not	RB	O
significant	JJ	O
increase	NN	O
in	IN	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

Our	PRP$	O
data	NNS	O
show	VBP	O
that	IN	O
succinate	JJ	O
sumatriptan	NNS	O
can	MD	O
be	VB	O
used	VBN	O
with	IN	O
safety	NN	O
in	IN	O
patients	NNS	O
without	IN	O
hypertension	NN	O
and	CC	O
other	JJ	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

Randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
of	IN	O
Behavioral	NNP	O
Family	NNP	O
Systems	NNP	O
Therapy	NNP	O
for	IN	O
Diabetes	NNPS	Condition
:	:	Condition
maintenance	NN	O
and	CC	O
generalization	NN	O
of	IN	O
effects	NNS	O
on	IN	O
parent-adolescent	JJ	O
communication	NN	O
.	.	O

We	PRP	O
report	VBP	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
revised	JJ	O
Behavioral	NNP	O
Family	NNP	O
Systems	NNP	O
Therapy	NNP	O
for	IN	O
Diabetes	NNP	O
(	(	O
BFST-D	NNP	O
)	)	O
intervention	NN	O
.	.	O

Families	NNS	O
of	IN	O
104	CD	O
adolescents	NNS	O
with	IN	O
diabetes	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
standard	VB	O
care	NN	O
(	(	O
SC	NNP	O
)	)	O
or	CC	O
to	TO	O
6	CD	O
months	NNS	O
of	IN	O
an	DT	O
educational	JJ	O
support	NN	O
group	NN	O
(	(	O
ES	NNP	O
)	)	O
or	CC	O
BFST-D.	JJ	O
Family	NNP	O
communication	NN	O
and	CC	O
problem-solving	JJ	O
skills	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
0	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
by	IN	O
independent	JJ	O
rating	NN	O
of	IN	O
videotaped	JJ	O
family	NN	O
problem-solving	JJ	O
discussions	NNS	O
.	.	O

BFST-D	NNP	O
improved	VBD	O
individual	JJ	O
communication	NN	O
of	IN	O
adolescents	NNS	O
and	CC	O
mothers	NNS	O
,	,	O
but	CC	O
not	RB	O
fathers	NNS	O
.	.	O

BFST-D	NNP	O
significantly	RB	O
improved	VBD	O
quality	NN	O
of	IN	O
family	NN	O
interaction	NN	O
compared	VBN	O
to	TO	O
SC	NNP	O
(	(	O
10	CD	O
of	IN	O
12	CD	O
comparisons	NNS	O
)	)	O
and	CC	O
ES	NNP	O
(	(	O
6	CD	O
of	IN	O
12	CD	O
comparisons	NNS	O
)	)	O
.	.	O

Changes	NNS	O
in	IN	O
family	NN	O
communication	NN	O
were	VBD	O
differentially	RB	O
associated	VBN	O
with	IN	O
changes	NNS	O
in	IN	O
glycemic	JJ	O
control	NN	O
,	,	O
adherence	NN	O
,	,	O
and	CC	O
family	NN	O
conflict	NN	O
.	.	O

BFST-D	NNP	O
improved	VBD	O
family	NN	O
communication	NN	O
and	CC	O
problem	NN	O
solving	VBG	O
relative	JJ	O
to	TO	O
SC	NNP	O
and	CC	O
modestly	RB	O
relative	JJ	O
to	TO	O
ES	NNP	O
.	.	O

Combination	NNP	O
therapy	NN	O
with	IN	O
methotrexate	NN	O
and	CC	O
hydroxychloroquine	NN	O
for	IN	O
rheumatoid	JJ	Condition
arthritis	NN	Condition
increases	NNS	O
exposure	VBP	O
to	TO	O
methotrexate	VB	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
methotrexate	NN	O
(	(	O
MTX	NNP	O
)	)	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
hydroxychloroquine	NN	O
(	(	O
HCQ	NNP	O
)	)	O
,	,	O
and	CC	O
vice	NN	O
versa	NN	O
,	,	O
to	TO	O
determine	VB	O
a	DT	O
possible	JJ	O
pharmacokinetic	JJ	O
explanation	NN	O
for	IN	O
the	DT	O
observation	NN	O
that	IN	O
combination	NN	O
treatment	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
with	IN	O
MTX	NNP	O
and	CC	O
HCQ	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
,	,	O
clinically	RB	O
,	,	O
to	TO	O
be	VB	O
more	RBR	O
potent	JJ	O
than	IN	O
MTX	NNP	O
used	VBD	O
alone	RB	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
,	,	O
10	CD	SampleSize
healthy	JJ	Condition
subjects	NNS	O
received	VBN	O
,	,	O
on	IN	O
each	DT	O
of	IN	O
5	CD	O
dosing	VBG	O
occasions	NNS	O
,	,	O
MTX	NNP	O
alone	RB	O
as	IN	O
tablets	NNS	O
or	CC	O
intravenous	JJ	O
solution	NN	O
,	,	O
HCQ	NNP	O
alone	RB	O
as	IN	O
a	DT	O
tablet	NN	O
or	CC	O
oral	JJ	O
solution	NN	O
,	,	O
or	CC	O
a	DT	O
coadministered	JJ	O
dose	NN	O
of	IN	O
MTX	NNP	O
tablets	NNS	O
with	IN	O
an	DT	O
HCQ	NNP	O
tablet	NN	O
.	.	O

The	DT	O
area	NN	O
under	IN	O
the	DT	O
concentration-time	JJ	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
was	VBD	O
determined	VBN	O
for	IN	O
each	DT	O
subject	NN	O
,	,	O
on	IN	O
each	DT	O
dosing	VBG	O
occasion	NN	O
,	,	O
for	IN	O
each	DT	O
compound	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
AUC	NNP	O
for	IN	O
MTX	NNP	O
was	VBD	O
increased	VBN	O
(	(	O
p	JJ	O
=	NNP	O
0.005	CD	O
)	)	O
and	CC	O
the	DT	O
maximum	JJ	O
MTX	NNP	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
decreased	VBD	O
(	(	O
p	JJ	O
=	NNP	O
0.025	CD	O
)	)	O
when	WRB	O
MTX	NNP	O
was	VBD	O
coadministered	VBN	O
with	IN	O
HCQ	NNP	O
,	,	O
compared	VBN	O
to	TO	O
MTX	NNP	O
administered	VBD	O
alone	RB	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
reach	VB	O
Cmax	NNP	O
for	IN	O
MTX	NNP	O
administration	NN	O
,	,	O
tmax	NN	O
,	,	O
was	VBD	O
also	RB	O
increased	VBN	O
during	IN	O
the	DT	O
coadministration	NN	O
with	IN	O
HCQ	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.072	CD	O
)	)	O
.	.	O

The	DT	O
AUC	NNP	O
of	IN	O
HCQ	NNP	O
showed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.957	CD	O
)	)	O
between	IN	O
any	DT	O
of	IN	O
the	DT	O
dosing	NN	O
occasions	NNS	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
may	MD	O
explain	VB	O
the	DT	O
increased	JJ	O
potency	NN	O
of	IN	O
the	DT	O
MTX-HCQ	NNP	O
combination	NN	O
over	RB	O
MTX	NNP	O
as	IN	O
a	DT	O
single	JJ	O
agent	NN	O
and	CC	O
also	RB	O
the	DT	O
sustained	JJ	O
effects	NNS	O
of	IN	O
MTX	NNP	O
when	WRB	O
administered	VBN	O
with	IN	O
HCQ	NNP	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
reduced	JJ	O
Cmax	NNP	O
of	IN	O
MTX	NNP	O
observed	VBD	O
during	IN	O
the	DT	O
coadministration	NN	O
may	MD	O
explain	VB	O
diminution	NN	O
of	IN	O
acute	JJ	O
liver	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

Extra	NNP	O
vigilance	NN	O
for	IN	O
MTX	NNP	O
adverse	JJ	O
effects	NNS	O
during	IN	O
combination	NN	O
therapy	NN	O
with	IN	O
HCQ	NNP	O
is	VBZ	O
recommended	VBN	O
,	,	O
especially	RB	O
if	IN	O
renal	JJ	O
function	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
decreased	VBN	O
.	.	O

Fluvoxamine	NNP	O
as	RB	O
effective	JJ	O
as	IN	O
clomipramine	NN	O
against	IN	O
symptoms	NNS	O
of	IN	O
severe	JJ	Condition
depression	NN	Condition
:	:	O
results	NNS	O
from	IN	O
a	DT	O
multicentre	NN	O
,	,	O
double-blind	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
selective	JJ	O
serotonin	NNS	O
reuptake	VBP	O
inhibitors	NNS	O
(	(	O
SSRIs	NNP	O
)	)	O
are	VBP	O
better	RBR	O
tolerated	VBN	O
than	IN	O
tricyclic	JJ	O
antidepressants	NNS	O
,	,	O
their	PRP$	O
efficacy	NN	O
in	IN	O
severe	JJ	O
depression	NN	O
remains	VBZ	O
to	TO	O
be	VB	O
further	RB	O
elucidated	VBN	O
.	.	O

METHOD	VB	O
A	DT	O
double-blind	NN	O
,	,	O
multicentre	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
86	CD	SampleSize
severely	RB	O
depressed	JJ	O
inpatients	NNS	O
(	(	O
>	JJ	O
or=	RB	O
25	CD	O
on	IN	O
the	DT	O
17-item	JJ	O
Hamilton	NNP	O
depression	NN	Condition
rating	NN	O
scale	NN	O
[	NNP	O
HAMD	NNP	O
]	NNP	O
total	JJ	O
score	NN	O
)	)	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
fluvoxamine	NN	O
with	IN	O
that	DT	O
of	IN	O
clomipramine	NN	O
.	.	O

Following	VBG	O
placebo	JJ	O
run-in	JJ	O
,	,	O
86	CD	SampleSize
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
fluvoxamine	NN	O
or	CC	O
clomipramine	NN	O
(	(	O
100-250	JJ	O
mg/day	NN	O
)	)	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Fluvoxamine	NNP	O
and	CC	O
clomipramine	VB	O
both	DT	O
resulted	VBN	O
in	IN	O
marked	JJ	O
improvements	NNS	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
them	PRP	O
on	IN	O
the	DT	O
17-item	JJ	O
HAMD	NNP	O
total	NN	O
score	NN	O
,	,	O
the	DT	O
clinical	JJ	O
global	JJ	O
impression	NN	O
severity	NN	O
of	IN	O
illness	NN	O
or	CC	O
global	JJ	O
improvement	NN	O
items	NNS	O
or	CC	O
the	DT	O
Montgomery-Asberg	JJ	O
depression	NN	O
rating	NN	O
scale	NN	O
,	,	O
at	IN	O
any	DT	O
visit	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
71	CD	O
%	NN	O
in	IN	O
the	DT	O
fluvoxamine	NN	O
group	NN	O
and	CC	O
69	CD	O
%	NN	O
in	IN	O
the	DT	O
clomipramine	NN	O
group	NN	O
were	VBD	O
responders	NNS	O
(	(	O
>	JJ	O
or=	RB	O
50	CD	O
%	NN	O
decrease	NN	O
in	IN	O
17-item	JJ	O
HAMD	NNP	O
total	NN	O
score	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
fluvoxamine	NN	O
was	VBD	O
better	RBR	O
tolerated	VBN	O
than	IN	O
clomipramine	NN	O
.	.	O

Clomipramine	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
overall	JJ	O
and	CC	O
treatment-related	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
discontinued	VBN	O
prematurely	RB	O
due	JJ	O
to	TO	O
adverse	JJ	O
events	NNS	O
was	VBD	O
more	JJR	O
than	IN	O
twice	RB	O
as	IN	O
high	JJ	O
with	IN	O
clomipramine	NN	O
than	IN	O
with	IN	O
fluvoxamine	NN	O
(	(	O
24	CD	O
%	NN	O
vs	JJ	O
11	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Fluvoxamine	NNP	O
and	CC	O
clomipramine	NN	O
are	VBP	O
equally	RB	O
effective	JJ	O
in	IN	O
severe	JJ	O
depression	NN	O
,	,	O
but	CC	O
fluvoxamine	NN	O
has	VBZ	O
a	DT	O
better	JJR	O
safety	NN	O
and	CC	O
tolerability	NN	O
profile	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
oral	JJ	O
human	JJ	O
immunoglobulin	NN	O
for	IN	O
gastrointestinal	JJ	Condition
dysfunction	NN	Condition
in	IN	O
children	NNS	Age
with	IN	O
autistic	JJ	Condition
disorder	NN	Condition
.	.	O

Controversy	NNP	O
exists	VBZ	O
regarding	VBG	O
the	DT	O
extent	NN	O
and	CC	O
possible	JJ	O
causal	NN	O
relationship	NN	O
between	IN	O
gastrointestinal	JJ	O
symptoms	NNS	O
and	CC	O
autism	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel	JJ	O
groups	NNS	O
,	,	O
dose-ranging	JJ	O
study	NN	O
of	IN	O
oral	JJ	O
,	,	O
human	JJ	O
immunoglobulin	NN	O
(	(	O
IGOH	NNP	O
140	CD	O
,	,	O
420	CD	O
,	,	O
or	CC	O
840	CD	O
mg/day	NN	O
)	)	O
was	VBD	O
utilized	VBN	O
with	IN	O
125	CD	SampleSize
children	NNS	O
(	(	O
ages	VBZ	O
2-17	CD	Age
years	NNS	Age
)	)	O
with	IN	O
autism	NN	Condition
and	CC	O
persistent	JJ	O
GI	NNP	Condition
symptoms	NNS	Condition
.	.	O

Endpoint	NNP	O
analysis	NN	O
revealed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
across	IN	O
treatment	NN	O
groups	NNS	O
on	IN	O
a	DT	O
modified	JJ	O
global	JJ	O
improvement	NN	O
scale	NN	O
(	(	O
validated	VBN	O
in	IN	O
irritable	JJ	O
bowel	NN	O
syndrome	JJ	O
studies	NNS	O
)	)	O
,	,	O
number	NN	O
of	IN	O
daily	JJ	O
bowel	NN	O
movements	NNS	O
,	,	O
days	NNS	O
of	IN	O
constipation	NN	O
,	,	O
or	CC	O
severity	NN	O
of	IN	O
problem	NN	O
behaviors	NNS	O
.	.	O

IGOH	NNP	O
was	VBD	O
well-tolerated	JJ	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

This	DT	O
study	NN	O
demonstrates	VBZ	O
the	DT	O
importance	NN	O
of	IN	O
conducting	VBG	O
rigorous	JJ	O
trials	NNS	O
in	IN	O
children	NNS	Age
with	IN	O
autism	NN	Condition
and	CC	O
casts	VBZ	O
doubt	NN	O
on	IN	O
one	CD	O
GI	NNP	O
mechanism	NN	O
presumed	VBD	O
to	TO	O
exert	VB	O
etiological	JJ	O
and/or	NN	O
symptomatic	JJ	O
effects	NNS	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Remifentanil	NNP	O
with	IN	O
morphine	JJ	O
transitional	JJ	O
analgesia	NN	O
shortens	VBZ	O
neurological	JJ	O
recovery	NN	O
compared	VBN	O
to	TO	O
fentanyl	VB	O
for	IN	O
supratentorial	JJ	O
craniotomy	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
recovery	NN	O
profiles	NNS	O
,	,	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
remifentanil	NN	O
and	CC	O
morphine	NN	O
for	IN	O
transitional	JJ	O
analgesia	NN	O
with	IN	O
fentanyl	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	Condition
craniotomy	NN	Condition
for	IN	O
supratentorial	JJ	Condition
mass	NN	Condition
lesions	NNS	Condition
.	.	O

METHODS	NNP	O
Ninety-one	JJ	SampleSize
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
multicentre	FW	O
study	NN	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
induced	VBN	O
with	IN	O
thiopental	JJ	O
and	CC	O
remifentanil	NN	O
(	(	O
1.0	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
bolus	NN	O
and	CC	O
a	DT	O
1	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
infusion	NN	O
)	)	O
or	CC	O
fentanyl	NN	O
(	(	O
1	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
bolus	NN	O
and	CC	O
a	DT	O
1.0	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
infusion	NN	O
)	)	O
.	.	O

The	DT	O
opioid	JJ	O
infusion	NN	O
continued	VBD	O
until	IN	O
the	DT	O
level	NN	O
of	IN	O
anesthesia	NN	O
was	VBD	O
deemed	VBN	O
appropriate	JJ	O
for	IN	O
intubation	NN	O
.	.	O

Anesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
N	NNP	O
(	(	O
2	CD	O
)	)	O
O/O	NNP	O
(	(	O
2	CD	O
)	)	O
,	,	O
isoflurane	$	O
0.5	CD	O
MAC	NNP	O
and	CC	O
remifentanil	VB	O
0.2	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	JJ	O
)	)	O
or	CC	O
fentanyl	$	O
0.04	CD	O
micro	NN	O
g	NN	O
x	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

At	IN	O
bone	NN	O
flap	NN	O
replacement	NN	O
,	,	O
either	DT	O
morphine	NN	O
0.08	CD	O
mg	NN	O
x	NN	O
kg	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
remifentanil	JJ	O
group	NN	O
)	)	O
or	CC	O
saline	NN	O
(	(	O
fentanyl	JJ	O
group	NN	O
)	)	O
was	VBD	O
given	VBN	O
.	.	O

RESULTS	NNP	O
Systolic	NNP	O
blood	NN	O
pressure	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
those	DT	O
receiving	VBG	O
fentanyl	NN	O
during	IN	O
induction	NN	O
(	(	O
145.6	CD	O
+/-17.5	JJ	O
mmHg	NN	O
vs	NN	O
128.8	CD	O
+/-18.3	JJ	O
mmHg	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
and	CC	O
intubation	NN	O
(	(	O
126.9	CD	O
+/-17.1	JJ	O
vs	NN	O
110.9	CD	O
+/-16.5	JJ	O
mmHg	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Median	JJ	O
time	NN	O
to	TO	O
tracheal	VB	O
extubation	NN	O
was	VBD	O
similar	JJ	O
but	CC	O
less	RBR	O
variable	JJ	O
in	IN	O
the	DT	O
remifentanil	NN	O
group	NN	O
(	(	O
remifentanil	JJ	O
=	$	O
8	CD	O
min	NN	O
:	:	O
range	NN	O
=	VBZ	O
2-44	JJ	O
min	NN	O
;	:	O
fentanyl	CC	O
=	$	O
8	CD	O
min	NN	O
:	:	O
range	NN	O
=	VBZ	O
1-732	JJ	O
min	NN	O
)	)	O
.	.	O

The	DT	O
fentanyl	JJ	O
patients	NNS	O
required	VBD	O
a	DT	O
longer	JJR	O
time	NN	O
to	TO	O
achieve	VB	O
the	DT	O
first	JJ	O
normal	JJ	O
neurological	JJ	O
score	NN	O
(	(	O
fentanyl	JJ	O
=	$	O
38.0	CD	O
min	NN	O
;	:	O
remifentanil	CC	O
=	$	O
26.0	CD	O
min	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.035	CD	O
)	)	O
.	.	O

Both	CC	O
the	DT	O
anesthesiologists	NNS	O
and	CC	O
the	DT	O
recovery	NN	O
room	NN	O
nurses	NNS	O
rated	VBD	O
remifentanil	JJ	O
better	RBR	O
with	IN	O
respect	NN	O
to	TO	O
level	NN	O
of	IN	O
consciousness	NN	O
.	.	O

Analgesics	NNS	O
were	VBD	O
required	VBN	O
earlier	RBR	O
in	IN	O
patients	NNS	O
receiving	VBG	O
remifentanil	NN	O
;	:	O
median	JJ	O
time	NN	O
0.5	CD	O
vs	NN	O
1.08	CD	O
hr	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.001	CD	O
.	.	O

CONCLUSIONS	NNP	O
Remifentanil	NNP	O
is	VBZ	O
a	DT	O
suitable	JJ	O
alternative	NN	O
to	TO	O
fentanyl	VB	O
in	IN	O
supratentorial	JJ	O
craniotomy	NN	O
.	.	O

Time	NN	O
to	TO	O
preoperative	VB	O
neurological	JJ	O
recovery	NN	O
is	VBZ	O
faster	RBR	O
and	CC	O
morphine	VB	O
provides	VBZ	O
some	DT	O
transitional	JJ	O
analgesia	NN	O
without	IN	O
compromising	VBG	O
the	DT	O
quality	NN	O
of	IN	O
recovery	NN	O
.	.	O

Analysis	NN	O
of	IN	O
face	NN	O
gaze	NN	O
in	IN	O
autism	NN	O
using	VBG	O
Bubbles	NNP	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
abnormal	JJ	O
social	JJ	O
functioning	NN	O
in	IN	O
autism	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
ability	NN	O
to	TO	O
direct	VB	O
eye	NN	O
gaze	NN	O
onto	IN	O
other	JJ	O
people	NNS	O
's	POS	O
faces	VBZ	O
in	IN	O
social	JJ	O
situations	NNS	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
gaze	NN	O
onto	IN	O
the	DT	O
eye	NN	O
and	CC	O
mouth	JJ	O
regions	NNS	O
of	IN	O
faces	VBZ	O
,	,	O
and	CC	O
the	DT	O
visual	JJ	O
information	NN	O
that	WDT	O
was	VBD	O
present	JJ	O
within	IN	O
those	DT	O
regions	NNS	O
.	.	O

We	PRP	O
used	VBD	O
the	DT	O
Bubbles	NNP	O
method	NN	O
to	TO	O
vary	VB	O
the	DT	O
facial	JJ	O
information	NN	O
available	JJ	O
on	IN	O
any	DT	O
given	VBN	O
trial	NN	O
by	IN	O
revealing	VBG	O
only	RB	O
small	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
and	CC	O
measured	VBD	O
the	DT	O
eye	NN	O
movements	NNS	O
made	VBN	O
as	IN	O
participants	NNS	O
viewed	IN	O
these	DT	O
stimuli	NNS	O
.	.	O

Compared	VBN	O
to	TO	O
ten	VB	O
IQ-	NNP	O
and	CC	O
age-matched	JJ	O
healthy	JJ	O
controls	NNS	O
,	,	O
eight	CD	O
participants	NNS	O
with	IN	O
autism	NN	O
showed	VBD	O
less	JJR	O
fixation	JJ	O
specificity	NN	O
to	TO	O
the	DT	O
eyes	NNS	O
and	CC	O
mouth	NN	O
,	,	O
a	DT	O
greater	JJR	O
tendency	NN	O
to	TO	O
saccade	VB	O
away	RB	O
from	IN	O
the	DT	O
eyes	NNS	O
when	WRB	O
information	NN	O
was	VBD	O
present	JJ	O
in	IN	O
those	DT	O
regions	NNS	O
,	,	O
and	CC	O
abnormal	JJ	O
directionality	NN	O
of	IN	O
saccades	NNS	O
.	.	O

The	DT	O
findings	NNS	O
provide	VBP	O
novel	JJ	O
detail	NN	O
to	TO	O
the	DT	O
abnormal	JJ	O
way	NN	O
in	IN	O
which	WDT	O
people	NNS	O
with	IN	O
autism	NN	O
look	NN	O
at	IN	O
faces	VBZ	O
,	,	O
an	DT	O
impairment	NN	O
that	WDT	O
likely	JJ	O
influences	VBZ	O
all	DT	O
subsequent	JJ	O
face	NN	O
processing	NN	O
.	.	O

Report	NN	O
on	IN	O
the	DT	O
second	JJ	O
myelomatosis	NN	O
trial	NN	O
after	IN	O
five	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

Medical	NNP	O
Research	NNP	O
Council	NNP	O
's	POS	O
Working	NNP	O
Party	NNP	O
on	IN	O
Leukaemia	NNP	Condition
in	IN	O
Adults	NNP	Age
.	.	O

Three	CD	SampleSize
hundred	VBD	SampleSize
and	CC	SampleSize
seventy-two	JJ	SampleSize
patients	NNS	O
were	VBD	O
randomized	VBN	O
between	IN	O
3	CD	O
regimens	NNS	O
of	IN	O
chemotherapy	NN	O
:	:	O
cyclophosphamide	NN	O
,	,	O
intermittent	NN	O
melphalan	NN	O
,	,	O
and	CC	O
melphalan	NN	O
with	IN	O
prednisone	NN	O
,	,	O
and	CC	O
were	VBD	O
followed	VBN	O
up	RP	O
to	TO	O
death	NN	O
or	CC	O
for	IN	O
at	IN	O
least	JJS	O
5	CD	O
years	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	O
between	IN	O
the	DT	O
treatments	NNS	O
,	,	O
either	RB	O
overall	JJ	O
or	CC	O
in	IN	O
any	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
choice	NN	O
among	IN	O
these	DT	O
3	CD	O
treatments	NNS	O
should	MD	O
be	VB	O
guided	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
comfort	NN	O
and	CC	O
convenience	NN	O
.	.	O

The	DT	O
most	RBS	O
important	JJ	O
prognostic	JJ	O
feature	NN	O
at	IN	O
presentation	NN	O
was	VBD	O
the	DT	O
quality	NN	O
of	IN	O
renal	JJ	O
function	NN	O
.	.	O

It	PRP	O
was	VBD	O
possible	JJ	O
to	TO	O
define	VB	O
good	JJ	Condition
,	,	Condition
intermediate	JJ	Condition
and	CC	Condition
poor	JJ	Condition
renal-function	NN	Condition
groups	NNS	O
which	WDT	O
were	VBD	O
highly	RB	O
correlated	VBN	O
with	IN	O
prognosis	NN	O
(	(	O
X2	NNP	O
for	IN	O
trend	NN	O
=	NNP	O
62.6	CD	O
)	)	O
.	.	O

The	DT	O
haemoglobin	JJ	O
level	NN	O
at	IN	O
presentation	NN	O
was	VBD	O
strongly	RB	O
correlated	VBN	O
with	IN	O
prognosis	NN	O
among	IN	O
patients	NNS	O
in	IN	O
the	DT	O
good	JJ	Condition
renal-function	NN	Condition
group	NN	O
.	.	O

Among	IN	O
107	CD	SampleSize
patients	NNS	O
who	WP	O
presented	VBD	O
with	IN	O
good	JJ	Condition
renal	JJ	Condition
function	NN	Condition
and	CC	O
with	IN	O
haemoglobin	NNS	O
above	IN	O
100	CD	O
g/l	NN	O
,	,	O
the	DT	O
5-year	JJ	O
survival	NN	O
was	VBD	O
43	CD	O
%	NN	O
.	.	O

Other	JJ	O
prognostic	JJ	O
features	NNS	O
were	VBD	O
much	RB	O
less	RBR	O
important	JJ	O
when	WRB	O
account	NN	O
was	VBD	O
taken	VBN	O
of	IN	O
renal	JJ	O
function	NN	O
and	CC	O
haemoglobin	JJ	O
level	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
metronidazole	NN	O
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	Condition
wound	NN	Condition
infection	NN	Condition
in	IN	O
elective	JJ	O
colon	NN	O
surgery	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
assessing	VBG	O
the	DT	O
relative	JJ	O
effectiveness	NN	O
of	IN	O
erythromycin-neomycin	JJ	O
and	CC	O
metronidazole-neomycin	JJ	O
as	IN	O
a	DT	O
preoperative	JJ	O
bowel	NN	O
preparation	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

Bacteriologic	NNP	O
studies	NNS	O
of	IN	O
feces	NNS	O
and	CC	O
colon	NN	O
content	NN	O
revealed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
reduction	NN	O
of	IN	O
aerobic	JJ	O
bacteria	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
,	,	O
however	RB	O
,	,	O
a	DT	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
in	IN	O
anaerobic	JJ	O
bacteria	NNS	O
in	IN	O
the	DT	O
feces	NNS	O
and	CC	O
colon	NN	O
contents	NNS	O
of	IN	O
patients	NNS	O
receiving	VBG	O
metronidazole	NN	O
.	.	O

Wound	IN	O
infection	NN	O
rate	NN	O
was	VBD	O
25	CD	O
%	NN	O
in	IN	O
the	DT	O
erythromycin	NN	O
group	NN	O
,	,	O
and	CC	O
organisms	NNS	O
recovered	VBN	O
from	IN	O
the	DT	O
wound	NN	O
in	IN	O
all	DT	O
cases	NNS	O
were	VBD	O
fecal	JJ	O
in	IN	O
nature	NN	O
.	.	O

Two	CD	O
wound	IN	O
infections	NNS	O
occurred	VBD	O
in	IN	O
the	DT	O
metronidazole	NN	O
group	NN	O
(	(	O
5	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
both	DT	O
cases	NNS	O
the	DT	O
organisms	NNS	O
recovered	VBN	O
were	VBD	O
staphylococci	NNS	O
of	IN	O
presumed	JJ	O
skin	JJ	O
origin	NN	O
.	.	O

These	DT	O
studies	NNS	O
suggest	VBP	O
that	IN	O
anaerobic	JJ	O
bacteria	NNS	O
are	VBP	O
the	DT	O
major	JJ	O
contributors	NNS	O
to	TO	O
wound	VB	O
infection	NN	O
after	IN	O
colon	NN	O
surgery	NN	O
and	CC	O
that	IN	O
their	PRP$	O
specific	JJ	O
reduction	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
wound	JJ	O
infection	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
strength	NN	O
training	NN	O
on	IN	O
central	JJ	O
arterial	JJ	O
compliance	NN	O
in	IN	O
middle-aged	JJ	O
and	CC	O
older	JJR	O
adults	NNS	O
.	.	O

BACKGROUND	NNP	O
Contrary	NNP	O
to	TO	O
aerobic	VB	O
exercise	NN	O
,	,	O
strength	NN	O
training	NN	O
(	(	O
ST	NNP	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
decreased	JJ	Condition
central	JJ	Condition
arterial	JJ	Condition
compliance	NN	Condition
in	IN	O
young	JJ	O
men	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
unknown	JJ	O
whether	IN	O
ST	NNP	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
concurrent	JJ	O
endurance	NN	O
training	NN	O
,	,	O
would	MD	O
have	VB	O
a	DT	O
similar	JJ	O
effect	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
reduced	JJ	Condition
baseline	NN	Condition
arterial	JJ	Condition
compliance	NN	Condition
.	.	O

OBJECTIVE	CC	O
The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
ST	NNP	O
program	NN	O
on	IN	O
central	JJ	O
arterial	JJ	O
compliance	NN	O
in	IN	O
middle-aged	JJ	O
and	CC	O
older	JJR	O
adults	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
intervention	NN	O
study	NN	O
in	IN	O
which	WDT	O
37	CD	SampleSize
healthy	JJ	Condition
,	,	O
sedentary	JJ	Condition
men	NNS	Sex
and	CC	O
women	NNS	Sex
(	(	O
52+/-2	JJ	Age
years	NNS	Age
)	)	O
performed	VBD	O
13	CD	O
weeks	NNS	O
of	IN	O
ST	NNP	O
(	(	O
n=13	NN	O
)	)	O
,	,	O
ST+aerobic	NNP	O
exercise	NN	O
(	(	O
n=12	JJ	O
)	)	O
or	CC	O
stretching	VBG	O
exercises	NNS	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
n=12	RB	O
)	)	O
.	.	O

METHODS	JJ	O
Participants	NNS	O
were	VBD	O
rigorously	RB	O
screened	VBN	O
for	IN	O
cardiovascular	JJ	Condition
disease	NN	Condition
and	CC	O
underwent	JJ	O
pre-post	JJ	O
testing	NN	O
for	IN	O
carotid	JJ	Condition
arterial	JJ	Condition
compliance	NN	Condition
(	(	O
via	IN	O
simultaneous	JJ	O
ultrasound	NN	O
and	CC	O
applanation	NN	O
tonometry	NN	O
)	)	O
,	,	O
carotid-femoral	JJ	O
pulse	NN	O
wave	NN	O
velocity	NN	O
,	,	O
plasma	JJ	O
endothelin-1	NN	O
and	CC	O
angiotensin	NN	O
II	NNP	O
concentrations	NNS	O
and	CC	O
carotid	JJ	O
artery	NN	O
vasoreactivity	NN	O
(	(	O
cold	JJ	O
pressor	NN	O
test	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
ST	NNP	O
performed	VBD	O
alone	RB	O
,	,	O
or	CC	O
in	IN	O
conjunction	NN	O
with	IN	O
aerobic	JJ	O
exercise	NN	O
,	,	O
improved	VBN	O
maximal	JJ	O
muscle	NN	O
strength	NN	O
and	CC	O
increased	VBD	O
total	JJ	O
lean	JJ	O
body	NN	O
mass	NN	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
carotid	NN	O
artery	NN	O
compliance	NN	O
or	CC	O
carotid-femoral	JJ	O
pulse	JJ	O
wave	NN	O
velocity	NN	O
following	VBG	O
ST	NNP	O
or	CC	O
ST+aerobic	NNP	O
exercise	NN	O
.	.	O

Carotid	NNP	O
artery	JJ	O
compliance	NN	O
increased	VBD	O
significantly	RB	O
(	(	O
23	CD	O
%	NN	O
)	)	O
following	VBG	O
stretching	VBG	O
which	WDT	O
may	MD	O
be	VB	O
attributed	VBN	O
to	TO	O
a	DT	O
reduction	NN	O
in	IN	O
carotid	NN	O
pulse	JJ	O
pressure	NN	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
plasma	JJ	O
vasoconstrictor	NN	O
hormones	NNS	O
or	CC	O
carotid	VB	O
artery	JJ	O
vasoreactivity	NN	O
following	VBG	O
the	DT	O
interventions	NNS	O
.	.	O

CONCLUSION	NNP	O
Thirteen	NNP	O
weeks	NNS	O
of	IN	O
moderate	JJ	O
ST	NNP	O
two	CD	O
or	CC	O
three	CD	O
times	NNS	O
per	IN	O
week	NN	O
does	VBZ	O
not	RB	O
reduce	VB	O
central	JJ	O
arterial	JJ	O
compliance	NN	O
in	IN	O
middle-aged	JJ	O
and	CC	O
older	JJR	O
adults	NNS	O
.	.	O

[	RB	O
Intravenous	JJ	O
treatment	NN	O
of	IN	O
postpartum	NN	O
anemia	NN	O
with	IN	O
trivalent	JJ	O
ferrum	NN	O
preparation	NN	O
]	NNP	O
.	.	O

AIM	NNP	O
OF	IN	O
THE	NNP	O
STUDY	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectivity	NN	O
and	CC	O
safeness	NN	O
of	IN	O
intravenous	JJ	O
treatment	NN	O
of	IN	O
pospartal	JJ	O
anemia	NN	O
with	IN	O
trivalent	JJ	O
ferrum	NN	O
preparation	NN	O
.	.	O

TYPE	NNP	O
OF	IN	O
THE	NNP	O
STUDY	NNP	O
Prospective	NNP	O
randomized	VBD	O
study	NN	O
.	.	O

SETTING	NNP	O
Department	NNP	O
of	IN	O
Obstetric	NNP	O
and	CC	O
Gynecology	NNP	O
2nd	CD	O
Medical	NNP	O
Faculty	NNP	O
Charles	NNP	O
University	NNP	O
and	CC	O
Teaching	NNP	O
Hospital	NNP	O
Motol	NNP	O
,	,	O
Prague	NNP	O
,	,	O
and	CC	O
Department	NNP	O
of	IN	O
Obstetric	NNP	O
and	CC	O
Gynecology	NNP	O
1st	CD	O
Medical	NNP	O
Faculty	NNP	O
and	CC	O
Teaching	NNP	O
Hospital	NNP	O
Bulovka	NNP	O
,	,	O
Prague	NNP	O
.	.	O

METHODS	NNP	O
500	CD	O
mg	NN	O
of	IN	O
sacharose	JJ	O
ferric	JJ	O
oxide	NN	O
(	(	O
Venofer	NNP	O
)	)	O
was	VBD	O
intravenously	RB	O
administered	VBN	O
in	IN	O
two	CD	O
days	NNS	O
regimen	NNS	O
to	TO	O
50	CD	SampleSize
women	NNS	SampleSize
with	IN	O
clinical	JJ	O
and	CC	O
lab	JJ	O
signs	NNS	O
of	IN	O
postpartal	JJ	Condition
anemia	NN	Condition
.	.	O

The	DT	O
effect	NN	O
of	IN	O
administered	JJ	O
drug	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
comparsion	NN	O
of	IN	O
values	NNS	O
of	IN	O
red	JJ	O
blood	NN	O
count	NN	O
recovered	VBD	O
before	IN	O
the	DT	O
treatment	NN	O
,	,	O
2nd	CD	O
or	CC	O
3rd	CD	O
day	NN	O
post	NN	O
administration	NN	O
and	CC	O
two	CD	O
weeks	NNS	O
later	RB	O
.	.	O

The	DT	O
serum	NN	O
values	NNS	O
of	IN	O
soluble	JJ	O
transferrin	NN	O
receptors	NNS	O
and	CC	O
ferritin	NNS	O
were	VBD	O
observed	VBN	O
as	IN	O
markers	NNS	O
of	IN	O
iron	NN	O
cell	NN	O
saturation	NN	O
and	CC	O
body	NN	O
iron	NN	O
reserves	NNS	O
,	,	O
too	RB	O
.	.	O

Integral	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
the	DT	O
monitoring	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
during	IN	O
the	DT	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Venofer	NNP	O
came	VBD	O
in	IN	O
sight	NN	O
as	IN	O
effective	JJ	O
drug	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pospartal	JJ	O
anemia	NN	O
and	CC	O
could	MD	O
become	VB	O
as	IN	O
the	DT	O
alternative	NN	O
to	TO	O
blood	VB	O
transfusion	NN	O
in	IN	O
mid-severe	JJ	O
cases	NNS	O
.	.	O

It	PRP	O
should	MD	O
be	VB	O
emphasized	VBN	O
that	IN	O
we	PRP	O
have	VBP	O
not	RB	O
encountered	VBN	O
any	DT	O
serious	JJ	O
adverse	JJ	O
event	NN	O
with	IN	O
intravenous	JJ	O
trivalent	NN	O
saccharose	VBD	O
ferric	JJ	O
oxide	JJ	O
treatment	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
home	NN	O
measurement	NN	O
and	CC	O
ambulatory	JJ	O
monitoring	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
the	DT	O
adjustment	NN	O
of	IN	O
antihypertensive	JJ	O
treatment	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
home	NN	O
and	CC	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
in	IN	O
the	DT	O
adjustment	NN	O
of	IN	O
antihypertensive	JJ	O
treatment	NN	O
.	.	O

METHODS	NNP	O
After	IN	O
a	DT	O
4-week	JJ	O
washout	NN	O
period	NN	O
,	,	O
patients	NNS	O
whose	WP$	O
untreated	JJ	O
daytime	JJ	O
diastolic	JJ	O
ambulatory	NN	O
BP	NNP	O
averaged	VBD	O
>	NNP	O
or	CC	O
=	$	O
85	CD	O
mm	NN	O
Hg	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
be	VB	O
treated	VBN	O
according	VBG	O
to	TO	O
their	PRP$	O
ambulatory	NN	O
or	CC	O
home	NN	O
BP	NNP	O
.	.	O

Antihypertensive	NNP	O
treatment	NN	O
was	VBD	O
adjusted	VBN	O
at	IN	O
6-week	JJ	O
intervals	NNS	O
according	VBG	O
to	TO	O
the	DT	O
mean	JJ	O
daytime	JJ	O
ambulatory	NN	O
diastolic	JJ	O
BP	NNP	O
or	CC	O
the	DT	O
mean	JJ	O
home	NN	O
diastolic	NN	O
BP	NNP	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
randomization	NN	O
group	NN	O
.	.	O

If	IN	O
the	DT	O
diastolic	JJ	O
BP	NNP	O
stayed	VBD	O
above	IN	O
80	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
the	DT	O
physician	NN	O
blinded	VBD	O
to	TO	O
randomization	VB	O
intensified	JJ	O
hypertensive	JJ	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Ninety-eight	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

During	IN	O
the	DT	O
24-week	JJ	O
follow-up	JJ	O
period	NN	O
both	DT	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
BP	NNP	O
decreased	VBD	O
significantly	RB	O
within	IN	O
both	DT	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
the	DT	O
systolic/diastolic	JJ	O
differences	NNS	O
between	IN	O
ambulatory	NN	O
(	(	O
n	JJ	O
=	NNP	O
46	CD	O
)	)	O
and	CC	O
home	NN	O
(	(	O
n	JJ	O
=	NNP	O
52	CD	O
)	)	O
BP	NNP	O
groups	NNS	O
in	IN	O
home	NN	O
,	,	O
daytime	JJ	O
ambulatory	NN	O
,	,	O
night-time	JJ	O
ambulatory	NN	O
,	,	O
and	CC	O
24-h	JJ	O
ambulatory	NN	O
BP	NNP	O
changes	NNS	O
averaged	VBD	O
2.6/2.6	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
0.6/1.7	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
1.0/1.4	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
and	CC	O
0.6/1.5	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
range	VBP	O
.06	NNP	O
to	TO	O
.75	VB	O
)	)	O
A	DT	O
nonsignificant	JJ	O
trend	NN	O
to	TO	O
more	RBR	O
intensive	JJ	O
drug	NN	O
therapy	NN	O
in	IN	O
the	DT	O
ambulatory	JJ	O
BP	NNP	O
group	NN	O
and	CC	O
a	DT	O
nonsignificant	JJ	O
trend	NN	O
to	TO	O
larger	JJR	O
share	NN	O
of	IN	O
patients	NNS	O
reaching	VBG	O
(	(	O
57.7	CD	O
%	NN	O
v	JJ	O
43.5	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
.16	NNP	O
)	)	O
the	DT	O
target	NN	O
pressure	NN	O
in	IN	O
the	DT	O
home	NN	O
BP	NNP	O
group	NN	O
was	VBD	O
observed	VBN	O
due	JJ	O
to	TO	O
the	DT	O
3.8	CD	O
mm	NN	O
Hg	NNP	O
difference	NN	O
in	IN	O
ambulatory	NN	O
and	CC	O
home	NN	O
diastolic	NN	O
BP	NNP	O
at	IN	O
randomization	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
adjustment	NN	O
of	IN	O
antihypertensive	JJ	O
treatment	NN	O
based	VBN	O
on	IN	O
either	DT	O
ambulatory	NN	O
or	CC	O
home	NN	O
BP	NNP	O
measurement	NN	O
led	VBD	O
to	TO	O
good	JJ	O
BP	NNP	O
control	NN	O
.	.	O

No	DT	O
significant	JJ	O
between-group	JJ	O
differences	NNS	O
in	IN	O
BP	NNP	O
changes	NNS	O
were	VBD	O
seen	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Additional	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
provide	VB	O
more	JJR	O
conclusive	JJ	O
results	NNS	O
.	.	O

Comparative	JJ	O
efficacy	NN	O
of	IN	O
intravenous	JJ	O
ibutilide	JJ	O
versus	NN	O
procainamide	NN	O
for	IN	O
enhancing	VBG	O
termination	NN	O
of	IN	O
atrial	JJ	O
flutter	NN	O
by	IN	O
atrial	JJ	O
overdrive	JJ	O
pacing	NN	O
.	.	O

This	DT	O
study	NN	O
compares	VBZ	O
the	DT	O
influence	NN	O
of	IN	O
intravenous	JJ	O
ibutilide	NN	O
,	,	O
a	DT	O
class	NN	O
III	NNP	O
antiarrhythmic	JJ	O
agent	NN	O
,	,	O
with	IN	O
procainamide	NN	O
,	,	O
a	DT	O
class	NN	O
IA	NNP	O
antiarrhythmic	JJ	O
agent	NN	O
,	,	O
and	CC	O
with	IN	O
placebo	NN	O
on	IN	O
its	PRP$	O
ability	NN	O
to	TO	O
terminate	VB	O
atrial	JJ	O
flutter	NN	O
using	VBG	O
rapid	JJ	O
atrial	JJ	O
pacing	NN	O
.	.	O

Fifty-nine	NNP	O
episodes	NNS	O
of	IN	O
atrial	JJ	Condition
flutter	NN	Condition
in	IN	O
54	CD	SampleSize
patients	NNS	O
who	WP	O
failed	VBD	O
to	TO	O
terminate	VB	O
with	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
ibutilide	NN	O
,	,	O
procainamide	NN	O
,	,	O
or	CC	O
placebo	VB	O
alone	JJ	O
underwent	JJ	O
attempts	NNS	O
at	IN	O
pacing	VBG	O
termination	NN	O
using	VBG	O
a	DT	O
standard	JJ	O
protocol	NN	O
of	IN	O
burst	JJ	O
atrial	JJ	O
overdrive	JJ	O
pacing	NN	O
.	.	O

Atrial	JJ	O
flutter	NN	O
cycle	NN	O
length	NN	O
and	CC	O
atrial	JJ	O
monophasic	JJ	O
action	NN	O
potential	JJ	O
duration	NN	O
recorded	VBN	O
from	IN	O
the	DT	O
right	JJ	O
atrium	NN	O
during	IN	O
atrial	JJ	O
flutter	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
following	VBG	O
infusion	NN	O
of	IN	O
ibutilide	NN	O
,	,	O
procainamide	NN	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Both	DT	O
ibutilide	JJ	O
and	CC	O
procainamide	JJ	O
significantly	RB	O
enhanced	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
pacing-induced	JJ	O
termination	NN	O
of	IN	O
atrial	JJ	O
flutter	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Pacing	VBG	O
converted	VBD	O
2	CD	O
of	IN	O
11	CD	O
patients	NNS	O
(	(	O
18	CD	O
%	NN	O
)	)	O
who	WP	O
received	VBD	O
placebo	NN	O
,	,	O
13	CD	O
of	IN	O
15	CD	O
patients	NNS	O
(	(	O
87	CD	O
%	NN	O
)	)	O
who	WP	O
received	VBD	O
ibutilide	RB	O
,	,	O
and	CC	O
29	CD	O
of	IN	O
33	CD	O
patients	NNS	O
(	(	O
88	CD	O
%	NN	O
)	)	O
who	WP	O
received	VBD	O
procainamide	RB	O
to	TO	O
sinus	VB	O
rhythm	NN	O
.	.	O

Ibutilide	NNP	O
and	CC	O
procainamide	RB	O
compared	VBN	O
with	IN	O
placebo	NN	O
markedly	RB	O
reduced	VBD	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
the	DT	O
incidence	NN	O
of	IN	O
pacing-induced	JJ	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

The	DT	O
atrial	JJ	O
flutter	NN	O
cycle	NN	O
length	NN	O
was	VBD	O
prolonged	VBN	O
significantly	RB	O
less	RBR	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
atrial	JJ	O
monophasic	JJ	O
action	NN	O
potential	JJ	O
duration	NN	O
was	VBD	O
increased	VBN	O
significantly	RB	O
more	RBR	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
by	IN	O
ibutilide	NN	O
than	IN	O
by	IN	O
procainamide	NN	O
.	.	O

Although	IN	O
the	DT	O
electrophysiologic	JJ	O
changes	NNS	O
induced	VBN	O
by	IN	O
these	DT	O
antiarrhythmic	JJ	O
agents	NNS	O
contributed	VBD	O
to	TO	O
facilitating	VBG	O
pacing-induced	JJ	O
termination	NN	O
,	,	O
neither	CC	O
tachycardia	JJ	O
cycle	NN	O
length	NN	O
nor	CC	O
action	NN	O
potential	JJ	O
duration	NN	O
were	VBD	O
useful	JJ	O
predictors	NNS	O
of	IN	O
the	DT	O
ability	NN	O
of	IN	O
pacing	VBG	O
to	TO	O
terminate	VB	O
atrial	JJ	O
flutter	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
despite	IN	O
differing	VBG	O
electrophysiologic	JJ	O
effects	NNS	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
intravenous	JJ	O
ibutilide	NN	O
or	CC	O
procainamide	NN	O
enhances	VBZ	O
the	DT	O
termination	NN	O
of	IN	O
atrial	JJ	O
flutter	NN	O
by	IN	O
atrial	JJ	O
overdrive	JJ	O
pacing	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
norgestimate	NN	O
and	CC	O
ethinyl	NN	O
estradiol	NN	O
in	IN	O
treating	VBG	O
moderate	JJ	Condition
acne	NN	Condition
vulgaris	NN	Condition
.	.	O

BACKGROUND	NNP	O
An	DT	O
excess	NN	O
of	IN	O
androgen	NN	O
is	VBZ	O
believed	VBN	O
to	TO	O
contribute	VB	O
to	TO	O
development	NN	O
of	IN	O
acne	NN	O
in	IN	O
some	DT	O
patients	NNS	O
.	.	O

Because	IN	O
oral	JJ	O
contraceptives	NNS	O
(	(	O
OCs	NNP	O
)	)	O
may	MD	O
reduce	VB	O
the	DT	O
active	JJ	O
androgen	NN	O
level	NN	O
,	,	O
hormonal	JJ	O
therapy	NN	O
with	IN	O
OCs	NNP	O
has	VBZ	O
been	VBN	O
used	VBN	O
successfully	RB	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
acne	NN	Condition
,	,	O
although	IN	O
this	DT	O
treatment	NN	O
has	VBZ	O
previously	RB	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
placebo-controlled	JJ	O
trials	NNS	O
.	.	O

OBJECTIVE	CC	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
triphasic	JJ	O
,	,	O
combination	NN	O
OC	NNP	O
(	(	O
ORTHO	NNP	O
TRI-CYCLEN	NNP	O
[	NNP	O
Ortho-McNeil	NNP	O
Pharmaceutical	NNP	O
,	,	O
Raritan	NNP	O
,	,	O
N.J.	NNP	O
]	NNP	O
,	,	O
norgestimate/ethinyl	RB	O
estradiol	NN	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
acne	NN	O
vulgaris	NN	O
.	.	O

METHODS	NNP	O
Two	CD	SampleSize
hundred	VBD	SampleSize
fifty-seven	RB	SampleSize
healthy	JJ	Condition
female	NN	Sex
subjects	NNS	O
,	,	O
15	CD	Age
to	TO	Age
49	CD	Age
years	NNS	Age
of	IN	O
age	NN	O
with	IN	O
moderate	JJ	Condition
acne	NNS	Condition
vulgaris	NN	Condition
,	,	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Each	DT	O
month	NN	O
for	IN	O
6	CD	O
months	NNS	O
,	,	O
subjects	VBZ	O
received	VBN	O
either	RB	O
3	CD	O
consecutive	JJ	O
weeks	NNS	O
of	IN	O
the	DT	O
OC	NNP	O
(	(	O
i.e.	FW	O
,	,	O
tablets	NNS	O
containing	VBG	O
a	DT	O
fixed	VBN	O
dose	NN	O
of	IN	O
ethinyl	JJ	O
estradiol	NN	O
[	VBD	O
0.035	CD	O
mg	NN	O
]	NN	O
and	CC	O
increasing	VBG	O
doses	NNS	O
of	IN	O
norgestimate	JJ	O
[	NNS	O
0.180	CD	O
mg	NNS	O
,	,	O
0.215	CD	O
mg	NN	O
,	,	O
0.250	CD	O
mg	NN	O
]	NN	O
)	)	O
followed	VBN	O
by	IN	O
7	CD	O
days	NNS	O
of	IN	O
inactive	JJ	O
drug	NN	O
or	CC	O
placebo	NN	O
(	(	O
color-matched	JJ	O
tablets	NNS	O
)	)	O
.	.	O

Efficacy	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
facial	JJ	O
acne	JJ	O
lesion	NN	O
counts	NNS	O
,	,	O
an	DT	O
investigator	NN	O
's	POS	O
global	JJ	O
assessment	NN	O
,	,	O
a	DT	O
subject	NN	O
's	POS	O
self-assessment	NN	O
,	,	O
and	CC	O
an	DT	O
analysis	NN	O
of	IN	O
within-cycle	JJ	O
variation	NN	O
(	(	O
cycle	NN	O
6	CD	O
)	)	O
in	IN	O
lesion	NN	O
counts	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
160	CD	SampleSize
subjects	NNS	O
in	IN	O
whom	WP	O
efficacy	NN	O
could	MD	O
be	VB	O
evaluated	VBN	O
,	,	O
the	DT	O
OC	NNP	O
group	NN	O
showed	VBD	O
a	DT	O
statistically	RB	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
than	IN	O
the	DT	O
placebo	NN	O
group	NN	O
for	IN	O
all	DT	O
primary	JJ	O
efficacy	NN	O
measures	NNS	O
.	.	O

The	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
inflammatory	JJ	O
lesion	NN	O
count	NN	O
from	IN	O
baseline	NN	O
to	TO	O
cycle	NN	O
6	CD	O
was	VBD	O
11.8	CD	O
(	(	O
62.0	CD	O
%	NN	O
)	)	O
versus	NN	O
7.6	CD	O
(	(	O
38.6	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
total	JJ	O
lesion	NN	O
count	NN	O
was	VBD	O
29.1	CD	O
(	(	O
53.1	CD	O
%	NN	O
)	)	O
versus	NN	O
14.1	CD	O
(	(	O
26.8	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.0001	CD	O
)	)	O
in	IN	O
the	DT	O
OC	NNP	O
and	CC	O
placebo	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
investigator	NN	O
's	POS	O
global	JJ	O
assessment	NN	O
,	,	O
93.7	CD	O
%	NN	O
of	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
versus	VBD	O
65.4	CD	O
%	NN	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
improved	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Six	CD	O
of	IN	O
the	DT	O
seven	CD	O
secondary	JJ	O
efficacy	NN	O
measures	NNS	O
(	(	O
total	JJ	O
comedones	NNS	O
,	,	O
open	JJ	O
comedones	NNS	O
,	,	O
closed	VBD	O
comedones	NNS	O
,	,	O
papules	NNS	O
,	,	O
pustules	NNS	O
,	,	O
and	CC	O
the	DT	O
subject	NN	O
's	POS	O
self-assessment	NN	O
of	IN	O
study	NN	O
treatment	NN	O
)	)	O
were	VBD	O
also	RB	O
significantly	RB	O
more	RBR	O
favorable	JJ	O
in	IN	O
the	DT	O
OC	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
An	DT	O
OC	NNP	O
containing	VBG	O
0.035	CD	O
mg	NN	O
of	IN	O
ethinyl	JJ	O
estradiol	NN	O
combined	VBN	O
with	IN	O
the	DT	O
triphasic	JJ	O
regimen	NNS	O
of	IN	O
norgestimate	NN	O
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
treatment	NN	O
of	IN	O
moderate	JJ	O
acne	NNS	O
vulgaris	VBP	O
in	IN	O
women	NNS	Sex
with	IN	O
no	DT	O
known	VBN	O
contraindication	NN	O
to	TO	O
OC	NNP	O
therapy	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
different	JJ	O
inhaled	JJ	O
combination	NN	O
therapies	NNS	O
(	(	O
EDICT	NNP	O
)	)	O
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
comparison	NN	O
of	IN	O
Seretide	NNP	O
(	(	O
50/250	CD	O
microg	NN	O
bd	NN	O
Diskus	NNP	O
vs.	FW	O
formoterol	NN	O
(	(	O
12	CD	O
microg	RB	O
bd	NN	O
)	)	O
and	CC	O
budesonide	NN	O
(	(	O
800	CD	O
microg	RB	O
bd	NN	O
)	)	O
given	VBN	O
concurrently	RB	O
(	(	O
both	DT	O
via	IN	O
Turbuhaler	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
moderate-to-severe	JJ	Condition
asthma	NN	Condition
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
safety	NN	O
and	CC	O
cost	NN	O
of	IN	O
Seretide	NNP	O
(	(	O
salmeterol/fluticasone	NN	O
propionate	NN	O
(	(	O
Salm/FP	NNP	O
)	)	O
,	,	O
50/250	CD	O
microg	NN	O
bd	NN	O
)	)	O
via	IN	O
Diskus	NNP	O
with	IN	O
formoterol	NN	O
(	(	O
Form	NNP	O
;	:	O
12	CD	O
microg	NN	O
bd	NN	O
)	)	O
and	CC	O
budesonide	NN	O
(	(	O
Bud	NNP	O
;	:	O
800	CD	O
microg	NN	O
bd	NN	O
)	)	O
given	VBN	O
concurrently	RB	O
(	(	O
Form+Bud	NNP	O
)	)	O
via	IN	O
Turbuhaler	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
moderate-to-severe	JJ	O
asthma	NNS	O
who	WP	O
were	VBD	O
uncontrolled	VBN	O
on	IN	O
existing	VBG	O
corticosteroid	JJ	O
therapy	NN	O
.	.	O

The	DT	O
study	NN	O
used	VBD	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
double-dummy	JJ	O
,	,	O
parallel-group	JJ	O
design	NN	O
,	,	O
consisting	VBG	O
of	IN	O
a	DT	O
2-week	JJ	O
run-in	JJ	O
period	NN	O
on	IN	O
current	JJ	O
corticosteroid	NN	O
therapy	NN	O
(	(	O
1000-1600	JJ	O
microg/day	NN	O
of	IN	O
BDP	NNP	O
or	CC	O
equivalent	NN	O
)	)	O
and	CC	O
a	DT	O
12-week	JJ	O
treatment	NN	O
period	NN	O
.	.	O

Symptomatic	JJ	O
patients	NNS	O
(	(	O
n	JJ	SampleSize
=	NNP	SampleSize
428	CD	SampleSize
)	)	O
with	IN	Condition
FEV1	NNP	Condition
of	IN	Condition
50-85	CD	Condition
%	NN	Condition
predicted	JJ	Condition
and	CC	Condition
increased	JJ	Condition
symptom	NN	Condition
scores	NNS	Condition
or	CC	Condition
reliever	NN	Condition
use	NN	Condition
during	IN	Condition
run-in	NN	Condition
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
either	DT	O
Salm/FP	NNP	O
(	(	O
50/250	CD	O
microg	RB	O
bd	NN	O
)	)	O
via	IN	O
a	DT	O
single	JJ	O
Diskus	NNP	O
inhaleror	NN	O
Form+Bud	NNP	O
(	(	O
12+800	CD	O
microg	RB	O
bd	NN	O
)	)	O
via	IN	O
separate	JJ	O
Turbuhalers	NNPS	O
.	.	O

Clinic	NNP	O
,	,	O
diary	JJ	O
card	NN	O
and	CC	O
asthma-related	JJ	O
health-care	JJ	O
resource	NN	O
utilisation	NN	O
data	NNS	O
were	VBD	O
collected	VBN	O
.	.	O

Improvement	NN	O
in	IN	O
mean	JJ	O
morning	NN	O
peak	NN	O
expiratory	NN	O
flow	NN	O
(	(	O
PEFam	NNP	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
Salm/FP	NNP	O
and	CC	O
Form+Bud	NNP	O
groups	NNS	O
.	.	O

Both	DT	O
PEFam	NNP	O
and	CC	O
mean	JJ	O
evening	NN	O
PEF	NNP	O
(	(	O
PEFpm	NNP	O
)	)	O
increased	VBN	O
by	IN	O
a	DT	O
clinically	RB	O
significant	JJ	O
amount	NN	O
(	(	O
>	JJ	O
20	CD	O
L/min	NNP	O
)	)	O
from	IN	O
baseline	NN	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
mean	JJ	O
rate	NN	O
of	IN	O
exacerbations	NNS	O
(	(	O
mild	NN	O
,	,	O
moderate	JJ	O
or	CC	O
severe	JJ	O
)	)	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
Salm/FP	NNP	O
group	NN	O
(	(	O
0.472	CD	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
Form+Bud	NNP	O
group	NN	O
(	(	O
0.735	CD	O
)	)	O
(	(	O
ratio	JJ	O
=	VBZ	O
0.64	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
despite	IN	O
the	DT	O
three-fold	JJ	O
lower	JJR	O
microgram	NN	O
inhaled	VBN	O
corticosteroid	NN	O
dose	NN	O
in	IN	O
the	DT	O
Salm/FP	NNP	O
group	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
Salm/FP	NNP	O
group	NN	O
also	RB	O
experienced	VBD	O
significantly	RB	O
fewer	JJR	O
nocturnal	JJ	O
symptoms	NNS	O
,	,	O
with	IN	O
a	DT	O
higher	JJR	O
median	JJ	O
percentage	NN	O
of	IN	O
symptom-free	JJ	O
nights	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
nights	NNS	O
with	IN	O
a	DT	O
symptom	NN	O
score	NN	O
<	$	O
2	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
and	CC	O
nights	NNS	O
with	IN	O
no	DT	O
awakenings	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Total	JJ	O
asthma-related	JJ	O
health-care	NN	O
costs	NNS	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
Salm/FP	NNP	O
group	NN	O
than	IN	O
the	DT	O
Form+Bud	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
with	IN	O
a	DT	O
similar	JJ	O
low	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
in	IN	O
symptomatic	JJ	O
patients	NNS	O
with	IN	O
moderate-to-severe	JJ	O
asthma	NN	O
,	,	O
Salm/FP	NNP	O
(	(	O
50/250	CD	O
microg	RB	O
bd	NN	O
)	)	O
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	O
convenient	NN	O
device	NN	O
(	(	O
Diskus	NNP	O
)	)	O
,	,	O
was	VBD	O
at	IN	O
least	JJS	O
as	RB	O
effective	JJ	O
as	IN	O
an	DT	O
approximately	RB	O
three-fold	JJ	O
higher	JJR	O
microgram	NN	O
corticosteroid	VBP	O
dose	NN	O
of	IN	O
Bud	NNP	O
(	(	O
800	CD	O
microg	RB	O
bd	NN	O
)	)	O
given	VBN	O
concurrently	RB	O
with	IN	O
Form	NNP	O
(	(	O
12	CD	O
microg	RB	O
bd	NN	O
)	)	O
in	IN	O
terms	NNS	O
of	IN	O
improvement	NN	O
in	IN	O
PEFam	NNP	O
,	,	O
and	CC	O
superior	JJ	O
at	IN	O
reducing	VBG	O
exacerbations	NNS	O
and	CC	O
nights	NNS	O
with	IN	O
symptoms	NNS	O
or	CC	O
night-time	JJ	O
awakenings	NNS	O
.	.	O

Salm/FP	NNP	O
was	VBD	O
also	RB	O
the	DT	O
less	RBR	O
costly	JJ	O
treatment	NN	O
due	JJ	O
primarily	RB	O
to	TO	O
lower	JJR	O
hospitalisation	NN	O
and	CC	O
drug	NN	O
costs	NNS	O
.	.	O

Factors	NNS	O
that	WDT	O
influence	NN	O
cancer	NN	Condition
patients	NNS	Condition
'	POS	Condition
anxiety	NN	Condition
following	VBG	O
a	DT	O
medical	JJ	O
consultation	NN	O
:	:	O
impact	NN	O
of	IN	O
a	DT	O
communication	NN	O
skills	VBZ	O
training	VBG	O
programme	NN	O
for	IN	O
physicians	NNS	O
.	.	O

BACKGROUND	NNP	O
No	NNP	O
study	NN	O
has	VBZ	O
yet	RB	O
assessed	VBN	O
the	DT	O
impact	NN	O
of	IN	O
physicians	NNS	O
'	POS	O
skills	NNS	O
acquisition	NN	O
after	IN	O
a	DT	O
communication	NN	O
skills	VBZ	O
training	VBG	O
programme	NN	O
on	IN	O
the	DT	O
evolution	NN	O
of	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
following	VBG	O
a	DT	O
medical	JJ	O
consultation	NN	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
compare	VB	O
the	DT	O
impact	NN	O
,	,	O
on	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
,	,	O
of	IN	O
a	DT	O
basic	JJ	O
communication	NN	O
skills	NNS	O
training	VBG	O
programme	NN	O
(	(	O
BT	NNP	O
)	)	O
and	CC	O
the	DT	O
same	JJ	O
programme	NN	O
consolidated	VBN	O
by	IN	O
consolidation	NN	O
workshops	NNS	O
(	(	O
CW	NNP	O
)	)	O
,	,	O
and	CC	O
to	TO	O
investigate	VB	O
physicians	NNS	O
'	POS	O
communication	NN	O
variables	NNS	O
associated	VBN	O
with	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Physicians	NNP	Condition
,	,	O
after	IN	O
attending	VBG	O
the	DT	O
BT	NNP	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
CW	NNP	O
or	CC	O
to	TO	O
a	DT	O
waiting	VBG	O
list	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
was	VBD	O
not	RB	O
a	DT	O
non-intervention	JJ	O
group	NN	O
.	.	O

Consultations	NNS	O
with	IN	O
a	DT	O
cancer	NN	O
patient	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

Patients	NNS	O
'	POS	O
anxiety	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
State	NNP	O
Trait	NNP	O
Anxiety	NNP	O
Inventory	NNP	O
before	IN	O
and	CC	O
after	IN	O
a	DT	O
consultation	NN	O
.	.	O

Communication	NNP	O
skills	NNS	O
were	VBD	O
analysed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Cancer	NNP	O
Research	NNP	O
Campaign	NNP	O
Workshop	NNP	O
Evaluation	NNP	O
Manual	NNP	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
change	NN	O
over	IN	O
time	NN	O
and	CC	O
between	IN	O
groups	NNS	O
was	VBD	O
observed	VBN	O
.	.	O

Mixed-effects	NNS	O
modelling	VBG	O
showed	VBD	O
that	IN	O
a	DT	O
decrease	NN	O
in	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
was	VBD	O
linked	VBN	O
with	IN	O
screening	JJ	O
questions	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.045	CD	O
)	)	O
,	,	O
physicians	NNS	O
'	POS	O
satisfaction	NN	O
about	IN	O
support	NN	O
given	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
and	CC	O
with	IN	O
patients	NNS	O
'	POS	O
distress	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

An	DT	O
increase	NN	O
in	IN	O
anxiety	NN	O
was	VBD	O
linked	VBN	O
with	IN	O
breaking	VBG	O
bad	JJ	O
news	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.050	CD	O
)	)	O
and	CC	O
with	IN	O
supportive	JJ	O
skills	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.013	CD	O
)	)	O
.	.	O

No	DT	O
impact	NN	O
of	IN	O
the	DT	O
training	NN	O
programme	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
the	DT	O
influence	NN	O
of	IN	O
some	DT	O
communication	NN	O
skills	NNS	O
on	IN	O
the	DT	O
evolution	NN	O
of	IN	O
patients	NNS	O
'	POS	O
anxiety	NN	O
.	.	O

Physicians	NNS	O
should	MD	O
be	VB	O
aware	JJ	O
of	IN	O
these	DT	O
influences	NNS	O
.	.	O

Lisinopril	NNP	O
administration	NN	O
improves	VBZ	O
insulin	JJ	O
action	NN	O
in	IN	O
aged	JJ	Age
patients	NNS	O
with	IN	O
hypertension	NN	Condition
.	.	O

Thirty	NNP	SampleSize
elderly	JJ	Age
,	,	O
mildly	RB	Condition
hypertensive	JJ	Condition
patients	NNS	O
were	VBD	O
enrolled	VBN	O
for	IN	O
a	DT	O
single-blind	NN	O
,	,	O
randomised	VBD	O
cross-over	NN	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
in	IN	O
which	WDT	O
placebo	NN	O
and	CC	O
lisinopril	NN	O
(	(	O
20	CD	O
mg/day	NN	O
before	IN	O
breakfast	NN	O
)	)	O
were	VBD	O
given	VBN	O
for	IN	O
4	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
,	,	O
respectively	RB	O
.	.	O

A	DT	O
wash-out	JJ	O
period	NN	O
of	IN	O
3	CD	O
weeks	NNS	O
between	IN	O
placebo	NN	O
and	CC	O
lisinopril	NN	O
was	VBD	O
observed	VBN	O
.	.	O

In	IN	O
each	DT	O
patient	NN	O
a	DT	O
euglycaemic	JJ	O
glucose	NN	O
clamp	NN	O
with	IN	O
simultaneous	JJ	O
indirect	JJ	O
calorimetry	NN	O
allowed	VBD	O
us	PRP	O
to	TO	O
determine	VB	O
whole	JJ	O
body	NN	O
glucose	JJ	O
disposal	NN	O
and	CC	O
substrate	JJ	O
oxidation	NN	O
.	.	O

Changes	NNS	O
in	IN	O
morning	NN	O
SBP	NNP	O
and	CC	O
DBP	NNP	O
were	VBD	O
also	RB	O
determined	VBN	O
.	.	O

Lisinopril	NNP	O
vs.	IN	O
placebo	NN	O
significantly	RB	O
improved	VBN	O
whole	JJ	O
body	NN	O
glucose	JJ	O
disposal	NN	O
(	(	O
40.4	CD	O
+/-	JJ	O
0.4	CD	O
vs.	FW	O
30.3	CD	O
+/-	JJ	O
0.4	CD	O
mumol/kg	NN	O
LBM	NNP	O
x	NNP	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
non-oxidative	JJ	O
glucose	JJ	O
metabolism	NN	O
(	(	O
18.1	CD	O
+/-	JJ	O
0.7	CD	O
vs.	FW	O
10.9	CD	O
+/-	JJ	O
0.6	CD	O
mumol/kg	NN	O
LBM	NNP	O
x	NNP	O
min	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
fasting	VBG	O
plasma	JJ	O
potassium	NN	O
levels	NNS	O
(	(	O
4.8	CD	O
+/-	JJ	O
3	CD	O
vs.	FW	O
4.4	CD	O
+/-	JJ	O
0.4	CD	O
mmol/l	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

SBP	NNP	O
(	(	O
175	CD	O
+/-	JJ	O
3.3	CD	O
vs.	FW	O
160	CD	O
+/-	JJ	O
3.0	CD	O
mm	NN	O
Hg	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
DBP	NNP	O
(	(	O
106	CD	O
+/-	JJ	O
2.3	CD	O
vs.	FW	O
95	CD	O
+/-	JJ	O
2.0	CD	O
mm	NN	O
Hg	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
lisinopril	JJ	O
administration	NN	O
.	.	O

After	IN	O
ACE	NNP	O
inhibition	NN	O
,	,	O
fasting	VBG	O
plasma	JJ	O
potassium	NN	O
levels	NNS	O
correlated	VBN	O
with	IN	O
the	DT	O
decline	NN	O
in	IN	O
mean	JJ	O
arterial	JJ	O
BP	NNP	O
(	(	O
r	NN	O
=	NNP	O
-0.71	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.006	CD	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
lisinopril	JJ	O
administration	NN	O
reduces	VBZ	O
arterial	JJ	O
BP	NNP	O
and	CC	O
improves	VBZ	O
insulin	JJ	O
sensitivity	NN	O
in	IN	O
elderly	JJ	Age
hypertensive	JJ	Condition
patients	NNS	O
.	.	O

Antiinflammatory	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
phosphodiesterase-4	JJ	O
inhibitor	NN	O
cilomilast	NN	O
(	(	O
Ariflo	NNP	O
)	)	O
in	IN	O
chronic	JJ	Condition
obstructive	JJ	Condition
pulmonary	JJ	Condition
disease	NN	Condition
.	.	O

Cilomilast	NNP	O
(	(	O
Ariflo	NNP	O
)	)	O
,	,	O
a	DT	O
new	JJ	O
oral	JJ	O
phosphodiesterase-4	JJ	O
selective	JJ	O
inhibitor	NN	O
,	,	O
improves	VBZ	O
lung	JJ	O
function	NN	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

We	PRP	O
have	VBP	O
evaluated	VBN	O
its	PRP$	O
antiinflammatory	JJ	O
effects	NNS	O
in	IN	O
59	CD	SampleSize
patients	NNS	O
with	IN	O
COPD	NNP	Condition
randomized	VBD	O
to	TO	O
receive	VB	O
cilomilast	NN	O
,	,	O
15	CD	O
mg	NN	O
two	CD	O
times	NNS	O
a	DT	O
day	NN	O
,	,	O
or	CC	O
placebo	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Induced	NNP	O
sputum	JJ	O
differential	NN	O
cell	NN	O
counts	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
five	CD	O
further	JJ	O
visits	NNS	O
.	.	O

Interleukin-8	NNP	O
and	CC	O
neutrophil	JJ	O
elastase	NN	O
were	VBD	O
measured	VBN	O
in	IN	O
sputum	NN	O
supernatant	NN	O
.	.	O

Bronchial	JJ	O
biopsies	NNS	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
Week	NNP	O
10	CD	O
were	VBD	O
immunostained	VBN	O
and	CC	O
counted	VBN	O
for	IN	O
neutrophils	NNS	O
,	,	O
CD8+	NNP	O
and	CC	O
CD4+	NNP	O
T-lymphocyte	NNP	O
subsets	NNS	O
,	,	O
and	CC	O
CD68+	NNP	O
macrophages	NNS	O
.	.	O

Cells	NNP	O
expressing	VBG	O
the	DT	O
genes	NNS	O
for	IN	O
interleukin-8	NN	O
and	CC	O
tumor	NN	O
necrosis	NN	O
factor-alpha	NN	O
were	VBD	O
identified	VBN	O
by	IN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
and	CC	O
quantified	VBD	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
analysis	NN	O
of	IN	O
variance	NN	O
(	(	O
ANOVA	NNP	O
)	)	O
of	IN	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
showed	VBD	O
that	IN	O
cilomilast	NN	O
did	VBD	O
not	RB	O
alter	VB	O
any	DT	O
sputum	JJ	O
endpoint	NN	O
or	CC	O
FEV1	NNP	O
.	.	O

However	RB	O
,	,	O
bronchial	JJ	O
biopsies	NNS	O
demonstrated	VBD	O
that	IN	O
cilomilast	NN	O
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
reductions	NNS	O
in	IN	O
CD8+	NNP	O
(	(	O
p	JJ	O
=	VBZ	O
0.001	CD	O
;	:	O
ANOVA	NNP	O
)	)	O
and	CC	O
CD68+	NNP	O
cells	NNS	O
(	(	O
p	JJ	O
<	VBZ	O
0.05	CD	O
;	:	O
ANOVA	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
by	IN	O
Poisson	NNP	O
analysis	NN	O
,	,	O
comparison	NN	O
of	IN	O
cell	NN	O
counts	NNS	O
analyzed	VBN	O
as	IN	O
a	DT	O
ratio	NN	O
of	IN	O
active	JJ	O
to	TO	O
placebo	VB	O
demonstrated	JJ	O
reductions	NNS	O
of	IN	O
CD8+	NNP	O
(	(	O
48	CD	O
%	NN	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
CD68+	NNP	O
(	(	O
47	CD	O
%	NN	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
cells	NNS	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
demonstration	NN	O
of	IN	O
reduction	NN	O
by	IN	O
any	DT	O
agent	NN	O
of	IN	O
airway	JJ	O
tissue	NN	O
inflammatory	NN	O
cells	NNS	O
characteristic	JJ	O
of	IN	O
COPD	NNP	O
.	.	O

Phosphodiesterase-4	JJ	O
inhibitors	NNS	O
represent	VBP	O
a	DT	O
promising	JJ	O
new	JJ	O
class	NN	O
of	IN	O
substances	NNS	O
for	IN	O
use	NN	O
in	IN	O
antiinflammatory	JJ	O
treatment	NN	O
of	IN	O
this	DT	O
disease	NN	O
.	.	O

Airway	NNP	O
management	NN	O
training	NN	O
using	VBG	O
the	DT	O
laryngeal	NN	O
mask	NN	O
airway	NN	O
:	:	O
a	DT	O
comparison	NN	O
of	IN	O
two	CD	O
different	JJ	O
training	VBG	O
programmes	NNS	O
.	.	O

Nurses	NNS	Condition
without	IN	O
prior	JJ	Condition
experience	NN	Condition
in	IN	Condition
the	DT	Condition
use	NN	Condition
of	IN	Condition
the	DT	Condition
laryngeal	JJ	Condition
mask	NN	Condition
airway	NN	Condition
(	(	Condition
LMA	NNP	Condition
)	)	Condition
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
to	TO	O
be	VB	O
trained	VBN	O
in	IN	O
the	DT	O
emergency	NN	O
technique	NN	O
of	IN	O
insertion	NN	O
of	IN	O
an	DT	O
LMA	NNP	O
.	.	O

Group	NNP	O
A	NNP	O
(	(	O
32	CD	SampleSize
nurses	NNS	Condition
)	)	O
were	VBD	O
trained	VBN	O
only	RB	O
on	IN	O
a	DT	O
manikin	NN	O
and	CC	O
group	NN	O
B	NNP	O
(	(	O
20	CD	SampleSize
nurses	NNS	Condition
)	)	O
were	VBD	O
trained	VBN	O
on	IN	O
a	DT	O
manikin	NN	O
and	CC	O
with	IN	O
live	JJ	O
anaesthetised	VBN	O
patient	JJ	O
practice	NN	O
in	IN	O
theatre	NN	O
(	(	O
five	CD	O
successful	JJ	O
insertions	NNS	O
)	)	O
.	.	O

Without	IN	O
further	JJ	O
practice	NN	O
,	,	O
both	DT	O
groups	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
insert	VB	O
an	DT	O
LMA	NNP	O
in	IN	O
a	DT	O
live	JJ	O
patient	NN	O
in	IN	O
theatre	JJ	O
3	CD	O
months	NNS	O
after	IN	O
initial	JJ	O
training	NN	O
.	.	O

Three	CD	O
attempts	NNS	O
per	IN	O
nurse	NN	O
were	VBD	O
allowed	VBN	O
.	.	O

In	IN	O
group	NN	O
A	NNP	O
,	,	O
75	CD	O
%	NN	O
passed	VBD	O
the	DT	O
LMA	NNP	O
successfully	RB	O
at	IN	O
the	DT	O
first	JJ	O
attempt	NN	O
,	,	O
22	CD	O
%	NN	O
at	IN	O
the	DT	O
second	JJ	O
attempt	NN	O
and	CC	O
3	CD	O
%	NN	O
(	(	O
one	CD	O
nurse	NN	O
)	)	O
at	IN	O
the	DT	O
third	JJ	O
attempt	NN	O
.	.	O

In	IN	O
group	NN	O
B	NNP	O
,	,	O
80	CD	O
%	NN	O
were	VBD	O
successful	JJ	O
at	IN	O
first	JJ	O
attempt	NN	O
and	CC	O
20	CD	O
%	NN	O
at	IN	O
the	DT	O
second	JJ	O
attempt	NN	O
.	.	O

Skill	NNP	O
performance	NN	O
and	CC	O
retention	NN	O
were	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
high	JJ	O
following	VBG	O
either	CC	O
training	VBG	O
method	NN	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
performance	NN	O
of	IN	O
either	DT	O
group	NN	O
(	(	O
chi	JJ	O
2	CD	O
)	)	O
.	.	O

We	PRP	O
have	VBP	O
shown	VBN	O
that	IN	O
manikin-only	JJ	O
training	NN	O
in	IN	O
the	DT	O
emergency	NN	O
technique	NN	O
for	IN	O
LMA	NNP	O
insertion	NN	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
live	JJ	O
patient	NN	O
training	NN	O
.	.	O

It	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
manikin	JJ	O
training	VBG	O
alone	NN	O
may	MD	O
be	VB	O
adopted	VBN	O
as	IN	O
a	DT	O
future	JJ	O
training	NN	O
modality	NN	O
if	IN	O
,	,	O
as	IN	O
is	VBZ	O
expected	VBN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
LMA	NNP	O
in	IN	O
resuscitation	NN	O
becomes	NNS	O
more	RBR	O
commonplace	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
a	DT	O
preventive	JJ	O
intervention	NN	O
for	IN	O
child	JJ	Age
anxiety	NN	Condition
in	IN	O
two	CD	O
randomized	JJ	O
attention-control	JJ	O
school	NN	O
trials	NNS	O
.	.	O

The	DT	O
present	JJ	O
research	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
cognitive-behavioral	JJ	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
based	VBN	O
intervention	NN	O
program	NN	O
,	,	O
FRIENDS	NNP	O
,	,	O
for	IN	O
children	NNS	Age
from	IN	O
grades	NNS	O
4	CD	O
to	TO	O
6	CD	O
,	,	O
using	VBG	O
random	JJ	O
assignment	NN	O
at	IN	O
the	DT	O
school-level	NN	O
and	CC	O
an	DT	O
attention-control	JJ	O
design	NN	O
in	IN	O
two	CD	O
longitudinal	JJ	O
studies	NNS	O
.	.	O

The	DT	O
first	JJ	O
study	NN	O
targeted	VBD	O
children	NNS	Age
with	IN	O
anxiety	NN	Condition
symptoms	NNS	O
(	(	O
N=191	NNP	SampleSize
,	,	O
mean	JJ	O
age=10.1	NN	Age
)	)	O
as	IN	O
screened	VBN	O
with	IN	O
self	NN	O
,	,	O
parent	NN	O
,	,	O
and	CC	O
teacher-reports	NNS	O
;	:	O
the	DT	O
second	JJ	O
study	NN	O
took	VBD	O
a	DT	O
universal	JJ	O
approach	NN	O
with	IN	O
full	JJ	O
classrooms	NNS	O
of	IN	O
children	NNS	O
participating	VBG	O
(	(	O
N=253	NNP	SampleSize
,	,	O
mean	JJ	O
age=9.8	NN	Age
)	)	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
no	DT	O
intervention	NN	O
effect	NN	O
in	IN	O
both	DT	O
studies	NNS	O
,	,	O
with	IN	O
children	NNS	O
's	POS	O
anxiety	NN	O
symptoms	NNS	O
decreasing	VBG	O
over	IN	O
time	NN	O
regardless	NN	O
of	IN	O
whether	IN	O
they	PRP	O
were	VBD	O
in	IN	O
the	DT	O
story-reading	NN	O
(	(	O
attention	NN	O
control	NN	O
)	)	O
or	CC	O
FRIENDS	JJ	O
condition	NN	O
.	.	O

The	DT	O
findings	NNS	O
also	RB	O
indicated	VBD	O
that	IN	O
girls	NNS	O
reported	VBD	O
a	DT	O
higher	JJR	O
level	NN	O
of	IN	O
anxiety	NN	O
than	IN	O
boys	NNS	O
and	CC	O
children	NNS	O
in	IN	O
higher	JJR	O
grades	NNS	O
reported	VBD	O
lower	JJR	O
anxiety	NN	O
relative	NN	O
to	TO	O
younger	JJR	O
children	NNS	O
in	IN	O
both	DT	O
studies	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
similar	JJ	O
patterns	NNS	O
were	VBD	O
found	VBN	O
using	VBG	O
a	DT	O
subgroup	NN	O
of	IN	O
children	NNS	O
with	IN	O
high-anxiety	NN	O
symptoms	NNS	O
from	IN	O
both	DT	O
studies	NNS	O
.	.	O

Pharmacokinetic	NNP	O
study	NN	O
of	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
protease	NN	O
inhibitors	NNS	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
amprenavir	NN	O
.	.	O

In	IN	O
an	DT	O
open-label	JJ	O
,	,	O
randomized	VBN	O
,	,	O
multicenter	RBR	O
,	,	O
multiple-dose	JJ	O
pharmacokinetic	JJ	O
study	NN	O
,	,	O
we	PRP	O
determined	VBD	O
the	DT	O
steady-state	JJ	O
pharmacokinetics	NNS	O
of	IN	O
amprenavir	NN	O
with	IN	O
and	CC	O
without	IN	O
coadministration	NN	O
of	IN	O
indinavir	NN	O
,	,	O
nelfinavir	NN	O
,	,	O
or	CC	O
saquinavir	VB	O
soft	JJ	O
gel	NNS	O
formulation	NN	O
in	IN	O
31	CD	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
type	JJ	O
1-infected	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
amprenavir	NN	O
plasma	NN	O
concentrations	NNS	O
were	VBD	O
decreased	VBN	O
by	IN	O
saquinavir	JJ	O
soft	JJ	O
gel	NN	O
capsule	NN	O
(	(	O
by	IN	O
32	CD	O
%	NN	O
for	IN	O
area	NN	O
under	IN	O
the	DT	O
concentration-time	JJ	O
curve	NN	O
at	IN	O
steady	JJ	O
state	NN	O
[	NNS	O
AUC	NNP	O
(	(	O
ss	NN	O
)	)	O
]	NN	O
and	CC	O
37	CD	O
%	NN	O
for	IN	O
peak	NN	O
plasma	NN	O
concentration	NN	O
at	IN	O
steady	JJ	O
state	NN	O
[	NNS	O
C	NNP	O
(	(	O
max	NN	O
,	,	O
ss	NN	O
)	)	O
]	NN	O
)	)	O
and	CC	O
increased	VBN	O
by	IN	O
indinavir	NN	O
(	(	O
33	CD	O
%	NN	O
for	IN	O
AUC	NNP	O
(	(	O
ss	NN	O
)	)	O
)	)	O
.	.	O

Nelfinavir	NNP	O
significantly	RB	O
increased	VBD	O
amprenavir	JJ	O
minimum	JJ	O
drug	NN	O
concentration	NN	O
at	IN	O
steady	JJ	O
state	NN	O
(	(	O
by	IN	O
189	CD	O
%	NN	O
)	)	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
amprenavir	NN	O
AUC	NNP	O
(	(	O
ss	NN	O
)	)	O
or	CC	O
C	NNP	O
(	(	O
max	NN	O
,	,	O
ss	NN	O
)	)	O
.	.	O

Nelfinavir	NNP	O
and	CC	O
saquinavir	JJ	O
steady-state	JJ	O
pharmacokinetics	NNS	O
were	VBD	O
unchanged	JJ	O
by	IN	O
coadministration	NN	O
with	IN	O
amprenavir	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
historical	JJ	O
monotherapy	NN	O
data	NNS	O
.	.	O

Concentrations	NNS	O
of	IN	O
indinavir	NN	O
,	,	O
coadministered	VBN	O
with	IN	O
amprenavir	NN	O
,	,	O
in	IN	O
plasma	NN	O
decreased	VBN	O
in	IN	O
both	DT	O
single-dose	JJ	O
and	CC	O
steady-state	JJ	O
evaluations	NNS	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
amprenavir	JJ	O
steady-state	JJ	O
pharmacokinetic	JJ	O
parameters	NNS	O
,	,	O
relative	JJ	O
to	TO	O
those	DT	O
for	IN	O
amprenavir	JJ	O
alone	RB	O
,	,	O
were	VBD	O
not	RB	O
consistent	JJ	O
among	IN	O
protease	JJ	O
inhibitors	NNS	O
,	,	O
nor	CC	O
were	VBD	O
the	DT	O
changes	NNS	O
consistent	VBP	O
with	IN	O
potential	JJ	O
interactions	NNS	O
in	IN	O
CYP3A4	NNP	O
metabolism	NN	O
or	CC	O
P-glycoprotein	JJ	O
transport	NN	O
.	.	O

No	UH	O
dose	JJ	O
adjustment	NN	O
of	IN	O
either	DT	O
protease	NN	O
inhibitor	NN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
combinations	NNS	O
studied	VBN	O
is	VBZ	O
needed	VBN	O
.	.	O

Increased	VBN	O
repetitive	JJ	O
behaviours	NNS	O
and	CC	O
prolactin	JJ	O
responsivity	NN	O
to	TO	O
oral	JJ	O
m-chlorophenylpiperazine	NN	O
in	IN	O
adults	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Autism	NNP	O
is	VBZ	O
a	DT	O
neurodevelopmental	JJ	O
disorder	NN	O
characterized	VBN	O
by	IN	O
dysfunction	NN	O
in	IN	O
three	CD	O
primary	JJ	O
behavioural	JJ	O
domains	NNS	O
:	:	O
repetitive	JJ	O
behaviours	NNS	O
,	,	O
social	JJ	O
deficits	NNS	O
,	,	O
and	CC	O
language	NN	O
abnormalities	NNS	O
.	.	O

There	EX	O
is	VBZ	O
evidence	NN	O
that	IN	O
abnormalities	NNS	O
exist	VBP	O
in	IN	O
the	DT	O
serotonin	NN	O
(	(	O
5-HT	JJ	O
)	)	O
system	NN	O
in	IN	O
autism	NN	O
spectrum	NN	O
patients	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
5-HT	JJ	O
is	VBZ	O
known	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
repetitive	JJ	O
and	CC	O
social	JJ	O
behaviours	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
m-chlorophenylpiperazine	NN	O
(	(	O
m-CPP	JJ	O
)	)	O
on	IN	O
repetitive	JJ	O
behaviours	NNS	O
and	CC	O
prolactin	JJ	O
response	NN	O
in	IN	O
11	CD	O
adults	NNS	O
with	IN	O
autism	NN	O
or	CC	O
Aspergers	NNS	O
disorder	VBP	O
and	CC	O
8	CD	O
age-	JJ	O
and	CC	O
gender-matched	JJ	O
healthy	JJ	O
controls	NNS	O
via	IN	O
randomized	VBN	O
double-blind	NN	O
,	,	O
m-CPP	JJ	O
and	CC	O
placebo	JJ	O
challenges	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
an	DT	O
instrument	NN	O
rating	NN	O
six	CD	O
repetitive	JJ	O
behaviours	NNS	O
:	:	O
need	NN	O
to	TO	O
know	VB	O
,	,	O
repeating	VBG	O
,	,	O
ordering	VBG	O
,	,	O
need	NN	O
to	TO	O
tell/ask	VB	O
,	,	O
self-injury	NN	O
,	,	O
and	CC	O
touching	VBG	O
.	.	O

Patients	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
showed	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
repetitive	JJ	O
behaviours	NNS	O
at	IN	O
end-point	NN	O
following	VBG	O
oral	JJ	O
m-CPP	NNS	O
in	IN	O
comparison	NN	O
to	TO	O
placebo	VB	O
.	.	O

Additionally	NNP	O
subjects	VBZ	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
showed	VBD	O
a	DT	O
significantly	RB	O
increased	VBN	O
prolactin	NN	O
response	NN	O
to	TO	O
m-CPP	NN	O
compared	VBN	O
to	TO	O
normal	JJ	O
controls	NNS	O
,	,	O
with	IN	O
neither	DT	O
group	NN	O
responding	VBG	O
to	TO	O
placebo	VB	O
.	.	O

This	DT	O
study	NN	O
provides	VBZ	O
further	JJ	O
evidence	NN	O
for	IN	O
altered	JJ	O
5-HT	JJ	O
sensitivity	NN	O
in	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
possible	JJ	O
relationship	NN	O
between	IN	O
repetitive	JJ	O
behaviours	NNS	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
abnormalities	NNS	O
in	IN	O
the	DT	O
5-HT	JJ	O
system	NN	O
.	.	O

Skin	NNP	O
concentrations	NNS	O
of	IN	O
thromboxane	NN	O
synthetase	NN	O
inhibitor	NN	O
after	IN	O
topical	JJ	O
application	NN	O
with	IN	O
bioelastic	JJ	O
membrane	NN	O
.	.	O

Elevated	VBN	O
thromboxane	NN	O
levels	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
number	NN	O
of	IN	O
disease	NN	O
states	NNS	O
,	,	O
including	VBG	O
dermal	JJ	O
pressure	NN	O
ulcers	NNS	O
.	.	O

When	WRB	O
dazmegrel	NN	O
was	VBD	O
orally	RB	O
administered	VBN	O
to	TO	O
greyhound	VB	O
dogs	NNS	O
wearing	VBG	O
leg	NN	O
casts	NNS	O
,	,	O
it	PRP	O
resulted	VBD	O
in	IN	O
a	DT	O
sparring	JJ	O
effect	NN	O
on	IN	O
the	DT	O
skin	JJ	O
areas	NNS	O
of	IN	O
potential	JJ	O
pressure	NN	O
ulcer	NN	O
development	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
research	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
bioelastic	JJ	O
matrices	NNS	O
could	MD	O
provide	VB	O
controlled	VBD	O
release	NN	O
of	IN	O
thromboxane	NN	O
A2	NNP	O
synthetase	NN	O
inhibitor	NN	O
(	(	O
dazmegrel	NN	O
)	)	O
at	IN	O
tissue	NN	O
concentrations	NNS	O
sufficient	NN	O
for	IN	O
inhibition	NN	O
of	IN	O
thromboxane	NN	O
synthesis	NN	O
.	.	O

The	DT	O
animal	NN	O
used	VBN	O
for	IN	O
these	DT	O
studies	NNS	O
was	VBD	O
the	DT	O
greyhound	NN	O
,	,	O
which	WDT	O
has	VBZ	O
thin	JJ	O
skin	NN	O
,	,	O
angular	JJ	O
conformation	NN	O
,	,	O
limited	JJ	O
body	NN	O
fat	JJ	O
and	CC	O
is	VBZ	O
predisposed	VBN	O
to	TO	O
pressure	VB	O
ulcers	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
occurring	VBG	O
in	IN	O
humans	NNS	O
.	.	O

In	IN	O
vivo	JJ	O
skin	JJ	O
penetration	NN	O
studies	NNS	O
showed	VBD	O
that	IN	O
epidermal	JJ	O
exposure	NN	O
to	TO	O
bioelastic	JJ	O
thromboxane	NN	O
synthetase	NN	O
inhibitor	NN	O
(	(	O
TSI	NNP	O
)	)	O
matrix	NN	O
resulted	VBD	O
in	IN	O
local	JJ	O
tissue	NN	O
concentrations	NNS	O
of	IN	O
TSI	NNP	O
sufficient	NN	O
for	IN	O
thromboxane	NN	O
synthetase	NN	O
inhibition	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
dazmegrel	NN	O
in	IN	O
the	DT	O
skin	NN	O
layers	NNS	O
(	(	O
epidermis	NN	O
,	,	O
dermis	NN	O
and	CC	O
subcutaneous	JJ	O
layers	NNS	O
)	)	O
on	IN	O
1	CD	O
,	,	O
7	CD	O
and	CC	O
14-day	JJ	O
exposures	NNS	O
.	.	O

Effect	NN	O
of	IN	O
phenylephrine	NN	O
on	IN	O
the	DT	O
haemodynamic	JJ	O
state	NN	O
and	CC	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
during	IN	O
anaesthesia	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
upright	JJ	O
sitting	NN	O
or	CC	O
beachchair	NN	O
position	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
hypotension	NN	O
,	,	O
risk	NN	O
of	IN	O
cerebral	JJ	O
hypoperfusion	NN	O
,	,	O
and	CC	O
cerebral	JJ	O
injury	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
by	IN	O
increasing	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	JJ	O
administration	NN	O
,	,	O
cerebral	JJ	O
perfusion	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
recovery	NN	O
would	MD	O
be	VB	O
improved	VBN	O
.	.	O

METHODS	NNP	O
Thirty-four	JJ	SampleSize
patients	NNS	O
undergoing	VBG	O
elective	JJ	Condition
shoulder	NN	Condition
surgery	NN	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
saline	NN	O
or	CC	O
phenylephrine	NN	O
infusion	NN	O
(	(	O
PE	NNP	O
)	)	O
5	CD	O
min	NN	O
before	IN	O
being	VBG	O
placed	VBN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

Simultaneous	JJ	O
measurements	NNS	O
of	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
,	,	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
velocity	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
function	NN	O
using	VBG	O
transthoracic	JJ	O
echocardiography	NN	O
were	VBD	O
made	VBN	O
.	.	O

Postoperative	JJ	O
neurocognitive	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
commencement	NN	O
of	IN	O
PE	NNP	O
,	,	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
significantly	RB	O
decreased	VBN	O
from	IN	O
77	CD	O
(	(	O
10	CD	O
)	)	O
to	TO	O
67	CD	O
(	(	O
13	CD	O
)	)	O
%	NN	O
(	(	O
P=0.02	NNP	O
)	)	O
,	,	O
and	CC	O
further	RB	O
to	TO	O
59	CD	O
(	(	O
11	CD	O
)	)	O
%	NN	O
on	IN	O
upright	JJ	O
positioning	NN	O
.	.	O

The	DT	O
level	NN	O
of	IN	O
cerebral	JJ	O
saturation	NN	O
upright	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
to	TO	O
patients	NNS	O
receiving	VBG	O
saline	NN	O
(	(	O
P=0.07	NNP	O
)	)	O
,	,	O
with	IN	O
values	NNS	O
remaining	VBG	O
at	IN	O
room-air	JJ	O
levels	NNS	O
.	.	O

Middle	NNP	O
cerebral	JJ	O
artery	RB	O
blood	NN	O
velocity	NN	O
increased	VBN	O
by	IN	O
20	CD	O
%	NN	O
(	(	O
P=0.04	NNP	O
)	)	O
.	.	O

Phenylephrine	NNP	O
prevented	VBD	O
hypotension	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
primarily	RB	O
by	IN	O
maintaining	VBG	O
preload	NN	O
and	CC	O
increasing	VBG	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
(	(	O
P=0.01	NNP	O
)	)	O
,	,	O
and	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
.	.	O

No	DT	O
postoperative	JJ	O
neurocognitive	JJ	O
dysfunction	NN	O
was	VBD	O
identified	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
maintaining	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	NN	O
,	,	O
cerebral	JJ	O
desaturation	NN	O
occurred	VBD	O
with	IN	O
upright	JJ	O
positioning	VBG	O
.	.	O

Cerebral	NNP	O
oxygen	IN	O
saturation	NN	O
can	MD	O
provide	VB	O
a	DT	O
valuable	JJ	O
endpoint	NN	O
when	WRB	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
vasopressor	NN	O
therapy	NN	O
on	IN	O
cerebral	JJ	O
perfusion	NN	O
.	.	O

A	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
R-salbutamol	NNP	O
for	IN	O
topical	JJ	O
treatment	NN	O
of	IN	O
discoid	JJ	O
lupus	NN	O
erythematosus	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
a	DT	O
recent	JJ	O
open	JJ	O
pilot	NN	O
trial	NN	O
,	,	O
R-salbutamol	NNP	O
sulphate	NN	O
,	,	O
a	DT	O
well-known	JJ	O
molecule	NN	O
with	IN	O
anti-inflammatory	JJ	O
effects	NNS	O
,	,	O
was	VBD	O
tested	VBN	O
successfully	RB	O
on	IN	O
patients	NNS	O
with	IN	O
therapy-resistant	JJ	O
discoid	NN	O
lupus	NN	O
erythematosus	NN	O
(	(	O
DLE	NNP	O
)	)	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
R-salbutamol	NNP	O
cream	NN	O
0.5	CD	O
%	NN	O
vs.	FW	O
placebo	NN	O
on	IN	O
DLE	NNP	O
lesions	NNS	O
in	IN	O
a	DT	O
multicentre	NN	O
,	,	O
double-blinded	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
.	.	O

METHODS	NNP	O
Thirty-seven	JJ	O
patients	NNS	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
newly	RB	O
developed	VBN	O
DLE	NNP	O
lesion	NN	O
were	VBD	O
randomized	VBN	O
-	:	O
19	CD	O
to	TO	O
the	DT	O
R-salbutamol	NNP	O
cream	NN	O
0.5	CD	O
%	NN	O
and	CC	O
18	CD	O
to	TO	O
placebo	VB	O
-	:	O
and	CC	O
treated	JJ	O
twice	RB	O
daily	RB	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Efficacy	NN	O
was	VBD	O
evaluated	VBN	O
through	IN	O
scores	NNS	O
of	IN	O
erythema	NN	O
,	,	O
scaling/hypertrophy	NN	O
and	CC	O
induration	NN	O
as	RB	O
well	RB	O
as	IN	O
pain	NN	O
and	CC	O
itching	NN	O
;	:	O
general	JJ	O
improvement	NN	O
scored	VBN	O
by	IN	O
the	DT	O
investigator	NN	O
and	CC	O
global	JJ	O
improvement	NN	O
scored	VBN	O
by	IN	O
patients	NNS	O
'	POS	O
assessment	NN	O
were	VBD	O
also	RB	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
of	IN	O
improvement	NN	O
for	IN	O
scaling/hypertrophy	NN	O
,	,	O
pain	NN	O
,	,	O
itching	NN	O
and	CC	O
global	JJ	O
patient	NN	O
assessment	NN	O
was	VBD	O
significantly	RB	O
better	JJR	O
for	IN	O
the	DT	O
actively	RB	O
treated	JJ	O
patients	NNS	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
scaling/hypertrophy	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0262	CD	O
;	:	O
pain	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0238	CD	O
;	:	O
itching	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0135	CD	O
;	:	O
global	JJ	O
patient	NN	O
assessment	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.045	CD	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
without	IN	O
induration	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.013	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
statistically	RB	O
significantly	RB	O
greater	JJR	O
decrease	NN	O
in	IN	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
lesional	JJ	O
area	NN	O
was	VBD	O
also	RB	O
seen	VBN	O
in	IN	O
the	DT	O
overall	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
R-salbutamol-treated	JJ	O
patients	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.0197	CD	O
)	)	O
.	.	O

No	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Application	NNP	O
of	IN	O
R-salbutamol	NNP	O
cream	NN	O
0.5	CD	O
%	NN	O
was	VBD	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
effects	NNS	O
were	VBD	O
seen	VBN	O
on	IN	O
scaling/hypertrophy	NN	O
,	,	O
induration	NN	O
,	,	O
pain	NN	O
and	CC	O
itching	NN	O
as	RB	O
well	RB	O
as	IN	O
patient	NN	O
global	JJ	O
assessment	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
R-salbutamol	NNP	O
could	MD	O
be	VB	O
a	DT	O
promising	JJ	O
new	JJ	O
topical	JJ	O
therapy	NN	O
alternative	NN	O
for	IN	O
DLE	NNP	O
.	.	O

[	VB	O
How	WRB	O
to	TO	O
treat	VB	O
the	DT	O
relapse	NN	O
of	IN	O
NSCLC	NNP	O
after	IN	O
surgery	NN	O
and	CC	O
chemotherapy	NN	O
?	.	O
IFTC	NNP	O
0702	CD	O
randomized	VBD	O
phase	NN	O
III	NNP	O
study	NN	O
]	NNP	O
.	.	O

BACKGROUND	NNP	O
As	IN	O
chemotherapy	NN	O
gains	NNS	O
wider	VBP	O
acceptance	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
earlier	JJR	O
stages	NNS	O
of	IN	O
NSCLC	NNP	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
adjuvant	NN	O
and	CC	O
neoadjuvant	JJ	O
setting	NN	O
,	,	O
physicians	NNS	O
face	VBP	O
a	DT	O
growing	VBG	O
population	NN	O
of	IN	O
high	JJ	O
performance	NN	O
status	NN	O
patients	NNS	O
who	WP	O
have	VBP	O
relapsed	VBN	O
after	IN	O
their	PRP$	O
first-line	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
type	NN	O
of	IN	O
second-line	JJ	O
chemotherapy	NN	O
after	IN	O
initial	JJ	O
adjuvant	NN	O
or	CC	O
neoadjuvant	JJ	O
treatment	NN	O
with	IN	O
a	DT	O
platinum-based	JJ	O
regimen	NN	O
remains	VBZ	O
largely	RB	O
undefined	JJ	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
has	VBZ	O
been	VBN	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
classical	JJ	O
mono	NN	O
chemotherapy	NN	O
docetaxel	NN	O
with	IN	O
a	DT	O
docetaxel	NN	O
cisplatin	NN	O
doublet	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
will	MD	O
be	VB	O
randomized	VBN	O
in	IN	O
2	CD	O
arms	NNS	O
.	.	O

Arm	NN	O
:	:	O
docetaxel	NN	O
cisplatin	NN	O
(	(	O
cycles	NNS	O
repeated	VBN	O
every	DT	O
21	CD	O
days	NNS	O
)	)	O
,	,	O
4	CD	O
cycles	NNS	O
followed	VBN	O
by	IN	O
2	CD	O
cycles	NNS	O
of	IN	O
docetaxel	NN	O
alone	RB	O
in	IN	O
case	NN	O
of	IN	O
objective	JJ	O
response	NN	O
or	CC	O
stabilisation	NN	O
.	.	O

Arm	NN	O
B	NN	O
:	:	O
docetaxel	NN	O
alone	RB	O
(	(	O
cycles	NNS	O
repeated	VBN	O
every	DT	O
21	CD	O
days	NNS	O
)	)	O
,	,	O
4	CD	O
cycles	NNS	O
followed	VBN	O
by	IN	O
2	CD	O
cycles	NNS	O
of	IN	O
docetaxel	NN	O
alone	RB	O
in	IN	O
case	NN	O
of	IN	O
objective	JJ	O
response	NN	O
or	CC	O
stabilisation	NN	O
.	.	O

EXPECTED	NNP	O
RESULTS	NNP	O
300	CD	O
patients	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
with	IN	O
a	DT	O
statistical	JJ	O
hypothesis	NN	O
of	IN	O
a	DT	O
progression	NN	O
free	JJ	O
survival	NN	O
of	IN	O
3	CD	O
months	NNS	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
and	CC	O
of	IN	O
4.5	CD	O
months	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
arm	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
topical	JJ	O
azithromycin	NN	O
ophthalmic	JJ	O
solution	NN	O
1	CD	O
%	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
posterior	JJ	Condition
blepharitis	NN	Condition
.	.	O

INTRODUCTION	NNP	O
Azithromycin	NNP	O
,	,	O
a	DT	O
broad-spectrum	JJ	O
antibiotic	JJ	O
with	IN	O
potent	JJ	O
anti-inflammatory	JJ	O
activities	NNS	O
,	,	O
has	VBZ	O
the	DT	O
potential	JJ	O
to	TO	O
effectively	RB	O
treat	VB	O
blepharitis	NN	Condition
,	,	O
an	DT	O
inflammatory	JJ	Condition
disease	NN	Condition
of	IN	O
the	DT	O
eyelid	JJ	O
with	IN	O
abnormal	JJ	O
eyelid	JJ	O
flora	NN	O
as	IN	O
an	DT	O
etiologic	JJ	O
determinant	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
topical	JJ	O
azithromycin	NN	O
ophthalmic	JJ	O
solution	NN	O
1	CD	O
%	NN	O
(	(	O
AzaSite	NNP	O
;	:	O
Inspire	NNP	O
Pharmaceuticals	NNP	O
,	,	O
Inc	NNP	O
,	,	O
NC	NNP	O
,	,	O
USA	NNP	O
)	)	O
combined	VBD	O
with	IN	O
warm	JJ	O
compresses	NNS	O
(	(	O
azithromycin	JJ	O
group	NN	O
)	)	O
to	TO	O
warm	JJ	O
compresses	NNS	O
alone	RB	O
(	(	O
compress	JJ	O
group	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
posterior	JJ	O
blepharitis	NN	O
.	.	O

METHODS	NNP	O
Twenty-one	CD	SampleSize
patients	NNS	O
diagnosed	VBN	O
with	IN	O
posterior	JJ	Condition
blepharitis	NN	Condition
were	VBD	O
randomized	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
study	NN	O
to	TO	O
receive	VB	O
either	DT	O
azithromycin	NN	O
plus	CC	O
warm	JJ	O
compresses	NNS	O
(	(	O
10	CD	O
patients	NNS	O
)	)	O
,	,	O
or	CC	O
compresses	VBZ	O
alone	RB	O
(	(	O
11	CD	O
patients	NNS	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
apply	VB	O
compresses	NNS	O
to	TO	O
each	DT	O
eye	NN	O
for	IN	O
5-10	JJ	O
minutes	NNS	O
twice	RB	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Each	DT	O
eye	NN	O
in	IN	O
the	DT	O
azithromycin	NN	O
group	NN	O
also	RB	O
received	VBD	O
azithromycin	JJ	O
solution	NN	O
(	(	O
1	CD	O
drop	NN	O
)	)	O
twice	RB	O
daily	RB	O
for	IN	O
the	DT	O
first	JJ	O
2	CD	O
days	NNS	O
followed	VBN	O
by	IN	O
once	RB	O
daily	JJ	O
for	IN	O
the	DT	O
next	JJ	O
12	CD	O
days	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
study	NN	O
initiation	NN	O
(	(	O
visit	IN	O
1	CD	O
)	)	O
and	CC	O
at	IN	O
end	NN	O
of	IN	O
treatment	NN	O
(	(	O
visit	IN	O
2	CD	O
)	)	O
for	IN	O
the	DT	O
severity	NN	O
of	IN	O
five	CD	O
clinical	JJ	O
signs	NNS	O
:	:	O
eyelid	JJ	O
debris	NN	O
,	,	O
eyelid	JJ	O
redness	NN	O
,	,	O
eyelid	JJ	O
swelling	NN	O
,	,	O
meibomian	JJ	O
gland	NN	O
(	(	O
MG	NNP	O
)	)	O
plugging	NN	O
,	,	O
and	CC	O
the	DT	O
quality	NN	O
of	IN	O
MG	NNP	O
secretion	NN	O
.	.	O

At	IN	O
visit	NN	O
2	CD	O
,	,	O
patients	NNS	O
also	RB	O
rated	VBD	O
their	PRP$	O
degree	NN	O
of	IN	O
overall	JJ	O
symptomatic	JJ	O
relief	NN	O
.	.	O

RESULTS	NNP	O
Twenty	NNP	SampleSize
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

At	IN	O
visit	NN	O
2	CD	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
azithromycin	NN	O
group	NN	O
demonstrated	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
MG	NNP	O
plugging	NN	O
,	,	O
MG	NNP	O
secretions	NNS	O
,	,	O
and	CC	O
eyelid	JJ	O
redness	NN	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
compress	NN	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
azithromycin	NN	O
group	NN	O
,	,	O
MG	NNP	O
plugging	VBG	O
resolved	VBN	O
completely	RB	O
in	IN	O
three	CD	O
patients	NNS	O
and	CC	O
MG	NNP	O
secretion	NN	O
returned	VBD	O
to	TO	O
normal	JJ	O
in	IN	O
two	CD	O
patients	NNS	O
;	:	O
no	DT	O
such	JJ	O
results	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
compress	NN	O
group	NN	O
.	.	O

Furthermore	RB	O
,	,	O
a	DT	O
higher	JJR	O
percentage	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
azithromycin	NN	O
group	NN	O
rated	VBD	O
overall	JJ	O
symptomatic	JJ	O
relief	NN	O
as	IN	O
excellent	NN	O
or	CC	O
good	JJ	O
.	.	O

Visual	JJ	O
acuity	NN	O
measurements	NNS	O
and	CC	O
biomicroscopic	JJ	O
evaluation	NN	O
revealed	VBD	O
no	DT	O
ocular	JJ	O
safety	NN	O
issues	NNS	O
.	.	O

CONCLUSION	NNP	O
Azithromycin	NNP	O
ophthalmic	JJ	O
solution	NN	O
in	IN	O
combination	NN	O
with	IN	O
warm	JJ	O
compresses	NNS	O
provided	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
clinical	JJ	O
benefit	NN	O
than	IN	O
warm	JJ	O
compresses	NNS	O
alone	RB	O
in	IN	O
treating	VBG	O
the	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
posterior	JJ	O
blepharitis	NN	O
.	.	O

Effect	NN	O
of	IN	O
adhesive	JJ	O
system	NN	O
type	NN	O
and	CC	O
tooth	DT	O
region	NN	O
on	IN	O
the	DT	O
bond	NN	O
strength	NN	O
to	TO	O
dentin	VB	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
bond	NN	O
strength	NN	O
of	IN	O
two	CD	O
etch-and-rinse	JJ	O
adhesive	JJ	O
systems	NNS	O
(	(	O
two-	JJ	O
and	CC	O
three-step	NN	O
)	)	O
and	CC	O
a	DT	O
self-etching	JJ	O
system	NN	O
to	TO	O
coronal	VB	O
and	CC	O
root	VB	O
canal	JJ	O
dentin	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
root	NN	O
canals	NNS	O
of	IN	O
30	CD	SampleSize
human	JJ	O
incisors	NNS	O
and	CC	O
canines	NNS	O
were	VBD	O
instrumented	VBN	O
and	CC	O
prepared	VBN	O
with	IN	O
burs	NNS	O
.	.	O

The	DT	O
posts	NNS	O
used	VBD	O
for	IN	O
luting	VBG	O
were	VBD	O
duplicated	VBN	O
with	IN	O
dual	JJ	O
resin	NN	O
cement	NN	O
(	(	O
Duo-link	NNP	O
)	)	O
inside	IN	O
Aestheti	NNP	O
Plus	NNP	O
#	#	O
2	CD	O
molds	NNS	O
.	.	O

Thus	RB	O
,	,	O
three	CD	O
groups	NNS	O
were	VBD	O
formed	VBN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
adhesive	JJ	O
system	NN	O
employed	VBN	O
:	:	O
All-Bond	JJ	O
2	CD	O
(	(	O
TE3	NNP	O
)	)	O
+	VBP	O
resin	JJ	O
cement	NN	O
post	NN	O
(	(	O
rcp	NN	O
)	)	O
+	VBZ	O
Duo-link	NNP	O
(	(	O
Dl	NNP	O
)	)	O
;	:	O
One-Step	JJ	O
Plus	NNP	O
(	(	O
TE2	NNP	O
)	)	O
+	VBP	O
rcp	JJ	O
+	NNP	O
Dl	NNP	O
;	:	O
Tyrian/One-Step	JJ	O
Plus	NNP	O
(	(	O
SE	NNP	O
)	)	O
+	VBP	O
rcp	JJ	O
+	NNP	O
Dl	NNP	O
.	.	O

Afterwards	NNP	O
,	,	O
8	CD	O
transverse	NN	O
sections	NNS	O
(	(	O
1.5	CD	O
mm	NN	O
)	)	O
were	VBD	O
cut	VBN	O
from	IN	O
4	CD	O
mm	NNS	O
above	IN	O
the	DT	O
CEJ	NNP	O
up	RB	O
to	TO	O
4	CD	O
mm	NNS	O
short	JJ	O
of	IN	O
the	DT	O
root	NN	O
canal	JJ	O
apex	NN	O
,	,	O
comprising	VBG	O
coronal	JJ	O
and	CC	O
root	JJ	O
canal	JJ	O
dentin	NN	O
.	.	O

The	DT	O
sections	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
push-out	JJ	O
testing	NN	O
in	IN	O
a	DT	O
universal	JJ	O
testing	VBG	O
machine	NN	O
EMIC	NNP	O
(	(	O
1	CD	O
mm/min	NN	O
)	)	O
.	.	O

Bond	NNP	O
strength	NN	O
data	NNS	O
were	VBD	O
analyzed	VBN	O
with	IN	O
two-way	JJ	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	O
and	CC	O
Tukey	NNP	O
's	POS	O
test	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
relationship	NN	O
between	IN	O
the	DT	O
adhesives	NNS	O
was	VBD	O
not	RB	O
the	DT	O
same	JJ	O
in	IN	O
the	DT	O
different	JJ	O
regions	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
means	NNS	O
achieved	VBN	O
with	IN	O
the	DT	O
adhesives	NNS	O
in	IN	O
each	DT	O
region	NN	O
(	(	O
Tukey	NNP	O
;	:	O
p	VBZ	O
<	$	O
0.05	CD	O
)	)	O
revealed	VBD	O
that	IN	O
TE3	NNP	O
(	(	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
deviation	NN	O
:	:	O
5.22	CD	O
+/-	JJ	O
1.70	CD	O
)	)	O
was	VBD	O
higher	JJR	O
than	IN	O
TE2	NNP	O
(	(	O
2.60	CD	O
+/-	JJ	O
1.74	CD	O
)	)	O
and	CC	O
SE	NNP	O
(	(	O
1.68	CD	O
+/-	JJ	O
1.85	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Under	IN	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
,	,	O
better	JJR	O
bonding	VBG	O
to	TO	O
dentin	VB	O
was	VBD	O
achieved	VBN	O
using	VBG	O
the	DT	O
three-step	JJ	O
etch-and-rinse	JJ	O
system	NN	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
coronal	JJ	O
region	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
traditional	JJ	O
etch-and-rinse	JJ	O
three-step	NN	O
adhesive	JJ	O
system	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
best	JJS	O
choice	NN	O
for	IN	O
teeth	NN	O
needing	VBG	O
adhesive	JJ	O
endodontic	JJ	O
restorations	NNS	O
.	.	O

Virtual	JJ	O
reality	NN	O
colonoscopy	NN	O
simulation	NN	O
:	:	O
a	DT	O
compulsory	NN	O
practice	NN	O
for	IN	O
the	DT	O
future	JJ	O
colonoscopist	NN	O
?	.	O
BACKGROUND	NNP	O
AND	NNP	O
STUDY	NNP	O
AIM	NNP	O
As	IN	O
for	IN	O
any	DT	O
manual	JJ	O
procedure	NN	O
,	,	O
the	DT	O
learning	NN	O
curves	NNS	O
for	IN	O
medical	JJ	O
interventions	NNS	O
can	MD	O
have	VB	O
undesirable	JJ	O
phases	NNS	O
,	,	O
occurring	VBG	O
mostly	RB	O
in	IN	O
the	DT	O
early	JJ	O
experience	NN	O
of	IN	O
applying	VBG	O
a	DT	O
technique	NN	O
.	.	O

There	EX	O
have	VBP	O
been	VBN	O
impressive	JJ	O
advances	NNS	O
in	IN	O
endoscopic	JJ	O
procedures	NNS	O
during	IN	O
recent	JJ	O
years	NNS	O
,	,	O
and	CC	O
there	EX	O
is	VBZ	O
an	DT	O
emerging	VBG	O
trend	NN	O
that	IN	O
the	DT	O
number	NN	O
of	IN	O
procedures	NNS	O
is	VBZ	O
increasing	VBG	O
in	IN	O
parallel	NN	O
with	IN	O
these	DT	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
introduction	NN	O
of	IN	O
screening	VBG	O
programs	NNS	O
for	IN	O
colorectal	JJ	O
cancer	NN	O
will	MD	O
also	RB	O
increase	VB	O
the	DT	O
numbers	NNS	O
of	IN	O
procedures	NNS	O
needed	VBN	O
.	.	O

Recent	JJ	O
developments	NNS	O
in	IN	O
medical	JJ	O
simulation	NN	O
seem	VBP	O
promising	VBG	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
possibility	NN	O
of	IN	O
training	VBG	O
out	RP	O
undesirable	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
learning	VBG	O
curve	NN	O
outside	IN	O
the	DT	O
operating	NN	O
room	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
AccuTouch	NNP	O
flexible	JJ	O
endoscopy	NN	O
simulator	NN	O
improves	VBZ	O
the	DT	O
early	JJ	O
part	NN	O
of	IN	O
the	DT	O
learning	VBG	O
curve	NN	O
in	IN	O
colonoscopy	NN	O
training	NN	O
.	.	O

METHOD	NNP	O
12	CD	Sex
endoscopy	NN	Sex
trainees	NNS	Sex
,	,	Sex
10	CD	Sex
surgeons	NNS	Sex
and	CC	Sex
two	CD	Sex
medical	JJ	Sex
gastroenterologists	NNS	Sex
,	,	Sex
all	DT	Sex
with	IN	Sex
experience	NN	Sex
in	IN	Sex
gastroscopy	NN	Sex
but	CC	Sex
with	IN	Sex
no	DT	Sex
specific	JJ	Sex
colonoscopy	NN	Sex
experience	NN	Sex
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
simulator	NN	O
training	NN	O
or	CC	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

They	PRP	O
all	DT	O
received	VBD	O
the	DT	O
same	JJ	O
theoretical	JJ	O
study	NN	O
package	NN	O
and	CC	O
the	DT	O
training	NN	O
group	NN	O
practiced	VBD	O
with	IN	O
the	DT	O
AccuTouch	NNP	O
colonoscopy	NN	O
simulator	NN	O
until	IN	O
a	DT	O
predefined	JJ	O
expert	JJ	O
level	NN	O
of	IN	O
performance	NN	O
was	VBD	O
reached	VBN	O
.	.	O

All	DT	O
trainees	NNS	O
performed	VBD	O
their	PRP$	O
first	JJ	O
ten	VBN	O
individual	JJ	O
colonoscopies	NNS	O
described	VBN	O
in	IN	O
detail	NN	O
in	IN	O
a	DT	O
separate	JJ	O
protocol	NN	O
.	.	O

RESULTS	NNP	O
Trainees	NNP	O
in	IN	O
the	DT	O
simulator-trained	JJ	O
group	NN	O
performed	VBD	O
significantly	RB	O
better	RBR	O
(	(	O
P=0.0011	NNP	O
)	)	O
and	CC	O
managed	VBN	O
to	TO	O
reach	VB	O
the	DT	O
cecum	NN	O
in	IN	O
52	CD	O
%	NN	O
of	IN	O
their	PRP$	O
cases	NNS	O
(	(	O
vs.	FW	O
19	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
)	)	O
,	,	O
and	CC	O
were	VBD	O
4.53	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
to	TO	O
succeed	VB	O
compared	VBN	O
with	IN	O
the	DT	O
controls	NNS	O
.	.	O

Additionally	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
shorter	JJR	O
procedure	NN	O
time	NN	O
and	CC	O
less	RBR	O
patient	JJ	O
discomfort	NN	O
in	IN	O
the	DT	O
hands	NNS	O
of	IN	O
the	DT	O
simulator-trained	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Skills	NNP	O
acquired	VBD	O
using	VBG	O
the	DT	O
AccuTouch	NNP	O
simulator	NN	O
transfer	NN	O
well	RB	O
into	IN	O
the	DT	O
clinical	JJ	O
colonoscopy	NN	O
environment	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
trial	NN	O
clearly	RB	O
support	VB	O
the	DT	O
plan	NN	O
to	TO	O
integrate	VB	O
simulator	NN	O
training	NN	O
into	IN	O
endoscopic	JJ	O
education	NN	O
curricula	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
placebo-	JJ	O
and	CC	O
active-controlled	JJ	O
study	NN	O
of	IN	O
paliperidone	NN	O
extended-release	NN	O
as	IN	O
maintenance	NN	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
bipolar	JJ	Condition
I	PRP	Condition
disorder	VBP	Condition
after	IN	O
an	DT	O
acute	JJ	Condition
manic	NN	Condition
or	CC	Condition
mixed	JJ	Condition
episode	NN	Condition
.	.	O

BACKGROUND	NNP	O
Paliperidone	NNP	O
ER	NNP	O
monotherapy	NN	O
was	VBD	O
efficacious	JJ	O
in	IN	O
treating	VBG	O
acute	NN	O
mania	NN	O
in	IN	O
two	CD	O
3-week	JJ	O
studies	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
bipolar	JJ	Condition
I	PRP	Condition
disorder	VBP	Condition
.	.	O

We	PRP	O
assessed	VBD	O
its	PRP$	O
efficacy	NN	O
in	IN	O
a	DT	O
study	NN	O
investigating	VBG	O
maintenance	NN	O
treatment	NN	O
of	IN	O
clinically	RB	Condition
stable	JJ	Condition
patients	NNS	O
with	IN	O
this	DT	O
disorder	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
(	(	O
n=766	JJ	SampleSize
)	)	O
,	,	O
aged	VBD	O
18	CD	Age
to	TO	Age
65	CD	Age
years	NNS	Age
inclusive	JJ	O
,	,	O
with	IN	O
current	JJ	Condition
manic	NN	Condition
or	CC	Condition
mixed	JJ	Condition
episodes	NNS	Condition
were	VBD	O
initially	RB	O
randomized	VBN	O
(	(	O
4:1	CD	O
)	)	O
to	TO	O
flexibly-dosed	JJ	O
paliperidone	NN	O
ER	NNP	O
(	(	O
3-12	JJ	O
mg/day	NN	O
)	)	O
or	CC	O
olanzapine	JJ	O
(	(	O
5-20	JJ	O
mg/day	NN	O
;	:	O
3-week	JJ	O
acute	NN	O
treatment	NN	O
phase	NN	O
)	)	O
;	:	O
responders	NNS	O
continued	VBD	O
the	DT	O
same	JJ	O
treatment	NN	O
(	(	O
12-week	JJ	O
continuation	NN	O
phase	NN	O
)	)	O
.	.	O

Patients	NNS	O
on	IN	O
paliperidone	NN	O
ER	NNP	O
who	WP	O
achieved	VBD	O
remission	NN	O
during	IN	O
this	DT	O
phase	NN	O
were	VBD	O
randomized	VBN	O
(	(	O
1:1	CD	O
)	)	O
to	TO	O
fixed-dose	JJ	O
paliperidone	NN	O
ER	NNP	O
(	(	O
n=152	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n=148	JJ	O
)	)	O
;	:	O
those	DT	O
on	IN	O
olanzapine	JJ	O
continued	VBN	O
to	TO	O
receive	VB	O
that	DT	O
at	IN	O
fixed	VBN	O
dose	NN	O
(	(	O
n=83	JJ	O
)	)	O
(	(	O
maintenance	NN	O
phase	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Median	JJ	O
time	NN	O
to	TO	O
recurrence	VB	O
of	IN	O
any	DT	O
mood	NN	O
symptoms	NNS	O
(	(	O
primary	JJ	O
endpoint	NN	O
)	)	O
was	VBD	O
:	:	O
558	CD	O
days	NNS	O
(	(	O
paliperidone	JJ	O
ER	NNP	O
)	)	O
,	,	O
283	CD	O
days	NNS	O
(	(	O
placebo	NN	O
)	)	O
and	CC	O
not	RB	O
observed	VBN	O
with	IN	O
olanzapine	NN	O
(	(	O
<	JJ	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
experienced	JJ	O
recurrence	NN	O
)	)	O
.	.	O

Time	NN	O
to	TO	O
recurrence	VB	O
of	IN	O
any	DT	O
mood	NN	O
symptoms	NNS	O
was	VBD	O
significantly	RB	O
longer	RBR	O
with	IN	O
paliperidone	NN	O
ER	NNP	O
than	IN	O
placebo	NN	O
(	(	O
p=0.017	NN	O
;	:	O
based	VBN	O
on	IN	O
weighted	JJ	O
Z-test	NNP	O
at	IN	O
0.0198	CD	O
significance	NN	O
level	NN	O
;	:	O
hazard	CC	O
ratio	VB	O
[	JJ	O
placebo	NN	O
:	:	O
paliperidone	NN	O
ER	NNP	O
;	:	O
unweighted	VBD	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
]	NN	O
:	:	O
1.43	CD	O
[	$	O
1.03	CD	O
;	:	O
1.98	CD	O
]	NN	O
)	)	O
;	:	O
the	DT	O
difference	NN	O
was	VBD	O
significant	JJ	O
for	IN	O
preventing	VBG	O
recurrence	NN	O
of	IN	O
manic	NN	O
,	,	O
but	CC	O
not	RB	O
depressive	JJ	O
,	,	O
symptoms	NNS	O
.	.	O

Treatment-emergent	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
maintenance	NN	O
phase	NN	O
)	)	O
occurred	VBD	O
more	RBR	O
often	RB	O
in	IN	O
olanzapine	JJ	O
group	NN	O
(	(	O
64	CD	O
%	NN	O
)	)	O
than	IN	O
placebo	NN	O
(	(	O
59	CD	O
%	NN	O
)	)	O
or	CC	O
paliperidone	NN	O
ER	NNP	O
groups	NNS	O
(	(	O
55	CD	O
%	NN	O
)	)	O
.	.	O

LIMITATIONS	JJ	O
Responder-enriched	JJ	O
design	NN	O
prevents	NNS	O
extrapolation	NN	O
of	IN	O
data	NNS	O
to	TO	O
patients	NNS	O
not	RB	O
previously	RB	O
stabilized	VBN	O
on	IN	O
paliperidone	NN	O
ER	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Paliperidone	NNP	O
ER	NNP	O
significantly	RB	O
delayed	VBD	O
the	DT	O
time	NN	O
to	TO	O
recurrence	VB	O
of	IN	O
any	DT	O
mood	NN	O
symptoms	NNS	O
,	,	O
versus	NN	O
placebo	NN	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
bipolar	JJ	Condition
I	PRP	Condition
disorder	VBP	Condition
.	.	O

No	DT	O
new	JJ	O
safety	NN	O
concerns	NNS	O
emerged	VBD	O
.	.	O

A	DT	O
randomized	JJ	O
cross-over	NN	O
study	NN	O
of	IN	O
inhalation	NN	O
of	IN	O
diesel	NN	O
exhaust	NN	O
,	,	O
hematological	JJ	O
indices	NNS	O
,	,	O
and	CC	O
endothelial	JJ	O
markers	NNS	O
in	IN	O
humans	NNS	O
.	.	O

BACKGROUND	NNP	O
Exposure	NNP	O
to	TO	O
traffic-related	JJ	O
air	NN	O
pollution	NN	O
(	(	O
TRAP	NNP	O
)	)	O
is	VBZ	O
considered	VBN	O
a	DT	O
trigger	NN	O
for	IN	O
acute	JJ	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

Diesel	NNP	O
Exhaust	NNP	O
(	(	O
DE	NNP	O
)	)	O
is	VBZ	O
a	DT	O
major	JJ	O
contributor	NN	O
to	TO	O
TRAP	NNP	O
in	IN	O
the	DT	O
world	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
DE	NNP	O
inhalation	NN	O
on	IN	O
circulating	VBG	O
blood	NN	O
cell	NN	O
populations	NNS	O
,	,	O
hematological	JJ	O
indices	NNS	O
,	,	O
and	CC	O
systemic	JJ	O
inflammatory	NN	O
cytokines	NNS	O
in	IN	O
humans	NNS	O
using	VBG	O
a	DT	O
specialized	JJ	O
facility	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
crossover	NN	O
study	NN	O
balanced	VBD	O
to	TO	O
order	NN	O
,	,	O
17	CD	SampleSize
metabolic	JJ	Condition
syndrome	NN	Condition
(	(	O
MetS	NNP	Condition
)	)	O
and	CC	O
15	CD	SampleSize
healthy	JJ	O
subjects	NNS	O
inhaled	VBN	O
filtered	JJ	O
air	NN	O
(	(	O
FA	NNP	O
)	)	O
or	CC	O
DE	NNP	O
exposure	NN	O
in	IN	O
two-hour	JJ	O
sessions	NNS	O
on	IN	O
different	JJ	O
days	NNS	O
with	IN	O
a	DT	O
minimum	JJ	O
2-week	JJ	O
washout	NN	O
period	NN	O
.	.	O

We	PRP	O
collected	VBD	O
blood	NN	O
pre-exposure	NN	O
,	,	O
7	CD	O
,	,	O
and	CC	O
22	CD	O
hours	NNS	O
after	IN	O
exposure	NN	O
initiation	NN	O
and	CC	O
measured	VBD	O
the	DT	O
complete	JJ	O
blood	NN	O
count	NN	O
and	CC	O
differential	JJ	O
.	.	O

We	PRP	O
performed	VBD	O
multiplex	JJ	O
cytokine	NN	O
assay	NN	O
to	TO	O
measure	VB	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
systemic	JJ	O
inflammatory	NN	O
cytokines	NNS	O
,	,	O
and	CC	O
endothelial	JJ	O
adhesion	NN	O
molecules	NNS	O
(	(	O
n=15	NN	O
)	)	O
.	.	O

A	DT	O
paired	JJ	O
analysis	NN	O
compared	VBN	O
the	DT	O
effect	NN	O
of	IN	O
DE	NNP	O
and	CC	O
FA	NNP	O
exposures	NNS	O
for	IN	O
the	DT	O
change	NN	O
from	IN	O
pre-exposure	NN	O
to	TO	O
the	DT	O
subsequent	JJ	O
time	NN	O
points	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
hematocrit	NN	O
was	VBD	O
noted	VBN	O
7	CD	O
hrs	NNS	O
after	IN	O
DE	NNP	O
[	FW	O
1.4	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.9	CD	O
to	TO	O
1.9	CD	O
%	NN	O
)	)	O
]	NN	O
compared	VBN	O
to	TO	O
FA	NNP	O
exposure	NN	O
[	VBZ	O
0.5	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-0.09	NN	O
to	TO	O
1.0	CD	O
%	NN	O
)	)	O
;	:	O
p=0.008	NN	O
.	.	O

The	DT	O
hemoglobin	NN	O
levels	NNS	O
increased	VBD	O
non-significantly	RB	O
at	IN	O
7	CD	O
hrs	JJ	O
post	NN	O
DE	NNP	O
[	NNP	O
0.3	CD	O
gm/dL	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.2	CD	O
to	TO	O
0.5	CD	O
gm/dL	NN	O
)	)	O
]	VBZ	O
versus	JJ	O
FA	NNP	O
exposure	NN	O
[	VBZ	O
0.2	CD	O
gm/dL	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0	CD	O
to	TO	O
0.3	CD	O
gm/dL	NN	O
)	)	O
]	NN	O
;	:	O
p=0.06	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
platelet	NN	O
count	NN	O
increased	VBD	O
22	CD	O
hrs	NN	O
after	IN	O
DE	NNP	O
exposure	NN	O
in	IN	O
healthy	JJ	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
MetS	NNP	O
subjects	NNS	O
[	FW	O
DE	NNP	O
:	:	O
16.6	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
10.2	CD	O
to	TO	O
23	CD	O
)	)	O
thousand	CD	O
platelets/mL	JJ	O
versus	NN	O
[	NN	O
FA	NNP	O
:	:	O
3.4	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-9.5	NN	O
to	TO	O
16.3	CD	O
)	)	O
thousand	CD	O
platelets/mL	NN	O
)	)	O
]	NN	O
;	:	O
p=0.04	NN	O
.	.	O

No	DT	O
DE	NNP	O
effect	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
WBC	NNP	O
,	,	O
neutrophils	RB	O
,	,	O
lymphocytes	VBZ	O
or	CC	O
erythrocytes	VBZ	O
.	.	O

Using	VBG	O
the	DT	O
multiplex	JJ	O
assay	NN	O
,	,	O
small	JJ	O
borderline	NN	O
significant	JJ	O
increases	NNS	O
in	IN	O
matrix	JJ	O
metalloproteinase-9	NN	O
,	,	O
interleukins	NNS	O
(	(	O
IL	NNP	O
)	)	O
-1	NNP	O
beta	NN	O
,	,	O
6	CD	O
and	CC	O
10	CD	O
occurred	VBD	O
7	CD	O
hrs	NN	O
post	NN	O
exposure	NN	O
initiation	NN	O
,	,	O
whereas	IN	O
E-selectin	NNP	O
,	,	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
,	,	O
and	CC	O
vascular	JJ	O
cell	NN	O
adhesion	NN	O
molecule	NN	O
-1	NNP	O
,	,	O
and	CC	O
myeloperoxidase	VB	O
22	CD	O
hrs	NN	O
post	NN	O
exposure	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
short-term	JJ	O
DE	NNP	O
exposure	NN	O
results	NNS	O
in	IN	O
hemoconcentration	NN	O
and	CC	O
thrombocytosis	NN	O
,	,	O
which	WDT	O
are	VBP	O
important	JJ	O
determinants	NNS	O
of	IN	O
acute	JJ	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

Multiplex	NNP	O
assay	VBP	O
showed	VBD	O
a	DT	O
non-significant	JJ	O
increase	NN	O
in	IN	O
IL-1?	NNP	O
and	CC	O
IL-6	NNP	O
immediately	RB	O
post	NN	O
exposure	NN	O
followed	VBN	O
by	IN	O
myeloperoxidase	NN	O
and	CC	O
endothelial	JJ	O
activation	NN	O
molecules	NNS	O
.	.	O

Further	NNP	O
specific	JJ	O
assays	NNS	O
in	IN	O
a	DT	O
larger	JJR	O
population	NN	O
will	MD	O
improve	VB	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
systemic	JJ	O
inflammatory	JJ	O
mechanisms	NNS	O
following	VBG	O
acute	NN	O
exposure	NN	O
to	TO	O
TRAP	NNP	O
.	.	O

Ambient	JJ	O
temperature	NN	O
and	CC	O
biomarkers	NNS	O
of	IN	O
heart	NN	O
failure	NN	O
:	:	O
a	DT	O
repeated	JJ	O
measures	NNS	O
analysis	NN	O
.	.	O

BACKGROUND	NNP	O
Extreme	NNP	O
temperatures	NNS	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
hospitalization	NN	O
and	CC	O
death	NN	O
among	IN	O
individuals	NNS	O
with	IN	O
heart	NN	Condition
failure	NN	Condition
,	,	O
but	CC	O
few	JJ	O
studies	NNS	O
have	VBP	O
explored	VBN	O
the	DT	O
underlying	JJ	O
mechanisms	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
hypothesized	VBD	O
that	IN	O
outdoor	JJ	O
temperature	NN	O
in	IN	O
the	DT	O
Boston	NNP	O
,	,	O
Massachusetts	NNP	O
,	,	O
area	NN	O
(	(	O
1-	JJ	O
to	TO	O
4-day	JJ	O
moving	NN	O
averages	NNS	O
)	)	O
would	MD	O
be	VB	O
associated	VBN	O
with	IN	O
higher	JJR	O
levels	NNS	O
of	IN	O
biomarkers	NNS	O
of	IN	O
inflammation	NN	O
and	CC	O
myocyte	JJ	O
injury	NN	O
in	IN	O
a	DT	O
repeated-measures	JJ	O
study	NN	O
of	IN	O
individuals	NNS	O
with	IN	O
stable	JJ	Condition
heart	NN	Condition
failure	NN	Condition
.	.	O

METHODS	NNP	O
We	PRP	O
analyzed	VBD	O
data	NNS	O
from	IN	O
a	DT	O
completed	VBN	O
clinical	JJ	O
trial	NN	O
that	WDT	O
randomized	VBD	O
100	CD	SampleSize
patients	NNS	O
to	TO	O
12	CD	O
weeks	NNS	O
of	IN	O
tai	NN	O
chi	NN	O
classes	NNS	O
or	CC	O
to	TO	O
time-matched	JJ	O
education	NN	O
control	NN	O
.	.	O

B-type	NNP	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
BNP	NNP	O
)	)	O
,	,	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
and	CC	O
tumor	NN	O
necrosis	NN	O
factor	NN	O
(	(	O
TNF	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
,	,	O
6	CD	O
weeks	NNS	O
,	,	O
and	CC	O
12	CD	O
weeks	NNS	O
.	.	O

Endothelin-1	NNP	O
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
12	CD	O
weeks	NNS	O
.	.	O

We	PRP	O
used	VBD	O
fixed	VBN	O
effects	NNS	O
models	NNS	O
to	TO	O
evaluate	VB	O
associations	NNS	O
with	IN	O
measures	NNS	O
of	IN	O
temperature	NN	O
that	WDT	O
were	VBD	O
adjusted	VBN	O
for	IN	O
time-varying	JJ	O
covariates	NNS	O
.	.	O

RESULTS	NNP	O
Higher	NNP	O
apparent	JJ	O
temperature	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
levels	NNS	O
of	IN	O
BNP	NNP	O
beginning	VBG	O
with	IN	O
2-day	JJ	O
moving	VBG	O
averages	NNS	O
and	CC	O
reached	VBD	O
statistical	JJ	O
significance	NN	O
for	IN	O
3-	JJ	O
and	CC	O
4-day	JJ	O
moving	NN	O
averages	NNS	O
.	.	O

CRP	NNP	O
results	NNS	O
followed	VBD	O
a	DT	O
similar	JJ	O
pattern	NN	O
but	CC	O
were	VBD	O
delayed	VBN	O
by	IN	O
1	CD	O
day	NN	O
.	.	O

A	DT	O
5?C	CD	O
change	NN	O
in	IN	O
3-	JJ	O
and	CC	O
4-day	JJ	O
moving	NN	O
averages	NNS	O
of	IN	O
apparent	JJ	O
temperature	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
11.3	CD	O
%	NN	O
[	JJ	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
:	:	O
1.1	CD	O
,	,	O
22.5	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.03	CD	O
)	)	O
and	CC	O
11.4	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.2	CD	O
,	,	O
22.5	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.03	CD	O
)	)	O
higher	JJR	O
BNP	NNP	O
.	.	O

A	DT	O
5?C	CD	O
change	NN	O
in	IN	O
the	DT	O
4-day	JJ	O
moving	JJ	O
average	NN	O
of	IN	O
apparent	JJ	O
temperature	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
21.6	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
2.5	CD	O
,	,	O
44.2	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.03	CD	O
)	)	O
higher	JJR	O
CRP	NNP	O
.	.	O

No	DT	O
clear	JJ	O
associations	NNS	O
with	IN	O
TNF	NNP	O
or	CC	O
endothelin-1	JJ	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Among	IN	O
patients	NNS	O
undergoing	VBG	O
treatment	NN	O
for	IN	O
heart	NN	O
failure	NN	O
,	,	O
we	PRP	O
observed	VBD	O
positive	JJ	O
associations	NNS	O
between	IN	O
temperature	NN	O
and	CC	O
both	DT	O
BNP	NNP	O
and	CC	O
CRP-predictors	NNS	O
of	IN	O
heart	NN	O
failure	NN	O
prognosis	NN	O
and	CC	O
severity	NN	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
of	IN	O
two	CD	O
regimens	NNS	O
of	IN	O
moderate	JJ	O
dose	JJ	O
chemoradiation	NN	O
therapy	NN	O
for	IN	O
patients	NNS	Condition
with	IN	Condition
non-small	JJ	Condition
cell	NN	Condition
lung	NN	Condition
cancer	NN	Condition
not	RB	Condition
suitable	JJ	Condition
for	IN	Condition
curative	JJ	Condition
therapy	NN	Condition
:	:	Condition
Trans	NNPS	O
Tasman	NNP	O
Radiation	NNP	O
Oncology	NNP	O
Study	NNP	O
TROG	NNP	O
03.07	CD	O
.	.	O

BACKGROUND	VB	O
There	EX	O
are	VBP	O
patients	NNS	O
with	IN	O
stage	JJ	O
I-III	JJ	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
who	WP	O
are	VBP	O
not	RB	O
suitable	JJ	O
for	IN	O
curative	JJ	O
radical	JJ	O
chemoradiation	NN	O
therapy	NN	O
.	.	O

There	EX	O
are	VBP	O
patients	NNS	O
with	IN	O
an	DT	O
isolated	JJ	O
solitary	JJ	O
extracranial	JJ	O
metastasis	NN	O
who	WP	O
have	VBP	O
improved	VBN	O
outcomes	NNS	O
compared	VBN	O
with	IN	O
those	DT	O
with	IN	O
cranial	JJ	O
or	CC	O
multiple	JJ	O
metastases	NNS	O
.	.	O

Patients	NNS	O
of	IN	O
good	JJ	O
performance	NN	O
status	NN	O
receiving	VBG	O
moderate	JJ	O
dose	NN	O
radiation	NN	O
therapy	NN	O
have	VBP	O
improved	VBN	O
survival	JJ	O
.	.	O

Two	CD	O
regimens	NNS	O
of	IN	O
moderate	JJ	O
dose	JJ	O
chemoradiation	NN	O
therapy	NN	O
for	IN	O
such	JJ	O
patients	NNS	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
eligible	JJ	O
if	IN	O
they	PRP	O
had	VBD	O
stage	VBN	O
I-IIIB	NNP	O
NSCLC	NNP	O
,	,	O
unsuitable	JJ	O
for	IN	O
curative	JJ	O
therapy	NN	O
,	,	O
or	CC	O
stage	NN	O
IV	NNP	O
with	IN	O
a	DT	O
PET-detected	JJ	O
extracranial	JJ	O
solitary	JJ	O
metastasis	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
following	JJ	O
groups-arm	NN	O
A	DT	O
:	:	O
40	CD	O
Gy/20	NNP	O
fractions/4	JJ	O
weeks	NNS	O
with	IN	O
concurrent	JJ	O
weekly	JJ	O
vinorelbine	NN	O
25	CD	O
mg/m	NN	O
+	NNP	O
cisplatin	VBZ	O
20	CD	O
mg/m	NN	O
or	CC	O
arm	NN	O
B	NN	O
:	:	O
30	CD	O
Gy/15	NNP	O
fractions/3	JJ	O
weeks	NNS	O
with	IN	O
concurrent	JJ	O
weekly	JJ	O
gemcitabine	NN	O
200	CD	O
mg.	NN	O
Primary	NNP	O
end	NN	O
points	NNS	O
were	VBD	O
feasibility	NN	O
,	,	O
response	NN	O
rates	NNS	O
,	,	O
and	CC	O
toxicity	NN	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
progression-free	JJ	O
survival	NN	O
,	,	O
overall	JJ	O
survival	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

RESULTS	NNP	O
Eighty-four	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

Compliance	NN	O
was	VBD	O
above	IN	O
90	CD	O
%	NN	O
for	IN	O
both	DT	O
arms	NNS	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
51	CD	O
%	NN	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
38	CD	O
%	NN	O
in	IN	O
arm	NN	O
B	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.147	CD	O
)	)	O
.	.	O

Grade	$	O
3/4	CD	O
toxicity	NN	O
in	IN	O
both	DT	O
arms	NNS	O
was	VBD	O
acceptable	JJ	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
median	JJ	O
progression-free	JJ	O
survival	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
(	(	O
5.5	CD	O
versus	NN	O
5.0	CD	O
months	NNS	O
,	,	O
p	VBP	O
=	RB	O
0.19	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
arm	NN	O
A	NN	O
had	VBD	O
longer	RBR	O
median	JJ	O
survival	NN	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
(	(	O
13.1	CD	O
versus	NN	O
8.3	CD	O
months	NNS	O
,	,	O
p	VBP	O
=	RB	O
0.25	CD	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Arm	NNP	O
A	NNP	O
was	VBD	O
chosen	VBN	O
for	IN	O
a	DT	O
future	JJ	O
phase	NN	O
II	NNP	O
comparison	NN	O
with	IN	O
radiation	NN	O
therapy	NN	O
alone	RB	O
as	IN	O
it	PRP	O
demonstrated	VBD	O
a	DT	O
response	NN	O
rate	NN	O
greater	JJR	O
than	IN	O
50	CD	O
%	NN	O
,	,	O
and	CC	O
data	NNS	O
suggested	VBD	O
that	IN	O
arm	NN	O
A	NNP	O
had	VBD	O
superior	JJ	O
survival	NN	O
to	TO	O
arm	NN	O
B	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
single-dose	JJ	O
oral	JJ	O
granisetron	NN	O
versus	NN	O
intravenous	JJ	O
ondansetron	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
induced	VBN	O
by	IN	O
moderately	RB	O
emetogenic	JJ	O
chemotherapy	NN	O
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
parallel	NN	O
study	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
antiemetic	JJ	O
effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
single-dose	JJ	O
oral	JJ	O
granisetron	NN	O
were	VBD	O
compared	VBN	O
with	IN	O
intravenous	JJ	O
(	(	O
I.V	NNP	O
.	.	O

)	)	O
ondansetron	NN	O
in	IN	O
chemotherapy-naive	JJ	O
patients	NNS	O
who	WP	O
received	VBD	O
moderately	RB	O
emetogenic	JJ	O
chemotherapy	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
parallel-group	NN	O
study	NN	O
,	,	O
patients	NNS	O
naive	VBP	O
to	TO	O
emetogenic	VB	O
chemotherapy	NN	O
(	(	O
N	NNP	O
=	NNP	O
1,085	CD	O
)	)	O
who	WP	O
were	VBD	O
scheduled	VBN	O
to	TO	O
receive	VB	O
cyclophosphamide-	NN	O
(	(	O
500	CD	O
to	TO	O
1,200	CD	O
mg/m2	NN	O
)	)	O
or	CC	O
carboplatin	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
300	CD	O
mg/m2	NN	O
)	)	O
based	VBN	O
chemotherapy	NN	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
oral	JJ	O
granisetron	NN	O
(	(	O
n	JJ	O
=	NNP	O
542	CD	O
)	)	O
or	CC	O
I.V	NNP	O
.	.	O

ondansetron	NN	O
(	(	O
n	JJ	O
=	NNP	O
543	CD	O
)	)	O
.	.	O

Efficacy	NN	O
assessments	NNS	O
included	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
in	IN	O
each	DT	O
treatment	NN	O
group	NN	O
with	IN	O
total	JJ	O
control	NN	O
over	IN	O
the	DT	O
24	CD	O
and	CC	O
48	CD	O
hours	NNS	O
following	VBG	O
chemotherapy	NN	O
initiation	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
nausea	NN	O
and	CC	O
emesis	NN	O
and	CC	O
use	NN	O
of	IN	O
antiemetic	JJ	O
rescue	NN	O
medication	NN	O
.	.	O

Prophylactic	JJ	O
corticosteroids	NNS	O
were	VBD	O
allowed	VBN	O
.	.	O

Safety	NNP	O
assessment	NN	O
was	VBD	O
based	VBN	O
on	IN	O
patients	NNS	O
'	POS	O
reports	NNS	O
of	IN	O
adverse	JJ	O
experiences	NNS	O
.	.	O

RESULTS	NNP	O
Approximately	RB	O
80	CD	O
%	NN	O
of	IN	O
patients	NNS	O
received	VBN	O
prophylactic	JJ	O
corticosteroids	NNS	O
.	.	O

Single-dose	JJ	O
oral	JJ	O
granisetron	NN	O
(	(	O
2	CD	O
mg	NN	O
)	)	O
and	CC	O
I.V	NNP	O
.	.	O

ondansetron	NN	O
(	(	O
32	CD	O
mg	NN	O
)	)	O
resulted	VBD	O
in	IN	O
equivalent	JJ	O
levels	NNS	O
of	IN	O
total	JJ	O
emetic	JJ	O
control	NN	O
during	IN	O
the	DT	O
first	JJ	O
48	CD	O
hours	NNS	O
after	IN	O
chemotherapy	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
nausea-	JJ	O
and	CC	O
emesis-free	JJ	O
patients	NNS	O
at	IN	O
24	CD	O
and	CC	O
48	CD	O
hours	NNS	O
were	VBD	O
also	RB	O
approximately	RB	O
equivalent	JJ	O
.	.	O

The	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
adverse	JJ	O
experiences	NNS	O
were	VBD	O
headache	NN	O
,	,	O
asthenia	NN	O
,	,	O
and	CC	O
constipation	NN	O
.	.	O

More	JJR	O
patients	NNS	O
who	WP	O
received	VBD	O
ondonsetron	JJR	O
than	IN	O
granisetron	NN	O
reported	VBN	O
dizziness	NN	O
(	(	O
9.6	CD	O
%	NN	O
v	JJ	O
5.4	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
.011	NNP	O
)	)	O
and	CC	O
abnormal	JJ	O
vision	NN	O
(	(	O
4.2	CD	O
%	NN	O
v	JJ	O
0.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	O
single	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
granisetron	NN	O
(	(	O
2	CD	O
mg	NN	O
)	)	O
resulted	VBD	O
in	IN	O
equivalent	JJ	O
levels	NNS	O
of	IN	O
antiemetic	JJ	O
protection	NN	O
as	IN	O
I.V	NNP	O
.	.	O

ondansetron	NN	O
(	(	O
32	CD	O
mg	NN	O
)	)	O
.	.	O

Both	DT	O
agents	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
although	IN	O
more	JJR	O
dizziness	NN	O
and	CC	O
abnormal	JJ	O
vision	NN	O
were	VBD	O
reported	VBN	O
with	IN	O
ondansetron	NN	O
.	.	O

Because	IN	O
the	DT	O
two	CD	O
antiemetic	JJ	O
regimens	NNS	O
exhibited	VBD	O
equivalent	JJ	O
efficacies	NNS	O
,	,	O
additional	JJ	O
factors	NNS	O
such	JJ	O
as	IN	O
convenience	NN	O
and	CC	O
cost	NN	O
of	IN	O
therapy	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

Gastric	JJ	Condition
carcinoma	NN	Condition
:	:	O
expression	NN	O
of	IN	O
c-erbB-2/neu	JJ	O
oncoprotein	NN	O
,	,	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
cathepsin	NN	O
D	NNP	O
,	,	O
progesterone	NN	O
receptor	NN	O
and	CC	O
tumor	NN	O
associated	VBN	O
glycoprotein-72	JJ	O
in	IN	O
different	JJ	O
histological	JJ	O
types	NNS	O
.	.	O

OBJECTIVE	NNP	O
Gastric	NNP	Condition
carcinoma	NN	Condition
can	MD	O
be	VB	O
divided	VBN	O
into	IN	O
two	CD	O
main	JJ	O
histological	JJ	O
and	CC	O
clinical	JJ	O
types	NNS	O
:	:	O
diffuse	NN	O
and	CC	O
intestinal	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
expression	NN	O
of	IN	O
neu/c-erbB-2	JJ	O
oncoprotein	NN	O
,	,	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
(	(	O
EGFR	NNP	O
)	)	O
,	,	O
cathepsin	JJ	O
D	NNP	O
(	(	O
catD	NN	O
)	)	O
,	,	O
progesterone	JJ	O
receptor	NN	O
(	(	O
PR	NNP	O
)	)	O
and	CC	O
tumor-associated	JJ	O
glycoprotein-72	NN	O
(	(	O
TAG-72	NNP	O
)	)	O
in	IN	O
gastric	JJ	O
carcinoma	NN	O
of	IN	O
these	DT	O
histological	JJ	O
types	NNS	O
.	.	O

METHOD	NN	O
In	IN	O
this	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
study	NN	O
we	PRP	O
analyzed	VBD	O
85	CD	O
biopsy	NN	O
samples	NNS	O
from	IN	O
patients	NNS	O
with	IN	O
gastric	JJ	Condition
adenocarcinoma	NN	Condition
.	.	O

The	DT	O
control	NN	O
group	NN	O
consisted	VBD	O
of	IN	O
40	CD	O
specimens	NNS	O
from	IN	O
normal	JJ	O
gastric	JJ	O
mucosa	NN	O
.	.	O

Neu	NNP	O
oncoprotein	NN	O
and	CC	O
PR	NNP	O
were	VBD	O
determined	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O

CatD	NNP	O
and	CC	O
TAG-72	NNP	O
were	VBD	O
quantified	VBN	O
with	IN	O
immunoradiometric	JJ	O
(	(	O
IRMA	NNP	O
)	)	O
methods	NNS	O
,	,	O
and	CC	O
EGFR	NNP	O
were	VBD	O
studied	VBN	O
by	IN	O
radioimmunoassay	NN	O
(	(	O
RIA	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Neu	NNP	O
,	,	O
EGFR	NNP	O
,	,	O
catD	NN	O
and	CC	O
TAG-72	JJ	O
concentrations	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
tumoral	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NN	O
0.02	CD	O
,	,	O
p	NN	O
=	VBD	O
0.00001	CD	O
,	,	O
p	NN	O
=	VBD	O
0.002	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.007	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

In	IN	O
diffuse	NN	O
adenocarcinomas	NN	O
,	,	O
catD	NN	O
and	CC	O
PR	NNP	O
expression	NN	O
was	VBD	O
increased	VBN	O
(	(	O
p	JJ	O
=	NN	O
0.01	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.04	CD	O
respectively	RB	O
)	)	O
,	,	O
whereas	JJ	O
TAG-72	NNP	O
concentration	NN	O
,	,	O
which	WDT	O
correlated	VBD	O
with	IN	O
neu	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.57	CD	O
)	)	O
,	,	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
intestinal	JJ	O
type	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
EGFR	NNP	O
and	CC	O
neu	JJ	O
concentrations	NNS	O
were	VBD	O
seen	VBN	O
between	IN	O
the	DT	O
two	CD	O
histological	JJ	O
types	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
higher	JJR	O
PR	NNP	O
and	CC	O
catD	JJ	O
concentrations	NNS	O
in	IN	O
diffuse	NN	O
adenocarcinomas	NN	O
,	,	O
and	CC	O
the	DT	O
overexpression	NN	O
of	IN	O
TAG-72	NNP	O
in	IN	O
the	DT	O
intestinal	JJ	O
type	NN	O
,	,	O
support	VB	O
the	DT	O
existence	NN	O
of	IN	O
two	CD	O
modes	NNS	O
of	IN	O
gastric	JJ	O
carcinogenesis	NN	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
a	DT	O
new	JJ	O
3.3	CD	O
g	NN	O
b.i.d	NN	O
.	.	O

tablet	NN	O
formulation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild-to-moderately-active	JJ	O
ulcerative	JJ	Condition
colitis	NN	Condition
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
a	DT	O
new	JJ	O
twice-daily	JJ	O
balsalazide	NN	O
disodium	NN	O
1.1	CD	O
g	NN	O
tablet	NN	O
dosing	VBG	O
regimen	NNS	O
(	(	O
6.6	CD	O
g/day	NN	O
,	,	O
three	CD	O
tablets	NNS	O
twice	RB	O
daily	RB	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
mild-to-moderately-active	JJ	O
ulcerative	JJ	O
colitis	NN	O
(	(	O
UC	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
multicenter	NN	O
study	NN	O
patients	NNS	O
with	IN	O
symptoms	NNS	O
of	IN	O
acute	JJ	Condition
UC	NNP	Condition
and	CC	O
a	DT	O
baseline	NN	O
Modified	NNP	O
Mayo	NNP	O
Disease	NNP	O
Activity	NNP	O
Index	NNP	O
(	(	O
MMDAI	NNP	O
)	)	O
score	NN	O
between	IN	O
6	CD	O
and	CC	O
10	CD	O
,	,	O
inclusive	JJ	O
,	,	O
with	IN	O
a	DT	O
subscale	JJ	O
rating	NN	O
of	IN	O
>	NNP	O
or	CC	O
=2	NN	O
for	IN	O
both	DT	O
rectal	JJ	O
bleeding	NN	O
and	CC	O
mucosal	JJ	O
appearance	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
3.3	CD	O
g	NN	O
of	IN	O
balsalazide	NN	O
or	CC	O
placebo	NN	O
tablets	NNS	O
twice	RB	O
daily	RB	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
achieving	VBG	O
clinical	JJ	O
improvement	NN	O
(	(	O
>	CD	O
or	CC	O
=3	VB	O
point	NN	O
improvement	NN	O
in	IN	O
MMDAI	NNP	O
)	)	O
and	CC	O
improvement	NN	O
in	IN	O
rectal	JJ	O
bleeding	NN	O
(	(	O
>	CD	O
or	CC	O
=1	VB	O
point	NN	O
improvement	NN	O
)	)	O
at	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Safety	NN	O
assessments	NNS	O
were	VBD	O
conducted	VBN	O
from	IN	O
baseline	NN	O
through	IN	O
2-weeks	JJ	O
post-treatment	JJ	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
249	CD	SampleSize
patients	NNS	O
(	(	O
166	CD	SampleSize
balsalazide	NN	O
,	,	O
83	CD	SampleSize
placebo	NN	O
)	)	O
received	VBD	O
at	IN	O
least	JJS	O
1	CD	O
dose	NN	O
of	IN	O
study	NN	O
medication	NN	O
.	.	O

The	DT	O
mean	JJ	O
MMDAI	NNP	O
score	NN	O
at	IN	O
baseline	NN	O
was	VBD	O
7.9	CD	O
;	:	O
62	CD	O
%	NN	O
of	IN	O
patients	NNS	O
had	VBD	O
a	DT	O
score	NN	O
>	NN	O
or	CC	O
=8.0	NN	O
(	(	O
moderate	JJ	O
disease	NN	O
)	)	O
.	.	O

A	DT	O
significantly	RB	O
larger	JJR	O
proportion	NN	O
of	IN	O
patients	NNS	O
achieved	VBN	O
clinical	JJ	O
improvement	NN	O
and	CC	O
improvement	NN	O
in	IN	O
rectal	JJ	O
bleeding	NN	O
in	IN	O
the	DT	O
balsalazide	NN	O
group	NN	O
vs.	FW	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
55	CD	O
vs.	FW	O
40	CD	O
%	NN	O
,	,	O
P=0.02	NNP	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
reported	VBN	O
were	VBD	O
worsening	VBG	O
of	IN	O
UC	NNP	O
and	CC	O
headache	NN	O
;	:	O
both	DT	O
were	VBD	O
reported	VBN	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Balsalazide	NNP	O
disodium	NN	O
1.1	CD	O
g	NN	O
tablets	NNS	O
administered	VBD	O
as	IN	O
3.3	CD	O
g	JJ	O
twice	RB	O
daily	RB	O
are	VBP	O
effective	JJ	O
,	,	O
well	RB	O
tolerated	VBN	O
and	CC	O
significantly	RB	O
better	JJR	O
than	IN	O
placebo	NN	O
for	IN	O
improving	VBG	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
mild-to-moderately-active	JJ	O
UC	NNP	O
.	.	O

This	DT	O
new	JJ	O
formulation	NN	O
with	IN	O
a	DT	O
reduced	VBN	O
pill	NN	O
and	CC	O
dosing	VBG	O
burden	NN	O
offers	VBZ	O
the	DT	O
potential	NN	O
to	TO	O
improve	VB	O
convenience	NN	O
and	CC	O
compliance	NN	O
in	IN	O
patients	NNS	O
with	IN	O
active	JJ	Condition
UC	NNP	Condition
.	.	O

Dexamethasone	NNP	O
therapy	NN	O
and	CC	O
cortisol	JJ	O
excretion	NN	O
in	IN	O
severe	JJ	Condition
pediatric	JJ	Condition
head	NN	Condition
injury	NN	Condition
.	.	Condition

Glucocorticoids	NNS	O
are	VBP	O
used	VBN	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
reduce	VB	O
brain	NN	O
edema	NN	O
secondary	JJ	O
to	TO	O
head	VB	O
injury	NN	O
.	.	O

Nevertheless	RB	O
,	,	O
their	PRP$	O
usefulness	JJ	O
remains	NNS	O
uncertain	JJ	O
and	CC	O
contradictory	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
of	IN	O
24	CD	O
children	NNS	O
with	IN	O
severe	JJ	O
head	NN	O
injury	NN	O
,	,	O
urinary	JJ	O
free	JJ	O
cortisol	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
radioimmunoassay	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
(	(	O
group	NN	O
1	CD	O
)	)	O
received	VBD	O
dexamethasone	NN	O
and	CC	O
12	CD	O
(	(	O
group	NN	O
2	CD	O
)	)	O
did	VBD	O
not	RB	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
standardized	JJ	O
regimen	NN	O
.	.	O

In	IN	O
group	NN	O
1	CD	O
there	EX	O
was	VBD	O
complete	JJ	O
suppression	NN	O
of	IN	O
endogenous	JJ	O
cortisol	NN	O
production	NN	O
.	.	O

In	IN	O
group	NN	O
2	CD	O
free	JJ	O
cortisol	NN	O
was	VBD	O
up	RB	O
to	TO	O
20-fold	CD	O
higher	JJR	O
than	IN	O
under	IN	O
basal	JJ	O
conditions	NNS	O
and	CC	O
reached	VBN	O
maximum	JJ	O
values	NNS	O
on	IN	O
days	NNS	O
1-3	RB	O
.	.	O

Since	IN	O
the	DT	O
excretion	NN	O
of	IN	O
cortisol	NN	O
in	IN	O
urine	JJ	O
reflects	VBZ	O
the	DT	O
production	NN	O
rate	NN	O
closely	RB	O
and	CC	O
is	VBZ	O
not	RB	O
influenced	VBN	O
by	IN	O
liver	NN	O
function	NN	O
and	CC	O
barbiturates	NNS	O
,	,	O
the	DT	O
results	NNS	O
in	IN	O
group	NN	O
2	CD	O
show	NN	O
that	IN	O
the	DT	O
endogenous	JJ	O
production	NN	O
of	IN	O
steroids	NNS	O
is	VBZ	O
an	DT	O
adequate	JJ	O
reaction	NN	O
to	TO	O
severe	VB	O
head	JJ	O
injury	NN	O
.	.	O

Exogenous	JJ	O
glucocorticoids	NNS	O
are	VBP	O
thus	RB	O
unlikely	JJ	O
to	TO	O
have	VB	O
any	DT	O
more	JJR	O
beneficial	JJ	O
effects	NNS	O
than	IN	O
endogenous	JJ	O
cortisol	NN	O
.	.	O

Long-term	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
Shouldice	NNP	Condition
,	,	Condition
Lichtenstein	NNP	Condition
and	CC	Condition
transabdominal	JJ	Condition
preperitoneal	NN	Condition
hernia	NN	Condition
repairs	NNS	O
.	.	O

INTRODUCTION	NNP	O
There	EX	O
is	VBZ	O
an	DT	O
ongoing	JJ	O
debate	NN	O
about	IN	O
the	DT	O
preferred	JJ	O
technique	NN	O
for	IN	O
inguinal	JJ	O
hernia	NN	O
repair	NN	O
.	.	O

In	IN	O
this	DT	O
randomized	VBN	O
study	NN	O
the	DT	O
long-term	JJ	O
results	NNS	O
of	IN	O
Shouldice	NNP	O
,	,	O
Lichtenstein	NNP	O
and	CC	O
transabdominal	JJ	O
preperitoneal	NN	O
(	(	O
TAPP	NNP	O
)	)	O
hernia	NN	O
repair	NN	O
were	VBD	O
compared	VBN	O
.	.	O

METHODS	NNP	O
Some	DT	O
280	CD	SampleSize
men	NNS	Sex
with	IN	O
a	DT	O
primary	JJ	Condition
hernia	NN	Condition
were	VBD	O
randomized	VBN	O
prospectively	RB	O
to	TO	O
undergo	VB	O
Shouldice	NNP	O
,	,	O
tension-free	JJ	O
Lichtenstein	NNP	O
or	CC	O
laparoscopic	JJ	O
TAPP	NNP	O
repair	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
examined	VBN	O
after	IN	O
52	CD	O
months	NNS	O
to	TO	O
assess	VB	O
hernia	NN	O
recurrence	NN	O
,	,	O
nerve	NN	O
damage	NN	O
,	,	O
testicular	JJ	O
atrophy	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
.	.	O

RESULTS	NNP	O
Hernia	NNP	O
recurrence	NN	O
occurred	VBD	O
in	IN	O
six	CD	O
patients	NNS	O
after	IN	O
Shouldice	NNP	O
repair	NN	O
,	,	O
and	CC	O
in	IN	O
one	CD	O
patient	NN	O
each	DT	O
after	IN	O
Lichtenstein	NNP	O
and	CC	O
TAPP	NNP	O
repairs	NNS	O
.	.	O

All	DT	O
recurrences	NNS	O
after	IN	O
tension-free	JJ	O
repairs	NNS	O
were	VBD	O
diagnosed	VBN	O
within	IN	O
the	DT	O
first	JJ	O
year	NN	O
after	IN	O
surgery	NN	O
.	.	O

Nerve	CC	O
injuries	NNS	O
were	VBD	O
significantly	RB	O
more	RBR	O
frequent	JJ	O
after	IN	O
open	JJ	O
Shouldice	NNP	O
and	CC	O
Lichtenstein	NNP	O
repairs	NNS	O
.	.	O

Patient	JJ	O
satisfaction	NN	O
was	VBD	O
greatest	JJS	O
after	IN	O
laparoscopic	JJ	O
TAPP	NNP	O
repair	NN	O
.	.	O

CONCLUSION	NNP	O
Tension-free	NNP	O
repair	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
non-mesh	JJ	O
Shouldice	NNP	O
technique	NN	O
.	.	O

The	DT	O
open	JJ	O
anterior	JJ	O
approach	NN	O
to	TO	O
the	DT	O
groin	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
demonstrable	JJ	O
nerve	NN	O
injury	NN	O
,	,	O
and	CC	O
laparoscopic	JJ	O
TAPP	NNP	O
repair	NN	O
was	VBD	O
the	DT	O
most	RBS	O
effective	JJ	O
approach	NN	O
in	IN	O
the	DT	O
hands	NNS	O
of	IN	O
an	DT	O
experienced	JJ	O
surgeon	NN	O
.	.	O

Do	VB	O
ACE	NNP	O
inhibitors	NNS	O
improve	VBP	O
the	DT	O
response	NN	O
to	TO	O
exercise	VB	O
training	NN	O
in	IN	O
functionally	RB	Condition
impaired	JJ	Condition
older	JJR	Condition
adults	NNS	Condition
?	.	O
A	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Loss	NNP	O
of	IN	O
muscle	NN	O
mass	NN	O
and	CC	O
strength	NN	O
with	IN	O
ageing	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
cause	NN	O
for	IN	O
falls	NNS	O
,	,	O
disability	NN	O
,	,	O
and	CC	O
morbidity	NN	O
in	IN	O
older	JJR	O
people	NNS	O
.	.	O

Previous	JJ	O
studies	NNS	O
have	VBP	O
found	VBN	O
that	IN	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
(	(	O
ACEi	NNP	O
)	)	O
may	MD	O
improve	VB	O
physical	JJ	O
function	NN	O
in	IN	O
older	JJR	O
people	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
unclear	JJ	O
whether	IN	O
ACEi	NNP	O
provide	VBP	O
additional	JJ	O
benefit	NN	O
when	WRB	O
added	VBD	O
to	TO	O
a	DT	O
standard	JJ	O
exercise	NN	O
training	NN	O
program	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
ACEi	NNP	O
therapy	NN	O
on	IN	O
physical	JJ	O
function	NN	O
in	IN	O
older	JJR	O
people	NNS	O
undergoing	VBG	O
exercise	NN	O
training	NN	O
.	.	O

METHODS	NNP	O
Community-dwelling	JJ	O
people	NNS	O
aged	VBN	O
?	.	O
65	CD	O
years	NNS	O
with	IN	O
functional	JJ	O
impairment	NN	O
were	VBD	O
recruited	VBN	O
through	IN	O
general	JJ	O
(	(	O
family	NN	O
)	)	O
practices	NNS	O
.	.	O

All	DT	O
participants	NNS	O
received	VBD	O
progressive	JJ	O
exercise	NN	O
training	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
4	CD	O
mg	NNS	O
perindopril	NN	O
or	CC	O
matching	VBG	O
placebo	JJ	O
daily	JJ	O
for	IN	O
20	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
between-group	JJ	O
change	NN	O
in	IN	O
6-minute	JJ	O
walk	NN	O
distance	NN	O
from	IN	O
baseline	NN	O
to	TO	O
20	CD	O
weeks	NNS	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
changes	NNS	O
in	IN	O
Short	NNP	O
Physical	NNP	O
Performance	NNP	O
Battery	NNP	O
,	,	O
handgrip	NN	O
and	CC	O
quadriceps	JJ	O
strength	NN	O
,	,	O
self-reported	JJ	O
quality	NN	O
of	IN	O
life	NN	O
using	VBG	O
the	DT	O
EQ-5D	NNP	O
,	,	O
and	CC	O
functional	JJ	O
impairment	NN	O
measured	VBD	O
using	VBG	O
the	DT	O
Functional	NNP	O
Limitations	NNP	O
Profile	NNP	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
170	CD	O
participants	NNS	O
(	(	O
n	JJ	O
=	$	O
86	CD	O
perindopril	NN	O
,	,	O
n	JJ	O
=	FW	O
84	CD	O
placebo	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
.	.	O

Mean	JJ	O
age	NN	O
was	VBD	O
75.7	CD	O
(	(	O
standard	JJ	O
deviation	NN	O
[	NNP	O
SD	NNP	O
]	NNP	O
6.8	CD	O
)	)	O
years	NNS	O
.	.	O

Baseline	NNP	O
6-minute	JJ	O
walk	NN	O
distance	NN	O
was	VBD	O
306	CD	O
m	NN	O
(	(	O
SD	NNP	O
99	CD	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
increased	VBD	O
their	PRP$	O
walk	NN	O
distance	NN	O
(	(	O
by	IN	O
29.6	CD	O
m	NNS	O
perindopril	NN	O
,	,	O
36.4	CD	O
m	NN	O
placebo	NN	O
group	NN	O
)	)	O
at	IN	O
20	CD	O
weeks	NNS	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
treatment	NN	O
effect	NN	O
between	IN	O
groups	NNS	O
(	(	O
-8.6m	JJ	O
[	RB	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
:	:	O
-30.1	NN	O
,	,	O
12.9	CD	O
]	NN	O
,	,	O
p	NN	O
=	NNP	O
.43	NNP	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
treatment	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
groups	NNS	O
for	IN	O
the	DT	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

Adverse	JJ	O
events	NNS	O
leading	VBG	O
to	TO	O
withdrawal	VB	O
were	VBD	O
few	JJ	O
(	(	O
n	JJ	O
=	$	O
0	CD	O
perindopril	NN	O
,	,	O
n	JJ	O
=	FW	O
4	CD	O
placebo	NN	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
ACE	NNP	O
inhibitors	NNS	O
did	VBD	O
not	RB	O
enhance	VB	O
the	DT	O
effect	NN	O
of	IN	O
exercise	NN	O
training	NN	O
on	IN	O
physical	JJ	O
function	NN	O
in	IN	O
functionally	RB	O
impaired	JJ	O
older	JJR	O
people	NNS	O
.	.	O

Teacher-implemented	JJ	O
joint	JJ	O
attention	NN	O
intervention	NN	O
:	:	O
pilot	NN	O
randomized	VBD	O
controlled	VBN	O
study	NN	O
for	IN	O
preschoolers	NNS	Age
with	IN	O
autism	NN	Condition
.	.	O

OBJECTIVE	CC	O
The	DT	O
vast	JJ	O
majority	NN	O
of	IN	O
children	NNS	Age
with	IN	O
an	DT	O
autism	NN	Condition
spectrum	NN	Condition
disorder	NN	Condition
(	(	Condition
ASD	NNP	Condition
)	)	Condition
attend	VBP	O
public	JJ	O
preschools	NNS	O
at	IN	O
some	DT	O
point	NN	O
in	IN	O
their	PRP$	O
childhood	NN	O
.	.	O

Community	NNP	O
preschool	NN	O
practices	NNS	O
often	RB	O
are	VBP	O
not	RB	O
evidence	NN	O
based	VBN	O
,	,	O
and	CC	O
almost	RB	O
none	NN	O
target	NN	O
the	DT	O
prelinguistic	JJ	O
core	NN	O
deficits	NNS	O
of	IN	O
ASD	NNP	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
public	JJ	Condition
preschool	NN	Condition
teachers	NNS	Condition
implementing	VBG	O
a	DT	O
validated	VBN	O
intervention	NN	O
(	(	O
the	DT	O
Joint	NNP	O
Attention	NNP	O
and	CC	O
Symbolic	NNP	O
Play/Engagement	NNP	O
and	CC	O
Regulation	NNP	O
intervention	NN	O
;	:	O
JASP/ER	NNP	O
)	)	O
on	IN	O
a	DT	O
core	NN	O
deficit	NN	O
of	IN	O
autism	NN	O
,	,	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
.	.	O

METHOD	NNP	O
Sixteen	NNP	SampleSize
dyads	NNS	O
(	(	O
preschoolers	NNS	Age
with	IN	O
ASD	NNP	Condition
and	CC	O
the	DT	O
public	JJ	O
school	NN	O
teachers	NNS	O
who	WP	O
worked	VBD	O
in	IN	O
the	DT	O
child	NN	O
's	POS	O
classroom	NN	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
6-week	JJ	O
JASP/ER	NNP	O
intervention	NN	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
,	,	O
JASP/ER	NNP	O
teachers	NNS	O
used	VBD	O
more	RBR	O
JASP/ER	NNP	O
strategies	NNS	O
than	IN	O
the	DT	O
control	NN	O
teachers	NNS	O
,	,	O
and	CC	O
JASP/ER	NNP	O
preschoolers	NNS	O
used	VBD	O
more	RBR	O
joint	JJ	O
attention	NN	O
in	IN	O
their	PRP$	O
classroom	NN	O
than	IN	O
control	NN	O
children	NNS	O
.	.	O

Additionally	RB	O
,	,	O
JASP/ER	NNP	O
children	NNS	O
spent	VBD	O
more	JJR	O
time	NN	O
in	IN	O
supported	JJ	O
engagement	NN	O
and	CC	O
less	JJR	O
time	NN	O
in	IN	O
object	JJ	O
engagement	NN	O
than	IN	O
control	NN	O
preschoolers	NNS	O
on	IN	O
a	DT	O
taped	VBN	O
play	NN	O
interaction	NN	O
.	.	O

CONCLUSIONS	NNP	O
Findings	NNP	O
suggest	VBP	O
that	IN	O
teachers	NNS	Condition
were	VBD	O
able	JJ	O
to	TO	O
improve	VB	O
a	DT	O
core	NN	O
deficit	NN	O
of	IN	O
children	NNS	Age
with	IN	O
ASD	NNP	Condition
in	IN	O
a	DT	O
public	JJ	Condition
preschool	NN	Condition
context	NN	O
.	.	O

Randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
of	IN	O
methylphenidate	NN	O
for	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
symptoms	NNS	O
in	IN	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
short-term	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
methylphenidate	NN	O
(	(	O
MPH	NNP	O
)	)	O
to	TO	O
treat	VB	O
attention-deficit/hyperactivity	JJ	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
symptoms	NNS	O
in	IN	O
an	DT	O
understudied	JJ	O
population	NN	O
of	IN	O
preschoolers	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
(	(	O
PDD	NNP	O
)	)	O
or	CC	O
intellectual	JJ	O
disability	NN	O
(	(	O
ID	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Fourteen	NNP	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
(	(	O
DD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
14	CD	O
;	:	O
PDD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
12	CD	O
;	:	O
ID	NNP	O
,	,	O
n	JJ	O
=	NNP	O
2	CD	O
)	)	O
underwent	NN	O
MPH	NNP	O
titration	NN	O
in	IN	O
a	DT	O
single-blind	JJ	O
manner	NN	O
followed	VBN	O
by	IN	O
a	DT	O
4-week	JJ	O
double-blind	NN	O
crossover	NN	O
phase	NN	O
.	.	O

Each	DT	O
child	NN	O
was	VBD	O
administered	VBN	O
placebo	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
optimal	JJ	O
dose	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
4	CD	O
(	(	O
th	NN	O
)	)	O
edition	NN	O
(	(	O
DSM-IV	NNP	O
)	)	O
ADHD	NNP	O
subscale	NN	O
of	IN	O
the	DT	O
Conners	NNP	O
'	POS	O
Parent	NN	O
Rating	VBG	O
Scale-Revised	JJ	O
(	(	O
CPRS-R-DSM-IV-ADHD	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
MPH	NNP	O
improved	VBD	O
parent-rated	JJ	O
ADHD	NNP	O
symptoms	NNS	O
of	IN	O
the	DT	O
preschoolers	NNS	O
;	:	O
50	CD	O
%	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
responders	NNS	O
.	.	O

The	DT	O
CPRS-R-DSM-IV-ADHD	JJ	O
subscale	NN	O
was	VBD	O
significant	JJ	O
for	IN	O
the	DT	O
PDD	NNP	O
subgroup	NN	O
(	(	O
p	JJ	O
=	NN	O
0.005	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.97	CD	O
)	)	O
and	CC	O
marginally	RB	O
significant	JJ	O
for	IN	O
the	DT	O
entire	JJ	O
DD	NNP	O
sample	NN	O
(	(	O
p	JJ	O
=	NN	O
0.08	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.50	CD	O
)	)	O
.	.	O

Half	NN	O
of	IN	O
the	DT	O
preschoolers	NNS	O
experienced	VBD	O
side	JJ	O
effects	NNS	O
with	IN	O
MPH	NNP	O
,	,	O
including	VBG	O
reports	NNS	O
of	IN	O
increased	VBN	O
stereotypic	NN	O
behavior	NN	O
,	,	O
upset	JJ	O
stomach	NN	O
,	,	O
sleep-related	JJ	O
difficulties	NNS	O
,	,	O
and	CC	O
emotional	JJ	O
lability	NN	O
.	.	O

One	CD	O
child	NN	O
discontinued	VBN	O
during	IN	O
titration	NN	O
due	JJ	O
to	TO	O
side	VB	O
effects	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
predominant	JJ	O
direction	NN	O
of	IN	O
response	NN	O
in	IN	O
these	DT	O
preschoolers	NNS	O
with	IN	O
both	DT	O
ADHD	NNP	O
and	CC	O
PDD/ID	NNP	O
favored	VBD	O
MPH	NNP	O
,	,	O
even	RB	O
though	IN	O
the	DT	O
response	NN	O
was	VBD	O
more	RBR	O
subtle	JJ	O
and	CC	O
variable	JJ	O
than	IN	O
in	IN	O
older	JJR	O
and	CC	O
typically	RB	O
developing	VBG	O
children	NNS	O
.	.	O

Due	NNP	O
to	TO	O
high	JJ	O
rates	NNS	O
of	IN	O
adverse	JJ	O
effects	NNS	O
,	,	O
preschoolers	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
.	.	O

Long-term	JJ	O
use	NN	O
of	IN	O
Viozan	NNP	O
(	(	O
sibenadet	JJ	O
HCl	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
obstructive	JJ	Condition
pulmonary	JJ	Condition
disease	NN	Condition
:	:	O
results	NNS	O
of	IN	O
a	DT	O
1-year	JJ	O
study	NN	O
.	.	O

Viozan	NNP	O
(	(	O
sibenadet	JJ	O
HCl	NNP	O
,	,	O
AR-C68397AA	NNP	O
)	)	O
is	VBZ	O
a	DT	O
novel	JJ	O
dual	JJ	O
D2	NNP	O
dopamine	NN	O
receptor	NN	O
,	,	O
beta2-adrenoceptor	JJ	O
agonist	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
investigated	VBN	O
for	IN	O
efficacy	NN	O
in	IN	O
alleviating	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

The	DT	O
slowly	RB	O
progressive	JJ	O
nature	NN	O
of	IN	O
this	DT	O
disease	NN	O
means	VBZ	O
that	IN	O
patients	NNS	O
will	MD	O
require	VB	O
ongoing	JJ	O
therapeutic	JJ	O
management	NN	O
for	IN	O
many	JJ	O
years	NNS	O
,	,	O
or	CC	O
even	RB	O
decades	NNS	O
.	.	O

With	IN	O
such	JJ	O
long-term	JJ	O
treatment	NN	O
,	,	O
the	DT	O
safety	NN	O
profile	NN	O
of	IN	O
new	JJ	O
agents	NNS	O
will	MD	O
be	VB	O
of	IN	O
paramount	JJ	O
importance	NN	O
.	.	O

As	IN	O
part	NN	O
of	IN	O
the	DT	O
large-scale	JJ	O
assessment	NN	O
of	IN	O
sibenadet	NN	O
,	,	O
a	DT	O
12-month	JJ	O
safety	NN	O
study	NN	O
has	VBZ	O
been	VBN	O
conducted	VBN	O
.	.	O

Following	VBG	O
completion	NN	O
of	IN	O
a	DT	O
2-week	JJ	O
baseline	NN	O
period	NN	O
,	,	O
435	CD	SampleSize
adults	NNS	Age
with	IN	O
stable	JJ	Condition
,	,	Condition
symptomatic	JJ	Condition
,	,	Condition
smoking-related	JJ	Condition
COPD	NNP	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
500	CD	O
microg	NN	O
sibenadet	NN	O
or	CC	O
placebo	NN	O
delivered	VBN	O
via	IN	O
pressurized	VBN	O
metered	VBD	O
dose	JJ	O
inhaler	NN	O
(	(	O
pMDI	NN	O
)	)	O
,	,	O
three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
52	CD	O
weeks	NNS	O
.	.	O

Sibenadet	NNP	O
therapy	NN	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
,	,	O
with	IN	O
the	DT	O
only	JJ	O
notable	JJ	O
differences	NNS	O
seen	VBN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
tremor	NN	O
and	CC	O
taste	NN	O
of	IN	O
treatment	NN	O
(	(	O
16.9	CD	O
%	NN	O
vs.	FW	O
4.1	CD	O
%	NN	O
and	CC	O
14.5	CD	O
%	NN	O
vs.	FW	O
4.1	CD	O
%	NN	O
in	IN	O
the	DT	O
sibenadet	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
respectively	RB	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
a	DT	O
total	NN	O
of	IN	O
79	CD	SampleSize
patients	NNS	O
with	IN	O
serious	JJ	Condition
adverse	JJ	Condition
events	NNS	Condition
(	(	O
SAEs	NNP	Condition
)	)	O
,	,	O
43	CD	SampleSize
(	(	O
14.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
sibenadet	NN	Condition
pMDI	NN	Condition
group	NN	O
and	CC	O
36	CD	SampleSize
(	(	O
24.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	Condition
group	NN	O
.	.	O

No	DT	O
clinically	RB	O
significant	JJ	O
abnormal	JJ	O
laboratory	NN	O
values	NNS	O
or	CC	O
overall	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
groups	NNS	O
were	VBD	O
noted	VBN	O
.	.	O

Similarly	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
clinically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
for	IN	O
cardiac	JJ	O
variables	NNS	O
,	,	O
or	CC	O
in	IN	O
vital	JJ	O
signs	NNS	O
.	.	O

The	DT	O
secondary	JJ	O
variables	NNS	O
showed	VBD	O
no	DT	O
notable	JJ	O
differences	NNS	O
with	IN	O
respect	NN	O
to	TO	O
lung	NN	O
function	NN	O
,	,	O
exacerbations	NNS	O
or	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Due	NNP	O
to	TO	O
the	DT	O
effective	JJ	O
beta2-agonist	NN	O
properties	NNS	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
sibenadet	NN	O
group	NN	O
did	VBD	O
,	,	O
however	RB	O
,	,	O
report	NN	O
reduced	VBD	O
rescue	JJ	O
medication	NN	O
usage	NN	O
at	IN	O
all	DT	O
timepoints	NNS	O
.	.	O

While	IN	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
show	NN	O
that	IN	O
,	,	O
overall	JJ	O
,	,	O
sibenadet	JJ	O
therapy	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
the	DT	O
lack	NN	O
of	IN	O
sustained	JJ	O
benefit	NN	O
reported	VBD	O
in	IN	O
large-scale	JJ	O
clinical	JJ	O
efficacy	NN	O
studies	NNS	O
means	VBZ	O
that	IN	O
sibenadet	NN	O
development	NN	O
will	MD	O
not	RB	O
be	VB	O
continued	VBN	O
.	.	O

Randomized	VBN	O
,	,	O
controlled	VBD	O
study	NN	O
of	IN	O
various	JJ	O
agents	NNS	O
for	IN	O
endoscopic	NN	O
injection	NN	O
sclerotherapy	NN	O
of	IN	O
bleeding	VBG	O
canine	NN	O
gastric	JJ	O
varices	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
relative	JJ	O
efficacy	NN	O
and	CC	O
technical	JJ	O
ease	NN	O
of	IN	O
use	NN	O
of	IN	O
eight	CD	O
different	JJ	O
agents	NNS	O
for	IN	O
endoscopic	JJ	O
hemostasis	NN	O
and	CC	O
obliteration	NN	O
of	IN	O
bleeding	VBG	O
gastric	JJ	O
varices	NNS	O
in	IN	O
a	DT	O
canine	NN	O
model	NN	O
,	,	O
as	IN	O
no	DT	O
comparative	JJ	O
data	NNS	O
are	VBP	O
available	JJ	O
on	IN	O
gastric	JJ	O
variceal	NN	O
sclerotherapy	NN	O
.	.	O

Large	JJ	O
bleeding	VBG	O
gastric	JJ	O
varices	NNS	O
in	IN	O
20	CD	SampleSize
heparinized	JJ	Condition
dogs	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
endoscopic	VB	O
injection	NN	O
treatment	NN	O
with	IN	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
agents	NNS	O
:	:	O
cyanoacrylate	NN	O
;	:	O
a	DT	O
1:1:1	CD	O
mixture	NN	O
of	IN	O
sodium	NN	O
tetradecyl	NN	O
sulfate	VBP	O
3	CD	O
%	NN	O
,	,	O
ethanol	RB	O
98	CD	O
%	NN	O
,	,	O
and	CC	O
normal	JJ	O
saline	JJ	O
solution	NN	O
;	:	O
ethanolamine	VB	O
oleate	VBP	O
5	CD	O
%	NN	O
;	:	O
sodium	NN	O
morrhuate	VBP	O
5	CD	O
%	NN	O
;	:	O
sodium	NN	O
tetradecyl	NN	O
sulfate	VBP	O
1.5	CD	O
%	NN	O
;	:	O
polidocanol	CC	O
1	CD	O
%	NN	O
;	:	O
normal	JJ	O
saline	JJ	O
solution	NN	O
with	IN	O
epinephrine	JJ	O
1:10,000	CD	O
;	:	O
or	CC	O
normal	JJ	O
saline	JJ	O
solution	NN	O
(	(	O
control	NN	O
)	)	O
.	.	O

The	DT	O
number	NN	O
and	CC	O
volume	NN	O
of	IN	O
injections	NNS	O
and	CC	O
the	DT	O
time	NN	O
required	VBN	O
to	TO	O
achieve	VB	O
complete	JJ	O
hemostasis	NN	O
were	VBD	O
evaluated	VBN	O
;	:	O
follow-up	JJ	O
endoscopy	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
1	CD	O
month	NN	O
to	TO	O
assess	VB	O
gastric	JJ	O
variceal	NN	O
obliteration	NN	O
.	.	O

Cyanoacrylate	NNP	O
was	VBD	O
the	DT	O
best	JJS	O
agent	NN	O
overall	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
immediate	JJ	O
efficacy	NN	O
,	,	O
low	JJ	O
volume	NN	O
requirement	NN	O
,	,	O
time	NN	O
required	VBN	O
for	IN	O
initial	JJ	O
hemostasis	NN	O
,	,	O
and	CC	O
reduction	NN	O
of	IN	O
gastric	JJ	O
variceal	NN	O
size	NN	O
.	.	O

Cyanoacrylate	NNP	O
,	,	O
tetradecyl	NN	O
sulfate	NN	O
,	,	O
and	CC	O
polidocanol	NN	O
were	VBD	O
the	DT	O
most	RBS	O
effective	JJ	O
agents	NNS	O
for	IN	O
reducing	VBG	O
gastric	JJ	O
variceal	NN	O
size	NN	O
.	.	O

Epinephrine	NNP	O
was	VBD	O
effective	JJ	O
for	IN	O
controlling	VBG	O
induced	JJ	O
or	CC	O
secondary	JJ	O
bleeding	NN	O
caused	VBN	O
by	IN	O
puncture	NN	O
of	IN	O
the	DT	O
gastric	JJ	O
varices	NNS	O
with	IN	O
the	DT	O
sclerotherapy	NN	O
needle	NN	O
during	IN	O
intravariceal	JJ	O
injections	NNS	O
.	.	O

Ongoing	VBG	O
studies	NNS	O
are	VBP	O
evaluating	VBG	O
combinations	NNS	O
of	IN	O
agents	NNS	O
with	IN	O
different	JJ	O
mechanisms	NNS	O
of	IN	O
action	NN	O
,	,	O
such	JJ	O
as	IN	O
epinephrine	NN	O
(	(	O
for	IN	O
vasoconstriction	NN	O
to	TO	O
minimize	VB	O
secondary	JJ	O
bleeding	NN	O
)	)	O
plus	CC	O
alcohol	NN	O
,	,	O
and/or	JJ	O
tetradecyl	NN	O
sulfate	NN	O
(	(	O
for	IN	O
variceal	NN	O
thrombosis	NN	O
and	CC	O
sclerosis	NN	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Subcutaneous	JJ	O
low-molecular-weight	JJ	O
heparin	NN	O
compared	VBN	O
with	IN	O
continuous	JJ	O
intravenous	JJ	O
unfractionated	JJ	O
heparin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
proximal	JJ	Condition
deep	JJ	Condition
vein	NN	Condition
thrombosis	NN	Condition
.	.	O

BACKGROUND	VB	O
A	DT	O
low-molecular-weight	JJ	O
heparin	NN	O
,	,	O
enoxaparin	JJ	O
sodium	NN	O
,	,	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
and	CC	O
safe	JJ	O
in	IN	O
preventing	VBG	O
deep	JJ	Condition
vein	NN	Condition
thrombosis	NN	Condition
both	DT	O
in	IN	O
general	JJ	O
surgery	NN	O
and	CC	O
in	IN	O
high-risk	JJ	O
orthopedic	JJ	O
surgery	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
controlled	VBN	O
,	,	O
randomized	VBN	O
trial	NN	O
with	IN	O
enoxaparin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
established	VBN	O
deep	JJ	O
vein	NN	O
thrombosis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
multicenter	NN	O
trial	NN	O
,	,	O
we	PRP	O
compared	VBN	O
fixed-dose	RB	O
subcutaneous	JJ	O
enoxaparin	NN	O
,	,	O
given	VBN	O
twice	RB	O
daily	RB	O
,	,	O
with	IN	O
adjusted-dose	JJ	O
intravenous	JJ	O
unfractionated	JJ	O
heparin	NN	O
(	(	O
UFH	NNP	O
)	)	O
given	VBN	O
by	IN	O
continuous	JJ	O
intravenous	JJ	O
infusion	NN	O
for	IN	O
the	DT	O
initial	JJ	O
10	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
proximal	JJ	Condition
vein	NN	Condition
thrombosis	NN	Condition
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
outcome	NN	O
was	VBD	O
the	DT	O
change	NN	O
of	IN	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
thrombus	NN	O
assessed	VBN	O
by	IN	O
repeated	JJ	O
venograms	NNS	O
between	IN	O
day	NN	O
0	CD	O
and	CC	O
day	NN	O
10	CD	O
.	.	O

The	DT	O
primary	JJ	O
analysis	NN	O
of	IN	O
safety	NN	O
was	VBD	O
based	VBN	O
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
major	JJ	O
bleeding	VBG	O
during	IN	O
10	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
67	CD	SampleSize
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Venographic	NNP	O
assessment	NN	O
of	IN	O
clot	NN	O
size	NN	O
evolution	NN	O
between	IN	O
day	NN	O
0	CD	O
and	CC	O
day	NN	O
10	CD	O
showed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
superiority	NN	O
(	(	O
P	NNP	O
<	NNP	O
.002	NNP	O
)	)	O
of	IN	O
enoxaparin	NN	O
over	IN	O
the	DT	O
reference	NN	O
treatment	NN	O
with	IN	O
UFH	NNP	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
overall	JJ	O
recurrent	JJ	O
thromboembolic	JJ	O
events	NNS	O
during	IN	O
10	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.002	NNP	O
)	)	O
in	IN	O
the	DT	O
UFH	NNP	O
group	NN	O
(	(	O
seven	CD	O
of	IN	O
67	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
enoxaparin	NN	O
group	NN	O
(	(	O
one	CD	O
of	IN	O
67	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
bleeding	VBG	O
complications	NNS	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Enoxaparin	NNP	O
is	VBZ	O
at	IN	O
least	JJS	O
as	IN	O
effective	JJ	O
and	CC	O
safe	JJ	O
as	IN	O
UFH	NNP	O
under	IN	O
the	DT	O
conditions	NNS	O
of	IN	O
this	DT	O
study	NN	O
.	.	O

Moreover	RB	O
,	,	O
it	PRP	O
is	VBZ	O
more	RBR	O
comfortable	JJ	O
for	IN	O
patients	NNS	O
and	CC	O
less	JJR	O
time-consuming	NN	O
for	IN	O
nurses	NNS	O
and	CC	O
laboratories	NNS	O
.	.	O

Thus	RB	O
,	,	O
our	PRP$	O
study	NN	O
confirmed	VBD	O
,	,	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
enoxaparin	NN	O
,	,	O
other	JJ	O
observations	NNS	O
that	IN	O
low-molecular-weight	JJ	O
heparin	NN	O
provides	VBZ	O
a	DT	O
real	JJ	O
therapeutic	JJ	O
advance	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
deep	JJ	Condition
vein	NN	Condition
thrombosis	NN	Condition
.	.	O

Analysis	NN	O
of	IN	O
multiple-dose	JJ	O
bioequivalence	NN	O
studies	NNS	O
.	.	O

In	IN	O
multiple-dose	JJ	Condition
bioequivalence	NN	Condition
studies	NNS	Condition
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
at	IN	O
steady	JJ	O
state	NN	O
to	TO	O
take	VB	O
repeated	JJ	O
measurements	NNS	O
of	IN	O
pharmacokinetic	JJ	O
variables	NNS	O
,	,	O
such	JJ	O
as	IN	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
and	CC	O
the	DT	O
maximum	JJ	O
concentration	NN	O
(	(	O
CMAX	NNP	O
)	)	O
of	IN	O
the	DT	O
blood	NN	O
concentration-time	NN	O
profile	NN	O
,	,	O
within	IN	O
each	DT	O
period	NN	O
of	IN	O
a	DT	O
crossover	NN	O
design	NN	O
.	.	O

We	PRP	O
develop	VBP	O
a	DT	O
bivariate	NN	O
random	NN	O
effects	NNS	O
model	NN	O
for	IN	O
such	JJ	O
a	DT	O
situation	NN	O
in	IN	O
a	DT	O
2	CD	O
x	NN	O
2	CD	O
crossover	NN	O
design	NN	O
using	VBG	O
the	DT	O
natural	JJ	O
log	NN	O
scale	NN	O
for	IN	O
AUC	NNP	O
and	CC	O
CMAX	NNP	O
that	WDT	O
assumes	VBZ	O
no	DT	O
differential	JJ	O
carryover	NN	O
effects	NNS	O
and	CC	O
includes	VBZ	O
components	NNS	O
for	IN	O
inter-	JJ	O
and	CC	O
intrasubject	JJ	O
variability	NN	O
with	IN	O
respect	NN	O
to	TO	O
both	DT	O
formulations	NNS	O
.	.	O

We	PRP	O
derive	VBP	O
the	DT	O
uniformly	JJ	O
minimum	JJ	O
variance	NN	O
unbiased	JJ	O
estimators	NNS	O
,	,	O
which	WDT	O
also	RB	O
happen	VBP	O
to	TO	O
be	VB	O
restricted	VBN	O
maximum	JJ	O
likelihood	NN	O
estimators	NNS	O
,	,	O
and	CC	O
we	PRP	O
provide	VBP	O
a	DT	O
sample	NN	O
size	NN	O
formula	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
manual	JJ	O
physical	JJ	O
therapy	NN	O
and	CC	O
exercise	NN	O
in	IN	O
osteoarthritis	NN	Condition
of	IN	Condition
the	DT	Condition
knee	NN	Condition
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Few	JJ	O
investigations	NNS	O
include	VBP	O
both	DT	O
subjective	JJ	O
and	CC	O
objective	JJ	O
measurements	NNS	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
treatments	NNS	O
for	IN	O
osteoarthritis	NN	Condition
of	IN	Condition
the	DT	Condition
knee	NN	Condition
.	.	O

Beneficial	JJ	O
interventions	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
disability	NN	O
associated	VBN	O
with	IN	O
osteoarthritis	NN	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
more	RBR	O
invasive	JJ	O
treatments	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
physical	JJ	O
therapy	NN	O
for	IN	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
,	,	O
applied	VBN	O
by	IN	O
experienced	JJ	O
physical	JJ	O
therapists	NNS	O
with	IN	O
formal	JJ	O
training	NN	O
in	IN	O
manual	JJ	O
therapy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	NNP	O
physical	JJ	O
therapy	NN	O
department	NN	O
of	IN	O
a	DT	O
large	JJ	O
military	JJ	O
medical	JJ	O
center	NN	O
.	.	O

PATIENTS	CC	O
83	CD	SampleSize
patients	NNS	O
with	IN	O
osteoarthritis	NN	Condition
of	IN	Condition
the	DT	Condition
knee	NN	Condition
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
treatment	NN	O
(	(	O
n	JJ	O
=	VBZ	O
42	CD	SampleSize
;	:	O
15	CD	SampleSize
men	NNS	Sex
and	CC	O
27	CD	SampleSize
women	NNS	Sex
[	JJ	O
mean	JJ	O
age	NN	O
,	,	O
60	CD	Age
+/-	JJ	Age
11	CD	Age
years	NNS	O
]	RB	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	VBZ	O
41	CD	SampleSize
;	:	O
19	CD	SampleSize
men	NNS	O
and	CC	O
22	CD	SampleSize
women	NNS	O
[	JJ	O
mean	JJ	O
age	NN	O
,	,	O
62	CD	Age
+/-	JJ	Age
10	CD	Age
years	NNS	O
]	RB	O
)	)	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
manual	JJ	O
therapy	NN	O
,	,	O
applied	VBN	O
to	TO	O
the	DT	O
knee	NN	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
the	DT	O
lumbar	NN	O
spine	NN	O
,	,	O
hip	NN	O
,	,	O
and	CC	O
ankle	RB	O
as	IN	O
required	VBN	O
,	,	O
and	CC	O
performed	VBD	O
a	DT	O
standardized	JJ	O
knee	NN	O
exercise	NN	O
program	NN	O
in	IN	O
the	DT	O
clinic	NN	O
and	CC	O
at	IN	O
home	NN	O
.	.	O

The	DT	O
placebo	NN	O
group	NN	O
had	VBD	O
subtherapeutic	JJ	O
ultrasound	NN	O
to	TO	O
the	DT	O
knee	NN	O
at	IN	O
an	DT	O
intensity	NN	O
of	IN	O
0.1	CD	O
W/cm2	NNP	O
with	IN	O
a	DT	O
10	CD	O
%	NN	O
pulsed	JJ	O
mode	NN	O
.	.	O

Both	DT	O
groups	NNS	O
were	VBD	O
treated	VBN	O
at	IN	O
the	DT	O
clinic	JJ	O
twice	JJ	O
weekly	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

MEASUREMENTS	NNP	O
Distance	NNP	O
walked	VBD	O
in	IN	O
6	CD	O
minutes	NNS	O
and	CC	O
sum	NN	O
of	IN	O
the	DT	O
function	NN	O
,	,	O
pain	NN	O
,	,	O
and	CC	O
stiffness	JJ	O
subscores	NNS	O
of	IN	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
.	.	O

A	DT	O
tester	NN	O
who	WP	O
was	VBD	O
blinded	VBN	O
to	TO	O
group	NN	O
assignment	NN	O
made	VBD	O
group	NN	O
comparisons	NNS	O
at	IN	O
the	DT	O
initial	JJ	O
visit	NN	O
(	(	O
before	IN	O
initiation	NN	O
of	IN	O
treatment	NN	O
)	)	O
,	,	O
4	CD	O
weeks	NNS	O
,	,	O
8	CD	O
weeks	NNS	O
,	,	O
and	CC	O
1	CD	O
year	NN	O
.	.	O

RESULTS	NNP	O
Clinically	NNP	O
and	CC	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
6-minute	JJ	O
walk	NN	O
distance	NN	O
and	CC	O
WOMAC	NNP	O
score	NN	O
at	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
8	CD	O
weeks	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
but	CC	O
not	RB	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

By	IN	O
8	CD	O
weeks	NNS	O
,	,	O
average	JJ	O
6-minute	JJ	O
walk	NN	O
distances	NNS	O
had	VBD	O
improved	VBN	O
by	IN	O
13.1	CD	O
%	NN	O
and	CC	O
WOMAC	NNP	O
scores	NNS	O
had	VBD	O
improved	VBN	O
by	IN	O
55.8	CD	O
%	NN	O
over	IN	O
baseline	NN	O
values	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

After	IN	O
controlling	VBG	O
for	IN	O
potential	JJ	O
confounding	NN	O
variables	NNS	O
,	,	O
the	DT	O
average	JJ	O
distance	NN	O
walked	VBD	O
in	IN	O
6	CD	O
minutes	NNS	O
at	IN	O
8	CD	O
weeks	NNS	O
among	IN	O
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
170	CD	O
m	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
71	CD	O
to	TO	O
270	CD	O
m	NN	O
)	)	O
more	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
the	DT	O
average	JJ	O
WOMAC	JJ	O
scores	NNS	O
were	VBD	O
599	CD	O
mm	NN	O
higher	JJR	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
197	CD	O
to	TO	O
1002	CD	O
mm	NN	O
)	)	O
.	.	O

At	IN	O
1	CD	O
year	NN	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
had	VBD	O
clinically	RB	O
and	CC	O
statistically	RB	O
significant	JJ	O
gains	NNS	O
over	IN	O
baseline	JJ	O
WOMAC	NNP	O
scores	NNS	O
and	CC	O
walking	VBG	O
distance	NN	O
;	:	O
20	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
5	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
had	VBD	O
undergone	JJ	O
knee	NN	O
arthroplasty	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
combination	NN	O
of	IN	O
manual	JJ	O
physical	JJ	O
therapy	NN	O
and	CC	O
supervised	VBD	O
exercise	NN	O
yields	NNS	O
functional	JJ	O
benefits	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
osteoarthritis	NN	Condition
of	IN	Condition
the	DT	Condition
knee	NN	Condition
and	CC	O
may	MD	O
delay	VB	O
or	CC	O
prevent	VB	O
the	DT	O
need	NN	O
for	IN	O
surgical	JJ	O
intervention	NN	O
.	.	O

Why	WRB	O
distinctive	JJ	O
information	NN	O
reduces	NNS	O
false	JJ	O
memories	NNS	O
:	:	O
evidence	NN	O
for	IN	O
both	DT	O
impoverished	JJ	Condition
relational-encoding	NN	Condition
and	CC	O
distinctiveness	NN	Condition
heuristic	JJ	Condition
accounts	NNS	Condition
.	.	O

Two	CD	O
accounts	NNS	O
explain	VBP	O
why	WRB	O
studying	VBG	O
pictures	NNS	O
reduces	VBZ	O
false	JJ	O
memories	NNS	O
within	IN	O
the	DT	O
Deese-Roediger-McDermott	NNP	O
paradigm	NN	O
(	(	O
J.	NNP	O
Deese	NNP	O
,	,	O
1959	CD	O
;	:	O
H.	NNP	O
L.	NNP	O
Roediger	NNP	O
&	CC	O
K.	NNP	O
B.	NNP	O
McDermott	NNP	O
,	,	O
1995	CD	O
)	)	O
.	.	O

The	DT	O
impoverished	JJ	O
relational-encoding	JJ	O
account	NN	O
suggests	VBZ	O
that	IN	O
studying	VBG	O
pictures	NNS	O
interferes	VBZ	O
with	IN	O
the	DT	O
encoding	NN	O
of	IN	O
relational	JJ	O
information	NN	O
,	,	O
which	WDT	O
is	VBZ	O
the	DT	O
primary	JJ	O
basis	NN	O
for	IN	O
false	JJ	O
memories	NNS	O
in	IN	O
this	DT	O
paradigm	NN	O
.	.	O

Alternatively	RB	O
,	,	O
the	DT	O
distinctiveness	NN	O
heuristic	JJ	O
assumes	NNS	O
that	WDT	O
critical	JJ	O
lures	NNS	O
are	VBP	O
actively	RB	O
withheld	VBN	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
retrieval	NN	O
strategy	NN	O
.	.	O

When	WRB	O
participants	NNS	O
were	VBD	O
given	VBN	O
inclusion	NN	Condition
recall	NN	Condition
instructions	NNS	Condition
to	TO	O
report	VB	O
studied	JJ	O
items	NNS	O
as	RB	O
well	RB	O
as	IN	O
related	JJ	O
items	NNS	O
,	,	O
they	PRP	O
still	RB	O
reported	VBD	O
critical	JJ	O
lures	NNS	O
less	RBR	O
often	RB	O
after	IN	O
picture	NN	O
encoding	VBG	O
than	IN	O
they	PRP	O
did	VBD	O
after	IN	O
word	NN	O
encoding	NN	O
.	.	O

As	IN	O
the	DT	O
impoverished	JJ	O
relational-encoding	JJ	O
account	NN	O
suggests	VBZ	O
,	,	O
critical	JJ	O
lures	NNS	O
appear	VBP	O
less	RBR	O
likely	JJ	O
to	TO	O
come	VB	O
to	TO	O
mind	VB	O
after	IN	O
picture	NN	O
encoding	VBG	O
than	IN	O
they	PRP	O
do	VBP	O
after	IN	O
word	NN	O
encoding	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
results	NNS	O
from	IN	O
a	DT	O
postrecall	NN	O
recognition	NN	O
test	NN	O
provide	NN	O
evidence	NN	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
distinctiveness	NN	O
heuristic	NN	O
.	.	O

Low	JJ	O
power	NN	O
Ga-Al-As	NNP	O
laser	NN	O
treatment	NN	O
of	IN	O
painful	JJ	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
double-blind	NN	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
low	JJ	O
power	NN	O
Ga-Al-As	NNP	O
laser	NN	O
treatment	NN	O
on	IN	O
chronic	JJ	O
pain	NN	O
related	VBN	O
to	TO	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
with	IN	O
periarticular	JJ	O
tender	NN	O
points	NNS	O
.	.	O

Twenty-nine	JJ	O
out-patients	NNS	O
with	IN	O
uni-	JJ	O
or	CC	O
bilateral	JJ	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
were	VBD	O
included	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
laser	NN	O
or	CC	O
placebo	NN	O
laser	NN	O
.	.	O

Fourteen	JJ	O
patients	NNS	O
received	VBD	O
active	JJ	O
laser	NN	O
treatment	NN	O
and	CC	O
all	DT	O
patients	NNS	O
included	VBD	O
completed	VBN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
effect	NN	O
variables	NNS	O
were	VBD	O
daily	JJ	O
levels	NNS	O
of	IN	O
pain	NN	O
,	,	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
palpation	NN	O
tenderness	NN	O
and	CC	O
isokinetic	JJ	O
quadriceps	NNS	O
strength	NN	O
.	.	O

Each	DT	O
patient	NN	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
for	IN	O
9	CD	O
weeks	NNS	O
and	CC	O
registered	VBD	O
daily	JJ	O
level	NN	O
of	IN	O
pain	NN	O
and	CC	O
consumption	NN	O
of	IN	O
analgesics	NNS	O
.	.	O

In	IN	O
weeks	NNS	O
4	CD	O
,	,	O
5	CD	O
and	CC	O
6	CD	O
the	DT	O
patients	NNS	O
received	VBD	O
a	DT	O
total	NN	O
of	IN	O
nine	CD	O
treatments	NNS	O
,	,	O
each	DT	O
of	IN	O
15	CD	O
min	NNS	O
and	CC	O
administered	VBN	O
to	TO	O
periarticular	VB	O
tender	NN	O
points	NNS	O
.	.	O

The	DT	O
dose	JJ	O
per	IN	O
treatment	NN	O
was	VBD	O
22.5	CD	O
joule	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
effect	NN	O
variables	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
before	IN	O
,	,	O
during	IN	O
or	CC	O
after	IN	O
treatment	NN	O
.	.	O

With	IN	O
regard	NN	O
to	TO	O
the	DT	O
patients	NNS	O
'	POS	O
overall	JJ	O
assessment	NN	O
there	EX	O
was	VBD	O
a	DT	O
clearly	RB	O
demonstrable	JJ	O
positive	JJ	O
effect	NN	O
of	IN	O
treatment	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

This	DT	O
is	VBZ	O
likely	JJ	O
to	TO	O
be	VB	O
due	JJ	O
to	TO	O
a	DT	O
placebo	NN	O
effect	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
intravenous	JJ	O
immunoglobulin	NN	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
fatigue	NN	Condition
syndrome	NN	Condition
.	.	O

PURPOSE	VB	O
The	DT	O
chronic	JJ	O
fatigue	NN	O
syndrome	NN	O
(	(	O
CFS	NNP	O
)	)	O
is	VBZ	O
characterized	VBN	O
by	IN	O
profound	NN	O
fatigue	NN	O
,	,	O
neuropsychiatric	JJ	O
dysfunction	NN	O
,	,	O
and	CC	O
frequent	JJ	O
abnormalities	NNS	O
in	IN	O
cell-mediated	JJ	O
immunity	NN	O
.	.	O

No	DT	O
effective	JJ	O
therapy	NN	O
is	VBZ	O
known	VBN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty-nine	NNP	SampleSize
patients	NNS	O
(	(	O
40	CD	SampleSize
with	IN	O
abnormal	JJ	Condition
cell-mediated	JJ	Condition
immunity	NN	Condition
)	)	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
to	TO	O
determine	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
high-dose	JJ	O
intravenously	RB	O
administered	VBN	O
immunoglobulin	NN	O
G.	NNP	O
The	DT	O
patients	NNS	O
received	VBD	O
three	CD	O
intravenous	JJ	O
infusions	NNS	O
of	IN	O
a	DT	O
placebo	JJ	O
solution	NN	O
or	CC	O
immunoglobulin	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
2	CD	O
g/kg/month	NN	O
.	.	O

Assessment	NN	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
associated	JJ	O
disability	NN	O
,	,	O
both	DT	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
,	,	O
was	VBD	O
completed	VBN	O
at	IN	O
detailed	JJ	O
interviews	NNS	O
by	IN	O
a	DT	O
physician	NN	O
and	CC	O
psychiatrist	NN	O
,	,	O
who	WP	O
were	VBD	O
unaware	NN	O
of	IN	O
the	DT	O
treatment	NN	O
status	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
any	DT	O
change	NN	O
in	IN	O
physical	JJ	O
symptoms	NNS	O
and	CC	O
functional	JJ	O
capacity	NN	O
was	VBD	O
recorded	VBN	O
using	VBG	O
visual	JJ	O
analogue	NN	O
scales	NNS	O
,	,	O
while	IN	O
changes	NNS	O
in	IN	O
psychologic	JJ	O
morbidity	NN	O
were	VBD	O
assessed	VBN	O
using	VBG	O
patient-rated	JJ	O
indices	NNS	O
of	IN	O
depression	NN	O
.	.	O

Cell-mediated	JJ	O
immunity	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
T-cell	NNP	O
subset	NN	O
analysis	NN	O
,	,	O
delayed-type	JJ	O
hypersensitivity	NN	O
skin	NN	O
testing	NN	O
,	,	O
and	CC	O
lymphocyte	JJ	O
transformation	NN	O
with	IN	O
phytohemagglutinin	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
interview	NN	O
conducted	VBN	O
by	IN	O
the	DT	O
physician	JJ	O
3	CD	O
months	NNS	O
after	IN	O
the	DT	O
final	JJ	O
infusion	NN	O
,	,	O
10	CD	O
of	IN	O
23	CD	O
(	(	O
43	CD	O
%	NN	O
)	)	O
immunoglobulin	NN	O
recipients	NNS	O
and	CC	O
three	CD	O
of	IN	O
the	DT	O
26	CD	O
(	(	O
12	CD	O
%	NN	O
)	)	O
placebo	NN	O
recipients	NNS	O
were	VBD	O
assessed	VBN	O
as	IN	O
having	VBG	O
responded	VBN	O
with	IN	O
a	DT	O
substantial	JJ	O
reduction	NN	O
in	IN	O
their	PRP$	O
symptoms	NNS	O
and	CC	O
recommencement	NN	O
of	IN	O
work	NN	O
,	,	O
leisure	NN	O
,	,	O
and	CC	O
social	JJ	O
activities	NNS	O
.	.	O

The	DT	O
patients	NNS	O
designated	VBN	O
as	IN	O
having	VBG	O
responded	VBN	O
had	VBD	O
improvement	NN	O
in	IN	O
physical	JJ	O
,	,	O
psychologic	JJ	O
,	,	O
and	CC	O
immunologic	JJ	O
measures	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
for	IN	O
each	DT	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Immunomodulatory	NNP	O
treatment	NN	O
with	IN	O
immunoglobulin	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
a	DT	O
significant	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
CFS	NNP	O
,	,	O
a	DT	O
finding	NN	O
that	WDT	O
supports	VBZ	O
the	DT	O
concept	NN	O
that	IN	O
an	DT	O
immunologic	JJ	O
disturbance	NN	O
may	MD	O
be	VB	O
important	JJ	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
this	DT	O
disorder	NN	O
.	.	O

Rett	NNP	O
syndrome	NN	O
:	:	O
randomized	VBN	O
controlled	VBD	O
trial	NN	O
of	IN	O
L-carnitine	NNP	O
.	.	O

Rett	NNP	O
syndrome	NN	O
is	VBZ	O
a	DT	O
severe	JJ	O
neurodevelopmental	JJ	O
disorder	NN	O
of	IN	O
unknown	JJ	O
etiology	NN	O
,	,	O
occurring	VBG	O
almost	RB	O
exclusively	RB	O
in	IN	O
female	JJ	O
patients	NNS	O
.	.	O

The	DT	O
etiology	NN	O
and	CC	O
functional	JJ	O
significance	NN	O
of	IN	O
plasma	JJ	O
carnitine	NN	O
deficiency	NN	O
seen	VBN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

To	TO	O
investigate	VB	O
whether	IN	O
L-carnitine	JJ	O
might	MD	O
be	VB	O
of	IN	O
benefit	NN	O
in	IN	O
Rett	NNP	O
syndrome	NN	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
of	IN	O
L-carnitine	NNP	O
has	VBZ	O
been	VBN	O
completed	VBN	O
in	IN	O
35	CD	O
subjects	NNS	O
.	.	O

Eight-week	JJ	O
treatment	NN	O
phases	NNS	O
were	VBD	O
completed	VBN	O
for	IN	O
both	DT	O
a	DT	O
placebo	NN	O
and	CC	O
L-carnitine	NNP	O
.	.	O

Outcome	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
parents/caregivers	NNS	O
and	CC	O
at	IN	O
medical	JJ	O
follow-up	NN	O
using	VBG	O
three	CD	O
established	VBN	O
tools	NNS	O
:	:	O
the	DT	O
Rett	NNP	O
Syndrome	NNP	O
Motor	NNP	O
Behavioral	NNP	O
Assessment	NNP	O
,	,	O
the	DT	O
Hand	NNP	O
Apraxia	NNP	O
Scale	NNP	O
,	,	O
and	CC	O
the	DT	O
Patient	NNP	O
Well-Being	NNP	O
Index	NNP	O
.	.	O

Analysis	NNP	O
comparing	VBG	O
change	NN	O
between	IN	O
baseline	NN	O
and	CC	O
week	NN	O
8	CD	O
of	IN	O
treatment	NN	O
for	IN	O
L-carnitine	NNP	O
and	CC	O
the	DT	O
placebo	NN	O
showed	VBD	O
that	IN	O
both	DT	O
parents/caregivers	NNS	O
and	CC	O
medical	JJ	O
follow-up	NN	O
detected	JJ	O
improvements	NNS	O
in	IN	O
the	DT	O
subjects	NNS	O
'	POS	O
well-being	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
medical	JJ	O
review	NN	O
showed	VBD	O
an	DT	O
improvement	NN	O
on	IN	O
the	DT	O
Hand	NNP	O
Apraxia	NNP	O
Scale	NNP	O
for	IN	O
a	DT	O
higher	JJR	O
proportion	NN	O
of	IN	O
girls	NNS	O
on	IN	O
L-carnitine	NNP	O
.	.	O

Identification	NN	O
of	IN	O
predictors	NNS	O
of	IN	O
clinical	JJ	O
improvement	NN	O
has	VBZ	O
been	VBN	O
limited	VBN	O
by	IN	O
the	DT	O
power	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
L-carnitine	NNP	O
is	VBZ	O
of	IN	O
benefit	NN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
Rett	NNP	O
syndrome	NN	O
.	.	O

While	IN	O
L-carnitine	NNP	O
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
major	JJ	O
functional	JJ	O
changes	NNS	O
in	IN	O
ability	NN	O
,	,	O
the	DT	O
type	NN	O
of	IN	O
changes	NNS	O
reported	VBN	O
could	MD	O
still	RB	O
have	VB	O
a	DT	O
substantial	JJ	O
impact	NN	O
on	IN	O
the	DT	O
girls	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
.	.	O

Information	NN	O
is	VBZ	O
still	RB	O
needed	VBN	O
,	,	O
however	RB	O
,	,	O
to	TO	O
determine	VB	O
if	IN	O
only	RB	O
subgroups	NNS	O
of	IN	O
girls	NNS	O
with	IN	O
the	DT	O
disorder	NN	O
are	VBP	O
responsive	JJ	O
to	TO	O
L-carnitine	NNP	O
and	CC	O
the	DT	O
appropriate	JJ	O
duration	NN	O
of	IN	O
therapy	NN	O
.	.	O

Gastric	NNP	O
dysrhythmia	NN	O
in	IN	O
infants	NNS	O
with	IN	O
gastrointestinal	JJ	Condition
diseases	NNS	Condition
measured	VBN	O
by	IN	O
epigastric	JJ	O
impedance	NN	O
.	.	O

BACKGROUND	NNP	O
Gastrointestinal	NNP	O
symptoms	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
association	NN	O
with	IN	O
myoelectrical	JJ	O
dysrhythmia	NN	O
,	,	O
where	WRB	O
different	JJ	O
types	NNS	O
of	IN	O
gastric	JJ	O
electrical	JJ	O
activity	NN	O
have	VBP	O
been	VBN	O
described	VBN	O
.	.	O

These	DT	O
types	NNS	O
of	IN	O
gastric	JJ	O
myoelectrical	JJ	O
activity	NN	O
and	CC	O
dysrhythmia	NN	O
can	MD	O
be	VB	O
measured	VBN	O
by	IN	O
electrogastrography	NN	O
using	VBG	O
cutaneous	JJ	O
electrodes	NNS	O
.	.	O

Epigastric	JJ	O
impedance	NN	O
is	VBZ	O
a	DT	O
non-invasive	JJ	O
method	NN	O
used	VBN	O
to	TO	O
study	VB	O
gastric	JJ	O
emptying	VBG	O
time	NN	O
and	CC	O
gastric	JJ	O
phasic	JJ	O
activity	NN	O
.	.	O

At	IN	O
present	JJ	O
no	DT	O
study	NN	O
of	IN	O
gastric	JJ	O
dysrhythmia	NN	O
,	,	O
measured	VBN	O
with	IN	O
epigastric	JJ	O
impedance	NN	O
,	,	O
has	VBZ	O
been	VBN	O
presented	VBN	O
,	,	O
and	CC	O
the	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
gastric	JJ	O
rhythms	NN	O
by	IN	O
means	NNS	O
of	IN	O
impedance	NN	O
gastrography	NN	O
in	IN	O
control	NN	O
infants	NNS	O
,	,	O
compared	VBN	O
to	TO	O
infants	NNS	Age
with	IN	O
different	JJ	O
gastrointestinal	JJ	O
diseases	NNS	O
,	,	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
of	IN	O
their	PRP$	O
disease	NN	O
.	.	O

METHOD	NNP	O
21	CD	SampleSize
patients	NNS	O
(	(	O
age	NN	O
0-2	CD	Age
months	NNS	Age
)	)	O
and	CC	O
40	CD	SampleSize
healthy	JJ	O
infants	NNS	O
(	(	O
age	NN	O
0-2	CD	Age
months	NNS	Age
)	)	O
were	VBD	O
investigated	VBN	O
.	.	O

The	DT	O
patients	NNS	O
suffered	VBD	O
from	IN	O
partial	JJ	O
or	CC	O
total	JJ	O
intestinal	JJ	O
obstruction	NN	O
,	,	O
necrotizing	VBG	O
enterocolitis	NN	O
or	CC	O
pyloric	JJ	O
stenosis.All	NN	O
infants	NNS	O
were	VBD	O
fasting	VBG	O
and	CC	O
studied	VBN	O
during	IN	O
periods	NNS	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
hour	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
examined	VBN	O
in	IN	O
the	DT	O
acute	NN	O
state	NN	O
and	CC	O
after	IN	O
treatment	NN	O
when	WRB	O
possible	JJ	O
.	.	O

RESULTS	VB	O
A	DT	O
pathologic	JJ	O
result	NN	O
was	VBD	O
found	VBN	O
in	IN	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

A	DT	O
persistent	JJ	O
phasic	JJ	O
activity	NN	O
pattern	NN	O
was	VBD	O
found	VBN	O
in	IN	O
19	CD	O
of	IN	O
the	DT	O
21	CD	O
patients	NNS	O
,	,	O
high	JJ	O
frequency	NN	O
phasic	JJ	O
activity	NN	O
in	IN	O
11	CD	O
of	IN	O
the	DT	O
21	CD	O
patients	NNS	O
.	.	O

Short-term	JJ	O
phasic	JJ	O
activity	NN	O
was	VBD	O
only	RB	O
found	VBN	O
in	IN	O
13	CD	O
out	IN	O
of	IN	O
40	CD	O
of	IN	O
the	DT	O
normal	JJ	O
infants	NNS	O
(	(	O
32.5	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Using	NNP	O
epigastric	JJ	O
impedance	NN	O
we	PRP	O
found	VBD	O
that	IN	O
infants	NNS	O
with	IN	O
partial	JJ	O
or	CC	O
total	JJ	O
intestinal	JJ	O
obstruction	NN	O
had	VBD	O
gastric	JJ	O
phasic	JJ	O
activity	NN	O
,	,	O
which	WDT	O
was	VBD	O
not	RB	O
found	VBN	O
in	IN	O
the	DT	O
control	NN	O
infants	NNS	O
.	.	O

The	DT	O
origin	NN	O
of	IN	O
the	DT	O
gastric	JJ	O
phasic	JJ	O
activity	NN	O
patterns	NNS	O
is	VBZ	O
unknown	JJ	O
,	,	O
but	CC	O
they	PRP	O
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
electrical	JJ	O
control	NN	O
activity	NN	O
.	.	O

Proposed	VBN	O
synergistic	JJ	O
effect	NN	O
of	IN	O
calcium	NN	O
channel	NN	O
blockers	NNS	O
with	IN	O
lipid-lowering	JJ	O
therapy	NN	O
in	IN	O
retarding	VBG	Condition
progression	NN	Condition
of	IN	Condition
coronary	JJ	Condition
atherosclerosis	NN	Condition
.	.	O

Lipid-lowering	JJ	O
therapy	NN	O
now	RB	O
has	VBZ	O
undoubtedly	RB	O
proven	VBN	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
therapeutic	JJ	O
modality	NN	O
to	TO	O
retard	VB	O
the	DT	O
progression	NN	O
of	IN	O
coronary	JJ	O
atherosclerosis	NN	O
.	.	O

An	DT	O
additional	JJ	O
approach	NN	O
for	IN	O
prevention	NN	O
of	IN	O
the	DT	O
progression	NN	O
of	IN	O
atherosclerosis	NN	O
is	VBZ	O
calcium	JJ	O
channel	NN	O
blocker	NN	O
(	(	O
CCB	NNP	O
)	)	O
treatment	NN	O
.	.	O

Evidence	NN	O
indicating	VBG	O
that	IN	O
CCBs	NNP	O
inhibit	NN	O
atherosclerosis	NN	O
is	VBZ	O
less	RBR	O
unequivocal	JJ	O
than	IN	O
the	DT	O
clear	JJ	O
evidence	NN	O
for	IN	O
lipid-lowering	JJ	O
therapy	NN	O
.	.	O

Many	JJ	O
investigations	NNS	O
support	VBP	O
the	DT	O
view	NN	O
that	IN	O
a	DT	O
number	NN	O
of	IN	O
key	JJ	O
processes	NNS	O
in	IN	O
atherosclerosis	NN	O
may	MD	O
be	VB	O
influenced	VBN	O
by	IN	O
CCBs	NNP	O
.	.	O

From	IN	O
the	DT	O
negative	JJ	O
and	CC	O
positive	JJ	O
studies	NNS	O
with	IN	O
CCBs	NNP	O
performed	VBD	O
in	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
we	PRP	O
must	MD	O
conclude	VB	O
that	DT	O
apparently	RB	O
some	DT	O
,	,	O
but	CC	O
not	RB	O
all	DT	O
,	,	O
types	NNS	O
or	CC	O
stages	NNS	O
of	IN	O
the	DT	O
atherosclerotic	JJ	O
process	NN	O
are	VBP	O
inhibited	VBN	O
by	IN	O
CCBs	NNP	O
.	.	O

To	TO	O
assess	VB	O
whether	IN	O
lipid-lowering	JJ	O
therapy	NN	O
and	CC	O
CCB	NNP	O
treatment	NN	O
may	MD	O
have	VB	O
an	DT	O
additive	JJ	O
or	CC	O
synergistic	JJ	O
beneficial	JJ	O
effect	NN	O
on	IN	O
human	JJ	O
atherosclerosis	NN	O
,	,	O
which	WDT	O
is	VBZ	O
conceivable	JJ	O
because	IN	O
their	PRP$	O
anti-atherosclerotic	JJ	O
properties	NNS	O
differ	VBP	O
,	,	O
data	NNS	O
from	IN	O
the	DT	O
angiographic	JJ	O
lipid-lowering	JJ	O
trial	NN	O
REGRESS	NNP	O
(	(	O
pravastatin	NN	O
vs.	FW	O
placebo	NN	O
)	)	O
were	VBD	O
reviewed	VBN	O
.	.	O

In	IN	O
REGRESS	NNP	O
,	,	O
patients	NNS	O
in	IN	O
the	DT	O
pravastatin	NN	O
group	NN	O
had	VBD	O
significantly	RB	O
less	JJR	O
progression	NN	O
if	IN	O
cotreated	VBN	O
with	IN	O
CCBs	NNP	O
as	IN	O
compared	VBN	O
with	IN	O
those	DT	O
with	IN	O
no	DT	O
CCB	NNP	O
cotreatment	NN	O
,	,	O
whereas	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
(	(	O
no	DT	O
pravastatin	NN	O
)	)	O
group	NN	O
no	DT	O
effect	NN	O
of	IN	O
CCB	NNP	O
treatment	NN	O
was	VBD	O
observed	VBN	O
.	.	O

With	IN	O
respect	NN	O
to	TO	O
angiographic	VB	O
new	JJ	O
lesion	NN	O
formation	NN	O
,	,	O
in	IN	O
the	DT	O
pravastatin	NN	O
group	NN	O
there	EX	O
were	VBD	O
50	CD	O
%	NN	O
less	JJR	O
patients	NNS	O
with	IN	O
new	JJ	O
angiographic	JJ	O
lesions	NNS	O
if	IN	O
cotreated	VBN	O
with	IN	O
CCBs	NNP	O
as	IN	O
compared	VBN	O
with	IN	O
no	DT	O
CCB	NNP	O
cotreatment	NN	O
,	,	O
whereas	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
(	(	O
no	DT	O
pravastatin	NN	O
)	)	O
group	NN	O
,	,	O
again	RB	O
,	,	O
no	DT	O
significant	JJ	O
effect	NN	O
of	IN	O
CCB	NNP	O
treatment	NN	O
was	VBD	O
observed	VBN	O
.	.	O

No	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
CCB	NNP	O
treatment	NN	O
on	IN	O
clinical	JJ	O
events	NNS	O
were	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
2-year	JJ	O
study	NN	O
follow-up	NN	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
the	DT	O
correlation	NN	O
between	IN	O
angiographic	JJ	O
progression	NN	O
and	CC	O
subsequent	JJ	O
clinical	JJ	O
events	NNS	O
as	IN	O
demonstrated	VBN	O
in	IN	O
several	JJ	O
large	JJ	O
trials	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
not	RB	O
unrealistic	JJ	O
to	TO	O
also	RB	O
anticipate	VB	O
in	IN	O
this	DT	O
population	NN	O
,	,	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
clinical	JJ	O
events	NNS	O
with	IN	O
longer	JJR	O
follow-up	NN	O
.	.	O

Although	IN	O
the	DT	O
REGRESS	NNP	O
trial	NN	O
was	VBD	O
not	RB	O
designed	VBN	O
to	TO	O
evaluate	VB	O
combination	NN	O
therapy	NN	O
,	,	O
the	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
addition	NN	O
of	IN	O
CCBs	NNP	O
to	TO	O
HMG-CoA	NNP	O
reductase	NN	O
inhibitor	NN	O
therapy	NN	O
(	(	O
pravastatin	NN	O
)	)	O
acts	VBZ	O
synergistically	RB	O
in	IN	O
retarding	VBG	O
the	DT	O
progression	NN	O
of	IN	O
established	VBN	O
coronary	JJ	O
atherosclerosis	NN	O
.	.	O

These	DT	O
results	NNS	O
appear	VBP	O
to	TO	O
warrant	VB	O
prospective	JJ	O
randomized	VBN	O
trials	NNS	O
to	TO	O
determine	VB	O
in	IN	O
a	DT	O
more	RBR	O
definitive	JJ	O
manner	NN	O
the	DT	O
merits	NNS	O
of	IN	O
this	DT	O
combination	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
progression	NN	O
of	IN	O
coronary	JJ	O
atherosclerosis	NN	O
.	.	O

Currently	RB	O
a	DT	O
number	NN	O
of	IN	O
studies	NNS	O
in	IN	O
these	DT	O
fields	NNS	O
are	VBP	O
being	VBG	O
designed	VBN	O
or	CC	O
are	VBP	O
already	RB	O
underway	RB	O
.	.	O

Novel	NNP	O
population	NN	O
pharmacokinetic	JJ	O
method	NN	O
compared	VBN	O
to	TO	O
the	DT	O
standard	JJ	O
noncompartmental	JJ	O
approach	NN	O
to	TO	O
assess	VB	O
bioequivalence	NN	O
of	IN	O
iron	NN	O
gluconate	NN	O
formulations	NNS	O
.	.	O

PURPOSE	NNP	O
Iron-containing	JJ	O
products	NNS	O
are	VBP	O
atypical	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
their	PRP$	O
pharmacokinetic	JJ	O
properties	NNS	O
because	IN	O
iron	NN	O
is	VBZ	O
only	RB	O
removed	VBN	O
by	IN	O
plasma	NN	O
sampling	NN	O
and	CC	O
is	VBZ	O
non-linear	JJ	O
.	.	O

This	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
present	VB	O
a	DT	O
novel	JJ	O
way	NN	O
of	IN	O
assessing	VBG	O
the	DT	O
relative	JJ	O
bioavailability	NN	O
of	IN	O
two	CD	O
sodium	NN	O
ferric	JJ	O
gluconate	NN	O
complex	NN	O
(	(	O
SFGC	NNP	O
)	)	O
formulations	NNS	O
and	CC	O
compare	VB	O
this	DT	O
approach	NN	O
to	TO	O
a	DT	O
standard	NN	O
previously	RB	O
published	VBN	O
noncompartmental	JJ	O
approach	NN	O
.	.	O

METHODS	NNP	O
Data	NNP	O
were	VBD	O
from	IN	O
open-label	JJ	O
,	,	O
randomized	VBN	O
,	,	O
single-dose	JJ	O
studies	NNS	O
(	(	O
Study	NNP	O
1	CD	O
was	VBD	O
parallel	JJ	O
whereas	NNS	O
Study	VBP	O
2	CD	O
was	VBD	O
crossover	NN	O
)	)	O
.	.	O

Subjects	NNS	O
with	IN	O
low	JJ	O
but	CC	O
normal	JJ	O
iron	NN	O
levels	NNS	O
were	VBD	O
infused	VBN	O
IV	NNP	O
SFGC	NNP	O
in	IN	O
sucrose	JJ	O
by	IN	O
GeneraMedix	NNP	O
Inc.	NNP	O
and/or	VBD	O
Ferrlecit	NNP	O
?	.	O
Injection	NNP	O
(	(	O
Watson	NNP	O
Laboratories	NNP	O
Inc.	NNP	O
)	)	O
.	.	O

In	IN	O
Study	NNP	O
1	CD	O
(	(	O
n=240	NN	O
)	)	O
,	,	O
125	CD	O
mg	NN	O
was	VBD	O
infused	VBN	O
over	IN	O
10	CD	O
minutes	NNS	O
.	.	O

In	IN	O
Study	NNP	O
2	CD	O
(	(	O
n=29	NN	O
)	)	O
,	,	O
62.5	CD	O
mg	NN	O
was	VBD	O
infused	VBN	O
over	IN	O
30	CD	O
minutes	NNS	O
.	.	O

Samples	NNS	O
were	VBD	O
assayed	VBN	O
for	IN	O
total	JJ	O
iron	NN	O
(	(	O
TI	NNP	O
)	)	O
and	CC	O
transferrin-bound	JJ	O
iron	NN	O
(	(	O
TBI	NNP	O
)	)	O
over	IN	O
36	CD	O
hours	NNS	O
(	(	O
Study	NNP	O
1	CD	O
)	)	O
or	CC	O
72	CD	O
hours	NNS	O
(	(	O
Study	NNP	O
2	CD	O
)	)	O
post-dose	NN	O
.	.	O

Studies	VBZ	O
1	CD	O
and	CC	O
2	CD	O
used	JJ	O
standard	NN	O
noncompartmental	JJ	O
analysis	NN	O
.	.	O

Study	NNP	O
2	CD	O
also	RB	O
used	VBN	O
population	NN	O
PK	NNP	O
(	(	O
PPK	NNP	O
)	)	O
analyses	VBZ	O
with	IN	O
ADAPT	NNP	O
5?	CD	O
.	.	O

The	DT	O
final	JJ	O
model	NN	O
predicted	VBD	O
SFGC	NNP	O
area-under-the-curve	NN	O
(	(	O
AUCpred	NNP	O
)	)	O
and	CC	O
maximal	JJ	O
concentration	NN	O
(	(	O
Cmaxpred	NNP	O
)	)	O
.	.	O

Analyses	NNS	O
of	IN	O
variance	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
ln-transformed	JJ	O
PK	NNP	O
parameters	NNS	O
.	.	O

Ratios	NNP	O
of	IN	O
means	NNS	O
and	CC	O
90	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CIs	NNP	O
)	)	O
were	VBD	O
estimated	VBN	O
.	.	O

Bioequivalence	NNP	O
was	VBD	O
demonstrated	VBN	O
if	IN	O
values	NNS	O
were	VBD	O
within	IN	O
80-125	JJ	O
%	NN	O
.	.	O

RESULTS	NNP	O
For	IN	O
Study	NNP	O
1	CD	O
,	,	O
ratios	NNS	O
and	CC	O
90	CD	O
%	NN	O
CIs	NNP	O
for	IN	O
TI	NNP	O
baseline-corrected	JJ	O
Cmax	NNP	O
and	CC	O
AUC0-36	NNP	O
were	VBD	O
100.4	CD	O
(	(	O
96.5	CD	O
-	:	O
104.5	CD	O
)	)	O
and	CC	O
99.7	CD	O
(	(	O
94.2	CD	O
-	:	O
105.5	CD	O
)	)	O
.	.	O

For	IN	O
TBI	NNP	O
,	,	O
results	NNS	O
for	IN	O
TI	NNP	O
baseline-corrected	JJ	O
Cmax	NNP	O
and	CC	O
AUC0-36	NNP	O
were	VBD	O
86.8	CD	O
(	(	O
82.7	CD	O
-	:	O
91.1	CD	O
)	)	O
and	CC	O
92.4	CD	O
(	(	O
85.6	CD	O
-	:	O
99.7	CD	O
)	)	O
.	.	O

For	IN	O
Study	NNP	O
2	CD	O
,	,	O
a	DT	O
multi-compartmental	JJ	O
model	NN	O
simultaneously	RB	O
described	VBD	O
the	DT	O
PK	NNP	O
of	IN	O
TI	NNP	O
,	,	O
TBI	NNP	O
and	CC	O
SFGC	NNP	O
.	.	O

Ratios	NNP	O
and	CC	O
90	CD	O
%	NN	O
CIs	NNP	O
for	IN	O
SFGC	NNP	O
Cmaxpred	NNP	O
and	CC	O
AUCpred	NNP	O
were	VBD	O
89.9	CD	O
(	(	O
85.9	CD	O
-	:	O
94.0	CD	O
)	)	O
and	CC	O
89.7	CD	O
(	(	O
85.7	CD	O
-	:	O
93.9	CD	O
)	)	O
,	,	O
while	IN	O
ratios	NNS	O
and	CC	O
90	CD	O
%	NN	O
CI	NNP	O
obtained	VBN	O
from	IN	O
the	DT	O
noncompartmental	JJ	O
analysis	NN	O
of	IN	O
Study	NNP	O
2	CD	O
did	VBD	O
not	RB	O
meet	VB	O
BE	NNP	O
criteria	NNS	O
because	IN	O
of	IN	O
low	JJ	O
power	NN	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
the	DT	O
standard	NN	O
and	CC	O
PPK	NNP	O
modeling	VBG	O
approach	NN	O
suggested	VBD	O
bioequivalence	NN	O
between	IN	O
the	DT	O
iron	NN	O
products	NNS	O
.	.	O

However	RB	O
,	,	O
with	IN	O
the	DT	O
PPK	NNP	O
method	NN	O
,	,	O
less	JJR	O
subjects	NNS	O
were	VBD	O
required	VBN	O
to	TO	O
meet	VB	O
study	NN	O
objectives	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
standard	JJ	O
noncompartmental	NN	O
approach	NN	O
which	WDT	O
required	VBD	O
considerably	RB	O
more	RBR	O
subjects	NNS	O
(	(	O
29	CD	O
vs	RB	O
240	CD	O
)	)	O
.	.	O

MSLT	NNP	O
in	IN	O
primary	JJ	O
insomnia	NN	O
:	:	O
stability	NN	O
and	CC	O
relation	NN	O
to	TO	O
nocturnal	JJ	O
sleep	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVES	NNP	O
To	TO	O
assess	VB	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
multiple	JJ	O
sleep	JJ	O
latency	NN	O
test	NN	O
(	(	O
MSLT	NNP	O
)	)	O
in	IN	O
primary	JJ	O
insomnia	NN	O
and	CC	O
its	PRP$	O
relation	NN	O
to	TO	O
total	JJ	O
sleep	JJ	O
time	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
,	,	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	NN	O
with	IN	O
sleep	JJ	O
laboratory	NN	O
assessments	NNS	O
in	IN	O
months	NNS	O
1	CD	O
and	CC	O
8	CD	O
of	IN	O
treatment	NN	O
.	.	O

PARTICIPANTS	VB	O
Ninety-five	JJ	SampleSize
primary	JJ	O
insomniacs	NN	Condition
,	,	O
32-64	CD	Age
years	NNS	Age
old	JJ	Age
and	CC	Age
55	CD	Age
age-	JJ	Age
and	CC	O
sex-matched	JJ	O
general	JJ	O
population-based	JJ	O
,	,	O
representative	JJ	O
controls	NNS	O
.	.	O

INTERVENTIONS	NNP	O
After	IN	O
a	DT	O
screening	JJ	O
nocturnal	JJ	O
polysomnograms	NNS	O
(	(	O
NPSG	NNP	O
)	)	O
and	CC	O
MSLT	NNP	O
the	DT	O
following	JJ	O
day	NN	O
,	,	O
participants	NNS	O
with	IN	O
primary	JJ	Condition
insomnia	NNS	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
take	VB	O
zolpidem	NN	O
10	CD	O
mg	NN	O
(	(	O
n	JJ	O
=	NNP	O
50	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
nightly	RB	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

During	IN	O
months	NNS	O
1	CD	O
and	CC	O
8	CD	O
,	,	O
while	IN	O
taking	VBG	O
their	PRP$	O
prescribed	JJ	O
treatments	NNS	O
,	,	O
NPSGs	NNP	O
and	CC	O
MSLTs	NNP	O
the	DT	O
following	JJ	O
day	NN	O
were	VBD	O
conducted	VBN	O
.	.	O

A	DT	O
population-based	JJ	O
sample	NN	O
served	VBD	O
as	IN	O
controls	NNS	O
and	CC	O
received	VBD	O
a	DT	O
single	JJ	O
NPSG	NNP	O
followed	VBN	O
by	IN	O
MSLT	NNP	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
daily	JJ	O
sleep	NN	O
latency	NN	O
on	IN	O
the	DT	O
screening	VBG	O
MSLT	NNP	O
of	IN	O
insomniacs	NN	O
was	VBD	O
normally	RB	O
distributed	VBN	O
across	IN	O
the	DT	O
full	JJ	O
range	NN	O
of	IN	O
MSLT	NNP	O
scores	NNS	O
and	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
a	DT	O
population-based	JJ	O
representative	NN	O
control	NN	O
sample	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.006	CD	O
)	)	O
.	.	O

The	DT	O
insomniacs	NN	O
with	IN	O
the	DT	O
highest	JJS	O
screening	NN	O
MSLTs	NNP	O
had	VBD	O
the	DT	O
shortest	JJS	O
screening	NN	O
total	JJ	O
sleep	JJ	O
times	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
MSLTs	NNP	O
of	IN	O
insomniacs	NN	O
during	IN	O
treatment	NN	O
in	IN	O
study	JJ	O
month	NN	O
1	CD	O
were	VBD	O
correlated	VBN	O
(	(	O
r	VB	O
=	RB	O
0.44	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
their	PRP$	O
month	NN	O
8	CD	O
MSLT	NNP	O
.	.	O

The	DT	O
mean	JJ	O
MSLT	NNP	O
score	NN	O
of	IN	O
the	DT	O
zolpidem	NNP	O
group	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
the	DT	O
stability	NN	O
within	IN	O
treatment	NN	O
groups	NNS	O
also	RB	O
did	VBD	O
not	RB	O
differ	VB	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
support	NN	O
the	DT	O
hypothesis	NN	O
that	IN	O
some	DT	O
insomniacs	NN	O
show	VBP	O
a	DT	O
reliable	JJ	O
disorder	NN	O
of	IN	O
hyperarousal	NN	O
with	IN	O
increased	JJ	O
wake	NN	O
drive	NN	O
both	DT	O
at	IN	O
night	NN	O
and	CC	O
during	IN	O
the	DT	O
day	NN	O
.	.	O

Double-blind	JJ	O
placebo-controlled	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
analgesic	JJ	O
effects	NNS	O
of	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
lornoxicam	NN	O
and	CC	O
aspirin	NN	O
in	IN	O
patients	NNS	O
with	IN	O
postoperative	JJ	Condition
dental	NN	Condition
pain	NN	Condition
.	.	O

The	DT	O
pain	NN	O
experienced	VBD	O
after	IN	O
third	JJ	O
molar	JJ	O
surgery	NN	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
model	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
a	DT	O
new	JJ	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
drug	NN	O
,	,	O
lornoxicam	NN	O
,	,	O
in	IN	O
a	DT	O
Phase	NNP	O
II	NNP	O
study	NN	O
.	.	O

One	CD	SampleSize
hundred	CD	SampleSize
and	CC	SampleSize
fifty	JJ	SampleSize
fit	NN	O
,	,	O
young	JJ	Age
adults	NNS	Age
participated	VBD	O
in	IN	O
this	DT	O
randomised	VBN	O
,	,	O
single	JJ	O
dose	NN	O
,	,	O
double-blind	NN	O
,	,	O
parallel	JJ	O
group	NN	O
clinical	JJ	O
study	NN	O
.	.	O

Three	CD	O
doses	NNS	O
of	IN	O
lornoxicam	NN	O
(	(	O
2	CD	O
mg	NN	O
,	,	O
4	CD	O
mg	NN	O
,	,	O
and	CC	O
8	CD	O
mg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
aspirin	JJ	O
650	CD	O
mg	NN	O
and	CC	O
placebo	NN	O
.	.	O

Patients	NNS	O
suffering	VBG	O
from	IN	O
moderate	JJ	Condition
to	TO	Condition
severe	VB	Condition
pain	NN	Condition
following	VBG	O
surgery	NN	O
were	VBD	O
monitored	VBN	O
for	IN	O
up	RB	O
to	TO	O
8	CD	O
hours	NNS	O
.	.	O

All	DT	O
indices	NNS	O
of	IN	O
efficacy	NN	O
showed	VBD	O
similar	JJ	O
results	NNS	O
,	,	O
all	DT	O
active	JJ	O
treatments	NNS	O
being	VBG	O
associated	VBN	O
with	IN	O
highly	RB	O
significant	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
reductions	NNS	O
in	IN	O
pain	NN	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

Lornoxicam	NNP	O
8	CD	O
mg	NN	O
demonstrated	VBD	O
significant	JJ	O
analgesic	JJ	O
efficacy	NN	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
two	CD	O
lower	JJR	O
doses	NNS	O
of	IN	O
lornoxicam	NN	O
and	CC	O
aspirin	VB	O
all	DT	O
showed	VBD	O
apparent	JJ	O
degrees	NNS	O
of	IN	O
efficacy	NN	O
intermediate	NN	O
between	IN	O
that	DT	O
of	IN	O
placebo	NN	O
and	CC	O
lornoxicam	$	O
8	CD	O
mg	NN	O
,	,	O
although	IN	O
the	DT	O
trial	NN	O
proved	VBD	O
to	TO	O
have	VB	O
inadequate	JJ	O
power	NN	O
to	TO	O
show	VB	O
significant	JJ	O
differences	NNS	O
between	IN	O
these	DT	O
three	CD	O
treatments	NNS	O
.	.	O

Lornoxicam	NNP	O
was	VBD	O
very	RB	O
well	RB	O
tolerated	VBN	O
at	IN	O
all	DT	O
three	CD	O
doses	NNS	O
studied	VBN	O
,	,	O
with	IN	O
no	DT	O
adverse	JJ	O
events	NNS	O
definitely	RB	O
attributable	JJ	O
to	TO	O
its	PRP$	O
administration	NN	O
.	.	O

Serum	NNP	O
selenium	NN	O
concentration	NN	O
and	CC	O
antioxidant	JJ	O
activity	NN	O
in	IN	O
cervical	JJ	Condition
cancer	NN	Condition
patients	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

AIM	NNP	O
In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
chemo	NN	O
and	CC	O
radio	NN	O
therapies	NNS	O
on	IN	O
serum	NN	O
trace	NN	O
elements	NNS	O
content	NN	O
and	CC	O
antioxidant	JJ	O
activity	NN	O
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	Condition
cancer	NN	Condition
patients	NNS	O
was	VBD	O
evaluated	VBN	O
.	.	O

METHODS	NNP	O
Among	IN	O
104	CD	SampleSize
cervical	JJ	O
cancer	NN	O
patients	NNS	O
selected	VBN	O
for	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
54	CD	SampleSize
and	CC	O
50	CD	SampleSize
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
chemo-	JJ	O
and	CC	O
radiotherapy	NN	O
respectively	RB	O
.	.	O

Plasma	NNP	O
Se	NNP	O
,	,	O
Zn	NNP	O
,	,	O
Cu	NNP	O
and	CC	O
some	DT	O
enzymatic	JJ	O
antioxidants	NNS	O
activities	NNS	O
were	VBD	O
estimated	VBN	O
in	IN	O
serum	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
decreased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
trace	NN	O
elements	NNS	O
,	,	O
glutathione	NN	O
peroxidase	NN	O
activity	NN	O
and	CC	O
total	JJ	O
antioxidant	JJ	O
capacity	NN	O
,	,	O
and	CC	O
increased	VBD	O
malondialdehyde	NN	O
,	,	O
glutathion	NN	O
reductase	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
cervical	JJ	Condition
cancer	NN	Condition
patients	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
healthy	JJ	O
controls	NNS	O
.	.	O

The	DT	O
increased	JJ	O
concentration	NN	O
of	IN	O
serum	NN	O
Se	NNP	O
,	,	O
Zn	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
.	.	O

Simultaneously	RB	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
increase	NN	O
in	IN	O
glutathione	JJ	O
peroxidase	NN	O
and	CC	O
total	JJ	O
antioxidant	JJ	O
capacity	NN	O
,	,	O
and	CC	O
significant	JJ	O
decrease	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
malondialdehyde	NN	O
and	CC	O
glutathion	NN	O
reductase	NN	O
levels	NNS	O
in	IN	O
the	DT	O
serum	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
chemotherapy	NN	O
compared	VBN	O
to	TO	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
radiotherapy	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
demonstrated	VBD	O
that	IN	O
chemotherapy	NN	O
but	CC	O
not	RB	O
radiotherapy	JJ	O
results	NNS	O
in	IN	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
trace	NN	O
elements	NNS	O
levels	NNS	O
and	CC	O
antioxidant	JJ	O
activities	NNS	O
in	IN	O
blood	NN	O
serum	NN	O
of	IN	O
cervical	JJ	Condition
cancer	NN	Condition
patients	NNS	O
.	.	O

Lactoferrin	NNP	O
supplementation	NN	O
to	TO	O
Holstein	NNP	O
calves	NNS	O
during	IN	O
the	DT	O
preweaning	NN	O
and	CC	O
postweaning	NN	O
phases	NNS	O
.	.	O

Sixty	NNP	O
Holstein	NNP	O
calves	VBZ	O
(	(	Condition
30	CD	Condition
bulls	NNS	Condition
,	,	Condition
30	CD	Condition
heifers	NNS	Condition
)	)	Condition
were	VBD	O
used	VBN	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
supplemental	JJ	O
lactoferrin	NN	O
on	IN	O
feed	NN	O
intake	NN	O
,	,	O
growth	NN	O
,	,	O
and	CC	O
health	NN	O
during	IN	O
the	DT	O
preweaning	NN	O
and	CC	O
postweaning	NN	O
periods	NNS	O
.	.	O

One	CD	O
of	IN	O
3	CD	O
levels	NNS	O
of	IN	O
lactoferrin	NN	O
was	VBD	O
supplemented	VBN	O
from	IN	O
3	CD	O
to	TO	O
56	CD	O
d	NN	O
in	IN	O
either	DT	O
whole	JJ	O
milk	NN	O
or	CC	O
water	NN	O
to	TO	O
produce	VB	O
3	CD	O
dietary	JJ	O
treatments	NNS	O
:	:	O
1	CD	O
)	)	O
0	CD	O
g/d	NN	O
,	,	O
2	CD	O
)	)	O
0.5	CD	O
g/d	NN	O
,	,	O
and	CC	O
3	CD	O
)	)	O
1	CD	O
g/d	NN	O
.	.	O

Whole	JJ	O
milk	NN	O
(	(	O
3.8	CD	O
L/d	NNP	O
)	)	O
containing	VBG	O
lactoferrin	JJ	O
supplements	NNS	O
was	VBD	O
fed	VBN	O
from	IN	O
bottles	NNS	O
until	IN	O
weaning	VBG	O
at	IN	O
35	CD	O
d.	NN	O
From	NNP	O
d	VBZ	O
36	CD	O
to	TO	O
56	CD	O
,	,	O
lactoferrin	JJ	O
supplements	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
water	NN	O
(	(	O
15	CD	O
to	TO	O
25	CD	O
mL	NN	O
)	)	O
and	CC	O
fed	VBN	O
from	IN	O
bottles	NNS	O
.	.	O

Lactoferrin	NNP	O
supplementation	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
feed	NN	O
intake	NN	O
,	,	O
body	NN	O
weight	NN	O
,	,	O
average	JJ	O
daily	JJ	O
gain	NN	O
,	,	O
heart	NN	O
girth	NN	O
,	,	O
body	NN	O
temperature	NN	O
,	,	O
fecal	JJ	O
scores	NNS	O
,	,	O
respiratory	NN	O
scores	NNS	O
,	,	O
or	CC	O
haptoglobin	JJ	O
concentrations	NNS	O
.	.	O

Calves	NNS	O
were	VBD	O
housed	VBN	O
in	IN	O
individual	JJ	O
pens	NNS	O
in	IN	O
either	DT	O
an	DT	O
open-sided	JJ	O
barn	NN	O
or	CC	O
hutches	NNS	O
.	.	O

Calves	NNS	O
raised	VBD	O
in	IN	O
the	DT	O
barn	NN	O
consumed	VBD	O
more	JJR	O
calf	JJ	O
starter	NN	O
and	CC	O
therefore	RB	O
grew	VBD	O
better	JJR	O
than	IN	O
calves	NNS	O
raised	VBN	O
in	IN	O
hutches	NNS	O
.	.	O

Under	IN	O
the	DT	O
conditions	NNS	O
of	IN	O
this	DT	O
study	NN	O
,	,	O
lactoferrin	JJ	O
supplementation	NN	O
was	VBD	O
not	RB	O
beneficial	JJ	O
.	.	O

Further	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
fully	RB	O
elucidate	VB	O
the	DT	O
role	NN	O
of	IN	O
lactoferrin	NN	O
,	,	O
and	CC	O
possible	JJ	O
benefits	NNS	O
during	IN	O
different	JJ	O
feeding	VBG	O
conditions	NNS	O
or	CC	O
milk	NN	O
sources	NNS	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
netilmicin-cefoxitin	JJ	O
and	CC	O
gentamicin-cefoxitin	JJ	O
in	IN	O
surgical	JJ	O
patients	NNS	O
with	IN	O
serious	JJ	Condition
systemic	JJ	Condition
infection	NN	Condition
.	.	O

A	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
study	NN	O
of	IN	O
gentamicin	NN	O
and	CC	O
netilmicin	NN	O
,	,	O
each	DT	O
in	IN	O
combination	NN	O
with	IN	O
cefoxitin	NN	O
,	,	O
was	VBD	O
done	VBN	O
to	TO	O
compare	VB	O
their	PRP$	O
respective	JJ	O
efficacy	NN	O
and	CC	O
toxicity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
serious	JJ	Condition
systemic	JJ	Condition
infection	NN	Condition
.	.	O

Thirty-seven	JJ	SampleSize
surgical	JJ	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
efficacy	NN	O
and	CC	O
46	CD	SampleSize
patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
toxicity	NN	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
cultured	VBN	O
organisms	NNS	O
were	VBD	O
Escherichia	NNP	O
coli	NNS	O
(	(	O
15	CD	O
)	)	O
,	,	O
Klebsiella	NNP	O
sp	NN	O
(	(	O
9	CD	O
)	)	O
,	,	O
Proteus	NNP	O
sp	NN	O
(	(	O
6	CD	O
)	)	O
,	,	O
and	CC	O
Bacteroides	NNP	O
sp	NN	O
(	(	O
4	CD	O
)	)	O
.	.	O

For	IN	O
23	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
gentamicin-cefoxitin	JJ	O
(	(	O
G-C	NNP	O
)	)	O
,	,	O
the	DT	O
clinical	JJ	O
response	NN	O
was	VBD	O
favorable	JJ	O
in	IN	O
20/21	CD	O
(	(	O
95.2	CD	O
%	NN	O
)	)	O
evaluable	JJ	O
cases	NNS	O
,	,	O
and	CC	O
elimination	NN	O
or	CC	O
marked	VBN	O
reduction	NN	O
of	IN	O
33/34	CD	O
(	(	O
97.1	CD	O
%	NN	O
)	)	O
organisms	NN	O
was	VBD	O
achieved	VBN	O
.	.	O

For	IN	O
14	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
netilmicin-cefoxitin	JJ	O
(	(	O
N-C	NNP	O
)	)	O
,	,	O
the	DT	O
clinical	JJ	O
response	NN	O
was	VBD	O
favorable	JJ	O
in	IN	O
13/13	CD	O
(	(	O
100	CD	O
%	NN	O
)	)	O
evaluable	JJ	O
cases	NNS	O
,	,	O
and	CC	O
19/20	CD	O
(	(	O
95	CD	O
%	NN	O
)	)	O
organisms	WDT	O
were	VBD	O
eliminated	VBN	O
or	CC	O
markedly	RB	O
reduced	VBN	O
.	.	O

Nephrotoxicity	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	JJ	O
creatinine	NN	O
to	TO	O
greater	JJR	O
than	IN	O
25	CD	O
%	NN	O
over	IN	O
baseline	NN	O
with	IN	O
an	DT	O
absolute	JJ	O
rise	NN	O
of	IN	O
at	IN	O
least	JJS	O
0.5	CD	O
mg/100	JJ	O
ml	NN	O
to	TO	O
a	DT	O
value	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
1.3	CD	O
mg/100	NN	O
ml	NN	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
criteria	NNS	O
,	,	O
nephrotoxicity	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
2/27	CD	O
(	(	O
7.4	CD	O
%	NN	O
)	)	O
patients	NNS	O
treated	VBN	O
with	IN	O
G-C	NNP	O
and	CC	O
in	IN	O
3/19	CD	O
(	(	O
15.8	CD	O
%	NN	O
)	)	O
patients	NNS	O
treated	VBN	O
with	IN	O
N-C.	NNP	O
Ototoxicity	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
a	DT	O
greater	JJR	O
than	IN	O
20	CD	O
dB	JJ	O
loss	NN	O
at	IN	O
any	DT	O
frequency	NN	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
criteria	NNS	O
,	,	O
ototoxicity	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
5/27	CD	O
(	(	O
18.5	CD	O
%	NN	O
)	)	O
patients	NNS	O
treated	VBN	O
with	IN	O
G-C	NNP	O
and	CC	O
2/19	CD	O
(	(	O
10.5	CD	O
%	NN	O
)	)	O
patients	NNS	O
treated	VBN	O
with	IN	O
N-C	NNP	O
.	.	O

The	DT	O
data	NN	O
show	NN	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
toxicity	NN	O
and	CC	O
suggest	VBP	O
that	IN	O
netilmicin	NN	O
and	CC	O
gentamicin	NN	O
are	VBP	O
both	DT	O
highly	RB	O
effective	JJ	O
in	IN	O
combination	NN	O
with	IN	O
cefoxitin	NN	O
in	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
serious	JJ	Condition
infections	NNS	Condition
after	IN	O
surgery	NN	O
.	.	O

Propofol	NNP	O
and	CC	O
midazolam	NNP	O
act	NN	O
synergistically	RB	O
in	IN	O
combination	NN	O
.	.	O

We	PRP	O
have	VBP	O
studied	VBN	O
interactions	NNS	O
between	IN	O
i.v	NN	O
.	.	O

propofol	NN	O
and	CC	O
midazolam	NN	O
for	IN	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
in	IN	O
200	CD	O
unpremedicated	JJ	O
female	NN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
gynaecological	JJ	O
surgery	NN	O
.	.	O

Using	VBG	O
end-points	NNS	O
of	IN	O
hypnosis	NN	O
(	(	O
loss	NN	O
of	IN	O
response	NN	O
to	TO	O
verbal	JJ	O
command	NN	O
)	)	O
and	CC	O
anaesthesia	$	O
(	(	O
loss	NN	O
of	IN	O
response	NN	O
to	TO	O
a	DT	O
5-s	JJ	O
transcutaneous	JJ	O
tetanic	JJ	O
stimulus	NN	O
)	)	O
,	,	O
we	PRP	O
determined	VBD	O
dose-response	JJ	O
curves	NNS	O
for	IN	O
propofol	NN	O
and	CC	O
midazolam	VB	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
.	.	O

For	IN	O
hypnosis	NN	O
,	,	O
synergistic	JJ	O
interaction	NN	O
was	VBD	O
found	VBN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
,	,	O
the	DT	O
combination	NN	O
having	VBG	O
1.44	CD	O
times	NNS	O
the	DT	O
potency	NN	O
of	IN	O
the	DT	O
individual	JJ	O
agents	NNS	O
.	.	O

Although	IN	O
midazolam	NN	O
failed	VBD	O
to	TO	O
produce	VB	O
anaesthesia	NN	O
in	IN	O
the	DT	O
dose	NN	O
range	NN	O
used	VBN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
propofol	NN	O
required	VBN	O
to	TO	O
produce	VB	O
anaesthesia	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
52	CD	O
%	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
midazolam	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
reduction	NN	O
in	IN	O
arterial	JJ	O
pressure	NN	O
at	IN	O
induction	NN	O
was	VBD	O
the	DT	O
same	JJ	O
for	IN	O
the	DT	O
combination	NN	O
as	IN	O
for	IN	O
the	DT	O
individual	JJ	O
agents	NNS	O
.	.	O

The	DT	O
cause	NN	O
of	IN	O
the	DT	O
synergism	NN	O
was	VBD	O
not	RB	O
clear	JJ	O
,	,	O
but	CC	O
may	MD	O
have	VB	O
been	VBN	O
interaction	NN	O
at	IN	O
CNS	NNP	O
GABAA	NNP	O
receptors	NNS	O
.	.	O

Prefrontal	JJ	O
neuromodulation	NN	O
using	VBG	O
rTMS	JJ	O
improves	NNS	O
error	VBP	O
monitoring	NN	O
and	CC	O
correction	NN	O
function	NN	O
in	IN	O
autism	NN	O
.	.	O

One	CD	O
important	JJ	O
executive	NN	O
function	NN	O
known	VBN	O
to	TO	O
be	VB	O
compromised	VBN	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
is	VBZ	O
related	VBN	O
to	TO	O
response	NN	O
error	NN	O
monitoring	NN	O
and	CC	O
post-error	JJ	O
response	NN	O
correction	NN	O
.	.	O

Several	JJ	O
reports	NNS	O
indicate	VBP	O
that	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
show	NN	O
reduced	VBD	O
error	NN	O
processing	NN	O
and	CC	O
deficient	JJ	O
behavioral	JJ	O
correction	NN	O
after	IN	O
an	DT	O
error	NN	O
is	VBZ	O
committed	VBN	O
.	.	O

Error	NNP	O
sensitivity	NN	O
can	MD	O
be	VB	O
readily	RB	O
examined	VBN	O
by	IN	O
measuring	VBG	O
event-related	JJ	O
potentials	NNS	O
(	(	O
ERP	NNP	O
)	)	O
associated	VBN	O
with	IN	O
responses	NNS	O
to	TO	O
errors	NNS	O
,	,	O
the	DT	O
fronto-central	JJ	O
error-related	JJ	O
negativity	NN	O
(	(	O
ERN	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
error-related	JJ	O
positivity	NN	O
(	(	O
Pe	NNP	O
)	)	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
our	PRP$	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
reaction	NN	O
time	NN	O
(	(	O
RT	NNP	O
)	)	O
,	,	O
error	NN	O
rate	NN	O
,	,	O
post-error	JJ	O
RT	NNP	O
change	NN	O
,	,	O
ERN	NNP	O
,	,	O
and	CC	O
Pe	NNP	O
will	MD	O
show	VB	O
positive	JJ	O
changes	NNS	O
following	VBG	O
12-week	JJ	O
long	JJ	O
slow	JJ	O
frequency	NN	O
repetitive	JJ	O
TMS	NNP	O
(	(	O
rTMS	NN	O
)	)	O
over	IN	O
dorsolateral	JJ	O
prefrontal	JJ	O
cortex	NN	O
(	(	O
DLPFC	NNP	O
)	)	O
in	IN	O
high	JJ	O
functioning	NN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
12	CD	O
sessions	NNS	O
of	IN	O
1	CD	O
Hz	NNP	O
rTMS	NN	O
bilaterally	RB	O
applied	VBN	O
over	IN	O
the	DT	O
DLPFC	NNP	O
will	MD	O
result	VB	O
in	IN	O
improvements	NNS	O
reflected	VBN	O
in	IN	O
both	DT	O
behavioral	JJ	O
and	CC	O
ERP	NNP	O
measures	NNS	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
active	JJ	O
rTMS	NN	O
treatment	NN	O
or	CC	O
wait-list	NN	O
(	(	O
WTL	NNP	O
)	)	O
groups	NNS	O
.	.	O

Baseline	NNP	O
and	CC	O
post-TMS/or	JJ	O
WTL	NNP	O
EEG	NNP	O
was	VBD	O
collected	VBN	O
using	VBG	O
128	CD	O
channel	NNS	O
EEG	NNP	O
system	NN	O
.	.	O

The	DT	O
task	NN	O
involved	VBD	O
the	DT	O
recognition	NN	O
of	IN	O
a	DT	O
specific	JJ	O
illusory	NN	O
shape	NN	O
,	,	O
in	IN	O
this	DT	O
case	NN	O
a	DT	O
square	NN	O
or	CC	O
triangle	NN	O
,	,	O
created	VBN	O
by	IN	O
three	CD	O
or	CC	O
four	CD	O
inducer	NN	O
disks	NNS	O
.	.	O

ERN	NNP	O
in	IN	O
TMS	NNP	O
treatment	NN	O
group	NN	O
became	VBD	O
significantly	RB	O
more	RBR	O
negative	JJ	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
omission	JJ	O
errors	NNS	O
decreased	VBD	O
post-TMS	NN	O
.	.	O

The	DT	O
RT	NNPS	O
did	VBD	O
not	RB	O
change	NN	O
,	,	O
but	CC	O
post-error	JJ	O
RT	NNP	O
became	VBD	O
slower	JJR	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
changes	NNS	O
in	IN	O
RT	NNP	O
,	,	O
error	NN	O
rate	NN	O
,	,	O
post-error	NN	O
RT	NNP	O
slowing	NN	O
,	,	O
nor	CC	O
in	IN	O
ERN/Pe	NNP	O
measures	NNS	O
in	IN	O
the	DT	O
wait-list	JJ	O
group	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
show	VBP	O
significant	JJ	O
post-TMS	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
response-locked	JJ	O
ERP	NNP	O
such	JJ	O
as	IN	O
ERN	NNP	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
behavioral	JJ	O
response	NN	O
monitoring	NN	O
measures	NNS	O
indicative	JJ	O
of	IN	O
improved	JJ	O
error	NN	O
monitoring	NN	O
and	CC	O
correction	NN	O
function	NN	O
.	.	O

The	DT	O
ERN	NNP	O
and	CC	O
Pe	NNP	O
,	,	O
along	IN	O
with	IN	O
behavioral	JJ	O
performance	NN	O
measures	NNS	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
functional	JJ	O
outcome	NN	O
measures	NNS	O
to	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
neuromodulation	NN	O
(	(	O
e.g.	JJ	O
,	,	O
rTMS	NN	O
)	)	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
thus	RB	O
may	MD	O
have	VB	O
important	JJ	O
practical	JJ	O
implications	NNS	O
.	.	O

Video	NNP	O
rating	NN	O
analysis	NN	O
of	IN	O
effect	NN	O
of	IN	O
maprotiline	NN	O
in	IN	O
patients	NNS	O
with	IN	O
dementia	NN	O
and	CC	O
depression	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
dementia	NN	O
and	CC	O
mild	JJ	O
depression	NN	O
(	(	O
DSM-III-R	NNP	O
290.21	CD	O
)	)	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
low	JJ	O
doses	NNS	O
of	IN	O
the	DT	O
antidepressant	JJ	O
maprotiline	NN	O
(	(	O
up	IN	O
to	TO	O
75	CD	O
mg/d	NN	O
)	)	O
was	VBD	O
examined	VBN	O
.	.	O

The	DT	O
main	JJ	O
parameter	NN	O
was	VBD	O
a	DT	O
video	NN	O
rating	NN	O
of	IN	O
global	JJ	O
impression	NN	O
.	.	O

The	DT	O
Mini-Mental	JJ	O
State	NNP	O
Examination	NNP	O
(	(	O
MMS	NNP	O
)	)	O
and	CC	O
the	DT	O
Geriatric	NNP	O
Depression	NNP	O
Scale	NNP	O
(	(	O
GDS	NNP	O
)	)	O
were	VBD	O
applied	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
maprotiline	NN	O
on	IN	O
cognitive	JJ	O
and	CC	O
depressive	JJ	O
symptoms	NNS	O
.	.	O

The	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
was	VBD	O
of	IN	O
eight	CD	O
weeks	NNS	O
'	POS	O
duration	NN	O
and	CC	O
included	VBD	O
127	CD	O
patients	NNS	O
,	,	O
randomized	VBN	O
in	IN	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
antidepressant	JJ	O
effect	NN	O
of	IN	O
maprotiline	NN	O
was	VBD	O
reflected	VBN	O
in	IN	O
the	DT	O
GDS	NNP	O
.	.	O

There	EX	O
was	VBD	O
,	,	O
however	RB	O
,	,	O
no	DT	O
indication	NN	O
of	IN	O
an	DT	O
effect	NN	O
of	IN	O
maprotiline	NN	O
on	IN	O
cognitive	JJ	O
performance	NN	O
.	.	O

The	DT	O
global	JJ	O
impression	NN	O
,	,	O
evaluated	VBN	O
by	IN	O
video	NN	O
rating	NN	O
,	,	O
gave	VBD	O
no	DT	O
indication	NN	O
as	IN	O
to	TO	O
a	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

-	:	O
The	DT	O
video	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
interrater	NN	O
reliability	NN	O
.	.	O

The	DT	O
discrepancy	NN	O
between	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
video	NN	O
rating	NN	O
and	CC	O
the	DT	O
GDS	NNP	O
is	VBZ	O
discussed	VBN	O
.	.	O

-	:	O
The	DT	O
results	NNS	O
confirm	VBP	O
similar	JJ	O
findings	NNS	O
of	IN	O
other	JJ	O
authors	NNS	O
;	:	O
i.e.	NN	O
,	,	O
that	IN	O
a	DT	O
sedating	VBG	O
antidepressant	NN	O
with	IN	O
some	DT	O
anticholinergic	JJ	O
effects	NNS	O
can	MD	O
not	RB	O
be	VB	O
expected	VBN	O
to	TO	O
improve	VB	O
cognitive	JJ	O
functions	NNS	O
despite	IN	O
its	PRP$	O
antidepressant	JJ	O
effect	NN	O
.	.	O

The	DT	O
main	JJ	O
interest	NN	O
of	IN	O
this	DT	O
study	NN	O
,	,	O
however	RB	O
,	,	O
lies	VBZ	O
in	IN	O
its	PRP$	O
methodology	NN	O
(	(	O
video	JJ	O
analysis	NN	O
)	)	O
.	.	O

The	DT	O
response	NN	O
of	IN	O
neuropathic	JJ	O
pain	NN	O
and	CC	O
pain	NN	O
in	IN	O
complex	JJ	Condition
regional	JJ	Condition
pain	NN	Condition
syndrome	NN	Condition
I	PRP	O
to	TO	O
carbamazepine	VB	O
and	CC	O
sustained-release	JJ	O
morphine	NN	O
in	IN	O
patients	NNS	O
pretreated	VBN	O
with	IN	O
spinal	JJ	O
cord	NN	O
stimulation	NN	O
:	:	O
a	DT	O
double-blinded	JJ	O
randomized	NN	O
study	NN	O
.	.	O

Forty-three	JJ	SampleSize
patients	NNS	O
with	IN	O
peripheral	JJ	Condition
neuropathic	JJ	Condition
pain	NN	Condition
,	,	O
exclusively	RB	O
pain	NN	O
reduced	VBN	O
by	IN	O
spinal	JJ	O
cord	NN	O
stimulation	NN	O
(	(	O
SCS	NNP	O
)	)	O
,	,	O
were	VBD	O
switched	VBN	O
into	IN	O
a	DT	O
painful	JJ	O
state	NN	O
after	IN	O
SCS	NNP	O
inactivation	NN	O
.	.	O

This	DT	O
mode	NN	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
pain-relieving	JJ	O
effect	NN	O
of	IN	O
carbamazepine	NN	O
(	(	O
CMZ	NNP	O
)	)	O
and	CC	O
opioids	NNS	O
in	IN	O
a	DT	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

In	IN	O
Phase	NNP	O
1	CD	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
either	DT	O
CMZ	NNP	O
(	(	O
600	CD	O
mg/d	NN	O
)	)	O
or	CC	O
placebo	NN	O
during	IN	O
an	DT	O
SCS-free	JJ	O
period	NN	O
of	IN	O
8	CD	O
days	NNS	O
.	.	O

In	IN	O
Phase	NNP	O
2	CD	O
,	,	O
after	IN	O
a	DT	O
CMZ	NNP	O
elimination	NN	O
interval	NN	O
of	IN	O
7	CD	O
days	NNS	O
,	,	O
38	CD	O
patients	NNS	O
received	VBD	O
either	RB	O
sustained-release	JJ	O
morphine	NN	O
(	(	O
90	CD	O
mg/d	NN	O
)	)	O
or	CC	O
placebo	NN	O
for	IN	O
8	CD	O
days	NNS	O
.	.	O

In	IN	O
cases	NNS	O
of	IN	O
intolerable	JJ	O
pain	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
authorized	VBN	O
to	TO	O
reactivate	VB	O
their	PRP$	O
SCS	NNP	O
.	.	O

The	DT	O
pain	NN	O
intensity	NN	O
was	VBD	O
rated	VBN	O
on	IN	O
a	DT	O
numeric	JJ	O
analog	NN	O
scale	NN	O
.	.	O

In	IN	O
38	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
Phase	NNP	O
1	CD	O
,	,	O
significant	JJ	O
delay	NN	O
in	IN	O
pain	JJ	O
increase	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
CMZ	NNP	O
group	NN	O
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
.	.	O

In	IN	O
Phase	NNP	O
2	CD	O
,	,	O
the	DT	O
trend	NN	O
observed	VBD	O
with	IN	O
morphine	NN	O
was	VBD	O
insignificant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.41	CD	O
)	)	O
.	.	O

Two	CD	O
CMZ	JJ	O
patients	NNS	O
and	CC	O
one	CD	O
morphine	NN	O
patient	NN	O
showed	VBD	O
complete	JJ	O
pain	NN	O
relief	NN	O
and	CC	O
preferred	VBN	O
to	TO	O
continue	VB	O
the	DT	O
medication	NN	O
.	.	O

Thirty-five	JJ	O
patients	NNS	O
returned	VBN	O
to	TO	O
SCS	NNP	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
CMZ	NNP	O
is	VBZ	O
effective	JJ	O
in	IN	O
peripheral	JJ	O
neuropathic	JJ	O
pain	NN	O
.	.	O

Morphine	NNP	O
obviously	RB	O
requires	VBZ	O
larger	JJR	O
individually	RB	O
titrated	VBD	O
dosages	NNS	O
than	IN	O
those	DT	O
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
for	IN	O
results	NNS	O
to	TO	O
be	VB	O
adequately	RB	O
interpreted	VBN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
different	JJ	O
doses	NNS	O
of	IN	O
medroxyprogesterone	NN	O
acetate	NN	O
on	IN	O
mood	NN	O
symptoms	NNS	O
in	IN	O
sequential	JJ	O
hormonal	JJ	O
therapy	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
adverse	JJ	O
mood	NN	O
effects	NNS	O
of	IN	O
two	CD	O
different	JJ	O
doses	NNS	O
of	IN	O
medroxyprogesterone	NN	O
acetate	NN	O
(	(	O
MPA	NNP	O
)	)	O
during	IN	O
postmenopausal	NN	Condition
hormone	CD	O
replacement	NN	O
therapy	NN	O
(	(	O
HRT	NNP	O
)	)	O
in	IN	O
women	NNS	Sex
with	IN	O
and	CC	O
without	IN	O
a	DT	O
history	NN	O
of	IN	O
premenstrual	JJ	Condition
syndrome	NN	Condition
(	(	Condition
PMS	NNP	Condition
)	)	Condition
.	.	Condition

The	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
cross-over	NN	O
study	NN	O
and	CC	O
included	VBD	O
36	CD	SampleSize
postmenopausal	JJ	Condition
women	NNS	Sex
at	IN	O
three	CD	O
health	NN	O
care	NN	O
areas	NNS	O
in	IN	O
northern	JJ	O
Sweden	NNP	O
.	.	O

The	DT	O
women	NNS	O
received	VBD	O
2	CD	O
mg	NNS	O
estradiol	RB	O
continuously	RB	O
during	IN	O
five	CD	O
28-day	JJ	O
cycles	NNS	O
and	CC	O
10	CD	O
mg	NN	O
or	CC	O
20	CD	O
mg	NNS	O
MPA	NNP	O
sequentially	RB	O
for	IN	O
12	CD	O
days	NNS	O
during	IN	O
each	DT	O
cycle	NN	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
mood	NN	O
and	CC	O
physical	JJ	O
symptoms	NNS	O
noted	VBD	O
on	IN	O
a	DT	O
daily	JJ	O
rating	NN	O
scale	NN	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
physical	JJ	O
symptoms	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
10	CD	O
and	CC	O
20	CD	O
mg	NN	O
MPA	NNP	O
.	.	O

Both	DT	O
women	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
PMS	NNP	O
and	CC	O
women	NNS	O
without	IN	O
responded	VBD	O
with	IN	O
more	RBR	O
negative	JJ	O
mood	NN	O
symptoms	NNS	O
with	IN	O
the	DT	O
lower	JJR	O
dose	NN	O
of	IN	O
MPA	NNP	O
.	.	O

In	IN	O
women	NNS	O
with	IN	O
previous	JJ	O
PMS	NNP	O
the	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
MPA	NNP	O
enhanced	VBD	O
positive	JJ	O
mood	NN	O
symptoms	NNS	O
.	.	O

With	IN	O
respect	NN	O
to	TO	O
mood	NN	O
and	CC	O
physical	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
aim	NN	O
to	TO	O
lower	VB	O
MPA	NNP	O
doses	NNS	O
in	IN	O
HRT	NNP	O
is	VBZ	O
unwarranted	JJ	O
.	.	O

Chemotherapy	NN	O
with	IN	O
cyclophosphamide	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
vincristine	NN	O
,	,	O
and	CC	O
prednisone	VB	O
alone	RB	O
or	CC	O
with	IN	O
levamisole	JJ	O
or	CC	O
with	IN	O
levamisole	JJ	O
plus	CC	O
BCG	NNP	O
for	IN	O
malignant	JJ	O
lymphoma	NN	O
:	:	O
a	DT	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
Study	NNP	O
.	.	O

Between	NNP	O
1977	CD	O
and	CC	O
1983	CD	O
the	DT	O
Southwest	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
SWOG	NNP	O
)	)	O
evaluated	VBD	O
chemotherapy	NN	O
alone	RB	O
(	(	O
cyclophosphamide	JJ	O
,	,	O
doxorubicin	NN	O
,	,	O
vincristine	NN	O
,	,	O
prednisone	NN	O
;	:	O
CHOP	NNP	O
)	)	O
or	CC	O
chemoimmunotherapy	NN	O
(	(	O
CHOP-levamisole	JJ	O
or	CC	O
CHOP-levamisole-BCG	JJ	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
involving	VBG	O
715	CD	SampleSize
eligible	JJ	O
patients	NNS	O
with	IN	O
all	DT	O
types	NNS	O
of	IN	O
malignant	JJ	Condition
lymphoma	NN	Condition
(	(	O
ML	NNP	O
)	)	O
.	.	O

Of	IN	O
281	CD	SampleSize
evaluable	JJ	O
patients	NNS	O
with	IN	O
favorable	JJ	O
histologic	JJ	O
types	NNS	O
of	IN	O
ML	NNP	Condition
,	,	O
171	CD	O
(	(	O
61	CD	O
%	NN	O
)	)	O
achieved	VBD	O
complete	JJ	O
remission	NN	O
(	(	O
CR	NNP	O
)	)	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
CR	NNP	O
rate	NN	O
,	,	O
CR	NNP	O
duration	NN	O
,	,	O
or	CC	O
survival	NN	O
according	VBG	O
to	TO	O
the	DT	O
type	NN	O
of	IN	O
initial	JJ	O
treatment	NN	O
.	.	O

Of	IN	O
388	CD	SampleSize
evaluable	JJ	O
patients	NNS	O
with	IN	O
unfavorable	JJ	O
histologic	JJ	O
types	NNS	O
of	IN	O
ML	NNP	O
,	,	O
194	CD	O
(	(	O
50	CD	O
%	NN	O
)	)	O
achieved	VBD	O
CR	NNP	O
.	.	O

Levamisole	NNP	O
appeared	VBD	O
to	TO	O
adversely	RB	O
affect	VB	O
CR	NNP	O
rates	NNS	O
in	IN	O
nodular	JJ	O
mixed	JJ	O
and	CC	O
nodular	JJ	O
large-cell	NN	O
lymphoma	NN	O
and	CC	O
CR	NNP	O
duration	NN	O
in	IN	O
patients	NNS	O
with	IN	O
unfavorable	JJ	O
histology	NN	O
ML	NNP	O
.	.	O

Chemoimmunotherapy	NNP	O
with	IN	O
levamisole	JJ	O
or	CC	O
levamisole-BCG	JJ	O
offers	NNS	O
no	DT	O
advantage	NN	O
in	IN	O
terms	NNS	O
of	IN	O
CR	NNP	O
rates	NNS	O
,	,	O
CR	NNP	O
duration	NN	O
,	,	O
or	CC	O
survival	NN	O
compared	VBN	O
to	TO	O
CHOP	NNP	O
chemotherapy	NN	O
alone	RB	O
,	,	O
and	CC	O
levamisole	NN	O
may	MD	O
have	VB	O
had	VBD	O
an	DT	O
adverse	JJ	O
impact	NN	O
on	IN	O
outcome	NN	O
in	IN	O
certain	JJ	O
subtypes	NNS	O
of	IN	O
ML	NNP	O
.	.	O

Timing	NN	O
of	IN	O
antibiotic	JJ	O
administration	NN	O
in	IN	O
knee	JJ	O
replacement	NN	O
under	IN	O
tourniquet	NN	O
.	.	O

Cephamandole	NNP	O
levels	NNS	O
in	IN	O
serum	NN	O
and	CC	O
drain	NN	O
fluid	NN	O
were	VBD	O
measured	VBN	O
in	IN	O
32	CD	O
knee	JJ	O
replacement	NN	O
operations	NNS	O
to	TO	O
determine	VB	O
the	DT	O
benefit	NN	O
of	IN	O
an	DT	O
intravenous	JJ	O
dose	NN	O
of	IN	O
antibiotic	JJ	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
tourniquet	JJ	O
deflation	NN	O
.	.	O

Concentrations	NNS	O
of	IN	O
cephamandole	NN	O
in	IN	O
drain	NN	O
fluid	NN	O
were	VBD	O
directly	RB	O
proportional	JJ	O
to	TO	O
the	DT	O
serum	NN	O
concentration	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
tourniquet	JJ	O
release	NN	O
.	.	O

A	DT	O
'tourniquet-release	JJ	O
'	POS	O
dose	NN	O
of	IN	O
antibiotic	JJ	O
increased	VBD	O
drain	NN	O
fluid	NN	O
concentration	NN	O
threefold	NN	O
.	.	O

Virtual	JJ	O
reality	NN	O
for	IN	O
acute	NN	O
pain	NN	O
reduction	NN	O
in	IN	O
adolescents	NNS	Age
undergoing	VBG	O
burn	NN	Condition
wound	NN	Condition
care	NN	Condition
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Effective	NNP	O
pain	NN	O
management	NN	O
remains	VBZ	O
a	DT	O
challenge	NN	O
for	IN	O
adolescents	NNS	Age
during	IN	O
conscious	JJ	O
burn	NN	O
wound	NN	O
care	NN	O
procedures	NNS	O
.	.	O

Virtual	JJ	O
reality	NN	O
(	(	O
VR	NNP	O
)	)	O
shows	VBZ	O
promise	NN	O
as	IN	O
a	DT	O
non-pharmacological	JJ	O
adjunct	NN	O
in	IN	O
reducing	VBG	O
pain	NN	O
.	.	O

AIMS	VB	O
This	DT	O
study	NN	O
assessed	VBD	O
off-the-shelf	JJ	O
VR	NNP	O
for	IN	O
(	(	O
1	CD	O
)	)	O
its	PRP$	O
effect	NN	O
on	IN	O
reducing	VBG	O
acute	JJ	O
pain	NN	O
intensity	NN	O
during	IN	O
adolescent	JJ	O
burn	NN	O
wound	NN	O
care	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
its	PRP$	O
clinical	JJ	O
utility	NN	O
in	IN	O
a	DT	O
busy	JJ	O
hospital	NN	O
setting	NN	O
.	.	O

METHODS	NNP	O
Forty-one	CD	SampleSize
adolescents	NNS	Age
(	(	O
11-17	CD	Age
years	NNS	Age
)	)	O
participated	VBD	O
in	IN	O
this	DT	O
prospective	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

Acute	NNP	O
pain	NN	O
outcomes	NNS	O
including	VBG	O
adolescent	JJ	O
self-report	NN	O
,	,	O
nursing	VBG	O
staff	NN	O
behavioral	JJ	O
observation	NN	O
,	,	O
caregiver	NN	O
observation	NN	O
and	CC	O
physiological	JJ	O
measures	NNS	O
were	VBD	O
collected	VBN	O
.	.	O

Length	NNP	O
of	IN	O
procedure	NN	O
times	NNS	O
and	CC	O
adolescent	JJ	O
reactions	NNS	O
were	VBD	O
also	RB	O
recorded	VBN	O
to	TO	O
inform	VB	O
clinical	JJ	O
utility	NN	O
.	.	O

RESULTS	NNP	O
Nursing	JJ	O
staff	NN	O
reported	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
pain	NN	O
scores	NNS	O
during	IN	O
dressing	VBG	O
removal	NN	O
,	,	O
and	CC	O
significantly	RB	O
less	JJR	O
rescue	JJ	O
doses	NNS	O
of	IN	O
Entonox	NNP	O
given	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
VR	NNP	O
,	,	O
compared	VBN	O
to	TO	O
those	DT	O
receiving	VBG	O
standard	JJ	O
distraction	NN	O
.	.	O

For	IN	O
all	DT	O
other	JJ	O
pain	NN	O
outcomes	NNS	O
and	CC	O
length	NN	O
of	IN	O
treatment	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
for	IN	O
lower	JJR	O
pain	NN	O
scores	NNS	O
and	CC	O
treatment	NN	O
times	NNS	O
for	IN	O
those	DT	O
receiving	VBG	O
VR	NNP	O
,	,	O
but	CC	O
these	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Despite	IN	O
only	RB	O
minimal	JJ	O
pain	NN	O
reduction	NN	O
achieved	VBD	O
using	VBG	O
off-the-shelf	JJ	O
VR	NNP	O
,	,	O
other	JJ	O
results	NNS	O
from	IN	O
this	DT	O
trial	NN	O
and	CC	O
previous	JJ	O
research	NN	O
on	IN	O
younger	JJR	O
children	NNS	O
with	IN	O
burns	NNS	O
suggest	VBP	O
a	DT	O
customized	JJ	O
,	,	O
adolescent	JJ	O
and	CC	O
hospital	JJ	O
friendly	JJ	O
device	NN	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
in	IN	O
pain	NN	O
reduction	NN	O
.	.	O

Generalizability	NNP	O
and	CC	O
durability	NN	O
of	IN	O
treatment	NN	O
effects	NNS	O
in	IN	O
an	DT	O
intervention	NN	O
program	NN	O
for	IN	O
coronary-prone	NN	O
(	(	O
Type	NNP	O
A	NNP	O
)	)	O
managers	NNS	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
reliability	NN	O
and	CC	O
durability	NN	O
of	IN	O
positive	JJ	O
treatment	NN	O
effects	NNS	O
obtained	VBN	O
in	IN	O
a	DT	O
type	NN	O
A	DT	O
intervention	NN	O
project	NN	O
for	IN	O
healthy	JJ	O
managers	NNS	O
,	,	O
the	DT	O
analysis	NN	O
was	VBD	O
extended	VBN	O
to	TO	O
data	NNS	O
available	JJ	O
from	IN	O
a	DT	O
third	JJ	O
treatment	NN	O
group	NN	O
(	(	O
a	DT	O
special	JJ	O
behavior	JJ	O
therapy	NN	O
group	NN	O
for	IN	O
participants	NNS	O
eliminated	VBN	O
from	IN	O
the	DT	O
main	JJ	O
sample	NN	O
because	IN	O
of	IN	O
manifestations	NNS	O
of	IN	O
clinical	JJ	O
CHD	NNP	O
)	)	O
and	CC	O
to	TO	O
measures	NNS	O
obtained	VBN	O
6	CD	O
months	NNS	O
following	VBG	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

Immediately	RB	O
after	IN	O
treatment	NN	O
all	DT	O
three	CD	O
groups	NNS	O
showed	VBD	O
a	DT	O
similar	JJ	O
pattern	NN	O
of	IN	O
improvement	NN	O
,	,	O
although	IN	O
the	DT	O
two	CD	O
behavior	JJ	O
therapy	NN	O
groups	NNS	O
did	VBD	O
show	VB	O
a	DT	O
greater	JJR	O
decrease	NN	O
in	IN	O
serum	NN	O
cholesterol	NN	O
levels	NNS	O
.	.	O

Six	NNP	O
months	NNS	O
after	IN	O
treatment	NN	O
the	DT	O
sample	NN	O
as	IN	O
a	DT	O
whole	NN	O
showed	VBD	O
good	JJ	O
maintenance	NN	O
of	IN	O
treatment	NN	O
effects	NNS	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
between	IN	O
groups	NNS	O
had	VBD	O
become	VBN	O
somewhat	RB	O
sharper	JJ	O
,	,	O
with	IN	O
the	DT	O
special	JJ	O
behavior	JJ	O
therapy	NN	O
group	NN	O
faring	VBG	O
best	JJS	O
,	,	O
the	DT	O
regular	JJ	O
behavior	NN	O
therapy	NN	O
group	NN	O
intermediate	NN	O
,	,	O
and	CC	O
the	DT	O
psychotherapy	NN	O
group	NN	O
worst	WDT	O
.	.	O

The	DT	O
logical	JJ	O
consistency	NN	O
of	IN	O
these	DT	O
findings	NNS	O
increases	VBZ	O
our	PRP$	O
confidence	NN	O
in	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
results	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
permitting	VBG	O
cautious	JJ	O
optimism	NN	O
concerning	VBG	O
the	DT	O
possibility	NN	O
of	IN	O
developing	VBG	O
effective	JJ	O
intervention	NN	O
programs	NNS	O
for	IN	O
coronary-type	NN	O
(	(	O
type	VB	O
A	DT	O
)	)	O
behavior	NN	O
.	.	O

Pemetrexed	NNP	O
in	IN	O
combination	NN	O
with	IN	O
cisplatin	JJ	O
versus	NN	O
cisplatin	NN	O
monotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
recurrent	NN	O
or	CC	O
metastatic	JJ	O
head	NN	Condition
and	CC	Condition
neck	NN	Condition
cancer	NN	Condition
:	:	O
final	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
phase	VB	O
3	CD	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Recurrent	NNP	O
or	CC	O
metastatic	JJ	O
squamous	JJ	Condition
cell	NN	Condition
carcinoma	NN	Condition
of	IN	O
the	DT	O
head	NN	O
and	CC	O
neck	NN	O
(	(	O
SCCHN	NNP	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
poor	JJ	O
survival	NN	O
.	.	O

Platinum-based	JJ	O
chemotherapy	NN	O
is	VBZ	O
often	RB	O
a	DT	O
first-line	JJ	O
treatment	NN	O
.	.	O

Pemetrexed	NNP	O
has	VBZ	O
shown	VBN	O
single-agent	JJ	O
activity	NN	O
in	IN	O
SCCHN	NNP	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
cisplatin	NN	O
for	IN	O
other	JJ	O
tumors	NNS	O
.	.	O

This	DT	O
trial	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
pemetrexed-cisplatin	NN	O
for	IN	O
SCCHN	NNP	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
phase	NN	O
3	CD	O
trial	NN	O
,	,	O
patients	NNS	O
with	IN	O
recurrent	NN	O
or	CC	O
metastatic	JJ	O
SCCHN	NNP	Condition
and	CC	O
no	DT	O
prior	JJ	O
systemic	JJ	O
therapy	NN	O
for	IN	O
metastatic	JJ	O
disease	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
pemetrexed	VB	O
(	(	O
500	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
plus	CC	O
cisplatin	NN	O
(	(	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
n	CC	O
=	VB	O
398	CD	O
)	)	O
or	CC	O
placebo	JJ	O
plus	CC	O
cisplatin	NN	O
(	(	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
n	CC	O
=	VB	O
397	CD	O
)	)	O
to	TO	O
assess	VB	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
and	CC	O
secondary	JJ	O
endpoints	NNS	O
.	.	O

RESULTS	NNP	O
Median	JJ	O
OS	NNP	O
was	VBD	O
7.3	CD	O
months	NNS	O
in	IN	O
the	DT	O
pemetrexed-cisplatin	JJ	O
arm	NN	O
and	CC	O
6.3	CD	O
months	NNS	O
in	IN	O
the	DT	O
placebo-cisplatin	JJ	O
arm	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
,	,	O
0.87	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.75-1.02	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.082	NNP	O
)	)	O
.	.	O

Median	JJ	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
,	,	O
months	NNS	O
)	)	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
(	(	O
pemetrexed-cisplatin	NN	O
,	,	O
3.6	CD	O
;	:	O
placebo-cisplatin	NN	O
,	,	O
2.8	CD	O
;	:	O
HR	NNP	O
,	,	O
0.88	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.76-1.03	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.166	NNP	O
)	)	O
.	.	O

Among	IN	O
patients	NNS	O
with	IN	O
performance	NN	O
status	NN	O
0	CD	O
or	CC	O
1	CD	O
,	,	O
pemetrexed-cisplatin	NN	O
(	(	O
n	JJ	O
=	NNP	O
347	CD	O
)	)	O
led	VBD	O
to	TO	O
longer	JJR	O
OS	NNP	O
and	CC	O
PFS	NNP	O
than	IN	O
placebo-cisplatin	NN	O
(	(	O
n	JJ	O
=	VBZ	O
343	CD	O
;	:	O
8.4	CD	O
vs	IN	O
6.7	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.83	CD	O
;	:	O
P	NNP	O
=	NNP	O
.026	NNP	O
;	:	O
4.0	CD	O
vs	IN	O
3.0	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.84	CD	O
;	:	O
P	NNP	O
=	NNP	O
.044	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Among	IN	O
patients	NNS	O
with	IN	O
oropharyngeal	JJ	Condition
cancers	NNS	Condition
,	,	O
pemetrexed-cisplatin	NN	O
(	(	O
n	JJ	O
=	NNP	O
86	CD	O
)	)	O
resulted	VBD	O
in	IN	O
longer	JJR	O
OS	NNP	O
and	CC	O
PFS	NNP	O
than	IN	O
placebo-cisplatin	NN	O
(	(	O
n	JJ	O
=	VBZ	O
106	CD	O
;	:	O
9.9	CD	O
vs	IN	O
6.1	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.59	CD	O
;	:	O
P	NNP	O
=	NNP	O
.002	NNP	O
;	:	O
4.0	CD	O
vs	IN	O
3.4	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.73	CD	O
;	:	O
P	NNP	O
=	NNP	O
.047	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Pemetrexed-cisplatin	JJ	O
toxicity	NN	O
was	VBD	O
consistent	JJ	O
with	IN	O
studies	NNS	O
in	IN	O
other	JJ	O
tumors	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Pemetrexed-cisplatin	NNP	O
compared	VBN	O
with	IN	O
placebo-cisplatin	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
improve	VB	O
survival	NN	O
for	IN	O
the	DT	O
intent-to-treat	JJ	O
population	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
a	DT	O
prespecified	JJ	O
subgroup	NN	O
analysis	NN	O
,	,	O
pemetrexed-cisplatin	NN	O
showed	VBD	O
OS	NNP	O
and	CC	O
PFS	NNP	O
advantage	NN	O
for	IN	O
patients	NNS	O
with	IN	O
performance	NN	O
status	NN	O
0	CD	O
or	CC	O
1	CD	O
or	CC	O
oropharyngeal	JJ	O
cancers	NNS	O
.	.	O

Comparative	JJ	O
bioavailability	NN	O
of	IN	O
two	CD	O
formulations	NNS	O
of	IN	O
terbinafine	NN	O
.	.	O

Data	NNS	O
from	IN	O
a	DT	O
cross-over	NN	O
,	,	O
randomised	VBN	O
,	,	O
open-label	JJ	O
bioequivalence	NN	O
study	NN	O
in	IN	O
healthy	JJ	Condition
volunteers	NNS	O
.	.	O

An	DT	O
open-label	JJ	O
,	,	O
randomised	JJ	O
,	,	O
cross-over	JJ	O
single	JJ	O
dose	NN	O
study	NN	O
,	,	O
using	VBG	O
2	CD	O
periods	NNS	O
x	RB	O
2	CD	O
sequences	NNS	O
,	,	O
with	IN	O
a	DT	O
minimum	JJ	O
washout	NN	O
period	NN	O
of	IN	O
21	CD	O
days	NNS	O
,	,	O
was	VBD	O
conducted	VBN	O
in	IN	O
order	NN	O
to	TO	O
assess	VB	O
the	DT	O
comparative	JJ	O
bioavailability	NN	O
of	IN	O
two	CD	O
formulations	NNS	O
of	IN	O
terbinafine	NN	O
(	(	O
CAS	NNP	O
78628-80-5	NNP	O
)	)	O
250	CD	O
mg	JJ	O
tablets	NNS	O
.	.	O

Plasma	NNP	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
,	,	O
+0.333	NNP	O
;	:	O
0.667	CD	O
;	:	O
1.00	CD	O
;	:	O
1.33	CD	O
;	:	O
1.67	CD	O
;	:	O
2.00	CD	O
;	:	O
2.33	CD	O
;	:	O
2.67	CD	O
;	:	O
3.00	CD	O
;	:	O
3.50	CD	O
;	:	O
4.00	CD	O
;	:	O
6.00	CD	O
;	:	O
8.00	CD	O
;	:	O
12.0	CD	O
;	:	O
24.0	CD	O
;	:	O
36.0	CD	O
;	:	O
48.0	CD	O
and	CC	O
72.0	CD	O
h	JJ	O
post-administration	NN	O
.	.	O

Terbinafine	NN	O
levels	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
high	JJ	O
pressure	NN	O
liquid	NN	O
chromatography	NN	O
with	IN	O
tandem	JJ	O
mass	NN	O
detection	NN	O
(	(	O
HPLC-MS/MS	NNP	O
)	)	O
and	CC	O
the	DT	O
lower	JJR	O
limit	NN	O
of	IN	O
quantification	NN	O
was	VBD	O
set	VBN	O
at	IN	O
9.99	CD	O
ng/mL	NN	O
.	.	O

The	DT	O
pharmacokinetic	JJ	O
parameters	NNS	O
used	VBN	O
for	IN	O
the	DT	O
bioequivalence	NN	O
assessment	NN	O
(	(	O
AUClast	NNP	O
,	,	O
AUCinf	NNP	O
and	CC	O
Cmax	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
from	IN	O
the	DT	O
terbinafine	JJ	O
concentration	NN	O
data	NNS	O
using	VBG	O
non-compartmental	JJ	O
analysis	NN	O
.	.	O

Classical	JJ	O
90	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
90CI	CD	O
)	)	O
were	VBD	O
calculated	VBN	O
for	IN	O
the	DT	O
overall	JJ	O
sample	NN	O
,	,	O
and	CC	O
for	IN	O
males	NNS	Sex
and	CC	O
females	NNS	Sex
separately	RB	O
,	,	O
and	CC	O
gender	NN	O
effects	NNS	O
were	VBD	O
investigated	VBN	O
using	VBG	O
an	DT	O
appropriate	JJ	O
model	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
overall	JJ	O
classical	JJ	O
90CI	CD	O
were	VBD	O
96.08-105.40	CD	O
%	NN	O
for	IN	O
AUCinf	NNP	O
,	,	O
95.68-105.33	CD	O
for	IN	O
AUClast	NNP	O
and	CC	O
88.24-112.83	JJ	O
for	IN	O
Cmax	NNP	O
,	,	O
that	WDT	O
is	VBZ	O
,	,	O
all	DT	O
within	IN	O
the	DT	O
predefined	JJ	O
ranges	NNS	O
for	IN	O
bioequivalence	NN	O
acceptance	NN	O
.	.	O

Separate	JJ	O
gender	NN	O
analysis	NN	O
showed	VBD	O
very	RB	O
similar	JJ	O
results	NNS	O
for	IN	O
males	NNS	Sex
and	CC	O
females	NNS	Sex
when	WRB	O
analysed	VBN	O
independently	RB	O
,	,	O
and	CC	O
no	DT	O
gender	NN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
(	(	O
p	JJ	O
>	VBP	O
0.05	CD	O
for	IN	O
all	DT	O
of	IN	O
the	DT	O
tested	JJ	O
model	NN	O
effects	NNS	O
)	)	O
.	.	O

It	PRP	O
may	MD	O
be	VB	O
therefore	RB	O
concluded	VBD	O
that	IN	O
the	DT	O
evaluated	JJ	O
formulations	NNS	O
are	VBP	O
bioequivalent	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
rate	NN	O
and	CC	O
extent	NN	O
of	IN	O
absorption	NN	O
.	.	O

Comparative	JJ	O
evaluation	NN	O
of	IN	O
cefotaxime	NN	O
and	CC	O
cephamandole	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
post-operative	JJ	O
infective	JJ	O
complications	NNS	O
following	VBG	O
emergency	NN	O
abdominal	JJ	Condition
surgery	NN	Condition
.	.	O

In	IN	O
previous	JJ	O
published	VBN	O
work	NN	O
we	PRP	O
described	VBD	O
57	CD	SampleSize
patients	NNS	O
undergoing	JJ	O
emergency	NN	O
abdominal	JJ	O
surgery	NN	O
,	,	O
prospectively	RB	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
cefotaxime	NN	O
or	CC	O
cephamandole	NN	O
as	IN	O
a	DT	O
single-antibiotic	JJ	O
,	,	O
three-dose	JJ	O
,	,	O
peri-operative	JJ	O
prophylaxis	NN	O
against	IN	O
post-operative	JJ	O
infective	JJ	O
complications	NNS	O
.	.	O

This	DT	O
earlier	JJR	O
work	NN	O
suggested	VBD	O
that	IN	O
cefotaxime	NN	O
might	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
cephamandole	NN	O
in	IN	O
preventing	VBG	O
wound	JJ	O
sepsis	NN	O
in	IN	O
emergency	NN	O
abdominal	JJ	O
surgery	NN	O
.	.	O

We	PRP	O
describe	VBP	O
here	RB	O
our	PRP$	O
findings	NNS	O
in	IN	O
a	DT	O
further	JJ	O
63	CD	SampleSize
patients	NNS	O
undergoing	JJ	O
emergency	NN	O
abdominal	JJ	O
surgery	NN	O
who	WP	O
were	VBD	O
similarly	RB	O
allocated	VBN	O
into	IN	O
either	CC	O
a	DT	O
cefotaxime	NN	O
or	CC	O
cephamandole	JJ	O
antibiotic	JJ	O
group	NN	O
.	.	O

Infective	JJ	O
complications	NNS	O
occurred	VBD	O
in	IN	O
12/32	CD	O
(	(	O
37	CD	O
per	IN	O
cent	NN	O
)	)	O
of	IN	O
the	DT	O
cefotaxime	NN	O
group	NN	O
and	CC	O
15/31	CD	O
(	(	O
48	CD	O
per	IN	O
cent	NN	O
)	)	O
of	IN	O
the	DT	O
cephamandole	NN	O
group	NN	O
.	.	O

Wound	IN	O
infections	NNS	O
occurred	VBD	O
in	IN	O
5/32	CD	O
(	(	O
16	CD	O
per	IN	O
cent	NN	O
)	)	O
of	IN	O
the	DT	O
cefotaxime	NN	O
group	NN	O
and	CC	O
9/31	CD	O
(	(	O
29	CD	O
per	IN	O
cent	NN	O
)	)	O
of	IN	O
the	DT	O
cephamandole	NN	O
group	NN	O
.	.	O

The	DT	O
organisms	NNS	O
cultured	VBD	O
and	CC	O
their	PRP$	O
sensitivities	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
detail	NN	O
.	.	O

The	DT	O
total	NN	O
of	IN	O
120	CD	SampleSize
patients	NNS	O
studied	VBN	O
in	IN	O
the	DT	O
two	CD	O
series	NN	O
showed	VBD	O
wound	JJ	O
infection	NN	O
to	TO	O
occur	VB	O
in	IN	O
13	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
62	CD	O
patients	NNS	O
receiving	VBG	O
cefotaxime	NN	O
and	CC	O
30	CD	O
per	IN	O
cent	NN	O
of	IN	O
the	DT	O
58	CD	O
patients	NNS	O
receiving	VBG	O
cephamandole	NN	O
.	.	O

This	DT	O
difference	NN	O
reaches	VBZ	O
statistical	JJ	O
significance	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Possible	JJ	O
mechanisms	NN	O
to	TO	O
explain	VB	O
this	DT	O
finding	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Again	NNP	O
we	PRP	O
found	VBD	O
the	DT	O
regime	NN	O
of	IN	O
4	CD	O
g	NN	O
of	IN	O
cefotaxime	JJ	O
given	VBN	O
peri-operatively	RB	O
to	TO	O
be	VB	O
a	DT	O
simple	JJ	O
,	,	O
safe	JJ	O
and	CC	O
effective	JJ	O
single	JJ	O
agent	NN	O
as	IN	O
prophylaxis	NN	O
for	IN	O
emergency	NN	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Abstinence	NNP	O
incentive	NN	O
effects	NNS	O
in	IN	O
a	DT	O
short-term	JJ	O
outpatient	JJ	O
detoxification	NN	O
program	NN	O
.	.	O

Despite	IN	O
being	VBG	O
widely	RB	O
available	JJ	O
,	,	O
outpatient	JJ	O
detoxification	NN	O
has	VBZ	O
limited	VBN	O
efficacy	NN	O
as	IN	O
a	DT	O
stand-alone	JJ	O
treatment	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
abstinence-contingent	JJ	O
incentives	NNS	O
would	MD	O
improve	VB	O
outcomes	NNS	O
for	IN	O
patients	NNS	O
entering	VBG	O
outpatient	JJ	O
opiate	JJ	O
detoxification	NN	O
.	.	O

Participants	NNS	O
(	(	O
N	NNP	O
=	NNP	O
211	CD	O
)	)	O
received	VBD	O
a	DT	O
100	CD	O
US	NNP	O
dollars	NNS	O
voucher	RB	O
on	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
detoxification	NN	O
either	CC	O
contingent	NN	O
on	IN	O
opiate	NN	O
and	CC	O
cocaine	NN	O
abstinence	NN	O
or	CC	O
noncontingently	RB	O
.	.	O

Urine	JJ	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
intake	NN	O
,	,	O
on	IN	O
Wednesday	NNP	O
,	,	O
Friday	NNP	O
(	(	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
detoxification	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
following	JJ	O
Monday	NNP	O
.	.	O

Among	IN	O
contingent-voucher	JJ	O
participants	NNS	O
,	,	O
31	CD	O
%	NN	O
were	VBD	O
drug-free	JJ	O
on	IN	O
Friday	NNP	O
compared	VBN	O
with	IN	O
18	CD	O
%	NN	O
of	IN	O
noncontingent	NN	O
controls	NNS	O
(	(	O
Z	NNP	O
=	NNP	O
2.4	CD	O
,	,	O
p	NN	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Few	JJ	O
(	(	O
12-13	CD	O
%	NN	O
)	)	O
participants	NNS	O
tested	VBN	O
negative	JJ	O
on	IN	O
Monday	NNP	O
.	.	O

Results	NNP	O
support	VBD	O
the	DT	O
ability	NN	O
of	IN	O
vouchers	NNS	O
to	TO	O
produce	VB	O
modest	JJ	O
improvements	NNS	O
in	IN	O
abstinence	NN	O
initiation	NN	O
rates	NNS	O
during	IN	O
brief	JJ	O
detoxification	NN	O
but	CC	O
suggest	VBP	O
that	IN	O
additional	JJ	O
interventions	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
sustain	VB	O
improvements	NNS	O
.	.	O

Influence	NN	O
of	IN	O
bony	NN	Condition
defects	NNS	Condition
on	IN	O
implant	JJ	O
stability	NN	O
.	.	O

INTRODUCTION	NNP	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
analyze	VB	O
the	DT	O
evolution	NN	O
of	IN	O
implant	JJ	O
mechanical	JJ	O
stability	NN	O
in	IN	O
different	JJ	O
types/sizes	NNS	O
of	IN	O
bony	NN	O
defects	NNS	O
using	VBG	O
both	DT	O
Periotest	NNP	O
and	CC	O
Osstell	NNP	O
devices	NNS	O
as	IN	O
objective	JJ	O
tools	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Thirty-two	NNP	O
implants	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
four	CD	O
types	NNS	O
of	IN	O
bone	NN	O
defects	NNS	O
:	:	O
marginal	JJ	O
bone	NN	O
loss	NN	O
,	,	O
peri-apical	JJ	Condition
bone	NN	Condition
defect	NN	Condition
,	,	O
constant	JJ	O
width	NN	O
dehiscence	NN	O
and	CC	O
constant	JJ	O
length	NN	O
dehiscences	NNS	O
.	.	O

Periotest/Osstell	NNP	O
measurements	NNS	O
were	VBD	O
completed	VBN	O
before	IN	O
and	CC	O
during	IN	O
staged	VBN	O
bone	NN	O
removal	NN	O
(	(	O
to	TO	O
enlarge	VB	O
defect	JJ	O
size	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
initial	JJ	O
values	NNS	O
were	VBD	O
found	VBN	O
after	IN	O
a	DT	O
2	CD	O
mm	NN	O
marginal	JJ	O
bone	NN	O
removal	NN	O
(	(	O
Osstell/Periotest	NNP	O
)	)	O
;	:	O
for	IN	O
a	DT	O
peri-apical	JJ	O
bone	NN	O
lesion	NN	O
,	,	O
after	IN	O
removal	NN	O
of	IN	O
5	CD	O
mm	NN	O
(	(	O
Osstell	NNP	O
)	)	O
or	CC	O
8	CD	O
mm	NN	O
(	(	O
Periotest	NNP	O
)	)	O
;	:	O
for	IN	O
a	DT	O
6-mm-long	JJ	O
dehiscence	NN	O
,	,	O
after	IN	O
removal	NN	O
up	RB	O
to	TO	O
180	CD	O
degrees	NNS	O
of	IN	O
the	DT	O
implant	JJ	O
perimeter	NN	O
(	(	O
Osstell/Periotest	NNP	O
)	)	O
;	:	O
for	IN	O
a	DT	O
3-mm-wide	JJ	O
dehiscence	NN	O
,	,	O
after	IN	O
removal	NN	O
of	IN	O
10	CD	O
mm	NN	O
(	(	O
Osstell	NNP	O
)	)	O
or	CC	O
6	CD	O
mm	NN	O
(	(	O
Periotest	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Periotest	NNP	O
and	CC	O
Osstell	NNP	O
are	VBP	O
in	IN	O
general	JJ	O
not	RB	O
very	RB	O
sensitive	JJ	O
in	IN	O
the	DT	O
identification	NN	O
of	IN	O
peri-implant	JJ	O
bone	NN	O
destruction	NN	O
,	,	O
except	IN	O
for	IN	O
marginal	JJ	O
bone	NN	O
loss	NN	O
.	.	O

Four-year	JJ	O
outcomes	NNS	O
from	IN	O
adolescent	JJ	Age
alcohol	NN	O
and	CC	O
drug	NN	O
treatment	NN	O
.	.	O

OBJECTIVE	NNP	O
Knowledge	NNP	O
of	IN	O
treatment	NN	O
response	NN	O
for	IN	O
alcohol	NN	O
and	CC	O
drug	NN	O
problems	NNS	O
among	IN	O
adults	NNS	O
is	VBZ	O
mounting	VBG	O
;	:	O
less	CC	O
is	VBZ	O
known	VBN	O
about	IN	O
long-term	JJ	O
outcome	NN	O
for	IN	O
adolescents	NNS	Age
who	WP	O
receive	VBP	O
treatment	NN	O
for	IN	O
alcohol	NN	Condition
and	CC	Condition
drug	NN	Condition
problems	NNS	Condition
.	.	O

The	DT	O
current	JJ	O
study	NN	O
examined	VBD	O
youth	JJR	O
substance	NN	O
involvement	NN	O
over	IN	O
4	CD	O
years	NNS	O
(	(	O
using	VBG	O
five	CD	O
waves	NNS	O
of	IN	O
data	NNS	O
collection	NN	O
)	)	O
following	VBG	O
treatment	NN	O
for	IN	O
alcohol	NN	O
and	CC	O
drug	NN	O
abuse	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
youth	NN	O
(	(	O
N	NNP	O
=	NNP	O
162	CD	O
,	,	O
60	CD	O
%	NN	O
male	NN	O
)	)	O
treated	VBD	O
during	IN	O
adolescence	NN	Age
(	(	O
mean	JJ	O
age	NN	O
=	VBD	O
16	CD	O
years	NNS	O
)	)	O
was	VBD	O
followed	VBN	O
into	IN	O
young	JJ	O
adulthood	NN	O
,	,	O
a	DT	O
period	NN	O
associated	VBN	O
with	IN	O
stabilization	NN	O
of	IN	O
alcohol	NN	O
use	NN	O
patterns	NNS	O
and	CC	O
elevated	VBN	O
risk	NN	O
for	IN	O
life	NN	O
problems	NNS	O
secondary	JJ	O
to	TO	O
both	DT	O
alcohol	NN	O
and	CC	O
drug	NN	O
use	NN	O
.	.	O

Participants	NNS	O
(	(	O
14-18	CD	Age
years	NNS	Age
old	JJ	Age
)	)	O
were	VBD	O
consecutive	JJ	O
admissions	NNS	O
to	TO	O
inpatient	VB	O
adolescent	JJ	O
alcohol	NN	O
and	CC	O
drug	NN	O
treatment	NN	O
centers	NNS	O
in	IN	O
San	NNP	O
Diego	NNP	O
that	WDT	O
were	VBD	O
abstinence	NN	O
focused	VBN	O
and	CC	O
based	VBN	O
on	IN	O
the	DT	O
12-step	JJ	O
approach	NN	O
.	.	O

RESULTS	NNP	O
Alcohol	NNP	O
and	CC	O
other	JJ	O
drug	NN	O
use	NN	O
were	VBD	O
reduced	VBN	O
during	IN	O
the	DT	O
4	CD	O
years	NNS	O
posttreatment	JJ	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
nicotine	NN	O
.	.	O

The	DT	O
greatest	JJS	O
prevalence	NN	O
reduction	NN	O
occurred	VBD	O
for	IN	O
stimulants	NNS	O
;	:	O
modest	JJ	O
changes	NNS	O
were	VBD	O
evident	JJ	O
in	IN	O
alcohol	NN	O
and	CC	O
marijuana	NN	O
use	NN	O
.	.	O

Nicotine	NN	O
was	VBD	O
the	DT	O
most	RBS	O
commonly	RB	O
used	VBN	O
substance	NN	O
throughout	IN	O
the	DT	O
4	CD	O
years	NNS	O
after	IN	O
treatment	NN	O
.	.	O

Several	JJ	O
distinct	JJ	O
substance	NN	O
involvement	NN	O
trajectories	NNS	O
were	VBD	O
evident	JJ	O
during	IN	O
the	DT	O
4	CD	O
years	NNS	O
following	VBG	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Alcohol	NNP	O
and	CC	O
drug	NN	O
use	NN	O
patterns	NNS	O
during	IN	O
the	DT	O
4	CD	O
years	NNS	O
following	VBG	O
treatment	NN	O
highlight	VBD	O
both	DT	O
changes	NNS	O
and	CC	O
diversity	NN	O
in	IN	O
substance	NN	O
involvement	NN	O
as	IN	O
youth	NN	O
make	VBP	O
the	DT	O
transitions	NNS	O
from	IN	O
middle	JJ	O
to	TO	O
late	JJ	O
adolescence	NN	O
and	CC	O
into	IN	O
young	JJ	O
adulthood	NN	O
.	.	O

Findings	NNS	O
demonstrate	VBP	O
the	DT	O
importance	NN	O
of	IN	O
identifying	VBG	O
transitional	JJ	O
periods	NNS	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
alternative	JJ	O
intervention	NN	O
strategies	NNS	O
that	WDT	O
may	MD	O
help	VB	O
the	DT	O
progression	NN	O
of	IN	O
this	DT	O
population	NN	O
into	IN	O
young	JJ	O
adulthood	NN	O
.	.	O

Fake	NNP	O
bad	JJ	O
test	NN	O
response	NN	O
bias	NN	O
effects	NNS	O
on	IN	O
the	DT	O
test	NN	O
of	IN	O
variables	NNS	O
of	IN	O
attention	NN	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
faking	VBG	O
bad	JJ	O
(	(	O
FB	NNP	O
)	)	O
on	IN	O
the	DT	O
Test	NNP	O
of	IN	O
Variables	NNP	O
of	IN	O
Attention	NNP	O
(	(	O
TOVA	NNP	O
)	)	O
using	VBG	O
subjects	NNS	O
randomly	RB	O
placed	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Subjects	NNS	O
in	IN	O
Group	NNP	O
1	CD	O
took	VBD	O
the	DT	O
TOVA	NNP	O
under	IN	O
normal	JJ	O
conditions	NNS	O
(	(	O
NC	NNP	O
)	)	O
first	RB	O
;	:	O
they	PRP	O
were	VBD	O
then	RB	O
requested	VBN	O
to	TO	O
subtly	RB	O
fake	VB	O
bad	JJ	O
.	.	O

Group	NNP	O
2	CD	O
subjects	NNS	O
took	VBD	O
the	DT	O
TOVA	NNP	O
under	IN	O
the	DT	O
same	JJ	O
fake	JJ	O
bad	JJ	O
instructions	NNS	O
first	RB	O
,	,	O
then	RB	O
took	VBD	O
the	DT	O
test	NN	O
under	IN	O
normal	JJ	O
conditions	NNS	O
the	DT	O
second	JJ	O
time	NN	O
.	.	O

An	DT	O
analysis	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
test	NN	O
order	NN	O
yielded	VBN	O
non-significant	JJ	O
differences	NNS	O
for	IN	O
basic	JJ	O
TOVA	NNP	O
variables	NNS	O
across	IN	O
all	DT	O
four	CD	O
quarters	NNS	O
,	,	O
both	DT	O
halves	NNS	O
and	CC	O
the	DT	O
total	JJ	O
score	NN	O
.	.	O

An	DT	O
analysis	NN	O
for	IN	O
group	NN	O
mean	NN	O
differences	NNS	O
between	IN	O
the	DT	O
NC	NNP	O
and	CC	O
the	DT	O
FB	NNP	O
instructions	NNS	O
yielded	VBD	O
significant	JJ	O
differences	NNS	O
across	IN	O
the	DT	O
basic	JJ	O
TOVA	NNP	O
variables	NNS	O
across	IN	O
the	DT	O
four	CD	O
quarters	NNS	O
,	,	O
two	CD	O
halves	NNS	O
and	CC	O
total	JJ	O
score	NN	O
.	.	O

The	DT	O
FB	NNP	O
group	NN	O
had	VBD	O
excessive	JJ	O
amounts	NNS	O
of	IN	O
omission	NN	O
and	CC	O
commission	NN	O
errors	NNS	O
,	,	O
a	DT	O
greater	JJR	O
response	NN	O
time	NN	O
mean	NN	O
(	(	O
i.e.	FW	O
,	,	O
slower	JJR	O
to	TO	O
respond	VB	O
)	)	O
and	CC	O
had	VBD	O
greater	JJR	O
variance	NN	O
around	IN	O
their	PRP$	O
mean	JJ	O
response	NN	O
time	NN	O
.	.	O

The	DT	O
study	NN	O
affirms	VBZ	O
that	IN	O
the	DT	O
professional	JJ	O
using	VBG	O
the	DT	O
TOVA	NNP	O
needs	VBZ	O
to	TO	O
carefully	RB	O
eliminate	VB	O
a	DT	O
fake	JJ	O
bad	JJ	O
test-taking	NN	O
bias	NN	O
when	WRB	O
subjects	NNS	O
produce	VBP	O
excessive	JJ	O
test	NN	O
results	NNS	O
.	.	O

Bridge	NNP	O
plate	NN	O
osteosynthesis	NN	O
using	VBG	O
dynamic	JJ	O
condylar	JJ	O
screw	NN	O
(	(	O
DCS	NNP	O
)	)	O
or	CC	O
retrograde	VBN	O
intramedullary	JJ	O
supracondylar	JJ	O
nail	NN	O
(	(	O
RIMSN	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
distal	JJ	Condition
femoral	JJ	Condition
fractures	NNS	Condition
:	:	O
comparison	NN	O
of	IN	O
two	CD	O
methods	NNS	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
treatment	NN	O
of	IN	O
distal	JJ	O
femoral	JJ	O
fractures	NNS	O
remains	VBZ	O
a	DT	O
significant	JJ	O
surgical	JJ	O
challenge	NN	O
.	.	O

With	IN	O
the	DT	O
rigid	JJ	O
fixation	NN	O
of	IN	O
the	DT	O
distal	JJ	O
femoral	JJ	O
fractures	NNS	O
,	,	O
bone	NN	O
grafting	NN	O
is	VBZ	O
frequently	RB	O
needed	VBN	O
.	.	O

Biological	JJ	O
osteosynthesis	NN	O
using	VBG	O
dynamic	JJ	O
condylar	JJ	O
screw	NN	O
(	(	O
DCS	NNP	O
)	)	O
and	CC	O
retrograde	JJ	O
intramedullary	JJ	O
supracondylar	NN	O
nail	NN	O
(	(	O
RIMSN	NNP	O
)	)	O
preserve	VBP	O
the	DT	O
blood	NN	O
supply	NN	O
and	CC	O
limit	NN	O
the	DT	O
need	NN	O
for	IN	O
bone	NN	O
grafting	NN	O
.	.	O

METHODS	NNP	O
From	IN	O
September	NNP	O
2002	CD	O
to	TO	O
December	NNP	O
2004	CD	O
,	,	O
68	CD	SampleSize
closed	VBD	O
fractures	NNS	O
of	IN	O
the	DT	O
distal	JJ	O
femur	NN	O
were	VBD	O
treated	VBN	O
by	IN	O
bridge	NN	O
plate	NN	O
osteosynthesis	NN	O
using	VBG	O
DCS	NNP	O
in	IN	O
31	CD	SampleSize
and	CC	O
RIMSN	NNP	O
in	IN	O
37	CD	SampleSize
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
randomly	RB	O
and	CC	O
followed	VBD	O
for	IN	O
24-36	JJ	O
months	NNS	O
(	(	O
average	JJ	O
:	:	O
30	CD	O
months	NNS	O
)	)	O
.	.	O

RESULTS	VBN	O
With	IN	O
respect	NN	O
to	TO	O
operation	NN	O
time	NN	O
,	,	O
the	DT	O
DCS	NNP	O
group	NN	O
presented	VBD	O
significantly	RB	O
better	JJR	O
results	NNS	O
than	IN	O
the	DT	O
RIMSN	NNP	O
group	NN	O
(	(	O
p=0.000	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
blood	NN	O
loss	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
the	DT	O
DCS	NNP	O
group	NN	O
(	(	O
p=0.000	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
cumulative	JJ	O
rate	NN	O
of	IN	O
union	NN	O
(	(	O
p=0.855	NN	O
)	)	O
,	,	O
range	NN	O
of	IN	O
motion	NN	O
of	IN	O
the	DT	O
knee	NN	O
(	(	O
p=0.727	NN	O
)	)	O
,	,	O
overall	JJ	O
results	NNS	O
(	(	O
p=0.925	NN	O
)	)	O
and	CC	O
complications	NNS	O
(	(	O
p=0.927	NN	O
)	)	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
No	NNP	O
implant	NN	O
or	CC	O
surgical	JJ	O
technique	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
any	DT	O
other	JJ	O
under	IN	O
all	DT	O
circumstances	NNS	O
for	IN	O
distal	JJ	O
femoral	JJ	O
fracture	NN	O
.	.	O

RIMSN	NNP	O
is	VBZ	O
standard	JJ	O
care	NN	O
,	,	O
yet	RB	O
the	DT	O
biological	JJ	O
osteosynthesis	NN	O
using	VBG	O
DCS	NNP	O
is	VBZ	O
a	DT	O
very	RB	O
good	JJ	O
alternative	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
distal	JJ	O
femoral	JJ	O
fractures	NNS	O
.	.	O

Inhibition	NN	O
of	IN	O
histamine-induced	JJ	O
skin	NN	O
wheal	NN	O
and	CC	O
flare	NN	O
after	IN	O
5	CD	O
days	NNS	O
of	IN	O
mizolastine	NN	O
.	.	O

Mizolastine	NNP	O
is	VBZ	O
a	DT	O
new	JJ	O
,	,	O
nonsedating	JJ	O
antihistamine	NN	O
providing	VBG	O
satisfactory	JJ	O
symptomatic	JJ	O
relief	NN	O
in	IN	O
allergic	JJ	Condition
rhinitis	NN	Condition
and	CC	O
urticaria	NN	Condition
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
use	VB	O
inhibition	NN	O
of	IN	O
wheal	NN	O
and	CC	O
flare	NN	O
formation	NN	O
after	IN	O
2-mu	JJ	O
g	NN	O
intradermal	JJ	O
histamine	NN	O
injections	NNS	O
as	IN	O
a	DT	O
measure	NN	O
of	IN	O
the	DT	O
antihistamine	JJ	O
effect	NN	O
of	IN	O
repeated	JJ	O
doses	NNS	O
of	IN	O
mizolastine	NN	O
.	.	O

Eight	CD	SampleSize
volunteers	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
four-arm	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

Three	CD	O
dose	JJ	O
levels	NNS	O
of	IN	O
once-daily	JJ	O
mizolastine	NN	O
(	(	O
5	CD	O
mg	NN	O
,	,	O
10	CD	O
mg	NN	O
,	,	O
and	CC	O
15	CD	O
mg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
placebo	NN	O
during	IN	O
5-day	JJ	O
dose	JJ	O
periods	NNS	O
.	.	O

Histamine	NN	O
tests	NNS	O
were	VBD	O
performed	VBN	O
before	IN	O
drug	NN	O
intake	NN	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
5	CD	O
,	,	O
and	CC	O
then	RB	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
14	CD	O
,	,	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
drug	NN	O
intake	NN	O
on	IN	O
day	NN	O
5	CD	O
.	.	O

All	DT	O
3	CD	O
doses	NNS	O
of	IN	O
mizolastine	NN	O
were	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
in	IN	O
suppressing	VBG	O
wheal	NN	O
and	CC	O
flare	NN	O
reactions	NNS	O
,	,	O
and	CC	O
the	DT	O
antihistamine	NN	O
activity	NN	O
was	VBD	O
highest	JJS	O
at	IN	O
both	DT	O
the	DT	O
10-	JJ	O
and	CC	O
15-mg	JJ	O
dose	NN	O
levels	NNS	O
.	.	O

The	DT	O
effect	NN	O
on	IN	O
the	DT	O
flare	JJ	O
reaction	NN	O
appeared	VBD	O
within	IN	O
1	CD	O
hour	NN	O
,	,	O
reached	VBD	O
a	DT	O
maximum	JJ	O
effect	NN	O
4	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
,	,	O
and	CC	O
persisted	VBD	O
for	IN	O
as	RB	O
long	RB	O
as	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
relative	JJ	O
changes	NNS	O
in	IN	O
wheal	NN	O
and	CC	O
flare	JJ	O
areas	NNS	O
were	VBD	O
correlated	VBN	O
with	IN	O
mizolastine	NN	O
trough	IN	O
plasma	NN	O
levels	NNS	O
on	IN	O
day	NN	O
5	CD	O
.	.	O

Safety	NN	O
was	VBD	O
satisfactory	JJ	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

This	DT	O
study	NN	O
confirms	VBZ	O
that	IN	O
mizolastine	NN	O
is	VBZ	O
a	DT	O
rapid	JJ	O
and	CC	O
potent	JJ	O
antihistamine	NN	O
;	:	O
and	CC	O
its	PRP$	O
long-lasting	JJ	O
effectiveness	NN	O
indicates	VBZ	O
that	IN	O
a	DT	O
once-daily	JJ	O
regimen	NN	O
is	VBZ	O
acceptable	JJ	O
for	IN	O
clinical	JJ	O
use	NN	O
.	.	O

Low-dose	JJ	O
intravenous	JJ	O
midazolam	NN	O
reduces	NNS	O
etomidate-induced	JJ	O
myoclonus	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
cardioversion	NN	O
.	.	O

BACKGROUND	NNP	O
Myoclonic	NNP	O
movements	NNS	O
are	VBP	O
a	DT	O
common	JJ	O
problem	NN	O
in	IN	O
unpremedicated	JJ	O
patients	NNS	O
during	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
with	IN	O
etomidate	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
,	,	O
40	CD	O
patients	NNS	O
(	(	O
ASA	NNP	O
physical	JJ	O
status	NN	O
III-IV	NNP	O
)	)	O
scheduled	VBD	O
for	IN	O
elective	JJ	O
cardioversion	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	RB	O
0.015	CD	O
mg/kg	NNS	O
midazolam	NN	O
or	CC	O
placebo	NN	O
90	CD	O
s	NN	O
before	IN	O
the	DT	O
injection	NN	O
of	IN	O
0.3	CD	O
mg/kg	JJ	O
etomidate	NN	O
.	.	O

Myoclonic	JJ	O
movements	NNS	O
and	CC	O
sedation	NN	O
were	VBD	O
recorded	VBN	O
on	IN	O
a	DT	O
scale	NN	O
between	IN	O
0	CD	O
and	CC	O
3	CD	O
.	.	O

Pulse	NNP	O
oximetry	NN	O
,	,	O
noninvasive	JJ	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
were	VBD	O
recorded	VBN	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

RESULTS	NNP	O
Two	CD	O
patients	NNS	O
(	(	O
10	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
midazolam	NN	O
group	NN	O
had	VBD	O
myoclonic	JJ	O
movements	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
etomidate	NN	O
,	,	O
whereas	IN	O
10	CD	O
of	IN	O
the	DT	O
20	CD	O
patients	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
receiving	VBG	O
placebo	NN	O
experienced	VBD	O
such	JJ	O
movements	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
.	.	O

No	UH	O
other	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
;	:	O
in	IN	O
particular	JJ	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
recovery	NN	O
5	CD	O
min	NN	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
etomidate	NN	O
.	.	O

CONCLUSIONS	NNP	O
IV	NNP	O
midazolam	VBD	O
0.015	CD	O
mg/kg	NN	O
administered	VBD	O
90	CD	O
s	NN	O
before	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
with	IN	O
etomidate	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
reducing	VBG	O
myoclonic	JJ	O
movements	NNS	O
and	CC	O
does	VBZ	O
not	RB	O
prolong	JJ	O
recovery	NN	O
in	IN	O
unpremedicated	JJ	O
patients	NNS	O
after	IN	O
short	JJ	O
procedures	NNS	O
.	.	O

The	DT	O
instruction	NN	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	VBG	O
affects	NNS	O
auditory	JJ	O
P3	NNP	O
and	CC	O
N1	NNP	O
amplitudes	NNS	O
.	.	O

Often	NNP	O
subjects	VBZ	O
have	VBP	O
been	VBN	O
instructed	VBN	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	VBG	O
lest	JJS	O
their	PRP$	O
evoked	JJ	O
EEG	NNP	O
potentials	NNS	O
should	MD	O
be	VB	O
distorted	VBN	O
.	.	O

We	PRP	O
studied	VBD	O
whether	IN	O
these	DT	O
very	RB	O
instructions	NNS	O
have	VBP	O
any	DT	O
impact	NN	O
on	IN	O
P3	NNP	O
amplitude	NN	O
.	.	O

Two	CD	O
tones	NNS	O
were	VBD	O
presented	VBN	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
and	CC	O
subjects	NNS	O
had	VBD	O
to	TO	O
count	VB	O
the	DT	O
high-pitched	JJ	O
tones	NNS	O
.	.	O

Half	PDT	O
the	DT	O
subjects	NNS	O
were	VBD	O
instructed	VBN	O
not	RB	Condition
to	TO	Condition
blink	VB	Condition
,	,	O
whereas	IN	O
this	DT	O
instruction	NN	O
was	VBD	O
omitted	VBN	O
for	IN	O
the	DT	O
other	JJ	O
subjects	NNS	O
.	.	O

Target	NNP	O
tones	NNS	O
evoked	VBD	O
larger	JJR	O
P3s	NNP	O
than	IN	O
non-targets	NNS	O
in	IN	O
the	DT	O
latter	JJ	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
former	JJ	O
,	,	O
in	IN	O
particular	JJ	O
not	RB	O
in	IN	O
those	DT	O
subjects	NNS	O
that	WDT	O
actually	RB	O
blinked	VBD	O
rarely	RB	O
.	.	O

The	DT	O
groups	NNS	O
also	RB	O
differed	VBN	O
in	IN	O
their	PRP$	O
N1	NNP	O
amplitudes	NNS	O
.	.	O

These	DT	O
findings	NNS	O
might	MD	O
be	VB	O
relevant	JJ	O
to	TO	O
P3	NNP	O
studies	NNS	O
working	VBG	O
with	IN	O
patients	NNS	O
and	CC	O
controls	NNS	O
:	:	O
the	DT	O
harder	NN	O
some	DT	O
frequently	RB	O
blinking	JJ	O
subjects	NNS	O
try	VBP	O
to	TO	O
refrain	VB	O
from	IN	O
blinking	NN	O
,	,	O
the	DT	O
smaller	JJR	O
might	MD	O
become	VB	O
their	PRP$	O
P3	NNP	O
amplitudes	NNS	O
.	.	O

Omitting	VBG	O
the	DT	O
instruction	NN	O
and	CC	O
using	VBG	O
off-line	JJ	O
blink	NN	O
subtraction	NN	O
procedures	NNS	O
seems	VBZ	O
a	DT	O
viable	JJ	O
alternative	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
actually	RB	O
motivated	VBN	O
by	IN	O
discrepant	JJ	O
findings	NNS	O
on	IN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
preceding	VBG	O
tone	NN	O
sequence	NN	O
on	IN	O
P3	NNP	O
.	.	O

These	DT	O
discrepancies	NNS	O
could	MD	O
be	VB	O
largely	RB	O
resolved	VBN	O
by	IN	O
the	DT	O
instructional	JJ	O
variable	NN	O
,	,	O
in	IN	O
conjunction	NN	O
with	IN	O
different	JJ	O
tone	NN	O
intensities	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
subjects	NNS	O
who	WP	O
are	VBP	O
discouraged	VBN	O
from	IN	O
blinking	VBG	O
try	NN	O
to	TO	O
protect	VB	O
themselves	PRP	O
against	IN	O
the	DT	O
arousing	JJ	O
effects	NNS	O
of	IN	O
stimuli	NN	O
.	.	O

Field	NNP	O
efficacy	NN	O
of	IN	O
an	DT	O
inactivated	JJ	O
bivalent	NN	O
influenza	NN	O
vaccine	NN	O
in	IN	O
a	DT	O
multi-site	JJ	O
swine	NN	O
production	NN	O
system	NN	O
during	IN	O
an	DT	O
outbreak	NN	O
of	IN	O
systemic	JJ	O
porcine	NN	O
circovirus	NN	O
associated	VBN	O
disease	NN	O
.	.	O

Swine	NNP	O
influenza	NN	O
(	(	O
SI	NNP	O
)	)	O
is	VBZ	O
a	DT	O
disease	NN	O
of	IN	O
significance	NN	O
for	IN	O
the	DT	O
swine	NN	O
industry	NN	O
,	,	O
and	CC	O
vaccination	NN	O
is	VBZ	O
often	RB	O
recommended	VBN	O
as	IN	O
a	DT	O
way	NN	O
to	TO	O
reduce	VB	O
its	PRP$	O
impact	NN	O
on	IN	O
production	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
SI	NNP	O
vaccines	NNS	O
is	VBZ	O
well	RB	O
established	VBN	O
under	IN	O
experimental	JJ	O
conditions	NNS	O
,	,	O
but	CC	O
information	NN	O
about	IN	O
field	NN	O
efficacy	NN	O
is	VBZ	O
scarce	JJ	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
commercial	JJ	O
inactivated	JJ	O
bivalent	NN	O
(	(	O
H1N1/H3N2	NNP	O
)	)	O
vaccine	NN	O
under	IN	O
conditions	NNS	O
of	IN	O
natural	JJ	O
exposure	NN	O
to	TO	O
a	DT	O
field	NN	O
SI	NNP	O
variant	NN	O
.	.	O

To	TO	O
accomplish	VB	O
our	PRP$	O
goal	NN	O
we	PRP	O
used	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
blinded	VBD	O
,	,	O
field	NN	O
trial	NN	O
in	IN	O
2	CD	SampleSize
cohorts	NNS	SampleSize
of	IN	O
finisher	NN	Age
pigs	NNS	Age
in	IN	O
a	DT	O
multi-site	JJ	O
swine	NN	O
production	NN	O
system	NN	O
located	VBN	O
in	IN	O
southern	JJ	O
Ontario	NNP	O
.	.	O

During	IN	O
the	DT	O
trial	NN	O
,	,	O
this	DT	O
herd	NN	O
experienced	VBD	O
an	DT	O
outbreak	NN	O
of	IN	O
porcine	NN	O
circovirus	NN	O
associated	VBN	O
disease	NN	O
(	(	O
PCVAD	NNP	O
)	)	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
SI	NNP	O
vaccine	NN	O
was	VBD	O
assessed	VBN	O
through	IN	O
its	PRP$	O
effect	NN	O
on	IN	O
average	JJ	O
daily	JJ	O
weight	NN	O
gain	NN	O
,	,	O
and	CC	O
serological	JJ	O
responses	NNS	O
to	TO	O
SI	VB	O
over	IN	O
time	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
vaccination	NN	O
on	IN	O
pig	NN	O
growth	NN	O
was	VBD	O
different	JJ	O
in	IN	O
the	DT	O
2	CD	O
cohorts	NNS	O
.	.	O

Weight	NNP	O
gain	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
vaccinated	JJ	O
pigs	NNS	O
than	IN	O
in	IN	O
control	NN	O
pigs	NNS	O
in	IN	O
Cohort	NNP	O
1	CD	O
,	,	O
but	CC	O
was	VBD	O
numerically	RB	O
higher	JJR	O
for	IN	O
control	NN	O
pigs	NNS	O
than	IN	O
for	IN	O
vaccinated	JJ	O
pigs	NNS	O
in	IN	O
Cohort	NNP	O
2	CD	O
.	.	O

Vaccination	NN	O
against	IN	O
swine	NN	O
influenza	NN	O
,	,	O
in	IN	O
a	DT	O
herd	NN	O
experiencing	VBG	O
an	DT	O
outbreak	NN	O
of	IN	O
PCVAD	NNP	O
,	,	O
was	VBD	O
of	IN	O
questionable	JJ	O
value	NN	O
.	.	O

Five-year	JJ	O
outcome	NN	O
of	IN	O
surgical	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
headaches	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
surgical	JJ	O
deactivation	NN	O
of	IN	O
migraine	NN	O
headache	NN	O
trigger	NN	O
sites	NNS	O
.	.	O

METHODS	NNP	O
One	CD	SampleSize
hundred	VBD	SampleSize
twenty-five	JJ	SampleSize
volunteers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
treatment	NN	SampleSize
(	(	SampleSize
n	JJ	SampleSize
=	NNP	SampleSize
100	CD	SampleSize
)	)	SampleSize
or	CC	O
control	VB	SampleSize
group	NN	SampleSize
(	(	SampleSize
n	JJ	SampleSize
=	NNP	SampleSize
25	CD	SampleSize
)	)	SampleSize
after	IN	O
examination	NN	O
by	IN	O
the	DT	O
team	NN	O
neurologist	NN	O
to	TO	O
ensure	VB	O
a	DT	O
diagnosis	NN	O
of	IN	O
migraine	NN	Condition
headache	NN	Condition
.	.	O

Patients	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
complete	VB	O
the	DT	O
Medical	NNP	O
Outcomes	NNP	O
Study	NNP	O
36-Item	JJ	O
Short	NNP	O
Form	NNP	O
Health	NNP	O
Survey	NNP	O
,	,	O
Migraine-Specific	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
,	,	O
and	CC	O
Migraine	NNP	O
Disability	NNP	O
Assessment	NNP	O
questionnaires	VBZ	O
before	IN	O
treatment	NN	O
and	CC	O
at	IN	O
12-	JJ	O
and	CC	O
60-month	JJ	O
postoperative	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
received	VBD	O
botulinum	RB	O
toxin	NN	O
to	TO	O
confirm	VB	O
the	DT	O
trigger	NN	O
sites	VBZ	O
;	:	O
controls	NNS	O
received	VBD	O
saline	JJ	O
injections	NNS	O
.	.	O

Treated	VBN	O
patients	NNS	O
underwent	JJ	O
surgical	JJ	O
deactivation	NN	O
of	IN	O
trigger	NN	O
site	NN	O
(	(	O
s	JJ	O
)	)	O
.	.	O

Results	NNS	O
were	VBD	O
analyzed	VBN	O
at	IN	O
1	CD	O
year	NN	O
(	(	O
previously	RB	O
published	VBN	O
)	)	O
and	CC	O
5	CD	O
years	NNS	O
postoperatively	RB	O
(	(	O
the	DT	O
subject	NN	O
of	IN	O
this	DT	O
report	NN	O
)	)	O
.	.	O

RESULTS	JJ	O
Eighty-nine	NNP	O
of	IN	O
100	CD	SampleSize
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
underwent	JJ	O
surgery	NN	O
,	,	O
and	CC	O
79	CD	O
were	VBD	O
followed	VBN	O
for	IN	O
5	CD	O
years	NNS	O
.	.	O

Ten	CD	O
patients	NNS	O
underwent	JJ	O
deactivation	NN	O
of	IN	O
additional	JJ	O
(	(	O
different	JJ	O
)	)	O
trigger	NN	O
sites	NNS	O
during	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
and	CC	O
were	VBD	O
not	RB	O
included	VBN	O
in	IN	O
the	DT	O
data	NN	O
analysis	NN	O
.	.	O

The	DT	O
final	JJ	O
outcome	NN	O
with	IN	O
or	CC	O
without	IN	O
inclusion	NN	O
of	IN	O
these	DT	O
10	CD	O
patients	NNS	O
was	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

Sixty-one	NN	O
(	(	O
88	CD	O
percent	NN	O
)	)	O
of	IN	O
69	CD	O
patients	NNS	O
have	VBP	O
experienced	VBN	O
a	DT	O
positive	JJ	O
response	NN	O
to	TO	O
the	DT	O
surgery	NN	O
after	IN	O
5	CD	O
years	NNS	O
.	.	O

Twenty	NNP	O
(	(	O
29	CD	O
percent	NN	O
)	)	O
reported	VBD	O
complete	JJ	O
elimination	NN	O
of	IN	O
migraine	NN	O
headache	NN	O
,	,	O
41	CD	O
(	(	O
59	CD	O
percent	NN	O
)	)	O
noticed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
,	,	O
and	CC	O
eight	CD	O
(	(	O
12	CD	O
percent	NN	O
)	)	O
experienced	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
.	.	O

When	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
baseline	NN	O
values	NNS	O
,	,	O
all	DT	O
measured	VBD	O
variables	NNS	O
at	IN	O
60	CD	O
months	NNS	O
improved	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Based	VBD	O
on	IN	O
the	DT	O
5-year	JJ	O
follow-up	JJ	O
data	NNS	O
,	,	O
there	EX	O
is	VBZ	O
strong	JJ	O
evidence	NN	O
that	IN	O
surgical	JJ	O
manipulation	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
migraine	JJ	O
trigger	NN	O
sites	NNS	O
can	MD	O
successfully	RB	O
eliminate	VB	O
or	CC	O
reduce	VB	O
the	DT	O
frequency	NN	O
,	,	O
duration	NN	O
,	,	O
and	CC	O
intensity	NN	O
of	IN	O
migraine	NN	O
headache	NN	O
in	IN	O
a	DT	O
lasting	JJ	O
manner	NN	O
.	.	O

[	IN	O
The	DT	O
effects	NNS	O
of	IN	O
antidepressant	JJ	O
treatment	NN	O
on	IN	O
efficacy	NN	O
of	IN	O
antihypertensive	JJ	O
therapy	NN	O
in	IN	O
elderly	JJ	Age
hypertension	NN	Condition
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
the	DT	O
effect	NN	O
of	IN	O
antidepressant	JJ	O
treatment	NN	O
on	IN	O
antihypertensive	JJ	O
therapy	NN	O
of	IN	O
senile	JJ	Condition
hypertension	NN	Condition
.	.	O

METHODS	NNP	O
138	CD	SampleSize
cases	NNS	O
of	IN	O
senile	JJ	Condition
hypertension	NN	Condition
complicating	VBG	O
with	IN	O
depression	NN	Condition
were	VBD	O
studied	VBN	O
.	.	O

103	CD	SampleSize
senile	JJ	Condition
hypertensive	JJ	Condition
patients	NNS	Condition
without	IN	Condition
depression	NN	Condition
in	IN	O
the	DT	O
same	JJ	O
period	NN	O
served	VBD	O
as	IN	O
controls	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
as	IN	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
for	IN	O
study	NN	O
.	.	O

12.5	CD	O
mg/d	JJ	O
hydrochlorothiazide	NN	O
and	CC	O
30	CD	O
mg/d	JJ	O
release-controlling	JJ	O
tablets	NNS	O
of	IN	O
nifedipine	NN	O
were	VBD	O
orally	RB	O
administrated	VBN	O
as	IN	O
basic	JJ	O
antihypertensive	JJ	O
medication	NN	O
each	DT	O
group	NN	O
.	.	O

Besides	NNP	O
,	,	O
20	CD	O
mg/d	NN	O
fluoxetine	NN	O
was	VBD	O
additionally	RB	O
given	VBN	O
to	TO	O
groups	NNS	O
A	NNP	O
and	CC	O
one	CD	O
tablet	NN	O
of	IN	O
almitrine	JJ	O
l/d	NN	O
and	CC	O
20	CD	O
mg	NN	O
oryzanol	NN	O
3/d	CD	O
were	VBD	O
given	VBN	O
to	TO	O
group	NN	O
B	NNP	O
.	.	O

The	DT	O
treatment	NN	O
lasted	VBD	O
12	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
comparison	NN	O
with	IN	O
pre-treatment	NN	O
,	,	O
the	DT	O
blood	NN	O
pressure	NN	O
at	IN	O
base	NN	O
line	NN	O
in	IN	O
sitting	VBG	O
position	NN	O
and	CC	O
the	DT	O
average	JJ	O
circadian	JJ	O
SBP	NNP	O
and	CC	O
DBP	NNP	O
monitored	VBD	O
with	IN	O
24-hour	JJ	O
ambulatory	NN	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
(	(	O
ABPM	NNP	O
)	)	O
was	VBD	O
remarkably	RB	O
decreased	VBN	O
in	IN	O
group	NN	O
A	NNP	O
with	IN	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

These	DT	O
blood	NN	O
pressure	NN	O
parameters	NNS	O
in	IN	O
group	NN	O
B	NNP	O
were	VBD	O
also	RB	O
decreased	VBN	O
as	IN	O
compared	VBN	O
ith	IN	O
the	DT	O
pretreatment	JJ	O
level	NN	O
brt	NN	O
with	IN	O
less	JJR	O
statistical	JJ	O
significance	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

It	PRP	O
was	VBD	O
also	RB	O
noted	VBN	O
tha	NN	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
antidepressant	JJ	O
fluoxetine	NN	O
,	,	O
the	DT	O
manifestations	NNS	O
of	IN	O
depression	NN	O
ere	RB	O
alleviated	VBN	O
as	IN	O
shown	VBN	O
by	IN	O
Hamilton	NNP	O
depression	NN	O
(	(	O
HAMD	NNP	O
)	)	O
scale	NN	O
.	.	O

untoward	JJ	O
reactions	NNS	O
such	JJ	O
as	IN	O
nausea	NN	O
,	,	O
perspiration	NN	O
and	CC	O
skin	NN	O
rash	NN	O
were	VBD	O
noted	VBN	O
in	IN	O
a	DT	O
few	JJ	O
patients	NNS	O
,	,	O
but	CC	O
none	NN	O
withdrew	NN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
Antidepressant	NNP	O
and	CC	O
antianxiety	NN	O
treatment	NN	O
is	VBZ	O
of	IN	O
benefit	NN	O
to	TO	O
the	DT	O
antihypertensive	JJ	O
therapy	NN	O
in	IN	O
senile	JJ	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
complications	NNS	O
of	IN	O
depression	NN	O
and/or	NN	O
anxiety	NN	O
neurosis	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
routine	JJ	O
administration	NN	O
of	IN	O
antidepressants	NNS	O
and	CC	O
antianxiety	NN	O
drugs	NNS	O
should	MD	O
be	VB	O
carried	VBN	O
out	RP	O
in	IN	O
senile	JJ	Condition
hypertensive	JJ	Condition
patients	NNS	Condition
complicating	VBG	O
with	IN	O
depression	NN	O
or	CC	O
anxiety	NN	O
.	.	O

A	DT	O
randomized	VBN	O
intervention	NN	O
to	TO	O
improve	VB	O
ongoing	VBG	O
participation	NN	O
in	IN	O
mammography	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
interventions	NNS	O
intended	VBN	O
to	TO	O
increase	VB	O
rates	NNS	O
of	IN	O
regular	JJ	O
breast	NN	O
cancer	NN	O
screening	NN	O
,	,	O
according	VBG	O
to	TO	O
recommended	VBN	O
guidelines	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
2	CD	O
outreach	NN	O
interventions	NNS	O
(	(	O
a	DT	O
mail	NN	O
reminder	NN	O
and	CC	O
a	DT	O
telephone	NN	O
reminder	NN	O
plus	CC	O
appointment	JJ	O
scheduling	NN	O
)	)	O
compared	VBN	O
with	IN	O
a	DT	O
routine	JJ	O
publicity	NN	O
campaign	NN	O
to	TO	O
encourage	VB	O
continued	JJ	O
participation	NN	O
in	IN	O
mammography	NN	O
screening	NN	O
.	.	O

PARTICIPANTS	NNP	O
AND	CC	O
METHODS	NNP	O
Participants	NNS	O
were	VBD	O
1908	CD	O
women	NNS	O
aged	VBD	O
50	CD	O
to	TO	O
75	CD	O
years	NNS	O
continuously	RB	O
enrolled	VBD	O
in	IN	O
a	DT	O
large	JJ	O
group-model	JJ	O
HMO	NNP	O
during	IN	O
the	DT	O
study	NN	O
who	WP	O
underwent	VBD	O
a	DT	O
bilateral	JJ	O
mammogram	NN	O
during	IN	O
the	DT	O
first	JJ	O
quarter	NN	O
of	IN	O
1994	CD	O
and	CC	O
no	DT	O
subsequent	JJ	O
mammogram	NN	O
during	IN	O
the	DT	O
next	JJ	O
18	CD	O
to	TO	O
21	CD	O
months	NNS	O
.	.	O

Data	NNS	O
were	VBD	O
obtained	VBN	O
from	IN	O
health	NN	O
plan	NN	O
administrative	JJ	O
data	NNS	O
files	NNS	O
supplemented	VBN	O
by	IN	O
medical	JJ	O
chart	NN	O
review	NN	O
.	.	O

Women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
(	(	O
1	CD	O
)	)	O
a	DT	O
mail	NN	O
reminder	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
a	DT	O
telephone	NN	O
reminder	NN	O
,	,	O
or	CC	O
(	(	O
3	CD	O
)	)	O
routine	JJ	O
publicity	NN	O
on	IN	O
mammography	NN	O
for	IN	O
all	DT	O
women	NNS	O
.	.	O

The	DT	O
outcome	NN	O
measure	NN	O
was	VBD	O
a	DT	O
mammogram	NN	O
received	VBN	O
after	IN	O
the	DT	O
intervention	NN	O
period	NN	O
and	CC	O
within	IN	O
2	CD	O
years	NNS	O
of	IN	O
the	DT	O
initial	JJ	O
mammogram	NN	O
date	NN	O
.	.	O

RESULTS	NNP	O
Bivariate	NNP	O
and	CC	O
multivariate	VB	O
statistical	JJ	O
analyses	NNS	O
showed	VBD	O
that	IN	O
participation	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
for	IN	O
women	NNS	O
contacted	VBN	O
by	IN	O
telephone	NN	O
than	IN	O
through	IN	O
routine	JJ	O
publicity	NN	O
.	.	O

Mail	NN	O
reminders	NNS	O
were	VBD	O
no	DT	O
more	RBR	O
effective	JJ	O
than	IN	O
a	DT	O
routine	JJ	O
publicity	NN	O
campaign	NN	O
.	.	O

Primary	NNP	O
care	NN	O
physician	NN	O
and	CC	O
gynecologist	JJ	O
visits	NNS	O
increased	VBD	O
the	DT	O
likelihood	NN	O
of	IN	O
a	DT	O
subsequent	JJ	O
mammogram	NN	O
for	IN	O
women	NNS	O
in	IN	O
all	DT	O
intervention	NN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Telephone	NNP	O
contact	NN	O
by	IN	O
regular	JJ	O
health	NN	O
plan	NN	O
staff	NN	O
was	VBD	O
more	RBR	O
successful	JJ	O
than	IN	O
publicity	NN	O
in	IN	O
encouraging	VBG	O
continued	JJ	O
participation	NN	O
in	IN	O
mammography	NN	O
screening	NN	O
in	IN	O
women	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
group-model	JJ	O
managed	NN	O
health	NN	O
care	NN	O
plan	NN	O
.	.	O

Because	IN	O
mailings	NNS	O
did	VBD	O
not	RB	O
influence	VB	O
participation	NN	O
in	IN	O
mammography	NN	O
screening	NN	O
,	,	O
health	NN	O
plans	NNS	O
should	MD	O
be	VB	O
cautious	JJ	O
about	IN	O
investing	VBG	O
in	IN	O
member	NN	O
mailings	NNS	O
without	IN	O
first	JJ	O
evaluating	VBG	O
their	PRP$	O
effectiveness	NN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
existing	VBG	O
outreach	NN	O
efforts	NNS	O
.	.	O

Absolute	NNP	O
bioavailability	NN	O
of	IN	O
a	DT	O
new	JJ	O
high	JJ	O
dose	NN	O
methylprednisolone	NN	O
tablet	NN	O
formulation	NN	O
.	.	O

This	DT	O
was	VBD	O
a	DT	O
single-blind	JJ	O
,	,	O
single-dose	JJ	O
,	,	O
randomized	VBN	O
crossover	NN	O
study	NN	O
to	TO	O
determine	VB	O
the	DT	O
absolute	JJ	O
bioavailability	NN	O
of	IN	O
Medrol	NNP	O
,	,	O
a	DT	O
new	JJ	O
high	JJ	O
dose	NN	O
(	(	O
100	CD	O
mg	NN	O
)	)	O
methylprednisolone	NN	O
tablet	NN	O
product	NN	O
,	,	O
by	IN	O
comparing	VBG	O
it	PRP	O
with	IN	O
100	CD	O
mg	NNS	O
methylprednisolone	NN	O
from	IN	O
an	DT	O
intravenous	JJ	O
formulation	NN	O
,	,	O
Solu-Medrol	NNP	O
.	.	O

Fourteen	NNP	SampleSize
healthy	JJ	O
,	,	O
non-smoking	JJ	O
,	,	O
Caucasian	JJ	O
male	NN	Sex
volunteers	NNS	O
took	VBD	O
part	NN	O
.	.	O

On	IN	O
treatment	NN	O
days	NNS	O
volunteers	NNS	O
remained	VBD	O
recumbent	NN	O
for	IN	O
4	CD	O
hours	NNS	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
with	IN	O
food	NN	O
and	CC	O
fluid	NN	O
intake	VBP	O
standardized	VBN	O
over	IN	O
this	DT	O
period	NN	O
.	.	O

Serial	JJ	O
blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
over	IN	O
a	DT	O
14-hour	JJ	O
period	NN	O
after	IN	O
drug	NN	O
administration	NN	O
.	.	O

Plasma	NNP	O
methylprednisolone	NN	O
concentrations	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
high	JJ	O
performance	NN	O
liquid	NN	O
chromatography	NN	O
.	.	O

The	DT	O
geometric	JJ	O
means	NNS	O
of	IN	O
AUCi.v	NNP	O
.	.	O

and	CC	O
AUCtablet	NNP	O
were	VBD	O
4,049	CD	O
and	CC	O
3,334	CD	O
ng.h/ml	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
absolute	JJ	O
bioavailability	NN	O
of	IN	O
the	DT	O
tablet	NN	O
product	NN	O
was	VBD	O
82	CD	O
%	NN	O
,	,	O
which	WDT	O
is	VBZ	O
in	IN	O
agreement	NN	O
with	IN	O
published	VBN	O
data	NNS	O
for	IN	O
other	JJ	O
oral	JJ	O
dosage	NN	O
forms	NNS	O
of	IN	O
methylprednisolone	NN	O
.	.	O

Volunteers	NNS	O
displayed	VBD	O
the	DT	O
expected	VBN	O
rise	NN	O
in	IN	O
peripheral	JJ	O
blood	NN	O
neutrophil	NN	O
count	NN	O
,	,	O
but	CC	O
no	DT	O
other	JJ	O
clinically	RB	O
relevant	JJ	O
changes	NNS	O
in	IN	O
hematology	NN	O
or	CC	O
clinical	JJ	O
chemistry	NN	O
were	VBD	O
observed	VBN	O
.	.	O

No	DT	O
adverse	JJ	O
drug	NN	O
reactions	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
tablet	NN	O
product	NN	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
substitute	NN	O
for	IN	O
parenteral	JJ	O
methylprednisolone	NN	O
in	IN	O
situations	NNS	O
requiring	VBG	O
high-dose	JJ	O
therapy	NN	O
.	.	O

Clinical	JJ	O
outcome	NN	O
of	IN	O
postoperative	JJ	O
adjuvant	JJ	O
immunochemotherapy	NN	O
with	IN	O
sizofiran	NN	O
for	IN	O
patients	NNS	O
with	IN	O
resectable	JJ	O
gastric	JJ	O
cancer	NN	O
:	:	O
a	DT	O
randomised	VBN	O
controlled	VBN	O
study	NN	O
.	.	O

Adjuvant	NNP	O
immunochemotherapy	NN	O
using	VBG	O
the	DT	O
antitumour	JJ	O
polysaccharide	NN	O
sizofiran	NN	O
(	(	O
SPG	NNP	O
)	)	O
,	,	O
an	DT	O
extract	NN	O
from	IN	O
the	DT	O
culture	NN	O
broth	NN	O
of	IN	O
Schizophyllum	NNP	O
commune	NN	O
Fries	NNS	O
,	,	O
was	VBD	O
prescribed	VBN	O
randomly	RB	O
for	IN	O
386	CD	O
Japanese	JJ	O
patients	NNS	O
with	IN	O
resectable	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

Although	IN	O
the	DT	O
overall	JJ	O
survival	NN	O
probability	NN	O
for	IN	O
5	CD	O
years	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
SPG	NNP	O
and	CC	O
control	NN	O
groups	NNS	O
,	,	O
in	IN	O
264	CD	O
patients	NNS	O
with	IN	O
curatively	RB	O
resected	VBN	O
cancer	NN	O
,	,	O
the	DT	O
probability	NN	O
to	TO	O
5	CD	O
year	NN	O
survival	NN	O
and	CC	O
to	TO	O
recurrence	VB	O
in	IN	O
the	DT	O
sizofiran-administered	JJ	O
patients	NNS	O
was	VBD	O
better	JJR	O
than	IN	O
in	IN	O
the	DT	O
controls	NNS	O
.	.	O

In	IN	O
the	DT	O
multivariate	NN	O
analysis	NN	O
,	,	O
four	CD	O
of	IN	O
six	CD	O
prognostic	JJ	O
factors	NNS	O
correlated	VBD	O
with	IN	O
the	DT	O
prognosis	NN	O
of	IN	O
the	DT	O
264	CD	O
patients	NNS	O
who	WP	O
underwent	VBP	O
curative	JJ	O
surgery	NN	O
,	,	O
that	WDT	O
is	VBZ	O
,	,	O
nodal	JJ	O
involvement	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
21.426	CD	O
,	,	O
P	NNP	O
=	NNP	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
,	,	O
age	NN	O
distribution	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
9.262	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.010	CD	O
)	)	O
,	,	O
sizofiran	JJ	O
administration	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
6.507	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
,	,	O
and	CC	O
primary	JJ	O
tumour	NN	O
size	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
9.345	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
patients	NNS	O
with	IN	O
a	DT	O
curatively	RB	O
resected	VBN	O
gastric	JJ	O
cancer	NN	O
had	VBD	O
a	DT	O
better	JJR	O
prognosis	NN	O
when	WRB	O
sizofiran	NN	O
was	VBD	O
prescribed	VBN	O
in	IN	O
combination	NN	O
with	IN	O
antitumour	JJ	O
drugs	NNS	O
.	.	O

Phase	NNP	O
II	NNP	O
trial	NN	O
of	IN	O
nab-paclitaxel	JJ	O
compared	VBN	O
with	IN	O
docetaxel	NN	O
as	IN	O
first-line	JJ	O
chemotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
:	:	O
final	JJ	O
analysis	NN	O
of	IN	O
overall	JJ	O
survival	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
in	IN	O
first-line	JJ	O
MBC	NNP	O
demonstrated	VBD	O
superior	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
weekly	JJ	O
nab-paclitaxel	NNS	O
compared	VBN	O
with	IN	O
docetaxel	NN	O
.	.	O

Final	NNP	O
survival	NN	O
analyses	NNS	O
and	CC	O
updated	JJ	O
safety	NN	O
results	NNS	O
are	VBP	O
reported	VBN	O
.	.	O

PATIENTS	NNS	O
AND	CC	O
METHODS	NNP	O
Three	NNP	SampleSize
hundred	VBD	SampleSize
two	CD	SampleSize
patients	NNS	O
with	IN	Condition
no	DT	Condition
previous	JJ	Condition
chemotherapy	NN	Condition
for	IN	O
MBC	NNP	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
nab-paclitaxel	JJ	O
300	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
q3w	NN	O
,	,	O
nab-paclitaxel	JJ	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
or	CC	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
the	DT	O
first	JJ	O
3	CD	O
of	IN	O
4	CD	O
weeks	NNS	O
(	(	O
qw	VB	O
3/4	CD	O
)	)	O
,	,	O
or	CC	O
docetaxel	VB	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
q3w	NN	O
.	.	O

The	DT	O
trial	NN	O
was	VBD	O
powered	VBN	O
for	IN	O
analyses	NNS	O
of	IN	O
antitumor	NN	O
activity	NN	O
and	CC	O
safety	NN	O
.	.	O

RESULTS	NNP	O
Treatment	NNP	O
with	IN	O
nab-paclitaxel	JJ	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
qw	NN	O
3/4	CD	O
resulted	VBD	O
in	IN	O
a	DT	O
median	JJ	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
of	IN	O
33.8	CD	O
months	NNS	O
compared	VBN	O
with	IN	O
22.2	CD	O
,	,	O
27.7	CD	O
,	,	O
and	CC	O
26.6	CD	O
months	NNS	O
for	IN	O
nab-paclitaxel	JJ	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
qw	NN	O
3/4	CD	O
,	,	O
nab-paclitaxel	JJ	O
300	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
q3w	NN	O
,	,	O
and	CC	O
docetaxel	NN	O
,	,	O
respectively	RB	O
(	(	O
overall	JJ	O
P	NNP	O
=	NNP	O
.047	NNP	O
)	)	O
.	.	O

Patients	NNPS	O
receiving	VBG	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
nab-paclitaxel	NN	O
had	VBD	O
prolonged	VBN	O
median	JJ	O
OS	NNP	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
nab-paclitaxel	JJ	O
arm	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.575	CD	O
;	:	O
P	NNP	O
=	NNP	O
.008	NNP	O
)	)	O
.	.	O

A	DT	O
trend	NN	O
toward	IN	O
a	DT	O
longer	JJR	O
OS	NNP	O
was	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
nab-paclitaxel	JJ	O
arm	NN	O
versus	NN	O
docetaxel	NN	O
arm	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.688	CD	O
)	)	O
.	.	O

Grade	$	O
3	CD	O
or	CC	O
4	CD	O
fatigue	NN	O
,	,	O
neutropenia	NN	O
,	,	O
and	CC	O
febrile	JJ	O
neutropenia	NN	O
were	VBD	O
less	JJR	O
frequent	JJ	O
in	IN	O
all	DT	O
nab-paclitaxel	JJ	O
arms	NNS	O
compared	VBN	O
with	IN	O
docetaxel	NN	O
.	.	O

CONCLUSIONS	NNP	O
Consistent	NNP	O
with	IN	O
previously	RB	O
published	VBN	O
efficacy	NN	O
results	NNS	O
,	,	O
these	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
qw	NN	O
3/4	CD	O
may	MD	O
represent	VB	O
the	DT	O
most	RBS	O
clinically	RB	O
efficacious	JJ	O
nab-paclitaxel	JJ	O
dosing	VBG	O
regimen	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
no	DT	O
previous	JJ	O
chemotherapy	NN	O
for	IN	O
MBC	NNP	O
.	.	O

A	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
confirming	VBG	O
these	DT	O
results	NNS	O
would	MD	O
be	VB	O
necessary	JJ	O
and	CC	O
prudent	JJ	O
before	RB	O
widespread	JJ	O
adoption	NN	O
of	IN	O
the	DT	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
dose	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

In-season	JJ	O
effect	NN	O
of	IN	O
short-term	JJ	O
sprint	NN	O
and	CC	O
power	NN	O
training	NN	O
programs	NNS	O
on	IN	O
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
2	CD	O
in-season	JJ	O
short-term	JJ	O
sprint	NN	O
and	CC	O
power	NN	O
training	NN	O
protocols	NNS	O
on	IN	O
vertical	JJ	O
countermovement	NN	O
jump	NN	O
height	NN	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
arms	NNS	O
)	)	O
,	,	O
sprint	NN	O
(	(	O
Sprint-15m	NNP	O
)	)	O
speed	NN	O
,	,	O
and	CC	O
agility	NN	O
(	(	O
Agility-15m	NNP	O
)	)	O
speed	NN	O
in	IN	O
male	JJ	Sex
elite	JJ	O
junior	JJ	O
soccer	NN	O
players	NNS	O
.	.	O

Twenty	NNP	O
highly	RB	O
trained	VBD	O
soccer	NN	O
players	NNS	O
(	(	O
age	NN	O
18.3	CD	Age
+/-	JJ	Age
0.6	CD	Age
years	NNS	Age
,	,	O
height	VBD	O
177	CD	O
+/-	JJ	O
4	CD	O
cm	NN	O
,	,	O
body	NN	O
mass	VBD	O
71.4	CD	O
+/-	JJ	O
6.9	CD	O
kg	NN	O
,	,	O
sum	NN	O
skinfolds	NNS	O
48.1	CD	O
+/-	JJ	O
11.4	CD	O
mm	NN	O
)	)	O
,	,	O
members	NNS	O
of	IN	O
a	DT	O
professional	JJ	O
soccer	NN	O
academy	NN	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
a	DT	O
CONTRAST	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
SPRINT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
group	NN	O
.	.	O

The	DT	O
training	NN	O
intervention	NN	O
consisted	VBD	O
of	IN	O
6	CD	O
supervised	JJ	O
training	NN	O
sessions	NNS	O
over	IN	O
7	CD	O
weeks	NNS	O
,	,	O
targeting	VBG	O
the	DT	O
improvement	NN	O
of	IN	O
the	DT	O
players	NNS	O
'	POS	O
speed	NN	O
and	CC	O
power	NN	O
.	.	O

CONTRAST	NNP	O
protocol	NN	O
consisted	VBD	O
of	IN	O
alternating	VBG	O
heavy-light	JJ	O
resistance	NN	O
(	(	O
15-50	CD	O
%	NN	O
body	NN	O
mass	NN	O
)	)	O
with	IN	O
soccer-specific	JJ	O
drills	NNS	O
(	(	O
small-sided	JJ	O
games	NNS	O
or	CC	O
technical	JJ	O
skills	NNS	O
)	)	O
.	.	O

SPRINT	NNP	O
training	NN	O
protocol	NN	O
used	VBN	O
line	NN	O
30-m	JJ	O
sprints	NNS	O
(	(	O
2-4	JJ	O
sets	NNS	O
of	IN	O
4	CD	O
x	JJ	O
30	CD	O
m	NN	O
with	IN	O
180	CD	O
and	CC	O
90	CD	O
seconds	NNS	O
of	IN	O
recovery	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

At	IN	O
baseline	JJ	O
no	DT	O
difference	NN	O
between	IN	O
physical	JJ	O
test	NN	O
performance	NN	O
was	VBD	O
evident	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
time	NN	O
x	VBZ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
vertical	JJ	O
jump	NN	O
and	CC	O
Agility-15m	JJ	O
variables	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
time	NN	O
x	JJ	O
training	VBG	O
group	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
for	IN	O
Sprint-15m	JJ	O
performance	NN	O
with	IN	O
the	DT	O
CONTRAST	NNP	O
group	NN	O
showing	VBG	O
significantly	RB	O
better	JJR	O
scores	NNS	O
than	IN	O
the	DT	O
SPRINT	NNP	O
group	NN	O
(	(	O
7.23	CD	O
+/-	JJ	O
0.18	CD	O
vs.	FW	O
7.09	CD	O
+/-	JJ	O
0.20	CD	O
m.s	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
light	NN	O
of	IN	O
these	DT	O
findings	NNS	O
CONTRAST	NNP	O
training	NN	O
should	MD	O
be	VB	O
preferred	VBN	O
to	TO	O
line	NN	O
sprint	NN	O
training	NN	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
in	IN	O
young	JJ	O
elite	JJ	O
soccer	NN	O
players	NNS	O
when	WRB	O
the	DT	O
aim	NN	O
is	VBZ	O
to	TO	O
improve	VB	O
soccer-specific	JJ	O
sprint	NN	O
performance	NN	O
(	(	O
15	CD	O
m	NN	O
)	)	O
during	IN	O
the	DT	O
competitive	JJ	O
season	NN	O
.	.	O

Do	VBP	O
readers	NNS	O
with	IN	O
autism	NN	Condition
make	VBP	O
bridging	VBG	O
inferences	NNS	O
from	IN	O
world	NN	O
knowledge	NN	O
?	.	O
Individuals	NNS	O
with	IN	O
autism	NN	O
frequently	RB	O
show	VBP	O
impairments	NNS	O
in	IN	O
text	JJ	O
reading	NN	O
comprehension	NN	O
.	.	O

This	DT	O
often	RB	O
is	VBZ	O
attributed	VBN	O
to	TO	O
poor	JJ	O
ability	NN	O
to	TO	O
draw	VB	O
inferences	NNS	O
during	IN	O
reading	NN	O
and	CC	O
to	TO	O
inadequate	VB	O
access	NN	O
to	TO	O
relevant	VB	O
knowledge	NN	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
tested	VBD	O
this	DT	O
hypothesis	NN	O
by	IN	O
measuring	VBG	O
the	DT	O
time	NN	O
taken	VBN	O
to	TO	O
read	VB	O
the	DT	O
same	JJ	O
question	NN	O
,	,	O
relating	VBG	O
to	TO	O
either	DT	O
physical	JJ	O
or	CC	O
social	JJ	O
world	NN	O
knowledge	NN	O
,	,	O
when	WRB	O
it	PRP	O
was	VBD	O
either	CC	O
relevant	JJ	O
or	CC	O
irrelevant	JJ	O
to	TO	O
the	DT	O
bridging	NN	O
inference	NN	O
evoked	VBN	O
by	IN	O
a	DT	O
preceding	VBG	O
two-sentence	NN	O
vignette	NN	O
.	.	O

In	IN	O
the	DT	O
study	NN	O
,	,	O
16	CD	Condition
normally	RB	Condition
developing	VBG	Condition
adolescents	NNS	O
and	CC	O
16	CD	Condition
adolescents	NNS	O
with	IN	O
autism	NN	Condition
were	VBD	O
matched	VBN	O
on	IN	O
word	NN	O
reading	NN	O
accuracy	NN	O
,	,	O
chronological	JJ	O
age	NN	O
,	,	O
and	CC	O
vocabulary	JJ	O
but	CC	O
differed	VBD	O
significantly	RB	O
in	IN	O
text	JJ	O
comprehension	NN	O
.	.	O

A	DT	O
strong	JJ	O
priming	NN	O
effect	NN	O
was	VBD	O
found	VBN	O
,	,	O
robust	VBZ	O
over	IN	O
participants	NNS	O
and	CC	O
over	IN	O
items	NNS	O
;	:	O
participants	NNS	O
read	VBP	O
those	DT	O
questions	NNS	O
that	WDT	O
were	VBD	O
relevant	JJ	O
to	TO	O
the	DT	O
inference	NN	O
evoked	VBN	O
by	IN	O
the	DT	O
vignette	NN	O
faster	RBR	O
than	IN	O
they	PRP	O
read	VBP	O
those	DT	O
questions	NNS	O
that	WDT	O
were	VBD	O
irrelevant	JJ	O
,	,	O
and	CC	O
no	DT	O
interaction	NN	O
with	IN	O
group	NN	O
membership	NN	O
or	CC	O
type	NN	O
of	IN	O
knowledge	NN	O
was	VBD	O
found	VBN	O
.	.	O

This	DT	O
indicates	VBZ	O
that	IN	O
readers	NNS	O
with	IN	O
autism	NN	Condition
,	,	O
just	RB	O
like	IN	O
controls	NNS	O
,	,	O
were	VBD	O
activating	VBG	O
appropriate	JJ	O
world	NN	O
knowledge	NN	O
primed	VBN	O
by	IN	O
implicit	JJ	O
inferences	NNS	O
while	IN	O
reading	VBG	O
the	DT	O
vignettes	NNS	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
comprehension	NN	O
problems	NNS	O
in	IN	O
these	DT	O
readers	NNS	O
can	MD	O
not	RB	O
be	VB	O
attributed	VBN	O
to	TO	O
an	DT	O
inability	NN	O
to	TO	O
make	VB	O
implicit	JJ	O
inferences	NNS	O
or	CC	O
to	TO	O
draw	VB	O
on	IN	O
relevant	JJ	O
world	NN	O
knowledge	NN	O
.	.	O

Instead	RB	O
,	,	O
we	PRP	O
suggest	VBP	O
that	IN	O
these	DT	O
problems	NNS	O
must	MD	O
be	VB	O
sought	VBN	O
at	IN	O
a	DT	O
higher	JJR	O
level	NN	O
of	IN	O
text	JJ	O
processing	NN	O
.	.	O

Registration	NNP	O
accuracy	NN	O
of	IN	O
153Gd	CD	O
transmission	NN	O
images	NNS	O
of	IN	O
the	DT	O
brain	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
accuracy	NN	O
of	IN	O
non-rigid	JJ	O
nine-parameter	JJ	O
image	NN	O
registrations	NNS	O
based	VBN	O
on	IN	O
153Gd	CD	O
transmission	NN	O
computed	VBN	O
tomography	NN	O
(	(	O
TCT	NNP	O
)	)	O
images	VBZ	O
as	IN	O
compared	VBN	O
with	IN	O
those	DT	O
based	VBN	O
on	IN	O
99mTc-ethyl	JJ	O
cysteinate	NN	O
dimer	NN	O
(	(	O
ECD	NNP	O
)	)	O
images	NNS	O
and	CC	O
to	TO	O
assess	VB	O
whether	IN	O
normalised	JJ	O
mutual	JJ	O
information	NN	O
(	(	O
NMI	NNP	O
)	)	O
or	CC	O
count	NN	O
difference	NN	O
(	(	O
CD	NN	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

METHODS	NNP	O
TCT	NNP	O
and	CC	O
ECD	NNP	O
data	NNS	O
were	VBD	O
acquired	VBN	O
in	IN	O
25	CD	O
randomly	RB	O
selected	VBN	O
patients	NNS	O
.	.	O

Emission	NN	O
images	NNS	O
were	VBD	O
registered	VBN	O
to	TO	O
an	DT	O
ECD	NNP	O
template	NN	O
with	IN	O
a	DT	O
CD	NN	O
cost	NN	O
function	NN	O
.	.	O

The	DT	O
same	JJ	O
registration	NN	O
parameters	NNS	O
were	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
transmission	NN	O
images	VBZ	O
to	TO	O
create	VB	O
a	DT	O
TCT	NNP	O
template	NN	O
.	.	O

All	DT	O
TCT	NNP	O
images	NNS	O
were	VBD	O
registered	VBN	O
to	TO	O
the	DT	O
TCT	NNP	O
template	NN	O
and	CC	O
the	DT	O
same	JJ	O
registration	NN	O
parameters	NNS	O
were	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
ECD	NNP	O
images	NNS	O
.	.	O

The	DT	O
procedure	NN	O
was	VBD	O
repeated	VBN	O
with	IN	O
NMI	NNP	O
as	IN	O
cost	NN	O
function	NN	O
.	.	O

Accuracy	NN	O
of	IN	O
both	DT	O
ECD-based	JJ	O
and	CC	O
TCT-based	JJ	O
registrations	NNS	O
was	VBD	O
assessed	VBN	O
by	IN	O
comparing	VBG	O
the	DT	O
normalisation	NN	O
parameter	NN	O
values	NNS	O
and	CC	O
regional	JJ	O
activities	NNS	O
in	IN	O
the	DT	O
spatially	RB	O
normalised	JJ	O
ECD	NNP	O
images	NNS	O
,	,	O
using	VBG	O
a	DT	O
mixed-model	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
(	(	O
ANOVA	NNP	O
)	)	O
.	.	O

Scheffe	NNP	O
post	NN	O
hoc	NN	O
tests	NNS	O
were	VBD	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
ECD/CD	NNP	O
,	,	O
ECD/NMI	NNP	O
and	CC	O
TCT/CD	NNP	O
,	,	O
suggesting	VBG	O
that	IN	O
ECD	NNP	O
registration	NN	O
can	MD	O
be	VB	O
done	VBN	O
with	IN	O
either	DT	O
CD	NN	O
or	CC	O
NMI	NNP	O
,	,	O
and	CC	O
that	IN	O
TCT	NNP	O
registration	NN	O
using	VBG	O
CD	NN	O
is	VBZ	O
equally	RB	O
as	RB	O
accurate	JJ	O
as	IN	O
ECD	NNP	O
registration	NN	O
.	.	O

The	DT	O
accuracy	NN	O
of	IN	O
TCT	NNP	O
registration	NN	O
with	IN	O
NMI	NNP	O
was	VBD	O
lower	JJR	O
,	,	O
with	IN	O
discrepancies	NNS	O
occurring	VBG	O
in	IN	O
the	DT	O
frontal	JJ	O
inferior	JJ	O
region	NN	O
and	CC	O
the	DT	O
cerebellum	NN	O
.	.	O

The	DT	O
analysis	NN	O
of	IN	O
normalisation	NN	O
parameters	NNS	O
indicated	VBD	O
that	IN	O
z-scaling	NN	O
is	VBZ	O
underestimated	JJ	O
and	CC	O
yz-rotation	NN	O
overestimated	VBN	O
with	IN	O
TCT/NMI	NNP	O
registration	NN	O
.	.	O

CONCLUSION	NNP	O
We	PRP	O
conclude	VBP	O
that	IN	O
ECD	NNP	O
registrations	NNS	O
with	IN	O
CD	NN	O
or	CC	O
NMI	NNP	O
are	VBP	O
as	RB	O
accurate	JJ	O
as	IN	O
TCT	NNP	O
registrations	NNS	O
with	IN	O
CD	NN	O
and	CC	O
that	DT	O
TCT	NNP	O
registrations	NNS	O
with	IN	O
NMI	NNP	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

[	JJ	O
Impact	NNP	O
of	IN	O
heparin	NN	O
on	IN	O
coagulation	NN	O
index	NN	O
during	IN	O
the	DT	O
therapy	NN	O
of	IN	O
molecular	JJ	O
adsorbent	NN	O
recirculating	VBG	O
system	NN	O
in	IN	O
patients	NNS	O
with	IN	O
liver	JJ	Condition
failure	NN	Condition
]	NNP	Condition
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
impact	NN	O
of	IN	O
coagulative	JJ	O
parameters	NNS	O
on	IN	O
different	JJ	O
anticoagulation	NN	O
systems	NNS	O
in	IN	O
molecular	JJ	O
adsorbent	NN	O
recirculating	VBG	O
system	NN	O
(	(	O
MARS	NNP	O
)	)	O
in	IN	O
subjects	NNS	O
with	IN	O
liver	JJ	O
failure	NN	O
,	,	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
of	IN	O
different	JJ	O
anticoagulation	NN	O
methods	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
experimental	JJ	O
observation	NN	O
was	VBD	O
designed	VBN	O
.	.	O

According	VBG	O
to	TO	O
anticoagulation	NN	O
Methods	NNP	O
,	,	O
174	CD	O
MARS	NNP	O
treatment	NN	O
sessions	NNS	O
for	IN	O
146	CD	O
patients	NNS	O
with	IN	O
liver	JJ	O
failure	NN	O
and	CC	O
prothrombin	JJ	O
time	NN	O
activity	NN	O
percentage	NN	O
(	(	O
PTA	NNP	O
)	)	O
?	.	O
40	CD	O
%	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
:	:	O
92	CD	O
MARS	NNP	O
treatment	NN	O
sessions	NNS	O
in	IN	O
the	DT	O
heparin-free	JJ	O
group	NN	O
and	CC	O
82	CD	O
in	IN	O
the	DT	O
low-dose	JJ	O
heparin	NN	O
group	NN	O
.	.	O

Time	NNP	O
points	NNS	O
of	IN	O
0	CD	O
,	,	O
0.5	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
and	CC	O
6	CD	O
h	NNS	O
were	VBD	O
selected	VBN	O
to	TO	O
observe	VB	O
the	DT	O
coagulation	NN	O
changes	NNS	O
of	IN	O
prothrombin	NN	O
time	NN	O
(	(	O
PT	NNP	O
)	)	O
,	,	O
PTA	NNP	O
,	,	O
thrombin	JJ	O
time	NN	O
(	(	O
TT	NNP	O
)	)	O
,	,	O
activated	VBN	O
partial	JJ	O
thromboplastin	NN	O
time	NN	O
(	(	O
APTT	NNP	O
)	)	O
and	CC	O
international	JJ	O
normalized	VBN	O
ratio	NN	O
(	(	O
INR	NNP	O
)	)	O
dynamically	RB	O
.	.	O

Adverse	JJ	O
events	NNS	O
such	JJ	O
as	IN	O
line	NN	O
/	VBP	O
filter	NN	O
coagulation	NN	O
,	,	O
rupture	NN	O
and	CC	O
bleeding	NN	O
were	VBD	O
also	RB	O
investigated	VBN	O
and	CC	O
compared	VBN	O
due	JJ	O
to	TO	O
frequency	NN	O
and	CC	O
severity	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
PT	NNP	O
,	,	O
PTA	NNP	O
,	,	O
INR	NNP	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
,	,	O
but	CC	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
APTT	NNP	O
and	CC	O
TT	NNP	O
and	CC	O
fibrinogen	NN	O
(	(	O
Fbg	NNP	O
)	)	O
.	.	O

APTT	NNP	O
and	CC	O
TT	NNP	O
levels	NNS	O
in	IN	O
the	DT	O
low-dose	JJ	O
heparin	NN	O
group	NN	O
was	VBD	O
increased	VBN	O
rapidly	RB	O
after	IN	O
the	DT	O
first	JJ	O
given	VBN	O
dose	NN	O
of	IN	O
anticoagulant	JJ	O
heparin	NN	O
and	CC	O
reached	VBD	O
the	DT	O
peak	NN	O
within	IN	O
30	CD	O
min.The	NN	O
levels	NNS	O
at	IN	O
each	DT	O
time	NN	O
point	NN	O
was	VBD	O
statistically	RB	O
different	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

A	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
Fbg	NNP	O
level	NN	O
was	VBD	O
obtained	VBN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
low-dose	JJ	O
heparin	NN	O
group	NN	O
it	PRP	O
was	VBD	O
stabilized	VBN	O
and	CC	O
increased	VBN	O
slightly	RB	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

While	IN	O
in	IN	O
the	DT	O
heparin-free	JJ	O
group	NN	O
it	PRP	O
was	VBD	O
decreased	VBN	O
gradually	RB	O
and	CC	O
reached	VBD	O
a	DT	O
ravine	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

A	DT	O
curve	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
2.5	CD	O
h	NN	O
treatment	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
P=0.001	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
2	CD	O
cases	NNS	O
of	IN	O
severe	JJ	O
bleeding	NN	O
after	IN	O
MARS	NNP	O
was	VBD	O
finished	VBN	O
in	IN	O
the	DT	O
heparin	NN	O
group	NN	O
,	,	O
and	CC	O
1	CD	O
was	VBD	O
terminated	VBN	O
because	IN	O
of	IN	O
degree	JJ	O
III	NNP	O
clotting	NN	O
in	IN	O
the	DT	O
heparin-free	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Fibrinogen	NNP	O
should	MD	O
be	VB	O
adsorbed	VBN	O
while	IN	O
the	DT	O
blood	NN	O
touches	VBZ	O
the	DT	O
MARS	NNP	O
circuit	NN	O
path	NN	O
and	CC	O
anticoagulants	NNS	O
can	MD	O
prevent	VB	O
it	PRP	O
.	.	O

Comprehensive	JJ	O
analysis	NN	O
of	IN	O
blood	NN	O
platelet	NN	O
count	NN	O
(	(	O
BPC	NNP	O
)	)	O
,	,	O
fibrin	JJ	O
degradation	NN	O
products	NNS	O
(	(	O
FDP	NNP	O
)	)	O
,	,	O
D-dimer	NNP	O
and	CC	O
clinical	JJ	O
symptoms	NNS	O
is	VBZ	O
critical	JJ	O
and	CC	O
required	VBN	O
to	TO	O
determine	VB	O
the	DT	O
coagulation	NN	O
status	NN	O
to	TO	O
select	VB	O
an	DT	O
anticoagulation	NN	O
system	NN	O
before	IN	O
MARS	NNP	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
low	JJ	O
dose	JJ	O
heparin	NN	O
in	IN	O
MARS	NNP	O
improves	VBZ	O
the	DT	O
disorder	NN	O
of	IN	O
hypercoagulable	JJ	O
state	NN	O
during	IN	O
the	DT	O
high	JJ	O
coaguation	NN	O
period	NN	O
,	,	O
while	IN	O
heparin-free	JJ	O
during	IN	O
low	JJ	O
coagulation	NN	O
period	NN	O
can	MD	O
effectively	RB	O
prevent	VB	O
the	DT	O
occurrence	NN	O
of	IN	O
bleeding	NN	O
and	CC	O
improve	VB	O
the	DT	O
mechanism	NN	O
of	IN	O
blood	NN	O
coagulation	NN	O
by	IN	O
reducing	VBG	O
heparin-like	JJ	O
substance	NN	O
in	IN	O
the	DT	O
blood	NN	O
.	.	O

Prevention	NN	O
of	IN	O
coronary	JJ	O
spasm	NN	O
by	IN	O
nicorandil	NNS	O
:	:	O
comparison	NN	O
with	IN	O
nifedipine	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
nicorandil	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
nifedipine	NN	O
in	IN	O
13	CD	O
patients	NNS	O
with	IN	O
vasospastic	JJ	O
angina	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
coronary	JJ	O
spasm	NN	O
during	IN	O
coronary	JJ	O
arteriography	NN	O
,	,	O
either	CC	O
spontaneously	RB	O
or	CC	O
ergometrine-induced	JJ	O
.	.	O

During	IN	O
two	CD	O
consecutive	JJ	O
periods	NNS	O
of	IN	O
2	CD	O
days	NNS	O
,	,	O
patients	NNS	O
received	VBD	O
active	JJ	O
drugs	NNS	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
30	CD	O
mg	NN	O
nicorandil	NN	O
,	,	O
10	CD	O
mg	NN	O
nifedipine	NN	O
,	,	O
and	CC	O
,	,	O
on	IN	O
2	CD	O
days	NNS	O
,	,	O
a	DT	O
placebo	NN	O
.	.	O

One	CD	O
hour	NN	O
after	IN	O
drug	NN	O
intake	NN	O
,	,	O
patients	NNS	O
underwent	VBD	O
an	DT	O
ergometrine	JJ	O
test	NN	O
with	IN	O
increasing	VBG	O
doses	NNS	O
of	IN	O
Methergin	NNP	O
(	(	O
ergometrine	NN	O
)	)	O
(	(	O
0.05	CD	O
,	,	O
0.10	CD	O
,	,	O
0.20	CD	O
,	,	O
and	CC	O
0.40	CD	O
mg	NN	O
every	DT	O
5	CD	O
min	NN	O
)	)	O
.	.	O

After	IN	O
placebo	NN	O
,	,	O
the	DT	O
tests	NNS	O
always	RB	O
were	VBD	O
positive	JJ	O
,	,	O
and	CC	O
the	DT	O
ECG	NNP	O
changes	NNS	O
occurred	VBD	O
at	IN	O
the	DT	O
same	JJ	O
+/-	JJ	O
1	CD	O
dose	NN	O
of	IN	O
ergometrine	NN	O
in	IN	O
10	CD	O
cases	NNS	O
,	,	O
showing	VBG	O
good	JJ	O
reproducibility	NN	O
.	.	O

After	IN	O
nicorandil	NN	O
,	,	O
the	DT	O
tests	NNS	O
were	VBD	O
negative	JJ	O
in	IN	O
nine	CD	O
patients	NNS	O
and	CC	O
positive	JJ	O
for	IN	O
a	DT	O
higher	JJR	O
or	CC	O
lower	JJR	O
dose	NN	O
of	IN	O
ergometrine	NN	O
in	IN	O
three	CD	O
and	CC	O
one	CD	O
patient	NN	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	$	O
0.0034	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

After	IN	O
nifedipine	NN	O
,	,	O
the	DT	O
tests	NNS	O
were	VBD	O
negative	JJ	O
in	IN	O
five	CD	O
patients	NNS	O
and	CC	O
positive	JJ	O
for	IN	O
a	DT	O
higher	JJR	O
or	CC	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
ergometrine	NN	O
in	IN	O
four	CD	O
and	CC	O
four	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
=	$	O
0.0039	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

Nifedipine	NNP	O
(	(	O
10	CD	O
mg	NN	O
)	)	O
and	CC	O
nicorandil	$	O
(	(	O
30	CD	O
mg	NN	O
)	)	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
eight	CD	O
patients	NNS	O
;	:	O
in	IN	O
the	DT	O
remaining	VBG	O
five	CD	O
patients	NNS	O
,	,	O
nicorandil	NNS	O
had	VBD	O
better	JJR	O
results	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.06	CD	O
)	)	O
.	.	O

Nicorandil	NNP	O
(	(	O
30	CD	O
mg	NN	O
)	)	O
prevents	VBZ	O
ergometrine-induced	JJ	O
coronary	JJ	O
spasm	NN	O
.	.	O

This	DT	O
compound	NN	O
may	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
vasospastic	JJ	O
angina	NN	O
.	.	O

Does	VBZ	O
a	DT	O
first	JJ	O
trimester	NN	O
dating	VBG	O
scan	JJ	O
using	VBG	O
crown	JJ	O
rump	NN	O
length	NN	O
measurement	NN	O
reduce	VB	O
the	DT	O
rate	NN	O
of	IN	O
induction	NN	O
of	IN	O
labour	NN	O
for	IN	O
prolonged	JJ	O
pregnancy	NN	O
?	.	O
An	DT	O
uncompleted	JJ	O
randomised	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
463	CD	SampleSize
women	NNS	Sex
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
first	JJ	O
trimester	NN	O
ultrasound	IN	O
dating	VBG	O
scan	JJ	O
on	IN	O
the	DT	O
rate	NN	O
of	IN	O
induction	NN	O
of	IN	O
labour	NN	O
for	IN	O
prolonged	JJ	O
pregnancy	NN	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
controlled	VBN	O
trial	NN	O
to	TO	O
include	VB	O
400	CD	SampleSize
women	NNS	Sex
in	IN	O
each	DT	O
arm	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

SETTING	NN	O
Participating	VBG	O
general	JJ	O
practices	NNS	O
and	CC	O
a	DT	O
district	NN	O
general	JJ	O
teaching	NN	O
hospital	NN	O
.	.	O

POPULATION	NNP	O
Women	NNP	Sex
attending	VBG	O
their	PRP$	O
general	JJ	O
practitioner	NN	O
in	IN	O
the	DT	O
first	JJ	Condition
trimester	NN	Condition
to	TO	O
confirm	VB	O
pregnancy	NN	Condition
,	,	O
in	IN	O
whom	WP	O
a	DT	O
first	JJ	O
trimester	NN	O
ultrasound	JJ	O
scan	NN	O
was	VBD	O
not	RB	O
indicated	VBN	O
.	.	O

METHODS	NNP	O
Women	NNP	O
randomised	VBD	O
to	TO	O
the	DT	O
study	NN	O
group	NN	O
(	(	O
scan	JJ	O
group	NN	O
)	)	O
underwent	VBD	O
an	DT	O
ultrasound	JJ	O
dating	NN	O
scan	NN	O
between	IN	O
8	CD	O
and	CC	O
12	CD	O
weeks	NNS	O
,	,	O
measuring	VBG	O
crown-rump	JJ	O
length	NN	O
.	.	O

The	DT	O
estimated	JJ	O
date	NN	O
of	IN	O
delivery	NN	O
(	(	O
EDD	NNP	O
)	)	O
was	VBD	O
changed	VBN	O
if	IN	O
there	EX	O
was	VBD	O
a	DT	O
discrepancy	NN	O
of	IN	O
more	JJR	O
than	IN	O
5	CD	O
days	NNS	O
from	IN	O
the	DT	O
gestation	NN	O
,	,	O
calculated	VBN	O
from	IN	O
the	DT	O
last	JJ	O
menstrual	JJ	O
period	NN	O
(	(	O
LMP	NNP	O
)	)	O
.	.	O

For	IN	O
the	DT	O
remaining	VBG	O
women	NNS	O
(	(	O
no-scan	JJ	O
group	NN	O
)	)	O
,	,	O
gestation	NN	O
was	VBD	O
determined	VBN	O
using	VBG	O
the	DT	O
LMP	NNP	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
rate	NN	O
of	IN	O
induction	NN	O
of	IN	O
labour	NN	O
for	IN	O
prolonged	JJ	O
pregnancy	NN	O
.	.	O

RESULTS	NNP	O
Due	NNP	O
to	TO	O
circumstances	NNS	O
beyond	IN	O
the	DT	O
researchers	NNS	O
'	POS	O
control	NN	O
,	,	O
recruitment	NN	O
was	VBD	O
abandoned	VBN	O
when	WRB	O
463	CD	SampleSize
women	NNS	Sex
had	VBD	O
been	VBN	O
enrolled	VBN	O
.	.	O

The	DT	O
EDD	NNP	O
was	VBD	O
adjusted	VBN	O
in	IN	O
13	CD	O
(	(	O
5.7	CD	O
%	NN	O
)	)	O
women	NNS	O
in	IN	O
the	DT	O
scan	JJ	O
group	NN	O
and	CC	O
in	IN	O
2	CD	O
(	(	O
0.9	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
no-scan	JJ	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
induction	NN	O
for	IN	O
prolonged	JJ	O
pregnancy	NN	O
between	IN	O
the	DT	O
scan	JJ	O
(	(	O
19	CD	O
[	RB	O
8.2	CD	O
%	NN	O
]	NN	O
)	)	O
and	CC	O
the	DT	O
no-scan	JJ	O
(	(	O
17	CD	O
[	RB	O
7.4	CD	O
%	NN	O
]	NN	O
)	)	O
groups	NNS	O
(	(	O
relative	JJ	O
risk	NN	O
1.10	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.59-2.07	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Acknowledging	VBG	O
the	DT	O
reduced	JJ	O
numbers	NNS	O
recruited	VBN	O
for	IN	O
study	NN	O
,	,	O
it	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
there	EX	O
is	VBZ	O
no	DT	O
evidence	NN	O
that	IN	O
a	DT	O
first	JJ	O
trimester	NN	O
ultrasound	IN	O
dating	VBG	O
scan	JJ	O
reduces	NNS	O
the	DT	O
rate	NN	O
of	IN	O
induction	NN	O
of	IN	O
labour	NN	O
for	IN	O
prolonged	JJ	O
pregnancy	NN	O
and	CC	O
may	MD	O
result	VB	O
in	IN	O
a	DT	O
more	RBR	O
expensive	JJ	O
healthcare	NN	O
strategy	NN	O
.	.	O

Primary	JJ	O
stenting	NN	O
of	IN	O
occluded	JJ	O
native	JJ	O
coronary	JJ	O
arteries	NNS	O
:	:	O
final	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Primary	NNP	O
Stenting	NNP	O
of	IN	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
(	(	O
PRISON	NNP	O
)	)	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Primary	NNP	O
intracoronary	JJ	O
stent	NN	O
placement	NN	O
after	IN	O
successfully	RB	O
crossing	VBG	O
chronic	JJ	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
high	JJ	O
restenosis	NN	O
rate	NN	O
at	IN	O
long-term	JJ	O
follow-up	JJ	O
compared	VBN	O
with	IN	O
conventional	JJ	O
balloon	NN	O
angioplasty	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
,	,	O
balloon	NN	O
angioplasty	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
stent	JJ	O
implantation	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	Condition
total	JJ	Condition
occlusions	NNS	Condition
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
12	CD	O
months	NNS	O
with	IN	O
angiographic	JJ	O
follow-up	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Quantitative	JJ	O
coronary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
core	NN	O
lab	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
200	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Baseline	JJ	O
characteristics	NNS	O
were	VBD	O
evenly	RB	O
distributed	VBN	O
.	.	O

After	IN	O
the	DT	O
procedure	NN	O
the	DT	O
mean	NN	O
minimal	JJ	O
luminal	JJ	O
diameter	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
was	VBD	O
2.34	CD	O
+/-	JJ	O
0.46	CD	O
mm	NN	O
versus	NN	O
2.90	CD	O
+/-	JJ	O
0.41	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

The	DT	O
6-month	JJ	O
angiographic	JJ	O
follow-up	NN	O
showed	VBD	O
a	DT	O
mean	JJ	O
minimal	JJ	O
luminal	JJ	O
diameter	NN	O
of	IN	O
1.57	CD	O
+/-	JJ	O
0.74	CD	O
mm	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
1.93	CD	O
+/-	JJ	O
0.85	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.009	NNP	O
)	)	O
and	CC	O
a	DT	O
mean	JJ	O
diameter	NN	O
stenosis	NN	O
of	IN	O
44.7	CD	O
%	NN	O
+/-	JJ	O
25.0	CD	O
%	NN	O
versus	IN	O
35.5	CD	O
%	NN	O
+/-	JJ	O
26.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=.036	NNP	O
)	)	O
.	.	O

Binary	JJ	O
angiographic	JJ	O
restenosis	NN	O
(	(	O
>	JJ	O
50	CD	O
%	NN	O
diameter	JJ	O
stenosis	NN	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
33	CD	O
%	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
22	CD	O
%	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.137	NNP	O
)	)	O
.	.	O

The	DT	O
reocclusion	NN	O
rates	NNS	O
were	VBD	O
7.3	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
1.00	CD	O
)	)	O
.	.	O

At	IN	O
12	CD	O
month	NN	O
follow-up	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
(	(	O
29	CD	O
%	NN	O
versus	IN	O
13	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
stenting	VBG	O
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
balloon	VB	O
angioplasty	JJ	O
alone	RB	O
with	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
need	NN	O
for	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
and	CC	O
a	DT	O
lower	JJR	O
,	,	O
but	CC	O
not	RB	O
significant	JJ	O
,	,	O
restenosis	NN	O
rate	NN	O
.	.	O

That	DT	O
looks	VBZ	O
familiar	JJ	O
:	:	O
attention	NN	O
allocation	NN	O
to	TO	O
familiar	JJ	O
and	CC	O
unfamiliar	JJ	O
faces	VBZ	O
in	IN	O
children	NNS	Age
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorder	NN	Condition
.	.	O

INTRODUCTION	NNP	O
Existing	VBG	O
eye-tracking	JJ	O
literature	NN	O
has	VBZ	O
shown	VBN	O
that	IN	O
both	DT	O
adults	NNS	Age
and	CC	O
children	NNS	Age
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorders	NNS	Condition
(	(	Condition
ASD	NNP	Condition
)	)	Condition
show	VBP	O
fewer	JJR	O
and	CC	O
slower	JJR	O
fixations	NNS	O
on	IN	O
faces	VBZ	O
.	.	O

Despite	IN	O
this	DT	O
reduced	JJ	O
saliency	NN	O
and	CC	O
processing	NN	O
of	IN	O
other	JJ	O
faces	VBZ	O
,	,	O
recognition	NN	O
of	IN	O
their	PRP$	O
own	JJ	O
face	NN	O
is	VBZ	O
reported	VBN	O
to	TO	O
be	VB	O
more	JJR	O
typical	JJ	O
in	IN	O
nature	NN	O
.	.	O

This	DT	O
study	NN	O
uses	VBZ	O
eye-tracking	VBG	O
to	TO	O
explore	VB	O
the	DT	O
typicality	NN	O
of	IN	O
gaze	NN	O
patterns	NNS	O
when	WRB	O
children	NNS	Age
with	IN	O
ASD	NNP	Condition
attend	VBP	O
their	PRP$	O
own	JJ	O
faces	VBZ	O
compared	VBN	O
to	TO	O
other	JJ	O
familiar	JJ	O
and	CC	O
unfamiliar	JJ	O
faces	VBZ	O
.	.	O

METHODS	NNP	O
Eye-tracking	JJ	O
methodology	NN	O
was	VBD	O
used	VBN	O
to	TO	O
explore	VB	O
fixation	NN	O
duration	NN	O
and	CC	O
time	NN	O
taken	VBN	O
to	TO	O
fixate	VB	O
on	IN	O
the	DT	O
Eye	NNP	O
and	CC	O
Mouth	NNP	O
regions	NNS	O
of	IN	O
familiar	JJ	O
,	,	O
unfamiliar	JJ	O
and	CC	O
Self	NNP	O
Faces	NNP	O
.	.	O

Twenty-one	CD	SampleSize
children	NNS	O
with	IN	O
ASD	NNP	Condition
(	(	O
9-16	CD	Age
years	NNS	Age
)	)	O
were	VBD	O
compared	VBN	O
to	TO	O
typically	RB	O
developing	VBG	O
matched	VBN	O
groups	NNS	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
children	NNS	Age
with	IN	O
ASD	NNP	Condition
and	CC	O
typically	RB	O
matched	VBD	O
groups	NNS	O
for	IN	O
fixation	NN	O
patterns	NNS	O
to	TO	O
the	DT	O
Eye	NNP	O
and	CC	O
Mouth	NNP	O
areas	NNS	O
of	IN	O
all	DT	O
face	NN	O
types	NNS	O
(	(	O
familiar	JJ	O
,	,	O
unfamiliar	JJ	O
and	CC	O
self	NN	O
)	)	O
.	.	O

Correlational	JJ	O
analyses	NNS	O
showed	VBD	O
that	IN	O
attention	NN	O
to	TO	O
the	DT	O
Eye	NNP	O
area	NN	O
of	IN	O
unfamiliar	JJ	O
and	CC	O
Self	NNP	O
Faces	NNP	O
was	VBD	O
related	VBN	O
to	TO	O
socio-communicative	JJ	O
ability	NN	O
in	IN	O
children	NNS	Age
with	IN	O
ASD	NNP	Condition
.	.	O

CONCLUSIONS	NNP	O
Levels	NNP	O
of	IN	O
socio-communicative	JJ	O
ability	NN	O
in	IN	O
children	NNS	Age
with	IN	O
ASD	NNP	Condition
were	VBD	O
related	VBN	O
to	TO	O
gaze	VB	O
patterns	NNS	O
on	IN	O
unfamiliar	JJ	O
and	CC	O
Self	NNP	O
Faces	NNP	O
,	,	O
but	CC	O
not	RB	O
familiar	JJ	O
faces	VBZ	O
.	.	O

This	DT	O
lack	NN	O
of	IN	O
relationship	NN	O
between	IN	O
ability	NN	O
and	CC	O
attention	NN	O
to	TO	O
familiar	JJ	O
faces	VBZ	O
may	MD	O
indicate	VB	O
that	IN	O
children	NNS	O
across	IN	O
the	DT	O
autism	NN	O
spectrum	NN	O
are	VBP	O
able	JJ	O
to	TO	O
fixate	VB	O
these	DT	O
faces	VBZ	O
in	IN	O
a	DT	O
similar	JJ	O
way	NN	O
.	.	O

The	DT	O
implications	NNS	O
for	IN	O
these	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

The	DT	O
Toronto	NNP	O
prehospital	NN	O
hypertonic	JJ	O
resuscitation	NN	Condition
--	:	Condition
head	JJ	Condition
injury	NN	O
and	CC	O
multiorgan	JJ	O
dysfunction	NN	O
trial	NN	O
:	:	O
feasibility	NN	O
study	NN	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
a	DT	O
prehospital	JJ	O
trial	NN	O
comparing	VBG	O
hypertonic	JJ	O
saline	NN	O
and	CC	O
dextran	NN	O
(	(	O
HSD	NNP	O
)	)	O
with	IN	O
normal	JJ	O
saline	NN	O
(	(	O
NS	NNP	O
)	)	O
in	IN	O
blunt	NN	O
head	NN	O
injury	NN	O
patients	NNS	O
.	.	O

DESIGN	NNP	O
The	DT	O
study	NN	O
used	VBD	O
a	DT	O
double	JJ	O
blind	NN	O
randomized	VBN	O
trial	NN	O
.	.	O

SETTING	VB	O
The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
air	NN	O
and	CC	O
land	NN	O
emergency	NN	O
medical	JJ	O
services	NNS	O
and	CC	O
2	CD	O
trauma	NN	O
centers	NNS	O
serving	VBG	O
a	DT	O
population	NN	O
of	IN	O
4	CD	SampleSize
million	CD	SampleSize
people	NNS	SampleSize
.	.	SampleSize

PATIENTS	VB	O
The	DT	O
study	NN	O
population	NN	O
consisted	VBD	O
of	IN	O
head	NN	O
injured	VBN	O
,	,	O
blunt	VB	O
trauma	JJ	O
adult	NN	Condition
patients	NNS	O
with	IN	O
a	DT	O
Glasgow	NNP	Condition
Coma	NNP	Condition
Scale	NNP	O
of	IN	O
lower	JJR	O
than	IN	O
9	CD	O
.	.	O

INTERVENTIONS	NN	O
We	PRP	O
used	VBD	O
250	CD	O
mL	NN	O
of	IN	O
HSD	NNP	O
vs	FW	O
NS	NNP	O
given	VBN	O
within	IN	O
4	CD	O
hours	NNS	O
of	IN	O
the	DT	O
accident	NN	O
.	.	O

MEASUREMENTS	PDT	O
The	DT	O
specific	JJ	O
objectives	NNS	O
were	VBD	O
to	TO	O
assess	VB	O
protocol-related	JJ	O
logistical	JJ	O
issues	NNS	O
,	,	O
randomization	NN	O
,	,	O
HSD	NNP	O
safety	NN	O
,	,	O
and	CC	O
follow	VB	O
up	RP	O
rates	NNS	O
and	CC	O
to	TO	O
obtain	VB	O
survival	JJ	O
and	CC	O
neurocognitive	JJ	O
end	NN	O
point	NN	O
estimates	NNS	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Of	IN	O
132	CD	SampleSize
eligible	JJ	SampleSize
patients	NNS	SampleSize
,	,	O
113	CD	SampleSize
were	VBD	O
randomized	VBN	O
.	.	O

Nineteen	NNP	O
eligible	JJ	O
patients	NNS	O
were	VBD	O
missed	VBN	O
because	IN	O
of	IN	O
lack	NN	O
of	IN	O
time	NN	O
(	(	O
9	CD	O
[	RB	O
22	CD	O
%	NN	O
]	NN	O
)	)	O
,	,	O
paramedic	JJ	O
discretion	NN	O
(	(	O
3	CD	O
[	RB	O
7	CD	O
%	NN	O
]	NN	O
)	)	O
,	,	O
the	DT	O
paramedic	JJ	O
forgot	NN	O
(	(	O
6	CD	O
[	RB	O
15	CD	O
%	NN	O
]	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
paramedic	NN	O
refused	VBD	O
(	(	O
1	CD	O
[	RB	O
2	CD	O
%	NN	O
]	NN	O
)	)	O
.	.	O

Randomization	NNP	O
compliance	NN	O
was	VBD	O
96	CD	O
%	NN	O
(	(	O
109/113	CD	O
)	)	O
.	.	O

Four	CD	O
randomized	JJ	O
cases	NNS	O
met	VBD	O
exclusion	NN	O
criteria	NNS	O
:	:	O
penetrating	NN	O
trauma	NN	O
(	(	O
1	CD	O
)	)	O
,	,	O
cardiac	JJ	O
arrest	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
and	CC	O
fall	NN	O
from	IN	O
standing	VBG	O
(	(	O
1	CD	O
)	)	O
.	.	O

Three	CD	O
randomized	JJ	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
final	JJ	O
analysis	NN	O
:	:	O
2	CD	O
patients	NNS	O
received	VBD	O
less	JJR	O
than	IN	O
50	CD	O
mL	NN	O
of	IN	O
study	NN	O
solution	NN	O
due	JJ	O
to	TO	O
an	DT	O
interstitial	JJ	O
intravenous	JJ	O
line	NN	O
and	CC	O
1	CD	O
lost	VBN	O
randomization	NN	O
identification	NN	O
.	.	O

Fifty	JJ	O
patients	NNS	O
(	(	O
47	CD	O
%	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
HSD	NNP	O
and	CC	O
56	CD	O
(	(	O
53	CD	O
%	NN	O
)	)	O
to	TO	O
NS	NNP	O
.	.	O

Mean	NNP	O
injury	NN	O
severity	NN	O
score	NN	O
was	VBD	O
32.7	CD	O
for	IN	O
HSD	NNP	O
and	CC	O
32.6	CD	O
for	IN	O
NS	NNP	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
length	NN	O
of	IN	O
stay	NN	O
,	,	O
Sequential	NNP	O
Organ	NNP	O
Failure	NNP	O
Assessment	NNP	O
maximum	NN	O
,	,	O
Multiple	NNP	O
Organ	NNP	O
Dysfunction	NNP	O
Score	NNP	O
maximum	NN	O
,	,	O
delta	JJ	O
Multiple	NNP	O
Organ	NNP	O
Dysfunction	NNP	O
Score	NNP	O
,	,	O
or	CC	O
Apache	NNP	O
scores	NNS	O
.	.	O

Initial	JJ	O
head	NN	O
scans	NNS	O
scored	VBD	O
3	CD	O
or	CC	O
higher	JJR	O
by	IN	O
Marshall	NNP	O
classification	NN	O
for	IN	O
12	CD	O
HSD	NNP	O
and	CC	O
11	CD	O
NS	NNP	O
patients	NNS	O
.	.	O

Zero	NNP	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
,	,	O
and	CC	O
follow-up	NN	O
for	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
100	CD	O
%	NN	O
.	.	O

Alive	JJ	O
at	IN	O
30	CD	O
days	NNS	O
for	IN	O
HSD	NNP	O
and	CC	O
NS	NNP	O
,	,	O
respectively	RB	O
,	,	O
was	VBD	O
70	CD	O
%	NN	O
(	(	O
35/50	CD	O
)	)	O
and	CC	O
75	CD	O
%	NN	O
(	(	O
42/56	CD	O
)	)	O
and	CC	O
at	IN	O
discharge	NN	O
was	VBD	O
68	CD	O
%	NN	O
(	(	O
34/50	CD	O
)	)	O
and	CC	O
73	CD	O
%	NN	O
(	(	O
41/56	CD	O
)	)	O
.	.	O

Only	RB	O
49.3	CD	O
%	NN	O
(	(	O
37/77	CD	O
)	)	O
of	IN	O
surviving	VBG	O
patients	NNS	O
consented	VBN	O
to	TO	O
follow-up	NN	O
at	IN	O
4	CD	O
months	NNS	O
and	CC	O
89	CD	O
%	NN	O
(	(	O
33/37	CD	O
)	)	O
completed	VBD	O
the	DT	O
assessment	NN	O
.	.	O

Disability	NN	O
rating	NN	O
scale	NN	O
(	(	O
median	JJ	O
,	,	O
interquartile	JJ	O
range	NN	O
)	)	O
was	VBD	O
3	CD	O
(	(	O
0	CD	O
,	,	O
6	CD	O
)	)	O
for	IN	O
HSD	NNP	O
and	CC	O
was	VBD	O
0	CD	O
(	(	O
0	CD	O
,	,	O
6	CD	O
)	)	O
for	IN	O
NS	NNP	O
.	.	O

Glasgow	NNP	O
Outcome	NNP	O
Scale	NNP	O
Evaluation	NNP	O
was	VBD	O
higher	JJR	O
than	IN	O
4	CD	O
for	IN	O
HSD	NNP	O
(	(	O
12/12	CD	O
[	RB	O
100	CD	O
%	NN	O
]	NN	O
)	)	O
and	CC	O
NS	NNP	O
(	(	O
15/21	CD	O
[	RB	O
72	CD	O
%	NN	O
]	NN	O
)	)	O
.	.	O

Functional	JJ	O
Independence	NNP	O
Measure	NNP	O
(	(	O
mean	NN	O
,	,	O
SD	NNP	O
)	)	O
was	VBD	O
62	CD	O
(	(	O
37	CD	O
)	)	O
for	IN	O
HSD	NNP	O
and	CC	O
80	CD	O
(	(	O
32	CD	O
)	)	O
for	IN	O
NS	NNP	O
.	.	O

CONCLUSIONS	VB	O
It	PRP	O
is	VBZ	O
feasible	JJ	O
to	TO	O
conduct	VB	O
a	DT	O
prehospital	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
with	IN	O
HSD	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
blunt	NN	Condition
trauma	NN	Condition
patients	NNS	Condition
with	IN	Condition
head	JJ	Condition
injuries	NNS	Condition
;	:	Condition
however	RB	O
,	,	O
consent	NN	O
for	IN	O
neurofunctional	JJ	O
outcomes	NNS	O
in	IN	O
this	DT	O
cohort	NN	O
is	VBZ	O
problematic	JJ	O
and	CC	O
threatens	VBZ	O
the	DT	O
feasibility	NN	O
of	IN	O
definitive	JJ	O
trials	NNS	O
using	VBG	O
these	DT	O
potentially	RB	O
meaningful	JJ	O
end	NN	O
points	NNS	O
.	.	O

Dose	NNP	O
dependent	JJ	O
response	NN	O
of	IN	O
symptoms	NNS	O
,	,	O
pituitary	JJ	O
,	,	O
and	CC	O
bone	NN	O
to	TO	O
transdermal	VB	O
oestrogen	NN	O
in	IN	O
postmenopausal	JJ	Condition
women	NNS	Condition
.	.	Condition

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
plasma	NN	O
oestradiol	JJ	O
concentration	NN	O
on	IN	O
climacteric	NN	O
symptoms	NNS	O
,	,	O
gonadotrophin	JJ	O
release	NN	O
,	,	O
and	CC	O
bone	NN	O
resorption	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
three	CD	O
groups	NNS	O
of	IN	O
postmenopausal	JJ	O
women	NNS	O
given	VBN	O
0.025	CD	O
mg	NNS	O
,	,	O
0.05	CD	O
mg	NN	O
,	,	O
or	CC	O
0.1	CD	O
mg	NNS	O
transdermal	JJ	O
oestradiol	JJ	O
daily	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
dose	JJ	O
related	JJ	O
reduction	NN	O
in	IN	O
symptoms	NNS	O
,	,	O
plasma	JJ	O
follicle	NN	O
stimulating	VBG	O
hormone	NN	O
concentration	NN	O
,	,	O
and	CC	O
urinary	JJ	O
calcium	NN	O
and	CC	O
hydroxyproline	JJ	O
excretion	NN	O
.	.	O

The	DT	O
relation	NN	O
of	IN	O
the	DT	O
response	NN	O
to	TO	O
plasma	VB	O
oestradiol	JJ	O
values	NNS	O
was	VBD	O
similar	JJ	O
for	IN	O
each	DT	O
variable	NN	O
with	IN	O
an	DT	O
initial	JJ	O
large	JJ	O
reduction	NN	O
and	CC	O
little	JJ	O
change	NN	O
in	IN	O
response	NN	O
to	TO	O
increases	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
oestradiol	JJ	O
concentration	NN	O
above	IN	O
150	CD	O
pmol/l	NN	O
(	(	O
41	CD	O
pg/ml	NN	O
)	)	O
.	.	O

Hormone	CD	O
replacement	NN	O
therapy	NN	O
producing	VBG	O
an	DT	O
effect	NN	O
equivalent	NN	O
to	TO	O
higher	JJR	O
oestradiol	JJ	O
concentrations	NNS	O
is	VBZ	O
likely	JJ	O
to	TO	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
side	NN	O
effects	NNS	O
without	IN	O
conferring	VBG	O
any	DT	O
additional	JJ	O
benefit	NN	O
.	.	O

Pulsatile	NNP	O
insulin	NN	O
delivery	NN	O
is	VBZ	O
more	RBR	O
efficient	JJ	O
than	IN	O
continuous	JJ	O
infusion	NN	O
in	IN	O
modulating	VBG	O
islet	NN	O
cell	NN	O
function	NN	O
in	IN	O
normal	JJ	Condition
subjects	NNS	Condition
and	CC	Condition
patients	NNS	Condition
with	IN	Condition
type	JJ	Condition
1	CD	Condition
diabetes	NNS	Condition
.	.	Condition

The	DT	O
respective	JJ	O
modulating	NN	O
effects	NNS	O
of	IN	O
continuous	JJ	O
and	CC	O
intermittent	JJ	O
insulin	NN	O
delivery	NN	O
on	IN	O
pancreatic	JJ	O
islet	NN	O
cell	NN	O
function	NN	O
were	VBD	O
studied	VBN	O
in	IN	O
seven	CD	O
normal	JJ	O
men	NNS	O
and	CC	O
nine	CD	O
insulin-dependent	NN	O
(	(	O
type	JJ	O
1	CD	O
)	)	O
diabetic	JJ	O
patients	NNS	O
.	.	O

In	IN	O
the	DT	O
normal	JJ	O
men	NNS	O
,	,	O
saline	NN	O
or	CC	O
continuous	JJ	O
(	(	O
0.8	CD	O
mU	RB	O
kg-1	JJ	O
min-1	NN	O
)	)	O
or	CC	O
pulsatile	NN	O
(	(	O
5.2	CD	O
mU	RB	O
kg-1	JJ	O
min-1	NNS	O
,	,	O
with	IN	O
a	DT	O
switching	VBG	O
on/off	RP	O
length	NN	O
of	IN	O
2/11	CD	O
min	NN	O
)	)	O
human	JJ	O
insulin	NN	O
were	VBD	O
delivered	VBN	O
on	IN	O
different	JJ	O
days	NNS	O
and	CC	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Despite	IN	O
hyperinsulinemia	NN	O
,	,	O
blood	NN	O
glucose	NN	O
was	VBD	O
kept	VBN	O
close	RB	O
to	TO	O
its	PRP$	O
basal	NN	O
value	NN	O
by	IN	O
the	DT	O
glucose	JJ	O
clamp	NN	O
technique	NN	O
.	.	O

The	DT	O
diabetic	JJ	O
patients	NNS	O
also	RB	O
were	VBD	O
infused	VBN	O
in	IN	O
random	JJ	O
order	NN	O
and	CC	O
on	IN	O
different	JJ	O
days	NNS	O
with	IN	O
either	DT	O
saline	NN	O
or	CC	O
a	DT	O
smaller	JJR	O
amount	NN	O
of	IN	O
insulin	NN	O
delivered	VBN	O
continuously	RB	O
(	(	O
0.15	CD	O
mU	RB	O
kg-1	JJ	O
min-1	NN	O
)	)	O
or	CC	O
in	IN	O
a	DT	O
pulsatile	JJ	O
manner	NN	O
(	(	O
0.97	CD	O
mU	RB	O
kg-1	JJ	O
min-1	NN	O
for	IN	O
2	CD	O
min	NN	O
,	,	O
followed	VBN	O
by	IN	O
11	CD	O
min	NNS	O
during	IN	O
which	WDT	O
no	DT	O
insulin	NN	O
was	VBD	O
infused	VBN	O
)	)	O
.	.	O

In	IN	O
all	DT	O
experiments	NNS	O
,	,	O
5	CD	O
g	NN	O
arginine	NN	O
were	VBD	O
given	VBN	O
iv	NNS	O
as	IN	O
a	DT	O
bolus	NN	O
dose	JJ	O
30	CD	O
min	NN	O
before	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
plasma	VB	O
C-peptide	NNP	O
and	CC	O
glucagon	NN	O
levels	NNS	O
were	VBD	O
determined	VBN	O
to	TO	O
assess	VB	O
islet	NN	O
cell	NN	O
function	NN	O
.	.	O

In	IN	O
the	DT	O
normal	JJ	O
men	NNS	O
,	,	O
insulin	NN	O
administration	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
decline	NN	O
of	IN	O
basal	NN	O
plasma	NN	O
glucagon	NN	O
and	CC	O
C-peptide	JJ	O
levels	NNS	O
and	CC	O
in	IN	O
a	DT	O
clear-cut	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
arginine-induced	JJ	O
glucagon	NN	O
response	NN	O
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
insulin	NN	O
were	VBD	O
significantly	RB	O
more	RBR	O
marked	JJ	O
when	WRB	O
insulin	NN	O
was	VBD	O
delivered	VBN	O
in	IN	O
a	DT	O
pulsatile	NN	O
rather	RB	O
than	IN	O
a	DT	O
continuous	JJ	O
manner	NN	O
.	.	O

In	IN	O
the	DT	O
insulin-dependent	JJ	O
diabetic	JJ	O
patients	NNS	O
,	,	O
the	DT	O
lower	JJR	O
dose	NN	O
of	IN	O
insulin	NN	O
infused	VBN	O
continuously	RB	O
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
basal	NN	O
or	CC	O
arginine-stimulated	JJ	O
glucagon	NN	O
response	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
when	WRB	O
the	DT	O
same	JJ	O
amount	NN	O
of	IN	O
insulin	NN	O
was	VBD	O
delivered	VBN	O
intermittently	RB	O
,	,	O
arginine-induced	JJ	O
glucagon	NN	O
release	NN	O
was	VBD	O
greatly	RB	O
reduced	VBN	O
.	.	O

Thus	RB	O
,	,	O
these	DT	O
data	NNS	O
support	NN	O
the	DT	O
concept	NN	O
that	WDT	O
insulin	VBZ	O
per	IN	O
se	NN	O
is	VBZ	O
a	DT	O
potent	JJ	O
physiological	JJ	O
modulator	NN	O
of	IN	O
islet	NN	O
A-	NNP	O
and	CC	O
B-cell	NNP	O
function	NN	O
.	.	O

Furthermore	RB	O
,	,	O
they	PRP	O
suggest	VBP	O
that	IN	O
these	DT	O
effects	NNS	O
of	IN	O
insulin	NN	O
are	VBP	O
reinforced	VBN	O
when	WRB	O
the	DT	O
hormone	NN	O
is	VBZ	O
administered	VBN	O
in	IN	O
an	DT	O
intermittent	JJ	O
manner	NN	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
reproduce	VB	O
the	DT	O
pulsatile	NN	O
physiological	JJ	O
release	NN	O
of	IN	O
insulin	NN	O
.	.	O

Rapid	JJ	O
injection	NN	O
of	IN	O
propofol	NN	O
reduces	NNS	O
vascular	JJ	O
pain	NN	O
and	CC	O
facilitates	NNS	O
Laryngeal	NNP	Condition
Mask	NNP	Condition
Airway	NNP	Condition
insertion	NN	Condition
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
clinical	JJ	O
efficacy	NN	O
of	IN	O
a	DT	O
rapid	JJ	O
injection	NN	O
of	IN	O
propofol	NN	O
in	IN	O
regard	NN	O
to	TO	O
pain	VB	O
and	CC	O
ability	NN	O
to	TO	O
facilitate	VB	O
Laryngeal	NNP	O
Mask	NNP	O
Airway	NNP	O
(	(	O
LMA	NNP	Condition
)	)	O
insertion	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
single-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
University	NNP	O
hospital	NN	O
.	.	O

PATIENTS	CC	O
120	CD	SampleSize
ASA	NNP	O
physical	JJ	O
status	NN	O
1	CD	O
and	CC	O
2	CD	O
patients	NNS	O
undergoing	JJ	O
elective	JJ	O
orthopedic	JJ	Condition
surgeries	NNS	Condition
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
4	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
A	NNP	O
patients	NNS	O
were	VBD	O
pretreated	VBN	O
with	IN	O
normal	JJ	O
saline	NN	O
followed	VBN	O
by	IN	O
propofol	NN	O
2.0	CD	O
mg/kg	NN	O
at	IN	O
3.3	CD	O
mg/sec	NN	O
.	.	O

Group	NNP	O
B	NNP	O
patients	NNS	O
were	VBD	O
pretreated	VBN	O
with	IN	O
lidocaine	JJ	O
0.5	CD	O
mg/kg	NN	O
followed	VBN	O
by	IN	O
propofol	NN	O
2.0	CD	O
mg/kg	NN	O
at	IN	O
3.3	CD	O
mg/sec	NN	O
.	.	O

In	IN	O
Group	NNP	O
C	NNP	O
,	,	O
patients	NNS	O
were	VBD	O
pretreated	VBN	O
with	IN	O
lidocaine	JJ	O
1.0	CD	O
mg/kg	NN	O
followed	VBN	O
by	IN	O
propofol	NN	O
2.0	CD	O
mg/kg	NN	O
at	IN	O
3.3	CD	O
mg/sec	NN	O
.	.	O

In	IN	O
Group	NNP	O
D	NNP	O
,	,	O
patients	NNS	O
were	VBD	O
pretreated	VBN	O
with	IN	O
normal	JJ	O
saline	NN	O
followed	VBN	O
by	IN	O
propofol	NN	O
2.0	CD	O
mg/kg	NN	O
at	IN	O
50	CD	O
mg/sec	NN	O
.	.	O

MEASUREMENTS	NNP	O
Pain	NNP	O
on	IN	O
injection	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
4-point	JJ	O
scale	NN	O
.	.	O

Scale	NNP	O
and	CC	O
success	NN	O
rate	NN	O
of	IN	O
smooth	JJ	O
LMA	NNP	O
insertion	NN	O
also	RB	O
were	VBD	O
recorded	VBN	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Rapid	NNP	O
injection	NN	O
was	VBD	O
less	RBR	O
painful	JJ	O
than	IN	O
after	IN	O
pretreatment	NN	O
with	IN	O
lidocaine	JJ	O
0.5	CD	O
mg/kg	NN	O
,	,	O
but	CC	O
was	VBD	O
similar	JJ	O
to	TO	O
slow	VB	O
injection	NN	O
after	IN	O
pretreatment	NN	O
with	IN	O
lidocaine	JJ	O
1.0	CD	O
mg/kg	NN	O
.	.	O

Rapid	JJ	O
injection	NN	O
facilitated	VBD	O
LMA	NNP	O
insertion	NN	O
,	,	O
unlike	IN	O
slow	JJ	O
injection	NN	O
with	IN	O
lidocaine	JJ	O
0.5	CD	O
mg/kg	NN	O
pretreatment	NN	O
,	,	O
and	CC	O
was	VBD	O
similarly	RB	O
successful	JJ	O
to	TO	O
slow	VB	O
injection	NN	O
after	IN	O
pretreatment	NN	O
with	IN	O
lidocaine	JJ	O
1.0	CD	O
mg/kg	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
rapid	JJ	O
administration	NN	O
of	IN	O
propofol	JJ	O
reduces	NNS	O
pain	NN	O
and	CC	O
facilitates	VBZ	O
LMA	NNP	O
insertion	NN	O
versus	NN	O
slow	JJ	O
administration	NN	O
of	IN	O
propofol	NN	O
.	.	O

Reducing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
coronary	JJ	O
events	NNS	O
:	:	O
evidence	NN	O
from	IN	O
the	DT	O
Scandinavian	JJ	O
Simvastatin	NNP	O
Survival	NNP	O
Study	NNP	O
(	(	O
4S	CD	O
)	)	O
.	.	O

The	DT	O
Scandinavian	JJ	O
Simvastatin	NNP	O
Survival	NNP	O
Study	NNP	O
(	(	O
4S	CD	O
)	)	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
cholesterol	NN	O
reduction	NN	O
with	IN	O
simvastatin	NN	O
on	IN	O
mortality	NN	O
and	CC	O
morbidity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	Condition
artery	NN	Condition
disease	NN	Condition
(	(	Condition
CAD	NNP	Condition
)	)	Condition
.	.	O

A	DT	O
total	NN	O
of	IN	O
4,444	CD	SampleSize
patients	NNS	O
with	IN	O
angina	JJ	Condition
pectoris	NN	Condition
or	CC	O
previous	JJ	O
myocardial	JJ	Condition
infarction	NN	Condition
and	CC	O
serum	VB	Condition
cholesterol	NN	Condition
levels	NNS	Condition
of	IN	O
213-310	JJ	O
mg/dl	NN	O
(	(	O
5.5-8.0	JJ	O
mmol/liter	NN	O
)	)	O
while	IN	O
treated	VBN	O
with	IN	O
a	DT	O
lipid-lowering	JJ	O
diet	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
with	IN	O
simvastatin	NN	O
or	CC	O
placebo	NN	O
.	.	O

Over	IN	O
the	DT	O
5.4	CD	O
years	NNS	O
of	IN	O
median	JJ	O
follow-up	NN	O
,	,	O
simvastatin	NN	O
produced	VBD	O
changes	NNS	O
in	IN	O
total	JJ	O
cholesterol	NN	O
,	,	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
(	(	O
LDL	NNP	O
)	)	O
cholesterol	NN	O
,	,	O
and	CC	O
high	JJ	O
density	NN	O
lipoprotein	NN	O
(	(	O
HDL	NNP	O
)	)	O
cholesterol	NN	O
of	IN	O
-25	NNP	O
%	NN	O
,	,	O
-35	CD	O
%	NN	O
,	,	O
and	CC	O
+8	NNP	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
minimal	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
256	CD	SampleSize
patients	NNS	O
(	(	O
12	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
died	VBD	O
compared	VBN	O
with	IN	O
182	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
simvastatin	NN	O
group	NN	O
,	,	O
a	DT	O
risk	NN	O
reduction	NN	O
of	IN	O
30	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0003	CD	O
)	)	O
attributable	NN	O
to	TO	O
a	DT	O
42	CD	O
%	NN	O
reduction	NN	O
in	IN	O
the	DT	O
risk	NN	O
of	IN	O
coronary	JJ	O
death	NN	O
.	.	O

Noncardiovascular	JJ	O
causes	NNS	O
accounted	VBD	O
for	IN	O
49	CD	O
and	CC	O
46	CD	O
deaths	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
and	CC	O
simvastatin	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Major	JJ	O
coronary	JJ	O
events	NNS	O
were	VBD	O
experienced	VBN	O
by	IN	O
622	CD	O
patients	NNS	O
(	(	O
28	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
431	CD	O
patients	NNS	O
(	(	O
19	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
simvastatin	NN	O
group	NN	O
,	,	O
corresponding	VBG	O
to	TO	O
a	DT	O
risk	NN	O
reduction	NN	O
of	IN	O
34	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.00001	CD	O
)	)	O
.	.	O

This	DT	O
risk	NN	O
was	VBD	O
also	RB	O
significantly	RB	O
reduced	VBN	O
in	IN	O
subgroups	NNS	O
consisting	VBG	O
of	IN	O
women	NNS	Sex
and	CC	O
patients	NNS	O
of	IN	O
both	DT	Sex
sexes	NNS	Sex
aged	VBN	O
>	CD	O
or	CC	O
=	$	O
60	CD	O
years	NNS	O
.	.	O

Other	JJ	O
benefits	NNS	O
of	IN	O
treatment	NN	O
included	VBD	O
a	DT	O
37	CD	O
%	NN	O
reduction	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.00001	CD	O
)	)	O
in	IN	O
the	DT	O
risk	NN	O
of	IN	O
undergoing	VBG	O
myocardial	JJ	O
revascularization	NN	O
procedures	NNS	O
.	.	O

Simvastatin	NNP	O
was	VBD	O
beneficial	JJ	O
regardless	NN	O
of	IN	O
whether	IN	O
patients	NNS	O
had	VBD	O
a	DT	O
history	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
whether	IN	O
they	PRP	O
were	VBD	O
smokers	NNS	O
or	CC	O
had	VBD	O
hypertension	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Efficiency	NN	O
of	IN	O
anaferon	NN	O
in	IN	O
complex	JJ	O
therapy	NN	O
of	IN	O
genital	JJ	Condition
herpes	NNS	Condition
.	.	O

We	PRP	O
studied	VBD	O
clinical	JJ	O
efficiency	NN	O
and	CC	O
IFN-inducing	JJ	O
activity	NN	O
of	IN	O
anaferon	NN	O
in	IN	O
chronic	JJ	Condition
recurrent	NN	Condition
genital	JJ	Condition
herpes	NNS	Condition
with	IN	Condition
high	JJ	Condition
incidence	NN	Condition
of	IN	Condition
relapses	NNS	Condition
.	.	O

The	DT	O
use	NN	O
of	IN	O
anaferon	NN	O
in	IN	O
complex	JJ	O
therapy	NN	O
reduced	VBD	O
the	DT	O
duration	NN	O
of	IN	O
intoxication	NN	O
symptoms	NNS	O
and	CC	O
local	JJ	O
symptoms	NNS	O
,	,	O
shortened	VBD	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
relapse	NN	O
,	,	O
activated	JJ	O
expression	NN	O
of	IN	O
IFN-gamma	NNP	O
mRNA	NN	O
,	,	O
and	CC	O
improved	VBD	O
IFN-gamma-producing	NNP	O
capacity	NN	O
of	IN	O
blood	NN	O
leukocytes	NNS	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
caudal	JJ	O
bupivacaine	NN	O
and	CC	O
midazolam-bupivacaine	JJ	O
mixture	NN	O
for	IN	O
post-operative	JJ	O
analgesia	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
genitourinary	JJ	O
surgery	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
caudal	JJ	O
midazolam-bupivacaine	JJ	O
combination	NN	O
in	IN	O
providing	VBG	O
post-operative	JJ	O
pain	NN	O
relief	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
genitourinary	JJ	O
surgery	NN	O
and	CC	O
to	TO	O
study	VB	O
the	DT	O
occurrence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
Thirty	NNP	O
children	NNS	O
,	,	O
aged	VBD	O
2	CD	O
to	TO	O
8	CD	O
years	NNS	O
,	,	O
scheduled	VBN	O
for	IN	O
genitourinary	JJ	O
surgery	NN	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
to	TO	O
receive	VB	O
either	RB	O
0.25	CD	O
%	NN	O
bupivacaine	NN	O
0.5	CD	O
ml/kg	NN	O
(	(	O
group	NN	O
B	NNP	O
;	:	O
n	CC	O
=	VB	O
15	CD	O
)	)	O
or	CC	O
0.25	CD	O
%	NN	O
bupivacaine	NN	O
0.5	CD	O
ml/kg	NN	O
with	IN	O
50	CD	O
microg/kg	NNS	O
midazolam	NN	O
(	(	O
group	NN	O
BM	NNP	O
;	:	O
n	CC	O
=	VB	O
15	CD	O
)	)	O
by	IN	O
the	DT	O
caudal	JJ	O
route	NN	O
immediately	RB	O
after	IN	O
induction	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

Heart	NNP	O
rate	NN	O
,	,	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
oxygen	NN	O
saturation	NN	O
were	VBD	O
monitored	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

Postoperative	JJ	O
pain	NN	O
was	VBD	O
assessed	VBN	O
at	IN	O
regular	JJ	O
intervals	NNS	O
for	IN	O
12	CD	O
hours	NNS	O
using	VBG	O
an	DT	O
objective	JJ	O
pain	NN	O
score	NN	O
.	.	O

Analgesia	NNP	O
was	VBD	O
supplemented	VBN	O
whenever	IN	O
the	DT	O
pain	NN	O
score	NN	O
was	VBD	O
>	JJ	O
or	CC	O
=	JJ	O
4	CD	O
.	.	O

Duration	NN	O
of	IN	O
analgesia	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
requirement	NN	O
of	IN	O
additional	JJ	O
analgesics	NNS	O
,	,	O
were	VBD	O
noted	VBN	O
.	.	O

RESULTS	NNP	O
Lowest	NNP	O
pain	NN	O
scores	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
midazolam	NN	O
to	TO	O
caudal	VB	O
bupivacaine	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Duration	NN	O
of	IN	O
analgesia	NN	O
was	VBD	O
longer	RBR	O
in	IN	O
group	NN	O
BM	NNP	O
(	(	O
11	CD	O
+/-	JJ	O
0.5	CD	O
h	NN	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
group	NN	O
B	NNP	O
(	(	O
7.4	CD	O
+/-	JJ	O
2.1	CD	O
hours	NNS	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Fewer	JJR	O
children	NNS	O
(	(	O
26.6	CD	O
%	NN	O
)	)	O
required	VBD	O
additional	JJ	O
analgesia	NN	O
in	IN	O
the	DT	O
combination	NN	O
group	NN	O
whereas	VBZ	O
in	IN	O
group	NN	O
B	NNP	O
,	,	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
children	NNS	O
received	VBD	O
analgesic	JJ	O
supplements	NNS	O
within	IN	O
6	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
and	CC	O
oxygen	NN	O
saturation	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

We	PRP	O
observed	VBD	O
no	DT	O
untoward	JJ	O
event	NN	O
in	IN	O
either	DT	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Caudal	NNP	O
administration	NN	O
of	IN	O
bupivacaine-midazolam	JJ	O
mixture	NN	O
prolongs	NNS	O
post-operative	JJ	O
analgesia	NNS	O
compared	VBN	O
to	TO	O
bupivacaine	VB	O
alone	RB	O
without	IN	O
causing	VBG	O
any	DT	O
adverse	JJ	O
effects	NNS	O
.	.	O

Is	VBZ	O
successful	JJ	O
rehabilitation	NN	O
of	IN	O
complex	JJ	Condition
regional	JJ	Condition
pain	NN	Condition
syndrome	NN	Condition
due	JJ	O
to	TO	O
sustained	JJ	O
attention	NN	O
to	TO	O
the	DT	O
affected	JJ	O
limb	NN	O
?	.	O
A	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

In	IN	O
complex	JJ	O
regional	JJ	O
pain	NN	O
syndrome	NN	O
(	(	O
CRPS1	NNP	O
)	)	O
initiated	VBN	O
by	IN	O
wrist	JJ	O
fracture	NN	O
,	,	O
a	DT	O
motor	NN	O
imagery	NN	O
program	NN	O
(	(	O
MIP	NNP	O
)	)	O
,	,	O
consisting	VBG	O
of	IN	O
hand	NN	O
laterality	NN	O
recognition	NN	O
followed	VBN	O
by	IN	O
imagined	JJ	O
movements	NNS	O
and	CC	O
then	RB	O
mirror	NN	O
movements	NNS	O
,	,	O
reduces	NNS	O
pain	VBP	O
and	CC	O
disability	NN	O
,	,	O
but	CC	O
the	DT	O
mechanism	NN	O
of	IN	O
effect	NN	O
is	VBZ	O
unclear	JJ	O
.	.	O

Possibilities	NNS	O
include	VBP	O
sustained	JJ	O
attention	NN	O
to	TO	O
the	DT	O
affected	JJ	O
limb	NN	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
the	DT	O
order	NN	O
of	IN	O
MIP	NNP	O
components	NNS	O
would	MD	O
not	RB	O
alter	VB	O
the	DT	O
effect	NN	O
,	,	O
and	CC	O
sequential	JJ	O
activation	NN	O
of	IN	O
cortical	JJ	O
motor	NN	O
networks	NNS	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
it	PRP	O
would	MD	O
.	.	O

Twenty	VB	SampleSize
subjects	NNS	O
with	IN	O
chronic	JJ	Condition
CRPS1	NNP	Condition
initiated	VBN	O
by	IN	O
wrist	JJ	Condition
fracture	NN	Condition
and	CC	O
who	WP	O
satisfied	VBD	O
stringent	JJ	O
inclusion	NN	O
criteria	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
hand	NN	O
laterality	NN	O
recognition	NN	O
,	,	O
imagined	VBD	O
movements	NNS	O
,	,	O
mirror	NN	O
movements	NNS	O
(	(	O
RecImMir	NNP	O
,	,	O
MIP	NNP	O
)	)	O
;	:	O
imagined	VBN	O
movements	NNS	O
,	,	O
recognition	NN	O
,	,	O
imagined	VBD	O
movements	NNS	O
(	(	O
ImRecIm	NNP	O
)	)	O
;	:	O
recognition	NN	O
,	,	O
mirror	NN	O
movements	NNS	O
,	,	O
recognition	NN	O
(	(	O
RecMirRec	NNP	O
)	)	O
.	.	O

At	IN	O
6	CD	O
and	CC	O
18	CD	O
weeks	NNS	O
,	,	O
reduced	VBD	O
pain	NN	O
and	CC	O
disability	NN	O
were	VBD	O
greater	JJR	O
for	IN	O
the	DT	O
RecImMir	NNP	O
group	NN	O
than	IN	O
for	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Hand	NNP	O
laterality	NN	O
recognition	NN	O
imparted	VBD	O
a	DT	O
consistent	JJ	O
reduction	NN	O
in	IN	O
pain	NN	O
and	CC	O
disability	NN	O
across	IN	O
groups	NNS	O
,	,	O
however	RB	O
,	,	O
this	DT	O
effect	NN	O
was	VBD	O
limited	VBN	O
in	IN	O
magnitude	NN	O
.	.	O

Imagined	VBD	O
movements	NNS	O
imparted	VBD	O
a	DT	O
further	JJ	O
reduction	NN	O
in	IN	O
pain	NN	O
and	CC	O
disability	NN	O
,	,	O
but	CC	O
only	RB	O
if	IN	O
they	PRP	O
followed	VBD	O
hand	NN	O
laterality	NN	O
recognition	NN	O
.	.	O

Mirror	NN	O
movements	NNS	O
also	RB	O
imparted	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
pain	NN	O
and	CC	O
disability	NN	O
,	,	O
but	CC	O
only	RB	O
when	WRB	O
they	PRP	O
followed	VBD	O
imagined	JJ	O
movements	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
MIP	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
dependent	JJ	O
on	IN	O
the	DT	O
order	NN	O
of	IN	O
components	NNS	O
,	,	O
which	WDT	O
suggests	VBZ	O
that	IN	O
it	PRP	O
is	VBZ	O
not	RB	O
due	JJ	O
to	TO	O
sustained	JJ	O
attention	NN	O
to	TO	O
the	DT	O
affected	JJ	O
limb	NN	O
,	,	O
but	CC	O
is	VBZ	O
consistent	JJ	O
with	IN	O
sequential	JJ	O
activation	NN	O
of	IN	O
cortical	JJ	O
motor	NN	O
networks	NNS	O
.	.	O

LDL	NNP	O
cholesterol-raising	JJ	O
effect	NN	O
of	IN	O
low-dose	JJ	O
docosahexaenoic	NN	O
acid	NN	O
in	IN	O
middle-aged	JJ	O
men	NNS	Sex
and	CC	O
women	NNS	Sex
.	.	O

BACKGROUND	NNP	O
Long-chain	JJ	O
n-3	JJ	O
polyunsaturated	VBN	O
fatty	JJ	O
acids	NNS	O
have	VBP	O
variable	JJ	O
effects	NNS	O
on	IN	O
LDL	NNP	O
cholesterol	NN	O
,	,	O
and	CC	O
the	DT	O
effects	NNS	O
of	IN	O
docosahexaenoic	NN	O
acid	NN	O
(	(	O
DHA	NNP	O
)	)	O
are	VBP	O
uncertain	JJ	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
on	IN	O
blood	NN	O
lipids	NNS	O
of	IN	O
a	DT	O
daily	JJ	O
intake	NN	O
of	IN	O
0.7	CD	O
g	JJ	O
DHA	NNP	O
as	IN	O
triacylglycerol	NN	O
in	IN	O
middle-aged	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

DESIGN	NNP	O
Men	NNP	O
and	CC	O
women	NNS	O
aged	VBN	O
40-65	JJ	Age
y	NN	Age
(	(	O
n	JJ	O
=	NNP	O
38	CD	SampleSize
)	)	O
underwent	NN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	JJ	O
trial	NN	O
of	IN	O
treatment	NN	O
with	IN	O
0.7	CD	O
g	NNS	O
DHA/d	NNP	O
for	IN	O
3	CD	O
mo	NNS	O
.	.	O

RESULTS	NNP	O
DHA	NNP	O
supplementation	NN	O
increased	VBD	O
the	DT	O
DHA	NNP	O
concentration	NN	O
in	IN	O
plasma	NN	O
by	IN	O
76	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
the	DT	O
proportion	NN	O
in	IN	O
erythrocyte	JJ	O
lipids	NNS	O
by	IN	O
58	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Values	NNS	O
for	IN	O
serum	NN	O
total	JJ	O
cholesterol	NN	O
,	,	O
LDL	NNP	O
cholesterol	NN	O
,	,	O
and	CC	O
plasma	NN	O
apolipoprotein	NN	O
B	NNP	O
concentrations	NNS	O
were	VBD	O
4.2	CD	O
%	NN	O
(	(	O
0.22	CD	O
mmol/L	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
7.1	CD	O
%	NN	O
(	(	O
0.23	CD	O
mmol/L	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
and	CC	O
3.4	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
higher	JJR	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
DHA	NNP	O
treatment	NN	O
than	IN	O
with	IN	O
placebo	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
LDL	NNP	O
cholesterol	NN	O
:	:	O
apolipoprotein	NN	O
B	NNP	O
ratio	NN	O
was	VBD	O
3.1	CD	O
%	NN	O
higher	JJR	O
with	IN	O
DHA	NNP	O
treatment	NN	O
than	IN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
which	WDT	O
suggested	VBD	O
an	DT	O
increase	NN	O
in	IN	O
LDL	NNP	O
size	NN	O
.	.	O

Plasma	NNP	O
lathosterol	NN	O
and	CC	O
plant	NN	O
sterol	NN	O
concentrations	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
treatment	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
daily	JJ	O
intake	NN	O
of	IN	O
approximately	RB	O
0.7	CD	O
g	JJ	O
DHA	NNP	O
increases	VBZ	O
LDL	NNP	O
cholesterol	NN	O
by	IN	O
7	CD	O
%	NN	O
in	IN	O
middle-aged	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
DHA	NNP	O
down-regulates	VBZ	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
LDL	NNP	O
receptor	NN	O
.	.	O

Differential	JJ	O
effects	NNS	O
on	IN	O
bone	NN	O
density	NN	O
of	IN	O
progestogen-only	JJ	O
methods	NNS	O
for	IN	O
contraception	NN	O
in	IN	O
premenopausal	JJ	Condition
women	NNS	Condition
.	.	Condition

The	DT	O
question	NN	O
of	IN	O
differential	JJ	O
effects	NNS	O
on	IN	O
bone	NN	O
density	NN	O
by	IN	O
two	CD	O
different	JJ	O
types	NNS	O
of	IN	O
progestogen-only	JJ	O
methods	NNS	O
for	IN	O
contraception	NN	O
in	IN	O
premenopausal	JJ	O
women	NNS	O
was	VBD	O
addressed	VBN	O
.	.	O

Data	NNS	O
from	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
among	IN	O
22	CD	O
premenopausal	JJ	O
women	NNS	O
,	,	O
age	NN	O
32.6	CD	O
(	(	O
range	JJ	O
20-45	CD	O
years	NNS	O
)	)	O
,	,	O
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
of	IN	O
two	CD	O
treatments	NNS	O
with	IN	O
continuous	JJ	O
progestogens	NNS	O
for	IN	O
contraception	NN	O
were	VBD	O
analyzed	VBN	O
;	:	O
depot-medroxyprogesterone	JJ	O
acetate	NN	O
(	(	O
DMPA	NNP	O
)	)	O
or	CC	O
continuous	JJ	O
levonorgestrel	NN	O
treatment	NN	O
with	IN	O
subdermal	JJ	O
implants	NNS	O
(	(	O
Norplant	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Forearm	NNP	O
bone	NN	O
density	NN	O
(	(	O
BMDprox	NNP	O
)	)	O
increased	VBD	O
with	IN	O
2.94	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
in	IN	O
women	NNS	O
who	WP	O
were	VBD	O
prescribed	VBN	O
levonorgestrel	NN	O
,	,	O
which	WDT	O
was	VBD	O
in	IN	O
contrast	NN	O
to	TO	O
stable	JJ	O
values	NNS	O
in	IN	O
those	DT	O
prescribed	JJ	O
depot-medroxy-progesterone	JJ	O
acetate	NN	O
;	:	O
group	NN	O
difference	NN	O
at	IN	O
6	CD	O
months	NNS	O
for	IN	O
BMDprox	NNP	O
3.4	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.3	CD	O
,	,	O
5.5	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.025	CD	O
)	)	O
and	CC	O
BMDdist	$	O
4.1	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-	:	O
1.3	CD	O
,	,	O
9.6	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.077	CD	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
bone	NN	O
density	NN	O
were	VBD	O
consistent	JJ	O
with	IN	O
the	DT	O
changes	NNS	O
in	IN	O
biochemical	JJ	O
indices	NNS	O
for	IN	O
bone	NN	O
metabolism	NN	O
;	:	O
DMPA	NNP	O
users	NNS	O
showed	VBD	O
signs	NNS	O
of	IN	O
increased	VBN	O
bone	NN	O
turnover	NN	O
and	CC	O
users	NNS	O
of	IN	O
levonorgestrel	NN	O
showed	VBD	O
increased	JJ	O
bone	NN	O
formation	NN	O
with	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
both	DT	O
alkaline	JJ	O
phosphatase	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
and	CC	O
osteocalcin	$	O
(	(	O
p	JJ	O
=	NNP	O
0.007	CD	O
)	)	O
.	.	O

The	DT	O
findings	NNS	O
suggest	VBP	O
an	DT	O
increase	NN	O
in	IN	O
bone	JJ	O
density	NN	O
during	IN	O
treatment	NN	O
with	IN	O
levonorgestrel	NN	O
and	CC	O
stable	JJ	O
values	NNS	O
during	IN	O
short-term	JJ	O
administration	NN	O
of	IN	O
DMPA	NNP	O
,	,	O
in	IN	O
standard	JJ	O
clinical	JJ	O
doses	NNS	O
for	IN	O
contraception	NN	O
.	.	O

Improving	VBG	O
emotion	NN	O
regulation	NN	O
with	IN	O
CBT	NNP	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
This	DT	O
pilot	NN	O
study	NN	O
tested	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
developmentally	RB	O
modified	VBN	O
CBT	NNP	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
to	TO	O
teach	VB	O
emotion	NN	O
regulation	NN	O
strategies	NNS	O
for	IN	O
reducing	VBG	O
anger	NN	O
and	CC	O
anxiety	NN	O
,	,	O
commonly	RB	O
noted	VBD	O
problems	NNS	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

METHOD	NNP	O
Eleven	NNP	O
5-7	JJ	O
year-old	JJ	O
children	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
CBT-group	NNP	O
while	IN	O
parents	NNS	O
participated	VBN	O
in	IN	O
psychoeducation	NN	O
.	.	O

Children	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
experimental	JJ	O
or	CC	O
delayed-treatment	JJ	O
control	NN	O
group	NN	O
.	.	O

RESULTS	CC	O
From	IN	O
pre-	JJ	O
to	TO	O
post-treatment	JJ	O
,	,	O
all	DT	O
children	NNS	O
had	VBD	O
less	RBR	O
parent	NN	O
reported	VBD	O
negativity/lability	NN	O
,	,	O
better	JJR	O
parent	NN	O
reported	VBD	O
emotion	NN	O
regulation	NN	O
,	,	O
and	CC	O
shorter	JJR	O
outbursts	NNS	O
,	,	O
and	CC	O
also	RB	O
generated	VBD	O
more	RBR	O
coping	JJ	O
strategies	NNS	O
in	IN	O
response	NN	O
to	TO	O
vignettes	NNS	O
.	.	O

Parents	NNS	O
also	RB	O
reported	VBD	O
increases	NNS	O
in	IN	O
their	PRP$	O
own	JJ	O
confidence	NN	O
and	CC	O
their	PRP$	O
child	NN	O
's	POS	O
ability	NN	O
to	TO	O
deal	VB	O
with	IN	O
anger	NN	O
and	CC	O
anxiety	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
young	JJ	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
ASD	NNP	O
may	MD	O
benefit	VB	O
from	IN	O
CBT	NNP	O
to	TO	O
improve	VB	O
regulation	NN	O
of	IN	O
anger	NN	O
and	CC	O
anxiety	NN	O
,	,	O
and	CC	O
parent	NN	O
training	NN	O
may	MD	O
improve	VB	O
parental	JJ	O
self-efficacy	NN	O
.	.	O

Future	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
make	VB	O
conclusions	NNS	O
about	IN	O
its	PRP$	O
efficacy	NN	O
.	.	O

Comparative	JJ	O
effects	NNS	O
of	IN	O
valsartan	JJ	O
versus	NN	O
amlodipine	NN	O
on	IN	O
left	JJ	O
ventricular	JJ	O
mass	NN	O
and	CC	O
reactive	JJ	O
oxygen	NN	O
species	NNS	O
formation	NN	O
by	IN	O
monocytes	NNS	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
hypertrophy	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
angiotensin	NN	O
receptor	NN	O
blocker	NN	O
(	(	O
ARB	NNP	O
)	)	O
valsartan	VBP	O
versus	IN	O
the	DT	O
calcium	NN	O
channel	NN	O
blocker	NN	O
amlodipine	NN	O
,	,	O
reactive	JJ	O
oxygen	NN	O
species	NNS	O
(	(	O
ROS	NNP	O
)	)	O
formation	NN	O
by	IN	O
monocytes	NNS	O
,	,	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
and	CC	O
left	VBD	O
ventricular	NN	O
(	(	O
LV	NNP	O
)	)	O
mass	NN	O
were	VBD	O
studied	VBN	O
in	IN	O
104	CD	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
hypertrophy	NN	O
(	(	O
LVH	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
evidence	NN	O
that	IN	O
ARBs	NNP	O
have	VBP	O
blood	VBN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
-independent	NN	O
effects	NNS	O
on	IN	O
LV	NNP	O
mass	NN	O
.	.	O

Whether	NNP	O
regression	NN	O
of	IN	O
LV	NNP	O
mass	NN	O
by	IN	O
ARBs	NNP	O
is	VBZ	O
correlated	VBN	O
to	TO	O
ROS	NNP	O
formation	NN	O
by	IN	O
monocytes	NNS	O
and	CC	O
CRP	NNP	O
is	VBZ	O
not	RB	O
fully	RB	O
understood	JJ	O
yet	RB	O
.	.	O

METHODS	VB	O
A	DT	O
cross-sectional	JJ	O
and	CC	O
prospective	JJ	O
study	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
the	DT	O
80-mg	JJ	O
valsartan	NN	O
(	(	O
n	JJ	O
=	NNP	O
52	CD	O
)	)	O
or	CC	O
5-mg	JJ	O
amlodipine	NN	O
(	(	O
n	JJ	O
=	NNP	O
52	CD	O
)	)	O
group	NN	O
and	CC	O
were	VBD	O
treated	VBN	O
for	IN	O
eight	CD	O
months	NNS	O
.	.	O

The	DT	O
left	JJ	O
ventricular	JJ	O
mass	NN	O
index	NN	O
(	(	O
LVMI	NNP	O
)	)	O
was	VBD	O
calculated	VBN	O
from	IN	O
two-dimensional	JJ	O
M-mode	NNP	O
echocardiography	NN	O
.	.	O

Formation	NN	O
of	IN	O
ROS	NNP	O
by	IN	O
monocytes	NNS	O
was	VBD	O
measured	VBN	O
by	IN	O
gated	VBN	O
flow	JJ	O
cytometry	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
CRP	NNP	O
,	,	O
plasma	JJ	O
renin	NN	O
activity	NN	O
,	,	O
plasma	NN	O
aldosterone	NN	O
,	,	O
and	CC	O
traditional	JJ	O
risk	NN	O
factors	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Multiple	NNP	O
regression	NN	O
analysis	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
correlation	NN	O
between	IN	O
LVMI	NNP	O
and	CC	O
ROS	NNP	O
formation	NN	O
by	IN	O
monocytes	NNS	O
and	CC	O
between	IN	O
LVMI	NNP	O
and	CC	O
CRP	NNP	O
.	.	O

Treatment	NNP	O
reduced	VBD	O
BP	NNP	O
to	TO	O
a	DT	O
similar	JJ	O
extent	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Valsartan	NNP	O
significantly	RB	O
reduced	VBD	O
LVMI	NNP	O
after	IN	O
eight	CD	O
months	NNS	O
,	,	O
but	CC	O
amlodipine	NN	O
had	VBD	O
less	RBR	O
effect	NN	O
(	(	O
16	CD	O
%	NN	O
vs.	FW	O
1.2	CD	O
%	NN	O
,	,	O
n	JJ	O
=	NN	O
50	CD	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Formation	NN	O
of	IN	O
ROS	NNP	O
by	IN	O
monocytes	NNS	O
was	VBD	O
reduced	VBN	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
with	IN	O
valsartan	NN	O
than	IN	O
with	IN	O
amlodipine	NN	O
(	(	O
28	CD	O
%	NN	O
vs.	FW	O
2	CD	O
%	NN	O
,	,	O
n	JJ	O
=	NN	O
50	CD	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Valsartan	NNP	O
but	CC	O
not	RB	O
amlodipine	VB	O
reduced	VBN	O
CRP	NNP	O
levels	NNS	O
.	.	O

A	DT	O
significant	JJ	O
correlation	NN	O
between	IN	O
changes	NNS	O
in	IN	O
ROS	NNP	O
formation	NN	O
by	IN	O
monocytes	NNS	O
and	CC	O
LVMI	NNP	O
or	CC	O
between	IN	O
CRP	NNP	O
and	CC	O
LVMI	NNP	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
ARB	NNP	O
valsartan	NN	O
has	VBZ	O
BP-independent	JJ	O
effects	NNS	O
on	IN	O
LVH	NNP	O
,	,	O
ROS	NNP	O
formation	NN	O
by	IN	O
monocytes	NNS	O
,	,	O
and	CC	O
CRP	NNP	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
LVH	NNP	O
.	.	O

Mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
small	JJ	O
choroidal	NNS	O
melanoma	NN	O
.	.	O

COMS	NNP	O
report	NN	O
no	DT	O
.	.	O

4	CD	O
.	.	O

The	DT	O
Collaborative	JJ	O
Ocular	NNP	O
Melanoma	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
describe	VB	O
the	DT	O
clinical	JJ	O
characteristics	NNS	O
and	CC	O
survival	JJ	O
experience	NN	O
of	IN	O
a	DT	O
prospectively	RB	O
followed	VBN	O
up	RP	O
group	NN	O
of	IN	O
patients	NNS	O
with	IN	O
small	JJ	O
choroidal	NNS	O
melanoma	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
Collaborative	NNP	O
Ocular	NNP	O
Melanoma	NNP	O
Study	NNP	O
(	(	O
COMS	NNP	O
)	)	O
is	VBZ	O
a	DT	O
set	NN	O
of	IN	O
clinical	JJ	O
trials	NNS	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
role	NN	O
of	IN	O
radiotherapy	NN	O
and	CC	O
enucleation	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
medium	NN	O
and	CC	O
large-size	JJ	O
choroidal	NN	O
melanoma	NN	O
.	.	O

From	IN	O
December	NNP	O
1986	CD	O
to	TO	O
August	NNP	O
1989	CD	O
,	,	O
patients	NNS	O
with	IN	O
small	JJ	O
choroidal	NN	O
melanoma	NN	O
,	,	O
not	RB	O
large	JJ	O
enough	RB	O
to	TO	O
be	VB	O
eligible	JJ	O
for	IN	O
the	DT	O
COMS	NNP	O
clinical	JJ	O
trials	NNS	O
,	,	O
were	VBD	O
offered	VBN	O
participation	NN	O
in	IN	O
a	DT	O
nonrandomized	JJ	O
prospective	JJ	O
follow-up	NN	O
study	NN	O
.	.	O

Small	NNP	O
choroidal	JJ	O
melanomas	NN	O
were	VBD	O
defined	VBN	O
as	IN	O
1.0	CD	O
to	TO	O
3.0	CD	O
mm	NNS	O
in	IN	O
apical	JJ	O
height	NN	O
and	CC	O
at	IN	O
least	JJS	O
5.0	CD	O
mm	NN	O
in	IN	O
basal	NN	O
diameter	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
204	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
annually	RB	O
through	IN	O
August	NNP	O
1989	CD	O
.	.	O

Two	CD	O
additional	JJ	O
assessments	NNS	O
of	IN	O
treatment	NN	O
status	NN	O
and	CC	O
mortality	NN	O
were	VBD	O
conducted	VBN	O
in	IN	O
1993-1994	JJ	O
and	CC	O
1995-1996	JJ	O
.	.	O

The	DT	O
median	JJ	O
length	NN	O
of	IN	O
follow-up	NN	O
was	VBD	O
92	CD	O
months	NNS	O
.	.	O

Eight	NNP	O
percent	NN	O
of	IN	O
patients	NNS	O
were	VBD	O
treated	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
study	NN	O
enrollment	NN	O
and	CC	O
an	DT	O
additional	JJ	O
33	CD	O
%	NN	O
were	VBD	O
treated	VBN	O
during	IN	O
follow-up	JJ	O
.	.	O

RESULTS	JJ	O
Twenty-seven	JJ	O
patients	NNS	O
have	VBP	O
died	VBN	O
;	:	O
6	CD	O
deaths	NNS	O
were	VBD	O
reported	VBN	O
by	IN	O
the	DT	O
clinical	JJ	O
center	NN	O
as	IN	O
due	JJ	O
to	TO	O
metastatic	JJ	O
melanoma	NN	O
.	.	O

The	DT	O
Kaplan-Meier	NNP	O
estimate	NN	O
of	IN	O
5-year	JJ	O
all-cause	JJ	O
mortality	NN	O
was	VBD	O
6.0	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
2.7	CD	O
%	NN	O
-9.3	NNP	O
%	NN	O
)	)	O
and	CC	O
8-year	JJ	O
all-cause	NN	O
mortality	NN	O
was	VBD	O
14.9	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
9.6	CD	O
%	NN	O
-20.2	NNP	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Otherwise	NNP	O
healthy	JJ	O
patients	NNS	O
,	,	O
average	JJ	O
age	NN	O
of	IN	O
60	CD	O
years	NNS	O
,	,	O
without	IN	O
a	DT	O
previous	JJ	O
diagnosis	NN	O
of	IN	O
malignant	JJ	O
disease	NN	O
who	WP	O
have	VBP	O
small	JJ	O
choroidal	JJ	O
lesions	NNS	O
judged	VBD	O
to	TO	O
be	VB	O
melanoma	VBN	O
have	VBP	O
a	DT	O
low	JJ	O
risk	NN	O
of	IN	O
dying	VBG	O
within	IN	O
5	CD	O
years	NNS	O
.	.	O

A	DT	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
of	IN	O
a	DT	O
CBT	NNP	O
intervention	NN	O
for	IN	O
anxiety	NN	Condition
in	IN	O
children	NNS	O
with	IN	O
Asperger	NNP	Condition
syndrome	NN	Condition
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
brief	JJ	O
CBT	NNP	O
intervention	NN	O
for	IN	O
anxiety	NN	O
with	IN	O
children	NNS	Age
diagnosed	VBN	O
with	IN	O
Asperger	NNP	Condition
syndrome	NN	Condition
(	(	Condition
AS	IN	Condition
)	)	Condition
.	.	O

A	DT	O
second	JJ	O
interest	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
whether	IN	O
more	RBR	O
intensive	JJ	O
parent	NN	O
involvement	NN	O
would	MD	O
increase	VB	O
the	DT	O
child	NN	O
's	POS	O
ability	NN	O
to	TO	O
manage	VB	O
anxiety	NN	O
outside	IN	O
of	IN	O
the	DT	O
clinic	JJ	O
setting	NN	O
.	.	O

METHODS	NNP	O
Seventy-one	JJ	Condition
children	NNS	O
aged	VBN	O
ten	NNS	O
to	TO	O
twelve	VB	O
years	NNS	O
were	VBD	O
recruited	VBN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
anxiety	NN	O
programme	NN	O
.	.	O

All	DT	O
children	NNS	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
AS	NNP	Condition
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
anxiety	NN	Condition
symptoms	NNS	Condition
was	VBD	O
accepted	VBN	O
on	IN	O
parent	NN	O
report	NN	O
via	IN	O
brief	JJ	O
interview	NN	O
.	.	O

Children	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
conditions	NNS	O
:	:	O
intervention	NN	O
for	IN	O
child	NN	O
only	RB	O
,	,	O
intervention	NN	O
for	IN	O
child	NN	O
and	CC	O
parent	NN	O
,	,	O
wait-list	JJ	O
control	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
two	CD	O
intervention	NN	O
groups	NNS	O
demonstrated	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
parent-reported	JJ	O
anxiety	NN	O
symptoms	NNS	O
at	IN	O
follow-up	JJ	O
and	CC	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
child	NN	O
's	POS	O
ability	NN	O
to	TO	O
generate	VB	O
positive	JJ	O
strategies	NNS	O
in	IN	O
an	DT	O
anxiety-provoking	JJ	O
situation	NN	O
.	.	O

There	EX	O
were	VBD	O
a	DT	O
number	NN	O
of	IN	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
interventions	NNS	O
to	TO	O
suggest	VB	O
parent	NN	O
involvement	NN	O
as	IN	O
beneficial	JJ	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
sample	NN	O
of	IN	O
children	NNS	O
with	IN	O
AS	NNP	O
in	IN	O
this	DT	O
study	NN	O
presented	VBD	O
with	IN	O
a	DT	O
profile	NN	O
of	IN	O
anxiety	NN	O
similar	JJ	O
to	TO	O
a	DT	O
sample	NN	O
of	IN	O
clinically	RB	O
diagnosed	VBN	O
anxious	JJ	O
children	NNS	O
.	.	O

The	DT	O
intervention	NN	O
was	VBD	O
endorsed	VBN	O
by	IN	O
parents	NNS	O
as	IN	O
a	DT	O
useful	JJ	O
programme	NN	O
for	IN	O
children	NNS	O
diagnosed	VBN	O
with	IN	O
Asperger	NNP	Condition
syndrome	NN	Condition
and	CC	O
exhibiting	VBG	O
anxiety	NN	Condition
symptoms	NNS	O
,	,	O
and	CC	O
active	JJ	O
parent	NN	O
involvement	NN	O
enhanced	VBD	O
the	DT	O
usefulness	NN	O
of	IN	O
the	DT	O
programme	NN	O
.	.	O

Limitations	NNS	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
future	JJ	O
research	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Lack	NN	O
of	IN	O
interaction	NN	O
between	IN	O
pantoprazole	NN	O
and	CC	O
digoxin	NN	O
at	IN	O
therapeutic	JJ	O
doses	NNS	O
in	IN	O
man	NN	Sex
.	.	O

Substituted	JJ	O
benzimidazole	JJ	O
inhibitors	NNS	O
of	IN	O
the	DT	O
gastric	JJ	O
H+/K+ATPase	NNP	O
may	MD	O
interact	VB	O
with	IN	O
the	DT	O
cytochrome	NN	O
P450	NNP	O
enzyme	NN	O
system	NN	O
and	CC	O
alter	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
coadministered	JJ	O
drugs	NNS	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
changes	NNS	O
in	IN	O
intragastric	JJ	O
pH	NN	O
might	MD	O
alter	VB	O
the	DT	O
absorption	NN	O
of	IN	O
other	JJ	O
drugs	NNS	O
.	.	O

The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
pantoprazole	JJ	O
modifies	NNS	O
the	DT	O
steady-state	JJ	O
serum	NN	O
concentrations	NNS	O
of	IN	O
orally	RB	O
administered	VBN	O
digoxin	NN	O
.	.	O

Secondary	JJ	O
aims	NNS	O
were	VBD	O
the	DT	O
influence	NN	O
of	IN	O
digoxin	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
pantoprazole	NN	O
as	RB	O
well	RB	O
as	IN	O
safety	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Eighteen	NNP	SampleSize
healthy	JJ	O
volunteers	NNS	O
received	VBD	O
a	DT	O
single	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
pantoprazole	NN	O
(	(	O
40	CD	O
mg	NN	O
)	)	O
and	CC	O
serum	JJ	O
concentrations	NNS	O
were	VBD	O
determined	VBN	O
.	.	O

Three	CD	O
to	TO	O
10	CD	O
days	NNS	O
later	RB	O
,	,	O
subjects	NNS	O
received	VBD	O
in	IN	O
a	DT	O
single-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
crossover	JJ	O
fashion	NN	O
oral	JJ	O
beta-acetyldigoxin	NN	O
(	(	O
0.2	CD	O
mg	NN	O
)	)	O
twice	RB	O
daily	RB	O
and	CC	O
concomitant	JJ	O
oral	JJ	O
pantoprazole	NN	O
(	(	O
40	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	JJ	O
once	RB	O
daily	JJ	O
for	IN	O
5	CD	O
days	NNS	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
of	IN	O
pantoprazole	NN	O
and	CC	O
digoxin	NN	O
were	VBD	O
determined	VBN	O
on	IN	O
day	NN	O
5	CD	O
.	.	O

Primary	JJ	O
characteristics	NNS	O
for	IN	O
confirmative	JJ	O
assessment	NN	O
of	IN	O
no	DT	O
interaction	NN	O
were	VBD	O
AUC	NNP	O
and	CC	O
Cmax	NNP	O
of	IN	O
digoxin	NN	O
.	.	O

Lack	NNP	O
of	IN	O
interaction	NN	O
in	IN	O
the	DT	O
sense	NN	O
of	IN	O
equivalence	NN	O
was	VBD	O
concluded	VBN	O
for	IN	O
both	DT	O
digoxin	NN	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
pantoprazole	NN	O
)	)	O
and	CC	O
pantoprazole	JJ	O
(	(	O
with	IN	O
and	CC	O
without	IN	O
digoxin	NN	O
)	)	O
as	IN	O
the	DT	O
90	CD	O
%	NN	O
-confidence	NN	O
intervals	NNS	O
of	IN	O
the	DT	O
respective	JJ	O
AUC-	NNP	O
and	CC	O
Cmax-ratios	NNP	O
were	VBD	O
within	IN	O
the	DT	O
equivalence	NN	O
range	NN	O
of	IN	O
0.8-1.25	NNP	O
.	.	O

Pantoprazole	NNP	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
characteristic	JJ	O
ECG	NNP	O
modifications	NNS	O
(	(	O
T-wave	NNP	O
)	)	O
caused	VBN	O
by	IN	O
digoxin	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
no	DT	O
adverse	JJ	O
events	NNS	O
or	CC	O
clinically	RB	O
relevant	JJ	O
alterations	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
or	CC	O
clinical	JJ	O
laboratory	NN	O
parameters	NNS	O
were	VBD	O
observed	VBN	O
during	IN	O
treatment	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
pantoprazole	NN	O
and	CC	O
digoxin	NN	O
may	MD	O
be	VB	O
administered	VBN	O
concomitantly	RB	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
dose	JJ	O
adjustment	NN	O
.	.	O

Pharmacokinetic-pharmacodynamic	JJ	O
relationship	NN	O
of	IN	O
rocuronium	NN	O
under	IN	O
stable	JJ	O
nitrous	JJ	O
oxide-fentanyl	JJ	O
or	CC	O
nitrous	JJ	O
oxide-sevoflurane	JJ	O
anesthesia	NN	Condition
in	IN	O
children	NNS	Age
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
pharmacokinetics	NNS	O
and	CC	O
pharmacokinetic-pharmacodynamic	JJ	O
(	(	O
PK-PD	NNP	O
)	)	O
relationship	NN	O
of	IN	O
rocuronium	NN	O
in	IN	O
children	NNS	Age
anesthetized	VBN	O
with	IN	O
nitrous	JJ	O
oxide	NN	O
(	(	O
N2O	NNP	O
)	)	O
and	CC	O
fentanyl	$	O
or	CC	O
with	IN	O
N2O	NNP	O
and	CC	O
sevoflurane	NN	O
.	.	O

METHODS	NNP	O
Twenty-four	JJ	SampleSize
children	NNS	Age
(	(	O
3-11	CD	Age
years	NNS	Age
old	JJ	Age
,	,	O
ASA	NNP	Condition
PS	NNP	Condition
I	PRP	Condition
or	CC	Condition
II	NNP	Condition
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
N2O/O2-fentanyl	NNP	O
or	CC	O
N2O/O2-sevoflurane	NNP	O
(	(	O
one	CD	O
MAC	NNP	O
)	)	O
anesthesia	NN	O
.	.	O

Neuromuscular	JJ	O
transmission	NN	O
was	VBD	O
monitored	VBN	O
electromyographically	RB	O
.	.	O

Initial	JJ	O
bolus	NN	O
dose	NN	O
of	IN	O
rocuronium	NN	O
,	,	O
0.6	CD	O
mg	NN	O
x	NN	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
was	VBD	O
followed	VBN	O
by	IN	O
continuous	JJ	O
infusion	NN	O
,	,	O
targeting	VBG	O
at	IN	O
steady-state	JJ	O
95	CD	O
%	NN	O
T1	NNP	O
depression	NN	O
.	.	O

Neuromuscular	JJ	O
transmission	NN	O
was	VBD	O
allowed	VBN	O
to	TO	O
recover	VB	O
spontaneously	RB	O
.	.	O

Plasma	NNP	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
the	DT	O
moment	NN	O
of	IN	O
discontinuation	NN	O
of	IN	O
infusion	NN	O
,	,	O
and	CC	O
10	CD	O
,	,	O
20	CD	O
,	,	O
30	CD	O
,	,	O
50	CD	O
,	,	O
60	CD	O
and	CC	O
75	CD	O
min	NN	O
afterwards	NNS	O
.	.	O

Concentrations	NNS	O
of	IN	O
rocuronium	NN	O
were	VBD	O
measured	VBN	O
using	VBG	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
with	IN	O
electrochemical	JJ	O
detection	NN	O
(	(	O
HPLC-EC	NNP	O
)	)	O
.	.	O

Rocuronium	NNP	O
PK	NNP	O
was	VBD	O
described	VBN	O
by	IN	O
a	DT	O
two-compartment	JJ	O
model	NN	O
and	CC	O
PD	NNP	O
parameters	NNS	O
were	VBD	O
estimated	VBN	O
using	VBG	O
effect	NN	O
compartment	NN	O
and	CC	O
sigmoidal	JJ	O
E	NNP	O
(	(	O
max	NN	O
)	)	O
models	NNS	O
.	.	O

RESULTS	NNP	O
No	NNP	O
differences	NNS	O
in	IN	O
rocuronium	NN	O
PK	NNP	O
parameters	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
study	NN	O
groups	NNS	O
.	.	O

Clearance	NNP	O
was	VBD	O
3.91	CD	O
+/-	JJ	O
2.07	CD	O
and	CC	O
3.62	CD	O
+/-	JJ	O
0.80	CD	O
ml	NN	O
x	NN	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
kg	NN	O
(	(	O
-1	NN	O
)	)	O
in	IN	O
sevoflurane	NN	O
and	CC	O
fentanyl	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.65	CD	O
)	)	O
.	.	O

Effect	JJ	O
compartment	JJ	O
concentrations	NNS	O
corresponding	VBG	O
to	TO	O
50	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
T1	NNP	O
(	(	O
EC50	NNP	O
)	)	O
were	VBD	O
1.41	CD	O
+/-	JJ	O
0.45	CD	O
and	CC	O
2.32	CD	O
+/-	JJ	O
1.00	CD	O
microg	NN	O
x	NN	O
ml	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
rate	NN	O
constants	NNS	O
for	IN	O
equilibration	NN	O
between	IN	O
plasma	NN	O
and	CC	O
effect	NN	O
compartment	NN	O
(	(	O
k	NN	O
(	(	O
e0	NN	O
)	)	O
)	)	O
values	NNS	O
were	VBD	O
0.10	CD	O
+/-	JJ	O
0.04	CD	O
and	CC	O
0.24	CD	O
+/-	JJ	O
0.14	CD	O
min	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.009	CD	O
)	)	O
in	IN	O
sevoflurane	NN	O
and	CC	O
fentanyl	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
Disposition	NNP	O
of	IN	O
rocuronium	NN	O
was	VBD	O
similar	JJ	O
under	IN	O
stable	JJ	O
N2O-fentanyl	JJ	O
and	CC	O
N2O-sevoflurane	JJ	O
anesthesia	NN	O
.	.	O

Sevoflurane	NNP	O
reduced	VBD	O
rocuronium	NN	O
requirements	NNS	O
as	RB	O
well	RB	O
as	IN	O
decreased	VBN	O
EC50	NNP	O
relevant	JJ	O
to	TO	O
inhibition	NN	O
of	IN	O
T1	NNP	O
and	CC	O
rocuronium	NN	O
transfer	NN	O
to	TO	O
effect	NN	O
compartment	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
potentiating	VBG	O
effect	NN	O
of	IN	O
sevoflurane	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
mainly	RB	O
of	IN	O
PD	NNP	O
origin	NN	O
,	,	O
probably	RB	O
due	JJ	O
to	TO	O
an	DT	O
increased	VBN	O
sensitivity	NN	O
of	IN	O
the	DT	O
neuromuscular	JJ	O
junction	NN	O
.	.	O

The	DT	O
interaction	NN	O
between	IN	O
propofol	NN	O
and	CC	O
clonidine	NN	O
for	IN	O
loss	NN	O
of	IN	O
consciousness	NN	O
.	.	O

UNLABELLED	NNP	O
Clonidine	NNP	O
premedication	NN	O
reduces	VBZ	O
the	DT	O
intraoperative	JJ	O
requirement	NN	O
for	IN	O
opioids	NNS	O
and	CC	O
volatile	JJ	O
anesthetics	NNS	O
.	.	O

Clonidine	NNP	O
also	RB	O
reduces	VBZ	O
the	DT	O
induction	NN	O
dose	NN	O
of	IN	O
IV	NNP	O
anesthetics	NNS	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
information	NN	O
,	,	O
however	RB	O
,	,	O
regarding	VBG	O
the	DT	O
effect	NN	O
of	IN	O
oral	JJ	O
clonidine	NN	O
premedication	NN	O
on	IN	O
the	DT	O
propofol	NN	O
blood	NN	O
concentrations	NNS	O
required	VBD	O
for	IN	O
loss	NN	O
of	IN	O
consciousness	NN	O
,	,	O
and	CC	O
the	DT	O
interaction	NN	O
between	IN	O
propofol	NN	O
and	CC	O
clonidine	NN	O
.	.	O

We	PRP	O
randomly	RB	O
administered	VBD	O
target	NN	O
effect-site	JJ	O
concentrations	NNS	O
of	IN	O
propofol	NN	O
ranging	VBG	O
from	IN	O
0.5	CD	O
to	TO	O
5	CD	O
.	.	O

0	CD	O
microg/mL	NN	O
by	IN	O
using	VBG	O
computer-assisted	JJ	O
target-controlled	JJ	O
infusion	NN	O
to	TO	O
3	CD	O
groups	NNS	O
of	IN	O
healthy	JJ	Condition
male	JJ	Sex
patients	NNS	O
:	:	O
Control	NNP	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	SampleSize
)	)	O
,	,	O
2.5	CD	O
microg/kg	NN	O
Clonidine	NNP	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	SampleSize
)	)	O
,	,	O
and	CC	O
5.0	CD	O
microg/kg	NNS	O
Clonidine	NNP	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	SampleSize
)	)	O
groups	NNS	O
.	.	O

Nothing	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
the	DT	O
Control	NNP	O
group	NN	O
.	.	O

Clonidine	NNP	O
(	(	O
2.5	CD	O
or	CC	O
5.0	CD	O
microg/kg	NN	O
)	)	O
was	VBD	O
administered	VBN	O
orally	RB	O
90	CD	O
min	NN	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
in	IN	O
the	DT	O
Clonidine	NNP	O
groups	NNS	O
.	.	O

After	IN	O
equilibration	NN	O
between	IN	O
the	DT	O
blood	NN	O
and	CC	O
effect-site	NN	O
for	IN	O
15	CD	O
min	NN	O
,	,	O
a	DT	O
verbal	JJ	O
command	NN	O
to	TO	O
open	VB	O
their	PRP$	O
eyes	NNS	O
was	VBD	O
given	VBN	O
two	CD	O
times	NNS	O
to	TO	O
the	DT	O
patients	NNS	O
.	.	O

Arterial	JJ	O
blood	NN	O
samples	NNS	O
for	IN	O
analysis	NN	O
of	IN	O
the	DT	O
serum	NN	O
propofol	NN	O
and	CC	O
clonidine	NN	O
concentrations	NNS	O
were	VBD	O
taken	VBN	O
immediately	RB	O
before	IN	O
verbal	JJ	O
commands	NNS	O
were	VBD	O
given	VBN	O
.	.	O

Measured	NNP	O
serum	VBD	O
propofol	JJ	O
concentrations	NNS	O
in	IN	O
equilibrium	NN	O
with	IN	O
the	DT	O
effect-site	NN	O
at	IN	O
which	WDT	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
did	VBD	O
not	RB	O
respond	VB	O
to	TO	O
verbal	VB	O
commands	NNS	O
(	(	O
EC50	NNP	O
for	IN	O
loss	NN	O
of	IN	O
consciousness	NN	O
)	)	O
were	VBD	O
determined	VBN	O
by	IN	O
logistic	JJ	O
regression	NN	O
.	.	O

The	DT	O
EC50	NNP	O
+/-	JJ	O
SE	NNP	O
values	NNS	O
in	IN	O
the	DT	O
Control	NNP	O
,	,	O
2.5	CD	O
microg/kg	NN	O
Clonidine	NNP	O
,	,	O
and	CC	O
5.0	CD	O
microg/kg	NNS	O
Clonidine	NNP	O
groups	NNS	O
were	VBD	O
2.67	CD	O
+/-	JJ	O
0.18	CD	O
,	,	O
1.31	CD	O
+/-	JJ	O
0.12	CD	O
,	,	O
and	CC	O
0.91	CD	O
+/-	JJ	O
0.13	CD	O
microg/mL	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
EC50	NNP	O
in	IN	O
the	DT	O
2.5	CD	O
and	CC	O
5.0	CD	O
microg/kg	NNS	O
clonidine	JJ	O
groups	NNS	O
was	VBD	O
significantly	RB	O
smaller	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
Control	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
a	DT	O
response	NN	O
surface	NN	O
modeling	VBG	O
analysis	NN	O
indicated	VBD	O
that	IN	O
there	EX	O
was	VBD	O
an	DT	O
additive	JJ	O
interaction	NN	O
between	IN	O
measured	VBN	O
arterial	JJ	O
propofol	NN	O
and	CC	O
clonidine	NN	O
concentrations	NNS	O
in	IN	O
relation	NN	O
to	TO	O
loss	NN	O
of	IN	O
consciousness	NN	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
propofol	NN	O
and	CC	O
clonidine	NN	O
act	NN	O
additively	RB	O
for	IN	O
loss	NN	O
of	IN	O
consciousness	NN	O
.	.	O

IMPLICATIONS	NNP	O
Oral	NNP	O
clonidine	NN	O
2.5	CD	O
and	CC	O
5.0	CD	O
microg/kg	NN	O
premedication	NN	O
decreases	VBZ	O
the	DT	O
propofol	JJ	O
concentration	NN	O
required	VBN	O
for	IN	O
loss	NN	O
of	IN	O
consciousness	NN	O
.	.	O

Valsartan	NNP	O
alone	RB	O
or	CC	O
with	IN	O
a	DT	O
diuretic	JJ	O
or	CC	O
ACE	NNP	O
inhibitor	NN	O
as	IN	O
treatment	NN	O
for	IN	O
African	JJ	O
American	JJ	O
hypertensives	NNS	Condition
:	:	O
relation	NN	O
to	TO	O
salt	VB	O
intake	NN	O
.	.	O

Previous	JJ	O
clinical	JJ	O
trials	NNS	O
have	VBP	O
demonstrated	VBN	O
the	DT	O
important	JJ	O
influence	NN	O
of	IN	O
ethnicity	NN	O
and	CC	O
dietary	JJ	O
salt	NN	O
on	IN	O
the	DT	O
antihypertensive	JJ	O
efficacy	NN	O
of	IN	O
drugs	NNS	O
that	WDT	O
block	VBP	O
the	DT	O
renin	NN	O
angiotensin	NN	O
system	NN	O
.	.	O

Angiotensin	NNP	O
II	NNP	O
receptor	NN	O
blockers	NNS	O
are	VBP	O
a	DT	O
new	JJ	O
therapeutic	JJ	O
entity	NN	O
that	WDT	O
have	VBP	O
not	RB	O
been	VBN	O
widely	RB	O
studied	VBN	O
in	IN	O
African	JJ	O
American	JJ	O
hypertensives	NNS	O
,	,	O
either	RB	O
alone	RB	O
,	,	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
therapies	NNS	O
such	JJ	O
as	IN	O
diuretics	NNS	O
or	CC	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitors	NNS	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
pilot	NN	O
,	,	O
prospective	JJ	O
,	,	O
open	JJ	O
label	NN	O
,	,	O
randomized	VBN	O
design	NN	O
clinical	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blocker	NN	O
valsartan	NN	O
(	(	O
160	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
)	)	O
on	IN	O
systolic	NN	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
in	IN	O
hypertensive	JJ	Condition
African	JJ	O
Americans	NNPS	O
(	(	O
n	JJ	O
=	NNP	O
88	CD	SampleSize
)	)	O
on	IN	O
a	DT	O
low	JJ	O
salt	NN	O
(	(	O
100	CD	O
mEq	NNS	O
Na+/day	NNP	O
)	)	O
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
the	DT	O
same	JJ	O
diet	NN	O
supplemented	VBN	O
by	IN	O
100	CD	O
mEq	NNS	O
Na+	NNP	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

After	IN	O
this	DT	O
evaluation	NN	O
,	,	O
while	IN	O
continuing	VBG	O
the	DT	O
Na+	NNP	O
supplementation	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
valsartan	VB	O
320	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
,	,	O
or	CC	O
the	DT	O
addition	NN	O
of	IN	O
hydrochlorothiazide	NN	O
(	(	O
HCTZ	NNP	O
)	)	O
12.5	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
,	,	O
or	CC	O
benazepril	VB	O
20	CD	O
mg/day	NN	O
to	TO	O
the	DT	O
valsartan	NN	O
160	CD	O
mg/day	NN	O
for	IN	O
an	DT	O
additional	JJ	O
6	CD	O
weeks	NNS	O
.	.	O

Valsartan	NNP	O
(	(	O
160	CD	O
mg/day	NN	O
)	)	O
lowered	VBD	O
blood	NN	O
pressure	NN	O
significantly	RB	O
in	IN	O
African	JJ	O
American	JJ	O
patients	NNS	O
on	IN	O
both	DT	O
low	JJ	O
salt	NN	O
(	(	O
-6.4/-4.8	JJ	O
mm	NN	O
Hg	NNP	O
:	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
a	DT	O
high	JJ	O
salt	NN	O
diet	NN	O
(	(	O
-4.9/-3.8	JJ	O
mm	NN	O
Hg	NNP	O
:	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

The	DT	O
high	JJ	O
salt	NN	O
diet	NN	O
attenuated	VBD	O
the	DT	O
antihypertensive	JJ	O
effect	NN	O
slightly	RB	O
(	(	O
1.6/1.3	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

When	WRB	O
comparing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
three	CD	O
randomized	VBN	O
therapeutic	JJ	O
regimens	NNS	O
while	IN	O
on	IN	O
the	DT	O
Na+	NNP	O
supplement	NN	O
,	,	O
the	DT	O
valsartan	NN	O
160	CD	O
mg/HCTZ	NN	O
12.5	CD	O
mg	NN	O
was	VBD	O
the	DT	O
most	RBS	O
effective	JJ	O
therapy	NN	O
with	IN	O
an	DT	O
incremental	JJ	O
reduction	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
of	IN	O
-10.5/-6.9	NNP	O
mm	FW	O
Hg	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
compared	VBN	O
to	TO	O
valsartan	VB	O
160	CD	O
mg/day	JJ	O
alone	RB	O
.	.	O

Doubling	VBG	O
the	DT	O
dose	NN	O
of	IN	O
valsartan	NN	O
to	TO	O
320	CD	O
mg	NNS	O
incrementally	RB	O
lowered	VBD	O
blood	NN	O
pressure	NN	O
by	IN	O
-3.8/-3.3	NNP	O
mm	NN	O
Hg	NNP	O
(	(	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

The	DT	O
least	JJS	O
effective	JJ	O
approach	NN	O
was	VBD	O
adding	VBG	O
benazepril	RB	O
20	CD	O
mg/day	NN	O
to	TO	O
valsartan	VB	O
160	CD	O
mg/day	NN	O
with	IN	O
no	DT	O
incremental	JJ	O
reduction	NN	O
in	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
reduction	NN	O
of	IN	O
only	RB	O
1.7	CD	O
mm	NNS	O
Hg	NNP	O
(	(	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
in	IN	O
our	PRP$	O
open	JJ	O
label	NN	O
pilot	NN	O
study	NN	O
,	,	O
the	DT	O
antihypertensive	JJ	O
activity	NN	O
of	IN	O
valsartan	NN	O
is	VBZ	O
not	RB	O
significantly	RB	O
attenuated	VBN	O
by	IN	O
supplemented	JJ	O
salt	NN	O
diet	NN	O
in	IN	O
hypertensive	JJ	Condition
African	JJ	O
Americans	NNPS	O
.	.	O

Moreover	RB	O
,	,	O
adding	VBG	O
a	DT	O
low	JJ	O
dose	NN	O
of	IN	O
HCTZ	NNP	O
appears	VBZ	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
effective	JJ	O
strategy	NN	O
in	IN	O
enhancing	VBG	O
the	DT	O
antihypertensive	JJ	O
activity	NN	O
of	IN	O
this	DT	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blocker	NN	O
in	IN	O
contrast	NN	O
to	TO	O
either	DT	O
doubling	VBG	O
the	DT	O
dose	NN	O
or	CC	O
adding	VBG	O
an	DT	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitor	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
inhaled	JJ	O
leukotriene	NN	O
D4	NNP	O
and	CC	O
methacholine	VB	O
on	IN	O
sputum	NN	O
cell	NN	O
differentials	NNS	O
in	IN	O
asthma	NN	O
.	.	O

The	DT	O
cysteinyl	JJ	O
leukotriene	NN	O
LTE4	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
induce	VB	O
airway	RP	O
eosinophilia	NNS	O
in	IN	O
asthmatics	NNS	O
in	IN	O
vivo	NN	O
.	.	O

This	DT	O
phenomenon	NN	O
has	VBZ	O
not	RB	O
yet	RB	O
been	VBN	O
reported	VBN	O
for	IN	O
LTD4	NNP	O
.	.	O

Hence	NNP	O
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
inhaled	JJ	O
LTD4	NNP	O
and	CC	O
a	DT	O
control	NN	O
bronchoconstrictor	NN	O
agent	NN	O
,	,	O
methacholine	NN	O
,	,	O
on	IN	O
cell	NN	O
differentials	NNS	O
in	IN	O
hypertonic	JJ	O
saline-induced	JJ	O
whole	JJ	O
sputum	NN	O
samples	NNS	O
of	IN	O
12	CD	O
nonsmoking	VBG	O
atopic	NN	O
asthmatic	JJ	O
subjects	NNS	O
(	(	O
three	CD	O
women	NNS	O
,	,	O
nine	CD	O
men	NNS	O
;	:	O
21	CD	O
to	TO	O
29	CD	O
yr	NN	O
of	IN	O
age	NN	O
;	:	O
FEV1	NNP	O
,	,	O
74	CD	O
to	TO	O
120	CD	O
%	NN	O
pred	VBD	O
;	:	O
PC20FEV1	NNP	O
methacholine	VBP	O
<	$	O
9.6	CD	O
mg/ml	NN	O
)	)	O
.	.	O

The	DT	O
study	NN	O
had	VBD	O
a	DT	O
cross-over	JJ	O
,	,	O
placebo-controlled	JJ	O
design	NN	O
consisting	NN	O
of	IN	O
4	CD	O
d	NN	O
separated	VBN	O
by	IN	O
>	NN	O
or	CC	O
=	$	O
1	CD	O
wk	NN	O
.	.	O

On	IN	O
each	DT	O
randomized	VBN	O
study	NN	O
day	NN	O
,	,	O
the	DT	O
subjects	NNS	O
inhaled	VBD	O
five	CD	O
serial	JJ	O
doses	NNS	O
of	IN	O
either	DT	O
LTD4	NNP	O
(	(	O
mean	JJ	O
cumulative	JJ	O
concentration	NN	O
:	:	O
95.7	CD	O
microM	NN	O
)	)	O
or	CC	O
methacholine	NN	O
(	(	O
mean	JJ	O
cumulative	JJ	O
concentration	NN	O
:	:	O
542	CD	O
mM	NN	O
)	)	O
or	CC	O
five	CD	O
doses	NNS	O
of	IN	O
their	PRP$	O
respective	JJ	O
diluents	NNS	O
(	(	O
PBS/ethanol	NNP	O
or	CC	O
PBS	NNP	O
)	)	O
.	.	O

The	DT	O
airway	JJ	O
response	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
FEV1	NNP	O
,	,	O
followed	VBN	O
by	IN	O
sputum	JJ	O
induction	NN	O
with	IN	O
4.5	CD	O
%	NN	O
NaCl	NNP	O
,	,	O
4	CD	O
h	NN	O
postchallenge	NN	O
.	.	O

Inflammatory	NNP	O
cells	NNS	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
250	CD	O
)	)	O
were	VBD	O
counted	VBN	O
twice	RB	O
on	IN	O
coded	JJ	O
cytospins	NNS	O
and	CC	O
expressed	VBD	O
as	IN	O
percentages	NNS	O
of	IN	O
nonsquamous	JJ	O
cells	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
maximal	JJ	O
percent	NN	O
fall	NN	O
in	IN	O
FEV1	NNP	O
from	IN	O
baseline	NN	O
between	IN	O
LTD4	NNP	O
(	(	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
,	,	O
49.5	CD	O
+/-	JJ	O
4.4	CD	O
%	NN	O
fall	NN	O
)	)	O
and	CC	O
methacholine	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
,	,	O
55.9	CD	O
+/-	JJ	O
3.4	CD	O
%	NN	O
fall	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.11	CD	O
)	)	O
.	.	O

LTD4	NNP	O
induced	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
sputum	NN	O
eosinophils	NNS	O
as	IN	O
compared	VBN	O
with	IN	O
its	PRP$	O
diluent	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
,	,	O
26.6	CD	O
+/-	JJ	O
21.3	CD	O
%	NN	O
and	CC	O
10.2	CD	O
+/-	JJ	O
8.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
=	$	O
0.025	CD	O
)	)	O
,	,	O
whereas	VBZ	O
a	DT	O
similar	JJ	O
trend	NN	O
for	IN	O
methacholine	NN	O
failed	VBD	O
to	TO	O
reach	VB	O
significance	NN	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
,	,	O
19.1	CD	O
+/-	JJ	O
22.9	CD	O
%	NN	O
and	CC	O
7.8	CD	O
+/-	JJ	O
5.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
p	VB	O
=	$	O
0.11	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
changes	NNS	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
sputum	NN	O
eosinophils	NNS	O
between	IN	O
LTD4	NNP	O
and	CC	O
methacholine	NN	O
(	(	O
mean	JJ	O
difference	NN	O
+/-	JJ	O
SD	NNP	O
,	,	O
7.5	CD	O
+/-	JJ	O
12.5	CD	O
%	NN	O
eosinophils	NNS	O
;	:	O
p	VB	O
=	$	O
0.09	CD	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
LTD4	NNP	O
induces	NNS	O
eosinophilia	VBP	O
in	IN	O
sputum	NN	O
of	IN	O
asthmatic	JJ	O
subjects	NNS	O
4	CD	O
h	NN	O
after	IN	O
inhalation	NN	O
.	.	O

Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
LTD4	NNP	O
recruits	VBZ	O
eosinophils	NNS	O
into	IN	O
the	DT	O
airways	NNS	O
of	IN	O
asthmatics	NNS	O
in	IN	O
vivo	NN	O
,	,	O
possibly	RB	O
by	IN	O
virtue	NN	O
of	IN	O
direct	JJ	O
or	CC	O
indirect	JJ	O
chemotactic	JJ	O
properties	NNS	O
,	,	O
whereas	IN	O
an	DT	O
additional	JJ	O
effect	NN	O
of	IN	O
vigourous	JJ	O
airway	NN	O
narrowing	VBG	O
per	IN	O
se	NN	O
can	MD	O
not	RB	O
be	VB	O
excluded	VBN	O
.	.	O

Home	NN	O
based	VBN	O
management	NN	O
in	IN	O
multiple	JJ	Condition
sclerosis	NN	Condition
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Home	NNP	O
based	VBN	O
medical	JJ	O
care	NN	O
is	VBZ	O
a	DT	O
popular	JJ	O
alternative	NN	O
to	TO	O
standard	VB	O
hospital	NN	O
care	NN	O
but	CC	O
there	EX	O
is	VBZ	O
uncertainty	NN	O
about	IN	O
its	PRP$	O
cost-effectiveness	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
the	DT	O
costs	NNS	O
of	IN	O
multidisciplinary	JJ	O
home	NN	O
based	VBN	O
care	NN	O
in	IN	O
multiple	JJ	O
sclerosis	NN	O
with	IN	O
hospital	NN	O
care	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
with	IN	O
a	DT	O
one	CD	O
year	NN	O
follow	VB	O
up	RP	O
.	.	O

METHODS	NNP	O
201	CD	SampleSize
patients	NNS	O
with	IN	O
clinically	RB	O
definite	JJ	O
multiple	JJ	O
sclerosis	NN	O
were	VBD	O
studied	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomised	VBN	O
in	IN	O
a	DT	O
ratio	NN	O
2:1	CD	O
to	TO	O
an	DT	O
intervention	NN	O
group	NN	O
(	(	O
133	CD	O
)	)	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
68	CD	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
one	CD	O
year	NN	O
after	IN	O
randomisation	NN	O
with	IN	O
validated	JJ	O
measures	NNS	O
of	IN	O
physical	JJ	O
and	CC	O
psychological	JJ	O
impairment	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
SF-36	NNP	O
health	NN	O
survey	NN	O
)	)	O
.	.	O

The	DT	O
costs	NNS	O
to	TO	O
the	DT	O
National	NNP	O
Health	NNP	O
Service	NNP	O
over	IN	O
the	DT	O
one	CD	O
year	NN	O
follow	VBP	O
up	RP	O
were	VBD	O
calculated	VBN	O
by	IN	O
a	DT	O
cost	NN	O
minimisation	NN	O
analysis	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
functional	JJ	O
status	NN	O
between	IN	O
the	DT	O
home	NN	O
based	VBN	O
care	NN	O
group	NN	O
and	CC	O
the	DT	O
hospital	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
favouring	VBG	O
home	NN	O
based	VBN	O
management	NN	O
in	IN	O
four	CD	O
SF-36	JJ	O
health	NN	O
dimensions-general	JJ	O
health	NN	O
,	,	O
bodily	RB	O
pain	NN	O
,	,	O
role-emotional	JJ	O
,	,	O
and	CC	O
social	JJ	O
functioning	NN	O
(	(	O
all	DT	O
p	VBP	O
<	CD	O
or	CC	O
=	VB	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
cost	NN	O
of	IN	O
home	NN	O
based	VBN	O
care	NN	O
was	VBD	O
slightly	RB	O
less	JJR	O
(	(	O
822	CD	O
euros/patient/year	NN	O
)	)	O
than	IN	O
hospital	NN	O
care	NN	O
,	,	O
mainly	RB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
a	DT	O
reduction	NN	O
in	IN	O
hospital	JJ	O
admissions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Comprehensive	NNP	O
planning	NN	O
of	IN	O
home	NN	O
based	VBN	O
intervention	NN	O
implemented	VBN	O
by	IN	O
an	DT	O
interdisciplinary	JJ	O
team	NN	O
and	CC	O
designed	VBN	O
specifically	RB	O
for	IN	O
people	NNS	O
with	IN	O
multiple	JJ	O
sclerosis	NN	O
may	MD	O
provide	VB	O
a	DT	O
cost-effective	JJ	O
approach	NN	O
to	TO	O
management	NN	O
and	CC	O
improve	VB	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Effectiveness	NN	O
of	IN	O
two	CD	O
quadruple	NNS	O
,	,	O
tetracycline-	JJ	O
or	CC	O
clarithromycin-containing	JJ	O
,	,	O
second-line	JJ	O
,	,	O
Helicobacter	NNP	O
pylori	VBP	O
eradication	NN	O
therapies	NNS	O
.	.	O

BACKGROUND	IN	O
There	EX	O
are	VBP	O
no	DT	O
guidelines	NNS	O
on	IN	O
second-line	JJ	O
therapies	NNS	O
for	IN	O
Helicobacter	NNP	O
pylori	FW	O
eradication	NN	O
failures	NNS	O
of	IN	O
omeprazole-clarithromycin-amoxicillin	JJ	O
triple	JJ	O
therapy	NN	O
.	.	O

AIM	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
two	CD	O
second-line	JJ	O
therapies	NNS	O
for	IN	O
persistent	JJ	O
H.	NNP	O
pylori	NN	O
infection	NN	O
.	.	O

METHODS	NNP	O
Over	IN	O
a	DT	O
6-year	JJ	O
period	NN	O
,	,	O
patients	NNS	O
with	IN	O
persistent	JJ	O
H.	NNP	O
pylori	FW	O
infection	NN	O
following	VBG	O
omeprazole-clarithromycin-amoxicillin	JJ	O
eradication	NN	O
therapy	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
omeprazole	NN	O
,	,	O
20	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
,	,	O
bismuth	NN	O
,	,	O
120	CD	O
mg	NN	O
four	CD	O
times	NNS	O
daily	RB	O
,	,	O
metronidazole	NN	O
,	,	O
500	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
,	,	O
and	CC	O
either	DT	O
tetracycline	NN	O
,	,	O
500	CD	O
mg	NN	O
four	CD	O
times	NNS	O
daily	RB	O
,	,	O
or	CC	O
clarithromycin	NN	O
,	,	O
500	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
,	,	O
given	VBN	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

Before	IN	O
therapy	NN	O
,	,	O
patients	NNS	O
underwent	JJ	O
endoscopy	NN	O
with	IN	O
biopsies	NNS	O
for	IN	O
histology	NN	O
,	,	O
culture	NN	O
and	CC	O
antibiotic	JJ	O
susceptibility	NN	O
tests	NNS	O
.	.	O

H.	NNP	O
pylori	JJ	O
infection	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
histology	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
95	CD	O
randomized	JJ	O
patients	NNS	O
,	,	O
88	CD	O
(	(	O
93	CD	O
%	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Age	NNP	O
,	,	O
sex	NN	O
,	,	O
smoking	NN	O
,	,	O
ulcer/non-ulcer	JJ	O
dyspepsia	NN	O
ratio	NN	O
and	CC	O
antibiotic	JJ	O
resistance	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

On	IN	O
intention-to-treat	JJ	O
analysis	NN	O
,	,	O
eradication	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
41	CD	O
of	IN	O
the	DT	O
49	CD	O
patients	NNS	O
(	(	O
84	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
70.4-92.7	CD	O
%	NN	O
)	)	O
and	CC	O
27	CD	O
of	IN	O
the	DT	O
46	CD	O
patients	NNS	O
(	(	O
59	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
43.3-73.0	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
tetracycline-	JJ	O
and	CC	O
clarithromycin-containing	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.007	NNP	O
)	)	O
.	.	O

On	IN	O
multivariate	JJ	O
regression	NN	O
analysis	NN	O
,	,	O
the	DT	O
sensitivity	NN	O
of	IN	O
H.	NNP	O
pylori	FW	O
to	TO	O
metronidazole	VB	O
had	VBD	O
a	DT	O
likelihood	NN	O
ratio	NN	O
of	IN	O
5.2	CD	O
(	(	O
P=0.022	NNP	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
the	DT	O
type	NN	O
of	IN	O
quadruple	JJ	O
therapy	NN	O
(	(	O
likelihood	JJ	O
ratio	NN	O
,	,	O
4.4	CD	O
;	:	O
P=0.036	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Tetracycline-containing	JJ	O
quadruple	NN	O
rescue	NN	O
therapy	NN	O
is	VBZ	O
highly	RB	O
effective	JJ	O
in	IN	O
treating	VBG	O
H.	NNP	O
pylori	JJ	O
eradication	NN	O
failures	NNS	O
of	IN	O
the	DT	O
omeprazole-amoxicillin-clarithromycin	JJ	O
regimen	NNS	O
.	.	O

Folate	NNP	O
and	CC	O
arsenic	JJ	O
metabolism	NN	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
folic	JJ	O
acid-supplementation	NN	O
trial	NN	O
in	IN	O
Bangladesh	NNP	O
.	.	O

BACKGROUND	NNP	O
Populations	NNPS	O
in	IN	O
South	NNP	O
and	CC	O
East	NNP	O
Asia	NNP	O
and	CC	O
many	JJ	O
other	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
world	NN	O
are	VBP	O
chronically	RB	Condition
exposed	VBN	Condition
to	TO	Condition
arsenic-contaminated	JJ	Condition
drinking	NN	Condition
water	NN	Condition
.	.	O

To	TO	O
various	JJ	O
degrees	NNS	O
,	,	O
ingested	VBN	O
inorganic	JJ	O
arsenic	NN	O
(	(	O
InAs	NNP	O
)	)	O
is	VBZ	O
methylated	VBN	O
to	TO	O
monomethylarsonic	JJ	O
acid	NN	O
(	(	O
MMA	NNP	O
)	)	O
and	CC	O
dimethylarsinic	JJ	O
acid	NN	O
(	(	O
DMA	NNP	O
)	)	O
via	IN	O
folate-dependent	JJ	O
one-carbon	JJ	O
metabolism	NN	O
;	:	O
impaired	JJ	O
methylation	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
adverse	JJ	O
health	NN	O
outcomes	NNS	O
.	.	O

Consequently	RB	O
,	,	O
folate	JJ	O
nutritional	JJ	O
status	NN	O
may	MD	O
influence	VB	O
arsenic	JJ	O
methylation	NN	O
and	CC	O
toxicity	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
folic	JJ	O
acid	DT	O
supplementation	NN	O
of	IN	O
arsenic-exposed	JJ	O
adults	NNS	O
would	MD	O
increase	VB	O
arsenic	JJ	O
methylation	NN	O
.	.	O

DESIGN	NNP	O
Two	CD	SampleSize
hundred	VBD	SampleSize
adults	NNS	O
in	IN	O
a	DT	O
rural	JJ	O
region	NN	O
of	IN	O
Bangladesh	NNP	O
,	,	O
previously	RB	O
found	VBN	O
to	TO	O
have	VB	O
low	JJ	Condition
plasma	JJ	Condition
concentrations	NNS	Condition
of	IN	Condition
folate	NN	Condition
(	(	Condition
<	JJ	Condition
/=9	NNP	Condition
nmol/L	NN	Condition
)	)	Condition
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
folic	JJ	O
acid-supplementation	NN	O
trial	NN	O
.	.	O

Plasma	NNP	O
concentrations	NNS	O
of	IN	O
folate	NN	O
and	CC	O
homocysteine	NN	O
and	CC	O
urinary	JJ	O
concentrations	NNS	O
of	IN	O
arsenic	JJ	O
metabolites	NNS	O
were	VBD	O
analyzed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
12	CD	O
wk	NN	O
of	IN	O
supplementation	NN	O
with	IN	O
folic	JJ	O
acid	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
400	CD	O
microg/d	NN	O
or	CC	O
placebo	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
increase	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
total	JJ	O
urinary	JJ	O
arsenic	NN	O
excreted	VBD	O
as	IN	O
DMA	NNP	O
in	IN	O
the	DT	O
folic	JJ	O
acid	NN	O
group	NN	O
(	(	O
72	CD	O
%	NN	O
before	IN	O
and	CC	O
79	CD	O
%	NN	O
after	IN	O
supplementation	NN	O
)	)	O
was	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
as	IN	O
was	VBD	O
the	DT	O
reduction	NN	O
in	IN	O
the	DT	O
proportions	NNS	O
of	IN	O
total	JJ	O
urinary	JJ	O
arsenic	NN	O
excreted	VBD	O
as	IN	O
MMA	NNP	O
(	(	O
13	CD	O
%	NN	O
and	CC	O
10	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
as	IN	O
InAs	NNP	O
(	(	O
15	CD	O
%	NN	O
and	CC	O
11	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
indicate	VBP	O
that	IN	O
folic	JJ	O
acid	JJ	O
supplementation	NN	O
to	TO	O
participants	NNS	O
with	IN	O
low	JJ	Condition
plasma	NN	Condition
folate	NN	Condition
enhances	NNS	O
arsenic	JJ	O
methylation	NN	O
.	.	O

Because	IN	O
persons	NNS	O
whose	WP$	O
urine	JJ	O
contains	NNS	O
low	JJ	O
proportions	NNS	O
of	IN	O
DMA	NNP	O
and	CC	O
high	JJ	O
proportions	NNS	O
of	IN	O
MMA	NNP	O
and	CC	O
InAs	NNP	O
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
at	IN	O
greater	JJR	O
risk	NN	O
of	IN	O
skin	NN	O
and	CC	O
bladder	NN	O
cancers	NNS	O
and	CC	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
,	,	O
these	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
folic	JJ	O
acid	DT	O
supplementation	NN	O
may	MD	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
arsenic-related	JJ	O
health	NN	O
outcomes	NNS	O
.	.	O

Mediterranean	NNP	O
diet	NN	O
and	CC	O
high	JJ	O
dietary	JJ	O
acid	NN	O
load	NN	O
associated	VBN	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
:	:	O
effect	NN	O
on	IN	O
bone	NN	O
metabolism	NN	O
in	IN	O
elderly	JJ	Age
subjects	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
analyze	VB	O
the	DT	O
effect	NN	O
of	IN	O
differing	VBG	O
diet	NN	O
on	IN	O
the	DT	O
acid	JJ	O
load	NN	O
content	NN	O
on	IN	O
bone	NN	O
metabolism	NN	O
.	.	O

DESIGN	NNP	O
Multicentric	NNP	O
,	,	O
randomized	VBD	O
,	,	O
single-blind	JJ	O
,	,	O
parallel-group	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Outpatient	JJ	O
clinics	NNS	O
.	.	O

PARTICIPANTS	VB	O
Two	CD	SampleSize
hundred	CD	SampleSize
thirty-eight	JJ	SampleSize
elderly	JJ	Age
men	NNS	Condition
and	CC	O
women	NNS	Condition
aged	VBD	O
60	CD	Age
to	TO	Age
80	CD	Age
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
cardiovascular	JJ	Condition
disease	NN	Condition
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
interventional	JJ	O
groups	NNS	O
:	:	O
a	DT	O
recommended	JJ	O
low-fat	JJ	O
diet	NN	O
(	(	O
control	VB	O
diet	JJ	O
group	NN	O
)	)	O
,	,	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
supplemented	VBD	O
with	IN	O
virgin	JJ	O
olive	JJ	O
oil	NN	O
,	,	O
or	CC	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
supplemented	VBD	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
.	.	O

MEASUREMENTS	NNP	O
Main	NNP	O
outcomes	NNS	O
were	VBD	O
12-month	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
in	IN	O
bone	NN	O
formation	NN	O
and	CC	O
resorption	NN	O
markers	NNS	O
and	CC	O
bone	NN	O
mass	NN	O
measured	VBD	O
according	VBG	O
to	TO	O
quantitative	JJ	O
ultrasound	JJ	O
scanning	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
baseline	NN	O
data	NNS	O
on	IN	O
the	DT	O
anthropometric	NN	O
,	,	O
bone	NN	O
densitometry	NN	O
,	,	O
and	CC	O
biochemical	JJ	O
variables	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Dietary	NNP	O
potential	JJ	O
renal	JJ	O
acid	NN	O
load	NN	O
(	(	O
PRAL	NNP	O
)	)	O
and	CC	O
daily	JJ	O
net	NN	O
endogenous	JJ	O
acid	NN	O
production	NN	O
(	(	O
NEAP	NNP	O
)	)	O
at	IN	O
baseline	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
groups	NNS	O
.	.	O

After	IN	O
intervention	NN	O
,	,	O
subjects	NNS	O
allocated	VBD	O
to	TO	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
mixed	JJ	O
nuts	NNS	O
had	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
PRAL	NNP	O
and	CC	O
NEAP	NNP	O
.	.	O

In	IN	O
comparison	NN	O
,	,	O
subjects	NNS	O
in	IN	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
nuts	NNS	O
group	NN	O
had	VBD	O
higher	JJR	O
parathyroid	NN	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
levels	NNS	O
(	(	O
2.63	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
=-1.01-6.35	NN	O
,	,	O
P=.02	NNP	O
)	)	O
and	CC	O
a	DT	O
nonsignificantly	RB	O
higher	JJR	O
(	(	O
0.31	CD	O
,	,	O
95	CD	O
%	NN	O
CI=-0.13-0.74	NNP	O
,	,	O
P=.14	NNP	O
)	)	O
urine	VBP	O
free	JJ	O
deoxypyridoxine	NN	O
:	:	O
creatinine	NN	O
ratio	NN	O
,	,	O
a	DT	O
marker	NN	O
of	IN	O
bone	NN	O
resorption	NN	O
,	,	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
the	DT	O
Mediterranean	NNP	O
diet	NN	O
with	IN	O
virgin	JJ	O
olive	JJ	O
oil	NN	O
group	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
Mediterranean	NNP	O
dietary	JJ	O
pattern	NN	O
associated	VBN	O
with	IN	O
a	DT	O
high	JJ	O
dietary	JJ	O
acid	NN	O
load	NN	O
derived	VBN	O
from	IN	O
consumption	NN	O
of	IN	O
mixed	JJ	O
nuts	NNS	O
does	VBZ	O
not	RB	O
seem	VB	O
to	TO	O
have	VB	O
a	DT	O
much	RB	O
greater	JJR	O
effect	NN	O
on	IN	O
bone	NN	O
metabolism	NN	O
biomarkers	NNS	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
PTH	NNP	O
levels	NNS	O
,	,	O
than	IN	O
a	DT	O
Mediterranean	NNP	O
diet	NN	O
without	IN	O
mixed	JJ	O
nuts	NNS	O
or	CC	O
a	DT	O
control	NN	O
diet	NN	O
in	IN	O
elderly	JJ	Age
subjects	NNS	O
.	.	O

Alternative	JJ	O
voice	NN	O
after	IN	O
laryngectomy	NN	Condition
using	VBG	O
a	DT	O
sound-producing	JJ	O
voice	NN	O
prosthesis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
improve	VB	O
the	DT	O
voice	NN	O
quality	NN	O
of	IN	O
female	JJ	Sex
laryngectomees	NNS	Condition
and/or	VBP	O
laryngectomees	NNS	Condition
with	IN	Condition
a	DT	Condition
hypotonic	JJ	Condition
pharyngoesophageal	NN	Condition
(	(	Condition
PE	NNP	Condition
)	)	Condition
segment	NN	Condition
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
pneumatic	JJ	O
artificial	JJ	O
source	NN	O
of	IN	O
voice	NN	O
incorporated	VBN	O
in	IN	O
a	DT	O
regular	JJ	O
tracheoesophageal	NN	O
(	(	O
TE	NNP	O
)	)	O
shunt	NN	O
valve	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Experimental	NNP	O
,	,	O
randomized	VBD	O
,	,	O
crossover	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
new	JJ	O
sound	NN	O
source	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	O
silicone	NN	O
lip	NN	O
,	,	O
which	WDT	O
performs	VBZ	O
an	DT	O
oscillatory	JJ	O
movement	NN	O
driven	VBN	O
by	IN	O
expired	JJ	O
pulmonary	JJ	O
air	NN	O
flowing	VBG	O
along	IN	O
the	DT	O
outward-striking	JJ	O
lip	NN	O
through	IN	O
the	DT	O
TE	NNP	O
shunt	NN	O
valve	NN	O
.	.	O

A	DT	O
prototype	NN	O
of	IN	O
this	DT	O
pneumatic	JJ	O
sound	NN	O
source	NN	O
is	VBZ	O
evaluated	VBN	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
six	CD	SampleSize
laryngectomees	NNS	Condition
.	.	O

In	IN	O
vivo	JJ	O
evaluation	NN	O
includes	VBZ	O
speech	JJ	O
rate	NN	O
,	,	O
maximal	JJ	O
phonation	NN	O
time	NN	O
,	,	O
perceptual	JJ	O
voice	NN	O
evaluation	NN	O
of	IN	O
read-aloud	JJ	O
prose	NN	O
by	IN	O
an	DT	O
expert	NN	O
listener	NN	O
,	,	O
speech	JJ	Condition
intelligibility	NN	Condition
measurements	NNS	Condition
with	IN	O
12	CD	O
listeners	NNS	O
,	,	O
and	CC	O
self-assessment	JJ	O
by	IN	O
the	DT	O
patients	NNS	O
.	.	O

Moreover	RB	O
,	,	O
extensive	JJ	O
acoustical	JJ	O
and	CC	O
aerodynamic	JJ	O
in	IN	O
vivo	JJ	O
registrations	NNS	O
are	VBP	O
performed	VBN	O
using	VBG	O
a	DT	O
newly	RB	O
developed	VBN	O
data	NNS	O
acquisition	NN	O
system	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
current	JJ	O
prototype	NN	O
seems	VBZ	O
beneficial	JJ	O
in	IN	O
female	JJ	Condition
laryngectomees	NNS	Condition
with	IN	Condition
a	DT	Condition
hypotonic	JJ	Condition
PE	NNP	Condition
segment	NN	Condition
only	RB	O
.	.	O

For	IN	O
them	PRP	O
the	DT	O
sound-producing	JJ	O
voice	NN	O
prosthesis	NN	O
improves	VBZ	O
voice	JJ	O
quality	NN	O
and	CC	O
increases	VBZ	O
the	DT	O
average	JJ	O
pitch	NN	O
of	IN	O
voice	NN	O
,	,	O
without	IN	O
decreasing	VBG	O
intelligibility	NN	O
or	CC	O
necessitating	VBG	O
other	JJ	O
pressure	NN	O
and	CC	O
airflow	NN	O
rates	NNS	O
than	IN	O
regular	JJ	O
TE	NNP	O
shunt	NN	O
speech	NN	O
.	.	O

Pitch	NNP	O
regulation	NN	O
of	IN	O
this	DT	O
prosthetic	JJ	O
voice	NN	O
is	VBZ	O
possible	JJ	O
,	,	O
yet	RB	O
limited	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
mechanism	NN	O
is	VBZ	O
feasible	JJ	O
and	CC	O
does	VBZ	O
not	RB	O
result	VB	O
in	IN	O
unacceptable	JJ	O
airflow	JJ	O
resistance	NN	O
.	.	O

For	IN	O
this	DT	O
new	JJ	O
mechanism	NN	O
of	IN	O
alaryngeal	JJ	O
voice	NN	O
to	TO	O
become	VB	O
an	DT	O
established	JJ	O
technique	NN	O
for	IN	O
postlaryngectomy	JJ	O
voice	NN	O
restoration	NN	O
,	,	O
a	DT	O
voice	NN	O
suitably	RB	O
pitched	VBN	O
for	IN	O
male	NN	Condition
laryngectomees	NNS	Condition
has	VBZ	O
to	TO	O
be	VB	O
generated	VBN	O
and	CC	O
a	DT	O
large	JJ	O
part	NN	O
of	IN	O
the	DT	O
melodic	NN	O
and	CC	O
dynamic	JJ	O
range	NN	O
of	IN	O
the	DT	O
sound	NN	O
source	NN	O
has	VBZ	O
to	TO	O
be	VB	O
attainable	JJ	O
within	IN	O
physiological	JJ	O
airflow	JJ	O
rates	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
buspirone	NN	O
in	IN	O
a	DT	O
patient	NN	O
with	IN	O
autism	NN	O
.	.	O

This	DT	O
study	NN	O
evaluates	VBZ	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
buspirone	NN	O
hydrochloride	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
patient	NN	O
with	IN	O
autism	NN	O
and	CC	O
hyperactivity	NN	O
disorder	NN	O
and	CC	O
determines	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
buspirone	NN	O
on	IN	O
the	DT	O
number	NN	O
of	IN	O
performance	NN	O
tasks	NNS	O
completed	VBN	O
by	IN	O
the	DT	O
patient	NN	O
at	IN	O
school	NN	O
.	.	O

A	DT	O
3-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
a	DT	O
private	JJ	O
physician	NN	O
,	,	O
office-based	JJ	O
practice	NN	O
.	.	O

A	DT	O
child	NN	O
with	IN	O
autism	NN	O
,	,	O
which	WDT	O
was	VBD	O
diagnosed	VBN	O
by	IN	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Third	NNP	O
Edition	NNP	O
,	,	O
Revised	VBN	O
,	,	O
criteria	NNS	O
,	,	O
was	VBD	O
studied	VBN	O
.	.	O

The	DT	O
child	NN	O
received	VBD	O
placebo	NN	O
for	IN	O
3	CD	O
weeks	NNS	O
and	CC	O
buspirone	NN	O
for	IN	O
3	CD	O
weeks	NNS	O
;	:	O
there	EX	O
was	VBD	O
a	DT	O
1-week	JJ	O
interval	NN	O
between	IN	O
the	DT	O
2	CD	O
treatments	NNS	O
.	.	O

The	DT	O
outcome	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
using	VBG	O
Conners	NNS	O
abbreviated	VBD	O
parent	NN	O
and	CC	O
teacher	NN	O
questionnaires	NNS	O
and	CC	O
by	IN	O
determining	VBG	O
the	DT	O
number	NN	O
of	IN	O
daily	JJ	O
performance	NN	O
tasks	NNS	O
completed	VBN	O
by	IN	O
the	DT	O
child	NN	O
at	IN	O
school	NN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
linear	JJ	O
models	NNS	O
and	CC	O
standard	JJ	O
F	NNP	O
tests	NNS	O
.	.	O

Buspirone	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
efficacious	JJ	O
,	,	O
without	IN	O
side	JJ	O
effects	NNS	O
,	,	O
for	IN	O
decreasing	VBG	O
hyperactivity	NN	O
and	CC	O
increasing	VBG	O
completed	VBN	O
performance	NN	O
tasks	NNS	O
.	.	O

The	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
buspirone	NN	O
in	IN	O
helping	VBG	O
this	DT	O
patient	NN	O
with	IN	O
autism	NN	O
in	IN	O
his	PRP$	O
natural	JJ	O
daily	JJ	O
settings	NNS	O
suggest	VBP	O
that	IN	O
buspirone	NN	O
may	MD	O
be	VB	O
an	DT	O
alternative	JJ	O
to	TO	O
neuroleptic	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
medical	JJ	O
therapy	NN	O
of	IN	O
autism	NN	O
;	:	O
further	JJ	O
study	NN	O
in	IN	O
other	JJ	O
patients	NNS	O
is	VBZ	O
needed	VBN	O
.	.	O

Aortic	JJ	O
valve	NN	O
replacement	NN	O
.	.	O

A	DT	O
randomized	JJ	O
study	NN	O
comparing	VBG	O
the	DT	O
Bj?rk-Shiley	NNP	O
and	CC	O
Lillehei-Kaster	NNP	O
disc	NN	O
valves	NNS	O
.	.	O

Late	JJ	O
haemodynamics	NNS	O
related	VBN	O
to	TO	O
clinical	JJ	O
results	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
78	CD	O
randomized	VBD	O
patients	NNS	O
with	IN	O
either	DT	O
Bj?rk-Shiley	NNP	O
(	(	O
B-S	NNP	O
)	)	O
or	CC	O
Lillehei-Kaster	JJ	O
(	(	O
L-K	NNP	O
)	)	O
aortic	JJ	O
disc	NN	O
valve	NN	O
prostheses	NNS	O
were	VBD	O
re-admitted	JJ	O
for	IN	O
clinical	JJ	O
and	CC	O
haemodynamic	JJ	O
evaluation	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
selected	VBN	O
that	IN	O
those	DT	O
with	IN	O
narrow	JJ	O
aortic	JJ	O
roots	NNS	O
were	VBD	O
over-represented	JJ	O
.	.	O

Cine-aortography	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
75	CD	O
patients	NNS	O
and	CC	O
left	VBD	O
ventricular	JJ	O
catheterisation	NN	O
via	IN	O
the	DT	O
transseptal	JJ	O
approach	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
42	CD	O
.	.	O

The	DT	O
clinical	JJ	O
improvement	NN	O
was	VBD	O
striking	VBG	O
,	,	O
although	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
still	RB	O
incapacitated	VBN	O
was	VBD	O
relatively	RB	O
large	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
the	DT	O
small	JJ	O
L-K	JJ	O
valves	NNS	O
(	(	O
Nos	NNP	O
.	.	O

14	CD	O
&	CC	O
16	CD	O
)	)	O
.	.	O

Peak-to-peak	JJ	O
and	CC	O
mean	JJ	O
systolic	JJ	O
pressure	NN	O
differences	NNS	O
across	IN	O
the	DT	O
valves	NNS	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
B-S	NNP	O
than	IN	O
in	IN	O
the	DT	O
L-K	NNP	O
valves	NNS	O
,	,	O
particularly	RB	O
when	WRB	O
the	DT	O
small	JJ	O
valve	NN	O
sizes	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

Left	NNP	O
ventricular	JJ	O
end-diastolic	JJ	O
pressure	NN	O
(	(	O
LVEDP	NNP	O
)	)	O
,	,	O
which	WDT	O
was	VBD	O
elevated	VBN	O
in	IN	O
most	JJS	O
patients	NNS	O
before	IN	O
operation	NN	O
,	,	O
decreased	VBN	O
significantly	RB	O
to	TO	O
normal	JJ	O
levels	NNS	O
in	IN	O
the	DT	O
B-S	NNP	O
group	NN	O
.	.	O

In	IN	O
the	DT	O
L-K	NNP	O
group	NN	O
,	,	O
LVEDP	NNP	O
did	VBD	O
not	RB	O
decrease	VB	O
significantly	RB	O
and	CC	O
was	VBD	O
on	IN	O
the	DT	O
average	NN	O
still	RB	O
above	IN	O
the	DT	O
normal	JJ	O
level	NN	O
after	IN	O
operation	NN	O
,	,	O
probably	RB	O
due	JJ	O
to	TO	O
the	DT	O
relatively	RB	O
large	JJ	O
pressure	NN	O
gradients	NNS	O
.	.	O

The	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
L-K	NNP	O
valves	NNS	O
Nos	NNP	O
.	.	O

14	CD	O
&	CC	O
16	CD	O
in	IN	O
particular	JJ	O
represents	VBZ	O
a	DT	O
resistance	NN	O
to	TO	O
flow	VB	O
that	DT	O
is	VBZ	O
too	RB	O
large	JJ	O
to	TO	O
be	VB	O
acceptable	JJ	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
of	IN	O
early	JJ	O
discharge	NN	O
after	IN	O
uncomplicated	JJ	O
myocardial	JJ	Condition
infarction	NN	Condition
.	.	O

Out	IN	O
of	IN	O
383	CD	SampleSize
myocardial	JJ	Condition
infarction	NN	Condition
(	(	Condition
MI	NNP	Condition
)	)	Condition
patients	NNS	O
aged	VBN	O
below	IN	O
70	CD	Age
years	NNS	O
,	,	O
252	CD	SampleSize
(	(	O
66	CD	O
%	NN	O
)	)	O
were	VBD	O
judged	VBN	O
after	IN	O
the	DT	O
third	JJ	O
day	NN	O
in	IN	O
hospital	NN	O
to	TO	O
have	VB	O
had	VBN	O
uncomplicated	VBN	Condition
infarctions	NNS	Condition
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
at	IN	O
random	NN	O
to	TO	O
two	CD	O
groups	NNS	O
,	,	O
one	CD	O
of	IN	O
which	WDT	O
was	VBD	O
given	VBN	O
treatment	NN	O
for	IN	O
8	CD	O
days	NNS	O
and	CC	O
the	DT	O
other	JJ	O
for	IN	O
15	CD	O
days	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
mortality	NN	O
,	,	O
morbidity	NN	O
or	CC	O
incapacity	NN	O
for	IN	O
work	NN	O
could	MD	O
be	VB	O
detected	VBN	O
during	IN	O
the	DT	O
three-month	JJ	O
period	NN	O
of	IN	O
follow-up	NN	O
.	.	O

The	DT	O
findings	NNS	O
thus	RB	O
support	VBP	O
previous	JJ	O
conclusions	NNS	O
that	WDT	O
early	RB	O
discharge	VBP	O
from	IN	O
hospital	NN	O
after	IN	O
uncomplicated	JJ	O
MI	NNP	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
greater	JJR	O
risk	NN	O
for	IN	O
the	DT	O
patient	NN	O
than	IN	O
later	RB	O
discharge	NN	O
.	.	O

Reducing	VBG	O
polycystic	JJ	Condition
liver	NN	Condition
volume	NN	Condition
in	IN	Condition
ADPKD	NNP	Condition
:	:	Condition
effects	NNS	O
of	IN	O
somatostatin	NN	O
analogue	NN	O
octreotide	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
No	NNP	O
medical	JJ	O
treatment	NN	O
is	VBZ	O
available	JJ	O
for	IN	O
polycystic	JJ	O
liver	NN	O
disease	NN	O
,	,	O
a	DT	O
frequent	JJ	O
manifestation	NN	O
of	IN	O
autosomal-dominant	JJ	O
polycystic	JJ	O
kidney	NN	O
disease	NN	O
(	(	O
ADPKD	NNP	O
)	)	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	NN	O
study	NN	O
,	,	O
6	CD	O
months	NNS	O
of	IN	O
octreotide	NN	O
(	(	O
40	CD	O
mg	NN	O
every	DT	O
28	CD	O
days	NNS	O
)	)	O
therapy	NN	O
limited	JJ	O
kidney	NN	O
volume	NN	O
growth	NN	O
more	RBR	O
effectively	RB	O
than	IN	O
placebo	NN	O
in	IN	O
12	CD	O
patients	NNS	O
with	IN	O
ADPKD	NNP	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
PARTICIPANTS	NNP	O
,	,	O
&	CC	O
MEASUREMENTS	NNP	O
In	IN	O
this	DT	O
secondary	JJ	O
,	,	O
post	NN	O
hoc	NN	O
analysis	NN	O
of	IN	O
the	DT	O
above	NN	O
study	NN	O
,	,	O
octreotide-induced	JJ	O
changes	NNS	O
in	IN	O
liver	NN	O
volumes	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
and	CC	O
the	DT	O
relationship	NN	O
between	IN	O
concomitant	NN	O
changes	NNS	O
in	IN	O
liver	NN	O
and	CC	O
kidney	NN	O
volumes	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

Those	DT	O
analyzing	VBG	O
liver	NN	O
and	CC	O
kidney	NN	O
volumes	NNS	O
were	VBD	O
blinded	VBN	O
to	TO	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Liver	NNP	O
volumes	VBZ	O
significantly	RB	O
decreased	VBN	O
from	IN	O
1595	CD	O
+/-	JJ	O
478	CD	O
ml	NN	O
to	TO	O
1524	CD	O
+/-	JJ	O
453	CD	O
ml	NN	O
with	IN	O
octreotide	JJ	O
whereas	IN	O
they	PRP	O
did	VBD	O
not	RB	O
appreciably	RB	O
change	NN	O
with	IN	O
placebo	NN	O
.	.	O

Changes	NNS	O
in	IN	O
liver	NN	O
volumes	NNS	O
were	VBD	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
periods	NNS	O
(	(	O
-71	JJ	O
+/-	JJ	O
57	CD	O
ml	NN	O
versus	NN	O
+14	VBD	O
+/-	JJ	O
85	CD	O
ml	NN	O
)	)	O
.	.	O

Octreotide-induced	JJ	O
liver	NN	O
volume	NN	O
reduction	NN	O
was	VBD	O
fully	RB	O
explained	VBN	O
by	IN	O
a	DT	O
reduction	NN	O
in	IN	O
parenchyma	JJ	O
volume	NN	O
from	IN	O
1506	CD	O
+/-	JJ	O
431	CD	O
ml	NN	O
to	TO	O
1432	CD	O
+/-	JJ	O
403	CD	O
ml	NN	O
.	.	O

Changes	NNS	O
in	IN	O
liver	NN	O
volumes	NNS	O
were	VBD	O
significantly	RB	O
correlated	VBN	O
with	IN	O
concomitant	JJ	O
changes	NNS	O
in	IN	O
kidney	NN	O
volumes	NNS	O
(	(	O
r	VB	O
=	RB	O
0.67	CD	O
)	)	O
during	IN	O
octreotide	NN	O
but	CC	O
not	RB	O
during	IN	O
placebo	JJ	O
treatment	NN	O
.	.	O

Liver	NNP	O
and	CC	O
kidney	NN	O
volume	NN	O
changes	NNS	O
significantly	RB	O
differed	VBN	O
with	IN	O
both	DT	O
treatments	NNS	O
(	(	O
octreotide	IN	O
:	:	O
-71	JJ	O
+/-	JJ	O
57	CD	O
ml	NN	O
versus	NN	O
+71	VBD	O
+/-	JJ	O
107	CD	O
;	:	O
placebo	NN	O
:	:	O
+14	JJ	O
+/-	JJ	O
85	CD	O
ml	NN	O
versus	NN	O
+162	VBD	O
+/-	JJ	O
114	CD	O
)	)	O
,	,	O
but	CC	O
net	JJ	O
reductions	NNS	O
in	IN	O
liver	NN	O
(	(	O
-85	JJ	O
+/-	JJ	O
103	CD	O
ml	NN	O
)	)	O
and	CC	O
kidney	NN	O
(	(	O
-91	JJ	O
+/-	JJ	O
125	CD	O
ml	NN	O
)	)	O
volume	NN	O
growth	NN	O
on	IN	O
octreotide	IN	O
versus	NN	O
placebo	NN	O
were	VBD	O
similar	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Octreotide	NNP	O
therapy	NN	O
reduces	NNS	O
liver	RB	O
volumes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ADPKD	NNP	O
and	CC	O
is	VBZ	O
safe	JJ	O
.	.	O

The	DT	O
biological	JJ	O
factors	NNS	O
in	IN	O
the	DT	O
etiopathogenesis	NN	O
and	CC	O
management	NN	O
of	IN	O
cervical	JJ	Condition
spondylosis	NN	Condition
.	.	O

Two	CD	SampleSize
hundred	JJ	SampleSize
cases	NNS	O
of	IN	O
cervical	JJ	Condition
spondylosis	NN	Condition
were	VBD	O
studied	VBN	O
for	IN	O
1	CD	O
to	TO	O
4	CD	O
average	NN	O
(	(	O
2	CD	O
1/2	CD	O
)	)	O
years	NNS	O
.	.	O

No	DT	O
co-relation	NN	O
could	MD	O
be	VB	O
established	VBN	O
between	IN	O
the	DT	O
clinical	JJ	O
features	NNS	O
and	CC	O
the	DT	O
radiological	JJ	O
findings	NNS	O
in	IN	O
these	DT	O
cases	NNS	O
.	.	O

It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
parasites	VBZ	O
play	VBP	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
the	DT	O
multifactorial	JJ	O
etiology	NN	O
of	IN	O
this	DT	O
condition	NN	O
and	CC	O
their	PRP$	O
eradication	NN	O
by	IN	O
deworming	VBG	O
drugs	NNS	O
gives	VBZ	O
better	JJR	O
results	NNS	O
than	IN	O
the	DT	O
traditional	JJ	O
therapies	NNS	O
.	.	O

Many	JJ	O
new	JJ	O
hypotheses	NNS	O
are	VBP	O
proposed	VBN	O
to	TO	O
explain	VB	O
the	DT	O
same	JJ	O
.	.	O

Tubeless	NNP	O
percutaneous	JJ	O
nephrolithotomy	NN	O
:	:	O
safe	JJ	O
even	RB	O
in	IN	O
supracostal	JJ	O
access	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
outcome	NN	O
and	CC	O
safety	NN	O
of	IN	O
tubeless	NN	O
percutaneous	JJ	O
nephrolithotomy	NN	O
(	(	O
PCNL	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
renal	JJ	Condition
calculi	NN	Condition
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
November	NNP	O
2005	CD	O
and	CC	O
March	NNP	O
2006	CD	O
,	,	O
48	CD	SampleSize
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
an	DT	O
18F	CD	O
Re-entry	JJ	O
nephrostomy	NN	O
tube	NN	O
(	(	O
group	NN	O
1	CD	O
)	)	O
or	CC	O
a	DT	O
6F	CD	O
Double-J	JJ	O
stent	NN	O
(	(	O
group	NN	O
2	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
for	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
stone	NN	O
size	NN	O
,	,	O
stone	NN	O
laterality	NN	O
,	,	O
and	CC	O
number	NN	O
of	IN	O
previous	JJ	O
renal	JJ	O
procedures	NNS	O
.	.	O

All	DT	O
PCNL	NNP	O
procedures	NNS	O
were	VBD	O
performed	VBN	O
by	IN	O
the	DT	O
same	JJ	O
surgeon	NN	O
.	.	O

Postoperative	JJ	O
visual	JJ	O
analog	NN	O
pain	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
scores	VBZ	O
at	IN	O
8	CD	O
and	CC	O
24	CD	O
hours	NNS	O
and	CC	O
14	CD	O
days	NNS	O
after	IN	O
surgery	NN	O
,	,	O
in-hospital	JJ	O
analgesic	JJ	O
use	NN	O
,	,	O
length	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
,	,	O
success	NN	O
rate	NN	O
,	,	O
blood	NN	O
transfusion	NN	O
rate	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
complications	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
hospital	NN	O
stays	NNS	O
in	IN	O
groups	NNS	O
1	CD	O
and	CC	O
2	CD	O
were	VBD	O
3.1	CD	O
and	CC	O
1.6	CD	O
days	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
VAS	NNP	O
scores	VBZ	O
8	CD	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
2	CD	O
than	IN	O
in	IN	O
group	NN	O
1	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
postoperative	JJ	O
analgesic	JJ	O
requirement	NN	O
(	(	O
diclofenac	JJ	O
sodium	NN	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
group	NN	O
1	CD	O
(	(	O
263	CD	O
mg	NN	O
)	)	O
than	IN	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
120	CD	O
mg	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
blood	NN	O
transfusion	NN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
was	VBD	O
similar	JJ	O
(	(	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
VAS	NNP	O
scores	NNS	O
on	IN	O
postoperative	JJ	O
day	NN	O
14	CD	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
supracostal	JJ	O
accesses	NNS	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
group	NN	O
2	CD	O
than	IN	O
in	IN	O
group	NN	O
1	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
stone-free	JJ	O
rates	NNS	O
and	CC	O
the	DT	O
numbers	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
insignificant	JJ	O
residual	JJ	O
fragments	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
urine	JJ	O
leakage	NN	O
or	CC	O
formation	NN	O
of	IN	O
urinoma	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Double-J	NNP	O
stents	NNS	O
.	.	O

CONCLUSION	NNP	O
Tubeless	NNP	O
PCNL	NNP	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
even	RB	O
after	IN	O
supracostal	JJ	O
access	NN	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
less	RBR	O
postoperative	JJ	O
pain	NN	O
and	CC	O
a	DT	O
shorter	JJR	O
hospital	NN	O
stay	NN	O
.	.	O

PDE5	NNP	O
inhibition	NN	O
with	IN	O
sildenafil	JJ	O
improves	NNS	O
left	VBD	O
ventricular	JJ	O
diastolic	JJ	O
function	NN	O
,	,	O
cardiac	JJ	O
geometry	NN	O
,	,	O
and	CC	O
clinical	JJ	O
status	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	Condition
systolic	JJ	Condition
heart	NN	Condition
failure	NN	Condition
:	:	Condition
results	NNS	O
of	IN	O
a	DT	O
1-year	JJ	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
heart	NN	O
failure	NN	O
(	(	O
HF	NNP	O
)	)	O
,	,	O
a	DT	O
defective	JJ	O
nitric	JJ	O
oxide	IN	O
signaling	VBG	O
is	VBZ	O
involved	VBN	O
in	IN	O
left	JJ	O
ventricular	NN	O
(	(	O
LV	NNP	O
)	)	O
diastolic	NN	O
abnormalities	NNS	O
and	CC	O
remodeling	VBG	O
.	.	O

PDE5	NNP	O
inhibition	NN	O
,	,	O
by	IN	O
blocking	VBG	O
degradation	NN	O
of	IN	O
nitric	JJ	O
oxide	IN	O
second-messenger	JJ	O
cyclic	JJ	O
guanosine	NN	O
monophosphate	NN	O
,	,	O
might	MD	O
be	VB	O
beneficial	JJ	O
.	.	O

In	IN	O
a	DT	O
cohort	NN	O
of	IN	O
systolic	JJ	Condition
HF	NNP	Condition
patients	NNS	O
,	,	O
we	PRP	O
tested	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
PDE5	NNP	O
inhibition	NN	O
(	(	O
sildenafil	NN	O
)	)	O
on	IN	O
LV	NNP	O
ejection	NN	O
fraction	NN	O
,	,	O
diastolic	JJ	O
function	NN	O
,	,	O
cardiac	JJ	O
geometry	NN	O
,	,	O
and	CC	O
clinical	JJ	O
status	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Forty-five	JJ	SampleSize
HF	NNP	Condition
patients	NNS	O
(	(	O
New	NNP	O
York	NNP	O
Heart	NNP	O
Association	NNP	O
class	NN	O
II-III	NNP	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
placebo	VB	O
or	CC	O
sildenafil	VB	O
(	(	O
50	CD	O
mg	NN	O
three	CD	O
times	NNS	O
per	IN	O
day	NN	O
)	)	O
for	IN	O
1	CD	O
year	NN	O
,	,	O
with	IN	O
assessment	NN	O
(	(	O
6	CD	O
months	NNS	O
and	CC	O
1	CD	O
year	NN	O
)	)	O
of	IN	O
LV	NNP	O
ejection	NN	O
fraction	NN	O
,	,	O
diastolic	JJ	O
function	NN	O
,	,	O
geometry	NN	O
,	,	O
cardiopulmonary	JJ	O
exercise	NN	O
performance	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

In	IN	O
the	DT	O
sildenafil	NN	O
group	NN	O
only	RB	O
,	,	O
at	IN	O
6	CD	O
months	NNS	O
and	CC	O
1	CD	O
year	NN	O
,	,	O
LV	NNP	O
ejection	NN	O
fraction	NN	O
,	,	O
early	JJ	O
diastolic	JJ	O
tissue	NN	O
Doppler	NNP	O
velocities	NNS	O
(	(	O
E	NNP	O
'	POS	O
)	)	O
at	IN	O
the	DT	O
mitral	JJ	O
lateral	JJ	O
(	(	O
from	IN	O
4.62	CD	O
to	TO	O
5.20	CD	O
and	CC	O
5.19	CD	O
m/s	NN	O
)	)	O
and	CC	O
septal	JJ	O
(	(	O
from	IN	O
4.71	CD	O
to	TO	O
5.23	CD	O
and	CC	O
5.24	CD	O
m/s	NN	O
)	)	O
annuli	VBZ	O
significantly	RB	O
increased	VBN	O
,	,	O
whereas	IN	O
the	DT	O
ratio	NN	O
of	IN	O
early	JJ	O
transmitral	NN	O
(	(	O
E	NNP	O
)	)	O
to	TO	O
E	NNP	O
'	POS	O
lateral	JJ	O
decreased	VBN	O
(	(	O
from	IN	O
13.1	CD	O
to	TO	O
9.8	CD	O
to	TO	O
9.4	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Changes	NNS	O
were	VBD	O
accompanied	VBN	O
by	IN	O
a	DT	O
reverse	NN	O
remodeling	NN	O
of	IN	O
left	JJ	O
atrial	JJ	O
volume	NN	O
index	NN	O
(	(	O
from	IN	O
32.0	CD	O
to	TO	O
29.0	CD	O
and	CC	O
29.1	CD	O
mL/m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
LV	NNP	O
mass	NNP	O
index	NN	O
(	(	O
from	IN	O
148.0	CD	O
to	TO	O
130.0	CD	O
and	CC	O
128.0	CD	O
g/m	NN	O
(	(	O
2	CD	O
)	)	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
sildenafil	JJ	O
improved	VBN	O
exercise	NN	O
performance	NN	O
(	(	O
peak	JJ	O
Vo	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
,	,	O
ventilation	NN	O
efficiency	NN	O
(	(	O
ventilation	NN	O
to	TO	O
CO	NNP	O
(	(	O
2	CD	O
)	)	O
production	NN	O
slope	NN	O
)	)	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Minor	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
noted	VBN	O
:	:	O
flushing	NN	O
in	IN	O
4	CD	O
and	CC	O
headache	NN	O
in	IN	O
2	CD	O
treated	JJ	O
patients	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Findings	NNP	O
confirm	NN	O
that	IN	O
in	IN	O
HF	NNP	O
,	,	O
sildenafil	NN	O
improves	VBZ	O
functional	JJ	O
capacity	NN	O
and	CC	O
clinical	JJ	O
status	NN	O
and	CC	O
provide	VB	O
the	DT	O
first	JJ	O
human	JJ	O
evidence	NN	O
that	IN	O
LV	NNP	O
diastolic	JJ	O
function	NN	O
and	CC	O
cardiac	JJ	O
geometry	NN	O
are	VBP	O
additional	JJ	O
targets	NNS	O
of	IN	O
benefits	NNS	O
related	VBN	O
to	TO	O
chronic	JJ	O
PDE5	NNP	O
inhibition	NN	O
.	.	O

Double	NNP	O
hearing	NN	O
protection	NN	O
and	CC	O
speech	NN	O
intelligibility-room	NN	O
for	IN	O
improvement	NN	O
.	.	O

INTRODUCTION	NNP	O
Double	NNP	O
hearing	NN	O
protection	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
many	JJ	O
air	NN	O
forces	NNS	O
around	IN	O
the	DT	O
world	NN	O
for	IN	O
protection	NN	O
in	IN	O
noisy	NN	O
aircraft	NN	O
environments	NNS	O
,	,	O
particularly	RB	O
in	IN	O
helicopters	NNS	O
.	.	O

The	DT	O
usual	JJ	O
combination	NN	O
is	VBZ	O
foam	JJ	O
ear	JJ	O
plugs	NNS	O
under	IN	O
headset	NN	O
or	CC	O
helmet	JJ	O
muffs	NNS	O
.	.	O

Much	RB	O
of	IN	O
the	DT	O
research	NN	O
that	WDT	O
spurred	VBD	O
the	DT	O
introduction	NN	O
of	IN	O
foam	NN	O
earplugs	NNS	O
indicated	VBD	O
little	JJ	O
change	NN	O
in	IN	O
speech	NN	O
intelligibility	NN	O
in	IN	O
persons	NNS	O
with	IN	O
normal	JJ	O
hearing	NN	O
.	.	O

However	RB	O
,	,	O
aircrew	VBD	O
often	RB	O
complain	VBP	O
about	IN	O
having	VBG	O
to	TO	O
maximize	VB	O
intercom	JJ	O
volume	NN	O
for	IN	O
speech	NN	O
understanding	NN	O
,	,	O
causing	VBG	O
a	DT	O
situation	NN	O
with	IN	O
no	DT	O
reserve	NN	O
volume	NN	O
and	CC	O
bad	JJ	O
sound	NN	O
quality	NN	O
.	.	O

In	IN	O
recent	JJ	O
years	NNS	O
,	,	O
further	JJ	O
developments	NNS	O
have	VBP	O
included	VBN	O
so-called	JJ	O
hi-fi	JJ	O
plugs	NNS	O
and	CC	O
custom	NN	O
made	VBD	O
ear	NN	O
plugs	NNS	O
which	WDT	O
are	VBP	O
claimed	VBN	O
to	TO	O
improve	VB	O
speech	NN	O
communication	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
project	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
different	JJ	O
types	NNS	O
of	IN	O
ear	NN	O
plugs	NNS	O
and	CC	O
their	PRP$	O
effect	NN	O
on	IN	O
speech	NN	O
intelligibility	NN	O
in	IN	O
helicopter	NN	O
noise	NN	O
.	.	O

METHODS	NNP	O
Each	DT	O
of	IN	O
nine	CD	O
normal-hearing	JJ	O
pilot	NN	O
subjects	NNS	O
were	VBD	O
placed	VBN	O
in	IN	O
an	DT	O
environment	NN	O
of	IN	O
recorded	VBN	O
helicopter	NN	O
noise	NN	O
from	IN	O
a	DT	O
BO-105	JJ	O
helicopter	NN	O
.	.	O

Speech	NNP	O
audiometry	NN	O
was	VBD	O
performed	VBN	O
under	IN	O
four	CD	O
different	JJ	O
conditions	NNS	O
:	:	O
headset	NN	O
only	RB	O
,	,	O
and	CC	O
three	CD	O
different	JJ	O
ear	NN	O
plugs	NNS	O
worn	VBN	O
under	IN	O
the	DT	O
headset	NN	O
.	.	O

Fitting	NN	O
of	IN	O
the	DT	O
ear	JJ	O
plugs	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
an	DT	O
ear	NN	O
,	,	O
nose	JJ	O
and	CC	O
throat	JJ	O
specialist	NN	O
to	TO	O
ensure	VB	O
similar	JJ	O
conditions	NNS	O
.	.	O

The	DT	O
sequence	NN	O
of	IN	O
test	NN	O
conditions	NNS	O
was	VBD	O
randomized	VBN	O
and	CC	O
double-blind	JJ	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
subjective	JJ	O
rating	NN	O
scale	NN	O
was	VBD	O
used	VBN	O
.	.	O

RESULTS	NNP	O
Wearing	NNP	O
foam	JJ	O
ear	NN	O
plugs	NNS	O
under	IN	O
the	DT	O
headset	NN	O
decreased	VBD	O
speech	JJ	O
intelligibility	NN	O
dramatically	RB	O
.	.	O

The	DT	O
hi-fi	JJ	O
plug	NN	O
was	VBD	O
somewhat	RB	O
better	JJR	O
than	IN	O
foam	NN	O
plugs	NNS	O
,	,	O
and	CC	O
the	DT	O
custom	NN	O
made	VBD	O
ear	JJ	O
plug	NN	O
provided	VBD	O
a	DT	O
speech	NN	O
intelligibility	NN	O
close	RB	O
to	TO	O
the	DT	O
headset-only	JJ	O
situation	NN	O
.	.	O

Subjective	JJ	O
rating	NN	O
scores	NNS	O
coincided	VBD	O
with	IN	O
these	DT	O
findings	NNS	O
.	.	O

DISCUSSION	NNP	O
In	IN	O
helicopter	NN	O
noise	NN	O
,	,	O
custom	NN	O
made	VBD	O
ear	JJ	O
plugs	NNS	O
may	MD	O
provide	VB	O
a	DT	O
much	RB	O
improved	VBN	O
speech	JJ	O
intelligibility	NN	O
over	IN	O
conventional	JJ	O
plugs	NNS	O
when	WRB	O
worn	VBN	O
under	IN	O
a	DT	O
headset	NN	O
,	,	O
while	IN	O
maintaining	VBG	O
improved	JJ	O
noise	NN	O
protection	NN	O
over	IN	O
the	DT	O
headset-alone	JJ	O
situation	NN	O
.	.	O

Custom	NNP	O
made	VBD	O
ear	JJ	O
plugs	NNS	O
might	MD	O
therefore	RB	O
be	VB	O
a	DT	O
good	JJ	O
alternative	NN	O
to	TO	O
other	JJ	O
forms	NNS	O
of	IN	O
enhanced	JJ	O
noise	NN	O
protection	NN	O
in	IN	O
helicopters	NNS	O
.	.	O

Left	NNP	O
thoracoabdominal	JJ	O
approach	NN	O
versus	IN	O
abdominal-transhiatal	JJ	O
approach	NN	O
for	IN	O
gastric	JJ	O
cancer	NN	O
of	IN	O
the	DT	O
cardia	NN	O
or	CC	O
subcardia	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Because	IN	O
of	IN	O
the	DT	O
inaccessibility	NN	O
of	IN	O
mediastinal	JJ	O
nodal	JJ	O
metastases	NNS	O
,	,	O
the	DT	O
left	JJ	O
thoracoabdominal	JJ	O
approach	NN	O
(	(	O
LTA	NNP	O
)	)	O
has	VBZ	O
often	RB	O
been	VBN	O
used	VBN	O
to	TO	O
treat	VB	O
gastric	JJ	O
cancer	NN	O
of	IN	O
the	DT	O
cardia	NN	O
or	CC	O
subcardia	NN	O
.	.	O

In	IN	O
a	DT	O
randomised	JJ	O
phase	NN	O
III	NNP	O
study	NN	O
,	,	O
we	PRP	O
aimed	VBD	O
to	TO	O
compare	VB	O
LTA	NNP	O
with	IN	O
the	DT	O
abdominal-transhiatal	JJ	O
approach	NN	O
(	(	O
TH	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
these	DT	O
tumours	NNS	O
.	.	O

METHODS	NNP	O
Between	NNP	O
July	NNP	O
,	,	O
1995	CD	O
,	,	O
and	CC	O
December	NNP	O
,	,	O
2003	CD	O
,	,	O
167	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
from	IN	O
27	CD	O
Japanese	JJ	O
hospitals	NNS	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
TH	NNP	O
(	(	O
n=82	NN	O
)	)	O
or	CC	O
LTA	NNP	O
(	(	O
n=85	NN	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
overall	JJ	O
survival	NN	O
,	,	O
and	CC	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
disease-free	JJ	O
survival	NN	O
,	,	O
postoperative	JJ	O
morbidity	NN	O
and	CC	O
hospital	NN	O
mortality	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
symptoms	NNS	O
and	CC	O
change	NN	O
of	IN	O
respiratory	NN	O
function	NN	O
.	.	O

The	DT	O
projected	JJ	O
sample	NN	O
size	NN	O
was	VBD	O
302	CD	O
.	.	O

After	IN	O
the	DT	O
first	JJ	O
interim	JJ	O
analysis	NN	O
,	,	O
the	DT	O
predicted	JJ	O
probability	NN	O
of	IN	O
LTA	NNP	O
having	VBG	O
a	DT	O
significantly	RB	O
better	RBR	O
overall	JJ	O
survival	NN	O
than	IN	O
TH	NNP	O
at	IN	O
the	DT	O
final	JJ	O
analysis	NN	O
was	VBD	O
only	RB	O
3.65	CD	O
%	NN	O
,	,	O
and	CC	O
the	DT	O
trial	NN	O
was	VBD	O
closed	VBN	O
immediately	RB	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
,	,	O
number	NN	O
NCT00149266	NNP	O
.	.	O

FINDINGS	NNP	O
5-year	JJ	O
overall	JJ	O
survival	NN	O
was	VBD	O
52.3	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
40.4-64.1	CD	O
)	)	O
in	IN	O
the	DT	O
TH	NNP	O
group	NN	O
and	CC	O
37.9	CD	O
%	NN	O
(	(	O
26.1-49.6	JJ	O
)	)	O
in	IN	O
the	DT	O
LTA	NNP	O
group	NN	O
.	.	O

The	DT	O
hazard	NN	O
ratio	NN	O
of	IN	O
death	NN	O
for	IN	O
LTA	NNP	O
compared	VBN	O
with	IN	O
TH	NNP	O
was	VBD	O
1.36	CD	O
(	(	O
0.89-2.08	CD	O
,	,	O
p=0.92	NN	O
)	)	O
.	.	O

Three	CD	O
patients	NNS	O
died	VBD	O
in	IN	O
hospital	NN	O
after	IN	O
LTA	NNP	O
but	CC	O
none	NN	O
after	IN	O
TH	NNP	O
.	.	O

Morbidity	NNP	O
was	VBD	O
worse	JJR	O
after	IN	O
LTA	NNP	O
than	IN	O
after	IN	O
TH	NNP	O
.	.	O

INTERPRETATION	NNP	O
Because	IN	O
LTA	NNP	O
does	VBZ	O
not	RB	O
improve	VB	O
survival	NN	O
after	IN	O
TH	NNP	O
and	CC	O
leads	VBZ	O
to	TO	O
increased	VBN	O
morbidity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
cancer	NN	O
of	IN	O
the	DT	O
cardia	NN	O
or	CC	O
subcardia	NN	O
,	,	O
LTA	NNP	O
can	MD	O
not	RB	O
be	VB	O
justified	VBN	O
to	TO	O
treat	VB	O
these	DT	O
tumours	NNS	O
.	.	O

Specific	JJ	O
immunoglobulin	NN	O
for	IN	O
treatment	NN	O
of	IN	O
whooping	JJ	Condition
cough	NN	Condition
.	.	O

Immunoglobulin	NNP	O
treatment	NN	O
for	IN	O
whooping	JJ	O
cough	NN	O
(	(	O
pertussis	NN	O
)	)	O
is	VBZ	O
widely	RB	O
believed	VBN	O
to	TO	O
be	VB	O
ineffective	JJ	O
although	IN	O
there	EX	O
are	VBP	O
sound	JJ	O
reasons	NNS	O
for	IN	O
regarding	VBG	O
the	DT	O
condition	NN	O
as	IN	O
a	DT	O
toxin-induced	JJ	O
disease	NN	O
.	.	O

We	PRP	O
wondered	VBD	O
whether	IN	O
the	DT	O
lack	NN	O
of	IN	O
success	NN	O
with	IN	O
pertussis	NN	O
immunoglobulins	NNS	O
might	MD	O
be	VB	O
attributable	JJ	O
to	TO	O
inadequate	VB	O
dose	NN	O
,	,	O
so	IN	O
we	PRP	O
designed	VBD	O
a	DT	O
randomised	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
two	CD	O
immunoglobulin	JJ	O
preparations	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
three	CD	O
Swedish	JJ	O
hospitals	NNS	O
.	.	O

We	PRP	O
enrolled	VBD	O
73	CD	SampleSize
children	NNS	Age
aged	VBD	Age
less	JJR	Age
than	IN	Age
36	CD	Age
months	NNS	Age
who	WP	O
were	VBD	O
admitted	VBN	O
with	IN	O
a	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
whooping	JJ	Condition
cough	NN	Condition
.	.	O

On	IN	O
admission	NN	O
they	PRP	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
monocomponent	NN	O
pertussis	NN	O
toxoid	JJ	O
vaccine	NN	O
;	:	O
(	(	O
b	NN	O
)	)	O
two-component	NN	O
acellular	JJ	O
vaccine	NN	O
also	RB	O
containing	VBG	O
filamentous	JJ	O
haemagglutinin	NN	O
;	:	O
or	CC	O
(	(	O
c	NN	O
)	)	O
20	CD	O
%	NN	O
albumin	JJ	O
solution	NN	O
(	(	O
placebo	NN	O
)	)	O
.	.	O

The	DT	O
immunoglobulins	NNS	O
had	VBD	O
a	DT	O
high	JJ	O
antitoxin	NN	O
content	NN	O
and	CC	O
had	VBD	O
been	VBN	O
raised	VBN	O
with	IN	O
acellular	JJ	O
pertussis	NN	O
vaccines	NNS	O
.	.	O

Diagnosis	NN	O
of	IN	O
pertussis	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
laboratory	NN	O
tests	NNS	O
and	CC	O
the	DT	O
follow-up	NN	O
was	VBD	O
completed	VBN	O
in	IN	O
67	CD	O
children	NNS	O
.	.	O

The	DT	O
main	JJ	O
study	NN	O
group	NN	O
consisted	VBD	O
of	IN	O
47	CD	SampleSize
children	NNS	O
with	IN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
14	CD	O
days	NNS	O
of	IN	O
disease	NN	O
before	IN	O
therapy	NN	O
.	.	O

Duration	NN	O
of	IN	O
whoops	JJ	O
post-treatment	NN	O
was	VBD	O
8.7	CD	O
days	NNS	O
(	(	O
95	CD	O
%	NN	O
Cl	NNP	O
4.8	CD	O
,	,	O
12.6	CD	O
)	)	O
in	IN	O
the	DT	O
33	CD	O
children	NNS	O
receiving	VBG	O
immunoglobulin	NN	O
vs	NN	O
20.6	CD	O
(	(	O
95	CD	O
%	NN	O
Cl	NNP	O
11.9	CD	O
,	,	O
29.3	CD	O
)	)	O
in	IN	O
the	DT	O
14	CD	O
receiving	NN	O
placebo	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0041	CD	O
)	)	O
.	.	O

Mean	JJ	O
number	NN	O
of	IN	O
whoops	NNS	O
during	IN	O
the	DT	O
first	JJ	O
week	NN	O
of	IN	O
follow-up	NN	O
was	VBD	O
also	RB	O
significantly	RB	O
reduced	VBN	O
(	(	O
p	JJ	O
=	NNP	O
0.0196	CD	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
early	JJ	O
treatment	NN	O
was	VBD	O
important	JJ	O
,	,	O
since	IN	O
the	DT	O
effect	NN	O
on	IN	O
duration	NN	O
of	IN	O
whoops	NNS	O
was	VBD	O
most	RBS	O
pronounced	JJ	O
when	WRB	O
disease	NN	O
duration	NN	O
before	IN	O
treatment	NN	O
was	VBD	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
7	CD	O
days	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
immunoglobulin	NN	O
preparations	NNS	O
.	.	O

High-dose	JJ	O
specific	JJ	O
pertussis	NN	O
immunoglobulin	NN	O
with	IN	O
a	DT	O
high	JJ	O
antitoxin	NN	O
concentration	NN	O
has	VBZ	O
a	DT	O
beneficial	JJ	O
effect	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
whooping	JJ	O
cough	NN	O
.	.	O

The	DT	O
accuracy	NN	O
of	IN	O
clinical	JJ	O
neurosensory	NN	O
testing	VBG	O
for	IN	O
nerve	JJ	O
injury	NN	O
diagnosis	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
accuracy	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
neurosensory	JJ	O
test	NN	O
to	TO	O
diagnose	VB	O
trigeminal	JJ	O
nerve	NN	O
injuries	NNS	O
has	VBZ	O
never	RB	O
been	VBN	O
statistically	RB	O
evaluated	VBN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
statistical	JJ	O
efficacy	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
neurosensory	JJ	O
test	NN	O
using	VBG	O
surgical	JJ	O
findings	NNS	O
as	IN	O
the	DT	O
gold	JJ	O
standard	NN	O
,	,	O
and	CC	O
to	TO	O
determine	VB	O
whether	IN	O
a	DT	O
correlation	NN	O
existed	VBN	O
between	IN	O
the	DT	O
sensory	JJ	O
impairment	NN	O
score	NN	O
obtained	VBN	O
by	IN	O
preoperative	JJ	O
testing	NN	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
nerve	NN	O
injury	NN	O
found	VBD	O
at	IN	O
surgery	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
multisite	NN	O
,	,	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
blinded	VBD	O
,	,	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
130	CD	Condition
patients	NNS	Condition
with	IN	Condition
inferior	JJ	Condition
alveolar	JJ	Condition
nerve	NN	Condition
(	(	Condition
IAN	NNP	Condition
)	)	Condition
and	CC	Condition
lingual	JJ	Condition
nerve	NN	Condition
(	(	Condition
LN	NNP	Condition
)	)	Condition
injuries	NNS	Condition
.	.	Condition

Preoperatively	RB	O
,	,	O
patients	NNS	O
were	VBD	O
provided	VBN	O
a	DT	O
sensory	JJ	O
impairment	NN	O
score	NN	O
using	VBG	O
a	DT	O
three-level	JJ	O
drop-out	JJ	O
clinical	JJ	O
neurosensory	NN	O
test	NN	O
(	(	O
NST	NNP	O
)	)	O
,	,	O
and	CC	O
blind	IN	O
comparisons	NNS	O
were	VBD	O
made	VBN	O
with	IN	O
the	DT	O
surgical	JJ	O
findings	NNS	O
postoperatively	RB	O
.	.	O

RESULTS	VB	O
The	DT	O
positive	JJ	O
predictive	NN	O
and	CC	O
negative	JJ	O
predictive	NN	O
values	NNS	O
for	IN	O
LN-injured	JJ	O
patients	NNS	O
were	VBD	O
95	CD	O
%	NN	O
and	CC	O
100	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
positive	JJ	O
predictive	NN	O
and	CC	O
negative	JJ	O
predictive	NN	O
values	NNS	O
for	IN	O
IAN	NNP	O
patients	NNS	O
were	VBD	O
77	CD	O
%	NN	O
and	CC	O
60	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
distribution	NN	O
of	IN	O
age	NN	O
,	,	O
duration	NN	O
of	IN	O
injury	NN	O
,	,	O
cause	NN	O
of	IN	O
injury	NN	O
,	,	O
presence	NN	O
of	IN	O
neuropathic	JJ	O
pain	NN	O
,	,	O
presence	NN	O
of	IN	O
trigger	NN	O
pain	NN	O
,	,	O
and	CC	O
degree	NN	O
of	IN	O
injury	NN	O
between	IN	O
the	DT	O
IAN	NNP	O
and	CC	O
LN	NNP	O
patient	JJ	O
populations	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
positive	JJ	O
relationship	NN	O
found	VBD	O
between	IN	O
the	DT	O
sensory	JJ	O
impairment	NN	O
score	NN	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
nerve	NN	O
injury	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
NST	NNP	O
is	VBZ	O
a	DT	O
clinically	RB	O
useful	JJ	O
method	NN	O
to	TO	O
diagnose	VB	O
IAN	NNP	O
and	CC	O
LN	NNP	O
injuries	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
NST	NNP	O
results	NNS	O
are	VBP	O
less	RBR	O
efficient	JJ	O
for	IN	O
IAN	NNP	O
injuries	NNS	O
than	IN	O
LN	NNP	O
injuries	NNS	O
,	,	O
and	CC	O
have	VBP	O
a	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
false-positive	JJ	O
(	(	O
23	CD	O
%	NN	O
)	)	O
and	CC	O
false-negative	JJ	O
(	(	O
40	CD	O
%	NN	O
)	)	O
results	NNS	O
when	WRB	O
testing	VBG	O
patients	NNS	O
with	IN	O
IAN	NNP	O
injuries	NNS	O
.	.	O

The	DT	O
different	JJ	O
rates	NNS	O
of	IN	O
statistical	JJ	O
efficiency	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
may	MD	O
be	VB	O
attributable	JJ	O
to	TO	O
differences	NNS	O
in	IN	O
prevalence	NN	O
and	CC	O
biologic	NN	O
covariates	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
analgesic	JJ	O
effect	NN	O
of	IN	O
locally	RB	O
and	CC	O
systemically	RB	O
administered	VBN	O
ketorolac	NN	O
in	IN	O
mastectomy	JJ	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Ketorolac	NNP	O
is	VBZ	O
a	DT	O
parenteral	JJ	O
nonsteroidal	JJ	O
antiinflammatory	JJ	O
drug	NN	O
(	(	O
NSAID	NNP	O
)	)	O
.	.	O

Two	CD	O
features	NNS	O
have	VBP	O
limited	VBN	O
its	PRP$	O
clinical	JJ	O
utility	NN	O
:	:	O
tendency	NN	O
to	TO	O
elicit	VB	O
kidney	NN	O
failure	NN	O
and	CC	O
inability	NN	O
to	TO	O
produce	VB	O
complete	JJ	O
analgesia	NN	O
.	.	O

Because	IN	O
most	JJS	O
NSAIDs	NNP	O
are	VBP	O
weak	JJ	O
acids	NNS	O
(	(	O
pKa	IN	O
3-5	NNP	O
)	)	O
and	CC	O
become	VBN	O
concentrated	JJ	O
in	IN	O
acidic	JJ	O
tissues	NNS	O
,	,	O
such	JJ	O
as	IN	O
injured	JJ	O
and	CC	O
inflamed	JJ	O
tissues	NNS	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	IN	O
local	JJ	O
administration	NN	O
may	MD	O
enhance	VB	O
its	PRP$	O
analgesic	JJ	O
efficacy	NN	O
while	IN	O
lowering	VBG	O
the	DT	O
potential	NN	O
for	IN	O
systemic	JJ	O
complications	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
of	IN	O
60	CD	O
group	NN	O
I-II	NNP	O
(	(	O
American	JJ	O
Society	NNP	O
of	IN	O
Anesthesiology	NNP	O
criteria	NNS	O
)	)	O
mastectomy	NN	O
patients	NNS	O
,	,	O
20	CD	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Near	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
and	CC	O
every	DT	O
6	CD	O
h	NN	O
postoperatively	RB	O
,	,	O
20	CD	O
ml	NN	O
of	IN	O
the	DT	O
study	NN	O
solution	NN	O
containing	VBG	O
normal	JJ	O
saline	NN	O
with	IN	O
or	CC	O
without	IN	O
30	CD	O
mg	NN	O
of	IN	O
ketorolac	NN	O
were	VBD	O
administered	VBN	O
simultaneously	RB	O
either	CC	O
via	IN	O
a	DT	O
Jackson-Pratt	JJ	O
drain	NN	O
or	CC	O
intravenously	RB	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
.	.	O

The	DT	O
quality	NN	O
of	IN	O
pain	NN	O
control	NN	O
,	,	O
the	DT	O
amount	NN	O
and	CC	O
character	NN	O
of	IN	O
the	DT	O
drain	NN	O
fluid	NN	O
,	,	O
incidence	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
length	NN	O
of	IN	O
stay	NN	O
in	IN	O
the	DT	O
postoperative	JJ	O
care	NN	O
unit	NN	O
,	,	O
and	CC	O
amount	NN	O
of	IN	O
morphine	NN	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
break-through	JJ	O
pain	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Intraoperative	NNP	O
administration	NN	O
of	IN	O
ketorolac	NN	O
resulted	VBD	O
in	IN	O
better	JJR	O
quality	NN	O
of	IN	O
pain	NN	O
control	NN	O
in	IN	O
the	DT	O
immediate	JJ	O
postoperative	JJ	O
period	NN	O
regardless	NN	O
of	IN	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
nausea	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
drain	NN	O
output	NN	O
in	IN	O
the	DT	O
ketorolac	NN	O
groups	NNS	O
did	VBD	O
not	RB	O
exceed	VB	O
the	DT	O
output	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Analgesic	NNP	O
of	IN	O
the	DT	O
locally	RB	O
administered	VBN	O
ketorolac	NN	O
is	VBZ	O
equally	RB	O
effective	JJ	O
to	TO	O
the	DT	O
efficacy	NN	O
of	IN	O
ketorolac	NN	O
administered	VBN	O
intravenously	RB	O
.	.	O

Untoward	NNP	O
effects	NNS	O
of	IN	O
fenfluramine	NN	O
in	IN	O
autistic	JJ	Condition
children	NNS	Age
.	.	O

Several	JJ	O
recent	JJ	O
studies	NNS	O
have	VBP	O
described	VBN	O
the	DT	O
benefits	NNS	O
of	IN	O
fenfluramine	NN	O
for	IN	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
infantile	JJ	Age
autism	NN	O
.	.	O

No	DT	O
large	JJ	O
surveys	NNS	O
of	IN	O
side	JJ	O
effects	NNS	O
of	IN	O
this	DT	O
drug	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
untoward	JJ	O
effects	NNS	O
of	IN	O
fenfluramine	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
12	CD	SampleSize
subjects	NNS	O
were	VBD	O
systematically	RB	O
studied	VBN	O
.	.	O

Medication	NNP	O
was	VBD	O
administered	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
cross-over	NN	O
study	NN	O
.	.	O

Parents	NNS	O
were	VBD	O
trained	VBN	O
in	IN	O
monitoring	VBG	O
untoward	JJ	O
effects	NNS	O
.	.	O

These	DT	O
observations	NNS	O
were	VBD	O
compiled	VBN	O
in	IN	O
detailed	JJ	O
daily	JJ	O
notes	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
four	CD	O
cases	NNS	Condition
describing	VBG	Condition
unusual	JJ	Condition
effects	NNS	Condition
found	VBN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
170	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
fenfluramine	NN	O
are	VBP	O
also	RB	O
reported	VBN	O
.	.	O

In	IN	O
the	DT	O
initial	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
active	JJ	O
drug	NN	O
listlessness	NN	O
,	,	O
food	NN	O
refusal	NN	O
,	,	O
and	CC	O
stomach	NN	O
upset	NN	O
were	VBD	O
frequently	RB	O
seen	VBN	O
.	.	O

A	DT	O
different	JJ	O
pattern	NN	O
of	IN	O
untoward	JJ	O
effects	NNS	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
final	JJ	O
14	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Irritability	NNP	O
,	,	O
agitation	NN	O
,	,	O
and	CC	O
crying	VBG	O
along	RB	O
with	IN	O
continued	VBN	O
food	NN	O
refusal	NN	O
were	VBD	O
noted	VBN	O
.	.	O

The	DT	O
subjects	NNS	O
lost	VBD	O
2.1	CD	O
%	NN	O
of	IN	O
body	NN	O
weight	NN	O
during	IN	O
active	JJ	O
drug	NN	O
phase	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
rebound	NN	O
weight	NN	O
gain	NN	O
during	IN	O
the	DT	O
subsequent	JJ	O
placebo	NN	O
phase	NN	O
.	.	O

A	DT	O
thorough	JJ	O
understanding	NN	O
of	IN	O
fenfluramine	NN	O
's	POS	O
side	NN	O
effects	NNS	O
and	CC	O
adverse	JJ	O
reactions	NNS	O
is	VBZ	O
necessary	JJ	O
so	RB	O
as	IN	O
to	TO	O
differentiate	VB	O
them	PRP	O
from	IN	O
the	DT	O
multiple	NN	O
symptoms	NNS	O
inherent	NN	O
in	IN	O
the	DT	O
syndrome	NN	O
of	IN	O
autism	NN	O
.	.	O

Esmolol	NNP	O
versus	NN	O
verapamil	NN	O
in	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
atrial	JJ	Condition
fibrillation	NN	Condition
or	CC	O
atrial	JJ	O
flutter	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
esmolol	NN	O
,	,	O
an	DT	O
ultrashort-acting	JJ	O
beta	NN	O
blocker	NN	O
,	,	O
and	CC	O
verapamil	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
controlling	VBG	O
ventricular	JJ	O
response	NN	O
in	IN	O
45	CD	SampleSize
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
or	CC	O
atrial	JJ	O
flutter	NN	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
parallel	JJ	O
,	,	O
open-label	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
with	IN	O
either	DT	O
new	JJ	O
onset	NN	O
(	(	O
less	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
,	,	O
n	JJ	O
=	NNP	O
31	CD	SampleSize
)	)	O
or	CC	O
old	JJ	O
onset	NN	O
(	(	O
greater	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
,	,	O
n	JJ	O
=	NNP	O
14	CD	SampleSize
)	)	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
or	CC	O
flutter	NN	O
with	IN	O
rapid	JJ	O
ventricular	JJ	O
rate	NN	O
were	VBD	O
stratified	VBN	O
to	TO	O
receive	VB	O
esmolol	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
or	CC	O
verapamil	NN	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
.	.	O

Drug	NNP	O
efficacy	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
ventricular	JJ	O
rate	NN	O
reduction	NN	O
and	CC	O
conversion	NN	O
to	TO	O
sinus	VB	O
rhythm	NN	O
.	.	O

The	DT	O
heart	NN	O
rate	NN	O
declined	VBD	O
with	IN	O
esmolol	NN	O
from	IN	O
139	CD	O
to	TO	O
100	CD	O
beats/min	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
with	IN	O
verapamil	NN	O
from	IN	O
142	CD	O
to	TO	O
97	CD	O
beats/min	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Fifty	NNP	O
percent	NN	O
of	IN	O
esmolol-treated	JJ	O
patients	NNS	O
with	IN	O
new	JJ	O
onset	NN	O
of	IN	O
arrhythmias	NNS	O
converted	VBN	O
to	TO	O
sinus	VB	O
rhythm	NN	O
,	,	O
whereas	IN	O
only	RB	O
12	CD	O
%	NN	O
of	IN	O
those	DT	O
who	WP	O
received	VBD	O
verapamil	RB	O
converted	VBN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.03	CD	O
)	)	O
.	.	O

Mild	NNP	O
hypotension	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

Esmolol	NNP	O
compares	VBZ	O
favorably	RB	O
with	IN	O
verapamil	NN	O
with	IN	O
respect	NN	O
to	TO	O
both	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
in	IN	O
acutely	RB	O
decreasing	VBG	O
ventricular	JJ	O
response	NN	O
during	IN	O
atrial	JJ	O
fibrillation	NN	O
or	CC	O
flutter	NN	O
.	.	O

Moreover	RB	O
,	,	O
conversion	NN	O
to	TO	O
sinus	VB	O
rhythm	NN	O
is	VBZ	O
significantly	RB	O
more	RBR	O
likely	JJ	O
with	IN	O
esmolol	NN	O
.	.	O

Insulin	NNP	O
pump	NN	O
therapy	NN	O
started	VBD	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
diagnosis	NN	O
:	:	O
effects	NNS	O
on	IN	O
glycemic	JJ	O
control	NN	O
and	CC	O
pancreatic	JJ	O
?-cell	NN	O
function	NN	O
in	IN	O
type	NN	O
1	CD	O
diabetes	NNS	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
the	DT	O
interest	NN	O
of	IN	O
preserving	VBG	O
residual	JJ	O
insulin	NN	O
secretory	NN	O
capacity	NN	O
present	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
diagnosis	NN	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
(	(	O
T1D	NNP	O
)	)	O
,	,	O
we	PRP	O
compared	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
starting	VBG	O
insulin	JJ	O
pump	NN	O
therapy	NN	O
at	IN	O
diagnosis	NN	O
with	IN	O
standard	JJ	O
multiple	JJ	O
daily	JJ	O
insulin	NN	O
injections	NNS	O
(	(	O
MDIs	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
pilot	JJ	O
trial	NN	O
comparing	VBG	O
MDI	NNP	O
therapy	NN	O
with	IN	O
continuous	JJ	O
subcutaneous	JJ	O
insulin	NN	O
therapy	NN	O
(	(	O
pump	JJ	O
therapy	NN	O
)	)	O
in	IN	O
24	CD	O
patients	NNS	O
,	,	O
8-18	CD	O
years	NNS	O
old	JJ	O
,	,	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
T1D	NNP	O
.	.	O

Subjects	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
enrollment	NN	O
and	CC	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
initial	JJ	O
diagnosis	NN	O
of	IN	O
T1D	NNP	O
.	.	O

Preservation	NN	O
of	IN	O
insulin	NN	O
secretion	NN	O
,	,	O
measured	VBN	O
by	IN	O
mixed-meal-stimulated	JJ	O
C-peptide	JJ	O
secretion	NN	O
,	,	O
was	VBD	O
compared	VBN	O
after	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Between-group	JJ	O
differences	NNS	O
in	IN	O
glycosylated	JJ	O
hemoglobin	NN	O
(	(	O
HbA1c	NNP	O
)	)	O
,	,	O
continuous	JJ	O
glucose	NN	O
sensor	NN	O
data	NNS	O
,	,	O
insulin	NN	O
utilization	NN	O
,	,	O
anthropometric	JJ	O
measures	NNS	O
,	,	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
therapy	NN	O
were	VBD	O
also	RB	O
compared	VBN	O
at	IN	O
multiple	JJ	O
time	NN	O
points	NNS	O
.	.	O

RESULTS	NNP	O
Initiation	NNP	O
of	IN	O
pump	NN	O
therapy	NN	O
within	IN	O
1	CD	O
month	NN	O
of	IN	O
diagnosis	NN	O
resulted	VBD	O
in	IN	O
consistently	RB	O
higher	JJR	O
mixed-meal	JJ	O
tolerance	NN	O
test-stimulated	JJ	O
C-peptide	JJ	O
values	NNS	O
at	IN	O
all	DT	O
time	NN	O
points	NNS	O
,	,	O
although	IN	O
these	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Nonetheless	NNP	O
,	,	O
improved	JJ	O
glycemic	JJ	O
control	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
insulin	JJ	O
pump-treated	JJ	O
subjects	NNS	O
(	(	O
more	JJR	O
time	NN	O
spent	VBN	O
with	IN	O
normoglycemia	NN	O
,	,	O
better	JJR	O
mean	JJ	O
HbA1c	NNP	O
)	)	O
,	,	O
and	CC	O
pump-treated	JJ	O
subjects	NNS	O
reported	VBN	O
comparatively	RB	O
greater	JJR	O
satisfaction	NN	O
with	IN	O
route	NN	O
of	IN	O
treatment	NN	O
administration	NN	O
.	.	O

CONCLUSIONS	NNP	O
Initiation	NNP	O
of	IN	O
insulin	NN	O
pump	NN	O
therapy	NN	O
at	IN	O
diagnosis	NN	O
improved	JJ	O
glycemic	JJ	O
control	NN	O
,	,	O
was	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
and	CC	O
contributed	VBD	O
to	TO	O
improved	VBN	O
patient	JJ	O
satisfaction	NN	O
with	IN	O
treatment	NN	O
.	.	O

This	DT	O
study	NN	O
also	RB	O
suggests	VBZ	O
that	IN	O
earlier	JJR	O
use	NN	O
of	IN	O
pump	NN	O
therapy	NN	O
might	MD	O
help	VB	O
to	TO	O
preserve	VB	O
residual	JJ	O
?-cell	NNP	O
function	NN	O
,	,	O
although	IN	O
a	DT	O
larger	JJR	O
clinical	JJ	O
trial	NN	O
would	MD	O
be	VB	O
required	VBN	O
to	TO	O
confirm	VB	O
this	DT	O
.	.	O

Bolus	NNP	O
injection	NN	O
of	IN	O
contrast	NN	O
agents	NNS	O
with	IN	O
various	JJ	O
iodine	JJ	O
concentrations	NNS	O
and	CC	O
delivery	NN	O
rates	NNS	O
for	IN	O
intracranial	JJ	O
three-dimensional	JJ	O
CT	NNP	O
angiography	NN	O
:	:	O
evaluation	NN	O
of	IN	O
intracranial	JJ	O
arteriovenous	JJ	O
contrast	NN	O
using	VBG	O
a	DT	O
multidetector-row	JJ	O
CT	NNP	O
scanner	NN	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
evaluated	VBD	O
the	DT	O
difference	NN	O
in	IN	O
computed	JJ	O
tomography	NN	O
(	(	O
CT	NNP	O
)	)	O
attenuation	NN	O
values	NNS	O
of	IN	O
the	DT	O
intracranial	JJ	O
arterial	NN	O
and	CC	O
venous	JJ	O
systems	NNS	O
among	IN	O
the	DT	O
various	JJ	O
contrast	NN	O
injection	NN	O
protocols	NNS	O
(	(	O
higher	JJR	O
iodine	NN	O
delivery	NN	O
rate	NN	O
or	CC	O
higher	JJR	O
concentration	NN	O
of	IN	O
the	DT	O
agent	NN	O
)	)	O
on	IN	O
the	DT	O
source	NN	O
images	NNS	O
of	IN	O
intracranial	JJ	O
three-dimensional	JJ	O
CT	NNP	O
angiography	NN	O
(	(	O
3D-CTA	JJ	O
)	)	O
using	VBG	O
a	DT	O
multidetector-row	JJ	O
CT	NNP	O
(	(	O
MDCT	NNP	O
)	)	O
scanner	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
We	PRP	O
used	VBD	O
100	CD	O
ml	NN	O
of	IN	O
iopamidol	JJ	O
300	CD	O
at	IN	O
an	DT	O
injection	NN	O
rate	NN	O
of	IN	O
3.0	CD	O
ml/s	NNS	O
,	,	O
100	CD	O
ml	NN	O
of	IN	O
iopamidol	JJ	O
300	CD	O
at	IN	O
an	DT	O
injection	NN	O
rate	NN	O
of	IN	O
3.7	CD	O
ml/s	NN	O
,	,	O
and	CC	O
80	CD	O
ml	NN	O
of	IN	O
iopamidol	JJ	O
370	CD	O
at	IN	O
an	DT	O
injection	NN	O
rate	NN	O
of	IN	O
3.0	CD	O
ml/s	NN	O
.	.	O

There	EX	O
were	VBD	O
10	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Attenuation	NNP	O
values	NNS	O
of	IN	O
the	DT	O
bilateral	JJ	O
internal	JJ	O
carotid	NN	O
arteries	NNS	O
(	(	O
ICAs	NNP	O
)	)	O
,	,	O
basilar	JJ	O
artery	NN	O
trunk	NN	O
,	,	O
bilateral	JJ	O
cavernous	JJ	O
sinuses	NNS	O
(	(	O
CSs	NNP	O
)	)	O
,	,	O
and	CC	O
Galenic	NNP	O
vein	NNS	O
were	VBD	O
measured	VBN	O
quantitatively	RB	O
on	IN	O
the	DT	O
axial	JJ	O
CT	NNP	O
angiographic	JJ	O
source	NN	O
images	NNS	O
obtained	VBN	O
by	IN	O
four-channel	JJ	O
MDCT	NNP	O
.	.	O

RESULTS	NNP	O
Injection	NNP	O
of	IN	O
the	DT	O
high-concentration	NN	O
contrast	NN	O
with	IN	O
a	DT	O
higher	JJR	O
iodine-delivery	JJ	O
rate	NN	O
achieved	VBN	O
good	JJ	O
arteriovenous	JJ	O
contrast	NN	O
at	IN	O
the	DT	O
cavernous	JJ	O
portion	NN	O
.	.	O

With	IN	O
the	DT	O
same	JJ	O
rate	NN	O
of	IN	O
iodine	NN	O
delivery	NN	O
,	,	O
injection	NN	O
of	IN	O
the	DT	O
intermediate	JJ	O
concentrate	NN	O
agent	NN	O
increased	VBD	O
the	DT	O
CT	NNP	O
value	NN	O
of	IN	O
not	RB	O
only	RB	O
the	DT	O
ICAs	NNP	O
but	CC	O
also	RB	O
the	DT	O
CSs	NNP	O
.	.	O

CONCLUSION	NNP	O
High-concentration	NNP	O
contrast	NN	O
could	MD	O
increase	VB	O
ICA	NNP	O
attenuation	NN	O
without	IN	O
intracavernous	JJ	O
attenuation	NN	O
gain	NN	O
during	IN	O
the	DT	O
first-pass	JJ	O
phase	NN	O
.	.	O

A	DT	O
randomised	JJ	O
group	NN	O
comparison	NN	O
controlled	VBD	O
trial	NN	O
of	IN	O
'preschoolers	NNS	O
with	IN	O
autism	NN	O
'	''	O
:	:	O
a	DT	O
parent	NN	O
education	NN	O
and	CC	O
skills	NNS	O
training	VBG	O
intervention	NN	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
parent	NN	O
education	NN	O
on	IN	O
adaptive	JJ	O
behaviour	NN	O
,	,	O
autism	NN	O
symptoms	NNS	O
and	CC	O
cognitive/language	NN	O
skills	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomised	VBD	O
group	NN	O
comparison	NN	O
design	NN	O
involving	VBG	O
a	DT	O
parent	NN	O
education	NN	O
and	CC	O
counselling	VBG	O
intervention	NN	O
and	CC	O
a	DT	O
parent	NN	O
education	NN	O
and	CC	O
behaviour	JJ	O
management	NN	O
intervention	NN	O
to	TO	O
control	VB	O
for	IN	O
parent	NN	O
skills	NNS	O
training	NN	O
and	CC	O
a	DT	O
control	NN	O
sample	NN	O
.	.	O

Two	CD	O
rural	JJ	O
and	CC	O
two	CD	O
metropolitan	JJ	O
regions	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
intervention	NN	O
groups	NNS	O
(	(	O
n	JJ	O
=	NNP	O
70	CD	O
)	)	O
or	CC	O
control	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
.	.	O

Parents	NNS	O
from	IN	O
autism	NN	O
assessment	NN	O
services	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
regions	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
parent	VB	O
education	NN	O
and	CC	O
behaviour	JJ	O
management	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
or	CC	O
parent	JJ	O
education	NN	O
and	CC	O
counselling	NN	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
.	.	O

RESULTS	JJ	O
Parent	JJ	O
education	NN	O
and	CC	O
behaviour	VB	O
management	NN	O
resulted	VBD	O
in	IN	O
significant	JJ	O
improvement	NN	O
in	IN	O
adaptive	JJ	O
behaviour	NN	O
and	CC	O
autism	NN	O
symptoms	NNS	O
at	IN	O
6	CD	O
months	NNS	O
follow-up	RB	O
for	IN	O
children	NNS	O
with	IN	O
greater	JJR	O
delays	NNS	O
in	IN	O
adaptive	JJ	O
behaviour	NN	O
.	.	O

Parent	NN	O
education	NN	O
and	CC	O
behaviour	JJ	O
management	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
parent	VB	O
education	NN	O
and	CC	O
counselling	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
a	DT	O
20-week	JJ	O
parent	NN	O
education	NN	O
programme	NN	O
including	VBG	O
skills	NNS	O
training	VBG	O
for	IN	O
parents	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
provides	VBZ	O
significant	JJ	O
improvements	NNS	O
in	IN	O
child	JJ	O
adaptive	JJ	O
behaviour	NN	O
and	CC	O
symptoms	NNS	O
of	IN	O
autism	NN	O
for	IN	O
low-functioning	JJ	O
children	NNS	O
.	.	O

Risperidone-induced	JJ	O
prolactin	NN	O
elevation	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
study	NN	O
of	IN	O
children	NNS	Age
,	,	Age
adolescents	NNS	Age
,	,	Age
and	CC	Age
adults	NNS	Age
with	IN	Age
mental	JJ	Age
retardation	NN	Age
and	CC	Age
pervasive	JJ	Age
developmental	NN	Age
disorders	NNS	Age
.	.	Age

OBJECTIVE	NNP	O
Risperidone	NNP	O
is	VBZ	O
widely	RB	O
prescribed	VBN	O
for	IN	O
aggression	NN	O
and	CC	O
self-injury	NN	O
in	IN	O
children	NNS	Age
,	,	Age
adolescents	NNS	Age
,	,	Age
and	CC	Age
adults	NNS	Age
with	IN	Age
mental	JJ	Age
retardation	NN	Age
(	(	Age
MR	NNP	Age
)	)	Age
and	CC	Age
pervasive	JJ	Age
developmental	NN	Age
disorders	NNS	Age
(	(	Age
PDD	NNP	Age
)	)	Age
.	.	Age

Risperidone	NNP	O
elevates	VBZ	O
prolactin	RB	O
more	JJR	O
than	IN	O
other	JJ	O
atypical	JJ	O
antipsychotic	JJ	O
medications	NNS	O
.	.	O

Females	NNS	O
may	MD	O
show	VB	O
greater	JJR	O
prolactin	NN	O
elevation	NN	O
than	IN	O
males	NNS	O
.	.	O

METHOD	NNP	O
In	IN	O
this	DT	O
relatively	RB	O
long-term	JJ	O
study	NN	O
of	IN	O
risperidone	NN	O
efficacy	NN	O
and	CC	O
safety	NN	O
for	IN	O
aggression	NN	O
and	CC	O
self-injury	NN	O
in	IN	O
children	NNS	Condition
,	,	Condition
adolescents	NNS	Condition
,	,	Condition
and	CC	Condition
adults	NNS	Condition
with	IN	Condition
MR	NNP	Condition
and	CC	Condition
PDDs	NNP	Condition
,	,	O
serum	NN	O
prolactin	NN	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
21-subject	JJ	O
subset	NN	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

Prolactin	NNP	O
was	VBD	O
measured	VBN	O
in	IN	O
ng/mL	NN	O
at	IN	O
baseline	NN	O
,	,	O
once	RB	O
during	IN	O
acute	JJ	O
treatment	NN	O
,	,	O
and	CC	O
once	RB	O
during	IN	O
maintenance	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
children	NNS	Age
and	CC	Age
adolescents	NNS	Age
(	(	Age
n=10	NN	Age
)	)	Age
,	,	Age
mean	JJ	Age
age	NN	Age
of	IN	Age
12.5	CD	Age
years	NNS	Age
,	,	O
prolactin	NN	O
increased	VBD	O
from	IN	O
mean	JJ	O
13.2+/-8.6	CD	O
at	IN	O
baseline	NN	O
to	TO	O
31.0+/-11.6	JJ	O
acutely	RB	O
and	CC	O
remained	VBD	O
elevated	VBN	O
at	IN	O
37.9+/-10.4	JJ	O
in	IN	O
maintenance	NN	O
.	.	O

In	IN	O
adults	NNS	Age
,	,	Age
mean	JJ	Age
age	NN	Age
of	IN	Age
35.3	CD	Age
years	NNS	Age
,	,	O
prolactin	NN	O
increased	VBD	O
more	JJR	O
markedly	RB	O
from	IN	O
11.6+/-7.4	JJ	O
baseline	NN	O
(	(	O
n=11	JJ	O
)	)	O
to	TO	O
93.3+/-54.2	CD	O
acutely	RB	O
but	CC	O
decreased	VBD	O
to	TO	O
67.8+/-62.9	JJ	O
in	IN	O
maintenance	NN	O
(	(	O
n=7	JJ	O
)	)	O
.	.	O

Prolactin	NNP	O
remained	VBD	O
significantly	RB	O
elevated	VBN	O
above	IN	O
normal	JJ	O
in	IN	O
all	DT	O
subjects	NNS	O
for	IN	O
at	IN	O
least	JJS	O
26	CD	O
weeks	NNS	O
.	.	O

Mean	NNP	O
prolactin	NN	O
of	IN	O
adult	NN	O
females	NNS	O
,	,	O
while	IN	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
adult	NN	O
males	NNS	O
at	IN	O
baseline	NN	O
,	,	O
was	VBD	O
2.2	CD	O
times	NNS	O
male	JJ	O
levels	NNS	O
acutely	RB	O
and	CC	O
3.7	CD	O
times	NNS	O
greater	JJR	O
in	IN	O
maintenance	NN	O
.	.	O

CONCLUSION	NN	O
In	IN	O
this	DT	O
small	JJ	O
subset	NN	O
,	,	O
mean	JJ	O
prolactin	NN	O
elevation	NN	O
persisted	VBD	O
for	IN	O
at	IN	O
least	JJS	O
26	CD	O
weeks	NNS	O
.	.	O

In	IN	O
adults	NNS	O
,	,	O
females	NNS	O
showed	VBD	O
significantly	RB	O
greater	JJR	O
elevations	NNS	O
than	IN	O
males	NNS	O
.	.	O

Double-blind	NNP	O
comparison	NN	O
of	IN	O
liquid	NN	O
antacid	NN	O
and	CC	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
symptomatic	JJ	Condition
reflux	NN	Condition
esophagitis	NN	Condition
.	.	O

Although	IN	O
antacids	NNS	O
have	VBP	O
been	VBN	O
the	DT	O
mainstay	NN	O
of	IN	O
pharmacologic	JJ	O
therapy	NN	O
for	IN	O
reflux	NN	O
esophagitis	NN	O
,	,	O
their	PRP$	O
effectiveness	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
tested	VBN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
double-blind	JJ	O
trial	NN	O
.	.	O

We	PRP	O
report	VBP	O
a	DT	O
double-blind	JJ	O
comparison	NN	O
of	IN	O
liquid	JJ	O
antacid	NN	O
vs	NN	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
reflux	NN	O
esophagitis	NN	O
in	IN	O
32	CD	SampleSize
patients	NNS	O
with	IN	O
chronic	JJ	Condition
heartburn	NN	Condition
.	.	O

Entry	NN	O
criteria	NNS	O
included	VBD	O
the	DT	O
presence	NN	O
of	IN	O
symptomatic	JJ	O
gastroesophageal	NN	O
reflux	NN	O
confirmed	VBN	O
by	IN	O
both	DT	O
an	DT	O
acid	JJ	O
perfusion	NN	O
(	(	O
Bernstein	NNP	O
)	)	O
test	NN	O
and	CC	O
by	IN	O
intraesophageal	JJ	O
pH	NN	O
probe	NN	O
.	.	O

Drug	NNP	O
treatment	NN	O
consisted	VBD	O
of	IN	O
15	CD	O
ml	NN	O
(	(	O
80	CD	O
mEq	NN	O
)	)	O
doses	VBZ	O
of	IN	O
antacid	NN	O
(	(	O
Maalox	NNP	O
Therapeutic	NNP	O
Concentration	NNP	O
,	,	O
William	NNP	O
H.	NNP	O
Rorer	NNP	O
)	)	O
or	CC	O
placebo	VB	O
taken	VBN	O
7	CD	O
times	NNS	O
daily	RB	O
,	,	O
ie	NN	O
,	,	O
1	CD	O
and	CC	O
3	CD	O
hr	NN	O
after	IN	O
meals	NNS	O
and	CC	O
at	IN	O
bedtime	NN	O
.	.	O

Both	DT	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
in	IN	O
both	DT	O
frequency	NN	O
and	CC	O
severity	NN	O
of	IN	O
heartburn	NN	O
.	.	O

The	DT	O
time	NN	O
to	TO	O
reproduce	VB	O
heartburn	NN	O
with	IN	O
the	DT	O
timed	JJ	O
Bernstein	NNP	O
test	NN	O
was	VBD	O
increased	VBN	O
with	IN	O
both	DT	O
active	JJ	O
drug	NN	O
and	CC	O
placebo	NN	O
therapy	NN	O
.	.	O

The	DT	O
mean	JJ	O
increase	NN	O
was	VBD	O
402	CD	O
%	NN	O
(	(	O
41	CD	O
+/-	JJ	O
20	CD	O
sec	NN	O
to	TO	O
169	CD	O
+/-	JJ	O
66	CD	O
sec	NN	O
)	)	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
286	CD	O
%	NN	O
(	(	O
42	CD	O
+/-	JJ	O
16	CD	O
to	TO	O
120	CD	O
+/-	JJ	O
57	CD	O
sec	NN	O
)	)	O
in	IN	O
the	DT	O
antacid	NN	O
group	NN	O
.	.	O

Both	CC	O
the	DT	O
antacid	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
showed	VBD	O
improvement	NN	O
in	IN	O
the	DT	O
degree	NN	O
of	IN	O
esophagitis	NN	O
as	IN	O
assessed	VBN	O
endoscopically	RB	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
asked	VBD	O
:	:	O
does	VBZ	O
regular	JJ	O
antacid	NN	O
therapy	NN	O
have	VBP	O
a	DT	O
favorable	JJ	O
influence	NN	O
on	IN	O
the	DT	O
natural	JJ	O
history	NN	O
of	IN	O
symptomatic	JJ	O
reflux	NN	O
esophagitis	NN	O
,	,	O
ie	NN	O
,	,	O
does	VBZ	O
therapy	VB	O
heal	NN	O
or	CC	O
otherwise	RB	O
change	NN	O
esophagitis	NN	O
so	IN	O
that	DT	O
painful	JJ	O
episodes	NNS	O
are	VBP	O
either	RB	O
less	RBR	O
frequent	JJ	O
,	,	O
less	RBR	O
severe	JJ	O
,	,	O
or	CC	O
both	DT	O
?	.	O
We	PRP	O
found	VBD	O
that	IN	O
the	DT	O
natural	JJ	O
history	NN	O
of	IN	O
symptomatic	JJ	O
reflux	NN	O
esophagitis	NN	O
was	VBD	O
to	TO	O
improve	VB	O
with	IN	O
either	DT	O
antacid	NN	O
or	CC	O
placebo	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
antacid	NN	O
or	CC	O
placebo	NN	O
on	IN	O
the	DT	O
(	(	O
short-term	JJ	O
)	)	O
natural	JJ	O
history	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

Classroom	NNP	O
intervention	NN	O
for	IN	O
illness-related	JJ	O
problem	NN	O
behavior	NN	O
in	IN	O
children	NNS	Age
with	IN	O
developmental	JJ	Condition
disabilities	NNS	Condition
.	.	O

There	EX	O
is	VBZ	O
growing	VBG	O
evidence	NN	O
of	IN	O
an	DT	O
association	NN	O
between	IN	O
physical	JJ	O
illness	NN	O
and	CC	O
problem	NN	O
behavior	NN	O
in	IN	O
children	NNS	Age
with	IN	O
developmental	JJ	Condition
disabilities	NNS	Condition
.	.	O

Such	JJ	O
behavior	NN	O
can	MD	O
compromise	VB	O
school	NN	O
performance	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
,	,	O
using	VBG	O
a	DT	O
group	NN	O
design	NN	O
,	,	O
the	DT	O
effectiveness	NN	O
of	IN	O
medical	JJ	O
intervention	NN	O
alone	RB	O
(	(	O
N	NNP	O
=	NNP	O
11	CD	O
)	)	O
versus	NN	O
behavioral	JJ	O
plus	CC	O
medical	JJ	O
intervention	NN	O
(	(	O
N	NNP	O
=	NNP	O
10	CD	O
)	)	O
for	IN	O
illness-related	JJ	O
problem	NN	O
behavior	NN	O
in	IN	O
a	DT	O
school	NN	O
setting	VBG	O
.	.	O

Following	VBG	O
intervention	NN	O
,	,	O
the	DT	O
behavioral	JJ	O
plus	CC	O
medical	JJ	O
intervention	NN	O
group	NN	O
showed	VBD	O
lower	JJR	O
levels	NNS	O
of	IN	O
problem	NN	O
behavior	NN	O
and	CC	O
completed	VBD	O
more	JJR	O
academic	JJ	O
tasks	NNS	O
than	IN	O
did	VBD	O
the	DT	O
medical	JJ	O
intervention	NN	O
alone	RB	O
group	NN	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
concept	NN	O
of	IN	O
illness	NN	O
and	CC	O
pain	NN	O
as	IN	O
a	DT	O
setting	NN	O
event	NN	O
for	IN	O
problem	NN	O
behavior	NN	O
.	.	O

The	DT	O
need	NN	O
for	IN	O
research	NN	O
to	TO	O
develop	VB	O
algorithms	NN	O
that	WDT	O
allow	VBP	O
one	CD	O
to	TO	O
select	VB	O
the	DT	O
best	JJS	O
combination	NN	O
of	IN	O
medical	JJ	O
and	CC	O
behavioral	JJ	O
interventions	NNS	O
for	IN	O
specific	JJ	O
illnesses	NNS	O
and	CC	O
contexts	NN	O
is	VBZ	O
noted	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
gabapentin	NN	O
on	IN	O
experimental	JJ	O
somatic	JJ	O
pain	NN	O
and	CC	O
temporal	JJ	O
summation	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Gabapentin	NNP	O
is	VBZ	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
neuropathic	JJ	O
pain	NN	O
,	,	O
but	CC	O
its	PRP$	O
effect	NN	O
on	IN	O
different	JJ	O
somatic	JJ	O
pain	NN	O
modalities	NNS	O
and	CC	O
integrative	JJ	O
mechanisms	NNS	O
are	VBP	O
not	RB	O
completely	RB	O
understood	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
experimental	NN	O
pain	NN	O
study	NN	O
,	,	O
conducted	VBN	O
on	IN	O
20	CD	SampleSize
healthy	JJ	O
volunteers	NNS	O
,	,	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
1200	CD	O
mg	NN	O
gabapentin	NN	O
on	IN	O
multi-modal	JJ	O
experimental	JJ	O
cutaneous	JJ	O
and	CC	O
muscle	NN	O
pain	NN	O
models	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
following	VBG	O
pain	NN	O
models	NNS	O
were	VBD	O
applied	VBN	O
:	:	O
(	(	O
1	CD	O
)	)	O
pain	NN	O
thresholds	NNS	O
to	TO	O
single	JJ	O
and	CC	O
repeated	VBD	O
cutaneous	JJ	O
and	CC	O
intramuscular	JJ	O
electrical	JJ	O
stimulation	NN	O
(	(	O
temporal	JJ	O
summation	NN	O
to	TO	O
5	CD	O
stimuli	NNS	O
delivered	VBN	O
at	IN	O
2	CD	O
Hz	NNP	O
)	)	O
;	:	O
(	(	O
2	CD	O
)	)	O
stimulus-response	NN	O
function	NN	O
relating	VBG	O
pain	NN	O
intensity	NN	O
scores	NNS	O
(	(	O
visual	JJ	O
analog	NN	O
scale	NN	O
,	,	O
VAS	NNP	O
)	)	O
to	TO	O
increasing	VBG	O
current	JJ	O
intensities	NNS	O
for	IN	O
electrical	JJ	O
skin	NN	O
and	CC	O
muscle	NN	O
stimuli	NNS	O
(	(	O
single	JJ	O
and	CC	O
repeated	VBD	O
,	,	O
determined	VBD	O
at	IN	O
baseline	NN	O
)	)	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
the	DT	O
pain	NN	O
intensity	NN	O
(	(	O
VAS	NNP	O
)	)	O
and	CC	O
pain	$	O
areas	NNS	O
after	IN	O
intramuscular	JJ	O
injection	NN	O
of	IN	O
hypertonic	JJ	O
saline	NN	O
.	.	O

Pain	NN	O
assessments	NNS	O
were	VBD	O
performed	VBN	O
prior	RB	O
to	TO	O
,	,	O
and	CC	O
at	IN	O
4	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
8	CD	O
hours	NNS	O
after	IN	O
medication	NN	O
.	.	O

RESULTS	VB	O
When	WRB	O
responses	NNS	O
were	VBD	O
averaged	VBN	O
across	IN	O
the	DT	O
post-dose	JJ	O
times	NNS	O
,	,	O
gabapentin	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
significantly	RB	O
increased	VBD	O
the	DT	O
temporal	JJ	O
summation	NN	O
pain	NN	O
threshold	NN	O
in	IN	O
skin	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
;	:	O
(	(	O
2	CD	O
)	)	O
significantly	RB	O
reduced	VBD	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
pain	NN	O
intensity	NN	O
curve	NN	O
to	TO	O
hypertonic	VB	O
saline	JJ	O
injections	NNS	O
in	IN	O
the	DT	O
muscle	NN	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
significantly	RB	O
reduced	VBD	O
the	DT	O
area	NN	O
of	IN	O
pain	NN	O
evoked	VBN	O
by	IN	O
hypertonic	JJ	O
saline	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Gabapentin	NNP	O
reduces	VBZ	O
temporal	JJ	O
summation	NN	O
of	IN	O
skin	JJ	O
stimuli	NNS	O
at	IN	O
pain	NN	O
threshold	JJ	O
intensities	NNS	O
;	:	O
this	DT	O
may	MD	O
have	VB	O
potential	JJ	O
as	IN	O
a	DT	O
biomarker	NN	O
for	IN	O
drugs	NNS	O
with	IN	O
efficacy	NN	O
on	IN	O
neurogenic	JJ	O
pain	NN	O
.	.	O

The	DT	O
data	NN	O
also	RB	O
suggest	VBP	O
that	IN	O
tonic	JJ	O
muscle	NN	O
pain	NN	O
is	VBZ	O
responsive	JJ	O
to	TO	O
gabapentin	VB	O
treatment	NN	O
and	CC	O
suggest	VB	O
further	RB	O
clinical	JJ	O
studies	NNS	O
.	.	O

Granulocyte-colony	JJ	O
stimulating	NN	O
factor	NN	O
for	IN	O
mobilizing	VBG	O
bone	NN	O
marrow	NN	O
stem	NN	O
cells	NNS	O
in	IN	O
subacute	JJ	O
stroke	NN	O
:	:	O
the	DT	O
stem	NN	O
cell	VBP	O
trial	NN	O
of	IN	O
recovery	NN	O
enhancement	NN	O
after	IN	O
stroke	VBD	Condition
2	CD	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Granulocyte-colony	NNP	O
stimulating	VBG	O
factor	NN	O
(	(	O
G-CSF	NNP	O
)	)	O
is	VBZ	O
neuroprotective	JJ	O
in	IN	O
experimental	JJ	O
stroke	NN	O
and	CC	O
mobilizes	VBZ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
peripheral	JJ	O
blood	NN	O
stem	NN	O
cells	NNS	O
into	IN	O
the	DT	O
circulation	NN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
safety	NN	O
of	IN	O
G-CSF	NNP	O
in	IN	O
recent	JJ	O
stroke	NN	O
in	IN	O
a	DT	O
phase	NN	O
IIb	NNP	O
single-center	NN	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

METHODS	NNP	O
G-CSF	NNP	O
(	(	O
10	CD	O
?g/kg	NN	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
ratio	VB	O
2:1	CD	O
)	)	O
was	VBD	O
given	VBN	O
SC	NNP	O
for	IN	O
5	CD	O
days	NNS	O
to	TO	O
60	CD	O
patients	NNS	O
3	CD	O
to	TO	O
30	CD	O
days	NNS	O
after	IN	O
ischemic	JJ	O
or	CC	O
hemorrhagic	JJ	O
stroke	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	O
of	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Peripheral	NNP	O
blood	NN	O
counts	NNS	O
,	,	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
count	NN	O
,	,	O
and	CC	O
functional	JJ	O
outcome	NN	O
were	VBD	O
measured	VBN	O
.	.	O

MRI	NNP	O
assessed	VBD	O
lesion	NN	O
volume	NN	O
,	,	O
atrophy	NN	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
iron-labeled	JJ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
reinjected	VBN	O
on	IN	O
day	NN	O
6	CD	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
at	IN	O
mean	NN	O
of	IN	O
8	CD	O
days	NNS	O
(	(	O
SD	NNP	O
?	.	O
5	CD	O
)	)	O
post	NN	O
ictus	NN	O
,	,	O
with	IN	O
mean	JJ	O
age	NN	O
71	CD	O
years	NNS	O
(	(	O
?	.	O
12	CD	O
years	NNS	O
)	)	O
and	CC	O
53	CD	O
%	NN	O
men	NNS	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
for	IN	O
baseline	JJ	O
minimization/prognostic	JJ	O
factors	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
participants	NNS	O
with	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
:	:	O
G-CSF	JJ	O
15	CD	O
(	(	O
37.5	CD	O
%	NN	O
)	)	O
of	IN	O
40	CD	O
versus	NN	O
placebo	NN	O
7	CD	O
(	(	O
35	CD	O
%	NN	O
)	)	O
of	IN	O
20	CD	O
,	,	O
death	NN	O
or	CC	O
dependency	NN	O
(	(	O
modified	JJ	O
Rankin	NNP	O
Score	NN	O
:	:	O
G-CSF	JJ	O
3.3	CD	O
?	.	O
1.3	CD	O
,	,	O
placebo	NN	O
3.0	CD	O
?	.	O
1.3	CD	O
)	)	O
at	IN	O
90	CD	O
days	NNS	O
,	,	O
or	CC	O
the	DT	O
number	NN	O
of	IN	O
injections	NNS	O
received	VBN	O
.	.	O

G-CSF	NNP	O
increased	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
and	CC	O
total	JJ	O
white	JJ	O
cell	NN	O
counts	NNS	O
of	IN	O
9.5-	CD	O
and	CC	O
4.2-fold	JJ	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
reduction	NN	O
in	IN	O
MRI	NNP	O
ischemic	JJ	O
lesion	NN	O
volume	NN	O
with	IN	O
respect	NN	O
to	TO	O
change	VB	O
from	IN	O
baseline	NN	O
in	IN	O
G-CSF-treated	JJ	O
patients	NNS	O
(	(	O
P=0.06	NNP	O
)	)	O
.	.	O

In	IN	O
1	CD	O
participant	NN	O
,	,	O
there	EX	O
was	VBD	O
suggestion	NN	O
that	IN	O
labeled	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
had	VBD	O
migrated	VBN	O
to	TO	O
the	DT	O
ischemic	JJ	O
lesion	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
suggests	VBZ	O
that	IN	O
G-CSF	NNP	O
is	VBZ	O
safe	JJ	O
when	WRB	O
administered	VBN	O
subacutely	RB	O
.	.	O

It	PRP	O
is	VBZ	O
feasible	JJ	O
to	TO	O
label	VB	O
and	CC	O
readminister	VB	O
iron-labeled	JJ	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ischemic	JJ	O
stroke	NN	O
.	.	O

CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
URL	NNP	O
:	:	O
www.controlled-trials.com	NN	O
.	.	O

Unique	NNP	O
identifier	NN	O
:	:	O
ISRCTN63336619	NNP	O
.	.	O

Single-dose	JJ	O
tranexamic	JJ	O
acid	NN	O
reduces	NNS	O
postoperative	VBP	O
bleeding	NN	O
after	IN	O
coronary	JJ	O
surgery	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
aspirin	NN	O
until	IN	O
surgery	NN	Condition
.	.	O

UNLABELLED	NNP	O
Tranexamic	NNP	O
acid	NN	O
reduces	NNS	O
postoperative	VBP	O
bleeding	NN	O
after	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
grafting	VBG	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
tranexamic	JJ	O
acid	NN	O
given	VBN	O
immediately	RB	O
before	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
(	(	O
CPB	NNP	O
)	)	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
aspirin	NN	O
until	IN	O
the	DT	O
day	NN	O
before	IN	O
surgery	NN	Condition
.	.	O

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel-group	JJ	O
trial	NN	O
.	.	O

Eighty	JJ	SampleSize
patients	NNS	SampleSize
were	VBD	O
included	VBN	O
and	CC	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
one	CD	O
group	NN	O
received	VBD	O
tranexamic	JJ	O
acid	NN	O
30	CD	O
mg/kg	NN	O
,	,	O
and	CC	O
one	CD	O
group	NN	O
received	VBD	O
placebo	NN	O
(	(	O
0.9	CD	O
%	NN	O
NaCl	NNP	O
)	)	O
as	IN	O
a	DT	O
bolus	JJ	O
injection	NN	O
before	IN	O
CPB	NNP	O
.	.	O

Postoperative	NNP	O
blood	NN	O
loss	NN	O
was	VBD	O
recorded	VBN	O
for	IN	O
16	CD	O
h.	JJ	O
Transfusions	NNS	O
of	IN	O
blood	NN	O
products	NNS	O
were	VBD	O
recorded	VBN	O
for	IN	O
the	DT	O
whole	JJ	O
hospital	NN	O
stay	NN	O
.	.	O

Transfusions	NNS	O
of	IN	O
packed	JJ	O
red	JJ	O
cells	NNS	O
were	VBD	O
given	VBN	O
when	WRB	O
the	DT	O
hematocrit	NN	O
value	NN	O
was	VBD	O
less	JJR	O
than	IN	O
20	CD	O
%	NN	O
during	IN	O
CPB	NNP	O
and	CC	O
less	JJR	O
than	IN	O
25	CD	O
%	NN	O
after	IN	O
surgery	NN	O
.	.	O

The	DT	SampleSize
patients	NNS	SampleSize
in	IN	SampleSize
the	DT	SampleSize
tranexamic	JJ	SampleSize
acid	NN	SampleSize
group	NN	SampleSize
had	VBD	O
significantly	RB	O
less	RBR	O
postoperative	JJ	O
bleeding	NN	O
compared	VBN	O
with	IN	O
the	DT	SampleSize
patients	NNS	SampleSize
in	IN	SampleSize
the	DT	SampleSize
placebo	NN	SampleSize
group	NN	SampleSize
(	(	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
)	)	O
(	(	O
475	CD	O
[	RB	O
274	CD	O
]	JJ	O
mL	NN	O
versus	NN	O
713	CD	O
[	NN	O
243	CD	O
]	NNP	O
mL	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

An	DT	O
effective	JJ	O
inhibition	NN	O
of	IN	O
fibrinolysis	NN	O
was	VBD	O
found	VBN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
tranexamic	JJ	O
acid	NN	O
.	.	O

Tranexamic	NNP	O
acid	NN	O
reduces	NNS	O
postoperative	VBP	O
bleeding	NN	O
in	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
grafting	VBG	O
patients	NNS	O
treated	VBN	O
with	IN	O
aspirin	NN	O
until	IN	O
the	DT	O
day	NN	O
before	IN	O
surgery	NN	O
.	.	O

IMPLICATIONS	NNP	O
Continuation	NNP	O
of	IN	O
aspirin	JJ	O
medication	NN	O
until	IN	O
the	DT	O
day	NN	O
before	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
grafting	NN	O
may	MD	O
increase	VB	O
postoperative	JJ	O
bleeding	NN	O
.	.	O

The	DT	O
administration	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
tranexamic	JJ	O
acid	NN	O
(	(	O
30	CD	O
mg/kg	NN	O
)	)	O
immediately	RB	O
before	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
significantly	RB	O
reduced	VBD	O
postoperative	JJ	O
bleeding	NN	O
and	CC	O
inhibited	JJ	O
fibrinolysis	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

Exposure	NN	O
to	TO	O
the	DT	O
self-face	NN	O
facilitates	VBZ	O
identification	NN	O
of	IN	O
dynamic	JJ	O
facial	JJ	O
expressions	NNS	O
:	:	O
influences	NNS	O
on	IN	O
individual	JJ	O
differences	NNS	O
.	.	O

A	DT	O
growing	VBG	O
literature	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
self-face	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
processing	VBG	O
the	DT	O
facial	JJ	O
expressions	NNS	O
of	IN	O
others	NNS	O
.	.	O

The	DT	O
authors	NNS	O
experimentally	RB	O
activated	VBD	O
self-face	JJ	O
representations	NNS	O
to	TO	O
assess	VB	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
recognition	NN	O
of	IN	O
dynamically	RB	O
emerging	VBG	O
facial	JJ	O
expressions	NNS	O
of	IN	O
others	NNS	O
.	.	O

They	PRP	O
exposed	VBD	O
participants	NNS	O
to	TO	O
videos	NNS	O
of	IN	O
either	DT	O
their	PRP$	O
own	JJ	O
faces	VBZ	O
(	(	O
self-face	JJ	O
prime	NN	O
)	)	O
or	CC	O
faces	VBZ	O
of	IN	O
others	NNS	O
(	(	O
nonself-face	JJ	O
prime	NN	O
)	)	O
prior	RB	O
to	TO	O
a	DT	O
facial	JJ	O
expression	NN	O
judgment	NN	O
task	NN	O
.	.	O

Their	PRP$	O
results	NNS	O
show	VBP	O
that	IN	O
experimentally	RB	O
activating	VBG	O
self-face	JJ	O
representations	NNS	O
results	NNS	O
in	IN	O
earlier	JJR	O
recognition	NN	O
of	IN	O
dynamically	RB	O
emerging	VBG	O
facial	JJ	O
expression	NN	O
.	.	O

As	IN	O
a	DT	O
group	NN	O
,	,	O
participants	NNS	O
in	IN	O
the	DT	O
self-face	JJ	O
prime	JJ	O
condition	NN	O
recognized	VBD	O
expressions	NNS	O
earlier	RBR	O
(	(	O
when	WRB	O
less	RBR	O
affective	JJ	O
perceptual	JJ	O
information	NN	O
was	VBD	O
available	JJ	O
)	)	O
compared	VBN	O
to	TO	O
participants	NNS	O
in	IN	O
the	DT	O
nonself-face	JJ	O
prime	JJ	O
condition	NN	O
.	.	O

There	EX	O
were	VBD	O
individual	JJ	O
differences	NNS	O
in	IN	O
performance	NN	O
,	,	O
such	JJ	O
that	IN	O
poorer	JJR	O
expression	NN	O
identification	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
autism	NN	Condition
traits	NNS	O
(	(	O
in	IN	O
this	DT	O
neurocognitively	RB	Condition
healthy	JJ	Condition
sample	NN	Condition
)	)	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
randomized	VBN	O
into	IN	O
the	DT	O
self-face	JJ	O
prime	JJ	O
condition	NN	O
,	,	O
participants	NNS	O
with	IN	O
high	JJ	Condition
autism	NN	Condition
traits	NNS	Condition
performed	VBN	O
as	RB	O
well	RB	O
as	IN	O
those	DT	O
with	IN	O
low	JJ	Condition
autism	NN	Condition
traits	NNS	Condition
.	.	O

Taken	VB	O
together	RB	O
,	,	O
these	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
ability	NN	O
to	TO	O
recognize	VB	O
facial	JJ	O
expressions	NNS	O
in	IN	O
others	NNS	O
is	VBZ	O
linked	VBN	O
with	IN	O
the	DT	O
internal	JJ	O
representations	NNS	O
of	IN	O
our	PRP$	O
own	JJ	O
faces	VBZ	O
.	.	O

Impact	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
on	IN	O
inflammatory	JJ	O
markers	NNS	O
in	IN	O
African	JJ	O
Americans	NNPS	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
four-arm	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

African	JJ	O
Americans	NNPS	O
have	VBP	O
a	DT	O
disproportionate	JJ	O
burden	NN	O
of	IN	O
inflammation-associated	JJ	O
chronic	JJ	O
diseases	NNS	O
such	JJ	O
as	IN	O
cancer	NN	O
and	CC	O
lower	JJR	O
circulating	NN	O
levels	NNS	O
of	IN	O
25-hydroxyvitamin	JJ	O
D	NNP	O
[	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
]	NNP	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
(	(	O
cholecalciferol	NN	O
)	)	O
supplementation	NN	O
on	IN	O
inflammatory	JJ	O
markers	NNS	O
is	VBZ	O
uncertain	JJ	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
supplemental	JJ	O
oral	JJ	O
vitamin	NN	O
D	NNP	O
(	(	O
placebo	NN	O
,	,	O
1,000	CD	O
,	,	O
2,000	CD	O
,	,	O
or	CC	O
4,000	CD	O
IU/day	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
orally	RB	O
for	IN	O
3	CD	O
months	NNS	O
)	)	O
in	IN	O
328	CD	O
African	JJ	O
Americans	NNPS	O
(	(	O
median	JJ	O
age	NN	O
,	,	O
51	CD	O
years	NNS	O
)	)	O
of	IN	O
public	JJ	O
housing	NN	O
communities	NNS	O
in	IN	O
Boston	NNP	O
,	,	O
MA	NNP	O
,	,	O
who	WP	O
were	VBD	O
enrolled	VBN	O
over	RP	O
three	CD	O
consecutive	JJ	O
winter	NN	O
periods	NNS	O
(	(	O
2007-2010	JJ	O
)	)	O
.	.	O

Change	NN	O
from	IN	O
0	CD	O
to	TO	O
3	CD	O
months	NNS	O
of	IN	O
plasma	NN	O
levels	NNS	O
of	IN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
,	,	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
interleukin	FW	O
(	(	O
IL	NNP	O
)	)	O
-6	NN	O
,	,	O
IL-10	NNP	O
,	,	O
and	CC	O
soluble	JJ	O
TNF-?	NNP	O
receptor	NN	O
type	NN	O
2	CD	O
(	(	O
sTNF-R2	NN	O
)	)	O
in	IN	O
292	CD	O
(	(	O
89	CD	O
%	NN	O
)	)	O
participants	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Overall	NNP	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
CRP	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
IL-10	NNP	O
,	,	O
and	CC	O
sTNF-R2	NNS	O
were	VBD	O
observed	VBN	O
after	IN	O
the	DT	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
period	NN	O
.	.	O

Baseline	NNP	O
CRP	NNP	O
was	VBD	O
significantly	RB	O
inversely	RB	O
associated	VBN	O
with	IN	O
the	DT	O
baseline	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
level	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
in	IN	O
unadjusted	JJ	O
and	CC	O
adjusted	JJ	O
models	NNS	O
.	.	O

An	DT	O
interaction	NN	O
between	IN	O
baseline	NN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
and	CC	O
vitamin	NNP	O
D	NNP	O
supplementation	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
outcome	JJ	O
change	NN	O
in	IN	O
log	NN	O
CRP	NNP	O
(	(	O
month	NN	O
3-month	RB	O
0	CD	O
;	:	O
P	NNP	O
for	IN	O
interaction	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Within	IN	O
an	DT	O
unselected	JJ	O
population	NN	O
of	IN	O
African	JJ	O
Americans	NNPS	O
,	,	O
short-term	JJ	O
exposure	NN	O
to	TO	O
vitamin	VB	O
D	NNP	O
supplementation	NN	O
produced	VBD	O
no	DT	O
change	NN	O
in	IN	O
circulating	VBG	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

This	DT	O
study	NN	O
confirms	VBZ	O
the	DT	O
strong	JJ	O
independent	JJ	O
association	NN	O
of	IN	O
CRP	NNP	O
with	IN	O
25	CD	O
(	(	O
OH	NNP	O
)	)	O
D	NNP	O
status	NN	O
even	RB	O
after	IN	O
adjusting	VBG	O
for	IN	O
body	NN	O
mass	NN	O
index	NN	O
.	.	O

Future	JJ	O
studies	NNS	O
of	IN	O
longer	JJR	O
supplemental	JJ	O
vitamin	NN	O
D3	NNP	O
duration	NN	O
are	VBP	O
necessary	JJ	O
to	TO	O
examine	VB	O
the	DT	O
complex	JJ	O
influence	NN	O
of	IN	O
vitamin	NN	O
D3	NNP	O
on	IN	O
CRP	NNP	O
and	CC	O
other	JJ	O
chronic	JJ	O
inflammatory	NN	O
cytokines	NNS	O
for	IN	O
possible	JJ	O
reduction	NN	O
of	IN	O
cancer	NN	O
health	NN	O
disparities	NNS	O
in	IN	O
African	JJ	O
Americans	NNPS	O
.	.	O

Effect	NN	O
of	IN	O
ibuprofen	NN	O
on	IN	O
cyclooxygenase	NN	O
and	CC	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
of	IN	O
gastric	JJ	O
mucosa	NN	O
:	:	O
correlation	NN	O
with	IN	O
endoscopic	JJ	O
lesions	NNS	O
and	CC	O
adverse	JJ	O
reactions	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
ibuprofen	NN	O
on	IN	O
gastric	JJ	O
mucosa	NN	O
and	CC	O
enzymes	NNS	O
involved	VBN	O
in	IN	O
gastroprotection	NN	O
in	IN	O
healthy	JJ	Condition
volunteers	NNS	O
.	.	O

Twenty-four	JJ	SampleSize
Helicobacter	NNP	Condition
pylori-negative	JJ	Condition
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
ibuprofen	NN	O
or	CC	O
ibuprofen-arginate	NN	O
(	(	O
each	DT	O
600	CD	O
mg/6	NN	O
hr	NN	O
during	IN	O
3	CD	O
days	NNS	O
)	)	O
.	.	O

Endoscopies	NNS	O
were	VBD	O
performed	VBN	O
1	CD	O
week	NN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

Biopsies	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
the	DT	O
gastric	JJ	O
antrum	NN	O
and	CC	O
corpus	NN	O
for	IN	O
determination	NN	O
of	IN	O
prostaglandin	NN	O
E2	NNP	O
(	(	O
PGE2	NNP	O
)	)	O
by	IN	O
ELISA	NNP	O
and	CC	O
cyclooxygenase	NN	O
(	(	O
COX-1	JJ	O
and	CC	O
COX-2	NNP	O
)	)	O
and	CC	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
(	(	O
eNOS	JJ	O
and	CC	O
iNOS	NN	O
)	)	O
by	IN	O
western	JJ	O
blot	NN	O
.	.	O

All	DT	O
subjects	NNS	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
gastric	JJ	O
lesion	NN	O
except	IN	O
for	IN	O
two	CD	O
individuals	NNS	O
taking	VBG	O
ibuprofen-arginate	NN	O
.	.	O

Ibuprofen-arginate	NNP	O
caused	VBD	O
a	DT	O
lower	JJR	O
rate	NN	O
of	IN	O
clinical	JJ	O
adverse	JJ	O
reactions	NNS	O
than	IN	O
ibuprofen	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
gastric	JJ	O
lesions	NNS	O
or	CC	O
adverse	JJ	O
reactions	NNS	O
had	VBD	O
lower	JJR	O
PGE2	NNP	O
levels	NNS	O
.	.	O

COX-1	NNP	O
,	,	O
COX-2	NNP	O
,	,	O
eNOS	NN	O
,	,	O
and	CC	O
iNOS	NNS	O
were	VBD	O
detectable	JJ	O
in	IN	O
all	DT	O
subjects	NNS	O
.	.	O

The	DT	O
constitutive	JJ	O
enzymes	NNS	O
(	(	O
COX-1	NNP	O
and	CC	O
eNOS	NN	O
)	)	O
did	VBD	O
not	RB	O
change	VB	O
after	IN	O
treatment	NN	O
.	.	O

COX-2	NNP	O
was	VBD	O
higher	RBR	O
in	IN	O
corpus	NN	O
than	IN	O
antrum	NN	O
and	CC	O
it	PRP	O
increased	VBD	O
after	IN	O
ibuprofen	JJ	O
treatment	NN	O
.	.	O

iNOS	NN	O
tended	VBD	O
to	TO	O
increase	VB	O
mildly	RB	O
in	IN	O
the	DT	O
corpus	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
adverse	JJ	O
reactions	NNS	O
or	CC	O
endoscopic	JJ	O
lesions	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
ibuprofen	NN	O
and	CC	O
ibuprofen-arginate	NN	O
in	IN	O
PGE2	NNP	O
,	,	O
or	CC	O
enzymes	NNS	O
.	.	O

Chlorthalidone	NN	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
hypotensive	JJ	O
effect	NN	O
of	IN	O
nifedipine	NN	O
in	IN	O
essential	JJ	O
hypertensives	NNS	O
:	:	O
a	DT	O
crossover	NN	O
multicentre	NN	O
study	NN	O
.	.	O

To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
combination	NN	O
of	IN	O
nifedipine	JJ	O
+	NNP	O
chlorthalidone	NN	O
exerts	VBZ	O
an	DT	O
additive	JJ	O
antihypertensive	JJ	O
effect	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
single-drug	JJ	O
treatment	NN	O
,	,	O
we	PRP	O
studied	VBD	O
66	CD	O
uncomplicated	JJ	O
essential	JJ	O
hypertensives	NNS	O
,	,	O
with	IN	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
of	IN	O
greater	JJR	O
than	IN	O
100	CD	O
and	CC	O
less	JJR	O
than	IN	O
115	CD	O
mmHg	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
a	DT	O
1-month	JJ	O
washout	NN	O
placebo	NN	O
period	NN	O
,	,	O
using	VBG	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
design	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
nifedipine	VB	O
(	(	O
20	CD	O
mg	NN	O
twice	RB	O
a	DT	O
day	NN	O
)	)	O
,	,	O
chlorthalidone	NN	O
(	(	O
25	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
)	)	O
,	,	O
the	DT	O
two	CD	O
drugs	NNS	O
combined	VBN	O
at	IN	O
the	DT	O
same	JJ	O
doses	NNS	O
and	CC	O
the	DT	O
corresponding	JJ	O
placebo	NN	O
.	.	O

Compared	VBN	O
with	IN	O
the	DT	O
randomly	NN	O
allocated	VBD	O
placebo	NN	O
,	,	O
the	DT	O
three	CD	O
active	JJ	O
treatments	NNS	O
significantly	RB	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
without	IN	O
changing	VBG	O
the	DT	O
heart	NN	O
rate	NN	O
or	CC	O
body	NN	O
weight	NN	O
.	.	O

Both	CC	O
the	DT	O
absolute	NN	O
and	CC	O
percentage	NN	O
decreases	NNS	O
in	IN	O
mean	JJ	O
blood	NN	O
pressure	NN	O
induced	VBN	O
by	IN	O
nifedipine	NN	O
and	CC	O
the	DT	O
combination	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
were	VBD	O
similar	JJ	O
and	CC	O
significantly	RB	O
greater	JJR	O
than	IN	O
those	DT	O
induced	VBN	O
by	IN	O
chlorthalidone	NN	O
.	.	O

Taken	VB	O
together	RB	O
,	,	O
these	DT	O
data	NNS	O
show	VBP	O
that	IN	O
the	DT	O
combination	NN	O
of	IN	O
nifedipine	JJ	O
+	FW	O
chlorthalidone	NN	O
does	VBZ	O
not	RB	O
exert	VB	O
any	DT	O
additive	JJ	O
antihypertensive	JJ	O
effect	NN	O
compared	VBN	O
with	IN	O
nifedipine	JJ	O
alone	RB	O
.	.	O

This	DT	O
finding	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
combination	NN	O
of	IN	O
a	DT	O
dihydropyridine	JJ	O
calcium	NN	O
antagonist	NN	O
+	VBD	O
a	DT	O
thiazide	JJ	O
diuretic	NN	O
is	VBZ	O
probably	RB	O
devoid	JJ	O
of	IN	O
any	DT	O
particular	JJ	O
clinical	JJ	O
significance	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
uncomplicated	JJ	O
essential	JJ	O
hypertensives	NNS	O
.	.	O

Non-Hodgkin	NNP	O
's	POS	O
malignant	JJ	O
lymphomas	NN	O
:	:	O
treatment	NN	O
of	IN	O
localized	JJ	O
relapses	NNS	O
with	IN	O
chemo	NN	O
+	NN	O
radio	NN	O
+	NNP	O
BCG-therapy	NNP	O
.	.	O

16	CD	SampleSize
patients	NNS	O
with	IN	O
relapsing	VBG	Condition
non-Hodgkin	NN	Condition
's	POS	Condition
malignant	JJ	Condition
lymphomas	NN	Condition
considered	VBN	O
as	IN	O
clinical	JJ	O
stage	NN	O
I	PRP	O
or	CC	O
II	NNP	O
were	VBD	O
treated	VBN	O
by	IN	O
an	DT	O
association	NN	O
of	IN	O
chemo	NN	O
+	NNP	O
radiotherapy	NN	O
and	CC	O
thereafter	RB	O
by	IN	O
maintenance	NN	O
BCG	NNP	O
therapy	NN	O
.	.	O

5	CD	SampleSize
of	IN	O
them	PRP	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
and	CC	O
have	VB	O
a	DT	O
significantly	RB	O
different	JJ	O
disease-free	JJ	O
survival	NN	O
from	IN	O
patients	NNS	O
receiving	VBG	O
the	DT	O
same	JJ	O
treatment	NN	O
but	CC	O
without	IN	O
BCG	NNP	O
.	.	O

11	CD	SampleSize
were	VBD	O
systematically	RB	O
treated	VBN	O
by	IN	O
BCG	NNP	O
and	CC	O
they	PRP	O
also	RB	O
have	VBP	O
a	DT	O
fairly	RB	O
good	JJ	O
disease-free	JJ	O
survival	NN	O
.	.	O

Such	PDT	O
a	DT	O
treatment	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
of	IN	O
value	NN	O
in	IN	O
treating	VBG	O
these	DT	O
patients	NNS	O
and	CC	O
even	RB	O
probably	RB	O
of	IN	O
curing	VBG	O
some	DT	O
of	IN	O
them	PRP	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
polyvinylpyrrolidone-iodine	NN	O
as	IN	O
an	DT	O
disinfectant	NN	O
in	IN	O
eye	NN	O
surgery	NN	O
.	.	O

105	CD	SampleSize
patients	NNS	O
admitted	VBN	O
for	IN	O
cataract	NN	Condition
surgery	NN	O
were	VBD	O
treated	VBN	O
pre-operatively	RB	O
with	IN	O
polyvinylpyrrolidone-iodine	JJ	O
(	(	O
PVP-I	NNP	O
)	)	O
as	IN	O
a	DT	O
disinfectant	NN	O
,	,	O
and	CC	O
consecutive	JJ	O
bacterial	JJ	O
cultures	NNS	O
were	VBD	O
obtained	VBN	O
before	IN	O
initiating	VBG	O
surgery	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
operation	NN	O
.	.	O

A	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
99	CD	SampleSize
)	)	O
only	RB	O
had	VBD	O
a	DT	O
standard	JJ	O
disinfection	NN	O
procedure	NN	O
of	IN	O
the	DT	O
eye	NN	O
(	(	O
including	VBG	O
instillation	NN	O
of	IN	O
Terramycin	NNP	O
cum	NN	O
polymyxin	NN	O
B	NNP	O
cream	NN	O
in	IN	O
the	DT	O
conjunctival	NN	O
sac	VBD	O
the	DT	O
evening	NN	O
before	IN	O
surgery	NN	O
)	)	O
.	.	O

The	DT	O
cultures	NNS	O
obtained	VBN	O
from	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
principally	RB	O
showed	VBD	O
growth	NN	O
of	IN	O
Staph	NNP	O
.	.	O

albus	NN	O
and	CC	O
Staph	NNP	O
.	.	O

aureus	NN	O
,	,	O
and	CC	O
to	TO	O
a	DT	O
minor	JJ	O
degree	NN	O
diphtheroids	NNS	O
(	(	O
Corynebacterium	NNP	O
species	NNS	O
)	)	O
.	.	O

Proteus	NNP	O
mirabilis	NN	O
,	,	O
Escherichia	NNP	O
coli	NN	O
and	CC	O
micrococci	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
quantitative	JJ	O
diminished	VBN	O
growth	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
of	IN	O
bacteria	NN	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
PVP-I	NNP	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Concerning	VBG	O
the	DT	O
growth	NN	O
of	IN	O
Staph	NNP	O
.	.	O

albus	NN	O
,	,	O
this	DT	O
was	VBD	O
reduced	VBN	O
to	TO	O
almost	RB	O
one	CD	O
third	JJ	O
and	CC	O
other	JJ	O
bacteria	NNS	O
were	VBD	O
almost	RB	O
eliminated	VBN	O
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
PVP-I	NNP	O
.	.	O

As	IN	O
we	PRP	O
disclosed	VBD	O
no	DT	O
toxic	NN	O
or	CC	O
allergic	JJ	O
reaction	NN	O
post-operatively	RB	O
which	WDT	O
could	MD	O
be	VB	O
related	VBN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
PVP-I	NNP	O
as	IN	O
a	DT	O
disinfectant	NN	O
,	,	O
this	DT	O
agent	NN	O
seems	VBZ	O
to	TO	O
constitute	VB	O
an	DT	O
effective	JJ	O
pre-operative	JJ	O
antimicrobial	JJ	O
treatment	NN	O
,	,	O
taking	VBG	O
into	IN	O
consideration	NN	O
the	DT	O
broad	JJ	O
antimicrobial	JJ	O
spectrum	NN	O
of	IN	O
PVP-I	NNP	O
shown	VBN	O
by	IN	O
other	JJ	O
authors	NNS	O
.	.	O

Human	NNP	O
psychopharmacology	NN	O
and	CC	O
dose-effects	NNS	O
of	IN	O
salvinorin	NN	O
A	NNP	O
,	,	O
a	DT	O
kappa	NN	O
opioid	JJ	O
agonist	NN	O
hallucinogen	NN	O
present	NN	O
in	IN	O
the	DT	O
plant	NN	O
Salvia	NNP	O
divinorum	NN	O
.	.	O

Salvinorin	VB	O
A	DT	O
is	VBZ	O
a	DT	O
potent	NN	O
,	,	O
selective	JJ	O
nonnitrogenous	JJ	O
kappa	NN	O
opioid	JJ	O
agonist	NN	O
and	CC	O
the	DT	O
known	VBN	O
psychoactive	JJ	O
constituent	NN	O
of	IN	O
Salvia	NNP	O
divinorum	NN	O
,	,	O
a	DT	O
member	NN	O
of	IN	O
the	DT	O
mint	NN	O
family	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
used	VBN	O
for	IN	O
centuries	NNS	O
by	IN	O
Mazatec	NNP	O
shamans	NNS	O
of	IN	O
Mexico	NNP	O
for	IN	O
divination	NN	O
and	CC	O
spiritual	JJ	O
healing	NN	O
.	.	O

S.	NNP	O
divinorum	NN	O
has	VBZ	O
over	RP	O
the	DT	O
last	JJ	O
several	JJ	O
years	NNS	O
gained	VBD	O
increased	JJ	O
popularity	NN	O
as	IN	O
a	DT	O
recreational	JJ	O
drug	NN	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo	NN	O
controlled	VBD	O
study	NN	O
of	IN	O
salvinorin	NN	O
A	NNP	O
in	IN	O
4	CD	SampleSize
psychologically	RB	O
and	CC	O
physically	RB	O
healthy	JJ	Condition
hallucinogen-using	NN	Condition
adults	NNS	O
.	.	O

Across	IN	O
sessions	NNS	O
,	,	O
participants	NNS	O
inhaled	VBD	O
16	CD	O
ascending	VBG	O
doses	NNS	O
of	IN	O
salvinorin	NN	O
A	NNP	O
and	CC	O
4	CD	O
intermixed	JJ	O
placebo	NN	O
doses	NNS	O
under	IN	O
comfortable	JJ	O
and	CC	O
supportive	JJ	O
conditions	NNS	O
.	.	O

Doses	NNS	O
ranged	VBD	O
from	IN	O
0.375	CD	O
?g/kg	NNS	O
to	TO	O
21	CD	O
?g/kg	NNS	O
.	.	O

Subject-rated	JJ	O
drug	NN	O
strength	NN	O
was	VBD	O
assessed	VBN	O
every	DT	O
2	CD	O
min	NN	O
for	IN	O
60	CD	O
min	NN	O
after	IN	O
inhalation	NN	O
.	.	O

Orderly	JJ	O
time-	JJ	O
and	CC	O
dose-related	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Drug	NNP	O
strength	NN	O
ratings	NNS	O
peaked	VBD	O
at	IN	O
2	CD	O
min	NN	O
(	(	O
first	JJ	O
time	NN	O
point	NN	O
)	)	O
and	CC	O
definite	JJ	O
subjective	JJ	O
effects	NNS	O
were	VBD	O
no	RB	O
longer	RBR	O
present	JJ	O
at	IN	O
approximately	RB	O
20	CD	O
min	NNS	O
after	IN	O
inhalation	NN	O
.	.	O

Dose-related	JJ	O
increases	NNS	O
were	VBD	O
observed	VBN	O
on	IN	O
questionnaire	NN	O
measures	NNS	O
of	IN	O
mystical-type	JJ	O
experience	NN	O
(	(	O
Mysticism	NNP	O
Scale	NNP	O
)	)	O
and	CC	O
subjective	JJ	O
effects	NNS	O
associated	VBN	O
with	IN	O
classic	JJ	O
serotonergic	NN	O
(	(	O
5-HT2	JJ	O
(	(	O
A	NNP	O
)	)	O
)	)	O
hallucinogens	VBZ	O
(	(	O
Hallucinogen	NNP	O
Rating	NNP	O
Scale	NNP	O
)	)	O
.	.	O

Salvinorin	CC	O
A	DT	O
did	VBD	O
not	RB	O
significantly	RB	O
increase	VB	O
heart	NN	O
rate	NN	O
or	CC	O
blood	NN	O
pressure	NN	O
.	.	O

Participant	NNP	O
narratives	VBZ	O
indicated	VBN	O
intense	JJ	O
experiences	NNS	O
characterized	VBN	O
by	IN	O
disruptions	NNS	O
in	IN	O
vestibular	JJ	O
and	CC	O
interoceptive	JJ	O
signals	NNS	O
(	(	O
e.g.	NN	O
,	,	O
change	NN	O
in	IN	O
spatial	JJ	O
orientation	NN	O
,	,	O
pressure	NN	O
on	IN	O
the	DT	O
body	NN	O
)	)	O
and	CC	O
unusual	JJ	O
and	CC	O
sometimes	RB	O
recurring	VBG	O
themes	NNS	O
across	IN	O
sessions	NNS	O
such	JJ	O
as	IN	O
revisiting	VBG	O
childhood	NN	O
memories	NNS	O
,	,	O
cartoon-like	JJ	O
imagery	NN	O
,	,	O
and	CC	O
contact	NN	O
with	IN	O
entities	NNS	O
.	.	O

Under	IN	O
these	DT	O
prepared	JJ	O
and	CC	O
supportive	JJ	O
conditions	NNS	O
,	,	O
salvinorin	VBP	O
A	DT	O
occasioned	VBD	O
a	DT	O
unique	JJ	O
profile	NN	O
of	IN	O
subjective	JJ	O
effects	NNS	O
having	VBG	O
similarities	NNS	O
to	TO	O
classic	VB	O
hallucinogens	NNS	O
,	,	O
including	VBG	O
mystical-type	JJ	O
effects	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
acute	JJ	O
asthma	NN	O
.	.	O

Lack	NNP	O
of	IN	O
therapeutic	JJ	O
benefit	NN	O
and	CC	O
increase	NN	O
of	IN	O
the	DT	O
toxicity	NN	O
from	IN	O
aminophylline	JJ	O
given	VBN	O
in	IN	O
addition	NN	O
to	TO	O
high	JJ	O
doses	NNS	O
of	IN	O
salbutamol	NN	O
delivered	VBN	O
by	IN	O
metered-dose	JJ	O
inhaler	NN	O
with	IN	O
a	DT	O
spacer	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
to	TO	O
determine	VB	O
if	IN	O
intravenous	JJ	O
aminophylline	NN	O
adds	VBZ	O
any	DT	O
benefit	NN	O
to	TO	O
high	JJ	O
doses	NNS	O
of	IN	O
inhaled	JJ	O
salbutamol	NN	O
in	IN	O
patients	NNS	O
who	WP	O
presented	VBD	O
for	IN	O
treatment	NN	O
of	IN	O
acute	JJ	Condition
asthma	NN	Condition
.	.	O

We	PRP	O
studied	VBD	O
94	CD	SampleSize
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
35.6	CD	O
+/-	JJ	O
11.2	CD	O
years	NNS	O
)	)	O
with	IN	O
moderate	JJ	Condition
to	TO	Condition
severe	VB	Condition
acute	JJ	Condition
asthma	NN	Condition
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
therapy	NN	O
with	IN	O
salbutamol	NN	O
delivered	VBN	O
with	IN	O
metered-dose	JJ	O
inhaler	NN	O
(	(	O
MDI	NNP	O
)	)	O
into	IN	O
a	DT	O
spacer	NN	O
device	NN	O
(	(	O
Volumatic	NNP	O
)	)	O
in	IN	O
four	CD	O
puffs	NNS	O
(	(	O
400	CD	O
micrograms	NNS	O
)	)	O
at	IN	O
10-min	JJ	O
interval	NN	O
,	,	O
and	CC	O
intravenous	JJ	O
hydrocortisone	NN	O
(	(	O
500	CD	O
mg	NN	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	CC	O
a	DT	O
loading	NN	O
dose	NN	O
of	IN	O
intravenous	JJ	O
aminophylline	NN	O
followed	VBN	O
by	IN	O
a	DT	O
routine	JJ	O
infusion	NN	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
placebo	NN	O
as	IN	O
a	DT	O
loading	NN	O
dose	NN	O
and	CC	O
infusion	NN	O
(	(	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
showed	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
measurements	NNS	O
of	IN	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
,	,	O
FEV1	NNP	O
,	,	O
and	CC	O
FVC	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
aminophylline	NN	O
had	VBD	O
significantly	RB	O
more	RBR	O
adverse	JJ	O
effects	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
final	JJ	O
mean	NN	O
dose	NN	O
of	IN	O
salbutamol	NN	O
(	(	O
6.3	CD	O
+/-	JJ	O
44.5	CD	O
mg	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
5.8	CD	O
+/-	JJ	O
4.2	CD	O
mg	NN	O
for	IN	O
the	DT	O
aminophylline	NN	O
group	NN	O
)	)	O
,	,	O
hospital	JJ	O
admission	NN	O
rate	NN	O
(	(	O
10.2	CD	O
percent	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
9.0	CD	O
percent	NN	O
for	IN	O
the	DT	O
aminophylline	NN	O
group	NN	O
)	)	O
,	,	O
and	CC	O
mean	JJ	O
duration	NN	O
of	IN	O
Emergency	NNP	O
Department	NNP	O
treatment	NN	O
(	(	O
2.5	CD	O
+/-	JJ	O
1.83	CD	O
h	NN	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
2.37	CD	O
+/-	JJ	O
1.75	CD	O
h	NN	O
for	IN	O
the	DT	O
aminophylline	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
similar	JJ	O
when	WRB	O
the	DT	O
patients	NNS	O
were	VBD	O
divided	VBN	O
in	IN	O
accord	NN	O
with	IN	O
the	DT	O
degree	NN	O
of	IN	O
respiratory	NN	O
obstruction	NN	O
(	(	O
baseline	JJ	O
FEV1	NNP	O
<	NNP	O
30	CD	O
percent	NN	O
of	IN	O
predicted	VBN	O
)	)	O
and	CC	O
theophylline	JJ	O
level	NN	O
at	IN	O
30	CD	O
min	NN	O
of	IN	O
treatment	NN	O
(	(	O
placebo	JJ	O
group	NN	O
patients	NNS	O
with	IN	O
theophylline	JJ	O
level	NN	O
<	VBD	O
10	CD	O
mg/L	NN	O
vs	NN	O
aminophylline	NN	O
group	NN	O
patients	NNS	O
with	IN	O
theophylline	JJ	O
level	NN	O
>	NN	O
or	CC	O
=	$	O
10	CD	O
mg/L	NN	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
intravenous	JJ	O
aminophylline	NN	O
adds	VBZ	O
to	TO	O
the	DT	O
toxicity	NN	O
but	CC	O
not	RB	O
the	DT	O
efficacy	NN	O
of	IN	O
inhaled	JJ	O
salbutamol	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
asthma	NN	O
.	.	O

Effects	NNS	O
of	IN	O
enalapril	NN	O
and	CC	O
eprosartan	NN	O
on	IN	O
the	DT	O
renal	JJ	O
vascular	NN	O
nitric	JJ	O
oxide	NN	O
system	NN	O
in	IN	O
human	JJ	Condition
essential	JJ	Condition
hypertension	NN	Condition
.	.	Condition

BACKGROUND	NNP	O
Experimental	NNP	O
data	NNS	O
in	IN	O
humans	NNS	O
on	IN	O
the	DT	O
contribution	NN	O
of	IN	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
and	CC	O
angiotensin	NN	O
II	NNP	O
type	NN	O
1	CD	O
receptor	NN	O
blockers	NNS	O
to	TO	O
the	DT	O
nitric	JJ	O
oxide	NN	O
system	NN	O
of	IN	O
the	DT	O
renal	JJ	O
vasculature	NN	O
are	VBP	O
inconsistent	JJ	O
.	.	O

Enalapril	NNP	O
and	CC	O
eprosartan	RB	O
,	,	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
,	,	O
were	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
their	PRP$	O
short-term	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
renal	JJ	O
nitric	JJ	O
oxide	NN	O
system	NN	O
and	CC	O
renal	JJ	O
hemodynamics	NNS	O
of	IN	O
human	JJ	Condition
subjects	NNS	Condition
with	IN	Condition
essential	JJ	Condition
hypertension	NN	Condition
.	.	Condition

METHODS	NNP	O
Twenty	NNP	Condition
male	NN	Condition
,	,	Condition
white	JJ	Condition
patients	NNS	Condition
(	(	Condition
27	CD	Condition
+/-	JJ	Condition
1	CD	Condition
years	NNS	Condition
)	)	Condition
with	IN	Condition
mild	JJ	Condition
essential	JJ	Condition
hypertension	NN	Condition
(	(	Condition
143	CD	Condition
+/-	JJ	Condition
11/95	CD	Condition
+/-	JJ	Condition
6	CD	Condition
mm	NN	Condition
Hg	NNP	Condition
)	)	Condition
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
fourfold	JJ	O
cross-over	NN	O
study	NN	O
with	IN	O
placebo	NN	O
,	,	O
enalapril	NN	O
(	(	O
20	CD	O
mg/day	NN	O
)	)	O
,	,	O
eprosartan	FW	O
(	(	O
600	CD	O
mg/day	NN	O
)	)	O
,	,	O
or	CC	O
combination	NN	O
of	IN	O
both	DT	O
drugs	NNS	O
(	(	O
10	CD	O
and	CC	O
300	CD	O
mg/day	NN	O
,	,	O
respectively	RB	O
)	)	O
each	DT	O
over	IN	O
a	DT	O
one	CD	O
week	NN	O
period	NN	O
followed	VBN	O
by	IN	O
a	DT	O
two-week	JJ	O
washout	NN	O
phase	NN	O
.	.	O

After	IN	O
each	DT	O
study	NN	O
phase	VBD	O
the	DT	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
GFR	NNP	O
)	)	O
and	CC	O
renal	JJ	O
plasma	NN	O
flow	NN	O
(	(	O
RPF	NNP	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

Basal	NNP	O
nitric	JJ	O
oxide	JJ	O
synthesis	NN	O
of	IN	O
the	DT	O
renal	JJ	O
vasculature	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
decrease	NN	O
in	IN	O
RPF	NNP	O
after	IN	O
inhibition	NN	O
of	IN	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
with	IN	O
NG-monomethyl-L-arginine	NNP	O
(	(	O
L-NMMA	NNP	O
;	:	O
4.25	CD	O
mg/kg	NN	O
)	)	O
.	.	O

RESULTS	CC	O
After	IN	O
one	CD	O
week	NN	O
of	IN	O
therapy	NN	O
,	,	O
the	DT	O
combination	NN	O
therapy	NN	O
decreased	VBD	O
casual	JJ	O
blood	NN	O
pressure	NN	O
by	IN	O
5	CD	O
+/-	JJ	O
2/3	CD	O
+/-	JJ	O
1	CD	O
mm	NN	O
Hg	NNP	O
versus	NN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Neither	CC	O
enalapril	JJ	O
alone	RB	O
(	(	O
-2	JJ	O
+/-	JJ	O
2/1	CD	O
+/-	JJ	O
2	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
NS	NNP	O
vs.	FW	O
placebo	NN	O
)	)	O
nor	CC	O
eprosartan	JJ	O
alone	NN	O
(	(	O
-1	JJ	O
+/-	JJ	O
1/0	CD	O
+/-	JJ	O
2	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
NS	NNP	O
vs.	FW	O
placebo	NN	O
)	)	O
had	VBD	O
a	DT	O
clear-cut	JJ	O
significant	JJ	O
effect	NN	O
on	IN	O
casual	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

In	IN	O
the	DT	O
combination	NN	O
phase	NN	O
,	,	O
RPF	NNP	O
increased	VBN	O
by	IN	O
123	CD	O
+/-	JJ	O
36	CD	O
mL/min	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Neither	CC	O
enalapril	JJ	O
alone	RB	O
(	(	O
+59	JJ	O
+/-	JJ	O
46	CD	O
mL/min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.21	CD	O
)	)	O
nor	CC	O
eprosartan	JJ	O
alone	NN	O
(	(	O
+113	JJ	O
+/-	JJ	O
51	CD	O
mL/min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.06	CD	O
)	)	O
had	VBD	O
a	DT	O
clear-cut	JJ	O
significant	JJ	O
effect	NN	O
on	IN	O
RPF	NNP	O
.	.	O

Changes	NNS	O
of	IN	O
RPF	NNP	O
induced	VBN	O
by	IN	O
treatment	NN	O
correlated	VBN	O
with	IN	O
the	DT	O
L-NMMA	NNP	O
induced	JJ	O
decrease	NN	O
in	IN	O
RPF	NNP	O
in	IN	O
the	DT	O
combination	NN	O
(	(	O
r	JJ	O
=	NN	O
0.70	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
eprosartan	JJ	O
phase	NN	O
(	(	O
r	JJ	O
=	NN	O
0.86	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
enalapril	JJ	O
phase	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.44	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.10	CD	O
)	)	O
.	.	O

Renal	JJ	O
vascular	JJ	O
resistance	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
each	DT	O
active	JJ	O
treatment	NN	O
with	IN	O
the	DT	O
most	RBS	O
prominent	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
combination	NN	O
phase	NN	O
.	.	O

GFR	NNP	O
was	VBD	O
unaffected	VBN	O
by	IN	O
any	DT	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
contrast	NN	O
to	TO	O
the	DT	O
effects	NNS	O
of	IN	O
either	DT	O
substance	NN	O
alone	RB	O
,	,	O
a	DT	O
combination	NN	O
of	IN	O
half	PDT	O
the	DT	O
dose	NN	O
of	IN	O
eprosartan	NN	O
with	IN	O
half	PDT	O
the	DT	O
dose	NN	O
of	IN	O
enalapril	NN	O
had	VBD	O
a	DT	O
prominent	JJ	O
effect	NN	O
on	IN	O
renal	JJ	O
perfusion	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
eprosartan	NN	O
on	IN	O
RPF	NNP	O
are	VBP	O
mediated	VBN	O
,	,	O
at	IN	O
least	JJS	O
in	IN	O
part	NN	O
,	,	O
by	IN	O
an	DT	O
increased	JJ	O
bioavailability	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
in	IN	O
the	DT	O
renal	JJ	O
vasculature	NN	O
.	.	O

Assessment	NN	O
of	IN	O
elementary	JJ	Age
school	NN	Age
students	NNS	O
'	POS	O
sun	NN	O
protection	NN	O
behaviors	NNS	O
.	.	O

BACKGROUND/OBJECTIVES	NNP	O
Studies	NNPS	O
suggest	VBP	O
that	IN	O
excessive	JJ	O
sun	NN	O
exposure	NN	O
in	IN	O
childhood	NN	O
contributes	NNS	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
skin	NN	O
cancer	NN	O
later	RBR	O
in	IN	O
life	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
explores	VBZ	O
4th	CD	Age
grade	NN	Age
student	NN	O
assessment	NN	O
of	IN	O
their	PRP$	O
sun	NN	O
protection	NN	O
behaviors	NNS	O
.	.	O

This	DT	O
study	NN	O
used	VBN	O
baseline	NN	O
data	NNS	O
collected	VBN	O
in	IN	O
the	DT	O
Fall	NN	O
of	IN	O
2006	CD	O
for	IN	O
the	DT	O
Sun	NNP	O
Protection	NNP	O
for	IN	O
Florida	NNP	O
's	POS	O
Children	NNP	O
(	(	O
SPF	NNP	O
)	)	O
project	NN	O
.	.	O

In	IN	O
brief	NN	O
,	,	O
the	DT	O
SPF	NNP	O
project	NN	O
is	VBZ	O
a	DT	O
group	NN	O
randomized	VBD	O
trial	NN	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
school	NN	O
based	VBN	O
intervention	NN	O
promoting	VBG	O
sun	JJ	O
protection	NN	O
in	IN	O
general	JJ	O
,	,	O
and	CC	O
hat	RB	O
use	NN	O
in	IN	O
particular	JJ	O
,	,	O
in	IN	O
Hillsborough	NNP	O
County	NNP	O
Schools	NNP	O
,	,	O
Florida	NNP	O
.	.	O

The	DT	O
data	NN	O
reported	VBD	O
in	IN	O
this	DT	O
study	NN	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
before	IN	O
any	DT	O
intervention	NN	O
activities	NNS	O
was	VBD	O
initiated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
self-reported	JJ	O
use	NN	O
of	IN	O
various	JJ	O
methods	NNS	O
of	IN	O
sun	NN	O
protection	NN	O
was	VBD	O
low	JJ	O
.	.	O

Only	RB	O
a	DT	O
small	JJ	O
percentage	NN	O
of	IN	O
students	NNS	O
wore	VBP	O
long	JJ	O
sleeves	NNS	O
or	CC	O
a	DT	O
hat	NN	O
with	IN	O
a	DT	O
brim	NN	O
before	IN	O
leaving	VBG	O
for	IN	O
school	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
few	JJ	O
students	NNS	O
wore	VBD	O
a	DT	O
hat	NN	O
with	IN	O
a	DT	O
wide	JJ	O
brim	NN	O
when	WRB	O
outside	NN	O
but	CC	O
not	RB	O
at	IN	O
school	NN	O
.	.	O

Students	NNS	O
spent	VBD	O
an	DT	O
average	NN	O
of	IN	O
59.1	CD	O
minutes	NNS	O
per	IN	O
week	NN	O
outdoors	NNS	O
while	IN	O
attending	VBG	O
school	NN	O
and	CC	O
35.5	CD	O
minutes	NNS	O
during	IN	O
peak	JJ	O
sun	NN	O
exposure	NN	O
.	.	O

CONCLUSION	NNP	O
Sun	NNP	O
exposure	NN	O
at	IN	O
school	NN	O
poses	NNS	O
a	DT	O
significant	JJ	O
risk	NN	O
to	TO	O
student	VB	O
health	NN	O
and	CC	O
more	JJR	O
needs	NNS	O
to	TO	O
be	VB	O
carried	VBN	O
out	IN	O
to	TO	O
promote	VB	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
wide-brimmed	JJ	O
hat	NN	O
and	CC	O
limiting	VBG	O
student	NN	O
sun	NN	O
exposure	NN	O
.	.	O

A	DT	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
of	IN	O
bumetanide	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
in	IN	O
children	NNS	O
.	.	O

Gamma	NNP	O
aminobutyric	JJ	O
acid	NN	O
(	(	O
GABA	NNP	O
)	)	O
-mediated	VBD	O
synapses	NNS	O
and	CC	O
the	DT	O
oscillations	NNS	O
they	PRP	O
orchestrate	VBP	O
are	VBP	O
altered	VBN	O
in	IN	O
autism	NN	O
.	.	O

GABA-acting	JJ	O
benzodiazepines	NNS	O
exert	NN	O
in	IN	O
some	DT	O
patients	NNS	O
with	IN	O
autism	NN	O
paradoxical	JJ	O
effects	NNS	O
,	,	O
raising	VBG	O
the	DT	O
possibility	NN	O
that	IN	O
like	IN	O
in	IN	O
epilepsies	NNS	O
,	,	O
GABA	NNP	O
excites	VBZ	O
neurons	NNS	O
because	IN	O
of	IN	O
elevated	JJ	O
intracellular	JJ	O
concentrations	NNS	O
of	IN	O
chloride	NN	O
.	.	O

Following	VBG	O
a	DT	O
successful	JJ	O
pilot	NN	O
study	NN	O
,	,	O
(	(	O
1	CD	O
)	)	O
we	PRP	O
have	VBP	O
now	RB	O
performed	VBN	O
a	DT	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
using	VBG	O
the	DT	O
diuretic	JJ	O
,	,	O
chloride-importer	JJ	O
antagonist	NN	O
bumetanide	IN	O
that	DT	O
reduces	VBZ	O
intracellular	JJ	O
chloride	NN	O
reinforcing	VBG	O
GABAergic	NNP	O
inhibition	NN	O
.	.	O

Sixty	NNP	O
children	NNS	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
syndrome	VBP	O
(	(	O
3-11	CD	O
years	NNS	O
old	JJ	O
)	)	O
received	VBD	O
for	IN	O
3	CD	O
months	NNS	O
placebo	NN	O
or	CC	O
bumetanide	NN	O
(	(	O
1	CD	O
mg	NNS	O
daily	RB	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
1-month	JJ	O
wash	NN	O
out	IN	O
.	.	O

Determination	NN	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
autism	NN	O
was	VBD	O
made	VBN	O
with	IN	O
video	JJ	O
films	NNS	O
at	IN	O
day	NN	O
0	CD	O
(	(	O
D0	NNP	O
)	)	O
and	CC	O
D90	NNP	O
by	IN	O
blind	NN	O
,	,	O
independent	JJ	O
evaluators	NNS	O
.	.	O

Bumetanide	NNP	O
reduced	VBD	O
significantly	RB	O
the	DT	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
CARS	NNP	O
)	)	O
(	(	O
D90-D0	NNP	O
;	:	O
P	NNP	O
<	VBD	O
0.004	CD	O
treated	JJ	O
vs	NN	O
placebo	NN	O
)	)	O
,	,	O
Clinical	JJ	O
Global	NNP	O
Impressions	NNP	O
(	(	O
P	NNP	O
<	VBZ	O
0.017	CD	O
treated	JJ	O
vs	NN	O
placebo	NN	O
)	)	O
and	CC	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule	NNP	O
values	NNS	O
when	WRB	O
the	DT	O
most	RBS	O
severe	JJ	O
cases	NNS	O
(	(	O
CARS	NNPS	O
values	NNS	O
above	IN	O
the	DT	O
mean	NN	O
?	.	O
s.d	NN	O
.	.	O

;	:	O
n=9	CC	O
)	)	O
were	VBD	O
removed	VBN	O
(	(	O
Wilcoxon	JJ	O
test	NN	O
:	:	O
P-value=0.031	NN	O
;	:	O
Student	NNP	O
's	POS	O
t-test	NN	O
:	:	O
P-value=0.017	NN	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
were	VBD	O
restricted	VBN	O
to	TO	O
an	DT	O
occasional	JJ	O
mild	NN	O
hypokalaemia	NN	O
(	(	O
3.0-3.5	JJ	O
mM	NN	O
l	NN	O
(	(	O
-1	NNP	O
)	)	O
K	NNP	O
(	(	O
+	NNP	O
)	)	O
)	)	O
that	WDT	O
was	VBD	O
treated	VBN	O
with	IN	O
supplemental	JJ	O
potassium	NN	O
.	.	O

In	IN	O
a	DT	O
companion	NN	O
study	NN	O
,	,	O
chronic	JJ	O
bumetanide	NN	O
treatment	NN	O
significantly	RB	O
improved	VBN	O
accuracy	NN	O
in	IN	O
facial	JJ	O
emotional	JJ	O
labelling	NN	O
,	,	O
and	CC	O
increased	VBD	O
brain	NN	O
activation	NN	O
in	IN	O
areas	NNS	O
involved	VBN	O
in	IN	O
social	JJ	O
and	CC	O
emotional	JJ	O
perception	NN	O
(	(	O
Hadjikhani	NNP	O
et	RB	O
al.	RB	O
,	,	O
submitted	VBN	O
)	)	O
.	.	O

Therefore	RB	O
,	,	O
bumetanide	NN	O
is	VBZ	O
a	DT	O
promising	JJ	O
novel	NN	O
therapeutic	JJ	O
agent	NN	O
to	TO	O
treat	VB	O
autism	NN	O
.	.	O

Larger	JJR	O
trials	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
better	RBR	O
determine	VB	O
the	DT	O
population	NN	O
best	RB	O
suited	VBN	O
for	IN	O
this	DT	O
treatment	NN	O
.	.	O

Reduced	VBN	O
platelet	NN	O
thromboxane	NN	O
formation	NN	O
after	IN	O
long-term	JJ	O
administration	NN	O
of	IN	O
a	DT	O
dihydropyridine	JJ	O
calcium	NN	O
channel	NN	O
blocker	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
with	IN	O
nitrendipine	NN	O
in	IN	O
borderline	JJ	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
IDDM-type	NNP	O
diabetes	NNS	O
mellitus	NN	O
.	.	O

Twenty-nine	JJ	O
IDDM	NNP	O
patients	NNS	O
with	IN	O
borderline	JJ	O
hypertension	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
placebo	VB	O
or	CC	O
nitrendipine	VB	O
treatment	NN	O
.	.	O

Nitrendipine	NNP	O
was	VBD	O
given	VBN	O
orally	RB	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
20	CD	O
mg	NNS	O
once	RB	O
daily	RB	O
over	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Stimulated	VBN	O
platelet	NN	O
thromboxane	NN	O
formation	NN	O
at	IN	O
rest	NN	O
and	CC	O
after	IN	O
standardized	VBN	O
,	,	O
non	JJ	O
exhausting	VBG	O
exercise	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
standard	JJ	O
methods	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
plasma	NN	O
levels	NNS	O
of	IN	O
platelet	NN	O
factor	NN	O
4	CD	O
and	CC	O
aggregation	NN	O
responses	NNS	O
to	TO	O
collagen	VB	O
and	CC	O
ADP	NNP	O
were	VBD	O
determined	VBN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
group	NN	O
thromboxane	NN	O
formation	NN	O
after	IN	O
stimulation	NN	O
with	IN	O
collagen	NN	O
(	(	O
0.3	CD	O
and	CC	O
1.0	CD	O
micrograms/ml	NN	O
)	)	O
and	CC	O
1	CD	O
mM	NN	O
arachidonic	JJ	O
acid	NN	O
(	(	O
AA	NNP	O
)	)	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
resting	NN	O
state	NN	O
.	.	O

Exercise	NN	O
induced	JJ	O
change	NN	O
of	IN	O
thromboxane	NN	O
synthesis	NN	O
in	IN	O
response	NN	O
to	TO	O
1.0	CD	O
micrograms/ml	NNS	O
collagen	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
parallel	JJ	O
,	,	O
PF4	NNP	O
plasma	NN	O
levels	NNS	O
were	VBD	O
significantly	RB	O
lowered	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Whole	JJ	O
blood	NN	O
aggregation	NN	O
after	IN	O
collagen	NN	O
stimulation	NN	O
(	(	O
1.0	CD	O
micrograms/ml	NN	O
)	)	O
was	VBD	O
reduced	VBN	O
after	IN	O
4	CD	O
weeks	NNS	O
of	IN	O
nitrendipine	JJ	O
treatment	NN	O
,	,	O
but	CC	O
ADP	NNP	O
(	(	O
5	CD	O
microM	NN	O
)	)	O
induced	VBD	O
aggregation	NN	O
was	VBD	O
not	RB	O
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
nitrendipine	NN	O
were	VBD	O
not	RB	O
seen	VBN	O
in	IN	O
platelet	NN	O
rich	JJ	O
plasma	NN	O
.	.	O

In	IN	O
conclusion	NN	O
long-term	JJ	O
nitrendipine	JJ	O
treatment	NN	O
may	MD	O
inhibit	VB	O
collagen	NN	O
dependent	JJ	O
platelet	NN	O
activation	NN	O
in	IN	O
the	DT	O
blood	NN	O
of	IN	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
borderline	JJ	O
hypertension	NN	O
.	.	O

Botulinum	NNP	O
toxin	NN	O
a	DT	O
has	VBZ	O
antinociceptive	JJ	O
effects	NNS	O
in	IN	O
treating	VBG	O
interstitial	JJ	O
cystitis	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
present	VB	O
clinical	JJ	O
evidence	NN	O
with	IN	O
botulinum	NN	O
toxin	NN	O
A	NNP	O
(	(	O
BTX-A	NNP	O
)	)	O
suggesting	VBG	O
an	DT	O
antinociceptive	JJ	O
role	NN	O
in	IN	O
patients	NNS	O
with	IN	O
interstitial	JJ	Condition
cystitis	NN	Condition
(	(	Condition
IC	NNP	Condition
)	)	Condition
.	.	Condition

Intriguing	VBG	O
evidence	NN	O
in	IN	O
a	DT	O
somatic	JJ	O
pain	NN	O
model	NN	O
has	VBZ	O
suggested	VBN	O
that	IN	O
BTX-A	NNP	O
injection	NN	O
may	MD	O
have	VB	O
an	DT	O
antinociceptive	JJ	O
effect	NN	O
on	IN	O
both	DT	O
acute	NN	O
and	CC	O
chronic	NN	O
(	(	O
inflammatory	NN	O
)	)	O
pain	NN	O
.	.	O

METHODS	NNP	O
Thirteen	NNP	SampleSize
female	JJ	O
patients	NNS	O
(	(	O
6	CD	SampleSize
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
and	CC	O
7	CD	SampleSize
in	IN	O
Poland	NNP	O
)	)	O
with	IN	O
IC	NNP	O
according	VBG	O
to	TO	O
the	DT	O
criteria	NNS	O
of	IN	O
the	DT	O
National	NNP	O
Institute	NNP	O
of	IN	O
Diabetes	NNP	O
,	,	O
Digestive	NNP	O
and	CC	O
Kidney	NNP	O
Disease	NNP	O
were	VBD	O
included	VBN	O
.	.	O

Under	IN	O
short	JJ	O
general	JJ	O
anesthesia	NN	O
or	CC	O
sedation	NN	O
,	,	O
100	CD	Condition
to	TO	Condition
200	CD	Condition
U	NNP	Condition
of	IN	Condition
Dysport	NNP	Condition
(	(	O
Polish	JJ	O
patients	NNS	O
)	)	O
or	CC	O
Botox	NNP	Condition
(	(	O
U.S.	NNP	O
patients	NNS	O
)	)	O
was	VBD	O
injected	VBN	O
through	IN	O
a	DT	O
cystoscope	NN	O
into	IN	O
20	CD	O
to	TO	O
30	CD	O
sites	NNS	O
submucosally	RB	O
in	IN	O
the	DT	O
trigone	NN	O
and	CC	O
floor	NN	O
of	IN	O
the	DT	O
bladder	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
with	IN	O
the	DT	O
O'Leary-Sant	NNP	O
validated	VBD	O
IC	NNP	O
questionnaire	NN	O
or	CC	O
with	IN	O
voiding	JJ	O
charts	NNS	O
and	CC	O
a	DT	O
visual	JJ	O
analog	NN	O
pain	VBP	O
scale	JJ	O
1	CD	O
month	NN	O
postoperatively	RB	O
and	CC	O
at	IN	O
subsequent	JJ	O
3-month	JJ	O
intervals	NNS	O
.	.	O

The	DT	O
Polish	JJ	O
patients	NNS	O
also	RB	O
underwent	JJ	O
pretreatment	NN	O
and	CC	O
post-treatment	JJ	O
urodynamic	JJ	O
evaluations	NNS	O
.	.	O

RESULTS	NNP	O
Overall	NNP	O
,	,	O
9	CD	O
(	(	O
69	CD	O
%	NN	O
)	)	O
of	IN	O
13	CD	O
patients	NNS	O
noted	JJ	O
subjective	JJ	O
improvement	NN	O
after	IN	O
BTX-A	NNP	O
treatment	NN	O
.	.	O

The	DT	O
Interstitial	NNP	O
Cystitis	NNP	O
Symptom	NNP	O
Index	NNP	O
and	CC	O
Interstitial	NNP	O
Cystitis	NNP	O
Problem	NNP	O
Index	NNP	O
mean	NN	O
scores	NNS	O
improved	VBN	O
by	IN	O
71	CD	O
%	NN	O
and	CC	O
69	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Daytime	NNP	O
frequency	NN	O
,	,	O
nocturia	NN	O
,	,	O
and	CC	O
pain	NN	O
by	IN	O
visual	JJ	O
analog	NN	O
scale	NN	O
decreased	VBN	O
by	IN	O
44	CD	O
%	NN	O
,	,	O
45	CD	O
%	NN	O
,	,	O
and	CC	O
79	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
first	JJ	O
desire	NN	O
to	TO	O
void	VB	O
and	CC	O
maximal	VB	O
cystometric	JJ	O
capacity	NN	O
increased	VBN	O
by	IN	O
58	CD	O
%	NN	O
and	CC	O
57	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
BTX-A	NNP	O
has	VBZ	O
an	DT	O
antinociceptive	JJ	O
effect	NN	O
on	IN	O
bladder	NN	O
afferent	NN	O
pathways	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
IC	NNP	O
,	,	O
producing	VBG	O
both	DT	O
symptomatic	JJ	O
and	CC	O
functional	JJ	O
(	(	O
ie	JJ	O
,	,	O
urodynamic	JJ	O
)	)	O
improvements	NNS	O
.	.	O

Antipyrine	NNP	O
clearance	NN	O
and	CC	O
response	NN	O
to	TO	O
interferon	VB	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
active	JJ	Condition
hepatitis	NN	Condition
C.	NNP	Condition
To	TO	O
determine	VB	O
whether	IN	O
hepatic	JJ	O
metabolic	JJ	O
function	NN	O
affects	VBZ	O
the	DT	O
response	NN	O
to	TO	O
interferon	VB	O
treatment	NN	O
,	,	O
we	PRP	O
measured	VBD	O
antipyrine	JJ	O
clearance	NN	O
(	(	O
APC	NNP	O
)	)	O
in	IN	O
85	CD	SampleSize
patients	NNS	O
with	IN	O
chronic	JJ	Condition
active	JJ	Condition
hepatitis	NN	Condition
C	NNP	Condition
and	CC	O
compared	VBN	O
the	DT	O
results	NNS	O
with	IN	O
treatment	NN	O
outcome	NN	O
.	.	O

Among	IN	O
55	CD	SampleSize
patients	NNS	O
who	WP	O
responded	VBD	O
to	TO	O
interferon	VB	O
by	IN	O
normalization	NN	O
of	IN	O
alanine	JJ	O
transaminase	NN	O
(	(	O
ALT	NNP	O
)	)	O
,	,	O
median	JJ	O
APC	NNP	O
before	IN	O
treatment	NN	O
was	VBD	O
0.47	CD	O
(	(	O
range	NN	O
,	,	O
0.12	CD	O
to	TO	O
0.98	CD	O
;	:	O
normal	JJ	O
range	NN	O
,	,	O
0.34	CD	O
to	TO	O
1.02	CD	O
mL/min/kg	NNS	O
body	NN	O
wt	NN	O
)	)	O
,	,	O
a	DT	O
value	NN	O
that	WDT	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
in	IN	O
30	CD	O
nonresponders	NNS	O
(	(	O
0.23	CD	O
;	:	O
0.08	CD	O
to	TO	O
0.67	CD	O
mL/min/kg	NNS	O
body	NN	O
wt	NN	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

APC	NNP	O
was	VBD	O
closely	RB	O
associated	VBN	O
with	IN	O
response	NN	O
to	TO	O
interferon	VB	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
among	IN	O
cases	NNS	O
with	IN	O
values	NNS	O
>	VBP	O
0.25	CD	O
mL/min/kg	NN	O
body	NN	O
weight	NN	O
was	VBD	O
79	CD	O
%	NN	O
,	,	O
the	DT	O
same	JJ	O
as	IN	O
in	IN	O
cases	NNS	O
without	IN	O
cirrhosis	NN	O
.	.	O

Cases	NNS	O
without	IN	O
cirrhosis	NN	O
and	CC	O
with	IN	O
APC	NNP	O
of	IN	O
>	NNP	O
0.25	CD	O
mL/min/kg	NN	O
body	NN	O
weight	NN	O
had	VBD	O
an	DT	O
85	CD	O
%	NN	O
chance	NN	O
of	IN	O
responding	VBG	O
to	TO	O
interferon	VB	O
;	:	O
this	DT	O
was	VBD	O
unlikely	JJ	O
a	DT	O
simple	JJ	O
reflection	NN	O
of	IN	O
histological	JJ	O
activity	NN	O
,	,	O
because	IN	O
the	DT	O
correlation	NN	O
with	IN	O
Scheuer	NNP	O
score	NN	O
was	VBD	O
poor	JJ	O
in	IN	O
this	DT	O
subgroup	NN	O
(	(	O
r	JJ	O
=	NNP	O
-.31	NNP	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

A	DT	O
second	JJ	O
,	,	O
independent	JJ	O
group	NN	O
of	IN	O
43	CD	SampleSize
patients	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
test	VB	O
the	DT	O
predictive	JJ	O
value	NN	O
of	IN	O
APC	NNP	O
(	(	O
using	VBG	O
0.25	CD	O
mL/min/kg	NN	O
body	NN	O
wt	VBD	O
as	IN	O
a	DT	O
cut-off	NN	O
)	)	O
for	IN	O
response	NN	O
to	TO	O
interferon	VB	O
treatment	NN	O
.	.	O

In	IN	O
this	DT	O
group	NN	O
,	,	O
APC	NNP	O
correctly	RB	O
predicted	VBD	O
positive	JJ	O
response	NN	O
to	TO	O
interferon	VB	O
in	IN	O
75	CD	O
%	NN	O
of	IN	O
cases	NNS	O
.	.	O

APC	NNP	O
was	VBD	O
also	RB	O
used	VBN	O
to	TO	O
measure	VB	O
the	DT	O
effects	NNS	O
of	IN	O
treatment	NN	O
on	IN	O
hepatic	JJ	O
metabolic	JJ	O
function	NN	O
.	.	O

Regardless	NNP	O
of	IN	O
outcome	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
change	NN	O
in	IN	O
APC	NNP	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
a	DT	O
6-month	JJ	O
course	NN	O
of	IN	O
interferon	NN	O
treatment	NN	O
.	.	O

Six	CD	O
months	NNS	O
later	RB	O
,	,	O
however	RB	O
,	,	O
improvement	NN	O
in	IN	O
APC	NNP	O
(	(	O
14	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
was	VBD	O
evident	JJ	O
among	IN	O
responders	NNS	O
but	CC	O
not	RB	O
in	IN	O
those	DT	O
who	WP	O
had	VBD	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
interferon	VB	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Exploring	VBG	O
effects	NNS	O
of	IN	O
different	JJ	O
treadmill	NN	O
interventions	NNS	O
on	IN	O
walking	VBG	O
onset	NN	O
and	CC	O
gait	NN	O
patterns	NNS	O
in	IN	O
infants	NNS	Age
with	IN	O
Down	NNP	Condition
syndrome	NN	Condition
.	.	O

Two	CD	O
cohorts	NNS	O
of	IN	O
participants	NNS	O
were	VBD	O
included	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
different	JJ	O
treadmill	NN	O
interventions	NNS	O
on	IN	O
walking	VBG	O
onset	NN	O
and	CC	O
gait	NN	O
patterns	NNS	O
in	IN	O
infants	NNS	Age
with	IN	O
Down	NNP	Condition
syndrome	NN	Condition
(	(	O
DS	NNP	Condition
)	)	O
.	.	O

The	DT	O
first	JJ	O
cohort	NN	O
included	VBD	O
30	CD	SampleSize
infants	NNS	Age
with	IN	O
DS	NNP	Condition
(	(	O
17	CD	SampleSize
males	NNS	Sex
,	,	O
13	CD	SampleSize
females	NNS	Sex
;	:	O
mean	JJ	O
age	NN	O
10	CD	Age
mo	NN	Age
[	NNP	O
SD	NNP	O
1.9	CD	O
mo	NN	O
]	NN	O
)	)	O
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	VB	O
a	DT	O
lower-intensity-generalized	JJ	O
(	(	O
LG	NNP	O
)	)	O
training	VBG	O
group	NN	O
,	,	O
or	CC	O
a	DT	O
higher-intensity-individualized	JJ	O
(	(	O
HI	NNP	O
)	)	O
training	VBG	O
group	NN	O
.	.	O

A	DT	O
control	NN	Condition
(	(	Condition
C	NNP	Condition
)	)	Condition
group	NN	Condition
from	IN	O
another	DT	O
study	NN	O
,	,	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
treadmill	NN	O
training	NN	O
,	,	O
served	VBD	O
as	IN	O
the	DT	O
control	NN	O
(	(	O
eight	CD	SampleSize
males	NNS	Sex
,	,	O
seven	CD	SampleSize
females	NNS	Sex
;	:	O
mean	JJ	O
age	NN	O
10.4	CD	Age
mo	NN	Age
[	NNP	O
SD	NNP	O
2.2	CD	O
mo	NN	O
]	NN	O
)	)	O
.	.	O

Mean	JJ	O
age	NN	O
at	IN	O
walking	VBG	O
onset	NN	O
was	VBD	O
19.2	CD	O
,	,	O
21.4	CD	O
,	,	O
and	CC	O
23.9	CD	O
months	NNS	O
for	IN	O
the	DT	O
HI	NNP	O
,	,	O
LG	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
respectively	RB	O
.	.	O

At	IN	O
walking	VBG	O
onset	RP	O
the	DT	O
HI	NNP	O
group	NN	O
was	VBD	O
significantly	RB	O
younger	JJR	O
than	IN	O
the	DT	O
C	NNP	O
group	NN	O
(	(	O
p=0.011	NN	O
)	)	O
.	.	O

At	IN	O
the	DT	O
gait	NN	O
follow-up	NN	O
that	WDT	O
was	VBD	O
conducted	VBN	O
between	IN	O
1	CD	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
walking	VBG	O
onset	NN	O
,	,	O
three	CD	O
groups	NNS	O
significantly	RB	O
different	JJ	O
in	IN	O
overall	JJ	O
gait	NN	O
patterns	NNS	O
(	(	O
p=0.037	NN	O
)	)	O
were	VBD	O
examined	VBN	O
by	IN	O
six	CD	O
basic	JJ	O
gait	NN	O
parameters	NNS	O
including	VBG	O
average	JJ	O
velocity	NN	O
,	,	O
stride	JJ	O
length	NN	O
,	,	O
step	NN	O
width	NN	O
,	,	O
stride	JJ	O
time	NN	O
,	,	O
stance	NN	O
time	NN	O
,	,	O
and	CC	O
dynamic	JJ	O
base	NN	O
.	.	O

Post-hoc	JJ	O
analyses	NNS	O
demonstrated	VBD	O
that	IN	O
stride	JJ	O
length	NN	O
was	VBD	O
the	DT	O
gait	NN	O
parameter	NN	O
largely	RB	O
contributing	VBG	O
to	TO	O
this	DT	O
overall	JJ	O
group	NN	O
difference	NN	O
(	(	O
p=0.033	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
HI	NNP	O
group	NN	O
produced	VBD	O
a	DT	O
significantly	RB	O
longer	RBR	O
stride	JJ	O
length	NN	O
than	IN	O
the	DT	O
C	NNP	O
group	NN	O
(	(	O
p=0.030	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
HI	NNP	O
treadmill	NN	O
intervention	NN	O
significantly	RB	O
promoted	VBN	O
earlier	RBR	O
walking	JJ	O
onset	NN	O
and	CC	O
elicited	VBD	O
more	RBR	O
advanced	JJ	O
gait	NN	O
patterns	NNS	O
(	(	O
particularly	RB	O
in	IN	O
stride	JJ	O
length	NN	O
)	)	O
in	IN	O
infants	NNS	Age
with	IN	O
DS	NNP	Condition
.	.	O

Control	NN	O
of	IN	O
perioperative	JJ	O
hypertension	NN	O
during	IN	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

A	DT	O
randomised	JJ	O
double-blind	NN	O
study	NN	O
comparing	VBG	O
isosorbide	JJ	O
dinitrate	NN	O
and	CC	O
nitroglycerin	NN	O
.	.	O

A	DT	O
reduction	NN	O
in	IN	O
the	DT	O
causes	NNS	O
of	IN	O
myocardial	JJ	O
ischaemia	NN	O
remains	VBZ	O
of	IN	O
prime	JJ	O
importance	NN	O
during	IN	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

Hypertension	NN	O
with	IN	O
the	DT	O
ensuing	VBG	O
increase	NN	O
in	IN	O
myocardial	JJ	O
oxygen	NN	O
demand	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
factor	NN	O
in	IN	O
the	DT	O
aetiology	NN	O
of	IN	O
perioperative	JJ	O
myocardial	JJ	O
ischaemia	NN	O
.	.	O

Nitroglycerin	NNP	O
(	(	O
NTG	NNP	O
)	)	O
has	VBZ	O
long	RB	O
been	VBN	O
used	VBN	O
beneficially	RB	O
to	TO	O
reduce	VB	O
myocardial	JJ	O
oxygen	NN	O
demand	NN	O
by	IN	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
systemic	JJ	O
and	CC	O
peripheral	JJ	O
vascular	JJ	O
resistances	NNS	O
.	.	O

An	DT	O
alternative	JJ	O
nitrate	NN	O
,	,	O
isosorbide	JJ	O
dinitrate	NN	O
(	(	O
ISDN	NNP	O
)	)	O
is	VBZ	O
now	RB	O
available	JJ	O
as	IN	O
an	DT	O
intravenous	JJ	O
preparation	NN	O
,	,	O
and	CC	O
may	MD	O
offer	VB	O
technical	JJ	O
advantages	NNS	O
,	,	O
both	DT	O
due	JJ	O
to	TO	O
its	PRP$	O
stability	NN	O
in	IN	O
solution	NN	O
and	CC	O
also	RB	O
its	PRP$	O
longer	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
.	.	O

We	PRP	O
designed	VBD	O
and	CC	O
carried	VBD	O
out	RP	O
a	DT	O
multi-centre	JJ	O
study	NN	O
to	TO	O
compare	VB	O
and	CC	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
ISDN	NNP	O
and	CC	O
NTG	NNP	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
perioperative	JJ	O
hypertension	NN	O
in	IN	O
85	CD	O
patients	NNS	O
undergoing	JJ	O
elective	JJ	O
coronary	JJ	O
artery	NN	O
surgery	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
288	CD	O
events	NNS	O
in	IN	O
which	WDT	O
the	DT	O
systolic	NN	O
blood	NN	O
pressure	NN	O
(	(	O
SBP	NNP	O
)	)	O
exceeded	VBD	O
a	DT	O
predetermined	JJ	O
trigger	NN	O
value	NN	O
were	VBD	O
observed	VBN	O
.	.	O

ISDN	NNP	O
was	VBD	O
successful	JJ	O
in	IN	O
treating	VBG	O
hypertension	NN	O
in	IN	O
63	CD	O
%	NN	O
of	IN	O
the	DT	O
events	NNS	O
,	,	O
whereas	NNS	O
NTG	NNP	O
had	VBD	O
an	DT	O
83	CD	O
%	NN	O
success	NN	O
.	.	O

The	DT	O
SBP	NNP	O
was	VBD	O
significantly	RB	O
lowered	VBN	O
after	IN	O
treatment	NN	O
with	IN	O
either	DT	O
ISDN	NNP	O
,	,	O
155	CD	O
mmHg	NN	O
to	TO	O
138	CD	O
mmHg	NN	O
,	,	O
or	CC	O
NTG	NNP	O
,	,	O
160	CD	O
mmHg	NN	O
to	TO	O
130	CD	O
mmHg	NN	O
.	.	O

The	DT	O
mean	JJ	O
successful	JJ	O
dose	NN	O
rate	NN	O
for	IN	O
ISDN	NNP	O
was	VBD	O
6.5	CD	O
micrograms	JJ	O
kg-1	JJ	O
min-1	NN	O
,	,	O
whereas	NNS	O
for	IN	O
NTG	NNP	O
this	DT	O
was	VBD	O
3.8	CD	O
micrograms	JJ	O
kg-1	JJ	O
min-1	NN	O
.	.	O

In	IN	O
the	DT	O
ISDN	NNP	O
group	NN	O
less	JJR	O
events	NNS	O
took	VBD	O
place	NN	O
possibly	RB	O
due	JJ	O
to	TO	O
the	DT	O
longer	JJR	O
duration	NN	O
of	IN	O
this	DT	O
drug	NN	O
.	.	O

In	IN	O
many	JJ	O
previous	JJ	O
studies	NNS	O
NTG	NNP	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
controlling	VBG	O
hypertension	NN	O
;	:	O
ISDN	NNP	O
offers	NNS	O
and	CC	O
alternative	JJ	O
approach	NN	O
in	IN	O
reducing	VBG	O
hypertension	NN	O
.	.	O

Effect	NN	O
of	IN	O
betamethasone	NN	O
valerate	NN	O
on	IN	O
the	DT	O
normal	JJ	Condition
human	JJ	Condition
facial	JJ	Condition
skin	NN	Condition
flora	NN	Condition
.	.	O

Eighteen	JJ	SampleSize
volunteers	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
and	CC	O
allocated	VBD	O
either	DT	O
an	DT	O
active	JJ	O
corticosteroid	NN	O
preparation	NN	O
(	(	O
Betamethasone	NNP	O
valerate	NN	O
)	)	O
or	CC	O
the	DT	O
basal	NN	O
formulation	NN	O
only	RB	O
(	(	O
placebo	NN	O
)	)	O
.	.	O

The	DT	O
cream	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
face	NN	O
twice	RB	O
daily	RB	O
for	IN	O
one	CD	O
month	NN	O
.	.	O

The	DT	O
treated	JJ	O
area	NN	O
was	VBD	O
sampled	VBN	O
by	IN	O
the	DT	O
scrub-wash	JJ	O
method	NN	O
immediately	RB	O
before	IN	O
treatment	NN	O
began	VBD	O
and	CC	O
after	IN	O
2	CD	O
and	CC	O
4	CD	O
weeks	NNS	O
,	,	O
and	CC	O
microorganisms	NNS	O
were	VBD	O
enumerated	VBN	O
and	CC	O
identified	VBN	O
.	.	O

Application	NN	O
of	IN	O
either	DT	O
cream	NN	O
produced	VBD	O
a	DT	O
very	RB	O
slight	JJ	O
increase	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.5	CD	O
log	NN	O
cycle	NN	O
)	)	O
in	IN	O
the	DT	O
skin	NN	O
flora	NN	O
during	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
changes	NNS	O
occurring	VBG	O
between	IN	O
volunteers	NNS	O
treated	VBN	O
with	IN	O
placebo	NN	O
and	CC	O
those	DT	O
on	IN	O
the	DT	O
steroid	JJ	O
formulation	NN	O
.	.	O

The	DT	O
results	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
relation	NN	O
to	TO	O
theories	NNS	O
of	IN	O
pathogenesis	NN	O
of	IN	O
perioral	JJ	O
dermatitis	NN	O
and	CC	O
steroid	JJ	O
acne	NN	O
.	.	O

[	JJ	O
Prevention	NNP	O
of	IN	O
migraine	NN	Condition
with	IN	O
flunarizine	NN	O
and	CC	O
acetylsalicylic	JJ	O
acid	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
study	NN	O
]	NNP	O
.	.	O

UNLABELLED	CC	O
30	CD	SampleSize
children	NNS	Age
between	IN	Age
7	CD	Age
and	CC	Age
17	CD	Age
years	NNS	O
suffering	VBG	O
from	IN	O
at	IN	O
least	JJS	O
2	CD	O
attacks/month	NN	O
of	IN	O
common	JJ	Condition
or	CC	Condition
classical	JJ	Condition
migraine	NN	Condition
since	IN	O
more	JJR	O
than	IN	O
1	CD	O
year	NN	O
were	VBD	O
studied	VBN	O
.	.	O

After	IN	O
clinical	JJ	O
exclusion	NN	O
of	IN	O
symptomatic	JJ	O
headache	NN	O
4	CD	O
weeks	NNS	O
were	VBD	O
documented	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
migraine	NN	O
diary	NN	O
.	.	O

Prophylaxis	NNP	O
with	IN	O
Calcium	NNP	O
entry	NN	O
blocker	NN	O
Flunarizine	NNP	O
(	(	O
Sibelium	NNP	O
)	)	O
or	CC	O
Thromboxane	VB	O
A	DT	O
inhibitor	NN	O
Acetylsalicylic	NNP	O
acid	NN	O
(	(	O
ASS	NNP	O
)	)	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
design	NN	O
for	IN	O
3	CD	O
months	NNS	O
.	.	O

Medication	NNP	O
was	VBD	O
given	VBN	O
as	IN	O
one	CD	O
dosage	NN	O
in	IN	O
the	DT	O
evening	NN	O
:	:	O
2-5	JJ	O
mg/kg	NN	O
KG	NNP	O
ASS	NNP	O
or	CC	O
5-10	JJ	O
mg	NN	O
Flunarizine	NNP	O
.	.	O

Documented	NNP	O
attack	NN	O
frequency	NN	O
and	CC	O
duration	NN	O
were	VBD	O
controlled	VBN	O
at	IN	O
monthly	JJ	O
physical	JJ	O
examinations	NNS	O
.	.	O

Final	JJ	O
results	NNS	O
showed	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
significant	JJ	O
reduction	NN	O
of	IN	O
attack	NN	O
frequency	NN	O
or	CC	O
symptoms	NNS	O
between	IN	O
both	DT	O
different	JJ	O
therapeutic	JJ	O
principals	NNS	O
.	.	O

72.4	CD	O
%	NN	O
(	(	O
ASS	NNP	O
73.3	CD	O
%	NN	O
;	:	O
Flunarizine	NNP	O
71.4	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
were	VBD	O
attack-free	JJ	O
or	CC	O
had	VBD	O
at	IN	O
least	JJS	O
a	DT	O
50	CD	O
%	NN	O
reduction	NN	O
.	.	O

Migraine	NNP	O
frequency	NN	O
of	IN	O
initially	RB	O
7-8	NNP	O
was	VBD	O
reduced	VBN	O
to	TO	O
1-2	JJ	O
attacks/month	NN	O
.	.	O

Duration	NN	O
remained	VBD	O
constant	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
1-3	JJ	O
h	NN	O
)	)	O
.	.	O

Side	JJ	O
effects	NNS	O
were	VBD	O
slight	JJ	O
body	NN	O
weight	VBD	O
gain	NN	O
or	CC	O
abdominal	JJ	O
pain	NN	O
after	IN	O
intake	NN	O
,	,	O
prophylaxis	NN	O
had	VBD	O
not	RB	O
to	TO	O
be	VB	O
interrupted	VBN	O
therefore	RB	O
.	.	O

Longtime	JJ	O
prognosis	NN	O
is	VBZ	O
not	RB	O
yet	RB	O
possible	JJ	O
because	IN	O
the	DT	O
time	NN	O
of	IN	O
observation	NN	O
is	VBZ	O
too	RB	O
short	JJ	O
so	RB	O
far	RB	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
substances	NNS	O
are	VBP	O
definitely	RB	O
useful	JJ	O
and	CC	O
have	VBP	O
few	JJ	O
side	NN	O
effects	NNS	O
in	IN	O
childhood	NN	Condition
migraine	NN	Condition
.	.	Condition

If	IN	O
the	DT	O
response	NN	O
to	TO	O
one	CD	O
is	VBZ	O
insufficient	JJ	O
the	DT	O
other	JJ	O
substance	NN	O
should	MD	O
be	VB	O
tried	VBN	O
.	.	O

Peritoneovenous	JJ	O
shunting	VBG	O
as	IN	O
compared	VBN	O
with	IN	O
medical	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
cirrhosis	NN	O
and	CC	O
massive	JJ	O
ascites	NNS	O
.	.	O

Veterans	NNPS	O
Administration	NNP	O
Cooperative	NNP	O
Study	NNP	O
on	IN	O
Treatment	NNP	O
of	IN	O
Alcoholic	NNP	O
Cirrhosis	NNP	O
with	IN	O
Ascites	NNP	O
.	.	O

The	DT	O
optimal	JJ	O
management	NN	O
of	IN	O
severe	JJ	O
ascites	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
cirrhosis	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
defined	VBN	O
.	.	O

in	IN	O
a	DT	O
5	CD	O
1/2-year	JJ	O
study	NN	O
,	,	O
we	PRP	O
randomly	VBP	O
assigned	VBN	O
299	CD	O
men	NNS	O
with	IN	O
alcoholic	JJ	O
cirrhosis	NN	O
,	,	O
who	WP	O
had	VBD	O
persistent	NN	O
or	CC	O
recurrent	NN	O
severe	JJ	O
ascites	VBZ	O
despite	IN	O
a	DT	O
standard	JJ	O
medical	JJ	O
regimen	NNS	O
,	,	O
to	TO	O
receive	VB	O
either	RB	O
intensive	JJ	O
medical	JJ	O
treatment	NN	O
or	CC	O
peritoneovenous	JJ	O
(	(	O
LeVeen	NNP	O
)	)	O
shunting	VBG	O
.	.	O

We	PRP	O
identified	VBD	O
three	CD	O
risk	NN	O
groups	NNS	O
:	:	O
Group	NNP	O
1	CD	O
had	VBD	O
normal	JJ	O
or	CC	O
mildly	RB	O
abnormal	JJ	O
results	NNS	O
on	IN	O
liver-function	NN	O
tests	NNS	O
,	,	O
Group	NNP	O
2	CD	O
had	VBD	O
more	RBR	O
severe	JJ	O
liver	NN	O
dysfunction	NN	O
or	CC	O
previous	JJ	O
complications	NNS	O
,	,	O
and	CC	O
Group	NNP	O
3	CD	O
had	VBD	O
severe	JJ	O
prerenal	JJ	O
azotemia	NN	O
without	IN	O
kidney	NN	O
disease	NN	O
.	.	O

For	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
the	DT	O
medical	JJ	O
treatment	NN	O
and	CC	O
those	DT	O
who	WP	O
received	VBD	O
the	DT	O
surgical	JJ	O
treatment	NN	O
combined	VBN	O
,	,	O
the	DT	O
median	JJ	O
survival	NN	O
times	NNS	O
were	VBD	O
1093	CD	O
days	NNS	O
in	IN	O
Group	NNP	O
1	CD	O
,	,	O
222	CD	O
days	NNS	O
in	IN	O
Group	NNP	O
2	CD	O
,	,	O
and	CC	O
37	CD	O
days	NNS	O
in	IN	O
Group	NNP	O
3	CD	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.01	CD	O
)	)	O
for	IN	O
all	DT	O
comparisons	NNS	O
)	)	O
.	.	O

For	IN	O
all	PDT	O
the	DT	O
groups	NNS	O
combined	VBN	O
,	,	O
the	DT	O
median	JJ	O
time	NN	O
to	TO	O
the	DT	O
resolution	NN	O
of	IN	O
ascites	NNS	O
was	VBD	O
5.4	CD	O
weeks	NNS	O
for	IN	O
medical	JJ	O
patients	NNS	O
and	CC	O
3.0	CD	O
weeks	NNS	O
for	IN	O
surgical	JJ	O
patients	NNS	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Within	IN	O
each	DT	O
risk	NN	O
group	NN	O
,	,	O
mortality	NN	O
during	IN	O
the	DT	O
initial	JJ	O
hospitalization	NN	O
and	CC	O
median	JJ	O
long-term	JJ	O
survival	NN	O
were	VBD	O
similar	JJ	O
among	IN	O
patients	NNS	O
receiving	VBG	O
either	DT	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
median	JJ	O
time	NN	O
to	TO	O
the	DT	O
recurrence	NN	O
of	IN	O
ascites	NNS	O
in	IN	O
Group	NNP	O
1	CD	O
was	VBD	O
4	CD	O
months	NNS	O
in	IN	O
medical	JJ	O
patients	NNS	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
18	CD	O
months	NNS	O
in	IN	O
surgical	JJ	O
patients	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
;	:	O
in	IN	O
Group	NNP	O
2	CD	O
it	PRP	O
was	VBD	O
3	CD	O
months	NNS	O
in	IN	O
medical	JJ	O
patients	NNS	O
as	IN	O
compared	VBN	O
with	IN	O
12	CD	O
months	NNS	O
in	IN	O
surgical	JJ	O
patients	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
hospitalization	NN	O
was	VBD	O
longer	RBR	O
in	IN	O
medical	JJ	O
patients	NNS	O
than	IN	O
in	IN	O
surgical	JJ	O
patients	NNS	O
(	(	O
6.1	CD	O
vs.	RB	O
2.4	CD	O
weeks	NNS	O
in	IN	O
Group	NNP	O
1	CD	O
[	NNP	O
P	NNP	O
less	JJR	O
than	IN	O
0.001	CD	O
]	NNS	O
and	CC	O
5.0	CD	O
vs.	FW	O
3.1	CD	O
weeks	NNS	O
in	IN	O
Group	NNP	O
2	CD	O
[	NNP	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
]	NN	O
)	)	O
.	.	O

Group	NNP	O
3	CD	O
was	VBD	O
too	RB	O
small	JJ	O
to	TO	O
permit	VB	O
a	DT	O
meaningful	JJ	O
comparison	NN	O
.	.	O

During	IN	O
the	DT	O
initial	JJ	O
hospitalization	NN	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
infections	NNS	O
,	,	O
gastrointestinal	JJ	O
bleeding	NN	O
,	,	O
and	CC	O
encephalopathy	NN	O
was	VBD	O
similar	JJ	O
among	IN	O
the	DT	O
medical	JJ	O
and	CC	O
surgical	JJ	O
patients	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
peritoneovenous	JJ	O
shunting	NN	O
alleviated	VBD	O
disabling	VBG	O
ascites	NNS	O
more	RBR	O
rapidly	RB	O
than	IN	O
medical	JJ	O
management	NN	O
.	.	O

However	RB	O
,	,	O
survival	NN	O
was	VBD	O
closely	RB	O
related	VBN	O
to	TO	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
illness	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
randomization	NN	O
and	CC	O
was	VBD	O
not	RB	O
altered	VBN	O
by	IN	O
shunting	VBG	O
.	.	O

Isoniazid	NNP	O
prophylaxis	NN	O
for	IN	O
tuberculosis	NN	O
in	IN	O
HIV	NNP	O
infection	NN	O
:	:	O
a	DT	O
meta-analysis	NN	O
of	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
isoniazid	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
tuberculosis	NN	O
in	IN	O
tuberculin	JJ	O
skin	JJ	O
test-positive	JJ	O
and	CC	O
negative	JJ	O
individuals	NNS	O
with	IN	O
HIV	NNP	O
infection	NN	O
.	.	O

DESIGN	NNP	O
Meta-analysis	NN	O
of	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
.	.	O

SETTING	NNP	O
Seven	NNP	O
trials	NNS	O
from	IN	O
Mexico	NNP	O
,	,	O
Haiti	NNP	O
,	,	O
the	DT	O
United	NNP	O
States	NNPS	O
,	,	O
Zambia	NNP	O
,	,	O
Uganda	NNP	O
and	CC	O
Kenya	NNP	O
.	.	O

PATIENTS	NNP	O
Individuals	NNP	O
free	JJ	O
from	IN	O
tuberculosis	NN	O
,	,	O
2367	CD	O
persons	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
and	CC	O
2162	CD	O
in	IN	O
the	DT	O
control	NN	O
groups	NNS	O
.	.	O

INTERVENTION	NNP	O
Comparison	NNP	O
of	IN	O
isoniazid	NN	O
with	IN	O
placebo	NN	O
or	CC	O
no	DT	O
prophylaxis	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
systematic	JJ	O
search	NN	O
of	IN	O
the	DT	O
literature	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
from	IN	O
1985	CD	O
to	TO	O
October	NNP	O
1997	CD	O
for	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
of	IN	O
isoniazid	JJ	O
prophylaxis	NN	O
in	IN	O
HIV-infected	JJ	O
persons	NNS	O
.	.	O

Two	CD	O
reviewers	NNS	O
evaluated	VBD	O
the	DT	O
relevance	NN	O
of	IN	O
each	DT	O
candidate	NN	O
study	NN	O
and	CC	O
the	DT	O
validity	NN	O
of	IN	O
eligible	JJ	O
trials	NNS	O
.	.	O

Studies	NNS	O
were	VBD	O
pooled	VBN	O
using	VBG	O
a	DT	O
random	JJ	O
effect	NN	O
model	NN	O
,	,	O
conducting	VBG	O
secondary	JJ	O
analyses	NNS	O
for	IN	O
tuberculin	JJ	O
skin	JJ	O
test-positive	JJ	O
and	CC	O
negative	JJ	O
persons	NNS	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
follow-up	NN	O
in	IN	O
trials	NNS	O
varied	VBD	O
between	IN	O
0.4	CD	O
and	CC	O
3.2	CD	O
years	NNS	O
.	.	O

Pooling	VBG	O
all	DT	O
seven	CD	O
trials	NNS	O
,	,	O
a	DT	O
risk	NN	O
ratio	NN	O
was	VBD	O
found	VBN	O
for	IN	O
persons	NNS	O
treated	VBN	O
with	IN	O
isoniazid	NN	O
for	IN	O
developing	VBG	O
tuberculosis	NN	O
of	IN	O
0.58	CD	O
[	JJ	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
,	,	O
0.43-0.80	JJ	O
]	NN	O
and	CC	O
0.94	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.83-1.07	NNP	O
)	)	O
for	IN	O
death	NN	O
.	.	O

In	IN	O
groups	NNS	O
of	IN	O
tuberculin	JJ	O
skin	JJ	O
test-positive	JJ	O
and	CC	O
negative	JJ	O
persons	NNS	O
,	,	O
the	DT	O
risk	NN	O
ratio	NN	O
of	IN	O
tuberculosis	NN	O
was	VBD	O
0.40	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.24-0.65	NNP	O
)	)	O
and	CC	O
0.84	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.54-1.30	NNP	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
difference	NN	O
in	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
isoniazid	JJ	O
versus	NN	O
placebo	NN	O
between	IN	O
these	DT	O
groups	NNS	O
was	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
,	,	O
for	IN	O
the	DT	O
difference	NN	O
of	IN	O
summary	JJ	O
estimates	NNS	O
)	)	O
.	.	O

Consistency	NN	O
of	IN	O
results	NNS	O
was	VBD	O
found	VBN	O
across	IN	O
trials	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.10	CD	O
,	,	O
heterogeneity	NN	O
value	NN	O
)	)	O
for	IN	O
all	DT	O
comparisons	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Prophylaxis	NNP	O
with	IN	O
isoniazid	JJ	O
reduces	NNS	O
the	DT	O
risk	NN	O
of	IN	O
tuberculosis	NN	O
in	IN	O
persons	NNS	O
with	IN	O
HIV	NNP	O
infection	NN	O
.	.	O

The	DT	O
effect	NN	O
is	VBZ	O
restricted	VBN	O
to	TO	O
tuberculin	VB	O
skin	JJ	O
test-positive	JJ	O
persons	NNS	O
.	.	O

Liposome-entrapped	JJ	O
D.	NNP	O
pteronyssinus	NN	O
vaccination	NN	O
in	IN	O
mild	JJ	O
asthma	JJ	O
patients	NNS	O
:	:	O
effect	NN	O
of	IN	O
1-year	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
on	IN	O
inflammation	NN	O
,	,	O
bronchial	JJ	O
hyperresponsiveness	NN	O
and	CC	O
immediate	JJ	O
and	CC	O
late	JJ	O
bronchial	NN	O
responses	NNS	O
to	TO	O
the	DT	O
allergen	NN	O
.	.	O

BACKGROUND	NNP	O
Allergen	NNP	O
vaccination	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
mite-allergic	JJ	O
asthma	NN	O
.	.	O

Liposomes	NNS	O
are	VBP	O
immunological	JJ	O
adjuvants	NNS	O
that	WDT	O
can	MD	O
act	VB	O
as	IN	O
allergen	NN	O
carriers	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
immunological	JJ	O
and	CC	O
functional	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
liposome-entrapped	JJ	O
D.	NNP	O
pteronyssinus	NN	O
vaccine	NN	O
on	IN	O
mite	JJ	O
monosensitive	NN	O
,	,	O
mild	JJ	O
asthma	NN	O
patients	NNS	O
.	.	O

METHODS	VB	O
A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
26	CD	O
asthma	JJ	O
patients	NNS	O
who	WP	O
randomly	VBP	O
received	VBN	O
vaccination	NN	O
or	CC	O
placebo	NN	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
exposure	NN	O
to	TO	O
Der	NNP	O
p	NN	O
1	CD	O
allergen	NN	O
were	VBD	O
constant	JJ	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

Allergen	NNP	O
bronchial	JJ	O
challenge	NN	O
was	VBD	O
made	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
(	(	O
T0	NNP	O
)	)	O
and	CC	O
after	IN	O
1	CD	O
year	NN	O
of	IN	O
treatment	NN	O
(	(	O
T12	NNP	O
)	)	O
.	.	O

The	DT	O
day	NN	O
before	IN	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
the	DT	O
allergen	NN	O
provocation	NN	O
,	,	O
patients	NNS	O
were	VBD	O
challenged	VBN	O
with	IN	O
methacholine	NN	O
(	(	O
Mth	NNP	O
)	)	O
(	(	O
until	IN	O
FEV1	NNP	O
fell	VBD	O
by	IN	O
40	CD	O
%	NN	O
)	)	O
and	CC	O
blood	NN	O
and	CC	O
sputum	NN	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
.	.	O

Dose-response	JJ	O
curves	NNS	O
to	TO	O
Mth	NNP	O
were	VBD	O
evaluated	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
Mth-PD20	NNP	O
(	(	O
dose	NN	O
of	IN	O
Mth	NNP	O
that	WDT	O
induced	VBD	O
20	CD	O
%	NN	O
drop	NN	O
in	IN	O
FEV1	NNP	O
)	)	O
,	,	O
slope	NN	O
(	(	O
Mth-DRS	NNP	O
)	)	O
and	CC	O
level	NN	O
of	IN	O
plateau	NN	O
.	.	O

Blood	NNP	O
and	CC	O
sputum	NN	O
eosinophils	NNS	O
and	CC	O
serum	NN	O
levels	NNS	O
of	IN	O
eosinophil	NN	O
cationic	JJ	O
protein	NN	O
(	(	O
ECP	NNP	O
)	)	O
and	CC	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
(	(	O
ICAM-1	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
Groups	NNP	O
were	VBD	O
comparable	JJ	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

At	IN	O
TI2	NNP	O
,	,	O
previous	JJ	O
to	TO	O
the	DT	O
allergen	NN	O
challenge	NN	O
,	,	O
the	DT	O
active	JJ	O
group	NN	O
showed	VBD	O
higher	JJR	O
values	NNS	O
of	IN	O
both	DT	O
FEV1	NNP	O
and	CC	O
Mth-PD20	NNP	O
and	CC	O
lower	JJR	O
values	NNS	O
of	IN	O
Mth-DRS	NNP	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
presenting	VBG	O
a	DT	O
level	NN	O
of	IN	O
plateau	NN	O
increased	VBN	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
(	(	O
from	IN	O
two	CD	O
to	TO	O
four	CD	O
)	)	O
and	CC	O
decreased	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
from	IN	O
two	CD	O
to	TO	O
one	CD	O
)	)	O
.	.	O

At	IN	O
T12	NNP	O
,	,	O
before	IN	O
the	DT	O
allergen	NN	O
challenge	NN	O
,	,	O
serum	NN	O
ECP	NNP	O
levels	NNS	O
increased	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
blood	NN	O
eosinophils	NNS	O
showed	VBD	O
a	DT	O
trend	NN	O
towards	NNS	O
lower	JJR	O
numbers	NNS	O
in	IN	O
the	DT	O
active	JJ	O
one	NN	O
.	.	O

The	DT	O
immediate	JJ	O
response	NN	O
and	CC	O
the	DT	O
changes	NNS	O
in	IN	O
Mth-DRS	NNP	O
values	NNS	O
,	,	O
sputum	NN	O
eosinophils	NNS	O
and	CC	O
serum	VB	O
ECP	NNP	O
levels	NNS	O
following	VBG	O
the	DT	O
allergen	NN	O
challenge	NN	O
were	VBD	O
attenuated	VBN	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Liposome-entrapped	NNP	O
D.	NNP	O
Pteronyssinus	NNP	O
vaccination	NN	O
:	:	O
(	(	O
i	NN	O
)	)	O
protects	VBZ	O
mild	JJ	O
asthma	JJ	O
patients	NNS	O
from	IN	O
the	DT	O
worsening	NN	O
of	IN	O
asthma	NNS	O
due	JJ	O
to	TO	O
sustained	VBN	O
mite	JJ	O
exposure	NN	O
;	:	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
reduces	VBZ	O
the	DT	O
functional	JJ	O
and	CC	O
inflammatory	JJ	O
changes	NNS	O
induced	VBN	O
by	IN	O
allergen	NN	O
bronchial	JJ	O
provocation	NN	O
.	.	O

Peripheral	JJ	O
arterial	JJ	O
disease	NN	O
:	:	O
therapeutic	JJ	O
confidence	NN	O
of	IN	O
CT	NNP	O
versus	NNP	O
digital	JJ	O
subtraction	NN	O
angiography	NN	O
and	CC	O
effects	NNS	O
on	IN	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
multi-detector	JJ	O
row	NN	O
computed	VBN	O
tomographic	JJ	O
(	(	O
CT	NNP	O
)	)	O
angiography	NN	O
and	CC	O
digital	JJ	O
subtraction	NN	O
angiography	NN	O
(	(	O
DSA	NNP	O
)	)	O
prior	RB	O
to	TO	O
revascularization	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
assessing	VBG	O
recommendations	NNS	O
for	IN	O
additional	JJ	O
imaging	NN	O
and	CC	O
physician	JJ	O
confidence	NN	O
ratings	NNS	O
for	IN	O
chosen	NN	O
therapy	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
73	CD	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
CT	NNP	O
angiography	NN	O
,	,	O
and	CC	O
72	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
DSA	NNP	O
.	.	O

Physician	JJ	O
confidence	NN	O
in	IN	O
the	DT	O
treatment	NN	O
decision	NN	O
was	VBD	O
measured	VBN	O
as	IN	O
a	DT	O
continuous	JJ	O
outcome	NN	O
on	IN	O
a	DT	O
scale	NN	O
of	IN	O
0-10	NNP	O
(	(	O
uncertain	JJ	O
to	TO	O
certain	JJ	O
)	)	O
and	CC	O
as	IN	O
a	DT	O
dichotomous	JJ	O
outcome	NN	O
(	(	O
further	JJ	O
imaging	NN	O
recommended	VBD	O
,	,	O
yes	UH	O
or	CC	O
no	DT	O
)	)	O
.	.	O

Mean	JJ	O
confidence	NN	O
scores	NNS	O
and	CC	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
were	VBD	O
compared	VBN	O
between	IN	O
CT	NNP	O
and	CC	O
DSA	NNP	O
groups	NNS	O
in	IN	O
an	DT	O
intention-to-diagnose-and-treat	JJ	O
analysis	NN	O
.	.	O

To	TO	O
detect	VB	O
trends	NNS	O
in	IN	O
confidence	NN	O
,	,	O
confidence	NN	O
scores	NNS	O
were	VBD	O
plotted	VBN	O
over	IN	O
time	NN	O
,	,	O
and	CC	O
multiple	JJ	O
linear	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
performed	VBN	O
.	.	O

To	TO	O
detect	VB	O
trends	NNS	O
in	IN	O
additional	JJ	O
imaging	NN	O
recommendations	NNS	O
,	,	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
was	VBD	O
used	VBN	O
.	.	O

Data	NNS	O
from	IN	O
eligible	JJ	O
nonrandomized	JJ	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
separately	RB	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
between	IN	O
randomized	VBN	O
groups	NNS	O
was	VBD	O
found	VBN	O
.	.	O

CT	NNP	O
had	VBD	O
a	DT	O
lower	JJR	O
confidence	NN	O
score	JJR	O
than	IN	O
did	VBD	O
DSA	NNP	O
(	(	O
7.2	CD	O
vs	NN	O
8.2	CD	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Further	JJ	O
imaging	NN	O
was	VBD	O
recommended	VBN	O
more	RBR	O
often	RB	O
after	IN	O
CT	NNP	O
(	(	O
25	CD	O
of	IN	O
71	CD	O
patients	NNS	O
,	,	O
35	CD	O
%	NN	O
)	)	O
than	IN	O
after	IN	O
DSA	NNP	O
(	(	O
nine	CD	O
of	IN	O
66	CD	O
patients	NNS	O
,	,	O
14	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
.	.	O

Analysis	NN	O
of	IN	O
trends	NNS	O
demonstrated	VBN	O
increasing	VBG	O
(	(	O
but	CC	O
not	RB	O
statistically	RB	O
significant	JJ	O
)	)	O
confidence	NN	O
in	IN	O
CT	NNP	O
and	CC	O
stable	JJ	O
confidence	NN	O
in	IN	O
DSA	NNP	O
.	.	O

No	NNP	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
between	IN	O
randomized	VBN	O
and	CC	O
nonrandomized	JJ	O
patients	NNS	O
.	.	O

Among	IN	O
nonrandomized	JJ	O
patients	NNS	O
,	,	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
mean	JJ	O
confidence	NN	O
score	NN	O
(	(	O
8.2	CD	O
vs	NN	O
8.3	CD	O
,	,	O
P	NNP	O
=	NNP	O
.26	NNP	O
)	)	O
was	VBD	O
found	VBN	O
between	IN	O
CT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
and	CC	O
DSA	NNP	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
With	IN	O
CT	NNP	O
angiography	NN	O
,	,	O
physician	JJ	O
confidence	NN	O
decreases	NNS	O
with	IN	O
an	DT	O
associated	JJ	O
increase	NN	O
in	IN	O
additional	JJ	O
imaging	NN	O
prior	RB	O
to	TO	O
revascularization	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
.	.	O

Given	VBN	O
that	IN	O
CT	NNP	O
is	VBZ	O
less	RBR	O
invasive	JJ	O
than	IN	O
DSA	NNP	O
,	,	O
results	NNS	O
suggest	VBP	O
that	IN	O
CT	NNP	O
may	MD	O
replace	VB	O
DSA	NNP	O
in	IN	O
selected	VBN	O
cases	NNS	O
.	.	O

The	DT	O
importance	NN	O
of	IN	O
the	DT	O
dual-switch	JJ	O
valve	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adult	NN	O
normotensive	JJ	O
or	CC	O
hypertensive	JJ	O
hydrocephalus	NN	O
.	.	O

Since	IN	O
the	DT	O
beginning	NN	O
of	IN	O
1995	CD	O
the	DT	O
new	JJ	O
hydrostatic	JJ	O
dual-switch	NN	O
valve	NN	O
(	(	O
DSV	NNP	O
)	)	O
was	VBD	O
implanted	VBN	O
in	IN	O
35	CD	O
adult	NN	O
patients	NNS	O
with	IN	O
hydrocephalus	NN	O
of	IN	O
different	JJ	O
etiology	NN	O
.	.	O

26	CD	O
patients	NNS	O
suffered	VBD	O
from	IN	O
normotensive	JJ	O
hydrocephalus	NN	O
(	(	O
10	CD	O
idiopathic	NN	O
and	CC	O
16	CD	O
symptomatic	JJ	O
)	)	O
,	,	O
and	CC	O
9	CD	O
patients	NNS	O
from	IN	O
hypertensive	JJ	O
hydrocephalus	NN	O
of	IN	O
various	JJ	O
origin	NN	O
.	.	O

The	DT	O
first	JJ	O
21	CD	O
cases	NNS	O
of	IN	O
this	DT	O
cohort	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
with	IN	O
a	DT	O
comparable	JJ	O
group	NN	O
of	IN	O
21	CD	O
hydrocephalic	JJ	O
patients	NNS	O
who	WP	O
received	VBD	O
a	DT	O
conventional	JJ	O
differential-pressure	NN	O
(	(	O
DP-	NNP	O
)	)	O
valve	NN	O
.	.	O

The	DT	O
clinical	JJ	O
status	NN	O
and	CC	O
CT	NNP	O
were	VBD	O
assessed	VBN	O
prior	RB	O
to	TO	O
shunting	VBG	O
,	,	O
14	CD	O
days	NNS	O
and	CC	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
the	DT	O
operation	NN	O
.	.	O

The	DT	O
reduction	NN	O
of	IN	O
ventricular	JJ	O
size	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
the	DT	O
measurement	NN	O
of	IN	O
the	DT	O
Evans	NNP	O
Index	NNP	O
.	.	O

The	DT	O
CT	NNP	O
follow-up	NN	O
in	IN	O
the	DT	O
DSV	NNP	O
group	NN	O
was	VBD	O
characterized	VBN	O
by	IN	O
an	DT	O
only	JJ	O
minimal	NN	O
(	(	O
14	CD	O
)	)	O
or	CC	O
only	RB	O
slight	JJ	O
(	(	O
16	CD	O
)	)	O
reduction	NN	O
of	IN	O
ventricular	JJ	O
size	NN	O
in	IN	O
the	DT	O
vast	JJ	O
majority	NN	O
of	IN	O
cases	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
21	CD	O
patients	NNS	O
with	IN	O
a	DT	O
DSV	NNP	O
and	CC	O
the	DT	O
patients	NNS	O
with	IN	O
DP	NNP	O
valves	NNS	O
,	,	O
evaluated	VBN	O
by	IN	O
measuring	VBG	O
the	DT	O
reduction	NN	O
of	IN	O
the	DT	O
Evans	NNP	O
Index	NNP	O
,	,	O
revealed	VBD	O
a	DT	O
distinctly	RB	O
higher	JJR	O
percentage	NN	O
of	IN	O
significant	JJ	O
regressions	NNS	O
in	IN	O
the	DT	O
DP	NNP	O
valve	NN	O
collective	NN	O
,	,	O
without	IN	O
doubt	NN	O
due	JJ	O
to	TO	O
chronic	JJ	O
overdrainage	NN	O
.	.	O

The	DT	O
overall	JJ	O
clinical	JJ	O
result	NN	O
of	IN	O
our	PRP$	O
35	CD	O
patients	NNS	O
with	IN	O
a	DT	O
DSV	NNP	O
was	VBD	O
excellent	JJ	O
and	CC	O
good	JJ	O
in	IN	O
31	CD	O
patients	NNS	O
,	,	O
but	CC	O
the	DT	O
outcome	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
more	RBR	O
dependent	JJ	O
on	IN	O
the	DT	O
preshunt	NN	O
damage	NN	O
of	IN	O
the	DT	O
brain	NN	O
than	IN	O
on	IN	O
hydrocephalic	JJ	O
aspects	NNS	O
.	.	O

A	DT	O
neglegible	JJ	O
incidence	NN	O
of	IN	O
subdural	JJ	O
effusions	NNS	O
in	IN	O
the	DT	O
DSV	NNP	O
group	NN	O
compared	VBN	O
to	TO	O
11	CD	O
cases	NNS	O
in	IN	O
the	DT	O
DP	NNP	O
valve	FW	O
collective	JJ	O
reflects	VBZ	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
DSV	NNP	O
to	TO	O
prevent	VB	O
overdrainage	NN	O
.	.	O

The	DT	O
capability	NN	O
of	IN	O
the	DT	O
DSV	NNP	O
to	TO	O
maintain	VB	O
the	DT	O
IVP	NNP	O
within	IN	O
physiological	JJ	O
limits	NNS	O
after	IN	O
shunting	VBG	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
,	,	O
is	VBZ	O
documented	VBN	O
by	IN	O
a	DT	O
comparison	NN	O
with	IN	O
possible	JJ	O
unphysiological	JJ	O
IVP	NNP	O
variations	NNS	O
in	IN	O
other	JJ	O
valve	NN	O
constructions	NNS	O
,	,	O
which	WDT	O
depend	VBP	O
on	IN	O
the	DT	O
level	NN	O
of	IN	O
implantation	NN	O
,	,	O
subcutaneous	JJ	O
pressure	NN	O
or	CC	O
CSF	NNP	O
flow	VBP	O
through	IN	O
the	DT	O
valve	NN	O
.	.	O

Prazosin	NNP	O
versus	NN	O
captopril	NN	O
as	IN	O
initial	JJ	O
therapy	NN	O
.	.	O

Effect	VB	O
on	IN	O
hypertension	NN	Condition
and	CC	Condition
lipid	JJ	Condition
levels	NNS	Condition
.	.	Condition

A	DT	O
randomized	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
evaluated	VBD	O
the	DT	O
safety	NN	O
,	,	O
efficacy	NN	O
,	,	O
and	CC	O
effect	NN	O
of	IN	O
the	DT	O
alpha	NN	O
blocking	VBG	O
agent	JJ	O
prazosin	NN	O
and	CC	O
the	DT	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitor	NN	O
captopril	NN	O
on	IN	O
serum	NN	O
lipid	JJ	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
hypertension	NN	O
.	.	O

Baseline	JJ	O
evaluations	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
31	CD	O
patients	NNS	O
after	IN	O
a	DT	O
four-week	JJ	O
placebo	NN	O
washout	IN	O
period	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
prazosin	NN	O
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
or	CC	O
captopril	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
.	.	O

Daily	JJ	O
doses	NNS	O
were	VBD	O
titrated	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
for	IN	O
prazosin	NN	O
,	,	O
1	CD	O
mg	NN	O
two	CD	O
times	NNS	O
daily	RB	O
to	TO	O
maximum	VB	O
of	IN	O
20	CD	O
mg	NNS	O
per	IN	O
day	NN	O
;	:	O
for	IN	O
captopril	NN	O
,	,	O
25	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
450	CD	O
mg	NNS	O
per	IN	O
day	NN	O
.	.	O

If	IN	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
was	VBD	O
not	RB	O
adequately	RB	O
controlled	VBN	O
(	(	O
less	JJR	O
than	IN	O
85	CD	O
mm	JJ	O
Hg	NNP	O
)	)	O
after	IN	O
four	CD	O
weeks	NNS	O
of	IN	O
monotherapy	NN	O
,	,	O
1	CD	O
mg	NN	O
of	IN	O
polythiazide	NN	O
was	VBD	O
added	VBN	O
to	TO	O
the	DT	O
daily	JJ	O
regimen	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
drug	NN	O
groups	NNS	O
for	IN	O
the	DT	O
measured	JJ	O
variables	NNS	O
in	IN	O
either	CC	O
the	DT	O
parallel	NN	O
or	CC	O
crossover	JJ	O
phase	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Five	CD	O
of	IN	O
15	CD	O
prazosin-treated	JJ	O
patients	NNS	O
and	CC	O
six	CD	O
of	IN	O
16	CD	O
captopril-treated	JJ	O
patients	NNS	O
required	VBD	O
the	DT	O
addition	NN	O
of	IN	O
thiazide	NN	O
to	TO	O
achieve	VB	O
blood	NN	O
pressure	NN	O
control	NN	O
.	.	O

In	IN	O
vitro	JJ	O
biocompatibility	NN	O
tests	NNS	O
of	IN	O
glass	NN	O
ionomer	NN	O
cements	NNS	O
impregnated	VBN	O
with	IN	O
collagen	NN	O
or	CC	O
bioactive	JJ	O
glass	NN	O
to	TO	O
fibroblasts	NNS	O
.	.	O

AIM	NNP	O
AND	CC	O
DESIGN	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
biocompatibility	NN	O
of	IN	O
glass	NN	O
ionomer	NN	O
cement	NN	O
(	(	O
GIC	NNP	O
)	)	O
impregnated	VBD	O
with	IN	O
collagen	NN	O
or	CC	O
bioactive	JJ	O
glass	NN	O
to	TO	O
BHK-21	NNP	O
fibroblasts	NNS	O
in	IN	O
vitro	NN	O
.	.	O

Mineral	NNP	O
Trioxide	NNP	O
Aggregate	NNP	O
was	VBD	O
used	VBN	O
as	IN	O
the	DT	O
standard	NN	O
for	IN	O
comparison	NN	O
.	.	O

Human	NNP	Condition
maxillary	JJ	Condition
central	JJ	Condition
incisors	NNS	Condition
(	(	O
n	JJ	O
=	NNP	O
70	CD	SampleSize
)	)	O
were	VBD	O
instrumented	VBN	O
with	IN	O
a	DT	O
rotary	JJ	O
NiTi	NNP	O
system	NN	O
and	CC	O
filled	VBN	O
.	.	O

Following	VBG	O
resection	NN	O
of	IN	O
the	DT	O
apical	JJ	O
3mm	CD	O
,	,	O
root	JJ	Condition
end	NN	Condition
cavities	NNS	Condition
were	VBD	O
prepared	JJ	O
and	CC	O
restored	VBN	O
with	IN	O
conventional	JJ	O
GIC	NNP	O
(	(	O
group	NN	O
1	CD	O
)	)	O
or	CC	O
GIC	NNP	O
with	IN	O
0.01	CD	O
%	NN	O
,	,	O
0.1	CD	O
%	NN	O
or	CC	O
1	CD	O
%	NN	O
collagen	NN	O
(	(	O
groups	NNS	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
respectively	RB	O
)	)	O
or	CC	O
,	,	O
10	CD	O
%	NN	O
,	,	O
30	CD	O
%	NN	O
or	CC	O
50	CD	O
%	NN	O
bioactive	JJ	O
glass	NN	O
(	(	O
groups	NNS	O
5	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
respectively	RB	O
)	)	O
,	,	O
or	CC	O
Mineral	NNP	O
Trioxide	NNP	O
Aggregate	NNP	O
(	(	O
group	NN	O
8	CD	O
)	)	O
.	.	O

The	DT	O
root	NN	Condition
slices	NNS	Condition
were	VBD	O
incubated	VBN	O
in	IN	O
tissue	NN	O
culture	NN	O
plates	VBZ	O
with	IN	O
BHK-21	NNP	O
fibroblast	NN	O
cell	NN	O
line	NN	O
.	.	O

Phase	NNP	O
contrast	NN	O
and	CC	O
scanning	VBG	O
electron	NN	O
microscopes	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
score	VB	O
cell	NN	O
quantity	NN	O
,	,	O
morphology	NN	O
and	CC	O
cell	NN	O
attachment	NN	O
.	.	O

The	DT	O
data	NNS	O
were	VBD	O
statistically	RB	O
analyzed	VBN	O
by	IN	O
one	CD	O
way	NN	O
ANOVA	NNP	O
with	IN	O
Post	NNP	O
Hoc	NNP	O
Tukey	NNP	O
HSD	NNP	O
test	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
AND	NNP	O
CONCLUSIONS	NNP	O
Group	NNP	O
5	CD	O
showed	VBD	O
the	DT	O
highest	JJS	O
scores	NNS	O
which	WDT	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
all	DT	O
other	JJ	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
except	IN	O
group	NN	O
8	CD	O
,	,	O
with	IN	O
which	WDT	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Glass	NNP	O
ionomer	JJ	O
cement	NN	O
with	IN	O
10	CD	O
%	NN	O
bioactive	JJ	O
glass	NN	O
showed	VBD	O
better	JJR	O
adhesion	NN	O
and	CC	O
spreading	NN	O
of	IN	O
cells	NNS	O
than	IN	O
glass	NN	O
ionomer	NN	O
cement	NN	O
with	IN	O
0.01	CD	O
%	NN	O
collagen	NN	O
.	.	O

The	DT	O
biocompatibility	NN	O
of	IN	O
collagen	NN	O
and	CC	O
bioactive	JJ	O
glass	NN	O
was	VBD	O
concentration	NN	O
dependent	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
bioactive	JJ	O
glass	NN	O
improved	VBD	O
the	DT	O
biocompatibility	NN	O
of	IN	O
glass	NN	O
ionomer	NN	O
cement	NN	O
to	TO	O
fibroblasts	NNS	O
better	JJR	O
than	IN	O
addition	NN	O
of	IN	O
collagen	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
phenytoin	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
in	IN	O
children	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
blunt	NN	O
head	JJ	O
injury	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
We	PRP	O
determine	VBP	O
the	DT	O
efficacy	NN	O
of	IN	O
prophylactic	JJ	O
phenytoin	NN	O
in	IN	O
preventing	VBG	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
in	IN	O
children	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
blunt	NN	O
head	JJ	O
injury	NN	O
.	.	O

METHODS	NNP	O
Children	NNP	O
younger	JJR	O
than	IN	O
16	CD	O
years	NNS	O
and	CC	O
experiencing	VBG	O
moderate	JJ	O
to	TO	O
severe	VB	O
blunt	NN	O
head	JJ	O
injury	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
phenytoin	NN	O
or	CC	O
placebo	NN	O
within	IN	O
60	CD	O
minutes	NNS	O
of	IN	O
presentation	NN	O
at	IN	O
3	CD	O
pediatric	JJ	O
trauma	NN	O
centers	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
posttraumatic	JJ	O
seizures	NNS	O
within	IN	O
48	CD	O
hours	NNS	O
;	:	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
survival	JJ	O
and	CC	O
neurologic	JJ	O
outcome	NN	O
30	CD	O
days	NNS	O
after	IN	O
injury	NN	O
.	.	O

A	DT	O
Bayesian	JJ	O
decision-theoretic	JJ	O
clinical	JJ	O
trial	NN	O
design	NN	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
probability	NN	O
of	IN	O
remaining	VBG	O
posttraumatic	JJ	O
seizure	NN	O
free	JJ	O
for	IN	O
each	DT	O
treatment	NN	O
group	NN	O
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
age	NN	O
of	IN	O
6.1	CD	O
years	NNS	O
.	.	O

Sixty-eight	JJ	O
percent	NN	O
were	VBD	O
boys	NNS	O
.	.	O

The	DT	O
2	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
.	.	O

During	IN	O
the	DT	O
48-hour	JJ	O
observation	NN	O
period	NN	O
,	,	O
3	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
of	IN	O
46	CD	SampleSize
patients	NNS	O
given	VBN	O
phenytoin	NNS	O
and	CC	O
3	CD	O
(	(	O
5	CD	O
%	NN	O
)	)	O
of	IN	O
56	CD	SampleSize
patients	NNS	O
given	VBN	O
placebo	NNS	O
experienced	VBD	O
a	DT	O
posttraumatic	JJ	O
seizure	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
in	IN	O
survival	NN	O
or	CC	O
neurologic	JJ	O
outcome	NN	O
after	IN	O
30	CD	O
days	NNS	O
.	.	O

According	VBG	O
to	TO	O
these	DT	O
results	NNS	O
,	,	O
the	DT	O
probability	NN	O
that	WDT	O
phenytoin	NN	O
has	VBZ	O
the	DT	O
originally	RB	O
hypothesized	VBN	O
effect	NN	O
of	IN	O
reducing	VBG	O
the	DT	O
rate	NN	O
of	IN	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
by	IN	O
12.5	CD	O
%	NN	O
is	VBZ	O
0.0053	CD	O
.	.	O

The	DT	O
probability	NN	O
that	WDT	O
phenytoin	NN	O
has	VBZ	O
any	DT	O
prophylactic	JJ	O
efficacy	NN	O
is	VBZ	O
0.383	CD	O
.	.	O

The	DT	O
median	JJ	O
effect	NN	O
size	NN	O
in	IN	O
this	DT	O
trial	NN	O
was	VBD	O
-0.015	NNP	O
(	(	O
seizure	JJ	O
rate	NN	O
increased	VBN	O
by	IN	O
1.5	CD	O
%	NN	O
in	IN	O
the	DT	O
phenytoin	NN	O
group	NN	O
)	)	O
,	,	O
95	CD	O
%	NN	O
probability	NN	O
interval	NN	O
-0.127	NN	O
to	TO	O
0.091	CD	O
(	(	O
12.7	CD	O
%	NN	O
higher	JJR	O
rate	NN	O
of	IN	O
posttraumatic	JJ	O
seizures	NNS	O
to	TO	O
a	DT	O
9.1	CD	O
%	NN	O
lower	JJR	O
rate	NN	O
of	IN	O
posttraumatic	JJ	O
seizures	NNS	O
with	IN	O
phenytoin	NN	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
rate	NN	O
of	IN	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
in	IN	O
children	NNS	O
may	MD	O
be	VB	O
much	RB	O
lower	JJR	O
than	IN	O
previously	RB	O
reported	VBN	O
.	.	O

Phenytoin	VB	O
did	VBD	O
not	RB	O
substantially	RB	O
reduce	VB	O
that	DT	O
rate	NN	O
.	.	O

Brief	JJ	O
report	NN	O
:	:	O
mediation	NN	O
of	IN	O
treatment	NN	O
effect	NN	O
in	IN	O
a	DT	O
communication	NN	O
intervention	NN	O
for	IN	O
pre-school	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Tests	NNS	O
of	IN	O
mediation	NN	O
in	IN	O
treatment	NN	O
trials	NNS	O
can	MD	O
illuminate	VB	O
processes	NNS	O
of	IN	O
change	NN	O
and	CC	O
suggest	NN	O
causal	NN	O
influences	NNS	O
in	IN	O
development	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
mediation	NN	O
analysis	NN	O
of	IN	O
a	DT	O
previously	RB	O
published	VBN	O
randomised	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
parent-mediated	JJ	O
communication-focused	JJ	O
treatment	NN	O
for	IN	O
autism	NN	O
against	IN	O
ordinary	JJ	O
care	NN	O
,	,	O
with	IN	O
28	CD	O
children	NNS	O
aged	VBN	O
2-5	CD	O
years	NNS	O
(	(	O
Aldred	NNP	O
et	RB	O
al	RB	O
.	.	O

in	IN	O
J	NNP	O
Child	NNP	O
Psychol	NNP	O
Psychiatr	NNP	O
45:1-11	CD	O
,	,	O
2004	CD	O
)	)	O
.	.	O

The	DT	O
hypothesised	JJ	O
mediating	NN	O
process	NN	O
,	,	O
targeted	VBN	O
by	IN	O
the	DT	O
intervention	NN	O
,	,	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
parental	JJ	O
synchronous	JJ	O
response	NN	O
within	IN	O
parent-child	JJ	O
interaction	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
partial	JJ	O
mediation	NN	O
,	,	O
with	IN	O
change	NN	O
in	IN	O
synchrony	NN	O
accounting	NN	O
for	IN	O
34	CD	O
%	NN	O
of	IN	O
the	DT	O
positive	JJ	O
intervention	NN	O
effect	NN	O
on	IN	O
autism	NN	O
symptomatology	NN	O
(	(	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule	NNP	O
communication	NN	O
and	CC	O
social	JJ	O
domain	NN	O
algorithm	NN	O
)	)	O
;	:	O
the	DT	O
result	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
bootstrap	NN	O
estimation	NN	O
.	.	O

Improved	VBN	O
parental	JJ	O
synchronous	JJ	O
response	NN	O
to	TO	O
child	VB	O
communication	NN	O
can	MD	O
alter	VB	O
short-term	JJ	O
autism	NN	O
symptom	VBZ	O
outcome	RP	O
with	IN	O
targeted	JJ	O
therapy	NN	O
.	.	O

Therapist	NNP	O
success	NN	O
and	CC	O
its	PRP$	O
determinants	NNS	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
relatively	RB	O
unexplored	JJ	O
contribution	NN	O
of	IN	O
the	DT	O
therapist	NN	O
's	POS	O
performance	NN	O
in	IN	O
determining	VBG	O
outcomes	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Nine	JJ	O
therapists	NNS	O
were	VBD	O
studied	VBN	O
:	:	O
three	CD	O
performed	VBD	O
supportive-expressive	JJ	O
psychotherapy	NN	O
;	:	O
three	CD	O
,	,	O
cognitive-behavioral	JJ	O
psychotherapy	NN	O
;	:	O
and	CC	O
three	CD	O
,	,	O
drug	NN	O
counseling	NN	O
.	.	O

Profound	NNP	O
differences	NNS	O
were	VBD	O
discovered	VBN	O
in	IN	O
the	DT	O
therapists	NNS	O
'	POS	O
success	NN	O
with	IN	O
the	DT	O
patients	NNS	O
in	IN	O
their	PRP$	O
case	NN	O
loads	VBZ	O
.	.	O

Four	CD	O
potential	JJ	O
determinants	NNS	O
of	IN	O
these	DT	O
differences	NNS	O
were	VBD	O
explored	VBN	O
:	:	O
patient	JJ	O
factors	NNS	O
;	:	O
therapist	JJ	O
factors	NNS	O
;	:	O
patient-therapist	JJ	O
relationship	NN	O
factors	NNS	O
;	:	O
and	CC	O
therapy	NN	O
factors	NNS	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
patient	NN	O
characteristics	NNS	O
within	IN	O
each	DT	O
case	NN	O
load	NN	O
(	(	O
after	IN	O
random	NN	O
assignments	NNS	O
)	)	O
were	VBD	O
similar	JJ	O
and	CC	O
disclosed	VBD	O
no	DT	O
differences	NNS	O
that	WDT	O
would	MD	O
have	VB	O
explained	VBN	O
the	DT	O
differences	NNS	O
in	IN	O
success	NN	O
;	:	O
therapist	NN	O
's	POS	O
personal	JJ	O
qualities	NNS	O
were	VBD	O
correlated	VBN	O
with	IN	O
outcomes	NNS	O
but	CC	O
not	RB	O
significantly	RB	O
(	(	O
mean	JJ	O
r	NN	O
=	NNP	O
.32	NNP	O
)	)	O
;	:	O
an	DT	O
early-in-treatment	JJ	O
measure	NN	O
of	IN	O
the	DT	O
patient-therapist	JJ	O
relationship	NN	O
,	,	O
the	DT	O
Helping	NNP	O
Alliance	NNP	O
Questionnaire	NNP	O
,	,	O
yielded	VBD	O
significant	JJ	O
correlations	NNS	O
with	IN	O
outcomes	NNS	O
(	(	O
mean	JJ	O
r	NN	O
=	NNP	O
.65	NNP	O
)	)	O
;	:	O
among	IN	O
the	DT	O
therapy	NN	O
techniques	NNS	O
,	,	O
purity	NN	O
provided	VBD	O
significant	JJ	O
correlations	NNS	O
with	IN	O
outcomes	NNS	O
(	(	O
mean	JJ	O
r	NN	O
=	NNP	O
.44	NNP	O
)	)	O
,	,	O
both	DT	O
across	IN	O
therapists	NNS	O
and	CC	O
within	IN	O
each	DT	O
therapist	NN	O
's	POS	O
case	NN	O
load	NN	O
.	.	O

The	DT	O
three	CD	O
therapist-related	JJ	O
factors	NNS	O
were	VBD	O
moderately	RB	O
associated	VBN	O
with	IN	O
each	DT	O
other	JJ	O
.	.	O

Pre-transplant	JJ	O
pharmacokinetic	JJ	O
profiling	NN	O
and	CC	O
tacrolimus	NN	O
requirements	NNS	O
post-transplant	JJ	O
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
achieving	VBG	O
tacrolimus	JJ	O
whole-blood	JJ	O
concentrations	NNS	O
of	IN	O
?10	NNP	O
ng/mL	NN	O
within	IN	O
3	CD	O
days	NNS	O
of	IN	O
kidney	NN	Condition
transplantation	NN	Condition
,	,	O
after	IN	O
randomization	NN	O
either	RB	O
to	TO	O
standard	VB	O
dosing	VBG	O
(	(	O
control	VB	O
group	NN	O
)	)	O
or	CC	O
post-transplantation	NN	O
dosing	NN	O
guided	VBN	O
by	IN	O
a	DT	O
2-hour	JJ	O
(	(	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
level	NN	O
following	VBG	O
a	DT	O
preoperative	JJ	O
tacrolimus	NN	O
dose	NN	O
(	(	O
T2	NNP	O
group	NN	O
)	)	O
.	.	O

METHODS	NNP	O
The	DT	O
first	JJ	O
postoperative	JJ	O
tacrolimus	NN	O
dose	NN	O
was	VBD	O
given	VBN	O
either	RB	O
according	VBG	O
to	TO	O
standard	NN	O
care	NN	O
(	(	O
control	VB	O
group	NN	O
)	)	O
or	CC	O
0.15	CD	O
mg/kg	JJ	O
b.d	NN	O
.	.	O

if	IN	O
the	DT	O
pre-transplant	JJ	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
level	NN	O
was	VBD	O
?20	JJ	O
ng/mL	RB	O
,	,	O
0.1	CD	O
mg/kg	NN	O
b.d	NN	O
.	.	O

if	IN	O
the	DT	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
level	NN	O
was	VBD	O
21-59	JJ	O
ng/mL	NN	O
or	CC	O
0.05	CD	O
mg/kg	JJ	O
b.d	NN	O
.	.	O

if	IN	O
the	DT	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
level	NN	O
was	VBD	O
?60	JJ	O
ng/mL	NN	O
(	(	O
T2	NNP	O
group	NN	O
)	)	O
.	.	O

Subsequent	JJ	O
dosing	NN	O
in	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
based	VBN	O
upon	IN	O
tacrolimus	JJ	O
trough	IN	O
level	NN	O
monitoring	NN	O
.	.	O

Participants	NNS	O
received	VBD	O
concomitant	JJ	O
mycophenolate	NN	O
mofetil	NN	O
and	CC	O
steroids	NNS	O
.	.	O

RESULTS	NNP	O
Ninety	NNP	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
,	,	O
of	IN	O
which	WDT	O
84	CD	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
analysis	NN	O
(	(	O
control	NN	O
group	NN	O
n=43	VBD	O
;	:	O
T2	NNP	O
group	NN	O
n=41	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
subjects	NNS	O
achieving	VBG	O
tacrolimus	JJ	O
trough	NN	O
levels	NNS	O
?10	VBP	O
ng/mL	RB	O
(	(	O
82.9	CD	O
%	NN	O
Control	NNP	O
vs	VBZ	O
93.0	CD	O
%	NN	O
T2	NNP	O
;	:	O
P=0.19	NNP	O
)	)	O
or	CC	O
between	IN	O
10	CD	O
and	CC	O
15	CD	O
ng/mL	NN	O
(	(	O
41.5	CD	O
%	NN	O
Control	NNP	O
vs	VBZ	O
41.9	CD	O
%	NN	O
T2	NNP	O
;	:	O
P=0.97	NNP	O
)	)	O
at	IN	O
day	NN	O
3	CD	O
post	NN	O
transplant	NN	O
.	.	O

The	DT	O
T2	NNP	O
group	NN	O
achieved	VBD	O
tacrolimus	RB	O
trough	JJ	O
levels	NNS	O
of	IN	O
?10	NNP	O
ng/mL	FW	O
significantly	RB	O
faster	RBR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
100	CD	O
%	NN	O
achievement	NN	O
in	IN	O
14	CD	O
days	NNS	O
(	(	O
Control	NNP	O
)	)	O
versus	VBP	O
4	CD	O
days	NNS	O
(	(	O
T2	NNP	O
)	)	O
;	:	O
P=0.01	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Performing	VBG	O
a	DT	O
pre-transplant	JJ	O
tacrolimus	NN	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
does	VBZ	O
not	RB	O
significantly	RB	O
increase	VB	O
the	DT	O
high	JJ	O
proportion	NN	O
of	IN	O
subjects	NNS	O
achieving	VBG	O
10	CD	O
ng/mL	JJ	O
tacrolimus	NN	O
concentrations	NNS	O
by	IN	O
day	NN	O
3	CD	O
using	VBG	O
routine	JJ	O
protocols	NNS	O
.	.	O

However	RB	O
,	,	O
compared	VBN	O
with	IN	O
standard	JJ	O
care	NN	O
,	,	O
performing	VBG	O
a	DT	O
pre-transplant	JJ	O
tacrolimus	NN	O
C	NNP	O
(	(	O
2	CD	O
)	)	O
does	VBZ	O
lead	JJ	O
to	TO	O
patients	NNS	O
achieving	VBG	O
a	DT	O
whole-blood	JJ	O
concentration	NN	O
of	IN	O
?10	NNP	O
ng/mL	JJ	O
sooner	NN	O
.	.	O

Lack	NN	O
of	IN	O
efficacy	NN	O
of	IN	O
citalopram	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
high	JJ	O
levels	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
:	:	O
citalopram	NN	O
ineffective	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

CONTEXT	NNP	O
Selective	NNP	O
serotonin	NN	O
reuptake	NN	O
inhibitors	NNS	O
are	VBP	O
widely	RB	O
prescribed	VBN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
citalopram	JJ	O
hydrobromide	NN	O
therapy	NN	O
for	IN	O
repetitive	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

DESIGN	NNP	O
National	NNP	O
Institutes	NNPS	O
of	IN	O
Health-sponsored	NNP	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
Six	NNP	O
academic	JJ	O
centers	NNS	O
,	,	O
including	VBG	O
Mount	NNP	O
Sinai	NNP	O
School	NNP	O
of	IN	O
Medicine	NNP	O
,	,	O
North	NNP	O
Shore-Long	NNP	O
Island	NNP	O
Jewish	NNP	O
Health	NNP	O
System	NNP	O
,	,	O
University	NNP	O
of	IN	O
North	NNP	O
Carolina	NNP	O
at	IN	O
Chapel	NNP	O
Hill	NNP	O
,	,	O
University	NNP	O
of	IN	O
California	NNP	O
at	IN	O
Los	NNP	O
Angeles	NNP	O
,	,	O
Yale	NNP	O
University	NNP	O
,	,	O
and	CC	O
Dartmouth	NNP	O
Medical	NNP	O
School	NNP	O
.	.	O

PARTICIPANTS	NNP	O
One	CD	O
hundred	VBD	O
forty-nine	JJ	O
volunteers	NNS	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
old	JJ	O
(	(	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
,	,	O
9.4	CD	O
[	NN	O
3.1	CD	O
]	CD	O
years	NNS	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
citalopram	NN	O
(	(	O
n	JJ	O
=	NNP	O
73	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
76	CD	O
)	)	O
.	.	O

Participants	NNS	O
had	VBD	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
,	,	O
Asperger	NNP	O
disorder	NN	O
,	,	O
or	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
,	,	O
not	RB	O
otherwise	RB	O
specified	VBN	O
;	:	O
had	VBD	O
illness	JJ	O
severity	NN	O
ratings	NNS	O
of	IN	O
at	IN	O
least	JJS	O
moderate	JJ	O
on	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
,	,	O
Severity	NNP	O
of	IN	O
Illness	NNP	O
Scale	NNP	O
;	:	O
and	CC	O
scored	VBD	O
at	IN	O
least	JJS	O
moderate	JJ	O
on	IN	O
compulsive	JJ	O
behaviors	NNS	O
measured	VBN	O
with	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scales	NNP	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

INTERVENTIONS	NNP	O
Twelve	NNP	O
weeks	NNS	O
of	IN	O
citalopram	NN	O
hydrobromide	NN	O
(	(	O
10	CD	O
mg/5	RB	O
mL	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
maximum	JJ	O
dosage	NN	O
of	IN	O
citalopram	NN	O
hydrobromide	NN	O
was	VBD	O
16.5	CD	O
(	(	O
6.5	CD	O
)	)	O
mg/d	NN	O
by	IN	O
mouth	NN	O
(	(	O
maximum	JJ	O
,	,	O
20	CD	O
mg/d	NN	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Positive	NNP	O
response	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
a	DT	O
score	NN	O
of	IN	O
much	JJ	O
improved	VBN	O
or	CC	O
very	RB	O
much	JJ	O
improved	VBN	O
on	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
,	,	O
Improvement	NNP	O
subscale	NN	O
.	.	O

An	DT	O
important	JJ	O
secondary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
score	NN	O
on	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scales	NNP	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
systematically	RB	O
elicited	VBN	O
using	VBG	O
the	DT	O
Safety	NNP	O
Monitoring	NNP	O
Uniform	NNP	O
Report	NNP	O
Form	NNP	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
positive	JJ	O
response	NN	O
on	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
,	,	O
Improvement	NNP	O
subscale	NN	O
between	IN	O
the	DT	O
citalopram-treated	JJ	O
group	NN	O
(	(	O
32.9	CD	O
%	NN	O
)	)	O
and	CC	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
34.2	CD	O
%	NN	O
)	)	O
(	(	O
relative	JJ	O
risk	NN	O
,	,	O
0.96	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.61-1.51	JJ	O
;	:	O
P	NNP	O
>	NNP	O
.99	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
score	NN	O
reduction	NN	O
on	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scales	NNP	O
modified	VBD	O
for	IN	O
pervasive	JJ	O
developmental	JJ	O
disorders	NNS	O
from	IN	O
baseline	NN	O
(	(	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
,	,	O
-2.0	NNP	O
[	VBZ	O
3.4	CD	O
]	NN	O
points	NNS	O
for	IN	O
the	DT	O
citalopram-treated	JJ	O
group	NN	O
and	CC	O
-1.9	NNP	O
[	NNP	O
2.5	CD	O
]	NN	O
points	NNS	O
for	IN	O
the	DT	O
placebo	NN	O
group	NN	O
;	:	O
P	NNP	O
=	NNP	O
.81	NNP	O
)	)	O
.	.	O

Citalopram	NNP	O
use	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
adverse	JJ	O
events	NNS	O
,	,	O
particularly	RB	O
increased	VBD	O
energy	NN	O
level	NN	O
,	,	O
impulsiveness	NN	O
,	,	O
decreased	VBN	O
concentration	NN	O
,	,	O
hyperactivity	NN	O
,	,	O
stereotypy	NN	O
,	,	O
diarrhea	NN	O
,	,	O
insomnia	NN	O
,	,	O
and	CC	O
dry	JJ	O
skin	NN	O
or	CC	O
pruritus	NN	O
.	.	O

CONCLUSION	NNP	O
Results	NNP	O
of	IN	O
this	DT	O
trial	NN	O
do	VBP	O
not	RB	O
support	VB	O
the	DT	O
use	NN	O
of	IN	O
citalopram	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Trial	JJ	O
Registration	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00086645	NN	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
six	CD	O
epoetin	JJ	O
alfa	NN	O
dosing	VBG	O
regimens	NNS	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
without	IN	O
acute	JJ	O
blood	NN	O
loss	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
describe	VB	O
the	DT	O
pharmacokinetic	JJ	O
profiles	NNS	O
of	IN	O
six	CD	O
different	JJ	O
dosing	VBG	O
regimens	NNS	O
for	IN	O
epoetin	NN	O
alfa	NN	O
,	,	O
and	CC	O
whether	IN	O
more	JJR	O
rapid	JJ	O
and	CC	O
robust	JJ	O
reticulocytosis	NN	O
can	MD	O
be	VB	O
elicited	VBN	O
with	IN	O
more	RBR	O
frequent	JJ	O
administration	NN	O
of	IN	O
epoetin	JJ	O
alfa	NN	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
open-label	NN	O
,	,	O
multicenter	NN	O
,	,	O
28-day	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Ten	CD	O
centers	NNS	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PATIENTS	VB	O
Adult	NNP	O
(	(	O
age	NN	O
>	VBN	O
or=18	CD	O
years	NNS	O
)	)	O
critically	RB	O
ill	JJ	O
patients	NNS	O
with	IN	O
hemoglobin	JJ	O
<	NNP	O
or=12	NN	O
g/dL	NN	O
,	,	O
expected	VBN	O
hospitalization	NN	O
of	IN	O
>	NNP	O
or=7	NNP	O
days	NNS	O
,	,	O
with	IN	O
no	DT	O
ongoing	VBG	O
acute	RB	O
blood	NN	O
loss	NN	O
.	.	O

INTERVENTIONS	NNP	O
One	CD	O
of	IN	O
six	CD	O
dosing	VBG	O
epoetin	NN	O
alfa	NN	O
regimens	VBZ	O
for	IN	O
15	CD	O
days	NNS	O
,	,	O
as	IN	O
follows	VBZ	O
:	:	O
40,000	CD	O
IU	NNP	O
once	RB	O
weekly	RB	O
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
intravenously	RB	O
(	(	O
IV	NNP	O
)	)	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
;	:	O
15,000	CD	O
IU	NNP	O
every	DT	O
other	JJ	O
day	NN	O
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
C	NNP	O
)	)	O
or	CC	O
IV	NNP	O
(	(	O
group	NN	O
D	NNP	O
)	)	O
;	:	O
or	CC	O
40,000	CD	O
IU	NNP	O
day	NN	O
1	CD	O
and	CC	O
3	CD	O
,	,	O
subcutaneously	RB	O
(	(	O
group	NN	O
E	NNP	O
)	)	O
or	CC	O
IV	NNP	O
(	(	O
group	NN	O
F	NNP	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
15,000	CD	O
IU	NNP	O
once	RB	O
every	DT	O
other	JJ	O
day	NN	O
on	IN	O
[	NN	O
corrected	VBN	O
]	JJ	O
days	NNS	O
5-15	JJ	O
[	NNP	O
corrected	VBD	O
]	NN	O
MEASUREMENTS	NNP	O
Serum	NNP	O
erythropoietin	NN	O
concentration	NN	O
,	,	O
absolute	JJ	O
reticulocyte	NN	O
count	NN	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Of	IN	O
the	DT	O
60	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
enrolled	VBN	O
(	(	O
60	CD	O
%	NN	O
men	NNS	O
,	,	O
mean	JJ	O
age	NN	O
53	CD	O
years	NNS	O
,	,	O
mean	VBP	O
Acute	NNP	O
Physiology	NNP	O
and	CC	O
Chronic	NNP	O
Health	NNP	O
Evaluation	NNP	O
II	NNP	O
score	NN	O
,	,	O
19.5	CD	O
)	)	O
,	,	O
30	CD	O
were	VBD	O
evaluable	JJ	O
for	IN	O
both	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
.	.	O

Erythropoietin	NNP	O
exposure	NN	O
was	VBD	O
approximately	RB	O
ten	JJ	O
times	NNS	O
greater	JJR	O
for	IN	O
IV	NNP	O
dosing	VBG	O
than	IN	O
for	IN	O
subcutaneous	JJ	O
dosing	NN	O
.	.	O

Mean	NNP	O
absolute	JJ	O
reticulocyte	NN	O
count	NN	O
peaked	VBD	O
at	IN	O
day	NN	O
11	CD	O
or	CC	O
15	CD	O
in	IN	O
each	DT	O
group	NN	O
and	CC	O
appeared	VBD	O
to	TO	O
be	VB	O
greater	JJR	O
for	IN	O
subcutaneous	JJ	O
dosing	NN	O
(	(	O
mean	JJ	O
peak	NN	O
response	NN	O
149-169	JJ	O
x	NN	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
compared	VBN	O
with	IN	O
IV	NNP	O
dosing	VBG	O
(	(	O
mean	JJ	O
peak	NN	O
response	NN	O
138-147	JJ	O
x	NN	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
)	)	O
at	IN	O
most	JJS	O
visits	NNS	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
adverse	JJ	O
events	NNS	O
were	VBD	O
pyrexia	NNS	O
(	(	O
18	CD	O
%	NN	O
)	)	O
,	,	O
hypokalemia	NN	O
(	(	O
15	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
hypophosphatemia	NN	O
(	(	O
15	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
of	IN	O
anemic	JJ	O
critically	NN	O
ill	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
epoetin	JJ	O
alfa	NN	O
,	,	O
all	DT	O
dosing	VBG	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
appeared	VBN	O
to	TO	O
effect	NN	O
reticulocytosis	NN	O
,	,	O
with	IN	O
a	DT	O
peak	NN	O
at	IN	O
day	NN	O
11	CD	O
or	CC	O
15	CD	O
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
of	IN	O
epoetin	JJ	O
alfa	NN	O
did	VBD	O
not	RB	O
predict	VB	O
pharmacodynamic	JJ	O
response	NN	O
in	IN	O
anemic	JJ	O
critically	RB	O
ill	JJ	O
patients	NNS	O
.	.	O

Intravesical	JJ	O
seeding	NN	O
of	IN	O
upper	JJ	O
urinary	JJ	O
tract	NN	O
urothelial	JJ	O
carcinoma	NN	O
cells	NNS	O
during	IN	O
nephroureterectomy	NN	O
:	:	O
an	DT	O
exploratory	JJ	O
analysis	NN	O
from	IN	O
the	DT	O
THPMG	NNP	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
Pirarubicin	NNP	O
Monotherapy	NNP	O
Study	NNP	O
Group	NNP	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
Phase	NNP	O
II	NNP	O
study	NN	O
that	WDT	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
intravesical	JJ	O
instillation	NN	O
of	IN	O
pirarubicin	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
bladder	NN	O
recurrence	NN	O
after	IN	O
nephroureterectomy	NN	O
for	IN	O
upper	JJ	Condition
urinary	JJ	Condition
tract	NN	Condition
urothelial	JJ	Condition
carcinoma	NN	Condition
.	.	O

This	DT	O
study	NN	O
conducted	VBD	O
further	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
Pirarubicin	NNP	O
Monotherapy	NNP	O
Study	NNP	O
Group	NNP	O
cohort	NN	O
,	,	O
focusing	VBG	O
on	IN	O
intravesical	JJ	O
seeding	NN	O
of	IN	O
cancer	NN	O
cells	NNS	O
.	.	O

METHODS	NNP	O
Using	VBG	O
the	DT	O
data	NN	O
from	IN	O
the	DT	O
Pirarubicin	NNP	O
Monotherapy	NNP	O
Study	NNP	O
Group	NNP	O
trial	NN	O
,	,	O
bladder	VB	O
recurrence-free	JJ	O
survival	NN	O
rates	NNS	O
and	CC	O
factors	NNS	O
associated	VBN	O
with	IN	O
bladder	NN	O
recurrence	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
36	CD	SampleSize
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
14	CD	SampleSize
with	IN	O
positive	JJ	O
urine	JJ	O
cytology	NN	O
had	VBD	O
more	RBR	O
frequent	JJ	O
recurrence	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
22	CD	SampleSize
patients	NNS	O
with	IN	O
negative	JJ	O
cytology	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
multivariate	NN	O
analysis	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
voided	VBD	O
urine	JJ	O
cytology	NN	O
was	VBD	O
an	DT	O
independent	JJ	O
predictive	JJ	O
factor	NN	O
of	IN	O
bladder	NN	O
recurrence	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
5.54	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
1.12-27.5	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.036	CD	O
)	)	O
.	.	O

Of	IN	O
72	CD	SampleSize
patients	NNS	O
in	IN	O
the	DT	O
Pirarubicin	NNP	O
Monotherapy	NNP	O
Study	NNP	O
Group	NNP	O
trial	NN	O
,	,	O
31	CD	O
had	VBD	O
positive	JJ	O
urine	JJ	O
cytology	NN	O
.	.	O

Among	IN	O
the	DT	O
31	CD	O
patients	NNS	O
,	,	O
17	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
pirarubicin	JJ	O
instillation	NN	O
had	VBD	O
fewer	JJR	O
recurrences	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
14	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
control	NN	O
treatment	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

On	IN	O
multivariate	NN	O
analysis	NN	O
,	,	O
pirarubicin	JJ	O
instillation	NN	O
was	VBD	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
better	JJR	O
recurrence-free	JJ	O
survival	NN	O
rates	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
with	IN	O
positive	JJ	O
urine	JJ	O
cytology	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.02	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.00-0.53	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.018	CD	O
)	)	O
.	.	O

Of	IN	O
21	CD	O
patients	NNS	O
with	IN	O
bladder	NN	O
recurrence	NN	O
,	,	O
17	CD	O
had	VBD	O
recurrent	JJ	O
tumor	NN	O
around	IN	O
cystotomy	NN	O
or	CC	O
in	IN	O
the	DT	O
bladder	NN	O
neck	NN	O
compromised	VBN	O
by	IN	O
the	DT	O
urethral	JJ	O
catheter	NN	O
,	,	O
supporting	VBG	O
the	DT	O
notion	NN	O
that	IN	O
tumor	NN	O
cells	NNS	O
seeded	VBN	O
in	IN	O
the	DT	O
injured	JJ	O
urothelium	NN	O
.	.	O

CONCLUSIONS	NNP	O
Intravesical	NNP	O
instillation	NN	O
of	IN	O
pirarubicin	NN	O
immediately	RB	O
after	IN	O
nephroureterectomy	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
bladder	NN	O
recurrence	NN	O
rate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
positive	JJ	O
voided	JJ	O
urine	JJ	O
cytology	NN	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
intravesical	JJ	O
seeding	NN	O
of	IN	O
upper	JJ	O
urinary	JJ	O
tract	NN	O
urothelial	JJ	O
carcinoma	NN	O
occurs	VBZ	O
during	IN	O
nephroureterectomy	NN	O
.	.	O

Effects	NNS	O
of	IN	O
formoterol	NN	O
,	,	O
salmeterol	NN	O
or	CC	O
oxitropium	NN	O
bromide	NN	O
on	IN	O
airway	NN	O
responses	NNS	O
to	TO	O
salbutamol	VB	O
in	IN	O
COPD	NNP	O
.	.	O

We	PRP	O
examined	VBD	O
whether	IN	O
a	DT	O
pretreatment	NN	O
with	IN	O
formoterol	NN	O
,	,	O
oxitropium	NN	O
bromide	NN	O
,	,	O
or	CC	O
salmeterol	NN	O
might	MD	O
modify	VB	O
the	DT	O
dose-response	JJ	O
curves	NNS	O
to	TO	O
inhaled	VB	O
salbutamol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
and	CC	O
partially	RB	O
reversible	JJ	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

Sixteen	JJ	O
outpatients	NNS	O
with	IN	O
partially	RB	Condition
reversible	JJ	Condition
,	,	O
stable	JJ	Condition
COPD	NNP	Condition
received	VBD	O
24	CD	O
microg	NNS	O
formoterol	NN	O
,	,	O
50	CD	O
microg	NN	O
salmeterol	NN	O
,	,	O
200	CD	O
microg	NN	O
oxitropium	NN	O
bromide	NN	O
,	,	O
or	CC	O
placebo	VB	O
on	IN	O
four	CD	O
non-consecutive	JJ	O
days	NNS	O
.	.	O

Spirometric	JJ	O
testing	NN	O
was	VBD	O
performed	VBN	O
immediately	RB	O
before	IN	O
inhalation	NN	O
of	IN	O
treatment	NN	O
and	CC	O
after	IN	O
2	CD	O
h.	VBD	O
A	DT	O
dose-response	JJ	O
curve	NN	O
to	TO	O
inhaled	VB	O
salbutamol	NN	O
was	VBD	O
then	RB	O
constructed	VBN	O
using	VBG	O
doses	NNS	O
of	IN	O
100	CD	O
,	,	O
100	CD	O
,	,	O
200	CD	O
microg	NN	O
and	CC	O
400	CD	O
microg	NN	O
--	:	O
that	WDT	O
is	VBZ	O
,	,	O
a	DT	O
total	JJ	O
cumulative	JJ	O
dose	NN	O
of	IN	O
800	CD	O
microg	NN	O
.	.	O

Dose	JJ	O
increments	NNS	O
were	VBD	O
given	VBN	O
at	IN	O
20	CD	O
min	NN	O
intervals	NNS	O
with	IN	O
measurements	NNS	O
being	VBG	O
made	VBD	O
15	CD	O
min	NNS	O
after	IN	O
each	DT	O
dose	NN	O
.	.	O

Formoterol	NNP	O
,	,	O
salmeterol	NN	O
,	,	O
or	CC	O
oxitropium	NN	O
bromide	RB	O
elicited	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV1	NNP	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
mean	JJ	O
differences	NNS	O
(	(	O
L	NNP	O
)	)	O
=	VBD	O
placebo	$	O
0.05	CD	O
;	:	O
formoterol	NN	O
0.34	CD	O
;	:	O
salmeterol	NN	O
0.27	CD	O
;	:	O
oxitropium	NN	O
bromide	IN	O
0.23	CD	O
)	)	O
.	.	O

Dose-dependent	JJ	O
increases	NNS	O
in	IN	O
FEV1	NNP	O
were	VBD	O
seen	VBN	O
(	(	O
mean	JJ	O
values	NNS	O
(	(	O
L	NNP	O
)	)	O
before	IN	O
salbutamol	NN	O
and	CC	O
after	IN	O
a	DT	O
cumulative	JJ	O
dose	NN	O
of	IN	O
100	CD	O
,	,	O
200	CD	O
,	,	O
400	CD	O
,	,	O
and	CC	O
800	CD	O
microg	NN	O
=	NN	O
placebo	NN	O
:	:	O
1.06	CD	O
,	,	O
1.28	CD	O
,	,	O
1.35	CD	O
,	,	O
1.39	CD	O
,	,	O
1.41	CD	O
;	:	O
formoterol	NN	O
:	:	O
1.33	CD	O
,	,	O
1.37	CD	O
,	,	O
1.41	CD	O
,	,	O
1.44	CD	O
,	,	O
1.44	CD	O
;	:	O
salmeterol	NN	O
:	:	O
1.30	CD	O
,	,	O
1.33	CD	O
,	,	O
1.36	CD	O
,	,	O
1.39	CD	O
,	,	O
1.42	CD	O
;	:	O
oxitropium	JJ	O
bromide	NN	O
:	:	O
1.27	CD	O
,	,	O
1.34	CD	O
,	,	O
1.37	CD	O
,	,	O
1.41	CD	O
,	,	O
1.40	CD	O
)	)	O
.	.	O

Statistical	JJ	O
analysis	NN	O
revealed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
FEV1	NNP	O
and	CC	O
forced	VBD	O
vital	JJ	O
capacity	NN	O
(	(	O
FVC	NNP	O
)	)	O
responses	VBZ	O
to	TO	O
salbutamol	VB	O
after	IN	O
therapy	NN	O
with	IN	O
formoterol	NN	O
,	,	O
salmeterol	NN	O
,	,	O
or	CC	O
oxitropium	NN	O
bromide	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

This	DT	O
study	NN	O
clearly	RB	O
shows	VBZ	O
that	IN	O
a	DT	O
pretreatment	NN	O
with	IN	O
a	DT	O
conventional	JJ	O
dose	NN	O
of	IN	O
formoterol	NN	O
,	,	O
salmeterol	NN	O
,	,	O
or	CC	O
oxitropium	JJ	O
bromide	NN	O
does	VBZ	O
not	RB	O
preclude	VB	O
the	DT	O
possibility	NN	O
of	IN	O
inducing	VBG	O
a	DT	O
further	JJ	O
bronchodilation	NN	O
with	IN	O
salbutamol	NN	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
partially	RB	O
reversible	JJ	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
a	DT	O
decision	NN	O
aid	NN	O
for	IN	O
individuals	NNS	Condition
considering	VBG	Condition
genetic	JJ	Condition
testing	NN	Condition
for	IN	Condition
hereditary	JJ	Condition
nonpolyposis	NN	Condition
colorectal	NN	Condition
cancer	NN	Condition
risk	NN	Condition
.	.	Condition

BACKGROUND	NNP	O
Despite	IN	O
the	DT	O
potential	JJ	O
benefits	NNS	O
of	IN	O
genetic	JJ	O
testing	VBG	O
for	IN	O
hereditary	JJ	O
nonpolyposis	NN	O
colorectal	NN	O
cancer	NN	O
(	(	O
HNPCC	NNP	O
)	)	O
risk	NN	O
,	,	O
individuals	NNS	O
can	MD	O
find	VB	O
the	DT	O
genetic	JJ	O
testing	VBG	O
decision-making	JJ	O
process	NN	O
complicated	VBN	O
and	CC	O
challenging	VBG	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
the	DT	O
current	JJ	O
study	NN	O
was	VBD	O
to	TO	O
measure	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
tailored	JJ	O
decision	NN	O
aid	NN	O
designed	VBN	O
specifically	RB	O
to	TO	O
assist	VB	O
individuals	NNS	O
to	TO	O
make	VB	O
informed	JJ	O
decisions	NNS	O
regarding	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
HNPCC	NNP	O
risk	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
all	DT	O
,	,	O
153	CD	O
individuals	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
the	DT	O
decision	NN	O
aid	NN	O
or	CC	O
a	DT	O
control	JJ	O
pamphlet	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
their	PRP$	O
first	JJ	O
genetic	JJ	O
counseling	NN	O
consultation	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
109	CD	O
(	(	O
71.2	CD	O
%	NN	O
)	)	O
completed	VBD	O
the	DT	O
first	JJ	O
questionnaire	NN	O
1	CD	O
week	NN	O
after	IN	O
consultation	NN	O
,	,	O
whereas	IN	O
95	CD	O
(	(	O
62.1	CD	O
%	NN	O
)	)	O
completed	VBD	O
the	DT	O
6-month	JJ	O
follow-up	JJ	O
questionnaire	NN	O
.	.	O

RESULTS	CC	O
Although	IN	O
the	DT	O
decision	NN	O
aid	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
postdecisional	JJ	O
regret	NN	O
or	CC	O
actual	JJ	O
genetic	JJ	O
testing	VBG	O
decision	NN	O
,	,	O
the	DT	O
trial	NN	O
results	NNS	O
demonstrated	VBD	O
that	IN	O
participants	NNS	O
who	WP	O
received	VBD	O
the	DT	O
decision	NN	O
aid	NN	O
had	VBD	O
significantly	RB	O
lower	JJR	O
levels	NNS	O
of	IN	O
decisional	JJ	O
conflict	NN	O
(	(	O
ie	JJ	O
,	,	O
uncertainty	NN	O
)	)	O
regarding	VBG	O
genetic	JJ	O
testing	NN	O
(	(	O
chi-square	JJ	O
(	(	O
1	CD	O
)	)	O
=	NN	O
8.97	CD	O
;	:	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
and	CC	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
classified	VBN	O
as	IN	O
having	VBG	O
made	VBN	O
an	DT	O
informed	JJ	O
choice	NN	O
concerning	VBG	O
genetic	JJ	O
testing	NN	O
(	(	O
chi-square	JJ	O
(	(	O
1	CD	O
)	)	O
=	NN	O
4.37	CD	O
;	:	O
P	NNP	O
=	NNP	O
.037	NNP	O
)	)	O
than	IN	O
participants	NNS	O
who	WP	O
received	VBD	O
a	DT	O
control	NN	O
pamphlet	NN	O
.	.	O

Also	RB	O
,	,	O
men	NNS	O
who	WP	O
received	VBD	O
the	DT	O
decision	NN	O
aid	NN	O
had	VBD	O
significantly	RB	O
higher	JJR	O
knowledge	NN	O
levels	NNS	O
regarding	VBG	O
genetic	JJ	O
testing	NN	O
compared	VBN	O
with	IN	O
men	NNS	Condition
who	WP	O
received	VBD	O
the	DT	O
control	NN	O
pamphlet	NN	O
,	,	O
whereas	JJ	O
no	DT	O
such	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
women	NNS	Condition
(	(	O
chi-square	NN	O
(	(	O
2	CD	O
)	)	O
=	NN	O
6.76	CD	O
;	:	O
P	NNP	O
=	NNP	O
.034	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
decision	NN	O
aid	NN	O
for	IN	O
individuals	NNS	O
considering	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
HNPCC	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	O
intervention	NN	O
to	TO	O
reduce	VB	O
uncertainty	NN	O
and	CC	O
assist	JJ	O
individuals	NNS	O
to	TO	O
make	VB	O
an	DT	O
informed	JJ	O
choice	NN	O
regarding	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
HNPCC	NNP	O
after	IN	O
genetic	JJ	O
counseling	NN	O
.	.	O

A	DT	O
randomized	JJ	O
prospective	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	O
versus	IN	O
oral	JJ	O
valacyclovir	NN	O
for	IN	O
prophylaxis	NN	O
of	IN	O
cytomegalovirus	NN	O
disease	NN	O
after	IN	O
renal	JJ	Condition
transplantation	NN	Condition
.	.	Condition

Oral	NNP	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
cytomegalovirus	NN	O
(	(	O
CMV	NNP	O
)	)	O
disease	NN	O
after	IN	O
renal	JJ	O
transplantation	NN	O
(	(	O
RTx	NNP	O
)	)	O
.	.	O

Our	PRP$	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
,	,	O
costs	NNS	O
,	,	O
and	CC	O
safety	NN	O
of	IN	O
oral	JJ	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
in	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
over	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
after	IN	O
RTx	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
38	CD	O
patients	NNS	O
was	VBD	O
randomized	VBN	O
to	TO	O
3-month	JJ	O
treatment	NN	O
with	IN	O
either	DT	O
oral	JJ	O
ganciclovir	NN	O
(	(	O
1	CD	O
g	NN	O
t.i.d.	NN	O
,	,	O
n=14	RB	O
,	,	O
GAN	NNP	O
group	NN	O
)	)	O
or	CC	O
oral	JJ	O
valacyclovir	NN	O
(	(	O
2	CD	O
g	NN	O
q.i.d.	NN	O
,	,	O
n=12	RB	O
,	,	O
VAL	NNP	O
group	NN	O
)	)	O
.	.	O

A	DT	O
third	JJ	O
group	NN	O
(	(	O
C	NNP	O
,	,	O
n=12	NN	O
)	)	O
received	VBD	O
no	DT	O
prophylaxis	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
monitored	VBN	O
by	IN	O
CMV-nested	JJ	O
PCR	NNP	O
in	IN	O
whole	JJ	O
blood	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
their	PRP$	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
immunosuppressive	JJ	O
protocols	NNS	O
,	,	O
or	CC	O
donor	NN	O
and	CC	O
recipient	NN	O
CMV	NNP	O
serology	NN	O
.	.	O

Thirty-six	CD	O
out	IN	O
of	IN	O
38	CD	O
(	(	O
94.7	CD	O
%	NN	O
)	)	O
recipients	NNS	O
were	VBD	O
CMV-seropositive	JJ	O
.	.	O

Over	IN	O
the	DT	O
6-month	JJ	O
post-RTx	JJ	O
period	NN	O
,	,	O
there	EX	O
were	VBD	O
13	CD	O
episodes	NNS	O
of	IN	O
CMV	NNP	O
disease	NN	O
in	IN	O
eight	CD	O
(	(	O
66.7	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
the	DT	O
C	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
none	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
and	CC	O
VAL	NNP	O
groups	NNS	O
(	(	O
P=0.0005	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.001	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
CMV	NNP	O
viremia	NN	O
was	VBD	O
30.8	CD	O
%	NN	O
,	,	O
50.0	CD	O
%	NN	O
,	,	O
and	CC	O
91.7	CD	O
%	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.004	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.07	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=NS	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
VAL	NNP	O
)	)	O
.	.	O

Treatment	JJ	O
failure	NN	O
(	(	O
death	NN	O
,	,	O
graft	NN	O
loss	NN	O
,	,	O
CMV	NNP	O
disease	NN	O
,	,	O
or	CC	O
withdrawal	NN	O
from	IN	O
study	NN	O
)	)	O
occurred	VBD	O
in	IN	O
14.3	CD	O
%	NN	O
,	,	O
0	CD	O
%	NN	O
and	CC	O
66.7	CD	O
%	NN	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.014	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=0.001	NNP	O
,	,	O
VAL	NNP	O
vs	NNP	O
C	NNP	O
;	:	O
P=NS	NNP	O
,	,	O
GAN	NNP	O
vs	NNP	O
VAL	NNP	O
)	)	O
.	.	O

The	DT	O
average	JJ	O
CMV-associated	JJ	O
costs	NNS	O
per	IN	O
patient	NN	O
(	(	O
in	IN	O
2001	CD	O
euros	NN	O
)	)	O
were	VBD	O
2,449+/-1,178	JJ	O
,	,	O
2,485+/-581	JJ	O
,	,	O
and	CC	O
4,259+/-4,616	JJ	O
in	IN	O
the	DT	O
GAN	NNP	O
,	,	O
VAL	NNP	O
,	,	O
and	CC	O
C	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Ganciclovir	NNP	O
and	CC	O
valacyclovir	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
,	,	O
with	IN	O
ganciclovir	JJ	O
having	VBG	O
had	VBD	O
to	TO	O
be	VB	O
withdrawn	VBN	O
shortly	RB	O
in	IN	O
one	CD	O
patient	NN	O
only	RB	O
because	IN	O
of	IN	O
thrombocytopenia	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
oral	JJ	O
ganciclovir	NN	O
and	CC	O
valacyclovir	NN	O
are	VBP	O
equally	RB	O
safe	JJ	O
and	CC	O
effective	JJ	O
in	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
CMV	NNP	O
disease	NN	O
after	IN	O
RTx	NNP	O
.	.	O

Both	DT	O
are	VBP	O
cost-effective	JJ	O
and	CC	O
help	VB	O
reduce	VB	O
CMV-associated	JJ	O
costs	NNS	O
by	IN	O
some	DT	O
40	CD	O
%	NN	O
compared	VBN	O
with	IN	O
patients	NNS	O
without	IN	O
prophylaxis	NN	O
.	.	O

Comparison	NNP	O
with	IN	O
computed	JJ	O
tomography	NN	O
of	IN	O
two	CD	O
ultrasound	JJ	O
devices	NNS	O
for	IN	O
diagnosis	NN	O
of	IN	O
abdominal	JJ	Condition
aortic	JJ	Condition
aneurysm	NN	Condition
.	.	Condition

Screening	VBG	O
for	IN	O
abdominal	JJ	O
aortic	JJ	O
aneurysms	NNS	O
(	(	O
AAAs	NNP	O
)	)	O
in	IN	O
patients	NNS	O
at	IN	O
risk	NN	O
will	MD	O
become	VB	O
more	RBR	O
cost	JJ	O
effective	JJ	O
if	IN	O
a	DT	O
simple	NN	O
,	,	O
inexpensive	JJ	O
,	,	O
and	CC	O
reliable	JJ	O
ultrasound	JJ	O
device	NN	O
is	VBZ	O
available	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
a	DT	O
2-dimensional	JJ	O
,	,	O
handheld	JJ	O
ultrasound	JJ	O
device	NN	O
and	CC	O
a	DT	O
newly	RB	O
developed	VBN	O
ultrasound	JJ	O
volume	NN	O
scanner	NN	O
(	(	O
based	VBN	O
on	IN	O
bladder	NN	O
scan	JJ	O
technology	NN	O
)	)	O
with	IN	O
computed	VBN	O
tomography	NN	O
(	(	O
CT	NNP	O
)	)	O
for	IN	O
diagnosing	VBG	O
AAA	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
146	CD	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
69	CD	O
+/-	JJ	O
10	CD	O
years	NNS	O
;	:	O
127	CD	O
men	NNS	O
)	)	O
were	VBD	O
screened	VBN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
AAAs	NNP	O
(	(	O
diameter	NN	O
>	VBZ	O
3	CD	O
cm	NN	O
)	)	O
using	VBG	O
CT.	NNP	O
All	NNP	O
patients	NNS	O
were	VBD	O
examined	VBN	O
with	IN	O
the	DT	O
handheld	NN	O
ultrasound	JJ	O
device	NN	O
and	CC	O
the	DT	O
volume	NN	O
scanner	NN	O
.	.	O

Maximal	JJ	O
diameters	NNS	O
and	CC	O
volumes	NNS	O
were	VBD	O
used	VBN	O
for	IN	O
the	DT	O
analyses	NNS	O
.	.	O

AAAs	NNP	O
were	VBD	O
diagnosed	VBN	O
by	IN	O
CT	NNP	O
in	IN	O
116	CD	O
patients	NNS	O
(	(	O
80	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
absolute	JJ	O
difference	NN	O
of	IN	O
aortic	JJ	O
diameter	NN	O
between	IN	O
ultrasound	NN	O
and	CC	O
CT	NNP	O
was	VBD	O
<	JJ	O
5	CD	O
mm	NN	O
in	IN	O
88	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Limits	NNS	O
of	IN	O
agreement	NN	O
between	IN	O
ultrasound	NN	O
and	CC	O
CT	NNP	O
(	(	O
-6.6	NNP	O
to	TO	O
9.4	CD	O
mm	NN	O
)	)	O
exceeded	VBD	O
the	DT	O
limits	NNS	O
of	IN	O
clinical	JJ	O
acceptability	NN	O
(	(	O
+/-5	JJ	O
mm	NN	O
)	)	O
.	.	O

An	DT	O
excellent	JJ	O
correlation	NN	O
between	IN	O
ultrasound	NN	O
and	CC	O
CT	NNP	O
was	VBD	O
observed	VBN	O
(	(	O
r	JJ	O
=	NNP	O
0.98	CD	O
)	)	O
.	.	O

The	DT	O
correlation	NN	O
coefficient	NN	O
between	IN	O
the	DT	O
volume	NN	O
scanner	NN	O
and	CC	O
CT	NNP	O
was	VBD	O
0.86	CD	O
,	,	O
with	IN	O
agreement	NN	O
of	IN	O
90	CD	O
%	NN	O
and	CC	O
kappa	JJ	O
value	NN	O
of	IN	O
0.73	CD	O
.	.	O

Using	VBG	O
an	DT	O
optimal	JJ	O
cut-off	NN	O
value	NN	O
of	IN	O
>	$	O
56	CD	O
ml	NN	O
,	,	O
defined	VBN	O
by	IN	O
receiver-operating	JJ	O
characteristic	JJ	O
curve	NN	O
analysis	NN	O
,	,	O
sensitivity	NN	O
,	,	O
specificity	NN	O
,	,	O
and	CC	O
the	DT	O
positive	JJ	O
and	CC	O
negative	JJ	O
predictive	JJ	O
values	NNS	O
of	IN	O
the	DT	O
volume	NN	O
scanner	NN	O
for	IN	O
detecting	VBG	O
AAA	NNP	O
were	VBD	O
90	CD	O
%	NN	O
,	,	O
90	CD	O
%	NN	O
,	,	O
97	CD	O
%	NN	O
,	,	O
and	CC	O
71	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
this	DT	O
study	NN	O
shows	VBZ	O
that	IN	O
a	DT	O
2-dimensional	JJ	O
,	,	O
handheld	JJ	O
ultrasound	JJ	O
device	NN	O
and	CC	O
a	DT	O
newly	RB	O
developed	VBN	O
ultrasound	JJ	O
volume	NN	O
scanner	NN	O
can	MD	O
effectively	RB	O
identify	VB	O
patients	NNS	O
with	IN	O
AAAs	NNP	O
confirmed	VBN	O
by	IN	O
CT	NNP	O
.	.	O

Controlled-release	NNP	O
melatonin	NN	O
,	,	O
singly	RB	O
and	CC	O
combined	VBN	O
with	IN	O
cognitive	JJ	O
behavioural	JJ	O
therapy	NN	O
,	,	O
for	IN	O
persistent	JJ	O
insomnia	NN	Condition
in	IN	O
children	NNS	Age
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorders	NNS	Condition
:	:	O
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

Although	IN	O
melatonin	NN	O
and	CC	O
cognitive-behavioural	JJ	O
therapy	NN	O
have	VBP	O
shown	VBN	O
efficacy	NN	O
in	IN	O
treating	VBG	O
sleep	JJ	O
disorders	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
their	PRP$	O
relative	NN	O
or	CC	O
combined	VBN	O
efficacy	NN	O
.	.	O

One	CD	SampleSize
hundred	CD	SampleSize
and	CC	SampleSize
sixty	JJ	SampleSize
children	NNS	O
with	IN	O
autism	NN	Condition
spectrum	NN	Condition
disorders	NNS	Condition
,	,	O
aged	VBN	Age
4-10	CD	Age
years	NNS	Age
,	,	O
suffering	VBG	O
from	IN	O
sleep	JJ	Condition
onset	NN	Condition
insomnia	NN	Condition
and	CC	Condition
impaired	JJ	Condition
sleep	JJ	Condition
maintenance	NN	Condition
,	,	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
either	DT	O
(	(	O
1	CD	O
)	)	O
combination	NN	O
of	IN	O
controlled-release	JJ	O
melatonin	NN	O
and	CC	O
cognitive-behavioural	JJ	O
therapy	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
controlled-release	NN	O
melatonin	NN	O
;	:	O
(	(	O
3	CD	O
)	)	O
four	CD	O
sessions	NNS	O
of	IN	O
cognitive-behavioural	JJ	O
therapy	NN	O
;	:	O
or	CC	O
(	(	O
4	CD	O
)	)	O
placebo	FW	O
drug	NN	O
treatment	NN	O
condition	NN	O
for	IN	O
12	CD	O
weeks	NNS	O
in	IN	O
a	DT	O
1	CD	O
:	:	O
1	CD	O
:	:	O
1	CD	O
:	:	O
1	CD	O
ratio	NN	O
.	.	O

Children	NNP	O
were	VBD	O
studied	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Treatment	NNP	O
response	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
1-week	JJ	O
actigraphic	JJ	O
monitoring	NN	O
,	,	O
sleep	JJ	O
diary	NN	O
and	CC	O
sleep	JJ	O
questionnaire	NN	O
.	.	O

Main	NNP	O
outcome	NN	O
measures	NNS	O
,	,	O
derived	VBN	O
actigraphically	RB	O
,	,	O
were	VBD	O
sleep	JJ	O
latency	NN	O
,	,	O
total	JJ	O
sleep	JJ	O
time	NN	O
,	,	O
wake	VBP	O
after	IN	O
sleep	JJ	O
onset	NN	O
and	CC	O
number	NN	O
of	IN	O
awakenings	NNS	O
.	.	O

The	DT	O
active	JJ	O
treatment	NN	O
groups	NNS	O
all	DT	O
resulted	VBD	O
in	IN	O
improvements	NNS	O
across	IN	O
all	DT	O
outcome	NN	O
measures	NNS	O
,	,	O
with	IN	O
moderate-to-large	JJ	O
effect	NN	O
sizes	VBZ	O
from	IN	O
baseline	NN	O
to	TO	O
a	DT	O
12-week	JJ	O
assessment	NN	O
.	.	O

Melatonin	NNP	O
treatment	NN	O
was	VBD	O
mainly	RB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
insomnia	NN	O
symptoms	NNS	O
,	,	O
while	IN	O
cognitive-behavioural	JJ	O
therapy	NN	O
had	VBD	O
a	DT	O
light	JJ	O
positive	JJ	O
impact	NN	O
mainly	RB	O
on	IN	O
sleep	JJ	O
latency	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
some	DT	O
behavioural	JJ	O
aspects	NNS	O
might	MD	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
determining	VBG	O
initial	JJ	O
insomnia	NN	O
.	.	O

The	DT	O
combination	NN	O
treatment	NN	O
group	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
to	TO	O
outperform	VB	O
other	JJ	O
active	JJ	O
treatment	NN	O
groups	NNS	O
,	,	O
with	IN	O
fewer	JJR	O
dropouts	NNS	O
and	CC	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
treatment	NN	O
responders	NNS	O
achieving	VBG	O
clinically	RB	O
significant	JJ	O
changes	NNS	O
(	(	O
63.38	CD	O
%	NN	O
normative	JJ	O
sleep	JJ	O
efficiency	NN	O
criterion	NN	O
of	IN	O
>	$	O
85	CD	O
%	NN	O
and	CC	O
84.62	CD	O
%	NN	O
,	,	O
sleep	JJ	O
onset	NN	O
latency	NN	O
<	VBD	O
30	CD	O
min	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
demonstrates	VBZ	O
that	IN	O
adding	VBG	O
behavioural	JJ	O
intervention	NN	O
to	TO	O
melatonin	VB	O
treatment	NN	O
seems	VBZ	O
to	TO	O
result	VB	O
in	IN	O
a	DT	O
better	JJR	O
treatment	NN	O
response	NN	O
,	,	O
at	IN	O
least	JJS	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
.	.	O

Effect	NN	O
of	IN	O
indomethacin	JJ	O
phonophoresis	NN	O
on	IN	O
the	DT	O
relief	NN	O
of	IN	O
temporomandibular	JJ	O
joint	NN	O
pain	NN	O
.	.	O

The	DT	O
pain-relieving	JJ	O
effect	NN	O
of	IN	O
indomethacin	JJ	O
phonophoresis	NN	O
on	IN	O
temporomandibular	NN	O
(	(	O
TMJ	NNP	O
)	)	O
joint	NN	O
pain	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Twenty	NNP	O
subjects	NNS	O
,	,	O
who	WP	O
have	VBP	O
TMJ	NNP	O
pain	NN	O
,	,	O
were	VBD	O
included	VBN	O
for	IN	O
this	DT	O
study	NN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

Each	DT	O
treatment	NN	O
consisted	VBN	O
of	IN	O
the	DT	O
application	NN	O
of	IN	O
ultrasound	JJ	O
massage	NN	O
(	(	O
1.0	CD	O
MHz	NNP	O
,	,	O
0.8	CD	O
to	TO	O
1.5	CD	O
W/cm2	NNP	O
continuous	JJ	O
output	NN	O
)	)	O
for	IN	O
15	CD	O
minutes	NNS	O
to	TO	O
the	DT	O
painful	JJ	O
temporomandibular	JJ	O
joint	NN	O
.	.	O

As	IN	O
a	DT	O
conducting	NN	O
medium	NN	O
,	,	O
1	CD	O
%	NN	O
indomethacin	JJ	O
cream	NN	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
and	CC	O
placebo	NN	O
cream	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
respectively	RB	O
.	.	O

Pre-	JJ	O
and	CC	O
post-treatment	JJ	O
pain	NN	O
levels	NNS	O
and	CC	O
pain	NN	O
sensitivity	NN	O
were	VBD	O
assessed	VBN	O
with	IN	O
visual	JJ	O
analogue	NN	O
scales	NNS	O
(	(	O
VAS	NNP	O
)	)	O
and	CC	O
pressure	NN	O
pain	NN	O
threshold	NN	O
(	(	O
PPT	NNP	O
)	)	O
.	.	O

Mean	NNP	O
data	NNS	O
indicated	VBD	O
that	IN	O
post-treatment	JJ	O
VAS	NNP	O
was	VBD	O
significantly	RB	O
decreased	VBN	O
and	CC	O
post-treatment	JJ	O
PPT	NNP	O
was	VBD	O
significantly	RB	O
increased	VBN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
,	,	O
not	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
indomethacin	JJ	O
phonophoresis	NN	O
provides	VBZ	O
significant	JJ	O
pain	NN	O
relieving	VBG	O
effect	NN	O
over	IN	O
the	DT	O
TMJ	NNP	O
pain	NN	O
.	.	O

West	NNP	O
Midlands	NNP	O
Oncology	NNP	O
Association	NNP	O
trials	NNS	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
in	IN	O
operable	JJ	O
breast	NN	Condition
cancer	NN	Condition
:	:	O
results	NNS	O
after	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
7	CD	O
years	NNS	O
.	.	O

I	PRP	O
.	.	O

Patients	NNS	O
with	IN	O
involved	JJ	Condition
axillary	JJ	Condition
lymph	NN	Condition
nodes	NNS	Condition
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
regimen	NNS	O
of	IN	O
combination	NN	O
chemotherapy	NN	O
known	VBN	O
to	TO	O
be	VB	O
active	JJ	O
in	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
when	WRB	O
given	VBN	O
as	IN	O
an	DT	O
adjuvant	JJ	O
treatment	NN	O
after	IN	O
mastectomy	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
569	CD	SampleSize
patients	NNS	O
with	IN	O
cancer	NN	Condition
of	IN	Condition
the	DT	Condition
breast	NN	Condition
and	CC	O
involvement	NN	Condition
of	IN	Condition
axillary	JJ	Condition
lymph	NN	Condition
nodes	NNS	Condition
were	VBD	O
randomised	VBN	O
,	,	O
after	IN	O
simple	JJ	O
mastectomy	NN	O
with	IN	O
axillary	JJ	O
sampling	NN	O
,	,	O
to	TO	O
receive	VB	O
either	DT	O
no	DT	O
adjuvant	JJ	O
treatment	NN	O
or	CC	O
intravenous	JJ	O
adriamycin	NNS	O
50	CD	O
mg	NN	O
,	,	O
vincristine	VBP	O
1	CD	O
mg	NN	O
,	,	O
cyclophosphamide	RB	O
250	CD	O
mg	NN	O
,	,	O
methotrexate	VB	O
150	CD	O
mg	NN	O
and	CC	O
fluorouracil	NN	O
250	CD	O
mg	NN	O
(	(	O
AVCMF	NNP	O
)	)	O
every	DT	O
21	CD	O
days	NNS	O
for	IN	O
eight	CD	O
cycles	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
menopausal	NN	O
status	NN	O
and	CC	O
tumour	NN	O
size	NN	O
.	.	O

Treatment	NN	O
was	VBD	O
started	VBN	O
within	IN	O
14	CD	O
days	NNS	O
of	IN	O
surgery	NN	O
in	IN	O
94	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Eighty-eight	JJ	O
per	IN	O
cent	NN	O
of	IN	O
patients	NNS	O
received	VBN	O
at	IN	O
least	JJS	O
seven	CD	O
cycles	NNS	O
of	IN	O
chemotherapy	NN	O
with	IN	O
no	DT	O
dose	JJ	O
reduction	NN	O
.	.	O

The	DT	O
median	JJ	O
relapse-free	JJ	O
survival	NN	O
was	VBD	O
prolonged	VBN	O
by	IN	O
14	CD	O
months	NNS	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
AVCMF	NNP	O
(	(	O
chi2	JJ	O
1	CD	O
=	JJ	O
11.7	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.0006	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
premenopausal	NN	Condition
group	NN	O
this	DT	O
period	NN	O
was	VBD	O
17	CD	O
months	NNS	O
(	(	O
chi2	JJ	O
1	CD	O
=	JJ	O
8.8	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
compared	VBN	O
with	IN	O
8	CD	O
months	NNS	O
in	IN	O
the	DT	O
post-menopausal	JJ	Condition
group	NN	O
(	(	O
chi2	JJ	O
1	CD	O
=	JJ	O
3.3	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.07	CD	O
)	)	O
.	.	O

Neither	CC	O
overall	JJ	O
survival	NN	O
nor	CC	O
survival	NN	O
in	IN	O
these	DT	O
subgroups	NNS	O
was	VBD	O
significantly	RB	O
influenced	VBN	O
by	IN	O
treatment	NN	O
.	.	O

Magnesium	NN	O
sulphate	NN	O
only	RB	O
slightly	RB	O
reduces	VBZ	O
the	DT	O
shivering	VBG	Condition
threshold	NN	Condition
in	IN	Condition
humans	NNS	Condition
.	.	Condition

BACKGROUND	NNP	O
Hypothermia	NNP	O
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
stroke	NN	O
or	CC	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
;	:	O
however	RB	O
,	,	O
it	PRP	O
provokes	VBZ	O
vigorous	JJ	O
shivering	NN	O
,	,	O
which	WDT	O
causes	VBZ	O
potentially	RB	O
dangerous	JJ	O
haemodynamic	JJ	O
responses	NNS	O
and	CC	O
prevents	NNS	O
further	RBR	O
hypothermia	NN	O
.	.	O

Magnesium	NNP	O
is	VBZ	O
an	DT	O
attractive	JJ	O
anti-shivering	NN	O
agent	NN	O
because	IN	O
it	PRP	O
is	VBZ	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
postoperative	JJ	O
shivering	NN	O
and	CC	O
provides	VBZ	O
protection	NN	O
against	IN	O
ischaemic	JJ	O
injury	NN	O
in	IN	O
animal	JJ	O
models	NNS	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
magnesium	NN	O
reduces	VBZ	O
the	DT	O
threshold	NN	O
(	(	O
triggering	VBG	O
core	RB	O
temperature	NN	O
)	)	O
and	CC	O
gain	NN	O
of	IN	O
shivering	VBG	O
without	IN	O
substantial	JJ	O
sedation	NN	O
or	CC	O
muscle	NN	O
weakness	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
studied	VBD	O
nine	CD	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
(	(	O
18-40	JJ	O
yr	NN	O
)	)	O
on	IN	O
two	CD	O
randomly	NNS	O
assigned	VBN	O
treatment	NN	O
days	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
control	NN	O
and	CC	O
(	(	O
2	CD	O
)	)	O
magnesium	NN	O
(	(	O
80	CD	O
mg	NN	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
followed	VBN	O
by	IN	O
infusion	NN	O
at	IN	O
2	CD	O
g	NN	O
h	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
.	.	O

Lactated	VBN	O
Ringer	NNP	O
's	POS	O
solution	NN	O
(	(	O
4	CD	O
degrees	NNS	O
C	NNP	O
)	)	O
was	VBD	O
infused	VBN	O
via	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
approximately	RB	O
2	CD	O
h	NN	O
to	TO	O
decrease	VB	O
tympanic	JJ	O
membrane	NN	O
temperature	NN	O
by	IN	O
approximately	RB	O
1.5	CD	O
degrees	NNS	O
C	NNP	O
h	NN	O
(	(	O
-1	NNP	O
)	)	O
.	.	O

A	DT	O
significant	JJ	O
and	CC	O
persistent	JJ	O
increase	NN	O
in	IN	O
oxygen	JJ	O
consumption	NN	O
identified	VBD	O
the	DT	O
threshold	NN	O
.	.	O

The	DT	O
gain	NN	O
of	IN	O
shivering	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
the	DT	O
slope	NN	O
of	IN	O
oxygen	NN	O
consumption	NN	O
vs	NN	O
core	NN	O
temperature	NN	O
regression	NN	O
.	.	O

Sedation	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
verbal	JJ	O
rating	NN	O
score	NN	O
(	(	O
VRS	NNP	O
)	)	O
from	IN	O
0	CD	O
to	TO	O
10	CD	O
and	CC	O
bispectral	JJ	O
index	NN	O
(	(	O
BIS	NNP	O
)	)	O
of	IN	O
the	DT	O
EEG	NNP	O
.	.	O

Peripheral	NNP	O
muscle	NN	O
strength	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
dynamometry	NN	O
and	CC	O
spirometry	NN	O
.	.	O

Data	NNS	O
were	VBD	O
analysed	VBN	O
using	VBG	O
repeated	JJ	O
measures	NNS	O
anova	VBP	O
;	:	O
P	NNP	O
<	VBD	O
0.05	CD	O
was	VBD	O
statistically	RB	O
significant	JJ	O
.	.	O

RESULTS	NNP	O
Magnesium	NNP	O
reduced	VBD	O
the	DT	O
shivering	NN	O
threshold	NN	O
(	(	O
36.3	CD	O
[	NNP	O
SD	NNP	O
0.4	CD	O
]	NNP	O
degrees	NNS	O
C	NNP	O
vs	VBD	O
36.6	CD	O
[	JJ	O
0.3	CD	O
]	NN	O
degrees	NNS	O
C	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.040	CD	O
)	)	O
.	.	O

It	PRP	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
gain	NN	O
of	IN	O
shivering	VBG	O
(	(	O
control	NN	O
,	,	O
437	CD	O
[	NN	O
289	CD	O
]	NN	O
ml	NN	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
degrees	VBZ	O
C	NNP	O
(	(	O
-1	NNP	O
)	)	O
;	:	O
magnesium	NN	O
,	,	O
573	CD	O
[	NN	O
370	CD	O
]	NN	O
ml	NN	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
degrees	VBZ	O
C	NNP	O
(	(	O
-1	NNP	O
)	)	O
;	:	O
P=0.344	NNP	O
)	)	O
.	.	O

The	DT	O
magnesium	NN	O
bolus	NN	O
did	VBD	O
not	RB	O
produce	VB	O
significant	JJ	O
sedation	NN	O
or	CC	O
appreciably	RB	O
reduce	VB	O
muscle	NN	O
strength	NN	O
.	.	O

CONCLUSIONS	NNP	O
Magnesium	NNP	O
significantly	RB	O
reduced	VBD	O
the	DT	O
shivering	NN	O
threshold	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
view	NN	O
of	IN	O
the	DT	O
modest	JJ	O
absolute	NN	O
reduction	NN	O
,	,	O
this	DT	O
finding	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
clinically	RB	O
unimportant	JJ	O
for	IN	O
induction	NN	O
of	IN	O
therapeutic	JJ	O
hypothermia	NN	O
.	.	O

Blind	NNP	O
versus	NN	O
open	JJ	O
approach	NN	O
to	TO	O
laparoscopic	VB	O
cholecystectomy	NN	O
:	:	O
a	DT	O
randomized	JJ	O
study	NN	O
.	.	O

Intraabdominal	NNP	O
structures	NNS	O
may	MD	O
be	VB	O
damaged	VBN	O
during	IN	O
blind	JJ	O
introduction	NN	O
of	IN	O
the	DT	O
first	JJ	O
trocar	NN	O
for	IN	O
laparoscopic	JJ	O
operations	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
150	CD	SampleSize
patients	NNS	O
with	IN	O
gallbladder	JJ	Condition
lithiasis	NN	Condition
who	WP	O
underwent	JJ	O
laparoscopy	NN	Condition
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
,	,	O
a	DT	O
blind	NN	O
(	(	O
V	NNP	O
group	NN	O
)	)	O
or	CC	O
an	DT	O
open	JJ	O
(	(	O
H	NNP	O
group	NN	O
)	)	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
compare	VB	O
the	DT	O
results	NNS	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
complications	NNS	O
.	.	O

No	DT	O
mortality	NN	O
was	VBD	O
observed	VBN	O
.	.	O

Major	JJ	O
complications	NNS	O
occurred	VBD	O
in	IN	O
3/75	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
the	DT	O
V	NNP	O
group	NN	O
and	CC	O
in	IN	O
1/75	CD	O
(	(	O
1.3	CD	O
%	NN	O
)	)	O
patient	NN	O
of	IN	O
the	DT	O
H	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Minor	JJ	O
complications	NNS	O
occurred	VBD	O
in	IN	O
5/75	CD	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
patients	NNS	O
of	IN	O
either	DT	O
group	NN	O
.	.	O

The	DT	O
achievement	NN	O
of	IN	O
pneumoperitoneum	NN	O
required	VBN	O
4.5+/-0.4	JJ	O
min	NN	O
in	IN	O
the	DT	O
V	NNP	O
group	NN	O
and	CC	O
3.2+/-0.2	JJ	O
min	NN	O
in	IN	O
the	DT	O
H	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
open	JJ	O
laparoscopic	NN	O
technique	NN	O
is	VBZ	O
safer	JJR	O
and	CC	O
faster	RBR	O
than	IN	O
the	DT	O
blind	JJ	O
approach	NN	O
;	:	O
therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
this	DT	O
approach	NN	O
be	VB	O
routinely	RB	O
used	VBN	O
in	IN	O
all	DT	O
laparoscopic	NN	O
procedures	NNS	O
.	.	O

Gastrointestinal	NNP	O
safety	NN	O
of	IN	O
NO-aspirin	NNP	O
(	(	O
NCX-4016	NNP	O
)	)	O
in	IN	O
healthy	JJ	Condition
human	JJ	Condition
volunteers	NNS	O
:	:	O
a	DT	O
proof	NN	O
of	IN	O
concept	NN	O
endoscopic	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
NCX-4016	NNP	O
is	VBZ	O
a	DT	O
nitric	JJ	O
oxide-releasing	JJ	O
derivative	NN	O
of	IN	O
aspirin	NN	O
with	IN	O
antiplatelet	NN	O
activity	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
NCX-4016	NNP	O
on	IN	O
gastrointestinal	JJ	O
mucosa	NN	O
and	CC	O
platelet	NN	O
functions	NNS	O
in	IN	O
healthy	JJ	Condition
human	JJ	Condition
volunteers	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Forty	NNP	SampleSize
healthy	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
7	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
NCX-4016	NNP	O
(	(	O
400	CD	O
and	CC	O
800	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
,	,	O
equimolar	JJ	O
doses	NNS	O
of	IN	O
aspirin	NN	O
(	(	O
200	CD	O
and	CC	O
420	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
.	.	O

Upper	IN	O
endoscopies	NNS	O
were	VBD	O
performed	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
and	CC	O
gastroduodenal	JJ	O
lesions	NNS	O
were	VBD	O
graded	VBN	O
using	VBG	O
a	DT	O
predefined	VBN	O
scoring	NN	O
system	NN	O
.	.	O

Basal	NNP	O
and	CC	O
posttreatment	JJ	O
platelet	NN	O
aggregation	NN	O
in	IN	O
response	NN	O
to	TO	O
arachidonic	JJ	O
acid	NN	O
(	(	O
AA	NNP	O
)	)	O
and	CC	O
serum	JJ	O
thromboxane	NN	O
(	(	O
TX	NNP	O
)	)	O
B	NNP	O
(	(	O
2	CD	O
)	)	O
and	CC	O
AA-stimulated	JJ	O
platelet	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
production	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

RESULTS	NNP	O
Mucosal	NNP	O
endoscopic	JJ	O
injury	NN	O
score	NN	O
on	IN	O
day	NN	O
7	CD	O
was	VBD	O
0.63	CD	O
+/-	JJ	O
0.16	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
11.0	CD	O
+/-	JJ	O
3.0	CD	O
and	CC	O
16.1	CD	O
+/-	JJ	O
1.6	CD	O
in	IN	O
healthy	JJ	Condition
volunteers	NNS	O
treated	VBD	O
with	IN	O
200	CD	O
and	CC	O
420	CD	O
mg	NN	O
aspirin	JJ	O
twice	RB	O
daily	RB	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	NN	O
was	VBD	O
virtually	RB	O
devoid	JJ	O
of	IN	O
gastric	JJ	O
and	CC	O
duodenal	JJ	O
toxicity	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
total	JJ	O
gastric	NN	O
and	CC	O
duodenal	JJ	O
endoscopic	NN	O
score	NN	O
of	IN	O
1.38	CD	O
+/-	JJ	O
0.3	CD	O
and	CC	O
1.25	CD	O
+/-	JJ	O
0.5	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	NN	O
aspirin	NN	O
,	,	O
not	RB	O
significant	JJ	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	JJ	O
inhibited	JJ	O
AA-induced	JJ	O
platelet	NN	O
aggregation	NN	O
as	RB	O
well	RB	O
as	IN	O
serum	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
and	CC	O
platelet	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
generation	NN	O
induced	VBN	O
by	IN	O
AA	NNP	O
to	TO	O
the	DT	O
same	JJ	O
extent	NN	O
as	IN	O
aspirin	NN	O
(	(	O
not	RB	O
significant	JJ	O
vs.	FW	O
aspirin	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
have	VBP	O
proven	VBN	O
the	DT	O
concept	NN	O
that	IN	O
addition	NN	O
of	IN	O
an	DT	O
NO-donating	JJ	O
moiety	NN	O
to	TO	O
aspirin	VB	O
results	NNS	O
in	IN	O
a	DT	O
new	JJ	O
chemical	NN	O
entity	NN	O
that	WDT	O
maintains	VBZ	O
cyclooxygenase-1	NN	O
and	CC	O
platelet	VB	O
inhibitory	JJ	O
activity	NN	O
while	IN	O
nearly	RB	O
avoiding	VBG	O
gastrointestinal	JJ	O
damage	NN	O
.	.	O

Hemodynamic	JJ	O
effects	NNS	O
during	IN	O
induction	NN	O
,	,	O
laryngoscopy	NN	O
,	,	O
and	CC	O
intubation	NN	O
with	IN	O
eltanolone	NN	O
(	(	O
5	CD	O
beta-pregnanolone	NN	O
)	)	O
or	CC	O
propofol	NN	O
.	.	O

A	DT	O
study	NN	O
in	IN	O
ASA	NNP	Condition
I	PRP	Condition
and	CC	Condition
II	NNP	Condition
patients	NNS	Condition
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
cardiovascular	JJ	O
changes	NNS	O
following	VBG	O
induction	NN	O
of	IN	O
anesthesia	NN	O
,	,	O
laryngoscopy	NN	O
,	,	O
and	CC	O
intubation	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
a	DT	O
bolus	NN	O
dose	NN	O
of	IN	O
either	CC	O
eltanolone	NN	O
or	CC	O
propofol	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
,	,	O
blind	NN	O
,	,	O
prospective	JJ	O
clinical	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
General	NNP	O
operating	VBG	O
theaters	NNS	O
of	IN	O
a	DT	O
university	NN	O
hospital	NN	O
.	.	O

PATIENTS	CC	O
40	CD	SampleSize
ASA	NNP	O
status	NN	O
I	PRP	O
and	CC	O
II	NNP	O
patients	NNS	O
scheduled	VBN	Condition
for	IN	Condition
elective	JJ	Condition
surgery	NN	Condition
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
were	VBD	O
premedicated	VBN	O
with	IN	O
oral	JJ	O
temazepam	NN	O
20	CD	O
mg.	NN	O
Anesthesia	NNP	O
was	VBD	O
induced	VBN	O
with	IN	O
either	DT	O
eltanolone	NN	O
0.58	CD	O
mg/kg	NN	O
or	CC	O
propofol	VB	O
1.7	CD	O
mg/kg	NN	O
,	,	O
neuromuscular	JJ	O
blockade	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
vecuronium	NN	O
0.1	CD	O
mg/kg	NN	O
,	,	O
and	CC	O
anesthesia	NN	O
was	VBD	O
maintained	VBN	O
with	IN	O
enflurane	JJ	O
0.5	CD	O
%	NN	O
to	TO	O
1.0	CD	O
%	NN	O
in	IN	O
nitrous	JJ	O
oxide	NN	O
(	(	O
67	CD	O
%	NN	O
)	)	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Blood	NNP	O
pressure	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
automatic	JJ	O
oscillometric	NN	O
technique	NN	O
,	,	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
was	VBD	O
derived	VBN	O
from	IN	O
the	DT	O
ECG	NNP	O
,	,	O
oxygen	NN	O
saturation	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
pulse	JJ	O
oximetry	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
output	NN	O
(	(	O
Q	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
thoracic	JJ	O
bioimpedance	NN	O
technique	NN	O
.	.	O

Induction	NN	O
of	IN	O
anesthesia	NN	O
with	IN	O
either	DT	O
drug	NN	O
,	,	O
eltanolone	NN	O
or	CC	O
propofol	NN	O
,	,	O
decreased	VBN	O
arterial	JJ	O
systolic	NN	O
(	(	O
SAP	NNP	O
)	)	O
and	CC	O
diastolic	JJ	O
(	(	O
DAP	NNP	O
)	)	O
blood	NN	O
pressure	NN	O
,	,	O
Q	NNP	O
,	,	O
and	CC	O
stroke	NN	O
volume	NN	O
(	(	O
SV	NNP	O
)	)	O
.	.	O

HR	NNP	O
increased	VBD	O
.	.	O

Systemic	NNP	O
vascular	JJ	O
resistance	NN	O
(	(	O
SVR	NNP	O
)	)	O
was	VBD	O
unaltered	VBN	O
.	.	O

After	IN	O
laryngoscopy	NN	O
and	CC	O
intubation	NN	O
,	,	O
SAP	NNP	O
and	CC	O
DAP	NNP	O
increased	VBD	O
secondary	JJ	O
to	TO	O
an	DT	O
increase	NN	O
in	IN	O
SVR	NNP	O
.	.	O

HR	NNP	O
also	RB	O
increased	VBD	O
;	:	O
SV	NNP	O
decreased	VBD	O
in	IN	O
patients	NNS	O
receiving	VBG	O
eltanolone	NN	O
.	.	O

Side	JJ	O
effects	NNS	O
(	(	O
e.g.	NN	O
,	,	O
apnea	NN	O
occurring	VBG	O
for	IN	O
more	JJR	O
than	IN	O
30	CD	O
seconds	NNS	O
,	,	O
involuntary	JJ	O
movements	NNS	O
,	,	O
limb	FW	O
hypertonus	NN	O
)	)	O
occurred	VBD	O
at	IN	O
a	DT	O
similar	JJ	O
incidence	NN	O
with	IN	O
both	DT	O
treatments	NNS	O
,	,	O
but	CC	O
pain	VBP	O
following	VBG	O
injection	NN	O
was	VBD	O
greater	JJR	O
with	IN	O
propofol	NN	O
(	(	O
59	CD	O
%	NN	O
vs.	FW	O
9	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	JJ	O
Patients	NNPS	O
receiving	VBG	O
either	CC	O
eltanolone	NN	O
or	CC	O
propofol	NN	O
showed	VBD	O
similar	JJ	O
cardiovascular	JJ	O
changes	NNS	O
to	TO	O
induction	NN	O
of	IN	O
anesthesia	NN	O
,	,	O
although	IN	O
there	EX	O
were	VBD	O
greater	JJR	O
increases	NNS	O
in	IN	O
arterial	JJ	O
pressure	NN	O
and	CC	O
HR	NNP	O
in	IN	O
those	DT	O
patients	NNS	O
receiving	VBG	O
eltanolone	NN	O
.	.	O

Recurrence	NN	O
of	IN	O
condylomata	NNS	Condition
acuminata	NNS	Condition
following	VBG	Condition
cryotherapy	NN	Condition
is	VBZ	O
not	RB	O
prevented	VBN	O
by	IN	O
systemically	RB	O
administered	VBN	O
interferon	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
whether	IN	O
interferon	JJ	O
alpha-2a	NN	O
,	,	O
when	WRB	O
utilised	JJ	O
as	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
following	VBG	O
ablation	NN	O
of	IN	O
condylomata	NN	O
acuminata	NNS	O
(	(	O
genital	JJ	O
warts	NNS	O
)	)	O
by	IN	O
cryotherapy	NN	O
,	,	O
is	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
recurrences	NNS	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
by	IN	O
2-tailed	JJ	O
Fisher	NNP	O
's	POS	O
Exact	NNP	O
Test	NNP	O
.	.	O

PATIENTS	CC	O
97	CD	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
condylomata	NN	O
acuminata	NN	O
.	.	Condition

INTERVENTION	NNP	O
49	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
cryotherapy	NN	O
plus	CC	O
subcutaneously	RB	O
administered	VBN	O
interferon	NN	O
alpha-2a	NN	O
,	,	O
and	CC	O
48	CD	O
received	VBD	O
cryotherapy	NN	O
plus	CC	O
placebo	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
36	CD	O
and	CC	O
37	CD	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
completed	VBD	O
the	DT	O
study	NN	O
and	CC	O
were	VBD	O
evaluable	JJ	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
Clinical	NNP	O
eradication	NN	O
of	IN	O
condylomata	NN	O
for	IN	O
six	CD	O
months	NNS	O
following	VBG	O
adjuvant	JJ	O
chemotherapy	NN	O
.	.	O

RESULTS	VBN	O
By	IN	O
completion	NN	O
of	IN	O
the	DT	O
adjuvant	JJ	O
chemotherapy	NN	O
,	,	O
10	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
interferon	NN	O
recipients	NNS	O
and	CC	O
16	CD	O
(	(	O
43	CD	O
%	NN	O
)	)	O
placebo	NN	O
recipients	NNS	O
experienced	VBD	O
recurrences	NNS	O
.	.	O

At	IN	O
six	CD	O
months	NNS	O
follow-up	RB	O
,	,	O
25	CD	O
(	(	O
69	CD	O
%	NN	O
)	)	O
interferon	NN	O
and	CC	O
27	CD	O
(	(	O
73	CD	O
%	NN	O
)	)	O
placebo	NN	O
recipients	NNS	O
experienced	VBD	O
recurrences	NNS	O
.	.	O

In	IN	O
the	DT	O
six	CD	O
months	NNS	O
following	VBG	O
interferon	NN	O
therapy	NN	O
,	,	O
only	RB	O
31	CD	O
%	NN	O
of	IN	O
interferon	NN	O
and	CC	O
27	CD	O
%	NN	O
of	IN	O
placebo	NN	O
recipients	NNS	O
remained	VBD	O
free	JJ	O
of	IN	O
recurrences	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.99	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Interferon	NNP	O
alpha-2a	NN	O
administered	VBD	O
subcutaneously	RB	O
offers	VBZ	O
no	DT	O
benefit	NN	O
as	IN	O
a	DT	O
chemotherapeutic	JJ	O
adjuvant	NN	O
to	TO	O
cryotherapy	VB	O
when	WRB	O
used	VBN	O
alone	RB	O
in	IN	O
the	DT	O
therapy	NN	O
of	IN	O
genital	JJ	O
warts	NNS	O
in	IN	O
this	DT	O
population	NN	O
of	IN	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
condylomata	NNS	O
.	.	O

Dose-dependent	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
CRF	NNP	O
(	(	O
1	CD	O
)	)	O
receptor	NN	O
antagonist	JJ	O
R317573	NNP	O
on	IN	O
regional	JJ	O
brain	NN	O
activity	NN	O
in	IN	O
healthy	JJ	Condition
male	JJ	Condition
subjects	NNS	Condition
.	.	Condition

BACKGROUND	NNP	O
Corticotropin-releasing	NNP	O
factor	NN	O
receptor	NN	O
type	NN	O
1	CD	O
(	(	O
CRF	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
antagonists	NNS	O
have	VBP	O
been	VBN	O
proposed	VBN	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
mood	NN	O
and	CC	O
anxiety	NN	O
disorders	NNS	O
although	IN	O
clinical	JJ	O
evidence	NN	O
supporting	VBG	O
their	PRP$	O
development	NN	O
and	CC	O
understanding	NN	O
of	IN	O
a	DT	O
dose-response	JJ	O
relationship	NN	O
has	VBZ	O
been	VBN	O
lacking	VBG	O
.	.	O

METHODS	NNP	O
We	PRP	O
tested	VBD	O
two	CD	O
doses	NNS	O
of	IN	O
the	DT	O
CRF	NNP	O
(	(	O
1	CD	O
)	)	O
antagonist	NN	O
R317573	NNP	O
for	IN	O
effects	NNS	O
on	IN	O
regional	JJ	O
cerebral	JJ	O
glucose	NN	O
metabolism	NN	O
(	(	O
rCMglu	NN	O
)	)	O
using	VBG	O
[	NNP	O
(	(	O
18	CD	O
)	)	O
F	NNP	O
]	JJ	O
fluoro-2-deoxy-D	NN	O
:	:	O
-glucose	NN	O
(	(	O
FDG	NNP	O
)	)	O
positron	NN	O
emission	NN	O
tomography	NN	O
(	(	O
PET	NNP	O
)	)	O
following	VBG	O
single-dose	JJ	O
challenges	NNS	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
cross-over	JJ	O
design	NN	O
,	,	O
in	IN	O
12	CD	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
.	.	O

RESULTS	NNP	O
Single	NNP	O
30-	JJ	O
and	CC	O
200-mg	JJ	O
doses	NNS	O
of	IN	O
R317573	NNP	O
resulted	VBD	O
in	IN	O
dose-related	JJ	O
changes	NNS	O
in	IN	O
rCMglu	NN	O
.	.	O

Relative	JJ	O
increases	NNS	O
in	IN	O
rCMglu	NN	O
were	VBD	O
observed	VBN	O
in	IN	O
frontal	JJ	O
cortical	JJ	O
regions	NNS	O
while	IN	O
relative	JJ	O
decreases	NNS	O
occurred	VBD	O
in	IN	O
the	DT	O
putamen	NNS	O
and	CC	O
right	JJ	O
amygdala	NN	O
after	IN	O
both	DT	O
doses	NNS	O
.	.	O

Relative	JJ	O
decreases	NNS	O
occurred	VBD	O
in	IN	O
cerebellum	NN	O
and	CC	O
right	JJ	O
parahippocampal	NN	O
gyrus	NN	O
following	VBG	O
the	DT	O
higher	JJR	O
dose	NN	O
.	.	O

CONCLUSIONS	NNP	O
R317573	NNP	O
appears	VBZ	O
to	TO	O
produce	VB	O
acute	JJ	O
dose-dependent	JJ	O
changes	NNS	O
in	IN	O
rCMglu	NN	O
.	.	O

Effects	NNS	O
occurred	VBD	O
in	IN	O
regions	NNS	O
that	WDT	O
may	MD	O
be	VB	O
behaviorally	RB	O
relevant	JJ	O
to	TO	O
mood	NN	O
and	CC	O
anxiety	NN	O
disorders	NNS	O
.	.	O

In	IN	O
some	DT	O
regions	NNS	O
,	,	O
these	DT	O
effects	NNS	O
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
the	DT	O
receptor	NN	O
(	(	O
target	NN	O
)	)	O
density	NN	O
.	.	O

Measuring	VBG	O
acute	JJ	O
effects	NNS	O
on	IN	O
rCMglu	NN	O
with	IN	O
FDG-PET	NNP	O
may	MD	O
offer	VB	O
a	DT	O
method	NN	O
for	IN	O
defining	VBG	O
pharmacologically	RB	O
active	JJ	O
doses	NNS	O
for	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
targets	NNS	O
for	IN	O
which	WDT	O
selective	JJ	O
radiotracers	NNS	O
are	VBP	O
lacking	VBG	O
.	.	O

Double	JJ	O
blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
study	NN	O
of	IN	O
metronidazole	NN	Condition
as	IN	Condition
a	DT	Condition
disease	NN	Condition
modifying	VBG	Condition
agent	NN	Condition
in	IN	Condition
the	DT	Condition
treatment	NN	Condition
of	IN	Condition
rheumatoid	JJ	Condition
arthritis	NN	Condition
.	.	Condition

Anecdotal	JJ	O
reports	NNS	O
suggest	VBP	O
that	IN	O
metronidazole	NN	O
may	MD	O
have	VB	O
disease	NN	O
modifying	VBG	O
activity	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

To	TO	O
assess	VB	O
possible	JJ	O
beneficial	JJ	O
effects	NNS	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
comparative	JJ	O
trial	NN	O
of	IN	O
metronidazole	NN	O
and	CC	O
placebo	NN	O
was	VBD	O
performed	VBN	O
.	.	O

Fifty	JJ	O
patients	NNS	O
with	IN	O
active	JJ	O
rheumatoid	NN	O
arthritis	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
active	JJ	O
drug	NN	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
and	CC	O
reviewed	VBN	O
at	IN	O
weeks	NNS	O
0	CD	O
,	,	O
1	CD	O
,	,	O
4	CD	O
,	,	O
8	CD	O
,	,	O
12	CD	O
,	,	O
16	CD	O
,	,	O
and	CC	O
24	CD	O
.	.	O

Detailed	JJ	O
assessment	NN	O
of	IN	O
drug	NN	O
safety	NN	O
,	,	O
biochemical	JJ	O
and	CC	O
haematological	JJ	O
parameters	NNS	O
,	,	O
and	CC	O
efficacy	NN	O
was	VBD	O
made	VBN	O
at	IN	O
these	DT	O
dates	NNS	O
.	.	O

Dose	NNP	O
regimen	NNS	O
was	VBD	O
400	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
from	IN	O
weeks	NNS	O
0	CD	O
to	TO	O
eight	CD	O
,	,	O
increasing	VBG	O
to	TO	O
400	CD	O
mg	NNS	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
from	IN	O
weeks	NNS	O
nine	CD	O
to	TO	O
24	CD	O
provided	VBD	O
that	IN	O
no	DT	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

Most	JJS	O
patients	NNS	O
were	VBD	O
unable	JJ	O
to	TO	O
tolerate	VB	O
metronidazole	NN	O
because	IN	O
of	IN	O
side	NN	O
effects	NNS	O
or	CC	O
lack	NN	O
of	IN	O
efficacy	NN	O
,	,	O
with	IN	O
only	RB	O
five	CD	O
(	(	O
21	CD	O
%	NN	O
)	)	O
continuing	VBG	O
to	TO	O
take	VB	O
the	DT	O
drug	NN	O
at	IN	O
24	CD	O
weeks	NNS	O
.	.	O

For	IN	O
those	DT	O
patients	NNS	O
attaining	VBG	O
12	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
an	DT	O
overall	JJ	O
improvement	NN	O
in	IN	O
articular	JJ	O
index	NN	O
and	CC	O
morning	NN	O
stiffness	NN	O
was	VBD	O
found	VBN	O
.	.	O

No	DT	O
improvement	NN	O
in	IN	O
laboratory	JJ	O
indices	NNS	O
of	IN	O
disease	NN	O
activity	NN	O
was	VBD	O
seen	VBN	O
,	,	O
however	RB	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
metronidazole	NN	O
did	VBD	O
not	RB	O
have	VB	O
disease	NN	O
modifying	VBG	O
properties	NNS	O
and	CC	O
was	VBD	O
unacceptably	RB	O
toxic	JJ	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
faropenem	JJ	O
daloxate	NN	O
and	CC	O
cefuroxime	NN	O
axetil	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	Condition
bacterial	JJ	Condition
maxillary	JJ	Condition
sinusitis	NN	Condition
in	IN	O
adults	NNS	Age
.	.	Age

In	IN	O
this	DT	O
multicentre	NN	O
,	,	O
multinational	JJ	O
,	,	O
comparative	JJ	O
,	,	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
outpatients	NNS	O
with	IN	O
both	DT	O
clinical	JJ	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
and	CC	O
radiographic	JJ	O
evidence	NN	O
of	IN	O
acute	JJ	Condition
sinusitis	NN	Condition
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
for	IN	O
7	CD	O
days	NNS	O
either	CC	O
a	DT	O
twice-daily	JJ	O
oral	JJ	O
regimen	NNS	O
of	IN	O
faropenem	JJ	O
daloxate	NN	O
(	(	O
300	CD	O
mg	NN	O
)	)	O
or	CC	O
a	DT	O
twice	JJ	O
daily	JJ	O
oral	JJ	O
regimen	NNS	O
of	IN	O
cefuroxime	NN	O
axetil	NN	O
(	(	O
250	CD	O
mg	NN	O
)	)	O
.	.	O

Among	IN	O
452	CD	SampleSize
patients	NNS	O
considered	VBN	O
valid	JJ	O
for	IN	O
clinical	JJ	O
efficacy	NN	O
,	,	O
faropenem	JJ	O
daloxate	NN	O
treatment	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
statistically	RB	O
equivalent	JJ	O
to	TO	O
cefuroxime	VB	O
axetil	NN	O
(	(	O
89.0	CD	O
%	NN	O
vs.	FW	O
88.4	CD	O
%	NN	O
-95	CD	O
%	NN	O
CI=-5.2	NNP	O
%	NN	O
;	:	O
+6.4	CD	O
%	NN	O
)	)	O
at	IN	O
the	DT	O
7-16	JJ	O
days	NNS	O
post-therapy	JJ	O
assessment	NN	O
.	.	O

At	IN	O
28-35	JJ	O
days	NNS	O
post-therapy	NN	O
,	,	O
the	DT	O
continued	JJ	O
clinical	JJ	O
cure	NN	O
rate	NN	O
in	IN	O
the	DT	O
faropenem	JJ	O
daloxate	NN	O
group	NN	O
was	VBD	O
92.6	CD	O
%	NN	O
and	CC	O
that	IN	O
for	IN	O
the	DT	O
cefuroxime	NN	O
axetil	NN	O
group	NN	O
was	VBD	O
94.9	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-6.8	CD	O
%	NN	O
;	:	O
+1.2	CD	O
%	NN	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
148	CD	O
organisms	NNS	O
was	VBD	O
obtained	VBN	O
in	IN	O
136	CD	O
microbiologically	RB	O
valid	JJ	O
patients	NNS	O
(	(	O
30.1	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
predominant	JJ	O
causative	JJ	O
organisms	NNS	O
were	VBD	O
Streptococcus	NNP	O
pneumoniae	NN	O
(	(	O
47.1	CD	O
%	NN	O
)	)	O
,	,	O
Haemophilus	NNP	O
influenzae	NN	O
(	(	O
30.1	CD	O
%	NN	O
)	)	O
,	,	O
Staphylococcus	NNP	O
aureus	NN	O
(	(	O
14.7	CD	O
%	NN	O
)	)	O
and	CC	O
Moraxella	NNP	O
catarrhalis	NN	O
(	(	O
8.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
bacteriological	JJ	O
success	NN	O
rate	NN	O
at	IN	O
the	DT	O
7-16	JJ	O
days	NNS	O
post-therapy	JJ	O
evaluation	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
:	:	O
91.5	CD	O
%	NN	O
and	CC	O
90.8	CD	O
%	NN	O
in	IN	O
the	DT	O
faropenem	NN	O
daloxate	NN	O
and	CC	O
cefuroxime	NN	O
axetil	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
95	CD	O
%	NN	O
CI=-9.2	NNP	O
%	NN	O
;	:	O
+9.5	CD	O
%	NN	O
)	)	O
.	.	O

Eradication	NN	O
or	CC	O
presumed	VBN	O
eradication	NN	O
was	VBD	O
detected	VBN	O
for	IN	O
97.3	CD	O
%	NN	O
and	CC	O
96.3	CD	O
%	NN	O
of	IN	O
S.	NNP	O
pneumoniae	NN	O
,	,	O
85.0	CD	O
%	NN	O
and	CC	O
90.5	CD	O
%	NN	O
of	IN	O
H.	NNP	O
influenzae	NN	O
,	,	O
88.9	CD	O
%	NN	O
and	CC	O
90.9	CD	O
%	NN	O
of	IN	O
S.	NNP	O
aureus	NN	O
and	CC	O
100.0	CD	O
%	NN	O
and	CC	O
83.3	CD	O
%	NN	O
of	IN	O
M.	NNP	O
catarrhalis	NN	O
in	IN	O
faropenem	JJ	O
daloxate	NN	O
and	CC	O
cefuroxime	NN	O
axetil	NN	O
recipients	NNS	O
,	,	O
respectively	RB	O
.	.	O

At	IN	O
least	JJS	O
one	CD	O
drug-related	JJ	O
event	NN	O
was	VBD	O
reported	VBN	O
by	IN	O
9.5	CD	O
%	NN	O
of	IN	O
the	DT	O
faropenem	JJ	O
daloxate-treated	JJ	O
patients	NNS	O
and	CC	O
by	IN	O
10.3	CD	O
%	NN	O
of	IN	O
those	DT	O
who	WP	O
received	VBD	O
cefuroxime	RB	O
axetil	JJ	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
drug-related	JJ	O
events	NNS	O
were	VBD	O
diarrhoea	NNS	O
(	(	O
2.2	CD	O
%	NN	O
versus	IN	O
2.9	CD	O
%	NN	O
)	)	O
,	,	O
nausea/vomiting	VBG	O
(	(	O
1.5	CD	O
%	NN	O
vs.	FW	O
0.7	CD	O
%	NN	O
)	)	O
,	,	O
abdominal	JJ	O
pain	NN	O
(	(	O
0.7	CD	O
%	NN	O
vs	JJ	O
1.5	CD	O
%	NN	O
)	)	O
and	CC	O
skin	JJ	O
reactions	NNS	O
(	(	O
1.5	CD	O
%	NN	O
vs.	FW	O
1.1	CD	O
%	NN	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
faropenem	JJ	O
daloxate	NN	O
was	VBD	O
at	IN	O
least	JJS	O
as	IN	O
effective	JJ	O
clinically	NN	O
and	CC	O
bacteriologically	RB	O
as	IN	O
cefuroxime	NN	O
axetil	NN	O
and	CC	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
conventional	JJ	O
PCNL	NNP	O
and	CC	O
two	CD	O
modifications	NNS	O
to	TO	O
standard	JJ	O
procedure	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
conventional	JJ	O
Percutaneous	JJ	O
Nephrolithotomy	NNP	O
(	(	O
PCNL	NNP	O
)	)	O
with	IN	O
two	CD	O
of	IN	O
its	PRP$	O
modified	JJ	O
procedures	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
,	,	O
was	VBD	O
performed	VBN	O
on	IN	O
60	CD	SampleSize
patients	NNS	O
undergoing	JJ	O
PCNL	NNP	Condition
.	.	O

Cases	NNS	Condition
of	IN	Condition
renal	JJ	Condition
stone	NN	Condition
regardless	NN	O
of	IN	O
stone	NN	O
size	NN	O
and	CC	O
configuration	NN	O
,	,	O
having	VBG	O
pre-operative	JJ	O
negative	JJ	O
urine	JJ	O
culture	NN	O
,	,	O
no	DT	O
coagulopathy	NN	O
,	,	O
and	CC	O
no	DT	O
visible	JJ	O
residual	JJ	O
stone	NN	O
in	IN	O
intra-operative	JJ	O
fluoroscopy	NN	O
,	,	O
were	VBD	O
included	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
of	IN	O
20	CD	O
cases	NNS	O
each	DT	O
with	IN	O
nephrostomy	JJ	O
tube	NN	O
(	(	O
NT	NNP	O
)	)	O
and	CC	O
temporary	JJ	O
ureteral	JJ	O
catheter	NN	O
(	(	O
TU	NNP	O
)	)	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
only	RB	O
TU	NNP	O
in	IN	O
group	NN	O
B	NNP	O
and	CC	O
only	RB	O
indwelling	VBG	O
ureteral	JJ	O
catheter	NN	O
(	(	O
IU	NNP	O
)	)	O
in	IN	O
group	NN	O
C.	NNP	O
Mean	NNP	O
age	NN	Age
of	IN	Age
cases	NNS	Age
were	VBD	Age
43.2	CD	Age
(	(	Age
25-70	JJ	Age
)	)	Age
,	,	Age
40.1	CD	Age
(	(	Age
25-73	JJ	Age
)	)	Age
,	,	Age
and	CC	Age
44	CD	Age
(	(	Age
25-70	JJ	Age
)	)	Age
years	NNS	Age
in	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.6	CD	O
)	)	O
.	.	O

Procedures	NNS	O
were	VBD	O
performed	VBN	O
under	IN	O
general	JJ	O
anaesthesia	NN	O
,	,	O
using	VBG	O
standard	JJ	O
techniques	NNS	O
for	IN	O
access	NN	O
and	CC	O
lithotomy	NN	O
.	.	O

Forty-eight	JJ	O
hours	NNS	O
,	,	O
2	CD	O
weeks	NNS	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
PCNL	NNP	O
,	,	O
plain	VBP	O
X-ray	JJ	O
abdomen	NNS	O
,	,	O
ultrasonography	NN	O
and	CC	O
IVP	NNP	O
were	VBD	O
performed	VBN	O
for	IN	O
each	DT	O
case	NN	O
.	.	O

RESULTS	NNP	O
Only	RB	O
one	CD	O
case	NN	O
in	IN	O
group	NN	O
A	NNP	O
had	VBD	O
urinary	JJ	O
leakage	NN	O
after	IN	O
removal	NN	O
of	IN	O
nephrostomy	JJ	O
tube	NN	O
.	.	O

No	DT	O
cases	NNS	O
in	IN	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
encountered	VBD	O
this	DT	O
problem	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
haemorrhagic	JJ	O
episode	NN	O
.	.	O

Ultrasonic	JJ	O
evaluation	NN	O
showed	VBD	O
mild	JJ	O
residue	NNS	O
in	IN	O
3	CD	O
,	,	O
1	CD	O
and	CC	O
1	CD	O
cases	NNS	O
of	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.2	CD	O
)	)	O
.	.	O

No	UH	O
collective	JJ	O
fluid	NN	O
was	VBD	O
found	VBN	O
in	IN	O
these	DT	O
groups	NNS	O
.	.	O

IVP	NNP	O
showed	VBD	O
dilatation	NN	O
without	IN	O
obstruction	NN	O
in	IN	O
3	CD	O
subjects	NNS	O
of	IN	O
group	NN	O
A	NNP	O
and	CC	O
none	NN	O
in	IN	O
group	NN	O
B	NNP	O
or	CC	O
C	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Tubeless	NNP	O
PCNL	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
accompanied	VBN	O
by	IN	O
better	JJR	O
outcome	NN	O
.	.	O

So	RB	O
,	,	O
further	JJ	O
evaluation	NN	O
on	IN	O
more	JJR	O
patients	NNS	O
seems	VBZ	O
necessary	JJ	O
.	.	O

Association	NNP	O
of	IN	O
chronic	JJ	Condition
kidney	NN	Condition
disease	NN	Condition
with	IN	O
outcomes	NNS	O
in	IN	O
chronic	JJ	Condition
heart	NN	Condition
failure	NN	Condition
:	:	O
a	DT	O
propensity-matched	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Chronic	NNP	O
kidney	NN	O
disease	NN	O
(	(	O
CKD	NNP	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	Condition
failure	NN	Condition
(	(	O
HF	NNP	Condition
)	)	O
.	.	O

However	RB	O
,	,	O
its	PRP$	O
association	NN	O
with	IN	O
hospitalization	NN	O
in	IN	O
HF	NNP	Condition
patients	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
well	RB	O
studied	VBN	O
.	.	O

METHODS	NNP	O
Of	IN	O
7788	CD	SampleSize
patients	NNS	O
in	IN	O
the	DT	O
Digitalis	NNP	O
Investigation	NNP	O
Group	NNP	O
trial	NN	O
,	,	O
3527	CD	SampleSize
had	VBD	O
CKD	NNP	Condition
,	,	O
defined	VBN	O
by	IN	O
an	DT	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
GFR	NNP	O
)	)	O
<	VBD	O
60	CD	O
ml/min/1.73	NNS	O
m	NN	O
(	(	O
2	CD	O
)	)	O
body	NN	O
surface	JJ	O
area	NN	O
(	(	O
BSA	NNP	O
)	)	O
.	.	O

Propensity	NN	O
scores	NNS	O
for	IN	O
CKD	NNP	O
were	VBD	O
calculated	VBN	O
using	VBG	O
a	DT	O
multivariable	JJ	O
logistic	JJ	O
regression	NN	O
model	NN	O
and	CC	O
used	VBN	O
to	TO	O
match	VB	O
2399	CD	O
pairs	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
CKD	NNP	O
.	.	O

Matched	NNP	O
Cox	NNP	O
regression	NN	O
analyses	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
association	NN	O
of	IN	O
CKD	NNP	O
with	IN	O
outcomes	NNS	O
.	.	O

RESULTS	NNP	O
All-cause	NNP	O
hospitalization	NN	O
occurred	VBD	O
in	IN	O
1636	CD	O
(	(	O
rate	NN	O
,	,	O
4233/10,000	CD	O
person-years	NNS	O
)	)	O
and	CC	O
1587	CD	O
(	(	O
rate	NN	O
,	,	O
3733/10,000	CD	O
person-years	NNS	O
)	)	O
patients	NNS	O
respectively	RB	O
,	,	O
with	IN	O
and	CC	O
without	IN	O
CKD	NNP	O
(	(	O
matched	VBN	O
hazard	RB	O
ratio	JJ	O
[	NNP	O
HR	NNP	O
]	NNP	O
for	IN	O
CKD	NNP	O
,	,	O
1.18	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.08-1.29	JJ	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Matched	VBN	O
HR	NNP	O
for	IN	O
cardiovascular	JJ	O
and	CC	O
HF	NNP	O
hospitalization	NN	O
were	VBD	O
respectively	RB	O
1.17	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.06-1.28	JJ	O
,	,	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
and	CC	O
1.28	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.13-1.45	JJ	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Compared	VBN	O
to	TO	O
GFR	NNP	O
>	NNP	O
or=60	MD	O
ml/min/1.73	VB	O
m	NN	O
(	(	O
2	CD	O
)	)	O
BSA	NNP	O
,	,	O
HR	NNP	O
for	IN	O
all-cause	JJ	O
hospitalization	NN	O
for	IN	O
GFR	NNP	O
45-59	CD	O
and	CC	O
<	$	O
45	CD	O
ml/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
BSA	NNP	O
were	VBD	O
respectively	RB	O
1.04	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.94-1.16	NNP	O
;	:	O
P	NNP	O
=	NNP	O
0.422	CD	O
)	)	O
and	CC	O
1.58	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.34-1.87	JJ	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
HR	NNP	O
for	IN	O
all-cause	JJ	O
death	NN	O
for	IN	O
GFR	NNP	O
45-59	CD	O
and	CC	O
<	$	O
45	CD	O
ml/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
BSA	NNP	O
were	VBD	O
respectively	RB	O
1.03	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.90-1.18	NNP	O
;	:	O
P	NNP	O
=	NNP	O
0.651	CD	O
)	)	O
and	CC	O
1.70	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.40-2.07	JJ	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Matched	VBN	O
HR	NNP	O
for	IN	O
death	NN	O
due	JJ	O
to	TO	O
cardiovascular	JJ	O
causes	NNS	O
and	CC	O
progressive	JJ	O
HF	NNP	O
were	VBD	O
respectively	RB	O
1.24	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.09-1.40	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
and	CC	O
1.42	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.16-1.72	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
CKD	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
mortality	NN	O
and	CC	O
hospitalization	NN	O
in	IN	O
ambulatory	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	Condition
HF	NNP	Condition
,	,	O
which	WDT	O
increased	VBD	O
progressively	RB	O
with	IN	O
worsening	VBG	O
kidney	NN	O
function	NN	O
.	.	O

Effect	NN	O
of	IN	O
recombinant	JJ	O
adenovirus-p53	NN	O
combined	VBN	O
with	IN	O
radiotherapy	NN	O
on	IN	O
long-term	JJ	O
prognosis	NN	O
of	IN	O
advanced	JJ	O
nasopharyngeal	JJ	Condition
carcinoma	NN	Condition
.	.	O

PURPOSE	NNP	O
To	TO	O
centrally	RB	O
assess	VB	O
the	DT	O
safety	NN	O
,	,	O
efficacy	NN	O
,	,	O
and	CC	O
6-year	JJ	O
follow-up	NN	O
of	IN	O
recombinant	JJ	O
adenovirus-p53	JJ	O
(	(	O
rAd-p53	NN	O
)	)	O
combined	VBN	O
with	IN	O
radiotherapy	NN	O
(	(	O
RT	NNP	O
)	)	O
for	IN	O
patients	NNS	O
with	IN	O
nasopharyngeal	JJ	O
carcinoma	NN	O
(	(	O
NPC	NNP	Condition
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
randomized	VBD	O
controlled	VBN	O
clinical	JJ	O
study	NN	O
on	IN	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
in	IN	O
42	CD	SampleSize
patients	NNS	SampleSize
with	IN	O
NPC	NNP	Condition
was	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
40	CD	SampleSize
patients	NNS	SampleSize
with	IN	O
NPC	NNP	O
treated	VBD	O
with	IN	O
RT	NNP	O
alone	RB	O
.	.	O

In	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
,	,	O
rAd-p53	NN	O
was	VBD	O
intratumorally	RB	O
injected	VBN	O
once	RB	O
a	DT	O
week	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Concurrent	NNP	O
RT	NNP	O
(	(	O
70	CD	O
Gy	NNP	O
in	IN	O
35	CD	O
fractions	NNS	O
)	)	O
was	VBD	O
given	VBN	O
to	TO	O
the	DT	O
nasopharyngeal	JJ	O
tumor	NN	O
and	CC	O
neck	NN	O
lymph	NN	O
node	NN	O
.	.	O

Patients	NNS	O
and	CC	O
tumors	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
adverse	JJ	O
events	NNS	O
and	CC	O
responses	NNS	O
.	.	O

RESULTS	NNP	O
rAd-p53-specific	JJ	O
p53	NN	O
mRNA	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
postinjection	NN	O
of	IN	O
rAd-p53	JJ	O
biopsies	NNS	O
from	IN	O
16	CD	O
(	(	O
94.1	CD	O
%	NN	O
)	)	O
of	IN	O
17	CD	O
patients	NNS	O
.	.	O

Upregulation	NN	O
of	IN	O
p21/WAF1	NN	O
and	CC	O
Bax	NNP	O
and	CC	O
downregulation	NN	O
of	IN	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
were	VBD	O
observed	VBN	O
in	IN	O
postinjection	NN	O
tumor	NN	O
biopsy	NN	O
.	.	O

Complete	JJ	O
response	NN	O
rate	NN	O
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
was	VBD	O
observed	VBN	O
at	IN	O
2.73	CD	O
times	NNS	O
that	WDT	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
RT	NNP	O
alone	RB	O
(	(	O
66.7	CD	O
%	NN	O
v	JJ	O
24.4	CD	O
%	NN	O
)	)	O
.	.	O

Six-year	JJ	O
follow-up	JJ	O
data	NN	O
showed	VBD	O
that	IN	O
rAd-p53	JJ	O
significantly	RB	O
increased	VBD	O
the	DT	O
5-year	JJ	O
locoregional	JJ	O
tumor	NN	O
control	NN	O
rate	NN	O
by	IN	O
25.3	CD	O
%	NN	O
for	IN	O
patients	NNS	O
with	IN	O
NPC	NNP	O
treated	VBD	O
with	IN	O
irradiation	NN	O
(	(	O
P	NNP	O
=	NNP	O
.002	NNP	O
)	)	O
.	.	O

The	DT	O
5-year	JJ	O
overall	JJ	O
survival	NN	O
rate	NN	O
and	CC	O
5-year	JJ	O
disease-free	JJ	O
survival	NN	O
rate	NN	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
rAd-p53	NN	O
combined	VBN	O
with	IN	O
RT	NNP	O
were	VBD	O
7.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.34	NNP	O
)	)	O
and	CC	O
11.7	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.21	NNP	O
)	)	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
RT	NNP	O
alone	RB	O
.	.	O

No	DT	O
dose-limiting	JJ	O
toxicity	NN	O
or	CC	O
adverse	JJ	O
events	NNS	O
appeared	VBD	O
,	,	O
except	IN	O
for	IN	O
transient	NN	O
fever	NN	O
after	IN	O
rAd-p53	JJ	O
administration	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
NPC	NNP	O
,	,	O
rAd-p53	NN	O
was	VBD	O
safe	JJ	O
and	CC	O
biologically	RB	O
active	JJ	O
.	.	O

Our	PRP$	O
results	NNS	O
indicated	VBD	O
that	IN	O
rAd-p53	JJ	O
improves	NNS	O
radiotherapeutic	JJ	O
tumor	NN	O
control	NN	O
and	CC	O
survival	JJ	O
rate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
NPC	NNP	O
.	.	O

Cognitive	JJ	O
effects	NNS	O
of	IN	O
lithium	NN	O
carbonate	NN	O
and	CC	O
haloperidol	NN	O
in	IN	O
treatment-resistant	JJ	Condition
aggressive	JJ	Condition
children	NNS	Condition
.	.	Condition

The	DT	O
effects	NNS	O
of	IN	O
lithium	NN	O
carbonate	NN	O
and	CC	O
haloperidol	NN	O
on	IN	O
cognition	NN	O
were	VBD	O
examined	VBN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
of	IN	O
61	CD	O
treatment-resistant	JJ	O
,	,	O
hospitalized	VBN	O
school-aged	JJ	O
children	NNS	O
.	.	O

They	PRP	O
all	DT	O
had	VBD	O
a	DT	O
DSM-III	JJ	O
diagnosis	NN	O
of	IN	O
conduct	NN	O
disorder	NN	O
--	:	O
undersocialized	JJ	O
,	,	O
aggressive	JJ	O
,	,	O
with	IN	O
a	DT	O
profile	NN	O
of	IN	O
highly	RB	O
explosive	JJ	O
and	CC	O
aggressive	JJ	O
behavior	NN	O
.	.	O

Children	NNP	O
were	VBD	O
assessed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
a	DT	O
two-week	JJ	O
placebo-baseline	JJ	O
period	NN	O
and	CC	O
again	RB	O
after	IN	O
four	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Drug	NNP	O
effects	NNS	O
on	IN	O
cognition	NN	O
were	VBD	O
mild	JJ	O
.	.	O

Haloperidol	NNP	O
(	(	O
mean	JJ	O
dose	NN	O
,	,	O
2.95	CD	O
mg/day	NN	O
)	)	O
caused	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
Porteus	NNP	O
Maze	NNP	O
test	NN	O
quotient	NN	O
scores	NNS	O
and	CC	O
a	DT	O
slowing	NN	O
of	IN	O
reaction	NN	O
time	NN	O
(	(	O
RT	NNP	O
)	)	O
on	IN	O
a	DT	O
simple	JJ	O
RT	NNP	O
task	NN	O
.	.	O

Lithium	JJ	O
carbonate	NN	O
(	(	O
mean	JJ	O
dose	NN	O
,	,	O
1,166	CD	O
mg/day	NN	O
)	)	O
adversely	RB	O
affected	JJ	O
qualitative	JJ	O
scores	NNS	O
on	IN	O
the	DT	O
Porteus	NNP	O
Maze	NNP	O
test	NN	O
.	.	O

No	DT	O
significant	JJ	O
treatment	NN	O
effects	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
the	DT	O
Matching	NNP	O
Familiar	NNP	O
Figures	NNP	O
Test	NNP	O
,	,	O
short-term	JJ	O
recognition	NN	O
memory	NN	O
and	CC	O
concept	NN	O
attainment	NN	O
tasks	NNS	O
,	,	O
or	CC	O
the	DT	O
Stroop	NNP	O
Test	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
alcohol	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
morphine	NN	O
sulfate	NN	O
and	CC	O
naltrexone	NN	O
hydrochloride	NN	O
extended	VBD	O
release	NN	O
capsules	NNS	O
.	.	O

Although	IN	O
contraindicated	VBN	O
,	,	O
coingestion	NN	O
of	IN	O
alcohol	NN	O
and	CC	O
opioids	NNS	O
by	IN	O
patients	NNS	O
or	CC	O
drug	NN	O
abusers	NNS	O
is	VBZ	O
a	DT	O
major	JJ	O
health	NN	O
concern	NN	O
because	IN	O
of	IN	O
dangerous	JJ	O
additive	JJ	O
and	CC	O
potentially	RB	O
life-threatening	JJ	O
sedative	JJ	O
and	CC	O
respiratory	JJ	O
effects	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
alcohol	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
disrupt	VB	O
the	DT	O
extended-release	JJ	O
characteristics	NNS	O
of	IN	O
certain	JJ	O
extended-release	JJ	O
opioid	NN	O
formulations	NNS	O
,	,	O
releasing	VBG	O
a	DT	O
hazardous	JJ	O
amount	NN	O
of	IN	O
opioid	NN	O
over	IN	O
a	DT	O
short	JJ	O
time	NN	O
period	NN	O
.	.	O

Morphine	NNP	O
sulfate	NN	O
and	CC	O
naltrexone	NN	O
hydrochloride	NN	O
extended	VBD	O
release	NN	O
capsules	NNS	O
(	(	O
MS-sNT	NNP	O
)	)	O
,	,	O
which	WDT	O
contain	VBP	O
naltrexone	RB	O
sequestered	VBN	O
in	IN	O
each	DT	O
pellet	NN	O
core	NN	O
,	,	O
are	VBP	O
indicated	VBN	O
for	IN	O
management	NN	O
of	IN	O
chronic	NN	O
,	,	O
moderate	VB	O
to	TO	O
severe	VB	O
pain	NN	O
.	.	O

Sequestered	NNP	O
naltrexone	NN	O
is	VBZ	O
designed	VBN	O
for	IN	O
release	NN	O
upon	IN	O
product	NN	O
tampering	NN	O
(	(	O
crushing	VBG	O
)	)	O
to	TO	O
potentially	RB	O
mitigate	VB	O
morphine-induced	JJ	O
subjective	JJ	O
effects	NNS	O
.	.	O

This	DT	O
open-label	JJ	O
,	,	O
single-dose	JJ	O
,	,	O
4-way	JJ	O
crossover	NN	O
,	,	O
pharmacokinetic	JJ	O
drug	NN	O
interaction	NN	O
study	NN	O
compared	VBN	O
the	DT	O
relative	JJ	O
bioavailability	NN	O
of	IN	O
morphine	NN	O
and	CC	O
naltrexone	NN	O
when	WRB	O
MS-sNT	NNP	O
is	VBZ	O
administered	VBN	O
(	(	O
under	IN	O
fasting	VBG	O
conditions	NNS	O
)	)	O
with	IN	O
increasing	VBG	O
doses	NNS	O
of	IN	O
alcohol	NN	O
.	.	O

Thirty-two	NNP	O
healthy	JJ	O
,	,	O
opioid-naive	JJ	O
adults	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
MS-sNT	NNP	O
administered	VBN	O
with	IN	O
240	CD	O
mL	NNS	O
of	IN	O
4	CD	O
%	NN	O
,	,	O
20	CD	O
%	NN	O
,	,	O
or	CC	O
40	CD	O
%	NN	O
alcohol	NN	O
or	CC	O
water	NN	O
.	.	O

No	DT	O
drug	NN	O
interaction	NN	O
was	VBD	O
found	VBN	O
between	IN	O
morphine	NN	O
in	IN	O
MS-sNT	NNP	O
and	CC	O
4	CD	O
%	NN	O
or	CC	O
20	CD	O
%	NN	O
alcohol	NN	O
.	.	O

Administration	NN	O
with	IN	O
40	CD	O
%	NN	O
alcohol	NN	O
did	VBD	O
not	RB	O
affect	VB	O
overall	JJ	O
morphine	NN	O
exposure	NN	O
but	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
2-fold	JJ	O
increase	NN	O
in	IN	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
and	CC	O
reduction	NN	O
of	IN	O
t	NN	O
(	(	O
max	NN	O
)	)	O
from	IN	O
9	CD	O
to	TO	O
4	CD	O
hours	NNS	O
versus	IN	O
MS-sNT	NNP	O
taken	VBN	O
with	IN	O
water	NN	O
.	.	O

Naltrexone	CD	O
sequestering	NN	O
was	VBD	O
successful	JJ	O
in	IN	O
all	DT	O
treatment	NN	O
arms	NNS	O
and	CC	O
not	RB	O
affected	VBN	O
by	IN	O
coadministration	NN	O
with	IN	O
alcohol	NN	O
over	IN	O
the	DT	O
dose	JJ	O
range	NN	O
tested	VBD	O
.	.	O

Theory-driven	JJ	O
intervention	NN	O
improves	VBZ	O
calcium	JJ	O
intake	NN	O
,	,	O
osteoporosis	NN	O
knowledge	NN	O
,	,	O
and	CC	O
self-efficacy	NN	O
in	IN	O
community-dwelling	JJ	Condition
older	JJR	Age
Black	NNP	Condition
adults	NNS	Age
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
osteoporosis	JJ	O
education	NN	O
program	NN	O
to	TO	O
improve	VB	O
calcium	NN	O
intake	NN	O
,	,	O
knowledge	NN	O
,	,	O
and	CC	O
self-efficacy	NN	O
in	IN	O
community-dwelling	JJ	Condition
older	JJR	Age
Black	NNP	Condition
adults	NNS	Age
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
repeated	VBD	O
measures	NNS	O
experimental	JJ	O
design	NN	O
.	.	O

SETTING	NN	O
Churches	NNP	O
and	CC	O
community-based	JJ	O
organizations	NNS	O
.	.	O

PARTICIPANTS	NNP	O
Men	NNP	O
and	CC	O
women	NNS	O
(	(	O
n	JJ	O
=	NNP	O
110	CD	SampleSize
)	)	O
50	CD	Age
years	NNS	Age
old	JJ	Age
and	CC	Age
older	JJR	Age
from	IN	Condition
3	CD	Condition
south	JJ	Condition
Florida	NNP	Condition
counties	NNS	Condition
.	.	O

INTERVENTION	NNP	O
Participants	NNP	O
randomly	RB	O
assigned	VBD	O
to	TO	O
either	DT	O
of	IN	O
2	CD	O
groups	NNS	O
:	:	O
Group	NNP	O
1	CD	O
(	(	O
experimental	JJ	O
group	NN	O
)	)	O
or	CC	O
Group	NNP	O
2	CD	O
(	(	O
wait-list	JJ	O
control	NN	O
group	NN	O
)	)	O
.	.	O

Group	NNP	O
1	CD	O
participated	VBD	O
in	IN	O
6	CD	O
weekly	JJ	O
education	NN	O
program	NN	O
sessions	NNS	O
immediately	RB	O
following	VBG	O
baseline	NN	O
assessment	NN	O
,	,	O
and	CC	O
Group	NNP	O
2	CD	O
started	VBD	O
the	DT	O
program	NN	O
following	VBG	O
Group	NNP	O
1	CD	O
's	POS	O
program	NN	O
completion	NN	O
.	.	O

A	DT	O
tested	JJ	O
curriculum	NN	O
was	VBD	O
adapted	VBN	O
to	TO	O
meet	VB	O
the	DT	O
needs	NNS	O
of	IN	O
the	DT	O
target	NN	O
population	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Dietary	NNP	O
calcium	NN	O
intake	NN	O
,	,	O
osteoporosis	NN	O
knowledge	NN	O
,	,	O
health	NN	O
beliefs	NNS	O
,	,	O
and	CC	O
self-efficacy	NN	O
.	.	O

ANALYSIS	NNP	O
Descriptive	NNP	O
and	CC	O
summary	JJ	O
statistics	NNS	O
,	,	O
repeated	VBD	O
measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
,	,	O
and	CC	O
regression	NN	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
total	JJ	O
participants	NNS	O
,	,	O
84.6	CD	O
%	NN	O
completed	VBD	O
the	DT	O
study	NN	O
(	(	O
mean	JJ	O
age	NN	O
=	VBD	O
70.2	CD	O
years	NNS	O
)	)	O
.	.	O

Overall	UH	O
,	,	O
an	DT	O
educational	JJ	O
program	NN	O
developed	VBN	O
with	IN	O
a	DT	O
theoretical	JJ	O
background	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
improvement	NN	O
in	IN	O
calcium	NN	O
intake	NN	O
,	,	O
knowledge	NN	O
,	,	O
and	CC	O
self-efficacy	NN	O
,	,	O
with	IN	O
no	DT	O
effect	NN	O
on	IN	O
most	JJS	O
health	NN	O
belief	NN	O
subscales	NNS	O
.	.	O

Assigned	VBN	O
group	NN	O
was	VBD	O
the	DT	O
major	JJ	O
predictor	NN	O
of	IN	O
change	NN	O
in	IN	O
calcium	NN	O
intake	NN	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
IMPLICATIONS	NNP	O
A	NNP	O
theory-driven	JJ	O
approach	NN	O
is	VBZ	O
valuable	JJ	O
in	IN	O
improving	VBG	O
behavior	NN	O
to	TO	O
promote	VB	O
bone	NN	O
health	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Health	NNP	O
professionals	NNS	O
should	MD	O
consider	VB	O
using	VBG	O
more	JJR	O
theory-driven	JJ	O
approaches	NNS	O
in	IN	O
intervention	NN	O
studies	NNS	O
.	.	O

A	DT	O
randomised	VBN	O
,	,	O
controlled	VBD	O
study	NN	O
of	IN	O
dietary	JJ	O
intervention	NN	O
in	IN	O
autistic	JJ	Condition
syndromes	NNS	Condition
.	.	Condition

Impaired	NNP	O
social	JJ	O
interaction	NN	O
,	,	O
communication	NN	O
and	CC	O
imaginative	JJ	O
skills	NNS	O
characterize	VBP	O
autistic	JJ	O
syndromes	NNS	O
.	.	O

In	IN	O
these	DT	O
syndromes	NNS	O
urinary	JJ	O
peptide	NN	O
abnormalities	NNS	O
,	,	O
derived	VBN	O
from	IN	O
gluten	NN	O
,	,	O
gliadin	NN	O
,	,	O
and	CC	O
casein	NN	O
,	,	O
are	VBP	O
reported	VBN	O
.	.	O

They	PRP	O
reflect	VBP	O
processes	NNS	O
with	IN	O
opioid	JJ	O
effect	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
single	JJ	O
blind	NN	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
effect	NN	O
of	IN	O
gluten	NN	O
and	CC	O
casein-free	JJ	O
diet	NN	O
for	IN	O
children	NNS	Age
with	IN	O
autistic	JJ	Condition
syndromes	NNS	Condition
and	CC	O
urinary	JJ	Condition
peptide	NN	Condition
abnormalities	NNS	Condition
.	.	Condition

A	DT	O
randomly	RB	O
selected	VBN	O
diet	JJ	O
and	CC	O
control	NN	O
group	NN	O
with	IN	O
10	CD	SampleSize
children	NNS	Age
in	IN	O
each	DT	O
group	NN	O
participated	VBD	O
.	.	O

Observations	NNS	O
and	CC	O
tests	NNS	O
were	VBD	O
done	VBN	O
before	RB	O
and	CC	O
after	IN	O
a	DT	O
period	NN	O
of	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
development	NN	O
for	IN	O
the	DT	O
group	NN	O
of	IN	O
children	NNS	O
on	IN	O
diet	NN	O
was	VBD	O
significantly	RB	O
better	JJR	O
than	IN	O
for	IN	O
the	DT	O
controls	NNS	O
.	.	O

Paromomycin	NNP	O
for	IN	O
cryptosporidiosis	NN	O
in	IN	O
AIDS	NNP	Condition
:	:	Condition
a	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

To	TO	O
test	VB	O
the	DT	O
effects	NNS	O
of	IN	O
paromomycin	NN	O
,	,	O
10	CD	O
patients	NNS	O
with	IN	O
AIDS	NNP	O
and	CC	O
cryptosporidiosis	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
paromomycin	VB	O
or	CC	O
placebo	VB	O
in	IN	O
a	DT	O
double-blind	JJ	O
trial	NN	O
.	.	O

After	IN	O
14	CD	O
days	NNS	O
,	,	O
patients	NNS	O
were	VBD	O
switched	VBN	O
to	TO	O
the	DT	O
other	JJ	O
treatment	NN	O
for	IN	O
14	CD	O
additional	JJ	O
days	NNS	O
.	.	O

Measures	NNS	O
included	VBD	O
the	DT	O
number	NN	O
and	CC	O
character	NN	O
of	IN	O
each	DT	O
stool	NN	O
and	CC	O
weekly	JJ	O
24-h	JJ	O
stool	NN	O
specimens	NNS	O
for	IN	O
weight	NN	O
and	CC	O
oocyst	NN	O
excretion	NN	O
.	.	O

During	IN	O
the	DT	O
paromomycin	NN	O
treatment	NN	O
phase	NN	O
,	,	O
oocyst	JJ	O
excretion	NN	O
decreased	VBD	O
from	IN	O
314	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
to	TO	O
109	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
24	CD	O
h	NN	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
.	.	O

Oocyst	NNP	O
excretion	NN	O
increased	VBD	O
for	IN	O
the	DT	O
4	CD	O
patients	NNS	O
initially	RB	O
on	IN	O
placebo	NNS	O
compared	VBN	O
to	TO	O
a	DT	O
median	JJ	O
decrease	NN	O
of	IN	O
128	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/24	NN	O
h	NN	O
for	IN	O
the	DT	O
6	CD	O
initially	RB	O
treated	VBN	O
with	IN	O
drug	NN	O
(	(	O
P	NNP	O
<	NNP	O
.02	NNP	O
)	)	O
.	.	O

Stool	NNP	O
frequency	NN	O
also	RB	O
decreased	VBD	O
more	RBR	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
drug	NN	O
(	(	O
3.6	CD	O
fewer	JJR	O
vs.	NN	O
1.25	CD	O
fewer/24	NN	O
h	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Trends	NNS	O
favored	JJ	O
drug	NN	O
over	IN	O
placebo	NN	O
for	IN	O
stool	NN	O
weight	NN	O
,	,	O
stool	JJ	O
character	NN	O
,	,	O
and	CC	O
Karnofsky	NNP	O
score	NN	O
.	.	O

Paromomycin	NNP	O
treatment	NN	O
resulted	VBD	O
in	IN	O
improvement	NN	O
in	IN	O
both	DT	O
clinical	JJ	O
and	CC	O
parasitologic	JJ	O
parameters	NNS	O
in	IN	O
cryptosporidiosis	NN	O
in	IN	O
AIDS	NNP	O
.	.	O

The	DT	O
radial	JJ	O
forearm	NN	O
flap	NN	O
:	:	O
a	DT	O
biomechanical	JJ	O
study	NN	O
of	IN	O
donor-site	JJ	O
morbidity	NN	O
utilizing	VBG	O
sheep	JJ	O
tibia	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
vascularized	JJ	O
bone	NN	O
grafts	NNS	O
to	TO	O
reconstruct	VB	O
extremity	NN	O
and	CC	O
mandibular	JJ	O
defects	NNS	O
is	VBZ	O
now	RB	O
commonplace	NN	O
in	IN	O
reconstructive	JJ	O
surgery	NN	O
.	.	O

Fibula	NNP	O
,	,	O
scapula	NN	O
,	,	O
iliac	JJ	O
crest	NN	O
,	,	O
rib	NN	O
,	,	O
and	CC	O
metatarsal	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
radial	JJ	O
forearm	NN	O
osseocutaneous	JJ	O
flaps	NNS	O
have	VBP	O
all	DT	O
been	VBN	O
utilized	VBN	O
for	IN	O
this	DT	O
purpose	NN	O
.	.	O

Troublesome	NNP	O
spiral	JJ	O
fractures	NNS	O
of	IN	O
the	DT	O
distal	JJ	O
radius	NN	O
are	VBP	O
the	DT	O
most	RBS	O
common	JJ	O
fractures	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
distal	JJ	O
radius	NN	O
as	IN	O
a	DT	O
vascularized	JJ	O
bone-graft	NN	O
donor	NN	O
site	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
proposed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
donor-site	JJ	O
bone	NN	O
loss	NN	O
on	IN	O
the	DT	O
strength	NN	O
of	IN	O
the	DT	O
radius	NN	O
under	IN	O
torsional	JJ	O
(	(	O
rotational	JJ	O
)	)	O
loading	NN	O
.	.	O

Previous	JJ	O
clinical	JJ	O
series	NN	O
and	CC	O
experimental	JJ	O
studies	NNS	O
have	VBP	O
not	RB	O
examined	VBN	O
this	DT	O
aspect	NN	O
of	IN	O
distal	JJ	O
radius	NN	O
loading	NN	O
after	IN	O
harvesting	VBG	O
the	DT	O
bone	NN	O
graft	NN	O
.	.	O

Fifty	NNP	SampleSize
pairs	NN	O
of	IN	O
sheep	JJ	O
tibiae	NN	O
were	VBD	O
utilized	VBN	O
in	IN	O
the	DT	O
experiment	NN	O
.	.	O

Five	CD	SampleSize
pairs	NNS	O
were	VBD	O
used	VBN	O
in	IN	O
a	DT	O
pilot	NN	O
study	NN	O
and	CC	O
45	CD	SampleSize
pairs	NNS	O
were	VBD	O
used	VBN	O
in	IN	O
the	DT	O
main	JJ	O
experiment	NN	O
.	.	O

Five	CD	SampleSize
pairs	NNS	O
of	IN	O
human	JJ	O
radii	NN	O
were	VBD	O
used	VBN	O
for	IN	O
the	DT	O
control	NN	O
in	IN	O
the	DT	O
pilot	NN	O
study	NN	O
.	.	O

The	DT	O
pilot	NN	O
study	NN	O
attempted	VBD	O
to	TO	O
make	VB	O
a	DT	O
comparison	NN	O
between	IN	O
the	DT	O
human	JJ	O
radius	NN	O
and	CC	O
the	DT	O
sheep	JJ	O
tibia	NN	O
for	IN	O
experimental	JJ	O
purposes	NNS	O
.	.	O

For	IN	O
the	DT	O
biomechanical	JJ	O
study	NN	O
of	IN	O
donor-site	JJ	O
defects	NNS	O
,	,	O
four	CD	O
study	NN	O
groups	NNS	O
were	VBD	O
examined	VBN	O
with	IN	O
random	JJ	O
assignment	NN	O
and	CC	O
matched	JJ	O
pairs	NNS	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
(	(	O
group	NN	O
1	CD	O
)	)	O
had	VBD	O
no	DT	O
alteration	NN	O
to	TO	O
the	DT	O
bone	NN	O
.	.	O

Each	DT	O
test	NN	O
condition	NN	O
included	VBD	O
five	CD	O
matched	VBN	O
pairs	NNS	O
of	IN	O
sheep	JJ	O
tibiae	NN	O
.	.	O

Experiment	JJ	O
1	CD	O
compared	VBN	O
the	DT	O
difference	NN	O
in	IN	O
the	DT	O
depth	NN	O
of	IN	O
the	DT	O
osteotomy	NN	O
defect	NN	O
.	.	O

In	IN	O
doing	VBG	O
this	DT	O
,	,	O
one-third	NN	O
of	IN	O
the	DT	O
total	JJ	O
length	NN	O
of	IN	O
the	DT	O
bone	NN	O
was	VBD	O
removed	VBN	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
following	VBG	O
specimens	NNS	O
to	TO	O
include	VB	O
(	(	O
1a	CD	O
)	)	O
30	CD	O
percent	NN	O
of	IN	O
the	DT	O
cross-sectional	JJ	O
area	NN	O
of	IN	O
the	DT	O
total	JJ	O
bone	NN	O
,	,	O
(	(	O
1b	CD	O
)	)	O
37	CD	O
percent	NN	O
of	IN	O
the	DT	O
cross-sectional	JJ	O
area	NN	O
of	IN	O
the	DT	O
total	JJ	O
bone	NN	O
,	,	O
and	CC	O
(	(	O
1c	CD	O
)	)	O
50	CD	O
percent	NN	O
of	IN	O
the	DT	O
cross-sectional	JJ	O
area	NN	O
of	IN	O
the	DT	O
total	JJ	O
bone	NN	O
.	.	O

In	IN	O
experiment	JJ	O
2	CD	O
,	,	O
the	DT	O
osteotomy	JJ	O
shape	NN	O
was	VBD	O
varied	VBN	O
.	.	O

Instead	RB	O
of	IN	O
the	DT	O
ends	NNS	O
of	IN	O
the	DT	O
cuts	NNS	O
being	VBG	O
squared	VBN	O
,	,	O
the	DT	O
ends	NNS	O
were	VBD	O
beveled	VBN	O
or	CC	O
rounded	VBN	O
.	.	O

Experiment	JJ	O
3	CD	O
compared	VBN	O
different	JJ	O
lengths	NNS	O
of	IN	O
bone	NN	O
removed	VBN	O
in	IN	O
the	DT	O
osteotomy	NN	O
defect	NN	O
and	CC	O
included	VBD	O
the	DT	O
following	NN	O
:	:	O
In	IN	O
experiment	NN	O
3a	CD	O
the	DT	O
diameter	NN	O
of	IN	O
the	DT	O
sheep	JJ	O
tibia	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
incisura	NN	O
fibularis	NN	O
.	.	O

This	DT	O
dimension	NN	O
was	VBD	O
one	CD	O
diameter	NN	O
of	IN	O
bone	NN	O
,	,	O
and	CC	O
a	DT	O
one-diameter	JJ	O
length	NN	O
of	IN	O
bone	NN	O
was	VBD	O
removed	VBN	O
.	.	O

In	IN	O
experiment	JJ	O
3b	CD	O
,	,	O
a	DT	O
two-diameter	JJ	O
length	NN	O
of	IN	O
bone	NN	O
was	VBD	O
removed	VBN	O
.	.	O

In	IN	O
experiment	JJ	O
3c	CD	O
,	,	O
a	DT	O
three-diameter	JJ	O
length	NN	O
of	IN	O
bone	NN	O
was	VBD	O
removed	VBN	O
.	.	O

In	IN	O
experiment	JJ	O
3d	CD	O
,	,	O
a	DT	O
four-diameter	JJ	O
length	NN	O
of	IN	O
bone	NN	O
was	VBD	O
removed	VBN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
400	CD	O
WORDS	NNP	O
)	)	O
Effect	NN	O
of	IN	O
intestinal	JJ	O
production	NN	O
of	IN	O
equol	NN	O
on	IN	O
menopausal	NN	O
symptoms	NNS	O
in	IN	O
women	NNS	O
treated	VBN	O
with	IN	O
soy	JJ	O
isoflavones	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
soy	NN	O
isoflavones	NNS	O
on	IN	O
menopausal	NN	O
symptoms	NNS	O
in	IN	O
women	NNS	O
who	WP	O
do	VBP	O
and	CC	O
who	WP	O
do	VBP	O
not	RB	O
produce	VB	O
equol	NN	O
,	,	O
a	DT	O
daidzein	NN	O
metabolite	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
over	IN	O
6	CD	O
months	NNS	O
with	IN	O
96	CD	O
healthy	JJ	O
menopausal	NN	O
women	NNS	O
.	.	O

After	IN	O
taking	VBG	O
take	VB	O
135	CD	O
mg	NN	O
of	IN	O
isoflavones	NNS	O
daily	RB	O
for	IN	O
1	CD	O
week	NN	O
,	,	O
the	DT	O
women	NNS	O
in	IN	O
the	DT	O
study	NN	O
group	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
equol-producing	NN	O
(	(	O
EP	NNP	O
)	)	O
or	CC	O
the	DT	O
non-EP	JJ	O
group	NN	O
according	VBG	O
to	TO	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
equol	NN	O
in	IN	O
their	PRP$	O
urine	NN	O
.	.	O

Menopausal	NNP	O
symptoms	NNS	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
modified	VBN	O
Kupperman	NNP	O
Index	NNP	O
.	.	O

RESULT	NNP	O
Compared	NNP	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
the	DT	O
scores	NNS	O
for	IN	O
hot	JJ	O
flashes	NNS	O
and	CC	O
excessive	JJ	O
sweating	NN	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
after	IN	O
3	CD	O
months	NNS	O
,	,	O
and	CC	O
the	DT	O
scores	NNS	O
for	IN	O
weakness	NN	O
,	,	O
palpitations	NNS	O
,	,	O
limb	NN	O
paresthesia	NN	O
,	,	O
and	CC	O
total	JJ	O
symptoms	NNS	O
after	IN	O
6	CD	O
months	NNS	O
,	,	O
in	IN	O
the	DT	O
EP	NNP	O
group	NN	O
only	RB	O
.	.	O

CONCLUSIONS	NNP	O
Isoflavone	NNP	O
supplementation	NN	O
improves	VBZ	O
menopausal	NN	O
symptoms	NNS	O
only	RB	O
in	IN	O
women	NNS	O
with	IN	O
the	DT	O
ability	NN	O
to	TO	O
produce	VB	O
equol	NN	O
.	.	O

Endobronchial	JJ	O
ultrasonography-guided	JJ	O
transbronchial	JJ	O
needle	JJ	O
aspiration	NN	O
increases	VBZ	O
the	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
peripheral	JJ	Condition
pulmonary	JJ	Condition
lesions	NNS	Condition
:	:	Condition
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
endobronchial	JJ	O
ultrasonography	NN	O
(	(	O
EBUS	NNP	O
)	)	O
-guided	VBD	O
transbronchial	JJ	O
needle	JJ	O
aspiration	NN	O
(	(	O
TBNA	NNP	O
)	)	O
for	IN	O
peripheral	JJ	O
pulmonary	JJ	O
lesions	NNS	O
(	(	O
PPLs	NNP	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	O

The	DT	O
diagnostic	JJ	O
impact	NN	O
of	IN	O
TBNA	NNP	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
is	VBZ	O
adjacent	JJ	O
to	TO	O
lesions	NNS	O
remains	VBZ	O
to	TO	O
be	VB	O
determined	VBN	O
.	.	O

DESIGN	VB	O
A	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
with	IN	O
PPLs	NNP	O
and	CC	O
positive	JJ	O
EBUS	NNP	O
findings	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
classified	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
EBUS	NNP	O
conventional	JJ	O
diagnostic	JJ	O
procedures	NNS	O
(	(	O
CDPs	NNP	O
)	)	O
group	NN	O
(	(	O
103	CD	O
patients	NNS	O
)	)	O
,	,	O
both	DT	O
transbronchial	JJ	O
biopsy	NN	O
(	(	O
TBB	NNP	O
)	)	O
and	CC	O
bronchial	JJ	O
washing	NN	O
(	(	O
BW	NNP	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

In	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
(	(	O
99	CD	O
patients	NNS	O
)	)	O
,	,	O
TBNA	NNP	O
,	,	O
TBB	NNP	O
,	,	O
and	CC	O
BW	NNP	O
were	VBD	O
performed	VBN	O
.	.	O

The	DT	O
diagnostic	JJ	O
yield	NN	O
in	IN	O
each	DT	O
group	NN	O
was	VBD	O
compared	VBN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
182	CD	O
patients	NNS	O
(	(	O
94	CD	O
in	IN	O
the	DT	O
EBUS	NNP	O
CDPs	NNP	O
group	NN	O
and	CC	O
88	CD	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
)	)	O
were	VBD	O
analyzed	VBN	O
.	.	O

The	DT	O
yield	NN	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
(	(	O
78.4	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
the	DT	O
EBUS	NNP	O
CDPs	NNP	O
group	NN	O
(	(	O
60.6	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.015	CD	O
)	)	O
.	.	O

Cases	NNS	O
in	IN	O
which	WDT	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
located	VBN	O
within	IN	O
the	DT	O
lesions	NNS	O
had	VBD	O
a	DT	O
significantly	RB	O
higher	RBR	O
diagnostic	JJ	O
yield	NN	O
(	(	O
78.3	CD	O
%	NN	O
)	)	O
than	IN	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
them	PRP	O
(	(	O
47.2	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Concerning	VBG	O
the	DT	O
three	CD	O
different	JJ	O
techniques	NNS	O
,	,	O
TBNA	NNP	O
showed	VBD	O
the	DT	O
highest	JJS	O
diagnostic	JJ	O
yield	NN	O
(	(	O
62.5	CD	O
%	NN	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
TBB	NNP	O
(	(	O
48.9	CD	O
%	NN	O
)	)	O
and	CC	O
to	TO	O
BW	NNP	O
(	(	O
19.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
TBNA	NNP	O
remained	VBD	O
unchanged	JJ	O
even	RB	O
when	WRB	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
the	DT	O
lesions	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.89	CD	O
)	)	O
.	.	O

No	DT	O
additional	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
EBUS-TBNA	JJ	O
plus	CC	O
CDPs	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Applying	NNP	O
TBNA	NNP	O
to	TO	O
EBUS-guided	NNP	O
CDPs	NNP	O
further	RBR	O
increased	VBD	O
the	DT	O
diagnostic	JJ	O
yield	NN	O
of	IN	O
PPLs	NNP	O
without	IN	O
additional	JJ	O
risk	NN	O
.	.	O

The	DT	O
diagnostic	JJ	O
advantage	NN	O
of	IN	O
TBNA	NNP	O
became	VBD	O
more	RBR	O
obvious	JJ	O
if	IN	O
the	DT	O
EBUS	NNP	O
probe	NN	O
was	VBD	O
adjacent	JJ	O
to	TO	O
the	DT	O
lesions	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Clinicaltrials.gov	NNP	O
Identifier	NNP	O
:	:	O
NCT00626587	NN	O
.	.	O

Memory	NN	O
monitoring	NN	O
by	IN	O
animals	NNS	Condition
and	CC	Condition
humans	NNS	Condition
.	.	Condition

The	DT	O
authors	NNS	O
asked	VBD	O
whether	IN	O
animals	NNS	O
and	CC	O
humans	NNS	O
would	MD	O
use	VB	O
similarly	RB	O
an	DT	O
uncertain	JJ	O
response	NN	O
to	TO	O
escape	VB	O
indeterminate	JJ	O
memories	NNS	O
.	.	O

Monkeys	NNS	O
and	CC	O
humans	NNS	O
performed	VBD	O
serial	JJ	O
probe	NN	O
recognition	NN	O
tasks	NNS	O
that	WDT	O
produced	VBD	O
differential	JJ	O
memory	NN	O
difficulty	NN	O
across	IN	O
serial	JJ	O
positions	NNS	O
(	(	O
e.g.	NN	O
,	,	O
primacy	NN	O
and	CC	O
recency	NN	O
effects	NNS	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
given	VBN	O
an	DT	O
escape	NN	O
option	NN	O
that	WDT	O
let	VBD	O
them	PRP	O
avoid	VB	O
any	DT	O
trials	NNS	O
they	PRP	O
wished	VBD	O
and	CC	O
receive	VB	O
a	DT	O
hint	NN	O
to	TO	O
the	DT	O
trial	NN	O
's	POS	O
answer	NN	O
.	.	O

Across	IN	O
species	NNS	O
,	,	O
across	IN	O
tasks	NNS	O
,	,	O
and	CC	O
even	RB	O
across	IN	O
conspecifics	NNS	O
with	IN	O
sharper	NN	O
or	CC	O
duller	NN	O
memories	NNS	O
,	,	O
monkeys	NNS	O
and	CC	O
humans	NNS	O
used	VBD	O
the	DT	O
escape	NN	O
option	NN	O
selectively	RB	O
when	WRB	O
more	RBR	O
indeterminate	JJ	O
memory	NN	O
traces	NNS	O
were	VBD	O
probed	VBN	O
.	.	O

Their	PRP$	O
pattern	NN	O
of	IN	O
escaping	VBG	O
always	RB	O
mirrored	VBN	O
the	DT	O
pattern	NN	O
of	IN	O
their	PRP$	O
primary	JJ	O
memory	NN	O
performance	NN	O
across	IN	O
serial	JJ	O
positions	NNS	O
.	.	O

Signal-detection	NN	O
analyses	NNS	O
confirm	VBP	O
the	DT	O
similarity	NN	O
of	IN	O
the	DT	O
animals	NNS	O
'	POS	O
and	CC	O
humans	NNS	O
'	POS	O
performances	NNS	O
.	.	O

Optimality	NNP	O
analyses	VBZ	O
assess	VB	O
their	PRP$	O
efficiency	NN	O
.	.	O

Several	JJ	O
aspects	NNS	O
of	IN	O
monkeys	NNS	O
'	POS	O
performance	NN	O
suggest	VBP	O
the	DT	O
cognitive	JJ	O
sophistication	NN	O
of	IN	O
their	PRP$	O
decisions	NNS	O
to	TO	O
escape	VB	O
.	.	O

Haemodynamic	NNP	O
profile	NN	O
of	IN	O
angiotensin	NN	O
II	NNP	O
antagonism	NN	O
in	IN	O
essential	JJ	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

1	CD	O
.	.	O

The	DT	O
haemodynamic	JJ	O
response	NN	O
to	TO	O
antagonistic	JJ	O
(	(	O
10	CD	O
microgram	RB	O
min-1	JJ	O
kg-1	NN	O
)	)	O
and	CC	O
agonistic	JJ	O
(	(	O
40	CD	O
microgram	RB	O
min-1	JJ	O
kg-1	NN	O
)	)	O
doses	VBZ	O
of	IN	O
saralasin	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
young	JJ	O
essential	JJ	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

Blood	NNP	O
pressure	NN	O
behaviour	NN	O
alone	RB	O
was	VBD	O
thought	VBN	O
to	TO	O
be	VB	O
inadequate	JJ	O
to	TO	O
describe	VB	O
the	DT	O
response	NN	O
pattern	NN	O
.	.	O

2	CD	O
.	.	O

Pre-saralasin	JJ	O
setting	NN	O
of	IN	O
the	DT	O
renin-angiotensin	JJ	O
axis	NN	O
was	VBD	O
varied	VBN	O
with	IN	O
salt	JJ	O
intake	NN	O
(	(	O
15	CD	O
and	CC	O
290	CD	O
mmol	NN	O
of	IN	O
Na+/day	NNP	O
)	)	O
each	DT	O
for	IN	O
10	CD	O
days	NNS	O
.	.	O

This	DT	O
failed	VBD	O
to	TO	O
influence	VB	O
blood	NN	O
pressure	NN	O
or	CC	O
plasma	NN	O
volume	NN	O
.	.	O

3	CD	O
.	.	O

Antagonist	NN	O
blockade	NN	O
after	IN	O
low	JJ	O
salt	NN	O
lowered	VBD	O
blood	NN	O
pressure	NN	O
in	IN	O
three	CD	O
patients	NNS	O
with	IN	O
the	DT	O
highest	JJS	O
plasma	NN	O
renin	NN	O
values	NNS	O
.	.	O

Cardiac	NNP	O
output	NN	O
rose	VBD	O
in	IN	O
two	CD	O
of	IN	O
these	DT	O
,	,	O
but	CC	O
it	PRP	O
dropped	VBD	O
in	IN	O
all	DT	O
others	NNS	O
.	.	O

4	CD	O
.	.	O

Decreases	NNS	O
in	IN	O
cardiac	JJ	O
output	NN	O
occurred	VBD	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
saralasin	NN	O
and	CC	O
even	RB	O
with	IN	O
suppression	NN	O
of	IN	O
the	DT	O
renin-angiotensin	JJ	O
axis	NN	O
.	.	O

This	DT	O
response	NN	O
is	VBZ	O
therefore	RB	O
unlikely	JJ	O
to	TO	O
be	VB	O
due	JJ	O
to	TO	O
removal	VB	O
of	IN	O
myocardial	JJ	O
or	CC	O
venous	JJ	O
angiotensin	NN	O
effects	NNS	O
.	.	O

5	CD	O
.	.	O

The	DT	O
renin-angiotensin	JJ	O
system	NN	O
played	VBD	O
a	DT	O
part	NN	O
in	IN	O
maintenance	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
only	RB	O
with	IN	O
severe	JJ	O
salt	NN	O
restriction	NN	O
and	CC	O
in	IN	O
a	DT	O
small	JJ	O
proportion	NN	O
of	IN	O
cases	NNS	O
.	.	O

6	CD	O
.	.	O

No	DT	O
heart	NN	O
rate	NN	O
effect	NN	O
was	VBD	O
seen	VBN	O
with	IN	O
sarcalasin	NN	O
.	.	O

7	CD	O
.	.	O

Blood	NN	O
pressure	NN	O
and	CC	O
total	JJ	O
peripheral	JJ	O
resistance	NN	O
responses	NNS	O
were	VBD	O
dependent	JJ	O
on	IN	O
pre-	NN	O
(	(	O
antagonist/agonist	NN	O
)	)	O
setting	NN	O
,	,	O
but	CC	O
heart	NN	O
rate	NN	O
and	CC	O
cardiac	JJ	O
output	NN	O
were	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
this	DT	O
factor	NN	O
.	.	O

A	DT	O
comparison	NN	O
between	IN	O
the	DT	O
effect	NN	O
of	IN	O
oxytocin	NN	O
only	RB	O
and	CC	O
oxytocin	JJ	O
plus	CC	O
propranolol	NN	O
on	IN	O
the	DT	O
labor	NN	O
(	(	O
a	DT	O
double	NN	O
blind	NN	O
randomized	VBN	O
trial	NN	O
)	)	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
comparison	NN	O
between	IN	O
the	DT	O
effect	NN	O
of	IN	O
oxytocin	NN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
propranolol	NN	O
on	IN	O
labor	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
double	JJ	O
blind	NN	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
150	CD	SampleSize
nulliparas	NNS	Condition
with	IN	O
a	DT	O
gestational	JJ	O
age	NN	O
of	IN	O
39-41	JJ	O
weeks	NNS	O
of	IN	O
pregnancy	NN	Condition
and	CC	O
a	DT	O
Bishop	NNP	O
score	NN	O
of	IN	O
<	NN	O
or	CC	O
=5	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
group	NN	O
(	(	O
oxytocin	JJ	O
group	NN	O
=	NNP	O
75	CD	O
)	)	O
,	,	O
oxytocin	FW	O
alone	RB	O
was	VBD	O
used	VBN	O
for	IN	O
induction	NN	O
of	IN	O
labor	NN	O
.	.	O

In	IN	O
the	DT	O
second	JJ	O
group	NN	O
(	(	O
propranolol	JJ	O
group	NN	O
=	VBD	O
75	CD	O
cases	NNS	O
)	)	O
,	,	O
before	IN	O
the	DT	O
beginning	NN	O
of	IN	O
oxytocin	NN	O
,	,	O
2	CD	O
mg	NN	O
propranolol	NN	O
was	VBD	O
slowly	RB	O
injected	VBN	O
intravenously	RB	O
then	RB	O
the	DT	O
oxytocin	NN	O
was	VBD	O
initiated	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
delivered	VBD	O
in	IN	O
the	DT	O
first	JJ	O
day	NN	O
showed	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
mean	JJ	O
duration	NN	O
for	IN	O
obtaining	VBG	O
good	JJ	O
contractions	NNS	O
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
propranolol	NN	O
group	NN	O
in	IN	O
both	CC	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
day	NN	O
of	IN	O
induction	NN	O
The	DT	O
mean	JJ	O
interval	NN	O
between	IN	O
the	DT	O
beginning	NN	O
of	IN	O
induction	NN	O
until	IN	O
the	DT	O
beginning	NN	O
of	IN	O
active	JJ	O
phase	NN	O
at	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
induction	NN	O
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
propranolol	NN	O
group	NN	O
.	.	O

The	DT	O
mean	JJ	O
interval	NN	O
between	IN	O
the	DT	O
beginning	NN	O
of	IN	O
induction	NN	O
until	IN	O
delivery	NN	O
at	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
induction	NN	O
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
propranolol	NN	O
group	NN	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
necessary	JJ	O
oxytocin	NN	O
for	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
induction	NN	O
was	VBD	O
less	RBR	O
in	IN	O
the	DT	O
propranolol	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Propranolol	NNP	O
may	MD	O
shorten	VB	O
the	DT	O
induction	NN	O
duration	NN	O
and	CC	O
labor	NN	O
and	CC	O
reduce	VB	O
the	DT	O
amount	NN	O
of	IN	O
necessary	JJ	O
oxytocin	NN	O
.	.	O

Cardiovascular	JJ	O
complications	NNS	O
to	TO	O
treatment	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
with	IN	O
estramustine	JJ	O
phosphate	NN	O
(	(	O
Estracyt	NNP	O
)	)	O
or	CC	O
conventional	JJ	O
estrogen	NN	O
.	.	O

A	DT	O
follow-up	NN	O
of	IN	O
212	CD	O
randomized	JJ	O
patients	NNS	O
.	.	O

Two	CD	O
hundred	VBD	O
and	CC	O
twelve	JJ	O
patients	NNS	O
treated	VBN	O
for	IN	O
prostatic	JJ	O
cancer	NN	O
grade	NN	O
I	PRP	O
or	CC	O
II	NNP	O
were	VBD	O
investigated	VBN	O
for	IN	O
cardiovascular	JJ	O
complications	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
part	NN	O
of	IN	O
a	DT	O
multicentre	NN	O
study	NN	O
in	IN	O
the	DT	O
Stockholm	NNP	O
area	NN	O
and	CC	O
had	VBD	O
been	VBN	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
estramustine	JJ	O
phosphate	NN	O
(	(	O
Estracyt	NNP	O
)	)	O
or	CC	O
polyestradiol	JJ	O
phosphate	NN	O
and	CC	O
ethinyl	JJ	O
estradiol	NN	O
.	.	O

Cardiovascular	JJ	O
complications	NNS	O
categorized	VBN	O
as	IN	O
impaired	JJ	O
arterial	JJ	O
circulation	NN	O
including	VBG	O
ischemic	JJ	O
heart	NN	O
disease	NN	O
,	,	O
venous	JJ	O
thromboembolism	NN	O
,	,	O
cardiac	JJ	O
incompensation	NN	O
and	CC	O
cerebral	JJ	O
depression	NN	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
equally	RB	O
frequent	JJ	O
following	VBG	O
the	DT	O
two	CD	O
different	JJ	O
forms	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Among	IN	O
the	DT	O
patients	NNS	O
getting	VBG	O
cardiovascular	JJ	O
complications	NNS	O
,	,	O
these	DT	O
occurred	VBD	O
within	IN	O
two	CD	O
months	NNS	O
after	IN	O
the	DT	O
start	NN	O
of	IN	O
treatment	NN	O
in	IN	O
50	CD	O
%	NN	O
and	CC	O
within	IN	O
one	CD	O
year	NN	O
in	IN	O
85	CD	O
%	NN	O
of	IN	O
them	PRP	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
incidence	NN	O
of	IN	O
cardiovascular	JJ	O
complications	NNS	O
and	CC	O
a	DT	O
history	NN	O
of	IN	O
previous	JJ	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

This	DT	O
criterion	NN	O
was	VBD	O
however	RB	O
in	IN	O
retrospect	NN	O
found	VBN	O
to	TO	O
predict	VB	O
cardiovascular	JJ	O
complications	NNS	O
in	IN	O
only	RB	O
67	CD	O
of	IN	O
the	DT	O
126	CD	O
patients	NNS	O
getting	VBG	O
one	CD	O
or	CC	O
several	JJ	O
of	IN	O
these	DT	O
complications	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
ursodeoxycholic	JJ	O
acid	NN	O
on	IN	O
serum	NN	O
liver	NN	O
enzymes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
hepatitis	JJ	Condition
C	NNP	Condition
virus-related	JJ	Condition
chronic	JJ	Condition
liver	NN	Condition
disease	NN	Condition
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
ursodeoxycholic	JJ	O
acid	NN	O
(	(	O
UDCA	NNP	O
)	)	O
on	IN	O
serum	NN	O
liver	NN	O
enzyme	NN	O
levels	NNS	O
[	VBP	O
alanine	JJ	O
aminotransferase	NN	O
(	(	O
ALT	NNP	O
)	)	O
and	CC	O
gamma-glutamyl	JJ	O
transferase	NN	O
(	(	O
GGT	NNP	O
)	)	O
]	VBP	O
in	IN	O
101	CD	SampleSize
patients	NNS	O
with	IN	O
hepatitis	JJ	Condition
C	NNP	Condition
virus-related	JJ	Condition
chronic	JJ	Condition
liver	NN	Condition
disease	NN	Condition
.	.	O

METHODS	NNP	O
Forty-nine	JJ	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
UDCA	NNP	O
(	(	O
450	CD	O
mg/day	NN	O
)	)	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
6	CD	O
months	NNS	O
and	CC	O
52	CD	O
to	TO	O
receive	VB	O
no	DT	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
UDCA	NNP	O
group	NN	O
,	,	O
serum	NN	O
ALT	NNP	O
and	CC	O
GGT	NNP	O
levels	NNS	O
significantly	RB	O
improved	VBN	O
.	.	O

ALT	NNP	O
values	NNS	O
decreased	VBN	O
from	IN	O
pre-treatment	JJ	O
levels	NNS	O
of	IN	O
157.0	CD	O
+/-	JJ	O
62.6	CD	O
IU/l	NNP	O
to	TO	O
82.5	CD	O
+/-	JJ	O
46.4	CD	O
IU/l	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
GGT	NNP	O
fell	VBD	O
from	IN	O
141.3	CD	O
+/-	JJ	O
86.2	CD	O
IU/l	NNP	O
to	TO	O
66.0	CD	O
+/-	JJ	O
49.5	CD	O
IU/l	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
change	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
mean	JJ	O
ALT	NNP	O
and	CC	O
GGT	NNP	O
levels	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Although	IN	O
our	PRP$	O
encouraging	JJ	O
preliminary	JJ	O
results	NNS	O
must	MD	O
be	VB	O
validated	VBN	O
by	IN	O
double-blind	JJ	O
histological	JJ	O
trials	NNS	O
,	,	O
UDCA	NNP	O
may	MD	O
be	VB	O
an	DT	O
alternative	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
who	WP	O
fail	VBP	O
to	TO	O
respond	VB	O
to	TO	O
interferon	VB	O
therapy	NN	O
.	.	O

Nasal	NNP	O
eosinophilia	NNS	O
and	CC	O
serum	NN	O
soluble	JJ	O
intercellular	JJ	O
adhesion	NN	O
molecule	NN	O
1	CD	O
in	IN	O
patients	NNS	O
with	IN	O
allergic	JJ	Condition
rhinitis	NN	Condition
treated	VBN	O
with	IN	O
montelukast	NN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
desloratadine	NN	O
or	CC	O
levocetirizine	NN	O
.	.	O

BACKGROUND	NNP	O
Because	IN	O
intercellular	JJ	O
adhesion	NN	O
molecule	NN	O
(	(	O
ICAM	NNP	O
)	)	O
1	CD	O
and	CC	O
recruitment	NN	O
of	IN	O
eosinophils	NNS	O
are	VBP	O
crucial	JJ	O
in	IN	O
supporting	VBG	O
allergic	JJ	O
inflammation	NN	O
,	,	O
their	PRP$	O
down-regulation	NN	O
may	MD	O
bring	VB	O
additional	JJ	O
benefits	NNS	O
in	IN	O
patients	NNS	O
'	POS	O
recovery	NN	O
.	.	O

We	PRP	O
have	VBP	O
assessed	VBN	O
nasal	JJ	O
eosinophilia	NNS	O
and	CC	O
serum	NN	O
soluble	JJ	O
ICAM-1	NNP	O
(	(	O
sICAM-1	JJ	O
)	)	O
concentrations	NNS	O
in	IN	O
relation	NN	O
to	TO	O
nasal	VB	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
persistent	JJ	O
allergic	JJ	O
rhinitis	NN	O
(	(	O
AR	NNP	O
)	)	O
treated	VBD	O
for	IN	O
6	CD	O
weeks	NNS	O
with	IN	O
either	DT	O
desloratadine	NN	O
,	,	O
levocetirizine	NN	O
,	,	O
montelukast	NN	O
alone	RB	O
,	,	O
or	CC	O
in	IN	O
combination	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
single-center	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
,	,	O
two-arm	JJ	O
study	NN	O
,	,	O
40	CD	SampleSize
patients	NNS	O
with	IN	O
persistent	JJ	O
AR	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
montelukast	NN	O
and/or	JJ	O
levocetirizine	NN	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
or	CC	O
to	TO	O
receive	VB	O
treatment	NN	O
with	IN	O
montelukast	NN	O
and/or	JJ	O
desloratadine	NN	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
.	.	O

Nasal	NNP	O
eosinophilia	JJ	O
and	CC	O
concentration	NN	O
of	IN	O
sICAM-1	NN	O
in	IN	O
peripheral	JJ	O
blood	NN	O
were	VBD	O
assessed	VBN	O
before	RB	O
and	CC	O
on	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
each	DT	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
active	JJ	O
treatments	NNS	O
in	IN	O
both	DT	O
arms	NNS	O
of	IN	O
the	DT	O
study	NN	O
resulted	VBD	O
in	IN	O
the	DT	O
decrease	NN	O
of	IN	O
sICAM-1	JJ	O
and	CC	O
nasal	JJ	O
eosinophilia	NN	O
,	,	O
which	WDT	O
correlated	VBD	O
with	IN	O
the	DT	O
severity	NN	O
of	IN	O
nasal	NN	O
symptoms	NNS	O
.	.	O

In	IN	O
the	DT	O
montelukast/levocetirizine	NN	O
arm	NN	O
,	,	O
montelukast	NN	O
decreased	VBD	O
nasal	JJ	O
eosinophilia	RB	O
more	RBR	O
significantly	RB	O
than	IN	O
levocetirizine	NN	O
,	,	O
whereas	NNS	O
in	IN	O
reduction	NN	O
of	IN	O
sICAM-1	JJ	O
all	DT	O
active	JJ	O
treatment	NN	O
options	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
desloratadine/montelukast	NN	O
arm	NN	O
,	,	O
the	DT	O
resulting	VBG	O
improvement	NN	O
of	IN	O
combination	NN	O
therapy	NN	O
of	IN	O
sICAM-1	NN	O
and	CC	O
the	DT	O
influx	NN	O
of	IN	O
eosinophils	NNS	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSION	VB	O
The	DT	O
improvement	NN	O
of	IN	O
nasal	NN	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
AR	NNP	O
treated	VBD	O
with	IN	O
antihistamines	NNS	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
montelukast	JJS	O
,	,	O
may	MD	O
additionally	RB	O
result	VB	O
from	IN	O
the	DT	O
reduction	NN	O
of	IN	O
sICAM-1	NN	O
and	CC	O
nasal	JJ	O
eosinophilia	NN	O
.	.	O

Because	IN	O
the	DT	O
combination	NN	O
therapy	NN	O
may	MD	O
bring	VB	O
inconclusive	JJ	O
benefits	NNS	O
in	IN	O
this	DT	O
area	NN	O
there	EX	O
is	VBZ	O
a	DT	O
strong	JJ	O
need	NN	O
of	IN	O
further	JJ	O
studies	NNS	O
to	TO	O
find	VB	O
mechanisms	NN	O
that	IN	O
favor	NN	O
combination	NN	O
therapy	NN	O
.	.	O

Clofibrate	NNP	O
and	CC	O
diabetes	VBZ	O
control	NN	O
in	IN	O
patients	NNS	Condition
treated	VBN	Condition
with	IN	Condition
oral	JJ	Condition
hypoglycaemic	JJ	Condition
agents	NNS	Condition
.	.	O

1	CD	O
.	.	O

Twenty-two	JJ	SampleSize
maturity-onset	JJ	O
type	NN	O
diabetics	NNS	Condition
treated	VBD	O
with	IN	O
oral	JJ	O
hypoglycaemic	JJ	O
agents	NNS	O
entered	VBD	O
a	DT	O
single-blind	JJ	O
crossover	NN	O
study	NN	O
using	VBG	O
placebo	NN	O
(	(	O
periods	VB	O
A	DT	O
and	CC	O
C	NNP	O
,	,	O
2	CD	O
months	NNS	O
each	DT	O
)	)	O
and	CC	O
clofibrate	NN	O
(	(	O
2	CD	O
g/day	NN	O
;	:	O
period	NN	O
B	NNP	O
;	:	O
2	CD	O
months	NNS	O
)	)	O
.	.	O

2	CD	O
.	.	O

In	IN	O
thirteen	JJ	SampleSize
patients	NNS	O
,	,	O
under	IN	O
reasonably	RB	O
good	JJ	O
control	NN	O
,	,	O
clofibrate	NN	O
did	VBD	O
not	RB	O
reduce	VB	O
fasting	VBG	O
or	CC	O
post-prandial	JJ	O
blood	NN	O
glucose	NN	O
,	,	O
nor	CC	O
24	CD	O
h	NN	O
glycosuria	NN	O
;	:	O
no	DT	O
improvement	NN	O
was	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
M-value	NNP	O
,	,	O
an	DT	O
index	NN	O
of	IN	O
diabetes	NNS	O
control	NN	O
.	.	O

3	CD	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
in	IN	O
nine	CD	O
patients	NNS	O
,	,	O
with	IN	O
poor	JJ	O
diabetes	NNS	O
control	NN	O
,	,	O
clofibrate	NN	O
reduced	VBD	O
24	CD	O
h	NN	O
glycosuria	NN	O
and	CC	O
significantly	RB	O
improved	VBD	O
the	DT	O
M-value	NNP	O
.	.	O

4	CD	O
.	.	O

In	IN	O
all	DT	O
patients	NNS	O
,	,	O
clofibrate	JJ	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
19-23	JJ	O
%	NN	O
reduction	NN	O
in	IN	O
plasma	NN	O
fibrinogen	NN	O
.	.	O

5	CD	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
addition	NN	O
of	IN	O
clofibrate	NN	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
maturity-onset	JJ	O
diabetics	NNS	O
not	RB	O
adequately	RB	O
controlled	VBN	O
by	IN	O
diet	NN	O
combined	VBN	O
with	IN	O
oral	JJ	O
hypoglycaemic	JJ	O
agents	NNS	O
.	.	O

Relief	NN	O
of	IN	O
periorbital	JJ	O
pain	NN	O
after	IN	O
acute	JJ	O
angle	JJ	O
closure	NN	O
glaucoma	NN	O
attack	NN	O
by	IN	O
botulinum	NN	O
toxin	NN	O
type	NN	O
A	NNP	O
.	.	O

PURPOSE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
botulinum	NN	O
toxin	NN	O
type	NN	O
A	NNP	O
(	(	O
BoNT-A	NNP	O
)	)	O
injection	NN	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
intractable	JJ	Condition
periorbital	NN	Condition
pain	NN	Condition
after	IN	O
acute	JJ	Condition
angle	JJ	Condition
closure	NN	Condition
glaucoma	NN	Condition
(	(	O
AACG	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
randomized	VBN	O
intervention	NN	O
study	NN	O
,	,	O
19	CD	SampleSize
patients	NNS	O
suffering	VBG	O
from	IN	O
periorbital	JJ	O
pain	NN	O
after	IN	O
an	DT	O
AACG	NNP	Condition
attack	NN	O
were	VBD	O
injected	VBN	O
with	IN	O
BoNT-A	NNP	O
or	CC	O
placebo	NN	O
for	IN	O
pain	NN	O
relief	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
7	CD	O
,	,	O
14	CD	O
,	,	O
30	CD	O
,	,	O
60	CD	O
,	,	O
and	CC	O
90	CD	O
.	.	O

The	DT	O
main	JJ	O
outcomes	NNS	O
were	VBD	O
mean	JJ	O
change	NN	O
of	IN	O
visual	JJ	O
analog	NN	O
rating	NN	O
scale	NN	O
(	(	O
VARS	NNP	O
)	)	O
and	CC	O
index	NN	O
scores	NNS	O
measured	VBN	O
through	IN	O
a	DT	O
quality-of-life	JJ	O
questionnaire	NN	O
(	(	O
EQ-5D	NNP	O
)	)	O
,	,	O
and	CC	O
changes	NNS	O
in	IN	O
the	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
were	VBD	O
assessed	VBN	O
at	IN	O
each	DT	O
visit	NN	O
.	.	O

A	DT	O
secondary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
frequency	NN	O
and	CC	O
nature	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
withdrew	VBP	O
from	IN	O
the	DT	O
study	NN	O
as	IN	O
a	DT	O
result	NN	O
.	.	O

RESULTS	NN	O
In	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
n=10	NN	O
)	)	O
,	,	O
the	DT	O
mean	JJ	O
index	NN	O
score	NN	O
of	IN	O
EQ-5D	NNP	O
and	CC	O
VAS	NNP	O
changed	VBD	O
significantly	RB	O
from	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
by	IN	O
0.299	CD	O
and	CC	O
2.61	CD	O
,	,	O
respectively	RB	O
)	)	O
from	IN	O
day	NN	O
2	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
VARS	NNP	O
of	IN	O
EQ-5D	NNP	O
also	RB	O
disclosed	VBD	O
significant	JJ	O
changes	NNS	O
from	IN	O
day	NN	O
2	CD	O
(	(	O
17	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
efficacy	NN	O
was	VBD	O
maintained	VBN	O
mainly	RB	O
between	IN	O
days	NNS	O
2	CD	O
and	CC	O
60	CD	O
but	CC	O
declined	VBD	O
slightly	RB	O
by	IN	O
day	NN	O
90	CD	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
treatment-related	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
were	VBD	O
local	JJ	O
tenderness	NN	O
(	(	O
21	CD	O
%	NN	O
)	)	O
,	,	O
subcutaneous	JJ	O
hemorrhage	NN	O
(	(	O
10.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
conjunctivitis	NN	O
(	(	O
10.5	CD	O
%	NN	O
)	)	O
.	.	O

No	UH	O
severe	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
during	IN	O
the	DT	O
study	NN	O
or	CC	O
follow-up	JJ	O
period	NN	O
.	.	O

CONCLUSIONS	NNP	O
BoNT-A	NNP	O
is	VBZ	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
periorbital	JJ	O
pain	NN	O
after	IN	O
an	DT	O
AACG	NNP	O
attack	NN	O
.	.	O

Its	PRP$	O
effects	NNS	O
may	MD	O
be	VB	O
maintained	VBN	O
for	IN	O
3	CD	O
months	NNS	O
.	.	O

Tramadol	NNP	O
suppository	NN	O
versus	NN	O
placebo	NN	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
perineal	NN	Condition
pain	NN	Condition
after	IN	O
perineorrhaphy	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
in	IN	O
Thailand	NNP	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
randomized	JJ	O
double-blinded	JJ	O
control	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
tramodol	NN	O
and	CC	O
placebo	NN	O
rectal	JJ	O
suppository	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
postpartum	NN	O
perineal	NN	O
pain	NN	O
after	IN	O
perineorrhaphy	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHOD	NNP	O
One	NNP	O
hundred	VBD	O
women	NNS	Age
who	WP	O
gave	VBD	O
birth	NN	O
vaginally	RB	O
with	IN	O
episiotomy	NN	O
and	CC	O
a	DT	O
second-	JJ	Condition
or	CC	Condition
third-degree	JJ	Condition
tear	NN	Condition
,	,	O
were	VBD	O
randomly	RB	O
assign	VBN	O
to	TO	O
receive	VB	O
two	CD	O
tablets	NNS	O
oftramadol	VBP	O
50	CD	O
mg	NNS	O
or	CC	O
two	CD	O
tablets	NNS	O
ofplacebo	RB	O
,	,	O
the	DT	O
pill	NN	O
were	VBD	O
physically	RB	O
similar	JJ	O
to	TO	O
the	DT	O
real	JJ	O
drug	NN	O
.	.	O

Pain	VB	O
ratings	NNS	O
were	VBD	O
recorded	VBN	O
immediately	RB	O
after	IN	O
perineorrhaphy	NN	O
,	,	O
30	CD	O
minutes	NNS	O
,	,	O
and	CC	O
1	CD	O
,	,	O
2	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
first	JJ	O
dose	NN	O
on	IN	O
a	DT	O
10-cm	JJ	O
visual	JJ	O
analogue	NN	O
scale	NN	O
.	.	O

Side	JJ	O
effects	NNS	O
and	CC	O
overall	JJ	O
opinion	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Tramadol	NNP	O
and	CC	O
placebo	NN	O
had	VBD	O
no	DT	O
statistical	JJ	O
significances	NNS	O
in	IN	O
analgesic	JJ	O
properties	NNS	O
,	,	O
assessed	VBN	O
by	IN	O
the	DT	O
means	NNS	O
of	IN	O
pain	NN	O
rating	NN	O
at	IN	O
the	DT	O
different	JJ	O
time	NN	O
intervals	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
reported	VBN	O
.	.	O

CONCLUSION	NNP	O
No	NNP	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
between	IN	O
Tramadol	NNP	O
and	CC	O
placebo	NN	O
in	IN	O
relief	NN	O
perineal	NN	O
pain	NN	O
after	IN	O
perineorrhaphy	NN	O
Dynamic	NNP	O
surface	NN	O
electromyographic	JJ	O
responses	NNS	O
in	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
treated	VBN	O
by	IN	O
traditional	JJ	O
bone	NN	O
setting	NN	O
and	CC	O
conventional	JJ	O
physical	JJ	O
therapy	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
dynamic	JJ	O
surface	NN	O
electromyographic	JJ	O
(	(	O
EMG	NNP	O
)	)	O
activities	NNS	O
of	IN	O
back	JJ	O
muscles	NNS	O
and	CC	O
pain	NN	O
before	IN	O
and	CC	O
after	IN	O
traditional	JJ	O
bone	NN	O
setting	NN	O
and	CC	O
physical	JJ	O
therapy	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
compared	VBN	O
surface	NN	O
EMG	NNP	O
dynamic	JJ	O
activities	NNS	O
after	IN	O
traditional	JJ	O
bone	NN	O
setting	NN	O
and	CC	O
physical	JJ	O
therapy	NN	O
.	.	O

Sixty-one	CD	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
41	CD	O
years	NNS	O
)	)	O
with	IN	O
nonspecific	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
subgroups	NNS	O
by	IN	O
treatment	NN	O
.	.	O

The	DT	O
patients	NNS	O
underwent	VBD	O
a	DT	O
dynamic	JJ	O
EMG	NNP	O
evaluation	NN	O
for	IN	O
which	WDT	O
they	PRP	O
were	VBD	O
asked	VBN	O
to	TO	O
stand	VB	O
and	CC	O
then	RB	O
bend	VB	O
forward	RB	O
as	RB	O
far	RB	O
as	IN	O
possible	JJ	O
,	,	O
stay	VB	O
fully	RB	O
flexed	VBN	O
,	,	O
and	CC	O
return	NN	O
to	TO	O
standing	VBG	O
.	.	O

A	DT	O
flexion-relaxation	JJ	O
ratio	NN	O
was	VBD	O
calculated	VBN	O
by	IN	O
comparing	VBG	O
maximal	JJ	O
EMG	NNP	O
activity	NN	O
while	IN	O
flexing	VBG	O
with	IN	O
the	DT	O
average	JJ	O
EMG	NNP	O
activity	NN	O
in	IN	O
full	JJ	O
flexion	NN	O
.	.	O

Concentric	NNP	O
(	(	O
maximal	JJ	O
EMG	NNP	O
activity	NN	O
during	IN	O
extension	NN	O
)	)	O
and	CC	O
eccentric	JJ	O
(	(	O
maximal	JJ	O
EMG	NNP	O
activity	NN	O
during	IN	O
flexion	NN	O
)	)	O
ratios	NNS	O
were	VBD	O
also	RB	O
used	VBN	O
in	IN	O
the	DT	O
analyses	NNS	O
.	.	O

RESULTS	NNP	O
Disability	NNP	O
,	,	O
depression	NN	O
,	,	O
and	CC	O
visual	JJ	O
analog	NN	O
scale	NN	O
scores	NNS	O
decreased	VBN	O
significantly	RB	O
after	IN	O
both	DT	O
treatments	NNS	O
.	.	O

The	DT	O
concentric	JJ	O
ratio	NN	O
increased	VBD	O
statistically	RB	O
in	IN	O
both	DT	O
groups	NNS	O
after	IN	O
the	DT	O
treatments	NNS	O
.	.	O

The	DT	O
study	NN	O
failed	VBD	O
to	TO	O
show	VB	O
a	DT	O
significant	JJ	O
association	NN	O
between	IN	O
experienced	VBN	O
back	RB	O
pain	NN	O
and	CC	O
EMG	NNP	O
parameters	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
treatments	NNS	O
seem	VBP	O
to	TO	O
have	VB	O
a	DT	O
positive	JJ	O
influence	NN	O
on	IN	O
back	JJ	O
muscle	NN	O
function	NN	O
by	IN	O
improving	VBG	O
muscle	NN	O
symmetry	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
treatments	NNS	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
flexion-relaxation	NN	O
phenomenon	NN	O
after	IN	O
1	CD	O
month	NN	O
.	.	O

Active	NNP	O
back	RB	O
exercise	NN	O
at	IN	O
home	NN	O
together	RB	O
with	IN	O
rehabilitation	NN	O
treatments	NNS	O
might	MD	O
be	VB	O
effective	JJ	O
and	CC	O
improve	VB	O
function	NN	O
for	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
AMSA	NNP	O
in	IN	O
children	NNS	Age
with	IN	O
acute	JJ	Condition
leukemia	NN	Condition
.	.	O

A	DT	O
Pediatric	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

One	CD	SampleSize
hundred	VBD	SampleSize
four	CD	SampleSize
children	NNS	Age
with	IN	O
advanced	JJ	Condition
leukemia	NN	Condition
in	IN	O
relapse	NN	O
(	(	O
74	CD	SampleSize
with	IN	O
acute	JJ	Condition
lymphocytic	JJ	Condition
leukemia	NN	Condition
[	NNP	Condition
ALL	NNP	Condition
]	NNP	Condition
and	CC	O
30	CD	SampleSize
with	IN	O
acute	JJ	Condition
nonlymphocytic	JJ	Condition
leukemia	NN	Condition
[	NNP	Condition
ANLL	NNP	Condition
]	NNP	Condition
)	)	Condition
received	VBD	O
AMSA	NNP	O
(	(	O
4'-	JJ	O
(	(	O
9-Acridinylamino	CD	O
)	)	O
methanesulfon	FW	O
-m-anisidide	NN	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
120	CD	O
mg/m2/day	NN	O
for	IN	O
5	CD	O
days	NNS	O
(	(	O
Regimen	NNP	O
I	PRP	O
)	)	O
or	CC	O
60	CD	O
mg/m2/day	NN	O
for	IN	O
10	CD	O
days	NNS	O
(	(	O
Regimen	NNP	O
II	NNP	O
)	)	O
.	.	O

Children	NNP	Age
with	IN	O
ALL	NNP	Condition
were	VBD	O
randomized	VBN	O
between	IN	O
Regimens	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
(	(	O
31	CD	O
and	CC	O
36	CD	O
evaluable	JJ	O
patients	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

All	DT	O
29	CD	O
evaluable	JJ	O
patients	NNS	O
with	IN	O
ANLL	NNP	Condition
were	VBD	O
treated	VBN	O
on	IN	O
Regimen	NNP	O
I.	NNP	O
Eighty-eight	NNP	O
percent	NN	O
of	IN	O
evaluable	JJ	O
patients	NNS	O
experienced	VBD	O
severe	JJ	O
or	CC	O
life-threatening	JJ	O
toxicity	NN	O
,	,	O
with	IN	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
Regimens	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
.	.	O

Bacterial	NNP	O
or	CC	O
fungal	JJ	O
infections	NNS	O
(	(	O
considered	VBN	O
life-threatening	NN	O
or	CC	O
fatal	NN	O
)	)	O
occurred	VBD	O
in	IN	O
17	CD	O
children	NNS	O
with	IN	O
ALL	DT	O
and	CC	O
in	IN	O
7	CD	O
with	IN	O
ANLL	NNP	O
.	.	O

Fatal	NNP	Condition
cardiac	JJ	Condition
toxicity	NN	Condition
occurred	VBD	O
in	IN	O
one	CD	O
patient	NN	O
.	.	O

Complete	NNP	O
or	CC	O
partial	JJ	O
response	NN	O
occurred	VBD	O
in	IN	O
25.0	CD	O
%	NN	O
(	(	O
SE	NNP	O
=	RB	O
8.8	CD	O
%	NN	O
)	)	O
,	,	O
28.1	CD	O
%	NN	O
(	(	O
SE	NNP	O
=	RB	O
8.0	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
25.9	CD	O
%	NN	O
(	(	O
SE	NNP	O
=	RB	O
8.4	CD	O
%	NN	O
)	)	O
of	IN	O
evaluable	JJ	O
patients	NNS	O
on	IN	O
ALL	NNP	O
Regimen	NNP	O
I	PRP	O
,	,	O
ALL	DT	O
Regimen	NNP	O
II	NNP	O
,	,	O
and	CC	O
ANLL	NNP	O
,	,	O
respectively	RB	O
.	.	O

However	RB	O
,	,	O
responses	NNS	O
were	VBD	O
of	IN	O
short	JJ	O
duration	NN	O
(	(	O
16-91	JJ	O
days	NNS	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
duration	NN	O
of	IN	O
survival	NN	O
from	IN	O
treatment	NN	O
start	NN	O
for	IN	O
the	DT	O
two	CD	O
ALL	DT	O
regimens	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.46	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
survival	NN	O
for	IN	O
ANLL	NNP	O
patients	NNS	O
was	VBD	O
significantly	RB	O
longer	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
than	IN	O
that	DT	O
of	IN	O
ALL	NNP	O
patients	NNS	O
treated	VBD	O
on	IN	O
Regimens	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
combined	VBD	O
.	.	O

Eighty-two	JJ	O
percent	NN	O
of	IN	O
the	DT	O
complete	JJ	O
or	CC	O
partial	JJ	O
responses	NNS	O
(	(	O
18	CD	O
of	IN	O
22	CD	O
)	)	O
occurred	VBD	O
after	IN	O
the	DT	O
first	JJ	O
course	NN	O
of	IN	O
AMSA	NNP	O
.	.	O

At	IN	O
the	DT	O
dose	JJ	O
schedules	NNS	O
investigated	VBN	O
,	,	O
and	CC	O
in	IN	O
a	DT	O
heavily	RB	O
pretreated	VBN	O
patient	JJ	O
population	NN	O
,	,	O
AMSA	NNP	O
had	VBD	O
activity	NN	O
in	IN	O
childhood	NN	O
leukemia	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
severe	JJ	O
,	,	O
life-threatening	JJ	O
,	,	O
or	CC	O
fatal	JJ	O
infections	NNS	O
meant	VBP	O
that	IN	O
the	DT	O
quality	NN	O
and	CC	O
quantity	NN	O
of	IN	O
responses	NNS	O
and	CC	O
survival	NN	O
was	VBD	O
not	RB	O
commensurate	JJ	O
with	IN	O
the	DT	O
toxicity	NN	O
,	,	O
and	CC	O
that	IN	O
it	PRP	O
would	MD	O
be	VB	O
difficult	JJ	O
to	TO	O
incorporate	VB	O
this	DT	O
drug	NN	O
into	IN	O
combination	NN	O
chemotherapy	NN	O
with	IN	O
other	JJ	O
myelosuppressive	JJ	O
agents	NNS	O
.	.	O

Topical	NNP	O
retapamulin	NN	O
ointment	NN	O
(	(	O
1	CD	O
%	NN	O
,	,	O
wt/wt	NN	O
)	)	O
twice	RB	O
daily	RB	O
for	IN	O
5	CD	O
days	NNS	O
versus	IN	O
oral	JJ	O
cephalexin	NN	O
twice	RB	O
daily	RB	O
for	IN	O
10	CD	O
days	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
secondarily	RB	O
infected	VBN	O
dermatitis	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
New	NNP	O
antibacterial	JJ	O
agents	NNS	O
with	IN	O
activity	NN	O
against	IN	O
pathogenic	JJ	O
strains	NNS	O
resistant	VBP	O
to	TO	O
established	VBN	O
antibiotics	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
secondarily	RB	O
infected	VBN	O
dermatitis	NN	O
(	(	O
SID	NNP	O
)	)	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
sought	VBD	O
to	TO	O
determine	VB	O
the	DT	O
clinical	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
topical	JJ	O
retapamulin	NN	O
ointment	VBD	O
1	CD	O
%	NN	O
versus	JJ	O
oral	JJ	O
cephalexin	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
SID	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
SID	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
retapamulin	VB	O
ointment	JJ	O
1	CD	O
%	NN	O
(	(	O
twice	JJ	O
daily	RB	O
[	NNP	O
bid	NN	O
]	NN	O
)	)	O
for	IN	O
5	CD	O
days	NNS	O
,	,	O
or	CC	O
oral	JJ	O
cephalexin	NN	O
(	(	O
500	CD	O
mg	RB	O
bid	NN	O
)	)	O
for	IN	O
10	CD	O
days	NNS	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	JJ	O
end	NN	O
point	NN	O
was	VBD	O
clinical	JJ	O
response	NN	O
at	IN	O
follow-up	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
microbiologic	JJ	O
response	NN	O
at	IN	O
follow-up	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
compliance	NN	O
.	.	O

RESULTS	NNP	O
Retapamulin	NNP	O
was	VBD	O
as	RB	O
effective	JJ	O
as	IN	O
cephalexin	NN	O
(	(	O
clinical	JJ	O
success	NN	O
rates	NNS	O
at	IN	O
follow-up	NN	O
:	:	O
85.9	CD	O
%	NN	O
and	CC	O
89.7	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Microbiologic	NNP	O
success	NN	O
rates	NNS	O
at	IN	O
follow-up	JJ	O
were	VBD	O
87.2	CD	O
%	NN	O
for	IN	O
retapamulin	NN	O
and	CC	O
91.8	CD	O
%	NN	O
for	IN	O
cephalexin	NN	O
.	.	O

Retapamulin	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
the	DT	O
topical	JJ	O
formulation	NN	O
was	VBD	O
preferred	VBN	O
over	IN	O
the	DT	O
oral	JJ	O
drug	NN	O
.	.	O

LIMITATIONS	NNP	O
An	DT	O
imbalance	NN	O
existed	VBN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
the	DT	O
clinical	JJ	O
outcome	NN	O
unable	JJ	O
to	TO	O
determine	VB	O
(	(	O
15	CD	O
retapamulin	NN	O
,	,	O
2	CD	O
cephalexin	NN	O
)	)	O
,	,	O
mainly	RB	O
because	IN	O
of	IN	O
their	PRP$	O
failure	NN	O
to	TO	O
attend	VB	O
the	DT	O
study	NN	O
visit	NN	O
.	.	O

If	IN	O
those	DT	O
who	WP	O
failed	VBD	O
to	TO	O
attend	VB	O
visits	NNS	O
(	(	O
who	WP	O
did	VBD	O
not	RB	O
withdraw	VB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
drug-related	JJ	O
events	NNS	O
)	)	O
are	VBP	O
removed	VBN	O
from	IN	O
the	DT	O
analysis	NN	O
,	,	O
the	DT	O
clinical	JJ	O
success	NN	O
rates	NNS	O
are	VBP	O
89.9	CD	O
%	NN	O
for	IN	O
retapamulin	NN	O
and	CC	O
89.7	CD	O
%	NN	O
for	IN	O
cephalexin	NN	O
.	.	O

CONCLUSIONS	NNP	O
Retapamulin	NNP	O
ointment	VBD	O
1	CD	O
%	NN	O
(	(	O
bid	NN	O
)	)	O
for	IN	O
5	CD	O
days	NNS	O
was	VBD	O
as	RB	O
effective	JJ	O
as	IN	O
oral	JJ	O
cephalexin	NN	O
(	(	O
bid	NN	O
)	)	O
for	IN	O
10	CD	O
days	NNS	O
in	IN	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
SID	NNP	O
,	,	O
and	CC	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

[	JJ	O
Value	NNP	O
of	IN	O
combining	VBG	O
64	CD	O
multi-slice	JJ	O
spiral	JJ	O
computer	NN	O
tomography	NN	O
and	CC	O
serum	NN	O
amyloid	VBP	O
A	DT	O
protein	NN	O
in	IN	O
surgical	JJ	O
decision-making	NN	O
in	IN	O
rectal	JJ	Condition
cancer	NN	Condition
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
accuracy	NN	O
and	CC	O
clinical	JJ	O
value	NN	O
of	IN	O
combining	VBG	O
64	CD	O
multi-slice	JJ	O
spiral	JJ	O
computer	NN	O
tomography	NN	O
(	(	O
MSCT	NNP	O
)	)	O
and	CC	O
serum	$	O
amyloid	VB	O
A	NNP	O
protein	NN	O
(	(	O
SAA	NNP	O
)	)	O
in	IN	O
the	DT	O
preoperative	JJ	O
staging	NN	O
of	IN	O
rectal	JJ	Condition
cancer	NN	Condition
.	.	O

METHODS	NNP	O
Prospectively	RB	O
enrolled	VBD	O
patients	NNS	O
with	IN	O
rectal	JJ	Condition
cancer	NN	Condition
from	IN	O
October	NNP	O
2007	CD	O
to	TO	O
October	NNP	O
2008	CD	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
MSCT	NNP	O
and	CC	O
SAA	NNP	O
combined	VBD	O
group	NN	O
:	:	O
both	DT	O
MSCT	NNP	O
and	CC	O
SAA	NNP	O
combinative	JJ	O
assessment	NN	O
were	VBD	O
performed	VBN	O
for	IN	O
preoperative	JJ	O
evaluation	NN	O
;	:	O
MSCT	NNP	O
group	NN	O
:	:	O
only	RB	O
MSCT	NNP	O
was	VBD	O
performed	VBN	O
preoperatively	RB	O
for	IN	O
tumor	NN	O
staging	NN	O
.	.	O

The	DT	O
accuracy	NN	O
of	IN	O
the	DT	O
preoperative	JJ	O
T	NNP	O
,	,	O
N	NNP	O
,	,	O
M	NNP	O
,	,	O
and	CC	O
TNM	NNP	O
staging	NN	O
and	CC	O
the	DT	O
concordance	NN	O
rate	NN	O
of	IN	O
predictive	JJ	O
operative	JJ	O
strategy	NN	O
were	VBD	O
compared	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Total	NNP	O
of	IN	O
225	CD	SampleSize
cases	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

There	EX	O
were	VBD	O
110	CD	SampleSize
cases	NNS	O
in	IN	O
MSCT	NNP	O
and	CC	O
SAA	NNP	O
combined	VBD	O
group	NN	O
and	CC	O
115	CD	SampleSize
cases	NNS	O
in	IN	O
MSCT	NNP	O
group	NN	O
.	.	O

The	DT	O
baseline	NN	O
characteristics	NNS	O
was	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

For	IN	O
MSCT	NNP	O
and	CC	O
SAA	NNP	O
combined	VBD	O
group	NN	O
,	,	O
the	DT	O
accuracies	NNS	O
of	IN	O
preoperative	JJ	O
staging	NN	O
of	IN	O
T	NNP	O
,	,	O
N	NNP	O
,	,	O
M	NNP	O
and	CC	O
TNM	NNP	O
was	VBD	O
87.3	CD	O
%	NN	O
,	,	O
85.2	CD	O
%	NN	O
,	,	O
100	CD	O
%	NN	O
and	CC	O
86.4	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
and	CC	O
for	IN	O
MSCT	NNP	O
group	NN	O
,	,	O
the	DT	O
corresponding	JJ	O
rates	NNS	O
was	VBD	O
85.2	CD	O
%	NN	O
,	,	O
67.0	CD	O
%	NN	O
,	,	O
100	CD	O
%	NN	O
and	CC	O
66.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Statistical	JJ	O
differences	NNS	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
accuracy	NN	O
of	IN	O
preoperative	JJ	O
N	NNP	O
and	CC	O
TNM	NNP	O
staging	VBG	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.009	CD	O
and	CC	O
0.001	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
there	EX	O
was	VBD	O
statistical	JJ	O
difference	NN	O
in	IN	O
the	DT	O
accuracy	NN	O
of	IN	O
prediction	NN	O
to	TO	O
operative	VB	O
procedures	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
94.7	CD	O
%	NN	O
vs.	FW	O
81.7	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Combinative	NNP	O
assessment	NN	O
of	IN	O
MSCT	NNP	O
and	CC	O
SAA	NNP	O
could	MD	O
improve	VB	O
the	DT	O
accuracy	NN	O
of	IN	O
preoperative	JJ	O
staging	NN	O
,	,	O
and	CC	O
thus	RB	O
provide	VB	O
higher	JJR	O
predictive	JJ	O
coincidence	NN	O
rate	NN	O
of	IN	O
operative	JJ	O
procedures	NNS	O
.	.	O

Correlates	NNS	O
of	IN	O
cognitive	JJ	O
deficits	NNS	O
in	IN	O
first	JJ	Condition
episode	NN	Condition
schizophrenia	NN	Condition
.	.	O

OBJECTIVE	CC	O
The	DT	O
presence	NN	O
of	IN	O
cognitive	JJ	O
dysfunction	NN	O
in	IN	O
schizophrenia	NN	Condition
has	VBZ	O
been	VBN	O
well	RB	O
documented	VBN	O
,	,	O
but	CC	O
questions	NNS	O
remain	VBP	O
about	IN	O
whether	IN	O
there	EX	O
are	VBP	O
relationships	NNS	O
between	IN	O
this	DT	O
dysfunction	NN	O
and	CC	O
clinical	JJ	O
symptomatology	NN	O
.	.	O

If	IN	O
present	JJ	O
,	,	O
such	JJ	O
relationships	NNS	O
should	MD	O
be	VB	O
most	RBS	O
clearly	RB	O
observable	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
first	JJ	Condition
episode	NN	Condition
schizophrenia	NN	Condition
;	:	O
that	WDT	O
is	VBZ	O
,	,	O
before	IN	O
the	DT	O
effects	NNS	O
of	IN	O
chronic	JJ	Condition
illness	NN	Condition
,	,	O
institutionalization	NN	O
,	,	O
or	CC	O
treatment	NN	O
might	MD	O
confound	VB	O
them	PRP	O
.	.	O

METHOD	CC	O
307	CD	SampleSize
schizophrenia	NN	Condition
subjects	NNS	O
in	IN	O
their	PRP$	O
first	JJ	Condition
episode	NN	Condition
of	IN	Condition
illness	NN	Condition
were	VBD	O
recruited	VBN	O
to	TO	O
participate	VB	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
haloperidol	NN	O
and	CC	O
risperidone	NN	O
.	.	O

The	DT	O
psychopathology	NN	O
,	,	O
cognitive	JJ	O
functioning	NN	O
,	,	O
early	JJ	O
treatment	NN	O
history	NN	O
,	,	O
and	CC	O
duration	NN	O
of	IN	O
untreated	JJ	O
psychosis	NN	O
of	IN	O
these	DT	O
subjects	NNS	O
were	VBD	O
assessed	VBN	O
prior	RB	O
to	TO	O
their	PRP$	O
assignment	NN	O
to	TO	O
randomized	VB	O
,	,	O
double-blind	JJ	O
treatment	NN	O
.	.	O

Approximately	RB	O
two-thirds	NNS	SampleSize
of	IN	O
the	DT	O
subjects	NNS	O
were	VBD	O
receiving	VBG	O
antipsychotic	JJ	O
treatment	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
assessment	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
duration	NN	O
of	IN	O
treatment	NN	O
was	VBD	O
limited	VBN	O
to	TO	O
12	CD	O
weeks	NNS	O
or	CC	O
less	JJR	O
.	.	O

RESULTS	VB	O
The	DT	O
severity	NN	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
assessment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
deficits	NNS	O
in	IN	O
memory	NN	O
,	,	O
verbal	JJ	O
fluency	NN	O
,	,	O
psychomotor	NN	O
speed	NN	O
and	CC	O
executive	NN	O
function	NN	O
.	.	O

Positive	JJ	O
symptoms	NNS	O
were	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
cognitive	JJ	O
deficits	NNS	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
duration	NN	O
of	IN	O
untreated	JJ	O
illness	NN	O
(	(	O
DUI	NNP	O
)	)	O
prior	RB	O
to	TO	O
assessment	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
associated	VBN	O
with	IN	O
cognitive	JJ	O
impairment	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
of	IN	O
first	JJ	Condition
episode	NN	Condition
schizophrenia	NN	Condition
patients	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
relationship	NN	O
exists	VBZ	O
between	IN	O
negative	JJ	O
symptoms	NNS	O
and	CC	O
cognitive	JJ	O
dysfunction	NN	O
.	.	O

However	RB	O
,	,	O
that	IN	O
relationship	NN	O
accounts	NNS	O
for	IN	O
only	RB	O
a	DT	O
minor	JJ	O
portion	NN	O
of	IN	O
the	DT	O
variance	NN	O
(	(	O
i.e.	JJ	O
,	,	O
10-15	JJ	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
severity	NN	O
of	IN	O
cognitive	JJ	O
dysfunction	NN	O
after	IN	O
controlling	VBG	O
for	IN	O
a	DT	O
number	NN	O
of	IN	O
potentially	RB	O
confounding	VBG	O
factors	NNS	O
.	.	O

This	DT	O
finding	NN	O
provides	VBZ	O
support	NN	O
for	IN	O
the	DT	O
theory	NN	O
that	IN	O
the	DT	O
neurobiological	JJ	O
processes	NNS	O
that	WDT	O
give	VBP	O
rise	NN	O
to	TO	O
symptomatology	NN	O
and	CC	O
cognitive	JJ	O
dysfunction	NN	O
in	IN	O
schizophrenia	NN	Condition
are	VBP	O
partially	RB	O
overlapping	VBG	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
fatty	JJ	O
acid	JJ	O
composition	NN	O
of	IN	O
the	DT	O
plasma	NN	O
lipid	JJ	O
esters	NNS	O
during	IN	O
lipid-lowering	JJ	O
treatment	NN	O
with	IN	O
diet	JJ	O
,	,	O
clofibrate	NN	O
and	CC	O
niceritrol	NN	O
.	.	O

Reduction	NN	O
of	IN	O
the	DT	O
proportion	NN	O
of	IN	O
linoleate	NN	O
by	IN	O
clofibrate	NN	O
but	CC	O
not	RB	O
by	IN	O
niceritrol	NN	O
.	.	O

The	DT	O
fatty	JJ	O
acid	JJ	O
composition	NN	O
of	IN	O
the	DT	O
plasma	NN	O
lipid	JJ	O
esters	NNS	O
has	VBZ	O
been	VBN	O
studied	VBN	O
during	IN	O
lipid-lowering	JJ	O
treatment	NN	O
of	IN	O
95	CD	SampleSize
patients	NNS	O
with	IN	O
atherosclerotic	JJ	Condition
disease	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
two	CD	O
months	NNS	O
of	IN	O
the	DT	O
trial	NN	O
only	RB	O
a	DT	O
diet	NN	O
was	VBD	O
prescribed	VBN	O
.	.	O

During	IN	O
the	DT	O
ensuing	VBG	O
two	CD	O
months	NNS	O
either	CC	O
clofibrate	NN	O
or	CC	O
niceritrol	NN	O
,	,	O
a	DT	O
nicotinic	JJ	O
acid	NN	O
ester	NN	O
,	,	O
was	VBD	O
added	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
.	.	O

During	IN	O
the	DT	O
last	JJ	O
two	CD	O
months	NNS	O
the	DT	O
second	JJ	O
drug	NN	O
was	VBD	O
added	VBN	O
.	.	O

The	DT	O
combined	JJ	O
treatment	NN	O
with	IN	O
diet	JJ	O
,	,	O
clofibrate	NN	O
and	CC	O
niceritrol	NN	O
caused	VBN	O
highly	RB	O
significant	JJ	O
serum	NN	O
lipid	JJ	O
reductions	NNS	O
.	.	O

The	DT	O
fatty	JJ	O
acid	JJ	O
composition	NN	O
in	IN	O
the	DT	O
plasma	NN	O
lipid	JJ	O
esters	NNS	O
was	VBD	O
determined	VBN	O
in	IN	O
samples	NNS	O
from	IN	O
each	DT	O
trial	NN	O
period	NN	O
to	TO	O
measure	VB	O
the	DT	O
degree	NN	O
of	IN	O
dietary	JJ	O
adherence	NN	O
.	.	O

During	IN	O
dietary	JJ	O
treatment	NN	O
the	DT	O
relative	JJ	O
content	NN	O
of	IN	O
saturated	JJ	O
and	CC	O
monounsaturated	VBD	O
fatty	JJ	O
acids	NNS	O
secreased	VBD	O
and	CC	O
the	DT	O
polyunsaturated	JJ	O
fatty	JJ	O
acids	NNS	O
increased	VBD	O
with	IN	O
an	DT	O
increasing	VBG	O
ratio	NN	O
between	IN	O
pulyunsaturated	VBN	O
and	CC	O
saturated	VBN	O
fatty	JJ	O
acids	NNS	O
(	(	O
P/S	NNP	O
ratio	NN	O
)	)	O
in	IN	O
the	DT	O
cholesterol	NN	O
esters	NNS	O
and	CC	O
triglycerides	NNS	O
.	.	O

Only	RB	O
minor	JJ	O
changes	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
phospholipids	NNS	O
.	.	O

The	DT	O
changes	NNS	O
caused	VBN	O
by	IN	O
the	DT	O
diet	NN	O
were	VBD	O
partly	RB	O
reversed	VBN	O
by	IN	O
clofibrate	NN	O
while	IN	O
niceritrol	NN	O
did	VBD	O
not	RB	O
cause	VB	O
any	DT	O
major	JJ	O
changes	NNS	O
of	IN	O
the	DT	O
fatty	JJ	O
acid	JJ	O
composition	NN	O
.	.	O

Clofibrate	NNP	O
treatment	NN	O
coincided	VBD	O
with	IN	O
increasing	VBG	O
amounts	NNS	O
of	IN	O
monounsaturated	JJ	O
fatty	JJ	O
acids	NNS	O
,	,	O
especially	RB	O
oleate	JJ	O
(	(	O
18	CD	O
:	:	O
1	CD	O
)	)	O
,	,	O
in	IN	O
the	DT	O
cholesterol	NN	O
esters	NNS	O
,	,	O
triglycerides	NNS	O
and	CC	O
phospholipids	NNS	O
while	IN	O
there	EX	O
were	VBD	O
significant	JJ	O
reductions	NNS	O
of	IN	O
the	DT	O
content	NN	O
of	IN	O
linoleic	NN	O
(	(	O
18	CD	O
:	:	O
2	CD	O
)	)	O
acid	NN	O
in	IN	O
both	CC	O
the	DT	O
cholesterol	NN	O
esters	NNS	O
and	CC	O
triglycerides	NNS	O
.	.	O

The	DT	O
18	CD	O
:	:	O
2/18	CD	O
:	:	O
1	CD	O
ratio	NN	O
decreased	VBN	O
significantly	RB	O
in	IN	O
all	PDT	O
the	DT	O
lipid	JJ	O
esters	NNS	O
analyzed	VBD	O
.	.	O

However	RB	O
,	,	O
the	DT	O
P/S	NNP	O
ratio	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
affected	VBN	O
,	,	O
partly	RB	O
because	IN	O
the	DT	O
relative	JJ	O
content	NN	O
of	IN	O
saturated	JJ	O
fatty	JJ	O
acids	NNS	O
also	RB	O
tended	VBD	O
to	TO	O
decrease	VB	O
during	IN	O
clofibrate	JJ	O
treatment	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
addition	NN	O
of	IN	O
clofibrate	NN	O
treatment	NN	O
to	TO	O
patients	NNS	O
who	WP	O
are	VBP	O
on	IN	O
a	DT	O
diet	JJ	O
enriched	VBN	O
with	IN	O
polyunsaturated	JJ	O
fats	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
change	NN	O
from	IN	O
polyunsaturated	VBN	O
to	TO	O
monounsaturated	VBN	O
fatty	JJ	O
acids	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
lipid	JJ	O
esters	NNS	O
but	CC	O
does	VBZ	O
not	RB	O
significantly	RB	O
effect	NN	O
the	DT	O
ratio	NN	O
between	IN	O
polyunsaturated	VBN	O
and	CC	O
saturated	VBN	O
fatty	JJ	O
acids	NNS	O
.	.	O

The	DT	O
fatty	JJ	O
acid	NN	O
changes	NNS	O
caused	VBN	O
by	IN	O
clofibrate	NN	O
treatment	NN	O
and	CC	O
counteracted	VBN	O
by	IN	O
an	DT	O
increased	JJ	O
amount	NN	O
of	IN	O
polyunsaturated	JJ	O
fat	NN	O
in	IN	O
the	DT	O
diet	NN	O
.	.	O

Angiotensin	NNP	O
converting	VBG	O
enzyme	JJ	O
inhibition	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
response	NN	O
to	TO	O
exogenous	JJ	O
angiotensin	NN	O
II	NNP	O
in	IN	O
the	DT	O
human	JJ	O
forearm	NN	O
.	.	O

Suppression	NN	O
of	IN	O
endogenous	JJ	O
levels	NNS	O
of	IN	O
angiotensin	NN	O
II	NNP	O
by	IN	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibition	NN	O
,	,	O
may	MD	O
result	VB	O
in	IN	O
up-regulation	NN	O
of	IN	O
vascular	JJ	O
AT1	NNP	O
receptors	NNS	O
.	.	O

We	PRP	O
have	VBP	O
evaluated	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
orally	RB	O
administered	VBN	O
enalapril	NN	O
on	IN	O
angiotensin	NN	O
II	NNP	O
induced	VBD	O
vasoconstriction	NN	O
in	IN	O
the	DT	O
human	JJ	O
forearm	NN	O
.	.	O

Subjects	VBZ	O
received	VBN	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
enalapril	NN	O
(	(	O
20	CD	O
mg	NN	O
)	)	O
or	CC	O
matched	VBN	O
placebo	JJ	O
daily	JJ	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Forearm	NNP	O
blood	NN	O
flow	NN	O
response	NN	O
to	TO	O
increasing	VBG	O
doses	NNS	O
of	IN	O
angiotensin	NN	O
II	NNP	O
was	VBD	O
measured	VBN	O
using	VBG	O
venous	JJ	O
occlusion	NN	O
plethysmography	NN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
2	CD	O
week	NN	O
treatment	NN	O
period	NN	O
.	.	O

Treatment	NN	O
with	IN	O
enalapril	NN	O
significantly	RB	O
reduced	VBN	O
plasma	NN	O
angiotensin	NN	O
II	NNP	O
levels	NNS	O
and	CC	O
supine	VB	O
blood	NN	O
pressure	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
percentage	NN	O
reductions	NNS	O
in	IN	O
forearm	NN	O
blood	NN	O
flow	NN	O
in	IN	O
the	DT	O
infused	JJ	O
arm	NN	O
,	,	O
in	IN	O
response	NN	O
to	TO	O
the	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
angiotensin	NN	O
II	NNP	O
(	(	O
50,000	CD	O
fmol	RB	O
min-1	NN	O
)	)	O
were	VBD	O
48.1	CD	O
+/-	JJ	O
3.6	CD	O
%	NN	O
at	IN	O
baseline	NN	O
,	,	O
57.5	CD	O
+/-	JJ	O
3.6	CD	O
%	NN	O
on	IN	O
placebo	NN	O
and	CC	O
54.5	CD	O
+/-	JJ	O
4.2	CD	O
%	NN	O
on	IN	O
enalapril	NN	O
.	.	O

The	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

This	DT	O
demonstrates	VBZ	O
that	IN	O
suppression	NN	O
of	IN	O
plasma	NN	O
angiotensin	NN	O
II	NNP	O
for	IN	O
a	DT	O
14	CD	O
day	NN	O
period	NN	O
does	VBZ	O
not	RB	O
enhance	VB	O
the	DT	O
response	NN	O
to	TO	O
exogenous	JJ	O
intra-arterial	JJ	O
angiotensin	NN	O
II	NNP	O
in	IN	O
the	DT	O
human	JJ	O
forearm	NN	O
of	IN	O
healthy	JJ	Condition
salt	NN	Condition
replete	JJ	Condition
subjects	NNS	O
.	.	O

Transthoracic	NNP	O
versus	NN	O
transesophageal	NN	O
cardioversion	NN	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
under	IN	O
light	JJ	O
sedation	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Electrical	JJ	O
cardioversion	NN	O
(	(	O
ECV	NNP	O
)	)	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
is	VBZ	O
limited	VBN	O
by	IN	O
a	DT	O
5-10	JJ	O
%	NN	O
failure	NN	O
rate	NN	O
and	CC	O
by	IN	O
the	DT	O
expense	NN	O
arising	VBG	O
from	IN	O
a	DT	O
perceived	JJ	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

A	DT	O
transesophageal	JJ	O
approach	NN	O
using	VBG	O
light	JJ	O
sedation	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
augmenting	VBG	O
the	DT	O
success	NN	O
rate	NN	O
and	CC	O
avoiding	VBG	O
the	DT	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
the	DT	O
high	JJ	O
rate	NN	O
of	IN	O
success	NN	O
and	CC	O
the	DT	O
lower	JJR	O
energy	NN	O
requirement	NN	O
associated	VBN	O
with	IN	O
biphasic	JJ	O
cardioversion	NN	O
might	MD	O
eliminate	VB	O
any	DT	O
advantage	NN	O
of	IN	O
the	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
60	CD	O
patients	NNS	O
attending	VBG	O
for	IN	O
ECV	NNP	O
of	IN	O
persistent	JJ	O
AF	NNP	O
to	TO	O
a	DT	O
transesophageal	NN	O
or	CC	O
a	DT	O
transthoracic	JJ	O
approach	NN	O
.	.	O

Sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
midazolam	NN	O
was	VBD	O
titrated	VBN	O
in	IN	O
the	DT	O
same	JJ	O
manner	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Sinus	NNP	O
rhythm	NN	O
was	VBD	O
restored	VBN	O
in	IN	O
29/30	CD	O
patients	NNS	O
(	(	O
97	CD	O
%	NN	O
)	)	O
in	IN	O
each	DT	O
group	NN	O
using	VBG	O
a	DT	O
similar	JJ	O
number	NN	O
of	IN	O
shocks	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
1.3	CD	O
+/-	JJ	O
0.6	CD	O
transesophageal	NN	O
vs	NN	O
1.4	CD	O
+/-	JJ	O
0.7	CD	O
transthoracic	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
with	IN	O
a	DT	O
similar	JJ	O
procedure	NN	O
duration	NN	O
(	(	O
14.1	CD	O
+/-	JJ	O
8.2	CD	O
minutes	NNS	O
vs	JJ	O
13.8	CD	O
+/-	JJ	O
7.5	CD	O
minutes	NNS	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
similar	JJ	O
doses	NNS	O
of	IN	O
midazolam	NN	O
(	(	O
4.2	CD	O
+/-	JJ	O
2.7	CD	O
mg	NN	O
vs	NN	O
4.4	CD	O
+/-	JJ	O
2.8	CD	O
mg	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
and	CC	O
both	DT	O
reported	VBD	O
a	DT	O
similar	JJ	O
discomfort	NN	O
score	NN	O
in	IN	O
(	(	O
0.9	CD	O
+/-	JJ	O
1.3	CD	O
vs	JJ	O
1.1	CD	O
+/-	JJ	O
1.8	CD	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

No	DT	O
complication	NN	O
occurred	VBD	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
AF	NNP	O
may	MD	O
be	VB	O
cardioverted	VBN	O
safely	RB	O
and	CC	O
effectively	RB	O
by	IN	O
either	CC	O
a	DT	O
transthoracic	NN	O
or	CC	O
a	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
renders	NNS	O
cardioversion	NN	O
by	IN	O
either	DT	O
approach	NN	O
acceptable	JJ	O
.	.	O

As	IN	O
transesophageal	NN	O
ECV	NNP	O
shows	VBZ	O
no	DT	O
clear	JJ	O
advantage	NN	O
,	,	O
transthoracic	JJ	O
cardioversion	NN	O
should	MD	O
remain	VB	O
the	DT	O
approach	NN	O
of	IN	O
first	JJ	O
choice	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
fenretinide	NN	O
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
using	VBG	O
DNA	NNP	O
flow	JJ	O
cytometry	NN	O
as	IN	O
an	DT	O
intermediate	JJ	O
end	NN	O
point	NN	O
.	.	O

Retinoids	NNS	O
have	VBP	O
shown	VBN	O
a	DT	O
potential	JJ	O
activity	NN	O
in	IN	O
preventing	VBG	O
tumor	NN	O
recurrence	NN	O
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
synthetic	JJ	O
retinoid	NN	O
fenretinide	NN	O
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
using	VBG	O
DNA	NNP	O
flow	JJ	O
cytometry	NN	O
and	CC	O
conventional	JJ	O
cytology	NN	O
as	IN	O
surrogate	JJ	O
biomarkers	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
99	CD	O
subjects	NNS	O
with	IN	O
resected	JJ	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
(	(	O
pTa	NN	O
,	,	O
pT1	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
fenretinide	NN	O
(	(	O
200	CD	O
mg	NNS	O
day	NN	O
p.o	NN	O
.	.	O

for	IN	O
24	CD	O
months	NNS	O
)	)	O
or	CC	O
no	DT	O
intervention	NN	O
.	.	O

Cystoscopy	NNP	O
and	CC	O
bladder	NN	O
washing	NN	O
for	IN	O
DNA	NNP	O
flow	NN	O
cytometry	NN	O
end	NN	O
points	NNS	O
(	(	O
proportion	NN	O
of	IN	O
DNA	NNP	O
aneuploid	JJ	O
histograms	NN	O
,	,	O
hyperdiploid	JJ	O
fraction	NN	O
,	,	O
and	CC	O
percentage	NN	O
of	IN	O
apoptotic	JJ	O
cells	NNS	O
)	)	O
and	CC	O
proportion	NN	O
of	IN	O
abnormal	JJ	O
cytological	JJ	O
examinations	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
4	CD	O
months	NNS	O
for	IN	O
up	IN	O
to	TO	O
36	CD	O
months	NNS	O
.	.	O

The	DT	O
primary	JJ	O
study	NN	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
DNA	NNP	O
aneuploid	JJ	O
histograms	NNS	O
after	IN	O
12	CD	O
months	NNS	O
.	.	O

This	DT	O
figure	NN	O
was	VBD	O
48.9	CD	O
%	NN	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
and	CC	O
41.9	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
(	(	O
odds	NNS	O
ratio	NN	O
,	,	O
1.16	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.44-3.07	JJ	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
any	DT	O
other	JJ	O
response	NN	O
biomarker	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
up	RB	O
to	TO	O
36	CD	O
months	NNS	O
,	,	O
nor	CC	O
was	VBD	O
any	DT	O
biomarker	NN	O
able	JJ	O
to	TO	O
predict	VB	O
recurrence	NN	O
risk	NN	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
arms	NNS	O
(	(	O
27	CD	O
events	NNS	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
versus	NN	O
21	CD	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.36	CD	O
)	)	O
.	.	O

Twelve	NNP	O
subjects	VBZ	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
complained	VBD	O
of	IN	O
diminished	JJ	O
dark	NN	O
adaptability	NN	O
,	,	O
and	CC	O
nine	CD	O
subjects	NNS	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
versus	IN	O
one	CD	O
control	NN	O
subject	NN	O
had	VBD	O
mild	JJ	O
dermatological	JJ	O
alterations	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
fenretinide	NN	O
showed	VBD	O
a	DT	O
lack	NN	O
of	IN	O
effect	NN	O
on	IN	O
the	DT	O
DNA	NNP	O
content	NN	O
distribution	NN	O
and	CC	O
the	DT	O
morphology	NN	O
of	IN	O
urothelial	JJ	O
cells	NNS	O
obtained	VBN	O
in	IN	O
serial	JJ	O
bladder	NN	O
washings	NNS	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
groups	NNS	O
.	.	O

Because	IN	O
our	PRP$	O
data	NNS	O
are	VBP	O
hampered	VBN	O
by	IN	O
the	DT	O
lack	NN	O
of	IN	O
predictivity	NN	O
of	IN	O
the	DT	O
selected	VBN	O
biomarkers	NNS	O
,	,	O
additional	JJ	O
studies	NNS	O
are	VBP	O
necessary	JJ	O
to	TO	O
assess	VB	O
the	DT	O
activity	NN	O
of	IN	O
fenretinide	NN	O
in	IN	O
preventing	VBG	O
bladder	NN	O
cancer	NN	O
.	.	O

Potential	JJ	O
effect	NN	O
of	IN	O
the	DT	O
risk	NN	O
of	IN	O
ovarian	JJ	O
cancer	NN	O
algorithm	NN	O
(	(	O
ROCA	NNP	O
)	)	O
on	IN	O
the	DT	O
mortality	NN	O
outcome	NN	O
of	IN	O
the	DT	O
Prostate	NNP	O
,	,	O
Lung	NNP	O
,	,	O
Colorectal	NNP	O
and	CC	O
Ovarian	NNP	O
(	(	O
PLCO	NNP	O
)	)	O
trial	NN	O
.	.	O

Recently	RB	O
,	,	O
the	DT	O
Prostate	NNP	O
,	,	O
Lung	NNP	O
,	,	O
Colorectal	NNP	O
and	CC	O
Ovarian	NNP	O
(	(	O
PLCO	NNP	O
)	)	O
Trial	NNP	O
reported	VBD	O
no	DT	O
mortality	NN	O
benefit	NN	O
for	IN	O
annual	JJ	O
screening	NN	O
with	IN	O
CA-125	NNP	O
and	CC	O
transvaginal	JJ	O
ultrasound	NN	O
(	(	O
TVU	NNP	O
)	)	O
.	.	O

Currently	NNP	O
ongoing	VBG	O
is	VBZ	O
the	DT	O
UK	NNP	O
Collaborative	NNP	O
Trial	NNP	O
of	IN	O
Ovarian	JJ	O
Cancer	NNP	O
Screening	NNP	O
(	(	O
UKCTOCS	NNP	O
)	)	O
,	,	O
which	WDT	O
utilizes	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
ovarian	JJ	O
cancer	NN	O
algorithm	NN	O
(	(	O
ROCA	NNP	O
)	)	O
,	,	O
a	DT	O
statistical	JJ	O
tool	NN	O
that	IN	O
considers	NNS	O
current	JJ	O
and	CC	O
past	JJ	O
CA125	NNP	O
values	NNS	O
to	TO	O
determine	VB	O
ovarian	JJ	O
cancer	NN	O
risk	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
PLCO	NNP	O
used	VBD	O
a	DT	O
single	JJ	O
cutoff	NN	O
for	IN	O
CA125	NNP	O
,	,	O
based	VBN	O
on	IN	O
current	JJ	O
levels	NNS	O
alone	RB	O
.	.	O

We	PRP	O
investigated	VBD	O
whether	IN	O
having	VBG	O
had	VBD	O
used	VBN	O
ROCA	NNP	O
in	IN	O
PLCO	NNP	O
could	MD	O
have	VB	O
,	,	O
under	IN	O
optimal	JJ	O
assumptions	NNS	O
,	,	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
mortality	NN	O
benefit	NN	O
by	IN	O
applying	VBG	O
ROCA	NNP	O
to	TO	O
PLCO	NNP	O
CA125	NNP	O
screening	VBG	O
values	NNS	O
.	.	O

A	DT	O
best-case	JJ	O
scenario	NN	O
assumed	VBD	O
that	IN	O
all	DT	O
cancers	NNS	O
showing	VBG	O
a	DT	O
positive	JJ	O
screen	NN	O
result	NN	O
earlier	RBR	O
with	IN	O
ROCA	NNP	O
than	IN	O
under	IN	O
the	DT	O
PLCO	NNP	O
protocol	NN	O
would	MD	O
have	VB	O
avoided	VBN	O
mortality	NN	O
;	:	O
under	IN	O
a	DT	O
stage-shift	JJ	O
scenario	NN	O
,	,	O
such	JJ	O
women	NNS	O
were	VBD	O
assigned	VBN	O
survival	JJ	O
equivalent	NN	O
to	TO	O
Stage	VB	O
I/II	NNP	O
screen-detected	JJ	O
cases	NNS	O
.	.	O

Updated	VBN	O
PLCO	NNP	O
data	NNS	O
show	VBP	O
132	CD	O
intervention	NN	O
arm	NN	O
ovarian	JJ	O
cancer	NN	O
deaths	NNS	O
versus	VBP	O
119	CD	O
in	IN	O
usual	JJ	O
care	NN	O
(	(	O
relative	JJ	O
risk	NN	O
,	,	O
RR	NNP	O
=	NNP	O
1.11	CD	O
)	)	O
.	.	O

Forty-three	JJ	O
ovarian	JJ	O
cancer	NN	O
cases	NNS	O
,	,	O
25	CD	O
fatal	NN	O
,	,	O
would	MD	O
have	VB	O
been	VBN	O
detected	VBN	O
earlier	RBR	O
with	IN	O
ROCA	NNP	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
(	(	O
minimum	JJ	O
)	)	O
advance	NN	O
time	NN	O
for	IN	O
fatal	JJ	O
cases	NNS	O
of	IN	O
344	CD	O
(	(	O
147	CD	O
)	)	O
days	NNS	O
.	.	O

Best-case	JJ	O
and	CC	O
stage-shift	JJ	O
scenarios	NNS	O
gave	VBD	O
25	CD	O
and	CC	O
19	CD	O
deaths	NNS	O
prevented	VBN	O
with	IN	O
ROCA	NNP	O
,	,	O
for	IN	O
RRs	NNP	O
of	IN	O
0.90	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.69-1.17	NN	O
)	)	O
and	CC	O
0.95	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.74-1.23	NN	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

Having	VBG	O
utilized	JJ	O
ROCA	NNP	O
in	IN	O
PLCO	NNP	O
would	MD	O
not	RB	O
have	VB	O
led	VBN	O
to	TO	O
a	DT	O
significant	JJ	O
mortality	NN	O
benefit	NN	O
of	IN	O
screening	VBG	O
.	.	O

However	RB	O
,	,	O
ROCA	NNP	O
could	MD	O
still	RB	O
show	VB	O
a	DT	O
significant	JJ	O
effect	NN	O
in	IN	O
other	JJ	O
screening	NN	O
trials	NNS	O
,	,	O
including	VBG	O
UKCTOCS	NNP	O
.	.	O

Prevention	NN	O
of	IN	O
postoperative	JJ	O
hypocalcemia	NN	O
with	IN	O
routine	JJ	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplements	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
papillary	JJ	O
thyroid	NN	O
carcinoma	NN	O
undergoing	JJ	O
total	JJ	O
thyroidectomy	NN	O
plus	CC	O
central	JJ	O
neck	NN	O
dissection	NN	O
.	.	O

BACKGROUND	NNP	O
Routine	NNP	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
may	MD	O
prevent	VB	O
hypocalcemic	JJ	O
crisis	NN	O
,	,	O
but	CC	O
its	PRP$	O
efficacy	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
thyroidectomy	JJ	O
plus	JJ	O
central	JJ	O
neck	NN	O
dissection	NN	O
(	(	O
CND	NNP	O
)	)	O
.	.	O

The	DT	O
authors	NNS	O
therefore	VBP	O
prospectively	RB	O
evaluated	VBN	O
the	DT	O
clinical	JJ	O
usefulness	NN	O
of	IN	O
routine	JJ	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
for	IN	O
prevention	NN	O
of	IN	O
hypocalcemia	NN	O
after	IN	O
total	JJ	O
thyroidectomy	NN	O
and	CC	O
CND	NNP	O
.	.	O

METHODS	NNP	O
Of	IN	O
197	CD	O
patients	NNS	O
with	IN	O
differentiated	JJ	O
papillary	JJ	O
thyroid	NN	O
carcinoma	NN	O
,	,	O
49	CD	O
underwent	JJ	O
total	JJ	O
thyroidectomy	NN	O
alone	RB	O
,	,	O
and	CC	O
148	CD	O
underwent	JJ	O
total	JJ	O
thyroidectomy	NN	O
plus	CC	O
CND	NNP	O
.	.	O

The	DT	O
latter	JJ	O
were	VBD	O
randomized	VBN	O
to	TO	O
oral	JJ	O
calcium	NN	O
(	(	O
3	CD	O
g/day	NN	O
)	)	O
plus	CC	O
vitamin	JJ	O
D	NNP	O
(	(	O
1	CD	O
mg/day	NN	O
)	)	O
(	(	O
Group	NNP	O
A	NNP	O
,	,	O
n=49	NN	O
)	)	O
,	,	O
calcium	NN	O
alone	RB	O
(	(	O
Group	NNP	O
B	NNP	O
,	,	O
n=49	NN	O
)	)	O
,	,	O
or	CC	O
no	DT	O
supplements	NNS	O
(	(	O
Group	NNP	O
C	NNP	O
,	,	O
n=50	RB	O
)	)	O
.	.	O

Hypocalcemic	NNP	O
symptoms	NNS	O
,	,	O
serum	JJ	O
calcium	NN	O
,	,	O
and	CC	O
parathyroid	VB	O
hormone	NN	O
(	(	O
PTH	NNP	O
)	)	O
levels	NNS	O
were	VBD	O
compared	VBN	O
among	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Group	NNP	O
C	NNP	O
had	VBD	O
significantly	RB	O
higher	JJR	O
incidences	NNS	O
of	IN	O
symptomatic	JJ	O
(	(	O
26.0	CD	O
%	NN	O
vs	JJ	O
6.1	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.015	NNP	O
)	)	O
and	CC	O
laboratory	NN	O
(	(	O
44.0	CD	O
%	NN	O
vs	JJ	O
14.3	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.015	NNP	O
)	)	O
hypocalcemia	NN	O
than	IN	O
the	DT	O
group	NN	O
without	IN	O
CND	NNP	O
.	.	O

The	DT	O
incidences	NNS	O
of	IN	O
symptomatic	JJ	O
and	CC	O
laboratory	JJ	O
hypocalcemia	NN	O
were	VBD	O
significantly	RB	O
decreased	VBN	O
in	IN	O
Groups	NNP	O
A	NNP	O
(	(	O
2.0	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
12.2	CD	O
%	NN	O
and	CC	O
24.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Serum	NNP	O
calcium	NN	O
levels	NNS	O
decreased	VBN	O
in	IN	O
most	JJS	O
patients	NNS	O
after	IN	O
surgery	NN	O
,	,	O
but	CC	O
recovered	VBD	O
earliest	JJS	O
in	IN	O
Group	NNP	O
A.	NNP	O
Hypercalcemia	NNP	O
and	CC	O
PTH	NNP	O
inhibition	NN	O
did	VBD	O
not	RB	O
occur	VB	O
in	IN	O
gs	NN	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Compared	NNP	O
with	IN	O
total	JJ	O
thyroidectomy	NN	O
alone	RB	O
,	,	O
CND	NNP	O
significantly	RB	O
increases	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
postoperative	JJ	O
hypocalcemia	NN	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
prevented	VBN	O
by	IN	O
routine	JJ	O
postoperative	JJ	O
supplementation	NN	O
with	IN	O
oral	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
.	.	O

An	DT	O
interactive	JJ	O
computer	NN	O
program	NN	O
can	MD	O
effectively	RB	O
educate	VB	O
potential	JJ	O
users	NNS	O
of	IN	O
cystic	JJ	Condition
fibrosis	NN	Condition
carrier	NN	Condition
tests	NNS	O
.	.	O

The	DT	O
demand	NN	O
for	IN	O
cystic	JJ	O
fibrosis	NN	O
(	(	O
CF	NNP	O
)	)	O
carrier	NN	O
testing	VBG	O
is	VBZ	O
steadily	RB	O
growing	VBG	O
,	,	O
not	RB	O
only	RB	O
from	IN	O
individuals	NNS	O
with	IN	O
raised	VBN	Condition
a	DT	Condition
priori	FW	Condition
carrier	NN	Condition
risk	NN	Condition
,	,	O
but	CC	O
also	RB	O
from	IN	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

This	DT	O
trend	NN	O
will	MD	O
likely	RB	O
exceed	VB	O
the	DT	O
availability	NN	O
of	IN	O
genetic	JJ	O
counselors	NNS	O
,	,	O
making	VBG	O
it	PRP	O
impossible	JJ	O
to	TO	O
provide	VB	O
standard	JJ	O
face-to-face	JJ	O
genetic	JJ	O
counseling	NN	O
to	TO	O
all	PDT	O
those	DT	O
asking	VBG	O
for	IN	O
the	DT	O
test	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
reduce	VB	O
the	DT	O
time	NN	O
needed	VBN	O
to	TO	O
educate	VB	O
individuals	NNS	O
on	IN	O
the	DT	O
basics	NNS	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
its	PRP$	O
genetic	JJ	O
transmission	NN	O
,	,	O
and	CC	O
carrier	NN	O
testing	VBG	O
peculiarities	NNS	O
,	,	O
we	PRP	O
developed	VBD	O
an	DT	O
educational	JJ	O
method	NN	O
based	VBN	O
on	IN	O
an	DT	O
interactive	JJ	O
computer	NN	O
program	NN	O
(	(	O
IC	NNP	O
)	)	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
this	DT	O
program	NN	O
and	CC	O
to	TO	O
compare	VB	O
it	PRP	O
to	TO	O
a	DT	O
classical	JJ	O
genetic	JJ	O
counseling	NN	O
session	NN	O
,	,	O
we	PRP	O
conducted	VBD	O
a	DT	O
comparative	JJ	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
population	NN	O
setting	NN	O
of	IN	O
people	NNS	O
undergoing	VBG	O
assisted	JJ	O
reproduction	NN	O
,	,	O
44	CD	SampleSize
individuals	NNS	SampleSize
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
receiving	VBG	O
standard	JJ	O
one-on-one	JJ	O
genetic	JJ	O
counseling	NN	O
or	CC	O
education	NN	O
by	IN	O
the	DT	O
IC	NNP	O
program	NN	O
.	.	O

We	PRP	O
measured	VBD	O
pre-	JJ	O
and	CC	O
post-intervention	NN	O
knowledge	NN	O
about	IN	O
CF	NNP	O
genetic	JJ	O
transmission	NN	O
and	CC	O
carrier	NN	O
testing	NN	O
.	.	O

Starting	VBG	O
from	IN	O
an	DT	O
equivalent	JJ	O
baseline	NN	O
of	IN	O
correct	JJ	O
answers	NNS	O
to	TO	O
a	DT	O
specially	RB	O
designed	VBN	O
multiple-choice	NN	O
questionnaire	NN	O
(	(	O
47	CD	O
%	NN	O
in	IN	O
the	DT	O
counselor	NN	O
group	NN	O
and	CC	O
45	CD	O
%	NN	O
in	IN	O
the	DT	O
computer	NN	O
group	NN	O
)	)	O
both	DT	O
groups	NNS	O
showed	VBD	O
a	DT	O
highly	RB	O
significant	JJ	O
and	CC	O
similar	JJ	O
increase	NN	O
(	(	O
reaching	VBG	O
84	CD	O
%	NN	O
in	IN	O
the	DT	O
counselor	NN	O
group	NN	O
and	CC	O
85	CD	O
%	NN	O
in	IN	O
the	DT	O
computer	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
computer	NN	O
program	NN	O
under	IN	O
evaluation	NN	O
can	MD	O
successfully	RB	O
educate	VB	O
individuals	NNS	O
considering	VBG	O
genetic	JJ	O
testing	NN	O
for	IN	O
CF	NNP	O
.	.	O

Efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
donepezil	NN	O
in	IN	O
vascular	JJ	Condition
dementia	NN	Condition
:	:	O
positive	JJ	O
results	NNS	O
of	IN	O
a	DT	O
24-week	JJ	O
,	,	O
multicenter	NN	O
,	,	O
international	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Clinical	NNP	O
observations	NNS	O
suggest	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
vascular	JJ	O
dementia	NN	O
(	(	O
VaD	NNP	O
)	)	O
may	MD	O
benefit	VB	O
from	IN	O
treatment	NN	O
with	IN	O
cholinesterase	NN	O
inhibitors	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
donepezil	NN	O
for	IN	O
relieving	VBG	O
symptoms	NNS	O
of	IN	O
dementia	NN	O
in	IN	O
VaD	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
(	(	O
n=603	JJ	SampleSize
;	:	O
mean	JJ	Age
age	NN	Age
,	,	Age
73.9	CD	Age
years	NNS	Age
;	:	O
55.2	CD	O
%	NN	O
men	NNS	Sex
)	)	O
with	IN	O
probable	JJ	O
(	(	O
70.5	CD	O
%	NN	O
)	)	O
or	CC	O
possible	JJ	O
(	(	O
29.5	CD	O
%	NN	O
)	)	O
VaD	NNP	O
,	,	O
according	VBG	O
to	TO	O
criteria	NNS	O
of	IN	O
the	DT	O
National	NNP	O
Institute	NNP	O
of	IN	O
Neurological	NNP	O
Disorders	NNP	O
and	CC	O
Stroke	NNP	O
(	(	O
NINDS	NNP	O
)	)	O
and	CC	O
the	DT	O
Association	NNP	O
Internationale	NNP	O
pour	VBP	O
la	NN	O
Recherche	NNP	O
et	CC	O
l'Enseignement	JJ	O
en	NN	O
Neurosciences	NNP	O
(	(	O
AIREN	NNP	O
)	)	O
,	,	O
were	VBD	O
randomized	VBN	O
to	TO	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
donepezil	JJ	O
5	CD	O
mg/d	NN	O
(	(	O
n=198	JJ	O
)	)	O
,	,	O
donepezil	$	O
10	CD	O
mg/d	NN	O
(	(	O
5	CD	O
mg/d	NN	O
for	IN	O
first	JJ	O
28	CD	O
days	NNS	O
;	:	O
n=206	CC	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
(	(	O
n=199	JJ	O
)	)	O
.	.	O

Analyses	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
the	DT	O
intent-to-treat	JJ	O
population	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
week	NN	O
24	CD	O
,	,	O
both	DT	O
donepezil	NN	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
cognition	NN	O
versus	NN	O
placebo	NN	O
on	IN	O
the	DT	O
Alzheimer	NNP	O
's	POS	O
Disease	NNP	O
Assessment	NNP	O
Scale-cognitive	JJ	O
subscale	NN	O
(	(	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
score	NN	O
effect	NN	O
size	NN	O
:	:	O
donepezil	NN	O
5	CD	O
mg/d	NN	O
,	,	O
-1.90	NNP	O
;	:	O
P=0.001	NNP	O
;	:	O
donepezil	VBZ	O
10	CD	O
mg/d	NN	O
,	,	O
-2.33	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Significant	JJ	O
improvements	NNS	O
in	IN	O
patients	NNS	O
'	POS	O
global	JJ	O
function	NN	O
were	VBD	O
seen	VBN	O
versus	NN	O
placebo	NN	O
at	IN	O
week	NN	O
24	CD	O
(	(	O
observed	JJ	O
cases	NNS	O
)	)	O
,	,	O
on	IN	O
the	DT	O
Clinician	NNP	O
's	POS	O
Interview-Based	JJ	O
Impression	NN	O
of	IN	O
Change-Plus	NNP	O
version	NN	O
only	RB	O
for	IN	O
patients	NNS	O
on	IN	O
donepezil	JJ	O
5	CD	O
mg/d	NN	O
(	(	O
P=0.014	NNP	O
)	)	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
Sum	NNP	O
of	IN	O
the	DT	O
Boxes	NNP	O
of	IN	O
the	DT	O
Clinical	NNP	O
Dementia	NNP	O
Rating	NNP	O
only	RB	O
for	IN	O
patients	NNS	O
on	IN	O
10	CD	O
mg/d	NN	O
(	(	O
P=0.007	NNP	O
)	)	O
.	.	O

Donepezil-treated	JJ	O
patients	NNS	O
showed	VBD	O
significant	JJ	O
benefits	NNS	O
in	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
over	IN	O
placebo	NN	O
on	IN	O
the	DT	O
Alzheimer	NNP	O
's	POS	O
Disease	NNP	O
Functional	NNP	O
Assessment	NNP	O
and	CC	O
Change	NNP	O
Scale	NNP	O
(	(	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
score	NN	O
effect	NN	O
size	NN	O
at	IN	O
week	NN	O
24	CD	O
:	:	O
donepezil	NN	O
5	CD	O
mg/d	NN	O
,	,	O
-1.31	NNP	O
,	,	O
P=0.02	NNP	O
;	:	O
donepezil	VBZ	O
10	CD	O
mg/d	NN	O
,	,	O
-1.31	NNP	O
,	,	O
P=0.02	NNP	O
)	)	O
.	.	O

Donepezil	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Withdrawal	NNP	O
rates	NNS	O
due	JJ	O
to	TO	O
adverse	JJ	O
events	NNS	O
were	VBD	O
relatively	RB	O
low	JJ	O
(	(	O
placebo	NN	O
,	,	O
11.1	CD	O
%	NN	O
;	:	O
donepezil	CC	O
5	CD	O
mg/d	NN	O
,	,	O
11.1	CD	O
%	NN	O
;	:	O
donepezil	CC	O
10	CD	O
mg/d	NN	O
,	,	O
21.8	CD	O
%	NN	O
;	:	O
P=0.005	NNP	O
versus	IN	O
placebo	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
donepezil	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
VaD	NNP	O
and	CC	O
show	VB	O
it	PRP	O
may	MD	O
have	VB	O
an	DT	O
important	JJ	O
place	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
this	DT	O
condition	NN	O
.	.	O

Ebeltoft	NNP	O
project	NN	O
:	:	O
baseline	NN	O
data	NNS	O
from	IN	O
a	DT	O
five-year	JJ	O
randomized	NN	O
,	,	O
controlled	VBN	O
,	,	O
prospective	JJ	O
health	NN	O
promotion	NN	O
study	NN	O
in	IN	O
a	DT	O
Danish	JJ	O
population	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
increasing	VBG	O
political	JJ	O
pressure	NN	O
on	IN	O
the	DT	O
medical	JJ	O
profession	NN	O
to	TO	O
approach	VB	O
welfare	NN	O
diseases	NNS	O
,	,	O
such	JJ	O
as	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
and	CC	O
diabetes	NNS	O
,	,	O
through	IN	O
prevention	NN	O
.	.	O

General	JJ	O
practitioners	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
offer	VB	O
regular	JJ	O
health	NN	O
checks	NNS	O
to	TO	O
healthy	JJ	Condition
people	NNS	O
,	,	O
in	IN	O
spite	NN	O
of	IN	O
the	DT	O
lack	NN	O
of	IN	O
scientific	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
universal	JJ	O
need	NN	O
,	,	O
usefulness	JJ	O
and	CC	O
side	JJ	O
effects	NNS	O
of	IN	O
such	JJ	O
an	DT	O
intervention	NN	O
.	.	O

Randomized	VBN	O
controlled	JJ	O
trials	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

AIM	VB	O
A	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
investigate	VB	O
people	NNS	O
's	POS	O
interest	NN	O
in	IN	O
participating	VBG	O
in	IN	O
health	NN	O
checks	NNS	O
and	CC	O
in	IN	O
discussions	NNS	O
about	IN	O
health	NN	O
with	IN	O
their	PRP$	O
own	JJ	O
general	JJ	O
practitioner	NN	O
,	,	O
participants	NNS	O
'	POS	O
health	NN	O
status	NN	O
,	,	O
the	DT	O
proportion	NN	O
who	WP	O
received	VBD	O
health	NN	O
advice	NN	O
following	VBG	O
health	NN	O
checks	NNS	O
,	,	O
and	CC	O
the	DT	O
lifestyle	JJ	O
goals	NNS	O
they	PRP	O
set	VBP	O
following	VBG	O
discussion	NN	O
with	IN	O
their	PRP$	O
general	JJ	O
practitioner	NN	O
.	.	O

This	DT	O
study	NN	O
reports	VBZ	O
the	DT	O
baseline	NN	O
data	NNS	O
from	IN	O
a	DT	O
five-year	JJ	O
randomized	NN	O
,	,	O
controlled	VBN	O
,	,	O
prospective	JJ	O
,	,	O
population-based	JJ	O
study	NN	O
in	IN	O
general	JJ	O
practices	NNS	O
in	IN	O
Ebeltoft	NNP	O
,	,	O
Denmark	NNP	O
.	.	O

METHOD	NNP	O
All	NNP	O
general	JJ	O
practitioners	NNS	O
from	IN	O
the	DT	O
four	CD	O
practices	NNS	O
in	IN	O
Ebeltoft	NNP	O
and	CC	O
a	DT	O
random	JJ	O
sample	NN	O
of	IN	O
2000	CD	SampleSize
people	NNS	O
aged	VBN	O
between	IN	O
30	CD	Age
and	CC	Age
50	CD	Age
years	NNS	O
were	VBD	O
invited	VBN	O
to	TO	O
participate	VB	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
--	:	O
one	CD	O
control	NN	O
group	NN	O
and	CC	O
two	CD	O
intervention	NN	O
groups	NNS	O
.	.	O

One	CD	O
intervention	NN	O
group	NN	O
were	VBD	O
given	VBN	O
a	DT	O
health	NN	O
check	NN	O
which	WDT	O
included	VBD	O
being	VBG	O
screened	VBN	O
for	IN	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
lung	NN	O
and	CC	O
liver	NN	O
function	NN	O
,	,	O
fitness	NN	O
,	,	O
sight	NN	O
and	CC	O
hearing	NN	O
and	CC	O
an	DT	O
optional	JJ	O
test	NN	O
for	IN	O
the	DT	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
;	:	O
this	DT	O
group	NN	O
received	VBD	O
written	VBN	O
feedback	RB	O
from	IN	O
the	DT	O
general	JJ	O
practitioner	NN	O
.	.	O

The	DT	O
other	JJ	O
intervention	NN	O
group	NN	O
were	VBD	O
also	RB	O
given	VBN	O
a	DT	O
health	NN	O
check	NN	O
and	CC	O
written	VBN	O
feedback	NN	O
;	:	O
in	IN	O
addition	NN	O
,	,	O
they	PRP	O
were	VBD	O
given	VBN	O
the	DT	O
opportunity	NN	O
to	TO	O
attend	VB	O
their	PRP$	O
general	JJ	O
practitioner	NN	O
to	TO	O
discuss	VB	O
preventive	JJ	O
health	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
1370	CD	SampleSize
people	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
(	(	O
69	CD	O
%	NN	O
response	NN	O
rate	NN	O
)	)	O
.	.	O

Health	NNP	O
advice	NN	O
was	VBD	O
given	VBN	O
to	TO	O
76	CD	O
%	NN	O
of	IN	O
905	CD	O
participants	NNS	O
following	VBG	O
health	NN	O
checks	NNS	O
.	.	O

Almost	NNP	O
all	DT	O
of	IN	O
the	DT	O
456	CD	SampleSize
participants	NNS	O
(	(	O
96	CD	O
%	NN	O
)	)	O
who	WP	O
were	VBD	O
offered	VBN	O
the	DT	O
opportunity	NN	O
of	IN	O
discussing	VBG	O
their	PRP$	O
health	NN	O
with	IN	O
their	PRP$	O
general	JJ	O
practitioner	NN	O
took	VBD	O
up	RP	O
the	DT	O
offer	NN	O
;	:	O
64	CD	O
%	NN	O
of	IN	O
the	DT	O
456	CD	SampleSize
participants	NNS	O
reported	VBD	O
that	IN	O
they	PRP	O
had	VBD	O
decided	VBN	O
to	TO	O
undertake	VB	O
lifestyle	JJ	O
changes	NNS	O
.	.	O

Eleven	NNP	SampleSize
of	IN	O
those	DT	O
who	WP	O
discussed	VBD	O
their	PRP$	O
health	NN	O
with	IN	O
the	DT	O
doctor	NN	O
were	VBD	O
referred	VBN	O
to	TO	O
a	DT	O
specialist	NN	O
(	(	O
2	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
There	EX	O
was	VBD	O
considerable	JJ	O
interest	NN	O
in	IN	O
participating	VBG	O
in	IN	O
health	NN	O
promotion	NN	O
.	.	O

Three	CD	O
out	IN	O
of	IN	O
four	CD	O
of	IN	O
those	DT	O
having	VBG	O
a	DT	O
health	NN	O
check	NN	O
were	VBD	O
given	VBN	O
health	NN	O
advice	NN	O
.	.	O

Two	CD	O
out	IN	O
of	IN	O
three	CD	O
of	IN	O
those	DT	O
offered	VBN	O
a	DT	O
health	NN	O
talk	NN	O
with	IN	O
the	DT	O
general	JJ	O
practitioner	NN	O
appeared	VBD	O
willing	JJ	O
to	TO	O
make	VB	O
relevant	JJ	O
lifestyle	JJ	O
changes	NNS	O
.	.	O

Long-term	NN	O
follow	NN	O
up	RP	O
is	VBZ	O
needed	VBN	O
to	TO	O
determine	VB	O
effects	NNS	O
and	CC	O
side	JJ	O
effects	NNS	O
of	IN	O
health	NN	O
checks	NNS	O
and	CC	O
health	NN	O
talks	NNS	O
.	.	O

Short-term	JJ	O
fluoxetine	NN	O
monotherapy	NN	O
for	IN	O
bipolar	JJ	Condition
type	NN	Condition
II	NNP	Condition
or	CC	Condition
bipolar	JJ	Condition
NOS	NNP	Condition
major	JJ	Condition
depression	NN	Condition
-	:	Condition
low	JJ	Condition
manic	JJ	Condition
switch	NN	Condition
rate	NN	Condition
.	.	O

OBJECTIVES	CC	O
Current	NNP	O
guidelines	NNS	O
for	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
of	IN	O
bipolar	JJ	Condition
type	NN	Condition
II	NNP	Condition
(	(	O
BP	NNP	Condition
II	NNP	Condition
)	)	O
major	JJ	O
depressive	JJ	O
episode	NN	O
(	(	O
MDE	NNP	O
)	)	O
recommend	VBP	O
using	VBG	O
either	CC	O
a	DT	O
mood	NN	O
stabilizer	NN	O
alone	RB	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
a	DT	O
mood	NN	O
stabilizer	NN	O
plus	CC	O
a	DT	O
selective	JJ	O
serotonin	NN	O
re-uptake	NN	O
inhibitor	NN	O
(	(	O
SSRI	NNP	O
)	)	O
.	.	O

This	DT	O
recommendation	NN	O
is	VBZ	O
the	DT	O
result	NN	O
of	IN	O
concern	NN	O
over	IN	O
antidepressant-induced	JJ	O
manic	JJ	O
switch	NN	O
episodes	NNS	O
.	.	O

However	RB	O
,	,	O
recent	JJ	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
the	DT	O
manic	JJ	O
switch	NN	O
rate	NN	O
may	MD	O
be	VB	O
low	JJ	O
in	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
during	IN	O
SSRI	NNP	O
therapy	NN	O
.	.	O

METHODS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
relapse-prevention	NN	O
study	NN	O
of	IN	O
fluoxetine	JJ	O
monotherapy	NN	O
in	IN	O
BP	NNP	Condition
II	NNP	Condition
MDE	NNP	O
,	,	O
37	CD	SampleSize
patients	NNS	O
received	VBD	O
open-label	JJ	O
fluoxetine	NN	O
20	CD	O
mg	NN	O
every	DT	O
day	NN	O
for	IN	O
up	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
(	(	O
HAM-D	NNP	O
17	CD	O
)	)	O
rating	NN	O
and	CC	O
the	DT	O
Young	NNP	O
Mania	NNP	O
Rating	NNP	O
(	(	O
YMR	NNP	O
)	)	O
scale	NN	O
.	.	O

RESULTS	NNP	O
Eleven	NNP	O
of	IN	O
23	CD	O
patients	NNS	O
(	(	O
48	CD	O
%	NN	O
)	)	O
who	WP	O
completed	VBD	O
8	CD	O
weeks	NNS	O
of	IN	O
fluoxetine	NN	O
treatment	NN	O
showed	VBD	O
a	DT	O
HAM-D	JJ	O
17	CD	O
reduction	NN	O
of	IN	O
>	NN	O
or	CC	O
=50	CD	O
%	NN	O
,	,	O
while	IN	O
14	CD	O
(	(	O
38	CD	O
%	NN	O
)	)	O
of	IN	O
all	DT	O
treated	JJ	O
patients	NNS	O
had	VBD	O
>	VBN	O
or	CC	O
=50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
baseline	JJ	O
HAM-D	JJ	O
17	CD	O
score	NN	O
.	.	O

Using	VBG	O
a	DT	O
conservative	JJ	O
YMR	NNP	O
score	NN	O
of	IN	O
>	NN	O
or	CC	O
=8	VB	O
to	TO	O
identify	VB	O
hypomanic	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
patients	NNS	O
with	IN	O
YMR	NNP	O
score	NN	O
>	NN	O
or	CC	O
=8	NN	O
during	IN	O
fluoxetine	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
seen	VBN	O
during	IN	O
the	DT	O
screen	NN	O
and	CC	O
baseline	JJ	O
period	NN	O
.	.	O

Only	RB	O
three	CD	O
patients	NNS	O
(	(	O
7.3	CD	O
%	NN	O
)	)	O
had	VBD	O
symptoms	NNS	O
suggestive	JJ	O
of	IN	O
hypomania	NN	O
,	,	O
and	CC	O
only	RB	O
one	CD	O
patient	NN	O
stopped	VBD	O
treatment	NN	O
because	IN	O
of	IN	O
a	DT	O
rapid	JJ	O
mood	NN	O
swing	VBG	O
into	IN	O
depression	NN	O
.	.	O

LIMITATIONS	NNP	O
Fluoxetine	NNP	O
was	VBD	O
given	VBN	O
at	IN	O
a	DT	O
fixed	JJ	O
dose	NN	O
of	IN	O
20	CD	O
mg	NNS	O
everyday	JJ	O
.	.	O

Fluoxetine	NNP	O
was	VBD	O
prescribed	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
manner	NN	O
,	,	O
and	CC	O
the	DT	O
sample	NN	O
size	NN	O
was	VBD	O
limited	VBN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
observations	NNS	O
support	VBP	O
the	DT	O
findings	NNS	O
of	IN	O
a	DT	O
low	JJ	O
manic	JJ	O
switch	NN	O
rate	NN	O
during	IN	O
SSRI	NNP	O
monotherapy	NN	O
of	IN	O
BP	NNP	O
II	NNP	O
MDE	NNP	O
,	,	O
and	CC	O
suggest	VBP	O
that	IN	O
fluoxetine	JJ	O
monotherapy	NN	O
may	MD	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
initial	JJ	O
treatment	NN	O
of	IN	O
BP	NNP	Condition
II	NNP	Condition
MDE	NNP	Condition
.	.	O

Trimetazidine	NN	O
:	:	O
a	DT	O
new	JJ	O
concept	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
angina	NN	O
.	.	O

Comparison	NNP	O
with	IN	O
propranolol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	Condition
angina	NN	Condition
.	.	O

Trimetazidine	JJ	O
European	JJ	O
Multicenter	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

1	CD	O
.	.	O

Trimetazidine	NN	O
has	VBZ	O
a	DT	O
direct	JJ	O
anti-ischaemic	JJ	O
effect	NN	O
on	IN	O
the	DT	O
myocardium	NN	O
without	IN	O
altering	VBG	O
the	DT	O
rate	NN	O
x	JJ	O
pressure	NN	O
product	NN	O
or	CC	O
coronary	JJ	O
blood	NN	O
flow	NN	O
.	.	O

2	CD	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
trimetazidine	NN	O
(	(	O
20	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
those	DT	O
of	IN	O
propranolol	NN	O
(	(	O
40	CD	O
mg	NN	O
three	CD	O
times	NNS	O
daily	RB	O
)	)	O
in	IN	O
a	DT	O
double-blind	JJ	O
parallel	NN	O
group	NN	O
multicentre	VBD	O
study	NN	O
in	IN	O
149	CD	SampleSize
men	NNS	O
with	IN	O
stable	JJ	Condition
angina	NN	Condition
.	.	O

3	CD	O
.	.	O

Reproducibility	NN	O
of	IN	O
exercise	NN	O
performance	NN	O
was	VBD	O
verified	VBN	O
during	IN	O
a	DT	O
3	CD	O
week	NN	O
run-in	JJ	O
placebo	NN	O
washout	IN	O
period	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
>	JJ	O
1	CD	O
mm	JJ	O
ST-depression	NN	O
on	IN	O
exercise	NN	O
test	NN	O
.	.	O

4	CD	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
,	,	O
similar	JJ	O
anti-anginal	JJ	O
efficacy	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
trimetazidine	NN	O
(	(	O
n	JJ	O
=	NNP	O
71	CD	O
)	)	O
and	CC	O
propranolol	NN	O
(	(	O
n	JJ	O
=	NNP	O
78	CD	O
)	)	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
trimetazidine	NN	O
and	CC	O
propranolol	NN	O
as	IN	O
regards	NNS	O
anginal	JJ	O
attack	NN	O
rate	NN	O
per	IN	O
week	NN	O
(	(	O
mean	JJ	O
difference	NN	O
P-TMZ	NN	O
:	:	O
2	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-4.4	NN	O
,	,	O
0.5	CD	O
)	)	O
and	CC	O
exercise	NN	O
duration	NN	O
(	(	O
mean	JJ	O
difference	NN	O
P-TMZ	NN	O
:	:	O
0	CD	O
s	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-33	NN	O
,	,	O
34	CD	O
)	)	O
or	CC	O
time	NN	O
to	TO	O
1	CD	O
mm	NNS	O
ST	NNP	O
segment	NN	O
depression	NN	O
(	(	O
mean	JJ	O
difference	NN	O
P-TMZ	NN	O
:	:	O
13	CD	O
s	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
-24	NN	O
,	,	O
51	CD	O
)	)	O
.	.	O

Heart	NNP	O
rate	NN	O
and	CC	O
rate	NN	O
x	JJ	O
pressure	NN	O
product	NN	O
at	IN	O
rest	NN	O
and	CC	O
at	IN	O
peak	JJ	O
exercise	NN	O
remained	VBD	O
unchanged	JJ	O
in	IN	O
the	DT	O
trimetazidine	NN	O
group	NN	O
but	CC	O
significantly	RB	O
decreased	VBN	O
with	IN	O
propranolol	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
in	IN	O
all	DT	O
cases	NNS	O
)	)	O
.	.	O

With	IN	O
both	DT	O
drugs	NNS	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
to	TO	O
decreased	VBN	O
ischaemic	JJ	O
episodes	NNS	O
in	IN	O
the	DT	O
46	CD	O
%	NN	O
patients	NNS	O
who	WP	O
experienced	VBD	O
ambulatory	JJ	O
ischaemia	NN	O
on	IN	O
Holter	NNP	O
monitoring	NN	O
.	.	O

Six	CD	O
patients	NNS	O
stopped	VBD	O
trimetazidine	NN	O
and	CC	O
12	CD	O
propranolol	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
five	CD	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
withdrawn	VBN	O
because	IN	O
of	IN	O
deterioration	NN	O
in	IN	O
cardiovascular	JJ	O
status	NN	O
.	.	O

5	CD	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
trimetazidine	NN	O
and	CC	O
propranolol	NN	O
at	IN	O
the	DT	O
doses	NNS	O
studied	VBN	O
have	VBP	O
similar	JJ	O
efficacy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	JJ	O
pectoris	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Developing	VBG	O
the	DT	O
Ho'ouna	NNP	O
Pono	NNP	O
substance	NN	O
use	NN	O
prevention	NN	O
curriculum	NN	O
:	:	O
collaborating	NN	O
with	IN	O
Hawaiian	JJ	O
youth	NN	O
and	CC	O
communities	NNS	O
.	.	O

This	DT	O
article	NN	O
briefly	NN	O
outlines	VBZ	O
a	DT	O
collaboration	NN	O
among	IN	O
communities	NNS	O
on	IN	O
Hawai'i	NNP	O
Island	NNP	O
and	CC	O
a	DT	O
university-based	JJ	O
research	NN	O
team	NN	O
to	TO	O
develop	VB	O
,	,	O
implement	NN	O
,	,	O
and	CC	O
evaluate	VB	O
a	DT	O
school-based	JJ	O
substance	NN	O
use	NN	O
prevention	NN	O
curriculum	NN	O
called	VBN	O
Ho'ouna	NNP	O
Pono	NNP	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
providing	VBG	O
a	DT	O
rationale	NN	O
for	IN	O
the	DT	O
project	NN	O
,	,	O
the	DT	O
goal	NN	O
of	IN	O
this	DT	O
paper	NN	O
is	VBZ	O
fourfold	JJ	O
.	.	O

First	NNP	O
,	,	O
an	DT	O
overview	NN	O
of	IN	O
the	DT	O
Ho'ouna	NNP	O
Pono	NNP	O
research	NN	O
results	NNS	O
to	TO	O
date	NN	O
(	(	O
2007-2013	JJ	O
)	)	O
is	VBZ	O
provided	VBN	O
.	.	O

Second	JJ	O
,	,	O
within	IN	O
this	DT	O
overview	NN	O
,	,	O
the	DT	O
ways	NNS	O
in	IN	O
which	WDT	O
selected	VBD	O
results	NNS	O
informed	JJ	O
program	NN	O
development	NN	O
are	VBP	O
highlighted	VBN	O
.	.	O

Third	NNP	O
,	,	O
the	DT	O
curriculum	NN	O
is	VBZ	O
briefly	JJ	O
described	VBN	O
,	,	O
and	CC	O
finally	RB	O
,	,	O
the	DT	O
role	NN	O
of	IN	O
the	DT	O
students	NNS	O
and	CC	O
community	NN	O
in	IN	O
the	DT	O
video	NN	O
production	NN	O
is	VBZ	O
described	VBN	O
.	.	O

Variability	NN	O
in	IN	O
isochronous	JJ	Condition
tapping	NN	Condition
:	:	O
higher	JJR	O
order	NN	O
dependencies	NNS	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
intertap	JJ	O
interval	NN	O
.	.	O

Isochronous	JJ	Condition
serial	JJ	Condition
interval	NN	Condition
production	NN	Condition
(	(	Condition
ISIP	NNP	Condition
)	)	O
data	NN	O
,	,	O
as	IN	O
from	IN	O
unpaced	JJ	O
finger	NN	O
tapping	NN	O
,	,	O
exhibit	NN	O
higher	JJR	O
order	NN	O
dependencies	NNS	O
(	(	O
drift	NN	O
)	)	O
.	.	O

This	DT	O
fact	NN	O
has	VBZ	O
largely	RB	O
been	VBN	O
ignored	VBN	O
by	IN	O
the	DT	O
timing	NN	O
literature	NN	O
,	,	O
one	CD	O
reason	NN	O
probably	RB	O
being	VBG	O
that	IN	O
influential	JJ	O
timing	NN	O
models	NNS	O
assume	VBP	O
random	JJ	O
variability	NN	O
.	.	O

Men	NNP	Sex
and	CC	O
women	NNS	Sex
,	,	O
22-36	JJ	Age
years	NNS	Age
old	JJ	O
,	,	O
performed	VBD	O
a	DT	O
synchronization-continuation	NN	O
task	NN	O
with	IN	O
intertap	JJ	O
intervals	NNS	O
(	(	O
ITI	NNP	O
)	)	O
from	IN	O
0.4	CD	O
s	NNS	O
to	TO	O
2.2	CD	O
s.	NNS	O
ISIP	NNP	O
variability	NN	O
was	VBD	O
partitioned	VBN	O
into	IN	O
components	NNS	O
attributable	JJ	O
to	TO	O
drift	VB	O
and	CC	O
1st-order	JJ	O
serial	JJ	O
correlation	NN	O
,	,	O
and	CC	O
the	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
(	(	O
a	DT	O
)	)	O
drift	NN	O
contributes	VBZ	O
substantially	RB	O
to	TO	O
the	DT	O
dispersion	NN	O
for	IN	O
longer	JJR	O
ITIs	NNP	O
,	,	O
(	(	O
b	NN	O
)	)	O
drift	NN	O
and	CC	O
1st-order	JJ	O
correlation	NN	O
are	VBP	O
different	JJ	O
functions	NNS	O
of	IN	O
the	DT	O
ITI	NNP	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
drift	NN	O
exhibits	VBZ	O
break	VBP	O
close	JJ	O
to	TO	O
1.0	CD	O
s	NNS	O
and	CC	O
1.4	CD	O
s	NN	O
ITI	NNP	O
.	.	O

These	DT	O
breaks	NNS	O
correspond	NN	O
to	TO	O
qualitative	JJ	O
changes	NNS	O
in	IN	O
performance	NN	O
for	IN	O
other	JJ	O
temporal	JJ	O
tasks	NNS	O
,	,	O
which	WDT	O
suggests	VBZ	O
common	JJ	O
timing	NN	O
processes	VBZ	O
across	IN	O
modalities	NNS	O
and	CC	O
tasks	NNS	O
.	.	O

Effect	NN	O
of	IN	O
age	NN	O
and	CC	O
radiation	NN	O
dose	NN	O
on	IN	O
local	JJ	O
control	NN	O
after	IN	O
breast	NN	O
conserving	NN	O
treatment	NN	O
:	:	O
EORTC	JJ	O
trial	NN	O
22881-10882	JJ	O
.	.	O

PURPOSE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
the	DT	O
effect	NN	O
of	IN	O
an	DT	O
additional	JJ	O
boost	NN	O
radiation	NN	O
after	IN	O
breast	NN	O
conservative	JJ	O
therapy	NN	O
(	(	O
BCT	NNP	O
)	)	O
on	IN	O
local	JJ	O
control	NN	O
depends	VBZ	O
on	IN	O
age	NN	O
and	CC	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
treatment	NN	O
policy	NN	O
with	IN	O
a	DT	O
threshold	NN	O
for	IN	O
age	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
We	PRP	O
used	VBD	O
data	NNS	O
from	IN	O
EORTC	NNP	O
22881-10882	JJ	O
trial	NN	O
,	,	O
with	IN	O
median	JJ	O
follow-up	NN	O
of	IN	O
77.4	CD	O
months	NNS	O
.	.	O

Patients	NNS	O
receiving	VBG	O
BCT	NNP	Condition
and	CC	Condition
50Gy	CD	Condition
whole	JJ	Condition
breast	NN	Condition
irradiation	NN	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
no	DT	O
boost	NN	O
and	CC	O
16Gy	CD	O
boost	NN	O
(	(	O
N=5318	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
In	IN	O
univariate	JJ	O
analysis	NN	O
,	,	O
a	DT	O
boost	NN	O
reduced	VBN	O
local	JJ	O
failure	NN	O
by	IN	O
a	DT	O
factor	NN	O
of	IN	O
2	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Multivariate	NNP	O
analysis	NN	O
showed	VBD	O
local	JJ	O
control	NN	O
increased	VBD	O
with	IN	O
age	NN	O
(	(	O
P=0.0003	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
the	DT	O
relative	JJ	O
effect	NN	O
of	IN	O
a	DT	O
boost	NN	O
on	IN	O
local	JJ	O
control	NN	O
depends	VBZ	O
on	IN	O
age	NN	O
(	(	O
P=0.97	NNP	O
)	)	O
However	RB	O
in	IN	O
younger	JJR	Age
patients	NNS	Age
the	DT	O
5-year	JJ	O
local	JJ	O
failure	NN	O
was	VBD	O
higher	JJR	O
,	,	O
therefore	IN	O
the	DT	O
absolute	JJ	O
reduction	NN	O
was	VBD	O
greater	JJR	O
.	.	O

If	IN	O
the	DT	O
threshold-age	NN	O
for	IN	O
boost	NN	O
treatment	NN	O
were	VBD	O
set	VBN	O
at	IN	O
40	CD	O
years	NNS	O
,	,	O
8.4	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
population	NN	O
would	MD	O
receive	VB	O
a	DT	O
boost	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
5-year	JJ	O
local	JJ	O
failure	NN	O
of	IN	O
6.1	CD	O
%	NN	O
in	IN	O
the	DT	O
study	NN	O
population	NN	O
.	.	O

Changing	VBG	O
the	DT	O
threshold-age	NN	O
to	TO	O
60	CD	O
years	NNS	O
,	,	O
67	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
population	NN	O
would	MD	O
receive	VB	O
a	DT	O
boost	NN	O
and	CC	O
the	DT	O
5-year	JJ	O
local	JJ	O
failure	NN	O
would	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
4.4	CD	O
%	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
younger	JJR	O
patients	NNS	O
a	DT	O
boost	NN	O
dose	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
greater	JJR	O
absolute	JJ	O
reduction	NN	O
of	IN	O
local	JJ	O
failure	NN	O
.	.	O

The	DT	O
relative	JJ	O
risk	NN	O
reduction	NN	O
was	VBD	O
however	RB	O
similar	JJ	O
for	IN	O
all	DT	O
ages	NNS	O
.	.	O

Applying	VBG	O
a	DT	O
treatment	NN	O
policy	NN	O
with	IN	O
a	DT	O
threshold-age	NN	O
of	IN	O
60	CD	O
would	MD	O
result	VB	O
in	IN	O
0.6	CD	O
%	NN	O
increase	NN	O
in	IN	O
local	JJ	O
failure	NN	O
in	IN	O
the	DT	O
total	NN	O
study	NN	O
population	NN	O
,	,	O
while	IN	O
sparing	VBG	O
the	DT	O
boost	NN	O
to	TO	O
1/3	CD	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

Sensitivity	NN	O
to	TO	O
musical	JJ	O
structure	NN	O
in	IN	O
the	DT	O
human	JJ	O
brain	NN	O
.	.	O

Evidence	NN	O
from	IN	O
brain-damaged	JJ	Condition
patients	NNS	O
suggests	VBZ	O
that	IN	O
regions	NNS	O
in	IN	O
the	DT	O
temporal	JJ	O
lobes	NNS	O
,	,	O
distinct	NN	O
from	IN	O
those	DT	O
engaged	VBN	O
in	IN	O
lower-level	JJ	O
auditory	NN	O
analysis	NN	O
,	,	O
process	NN	O
the	DT	O
pitch	NN	O
and	CC	O
rhythmic	JJ	O
structure	NN	O
in	IN	O
music	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
neuroimaging	VBG	O
studies	NNS	O
targeting	VBG	O
the	DT	O
representation	NN	O
of	IN	O
music	NN	O
structure	NN	O
have	VBP	O
primarily	RB	O
implicated	VBN	O
regions	NNS	O
in	IN	O
the	DT	O
inferior	JJ	O
frontal	JJ	O
cortices	NNS	O
.	.	O

Combining	VBG	O
individual-subject	JJ	O
fMRI	NN	O
analyses	NNS	O
with	IN	O
a	DT	O
scrambling	VBG	O
method	NN	O
that	WDT	O
manipulated	VBD	O
musical	JJ	O
structure	NN	O
,	,	O
we	PRP	O
provide	VBP	O
evidence	NN	O
of	IN	O
brain	NN	O
regions	NNS	O
sensitive	VBP	O
to	TO	O
musical	JJ	O
structure	NN	O
bilaterally	RB	O
in	IN	O
the	DT	O
temporal	JJ	O
lobes	NNS	O
,	,	O
thus	RB	O
reconciling	VBG	O
the	DT	O
neuroimaging	NN	O
and	CC	O
patient	JJ	O
findings	NNS	O
.	.	O

We	PRP	O
further	VBP	O
show	VB	O
that	IN	O
these	DT	O
regions	NNS	O
are	VBP	O
sensitive	JJ	O
to	TO	O
the	DT	O
scrambling	NN	O
of	IN	O
both	DT	O
pitch	NN	O
and	CC	O
rhythmic	JJ	O
structure	NN	O
but	CC	O
are	VBP	O
insensitive	JJ	O
to	TO	O
high-level	JJ	O
linguistic	JJ	O
structure	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
the	DT	O
existence	NN	O
of	IN	O
brain	NN	O
regions	NNS	O
with	IN	O
representations	NNS	O
of	IN	O
musical	JJ	O
structure	NN	O
that	WDT	O
are	VBP	O
distinct	JJ	O
from	IN	O
high-level	JJ	O
linguistic	JJ	O
representations	NNS	O
and	CC	O
lower-level	JJ	O
acoustic	JJ	O
representations	NNS	O
.	.	O

These	DT	O
regions	NNS	O
provide	VBP	O
targets	NNS	O
for	IN	O
future	JJ	O
research	NN	O
investigating	VBG	O
possible	JJ	O
neural	JJ	O
specialization	NN	O
for	IN	O
music	NN	O
or	CC	O
its	PRP$	O
associated	JJ	O
mental	JJ	O
processes	NNS	O
.	.	O

Ascaris	NNP	O
and	CC	O
growth	NN	O
rates	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
treatment	NN	O
.	.	O

Three	CD	O
hundred	VBD	O
forty-one	NN	O
Tanzanian	JJ	O
preschool	NN	O
children	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
levamisole	VB	O
or	CC	O
placebo	VB	O
treatment	NN	O
given	VBN	O
at	IN	O
three-month	JJ	O
intervals	NNS	O
.	.	O

Weights	NNS	O
and	CC	O
heights	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
tri-monthly	JJ	O
treatment	NN	O
visits	NNS	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
one	CD	O
year	NN	O
.	.	O

Among	IN	O
the	DT	O
273	CD	O
children	NNS	O
who	WP	O
were	VBD	O
seen	VBN	O
and	CC	O
weighed	VBN	O
at	IN	O
the	DT	O
one-year	JJ	O
follow-up	JJ	O
visit	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
weight	NN	O
gain	NN	O
was	VBD	O
8	CD	O
per	IN	O
cent	NN	O
greater	JJR	O
for	IN	O
those	DT	O
receiving	VBG	O
levamisole	JJR	O
than	IN	O
for	IN	O
placebo-treated	JJ	O
controls	NNS	O
(	(	O
p	JJ	O
=	NNP	O
.06	NNP	O
)	)	O
.	.	O

In	IN	O
78	CD	O
children	NNS	O
known	VBN	O
to	TO	O
be	VB	O
infected	VBN	O
with	IN	O
Ascaris	NNP	O
at	IN	O
baseline	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
weight	NN	O
gain	NN	O
was	VBD	O
21	CD	O
per	IN	O
cent	NN	O
greater	JJR	O
in	IN	O
children	NNS	O
treated	VBN	O
with	IN	O
levamisole	NN	O
than	IN	O
in	IN	O
those	DT	O
receiving	VBG	O
placebo	NN	O
(	(	O
p	JJ	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
height	NN	O
gain	NN	O
was	VBD	O
no	DT	O
different	JJ	O
for	IN	O
treatment	NN	O
and	CC	O
placebo	NN	O
groups	NNS	O
.	.	O

Efficacy	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
steady-state	JJ	O
pharmacokinetics	NNS	O
of	IN	O
once-a-day	JJ	O
controlled-release	JJ	O
morphine	NN	O
(	(	O
MS	NNP	O
Contin	NNP	O
XL	NNP	O
)	)	O
in	IN	O
cancer	NN	Condition
pain	NN	Condition
.	.	O

The	DT	O
efficacy	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
pharmacokinetics	NNS	O
of	IN	O
a	DT	O
novel	JJ	O
once-daily	JJ	O
morphine	NN	O
formulation	NN	O
(	(	O
OAD	NNP	O
morphine	NN	O
)	)	O
and	CC	O
a	DT	O
12-hourly	JJ	O
formulation	NN	O
(	(	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
)	)	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
multi-centered	JJ	O
crossover	NN	O
study	NN	O
.	.	O

Chronic	NNP	Condition
cancer	NN	Condition
pain	NN	Condition
patients	NNS	O
(	(	O
n=25	JJ	SampleSize
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
OAD	NNP	O
morphine	NN	O
(	(	O
mean	JJ	O
238	CD	O
+/-	JJ	O
319	CD	O
mg	NN	O
q24h	NN	O
)	)	O
or	CC	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
(	(	O
mean	JJ	O
119	CD	O
+/-	JJ	O
159	CD	O
mg	NN	O
q12h	NN	O
)	)	O
for	IN	O
one	CD	O
week	NN	O
.	.	O

They	PRP	O
then	RB	O
crossed	VBD	O
over	IN	O
to	TO	O
the	DT	O
alternate	JJ	O
drug	NN	O
,	,	O
which	WDT	O
also	RB	O
was	VBD	O
taken	VBN	O
for	IN	O
one	CD	O
week	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
treatments	NNS	O
for	IN	O
evaluations	NNS	O
of	IN	O
overall	JJ	O
pain	NN	O
intensity	NN	O
,	,	O
analgesic	JJ	O
efficacy	NN	O
,	,	O
or	CC	O
adverse	JJ	O
events	NNS	O
.	.	O

However	RB	O
,	,	O
whereas	JJ	O
pain	NN	O
scores	NNS	O
increased	VBD	O
during	IN	O
the	DT	O
day	NN	O
on	IN	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
(	(	O
P=0.0108	NNP	O
)	)	O
,	,	O
they	PRP	O
remained	VBD	O
stable	JJ	O
on	IN	O
OAD	NNP	O
morphine	NN	O
.	.	O

Most	JJS	O
patients	NNS	O
(	(	O
68	CD	O
%	NN	O
)	)	O
chose	VBD	O
once-daily	JJ	O
dosing	NN	O
for	IN	O
continuing	VBG	O
pain	JJ	O
management	NN	O
(	(	O
P=0.015	NNP	O
)	)	O
.	.	O

The	DT	O
AUC	NNP	O
ratio	NN	O
was	VBD	O
100.3	CD	O
%	NN	O
,	,	O
indicating	VBG	O
equivalent	JJ	O
absorption	NN	O
.	.	O

Fluctuation	NN	O
indices	NNS	O
were	VBD	O
93.5	CD	O
+/-	JJ	O
28.8	CD	O
%	NN	O
and	CC	O
179.3	CD	O
+/-	JJ	O
41.3	CD	O
%	NN	O
(	(	O
P=0.0001	NNP	O
)	)	O
for	IN	O
OAD	NNP	O
morphine	NN	O
and	CC	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
,	,	O
respectively	RB	O
.	.	O

OAD	NNP	O
morphine	NN	O
provides	VBZ	O
analgesia	RB	O
similar	JJ	O
to	TO	O
twice-daily	JJ	O
CR	NNP	O
morphine	NN	O
with	IN	O
reduced	JJ	O
fluctuation	NN	O
in	IN	O
plasma	JJ	O
morphine	NN	O
concentration	NN	O
and	CC	O
more	RBR	O
stable	JJ	O
pain	NN	O
control	NN	O
.	.	O

A	DT	O
dose-ranging	JJ	O
study	NN	O
of	IN	O
pramipexole	NN	O
for	IN	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
restless	JJ	O
legs	JJ	O
syndrome	NN	O
:	:	O
polysomnographic	JJ	O
evaluation	NN	O
of	IN	O
periodic	JJ	O
leg	NN	O
movements	NNS	O
and	CC	O
sleep	JJ	O
disturbance	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
,	,	O
both	DT	O
polysomnographically	RB	O
and	CC	O
by	IN	O
subjective	JJ	O
scales	NNS	O
,	,	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
profile	NN	O
of	IN	O
pramipexole	NN	O
for	IN	O
restless	JJ	O
legs	JJ	O
syndrome	NN	O
(	(	O
RLS	NNP	O
)	)	O
via	IN	O
a	DT	O
3-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
dose-ranging	JJ	O
study	NN	O
.	.	O

METHODS	NNP	O
At	IN	O
baseline	NN	O
and	CC	O
after	IN	O
3	CD	O
weeks	NNS	O
,	,	O
periodic	JJ	O
limb	NN	O
movements	NNS	O
(	(	O
PLM	NNP	O
)	)	O
and	CC	O
sleep	JJ	O
parameters	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
polysomnography	NN	O
,	,	O
and	CC	O
patients	NNS	O
self-assessed	JJ	O
their	PRP$	O
sleep	JJ	O
disturbance	NN	O
and	CC	O
overall	JJ	O
RLS	NNP	O
severity	NN	O
using	VBG	O
the	DT	O
international	JJ	O
RLS	NNP	O
study	NN	O
group	NN	O
rating	NN	O
scale	NN	O
(	(	O
IRLS	NNP	O
)	)	O
.	.	O

Four	CD	O
pramipexole	NN	O
doses	NNS	O
were	VBD	O
evaluated	VBN	O
:	:	O
0.125	CD	O
,	,	O
0.25	CD	O
,	,	O
0.50	CD	O
,	,	O
and	CC	O
0.75mg/d	CD	O
.	.	O

Data	NNS	O
from	IN	O
107	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
intent-to-treat	NN	O
(	(	O
ITT	NNP	O
)	)	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
For	IN	O
pramipexole	JJ	O
recipients	NNS	O
,	,	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
,	,	O
PLM	NNP	O
per	IN	O
hour	NN	O
in	IN	O
bed	NN	O
asleep	NN	O
or	CC	O
awake	NN	O
(	(	O
the	DT	O
PLM	NNP	O
index	NN	O
,	,	O
or	CC	O
PLMI	NNP	O
)	)	O
,	,	O
decreased	VBN	O
by	IN	O
a	DT	O
median	NN	O
of	IN	O
-26.55	NN	O
to	TO	O
-52.70	VB	O
depending	VBG	O
on	IN	O
dosage	NN	O
group	NN	O
,	,	O
vs.	FW	O
-3.00	NN	O
for	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	VBP	O
0.01	CD	O
or	CC	O
0.001	CD	O
for	IN	O
each	DT	O
group	NN	O
vs.	FW	O
placebo	NN	O
;	:	O
Wilcoxon-Mann-Whitney	NNP	O
test	NN	O
)	)	O
.	.	O

Improvements	NNS	O
in	IN	O
the	DT	O
secondary	JJ	O
endpoints	NNS	O
of	IN	O
PLM	NNP	O
while	IN	O
asleep	RB	O
and	CC	O
while	IN	O
awake	NN	O
were	VBD	O
also	RB	O
significantly	RB	O
superior	JJ	O
for	IN	O
pramipexole	NN	O
.	.	O

At	IN	O
3	CD	O
weeks	NNS	O
,	,	O
all	DT	O
pramipexole	NN	O
doses	NNS	O
reduced	VBD	O
the	DT	O
median	NN	O
for	IN	O
PLM	NNP	O
while	IN	O
asleep	RB	O
to	TO	O
levels	NNS	O
considered	VBN	O
normal	JJ	O
(	(	O
<	JJ	O
5PLM/h	CD	O
)	)	O
.	.	O

Except	IN	O
for	IN	O
delta-sleep	JJ	O
time	NN	O
and	CC	O
awakenings/arousals	NNS	O
,	,	O
sleep	JJ	O
parameters	NNS	O
remained	VBD	O
unchanged	JJ	O
or	CC	O
favored	JJ	O
pramipexole	NN	O
.	.	O

Median	JJ	O
sleep	JJ	O
latency	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
-5.00	NN	O
to	TO	O
-11.75min	VB	O
in	IN	O
the	DT	O
pramipexole	NN	O
groups	NNS	O
,	,	O
vs.	FW	O
-2.00	NN	O
for	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	VBP	O
0.05	CD	O
for	IN	O
all	DT	O
groups	NNS	O
except	IN	O
0.25mg/d	CD	O
)	)	O
.	.	O

Median	JJ	O
total	JJ	O
sleep	JJ	O
time	NN	O
increased	VBN	O
by	IN	O
25.75-66.75min	JJ	O
,	,	O
vs.	FW	O
25.50	CD	O
(	(	O
p	NN	O
<	VBZ	O
0.05	CD	O
for	IN	O
0.50mg/d	CD	O
)	)	O
,	,	O
and	CC	O
median	JJ	O
time	NN	O
in	IN	O
stages	NNS	O
2-4/rapid	JJ	O
eye	NN	O
movement	NN	O
(	(	O
REM	NNP	O
)	)	O
sleep	NN	O
increased	VBN	O
by	IN	O
37.00-68.00min	JJ	O
,	,	O
vs.	FW	O
26.75	CD	O
(	(	O
p	NN	O
<	VBZ	O
0.05	CD	O
for	IN	O
0.50mg/d	CD	O
)	)	O
.	.	O

By	IN	O
subjective	JJ	O
IRLS	NNP	O
ratings	NNS	O
,	,	O
all	DT	O
pramipexole	JJ	O
doses	NNS	O
were	VBD	O
significantly	RB	O
superior	JJ	O
to	TO	O
placebo	VB	O
.	.	O

Safety	NNP	O
analysis	NN	O
demonstrated	VBD	O
no	DT	O
dose-dependent	JJ	O
increase	NN	O
in	IN	O
adverse	JJ	O
events	NNS	O
,	,	O
and	CC	O
no	DT	O
drug-related	JJ	O
increase	NN	O
in	IN	O
daytime	JJ	O
somnolence	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Pramipexole	NNP	O
is	VBZ	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
RLS	NNP	O
,	,	O
most	RBS	O
notably	RB	O
among	IN	O
objective	JJ	O
measures	NNS	O
,	,	O
for	IN	O
reducing	VBG	O
PLM	NNP	O
and	CC	O
decreasing	VBG	O
sleep	JJ	O
latency	NN	O
.	.	O

Although	IN	O
other	JJ	O
sleep	JJ	O
parameters	NNS	O
showed	VBD	O
lesser	JJR	O
,	,	O
usually	RB	O
insignificant	JJ	O
change	NN	O
,	,	O
patients	NNS	O
'	POS	O
subjective	JJ	O
ratings	NNS	O
of	IN	O
RLS	NNP	O
severity	NN	O
and	CC	O
sleep	JJ	O
disturbance	NN	O
were	VBD	O
significantly	RB	O
improved	VBN	O
(	(	O
p0.0023	NN	O
)	)	O
.	.	O

Cholesterol-lowering	JJ	O
effect	NN	O
of	IN	O
stanol	NN	O
ester	NN	O
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
of	IN	O
mildly	RB	Condition
hypercholesterolemic	JJ	Condition
men	NNS	Sex
and	CC	O
women	NNS	Sex
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
stanol	NN	O
esters	NNS	O
in	IN	O
lowering	VBG	O
cholesterol	NN	O
in	IN	O
a	DT	O
US	NNP	O
population	NN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
After	IN	O
a	DT	O
run-in	JJ	O
phase	NN	O
,	,	O
318	CD	SampleSize
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
margarine-like	JJ	O
spreads	NNS	O
containing	VBG	O
stanol	JJ	O
ester	NN	O
or	CC	O
placebo	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
:	:	O
EU	NNP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
European	JJ	O
formula	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
3	CD	O
G	NNP	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
US	PRP	O
2	CD	O
G	NNP	O
:	:	O
0.67	CD	O
g	NN	O
of	IN	O
stanol	NN	O
(	(	O
ester	JJ	O
form	NN	O
)	)	O
per	IN	O
8-g	JJ	O
serving	NN	O
of	IN	O
a	DT	O
US	NNP	O
reformulation	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
;	:	O
or	CC	O
placebo	VB	O
spread	NN	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
+/-	JJ	O
SD	NNP	O
baseline	NN	O
total	NN	O
cholesterol	NN	O
(	(	O
TC	NNP	O
)	)	O
and	CC	O
low-density	JJ	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
LDL-C	NNP	O
)	)	O
levels	NNS	O
were	VBD	O
233+/-20	JJ	O
and	CC	O
153+21	CD	O
mg+/-dL	NN	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
US	NNP	O
3	CD	O
G	NNP	O
group	NN	O
,	,	O
3	CD	O
g	JJ	O
daily	NN	O
of	IN	O
stanol	JJ	O
esters	NNS	O
lowered	VBD	O
TC	NNP	O
and	CC	O
LDL-C	NNP	O
levels	NNS	O
by	IN	O
6.4	CD	O
%	NN	O
and	CC	O
10.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
dose-dependent	JJ	O
response	NN	O
compared	VBN	O
with	IN	O
2	CD	O
g	NNS	O
daily	RB	O
(	(	O
US	PRP	O
2	CD	O
G	NNP	O
)	)	O
.	.	O

Triglyceride	NNP	O
and	CC	O
high-density	NN	O
lipoprotein	NNS	O
cholesterol	NN	O
levels	NNS	O
were	VBD	O
unchanged	JJ	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
placebo	NN	O
.	.	O

Serum	NNP	O
vitamin	VBD	O
A	DT	O
and	CC	O
25-hydroxyvitamin	JJ	O
D	NNP	O
levels	NNS	O
were	VBD	O
not	RB	O
affected	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Stanol	NNP	O
esters	NNS	O
lowered	VBD	O
TC	NNP	O
and	CC	O
LDL-C	NNP	O
levels	NNS	O
in	IN	O
a	DT	O
mildly	RB	Condition
hypercholesterolemic	JJ	Condition
US	NNP	O
population	NN	O
without	IN	O
evidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
.	.	O

It	PRP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
dietary	JJ	O
adjunct	NN	O
to	TO	O
lower	VB	O
cholesterol	NN	O
.	.	O

Alendronate	NNP	O
daily	RB	O
,	,	O
weekly	JJ	O
in	IN	O
conventional	JJ	O
tablets	NNS	O
and	CC	O
weekly	JJ	O
in	IN	O
enteric	JJ	O
tablets	NNS	O
:	:	O
preliminary	JJ	O
study	NN	O
on	IN	O
the	DT	O
effects	NNS	O
in	IN	O
bone	NN	O
turnover	NN	O
markers	NNS	O
and	CC	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

Bisphosphonates	NNS	O
are	VBP	O
now	RB	O
in	IN	O
the	DT	O
vanguard	NN	O
of	IN	O
osteoporosis	NN	O
treatment	NN	O
.	.	O

Frequently	RB	O
,	,	O
gastro-oesophageal	JJ	O
symptoms	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
these	DT	O
drugs	NNS	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
side	JJ	O
effects	NNS	O
and	CC	O
bone	NN	O
turnover	NN	O
markers	NNS	O
in	IN	O
postmenopausal	JJ	Condition
women	NNS	Condition
who	WP	Condition
had	VBD	Condition
received	VBN	Condition
alendronate	JJ	Condition
daily	JJ	Condition
or	CC	Condition
weekly	JJ	Condition
in	IN	Condition
tablets	NNS	Condition
with	IN	Condition
or	CC	Condition
without	IN	Condition
enteric	JJ	Condition
coating	NN	Condition
.	.	Condition

We	PRP	O
conducted	VBD	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
3-month	JJ	O
trial	NN	O
.	.	O

The	DT	O
trial	NN	O
involved	VBD	O
75	CD	O
volunteers	NNS	O
,	,	O
aged	VBD	Age
45-58	JJ	Age
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
osteopenia	NN	O
(	(	O
T-score	NNP	O
lower	JJR	O
than	IN	O
-2	JJR	O
SD	NNP	O
)	)	O
assessed	VBN	O
by	IN	O
quantitative	JJ	O
ultrasound	NN	O
.	.	O

Women	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
receive	VB	O
:	:	O
(	(	O
a	DT	O
)	)	O
alendronate	NN	O
10mg/day	CD	O
:	:	O
(	(	O
b	NN	O
)	)	O
alendronate	NN	O
70	CD	O
mg	NN	O
once	RB	O
a	DT	O
week	NN	O
:	:	O
or	CC	O
(	(	O
c	NN	O
)	)	O
enteric	JJ	O
alendronate	NN	O
70	CD	O
mg	NN	O
per	IN	O
week	NN	O
.	.	O

We	PRP	O
recorded	VBD	O
side	JJ	O
effects	NNS	O
,	,	O
C-telopeptide	NNP	O
,	,	O
osteocalcin	NN	O
and	CC	O
urine	JJ	O
hydroxyproline	NN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
,	,	O
pyrosis	NN	O
(	(	O
heartburn	NN	O
)	)	O
was	VBD	O
noted	VBN	O
by	IN	O
seven	CD	O
women	NNS	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
28	CD	O
%	NN	O
)	)	O
,	,	O
three	CD	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
12	CD	O
%	NN	O
)	)	O
and	CC	O
two	CD	O
in	IN	O
group	NN	O
C	NNP	O
(	(	O
8	CD	O
%	NN	O
)	)	O
;	:	O
nausea	NN	O
:	:	O
by	IN	O
one	CD	O
woman	NN	O
in	IN	O
group	NN	O
B	NNP	O
;	:	O
and	CC	O
headache	NN	O
by	IN	O
one	CD	O
patient	NN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

C-telopeptide	NNP	O
(	(	O
A	DT	O
:	:	O
40.7	CD	O
%	NN	O
;	:	O
B	NNP	O
:	:	O
34.1	CD	O
%	NN	O
and	CC	O
C	NNP	O
:	:	O
38.5	CD	O
%	NN	O
)	)	O
;	:	O
hydroxyproline	NN	O
(	(	O
A	DT	O
:	:	O
31.1	CD	O
%	NN	O
;	:	O
B	NNP	O
:	:	O
25.3	CD	O
%	NN	O
and	CC	O
C	NNP	O
:	:	O
31.5	CD	O
%	NN	O
)	)	O
and	CC	O
osteocalcin	$	O
(	(	O
A	DT	O
:	:	O
27.0	CD	O
%	NN	O
;	:	O
B	NNP	O
:	:	O
25.4	CD	O
%	NN	O
and	CC	O
C	NNP	O
:	:	O
25.1	CD	O
%	NN	O
)	)	O
decreased	VBD	O
similarly	RB	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Weekly	JJ	O
intake	NN	O
of	IN	O
alendronate	NN	O
,	,	O
whether	IN	O
conventional	JJ	O
or	CC	O
enteric-coated	JJ	O
;	:	O
is	VBZ	O
associated	VBN	O
with	IN	O
less	JJR	O
heartburn	NN	O
and	CC	O
nausea	NN	O
.	.	O

Enteric	JJ	O
alendronate	NN	O
has	VBZ	O
a	DT	O
similar	JJ	O
action	NN	O
to	TO	O
the	DT	O
conventional	JJ	O
tablets	NNS	O
on	IN	O
biochemical	JJ	O
markers	NNS	O
.	.	O

An	DT	O
open	JJ	O
and	CC	O
randomized	JJ	O
study	NN	O
comparing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
standard	JJ	O
danazol	NN	O
and	CC	O
modified	VBD	O
triptorelin	NN	O
regimens	NNS	O
for	IN	O
postoperative	JJ	O
disease	NN	O
management	NN	O
of	IN	O
moderate	JJ	Condition
to	TO	Condition
severe	JJ	Condition
endometriosis	NN	Condition
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
danazol	NN	O
and	CC	O
triptorelin	NN	O
(	(	O
Decapeptyl	NNP	O
CR	NNP	O
,	,	O
Ferring	NNP	O
,	,	O
Kiel	NNP	O
,	,	O
Germany	NNP	O
)	)	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
moderate	JJ	O
and	CC	O
severe	JJ	O
endometriosis	NN	O
in	IN	O
terms	NNS	O
of	IN	O
symptom	NN	O
control	NN	O
and	CC	O
revised	VBN	O
American	JJ	O
Fertility	NNP	O
Society	NNP	O
(	(	O
AFS	NNP	O
)	)	O
score	NN	O
reduction	NN	O
,	,	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
hormonal	JJ	O
profile	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
triptorelin	NN	O
every	DT	O
6	CD	O
weeks	NNS	O
.	.	O

DESIGN	NNP	O
Open	NNP	O
and	CC	O
randomized	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
Kwong	NNP	O
Wah	NNP	O
Hospital	NNP	O
,	,	O
a	DT	O
large	JJ	O
public	JJ	O
hospital	NN	O
in	IN	O
an	DT	O
urban	JJ	O
location	NN	O
(	(	O
Hong	NNP	O
Kong	NNP	O
)	)	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
Forty	NNP	SampleSize
patients	NNS	O
after	IN	O
their	PRP$	O
first	JJ	O
conservative	JJ	O
operation	NN	O
for	IN	O
endometriosis	NN	O
,	,	O
with	IN	O
surgical	JJ	O
confirmation	NN	O
of	IN	O
revised	VBN	O
AFS	NNP	Condition
stage	NN	Condition
III	NNP	Condition
or	CC	Condition
IV	NNP	Condition
endometriosis	NN	Condition
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
Postoperative	VBP	O
6	CD	O
months	NNS	O
'	POS	O
therapy	NN	O
of	IN	O
danazol	NN	O
or	CC	O
triptorelin	NN	O
every	DT	O
6	CD	O
weeks	NNS	O
,	,	O
postmedical	JJ	O
therapy	NN	O
second-look	NN	O
laparoscopy	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Symptom	NNP	O
control	NN	O
and	CC	O
patients	NNS	O
'	POS	O
tolerance	NN	O
during	IN	O
medical	JJ	O
therapy	NN	O
,	,	O
posttherapy	NN	O
revised	VBD	O
AFS	NNP	O
score	NN	O
,	,	O
hormonal	JJ	O
profile	NN	O
during	IN	O
triptorelin	JJ	O
therapy	NN	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
Pain	NNP	O
control	NN	O
was	VBD	O
similar	JJ	O
between	IN	O
danazol	NN	O
and	CC	O
triptorelin	NN	O
therapy	NN	O
.	.	O

There	EX	O
was	VBD	O
less	JJR	O
breakthrough	IN	O
bleeding	NN	O
with	IN	O
triptorelin	NN	O
.	.	O

More	JJR	O
patients	NNS	O
failed	VBD	O
to	TO	O
complete	VB	O
the	DT	O
whole	JJ	O
course	NN	O
of	IN	O
danazol	NN	O
because	IN	O
of	IN	O
its	PRP$	O
side	NN	O
effects	NNS	O
.	.	O

The	DT	O
revised	JJ	O
AFS	NNP	O
score	NN	O
at	IN	O
second-look	JJ	O
laparoscopy	NN	O
did	VBD	O
not	RB	O
show	VB	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
medications	NNS	O
.	.	O

Adequate	NNP	O
pituitary	JJ	O
suppression	NN	O
was	VBD	O
observed	VBN	O
with	IN	O
injection	NN	O
of	IN	O
triptorelin	NN	O
every	DT	O
6	CD	O
weeks	NNS	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
Lengthening	NNP	O
of	IN	O
triptorelin	JJ	O
administration	NN	O
intervals	NNS	O
from	IN	O
4	CD	O
weeks	NNS	O
to	TO	O
6	CD	O
weeks	NNS	O
is	VBZ	O
effective	JJ	O
in	IN	O
maintaining	VBG	O
a	DT	O
hypoestrogenic	JJ	O
state	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
more	RBR	O
compliant	JJ	O
with	IN	O
triptorelin	NN	O
than	IN	O
danazol	NN	O
.	.	O

Thus	RB	O
,	,	O
triptorelin	JJ	O
injection	NN	O
every	DT	O
6	CD	O
weeks	NNS	O
is	VBZ	O
more	JJR	O
cost-effective	JJ	O
than	IN	O
conventional	JJ	O
regimens	NNS	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
topical	JJ	O
agents	NNS	O
on	IN	O
radiation-induced	JJ	O
skin	NN	O
disease	NN	O
by	IN	O
reflectance	NN	O
spectrophotometry	NN	O
.	.	O

OBJECTIVES	NNP	O
Radiotherapy	NNP	O
may	MD	O
cause	VB	O
severe	JJ	O
skin	NN	O
changes	NNS	O
that	WDT	O
significantly	RB	O
interfere	VBZ	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
reduce	VB	O
radiotherapy	NN	O
effectiveness	NN	O
.	.	O

Many	JJ	O
skin	NN	O
care	NN	O
instructions	NNS	O
and	CC	O
various	JJ	O
topical	JJ	O
agents	NNS	O
are	VBP	O
recommended	VBN	O
to	TO	O
help	VB	O
patients	NNS	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
radiation	NN	O
skin	NN	O
reactions	NNS	O
,	,	O
but	CC	O
evidence	NN	O
to	TO	O
support	VB	O
the	DT	O
value	NN	O
of	IN	O
the	DT	O
topical	JJ	O
treatments	NNS	O
of	IN	O
the	DT	O
irradiated	JJ	O
skin	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
we	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
topical	JJ	O
agents	NNS	O
used	VBN	O
as	IN	O
supportive	JJ	O
care	NN	O
to	TO	O
minimise	VB	O
radiation-induced	JJ	O
skin	NN	O
disease	NN	O
using	VBG	O
an	DT	O
instrumental	JJ	O
method	NN	O
.	.	O

METHODS	NNP	O
Subjects	NNPS	O
who	WP	O
were	VBD	O
undergoing	VBG	O
a	DT	O
planned	JJ	O
course	NN	O
of	IN	O
radiation	NN	O
therapy	NN	O
after	IN	O
breast-conserving	JJ	O
surgery	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
treatment	NN	O
(	(	O
using	VBG	O
one	CD	O
of	IN	O
two	CD	O
topical	JJ	O
agents	NNS	O
)	)	O
or	CC	O
non-treatment	JJ	O
(	(	O
control	NN	O
)	)	O
groups	NNS	O
and	CC	O
monitored	VBD	O
over	IN	O
8	CD	O
weeks	NNS	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
skin	NN	O
erythema	NN	O
was	VBD	O
evaluated	VBN	O
once	RB	O
per	IN	O
week	NN	O
by	IN	O
non-invasive	JJ	O
instrumental	JJ	O
reflectance	NN	O
spectrophotometry	NN	O
in	IN	O
comparison	NN	O
with	IN	O
a	DT	O
visual	JJ	O
scoring	NN	O
system	NN	O
.	.	O

KEY	NNP	O
FINDINGS	NNP	O
Examination	NNP	O
of	IN	O
the	DT	O
erythema	JJ	O
time	NN	O
course	NN	O
by	IN	O
a	DT	O
sensitive	JJ	O
spectrophotometric	JJ	O
reflectance	NN	O
method	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
skin	JJ	O
reactions	NNS	O
in	IN	O
the	DT	O
non-treated	JJ	O
group	NN	O
after	IN	O
the	DT	O
second	JJ	O
week	NN	O
of	IN	O
treatment	NN	O
and	CC	O
maximal	JJ	O
alterations	NNS	O
between	IN	O
the	DT	O
fourth	JJ	O
and	CC	O
sixth	JJ	O
week	NN	O
.	.	O

CONCLUSIONS	NN	O
From	IN	O
the	DT	O
results	NNS	O
obtained	VBD	O
,	,	O
we	PRP	O
observed	VBD	O
that	DT	O
application	NN	O
of	IN	O
topical	JJ	O
agents	NNS	O
used	VBN	O
in	IN	O
radio-induced	JJ	O
skin	JJ	O
disease	NN	O
were	VBD	O
able	JJ	O
to	TO	O
significantly	RB	O
reduce	VB	O
the	DT	O
erythema	NN	O
extent	NN	O
compared	VBN	O
to	TO	O
the	DT	O
non-treated	JJ	O
group	NN	O
.	.	O

The	DT	O
long-term	JJ	O
effect	NN	O
of	IN	O
oxandrolone	NN	O
on	IN	O
hepatic	JJ	O
acute	NN	O
phase	NN	O
proteins	VBZ	O
in	IN	O
severely	RB	Condition
burned	JJ	Condition
children	NNS	Age
.	.	O

BACKGROUND	NNP	O
Acute	NNP	O
phase	NN	O
protein	NN	O
production	NN	O
is	VBZ	O
a	DT	O
hallmark	NN	O
of	IN	O
severe	JJ	O
burns	NNS	O
.	.	O

We	PRP	O
wondered	VBD	O
whether	IN	O
anabolic	JJ	O
treatment	NN	O
with	IN	O
oxandrolone	NN	O
would	MD	O
affect	VB	O
these	DT	O
proteins	NNS	O
.	.	O

METHODS	NNP	O
Thirty-five	JJ	SampleSize
children	NNS	Age
with	IN	O
>	NN	O
or	CC	O
=40	CD	O
%	NN	O
total	JJ	O
body	NN	O
surface	NN	O
area	NN	O
burns	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
placebo	NN	O
or	CC	O
oxandrolone	NN	O
(	(	O
0.1	CD	O
mg/kg	NN	O
by	IN	O
mouth	JJ	O
twice	JJ	O
daily	RB	O
)	)	O
from	IN	O
postoperative	JJ	O
day	NN	O
5	CD	O
to	TO	O
1	CD	O
year	NN	O
postburn	NN	O
.	.	O

Levels	NNP	O
of	IN	O
constitutive	JJ	O
proteins	NNS	O
and	CC	O
acute	JJ	O
phase	NN	O
proteins	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
admission	NN	O
;	:	O
at	IN	O
discharge	NN	O
;	:	O
and	CC	O
at	IN	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
burn	NN	O
.	.	O

Total	JJ	O
albumin	JJ	O
supplementation	NN	O
and	CC	O
hepatic	JJ	O
transaminases	NNS	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Constitutive	JJ	O
proteins	NNS	O
such	JJ	O
as	IN	O
albumin	NN	O
,	,	O
prealbumin	NN	O
,	,	O
and	CC	O
retinol-binding	JJ	O
protein	NN	O
levels	NNS	O
increased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
and	CC	O
acute	JJ	O
phase	NN	O
proteins	NNS	O
such	JJ	O
as	IN	O
alpha	JJ	O
1-acid	JJ	O
glycoprotein	NN	O
,	,	O
C3	NNP	O
complement	NN	O
,	,	O
alpha	JJ	O
2-macroglobulin	JJ	O
,	,	O
and	CC	O
fibrinogen	NN	O
levels	NNS	O
significantly	RB	O
decreased	VBN	O
in	IN	O
the	DT	O
oxandrolone	NN	O
group	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Albumin	NNP	O
supplementation	NN	O
during	IN	O
the	DT	O
acute	JJ	O
hospitalization	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
oxandrolone	NN	O
group	NN	O
.	.	O

Hepatic	JJ	O
transaminases	NNS	O
remained	VBD	O
within	IN	O
normal	JJ	O
levels	NNS	O
.	.	O

CONCLUSION	NNP	O
Treatment	NNP	O
with	IN	O
oxandrolone	NN	O
in	IN	O
severe	JJ	O
burns	NNS	O
significantly	RB	O
increases	VBZ	O
constitutive	JJ	O
protein	NN	O
and	CC	O
reduces	NNS	O
acute	JJ	O
phase	NN	O
protein	NN	O
levels	NNS	O
.	.	O

Studies	NNS	O
on	IN	O
leptin	NN	O
and	CC	O
leptin	NN	O
receptor	NN	O
gene	NN	O
expression	NN	O
in	IN	O
myometrium	NN	O
and	CC	O
uterine	JJ	O
myomas	NN	O
of	IN	O
gnRH	JJ	O
analogue-treated	JJ	O
women	NNS	O
.	.	O

AIM	NNP	O
To	TO	O
test	VB	O
if	IN	O
treatment	NN	O
with	IN	O
GnRH	NNP	O
analogue	NN	O
,	,	O
which	WDT	O
leads	VBZ	O
to	TO	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
myoma	NN	O
volume	NN	O
,	,	O
changes	NNS	O
expression	NN	O
of	IN	O
leptin	NN	O
genes	NNS	O
and	CC	O
gene	NN	O
coding	VBG	O
leptin	JJ	O
receptor	NN	O
isoforms	NNS	O
in	IN	O
uterine	JJ	O
myomas	NN	O
and	CC	O
in	IN	O
the	DT	O
surrounding	NN	O
unaltered	JJ	O
myometrium	NN	O
.	.	O

METHODS	NNP	O
Using	VBG	O
RT-PCR	NNP	O
,	,	O
expression	NN	O
of	IN	O
leptin	NN	O
genes	NNS	O
and	CC	O
leptin	NN	O
receptor	NN	O
genes	NNS	O
was	VBD	O
studied	VBN	O
in	IN	O
myomas	NN	O
and	CC	O
in	IN	O
the	DT	O
surrounding	VBG	O
myometrium	NN	O
in	IN	O
women	NNS	Sex
with	IN	O
uterine	JJ	Condition
myomas	NN	Condition
,	,	O
untreated	VBD	Condition
or	CC	Condition
treated	VBN	Condition
with	IN	Condition
GnRH	NNP	Condition
analogue	NN	Condition
.	.	O

In	IN	O
the	DT	O
randomly	RB	O
selected	VBN	O
cases	NNS	O
presence	NN	O
of	IN	O
leptin	NN	O
protein	NN	O
and	CC	O
of	IN	O
leptin	JJ	O
receptor	NN	O
proteins	NNS	O
was	VBD	O
examined	VBN	O
also	RB	O
by	IN	O
Western	JJ	O
blotting	NN	O
.	.	O

RESULTS	NNP	O
Expression	NNP	O
of	IN	O
leptin	NN	O
genes	NNS	O
was	VBD	O
demonstrated	VBN	O
both	DT	O
in	IN	O
myomas	NN	O
and	CC	O
in	IN	O
the	DT	O
surrounding	VBG	O
myometrium	NN	O
,	,	O
and	CC	O
a	DT	O
similar	JJ	O
pattern	NN	O
of	IN	O
expression	NN	O
was	VBD	O
found	VBN	O
for	IN	O
leptin	JJ	O
receptor	NN	O
isoforms	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
RT-PCR	NNP	O
were	VBD	O
confirmed	VBN	O
by	IN	O
Western	JJ	O
blotting	NN	O
,	,	O
which	WDT	O
documented	VBD	O
the	DT	O
identical	JJ	O
distribution	NN	O
of	IN	O
leptin	NN	O
proteins	NNS	O
and	CC	O
leptin	JJ	O
receptor	NN	O
proteins	NNS	O
in	IN	O
studied	JJ	O
tissues	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
GnRH	NNP	O
analogue	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
expression	NN	O
pattern	NN	O
of	IN	O
studied	VBN	O
genes	NNS	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
on	IN	O
the	DT	O
administration	NN	O
of	IN	O
GnRH	NNP	O
analogue	NN	O
to	TO	O
females	NNS	O
with	IN	O
myomas	NN	O
suggest	VBP	O
that	IN	O
no	DT	O
direct	JJ	O
or	CC	O
immediate	JJ	O
inter-relationship	JJ	O
exists	NNS	O
between	IN	O
expression	NN	O
of	IN	O
leptin	NN	O
genes	NNS	O
in	IN	O
uterine	JJ	O
myomas	NN	O
on	IN	O
one	CD	O
hand	NN	O
and	CC	O
estrogen	NN	O
,	,	O
progesterone	NN	O
and	CC	O
leptin	NN	O
levels	NNS	O
in	IN	O
the	DT	O
blood	NN	O
on	IN	O
the	DT	O
other	JJ	O
.	.	O

Expression	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
of	IN	O
a	DT	O
more	RBR	O
durable	JJ	O
nature	NN	O
but	CC	O
factors	NNS	O
that	WDT	O
induce	VBP	O
such	JJ	O
expression	NN	O
remain	VBP	O
unknown	JJ	O
.	.	O

Efficacy	NN	O
of	IN	O
intramuscular	JJ	O
oxytetracycline	NN	O
as	IN	O
a	DT	O
dry	JJ	O
cow	NN	O
treatment	NN	O
for	IN	O
Staphylococcus	NNP	O
aureus	NN	O
mastitis	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
intramuscular	JJ	O
oxytetracycline	NN	O
as	IN	O
a	DT	O
supplemental	JJ	O
dry	JJ	O
cow	NN	O
treatment	NN	O
for	IN	O
Staphylococcus	NNP	O
aureus	NN	O
mastitis	NN	O
,	,	O
37	CD	O
Holstein	NNP	O
cows	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
intracisternal	JJ	O
infusion	NN	O
with	IN	O
a	DT	O
commercial	JJ	O
preparation	NN	O
of	IN	O
cephapirin	JJ	O
benzathine	NN	O
at	IN	O
drying	VBG	O
off	RP	O
(	(	O
20	CD	O
cows	NNS	O
)	)	O
and	CC	O
infusion	NN	O
with	IN	O
cephapirin	JJ	O
benzathine	NN	O
at	IN	O
drying	VBG	O
off	RP	O
and	CC	O
intramuscular	JJ	O
oxytetracycline	NN	O
at	IN	O
11	CD	O
mg/kg	NNS	O
once	RB	O
daily	RB	O
on	IN	O
d	NN	O
7	CD	O
,	,	O
8	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
10	CD	O
after	IN	O
drying	VBG	O
off	RB	O
(	(	O
17	CD	O
cows	NNS	O
)	)	O
.	.	O

Milk	NN	O
samples	NNS	O
collected	VBD	O
7	CD	O
,	,	O
14	CD	O
,	,	O
30	CD	O
,	,	O
and	CC	O
60	CD	O
d	NN	O
after	IN	O
calving	VBG	O
were	VBD	O
plated	VBN	O
for	IN	O
bacterial	JJ	O
isolation	NN	O
within	IN	O
24	CD	O
h	NN	O
after	IN	O
collection	NN	O
and	CC	O
after	IN	O
24	CD	O
to	TO	O
72	CD	O
h	NN	O
of	IN	O
storage	NN	O
at	IN	O
-20	NNP	O
degrees	NNS	O
C.	NNP	O
Quarters	NNS	O
were	VBD	O
defined	VBN	O
as	IN	O
infected	JJ	O
if	IN	O
S.	NNP	O
aureus	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
the	DT	O
fresh	JJ	O
and	CC	O
frozen	JJ	O
cultures	NNS	O
from	IN	O
any	DT	O
one	CD	O
sample	NN	O
collected	VBD	O
before	IN	O
drying	VBG	O
off	RP	O
.	.	O

An	DT	O
infected	JJ	O
quarter	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
cured	JJ	O
if	IN	O
S.	NNP	O
aureus	NN	O
was	VBD	O
not	RB	O
isolated	VBN	O
from	IN	O
the	DT	O
fresh	JJ	O
or	CC	O
frozen	JJ	O
culture	NN	O
from	IN	O
milk	NN	O
samples	NNS	O
obtained	VBD	O
following	VBG	O
calving	NN	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
cure	NN	O
by	IN	O
30	CD	O
d	NN	O
after	IN	O
calving	VBG	O
for	IN	O
systemic	JJ	O
oxytetracycline	NN	O
(	(	O
in	IN	O
combination	NN	O
with	IN	O
cephapirin	JJ	O
treatment	NN	O
)	)	O
was	VBD	O
29.4	CD	O
%	NN	O
for	IN	O
infected	JJ	O
quarters	NNS	O
and	CC	O
29.4	CD	O
%	NN	O
for	IN	O
infected	JJ	O
cows	NNS	O
,	,	O
compared	VBN	O
with	IN	O
27.5	CD	O
and	CC	O
25.0	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
cephapirin	NN	O
treatment	NN	O
only	RB	O
.	.	O

Results	NNS	O
including	VBG	O
the	DT	O
culture	NN	O
at	IN	O
60	CD	O
d	NN	O
after	IN	O
calving	VBG	O
were	VBD	O
21.2	CD	O
and	CC	O
22.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
combination	NN	O
therapy	NN	O
and	CC	O
cephapirin	NN	O
therapy	NN	O
only	RB	O
.	.	O

Systemic	NNP	O
oxytetracycline	NN	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
intramammary	JJ	O
dry	JJ	O
cow	NN	O
treatment	NN	O
,	,	O
did	VBD	O
not	RB	O
improve	VB	O
the	DT	O
rate	NN	O
of	IN	O
cure	NN	O
for	IN	O
S.	NNP	O
aureus	JJ	O
mastitis	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
prostaglandin	NN	O
inhibition	NN	O
by	IN	O
indomethacin	NN	O
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
renal	JJ	O
function	NN	O
in	IN	O
hypertensive	JJ	Condition
patients	NNS	O
treated	VBN	O
with	IN	O
cilazapril	NN	O
.	.	O

1	CD	O
.	.	O

In	IN	O
a	DT	O
placebo-controlled	JJ	O
double-blind	JJ	O
cross-over	NN	O
study	NN	O
lasting	VBG	O
6	CD	O
weeks	NNS	O
,	,	O
twenty	JJ	SampleSize
patients	NNS	O
with	IN	O
essential	JJ	Condition
hypertension	NN	Condition
were	VBD	O
treated	VBN	O
with	IN	O
placebo	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
oral	JJ	O
cilazapril	NN	O
2.5	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
or	CC	O
oral	JJ	O
indomethacin	NN	O
50	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Afterwards	NNS	O
they	PRP	O
received	VBD	O
the	DT	O
combination	NN	O
of	IN	O
both	DT	O
drugs	NNS	O
for	IN	O
a	DT	O
further	JJ	O
2	CD	O
weeks	NNS	O
.	.	O

2	CD	O
.	.	O

Cilazapril	NNP	O
significantly	RB	O
lowered	VBD	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
24	CD	O
h	NNS	O
post	JJ	O
administration	NN	O
.	.	O

3	CD	O
.	.	O

Indomethacin	NNP	O
significantly	RB	O
attenuated	VBD	O
the	DT	O
antihypertensive	JJ	O
activity	NN	O
of	IN	O
cilazapril	NN	O
.	.	O

This	DT	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
those	DT	O
patients	NNS	O
who	WP	O
were	VBD	O
treated	VBN	O
for	IN	O
the	DT	O
initial	JJ	O
2	CD	O
weeks	NNS	O
with	IN	O
indomethacin	JJ	O
plus	CC	O
placebo	NN	O
(	(	O
and	CC	O
subsequently	RB	O
with	IN	O
cilazapril	NN	O
in	IN	O
addition	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
subjects	NNS	O
who	WP	O
first	RB	O
received	VBD	O
cilazapril	JJ	O
plus	CC	O
placebo	NN	O
and	CC	O
then	RB	O
the	DT	O
combination	NN	O
.	.	O

4	CD	O
.	.	O

Correspondingly	VB	O
the	DT	O
decrease	NN	O
of	IN	O
plasma	JJ	O
renin	NN	O
activity	NN	O
(	(	O
PRA	NNP	O
)	)	O
and	CC	O
urinary	JJ	O
prostaglandin	NN	O
excretion	NN	O
(	(	O
PGE2	NNP	O
)	)	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
those	DT	O
patients	NNS	O
treated	VBD	O
initially	RB	O
with	IN	O
indomethacin	NN	O
.	.	O

5	CD	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
indomethacin	NN	O
on	IN	O
the	DT	O
antihypertensive	JJ	O
effect	NN	O
of	IN	O
cilazapril	NN	O
appears	VBZ	O
to	TO	O
depend	VB	O
upon	IN	O
the	DT	O
sequence	NN	O
of	IN	O
drug	NN	O
administration	NN	O
.	.	O

Safety	NN	O
of	IN	O
an	DT	O
astaxanthin-rich	JJ	O
Haematococcus	NNP	O
pluvialis	NN	O
algal	JJ	O
extract	NN	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

A	DT	O
growing	VBG	O
body	NN	O
of	IN	O
scientific	JJ	O
literature	NN	O
indicates	VBZ	O
that	IN	O
astaxanthin	NN	O
is	VBZ	O
a	DT	O
more	RBR	O
powerful	JJ	O
antioxidant	JJ	O
than	IN	O
other	JJ	O
carotenoids	NNS	O
and	CC	O
vitamin	NN	O
E	NNP	O
and	CC	O
may	MD	O
confer	VB	O
numerous	JJ	O
health	NN	O
benefits	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
investigation	NN	O
was	VBD	O
to	TO	O
conduct	VB	O
a	DT	O
human	JJ	O
safety	NN	O
study	NN	O
with	IN	O
a	DT	O
Haematococcus	NNP	O
pluvialis	NN	O
algal	JJ	O
extract	NN	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
astaxanthin	NN	O
.	.	O

Thirty-five	JJ	O
healthy	JJ	O
adults	NNS	O
age	NN	O
35-69	CD	O
years	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
'	POS	O
duration	NN	O
.	.	O

All	DT	O
participants	NNS	O
took	VBD	O
three	CD	O
gelcaps	NNS	O
per	IN	O
day	NN	O
,	,	O
one	CD	O
at	IN	O
each	DT	O
meal	NN	O
.	.	O

Nineteen	JJ	O
participants	NNS	O
received	VBD	O
gelcaps	NNS	O
with	IN	O
an	DT	O
algal	JJ	O
extract	NN	O
in	IN	O
safflower	JJR	O
oil	NN	O
,	,	O
containing	VBG	O
2	CD	O
mg	NN	O
of	IN	O
astaxanthin	JJ	O
each	DT	O
(	(	O
treatment	NN	O
)	)	O
;	:	O
16	CD	O
participants	NNS	O
received	VBD	O
gelcaps	NNS	O
containing	VBG	O
safflower	NN	O
oil	NN	O
only	RB	O
(	(	O
placebo	NN	O
)	)	O
.	.	O

Blood	NNP	O
pressure	NN	O
and	CC	O
blood	NN	O
chemistry	NN	O
tests	NNS	O
,	,	O
including	VBG	O
a	DT	O
comprehensive	JJ	O
metabolic	JJ	O
panel	NN	O
and	CC	O
cell	NN	O
blood	NN	O
count	NN	O
,	,	O
were	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
trial	NN	O
and	CC	O
after	IN	O
4	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
of	IN	O
supplementation	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
detected	VBN	O
between	IN	O
the	DT	O
treatment	NN	O
and	CC	O
the	DT	O
placebo	NN	O
groups	NNS	O
after	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
supplementation	NN	O
with	IN	O
the	DT	O
algal	JJ	O
extract	NN	O
in	IN	O
the	DT	O
parameters	NNS	O
analyzed	VBD	O
,	,	O
except	IN	O
for	IN	O
serum	NN	O
calcium	NN	O
,	,	O
total	JJ	O
protein	NN	O
,	,	O
and	CC	O
eosinophils	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
differences	NNS	O
in	IN	O
these	DT	O
three	CD	O
parameters	NNS	O
were	VBD	O
statistically	RB	O
significant	JJ	O
,	,	O
they	PRP	O
were	VBD	O
very	RB	O
small	JJ	O
and	CC	O
are	VBP	O
of	IN	O
no	DT	O
clinical	JJ	O
importance	NN	O
.	.	O

These	DT	O
results	NNS	O
reveal	VBP	O
that	IN	O
6	CD	O
mg	NN	O
of	IN	O
astaxanthin	JJ	O
per	IN	O
day	NN	O
from	IN	O
a	DT	O
H.	NNP	O
pluvialis	NN	O
algal	JJ	O
extract	NN	O
can	MD	O
be	VB	O
safely	RB	O
consumed	VBN	O
by	IN	O
healthy	JJ	O
adults	NNS	O
.	.	O

A	DT	O
prospective	JJ	O
randomised	JJ	O
comparison	NN	O
of	IN	O
sublingual	JJ	Condition
and	CC	Condition
vaginal	JJ	Condition
misoprostol	NN	Condition
in	IN	Condition
second	JJ	Condition
trimester	NN	Condition
termination	NN	Condition
of	IN	Condition
pregnancy	NN	Condition
.	.	Condition

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
,	,	O
side	NN	O
effects	NNS	O
and	CC	O
acceptability	NN	O
of	IN	O
sublingual	JJ	O
and	CC	O
vaginal	JJ	O
misoprostol	NN	O
for	IN	O
second	JJ	O
trimester	NN	O
medical	JJ	O
abortion	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
Tertiary	JJ	O
referral	JJ	O
unit	NN	O
and	CC	O
a	DT	O
teaching	JJ	O
hospital	NN	O
.	.	O

POPULATION	NNP	O
Two	CD	O
hundred	VBD	O
and	CC	O
twenty-four	JJ	O
women	NNS	O
at	IN	O
12	CD	O
to	TO	O
20	CD	O
weeks	NNS	O
of	IN	O
gestation	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
women	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
sublingual	JJ	O
or	CC	O
vaginal	JJ	O
misoprostol	NN	O
400	CD	O
microg	NN	O
every	DT	O
3	CD	O
hours	NNS	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
five	CD	O
doses	NNS	O
.	.	O

The	DT	O
course	NN	O
of	IN	O
misoprostol	NN	O
was	VBD	O
repeated	VBN	O
if	IN	O
the	DT	O
woman	NN	O
did	VBD	O
not	RB	O
abort	VB	O
within	IN	O
24	CD	O
hours	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
success	NN	O
rate	NN	O
at	IN	O
48	CD	O
hours	NNS	O
,	,	O
induction-to-abortion	NN	O
interval	NN	O
and	CC	O
the	DT	O
side	NN	O
effects	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
success	NN	O
rate	NN	O
at	IN	O
48	CD	O
hours	NNS	O
(	(	O
sublingual	JJ	O
:	:	O
91	CD	O
%	NN	O
;	:	O
vaginal	JJ	O
:	:	O
95	CD	O
%	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
success	NN	O
rate	NN	O
at	IN	O
24	CD	O
hours	NNS	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
vaginal	JJ	O
group	NN	O
(	(	O
85	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
sublingual	JJ	O
group	NN	O
(	(	O
64	CD	O
%	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
median	JJ	O
induction-to-abortion	NN	O
interval	NN	O
(	(	O
sublingual	JJ	O
:	:	O
13.8	CD	O
hours	NNS	O
;	:	O
vaginal	JJ	O
:	:	O
12.0	CD	O
hours	NNS	O
)	)	O
.	.	O

Significantly	RB	O
more	JJR	O
women	NNS	O
in	IN	O
the	DT	O
sublingual	JJ	O
group	NN	O
preferred	VBD	O
the	DT	O
route	NN	O
to	TO	O
which	WDT	O
they	PRP	O
were	VBD	O
assigned	VBN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
vaginal	JJ	O
group	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
fever	NN	O
was	VBD	O
also	RB	O
less	RBR	O
in	IN	O
the	DT	O
sublingual	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
use	NN	O
of	IN	O
vaginal	JJ	O
misoprostol	NN	O
for	IN	O
second	JJ	O
trimester	NN	O
medical	JJ	O
abortion	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
higher	JJR	O
success	NN	O
rate	NN	O
than	IN	O
sublingual	JJ	O
misoprostol	NN	O
at	IN	O
24	CD	O
hours	NNS	O
but	CC	O
the	DT	O
abortion	NN	O
rate	NN	O
was	VBD	O
similar	JJ	O
at	IN	O
48	CD	O
hours	NNS	O
.	.	O

Vaginal	NNP	O
misoprostol	NN	O
should	MD	O
be	VB	O
the	DT	O
regimen	NNS	O
of	IN	O
choice	NN	O
but	CC	O
sublingual	JJ	O
misoprostol	NN	O
is	VBZ	O
also	RB	O
an	DT	O
effective	JJ	O
alternative	NN	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
liu	NN	O
wei	NN	O
di	NN	O
huang	NN	O
or	CC	O
jin	NN	O
gui	NN	O
shen	NN	O
qi	JJ	O
decoction	NN	O
as	IN	O
on	IN	O
adjuvant	JJ	O
treatment	NN	O
in	IN	O
small	JJ	Condition
cell	NN	Condition
lung	NN	Condition
cancer	NN	Condition
]	NNP	O
.	.	O

Eighty-three	JJ	O
patients	NNS	O
with	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
with	IN	O
or	CC	O
without	IN	O
using	VBG	O
a	DT	O
traditional	JJ	O
Chinese	JJ	O
Kidney-tonifying	NNP	O
decoction	NN	O
(	(	O
Liu	NNP	O
Wei	NNP	O
Di	NNP	O
Huang	NNP	O
or	CC	O
Jin	NNP	O
Gui	NNP	O
Shen	NNP	O
Qi	NNP	O
medicinal	JJ	O
decoction	NN	O
)	)	O
in	IN	O
chemotherapy	NN	O
or	CC	O
radiotherapy	NN	O
courses	NNS	O
.	.	O

74	CD	O
patients	NNS	O
were	VBD	O
availble	JJ	O
to	TO	O
be	VB	O
analysis	NN	O
.	.	O

The	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
well-matched	JJ	O
in	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
stage	NN	O
and	CC	O
performance	NN	O
status	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
response	NN	O
rate	NN	O
and	CC	O
the	DT	O
median	JJ	O
survival	NN	O
between	IN	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
(	(	O
CR+PR	NNP	O
)	)	O
was	VBD	O
91.5	CD	O
%	NN	O
for	IN	O
Chinese	JJ	O
herb	NN	O
group	NN	O
and	CC	O
46.9	CD	O
%	NN	O
for	IN	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
16	CD	O
months	NNS	O
for	IN	O
the	DT	O
traditional	JJ	O
Chinese	JJ	O
Kidney-tonifying	NNP	O
decoction	NN	O
group	NN	O
,	,	O
and	CC	O
10	CD	O
months	NNS	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Survival	JJ	O
curve	NN	O
(	(	O
Kaplan-meire	NNP	O
's	POS	O
)	)	O
of	IN	O
the	DT	O
Chinese	NNP	O
herb	NN	O
group	NN	O
was	VBD	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

10	CD	O
patients	NNS	O
of	IN	O
Chinese	JJ	O
herb	NN	O
group	NN	O
was	VBD	O
alive	JJ	O
beyond	IN	O
more	JJR	O
than	IN	O
2	CD	O
years	NNS	O
.	.	O

Until	IN	O
now	RB	O
,	,	O
4	CD	O
patients	NNS	O
in	IN	O
the	DT	O
Chinese	JJ	O
herb	NN	O
group	NN	O
,	,	O
one	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
are	VBP	O
still	RB	O
enjoying	VBG	O
their	PRP$	O
disease-free	JJ	O
life	NN	O
for	IN	O
more	JJR	O
than	IN	O
7	CD	O
years	NNS	O
.	.	O

Hematologic	NNP	O
toxicities	NNS	O
were	VBD	O
observed	VBN	O
much	RB	O
frequently	RB	O
in	IN	O
the	DT	O
patients	NNS	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.005	CD	O
and	CC	O
0.01/WBC	CD	O
and	CC	O
BPC	NNP	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
animal	JJ	O
experiments	NNS	O
with	IN	O
the	DT	O
same	JJ	O
traditional	JJ	O
medicinal	JJ	O
decoctions	NNS	O
as	IN	O
used	VBN	O
in	IN	O
clinic	NN	O
have	VBP	O
showed	VBN	O
immuno-enhancement	JJ	O
activities	NNS	O
.	.	O

These	DT	O
results	NNS	O
have	VBP	O
showed	VBN	O
that	IN	O
the	DT	O
traditional	JJ	O
Chinese	JJ	O
Kidney-tonifying	NNP	O
decoction	NN	O
may	MD	O
enhance	VB	O
non-specific	JJ	O
immunology	NN	O
activities	NNS	O
and	CC	O
may	MD	O
be	VB	O
much	JJ	O
useful	JJ	O
for	IN	O
solid	JJ	O
cancer	NN	O
patients	NNS	O
as	IN	O
an	DT	O
adjuvant	JJ	O
treatment	NN	O
.	.	O

Negative	JJ	O
emotional	JJ	O
experiences	NNS	O
during	IN	O
navigation	NN	O
enhance	NN	O
parahippocampal	JJ	O
activity	NN	O
during	IN	O
recall	NN	O
of	IN	O
place	NN	O
information	NN	O
.	.	O

It	PRP	O
is	VBZ	O
known	VBN	O
that	IN	O
the	DT	O
parahippocampal	JJ	O
cortex	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
object-place	JJ	O
associations	NNS	O
in	IN	O
spatial	JJ	O
learning	NN	O
,	,	O
but	CC	O
it	PRP	O
remains	VBZ	O
unknown	JJ	O
whether	IN	O
activity	NN	O
within	IN	O
this	DT	O
region	NN	O
is	VBZ	O
modulated	VBN	O
by	IN	O
affective	JJ	O
signals	NNS	O
during	IN	O
navigation	NN	O
.	.	O

Here	RB	O
we	PRP	O
used	VBD	O
fMRI	NN	O
to	TO	O
measure	VB	O
the	DT	O
neural	JJ	O
consequences	NNS	O
of	IN	O
emotional	JJ	O
experiences	NNS	O
on	IN	O
place	NN	O
memory	NN	O
during	IN	O
navigation	NN	O
.	.	O

A	DT	O
day	NN	O
before	IN	O
scanning	VBG	O
,	,	O
participants	NNS	O
undertook	VBP	O
an	DT	O
active	JJ	O
object	NN	Condition
location	NN	Condition
memory	NN	Condition
task	NN	Condition
within	IN	O
a	DT	O
virtual	JJ	O
house	NN	O
in	IN	O
which	WDT	O
each	DT	O
room	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
different	JJ	O
schedule	NN	O
of	IN	O
task-irrelevant	JJ	O
emotional	JJ	O
events	NNS	O
.	.	O

The	DT	O
events	NNS	O
varied	VBN	O
in	IN	O
valence	NN	O
(	(	O
positive	JJ	O
,	,	O
negative	JJ	O
,	,	O
or	CC	O
neutral	JJ	O
)	)	O
and	CC	O
in	IN	O
their	PRP$	O
rate	NN	O
of	IN	O
occurrence	NN	O
(	(	O
intermittent	JJ	O
vs.	FW	O
constant	NN	O
)	)	O
.	.	O

On	IN	O
a	DT	O
subsequent	JJ	O
day	NN	O
,	,	O
we	PRP	O
measured	VBD	O
neural	JJ	O
activity	NN	O
while	IN	O
participants	NNS	O
were	VBD	O
shown	VBN	O
static	JJ	O
images	NNS	O
of	IN	O
the	DT	O
previously	RB	O
learned	VBN	O
virtual	JJ	O
environment	NN	O
,	,	O
now	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
any	DT	O
affective	JJ	O
stimuli	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
showed	VBD	O
that	IN	O
parahippocampal	JJ	O
activity	NN	O
was	VBD	O
significantly	RB	O
enhanced	VBN	O
bilaterally	RB	O
when	WRB	O
participants	NNS	O
viewed	VBD	O
images	NNS	O
of	IN	O
a	DT	O
room	NN	O
in	IN	O
which	WDT	O
they	PRP	O
had	VBD	O
previously	RB	O
encountered	VBN	O
negatively	RB	O
arousing	VBG	O
events	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
such	JJ	O
automatic	JJ	O
enhancement	NN	O
of	IN	O
place	NN	O
representations	NNS	O
by	IN	O
aversive	JJ	O
emotional	JJ	O
events	NNS	O
serves	VBZ	O
as	IN	O
an	DT	O
important	JJ	O
adaptive	NN	O
mechanism	NN	O
for	IN	O
avoiding	VBG	O
future	JJ	O
threats	NNS	O
.	.	O

Effect	NN	O
of	IN	O
m-chlorophenylpiperazine	NN	O
on	IN	O
plasma	NN	O
homovanillic	JJ	O
acid	NN	O
concentrations	NNS	O
in	IN	O
healthy	JJ	Condition
subjects	NNS	Condition
.	.	O

In	IN	O
view	NN	O
of	IN	O
the	DT	O
abundant	JJ	O
anatomical	JJ	O
and	CC	O
functional	JJ	O
interactions	NNS	O
between	IN	O
serotonin	NN	O
and	CC	O
dopamine	NN	O
systems	NNS	O
,	,	O
this	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
serotonin	JJ	O
agonist	NN	O
,	,	O
m-chlorophenylpiperazine	NN	O
(	(	O
mCPP	NN	O
)	)	O
on	IN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
the	DT	O
dopamine	NN	O
metabolite	NN	O
,	,	O
homovanillic	JJ	O
acid	NN	O
.	.	O

Plasma	NNP	O
prolactin	NN	O
levels	NNS	O
,	,	O
body	NN	O
temperature	NN	O
,	,	O
and	CC	O
mCPP	RB	O
blood	NN	O
level	NN	O
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O

mCPP	NN	O
(	(	O
0.35	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
placebo	$	O
were	VBD	O
administered	VBN	O
orally	RB	O
to	TO	O
10	CD	O
healthy	JJ	O
men	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
design	NN	O
.	.	O

Variables	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
210	CD	O
min	NNS	O
after	IN	O
administration	NN	O
of	IN	O
capsules	NNS	O
.	.	O

mCPP	NNS	O
raised	VBD	O
prolactin	NN	O
and	CC	O
temperature	NN	O
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
plasma	NN	O
homovanillic	JJ	O
acid	JJ	O
concentrations	NNS	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
mCPP	NN	O
does	VBZ	O
not	RB	O
alter	VB	O
dopamine	NN	O
function	NN	O
.	.	O

Late	JJ	Condition
miscarriage	NN	Condition
and	CC	O
preterm	JJ	Condition
birth	NN	Condition
after	IN	O
treatment	NN	O
with	IN	O
clindamycin	NN	O
:	:	O
a	DT	O
randomised	JJ	O
consent	NN	O
design	NN	O
study	NN	O
according	VBG	O
to	TO	O
Zelen	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
screen	VB	O
for	IN	O
bacterial	JJ	Condition
vaginosis	NN	Condition
(	(	Condition
BV	NNP	Condition
)	)	Condition
and	CC	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
vaginal	JJ	O
clindamycin	NN	O
in	IN	O
order	NN	O
to	TO	O
observe	VB	O
the	DT	O
effect	NN	O
on	IN	O
late	JJ	O
miscarriage	NN	O
and	CC	O
delivery	NN	O
prior	RB	O
to	TO	O
37	CD	O
completed	VBN	O
weeks	NNS	O
(	(	O
primary	JJ	O
outcome	NN	O
)	)	O
.	.	O

DESIGN	NNP	O
Randomised	VBD	O
consent	NN	O
design	NN	O
for	IN	O
clinical	JJ	O
trials	NNS	O
according	VBG	O
to	TO	O
Zelen	NNP	O
.	.	O

SETTING	NNP	O
Southeast	NNP	O
region	NN	O
of	IN	O
Sweden	NNP	O
.	.	O

POPULATION	VB	O
A	DT	O
total	NN	O
of	IN	O
9025	CD	SampleSize
women	NNS	Sex
were	VBD	O
screened	VBN	O
in	IN	O
early	JJ	O
pregnancy	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
819	CD	SampleSize
women	NNS	O
with	IN	O
a	DT	O
Nugent	NNP	O
score	NN	O
of	IN	O
6	CD	O
and	CC	O
above	VB	O
were	VBD	O
considered	VBN	O
to	TO	O
have	VB	O
BV	NNP	O
and	CC	O
treated	VBD	O
according	VBG	O
to	TO	O
Zelen	NNP	O
allocation	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
late	JJ	O
miscarriage	NN	O
and	CC	O
spontaneous	JJ	O
(	(	O
noniatrogenic	JJ	O
)	)	O
preterm	FW	O
birth	NN	O
was	VBD	O
assessed	VBN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Late	NNP	O
miscarriage	NN	O
and	CC	O
spontaneous	JJ	O
preterm	NNS	O
delivery	NN	O
before	IN	O
37	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Therapy	NNP	O
with	IN	O
vaginal	JJ	O
clindamycin	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
impact	NN	O
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
spontaneous	JJ	O
preterm	JJ	O
delivery	NN	O
prior	RB	O
to	TO	O
37	CD	O
completed	VBN	O
weeks	NNS	O
;	:	O
OR	CC	O
0.90	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.40-2.02	NN	O
(	(	O
primary	JJ	O
outcome	NN	O
variable	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
only	RB	O
1	CD	O
of	IN	O
11	CD	O
women	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
versus	VBD	O
5	CD	O
of	IN	O
12	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
delivered	VBD	O
prior	RB	O
to	TO	O
33	CD	O
completed	VBN	O
weeks	NNS	O
;	:	O
OR	CC	O
0.14	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.02-0.95	NN	O
.	.	O

Treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
32	CD	O
days	NNS	O
longer	JJR	O
gestation	NN	O
for	IN	O
the	DT	O
23	CD	SampleSize
participants	NNS	O
who	WP	O
had	VBD	O
late	JJ	O
miscarriage	NN	O
or	CC	O
spontaneous	JJ	Condition
preterm	NNS	Condition
birth	NN	Condition
(	(	O
P=	NNP	O
0.024	CD	O
,	,	O
Mann-Whitney	NNP	O
U	NNP	O
test	NN	O
)	)	O
and	CC	O
significantly	RB	O
fewer	JJR	O
infants	NNS	O
had	VBD	O
a	DT	O
birthweight	NN	O
below	IN	O
2,500	CD	O
g	NN	O
(	(	O
secondary	JJ	O
outcome	NN	O
)	)	O
.	.	O

A	DT	O
follow	JJ	O
up	NN	O
of	IN	O
infants	NNS	O
born	JJ	O
preterm	VBP	O
4	CD	O
years	NNS	O
postnatally	RB	O
indicated	VBD	O
that	IN	O
extending	VBG	O
gestational	JJ	O
age	NN	O
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
number	NN	O
of	IN	O
sequelae	NN	O
.	.	O

CONCLUSIONS	NNP	O
Clindamycin	NNP	O
vaginal	JJ	O
cream	NN	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
prolonged	VBN	O
gestation	NN	O
and	CC	O
reduced	JJ	O
cost	NN	O
of	IN	O
neonatal	JJ	O
care	NN	O
in	IN	O
women	NNS	O
with	IN	O
BV	NNP	Condition
.	.	O

Early	JJ	O
screening	NN	O
for	IN	O
BV	NNP	O
and	CC	O
treatment	NN	O
with	IN	O
clindamycin	NN	O
saved	VBD	O
approximately	RB	O
27	CD	O
euro	JJ	O
per	IN	O
woman	NN	O
.	.	O

Response	NN	O
of	IN	O
pre-core	NN	O
mutant	NN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
to	TO	O
lamivudine	VB	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
chronic	JJ	O
liver	NN	O
disease	NN	O
associated	VBN	O
with	IN	O
the	DT	O
pre-core	JJ	O
mutant	NN	O
of	IN	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
(	(	O
HBV	NNP	O
)	)	O
infection	NN	O
is	VBZ	O
increasing	VBG	O
,	,	O
particularly	RB	O
in	IN	O
Mediterranean	NNP	O
Europe	NNP	O
and	CC	O
in	IN	O
Asia	NNP	O
.	.	O

The	DT	O
pre-core	JJ	O
mutant	NN	O
HBV	NNP	O
is	VBZ	O
unable	JJ	O
to	TO	O
produce	VB	O
hepatitis	NN	O
B	NNP	O
e	NN	O
antigen	NN	O
(	(	O
HBeAg	NNP	O
)	)	O
,	,	O
so	RB	O
that	IN	O
patients	NNS	O
with	IN	O
this	DT	O
variant	NN	O
do	VBP	O
not	RB	O
present	VB	O
with	IN	O
HBV	NNP	O
characterised	VBN	O
by	IN	O
HBeAg	NNP	O
in	IN	O
the	DT	O
serum	NN	O
.	.	O

Pre-core	NN	O
mutant	JJ	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
usually	RB	O
proceeds	VBZ	O
to	TO	O
serious	JJ	O
liver	JJ	O
disease	NN	O
.	.	O

Wild-type	JJ	O
HBV	NNP	O
infection	NN	O
may	MD	O
be	VB	O
mild	JJ	O
and	CC	O
respond	NN	O
relatively	RB	O
well	RB	O
to	TO	O
interferon	VB	O
(	(	O
IFN	NNP	O
)	)	O
alpha	NN	O
therapy	NN	O
,	,	O
but	CC	O
IFN	NNP	O
alpha	NN	O
is	VBZ	O
not	RB	O
an	DT	O
effective	JJ	O
therapeutic	JJ	O
option	NN	O
in	IN	O
pre-core	NN	O
mutant	NN	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
and	CC	O
new	JJ	O
therapeutic	JJ	O
options	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

Clinical	JJ	O
data	NNS	O
show	VBP	O
that	IN	O
lamivudine	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	Condition
with	IN	Condition
pre-core	JJ	Condition
mutant	NN	Condition
hepatitis	NN	Condition
B	NNP	Condition
.	.	O

There	EX	O
is	VBZ	O
profound	JJ	O
suppression	NN	O
of	IN	O
HBV	NNP	O
replication	NN	O
and	CC	O
improvement	NN	O
in	IN	O
indicators	NNS	O
of	IN	O
liver	JJ	O
disease	NN	O
in	IN	O
most	JJS	O
patients	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
lamivudine	NN	O
is	VBZ	O
suitable	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
patients	NNS	Condition
with	IN	Condition
chronic	JJ	Condition
hepatitis	NN	Condition
B	NNP	Condition
,	,	Condition
including	VBG	Condition
those	DT	Condition
with	IN	Condition
pre-core	JJ	Condition
mutant	JJ	Condition
HBV	NNP	Condition
infection	NN	Condition
.	.	O

Weighted	VBN	O
blankets	NNS	O
and	CC	O
sleep	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
--	:	O
a	DT	O
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
weighted-blanket	JJ	O
intervention	NN	O
in	IN	O
treating	VBG	O
severe	JJ	O
sleep	NN	O
problems	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
design	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
aged	VBN	O
between	IN	O
5	CD	O
years	NNS	O
and	CC	O
16	CD	O
years	NNS	O
10	CD	O
months	NNS	O
,	,	O
with	IN	O
a	DT	O
confirmed	JJ	O
ASD	NNP	O
diagnosis	NN	O
and	CC	O
severe	JJ	O
sleep	NN	O
problems	NNS	O
,	,	O
refractory	NN	O
to	TO	O
community-based	JJ	O
interventions	NNS	O
.	.	O

The	DT	O
interventions	NNS	O
were	VBD	O
either	RB	O
a	DT	O
commercially	RB	O
available	JJ	O
weighted	JJ	O
blanket	NN	O
or	CC	O
otherwise	RB	O
identical	JJ	O
usual	JJ	O
weight	NN	O
blanket	NN	O
(	(	O
control	NN	O
)	)	O
,	,	O
introduced	VBN	O
at	IN	O
bedtime	NN	O
;	:	O
each	DT	O
was	VBD	O
used	VBN	O
for	IN	O
a	DT	O
2-week	JJ	O
period	NN	O
before	IN	O
crossover	NN	O
to	TO	O
the	DT	O
other	JJ	O
blanket	NN	O
.	.	O

Primary	JJ	O
outcome	NN	O
was	VBD	O
total	JJ	O
sleep	JJ	O
time	NN	O
(	(	O
TST	NNP	O
)	)	O
recorded	VBN	O
by	IN	O
actigraphy	NN	O
over	IN	O
each	DT	O
2-week	JJ	O
period	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
actigraphically	RB	O
recorded	VBN	O
sleep-onset	JJ	O
latency	NN	O
,	,	O
sleep	JJ	O
efficiency	NN	O
,	,	O
assessments	NNS	O
of	IN	O
child	NN	O
behavior	NN	O
,	,	O
family	NN	O
functioning	NN	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
.	.	O

Sleep	NNP	O
was	VBD	O
also	RB	O
measured	VBN	O
by	IN	O
using	VBG	O
parent-report	JJ	O
diaries	NNS	O
.	.	O

RESULTS	NNP	O
Seventy-three	JJ	O
children	NNS	O
were	VBD	O
randomized	VBN	O
and	CC	O
analysis	NN	O
conducted	VBN	O
on	IN	O
67	CD	O
children	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Using	VBG	O
objective	JJ	O
measures	NNS	O
,	,	O
the	DT	O
weighted	JJ	O
blanket	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
blanket	NN	O
,	,	O
did	VBD	O
not	RB	O
increase	VB	O
TST	NNP	O
as	IN	O
measured	VBN	O
by	IN	O
actigraphy	NN	O
and	CC	O
adjusted	VBN	O
for	IN	O
baseline	NN	O
TST	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
group	NN	O
differences	NNS	O
in	IN	O
any	DT	O
other	JJ	O
objective	NN	O
or	CC	O
subjective	JJ	O
measure	NN	O
of	IN	O
sleep	NN	O
,	,	O
including	VBG	O
behavioral	JJ	O
outcomes	NNS	O
.	.	O

On	IN	O
subjective	JJ	O
preference	NN	O
measures	NNS	O
,	,	O
parents	NNS	O
and	CC	O
children	NNS	O
favored	VBD	O
the	DT	O
weighted	JJ	O
blanket	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
use	NN	O
of	IN	O
a	DT	O
weighted	JJ	O
blanket	NN	O
did	VBD	O
not	RB	O
help	VB	O
children	NNS	O
with	IN	O
ASD	NNP	O
sleep	NN	O
for	IN	O
a	DT	O
longer	JJR	O
period	NN	O
of	IN	O
time	NN	O
,	,	O
fall	VB	O
asleep	RB	O
significantly	RB	O
faster	RBR	O
,	,	O
or	CC	O
wake	VB	O
less	JJR	O
often	RB	O
.	.	O

However	RB	O
,	,	O
the	DT	O
weighted	JJ	O
blanket	NN	O
was	VBD	O
favored	VBN	O
by	IN	O
children	NNS	O
and	CC	O
parents	NNS	O
,	,	O
and	CC	O
blankets	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
over	IN	O
this	DT	O
period	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
calcium	NN	O
supplementation	NN	O
on	IN	O
bone	NN	O
density	NN	O
in	IN	O
premenarcheal	JJ	O
females	NNS	O
:	:	O
a	DT	O
co-twin	JJ	O
approach	NN	O
.	.	O

The	DT	O
age	NN	O
and	CC	O
developmental	JJ	O
stage	NN	O
at	IN	O
which	WDT	O
calcium	NN	O
supplementation	NN	O
produces	VBZ	O
the	DT	O
greatest	JJS	O
bone	NN	O
effects	NNS	O
remain	VBP	O
controversial	JJ	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
calcium	NN	O
supplementation	NN	O
may	MD	O
improve	VB	O
bone	NN	O
accrual	JJ	O
in	IN	O
premenarcheal	JJ	O
females	NNS	O
.	.	O

Fifty-one	CD	O
pairs	NNS	O
of	IN	O
premenarcheal	JJ	O
female	NN	O
twins	NNS	O
(	(	O
27	CD	O
monozygotic	NN	O
and	CC	O
24	CD	O
dizygotic	JJ	O
;	:	O
mean	JJ	O
+/-	JJ	O
sd	NN	O
age	NN	O
,	,	O
10.3	CD	O
+/-	JJ	O
1.5	CD	O
yr	NN	O
)	)	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
with	IN	O
one	CD	O
twin	NN	O
of	IN	O
each	DT	O
pair	NN	O
receiving	VBG	O
a	DT	O
1200-mg	JJ	O
calcium	NN	O
carbonate	NN	O
(	(	O
Caltrate	NNP	O
)	)	O
supplement	NN	O
.	.	O

Areal	NNP	O
bone	JJ	O
mineral	NN	O
density	NN	O
(	(	O
aBMD	NN	O
)	)	O
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
,	,	O
12	CD	O
,	,	O
18	CD	O
and	CC	O
24	CD	O
months	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
within-pair	JJ	O
differences	NNS	O
in	IN	O
height	NN	O
,	,	O
weight	NN	O
,	,	O
or	CC	O
calcium	NN	O
intake	NN	O
at	IN	O
baseline	NN	O
.	.	O

Calcium	NNP	O
supplementation	NN	O
was	VBD	O
associated	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
increased	VBN	O
aBMD	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
adjusted	VBN	O
for	IN	O
age	NN	O
,	,	O
height	NN	O
,	,	O
and	CC	O
weight	NN	O
at	IN	O
the	DT	O
following	JJ	O
time	NN	O
points	NNS	O
from	IN	O
baseline	NN	O
:	:	O
total	JJ	O
hip	NN	O
,	,	O
6	CD	O
months	NNS	O
(	(	O
1.9	CD	O
%	NN	O
)	)	O
,	,	O
12	CD	O
months	NNS	O
(	(	O
1.6	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
(	(	O
2.4	CD	O
%	NN	O
)	)	O
;	:	O
lumbar	CC	O
spine	NN	O
,	,	O
12	CD	O
months	NNS	O
(	(	O
1.0	CD	O
%	NN	O
)	)	O
;	:	O
femoral	JJ	O
neck	NN	O
,	,	O
6	CD	O
months	NNS	O
(	(	O
1.9	CD	O
%	NN	O
)	)	O
.	.	O

Adjusted	VBN	O
total	JJ	O
body	NN	O
bone	JJ	O
mineral	JJ	O
content	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
calcium	NN	O
group	NN	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
2.0	CD	O
%	NN	O
)	)	O
,	,	O
12	CD	O
months	NNS	O
(	(	O
2.5	CD	O
%	NN	O
)	)	O
,	,	O
18	CD	O
months	NNS	O
(	(	O
4.6	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
24	CD	O
months	NNS	O
(	(	O
3.7	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Calcium	NNP	O
supplementation	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
increasing	VBG	O
aBMD	NN	O
at	IN	O
regional	JJ	O
sites	NNS	O
over	IN	O
the	DT	O
first	JJ	O
12-18	JJ	O
months	NNS	O
,	,	O
but	CC	O
these	DT	O
gains	NNS	O
were	VBD	O
not	RB	O
maintained	VBN	O
to	TO	O
24	CD	O
months	NNS	O
.	.	O

[	JJ	O
Antazoline/tetryzoline	NNP	O
eyedrops	NNS	O
in	IN	O
comparison	NN	O
with	IN	O
levocabastine	JJ	O
eyedrops	NNS	O
in	IN	O
acute	JJ	O
allergic	JJ	Condition
conjunctivitis	NN	Condition
]	NNP	O
.	.	O

BACKGROUND	NNP	O
Allergic	NNP	Condition
conjunctivitis	NN	Condition
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
frequent	JJ	O
allergic	JJ	O
diseases	NNS	O
of	IN	O
the	DT	O
anterior	JJ	O
eye	NN	O
segment	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
multicentre	NN	O
,	,	O
clinical	JJ	O
trial	NN	O
was	VBD	O
an	DT	O
investigation	NN	O
to	TO	O
compare	VB	O
the	DT	O
antiallergic	JJ	O
efficacy	NN	O
,	,	O
local	JJ	O
tolerance	NN	O
and	CC	O
safety	NN	O
of	IN	O
Antazolin/Tetryzolin	NNP	O
eye	NN	O
drops	NNS	O
and	CC	O
Levocabastine	NNP	O
eye	NN	O
drops	NNS	O
.	.	O

69	CD	SampleSize
patients	NNS	O
were	VBD	O
treated	VBN	O
over	IN	O
a	DT	O
2	CD	O
weeks	NNS	O
course	NN	O
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
subjective	JJ	O
and	CC	O
objective	JJ	O
ocular	NN	O
symptoms	NNS	O
were	VBD	O
documented	VBN	O
over	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
eye	NN	O
drops	NNS	O
reduced	VBD	O
subjective	JJ	O
and	CC	O
objective	JJ	O
ocular	NN	O
symptoms	NNS	O
effective	JJ	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
the	DT	O
treatments	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.0395	CD	O
)	)	O
was	VBD	O
the	DT	O
faster	JJ	O
onset	NN	O
of	IN	O
action	NN	O
of	IN	O
Antazolin/Tetryzolin	NNP	O
30	CD	O
minutes	NNS	O
after	IN	O
administration	NN	O
of	IN	O
the	DT	O
first	JJ	O
drop	NN	O
of	IN	O
trial	NN	O
medication	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
fast	JJ	O
and	CC	O
effective	JJ	O
onset	NN	O
of	IN	O
action	NN	O
is	VBZ	O
of	IN	O
high	JJ	O
clinical	JJ	O
relevance	NN	O
.	.	O

Therefore	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
using	VBG	O
Antazolin/Tetryzolin	NNP	O
eye	NN	O
drops	NN	O
was	VBD	O
clearly	RB	O
outweigh	JJ	O
.	.	O

Growth	NNP	O
hormone	NN	O
(	(	O
GH	NNP	O
)	)	O
responses	VBZ	O
to	TO	O
GH-releasing	NNP	O
hormone	NN	O
alone	RB	O
or	CC	O
combined	VBN	O
with	IN	O
arginine	NN	O
in	IN	O
patients	NNS	O
with	IN	O
adrenal	JJ	Condition
incidentaloma	NN	Condition
:	:	O
evidence	NN	O
for	IN	O
enhanced	JJ	O
somatostatinergic	JJ	O
tone	NN	O
.	.	O

Spontaneous	JJ	O
and	CC	O
stimulated	VBD	O
GH	NNP	O
secretion	NN	O
is	VBZ	O
blunted	VBN	O
in	IN	O
hypercortisolemic	JJ	O
states	NNS	O
due	JJ	O
to	TO	O
increased	VBN	O
hypothalamic	JJ	O
somatostatinergic	NN	O
tone	NN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
data	NNS	O
are	VBP	O
available	JJ	O
on	IN	O
the	DT	O
characteristics	NNS	O
of	IN	O
GH	NNP	O
secretion	NN	O
in	IN	O
patients	NNS	O
with	IN	O
incidentally	RB	O
discovered	VBN	O
adrenal	JJ	Condition
adenomas	NN	Condition
.	.	O

They	PRP	O
represent	VBP	O
an	DT	O
interesting	JJ	O
model	NN	O
for	IN	O
studying	VBG	O
GH	NNP	O
secretion	NN	O
,	,	O
as	IN	O
a	DT	O
slight	JJ	O
degree	NN	O
of	IN	O
cortisol	NN	O
excess	NN	O
may	MD	O
frequently	RB	O
be	VB	O
observed	VBN	O
in	IN	O
such	JJ	O
patients	NNS	O
who	WP	O
do	VBP	O
not	RB	O
present	VB	O
with	IN	O
any	DT	O
clear	JJ	O
Cushingoid	NNP	O
sign	NN	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
10	CD	SampleSize
patients	NNS	O
(	(	O
3	CD	SampleSize
men	NNS	Sex
and	CC	O
7	CD	SampleSize
women	NNS	Sex
,	,	O
aged	VBD	O
48-63	JJ	Age
yr	NN	Age
)	)	O
with	IN	O
an	DT	O
adrenal	JJ	O
mass	NN	O
discovered	VBD	O
serendipitously	RB	O
underwent	JJ	O
,	,	O
on	IN	O
separate	JJ	O
occasions	NNS	O
,	,	O
a	DT	O
GHRH	NNP	O
injection	NN	O
alone	RB	O
or	CC	O
combined	VBN	O
with	IN	O
an	DT	O
infusion	NN	O
of	IN	O
the	DT	O
functional	JJ	O
somatostatin	NN	O
antagonist	NN	O
,	,	O
arginine	NN	O
.	.	O

Thirteen	JJ	SampleSize
age-matched	JJ	O
healthy	JJ	Condition
volunteers	NNS	Condition
served	VBD	O
as	IN	O
controls	NNS	Condition
.	.	O

Briefly	NNP	O
,	,	O
arginine	NN	O
(	(	O
30	CD	O
g	NN	O
)	)	O
was	VBD	O
infused	VBN	O
from	IN	O
-30	NN	O
to	TO	O
0	CD	O
min	NN	O
,	,	O
and	CC	O
GHRH	NNP	O
(	(	O
100	CD	O
microg	NN	O
)	)	O
was	VBD	O
injected	VBN	O
as	IN	O
a	DT	O
bolus	NN	O
at	IN	O
0	CD	O
min	NNS	O
,	,	O
with	IN	O
measurement	NN	O
of	IN	O
serum	NN	O
GH	NNP	O
[	NNP	O
immunoradiometric	JJ	O
assay	NN	O
(	(	O
IRMA	NNP	O
)	)	O
]	VBP	O
every	DT	O
15	CD	O
min	NN	O
for	IN	O
150	CD	O
min	NN	O
.	.	O

Plasma	NNP	O
IGF-I	NNP	O
(	(	O
RIA	NNP	O
after	IN	O
acid-ethanol	JJ	O
extraction	NN	O
)	)	O
was	VBD	O
measured	VBN	O
in	IN	O
a	DT	O
morning	NN	O
sample	NN	O
.	.	O

The	DT	O
diagnosis	NN	O
of	IN	O
cortical	JJ	O
adenoma	NN	O
was	VBD	O
based	VBN	O
on	IN	O
computed	JJ	O
tomography	NN	O
features	NNS	O
and	CC	O
pattern	NN	O
of	IN	O
uptake	NN	O
on	IN	O
adrenal	JJ	O
scintigraphy	NN	O
.	.	O

Patients	NNS	O
with	IN	O
obesity	NN	Condition
and/or	NN	Condition
diabetes	NNS	Condition
were	VBD	Condition
excluded	VBN	Condition
.	.	O

The	DT	O
study	NN	O
design	NN	O
included	VBD	O
also	RB	O
an	DT	O
endocrine	JJ	O
work-up	NN	O
aimed	VBN	O
to	TO	O
study	VB	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
axis	NN	O
[	NNP	O
urinary	JJ	O
free	JJ	O
cortisol	NN	O
(	(	O
UFC	NNP	O
)	)	O
excretion	NN	O
,	,	O
serum	NN	O
cortisol	NN	O
at	IN	O
0800	CD	O
h	NN	O
,	,	O
plasma	JJ	O
ACTH	NNP	O
at	IN	O
0800	CD	O
h	NN	O
,	,	O
morning	NN	O
cortisol	NN	O
after	IN	O
overnight	JJ	O
1	CD	O
mg	NN	O
dexamethasone	NN	O
]	NN	O
.	.	O

Five	CD	O
of	IN	O
10	CD	O
patients	NNS	O
showed	VBD	O
abnormalities	NNS	O
of	IN	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
axis	NN	O
,	,	O
including	VBG	O
borderline	NN	O
or	CC	O
increased	VBN	O
UFC	JJ	O
excretion	NN	O
in	IN	O
4	CD	O
of	IN	O
them	PRP	O
accompanied	VBN	O
by	IN	O
blunted	JJ	O
ACTH	NNP	O
in	IN	O
2	CD	O
cases	NNS	O
and	CC	O
failure	NN	O
of	IN	O
cortisol	NN	O
to	TO	O
suppress	VB	O
after	IN	O
dexamethasone	NN	O
in	IN	O
1	CD	O
;	:	O
the	DT	O
fifth	JJ	O
patient	NN	O
displayed	VBD	O
low	JJ	O
ACTH	NNP	O
and	CC	O
resistance	NN	O
to	TO	O
dexamethasone	VB	O
suppression	NN	O
.	.	O

However	RB	O
,	,	O
all	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
unilateral	JJ	O
uptake	NN	O
of	IN	O
the	DT	O
tracer	NN	O
on	IN	O
the	DT	O
side	NN	O
of	IN	O
the	DT	O
mass	NN	O
with	IN	O
suppression	NN	O
of	IN	O
the	DT	O
contralateral	JJ	O
normal	JJ	O
adrenal	JJ	O
gland	NN	O
.	.	O

As	IN	O
a	DT	O
group	NN	O
,	,	O
the	DT	O
patients	NNS	O
displayed	VBD	O
greater	JJR	O
UFC	NNP	O
excretion	NN	O
and	CC	O
lower	JJR	O
ACTH	NNP	O
concentrations	NNS	O
than	IN	O
the	DT	O
controls	NNS	O
.	.	O

GH	NNP	O
release	NN	O
after	IN	O
GHRH	NNP	O
treatment	NN	O
was	VBD	O
blunted	VBN	O
in	IN	O
patients	NNS	O
bearing	VBG	O
adrenal	JJ	Condition
incidentaloma	NNS	Condition
compared	VBN	O
with	IN	O
controls	NNS	O
(	(	O
GH	NNP	O
peak	NN	O
,	,	O
5.7	CD	O
+/-	JJ	O
5.2	CD	O
vs.	FW	O
18.0	CD	O
+/-	JJ	O
7.0	CD	O
microg/L	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
whereas	JJ	O
GHRH	NNP	O
plus	CC	O
arginine	NN	O
was	VBD	O
able	JJ	O
to	TO	O
elicit	VB	O
a	DT	O
comparable	JJ	O
response	NN	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
GH	NNP	O
peak	NN	O
,	,	O
33.5	CD	O
+/-	JJ	O
20.3	CD	O
vs.	FW	O
33.7	CD	O
+/-	JJ	O
17.5	CD	O
microg/L	NN	O
;	:	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

The	DT	O
ratio	NN	O
between	IN	O
GH	NNP	O
peaks	NNS	O
after	IN	O
GHRH	NNP	O
plus	CC	O
arginine	NN	O
and	CC	O
after	IN	O
GHRH	NNP	O
plus	CC	O
saline	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
patients	NNS	O
than	IN	O
in	IN	O
controls	NNS	O
(	(	O
751	CD	O
+/-	JJ	O
531	CD	O
%	NN	O
vs.	FW	O
81	CD	O
+/-	JJ	O
45	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Similar	JJ	O
data	NNS	O
were	VBD	O
obtained	VBN	O
when	WRB	O
comparing	VBG	O
GH	NNP	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
after	IN	O
GHRH	NNP	O
plus	CC	O
saline	NN	O
or	CC	O
GHRH	NNP	O
plus	CC	O
arginine	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
the	DT	O
present	JJ	O
data	NNS	O
suggest	VBP	O
that	IN	O
in	IN	O
patients	NNS	O
with	IN	O
incidental	JJ	Condition
adrenal	JJ	Condition
adenomas	IN	Condition
the	DT	O
GH	NNP	O
response	NN	O
to	TO	O
GHRH	NNP	O
is	VBZ	O
blunted	VBN	O
due	JJ	O
to	TO	O
increased	VBN	O
somatostatinergic	NN	O
tone	NN	O
,	,	O
as	IN	O
it	PRP	O
can	MD	O
be	VB	O
restored	VBN	O
to	TO	O
normal	JJ	O
by	IN	O
pretreatment	NN	O
with	IN	O
the	DT	O
functional	JJ	O
somatostatin	NN	O
antagonist	JJ	O
arginine	NN	O
.	.	O

The	DT	O
blunted	JJ	O
GH	NNP	O
release	NN	O
to	TO	O
GHRH	NNP	O
may	MD	O
be	VB	O
an	DT	O
early	JJ	O
and	CC	O
long	JJ	O
lasting	JJ	O
sign	NN	O
of	IN	O
autonomous	JJ	O
cortisol	NNS	O
secretion	NN	O
by	IN	O
the	DT	O
adrenal	JJ	O
adenoma	NN	O
.	.	O

Early	JJ	O
treatment	NN	O
of	IN	O
cold	JJ	O
sores	NNS	O
with	IN	O
topical	JJ	O
ME-609	NNP	O
decreases	VBZ	O
the	DT	O
frequency	NN	O
of	IN	O
ulcerative	JJ	O
lesions	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
patient-initiated	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Prior	NNP	O
pilot	NN	O
studies	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
antiviral	JJ	O
medications	NNS	O
with	IN	O
topical	JJ	O
corticosteroids	NNS	O
for	IN	O
herpes	NNS	Condition
simplex	JJ	Condition
labialis	NN	Condition
(	(	O
HSL	NNP	O
)	)	O
.	.	O

ME-609	NNP	O
(	(	O
Xerese	JJ	O
,	,	O
Xerclear	NNP	O
)	)	O
is	VBZ	O
a	DT	O
combination	NN	O
of	IN	O
5	CD	O
%	NN	O
acyclovir	NN	O
and	CC	O
1	CD	O
%	NN	O
hydrocortisone	NN	O
developed	VBD	O
for	IN	O
the	DT	O
topical	JJ	O
treatment	NN	O
of	IN	O
HSL	NNP	O
.	.	O

OBJECTIVES	NNP	O
The	DT	O
primary	NN	O
study	VBD	O
end	JJ	O
point	NN	O
was	VBD	O
the	DT	O
prevention	NN	O
of	IN	O
ulcerative	JJ	O
HSL	NNP	O
lesions	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
all	DT	O
,	,	O
2437	CD	SampleSize
patients	NNS	O
with	IN	O
a	DT	O
history	NN	Condition
of	IN	Condition
HSL	NNP	Condition
were	VBD	O
randomized	VBN	O
to	TO	O
self-initiate	JJ	O
treatment	NN	O
with	IN	O
ME-609	NNP	O
,	,	O
5	CD	O
%	NN	O
acyclovir	NN	O
in	IN	O
ME-609	NNP	O
vehicle	NN	O
,	,	O
or	CC	O
ME-609	JJ	O
vehicle	NN	O
(	(	O
placebo	NN	O
)	)	O
at	IN	O
the	DT	O
earliest	JJS	O
sign	NN	O
of	IN	O
a	DT	O
cold	JJ	O
sore	NN	O
recurrence	NN	O
.	.	O

Cream	NNP	O
was	VBD	O
applied	VBN	O
5	CD	O
times/d	NN	O
for	IN	O
5	CD	O
days	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1443	CD	O
patients	NNS	O
experienced	VBD	O
a	DT	O
recurrence	NN	O
and	CC	O
initiated	JJ	O
treatment	NN	O
with	IN	O
ME-609	NNP	O
(	(	O
n	JJ	O
=	NNP	O
601	CD	O
)	)	O
,	,	O
acyclovir	FW	O
(	(	O
n	JJ	O
=	NNP	O
610	CD	O
)	)	O
,	,	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
232	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
Of	IN	O
patients	NNS	O
receiving	VBG	O
ME-609	NNP	O
,	,	O
42	CD	O
%	NN	O
did	VBD	O
not	RB	O
develop	VB	O
an	DT	O
ulcerative	JJ	O
lesion	NN	O
compared	VBN	O
with	IN	O
35	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
acyclovir	NN	O
in	IN	O
ME-609	NNP	O
vehicle	NN	O
(	(	O
P	NNP	O
=	NNP	O
.014	NNP	O
)	)	O
and	CC	O
26	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
ulcerative	JJ	O
lesions	NNS	O
,	,	O
healing	VBG	O
times	NNS	O
were	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
ME-609	NNP	O
and	CC	O
acyclovir	NN	O
groups	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
for	IN	O
both	DT	O
)	)	O
.	.	O

The	DT	O
cumulative	JJ	O
lesion	NN	O
area	NN	O
for	IN	O
all	DT	O
lesions	NNS	O
was	VBD	O
reduced	VBN	O
50	CD	O
%	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
ME-609	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
among	IN	O
groups	NNS	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
positive	JJ	O
herpes	NNS	O
simplex	JJ	O
virus	NN	O
cultures	NNS	O
.	.	O

The	DT	O
side-effect	JJ	O
profile	NN	O
was	VBD	O
similar	JJ	O
among	IN	O
treatments	NNS	O
.	.	O

LIMITATIONS	VB	O
The	DT	O
study	NN	O
did	VBD	O
not	RB	O
contain	VB	O
a	DT	O
group	NN	O
treated	VBD	O
with	IN	O
a	DT	O
topical	JJ	O
corticosteroid	NN	O
alone	RB	O
.	.	O

CONCLUSIONS	NNP	O
ME-609	NNP	O
prevented	VBD	O
progression	NN	O
of	IN	O
cold	JJ	O
sores	NNS	O
to	TO	O
ulcerative	JJ	O
lesions	NNS	O
and	CC	O
significantly	RB	O
reduced	VBD	O
the	DT	O
cumulative	JJ	O
lesion	NN	O
area	NN	O
compared	VBN	O
with	IN	O
acyclovir	NN	O
and	CC	O
placebo	NN	O
.	.	O

ME-609	NNP	O
treatment	NN	O
offers	NNS	O
additional	JJ	O
therapeutic	JJ	O
benefit	NN	O
compared	VBN	O
with	IN	O
therapy	NN	O
with	IN	O
topical	JJ	O
acyclovir	NN	O
alone	RB	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
hypoxemia	NN	Condition
on	IN	O
cardiac	JJ	O
output	NN	O
.	.	O

A	DT	O
dose-response	JJ	O
curve	NN	O
.	.	O

To	TO	O
establish	VB	O
a	DT	O
dose-response	JJ	O
curve	NN	O
for	IN	O
the	DT	O
effects	NNS	O
of	IN	O
isocapnic	JJ	O
hypoxemia	NN	O
on	IN	O
cardiac	JJ	O
output	NN	O
(	(	O
CO	NNP	O
)	)	O
,	,	O
we	PRP	O
studied	VBD	O
20	CD	SampleSize
healthy	JJ	O
men	NNS	Sex
,	,	O
aged	VBD	O
20	CD	Age
to	TO	Age
34	CD	Age
years	NNS	O
,	,	O
using	VBG	O
a	DT	O
tight-fitting	JJ	O
face	NN	O
mask	NN	O
and	CC	O
an	DT	O
isocapnic	JJ	O
partial	NN	O
rebreathing	NN	O
system	NN	O
(	(	O
a	DT	O
modified	VBN	O
anesthesia	NN	O
machine	NN	O
)	)	O
.	.	O

We	PRP	O
blended	VBD	O
oxygen	NN	O
and	CC	O
hypoxic	NN	O
gas	NN	O
to	TO	O
achieve	VB	O
arterial	JJ	O
oxygen	NN	O
saturations	NNS	O
(	(	O
SaO2	NNP	O
)	)	O
of	IN	O
80	CD	O
,	,	O
85	CD	O
,	,	O
and	CC	O
90	CD	O
percent	NN	O
;	:	O
subjects	NNS	O
also	RB	O
breathed	VBD	O
100	CD	O
percent	NN	O
oxygen	NN	O
and	CC	O
room	NN	O
air	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

Target	NNP	O
SaO2	NNP	O
and	CC	O
end-tidal	JJ	O
carbon	NN	O
dioxide	NN	O
were	VBD	O
continuously	RB	O
monitored	VBN	O
using	VBG	O
an	DT	O
ear	JJ	O
oximeter	NN	O
and	CC	O
CO2	NNP	O
gas	NN	O
analyzer	NN	O
.	.	O

Subjects	NNS	O
experienced	VBD	O
the	DT	O
five	CD	O
SaO2	NNP	O
measurements	NNS	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

CO	NNP	O
was	VBD	O
measured	VBN	O
noninvasively	RB	O
at	IN	O
approximately	RB	O
two-minute	JJ	O
intervals	NNS	O
,	,	O
using	VBG	O
continuous-wave	JJ	O
Doppler	NNP	O
echocardiography	NN	O
.	.	O

Mean	NNP	O
cardiac	JJ	O
output	NN	O
increased	VBD	O
with	IN	O
increasing	VBG	O
hypoxemia	NN	O
from	IN	O
6.84	CD	O
L/min	NNP	O
at	IN	O
FIo2	NNP	O
1.0	CD	O
to	TO	O
8.44	CD	O
L/min	NNP	O
at	IN	O
SaO2	NNP	O
80	CD	O
percent	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0005	CD	O
)	)	O
;	:	O
the	DT	O
increase	NN	O
was	VBD	O
entirely	RB	O
due	JJ	O
to	TO	O
increased	JJ	O
heart	NN	O
rate	NN	O
.	.	O

We	PRP	O
concluded	VBD	O
that	IN	O
cardiac	JJ	O
output	NN	O
increases	NNS	O
significantly	RB	O
in	IN	O
a	DT	O
dose-response	JJ	O
manner	NN	O
in	IN	O
response	NN	O
to	TO	O
acute	VB	O
isocapnic	JJ	O
hypoxemia	NN	O
in	IN	O
normal	JJ	O
persons	NNS	O
.	.	O

[	IN	O
The	DT	O
chemotherapy	NN	O
of	IN	O
advanced	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
.	.	O

A	DT	O
report	NN	O
on	IN	O
the	DT	O
first	JJ	O
600	CD	O
cases	NNS	O
in	IN	O
a	DT	O
cooperative	JJ	O
programme	NN	O
to	TO	O
carry	VB	O
out	RP	O
a	DT	O
systematic	JJ	O
study	NN	O
(	(	O
1974-1977	JJ	O
)	)	O
(	(	O
author	NN	O
's	POS	O
transl	NN	O
)	)	O
]	NN	O
.	.	O

The	DT	O
authors	NNS	O
explain	VBP	O
the	DT	O
objectives	NNS	O
and	CC	O
the	DT	O
structure	NN	O
of	IN	O
a	DT	O
programme	NN	O
evolved	VBN	O
for	IN	O
the	DT	O
methodic	JJ	O
study	NN	O
of	IN	O
advanced	JJ	Condition
breast	NN	Condition
cancers	NNS	Condition
which	WDT	O
they	PRP	O
have	VBP	O
worked	VBN	O
out	RP	O
and	CC	O
carried	VBD	O
out	RP	O
in	IN	O
cooperation	NN	O
with	IN	O
the	DT	O
departments	NNS	O
of	IN	O
medicine	NN	O
in	IN	O
eight	CD	O
French	JJ	O
anticancer	NN	O
centres	NNS	O
.	.	O

They	PRP	O
analyse	VBP	O
the	DT	O
initial	JJ	O
phases	NNS	O
,	,	O
which	WDT	O
correspond	NN	O
to	TO	O
the	DT	O
three	CD	O
first	JJ	O
years	NNS	O
of	IN	O
work	NN	O
.	.	O

They	PRP	O
give	VBP	O
the	DT	O
state	NN	O
of	IN	O
the	DT	O
results	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
obtained	VBN	O
in	IN	O
603	CD	O
patients	NNS	O
using	VBG	O
three	CD	O
protocols	NNS	O
for	IN	O
treatment	NN	O
.	.	O

These	DT	O
consisted	VBN	O
of	IN	O
the	DT	O
administration	NN	O
in	IN	O
interrupted	JJ	O
doses	NNS	O
of	IN	O
chemotherapy	NN	O
which	WDT	O
consisted	VBD	O
of	IN	O
vincristine	NN	O
associated	VBN	O
for	IN	O
the	DT	O
one	CD	O
part	NN	O
with	IN	O
cyclophosphamide	NN	O
and	CC	O
5-fluoro-uracil	JJ	O
and	CC	O
on	IN	O
the	DT	O
other	JJ	O
hand	NN	O
with	IN	O
doxorubicine	NN	O
or/and	NN	O
with	IN	O
methotrexate	NN	O
.	.	O

From	IN	O
this	DT	O
study	NN	O
there	RB	O
emerged	VBD	O
the	DT	O
value	NN	O
of	IN	O
combined	JJ	O
therapy	NN	O
using	VBG	O
doxorubicine	NN	O
as	IN	O
much	JJ	O
because	IN	O
of	IN	O
the	DT	O
frequency	NN	O
with	IN	O
which	WDT	O
results	NNS	O
better	JJR	O
than	IN	O
50	CD	O
%	NN	O
were	VBD	O
obtained	VBN	O
(	(	O
in	IN	O
a	DT	O
randomised	JJ	O
trial	NN	O
)	)	O
as	IN	O
by	IN	O
their	PRP$	O
quality	NN	O
,	,	O
which	WDT	O
was	VBD	O
made	VBN	O
clear	JJ	O
in	IN	O
an	DT	O
important	JJ	O
series	NN	O
of	IN	O
240	CD	O
cases	NNS	O
.	.	O

They	PRP	O
point	VBP	O
out	RP	O
the	DT	O
conditions	NNS	O
required	VBN	O
to	TO	O
initiate	VB	O
the	DT	O
place	NN	O
of	IN	O
such	PDT	O
a	DT	O
scheme	NN	O
in	IN	O
all	DT	O
complex	JJ	O
therapy	NN	O
which	WDT	O
aims	VBZ	O
as	RB	O
much	JJ	O
at	IN	O
palliation	NN	O
as	IN	O
at	IN	O
cure	NN	O
,	,	O
and	CC	O
point	VB	O
out	RP	O
how	WRB	O
important	JJ	O
it	PRP	O
is	VBZ	O
to	TO	O
be	VB	O
methodical	JJ	O
in	IN	O
the	DT	O
application	NN	O
of	IN	O
chemotherapy	NN	O
in	IN	O
order	NN	O
to	TO	O
ensure	VB	O
its	PRP$	O
development	NN	O
as	IN	O
an	DT	O
anticancer	NN	O
therapy	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
regimens	NNS	O
of	IN	O
amphotericin	NN	O
B	NNP	O
deoxycholate	NN	O
in	IN	O
kala-azar	NN	Condition
.	.	O

A	DT	O
total	NN	O
of	IN	O
288	CD	SampleSize
parasitologically	RB	Condition
proved	JJ	Condition
patients	NNS	Condition
of	IN	Condition
kala-azar	NNS	Condition
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
three	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
received	VBD	O
amphotericin	JJ	O
B	NNP	O
(	(	O
AMB	NNP	O
)	)	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
mg/kg	NNS	O
body	NN	O
weight	NN	O
(	(	O
bw	NN	O
)	)	O
/day	NN	O
,	,	O
0.75	CD	O
mg/kg	NN	O
bw/day	NN	O
and	CC	O
0.5	CD	O
mg/kg	NNS	O
bw/day	NN	O
for	IN	O
20	CD	O
days	NNS	O
respectively	RB	O
.	.	O

Apparent	JJ	O
cure	NN	O
(	(	O
afebrile	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
therapy	NN	O
)	)	O
occurred	VBD	O
in	IN	O
all	DT	O
patients	NNS	O
and	CC	O
parasitological	JJ	O
cure	NN	O
in	IN	O
96	CD	O
(	(	O
100	CD	O
%	NN	O
)	)	O
,	,	O
92	CD	O
(	(	O
96	CD	O
%	NN	O
)	)	O
and	CC	O
84	CD	O
(	(	O
88	CD	O
%	NN	O
)	)	O
patients	NNS	O
respectively	RB	O
in	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C.	NNP	O
Ultimate	NNP	O
cure	NN	O
(	(	O
no	DT	O
relapse	NN	O
in	IN	O
six	CD	O
months	NNS	O
of	IN	O
follow	VBP	O
up	RP	O
)	)	O
occurred	VBD	O
in	IN	O
95	CD	O
(	(	O
99	CD	O
%	NN	O
)	)	O
,	,	O
87	CD	O
(	(	O
91	CD	O
%	NN	O
)	)	O
and	CC	O
79	CD	O
(	(	O
82	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
respectively	RB	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
the	DT	O
ultimate	JJ	O
cure	NN	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
was	VBD	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
(	(	O
rise	NN	O
in	IN	O
serum	JJ	O
creatinine	NN	O
and	CC	O
fall	NN	O
in	IN	O
serum	JJ	O
potassium	NN	O
,	,	O
loss	NN	O
of	IN	O
appetite	NN	O
and	CC	O
shivering	NN	O
,	,	O
rigor	NN	O
and	CC	O
fever	NN	O
during	IN	O
infusion	NN	O
indicative	NN	O
of	IN	O
renal	JJ	O
,	,	O
GIT	NNP	O
and	CC	O
infusion	NN	O
related	JJ	O
toxicities	NNS	O
respectively	RB	O
)	)	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
amphotericin	NN	O
B	NNP	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
1	CD	O
mg/kg	NNS	O
bw/day	NN	O
for	IN	O
20	CD	O
days	NNS	O
for	IN	O
Indian	JJ	Condition
kala-azar	JJ	Condition
patients	NNS	Condition
to	TO	O
minimise	VB	O
relapses	NNS	O
and	CC	O
prevent	NN	O
development	NN	O
of	IN	O
drug	NN	O
unresponsiveness	NN	O
.	.	O

Sun	NNP	O
protection	NN	O
counseling	VBG	O
for	IN	O
children	NNS	O
:	:	O
primary	NN	O
care	NN	O
practice	NN	O
patterns	NNS	O
and	CC	O
effect	NN	O
of	IN	O
an	DT	O
intervention	NN	O
on	IN	O
clinicians	NNS	Condition
.	.	O

OBJECTIVES	NNP	O
To	TO	O
describe	VB	O
current	JJ	O
primary	JJ	O
care	NN	O
sun	NN	O
protection	NN	O
advice	NN	O
for	IN	O
children	NNS	O
and	CC	O
assess	VB	O
the	DT	O
effect	NN	O
on	IN	O
clinicians	NNS	O
of	IN	O
an	DT	O
intervention	NN	O
to	TO	O
enhance	VB	O
their	PRP$	O
sun	NN	O
protection	NN	O
advocacy	NN	O
.	.	O

SETTING	NN	O
Primary	NNP	O
care	NN	O
practices	NNS	O
caring	VBG	O
for	IN	O
children	NNS	O
in	IN	O
New	NNP	O
Hampshire	NNP	O
with	IN	O
special	JJ	O
attention	NN	O
to	TO	O
clinicians	NNS	O
serving	VBG	O
10	CD	O
towns	NNS	O
that	WDT	O
were	VBD	O
involved	VBN	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
the	DT	O
multicomponent	NN	O
SunSafe	NNP	O
intervention	NN	O
involving	VBG	O
schools	NNS	O
,	,	O
recreation	NN	O
areas	NNS	O
,	,	O
and	CC	O
primary	JJ	O
care	NN	O
practices	NNS	O
.	.	O

DESIGN/INTERVENTION	VB	O
A	NNP	O
statewide	JJ	O
survey	NN	O
of	IN	O
all	DT	O
primary	JJ	Condition
care	NN	Condition
clinicians	NNS	Condition
serving	VBG	Condition
children	NNS	Condition
addressed	VBD	O
their	PRP$	O
self-reported	JJ	O
sun	NN	O
protection	NN	O
advocacy	NN	O
practices	NNS	O
.	.	O

Clinicians	NNPS	O
in	IN	O
10	CD	O
systematically	RB	O
selected	VBN	O
rural	JJ	O
towns	NNS	O
were	VBD	O
involved	VBN	O
in	IN	O
the	DT	O
subsequent	JJ	O
intervention	NN	O
study	NN	O
.	.	O

The	DT	O
primary	JJ	O
care	NN	O
intervention	NN	O
provided	VBD	O
assistance	NN	O
to	TO	O
practices	NNS	O
in	IN	O
establishing	VBG	O
an	DT	O
office	NN	O
system	NN	O
that	WDT	O
promoted	VBD	O
sun	JJ	O
protection	NN	O
advice	NN	O
to	TO	O
children	NNS	O
and	CC	O
their	PRP$	O
parents	NNS	O
during	IN	O
office	NN	O
visits	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Sun	NNP	O
protection	NN	O
promotion	NN	O
activities	NNS	O
of	IN	O
primary	JJ	O
care	NN	O
clinicians	NNS	O
as	IN	O
determined	VBN	O
by	IN	O
their	PRP$	O
self	JJ	O
report	NN	O
,	,	O
research	NN	O
assistant	NN	O
observation	NN	O
,	,	O
and	CC	O
parent	NN	O
interviews	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
261	CD	SampleSize
eligible	JJ	SampleSize
clinicians	NNS	SampleSize
responding	VBG	O
to	TO	O
the	DT	O
statewide	NN	O
survey	NN	O
,	,	O
about	IN	O
half	PDT	O
provide	JJ	O
sun	NN	O
protection	NN	O
counseling	VBG	O
most	JJS	O
of	IN	O
the	DT	O
time	NN	O
or	CC	O
almost	RB	O
always	RB	O
during	IN	O
summer	NN	O
well	RB	O
care	VB	O
visits	NNS	O
.	.	O

Pediatricians	NNPS	O
do	VBP	O
so	RB	O
more	RBR	O
often	RB	O
than	IN	O
family	NN	O
physicians	NNS	O
.	.	O

Clinicians	NNPS	O
involved	VBN	O
in	IN	O
the	DT	O
intervention	NN	O
increased	VBD	O
their	PRP$	O
use	NN	O
of	IN	O
handouts	NNS	O
,	,	O
waiting	VBG	O
room	NN	O
educational	JJ	O
materials	NNS	O
,	,	O
and	CC	O
sunscreen	JJ	O
samples	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
control	NN	O
town	NN	O
parents	NNS	O
,	,	O
parents	NNS	O
in	IN	O
intervention	NN	O
towns	NNS	O
reported	VBD	O
an	DT	O
increase	NN	O
in	IN	O
clinician	JJ	O
sun	NN	O
protection	NN	O
advice	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
SunSafe	NNP	O
primary	JJ	O
care	NN	O
intervention	NN	O
increased	VBD	O
sun	JJ	O
protection	NN	O
counseling	VBG	O
activities	NNS	O
of	IN	O
participating	VBG	O
clinicians	NNS	O
.	.	O

A	DT	O
single-focus	JJ	O
preventive	JJ	O
service	NN	O
office	NN	O
system	NN	O
is	VBZ	O
feasible	JJ	O
to	TO	O
include	VB	O
in	IN	O
community	NN	O
interventions	NNS	O
to	TO	O
promote	VB	O
sun	NN	O
protection	NN	O
.	.	O

Prospective	JJ	O
randomised	VBD	O
multicentre	JJ	O
trial	NN	O
with	IN	O
the	DT	O
birth	NN	O
trainer	NN	O
EPI-NO	NNP	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
perineal	JJ	Condition
trauma	NN	Condition
.	.	Condition

BACKGROUND	NNP	O
In	IN	O
several	JJ	O
non-randomised	JJ	O
trials	NNS	O
training	VBG	O
with	IN	O
EPI-NO	NNP	O
increased	VBD	O
the	DT	O
rate	NN	O
of	IN	O
intact	JJ	O
perineum	NN	O
and	CC	O
decreased	JJ	O
episiotomy	NN	O
rates	NNS	O
,	,	O
shortened	VBD	O
the	DT	O
second	JJ	O
stage	NN	O
of	IN	O
labour	NN	O
and	CC	O
lowered	VBN	O
use	NN	O
of	IN	O
pain	NN	O
killers	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
verify	VB	O
the	DT	O
preliminary	JJ	O
results	NNS	O
with	IN	O
EPI-NO	NNP	O
in	IN	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
trial	NN	O
.	.	O

METHODS	NNP	O
Randomised	VBD	O
,	,	O
single-blind	JJ	Condition
multicentre	NN	O
trial	NN	O
in	IN	O
four	CD	O
university	NN	O
hospitals	NNS	O
in	IN	O
Germany	NNP	O
including	VBG	O
276	CD	SampleSize
primigravidae	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
training	VBG	O
with	IN	O
EPI-NO	NNP	O
we	PRP	O
observed	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
intact	JJ	O
perineum	NN	O
(	(	O
37.4	CD	O
%	NN	O
vs	JJ	O
25.7	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
and	CC	O
a	DT	O
tendency	NN	O
towards	NNS	O
lower	JJR	O
episiotomy	NN	O
rates	NNS	O
(	(	O
41.9	CD	O
%	NN	O
vs	JJ	O
50.5	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.11	CD	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
regarding	VBG	O
incidence	NN	O
of	IN	O
perineal	NN	O
tears	NNS	O
,	,	O
duration	NN	O
of	IN	O
second	JJ	O
stage	NN	O
of	IN	O
labour	NN	O
,	,	O
use	NN	O
of	IN	O
pain	NN	O
relief	NN	O
and	CC	O
rate	NN	O
of	IN	O
vaginal	JJ	O
infection	NN	O
.	.	O

CONCLUSIONS	NNP	O
Training	VBG	O
with	IN	O
EPI-NO	NNP	O
increases	NNS	O
significantly	RB	O
the	DT	O
likelihood	NN	O
of	IN	O
having	VBG	O
an	DT	O
intact	JJ	O
perineum	NN	O
and	CC	O
reduces	VBZ	O
the	DT	O
episiotomy	NN	O
rate	NN	O
.	.	O

Comparative	NNP	O
study	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
eprinomectin	JJ	O
versus	NN	O
ivermectin	NN	O
,	,	O
and	CC	O
field	NN	O
efficacy	NN	O
of	IN	O
eprinomectin	NN	O
only	RB	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chorioptic	JJ	Condition
mange	NN	Condition
in	IN	O
alpacas	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
eprinomectin	JJ	O
versus	NN	O
ivermectin	NN	O
(	(	O
Study	NNP	O
1	CD	O
:	:	O
a	DT	O
single-centre	JJ	O
,	,	O
randomised	JJ	O
,	,	O
treatment-controlled	JJ	O
,	,	O
blinded	VBD	O
field	NN	O
trial	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
field	NN	O
efficacy	NN	O
of	IN	O
eprinomectin	NN	O
(	(	O
Study	NNP	O
2	CD	O
:	:	O
a	DT	O
single-centre	JJ	O
,	,	O
open	JJ	O
,	,	O
un-controlled	JJ	O
field	NN	O
trial	NN	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chorioptic	JJ	O
infestation	NN	O
in	IN	O
naturally	RB	O
infested	VBN	O
alpacas	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
two	CD	O
studies	NNS	O
.	.	O

Thirty	NNP	SampleSize
alpacas	NN	O
,	,	O
all	DT	O
positive	JJ	O
for	IN	O
Chorioptes	NNP	O
sp	NN	O
.	.	O

mite	NN	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
two	CD	O
treatment	NN	O
groups	NNS	O
in	IN	O
Study	NNP	O
1	CD	O
.	.	O

Group	NNP	O
A	NNP	O
received	VBD	O
a	DT	O
single	JJ	O
topical	JJ	O
administration	NN	O
of	IN	O
a	DT	O
0.5	CD	O
%	NN	O
formulation	NN	O
of	IN	O
eprinomectin	NN	O
at	IN	O
the	DT	O
dose	JJ	O
rate	NN	O
of	IN	O
500mug/kg	CD	O
.	.	O

Group	NNP	O
B	NNP	O
received	VBD	O
three	CD	O
subcutaneous	JJ	O
administrations	NNS	O
at	IN	O
14	CD	O
days	NNS	O
interval	NN	O
of	IN	O
a	DT	O
1	CD	O
%	NN	O
formulation	NN	O
of	IN	O
ivermectin	NN	O
at	IN	O
the	DT	O
dose	JJ	O
rate	NN	O
of	IN	O
400mug/kg	CD	O
.	.	O

Response	NN	O
to	TO	O
treatment	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
periodic	JJ	O
mite	NN	O
count	NN	O
,	,	O
and	CC	O
skin	JJ	O
lesions	NNS	O
scored	VBN	O
.	.	O

In	IN	O
Study	NNP	O
2	CD	O
,	,	O
one	CD	O
group	NN	O
of	IN	O
19	CD	SampleSize
alpacas	NNS	O
received	VBD	O
four	CD	O
administrations	NNS	O
at	IN	O
weekly	JJ	O
interval	NN	O
of	IN	O
topical	JJ	O
eprinomectin	NN	O
at	IN	O
the	DT	O
dose	JJ	O
rate	NN	O
of	IN	O
500mug/kg	CD	O
,	,	O
and	CC	O
response	NN	O
to	TO	O
treatment	NN	O
was	VBD	O
monitored	VBN	O
by	IN	O
mite	JJ	O
counts	NNS	O
.	.	O

No	DT	O
localised	VBD	O
or	CC	O
systemic	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
either	DT	O
trial	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
decrease	NN	O
in	IN	O
mite	JJ	O
counts	NNS	O
on	IN	O
day	NN	O
7	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
within	IN	O
treatment	NN	O
Groups	NNP	O
A	NNP	O
and	CC	O
B	NNP	O
of	IN	O
Study	NNP	O
1	CD	O
,	,	O
but	CC	O
mite	JJ	O
counts	NNS	O
increased	VBD	O
again	RB	O
on	IN	O
day	NN	O
14	CD	O
and	CC	O
remained	VBD	O
high	JJ	O
for	IN	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
trial	NN	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

On	IN	O
day	NN	O
14	CD	O
of	IN	O
Study	NNP	O
2	CD	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
mite	JJ	O
counts	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.008	CD	O
)	)	O
and	CC	O
the	DT	O
mite	JJ	O
counts	NNS	O
remained	VBD	O
very	RB	O
low	JJ	O
throughout	IN	O
the	DT	O
remainder	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
eprinomectin	NN	O
protocol	NN	O
employed	VBN	O
in	IN	O
Study	NNP	O
2	CD	O
,	,	O
consisting	VBG	O
of	IN	O
four	CD	O
weekly	JJ	O
topical	JJ	O
administrations	NNS	O
at	IN	O
the	DT	O
dose	JJ	O
rate	NN	O
of	IN	O
500mug/kg	CD	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
proved	VBD	O
highly	RB	O
effective	JJ	O
at	IN	O
reducing	VBG	O
the	DT	O
Chorioptes	NNPS	Condition
mite	JJ	Condition
burden	NN	Condition
in	IN	O
alpacas	NN	O
.	.	O

Teaching	VBG	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
young	JJ	Condition
children	NNS	Age
with	IN	Condition
autism	NN	Condition
:	:	Condition
a	DT	O
randomised	JJ	O
controlled	JJ	O
trial	NN	O
of	IN	O
an	DT	O
emotion	NN	O
training	NN	O
programme	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
have	VBP	O
difficulties	NNS	O
in	IN	O
emotion	NN	O
recognition	NN	O
and	CC	O
a	DT	O
number	NN	O
of	IN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
designed	VBN	O
to	TO	O
target	VB	O
these	DT	O
problems	NNS	O
.	.	O

However	RB	O
,	,	O
few	JJ	O
emotion	NN	O
training	NN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
trialled	VBN	O
with	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
co-morbid	JJ	O
ID	NNP	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
emotion	NN	O
training	NN	O
programme	NN	O
for	IN	O
a	DT	O
group	NN	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
range	NN	O
of	IN	O
intellectual	JJ	O
ability	NN	O
.	.	O

METHODS	NNP	O
Participants	NNPS	O
were	VBD	O
55	CD	SampleSize
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBN	O
4-7	CD	O
years	NNS	O
(	(	O
FSIQ	NNP	O
42-107	CD	O
)	)	O
.	.	O

Children	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
or	CC	O
control	VB	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
watched	VBD	O
a	DT	O
DVD	NNP	O
designed	VBN	O
to	TO	O
teach	VB	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
(	(	O
the	DT	O
Transporters	NNPS	O
)	)	O
,	,	O
whereas	IN	O
the	DT	O
control	NN	O
group	NN	O
watched	VBD	O
a	DT	O
DVD	NNP	O
of	IN	O
Thomas	NNP	O
the	DT	O
Tank	NNP	O
Engine	NNP	O
.	.	O

Participants	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
complete	VB	O
basic	JJ	O
emotion	NN	O
recognition	NN	O
tasks	NNS	O
,	,	O
mindreading	VBG	O
and	CC	O
theory	NN	O
of	IN	O
mind	NN	O
(	(	O
TOM	NNP	O
)	)	O
tasks	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
4-week	JJ	O
intervention	NN	O
period	NN	O
,	,	O
and	CC	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
Analyses	NNP	O
controlled	VBD	O
for	IN	O
the	DT	O
effect	NN	O
of	IN	O
chronological	JJ	O
age	NN	O
,	,	O
verbal	JJ	O
intelligence	NN	O
,	,	O
gender	NN	O
and	CC	O
DVD	NNP	O
viewing	VBG	O
time	NN	O
on	IN	O
outcomes	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
improved	JJ	O
performance	NN	O
in	IN	O
the	DT	O
recognition	NN	O
of	IN	O
anger	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
with	IN	O
few	JJ	O
improvements	NNS	O
maintained	VBD	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
generalisation	NN	O
of	IN	O
skills	NNS	O
to	TO	O
TOM	NNP	O
or	CC	O
social	JJ	O
skills	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
Transporters	NNP	O
programme	NN	O
showed	VBD	O
limited	JJ	O
efficacy	NN	O
in	IN	O
teaching	VBG	O
basic	JJ	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
lower	JJR	O
range	NN	O
of	IN	O
cognitive	JJ	O
ability	NN	O
.	.	O

Improvements	NNS	O
were	VBD	O
limited	VBN	O
to	TO	O
the	DT	O
recognition	NN	O
of	IN	O
expressions	NNS	O
of	IN	O
anger	NN	O
,	,	O
with	IN	O
poor	JJ	O
maintenance	NN	O
of	IN	O
these	DT	O
skills	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

These	DT	O
findings	NNS	O
provide	VBP	O
limited	JJ	O
support	NN	O
for	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
Transporters	NNP	O
programme	NN	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
of	IN	O
a	DT	O
lower	JJR	O
cognitive	JJ	O
range	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
postural	JJ	O
stability	NN	O
by	IN	O
computerised	JJ	O
posturography	NN	O
following	VBG	O
outpatient	JJ	O
paediatric	JJ	O
anaesthesia	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
propofol/alfentanil/N2O	NN	O
anaesthesia	NN	O
with	IN	O
thiopentone/halothane/N2O	JJ	O
anaesthesia	NN	O
.	.	O

Simple	JJ	O
clinical	JJ	O
tests	NNS	O
,	,	O
like	IN	O
Romberg	NNP	O
's	POS	O
test	NN	O
or	CC	O
a	DT	O
walking	JJ	O
test	NN	O
,	,	O
have	VBP	O
proved	VBN	O
to	TO	O
be	VB	O
inadequate	JJ	O
guidelines	NNS	O
for	IN	O
safe	JJ	O
discharge	NN	O
after	IN	O
outpatient	JJ	O
anaesthesia	NN	O
.	.	O

A	DT	O
randomised	JJ	O
study	NN	O
was	VBD	O
therefore	RB	O
planned	VBN	O
to	TO	O
compare	VB	O
postural	JJ	O
stability	NN	O
measured	VBN	O
by	IN	O
computerised	JJ	O
posturography	NN	O
in	IN	O
31	CD	Age
oral	JJ	Age
midazolam-atropine	NN	Age
premedicated	VBD	Age
children	NNS	Age
aged	VBN	Age
6.9	CD	Age
(	(	Age
s.e	NN	Age
.	.	Age

0.4	CD	O
)	)	O
years	NNS	O
who	WP	O
had	VBD	O
been	VBN	O
anaesthetised	VBN	Condition
with	IN	Condition
either	DT	Condition
propofol/alfentanil/N2O	NN	Condition
or	CC	Condition
thiopentone/halothane/N2O	NN	Condition
.	.	O

The	DT	O
sway	JJ	O
velocity	NN	O
of	IN	O
the	DT	O
children	NNS	O
was	VBD	O
measured	VBN	O
before	IN	O
premedication	NN	O
and	CC	O
1	CD	O
,	,	O
2	CD	O
and	CC	O
3	CD	O
h	NN	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
anaesthesia	NN	O
.	.	O

Results	NNP	O
show	VBP	O
that	IN	O
sway	JJ	O
velocity	NN	O
had	VBD	O
returned	VBN	O
to	TO	O
baseline	VB	O
values	NNS	O
3	CD	O
h	NN	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
anaesthesia	NN	O
in	IN	O
all	DT	O
children	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
propofol/alfentanil/N2O	NNS	O
and	CC	O
in	IN	O
12	CD	O
of	IN	O
the	DT	O
15	CD	O
children	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
thiopentone/halothane/N2O	RB	O
.	.	O

The	DT	O
quantified	JJ	O
version	NN	O
of	IN	O
the	DT	O
Romberg	NNP	O
test	NN	O
performed	VBD	O
with	IN	O
eyes	NNS	O
open	VBP	O
or	CC	O
closed	VBD	O
was	VBD	O
not	RB	O
impaired	VBN	O
after	IN	O
anaesthesia	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
values	VBZ	O
,	,	O
indicating	VBG	O
that	IN	O
in	IN	O
children	NNS	O
poor	JJ	O
equilibrium	NN	O
is	VBZ	O
not	RB	O
compensated	VBN	O
by	IN	O
vision	NN	O
.	.	O

The	DT	O
clinical	JJ	O
recovery	NN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
times	NNS	O
to	TO	O
eye	NN	O
opening	NN	O
,	,	O
to	TO	O
responding	VBG	O
to	TO	O
command	VB	O
or	CC	O
to	TO	O
being	VBG	O
fully	RB	O
awake	VB	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
two	CD	O
anaesthesia	NN	O
methods	NNS	O
.	.	O

On	IN	O
the	DT	O
basis	NN	O
of	IN	O
recovery	NN	O
assessed	VBN	O
by	IN	O
postural	JJ	O
stability	NN	O
,	,	O
propofol/alfentanil/N2O	NN	O
anaesthesia	NN	O
was	VBD	O
not	RB	O
preferable	JJ	O
to	TO	O
thiopentone/halothane/N2O	VB	O
anaesthesia	NN	O
after	IN	O
minor	JJ	O
paediatric	JJ	O
otolaryngological	JJ	O
surgery	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
enflurane	NN	O
and	CC	O
halothane	NN	O
in	IN	O
hypotensive	JJ	Condition
eye	NN	Condition
surgery	NN	Condition
.	.	O

Thirty	NN	SampleSize
patients	NNS	O
undergoing	VBG	O
elective	JJ	Condition
eye	NN	Condition
surgery	NN	Condition
had	VBD	O
anaesthesia	NNS	O
induced	VBN	O
with	IN	O
sodium	NN	O
thiopentone	NN	O
,	,	O
suxamethonium	NN	O
and	CC	O
d-tubocurarine	JJ	O
chloride	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
ventilated	VBN	O
with	IN	O
nitrous	JJ	O
oxide	NN	O
,	,	O
oxygen	NN	O
and	CC	O
either	DT	O
halothane	NN	O
or	CC	O
enflurane	NN	O
.	.	O

The	DT	O
volatile	JJ	O
agents	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
decrease	VB	O
the	DT	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
to	TO	O
80	CD	O
mmHg	NN	O
.	.	O

The	DT	O
volatile	JJ	O
agent	NN	O
concentration	NN	O
in	IN	O
the	DT	O
blood	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
30	CD	O
min	NN	O
intervals	NNS	O
.	.	O

Both	DT	O
agents	NNS	O
were	VBD	O
effective	JJ	O
in	IN	O
producing	VBG	O
hypotension	NN	O
,	,	O
but	CC	O
enflurane	NN	O
was	VBD	O
the	DT	O
more	RBR	O
potent	JJ	O
hypotensive	JJ	O
agent	NN	O
in	IN	O
terms	NNS	O
of	IN	O
MAC	NNP	O
equivalents	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
agents	NNS	O
with	IN	O
respect	NN	O
to	TO	O
speed	NN	O
of	IN	O
recovery	NN	O
.	.	O

Remote	NNP	O
ischaemic	JJ	O
conditioning	NN	O
before	IN	O
hospital	JJ	O
admission	NN	O
,	,	O
as	IN	O
a	DT	O
complement	NN	O
to	TO	O
angioplasty	VB	O
,	,	O
and	CC	O
effect	NN	O
on	IN	O
myocardial	JJ	O
salvage	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	Condition
myocardial	JJ	Condition
infarction	NN	Condition
:	:	O
a	DT	O
randomised	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Remote	NNP	O
ischaemic	JJ	O
preconditioning	NN	O
attenuates	NNS	O
cardiac	JJ	O
injury	NN	O
at	IN	O
elective	JJ	O
surgery	NN	O
and	CC	O
angioplasty	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
remote	VBP	O
ischaemic	JJ	O
conditioning	NN	O
during	IN	O
evolving	VBG	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
done	VBN	O
before	IN	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
,	,	O
increases	VBZ	O
myocardial	JJ	O
salvage	NN	O
.	.	O

METHODS	NNP	O
333	CD	SampleSize
consecutive	JJ	O
adult	NN	O
patients	NNS	O
with	IN	O
a	DT	O
suspected	VBN	O
first	JJ	O
acute	JJ	Condition
myocardial	JJ	Condition
infarction	NN	Condition
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
1:1	CD	O
ratio	NN	O
by	IN	O
computerised	JJ	O
block	NN	O
randomisation	NN	O
to	TO	O
receive	VB	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
with	IN	O
(	(	O
n=166	JJ	O
patients	NNS	O
)	)	O
versus	NN	O
without	IN	O
(	(	O
n=167	NN	O
)	)	O
remote	VBP	O
conditioning	VBG	O
(	(	O
intermittent	JJ	O
arm	NN	O
ischaemia	NN	O
through	IN	O
four	CD	O
cycles	NNS	O
of	IN	O
5-min	JJ	O
inflation	NN	O
and	CC	O
5-min	JJ	O
deflation	NN	O
of	IN	O
a	DT	O
blood-pressure	JJ	O
cuff	NN	O
)	)	O
.	.	O

Allocation	NN	O
was	VBD	O
concealed	VBN	O
with	IN	O
opaque	NN	O
sealed	VBN	O
envelopes	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
remote	JJ	O
conditioning	NN	O
during	IN	O
transport	NN	O
to	TO	O
hospital	NN	O
,	,	O
and	CC	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
in	IN	O
hospital	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
myocardial	JJ	O
salvage	NN	O
index	NN	O
at	IN	O
30	CD	O
days	NNS	O
after	IN	O
primary	JJ	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
,	,	O
measured	VBN	O
by	IN	O
myocardial	JJ	O
perfusion	NN	O
imaging	NN	O
as	IN	O
the	DT	O
proportion	NN	O
of	IN	O
the	DT	O
area	NN	O
at	IN	O
risk	NN	O
salvaged	VBN	O
by	IN	O
treatment	NN	O
;	:	O
analysis	NN	O
was	VBD	O
per	IN	O
protocol	NN	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00435266	NNP	O
.	.	O

FINDINGS	NNP	O
82	CD	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
on	IN	O
arrival	NN	O
at	IN	O
hospital	NN	O
because	IN	O
they	PRP	O
did	VBD	O
not	RB	O
meet	VB	O
inclusion	NN	O
criteria	NNS	O
,	,	O
32	CD	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	NN	O
,	,	O
and	CC	O
77	CD	O
did	VBD	O
not	RB	O
complete	VB	O
the	DT	O
follow-up	JJ	O
with	IN	O
data	NNS	O
for	IN	O
salvage	NN	O
index	NN	O
.	.	O

Median	JJ	O
salvage	NN	O
index	NN	O
was	VBD	O
0.75	CD	O
(	(	O
IQR	NNP	O
0.50-0.93	CD	O
,	,	O
n=73	NN	O
)	)	O
in	IN	O
the	DT	O
remote	JJ	O
conditioning	NN	O
group	NN	O
versus	VBD	O
0.55	CD	O
(	(	O
0.35-0.88	CD	O
,	,	O
n=69	NN	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
with	IN	O
median	JJ	O
difference	NN	O
of	IN	O
0.10	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.01-0.22	CD	O
;	:	O
p=0.0333	NN	O
)	)	O
;	:	O
mean	JJ	O
salvage	NN	O
index	NN	O
was	VBD	O
0.69	CD	O
(	(	O
SD	NNP	O
0.27	CD	O
)	)	O
versus	NN	O
0.57	CD	O
(	(	O
0.26	CD	O
)	)	O
,	,	O
with	IN	O
mean	JJ	O
difference	NN	O
of	IN	O
0.12	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.01-0.21	CD	O
;	:	O
p=0.0333	NN	O
)	)	O
.	.	O

Major	JJ	O
adverse	JJ	O
coronary	JJ	O
events	NNS	O
were	VBD	O
death	NN	O
(	(	O
n=3	JJ	O
per	IN	O
group	NN	O
)	)	O
,	,	O
reinfarction	NN	O
(	(	O
n=1	JJ	O
per	IN	O
group	NN	O
)	)	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
(	(	O
n=3	JJ	O
per	IN	O
group	NN	O
)	)	O
.	.	O

INTERPRETATION	NNP	O
Remote	NNP	O
ischaemic	JJ	O
conditioning	NN	O
before	IN	O
hospital	JJ	O
admission	NN	O
increases	VBZ	O
myocardial	JJ	O
salvage	NN	O
,	,	O
and	CC	O
has	VBZ	O
a	DT	O
favourable	JJ	O
safety	NN	O
profile	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
merit	VBP	O
a	DT	O
larger	JJR	O
trial	NN	O
to	TO	O
establish	VB	O
the	DT	O
effect	NN	O
of	IN	O
remote	JJ	O
conditioning	NN	O
on	IN	O
clinical	JJ	O
outcomes	NNS	O
.	.	O

FUNDING	NN	O
Fondation	NNP	O
Leducq	NNP	O
.	.	O

End-expiratory	JJ	Condition
lung	NN	Condition
volume	NN	Condition
recovers	NNS	O
more	RBR	O
slowly	RB	O
after	IN	O
closed	JJ	O
endotracheal	NN	O
suctioning	VBG	O
than	IN	O
after	IN	O
open	JJ	O
suctioning	NN	O
:	:	O
a	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
.	.	O

PURPOSE	NNP	O
Endotracheal	NNP	O
suctioning	VBG	O
causes	NNS	O
significant	JJ	O
lung	JJ	O
derecruitment	NN	O
.	.	O

Closed	VBN	O
suction	NN	O
(	(	O
CS	NNP	O
)	)	O
minimizes	VBZ	O
lung	JJ	O
volume	NN	O
loss	NN	O
during	IN	O
suction	NN	O
,	,	O
and	CC	O
therefore	RB	O
,	,	O
volumes	NNS	O
are	VBP	O
presumed	VBN	O
to	TO	O
recover	VB	O
more	RBR	O
quickly	RB	O
postsuctioning	VBG	O
.	.	O

Conflicting	VBG	O
evidence	NN	O
exists	VBZ	O
regarding	VBG	O
this	DT	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
open	JJ	O
suction	NN	O
(	(	O
OS	NNP	O
)	)	O
and	CC	O
CS	NNP	O
on	IN	O
lung	NN	O
volume	NN	O
loss	NN	O
during	IN	O
suctioning	NN	O
,	,	O
and	CC	O
recovery	NN	O
of	IN	O
end-expiratory	JJ	O
lung	NN	O
volume	NN	O
(	(	O
EELV	NNP	O
)	)	O
up	RB	O
to	TO	O
30	CD	O
minutes	NNS	O
postsuction	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
Randomized	NNP	O
crossover	NN	O
study	NN	O
examining	VBG	O
20	CD	O
patients	NNS	O
postcardiac	JJ	O
surgery	NN	O
.	.	O

CS	NNP	O
and	CC	O
OS	NNP	O
were	VBD	O
performed	VBN	O
in	IN	O
random	JJ	O
order	NN	O
,	,	O
30	CD	O
minutes	NNS	O
apart	RB	O
.	.	O

Lung	NNP	O
impedance	NN	O
was	VBD	O
measured	VBN	O
during	IN	O
suction	NN	O
,	,	O
and	CC	O
end-expiratory	JJ	O
lung	NN	O
impedance	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
postsuctioning	VBG	O
using	VBG	O
electrical	JJ	O
impedance	NN	O
tomography	NN	O
.	.	O

Oximetry	NNP	O
,	,	O
partial	JJ	O
pressure	NN	O
of	IN	O
oxygen	NN	O
in	IN	O
the	DT	O
alveoli/fraction	NN	O
of	IN	O
inspired	JJ	O
oxygen	NN	O
ratio	NN	O
and	CC	O
compliance	NN	O
were	VBD	O
collected	VBN	O
.	.	O

RESULTS	JJ	O
Reductions	NNPS	O
in	IN	O
lung	NN	O
impedance	NN	O
during	IN	O
suctioning	VBG	O
were	VBD	O
less	JJR	O
for	IN	O
CS	NNP	O
than	IN	O
for	IN	O
OS	NNP	O
(	(	O
mean	JJ	O
difference	NN	O
,	,	O
-905	JJ	O
impedance	NN	O
units	NNS	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
-1234	NNP	O
to	TO	O
-587	VB	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
at	IN	O
all	DT	O
points	NNS	O
postsuctioning	VBG	O
,	,	O
EELV	NNP	O
recovered	VBD	O
more	RBR	O
slowly	RB	O
after	IN	O
CS	NNP	O
than	IN	O
after	IN	O
OS	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
other	JJ	O
respiratory	NN	O
parameters	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Closed	VBD	O
suctioning	VBG	O
minimized	VBN	O
lung	NN	O
volume	NN	O
loss	NN	O
during	IN	O
suctioning	VBG	O
but	CC	O
,	,	O
counterintuitively	RB	O
,	,	O
resulted	VBD	O
in	IN	O
slower	JJR	O
recovery	NN	O
of	IN	O
EELV	NNP	O
postsuction	NN	O
compared	VBN	O
with	IN	O
OS	NNP	O
.	.	O

Therefore	NNP	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
CS	NNP	O
can	MD	O
not	RB	O
be	VB	O
assumed	VBN	O
to	TO	O
be	VB	O
protective	JJ	O
of	IN	O
lung	NN	O
volumes	NNS	O
postsuctioning	VBG	O
.	.	O

Consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
restoring	VBG	O
EELV	NNP	O
after	IN	O
either	DT	O
suction	NN	O
method	NN	O
via	IN	O
a	DT	O
recruitment	JJ	O
maneuver	NN	O
.	.	O

Network	NNP	O
support	NN	O
for	IN	O
drinking	NN	O
,	,	O
Alcoholics	NNP	O
Anonymous	NNP	O
and	CC	O
long-term	JJ	O
matching	NN	O
effects	NNS	O
.	.	O

AIMS	NNP	O
(	(	O
1	CD	O
)	)	O
To	TO	O
examine	VB	O
the	DT	O
matching	JJ	O
hypothesis	NN	O
that	WDT	O
Twelve	NNP	O
Step	NNP	O
Facilitation	NNP	O
Therapy	NNP	O
(	(	O
TSF	NNP	O
)	)	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
Motivational	NNP	O
Enhancement	NNP	O
Therapy	NNP	O
(	(	O
MET	NNP	O
)	)	O
for	IN	O
alcohol-dependent	JJ	Condition
clients	NNS	O
with	IN	O
networks	NNS	O
highly	RB	O
supportive	JJ	O
of	IN	O
drinking	VBG	O
3	CD	O
years	NNS	O
following	VBG	O
treatment	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
to	TO	O
test	VB	O
a	DT	O
causal	NN	O
chain	NN	O
providing	VBG	O
the	DT	O
rationale	NN	O
for	IN	O
this	DT	O
effect	NN	O
.	.	O

DESIGN	NN	O
Outpatients	NNPS	O
were	VBD	O
re-interviewed	JJ	O
3	CD	O
years	NNS	O
following	VBG	O
treatment	NN	O
.	.	O

ANCOVAs	NNP	O
tested	VBD	O
the	DT	O
matching	JJ	O
hypothesis	NN	O
.	.	O

SETTING	NN	O
Outpatients	NNS	O
from	IN	O
five	CD	O
clinical	JJ	O
research	NN	O
units	NNS	O
distributed	VBN	O
across	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PARTICIPANTS	NNP	O
Eight	NNP	SampleSize
hundred	VBD	SampleSize
and	CC	SampleSize
six	CD	SampleSize
alcohol-dependent	JJ	Condition
clients	NNS	O
.	.	O

INTERVENTION	JJ	O
Clients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
12-week	JJ	O
,	,	O
manually-guided	JJ	O
,	,	O
individual	JJ	O
treatments	NNS	O
:	:	O
TSF	NNP	O
,	,	O
MET	NNP	O
or	CC	O
Cognitive	NNP	O
Behavioral	NNP	O
Coping	NNP	O
Skills	NNP	O
Therapy	NNP	O
(	(	O
CBT	NNP	O
)	)	O
.	.	O

MEASUREMENTS	NNP	O
Network	NNP	O
support	NN	O
for	IN	O
drinking	VBG	O
prior	JJ	O
to	TO	O
treatment	NN	O
,	,	O
Alcoholics	NNP	O
Anonymous	NNP	O
(	(	O
AA	NNP	O
)	)	O
involvement	NN	O
during	IN	O
and	CC	O
following	VBG	O
treatment	NN	O
,	,	O
percentage	NN	O
of	IN	O
days	NNS	O
abstinent	JJ	O
and	CC	O
drinks	NNS	O
per	IN	O
drinking	NN	O
day	NN	O
during	IN	O
months	NNS	O
37-39	JJ	O
.	.	O

FINDINGS	NNP	O
(	(	O
1	CD	O
)	)	O
The	DT	O
a	DT	O
priori	JJ	O
matching	NN	O
hypothesis	NN	O
that	IN	O
TSF	NNP	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
MET	NNP	O
for	IN	O
clients	NNS	O
with	IN	O
networks	NNS	O
supportive	NN	O
of	IN	O
drinking	NN	O
was	VBD	O
supported	VBN	O
at	IN	O
the	DT	O
3	CD	O
year	NN	O
follow-up	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
AA	NNP	O
involvement	NN	O
was	VBD	O
a	DT	O
partial	JJ	O
mediator	NN	O
of	IN	O
this	DT	O
effect	NN	O
;	:	O
clients	NNS	O
with	IN	O
networks	NNS	O
supportive	NN	O
of	IN	O
drinking	NN	O
assigned	VBN	O
to	TO	O
TSF	VB	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
AA	NNP	O
;	:	O
AA	NNP	O
involvement	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
better	JJR	O
3-year	JJ	O
drinking	NN	O
outcomes	NNS	O
for	IN	O
such	JJ	O
clients	NNS	O
.	.	O

CONCLUSIONS	NNP	O
(	(	O
1	CD	O
)	)	O
In	IN	O
the	DT	O
long-term	JJ	O
TSF	NNP	O
may	MD	O
be	VB	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
alcohol-dependent	JJ	O
clients	NNS	O
with	IN	O
networks	NNS	O
supportive	NN	O
of	IN	O
drinking	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
involvement	NN	O
in	IN	O
AA	NNP	O
should	MD	O
be	VB	O
given	VBN	O
special	JJ	O
consideration	NN	O
for	IN	O
clients	NNS	O
with	IN	O
networks	NNS	O
supportive	NN	O
of	IN	O
drinking	NN	O
,	,	O
irrespective	NN	O
of	IN	O
the	DT	O
therapy	NN	O
they	PRP	O
will	MD	O
receive	VB	O
.	.	O

Primary	JJ	O
deep	JJ	O
sclerectomy	NN	O
versus	IN	O
primary	JJ	O
deep	JJ	O
sclerectomy	NN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
mitomycin	NN	O
C	NNP	O
in	IN	O
primary	JJ	Condition
open-angle	JJ	Condition
glaucoma	NN	Condition
.	.	O

PURPOSE	NNP	O
To	TO	O
prospectively	RB	O
study	VB	O
and	CC	O
compare	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
the	DT	O
safety	NN	O
of	IN	O
primary	JJ	O
deep	JJ	O
sclerectomy	NN	O
with	IN	O
and	CC	O
without	IN	O
the	DT	O
use	NN	O
of	IN	O
mitomycin	NN	O
C	NNP	O
in	IN	O
eyes	NNS	Condition
with	IN	Condition
open-angle	JJ	Condition
glaucoma	NN	Condition
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
90	CD	SampleSize
eyes	NNS	SampleSize
of	IN	SampleSize
90	CD	SampleSize
patients	NNS	SampleSize
with	IN	O
primary	JJ	Condition
open-angle	JJ	Condition
glaucoma	NN	Condition
or	CC	Condition
pseudoexfoliative	JJ	Condition
glaucoma	NN	Condition
underwent	JJ	O
deep	JJ	O
sclerectomy	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
enrolled	VBN	O
consecutively	RB	O
and	CC	O
assigned	VBD	O
randomly	RB	O
to	TO	O
undergo	VB	O
deep	JJ	O
sclerectomy	NN	O
without	IN	O
the	DT	O
use	NN	O
of	IN	O
mitomycin	NN	O
C	NNP	O
(	(	O
DS	NNP	O
group	NN	O
)	)	O
and	CC	O
deep	JJ	O
sclerectomy	NN	O
with	IN	O
the	DT	O
application	NN	O
of	IN	O
mitomycin	NN	O
C	NNP	O
(	(	O
DSMMC	NNP	O
group	NN	O
)	)	O
in	IN	O
a	DT	O
concentration	NN	O
of	IN	O
0.2	CD	O
mg/mL	NN	O
for	IN	O
2.5	CD	O
minutes	NNS	O
,	,	O
before	IN	O
the	DT	O
superficial	JJ	O
scleral	JJ	O
flap	NN	O
formation	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
intraocular	JJ	O
pressure	NN	O
was	VBD	O
significantly	RB	O
decreased	VBN	O
by	IN	O
7.13	CD	O
mm	NNS	O
Hg	NNP	O
or	CC	O
27.59	CD	O
%	NN	O
in	IN	O
the	DT	O
DS	NNP	O
group	NN	O
and	CC	O
by	IN	O
11.68	CD	O
mm	NNS	O
Hg	NNP	O
or	CC	O
42.25	CD	O
%	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

The	DT	O
intraocular	JJ	O
pressure	NN	O
reduction	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
was	VBD	O
statistically	RB	O
significant	JJ	O
when	WRB	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
the	DT	O
DS	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
complete	JJ	O
(	(	O
IOP	NNP	O
<	VBZ	O
22	CD	O
mm	NN	O
Hg	NNP	O
without	IN	O
medication	NN	O
)	)	O
and	CC	O
qualified	VBN	O
(	(	O
IOP	NNP	O
<	VBZ	O
22	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
or	CC	O
without	IN	O
medication	NN	O
)	)	O
success	NN	O
rates	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
were	VBD	O
42.5	CD	O
%	NN	O
and	CC	O
72.5	CD	O
%	NN	O
in	IN	O
the	DT	O
DS	NNP	O
group	NN	O
and	CC	O
50	CD	O
%	NN	O
and	CC	O
95	CD	O
%	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
.	.	O

The	DT	O
qualified	JJ	O
success	NN	O
rate	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
was	VBD	O
statistically	RB	O
significant	JJ	O
when	WRB	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
the	DT	O
DS	NNP	O
group	NN	O
.	.	O

Differences	NNS	O
in	IN	O
complications	NNS	O
(	(	O
choroidal	JJ	O
detachment	NN	O
,	,	O
hyphema	NN	O
,	,	O
leakage	NN	O
)	)	O
seen	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
statistically	RB	O
nonsignificant	JJ	O
.	.	O

A	DT	O
hemorrhagic	JJ	O
detachment	NN	O
of	IN	O
the	DT	O
Descemet	NNP	O
membrane	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
one	CD	O
eye	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
use	NN	O
of	IN	O
intraoperative	JJ	O
mitomycin	NN	O
C	NNP	O
during	IN	O
deep	JJ	O
sclerectomy	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
postoperative	JJ	O
IOP	NNP	O
and	CC	O
increased	VBD	O
the	DT	O
success	NN	O
rate	NN	O
of	IN	O
the	DT	O
procedure	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
three	CD	O
solutions	NNS	O
of	IN	O
ropivacaine/fentanyl	NN	O
for	IN	O
postoperative	JJ	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
.	.	O

BACKGROUND	NNP	O
Ropivacaine	NNP	O
,	,	O
0.2	CD	O
%	NN	O
,	,	O
is	VBZ	O
a	DT	O
new	JJ	O
local	JJ	O
anesthetic	JJ	O
approved	VBN	O
for	IN	O
epidural	JJ	O
analgesia	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
4	CD	O
microg/ml	NNS	O
fentanyl	JJ	O
improves	NNS	O
analgesia	VBP	O
from	IN	O
epidural	JJ	O
ropivacaine	NN	O
.	.	O

Use	NNP	O
of	IN	O
a	DT	O
lower	JJR	O
concentration	NN	O
of	IN	O
ropivacaine-fentanyl	NN	O
may	MD	O
further	VB	O
improve	VB	O
analgesia	NN	O
or	CC	O
decrease	JJ	O
side	NN	O
effects	NNS	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
undergoing	VBG	O
lower	JJR	O
abdominal	JJ	O
surgery	NN	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blinded	JJ	O
manner	NN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
three	CD	O
solutions	NNS	O
:	:	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	O
microg	NN	O
fentanyl	VBD	O
0.1	CD	O
%	NN	O
ropivacaine-2	JJ	O
microg	NN	O
fentanyl	NN	O
,	,	O
or	CC	O
0.05	CD	O
%	NN	O
ropivacaine-1	JJ	O
microg	NN	O
fentanyl	NN	O
for	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
after	IN	O
standardized	VBN	O
combined	JJ	O
epidural	JJ	O
and	CC	O
general	JJ	O
anesthesia	NN	O
.	.	O

Patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
settings	NNS	O
and	CC	O
adjustments	NNS	O
for	IN	O
the	DT	O
three	CD	O
solutions	NNS	O
were	VBD	O
standardized	VBN	O
to	TO	O
deliver	VB	O
equivalent	JJ	O
drug	NN	O
doses	NNS	O
.	.	O

Pain	NN	O
scores	NNS	O
(	(	O
rest	NN	O
,	,	O
cough	NN	O
,	,	O
and	CC	O
ambulation	NN	O
)	)	O
,	,	O
side	JJ	O
effects	NNS	O
(	(	O
nausea	NN	O
,	,	O
pruritus	NN	O
,	,	O
sedation	NN	O
,	,	O
motor	NN	O
block	NN	O
,	,	O
hypotension	NN	O
,	,	O
and	CC	O
orthostasis	NN	O
)	)	O
,	,	O
and	CC	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
consumption	NN	O
were	VBD	O
measured	VBN	O
for	IN	O
48	CD	O
h.	JJ	O
RESULTS	NNP	O
All	NNP	O
three	CD	O
solutions	NNS	O
produced	VBD	O
equivalent	JJ	O
analgesia	NN	O
.	.	O

Motor	NNP	O
block	NN	O
was	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
(	(	O
30	CD	O
vs.	FW	O
0	CD	O
%	NN	O
)	)	O
and	CC	O
more	JJR	O
intense	JJ	O
with	IN	O
the	DT	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	O
microg	NN	O
fentanyl	JJ	O
solution	NN	O
.	.	O

Other	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
equivalent	JJ	O
between	IN	O
solutions	NNS	O
and	CC	O
mild	NN	O
in	IN	O
severity	NN	O
.	.	O

A	DT	O
significantly	RB	O
smaller	JJR	O
volume	NN	O
of	IN	O
0.2	CD	O
%	NN	O
ropivacaine-4	JJ	O
microg	NN	O
fentanyl	JJ	O
solution	NN	O
was	VBD	O
used	VBN	O
,	,	O
whereas	IN	O
the	DT	O
0.1	CD	O
%	NN	O
ropivacaine-2	JJ	O
microg	NN	O
fentanyl	NN	O
group	NN	O
used	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
amount	NN	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	NN	O
.	.	O

CONCLUSIONS	NNP	O
Lesser	NNP	O
concentrations	NNS	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	JJ	O
provide	NN	O
comparable	JJ	O
analgesia	NN	O
with	IN	O
less	JJR	O
motor	NN	O
block	NN	O
despite	IN	O
the	DT	O
use	NN	O
of	IN	O
similar	JJ	O
amounts	NNS	O
of	IN	O
ropivacaine	NN	O
and	CC	O
fentanyl	NN	O
.	.	O

This	DT	O
finding	NN	O
suggests	VBZ	O
that	IN	O
concentration	NN	O
of	IN	O
local	JJ	O
anesthetic	JJ	O
solution	NN	O
at	IN	O
low	JJ	O
doses	NNS	O
is	VBZ	O
a	DT	O
primary	JJ	O
determinant	NN	O
of	IN	O
motor	NN	O
block	NN	O
with	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
after	IN	O
lower	JJR	O
abdominal	JJ	O
surgery	NN	O
.	.	O

Sustained	JJ	O
effect	NN	O
of	IN	O
SQ-standardized	NNP	O
grass	NN	O
allergy	NN	O
immunotherapy	NN	O
tablet	NN	O
on	IN	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
prevalence	NN	O
of	IN	O
allergic	JJ	O
rhinoconjunctivitis	NN	O
has	VBZ	O
increased	VBN	O
significantly	RB	O
over	IN	O
the	DT	O
past	JJ	O
decades	NNS	O
with	IN	O
grass	NN	O
pollen	NN	O
being	VBG	O
a	DT	O
common	JJ	O
trigger	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
allergy	NN	O
on	IN	O
patient	NN	O
's	POS	O
quality	NN	O
of	IN	O
life	NN	O
is	VBZ	O
substantial	JJ	O
.	.	O

AIM	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
sustained	JJ	O
effect	NN	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
during	IN	O
the	DT	O
grass	NN	O
pollen	NN	O
season	NN	O
1	CD	O
year	NN	O
after	IN	O
3	CD	O
years	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
the	DT	O
SQ-standardized	JJ	O
grass	NN	O
allergy	NN	O
immunotherapy	NN	O
tablet	NN	O
(	(	O
AIT	NNP	O
)	)	O
,	,	O
Graza	NNP	O
(	(	O
Phleum	NNP	O
pratense	VBZ	O
75,000	CD	O
SQ-T/2800	JJ	O
BAU	NNP	O
;	:	O
ALK	NNP	O
,	,	O
Denmark	NNP	O
)	)	O
.	.	O

METHODS	PDT	O
The	DT	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
adult	NN	Age
subjects	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
moderate-severe	JJ	Condition
grass	NN	Condition
pollen	NN	Condition
induced	VBD	Condition
rhinoconjunctivitis	NN	Condition
inadequately	RB	Condition
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
.	.	O

Subjects	NNS	O
received	VBD	O
3	CD	O
years	NNS	O
of	IN	O
grass	NN	O
AIT	NNP	O
(	(	O
n	JJ	O
=	NNP	O
157	CD	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
126	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
1	CD	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
assessments	NNS	O
were	VBD	O
based	VBN	O
on	IN	O
the	DT	O
standardized	JJ	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
questionnaire	NN	O
(	(	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
)	)	O
;	:	O
completed	VBN	O
weekly	JJ	O
during	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
follow-up	JJ	O
,	,	O
the	DT	O
overall	JJ	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
score	NN	O
for	IN	O
the	DT	O
entire	JJ	O
grass	NN	O
pollen	NN	O
season	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
(	(	O
relative	JJ	O
difference	NN	O
to	TO	O
placebo	VB	O
:	:	O
23	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
improvement	NN	O
was	VBD	O
higher	JJR	O
during	IN	O
the	DT	O
peak	NN	O
pollen	NN	O
season	NN	O
(	(	O
28	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
effect	NN	O
of	IN	O
grass	NN	O
AIT	NNP	O
during	IN	O
the	DT	O
follow-up	JJ	O
year	NN	O
and	CC	O
the	DT	O
previous	JJ	O
three	CD	O
treatment	NN	O
years	NNS	O
was	VBD	O
similar	JJ	O
.	.	O

Improvements	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
all	DT	O
seven	CD	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
domains	VBZ	O
.	.	O

The	DT	O
RQLQ	NNP	O
(	(	O
S	NNP	O
)	)	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
weekly	JJ	O
average	NN	O
pollen	NN	O
counts	VBZ	O
showed	VBD	O
a	DT	O
clear	JJ	O
separation	NN	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
subjects	NNS	O
inadequately	RB	O
controlled	VBN	O
by	IN	O
symptomatic	JJ	O
medications	NNS	O
,	,	O
grass	NN	O
AIT	NNP	O
provided	VBD	O
sustained	VBN	O
and	CC	O
clinically	RB	O
relevant	JJ	O
improvements	NNS	O
in	IN	O
rhinoconjunctivitis	NN	O
quality	NN	O
of	IN	O
life	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

The	DT	O
effect	NN	O
increased	VBD	O
with	IN	O
increasing	VBG	O
grass	NN	O
pollen	NN	O
exposure	NN	O
.	.	O

Gefitinib	NNP	O
or	CC	O
placebo	NN	O
in	IN	O
combination	NN	O
with	IN	O
tamoxifen	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hormone	JJ	O
receptor-positive	JJ	O
metastatic	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
:	:	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
.	.	O

PURPOSE	NNP	O
Increased	VBD	O
growth	NN	O
factor	NN	O
signaling	VBG	O
may	MD	O
contribute	VB	O
to	TO	O
tamoxifen	VB	O
resistance	NN	O
.	.	O

This	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
assessed	VBD	O
tamoxifen	JJ	O
plus	CC	O
placebo	NN	O
or	CC	O
the	DT	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
inhibitor	NN	O
gefitinib	NN	O
in	IN	O
estrogen	NN	O
receptor	NN	O
(	(	O
ER	NNP	O
)	)	O
-positive	VBP	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

EXPERIMENTAL	NNP	O
DESIGN	NNP	O
Patients	NNPS	O
with	IN	O
newly	RB	O
metastatic	JJ	Condition
disease	NN	Condition
or	CC	O
recurred	VBN	O
after	IN	O
adjuvant	JJ	O
tamoxifen	NN	O
(	(	O
stratum	JJ	O
1	CD	O
)	)	O
,	,	O
or	CC	O
recurred	VBD	O
during/after	NN	O
adjuvant	JJ	O
aromatase	NN	O
inhibitor	NN	O
(	(	O
AI	NNP	O
)	)	O
or	CC	O
after	IN	O
failed	VBN	O
first-line	NN	O
AI	NNP	O
(	(	O
stratum	JJ	O
2	CD	O
)	)	O
,	,	O
were	VBD	O
eligible	JJ	O
.	.	O

Primary	JJ	O
variables	NNS	O
were	VBD	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
;	:	O
stratum	VBZ	O
1	CD	O
)	)	O
and	CC	O
clinical	JJ	O
benefit	NN	O
rate	NN	O
(	(	O
CBR	NNP	O
;	:	O
stratum	VBZ	O
2	CD	O
)	)	O
.	.	O

A	DT	O
5	CD	O
%	NN	O
or	CC	O
more	JJR	O
improvement	NN	O
in	IN	O
response	NN	O
variables	NNS	O
with	IN	O
gefitinib	NN	O
was	VBD	O
considered	VBN	O
to	TO	O
warrant	VB	O
further	JJ	O
investigation	NN	O
.	.	O

Outcome	NNP	O
was	VBD	O
correlated	VBN	O
with	IN	O
biomarkers	NNS	O
measured	VBN	O
on	IN	O
the	DT	O
primary	JJ	O
tumor	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
stratum	JJ	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
206	CD	O
)	)	O
,	,	O
the	DT	O
PFS	NNP	O
HR	NNP	O
(	(	O
gefitinib	NN	O
:	:	O
placebo	NN	O
)	)	O
was	VBD	O
0.84	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.59-1.18	NNP	O
;	:	O
median	JJ	O
PFS	NNP	O
10.9	CD	O
versus	NN	O
8.8	CD	O
months	NNS	O
)	)	O
.	.	O

In	IN	O
the	DT	O
stratum	NN	O
1	CD	O
endocrine	JJ	O
therapy-na?ve	JJ	O
subset	NN	O
(	(	O
n	JJ	O
=	NNP	O
158	CD	O
)	)	O
the	DT	O
HR	NNP	O
was	VBD	O
0.78	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.52-1.15	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
prior	JJ	O
endocrine-treated	JJ	O
subgroup	NN	O
(	(	O
n	JJ	O
=	NNP	O
48	CD	O
)	)	O
1.47	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.63-3.45	NN	O
)	)	O
.	.	O

In	IN	O
stratum	NN	O
1	CD	O
,	,	O
CBRs	NNP	O
were	VBD	O
50.5	CD	O
%	NN	O
with	IN	O
gefitinib	NN	O
and	CC	O
45.5	CD	O
%	NN	O
with	IN	O
placebo	NN	O
.	.	O

In	IN	O
stratum	NN	O
2	CD	O
(	(	O
n	JJ	O
=	NNP	O
84	CD	O
)	)	O
,	,	O
CBRs	NNP	O
were	VBD	O
29.2	CD	O
%	NN	O
with	IN	O
gefitinib	NN	O
and	CC	O
31.4	CD	O
%	NN	O
with	IN	O
placebo	NN	O
.	.	O

Biomarker	NNP	O
analysis	NN	O
suggested	VBD	O
that	IN	O
in	IN	O
stratum	NN	O
1	CD	O
there	EX	O
was	VBD	O
greater	JJR	O
benefit	NN	O
with	IN	O
gefitinib	NN	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
ER-negative	JJ	O
or	CC	O
had	VBD	O
lower	JJR	O
levels	NNS	O
of	IN	O
ER	NNP	O
protein	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
stratum	NN	O
1	CD	O
,	,	O
the	DT	O
improved	JJ	O
PFS	NNP	O
with	IN	O
gefitinib	JJ	O
plus	CC	O
tamoxifen	JJ	O
met	VBD	O
the	DT	O
protocol	NN	O
criteria	NNS	O
to	TO	O
warrant	VB	O
further	JJ	O
investigation	NN	O
of	IN	O
this	DT	O
strategy	NN	O
.	.	O

In	IN	O
stratum	NN	O
2	CD	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
numerical	JJ	O
disadvantage	NN	O
for	IN	O
gefitinib	NN	O
;	:	O
additional	JJ	O
investigation	NN	O
after	IN	O
AI	NNP	O
therapy	NN	O
is	VBZ	O
not	RB	O
warranted	VBN	O
.	.	O

Studies	NNS	O
of	IN	O
predictive	JJ	O
biomarkers	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
subset	VB	O
appropriate	JJ	O
patients	NNS	O
.	.	O

[	JJ	O
Effect	NNP	O
on	IN	O
pressure	NN	O
after	IN	O
instillation	NN	O
of	IN	O
a	DT	O
drop	NN	O
of	IN	O
depot-pilocarpine	NN	O
.	.	O

Clinical	JJ	O
results	NNS	O
of	IN	O
its	PRP$	O
medium-term	JJ	O
action	NN	O
]	NNP	O
.	.	O

A	NNP	O
clinical	JJ	O
comparison	NN	O
of	IN	O
an	DT	O
emulsion	NN	O
containing	VBG	O
a	DT	O
new	JJ	O
pilocarpine	NN	O
polymer	NN	O
(	(	O
Polym	NNP	O
)	)	O
compound	NN	O
to	TO	O
that	DT	O
of	IN	O
a	DT	O
traditional	JJ	O
pilocarpine	NN	O
salt	NN	O
solution	NN	O
(	(	O
Plc	NNP	O
)	)	O
on	IN	O
the	DT	O
intraocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
performed	VBN	O
in	IN	O
40	CD	Condition
open-angle	JJ	Condition
patients	NNS	Condition
treated	VBN	Condition
with	IN	Condition
the	DT	Condition
long	JJ	Condition
acting	JJ	Condition
pilocarpine-complex	NN	Condition
for	IN	Condition
120	CD	Condition
days	NNS	Condition
.	.	Condition

The	DT	O
treatment	NN	O
protocol	NN	O
was	VBD	O
divided	VBN	O
into	IN	O
3	CD	O
stages	NNS	O
:	:	O
Stage	NN	O
1	CD	O
is	VBZ	O
a	DT	O
single	JJ	O
dose	NN	O
treatment	NN	O
where	WRB	O
12	CD	O
patients	NNS	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
2	CD	O
groups	NNS	O
of	IN	O
6	CD	O
each	DT	O
.	.	O

The	DT	O
patients	NNS	O
of	IN	O
each	DT	O
group	NN	O
were	VBD	O
given	VBN	O
1	CD	O
drop	NN	O
into	IN	O
each	DT	O
eye	NN	O
:	:	O
1	CD	O
drop	NN	O
every	DT	O
12	CD	O
hours	NNS	O
for	IN	O
Polym	NNP	O
,	,	O
1	CD	O
drop	NN	O
every	DT	O
6	CD	O
hours	NNS	O
for	IN	O
Plc	NNP	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

After	IN	O
24	CD	O
hours	NNS	O
without	IN	O
medication	NN	O
,	,	O
the	DT	O
treatments	NNS	O
were	VBD	O
crossed	VBN	O
over	IN	O
and	CC	O
nycthemeral	JJ	O
graph	NN	O
curves	NNS	O
were	VBD	O
registered	VBN	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

Stage	NN	O
2	CD	O
is	VBZ	O
a	DT	O
medium	JJ	O
term	NN	O
study	NN	O
were	VBD	O
the	DT	O
12	CD	O
patients	NNS	O
used	VBN	O
in	IN	O
Stage	NNP	O
1	CD	O
were	VBD	O
added	VBN	O
to	TO	O
another	DT	O
28	CD	O
patients	NNS	O
.	.	O

All	DT	O
40	CD	O
were	VBD	O
then	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
2	CD	O
treatment	NN	O
groups	NNS	O
(	(	O
2	CD	O
groups	NNS	O
of	IN	O
20	CD	O
patients	NNS	O
each	DT	O
)	)	O
according	VBG	O
to	TO	O
a	DT	O
table	NN	O
of	IN	O
random	NN	O
numbers	NNS	O
.	.	O

Treatments	NNS	O
were	VBD	O
administered	VBN	O
during	IN	O
one	CD	O
month	NN	O
,	,	O
then	RB	O
cross-overed	JJ	O
again	RB	O
during	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Stage	NN	O
3	CD	O
:	:	O
finally	RB	O
,	,	O
every	DT	O
patient	NN	O
could	MD	O
choose	VB	O
his	PRP$	O
treatment	NN	O
(	(	O
either	CC	O
Polym	NNP	O
or	CC	O
Plc	NNP	O
)	)	O
for	IN	O
the	DT	O
rest	NN	O
of	IN	O
the	DT	O
period	NN	O
(	(	O
2	CD	O
months	NNS	O
)	)	O
.	.	O

The	DT	O
clinical	JJ	O
study	NN	O
shows	VBZ	O
that	IN	O
the	DT	O
polymer	NN	O
complex	NN	O
(	(	O
Polym	NNP	O
)	)	O
produced	VBD	O
a	DT	O
prolonged	JJ	O
therapeutic	JJ	O
effect	NN	O
,	,	O
this	DT	O
being	VBG	O
consistant	JJ	O
with	IN	O
a	DT	O
slow	JJ	O
release	NN	O
pattern	NN	O
and	CC	O
maintained	VBD	O
a	DT	O
more	RBR	O
effective	JJ	O
around-the-clock	NN	O
control	NN	O
than	IN	O
pilocarpine	JJ	O
solution	NN	O
.	.	O

These	DT	O
results	NNS	O
were	VBD	O
accomplished	VBN	O
by	IN	O
two	CD	O
applications	NNS	O
per	IN	O
day	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
four	CD	O
necessary	JJ	O
applications	NNS	O
of	IN	O
Plc	NNP	O
,	,	O
on	IN	O
a	DT	O
half	JJ	O
daily	JJ	O
pilocarpine	NN	O
dose	NN	O
with	IN	O
Polym	NNP	O
.	.	O

The	DT	O
medium	JJ	O
term	NN	O
results	NNS	O
confirmed	VBD	O
the	DT	O
efficacity	NN	O
noted	VBD	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
survey	NN	O
.	.	O

Most	JJS	O
patients	NNS	O
preferred	JJ	O
Polym	NNP	O
to	TO	O
Plc	VB	O
when	WRB	O
they	PRP	O
were	VBD	O
asked	VBN	O
.	.	O

Throughout	IN	O
the	DT	O
4	CD	O
months	NNS	O
study	JJ	O
period	NN	O
,	,	O
no	DT	O
adverse	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
reported	VBN	O
.	.	O

Visual	JJ	O
disturbances	NNS	O
characteristic	NN	O
of	IN	O
pilocarpine	JJ	O
eye-drops	NNS	O
were	VBD	O
reduced	VBN	O
from	IN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
on	IN	O
pilocarpine	NN	O
salt	NN	O
solution	NN	O
to	TO	O
once	VB	O
a	DT	O
day	NN	O
on	IN	O
pilocarpine	JJ	O
polymer	NN	O
complex	NN	O
.	.	O

Efficient	JJ	O
tetanus	NN	O
toxoid	JJ	O
immunization	NN	O
on	IN	O
vitamin	NN	O
D	NNP	O
supplementation	NN	O
.	.	O

BACKGROUND/OBJECTIVES	NNP	O
Vitamin	NNP	O
D	NNP	O
mediates	VBZ	O
immunomodulatory	JJ	O
functions	NNS	O
,	,	O
and	CC	O
its	PRP$	O
deficiency	NN	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
an	DT	O
increased	JJ	O
prevalence	NN	O
of	IN	O
immunological	JJ	O
diseases	NNS	O
.	.	O

The	DT	O
supplementation	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
might	MD	O
be	VB	O
therapeutically	RB	O
beneficial	JJ	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
lupus	JJ	O
erythematosus	NN	O
patients	NNS	O
.	.	O

However	RB	O
,	,	O
its	PRP$	O
affect	NN	O
on	IN	O
established	VBN	O
recall	NN	O
immune	NN	O
responses	NNS	O
is	VBZ	O
undefined	JJ	O
.	.	O

SUBJECTS/METHODS	NNP	O
In	IN	O
all	DT	O
,	,	O
32	CD	SampleSize
individuals	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
placebo	NN	O
controlled	VBN	O
,	,	O
double-blind	JJ	O
setting	NN	O
,	,	O
and	CC	O
received	VBD	O
vitamin	NNS	O
D	NNP	O
(	(	O
daily	JJ	O
2000	CD	O
IU	NNP	O
)	)	O
for	IN	O
10	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
tetanus	NN	O
toxoid	NN	O
(	(	O
TT	NNP	O
)	)	O
booster	NN	O
immunization	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
vitamin	JJ	O
D	NNP	O
supplementation	NN	O
the	DT	O
median	JJ	O
25-hydroxyvitamin	JJ	O
D	NNP	O
serum	NN	O
concentration	NN	O
increased	VBD	O
to	TO	O
80.3	CD	O
nM	NNS	O
,	,	O
which	WDT	O
as	IN	O
expected	VBN	O
decreased	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
to	TO	O
29.1	CD	O
nM	NNS	O
during	IN	O
the	DT	O
ultraviolet-deprived	JJ	O
winter	NN	O
months	NNS	O
.	.	O

The	DT	O
TT-specific	JJ	O
immunoglobulin	NN	O
G	NNP	O
(	(	O
IgG	NNP	O
)	)	O
boost	VBD	O
efficiency	NN	O
was	VBD	O
marginal	JJ	O
higher	JJR	O
in	IN	O
the	DT	O
vitamin	NN	O
D	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
of	IN	O
the	DT	O
25-hydroxyvitamin	JJ	O
D	NNP	O
levels	NNS	O
correlated	VBN	O
with	IN	O
the	DT	O
increase	NN	O
of	IN	O
TT-IgG	NNP	O
serum	NN	O
concentrations	NNS	O
.	.	O

The	DT	O
induction	NN	O
of	IN	O
specific	JJ	O
serum	NN	O
IgA	NNP	O
and	CC	O
specific	JJ	O
antibody	NN	O
secreting	VBG	O
cells	NNS	O
was	VBD	O
comparable	JJ	O
between	IN	O
both	DT	O
groups	NNS	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
TT-specific	NNP	O
and	CC	O
polyclonally	RB	O
triggered	VBD	O
T-cell	NNP	O
cytokine	NN	O
profiles	NNS	O
were	VBD	O
stable	JJ	O
as	RB	O
well	RB	O
.	.	O

CONCLUSIONS	NNP	O
Vitamin	NNP	O
D	NNP	O
supplementation	NN	O
was	VBD	O
successful	JJ	O
and	CC	O
booster	JJ	O
immunization	NN	O
induced	VBD	O
efficiently	RB	O
specific	JJ	O
antibodies	NNS	O
titers	NNS	O
.	.	O

Targeting	VBG	O
alpha-7	JJ	O
nicotinic	JJ	O
neurotransmission	NN	O
in	IN	O
schizophrenia	NN	O
:	:	O
a	DT	O
novel	JJ	O
agonist	NN	O
strategy	NN	O
.	.	O

Alpha7	NNP	O
nicotinic	JJ	O
acetylcholine	NN	O
receptor	NN	O
(	(	O
?7	NNP	O
nAChR	RB	O
)	)	O
agonists	NNS	O
may	MD	O
be	VB	O
valuable	JJ	O
treatments	NNS	O
for	IN	O
negative	JJ	O
symptoms	NNS	O
and	CC	O
cognitive	JJ	O
impairment	NN	O
in	IN	O
schizophrenia	NN	O
.	.	O

Unfortunately	RB	O
,	,	O
chronic	JJ	O
exposure	NN	O
to	TO	O
an	DT	O
agonist	NN	O
may	MD	O
reduce	VB	O
the	DT	O
receptor	NN	O
's	POS	O
sensitivity	NN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
combined	VBD	O
CDP-choline	NNP	O
,	,	O
a	DT	O
dietary	JJ	O
source	NN	O
of	IN	O
the	DT	O
direct	JJ	O
agonist	NN	O
choline	NN	O
,	,	O
with	IN	O
galantamine	NN	O
,	,	O
a	DT	O
positive	JJ	O
allosteric	JJ	O
modulator	NN	O
(	(	O
PAM	NNP	O
)	)	O
of	IN	O
nicotinic	JJ	O
acetylcholine	NN	O
receptors	NNS	O
,	,	O
to	TO	O
improve	VB	O
the	DT	O
efficiency	NN	O
of	IN	O
transducing	VBG	O
the	DT	O
choline	JJ	O
signal	NN	O
and	CC	O
,	,	O
possibly	RB	O
,	,	O
preserve	VB	O
the	DT	O
receptor	NN	O
in	IN	O
a	DT	O
sensitive	JJ	O
state	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
single-site	JJ	O
,	,	O
double-blind	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
galantamine/CDP-choline	NN	O
to	TO	O
placebos	VB	O
in	IN	O
schizophrenia	NN	O
patients	NNS	O
with	IN	O
negative	JJ	O
symptoms	NNS	O
who	WP	O
were	VBD	O
receiving	VBG	O
second	JJ	O
generation	NN	O
antipsychotics	NNS	O
.	.	O

Forty-three	JJ	O
subjects	NNS	O
received	VBN	O
galantamine	JJ	O
and	CC	O
CDP-choline	JJ	O
or	CC	O
matching	JJ	O
placebos	NNS	O
for	IN	O
16weeks	CD	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
5-item	JJ	O
Marder	NNP	O
negative-symptoms	JJ	O
factor	NN	O
of	IN	O
the	DT	O
Positive	NNP	O
and	CC	O
Negative	NNP	O
Syndrome	NNP	O
Scale	NNP	O
(	(	O
PANSS	NNP	O
)	)	O
.	.	O

Cognition	NN	O
and	CC	O
functioning	NN	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

Trial	JJ	O
completion	NN	O
was	VBD	O
high	JJ	O
;	:	O
79	CD	O
%	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
treatment	NN	O
effect	NN	O
on	IN	O
negative	JJ	O
symptoms	NNS	O
,	,	O
other	JJ	O
PANSS	NNP	O
symptom	NN	O
factors	NNS	O
,	,	O
or	CC	O
the	DT	O
MATRICS	NNP	O
Cognitive	NNP	O
Consensus	NNP	O
Battery	NNP	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
treatment	NN	O
effects	NNS	O
in	IN	O
overall	JJ	O
functioning	NN	O
and	CC	O
a	DT	O
test	NN	O
of	IN	O
free	JJ	O
verbal	JJ	O
recall	NN	O
.	.	O

Three	CD	O
subjects	NNS	O
discontinued	VBN	O
treatment	NN	O
in	IN	O
the	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
for	IN	O
gastro-intestinal	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AE	NNP	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
AE	NNP	O
for	IN	O
galantamine/CDP-choline	NN	O
was	VBD	O
abdominal	JJ	O
pain	NN	O
;	:	O
for	IN	O
placebo	NN	O
it	PRP	O
was	VBD	O
headache	NN	O
and	CC	O
sweating	NN	O
.	.	O

Although	IN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
treatment	NN	O
effect	NN	O
on	IN	O
negative	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
direction	NN	O
of	IN	O
effect	NN	O
mirrored	VBD	O
the	DT	O
effects	NNS	O
on	IN	O
a	DT	O
cognitive	JJ	O
measure	NN	O
and	CC	O
overall	JJ	O
functioning	NN	O
.	.	O

Further	NNP	O
study	NN	O
of	IN	O
?7	NNP	O
nAChR	JJ	O
agonist/PAMs	NN	O
is	VBZ	O
warranted	VBN	O
in	IN	O
larger	JJR	O
studies	NNS	O
that	WDT	O
will	MD	O
have	VB	O
greater	JJR	O
power	NN	O
.	.	O

The	DT	O
NORwegian	JJ	O
study	NN	O
on	IN	O
DIstrict	NNP	O
treatment	NN	O
of	IN	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
(	(	O
NORDISTEMI	NNP	O
)	)	O
.	.	O

OBJECTIVES	NNP	O
Thrombolysis	NNP	O
is	VBZ	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
patients	NNS	O
with	IN	O
ST-elevation	NNP	O
myocardial	JJ	O
infarction	NN	O
(	(	O
STEMI	NNP	O
)	)	O
living	NN	O
in	IN	O
rural	JJ	O
areas	NNS	O
with	IN	O
long	JJ	O
transfer	NN	O
delays	NNS	O
to	TO	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

This	DT	O
trial	NN	O
compares	VBZ	O
two	CD	O
different	JJ	O
strategies	NNS	O
following	VBG	O
thrombolysis	NN	O
:	:	O
to	TO	O
transfer	VB	O
all	DT	O
patients	NNS	O
for	IN	O
immediate	JJ	O
coronary	JJ	O
angiography	NN	O
and	CC	O
intervention	NN	O
,	,	O
or	CC	O
to	TO	O
manage	VB	O
the	DT	O
patients	NNS	O
more	RBR	O
conservatively	RB	O
.	.	O

DESIGN	VB	O
The	DT	O
NORwegian	JJ	O
study	NN	O
on	IN	O
DIstrict	NNP	O
treatment	NN	O
of	IN	O
STEMI	NNP	O
(	(	O
NORDISTEMI	NNP	O
)	)	O
is	VBZ	O
an	DT	O
open	JJ	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
STEMI	NNP	O
of	IN	O
less	JJR	O
than	IN	O
6	CD	O
hours	NNS	O
of	IN	O
duration	NN	O
and	CC	O
more	JJR	O
than	IN	O
90	CD	O
minutes	NNS	O
expected	VBD	O
time	NN	O
delay	NN	O
to	TO	O
PCI	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
266	CD	O
patients	NNS	O
will	MD	O
receive	VB	O
full-dose	JJ	O
thrombolysis	NN	O
,	,	O
preferably	RB	O
pre-hospital	JJ	O
,	,	O
and	CC	O
then	RB	O
be	VB	O
randomized	VBN	O
to	TO	O
either	DT	O
strategy	NN	O
.	.	O

Our	PRP$	O
primary	JJ	O
endpoint	NN	O
is	VBZ	O
the	DT	O
one	CD	O
year	NN	O
combined	VBN	O
incidence	NN	O
of	IN	O
death	NN	O
,	,	O
reinfarction	NN	O
,	,	O
stroke	VBD	O
or	CC	O
new	JJ	O
myocardial	JJ	O
ischaemia	NN	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00161005	NNP	O
.	.	O

RESULTS	VBN	O
By	IN	O
April	NNP	O
2006	CD	O
,	,	O
109	CD	O
patients	NNS	O
have	VBP	O
been	VBN	O
randomized	VBN	O
.	.	O

Thrombolysis	NN	O
has	VBZ	O
been	VBN	O
given	VBN	O
pre-hospital	JJ	O
to	TO	O
52	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
median	JJ	O
transport	NN	O
distance	NN	O
from	IN	O
first	JJ	O
medical	JJ	O
contact	NN	O
to	TO	O
catheterization	NN	O
laboratory	NN	O
was	VBD	O
155	CD	O
km	NN	O
(	(	O
range	JJ	O
90-396	CD	O
km	NN	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
study	NN	O
are	VBP	O
expected	VBN	O
in	IN	O
2008	CD	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
the	DT	O
serologic	JJ	O
responses	NNS	O
to	TO	O
oral	JJ	O
and	CC	O
injectable	JJ	O
trivalent	NN	O
poliovirus	NN	O
vaccines	NNS	O
.	.	O

United	NNP	O
States	NNPS	O
children	NNS	Age
two	CD	Age
months	NNS	Age
of	IN	O
age	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
that	WDT	O
received	VBD	O
either	RB	O
the	DT	O
commercially	RB	O
available	JJ	O
oral	JJ	O
trivalent	NN	O
poliovirus	NN	O
vaccine	NN	O
(	(	O
OPV	NNP	O
)	)	O
or	CC	O
an	DT	O
injectable	JJ	O
(	(	O
inactivated	VBN	O
)	)	O
trivalent	NN	O
poliovirus	NN	O
vaccine	NN	O
(	(	O
IPV	NNP	O
)	)	O
with	IN	O
a	DT	O
confirmed	JJ	O
minimum	JJ	O
D-antigen	NNP	O
content	NN	O
of	IN	O
27	CD	O
,	,	O
3.5	CD	O
,	,	O
and	CC	O
29	CD	O
units	NNS	O
for	IN	O
poliovirus	NN	O
types	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
.	.	O

Vaccine	NNP	O
was	VBD	O
given	VBN	O
at	IN	O
two	CD	O
,	,	O
four	CD	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Sera	NN	O
obtained	VBN	O
from	IN	O
439	CD	SampleSize
children	NNS	Age
at	IN	Age
two	CD	Age
,	,	Age
four	CD	Age
,	,	Age
and	CC	Age
six	CD	Age
months	NNS	Age
of	IN	Age
age	NN	Age
and	CC	O
from	IN	O
85	CD	SampleSize
children	NNS	Age
at	IN	Age
18	CD	Age
and	CC	Age
20	CD	Age
months	NNS	Age
of	IN	Age
age	NN	Age
were	VBD	O
examined	VBN	O
for	IN	O
neutralizing	VBG	O
antibodies	NNS	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
children	NNS	O
with	IN	O
detectable	JJ	O
antibodies	NNS	O
and	CC	O
the	DT	O
reciprocal	JJ	O
geometric	JJ	O
mean	NN	O
titers	NNS	O
were	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
at	IN	O
two	CD	O
months	NNS	O
of	IN	O
age	NN	O
for	IN	O
antibodies	NNS	O
to	TO	O
all	DT	O
three	CD	O
poliovirus	NN	O
types	NNS	O
.	.	O

At	IN	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
all	DT	O
children	NNS	O
but	CC	O
one	CD	O
had	VBD	O
detectable	JJ	O
antibodies	NNS	O
to	TO	O
all	DT	O
three	CD	O
poliovirus	NN	O
types	NNS	O
.	.	O

Significantly	RB	O
higher	JJR	O
geometric	JJ	O
mean	NN	O
titers	NNS	O
against	IN	O
types	NNS	O
2	CD	O
and	CC	O
3	CD	O
were	VBD	O
noted	VBN	O
at	IN	O
20	CD	O
months	NNS	O
of	IN	O
age	NN	O
for	IN	O
the	DT	O
IPV	NNP	O
group	NN	O
.	.	O

Epidemiology	NN	O
of	IN	O
stroke	NN	O
.	.	O

Importance	NN	O
of	IN	O
preventive	JJ	O
pharmacological	JJ	O
strategies	NNS	O
in	IN	O
elderly	JJ	O
patients	NNS	O
and	CC	O
associated	JJ	O
costs	NNS	O
.	.	O

Stroke	NNP	O
is	VBZ	O
a	DT	O
major	JJ	O
cause	NN	O
of	IN	O
death	NN	O
and	CC	O
disability	NN	O
in	IN	O
developed	JJ	O
countries	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
stroke	NN	O
increases	NNS	O
exponentially	RB	O
with	IN	O
age	NN	O
,	,	O
yet	RB	O
,	,	O
traditionally	RB	O
,	,	O
many	JJ	O
medical	JJ	O
practitioners	NNS	O
have	VBP	O
been	VBN	O
reluctant	JJ	O
to	TO	O
treat	VB	O
hypertension	NN	O
in	IN	O
older	JJR	O
patients	NNS	O
.	.	O

Since	IN	O
1991	CD	O
,	,	O
the	DT	O
results	NNS	O
of	IN	O
3	CD	O
major	JJ	O
trials	NNS	O
--	:	O
the	DT	O
British	JJ	O
Medical	NNP	O
Research	NNP	O
Council	NNP	O
(	(	O
MRC	NNP	O
)	)	O
trial	NN	O
of	IN	O
treatment	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
,	,	O
the	DT	O
Swedish	JJ	O
Trial	NNP	O
in	IN	O
Old	NNP	O
Patients	NNPS	O
with	IN	O
Hypertension	NNP	O
(	(	O
STOP-Hypertension	NNP	O
)	)	O
and	CC	O
the	DT	O
Systolic	NNP	O
Hypertension	NNP	O
in	IN	O
the	DT	O
Elderly	JJ	O
Program	NNP	O
(	(	O
SHEP	NNP	O
)	)	O
--	:	O
have	VBP	O
conclusively	RB	O
established	VBN	O
the	DT	O
benefits	NNS	O
of	IN	O
treating	VBG	O
older	JJR	O
patients	NNS	O
(	(	O
>	JJ	O
60	CD	O
years	NNS	O
)	)	O
with	IN	O
both	DT	O
diastolic	JJ	O
and	CC	O
isolated	JJ	O
systolic	JJ	O
hypertension	NN	O
.	.	O

International	NNP	O
guidelines	NNS	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
hypertension	NN	O
--	:	O
including	VBG	O
the	DT	O
Fifth	NNP	O
Report	NNP	O
of	IN	O
the	DT	O
Joint	NNP	O
National	NNP	O
Committee	NNP	O
,	,	O
the	DT	O
1993	CD	O
report	NN	O
of	IN	O
the	DT	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
and	CC	O
the	DT	O
International	NNP	O
Society	NNP	O
of	IN	O
Hypertension	NNP	O
and	CC	O
the	DT	O
second	JJ	O
report	NN	O
of	IN	O
the	DT	O
British	JJ	O
Hypertension	NNP	O
Society	NNP	O
Working	NNP	O
Party	NNP	O
--	:	O
have	VBP	O
all	DT	O
been	VBN	O
modified	VBN	O
to	TO	O
reflect	VB	O
the	DT	O
emerging	VBG	O
evidence	NN	O
concerning	VBG	O
the	DT	O
benefits	NNS	O
of	IN	O
treating	VBG	O
older	JJR	O
patients	NNS	O
.	.	O

Cost-effectiveness	JJ	O
data	NNS	O
are	VBP	O
similarly	RB	O
in	IN	O
accord	NN	O
with	IN	O
giving	VBG	O
high	JJ	O
priority	NN	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
older	JJR	O
individuals	NNS	O
with	IN	O
hypertension	NN	O
.	.	O

Enalapril	NNP	O
and	CC	O
lisinopril	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
essential	JJ	O
hypertension	NN	Condition
.	.	O

Hypertensive	JJ	Condition
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
5	CD	O
mg	NN	O
of	IN	O
enalapril	NN	O
(	(	O
n	JJ	O
=	NNP	O
50	CD	O
)	)	O
or	CC	O
10	CD	O
mg	NN	O
of	IN	O
lisinopril	NN	O
(	(	O
n	JJ	O
=	NNP	O
47	CD	O
)	)	O
daily	RB	O
.	.	O

During	IN	O
a	DT	O
four-week	JJ	O
titration	NN	O
period	NN	O
,	,	O
the	DT	O
doses	NNS	O
were	VBD	O
increased	VBN	O
weekly	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
40	CD	O
mg	NNS	O
once	RB	O
daily	RB	O
until	IN	O
the	DT	O
treatment	NN	O
goal	NN	O
of	IN	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
of	IN	O
less	JJR	O
than	IN	O
90	CD	O
mmHg	NN	O
was	VBD	O
reached	VBN	O
;	:	O
treatment	NN	O
was	VBD	O
then	RB	O
continued	VBN	O
for	IN	O
four	CD	O
weeks	NNS	O
.	.	O

Systolic	NNP	O
and	CC	O
diastolic	JJ	O
BP	NNP	O
declined	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
two	CD	SampleSize
treatment	NN	O
groups	NNS	O
,	,	O
from	IN	O
147/98	CD	O
mmHg	NN	O
in	IN	O
both	CC	O
the	DT	O
enalapril	NN	O
and	CC	O
lisinopril	NN	O
groups	NNS	O
to	TO	O
126/82	CD	O
and	CC	O
122/81	CD	O
mmHg	NN	O
,	,	O
respectively	RB	O
,	,	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
treatment	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
week	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
goal	NN	O
of	IN	O
diastolic	JJ	O
BP	NNP	O
of	IN	O
less	JJR	O
than	IN	O
90	CD	O
mmHg	NN	O
was	VBD	O
reached	VBN	O
by	IN	O
40	CD	O
%	NN	O
of	IN	O
the	DT	O
enalapril	NN	O
group	NN	O
and	CC	O
62	CD	O
%	NN	O
of	IN	O
the	DT	O
lisinopril	NN	O
group	NN	O
;	:	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
titration	NN	O
period	NN	O
,	,	O
98	CD	O
%	NN	O
and	CC	O
96	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
had	VBD	O
achieved	VBN	O
the	DT	O
BP	NNP	O
goal	NN	O
.	.	O

Few	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
reported	VBN	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
abnormal	JJ	O
laboratory	NN	O
findings	NNS	O
during	IN	O
treatment	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
once-daily	JJ	O
administration	NN	O
of	IN	O
enalapril	NN	O
or	CC	O
lisinopril	NN	O
was	VBD	O
generally	RB	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
uncomplicated	JJ	O
essential	JJ	O
hypertension	NN	Condition
.	.	O

[	JJ	O
Drug	NNP	O
therapy	NN	O
of	IN	O
condylomata	NN	O
acuminata	NNS	O
]	RB	O
.	.	O

This	DT	O
study	NN	O
seeks	VBZ	O
to	TO	O
evaluate	VB	O
two	CD	O
candidate	NN	O
regimens	NNS	O
(	(	O
5-fluorouracil	JJ	O
and	CC	O
interferon	NN	O
)	)	O
as	IN	O
adjuvants	NNS	O
to	TO	O
optimally	RB	O
performed	VBN	O
laser	NN	O
surgery	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
condylomata	NN	Condition
acuminata	NNS	Condition
.	.	O

Skillful	NNP	O
laser	NN	O
ablation	NN	O
can	MD	O
remove	VB	O
any	DT	O
volume	NN	O
of	IN	O
human	JJ	O
papillomavirus-associated	JJ	O
vulvar	NN	O
disease	NN	O
but	CC	O
can	MD	O
not	RB	O
prevent	VB	O
reactivation	NN	O
of	IN	O
the	DT	O
surrounding	VBG	O
latent	JJ	O
viral	JJ	O
reservoir	NN	O
during	IN	O
postoperative	JJ	O
healing	NN	O
.	.	O

Conversely	RB	O
,	,	O
interferon	NN	O
and	CC	O
5-fluorouracil	JJ	O
are	VBP	O
relatively	RB	O
ineffective	JJ	O
as	IN	O
primary	JJ	O
therapies	NNS	O
.	.	O

This	DT	O
study	NN	O
involves	VBZ	O
118	CD	SampleSize
evaluable	JJ	O
patients	NNS	O
:	:	O
32	CD	SampleSize
in	IN	O
the	DT	O
laser-CO2	JJ	O
group	NN	O
,	,	O
34	CD	SampleSize
in	IN	O
the	DT	O
5-fluorouracil	JJ	O
group	NN	O
and	CC	O
52	CD	SampleSize
in	IN	O
the	DT	O
interferon	NN	O
group	NN	O
.	.	O

At	IN	O
assessment	NN	O
of	IN	O
final	JJ	O
outcome	NN	O
,	,	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
43	CD	O
of	IN	O
52	CD	O
(	(	O
82	CD	O
%	NN	O
)	)	O
assessable	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
adjuvant	JJ	O
interferon	NN	O
arm	NN	O
were	VBD	O
controlled	VBN	O
by	IN	O
a	DT	O
single	JJ	O
laser	NN	O
ablation	NN	O
as	IN	O
compared	VBN	O
with	IN	O
only	RB	O
17	CD	O
of	IN	O
34	CD	O
(	(	O
50	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
5-fluorouracil	JJ	O
group	NN	O
and	CC	O
13	CD	O
of	IN	O
32	CD	O
(	(	O
40	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
laser	NN	O
alone	RB	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistical	JJ	O
difference	NN	O
in	IN	O
outcome	NN	O
within	IN	O
the	DT	O
5-fluorouracil	JJ	O
and	CC	O
laser	VBZ	O
only	RB	O
arms	NNS	O
.	.	O

Conversely	RB	O
,	,	O
a	DT	O
relatively	RB	O
low	JJ	O
dose	NN	O
of	IN	O
recombinant	JJ	O
interferon	NN	O
,	,	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
effective	JJ	O
surgical	JJ	O
deleulking	NN	O
,	,	O
can	MD	O
markedly	RB	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
postoperative	JJ	O
recurrence	NN	O
.	.	O

Additive	JJ	O
IOP-reducing	JJ	O
effect	NN	O
of	IN	O
latanoprost	NN	O
in	IN	O
patients	NNS	O
insufficiently	RB	Condition
controlled	VBN	Condition
on	IN	O
timolol	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
on	IN	O
intraocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
of	IN	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
or	CC	O
adding	VBG	O
latanoprost	NN	O
to	TO	O
timolol	VB	O
in	IN	O
patients	NNS	O
with	IN	O
open	JJ	O
angle	NN	Condition
glaucoma	NN	Condition
or	CC	Condition
ocular	JJ	Condition
hypertension	NN	Condition
where	WRB	O
IOP	NNP	O
is	VBZ	O
not	RB	O
adequately	RB	O
controlled	VBN	O
with	IN	O
timolol	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
6-week	JJ	O
,	,	O
double-masked	JJ	O
,	,	O
randomised	VBD	O
multi-centre	NN	O
study	NN	O
.	.	O

53	CD	SampleSize
patients	NNS	O
with	IN	O
primary	JJ	Condition
open	JJ	Condition
angle	NN	Condition
glaucoma	NN	Condition
,	,	O
capsular	JJ	Condition
glaucoma	NN	Condition
,	,	O
or	CC	O
ocular	JJ	Condition
hypertension	NN	Condition
with	IN	O
an	DT	O
IOP	NNP	O
of	IN	O
at	IN	O
least	JJS	O
21	CD	O
mmHg	NN	O
on	IN	O
current	JJ	O
therapy	NN	O
were	VBD	O
recruited	VBN	O
.	.	O

After	IN	O
a	DT	O
run-in	JJ	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
2	CD	O
weeks	NNS	O
on	IN	O
timolol	NN	O
,	,	O
5	CD	O
mg/ml	NN	O
twice	RB	O
daily	RB	O
,	,	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
continued	VBD	O
on	IN	O
timolol	NN	O
,	,	O
one	CD	O
switched	VBN	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
,	,	O
50	CD	O
microg/ml	NN	O
once	RB	O
daily	JJ	O
,	,	O
and	CC	O
a	DT	O
third	JJ	O
group	NN	O
received	VBD	O
latanoprost	RB	O
in	IN	O
addition	NN	O
to	TO	O
timolol	VB	O
.	.	O

The	DT	O
efficacy	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
comparing	VBG	O
IOP	NNP	O
at	IN	O
9	CD	O
AM	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
IOP	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SEM	NNP	O
)	)	O
were	VBD	O
24.2	CD	O
+/-	JJ	O
0.9	CD	O
and	CC	O
23.8	CD	O
+/-	JJ	O
1.0	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
for	IN	O
patients	NNS	O
continuing	VBG	O
on	IN	O
timolol	NN	O
,	,	O
26.3	CD	O
+/-	JJ	O
1.2	CD	O
and	CC	O
19.6	CD	O
+/-	JJ	O
1.1	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
for	IN	O
patients	NNS	O
switching	VBG	O
to	TO	O
latanoprost	VB	O
,	,	O
and	CC	O
23.2	CD	O
+/-	JJ	O
1.0	CD	O
and	CC	O
17.5	CD	O
+/-	JJ	O
0.8	CD	O
mmHg	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
for	IN	O
patients	NNS	O
with	IN	O
combined	JJ	O
treatment	NN	O
.	.	O

Adding	VBG	O
latanoprost	NN	O
to	TO	O
timolol	VB	O
reduced	VBN	O
IOP	NNP	O
with	IN	O
5.9	CD	O
+/-	JJ	O
0.9	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
reduced	VBN	O
IOP	NNP	O
with	IN	O
5.0	CD	O
+/-	JJ	O
0.9	CD	O
mmHg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
which	WDT	O
caused	VBD	O
in	IN	O
each	DT	O
group	NN	O
a	DT	O
significant	JJ	O
IOP	NNP	O
reduction	NN	O
of	IN	O
about	RB	O
25	CD	O
%	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
effect	NN	O
of	IN	O
latanoprost	NN	O
was	VBD	O
additive	JJ	O
to	TO	O
that	DT	O
of	IN	O
timolol	NN	O
,	,	O
and	CC	O
a	DT	O
good	JJ	O
effect	NN	O
on	IN	O
IOP	NNP	O
reduction	NN	O
was	VBD	O
also	RB	O
achieved	VBN	O
by	IN	O
switching	VBG	O
from	IN	O
timolol	NN	O
to	TO	O
latanoprost	VB	O
,	,	O
suggesting	VBG	O
that	IN	O
a	DT	O
switch	NN	O
in	IN	O
many	JJ	O
patients	NNS	O
is	VBZ	O
an	DT	O
effective	JJ	O
alternative	NN	O
to	TO	O
combination	NN	O
treatment	NN	O
.	.	O

Unopposed	VBN	O
estrogen	NN	O
increases	NNS	O
total	JJ	O
plasma	JJ	O
factor	NN	O
VII	NNP	O
,	,	O
but	CC	O
not	RB	O
active	JJ	O
factor	NN	O
VII	NNP	O
--	:	O
a	DT	O
short-term	JJ	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
healthy	JJ	Condition
postmenopausal	NN	Condition
women	NNS	Sex
.	.	O

Estrogen	NNP	O
therapy	NN	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
arterial	JJ	O
thromboembolism	NN	O
,	,	O
at	IN	O
least	JJS	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
25	CD	SampleSize
healthy	JJ	Condition
postmenopausal	NN	Condition
women	NNS	Sex
(	(	O
52.5	CD	Age
+/-	JJ	Age
2.8	CD	Age
years	NNS	O
)	)	O
,	,	O
we	PRP	O
therefore	VBP	O
examined	VBD	O
the	DT	O
short-term	JJ	O
effect	NN	O
of	IN	O
unopposed	JJ	O
estrogen	NN	O
on	IN	O
the	DT	O
fasting	NN	O
and	CC	O
fat-load-stimulated	JJ	O
plasma	NN	O
levels	NNS	O
of	IN	O
total	JJ	O
factor	NN	O
VII	NNP	O
versus	NN	O
active	JJ	O
factor	NN	O
VII	NNP	O
.	.	O

Plasma	NNP	O
total	JJ	O
factor	NN	O
VII	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
use	NN	O
of	IN	O
a	DT	O
chromogenic	JJ	O
assay	NN	O
;	:	O
plasma	CC	O
active	JJ	O
FVII	NNP	O
by	IN	O
a	DT	O
recently	RB	O
developed	VBN	O
method	NN	O
using	VBG	O
truncated	JJ	O
tissue	NN	O
factor	NN	O
.	.	O

As	IN	O
compared	VBN	O
to	TO	O
placebo	VB	O
,	,	O
8	CD	O
weeks	NNS	O
of	IN	O
oral	JJ	O
17beta-estradiol	JJ	O
(	(	O
2	CD	O
mg	NNS	O
daily	RB	O
)	)	O
increased	VBD	O
the	DT	O
mean	NN	O
fasting	NN	O
and	CC	O
postprandial	JJ	O
plasma	NN	O
levels	NNS	O
of	IN	O
total	JJ	O
factor	NN	O
VII	NNP	O
by	IN	O
17	CD	O
and	CC	O
21	CD	O
%	NN	O
points	NNS	O
,	,	O
respectively	RB	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
fasting	NN	O
and/or	JJ	O
postprandial	JJ	O
plasma	NN	O
levels	NNS	O
of	IN	O
active	JJ	O
factor	NN	O
VII	NNP	O
(	(	O
mean	JJ	O
change	NN	O
both	DT	O
0.05	CD	O
ng/mL	NN	O
;	:	O
P	NNP	O
>	NNP	O
0.35	CD	O
)	)	O
.	.	O

Furthermore	UH	O
,	,	O
the	DT	O
change	NN	O
in	IN	O
the	DT	O
fasting	JJ	O
level	NN	O
of	IN	O
total	JJ	O
factor	NN	O
VII	NNP	O
after	IN	O
therapy	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
the	DT	O
change	NN	O
in	IN	O
the	DT	O
fasting	JJ	O
level	NN	O
of	IN	O
active	JJ	O
factor	NN	O
VII	NNP	O
(	(	O
r	VB	O
=	RB	O
0.27	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.21	CD	O
)	)	O
.	.	O

These	DT	O
findings	NNS	O
argue	VBP	O
against	IN	O
the	DT	O
idea	NN	O
that	WDT	O
elevated	VBD	O
levels	NNS	O
of	IN	O
total	JJ	O
factor	NN	O
VII	NNP	O
underlie	VBZ	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
arterial	JJ	O
thromboembolism	NN	O
in	IN	O
postmenopausal	JJ	Condition
women	NNS	Sex
using	VBG	O
unopposed	JJ	O
estrogen	NN	O
replacement	NN	O
.	.	O

POG	JJ	O
8625	CD	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
chemotherapy	NN	O
with	IN	O
chemoradiotherapy	NN	O
for	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
Stages	NNP	Condition
I	PRP	Condition
,	,	Condition
IIA	NNP	Condition
,	,	Condition
IIIA1	NNP	Condition
Hodgkin	NNP	Condition
Disease	NNP	Condition
:	:	O
a	DT	O
report	NN	O
from	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Oncology	NNP	O
Group	NNP	O
.	.	O

To	TO	O
determine	VB	O
if	IN	O
6	CD	O
courses	NNS	O
of	IN	O
chemotherapy	NN	O
alone	RB	O
could	MD	O
achieve	VB	O
the	DT	O
same	JJ	O
or	CC	O
better	JJR	O
outcome	NN	O
than	IN	O
4	CD	O
courses	NNS	O
of	IN	O
chemotherapy	NN	O
followed	VBN	O
by	IN	O
radiation	NN	O
therapy	NN	O
(	(	O
chemoradiotherapy	NN	O
)	)	O
in	IN	O
pediatric	JJ	Age
and	CC	O
adolescent	JJ	Age
patients	NNS	O
with	IN	O
Hodgkin	NNP	Condition
disease	NN	Condition
.	.	O

Children	NNP	Age
<	VBD	O
or	CC	O
=21	CD	O
years	NNS	O
old	JJ	O
with	IN	O
biopsy-proven	JJ	Condition
,	,	Condition
pathologically	RB	Condition
staged	VBD	Condition
I	PRP	Condition
,	,	Condition
IIA	NNP	Condition
,	,	Condition
or	CC	Condition
IIIA1	NNP	Condition
Hodgkin	NNP	Condition
disease	NN	Condition
were	VBD	O
randomly	RB	O
assigned	VBN	O
6	CD	O
courses	NNS	O
of	IN	O
alternating	VBG	O
nitrogen	JJ	O
mustard	NN	O
,	,	O
oncovin	NN	O
,	,	O
prednisone	NN	O
,	,	O
and	CC	O
procarbazine/doxorubicin	NN	O
,	,	O
bleomycin	NN	O
,	,	O
vinblastine	NN	O
,	,	O
and	CC	O
dacarbazine	NN	O
(	(	O
treatment	NN	O
1	CD	O
)	)	O
or	CC	O
4	CD	O
courses	NNS	O
of	IN	O
alternating	VBG	O
nitrogen	JJ	O
mustard	NN	O
,	,	O
oncovin	NN	O
,	,	O
prednisone	NN	O
,	,	O
and	CC	O
procarbazine/doxorubicin	NN	O
,	,	O
bleomycin	NN	O
,	,	O
vinblastine	NN	O
,	,	O
and	CC	O
dacarbazine	VB	O
+2550	JJ	O
cGy	JJ	O
involved-field	JJ	O
radiotherapy	NN	O
(	(	O
treatment	NN	O
2	CD	O
)	)	O
.	.	O

The	DT	O
complete	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
89	CD	O
%	NN	O
,	,	O
with	IN	O
a	DT	O
complete	JJ	O
response	NN	O
and	CC	O
partial	JJ	O
response	NN	O
rate	NN	O
of	IN	O
99.4	CD	O
%	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
event-free	JJ	O
survival	NN	O
(	(	O
EFS	NNP	O
)	)	O
or	CC	O
overall	JJ	O
survival	NN	O
between	IN	O
arms	NNS	O
.	.	O

The	DT	O
EFS	NNP	O
for	IN	O
those	DT	O
who	WP	O
achieved	VBD	O
an	DT	O
early	JJ	O
complete	JJ	O
response	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
for	IN	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

For	IN	O
pediatric	JJ	Age
patients	NNS	O
with	IN	O
asymptomatic	JJ	Condition
low-stage	NN	Condition
and	CC	Condition
intermediate-stage	NN	Condition
Hodgkin	NNP	Condition
disease	NN	Condition
,	,	O
chemotherapy	NN	O
and	CC	O
chemoradiotherapy	VB	O
both	DT	O
resulted	VBN	O
in	IN	O
3-year	JJ	O
EFS	NNP	O
of	IN	O
approximately	RB	O
90	CD	O
%	NN	O
and	CC	O
statistically	RB	O
indistinguishable	JJ	O
8-year	JJ	O
EFS	NNP	O
and	CC	O
overall	JJ	O
survival	NN	O
,	,	O
without	IN	O
significant	JJ	O
long-term	JJ	O
toxicity	NN	O
.	.	O

Early	JJ	O
response	NN	O
to	TO	O
therapy	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
higher	JJR	O
EFS	NNP	O
,	,	O
a	DT	O
concept	NN	O
that	WDT	O
has	VBZ	O
led	VBN	O
to	TO	O
the	DT	O
Children	NNP	O
's	POS	O
Oncology	NNP	O
Group	NNP	O
paradigm	NN	O
of	IN	O
response-based	JJ	O
risk-adapted	JJ	O
therapy	NN	O
for	IN	O
pediatric	JJ	O
Hodgkin	NNP	O
disease	NN	O
.	.	O

Acute	NNP	O
and	CC	O
long-term	JJ	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
risperidone	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	Condition
.	.	O

Treatment-emergent	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
monitored	VBN	O
during	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
risperidone	NN	O
(	(	O
0.5-3.5	JJ	O
mg/day	NN	O
)	)	O
in	IN	O
101	CD	Age
children	NNS	Age
and	CC	O
adolescents	NNS	Age
with	IN	O
a	DT	O
lifetime	JJ	O
diagnosis	NN	O
of	IN	O
autistic	JJ	Condition
disorder	NN	Condition
.	.	O

In	IN	O
addition	NN	O
,	,	O
37	CD	O
placebo	NN	O
nonresponders	NNS	O
received	VBD	O
open-label	JJ	O
risperidone	NN	O
for	IN	O
another	DT	O
8	CD	O
weeks	NNS	O
.	.	O

Of	IN	O
all	PDT	O
the	DT	O
risperidone	NN	O
responders	NNS	O
(	(	O
n=65	NN	O
)	)	O
,	,	O
63	CD	O
entered	VBD	O
an	DT	O
open	JJ	O
extension	NN	O
of	IN	O
another	DT	O
16	CD	O
weeks	NNS	O
(	(	O
6	CD	O
months	NNS	O
total	JJ	O
risperidone	NN	O
exposure	NN	O
)	)	O
,	,	O
and	CC	O
32	CD	O
of	IN	O
them	PRP	O
were	VBD	O
rerandomized	VBN	O
to	TO	O
either	DT	O
continued	VBN	O
risperidone	NN	O
therapy	NN	O
(	(	O
n=16	JJ	O
)	)	O
or	CC	O
gradual	JJ	O
replacement	NN	O
with	IN	O
placebo	NN	O
(	(	O
n=16	JJ	O
)	)	O
over	IN	O
8	CD	O
weeks	NNS	O
.	.	O

We	PRP	O
collected	VBD	O
the	DT	O
following	JJ	O
measures	NNS	O
of	IN	O
safety	NN	O
and	CC	O
tolerability	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
laboratory	NN	O
blood	NN	O
assessments	NNS	O
(	(	O
CBC	NNP	O
with	IN	O
differential	JJ	O
,	,	O
electrolytes	NNS	O
,	,	O
and	CC	O
liver	JJ	O
function	NN	O
tests	NNS	O
)	)	O
and	CC	O
urinalyses	NNS	O
,	,	O
(	(	O
2	CD	O
)	)	O
vital	NN	O
signs	NNS	O
,	,	O
(	(	O
3	CD	O
)	)	O
Side	NNP	O
Effects	NNP	O
Review	NNP	O
of	IN	O
AEs	NNP	O
thought	VBD	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
risperidone	NN	O
,	,	O
(	(	O
4	CD	O
)	)	O
sleep	NN	O
records	NNS	O
,	,	O
(	(	O
5	CD	O
)	)	O
Simpson	NNP	O
Angus	NNP	O
Neurological	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
SARS	NNP	O
)	)	O
,	,	O
(	(	O
6	CD	O
)	)	O
Abnormal	NNP	O
Involuntary	NNP	O
Movement	NNP	O
Scale	NNP	O
(	(	O
AIMS	NNP	O
)	)	O
,	,	O
and	CC	O
(	(	O
7	CD	O
)	)	O
height	NN	O
and	CC	O
weight	NN	O
.	.	O

No	DT	O
clinically	RB	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
on	IN	O
the	DT	O
lab	NN	O
tests	NNS	O
.	.	O

During	IN	O
the	DT	O
8-week	JJ	O
acute	JJ	O
trial	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
AEs	NNP	O
on	IN	O
the	DT	O
Side	NNP	O
Effects	NNP	O
Review	NNP	O
,	,	O
scored	VBD	O
as	IN	O
moderate	JJ	O
or	CC	O
higher	JJR	O
,	,	O
were	VBD	O
as	IN	O
follows	VBZ	O
(	(	O
placebo	NN	O
and	CC	O
risperidone	NN	O
,	,	O
respectively	RB	O
)	)	O
:	:	O
Somnolence	NN	O
(	(	O
12	CD	O
%	NN	O
and	CC	O
37	CD	O
%	NN	O
)	)	O
,	,	O
enuresis	NN	O
(	(	O
29	CD	O
%	NN	O
and	CC	O
33	CD	O
%	NN	O
)	)	O
,	,	O
excessive	JJ	O
appetite	NN	O
(	(	O
10	CD	O
%	NN	O
and	CC	O
33	CD	O
%	NN	O
)	)	O
,	,	O
rhinitis	NN	O
(	(	O
8	CD	O
%	NN	O
and	CC	O
16	CD	O
%	NN	O
)	)	O
,	,	O
difficulty	NN	O
waking	NN	O
(	(	O
8	CD	O
%	NN	O
and	CC	O
12	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
constipation	NN	O
(	(	O
12	CD	O
%	NN	O
and	CC	O
10	CD	O
%	NN	O
)	)	O
.	.	O

Difficulty	NN	O
falling	VBG	O
asleep	JJ	O
and	CC	O
anxiety	NN	O
actually	RB	O
favored	VBD	O
the	DT	O
risperidone	NN	O
condition	NN	O
at	IN	O
statistically	RB	O
significant	JJ	O
levels	NNS	O
.	.	O

The	DT	O
same	JJ	O
AEs	NNP	O
tended	VBD	O
to	TO	O
recur	VB	O
through	IN	O
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
,	,	O
although	IN	O
often	RB	O
at	IN	O
reduced	VBN	O
levels	NNS	O
.	.	O

Using	VBG	O
Centers	NNPS	O
for	IN	O
Disease	NNP	O
Control	NNP	O
(	(	O
CDC	NNP	O
)	)	O
standardized	VBD	O
scores	NNS	O
,	,	O
both	DT	O
weight	NN	O
and	CC	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
increased	VBD	O
with	IN	O
risperidone	NN	O
during	IN	O
the	DT	O
acute	JJ	O
trial	NN	O
(	(	O
0.5	CD	O
and	CC	O
0.6	CD	O
SDs	NNP	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
risperidone	NN	O
;	:	O
0.0	CD	O
and	CC	O
0.1	CD	O
SDs	NNP	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
placebo	NN	O
)	)	O
and	CC	O
into	IN	O
open-label	JJ	O
extension	NN	O
(	(	O
0.19	CD	O
and	CC	O
0.16	CD	O
SDs	NNP	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
although	IN	O
the	DT	O
amount	NN	O
of	IN	O
gain	NN	O
decelerated	VBN	O
with	IN	O
time	NN	O
.	.	O

Extrapyramidal	NNP	O
symptoms	NNS	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
the	DT	O
SARS	NNP	O
,	,	O
were	VBD	O
no	DT	O
more	RBR	O
common	JJ	O
for	IN	O
drug	NN	O
than	IN	O
placebo	NN	O
,	,	O
although	IN	O
drooling	NN	O
was	VBD	O
reported	VBN	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
risperidone	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
groups	NNS	O
on	IN	O
the	DT	O
AIMS	NNP	O
.	.	O

Two	CD	O
subjects	NNS	O
had	VBD	O
seizures	NNS	O
(	(	O
one	CD	O
taking	VBG	O
placebo	NN	O
)	)	O
,	,	O
but	CC	O
these	DT	O
were	VBD	O
considered	VBN	O
unrelated	JJ	O
to	TO	O
active	JJ	O
drug	NN	O
.	.	O

Most	JJS	O
AEs	NNPS	O
were	VBD	O
mild	JJ	O
to	TO	O
moderate	VB	O
and	CC	O
failed	VBD	O
to	TO	O
interfere	VB	O
with	IN	O
therapeutic	JJ	O
changes	NNS	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
unanticipated	JJ	O
AEs	NNP	O
.	.	O

The	DT	O
side	NN	O
effects	NNS	O
of	IN	O
most	JJS	O
concern	NN	O
were	VBD	O
somnolence	NN	O
and	CC	O
weight	JJ	O
gain	NN	O
.	.	O

The	DT	O
tension-free	JJ	O
hernioplasty	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
tension-free	JJ	O
hernioplasty	NN	O
as	IN	O
introduced	VBN	O
by	IN	O
Lichtenstein	NNP	O
has	VBZ	O
gained	VBN	O
increasing	VBG	O
acceptance	NN	O
during	IN	O
the	DT	O
last	JJ	O
decade	NN	O
although	IN	O
the	DT	O
technique	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
randomized	VBN	O
study	NN	O
compares	VBZ	O
the	DT	O
2-year	JJ	O
follow-up	JJ	O
results	NNS	O
after	IN	O
102	CD	SampleSize
tension-free	JJ	O
hernioplasties	NNS	Condition
with	IN	O
implantation	NN	O
of	IN	O
a	DT	O
prolene	NN	O
mesh	NN	O
in	IN	O
all	DT	O
groin	NN	Condition
hernias	VBD	Condition
to	TO	O
53	CD	SampleSize
Cooper	NNP	O
ligament	NN	O
repairs	NNS	O
in	IN	O
direct	JJ	Condition
hernias	NN	Condition
and	CC	O
53	CD	SampleSize
abdominal	JJ	O
ring	NN	O
repairs	NNS	O
in	IN	O
indirect	JJ	Condition
hernias	NN	Condition
.	.	O

RESULTS	NNP	O
After	IN	O
tension-free	JJ	O
repairs	NNS	O
five	CD	O
hernias	NNS	O
recurred	VBN	O
(	(	O
5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
after	IN	O
either	DT	O
Cooper	NNP	O
ligament	NN	O
or	CC	O
abdominal	JJ	O
ring	NN	O
repair	NN	O
,	,	O
16	CD	O
recurrences	NNS	O
were	VBD	O
found	VBN	O
(	(	O
15	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

No	UH	O
indirect	JJ	O
hernias	NN	O
recurred	VBD	O
after	IN	O
a	DT	O
tension-free	JJ	O
repair	NN	O
;	:	O
2	CD	O
recurred	VBD	O
after	IN	O
abdominal	JJ	O
ring	NN	O
repair	NN	O
(	(	O
4	CD	O
%	NN	O
;	:	O
NS	NNP	O
)	)	O
.	.	O

The	DT	O
recurrence	NN	O
rate	NN	O
after	IN	O
tension-free	JJ	O
repairs	NNS	O
for	IN	O
primary	JJ	O
direct	JJ	O
inguinal	JJ	O
hernias	NN	O
was	VBD	O
7	CD	O
%	NN	O
as	IN	O
compared	VBN	O
with	IN	O
30	CD	O
%	NN	O
after	IN	O
Cooper	NNP	O
ligament	NN	O
repair	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0081	CD	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
complication	NN	O
rate	NN	O
between	IN	O
the	DT	O
tested	JJ	O
methods	NNS	O
was	VBD	O
found	VBN	O
.	.	O

CONCLUSION	JJ	O
Recurrence	NNP	O
rate	NN	O
is	VBZ	O
reduced	VBN	O
to	TO	O
one-third	JJ	O
after	IN	O
tension-free	JJ	Condition
herniotomies	NNS	Condition
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
conventionel	NN	O
herniotomies	NNS	O
without	IN	O
increase	NN	O
in	IN	O
complication	NN	O
rate	NN	O
.	.	O

Investigation	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
FK506	NNP	O
(	(	O
tacrolimus	NN	O
)	)	O
and	CC	O
cyclosporin	NN	O
on	IN	O
gingival	JJ	O
overgrowth	NN	O
following	VBG	O
paediatric	JJ	Age
liver	JJ	O
transplantation	NN	O
.	.	O

INTRODUCTION	NNP	O
Gingival	NNP	O
overgrowth	NN	O
associated	VBN	O
with	IN	O
immunosuppression	NN	O
following	VBG	O
liver	JJ	O
transplantation	NN	O
is	VBZ	O
a	DT	O
commonly	RB	O
recognized	VBN	O
clinical	JJ	O
problem	NN	O
.	.	O

The	DT	O
aims	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
determine	VB	O
the	DT	O
incidence	NN	O
of	IN	O
gingival	JJ	O
overgrowth	NN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
children	NNS	Age
post	VBN	O
liver	JJ	O
transplantation	NN	O
and	CC	O
to	TO	O
compare	VB	O
gingival	JJ	Condition
overgrowth	NN	Condition
in	IN	O
children	NNS	O
receiving	VBG	O
FK506	NNP	O
with	IN	O
those	DT	O
receiving	VBG	O
cyclosporin	NN	O
.	.	O

METHODS	NNP	O
Seventy-nine	JJ	SampleSize
children	NNS	O
(	(	O
aged	VBN	O
15-196	CD	O
months	NNS	O
)	)	O
undergoing	VBG	O
liver	JJ	O
transplantation	NN	O
at	IN	O
Birmingham	NNP	O
Children	NNP	O
's	POS	O
Hospital	NNP	O
between	IN	O
October	NNP	O
1998	CD	O
and	CC	O
October	NNP	O
2000	CD	O
were	VBD	O
studied	VBN	O
.	.	O

Gingival	NNP	O
overgrowth	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
blinded	JJ	O
fashion	NN	O
and	CC	O
scored	VBN	O
in	IN	O
a	DT	O
previously	RB	O
validated	VBN	O
manner	NN	O
.	.	O

Gingival	NNP	O
overgrowth	NN	O
scores	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
on	IN	O
each	DT	O
immunosuppressant	JJ	O
drug	NN	O
were	VBD	O
then	RB	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
Fifty-two	JJ	Condition
patients	NNS	Condition
were	VBD	O
treated	VBN	O
with	IN	O
cyclosporin	NN	O
and	CC	O
27	CD	O
treated	VBN	O
with	IN	O
tacrolimus	NN	O
.	.	O

Eighteen	JJ	O
children	NNS	Age
were	VBD	O
also	RB	O
receiving	VBG	O
nifedipine	NN	O
(	(	O
also	RB	O
known	VBN	O
to	TO	O
cause	VB	O
gingival	JJ	O
overgrowth	NN	O
)	)	O
and	CC	O
were	VBD	O
considered	VBN	O
separately	RB	O
.	.	O

Of	IN	O
the	DT	O
41	CD	SampleSize
children	NNS	Age
receiving	VBG	O
cyclosporin	NN	O
alone	RB	O
,	,	O
26	CD	SampleSize
exhibited	VBD	O
gingival	NN	Condition
overgrowth	NN	Condition
compared	VBN	O
to	TO	O
zero	CD	SampleSize
of	IN	SampleSize
20	CD	SampleSize
patients	NNS	SampleSize
receiving	VBG	O
tacrolimus	JJ	O
alone	RB	O
.	.	O

Those	DT	O
children	NNS	O
treated	VBN	O
with	IN	O
immunosuppression	NN	O
plus	CC	O
nifedipine	NN	O
developed	VBD	O
gingival	JJ	O
overgrowth	NN	O
,	,	O
however	RB	O
,	,	O
this	DT	O
was	VBD	O
much	RB	O
less	JJR	O
marked	VBN	O
in	IN	O
the	DT	O
tacrolimus	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Tacrolimus	NNP	O
,	,	O
unlike	IN	O
cyclosporin	NN	O
,	,	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
gingival	NN	O
overgrowth	NN	O
when	WRB	O
used	VBN	O
for	IN	O
immunosuppression	NN	O
following	VBG	O
liver	JJ	O
transplantation	NN	O
in	IN	O
children	NNS	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
the	DT	O
drug	NN	O
of	IN	O
choice	NN	O
for	IN	O
children	NNS	O
.	.	O

Temporal	JJ	O
variation	NN	O
in	IN	O
the	DT	O
effects	NNS	O
of	IN	O
ophthalmic	JJ	O
timolol	NN	O
on	IN	O
cardiovascular	NN	O
and	CC	O
respiratory	JJ	O
functions	NNS	O
in	IN	O
healthy	JJ	O
men	NNS	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
ophthalmic	JJ	O
timolol	NN	O
and	CC	O
time	NN	O
of	IN	O
administration	NN	O
on	IN	O
cardiovascular	JJ	O
and	CC	O
respiratory	JJ	O
functions	NNS	O
in	IN	O
healthy	JJ	O
young	JJ	O
male	NN	O
volunteers	NNS	O
.	.	O

Eight	CD	O
participants	NNS	O
(	(	O
mean	JJ	O
age	NN	O
+/-	JJ	O
standard	NN	O
deviation	NN	O
,	,	O
22	CD	O
+/-	JJ	O
0.9	CD	O
years	NNS	O
)	)	O
received	VBD	O
either	CC	O
50	CD	O
microL	NN	O
of	IN	O
0.5	CD	O
%	NN	O
timolol	NN	O
or	CC	O
placebo	NN	O
in	IN	O
the	DT	O
lower	JJR	O
conjunctival	NN	O
sacs	NN	O
of	IN	O
both	DT	O
eyes	NNS	O
in	IN	O
the	DT	O
morning	NN	O
or	CC	O
evening	NN	O
.	.	O

Intraocular	JJ	O
pressure	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
and	CC	O
respiratory	JJ	O
functions	NNS	O
,	,	O
including	VBG	O
percent	NN	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
1	CD	O
second	JJ	O
and	CC	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
rate	NN	O
,	,	O
were	VBD	O
then	RB	O
measured	VBN	O
for	IN	O
3	CD	O
hours	NNS	O
after	IN	O
drug	NN	O
administration	NN	O
.	.	O

Timolol	NNP	O
reduced	VBD	O
intraocular	JJ	O
pressure	NN	O
and	CC	O
cardiovascular	JJ	O
function	NN	O
at	IN	O
both	DT	O
administration	NN	O
times	NNS	O
.	.	O

However	RB	O
,	,	O
a	DT	O
timolol-induced	JJ	O
reduction	NN	O
in	IN	O
respiratory	NN	O
function	NN	O
was	VBD	O
observed	VBN	O
only	RB	O
in	IN	O
the	DT	O
evening	NN	O
:	:	O
percent	NN	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
1	CD	O
second	JJ	O
,	,	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
rate	NN	O
,	,	O
and	CC	O
expiratory	JJ	O
flow	NN	O
rate	NN	O
at	IN	O
75	CD	O
%	NN	O
vital	JJ	O
capacity	NN	O
were	VBD	O
reduced	VBN	O
by	IN	O
3	CD	O
%	NN	O
,	,	O
7	CD	O
%	NN	O
,	,	O
and	CC	O
12	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
3	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
ophthalmic	JJ	O
timolol	NN	O
reduces	NNS	O
cardiovascular	JJ	O
and	CC	O
respiratory	JJ	O
functions	NNS	O
in	IN	O
healthy	JJ	O
young	JJ	O
male	JJ	O
subjects	NNS	O
and	CC	O
that	DT	O
bronchial	JJ	O
sensitivity	NN	O
to	TO	O
timolol	VB	O
differs	NNS	O
between	IN	O
morning	NN	O
and	CC	O
evening	NN	O
.	.	O

Minimal	JJ	O
tolerance	NN	O
to	TO	O
the	DT	O
bronchoprotective	JJ	O
effect	NN	O
of	IN	O
inhaled	JJ	O
salmeterol/fluticasone	NN	O
combination	NN	O
on	IN	O
allergene	JJ	O
challenge	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
assess	VB	O
whether	IN	O
the	DT	O
administration	NN	O
of	IN	O
salmeterol/fluticasone	JJ	O
propionate	NN	O
combination	NN	O
(	(	O
50/250	CD	O
mcg	NN	O
by	IN	O
Diskus	NNP	O
)	)	O
for	IN	O
1	CD	O
week	NN	O
induces	NNS	O
tolerance	NN	O
to	TO	O
the	DT	O
bronchoprotective	JJ	O
effect	NN	O
of	IN	O
salmeterol	NN	O
on	IN	O
allergen	NN	O
challenge	NN	O
,	,	O
a	DT	O
single-blind	JJ	O
,	,	O
cross-over	JJ	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

We	PRP	O
studied	VBD	O
nine	CD	O
subjects	NNS	O
(	(	O
eight	CD	O
men	NNS	O
and	CC	O
one	CD	O
woman	NN	O
;	:	O
mean	JJ	O
age+/-SD	NN	O
:	:	O
31.3+/-11.0	JJ	O
yr	NN	O
)	)	O
with	IN	O
mild	JJ	O
intermittent	JJ	O
allergic	NN	O
asthma	NN	O
,	,	O
never	RB	O
treated	VBN	O
with	IN	O
regular	JJ	O
beta2-agonists	NNS	O
or	CC	O
inhaled	JJ	O
corticosteroids	NNS	O
.	.	O

In	IN	O
a	DT	O
previous	JJ	O
allergen	NN	O
challenge	NN	O
all	DT	O
subjects	NNS	O
had	VBD	O
shown	VBN	O
a	DT	O
positive	JJ	O
early	JJ	O
airway	NN	O
response	NN	O
(	(	O
EAR	NNP	O
)	)	O
to	TO	O
allergen	VB	O
.	.	O

They	PRP	O
underwent	JJ	O
allergen	NN	O
challenge	NN	O
after	IN	O
1-week	JJ	O
treatment	NN	O
with	IN	O
placebo	NN	O
and	CC	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
placebo	NN	O
immediately	RB	O
before	IN	O
allergen	NN	O
challenge	NN	O
(	(	O
T1	NNP	O
)	)	O
,	,	O
or	CC	O
1-week	JJ	O
treatment	NN	O
with	IN	O
placebo	NN	O
and	CC	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
salmeterol/fluticasone	NN	O
immediately	RB	O
before	IN	O
allergen	NN	O
challenge	NN	O
(	(	O
T2	NNP	O
)	)	O
,	,	O
or	CC	O
1-week	JJ	O
treatment	NN	O
with	IN	O
salmeterol/fluticasone	JJ	O
combination	NN	O
bid	NN	O
and	CC	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
salmeterol/fluticasone	NN	O
immediately	RB	O
before	IN	O
allergen	NN	O
challenge	NN	O
(	(	O
T3	NNP	O
)	)	O
.	.	O

EAR	NN	O
was	VBD	O
evaluated	VBN	O
both	DT	O
as	IN	O
maximum	NN	O
decrease	NN	O
in	IN	O
FEV1	NNP	O
(	(	O
MaxDeltaFEV1	NNP	O
%	NN	O
)	)	O
after	IN	O
allergen	NN	O
challenge	NN	O
and	CC	O
as	IN	O
area	NN	O
under	IN	O
FEV1	NNP	O
-time	NNP	O
curve	NN	O
.	.	O

MaxDeltaFEV1	NNP	O
%	NN	O
during	IN	O
allergen	NN	O
challenge	NN	O
protected	VBN	O
by	IN	O
placebo	NN	O
(	(	O
T1	NNP	O
)	)	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
MaxDeltaFEV1	NNP	O
%	NN	O
during	IN	O
allergen	NN	O
challenges	NNS	O
protected	VBN	O
by	IN	O
single	JJ	O
dose	NN	O
of	IN	O
salmeterol/fluticasone	NN	O
(	(	O
T2	NNP	O
)	)	O
and	CC	O
by	IN	O
salmeterol/fluticasone	JJ	O
1-week	JJ	O
treatment	NN	O
(	(	O
T3	NNP	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
found	VBN	O
in	IN	O
MaxDeltaFEV1	NNP	O
%	NN	O
between	IN	O
T2	NNP	O
and	CC	O
T3	NNP	O
.	.	O

The	DT	O
same	JJ	O
results	NNS	O
were	VBD	O
observed	VBN	O
also	RB	O
after	IN	O
computing	VBG	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
for	IN	O
each	DT	O
challenge	NN	O
.	.	O

When	WRB	O
individually	RB	O
considered	VBN	O
,	,	O
all	DT	O
subjects	NNS	O
were	VBD	O
protected	VBN	O
against	IN	O
EAR	NNP	O
(	(	O
protection	NN	O
index	NN	O
>	VBD	O
or	CC	O
=	VB	O
80	CD	O
%	NN	O
)	)	O
at	IN	O
T2	NNP	O
,	,	O
while	IN	O
at	IN	O
3	CD	O
seven	CD	O
out	IN	O
of	IN	O
nine	CD	O
subjects	NNS	O
were	VBD	O
still	RB	O
protected	VBN	O
against	IN	O
EAR	NNP	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
simultaneous	JJ	O
administration	NN	O
of	IN	O
salmeterol	NN	O
and	CC	O
fluticasone	NN	O
in	IN	O
the	DT	O
same	JJ	O
device	NN	O
prevents	NNS	O
in	IN	O
almost	RB	O
80	CD	O
%	NN	O
of	IN	O
examined	JJ	O
subjects	NNS	O
the	DT	O
development	NN	O
of	IN	O
tolerance	NN	O
to	TO	O
the	DT	O
protective	JJ	O
effect	NN	O
of	IN	O
salmeterol	NN	O
on	IN	O
allergen	NN	O
challenge	NN	O
.	.	O

This	DT	O
observation	NN	O
may	MD	O
contribute	VB	O
to	TO	O
explain	VB	O
the	DT	O
positive	JJ	O
interaction	NN	O
between	IN	O
inhaled	VBN	O
beta2-agonists	NNS	O
and	CC	O
corticosteroids	NNS	O
in	IN	O
the	DT	O
long-term	JJ	O
treatment	NN	O
of	IN	O
asthma	NN	O
.	.	O

Paracervical	JJ	O
anesthesia	NN	O
for	IN	O
outpatient	JJ	O
hysteroscopy	NN	O
.	.	O

One	CD	SampleSize
hundred	VBD	SampleSize
seventy-seven	JJ	SampleSize
women	NNS	Sex
aged	VBD	O
41	CD	Age
+/-	JJ	Age
8	CD	Age
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
years	NNS	O
,	,	O
referred	VBD	O
for	IN	O
evaluation	NN	O
of	IN	O
excessive	JJ	Condition
uterine	JJ	Condition
bleeding	NN	Condition
,	,	O
were	VBD	O
enrolled	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
randomized	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
local	JJ	O
anesthesia	NN	O
before	IN	O
hysteroscopy	NN	O
in	IN	O
an	DT	O
outpatient	JJ	O
population	NN	O
.	.	O

The	DT	O
patients	NNS	O
underwent	JJ	O
hysteroscopy	NN	O
and	CC	O
endometrial	JJ	O
biopsy	NN	O
with	IN	O
paracervical	JJ	O
block	NN	O
by	IN	O
10	CD	O
mL	NNS	O
of	IN	O
1	CD	O
%	NN	O
mepivacaine	NN	O
hydrochloride	JJ	O
solution	NN	O
(	(	O
n	JJ	O
=	NNP	O
87	CD	O
)	)	O
or	CC	O
no	DT	O
local	JJ	O
anesthesia	NN	O
(	(	O
n	JJ	O
=	NNP	O
90	CD	O
)	)	O
and	CC	O
assessed	VBD	O
lower	JJR	O
abdominal	JJ	O
and	CC	O
pelvic	JJ	O
pain	NN	O
according	VBG	O
to	TO	O
a	DT	O
10-point	JJ	O
linear	JJ	O
analog	NN	O
scale	NN	O
.	.	O

The	DT	O
mean	JJ	O
+/-	JJ	O
SD	NNP	O
pain	NN	O
score	NN	O
was	VBD	O
4.5	CD	O
+/-	JJ	O
2.0	CD	O
at	IN	O
hysteroscopy	NN	O
and	CC	O
5.2	CD	O
+/-	JJ	O
2.1	CD	O
at	IN	O
endometrial	JJ	O
biopsy	NN	O
in	IN	O
the	DT	O
87	CD	O
subjects	NNS	O
given	VBN	O
a	DT	O
paracervical	JJ	O
block	NN	O
versus	NN	O
4.9	CD	O
+/-	JJ	O
2.2	CD	O
and	CC	O
5.7	CD	O
+/-	JJ	O
2.4	CD	O
in	IN	O
the	DT	O
90	CD	O
women	NNS	O
not	RB	O
given	VBN	O
local	JJ	O
anesthesia	NN	O
,	,	O
without	IN	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
.	.	O

Paracervical	JJ	O
anesthesia	NN	O
for	IN	O
routine	JJ	O
outpatient	NN	O
hysteroscopy	NN	O
in	IN	O
premenopausal	JJ	Age
women	NNS	O
may	MD	O
be	VB	O
superfluous	JJ	O
.	.	O

[	JJ	O
Complaints	NNS	O
in	IN	O
the	DT	O
postoperative	JJ	O
phase	NN	O
related	VBN	O
to	TO	O
anesthetics	NNS	Condition
]	NNP	O
.	.	O

In	IN	O
two	CD	O
prospective	JJ	O
,	,	O
randomized	JJ	O
studies	NNS	O
the	DT	O
frequency	NN	O
of	IN	O
headache	NN	O
,	,	O
nausea	NN	O
,	,	O
vomiting	NN	O
,	,	O
and	CC	O
analgesic	JJ	O
requirement	NN	O
during	IN	O
the	DT	O
first	JJ	O
postoperative	JJ	O
24	CD	O
h	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
order	NN	O
to	TO	O
study	VB	O
differences	NNS	O
between	IN	O
the	DT	O
sexes	NNS	O
and	CC	O
the	DT	O
inhalation	NN	O
anesthetics	NNS	O
halothane	NN	O
,	,	O
enflurane	NN	O
,	,	O
isoflurane	NN	O
,	,	O
or	CC	O
balanced	VBD	O
anesthesia	NNS	O
with	IN	O
enflurane/alfentanil	NN	O
.	.	O

Nausea	NN	O
and	CC	O
vomiting	NN	O
were	VBD	O
more	RBR	O
frequent	JJ	O
after	IN	O
enflurane	NN	O
than	IN	O
after	IN	O
halothane	NN	O
or	CC	O
isoflurane	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
anesthetics	NNS	O
and	CC	O
frequency	NN	O
of	IN	O
headache	NN	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
significant	JJ	O
differences	NNS	O
in	IN	O
postoperative	JJ	O
analgesic	NN	O
requirements	NNS	O
which	WDT	O
were	VBD	O
highest	JJS	O
after	IN	O
halothane	NN	O
and	CC	O
lowest	JJS	O
after	IN	O
isoflurane	NN	O
.	.	O

Postoperative	JJ	O
complaints	NNS	O
were	VBD	O
always	RB	O
significantly	RB	O
greater	JJR	O
among	IN	O
women	NNS	O
than	IN	O
among	IN	O
men	NNS	O
.	.	O

The	DT	O
second	JJ	O
study	NN	O
indicated	VBD	O
that	IN	O
balanced	VBD	O
anesthesia	NN	O
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
analgesic	JJ	O
requirement	NN	O
compared	VBN	O
to	TO	O
enflurane	VB	O
without	IN	O
alfentanil	NN	O
,	,	O
but	CC	O
lead	VBP	O
to	TO	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
vomiting	VBG	O
.	.	O

After	IN	O
premedication	NN	O
with	IN	O
flunitrazepam	NN	O
and	CC	O
atropine	NN	O
and	CC	O
combined	VBN	O
with	IN	O
70	CD	O
%	NN	O
N2O/30	NNP	O
%	NN	O
O2	NNP	O
,	,	O
isoflurane	NN	O
was	VBD	O
the	DT	O
most	RBS	O
favorable	JJ	O
anesthetic	JJ	O
agent	NN	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
parameters	NNS	O
studied	VBN	O
.	.	O

Balanced	NNP	O
anesthesia	NN	O
with	IN	O
enflurane/alfentanil	NN	O
did	VBD	O
not	RB	O
show	VB	O
any	DT	O
advantages	NNS	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
postoperative	JJ	Condition
phase	NN	Condition
under	IN	O
the	DT	O
given	VBN	O
conditions	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
amlodipine	NN	O
and	CC	O
enalapril	NN	O
on	IN	O
platelet	NN	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
hypertension	NN	Condition
.	.	O

OBJECTIVE	CC	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
amlodipine	NN	O
and	CC	O
enalapril	NN	O
on	IN	O
platelet	NN	O
aggregation	NN	O
,	,	O
and	CC	O
platelet	NN	O
production	NN	O
of	IN	O
malondialdehyde	NN	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
arterial	JJ	Condition
hypertension	NN	Condition
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
parallel	NN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
24	CD	SampleSize
patients	NNS	O
(	(	O
2	CD	O
groups	NNS	O
of	IN	O
12	CD	SampleSize
patients	NNS	O
each	DT	O
)	)	O
.	.	O

Initially	RB	O
all	DT	O
patients	NNS	O
received	VBD	O
placebo	NNS	O
for	IN	O
four	CD	O
weeks	NNS	O
;	:	O
then	RB	O
amlodipine	VB	O
,	,	O
5	CD	O
mg	JJ	O
daily	JJ	O
or	CC	O
enalapril	JJ	O
20	CD	O
mg	JJ	O
daily	RB	O
taken	VBN	O
once	RB	O
a	DT	O
day	NN	O
at	IN	O
7	CD	O
am	VBP	O
.	.	O

Dosage	NN	O
was	VBD	O
doubled	VBN	O
after	IN	O
4	CD	O
weeks	NNS	O
when	WRB	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
was	VBD	O
>	JJ	O
90	CD	O
mmHg	NN	O
in	IN	O
sitting	VBG	O
position	NN	O
,	,	O
the	DT	O
treatment	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
placebo	NN	O
and	CC	O
active	JJ	O
phases	NNS	O
a	DT	O
platelet	NN	O
aggregation	NN	O
test	NN	O
,	,	O
using	VBG	O
adenosine	JJ	O
diphosphate	NN	O
,	,	O
collagen	NN	O
and	CC	O
adrenaline	NN	O
,	,	O
and	CC	O
a	DT	O
platelet	NN	O
malondialdehyde	NN	O
production	NN	O
test	NN	O
,	,	O
either	RB	O
in	IN	O
basal	NN	O
conditions	NNS	O
(	(	O
MDA-basal	NNP	O
)	)	O
and	CC	O
after	IN	O
the	DT	O
stimulation	NN	O
of	IN	O
arachidonic	JJ	O
acid	NNS	O
pathway	RB	O
by	IN	O
adding	VBG	O
ethylmaleimide	NN	O
(	(	O
MDA-activated	JJ	O
)	)	O
were	VBD	O
carried	VBN	O
out	RP	O
.	.	O

RESULTS	VB	O
Blood	NNP	O
pressure	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
both	DT	O
agents	NNS	O
,	,	O
enalapril	NN	O
and	CC	O
amlodipine	NN	O
.	.	O

Enalapril	NNP	O
controlled	VBD	O
58.3	CD	O
%	NN	O
of	IN	O
hypertensive	JJ	Condition
patients	NNS	O
with	IN	O
an	DT	O
average	JJ	O
dosage	NN	O
of	IN	O
31.7	CD	O
mg/daily	RB	O
.	.	O

Amlodipine	NNP	O
controlled	VBD	O
75	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
dosage	NN	O
of	IN	O
7.1	CD	O
mg/daily	RB	O
.	.	O

Platelet	NNP	O
aggregation	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
amlodipine	NN	O
in	IN	O
15.9	CD	O
%	NN	O
for	IN	O
ADP	NNP	O
(	(	O
10	CD	O
microM	NN	O
)	)	O
;	:	O
17.4	CD	O
%	NN	O
for	IN	O
collagen	NN	O
(	(	O
2	CD	O
microg/ml	NN	O
)	)	O
and	CC	O
19.9	CD	O
%	NN	O
for	IN	O
adrenaline	NN	O
(	(	O
2	CD	O
microM	NN	O
)	)	O
(	(	O
p	JJ	O
<	NNP	O
0.025	CD	O
)	)	O
.	.	O

Meanwhile	RB	O
enalapril	JJ	O
slightly	RB	O
increased	VBN	O
platelet	NN	O
aggregation	NN	O
by	IN	O
6.7	CD	O
%	NN	O
,	,	O
1.3	CD	O
%	NN	O
and	CC	O
5.6	CD	O
%	NN	O
for	IN	O
the	DT	O
three	CD	O
agents	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
>	NN	O
0.05	CD	O
,	,	O
ns	NN	O
)	)	O
.	.	O

Malondialdehyde	NNP	O
was	VBD	O
reduced	VBN	O
by	IN	O
amlodipine	NN	O
in	IN	O
45.33	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
for	IN	O
MDA-basal	NNP	O
;	:	O
3.76	CD	O
%	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
for	IN	O
MDA-activated	NNP	O
;	:	O
and	CC	O
the	DT	O
ratio	JJ	O
MDA-basal	JJ	O
:	:	O
MDA-activated	JJ	O
in	IN	O
36.79	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

Meanwhile	RB	O
enalapril	JJ	O
increased	VBD	O
MDA-basal	NNP	O
in	IN	O
2.89	CD	O
%	NN	O
;	:	O
MDA-activated	NNP	O
in	IN	O
3.58	CD	O
%	NN	O
and	CC	O
reduced	VBD	O
the	DT	O
ratio	NN	O
MDA-basal	JJ	O
:	:	O
MDA-activated	JJ	O
,	,	O
in	IN	O
10.34	CD	O
%	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Both	DT	O
agents	NNS	O
,	,	O
enalapril	NN	O
and	CC	O
amlodipine	NN	O
,	,	O
reduced	VBD	O
blood	NN	O
pressure	NN	O
,	,	O
but	CC	O
only	RB	O
amlodipine	VB	O
reduced	VBN	O
platelet	JJ	O
aggregation	NN	O
and	CC	O
platelet	NN	O
production	NN	O
of	IN	O
malondialdehyde	NN	O
,	,	O
indicating	VBG	O
its	PRP$	O
action	NN	O
on	IN	O
the	DT	O
arachidonic	JJ	O
acid	NN	O
metabolic	JJ	O
pathway	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
asthma	NN	O
knowledge	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
Hungarian	JJ	O
asthmatics	NNS	Condition
.	.	O

BACKGROUND	IN	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
develop	VB	O
an	DT	O
educational	JJ	O
instrument	NN	O
,	,	O
to	TO	O
assess	VB	O
its	PRP$	O
impact	NN	O
as	IN	O
an	DT	O
intervention	NN	O
instrument	NN	O
and	CC	O
to	TO	O
examine	VB	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
.	.	O

METHODS	$	O
119	CD	SampleSize
asthmatics	NNS	O
were	VBD	O
randomized	VBN	O
(	(	O
64	CD	O
in	IN	O
the	DT	O
intervention	NN	O
and	CC	O
55	CD	O
in	IN	O
the	DT	O
reference	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
education	NN	O
instrument	NN	O
was	VBD	O
developed	VBN	O
based	VBN	O
on	IN	O
the	DT	O
EuroPharm-Forum	NNP	O
Guidelines	NNP	O
and	CC	O
its	PRP$	O
impact	NN	O
assessed	VBN	O
by	IN	O
a	DT	O
self-developed	JJ	O
questionnaire	NN	O
.	.	O

Patients	NNS	O
'	POS	O
QoL	NNP	O
,	,	O
asthma	NN	O
knowledge	NN	O
was	VBD	O
assessed	VBN	O
twice	RB	O
,	,	O
once	RB	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
education	NN	O
seminar	NN	O
,	,	O
education	NN	O
was	VBD	O
only	RB	O
provided	VBN	O
for	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

QoL	NNP	O
was	VBD	O
measured	VBN	O
with	IN	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
and	CC	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
We	PRP	O
found	VBD	O
significant	JJ	O
differences	NNS	O
in	IN	O
answers	NNS	O
to	TO	O
the	DT	O
asthma	JJ	O
questions	NNS	O
,	,	O
by	IN	O
40	CD	O
%	NN	O
improvement	NN	O
,	,	O
but	CC	O
no	DT	O
changes	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
inhaler-use	NN	O
technique	NN	O
,	,	O
we	PRP	O
could	MD	O
not	RB	O
find	VB	O
significant	JJ	O
changes	NNS	O
neither	CC	O
in	IN	O
the	DT	O
intervention	NN	O
nor	CC	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
two	CD	O
visits	NNS	O
neither	CC	O
with	IN	O
the	DT	O
VAS	NNP	O
nor	CC	O
with	IN	O
the	DT	O
SGRQ	NNP	O
on	IN	O
the	DT	O
QoL	NNP	O
data	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
asthmatics	NNS	O
experience	VB	O
lower	JJR	O
QoL	NNP	O
.	.	O

As	IN	O
the	DT	O
subjects	NNS	O
were	VBD	O
regularly	RB	O
controlled	VBN	O
asthmatics	NNS	O
they	PRP	O
had	VBD	O
better	RBR	O
general	JJ	O
knowledge	NN	O
and	CC	O
inhaler-use	NN	O
technique	NN	O
was	VBD	O
expected	VBN	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
regularly	VB	O
refresh	JJ	O
asthma	NN	O
knowledge	NN	O
,	,	O
to	TO	O
assess	VB	O
patients	NNS	O
'	POS	O
self-management	JJ	O
plans	NNS	O
to	TO	O
achieve	VB	O
long-term	JJ	O
effectiveness	NN	O
of	IN	O
asthma	JJ	O
management	NN	O
.	.	O

Intermittent	JJ	O
theta-burst	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
for	IN	O
treatment	NN	O
of	IN	O
Parkinson	NNP	Condition
disease	NN	Condition
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
intermittent	JJ	O
theta-burst	JJ	O
stimulation	NN	O
(	(	O
iTBS	NN	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
motor	NN	O
symptoms	NNS	O
in	IN	O
Parkinson	NNP	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Progression	NNP	O
of	IN	O
PD	NNP	O
is	VBZ	O
characterized	VBN	O
by	IN	O
the	DT	O
emergence	NN	O
of	IN	O
motor	NN	O
deficits	NNS	O
,	,	O
which	WDT	O
eventually	RB	O
respond	VBZ	O
less	JJR	O
to	TO	O
dopaminergic	VB	O
therapy	NN	O
and	CC	O
pose	VB	O
a	DT	O
therapeutic	JJ	O
challenge	NN	O
.	.	O

Repetitive	JJ	O
transcranial	JJ	O
magnetic	JJ	O
stimulation	NN	O
(	(	O
rTMS	NN	O
)	)	O
has	VBZ	O
shown	VBN	O
promising	JJ	O
results	NNS	O
in	IN	O
improving	VBG	O
gait	NN	O
,	,	O
a	DT	O
major	JJ	O
cause	NN	O
of	IN	O
disability	NN	O
,	,	O
and	CC	O
may	MD	O
provide	VB	O
a	DT	O
therapeutic	JJ	O
alternative	NN	O
.	.	O

iTBS	NN	O
is	VBZ	O
a	DT	O
novel	JJ	O
type	NN	O
of	IN	O
rTMS	NN	O
that	WDT	O
may	MD	O
be	VB	O
more	RBR	O
efficacious	JJ	O
than	IN	O
conventional	JJ	O
rTMS	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
sham-controlled	JJ	O
study	NN	O
,	,	O
we	PRP	O
investigated	VBD	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
iTBS	NN	O
of	IN	O
the	DT	O
motor	NN	O
and	CC	O
dorsolateral	JJ	O
prefrontal	NN	O
cortices	NNS	O
in	IN	O
8	CD	O
sessions	NNS	O
over	IN	O
2	CD	O
weeks	NNS	O
(	(	O
evidence	NN	O
Class	NNP	O
I	PRP	O
)	)	O
.	.	O

Assessment	NN	O
of	IN	O
safety	NN	O
and	CC	O
clinical	JJ	O
efficacy	NN	O
over	IN	O
a	DT	O
1-month	JJ	O
period	NN	O
included	VBD	O
timed	JJ	O
tests	NNS	O
of	IN	O
gait	NN	O
and	CC	O
bradykinesia	NN	O
,	,	O
Unified	NNP	O
Parkinson	NNP	O
's	POS	O
Disease	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
UPDRS	NNP	O
)	)	O
,	,	O
and	CC	O
additional	JJ	O
clinical	NN	O
,	,	O
neuropsychological	JJ	O
,	,	O
and	CC	O
neurophysiologic	JJ	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
investigated	VBD	O
26	CD	Condition
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
PD	NNP	Condition
:	:	O
13	CD	O
received	VBD	O
iTBS	NN	O
and	CC	O
13	CD	O
sham	JJ	O
stimulation	NN	O
.	.	O

We	PRP	O
found	VBD	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
iTBS	NN	O
on	IN	O
mood	NN	O
,	,	O
but	CC	O
no	DT	O
improvement	NN	O
of	IN	O
gait	NN	O
,	,	O
bradykinesia	NN	O
,	,	O
UPDRS	NNP	O
,	,	O
and	CC	O
other	JJ	O
measures	NNS	O
.	.	O

EEG/EMG	NNP	O
monitoring	NN	O
recorded	VBD	O
no	DT	O
pathologic	JJ	O
increase	NN	O
of	IN	O
cortical	JJ	O
excitability	NN	O
or	CC	O
epileptic	JJ	O
activity	NN	O
.	.	O

Few	JJ	O
reported	VBD	O
discomfort	NN	O
or	CC	O
pain	NN	O
and	CC	O
one	CD	O
experienced	JJ	O
tinnitus	NN	O
during	IN	O
real	JJ	O
stimulation	NN	O
.	.	O

CONCLUSION	NNP	O
iTBS	NN	O
of	IN	O
the	DT	O
motor	NN	O
and	CC	O
prefrontal	JJ	O
cortices	NNS	O
appears	VBZ	O
safe	JJ	O
and	CC	O
improves	VBZ	O
mood	NN	O
,	,	O
but	CC	O
failed	VBD	O
to	TO	O
improve	VB	O
motor	NN	O
performance	NN	O
and	CC	O
functional	JJ	O
status	NN	O
in	IN	O
PD	NNP	O
.	.	O

CLASSIFICATION	NNP	O
OF	IN	O
EVIDENCE	NNP	O
This	DT	O
study	NN	O
provides	VBZ	O
Class	NNP	O
I	PRP	O
evidence	NN	O
that	IN	O
iTBS	NN	O
was	VBD	O
not	RB	O
effective	JJ	O
for	IN	O
gait	NN	O
,	,	O
upper	JJ	O
extremity	NN	O
bradykinesia	NN	O
,	,	O
or	CC	O
other	JJ	O
motor	NN	O
symptoms	NNS	O
in	IN	O
PD	NNP	O
.	.	O

Influenza	NNP	O
and	CC	O
pneumococcal	JJ	O
vaccination	NN	O
as	IN	O
a	DT	O
model	NN	O
to	TO	O
assess	VB	O
C-reactive	JJ	O
protein	NN	O
response	NN	O
to	TO	O
mild	VB	Condition
inflammation	NN	Condition
.	.	Condition

This	DT	O
study	NN	O
was	VBD	O
set	VBN	O
up	RP	O
to	TO	O
examine	VB	O
whether	IN	O
an	DT	O
influenza	JJ	O
vaccine	NN	O
or	CC	O
an	DT	O
influenza	JJ	O
vaccine	NN	O
in	IN	O
combination	NN	O
with	IN	O
pneumococcal	JJ	O
vaccine	NN	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
model	NN	O
to	TO	O
study	VB	O
responses	NNS	O
to	TO	O
mild	VB	O
stimulation	NN	O
of	IN	O
the	DT	O
inflammatory	NN	O
system	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
19	CD	Condition
subjects	NNS	O
received	VBD	O
the	DT	O
influenza	JJ	O
vaccine	NN	O
,	,	O
20	CD	Condition
subjects	NNS	O
the	DT	O
combination	NN	O
of	IN	O
influenza	NN	O
and	CC	O
pneumococcal	JJ	O
vaccine	NN	O
.	.	O

CRP	NNP	O
and	CC	O
prothrombin	VB	O
fragment	JJ	O
1	CD	O
and	CC	O
2	CD	O
(	(	O
F1+2	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
two	CD	O
times	NNS	O
after	IN	O
vaccination	NN	O
.	.	O

Influenza	NNP	O
vaccination	NN	O
increased	VBD	O
CRP	NNP	O
by	IN	O
0.20	CD	O
mg/L	NNS	O
,	,	O
and	CC	O
influenza	NN	O
in	IN	O
combination	NN	O
with	IN	O
pneumococcal	JJ	O
vaccine	NN	O
increased	VBN	O
CRP	NNP	O
by	IN	O
0.60	CD	O
mg/L	NN	O
.	.	O

F1+2	NNP	O
increased	VBD	O
0.15	CD	O
nmol/L	NN	O
after	IN	O
the	DT	O
combined	JJ	O
vaccination	NN	O
;	:	O
an	DT	O
increase	NN	O
in	IN	O
response	NN	O
to	TO	O
the	DT	O
influenza	JJ	O
vaccination	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Our	PRP$	O
findings	NNS	O
show	VBP	O
that	IN	O
the	DT	O
influenza	JJ	O
vaccine	NN	O
alone	RB	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
combination	NN	O
of	IN	O
the	DT	O
influenza	NN	O
and	CC	O
pneumococcal	JJ	O
vaccine	NN	O
increases	VBZ	O
CRP-levels	NNP	O
with	IN	O
a	DT	O
peak	JJ	O
2	CD	O
days	NNS	O
after	IN	O
vaccination	NN	O
.	.	O

Preventive	JJ	O
treatment	NN	O
of	IN	O
serotonin-migraine	JJ	Condition
with	IN	O
1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo	JJ	O
(	(	O
b	NN	O
,	,	O
f	NN	O
)	)	O
pyrazino-	NN	O
(	(	O
1,2	CD	O
--	:	O
d	NN	O
)	)	O
-	:	O
(	(	O
1,4	CD	O
)	)	O
-oxazepine	NN	O
hydrogen	NN	O
maleate	NN	O
(	(	O
Org	NNP	O
GC	NNP	O
94	CD	O
)	)	O
.	.	O

A	DT	O
double-blind	JJ	O
study	NN	O
.	.	O

1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo	JJ	O
(	(	O
b	NN	O
,	,	O
f	NN	O
)	)	O
pyrazino-	NN	O
(	(	O
1,2-d	CD	O
)	)	O
-	:	O
(	(	O
1,4	CD	O
)	)	O
-oxazepine	NN	O
hydrogen	NN	O
maleate	NN	O
(	(	O
Org	NNP	O
GC	NNP	O
94	CD	O
)	)	O
is	VBZ	O
an	DT	O
oral	JJ	O
antamine	NN	O
preparation	NN	O
with	IN	O
anti-serotoninergic	JJ	O
and	CC	O
anti-histaminic	JJ	O
effects	NNS	O
.	.	O

Its	PRP$	O
lack	NN	O
of	IN	O
unpleasant	JJ	O
side-effects	NNS	O
permits	NNS	O
protracted	VBN	O
use	NN	O
for	IN	O
the	DT	O
preventive	JJ	O
treatment	NN	O
of	IN	O
serotonin-migraine	NN	O
.	.	O

Its	PRP$	O
chemical	NN	O
structure	NN	O
--	:	O
tetracyclic	JJ	O
ring	NN	O
,	,	O
C-beta	NNP	O
,	,	O
C-alpha	NNP	O
,	,	O
amine	NN	O
in	IN	O
a	DT	O
secondary	JJ	O
position	NN	O
--	:	O
allows	VBZ	O
block	NN	O
of	IN	O
the	DT	O
receptors	NNS	O
for	IN	O
serotonin	NN	O
and	CC	O
histamine	NN	O
.	.	O

Preventive	JJ	O
treatment	NN	O
with	IN	O
3	CD	O
x	NNS	O
5	CD	O
mg/day	NN	O
of	IN	O
Org	NNP	O
GC	NNP	O
94	CD	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
3	CD	O
months	NNS	O
can	MD	O
almost	RB	O
completely	RB	O
eliminate	JJ	O
migraine	NN	O
attacks	NNS	O
.	.	O

21	CD	O
out	IN	O
of	IN	O
30	CD	SampleSize
patients	NNS	O
(	(	O
70	CD	O
%	NN	O
)	)	O
profited	VBN	O
from	IN	O
such	JJ	O
a	DT	O
treatment	NN	O
,	,	O
showing	VBG	O
a	DT	O
drop	NN	O
from	IN	O
5	CD	O
--	:	O
30	CD	O
attacks	NNS	O
to	TO	O
0	CD	O
--	:	O
1	CD	O
attack	NN	O
per	IN	O
month	NN	O
and	CC	O
normalization	NN	O
of	IN	O
high	JJ	O
urinary	JJ	O
serotonin	NN	O
,	,	O
5-HIAA	JJ	O
or	CC	O
histamine	JJ	O
levels	NNS	O
.	.	O

However	RB	O
,	,	O
30	CD	SampleSize
patients	NNS	SampleSize
receiving	VBG	O
3	CD	O
x	JJ	O
0.5	CD	O
mg	NN	O
or	CC	O
placebo	JJ	O
daily	RB	O
reacted	VBD	O
only	RB	O
rarely	RB	O
.	.	O

The	DT	O
typical	JJ	O
side-effects	NNS	O
of	IN	O
anti-serotonin	JJ	O
drugs	NNS	O
,	,	O
especially	RB	O
sedation	NN	O
or	CC	O
dizziness	NN	O
and	CC	O
hyperorexia	NN	O
were	VBD	O
hardly	RB	O
observed	VBN	O
.	.	O

Randomization	NN	O
of	IN	O
the	DT	O
serotonin-migraine	JJ	O
cases	NNS	O
and	CC	O
double-blind	JJ	O
methodology	NN	O
were	VBD	O
applied	VBN	O
throughout	IN	O
the	DT	O
trial	NN	O
.	.	O

Sedation	NNP	O
depth	NN	O
during	IN	O
spinal	JJ	O
anesthesia	NN	O
and	CC	O
survival	NN	O
in	IN	O
elderly	JJ	Condition
patients	NNS	Condition
undergoing	VBG	Condition
hip	JJ	Condition
fracture	NN	Condition
repair	NN	Condition
.	.	Condition

Low	JJ	O
intraoperative	JJ	O
Bispectral	NNP	O
Index	NNP	O
(	(	O
BIS	NNP	O
)	)	O
values	NNS	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
increased	JJ	O
mortality	NN	O
.	.	O

In	IN	O
a	DT	O
previously	RB	O
reported	VBN	O
trial	NN	O
to	TO	O
prevent	VB	O
delirium	NN	O
,	,	O
we	PRP	O
randomized	VBD	O
patients	NNS	O
undergoing	VBG	O
hip	JJ	O
fracture	NN	O
repair	NN	O
under	IN	O
spinal	JJ	O
anesthesia	NN	O
to	TO	O
light	NN	O
(	(	O
BIS	NNP	O
>	NNP	O
80	CD	O
)	)	O
or	CC	O
deep	JJ	O
(	(	O
BIS	NNP	O
approximately	RB	O
50	CD	O
)	)	O
sedation	NN	O
.	.	O

We	PRP	O
analyzed	VBD	O
survival	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
original	JJ	O
trial	NN	O
.	.	O

Among	IN	O
all	DT	O
patients	NNS	O
,	,	O
mortality	NN	O
was	VBD	O
equivalent	JJ	O
across	IN	O
sedation	NN	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
among	IN	O
patients	NNS	O
with	IN	O
serious	JJ	O
comorbidities	NNS	O
(	(	O
Charlson	NNP	O
score	RB	O
>	VBZ	O
4	CD	O
)	)	O
,	,	O
1-year	JJ	O
mortality	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
light	NN	O
(	(	O
22.2	CD	O
%	NN	O
)	)	O
vs	NN	O
deep	JJ	O
(	(	O
43.6	CD	O
%	NN	O
)	)	O
sedation	NN	O
group	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
,	,	O
0.43	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.19-0.97	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
during	IN	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

Similarly	RB	O
,	,	O
among	IN	O
patients	NNS	O
with	IN	O
Charlson	NNP	O
score	VBD	O
>	JJ	O
6	CD	O
,	,	O
1-year	JJ	O
mortality	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
light	NN	O
(	(	O
28.6	CD	O
%	NN	O
)	)	O
vs	NN	O
deep	JJ	O
(	(	O
52.6	CD	O
%	NN	O
)	)	O
sedation	NN	O
group	NN	O
(	(	O
HR	NNP	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.12-0.94	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
during	IN	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

Further	NNP	O
research	NN	O
on	IN	O
reduced	JJ	O
mortality	NN	O
after	IN	O
light	JJ	O
sedation	NN	O
during	IN	O
spinal	JJ	O
anesthesia	NN	O
is	VBZ	O
needed	VBN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double	JJ	O
dummy	NN	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
oral	JJ	O
cefditoren	NNS	O
pivoxil	VBP	O
400mg	CD	O
once	RB	O
daily	JJ	O
as	IN	O
switch	NN	O
therapy	NN	O
after	IN	O
intravenous	JJ	O
ceftriaxone	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
pyelonephritis	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
clinical	JJ	O
and	CC	O
bacteriological	JJ	O
effectiveness	NN	O
of	IN	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
ceftriaxone	NN	O
followed	VBN	O
by	IN	O
oral	JJ	O
cefditoren	NNS	O
pivoxil	VBP	O
or	CC	O
IV	NNP	O
ceftriaxone	NN	O
for	IN	O
acute	JJ	O
pyelonephritis	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
presumptive	JJ	O
diagnosis	NN	O
of	IN	O
acute	JJ	Condition
pyelonephritis	NN	Condition
was	VBD	O
performed	VBN	O
.	.	O

Daily	JJ	O
2g	CD	O
IV	NNP	O
ceftriaxone	NN	O
was	VBD	O
initially	RB	O
given	VBN	O
to	TO	O
all	DT	O
patients	NNS	O
.	.	O

After	IN	O
day	NN	O
3	CD	O
,	,	O
patients	NNS	O
who	WP	O
satisfied	VBD	O
the	DT	O
criteria	NNS	O
for	IN	O
switch	NN	O
therapy	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
group	NN	O
A	NNP	O
(	(	O
IV	NNP	O
ceftriaxone	NN	O
)	)	O
or	CC	O
group	NN	O
B	NNP	O
(	(	O
oral	JJ	O
cefditoren	NNS	O
pivoxil	VBP	O
400mg	CD	O
once	RB	O
daily	JJ	O
)	)	O
.	.	O

RESULTS	JJ	O
Eighty-two	JJ	SampleSize
patients	NNS	O
were	VBD	O
enrolled	VBN	O
;	:	O
41	CD	SampleSize
(	(	O
50	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
41	CD	SampleSize
(	(	O
50	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
group	NN	O
B	NNP	O
were	VBD	O
evaluated	VBN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
baseline	NN	O
characteristics	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Clinical	JJ	O
cure	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
39	CD	O
of	IN	O
41	CD	O
(	(	O
95.1	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
41	CD	O
of	IN	O
41	CD	O
(	(	O
100	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
p=0.15	NN	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
-0.12	VBP	O
to	TO	O
0.02	CD	O
)	)	O
.	.	O

Urine	NNP	O
bacteriological	JJ	O
eradication	NN	O
was	VBD	O
found	VBN	O
in	IN	O
63.4	CD	O
%	NN	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
60	CD	O
%	NN	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
p=0.75	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
-0.18	NNP	O
to	TO	O
0.25	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
adverse	JJ	O
effects	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
IV	NNP	O
ceftriaxone	NN	O
followed	VBN	O
by	IN	O
oral	JJ	O
cefditoren	NNS	O
pivoxil	NN	O
is	VBZ	O
highly	RB	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
pyelonephritis	NN	O
,	,	O
even	RB	O
for	IN	O
uropathogens	NNS	O
with	IN	O
a	DT	O
high	JJ	O
proportion	NN	O
of	IN	O
quinolone-resistant	JJ	O
strains	NNS	O
.	.	O

Multiple	NNP	O
risk	NN	O
factor	NN	O
intervention	NN	O
reduces	VBZ	O
cardiovascular	JJ	O
risk	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
echolucent	JJ	O
plaques	NNS	O
in	IN	O
the	DT	O
carotid	NN	O
artery	NN	O
.	.	O

OBJECTIVE	NNP	O
In	IN	O
a	DT	O
previously	RB	O
published	VBN	O
randomized	VBN	O
6-year	JJ	O
study	NN	O
we	PRP	O
observed	VBD	O
that	IN	O
multiple	JJ	O
risk	NN	O
factor	NN	O
intervention	NN	O
reduced	VBD	O
cardiovascular	JJ	O
risk	NN	O
in	IN	O
high-risk	JJ	O
hypertensive	JJ	O
men	NNS	O
,	,	O
and	CC	O
that	IN	O
this	DT	O
effect	NN	O
was	VBD	O
confined	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
carotid	JJ	O
artery	NN	O
plaques	NNS	O
.	.	O

Hypothetically	RB	O
,	,	O
the	DT	O
underlying	VBG	O
mechanism	NN	O
might	MD	O
have	VB	O
been	VBN	O
a	DT	O
stabilization	NN	O
of	IN	O
echolucent	NN	O
,	,	O
instable	JJ	O
,	,	O
rupture-prone	JJ	O
plaques	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
plaque	NN	O
characteristics	NNS	O
by	IN	O
B-mode	NNP	O
ultrasound	NN	O
in	IN	O
the	DT	O
previous	JJ	O
intervention	NN	O
study	NN	O
,	,	O
and	CC	O
also	RB	O
to	TO	O
investigate	VB	O
the	DT	O
relationship	NN	O
between	IN	O
plaque	NN	O
characteristics	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
cardiovascular	JJ	O
events	NNS	O
during	IN	O
the	DT	O
6-year	JJ	O
follow-up	NN	O
in	IN	O
the	DT	O
two	CD	O
randomization	NN	O
groups	NNS	O
.	.	O

METHODS	NNP	O
High	NNP	O
resolution	NN	O
B-mode	NNP	O
ultrasound	NN	O
was	VBD	O
used	VBN	O
to	TO	O
characterize	VB	O
plaque	JJ	O
echogenicity	NN	O
in	IN	O
four	CD	O
subgroups	NNS	O
-	:	O
dominantly	RB	O
echolucent	NN	O
,	,	O
substantially	RB	O
echolucent	JJ	O
,	,	O
dominantly	RB	O
echogenic	JJ	O
,	,	O
and	CC	O
uniformly	RB	O
echogenic	JJ	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
usual	JJ	O
care	NN	O
group	NN	O
17	CD	O
of	IN	O
32	CD	O
(	(	O
53	CD	O
%	NN	O
)	)	O
patients	NNS	O
with	IN	O
echolucent	JJ	O
plaques	NNS	O
at	IN	O
baseline	NN	O
suffered	VBN	O
from	IN	O
a	DT	O
combined	VBN	O
end-point	NN	O
(	(	O
any	DT	O
death	NN	O
or	CC	O
nonfatal	JJ	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
nonfatal	JJ	O
stroke	NN	O
)	)	O
during	IN	O
follow-up	JJ	O
compared	VBN	O
with	IN	O
seven	CD	O
of	IN	O
28	CD	O
(	(	O
25	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.036	CD	O
)	)	O
.	.	O

The	DT	O
corresponding	JJ	O
numbers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
echogenic	JJ	O
plaques	NNS	O
were	VBD	O
n	JJ	O
=	JJ	O
4/13	CD	O
(	(	O
31	CD	O
%	NN	O
)	)	O
and	CC	O
n	JJ	O
=	NN	O
4/17	CD	O
(	(	O
24	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
NS	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
usual	JJ	O
care	NN	O
group	NN	O
11	CD	O
of	IN	O
33	CD	O
(	(	O
33	CD	O
%	NN	O
)	)	O
patients	NNS	O
with	IN	O
no	DT	O
plaques	NNS	O
suffered	VBD	O
from	IN	O
a	DT	O
combined	JJ	O
end-point	NN	O
during	IN	O
follow-up	JJ	O
compared	VBN	O
with	IN	O
11	CD	O
of	IN	O
30	CD	O
(	(	O
37	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
the	DT	O
multiple	NN	O
risk	NN	O
intervention	NN	O
programme	NN	O
was	VBD	O
confined	VBN	O
to	TO	O
those	DT	O
patients	NNS	O
with	IN	O
echolucent	JJ	O
plaques	NNS	O
.	.	O

The	DT	O
data	NNS	O
have	VBP	O
to	TO	O
be	VB	O
confirmed	VBN	O
with	IN	O
a	DT	O
large-scale	JJ	O
trial	NN	O
.	.	O

Modulation	NN	O
of	IN	O
oxidant	JJ	O
stress	NN	O
in	IN	O
vivo	NN	O
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

BACKGROUND	NNP	O
Free	JJ	O
radical-induced	JJ	O
oxidative	JJ	O
damage	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
diseases	NNS	O
associated	VBN	O
with	IN	O
cigarette	NN	O
smoking	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
production	NN	O
of	IN	O
8-epi-prostaglandin	JJ	O
(	(	O
PG	NNP	O
)	)	O
F2	NNP	O
alpha	NN	O
,	,	O
a	DT	O
stable	JJ	O
product	NN	O
of	IN	O
lipid	JJ	O
peroxidation	NN	O
in	IN	O
vivo	NN	O
,	,	O
and	CC	O
its	PRP$	O
modulation	NN	O
by	IN	O
aspirin	NN	O
and	CC	O
antioxidant	JJ	O
vitamins	NNS	O
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
the	DT	O
following	JJ	O
studies	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
a	DT	O
cross-sectional	JJ	O
comparison	NN	O
of	IN	O
smokers	NNS	O
and	CC	O
control	NN	O
subjects	NNS	O
,	,	O
(	(	O
2	CD	O
)	)	O
an	DT	O
examination	NN	O
of	IN	O
the	DT	O
dose-response	JJ	O
relationship	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
an	DT	O
exploration	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
smoking	VBG	O
cessation	NN	O
(	(	O
3	CD	O
weeks	NNS	O
)	)	O
and	CC	O
nicotine	JJ	O
patch	NN	O
supplementation	NN	O
,	,	O
(	(	O
4	CD	O
)	)	O
the	DT	O
effect	NN	O
of	IN	O
aspirin	NN	O
consumption	NN	O
,	,	O
and	CC	O
(	(	O
5	CD	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
5	CD	O
days	NNS	O
'	POS	O
dosing	VBG	O
with	IN	O
vitamin	NN	O
E	NNP	O
(	(	O
100	CD	O
and	CC	O
800	CD	O
U	NNP	O
)	)	O
,	,	O
vitamin	FW	O
C	NNP	O
(	(	O
2	CD	O
g	NN	O
)	)	O
,	,	O
and	CC	O
their	PRP$	O
combination	NN	O
.	.	O

8-epi-PGF2	JJ	O
alpha	JJ	O
excretion	NN	O
(	(	O
in	IN	O
pmol/mmol	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
)	)	O
was	VBD	O
176.5+/-30.6	JJ	O
in	IN	O
heavy	JJ	O
smokers	NNS	O
,	,	O
92.7+/-4.8	CD	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
in	IN	O
moderate	JJ	Condition
smokers	NNS	Condition
,	,	O
and	CC	O
54.1+/-2.7	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
in	IN	O
nonsmokers	NNS	Condition
.	.	O

Urinary	JJ	O
levels	NNS	O
fell	VBD	O
from	IN	O
145.5+/-24.9	CD	O
to	TO	O
114.6+/-27.1	CD	O
(	(	O
week	NN	O
2	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
112.6+/-24.9	JJ	O
(	(	O
week	NN	O
3	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
on	IN	O
cessation	NN	O
of	IN	O
smoking	NN	O
.	.	O

Aspirin	NNP	O
treatment	NN	O
failed	VBD	O
to	TO	O
suppress	VB	O
urinary	JJ	O
levels	NNS	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
despite	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
urinary	JJ	O
11-dehydro-TxB2	JJ	O
production	NN	O
and	CC	O
suppression	NN	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
and	CC	O
TxB2	NNP	O
in	IN	O
serum	NN	O
.	.	O

Vitamin	NNP	O
C	NNP	O
(	(	O
pre	NN	O
,	,	O
194.6+/-40.9	JJ	O
;	:	O
post	NN	O
,	,	O
137.2+/-34.1	JJ	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
a	DT	O
combination	NN	O
of	IN	O
vitamin	JJ	O
C	NNP	O
and	CC	O
E	NNP	O
(	(	O
pre	NN	O
,	,	O
171.0+/-39.8	JJ	O
;	:	O
post	NN	O
,	,	O
133.5+/-29.6	JJ	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
suppressed	VBD	O
urinary	JJ	O
8-epi-PGF2	JJ	O
alpha	NN	O
,	,	O
whereas	IN	O
vitamin	JJ	O
E	NNP	O
alone	RB	O
had	VBD	O
no	DT	O
effect	NN	O
.	.	O

CONCLUSIONS	NNP	O
Urinary	NNP	O
8-epi-PGF2	JJ	O
alpha	NN	O
may	MD	O
represent	VB	O
a	DT	O
noninvasive	JJ	O
,	,	O
quantitative	JJ	O
index	NN	O
of	IN	O
oxidant	JJ	O
stress	NN	O
in	IN	O
vivo	NN	O
.	.	O

Elevated	JJ	O
levels	NNS	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
in	IN	O
smokers	NNS	O
may	MD	O
be	VB	O
modulated	VBN	O
by	IN	O
quitting	VBG	O
cigarettes	NNS	O
and	CC	O
switching	VBG	O
to	TO	O
nicotine	VB	O
patches	NNS	O
or	CC	O
by	IN	O
antioxidant	JJ	O
vitamin	NN	O
therapy	NN	O
.	.	O

A	DT	O
phase	NN	O
II	NNP	O
,	,	O
randomized	VBD	O
,	,	O
multicenter	NN	O
study	NN	O
evaluating	VBG	O
the	DT	O
combination	NN	O
of	IN	O
lapatinib	NN	O
and	CC	O
vinorelbine	NN	O
in	IN	O
women	NNS	Sex
with	IN	O
ErbB2	NNP	Condition
overexpressing	VBG	Condition
metastatic	JJ	Condition
breast	NN	Condition
cancer	NN	Condition
.	.	O

Lapatinib	NNP	O
is	VBZ	O
approved	VBN	O
in	IN	O
combination	NN	O
with	IN	O
capecitabine	NN	O
for	IN	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
human	JJ	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
2	CD	O
(	(	O
HER2	NNP	O
)	)	O
-positive	VBP	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
(	(	O
MBC	NNP	O
)	)	O
who	WP	O
have	VBP	O
progressed	VBN	O
on	IN	O
prior	JJ	O
trastuzumab	NN	O
in	IN	O
the	DT	O
metastatic	JJ	O
setting	NN	O
.	.	O

Vinorelbine	NNP	O
is	VBZ	O
an	DT	O
important	JJ	O
chemotherapy	NN	O
option	NN	O
for	IN	O
MBC	NNP	O
.	.	O

We	PRP	O
evaluated	VBD	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
lapatinib	JJ	O
plus	CC	O
vinorelbine	JJ	O
,	,	O
compared	VBN	O
with	IN	O
lapatinib	JJ	O
plus	CC	O
capecitabine	JJ	O
,	,	O
in	IN	O
women	NNS	O
with	IN	O
HER2-positive	JJ	O
MBC	NNP	O
.	.	O

In	IN	O
this	DT	O
open-label	JJ	O
,	,	O
multicenter	NN	O
,	,	O
phase	NN	O
II	NNP	O
study	NN	O
,	,	O
eligible	JJ	O
patients	NNS	O
(	(	O
N	NNP	O
=	NNP	O
112	CD	SampleSize
)	)	O
were	VBD	O
randomized	VBN	O
2:1	CD	O
to	TO	O
lapatinib	VB	O
plus	JJ	O
vinorelbine	NN	O
[	NNP	O
(	(	O
N	NNP	O
=	NNP	O
75	CD	O
)	)	O
1,250	CD	O
mg	NN	O
orally	RB	O
once	RB	O
daily	JJ	O
(	(	O
QD	NNP	O
)	)	O
continuously	RB	O
plus	CC	O
20	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
intravenously	RB	O
]	VBZ	O
or	CC	O
lapatinib	JJ	O
plus	CC	O
capecitabine	JJ	O
[	NNP	O
(	(	O
N	NNP	O
=	NNP	O
37	CD	O
)	)	O
1,250	CD	O
mg	NN	O
orally	RB	O
QD	NNP	O
continuously	RB	O
plus	CC	O
2,000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/day	NN	O
orally	RB	O
,	,	O
2	CD	O
doses	NNS	O
]	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

Other	JJ	O
endpoints	NNS	O
included	VBD	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
and	CC	O
safety	NN	O
.	.	O

Patients	NNS	O
progressing	VBG	O
within	IN	O
the	DT	O
study	NN	O
were	VBD	O
given	VBN	O
the	DT	O
option	NN	O
of	IN	O
crossover	NN	O
to	TO	O
the	DT	O
other	JJ	O
treatment	NN	O
arm	NN	O
;	:	O
time	NN	O
to	TO	O
second	JJ	O
progression	NN	O
was	VBD	O
an	DT	O
exploratory	JJ	O
endpoint	NN	O
.	.	O

Patient	JJ	O
demographics	NNS	O
,	,	O
stratification	NN	O
,	,	O
and	CC	O
prognostic	JJ	O
factors	NNS	O
were	VBD	O
well	RB	O
balanced	VBN	O
between	IN	O
treatments	NNS	O
.	.	O

Median	JJ	O
PFS	NNP	O
in	IN	O
both	DT	O
arms	NNS	O
was	VBD	O
6.2	CD	O
months	NNS	O
[	RB	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
4.2	CD	O
,	,	O
8.8	CD	O
(	(	O
lapatinib	JJ	O
plus	CC	O
vinorelbine	JJ	O
)	)	O
;	:	O
4.4	CD	O
,	,	O
8.3	CD	O
(	(	O
lapatinib	JJ	O
plus	CC	O
capecitabine	NN	O
)	)	O
]	NN	O
.	.	O

Median	JJ	O
OS	NNP	O
on	IN	O
lapatinib	JJ	O
plus	CC	O
vinorelbine	NN	O
was	VBD	O
24.3	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
16.4	CD	O
,	,	O
NE	NNP	O
)	)	O
and	CC	O
19.4	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
16.4	CD	O
,	,	O
27.2	CD	O
)	)	O
on	IN	O
lapatinib	NN	O
plus	CC	O
capecitabine	NN	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
42	CD	O
patients	NNS	O
opted	VBN	O
to	TO	O
cross	VB	O
over	RP	O
;	:	O
median	JJ	O
PFS	NNP	O
was	VBD	O
3.2	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1.7	CD	O
,	,	O
5.1	CD	O
)	)	O
on	IN	O
lapatinib	NN	O
plus	CC	O
vinorelbine	NN	O
and	CC	O
4.0	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
2.1	CD	O
,	,	O
5.8	CD	O
)	)	O
on	IN	O
lapatinib	NN	O
plus	CC	O
capecitabine	NN	O
.	.	O

Lapatinib	NNP	O
plus	CC	O
vinorelbine	NN	O
offers	NNS	O
an	DT	O
effective	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
patients	NNS	O
with	IN	O
HER2-overexpressing	NNP	O
MBC	NNP	O
,	,	O
having	VBG	O
displayed	VBN	O
comparable	JJ	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
rates	NNS	O
to	TO	O
lapatinib	VB	O
plus	JJ	O
capecitabine	NN	O
.	.	O

Measurement	NN	O
of	IN	O
peptidase	NN	O
activity	NN	O
and	CC	O
evaluation	NN	O
of	IN	O
effectiveness	NN	O
of	IN	O
administration	NN	O
of	IN	O
minocycline	NN	O
for	IN	O
treatment	NN	O
of	IN	O
dogs	NNS	Condition
with	IN	O
periodontitis	NN	Condition
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
clinical	JJ	O
,	,	O
enzymatic	JJ	O
,	,	O
and	CC	O
microbiologic	JJ	O
effects	NNS	O
of	IN	O
controlled-release	NN	O
localized	JJ	O
administration	NN	O
of	IN	O
minocycline	NN	O
on	IN	O
dogs	NNS	Condition
with	IN	O
periodontitis	NN	Condition
.	.	O

ANIMALS	NNP	O
Five	CD	SampleSize
adult	NN	Age
Beagles	NNS	Condition
with	IN	O
periodontitis	NN	Condition
.	.	O

PROCEDURE	NNP	O
After	IN	O
tooth	CC	O
scaling	VBG	O
and	CC	O
root	NN	O
planing	NN	O
,	,	O
2	CD	O
treatment	NN	O
,	,	O
1	CD	O
placebo	NN	O
,	,	O
and	CC	O
1	CD	O
control	NN	O
site	NN	O
were	VBD	O
selected	VBN	O
for	IN	O
each	DT	O
dog	NN	O
.	.	O

Treatment	NN	O
sites	NNS	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
received	VBD	O
a	DT	O
periodontal	JJ	O
formulation	NN	O
of	IN	O
minocycline	NN	O
hydrochloride	NN	O
,	,	O
placebo	NN	O
sites	NNS	O
(	(	O
5	CD	O
)	)	O
received	VBD	O
ointment	JJ	O
without	IN	O
minocycline	NN	O
,	,	O
and	CC	O
control	VB	O
sites	NNS	O
(	(	O
5	CD	O
)	)	O
did	VBD	O
not	RB	O
receive	VB	O
ointment	NN	O
.	.	O

Treatments	NNS	O
were	VBD	O
administered	VBN	O
4	CD	O
times	NNS	O
at	IN	O
weekly	JJ	O
intervals	NNS	O
.	.	O

Peptidase	NNP	O
activity	NN	O
and	CC	O
clinical	JJ	O
and	CC	O
microbiologic	JJ	O
effects	NNS	O
were	VBD	O
evaluated	VBN	O
and	CC	O
compared	VBN	O
among	IN	O
sites	NNS	O
for	IN	O
17	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Bleeding	NNP	O
of	IN	O
the	DT	O
gums	NNS	O
on	IN	O
probing	VBG	O
(	(	O
BOP	NNP	O
)	)	O
and	CC	O
pocket	NN	O
depth	NN	O
(	(	O
PD	NNP	O
)	)	O
improved	VBD	O
at	IN	O
the	DT	O
treatment	NN	O
site	NN	O
and	CC	O
were	VBD	O
maintained	VBN	O
for	IN	O
13	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
BOP	NNP	O
and	CC	O
PD	NNP	O
in	IN	O
placebo	NN	O
and	CC	O
control	VB	O
sites	NNS	O
increased	VBN	O
from	IN	O
weeks	NNS	O
9	CD	O
to	TO	O
17	CD	O
Peptidase	NNP	O
activity	NN	O
in	IN	O
the	DT	O
periodontal	JJ	O
pocket	NN	O
decreased	VBD	O
noticeably	RB	O
from	IN	O
week	NN	O
1	CD	O
to	TO	O
17	CD	O
,	,	O
compared	VBN	O
with	IN	O
baseline	NN	O
values	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
site	NN	O
.	.	O

However	RB	O
,	,	O
peptidase	NN	O
activity	NN	O
for	IN	O
placebo	NN	O
and	CC	O
control	VB	O
sites	NNS	O
increased	VBN	O
and	CC	O
were	VBD	O
above	RB	O
baseline	JJ	O
values	NNS	O
on	IN	O
week	NN	O
9	CD	O
and	CC	O
week	NN	O
13	CD	O
,	,	O
respectively	RB	O
.	.	O

Total	JJ	O
bacterial	JJ	O
counts	NNS	O
decreased	VBN	O
by	IN	O
90	CD	O
%	NN	O
for	IN	O
treatment	NN	O
sites	NNS	O
and	CC	O
remained	VBD	O
at	IN	O
that	DT	O
value	NN	O
for	IN	O
13	CD	O
weeks	NNS	O
.	.	O

However	RB	O
,	,	O
for	IN	O
placebo	NN	O
and	CC	O
control	NN	O
sites	NNS	O
,	,	O
bacterial	JJ	O
counts	NNS	O
increased	VBD	O
and	CC	O
reached	VBD	O
the	DT	O
baseline	NN	O
value	NN	O
on	IN	O
week	NN	O
17	CD	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
Increased	VBD	O
peptidase	NN	O
activity	NN	O
is	VBZ	O
correlated	VBN	O
with	IN	O
the	DT	O
progression	NN	O
of	IN	O
periodontitis	NN	Condition
in	IN	O
dogs	NNS	Condition
.	.	O

Treatment	NN	O
with	IN	O
minocycline	NN	O
,	,	O
using	VBG	O
a	DT	O
localized	VBN	O
delivery	NN	O
system	NN	O
,	,	O
was	VBD	O
effective	JJ	O
in	IN	O
dogs	NNS	O
for	IN	O
at	IN	O
least	JJS	O
13	CD	O
weeks	NNS	O
after	IN	O
cessation	NN	O
of	IN	O
drug	NN	O
administration	NN	O
.	.	O

